<SEC-DOCUMENT>0000950103-21-004378.txt : 20210323
<SEC-HEADER>0000950103-21-004378.hdr.sgml : 20210323
<ACCEPTANCE-DATETIME>20210323090107
ACCESSION NUMBER:		0000950103-21-004378
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		157
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210323
DATE AS OF CHANGE:		20210323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37891
		FILM NUMBER:		21763290

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>dp148007_20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-top: black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549<BR>
<B>FORM 20-F</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9744;</TD>
    <TD STYLE="font-size: 10pt"><B>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9746;</TD>
    <TD><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B><BR>
<B>for the fiscal year ended December 31, 2020</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><B>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B><BR>
<B>Date of event requiring this shell company report</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-37891</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC IMMUNE SA<BR>
</B><I>(Exact name of Registrant as specified in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Switzerland<BR>
</B><I>(Jurisdiction of incorporation)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EPFL INNOVATION PARK<BR>
Building B<BR>
1015 Lausanne<BR>
Switzerland<BR>
</B><I>(Address of principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Andrea Pfeifer</B><BR>
<B>Tel: +41 21 345 91 21</B><BR>
<B>EPFL INNOVATION PARK</B><BR>
<B>Building B</B><BR>
<B>1015 Lausanne</B><BR>
<B>Switzerland </B><BR>
<I>(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</I><BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; text-align: center"><B>Richard D. Truesdell, Jr.</B><BR>
<B>Derek J. Dostal</B><BR>
<B>Davis Polk &amp; Wardwell LLP</B><BR>
<B>450 Lexington Avenue</B><BR>
<B>New York, NY 10017</B><BR>
<B>(212) 450-4000</B></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered or to be registered
pursuant to Section 12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid">Title
        of each class</P>
</TD>
    <TD STYLE="width: 20%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid">Trading
        Symbol</P>
</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid">Name of
        each exchange on which registered</P>
</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">Common Shares, nominal value CHF 0.02 per share</TD>
    <TD STYLE="font-size: 10pt; text-align: center">ACIU</TD>
    <TD STYLE="font-size: 10pt; text-align: center">The Nasdaq Global Market</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered or to be registered
pursuant to Section 12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities for which there is a reporting
obligation pursuant to Section 15(d) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate the number of outstanding shares of each of the issuer&rsquo;s
classes of capital stock or common stock as of the close of the period covered by the annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common shares: 71,936,738</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9746; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this report is an annual or transition report, indicate by
check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act&nbsp;of&nbsp;1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9746; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note &ndash; Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those
Sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: center">Large accelerated filer &#9744;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center">Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center">Non-accelerated filer &#9744;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with US GAAP, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold"></A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has filed a report
on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control over financial reporting under
Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9746; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark which basis of accounting the registrant
has used to prepare the financial statements included in this filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: center">US GAAP &#9744;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center">International Financial Reporting Standards as issued by the International Accounting Standards Board &#9746;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center">Other &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Other&rdquo; has been checked in response to the previous
question indicate by check mark which financial statement item the registrant has elected to follow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Item 17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; Item 18</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this is an annual report, indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9746; No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="toc"></A>table
of contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 93%; text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#forwardlooking">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="width: 7%; text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#forwardlooking">1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#part01">PART I</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#part01">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item01">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item01">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item01a">A.&nbsp;&nbsp;&nbsp;Directors and senior management</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item01a">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item01b">B.&nbsp;&nbsp;&nbsp;Advisers</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item01b">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item01c">C.&nbsp;&nbsp;&nbsp;Auditors</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item01c">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item02">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item02">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item02a">A.&nbsp;&nbsp;&nbsp;Offer statistics</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item02a">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item02b">B.&nbsp;&nbsp;&nbsp;Method and expected timetable</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item02b">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item03">ITEM 3. KEY INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item03">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item03a">A.&nbsp;&nbsp;&nbsp;Selected Financial Data</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item03a">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item03b">B.&nbsp;&nbsp;&nbsp;Capitalization and indebtedness</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item03b">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item03c">C.&nbsp;&nbsp;&nbsp;Reasons for the offer and use of proceeds</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item03c">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item03d">D.&nbsp;&nbsp;&nbsp;Risk factors</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item03d">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item04">ITEM 4. INFORMATION ON THE COMPANY</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04">47</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item04a">A.&nbsp;&nbsp;&nbsp;History and development of the company</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04a">47</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item04b">B.&nbsp;&nbsp;&nbsp;Business overview</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04b">47</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item04c">C.&nbsp;&nbsp;&nbsp;Organizational structure</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04c">106</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item04d">D.&nbsp;&nbsp;&nbsp;Property, plant and equipment</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04d">106</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item04aunresolvedstaffcomments">ITEM 4A. UNRESOLVED STAFF COMMENTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item04aunresolvedstaffcomments">106</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item05">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05">106</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05a">A.&nbsp;&nbsp;&nbsp;Operating results</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05a">107</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05b">B.&nbsp;&nbsp;&nbsp;Liquidity and capital resources</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05b">121</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05c">C.&nbsp;&nbsp;&nbsp;Research and development, patents and licenses, etc.</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05c">123</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05d">D.&nbsp;&nbsp;&nbsp;Trend information</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05d">123</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05e">E.&nbsp;&nbsp;&nbsp;Safe harbor</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05e">123</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item05f">F.&nbsp;&nbsp;&nbsp;Non-IFRS financial measures</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item05f">123</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item06">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06">124</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item06a">A.&nbsp;&nbsp;&nbsp;Directors and senior management</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06a">124</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item06b">B.&nbsp;&nbsp;&nbsp;Compensation</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06b">128</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item06c">C.&nbsp;&nbsp;&nbsp;Board practices</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06c">130</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item06d">D.&nbsp;&nbsp;&nbsp;Employees</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06d">133</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item06e">E.&nbsp;&nbsp;&nbsp;Share ownership</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item06e">133</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item07">ITEM 7. MAJOR SHAREHOLDERS AND RELATED-PARTY TRANSACTIONS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item07">133</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item07a">A.&nbsp;&nbsp;&nbsp;Major shareholders</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item07a">133</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item07b">B.&nbsp;&nbsp;&nbsp;Related-party transactions</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item07b">135</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item07c">C.&nbsp;&nbsp;&nbsp;Interests of experts and counsel</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item07c">136</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item08">ITEM 8. FINANCIAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item08">136</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item08a">A.&nbsp;&nbsp;&nbsp;Consolidated statements and other financial information</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item08a">136</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item08b">B.&nbsp;&nbsp;&nbsp;Significant changes</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item08b">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item09">ITEM 9. THE OFFER AND LISTING</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09a">A.&nbsp;&nbsp;&nbsp;Offering and listing details</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09a">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09b">B.&nbsp;&nbsp;&nbsp;Plan of distribution</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09b">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09c">C.&nbsp;&nbsp;&nbsp;Markets</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09c">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09d">D.&nbsp;&nbsp;&nbsp; Selling shareholders</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09d">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09e">E.&nbsp;&nbsp;&nbsp;Dilution</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09e">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item09f">F.&nbsp;&nbsp;&nbsp;Expenses of the issue</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item09f">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item10">ITEM 10. ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10a">A.&nbsp;&nbsp;&nbsp;Share capital</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10a">137</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10b">B.&nbsp;&nbsp;&nbsp;Memorandum and articles of association</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10b">138</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10c">C.&nbsp;&nbsp;&nbsp;Material contracts</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10c">138</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10d">D.&nbsp;&nbsp;&nbsp;Exchange controls</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10d">138</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10e">E.&nbsp;&nbsp;&nbsp;Taxation</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10e">138</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt; width: 93%"><A HREF="#item10f">F.&nbsp;&nbsp;&nbsp;Dividends and paying agents</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt; width: 7%"><A HREF="#item10f">144</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10g">G.&nbsp;&nbsp;&nbsp;Statement by experts</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10g">144</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10h">H.&nbsp;&nbsp;&nbsp;Documents on display</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10h">144</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item10i">I.&nbsp;&nbsp;&nbsp;Subsidiary information</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item10i">144</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item11">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item11">144</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item12">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item12">145</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item12a">A.&nbsp;&nbsp;&nbsp;Debt securities</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item12a">145</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item12b">B.&nbsp;&nbsp;&nbsp;Warrants and rights</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item12b">145</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item12c">C.&nbsp;&nbsp;&nbsp;Other securities</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item12c">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item12d">D.&nbsp;&nbsp;&nbsp;American depositary shares</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item12d">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#part02">PART II</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#part02">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item13">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item13">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item13a">A.&nbsp;&nbsp;&nbsp;Defaults</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item13a">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item13b">B.&nbsp;&nbsp;&nbsp;Arrears and delinquencies</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item13b">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item14">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item14">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item14e">E.&nbsp;&nbsp;&nbsp;Use of proceeds</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item14e">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item15">ITEM 15. CONTROLS AND PROCEDURES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item15">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item15a">A.&nbsp;&nbsp;&nbsp;Disclosure controls and procedures</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item15a">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item15b">B.&nbsp;&nbsp;&nbsp;Management&rsquo;s Annual Report on internal control over financial reporting</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item15b">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item15c">C.&nbsp;&nbsp;&nbsp;Attestation report of the registered public accounting firm</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item15c">146</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 12.25pt"><A HREF="#item15d">D.&nbsp;&nbsp;&nbsp;Changes in internal control over financial reporting</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item15d">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16">ITEM 16. [RESERVED]</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16a">ITEM 16A. Audit committee financial experts</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16a">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16b">ITEM 16B. Code of Ethics</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16b">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16c">ITEM 16C. Principal accountant fees and services</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16c">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16d">ITEM 16D. Exemptions from the listing standards for audit committees</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16d">147</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16e">ITEM 16E. Purchases of equity securities by the issuer and affiliated purchasers</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16e">148</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16f">ITEM 16F. Change in registrant&rsquo;s certifying accountant</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16f">148</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16g">ITEM 16G. Corporate governance</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16g">148</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item16h">ITEM 16H. Mine safety disclosure</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item16h">148</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#part03">PART III</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#part03">149</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item17">ITEM 17. Financial statements</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item17">149</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item18">ITEM 18. Financial statements</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item18">149</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#item19">ITEM 19. Exhibits</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#item19">149</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise indicated or the context
otherwise requires, all references in this annual report on Form 20-F (the &ldquo;Annual Report&rdquo;) to &ldquo;AC Immune&rdquo;
or the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours,&rdquo; &ldquo;us&rdquo; or similar terms refer
to AC Immune SA. The Company owns various registered and unregistered trademarks, for some of which formal protection has been
obtained or is being sought, including Morphomer&trade;, SupraAntigen&trade; and its corporate name, logo and Nasdaq Global Market
symbol. All other trademarks, trade names and service marks of other companies appearing in this Annual Report are the property
of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without
the &trade; symbols, but such references should not be construed as any indicator that their respective owners will not assert,
to the fullest extent under applicable law, their rights thereto. The Company does not intend to use or display other companies&rsquo;
trademarks and/or trade names to imply a relationship with, or endorsement or sponsorship of the Company by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our financial statements are presented
in Swiss Francs and in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting
Standards Board (IASB). None of the financial statements was prepared in accordance with generally accepted accounting principles
in the United States (US). The terms &ldquo;dollar&rdquo; and &ldquo;USD&rdquo; refer to US dollars, and the terms &ldquo;Swiss
Franc&rdquo; and &ldquo;CHF&rdquo; refer to the legal currency of Switzerland, unless otherwise indicated. We have made rounding
adjustments to some of the figures included in this Annual Report. Accordingly, any numerical discrepancies in any table between
totals and sums of the amounts listed are due to rounding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="forwardlooking"></A>FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Annual Report contains statements
that constitute forward-looking statements. All statements other than statements of historical facts contained in this Annual Report,
including statements regarding our future results of operations and financial position, business strategy, product candidates,
product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research
and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations, are
forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use
of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo;
&ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;will&rdquo; and &ldquo;potential,&rdquo; among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Forward-looking statements appear in a
number of places in this Annual Report and include, but are not limited to, statements regarding our intent, belief or current
expectations. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions, and on information currently
available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified
under &ldquo;Item 3. Key information &ndash; D. Risk factors&rdquo; in this Annual Report. These risks and uncertainties include
multiple factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success of our and our collaboration partners&rsquo; clinical studies, and our and their ability to obtain and maintain
regulatory approval and to commercialize ACI-35, semorinemab, Morphomer Tau, ACI-24 for Alzheimer&rsquo;s disease (AD) and for
Down syndrome-related AD (ACI-24 for DS), crenezumab, and PI-2620, our Tau-positron emission tomography (PET) imaging tracer and
to a lesser extent our preclinical candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the preclinical and clinical safety, efficacy and utility of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we
do;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our plans to research, develop and commercialize our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain our current strategic relationships with our collaboration partners;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to protect and maintain our, and not infringe on third parties&rsquo;, intellectual property rights throughout
the world;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to raise capital when needed in order to continue our product development programs or commercialization efforts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to attract and retain qualified employees and key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the acceptance by the Food and Drug Administration (FDA) and applicable foreign regulatory authorities of data from studies
that we and our collaboration partners conduct within and outside the US now and in the future;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our foreign private issuer status, the loss of which would require us to comply with the Exchange Act&rsquo;s domestic reporting
regime, and cause us to incur significant legal, accounting and other expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies
incorporated in the US; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the other risk factors discussed under &ldquo;Item 3. Key information &ndash; D. Risk factors.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These forward-looking statements are applicable
only as of the date of this Annual Report, and are subject to a number of risks, uncertainties and assumptions described under
the sections in this Annual Report entitled &ldquo;Item 3. Key information&mdash;D. Risk factors&rdquo; and &ldquo;Item 5. Operating
and financial review and prospects,&rdquo; and elsewhere in this Annual Report. Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you
should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in
our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in
the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable
law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="part01"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item01"></A>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item01a"></A>A.</TD><TD>Directors and senior management</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item01b"></A>B.</TD><TD>Advisers</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item01c"></A>C.</TD><TD>Auditors</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item02"></A>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item02a"></A>A.</TD><TD>Offer statistics</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item02b"></A>B.</TD><TD>Method and expected timetable</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item03"></A>ITEM 3. KEY INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item03a"></A>A.</TD><TD>Selected Financial Data</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item03b"></A>B.</TD><TD>Capitalization and indebtedness</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item03c"></A>C.</TD><TD>Reasons for the offer and use of proceeds</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item03d"></A>D.</TD><TD>Risk factors</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>You should carefully consider the risks
and uncertainties described below and the other information in this Annual Report before making an investment in our common shares.
Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs,
and as a result, the market price of our common shares could decline and you could lose all or part of your investment. This Annual
Report also contains forward-looking statements that involve risks and uncertainties. See &ldquo;Forward-Looking Statements.&rdquo;
Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result
of certain factors.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>The
below provides a summary of our principal risk factors:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to our business:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We depend heavily on the success of our clinical and, to a lesser extent, preclinical
products: </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD><FONT STYLE="background-color: white">Our ability to generate product revenues, which we do not expect to occur for several
years, will depend on clinical and regulatory success which have low probabilities of success in the central nervous system (CNS)
space in which we operate.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Results of early preclinical and clinical studies may not be predictive of future results:
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #222222">a.</FONT></TD><TD>Products that show positive or timely preclinical or early clinical results may not show sufficient safety or efficacy in later-stage
clinical studies and therefore may fail to obtain regulatory approvals.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #222222">&middot;</FONT></TD><TD>Our products may not gain market acceptance or may be preempted by competitors:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #222222">a.</FONT></TD><TD>Even if our products obtain regulatory approval, they may not be accepted by healthcare providers, patients or the medical
community.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><FONT STYLE="background-color: white">Our success is dependent on the ability to discover, develop and obtain marketing approval
for our products. We face and will continue to face intense competition from a variety of businesses, including large fully integrated
biopharmaceutical and pharmaceutical companies and others that may have greater financial, technical and human resources.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #222222">c.</FONT></TD><TD>A competitor may enter with a generic of an approved innovator product.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We may not be successful in using and expanding our Morphomer and SupraAntigen proprietary
technology platforms.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We operate in highly competitive and rapidly changing industries, which may result in
others discovering, developing or commercializing competing products before or more successfully than we <FONT STYLE="background-color: white">do.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Our future growth and ability to compete depends on retaining our key personnel and recruiting
additional qualified personnel including members of our Executive Committee.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to our relationships with third parties:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">If we fail to maintain, or realize the benefits from, our current strategic relationships
with our current and potential future license and collaboration partners our financial condition may be materially adversely affected.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We may seek to form additional strategic alliances in the future with respect to our
product candidates, and if we do not realize the benefits of such alliances, our business, financial condition, commercialization
prospects and results of operations may be materially adversely affected.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Our collaboration agreements may make us an attractive acquisition target under certain
circumstances.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to intellectual property:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We or our licensing or collaboration partners may not have sufficient patent terms to
protect our products and business effectively which may adversely affect our product sales and technology development.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">If we fail to comply with the obligations to obtain and maintain patent protection such
as compliance with intellectual property agreements, including those under which we license intellectual property and other rights
to or from third parties, or otherwise experience disruptions to our business relationships with our licensees, our licensors and
partners, we could lose intellectual property rights that are important to our business.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We may be subject to claims challenging the inventorship of our patents and other intellectual
property.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to our financial condition and capital requirements:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We are a clinical stage biopharmaceutical company with a history of losses. We anticipate
incurring losses for the foreseeable future. As such, if we fail to obtain additional funding via product revenues, license and
collaboration agreement, equity offerings or other forms of financing, we may need to delay, reduce or eliminate certain of our
product development programs.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to the regulatory environment:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We cannot give any assurance that any of our product candidates will receive regulatory
approval, which is necessary before they can be commercialized. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Even if we obtain regulatory approvals in one jurisdiction, we may not be able to obtain
approval in other jurisdictions. Additionally, we will be subject to ongoing obligations and review which may result in significant
additional expense.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We have conducted and may in the future conduct clinical studies for our drug candidates
outside the US, and the FDA and applicable foreign regulatory authorities may not accept data from such studies.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Enacted and future legislation may increase the difficulty and cost for us to obtain
marketing approval of and commercialize our product candidates and may affect the prices we may set.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"><FONT STYLE="background-color: white"><B>Risks
related to our common shares:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We have limited free float in our common shares which may have a negative impact on the
liquidity and market price of our common shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">Certain of our existing shareholders exercise significant control over us, and your or
other shareholders&rsquo; interests may conflict with the interests of our existing shareholders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We are a Swiss corporation. The rights of our shareholders may be different from the
rights of shareholders in companies governed by the laws of US jurisdictions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">We are a foreign private issuer (FPI) and, as a result, we are not subject to US proxy
rules and are subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those
of a US domestic public company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="background-color: white">As an FPI and as permitted by the listing requirements of Nasdaq, we rely on certain
home country governance practices rather than the corporate governance requirements of Nasdaq. Should we lose our FPI status, we
would be required to comply with the Exchange Act&rsquo;s domestic reporting regime, which would cause us to incur significant
legal, accounting and other expenses.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="color: #222222; background-color: white">We believe that it is likely that we were a &ldquo;passive foreign investment
company,&rdquo; (PFIC) for US federal income tax purposes in 2020, and may also be a PFIC in 2021 or later years. If we were a
PFIC in 2020 or are a PFIC in 2021 or any later year, US shareholders could be subject to adverse US federal income tax consequences.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to our business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We depend heavily on the success of our clinical
and, to a lesser extent, preclinical products. Our clinical product candidates include ACI-35, semorinemab, Morphomer Tau, ACI-24
for AD and for DS, crenezumab and PI-2620. If our clinical studies are unsuccessful, if we or our collaboration partners do not
obtain regulatory approval or if we or our collaboration partners are unable to commercialize ACI-35, semorinemab, Morphomer Tau,
ACI-24 for AD and for DS, crenezumab and PI-2620, or if we experience significant delays in doing so, our business, financial condition
and results of operations will be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently have no products approved
for sale and have invested a significant portion of our efforts and financial resources in the development of ACI-35, semorinemab,
Morphomer Tau, ACI-24 for AD and for DS, crenezumab and PI-2620, all of which are in clinical development as well as other preclinical
candidates. Our ability to generate product revenues, which we do not expect will occur for at least the next several years, if
ever, will depend heavily on successful clinical development, obtaining regulatory approval and eventual commercialization of
these product candidates. In this regard, we rely heavily on our collaboration partners for clinical development of certain of
our product candidates, and they may choose to discontinue the clinical development process in certain cases. For example, in
January 2019, Roche, the parent of our collaboration partner, discontinued the CREAD and CREAD 2 Phase 3 studies of crenezumab
in patients with prodromal-to-mild sporadic AD. The decision came after an interim analysis was conducted by the Independent Data
Monitoring Committee (IDMC). The IDMC analysis indicated that crenezumab was unlikely to meet its primary endpoint of change from
baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score. However, the Phase 2 development of crenezumab continues in
a preventive trial in Colombia of cognitively healthy individuals with a risk of developing AD. In addition, we currently generate
no revenues from sales of any drugs or diagnostics, and we may never be able to develop or commercialize a marketable drug or
diagnostic. The success of our current and future product candidates will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>completing preclinical and clinical studies that demonstrate the efficacy, safety and clinical utility of our preclinical and
product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>receiving marketing approvals from applicable regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establishing commercial manufacturing capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>launching commercial sales, marketing and distribution operations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>acceptance of our product candidates by patients, the medical community and third-party payors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued acceptable safety profile following approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competing effectively with other therapies or diagnostic approaches; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining, maintaining, enforcing and defending our intellectual property rights and claims and not infringing on third parties&rsquo;
intellectual property rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we or our collaboration partners do
not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully commercialize our current or future product candidates, which would materially adversely affect our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Results of early clinical studies may not be
predictive of future study results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Positive or timely results from preclinical
or early-stage clinical studies do not ensure positive or timely results in late-stage clinical studies or product approval by
the US FDA, the European Medicines Agency (EMA), or comparable foreign regulatory authorities. Products that show positive preclinical
or early clinical results may not show sufficient safety or efficacy in later-stage clinical studies and therefore may fail to
obtain regulatory approvals. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses.
Many companies that believed their product candidates performed satisfactorily in preclinical and clinical studies have nonetheless
failed to obtain marketing approval for the product candidates. The FDA, the EMA and comparable foreign regulatory authorities
have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained for
any of our product candidates. Even if we believe that the data collected from clinical studies of our product candidates are promising,
such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In some instances, there can be significant
variability in safety and/or efficacy results between different studies of the same product candidate due to numerous factors,
including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, adherence
to the dosing regimen and other study protocols, and the rate of dropout among clinical study participants. In the case of our
later-stage clinical product candidates, results may differ in general on the basis of the larger number of clinical study sites
and the additional countries and languages involved in these clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical studies may include subject-reported
outcomes, some of which may be captured with electronic diaries. We have no assurance and cannot rely on past experience that the
high frequency of questioning is not influencing the measured outcome. In addition, low compliance with daily reporting requirements
may impact the studies&rsquo; validity or statistical power. We cannot assure you that any Phase 2, Phase 3 or other clinical studies
that either we or our collaboration partners may conduct will demonstrate consistent or adequate efficacy and safety to obtain
regulatory approval to market our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we or our collaboration partners are
required to conduct additional clinical studies or other testing of any of our current or future product candidates that we or
our collaboration partners develop, beyond the studies and testing that we or our collaboration partners contemplate, if we or
our collaboration partners are unable to successfully complete clinical studies of our product candidates or other testing, if
the results of these studies or tests are unfavorable or are only modestly favorable, or if there are safety concerns associated
with our current or future product candidates, we may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>be delayed in obtaining marketing approval for our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>not obtain marketing approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain approval for indications or patient populations that are not as broad as intended or desired;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including
boxed warnings;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>be subject to conditional approval or otherwise to additional post-marketing studies or other requirements; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>remove the product from the market after obtaining marketing approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt">Our product development costs will also
increase if we experience delays in testing or receiving marketing approvals and we may be required to obtain additional funds
to complete clinical studies. We cannot assure you that our clinical studies will begin as planned or be completed on schedule,
if at all, or that we will not need to amend our studies after they have begun. Significant clinical study delays could also shorten
any periods during which we or our collaboration partners may have the exclusive right to commercialize our product candidates,
or allow our competitors to bring products to market before we do, which may harm our business and results of operations. In addition,
some of the factors that cause, or lead to, clinical study delays may ultimately lead to the denial of regulatory approval of our
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Additional competitors could enter the market
with generic versions of our products, which may result in a material decline in sales of affected products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Drug Price Competition and Patent
Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application
(ANDA), seeking approval of a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">generic
copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application (NDA)
under Section 505(b)(2) that references the FDA&rsquo;s prior approval of the innovator product. A 505(b)(2) NDA product may be
submitted for a new or improved version of the original innovator product. Hatch-Waxman also provides for certain periods of regulatory
exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and reviewing) of an ANDA or 505(b)(2) NDA. These
include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan-drug exclusivity. In
addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product
formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &ldquo;Approved Drug
Products with Therapeutic Equivalence Evaluations,&rdquo; known as the &ldquo;Orange Book.&rdquo; If there are patents listed
in the Orange Book, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include
in the ANDA what is known as a &ldquo;Paragraph IV certification,&rdquo; challenging the validity or enforceability of, or claiming
non-infringement of, the listed patent or patents. Notice of the certification must also be given to the innovator, and if within
45 days of receiving notice the innovator, in order to protect its patents, sues the company that manufactures the generic, approval
of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accordingly, if ACI-35, semorinemab, Morphomer
Tau, ACI-24 for AD and for DS, crenezumab and PI-2620 are approved, competitors could file ANDAs for generic versions of ACI-35,
semorinemab, Morphomer Tau, ACI-24 for AD and for DS, crenezumab and PI-2620 or 505(b) (2) NDAs that reference ACI-35, semorinemab,
Morphomer Tau, ACI-24 for AD and for DS, crenezumab and PI-2620, respectively. If there are patents listed in the Orange Book for
ACI-35, semorinemab, Morphomer Tau, ACI-24 for AD and for DS, crenezumab and PI-2620, respectively, those ANDAs and 505(b) (2)
NDAs would be required to include a certification for each listed patent, indicating whether the ANDA applicant does or does not
intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible
for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents
or the outcome of any such suit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be successful in securing or
maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any patents that are
granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation,
the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. Should
sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product, and our
results of operations and cash flows could be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>The successful commercialization of our product
candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage
and reimbursement levels and pricing policies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The successful commercialization of our
product candidates will depend, in part, on the extent to which coverage and reimbursement for our products will be available from
government and health administration authorities, private health insurers and other third-party payors. To manage healthcare costs,
many governments and third-party payors increasingly scrutinize the pricing of new technologies and require greater levels of evidence
of favorable clinical outcomes and cost-effectiveness before extending coverage. In light of such challenges to prices and the
requirement for increasing levels of evidence of the benefits and clinical outcomes of new technologies, we cannot be sure that
coverage will be available for any of our current or future product candidates that we or our collaboration partners will commercialize
or, if available, that the reimbursement rates will be adequate in each respective region. If we are unable to obtain adequate
levels of coverage and reimbursement for our product candidates, their marketability will be negatively and materially impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Third-party payors may deny coverage and
reimbursement status altogether for a given drug product, or may cover the product but also establish prices at levels that are
too low to enable us to realize an appropriate return on our investment in product development. Because the rules and regulations
regarding coverage and reimbursement change frequently, in some cases at short notice, even when there is favorable coverage and
reimbursement, future changes may occur that adversely impact the favorable status. Further, the net reimbursement for drug products
may be subject to additional reductions in the future depending on policy changes enacted by the US Congress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The unavailability or inadequacy and variability
of third-party coverage and reimbursement could have a material adverse effect on the market acceptance of our product candidates
and the future revenues we may expect to receive from those products. In addition, we are unable to predict what additional legislation
or regulation relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future, or what
effect such legislation or regulation would have on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our products may not gain market acceptance,
in which case we or our collaboration partners may not be able to generate product revenues, which will materially adversely affect
our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even if the FDA, the EMA or any other regulatory
authority approves the marketing of any product candidates that we develop, physicians, healthcare providers, patients or the medical
community may not accept or use them. Efforts to educate the medical community and third-party payors on the benefits of our product
candidates may require significant resources and may not be successful. If any of our current or future product candidates does
not achieve an adequate level of acceptance, we or our collaboration partners may not generate significant product or royalty revenues
or any profits from operations. The degree of market acceptance of our product candidates that are approved for commercial sale
will depend on a variety of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>how clinicians and potential patients perceive our novel products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing of market introduction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number and clinical profile of competing products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to provide acceptable evidence of safety and efficacy or clinical utility;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence and severity of any side effects;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>relative convenience and ease of administration;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>cost-effectiveness;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patient diagnostics and screening infrastructure in each market;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>marketing and distribution support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third-party payors,
both public and private; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other potential advantages over alternative treatment methods.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If our product candidates fail to gain
market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any,
return on our investments. Even if some products achieve market acceptance, the market may prove to not be large enough to allow
us to generate significant revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the potential market opportunity
of our product candidates is difficult to estimate precisely. Our estimates of the potential market opportunity are predicated
on several key assumptions such as industry knowledge and publications, third-party research reports and other surveys. These assumptions
involve the exercise of significant judgment on the part of our management and are inherently uncertain, and the reasonableness
of these assumptions could not have been assessed by an independent source in every detail. If any of the assumptions proves to
be inaccurate, then the actual market for our product candidates could be smaller than our estimates of the potential market opportunity.
If the actual market for our product candidates is smaller than we expect, or if any approved products fail to achieve an adequate
level of acceptance by physicians, healthcare payors and patients, our product or royalty revenue may be limited and it may be
more difficult for us to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We depend on enrollment of patients in our
clinical studies for our product candidates. If we are unable to enroll patients in our clinical studies, our research and development
efforts could be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Successful and timely completion of clinical
studies will require that we enroll a sufficient number of patient candidates. Studies may be subject to delays as a result of
patient enrollment taking longer than anticipated or by patient withdrawal. Patient enrollment depends on many factors, including
the size and nature of the patient population, the eligibility criteria for the study, the proximity of patients to clinical sites,
the design of the clinical protocol, the existence of competing clinical studies, the availability of new drugs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">approved
for the indication the clinical study is investigating, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential
advantages of the drug being studied in relation to other available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Generally, the specific target population
of patients and therapeutic time windows may make it difficult for us to enroll enough patients to complete clinical studies for
our products in a timely and cost-effective manner. Delays in the completion of any clinical study of our product candidates will
increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our or
our collaboration partners&rsquo; ability to commence product sales and generate revenue. In addition, many of the factors that
cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If serious adverse, undesirable or unacceptable
side effects are identified during the development of our product candidates or following approval, if any, we may need to abandon
our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to
other significant negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If our product candidates are associated
with serious adverse, undesirable or unacceptable side effects, we may need to abandon their development or limit development to
certain uses or subpopulations in which such side effects are less prevalent, less severe or more acceptable from a risk&ndash;benefit
perspective. Many compounds that initially showed promise in preclinical or early-stage testing were later found to cause side
effects that restricted their use and prevented further development of the compound for larger indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Occurrence of serious procedure- or treatment-related
side effects could impede clinical study enrollment and receipt of marketing approval from the FDA, the EMA and comparable foreign
regulatory authorities. Adverse events (AEs) could also adversely affect physician or patient acceptance of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, if one or more of our product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number
of potentially significant negative consequences could result, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may withdraw approvals of such product and require us or our collaboration partners to take any approved
products off the market;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts
to physicians and pharmacies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be required to change the way the product is administered, to conduct additional studies or to change the labeling of
the product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we or our collaboration partners may be subject to limitations in how we promote the product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sales of the product may decrease significantly;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we could be sued and held liable for harm caused to patients; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our reputation and physician or patient acceptance of our products may suffer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of these events could prevent us from achieving or maintaining
market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We operate in highly competitive and rapidly
changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully
than we do.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The biopharmaceutical and pharmaceutical
industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on
our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to
market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including
large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">companies,
academic institutions, government agencies and other private and public research institutions in Europe, the US and other jurisdictions.
Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and
human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining
FDA and other regulatory approvals of treatments, and the commercialization of those treatments. Mergers and acquisitions in the
pharmaceutical and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of
our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The highly competitive nature of and rapid
technological changes in the pharmaceutical and biopharmaceutical industries could render our product candidates or our technology
obsolete or noncompetitive. The commercial opportunity for our products could be reduced or eliminated if our competitors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>develop and commercialize products that are safer, more effective, less expensive, or more convenient or easier to administer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain quicker FDA or other regulatory approval for their products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish superior intellectual property and proprietary positions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>have access to more manufacturing capacity;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>implement more effective approaches to sales, marketing and distribution; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>form more advantageous strategic alliances.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Should any of these occur, our business,
financial condition and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that our key competitor product
candidates are (i) gosuranemab (Biogen), tilavonemab (AbbVie), zagotenemab (Eli Lilly and Company) and bepranemab (UCB/Roche) for
semorinemab; (ii) AADvac1 (Axon Neuroscience) for ACI-35; (iii) UB-311 (Vaxxinity) and ABvac40 (Araclon Biotech) for ACI-24; (iv)
aducanumab (Biogen), gantenerumab (Roche), lecanemab (BioArctic/Eisai) and solanezumab (Eli Lilly and Company) for crenezumab;
and (v) Tauvid (Eli Lilly and Company), APN-1607 (Aprinoia Therapeutics), MK-6240 (Cerveau/Merck), GTP1 (Genentech) and THK-5351
(GE Healthcare) for PI-2620, as described under &ldquo;Item 4. Information on the Company &ndash; B. Business overview &ndash;
Competition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may not be successful in our efforts to
use and expand our Morphomer and SupraAntigen proprietary technology platforms to build additional product candidates for our pipeline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A key element of our strategy is to use
and expand our Morphomer and SupraAntigen proprietary technology platforms to create unique therapies and diagnostics for conformational
diseases, such as AD, and progress these product candidates through clinical development. Although our research and development
efforts to date have resulted in a pipeline of product candidates, we may not be able in the future to develop product candidates
that are safe and effective. Even if we are successful in continuing to build our pipelines, the potential product candidates that
we identify may not be suitable for clinical development, potentially as a result of having harmful side effects or other characteristics
indicating they may be unlikely to receive marketing approval and achieve market acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our business is subject to economic, political,
regulatory and other risks associated with international operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business is subject to risks associated
with conducting business internationally. We and a number of our suppliers and collaborative and clinical study relationships are
located outside the US. Accordingly, our future results could be harmed by a variety of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>economic weakness, including inflation, or political instability in particular non-US economies and markets;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>differing regulatory requirements for drug approvals in non-US countries;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potentially reduced protection for intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>difficulties in compliance with non-US laws and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in non-US regulations and customs, tariffs and trade barriers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in non-US currency exchange rates and currency controls;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in a specific country&rsquo;s or region&rsquo;s political or economic environment;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>trade protection measures, import or export licensing requirements or other restrictive actions such as sanctions by US or
non-US governments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negative consequences from changes in tax laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>workforce uncertainty in countries where labor unrest is more common than in the US;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>difficulties associated with staffing and managing international operations, including differing labor relations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes,
typhoons, floods and fires.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Covid-19 pandemic has adversely
impacted, and may continue to impact, our business, including preclinical and clinical trials and regulatory approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">In December 2019, a novel strain of coronavirus,
Covid-19, surfaced in Wuhan, Hubei Province, China. By March 2020, Covid-19 had spread to other countries, including Switzerland
and the United States, and was declared a pandemic by the World Health Organization on March 11, 2020. Since the beginning of the
pandemic, governments, public institutions, and other organizations in countries and localities where Covid-19 cases have been
identified are taking certain preventative or protective measures to combat the transmission of the virus, including implementation
of travel restrictions or bans, closures of non-essential businesses, limitations of public gatherings, other social distancing
and shelter-in-place measures, and delays or cancellations of elective surgeries. The Covid-19 pandemic poses the risk that the
Company, our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an
indefinite period of time due to shutdowns that may be requested or mandated by state and federal governmental authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">As Covid-19 continues to spread around
the globe, we have experienced disruptions impacting our business and clinical trials and we may continue to experience disruptions
that could materially impact our business and planned clinical trials, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays or difficulties in conducting preclinical research and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interruption in global manufacturing and shipping that may affect the manufacturing and/or transport of clinical trial materials
and other materials, including testing equipment and personal protective equipment, used at our or our contract research organizations&rsquo;
(CROs&rsquo;) and contract manufacturing organizations&rsquo; (CMOs&rsquo;) facilities;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in local regulations as part of a response to the Covid-19 coronavirus outbreak which may require us to change the
way in which clinical trials are conducted and may result in unexpected costs; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>impact our ability to secure additional financing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the outbreak of Covid-19 could
disrupt our operations due to absenteeism by infected or ill members of Executive Management or other employees, or absenteeism
by members of Executive Management and other employees who elect not to come to work due to the illness affecting others in our
office or laboratory facilities, or due to quarantines. Covid-19 illness could also impact members of our Board and its ability
to hold meetings. Further information concerning details of the impact of Covid-19 on our programs can be found under &ldquo;Item
5: Operating and financial review and prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We have no history of commercializing biologics
or pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We began our operations in 2003. Our operations
to date have been limited to financing and staffing our company, developing our technology and developing our product candidates
as well as early-stage clinical trials. We have not yet demonstrated an ability to successfully complete a large-scale, pivotal
clinical study, obtain marketing approval, manufacture a commercial-scale product, or conduct sales and marketing activities necessary
for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate
as they could be if we had a history of successfully developing and commercializing biologics or pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our future growth and ability to compete depends
on retaining our key personnel and recruiting additional qualified personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our success depends upon the continued
contributions of our key management, scientific and technical personnel, many of whom have substantial experience with or been
instrumental for us and our projects. Members of our key management include Dr. Andrea Pfeifer, our Chief Executive Officer; Dr.
Marie Kosco-Vilbois, our Chief Scientific Officer; Dr. Johannes Rolf Streffer, our Chief Medical Officer; Piergiorgio Donati,
our Chief Technical Operations Officer; Joerg Hornstein, our Chief Financial Officer; Jean-Fabien Monin, our Chief Administrative
Officer; Dr. Julien Rong&egrave;re, our Vice President (VP) for Regulatory Affairs and Quality Assurance; Dr. Olivier Sol, our
Associate Vice President Medical Sciences and Clinical Operations; Dr. Bojana Portmann, our Associate Vice President for Intellectual
Property and Business Development (AVP IP); Alexandre Caratsch, our General Counsel; and Mark Danton, our VP Information Systems,
Security and Digital Technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The loss of our key managers and senior
scientists could delay our research and development activities. Laws and regulations on executive compensation, including legislation
in our home country, Switzerland, may restrict our ability to attract, motivate and retain the required level of qualified personnel.
In Switzerland, legislation affecting public companies has been passed that, among other things, imposes an annual binding shareholder&rsquo;s
&ldquo;say on pay&rdquo; vote with respect to the compensation of executive management, including executive officers and the board
of directors, and prohibits severance or similar payment, bonuses for company purchases and sales, and additional contracts as
consultants to or employees of other companies in the group. In addition, the competition for qualified personnel in the pharmaceutical
and biopharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly
skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public
and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future,
it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt"><B><I>We may become exposed to costly and damaging
liability claims, either when testing our product candidates in the clinic or at the commercial stage or as a result of claims
against our directors and officers; and our liability insurance may not cover all damages from such claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are exposed to potential product liability
and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical
or biopharmaceutical products. Currently we have no products that have been approved for commercial sale; however, our current
and future use of product candidates in clinical studies, and the sale of any approved products in the future, may expose us to
liability claims. These claims might be made by patients that use the product, by healthcare providers, or by pharmaceutical or
biopharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult
and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although the clinical study process is
designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may
exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical studies or
after approval of the product candidate,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">we
may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential
adverse effects and patients who should not use our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We purchase liability insurance in connection
with the clinical studies that we undertake and for purposes of indemnifying our directors and officers for claims against them
in amounts that we consider to be consistent with industry norms. It is possible that our liabilities could exceed our insurance
coverage. For example, we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing
approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or
obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful liability claim or series
of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient
to cover such claims and our business operations could be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Should any of the events described above
occur, this could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may seek to obtain orphan-drug designation
for certain of our product candidates. Orphan-drug designation may not ensure that we will enjoy market exclusivity in a particular
market, and if we fail to obtain or maintain orphan-drug exclusivity for such product candidates, we may be subject to earlier
competition and our potential revenue will be reduced.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Orphan Drug Act, the FDA may
designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population
of fewer than 200,000 in the US, or a patient population greater than 200,000 in the US where there is no reasonable expectation
that the cost of developing the drug will be recovered from sales in the US. In the European Union (EU), the EMA&rsquo;s Committee
for Orphan Medicinal Products grants orphan-drug designation to promote the development of products that meet the following criteria:
a) they are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting
not more than 5 in 10,000 persons in the EU or for products that are intended for the diagnosis, prevention or treatment of a
life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales
of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product; and
b) there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of
significant benefit to those affected by the condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the US, orphan-drug designation entitles
a party to financial incentives such as opportunities for grant funding toward clinical study costs, tax advantages and user-fee
waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the
product is entitled to orphan-drug exclusivity, which means that the FDA cannot approve any other application to market the same
drug for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority
over the product with orphan exclusivity or if the manufacturer is unable to assure sufficient product quantity. In the EU, orphan-drug
designation entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity
for the orphan indication following drug or biological product approval, provided that the criteria for orphan designation are
still applicable at the time of the granting of the marketing authorization. This period may be reduced to 6 years if at the end
of the fifth year, the orphan-drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be able to obtain orphan-drug
designation for any of our product candidates, and even if we do, we may not be the first to obtain marketing approval for any
particular orphan indication due to the uncertainties associated with developing pharmaceutical or biopharmaceutical products.
Further, even if we obtain orphan-drug designation for a product, that exclusivity may not effectively protect the product from
competition because different drugs with different active moieties can be approved for the same condition. Orphan-drug designation
neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review
or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Due to our limited resources and access to
capital, we must prioritize development of certain product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because we have limited resources and access
to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to
each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular
compounds, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert
resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">with
third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable
opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends
in the pharmaceutical or biopharmaceutical industry, in particular for neurological disorders, our business, financial condition
and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our research and development activities could
be affected or delayed as a result of possible restrictions on animal testing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain laws and regulations require us
to test our product candidates on animals before initiating clinical studies in humans. Animal testing activities have been the
subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop
animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through
protests and other means. To the extent that the activities of these groups are successful, our research and development activities
may be interrupted, delayed or become more expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt"><B><I>A breakdown or breach of our information
technology systems and cybersecurity efforts, or those of our key business partners, CROs or service providers, could subject us
to liability or reputational damage or interrupt the operation of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Despite the implementation of security
measures, our internal computer systems and those of our CROs and other contractors and consultants may be vulnerable to damage
from computer viruses and unauthorized access. If such an event were to occur and cause interruptions in our operations, it could
result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial
data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for
research and development of our product candidates and on other third parties for the manufacture of our product candidates and
to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on
our business. Our ability to monitor our CROs&rsquo;, contractors&rsquo; and consultants&rsquo; data security practices are limited,
and due to applicable laws and regulations or contractual obligations, we may be held responsible for any security breaches or
cybersecurity attack attributed to them as they relate to the information we share with them. To the extent that any disruption
or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential
or proprietary information or personal data of our employees, partners or study subjects, we could incur liability and the further
development and commercialization of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are increasingly dependent upon technology
systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making
them potentially vulnerable to breakdown, malicious intrusion and random attack.&nbsp;Data privacy or security breaches, including
those by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual
property, trade secrets or personal information belonging to us, our patients, study subjects or other business partners, may be
exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity,
and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent
actors, including nation states, organized crime groups, &ldquo;hacktivists&rdquo; and employees or contractors acting with malicious
intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack,
a malicious website, phishing attacks, computer viruses, social engineering and other means to affect the confidentiality, integrity
and availability of our technology systems and data. Our key business partners, CROs and service providers face similar risks and
any security breach of their systems could adversely affect our security posture. Although we continue to build and improve our
systems and infrastructure, and believe we have taken appropriate security measures to reduce these risks to our data and information
technology systems, there can be no assurance that our efforts will prevent, detect or appropriately respond to breakdowns or breaches
in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information,
including personal information, which could result in financial, legal, business or reputational harm to us. We continue to invest
in industry standard IS/IT solutions and managed services that often include the relevant, layered protection and monitoring practices
surrounding our data and IT systems and related infrastructure. These investments reduce further these risks in that they enable
organizations such as ours to leverage the resources necessary to monitor IT systems and infrastructure for any current or potential
threats. These investments are costly, and as cyber threats continue to evolve, we may be required to expend significant, additional
resources to continue to modify and/or enhance our protective, detective and responsive measures required to remediate any identified
information security vulnerabilities. In addition, our liability insurance may</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">not
be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.
We may be required to expend significant capital and other resources to protect against and respond to any attempted or existing
cybersecurity incidents. In addition, our remediation efforts may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Changes in laws, rules or regulations
relating to data privacy and security, or any actual or perceived failure by us to comply with such laws, rules, regulations and
standards, or contractual or other obligations relating to data privacy and security, could have a material adverse effect on our
reputation, results of operations, financial condition and cash flows.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are, and may increasingly become, subject
to various laws, rules, regulations and standards, as well as contractual obligations, relating to data privacy and security in
the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous,
with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain
for the foreseeable future. These laws, rules, regulations and standards may be interpreted and applied differently over time
and from jurisdiction to jurisdiction in a manner that could have a material adverse effect on our results of operations, financial
condition and cash flows. New laws, amendments to or reinterpretations of existing laws, rules, regulations, standards and other
obligations may require us to incur additional costs and restrict our business operations, and may require us to change how we
use, collect, store, transfer or otherwise process certain types of personal information and to implement new processes to comply
with those laws. There are numerous US federal and state laws and regulations related to the privacy and security of personal
information. Regulations promulgated pursuant to the US Health Insurance Portability and Accountability Act of 1996 (HIPAA) establish
privacy and security standards that limit the use and disclosure of protected health information, and require the implementation
of administrative, physical and technological safeguards to protect the privacy of protected health information and to ensure
the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health
information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and
may be subject to changing interpretation. Numerous states have enacted or are in the process of enacting state level data privacy
laws and regulations governing the collection, use, and other processing of state residents&rsquo; personal information, such
as the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020 and provides new and enhanced data privacy
rights to California residents, such as affording California residents the right to access and delete their information and to
opt out of certain sharing and sales of personal information, and the California Privacy Rights Act of 2020 (CPRA), which is effective
in most material respects starting on January 1, 2023 and imposes additional obligations on covered companies and will significantly
modify the CCPA. In addition, laws in all 50 states require businesses to provide notice to individuals whose personal information
has been disclosed as a result of a data breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of these evolving compliance and operational
requirements impose significant costs, which are likely to increase over time. In addition, such requirements may require us to
modify our data-processing practices and policies, distract management or divert resources from other initiatives and projects.
For instance, the European Union Court of Justice and the Swiss Data Protection Authority have declared the US Privacy Shield to
be inadequate for transfers of personal data out of the EU and Switzerland, which could increase our compliance burden. If we are
unable to properly protect the privacy and security of personal information, including protected health information, we could be
found to have breached our contracts. In addition, any failure or perceived failure by us to comply with any applicable federal,
state or similar foreign laws and regulations relating to data privacy and security could result in damage to our reputation and
our relationship with our customers, as well as proceedings or litigation by governmental agencies, customers, partners, collaborators
and/or study subjects, including class action privacy litigation in certain jurisdictions, which would subject us to significant
fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, results of
operations, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Business disruptions could seriously
harm our future revenue and financial condition and increase our costs and expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our operations, and those of our third-party
research institution collaborators, CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes,
power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions,
medical epidemics, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition,
we rely on our third-party research institution collaborators for conducting research and development of our product candidates,
and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could
seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers
to produce and process our product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">candidates.
Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are
affected by a man-made or natural disaster or by other business interruption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of our operations including our corporate
headquarters are located in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Damage or extended periods of interruption to
our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized
entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain
property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under
such circumstances and our business may be seriously harmed by such delays and interruption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We have never commercialized a product candidate
before and may lack the necessary expertise, personnel and resources to successfully commercialize our products on our own or together
with suitable partners.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have never commercialized a product
candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for our
product candidates, we will have to develop our own sales, marketing and supply organization or outsource these activities to third
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Factors that may affect our ability to
commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing
personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our drug candidates, and other unforeseen
costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization requires
significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an
effective sales and marketing organization. In addition, successful commercialization also requires an enhanced regulatory organization
which we currently do not have. If we are unable to build our own distribution and marketing capabilities, are unable to find suitable
partners for the commercialization of our product candidates or do not successfully obtain the necessary regulatory capabilities,
we may not generate revenues from them or be able to reach or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to our relationships with third parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we fail to maintain our current strategic
relationships with Genentech, a member of the Roche Group, Eli Lilly and Company (Lilly), Janssen Pharmaceuticals Inc. (Janssen),
Life Molecular Imaging SA (LMI) (formerly Piramal Imaging SA) and other of our current or future strategic partners, our business,
commercialization prospects and financial condition may be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have two partnerships with Genentech.
In 2006, we granted Genentech an exclusive, worldwide license for crenezumab. In 2012, we entered into a second partnership to
commercialize anti-Tau antibodies for use as immunotherapies. In December 2018, we signed a license agreement with Lilly to research
and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. This collaboration commenced
in Q1 2019. We are in a partnership with Janssen to develop and commercialize therapeutic anti-Tau vaccines for the treatment of
AD and potentially other Tauopathies. We also have a diagnostic partnership with LMI for one of our compounds from our Morphomer
chemical library, which bind pathological Tau for use as a PET tracer. Our collaboration partners each have the right to terminate
their agreements with us for any reason upon providing us with a certain notice period. If Genentech, Lilly, Janssen, LMI or other
of our current or future strategic partners terminates its agreement with us at any time, it could delay or prevent development
of our product candidates and materially harm our business, financial condition, commercialization prospects and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Good relationships with Genentech, Lilly,
Janssen, LMI and other of our current or future strategic partners are important for our business prospects. If our relationships
with Genentech, Lilly, Janssen, LMI or other of our current or future strategic partners were to deteriorate substantially or if
Genentech, Lilly, Janssen, LMI or other of our current or future strategic partners were to challenge our use of their intellectual
property or our calculations of the payments we are owed under our agreements, our business, financial condition, commercialization
prospects and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Lastly, our collaboration agreements with
Genentech, Lilly, Janssen and LMI provide each partner with control over, and responsibility for, the clinical development process,
including obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Our other existing collaboration
agreements provide our collaboration partners with similar control over the clinical development process, and future collaboration
agreements may also relinquish development control to our partners. Genentech or our other current or future collaboration partners
may and do separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases
targeted by us or our collaborative efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Even
if our partners continue their contributions to the collaborative agreements to which we are a party, they may nevertheless determine
not to actively pursue the development or commercialization of any resulting products. Our partners may also fail to perform their
obligations under the collaboration agreements or may be slow in performing their obligations. Any of these circumstances could
result in a material adverse impact on our business, financial condition, commercialization prospects or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may seek to form additional strategic alliances
in the future with respect to our product candidates, and if we do not realize the benefits of such alliances, our business, financial
condition, commercialization prospects and results of operations may be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our product development programs and the
potential commercialization of our product candidates will require substantial additional liquidity to fund expenses and may require
expertise, such as sales and marketing expertise, which we do not currently possess. Therefore, in addition to our relationships
with Genentech, Lilly, Janssen and LMI, we may decide to enter into strategic alliances or to create joint ventures or collaborations
with pharmaceutical or biopharmaceutical companies for the further development and potential commercialization of those and other
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We face significant competition in seeking
appropriate collaborators. Collaborations are complex and time-consuming to negotiate, document and manage. Any delays in entering
into new strategic partnership agreements related to our product candidates could delay the development and commercialization
of our product candidates and reduce their competitiveness even if they reach the market. We may also be restricted under existing
and future collaboration agreements from entering into strategic partnerships or collaboration agreements on certain terms with
other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all, for any of our existing
or future product candidates and programs because the potential partner may consider that our research and development pipeline
is insufficiently developed to justify a collaborative effort, or that our product candidates and programs do not have the requisite
potential to demonstrate safety and efficacy in the target population. If we are unsuccessful in establishing and maintaining
a collaboration with respect to a particular product candidate, we may have to curtail the development of that product candidate,
reduce the scope of or delay its development program or one or more of our other development programs, delay its potential commercialization
or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense, for which we have not budgeted. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable
terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate
product revenue. Even if we are successful in establishing a new strategic partnership or entering into a collaboration agreement,
we cannot be certain that, following such a strategic transaction or license, we will be able to progress the development and
commercialization of the applicable product candidates as envisaged, or that we will achieve the revenues that would justify such
transaction, and we could be subject to the following risks, each of which may materially harm our business, commercialization
prospects and financial condition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may not be able to control the amount and timing of resources that the collaboration partner devotes to the product development
program;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the collaboration partner may experience financial difficulties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be required to grant or otherwise relinquish important rights such as marketing, distribution and intellectual property
rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a collaboration partner could move forward with a competing product developed either independently or in collaboration with
third parties, including our competitors; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>business combinations or significant changes in a collaboration partner&rsquo;s business strategy may adversely affect our
willingness to continue any arrangement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We rely on third parties to conduct our nonclinical
and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties,
meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates, and our business could be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have relied upon and plan to continue
to rely upon third-party clinical CROs, to monitor and manage data for our ongoing nonclinical and clinical programs, including
the clinical studies of our product candidates. We rely on these parties for execution of our nonclinical and clinical studies
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is
conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the clinical
CROs does not relieve us of our regulatory responsibilities. We and our clinical CROs and other vendors are required to comply
with current Good Manufacturing Practice (cGMP), current Good Clinical Practice (cGCP), and current Good Laboratory Practice (cGLP),
which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EU and comparable
foreign regulatory authorities for our product candidates in nonclinical and clinical development (where applicable). Regulatory
authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and
other contractors. If we or any of our clinical CROs or vendors fail to comply with applicable regulations, the data generated
in our nonclinical and clinical studies may be deemed unreliable and the EMA, FDA, other regulatory authorities may require us
to perform additional nonclinical and clinical studies before approving our marketing applications. We cannot assure you that upon
inspection by a given regulatory authority, such regulatory authority will determine that all of our clinical studies comply with
cGCP regulations. In addition, our clinical studies must be conducted with products produced under cGMP regulations. Our failure
to comply with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any of our relationships with these
third-party clinical CROs terminates, we may not be able to enter into arrangements with alternative clinical CROs or do so on
commercially reasonable terms. In addition, our clinical CROs are not our employees, and except for remedies available to us under
our agreements with such clinical CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing
nonclinical and clinical programs. If clinical CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their
failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical studies may be extended, delayed,
or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Clinical
CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our
product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Switching or adding additional clinical
CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a
new clinical CROs commences work. As a result, delays occur, which could materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our clinical CROs, there can be no assurance that we will
not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact
on our business, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We currently rely on third-party suppliers
and other third parties for production of our product candidates and our dependence on these third parties may impair the advancement
of our research and development programs and the development of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently rely on and expect to continue
to rely, on third parties for the manufacturing and supply of chemical and biological compounds and formulations for the clinical
studies of our current and future product candidates. For the foreseeable future, we expect to continue to rely on such third parties
for the manufacture of any of our product candidates on a clinical or commercial scale, if any of our product candidates receives
regulatory approval. Reliance on third-party providers may expose us to different risks than if we were to manufacture product
candidates ourselves. The facilities used by our contract manufacturers to manufacture our product candidates must be approved
by the FDA or other regulatory authorities, pursuant to inspections that will be conducted after we submit our NDA or comparable
marketing application to the FDA or other regulatory authority. We do not have control over a supplier&rsquo;s or manufacturer&rsquo;s
compliance with these laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to
environmental health and safety matters. If our contract manufacturers cannot successfully manufacture material that conforms to
our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain
regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers
to maintain adequate quality control (QC), quality assurance (QA) and qualified personnel. If we are compelled or we wish to find
alternative manufacturing facilities, this could significantly impact our ability to develop, obtain regulatory approval for or
market our product candidates. Any failure to achieve and maintain compliance with these laws, regulations and standards could
subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained approvals could
be revoked, which would adversely affect our business and reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Third-party providers may breach agreements
they have with us because of factors beyond our control. Contract manufacturers often encounter difficulties involving production
yields, QC and QA, as well as shortages of qualified personnel. They may also terminate or refuse to renew their agreements because
of their own financial difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for
us. If we are unable to find adequate replacement or another acceptable solution in time, our clinical studies could be delayed
or our commercial activities could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the fact that we are dependent
on our suppliers and other third parties for the manufacture, storage and distribution of our product candidates means that we
are subject to the risk that our product candidates and, if approved, commercial products may have manufacturing defects that we
have limited ability to prevent or control. The sale of products containing such defects could result in recalls or regulatory
enforcement action that could adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Growth in the costs and expenses of components
or raw materials may also adversely influence our business, financial condition and results of operations. Supply sources could
be interrupted from time to time and, if interrupted, we cannot be certain that supplies could be resumed (whether in part or in
whole) within a reasonable timeframe and at an acceptable cost or at all. Our current and anticipated future dependence upon others
for the manufacturing of our current and future product candidates may adversely affect our future profit margins and our, or our
collaboration partners&rsquo;, ability to commercialize any products that receive marketing approval on a timely and competitive
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our collaboration arrangements with our strategic
partners may make us an attractive target for potential acquisitions under certain circumstances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under certain circumstances, due to the
structure of our collaboration arrangements with our strategic partners, our strategic partners may prefer to acquire us rather
than paying the milestone payments or royalties under the collaboration arrangements, which may bring additional uncertainties
to our business development and prospects. For example, under our collaboration arrangements with Genentech, Lilly and Janssen,
we may become entitled to substantial milestone payments and royalties. As a result, rather than paying the milestone payments
or royalties, Genentech, Lilly or Janssen, or one of their affiliates including Roche or Johnson &amp; Johnson, may choose to
acquire us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to intellectual property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may not have sufficient patent terms to
protect our products and business effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Patents have a limited lifespan. In the
US, the natural expiration of a patent is generally 20 years after it is filed. Although various extensions or adjustments may
be available, such as adjustments based on certain delays caused by the US Patent and Trademark Office (USPTO) the life of a patent,
and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our owned, co-owned and licensed patent portfolios may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. Even if patents covering
our product candidates are obtained and unchallenged, once the patent life has expired for a product, we may be open to competition
from generic medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although patent term extensions under the
Hatch-Waxman Act, in the US and under supplementary protection certificates (SPCs) in Europe may be available to extend the patent
exclusivity term for our products, we cannot provide any assurances that any such patent term extension will be obtained and, if
so, for how long. The Hatch-Waxman Act permits a patent extension term of up to 5 years as compensation for patent term lost during
the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years
from the date of product approval, only one patent may be extended, and only those claims covering the approved drug, a method
for using it or a method for manufacturing it may be extended. However, we may not be granted any extension because of, for example,
failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. It is not possible
to base an SPC in Europe on a patent in a European Member State if that patent expires before the MA of the clinical product, protected
by the patent, is obtained. As the &ldquo;product&rdquo; (active ingredient(s)) must be &ldquo;protected by a basic patent in force,&rdquo;
only a granted patent that is in force, and remains in force until it reaches the end of its full term, can serve as a &ldquo;basic
patent&rdquo; upon which an SPC can be based. Therefore, expired patents and pending patent applications cannot serve as the basis
for an SPC. Given the relatively long clinical</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">development
timelines of biologicals and new chemical entities for therapeutic purpose, we may not be granted any patent extensions as we
might fail to apply for the extensions prior to expiration of relevant patents. Moreover, the applicable time period or the scope
of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or if the term of
any such extension is less than we request, such result could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We or our licensing or collaboration partners
may become subject to intellectual property-related litigation or other proceedings to protect or enforce our patents or the patents
of our licensors or licensees and collaborators, any of which could be expensive, time-consuming, and unsuccessful, and may ultimately
result in our loss of ownership of intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Competitors may infringe our patents or
the patents of our licensors or collaborators. To counter such infringement, we may be required to file infringement claims against
those competitors, which can be expensive and time-consuming. If we or one of our licensing or collaboration partners were to
initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could
counterclaim that the patent covering our product candidate is invalid or unenforceable or that the defendant&rsquo;s products
do not infringe our or our licensing collaborators&rsquo; patents or that we or our licensing collaborators infringe the defendant&rsquo;s
patents. In patent litigation in the US, defendant counterclaims alleging invalidity, unenforceability and non-infringement are
commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, obviousness-type double patenting, lack of written description, or non-enablement. Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information
from the USPTO, or made a misleading statement, during prosecution. In addition, third parties may raise similar claims before
administrative bodies in the US or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant
review<I>, inter partes</I> review, interference and derivation proceedings as well as equivalent proceedings in foreign jurisdictions,
such as opposition proceedings in Europe. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Such proceedings or patent litigations could result in the revocation or cancellation of or amendment to our patents in such a
way that they no longer cover our product candidates or otherwise provide any competitive advantage. With respect to the validity
question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our
licensing or collaboration partners were unaware during prosecution. A court may also refuse to stop a third party from using
the technology in question on the grounds that our patents do not cover that technology. An adverse result in any proceeding could
put one or more of our patents at risk of being invalidated or interpreted narrowly, which could have a material adverse effect
on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Interference proceedings provoked by third
parties or brought by us, or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patents or patent applications or those of our licensors, licensees or collaborators. An unfavorable outcome could require us or
our licensing or collaboration partners to cease using the related technology or to attempt to license rights to it from the prevailing
party. Our business could be materially harmed if the prevailing party does not offer us or our licensing or collaboration partners
a license on commercially reasonable terms or at all. If we or our licensing or collaboration partners are unsuccessful in any
interference proceedings, we may lose our ownership of intellectual property or our patents may be narrowed or invalidated. There
can be no assurance as to the outcome of the interference and opposition proceedings, and any of the foregoing could result in
a material adverse effect on our business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our defense of litigation, interference
proceedings or other intellectual property-related proceedings may fail and, even if successful, may result in substantial costs
and distract our management and other employees from their normal responsibilities. Such litigation or proceedings could substantially
increase our operating losses and could substantially reduce the funds necessary to continue our clinical studies and research
programs or force us to license necessary technology from third parties, or enter into development partnerships that would help
us bring our product candidates to market. We may not be able to prevent, alone or with our licensing or collaboration partners,
misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as
fully as in the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the
results of hearings, motions, decisions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we or our licensing or collaboration partners
are unable to obtain and maintain effective patent rights for our technologies, product candidates or any future product candidates,
or if the scope of the patent rights obtained is not sufficiently broad, our competitors could develop and commercialize products
and technology similar or identical to ours, and our, or our collaboration partners&rsquo; ability to successfully commercialize
our products and technology may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely upon a combination of patents,
trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Our success depends in large part on our and our licensing or collaboration partners&rsquo; ability to obtain and maintain
patent and other intellectual property protection in the US, the EU and other countries with respect to our proprietary technologies
and product candidates. In particular, Genentech, Lilly, Janssen or our other licensing or collaboration partners may be dependent
on a license with a third party for the development and future commercialization of our product candidates. If such license is
not granted or terminated, Genentech, Lilly, Janssen or other licensing or collaboration partners may be required to cease development
and commercialization of our product candidates, any of which could have a material adverse effect on our business, financial condition,
results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have sought to protect our proprietary
position by filing patent applications in the US and abroad related to any of our novel technologies and products that are important
to our business. This process is expensive, time-consuming, and complex, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost, in a timely manner or in all jurisdictions. It is also possible that we
will fail to identify patentable aspects of our or our licensing or collaboration partners&rsquo; research and development output
before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation,
filing and prosecution of patent applications, or to maintain the patents, covering technology that we license to or from third
parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests
of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The patent position of pharmaceutical
and biopharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal
principles remain unsolved. As a result, the inventorship, issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. The pending or future patent applications that we own, co-own or in-license may fail to issue,
fail to result in issued patents with claims that cover our product candidates in the US or in other foreign countries, or fail
to effectively prevent others from commercializing competitive technologies and product candidates. Changes in either the patent
laws or interpretation of the patent laws in the US and other countries may diminish the value of our patents or narrow the scope
of our patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be aware of all third-party
intellectual property rights potentially relating to our technologies or product candidates. Publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the US and other jurisdictions remain
confidential for a period of time after filing, and some remain so until issued. Therefore, we cannot be certain that we were the
first to file any patent application related to our product candidates or technologies, or whether we were the first to make the
inventions claimed in our owned or co-owned patents or pending patent applications, nor can we know whether those from whom we
license patents were the first to make the inventions claimed or were the first to file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no assurance that all potentially
relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent
from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product
candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed,
found unenforceable or invalidated, which could allow third parties to commercialize our technology or products and compete directly
with us, without payment to us, or result in our or our collaboration partners&rsquo; inability to manufacture or commercialize
products without infringing third-party patent rights. Furthermore, even if they are unchallenged, our patents and patent applications
may not adequately protect our intellectual property, provide exclusivity for our product candidates, prevent others from designing
around our claims or provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent competition
from third parties, which may have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may be subject to claims challenging the
inventorship of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may be subject to claims that former
employees, collaborators or other third parties have an interest or title in our patents or other intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants, CROs, CMOs, academic
institutions or others who are involved in developing our product candidates. Litigation may be necessary to defend against</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">these
and other claims challenging inventorship or our ownership of our patents or other intellectual property. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
ownership of, or the right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents, thereby impairing our ability to protect our technologies and products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Changes in either the patent laws or interpretation
of the patent laws in the US, EU or elsewhere could increase the uncertainties and costs surrounding the prosecution of patent
applications and the enforcement or defense of issued patents. Assuming the other requirements for patentability are met, in the
US prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, whereas outside the US, the first
to file a patent application was entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith
Act), enacted on September 16, 2011, the US has moved to a first-to-file system. Under a first-to-file system, assuming the other
requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent
on an invention regardless of whether a third party was the first to invent the invention. The Leahy-Smith Act also includes a
number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack
the validity of a patent by the USPTO administered during post grant proceedings, including re-examination proceedings, <I>inter
partes </I>review, post-grant review and derivation proceedings. Therefore, the Leahy-Smith Act and its implementation increases
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, future actions by the US Congress, the federal courts and the USPTO could cause the laws and regulations governing
patents to change in unpredictable ways. Any of the foregoing could harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the patent positions of companies
in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. US Supreme Court rulings
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once
obtained. Depending on future actions by the US Congress, the federal courts, and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability
to protect and enforce our intellectual property in the future in the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we are unable to maintain effective proprietary
rights for our technologies, product candidates or any future product candidates, we may not be able to compete effectively in
our markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the protection afforded
by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable
or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidate
discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect and some courts inside and outside the US are less willing or unwilling to protect
trade secrets. For instance, the EU has introduced a new Directive on trade secrets increasing the standards for protection. Because
we rely on our advisors, employees and third-party contractors and consultants to research and develop and to manufacture our product
candidates, we must, at times, share our intellectual property with them. We seek to protect our intellectual property and other
proprietary technology in part by entering into confidentiality agreements and master service agreements, if applicable, material
transfer agreements, consulting agreements or other similar agreements with our advisors, employees, contractors, consultants,
licensing and collaboration partners, and other third parties with confidentiality provisions. These agreements typically limit
the rights of these third parties to use or disclose our confidential information, including our intellectual property and trade
secrets. These agreements also typically restrict the ability of third parties to publish data potentially relating to our intellectual
property, although our agreements may contain certain limited publication rights. For example, any academic institution that we
may collaborate with in the future may expect to be granted rights to publish data arising out of such collaboration, provided
that we may have the right to be notified in advance and given the opportunity to delay publication for a limited time period in
order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity
to remove confidential or trade secret information from any such publication. We also conduct joint research and development programs
that may require us to share intellectual</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">property
under the terms of our research and development or similar agreements. However, we cannot guarantee that we have entered into
such agreements with each party that may have or have had access to our trade secrets or other confidential information or proprietary
technology and processes, or that such agreements will not be breached or that our trade secrets or other confidential information
will not otherwise be disclosed. Despite the contractual provisions employed when working with these advisors, employees and third-party
contractors and consultants, the need to share intellectual property and other confidential information increases the risk that
such confidential information becomes known by our competitors, is inadvertently incorporated into the product development of
others or is disclosed or used in violation of these agreements. Additionally, our grant agreements typically provide for dissemination
of results to academic institutions and to the general public. As a result, our information may be disseminated with the loss
of protection status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We also seek to preserve the integrity
and confidentiality of our data and trade secrets by maintaining the physical security of our premises and the physical and electronic
security of our information technology systems. Despite our efforts to protect our intellectual property, our competitors may discover
our trade secrets through breach of our agreements by third parties, for which we may not have adequate remedies for any breach,
or publication of information by any of our CROs, academic partners, funding organizations or our licensing or collaboration partners.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate by law, we may have insufficient recourse
against third parties for misappropriating such trade secrets. Misappropriation or unauthorized disclosure of our trade secrets
could impair our competitive position and may have a material adverse effect on our business. Moreover, if any of our trade secrets
were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent
such competitor or other third party from using that technology or information to compete with us. A competitor&rsquo;s or other
third party&rsquo;s discovery of our intellectual property would impair our competitive position and have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Further, the laws of some foreign countries
do not protect proprietary rights to the same extent or in the same manner as the laws of the US. As a result, we may encounter
significant problems in protecting and defending our intellectual property both in the US and abroad. If we are unable to prevent
material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish
or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Despite confidentiality clauses within
our employment agreements, we cannot ensure that departing employees will not breach any post-termination commitments in such agreements
by allowing others to access our trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document-submission, fee-payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Periodic maintenance fees, renewal fees,
annuity fees and various other government fees on a patent and patent application are due to be paid to the USPTO and foreign patent
agencies in several stages over the lifetime of the patent and patent application. The USPTO and various foreign governmental patent
agencies require compliance with a number of procedural, documentary, fee-payment and other similar provisions during the patent
application process. We employ reputable law firms and other professionals to help us comply with these requirements and we are
also dependent on our licensors or collaboration partners to take the necessary action to comply with these requirements with respect
to certain of our intellectual property. Although an inadvertent lapse can in many cases be cured by payment of a late fee or by
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse
of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to
respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal
documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>The patent protection and patent prosecution
for some of our product candidates is dependent on third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we normally seek to obtain the
right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times
when the filing and prosecution activities for patents relating to our product candidates are controlled by our licensors or collaboration
partners. If any of our current or future licensing or collaboration partners fail to prosecute, maintain and enforce such patents
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">patent
applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents
covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those
rights, our or our collaboration partners&rsquo; ability to develop and commercialize those product candidates may be adversely
affected and we may not be able to prevent competitors from making, using, and selling competing products. In addition, even where
we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties,
we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that
took place prior to the date upon which we assumed control over patent prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, we may be adversely affected
or prejudiced by actions or inactions of our external and internal patent counsels working solely on our projects or our joint
patent counsels representing us and our collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we fail to comply with the obligations in
our intellectual property agreements, including those under which we license intellectual property and other rights to or from
third parties, or otherwise experience disruptions to our business relationships with our licensees, our licensors and partners,
we could lose intellectual property rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a party to a number of intellectual
property license and co-ownership agreements and research and development collaborations that are important to our business and
expect to enter into additional such agreements in the future. Under certain circumstances, the royalties payable to us under these
agreements are subject to certain reductions, which may have a materially adverse effect on our business, financial condition,
results of operations and prospects. In addition, our existing agreements impose, and we expect that future agreements will impose,
various diligence, commercialization, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations
under these agreements, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license
or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products
covered by the license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Licensing of intellectual property is of
critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise regarding intellectual
property subject to a licensing or co-ownership agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope of rights granted under the agreement, any restrictions in licensed fields and other interpretation-related issues;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which our technology and processes infringe or otherwise violate the intellectual property of the licensor, the
licensee or partner that is not subject to the agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the sublicensing of patent and other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the diligence, development and commercialization obligations under the agreement and what activities satisfy those obligations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the ownership of inventions and know-how resulting from the joint or mutual creation or use of intellectual property by our
licensors or collaboration partners and us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the priority of invention in patented technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>non-compete commitments; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>consequences for changes in control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If disputes over intellectual property
and other rights that we own, have licensed or co-own prevent or impair our ability to maintain our current licensing or exclusivity
arrangements on acceptable terms, we or our collaboration partners may be unable to successfully develop and commercialize the
affected product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, certain provisions in the
agreements under which we currently license intellectual property or technology to and from third parties may be susceptible to
multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe
to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial
or other obligations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">under
the relevant agreement, or decrease the third party&rsquo;s financial or other obligations under the relevant agreement, any of
which could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We or our licensors or licensees and collaborators
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our or our licensors or licensees and collaborators
programs may require the use of proprietary rights held by third parties in the future, and the growth of our business will likely
depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our product candidates
may require specific processes and/or formulations to work effectively and efficiently and the rights to these processes and/or
formulations may be held by others. We or our licensors or licensees may be unable to acquire or in-license from third parties
any compositions, methods of use, processes, or other third-party intellectual property rights that we identify as necessary for
our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that
we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size,
cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. We or our licensors or licensees also may be unable to license
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For example, we sometimes collaborate
with US and foreign academic institutions to accelerate our preclinical research or development under written agreements with
these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&rsquo;s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within
the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual
property rights to other parties, potentially blocking our ability to pursue our applicable product candidate or program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to successfully obtain
a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have
to abandon development of that product candidate or program and our business and financial condition could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Third-party claims of intellectual property
infringement may expose us to substantial liability or may prevent or delay our or our collaboration partners&rsquo; development
and commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Numerous US- and foreign-issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates.
For example, we are aware of third-party patents or patent applications that may be construed to cover one or more of our product
candidates. If these patents are asserted against us or our licensing or collaboration partners and either we or our licensing
or collaboration partners are found to infringe any of these patents, and are unsuccessful in demonstrating that such patents are
invalid or unenforceable, then we and our licensing or collaboration partners could be required to pay substantial monetary damages
or cease further development or commercialization of one or more of our product candidates or be compelled to enter into onerous
licenses with such third parties. There may also be other third-party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods of treatment related to the use or manufacture of our product candidates and technology.
Although we generally conduct a freedom-to-operate search and review with respect to our product candidates, we cannot guarantee
that our search and review is complete and thorough, nor can we be sure that we have identified each and every patent and pending
application in the US and abroad that is relevant or necessary to the manufacturing or commercialization of our product candidates
or use of our technology. Because patent applications can take many years to issue, there may be currently pending patent applications
that may later result in issued patents that our product candidates may infringe. In addition, third parties may file and obtain
additional patents in the future and claim that use of our technologies infringes upon these patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Third parties may assert infringement claims
against us based on existing patents or on patents that may be granted in the future, regardless of merit. Even if we believe such
claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and
infringed, which could materially and adversely affect our or our collaboration partners&rsquo; ability to commercialize our product
candidates or technologies covered by the asserted third-party patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Parties making claims against us may also
obtain injunctive or other equitable relief, which could effectively block our or our collaboration partners&rsquo; ability to
further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would
involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business.
In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages
and attorneys&rsquo; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses
from third parties, which may be impossible or require substantial time and monetary expenditure. Any of the foregoing could have
a material and adverse effect on our business, financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, claims that we have misappropriated
the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial
condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There could also be public announcements
of the results of hearings, motions, decisions, or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Some of our competitors may have substantially
greater resources and more mature and developed intellectual property portfolios than we do, and may be able to sustain the costs
of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent-holding
companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the pharmaceutical
and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject
to claims of infringement of the patent rights of third parties. The uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may be subject to claims that our employees,
consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our
employees have wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We employ and utilize the services of individuals
who were previously employed or provided services to universities or other pharmaceutical or biopharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees,
consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade
secrets or other proprietary information, of any of our employees&rsquo;, consultants&rsquo; or independent contractors&rsquo;
former employers or of other third parties. Litigation may be necessary to defend against these claims. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which
could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, although it is our policy
to require our employees, consultants and independent contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual
property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against
third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We may not be able to protect our
intellectual property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Filing, prosecuting and defending patents
on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights
in some countries outside the US may be less extensive than those in the US. In addition, the laws of some foreign countries do
not protect intellectual property rights to the same extent as the laws in the US. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the US, or from selling or importing products made using
our inventions in and into the US or other jurisdictions. In the ordinary course of prosecution and maintenance activities, we
determine whether to seek patent protection outside the US and in which countries. This also applies to patents we have acquired
or in-licensed from third parties. In some cases, we, or our predecessors in interest or licensors of patents within our portfolio,
have sought patent protection in a limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">number
of countries for patents covering our product candidates. Competitors may use our technologies and products in jurisdictions where
we have not obtained or are unable to adequately enforce patent protection to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the US.
These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing, which would have a material adverse effect on our business and financial positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property
protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement,
misappropriation or other violations of our intellectual property and proprietary rights. Proceedings to enforce our patent rights
in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from
other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications
at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we
initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>If our trademarks and trade names
are not adequately protected, then we may not be able to build name recognition in our markets of interest, our names and brands
may be misappropriated by third parties, and our business may be adversely affected</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed trademark applications seeking
protection for our corporate name, logo, Nasdaq Global Market symbol and selected names of our technology platforms in selected
geographies. While we have been granted registrations in certain geographies for certain trademarks, there is no guarantee that
our trademark applications will be approved by the respective authorities at all or that we will not be required to narrow the
scope of protection in certain or all geographies. Our applications may face opposition from third parties, potentially resulting
in the lack of protection or narrower protection. Our trademarks or trade names may be challenged, infringed, circumvented, declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade
names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors
or other third parties may adopt trade names, domain names or trademarks similar to ours, thereby impeding our ability to build
brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement
claims brought by owners of other registered trademarks or trademarks that incorporate variations of our trademarks or trade names.
Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be
able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights
related to trademarks and domain names may be ineffective and could result in substantial costs and diversion of resources, and
could adversely affect our business, financial condition, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to our financial condition and capital requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.1pt"><B><I>We are a clinical-stage company and
have a history of operating losses. We anticipate that we will</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.1pt"><B><I>continue to incur losses for the foreseeable
future</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a clinical-stage biopharmaceutical
company. Since 2003, although we have received upfront and milestone payments from our collaboration partners and certain other
contract revenue, we have also incurred significant operating losses. We incurred net losses (defined as net loss attributable
to owners of the Company) of CHF 61.9 million for the year ended December 31, 2020. In addition, we had accumulated losses of CHF
132.9 million as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our losses have resulted principally from
research and development expenses and from general business and administrative expenses. We expect to continue to incur significant
operating losses in the future as we continue our research and development efforts for our current and future product candidates
and seek to obtain regulatory approval and commercialization of such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, the Company has financed its liquidity
requirements primarily from its public offerings, share issuances, contract revenues from license and collaboration agreements
and grants. We have no products approved for commercialization and have never generated any revenues from product sales. Biopharmaceutical
and pharmaceutical product development is a highly speculative undertaking and involves a substantial degree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">of
risk. It may be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a product
candidate approved for commercialization and we begin to generate revenue or royalties from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Although we have generated revenues from upfront
and milestone payments related to our collaboration agreements, we have never generated any revenue from product sales and may
never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we have generated contract revenue
from upfront and milestone payments related to our collaboration agreements, we have no products approved for commercialization
and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our
ability to successfully complete the development of, and obtain the marketing approvals necessary, to commercialize one or more
of our product candidates. We do not anticipate generating revenue from product sales unless and until we or our collaboration
partners obtain regulatory approval for, and commercialize, our product candidates. Our ability to generate future revenue from
product sales depends heavily on our and our collaboration partners&rsquo; success in many areas, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successfully completing research and clinical development of our product candidates, by we or our collaboration partners, as
the case may be;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining marketing approvals for our product candidates, including ACI-35, semorinemab, Morphomer Tau, ACI-24 for AD and for
DS, crenezumab and PI-2620, for which we complete clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developing a sustainable and scalable manufacturing process for any approved product candidates, and maintaining supply and
manufacturing relationships with third parties that can conduct the process and provide adequate (in amount,
quality and time) products to support clinical development and the market demand for our product candidates, if approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>launching and commercializing product candidates for which we obtain marketing approval, either directly or with a collaborator
or distributor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining market acceptance of our product candidates as viable treatment or diagnostic options;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>addressing any competing technological and market developments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>identifying, assessing, acquiring and/or developing new product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negotiating favorable terms in any collaboration, licensing, or other similar arrangements into which we may enter;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining, protecting, acquiring and expanding our portfolio of intellectual property rights, including patents, trade secrets
and know-how; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>attracting, hiring and retaining qualified personnel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because of the numerous risks and uncertainties
with biopharmaceutical and pharmaceutical product development, we are unable to accurately predict the timing or amount of increased
expenses and when, or if, we will be able to achieve profitability. Our expenses could increase beyond expectations if we are required
by the FDA, the EMA or other regulatory agencies, domestic or foreign, to change our manufacturing processes, or to perform clinical,
nonclinical or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining
regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of
the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain
coverage and reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or
the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant
revenue from sales of such products, even if approved. Accordingly, we may not be profitable in the future from the sale of any
approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We or our collaboration partners may be
unable to develop and commercialize any of our current or future product candidates and, even if we do, may not achieve profitability
in the future. Even if we do achieve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">profitability
in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to be profitable
in the future would decrease the value of our company and could impair our ability to raise capital, expand our business or continue
our operations. A decline in the value of our company could cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we fail to obtain additional funding, we
may delay, reduce or eliminate our product development programs or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are currently advancing our product
candidates through clinical development, either together with a collaboration partner (ACI-35, semorinemab, Morphomer Tau, crenezumab
and PI-2620) or independently (ACI-24 for AD and for DS). We expect our research and development expenses to continue to increase
in connection with our ongoing activities, particularly as we and/or our collaboration partners continue our ongoing studies and
initiate new studies of ACI-35, semorinemab, Morphomer Tau, ACI-24 for AD and for DS, crenezumab and PI-2620 and initiate preclinical
and clinical development of our other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December&nbsp;31, 2020, we had cash
and cash equivalents of CHF 160.9&nbsp;million and short-term financial assets of CHF 65 million resulting in a total liquidity
position of CHF 225.9 million. We currently believe that our existing capital resources, not including potential milestone payments,
will be sufficient to meet our projected operating requirements through at least Q1 2024. We have based this estimate on assumptions
that may prove to be wrong, and we could exhaust our capital resources sooner than we currently expect. In addition, changing circumstances
may cause us to adjust our projected spending to amounts more than currently expected. We may also need to raise additional funds
sooner than we anticipate due to various factors such as the scope and rate of progress of our development activities, regulatory
approval outcomes and emergence of competing technologies, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect that we will require additional
capital to develop and commercialize certain of our product candidates. If we receive regulatory approval for our current and future
product candidates, and if we have not already licensed such product candidate to a collaboration partner and choose to commercialize
such product candidate independently, we expect to incur significant commercialization expenses related to product manufacturing,
sales, marketing, distribution and establishing a regulatory structure, depending on where we choose to commercialize. Additional
funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to
enable us to continue to implement our long-term business strategy. Additionally, we may be dependent on the status of the capital
markets at the time such capital is sought. If we are not able to raise capital when needed, we could be forced to delay, reduce
or eliminate our product development programs or commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Raising additional capital may cause dilution
to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue
streams.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Until such time, if ever, as we can generate
substantial product royalty revenue, we expect to finance our liquidity needs through a combination of equity offerings, debt financings,
grants, and license and development agreements in connection with collaborations. In September 2020, the Company established an
&ldquo;at the market offering&rdquo; (ATM) for the sale of up to USD 80 (CHF 71.3) million worth of our common shares from time
to time by entering into an Open Market Sale Agreement (Sales Agreement) with Jefferies LLC (Jefferies). We do not have any material
committed external source of funds. In the event we need to seek additional funds, we may raise additional capital through the
sale of equity, convertible debt or other securities. In such an event, your ownership interest will be diluted, and the terms
of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares.
Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or proposing dividends to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we raise additional funds through collaborations,
strategic alliances, or marketing, distribution or licensing arrangements with third parties, we may have to grant or otherwise
relinquish valuable rights to our intellectual property or future revenue streams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our ability to use tax loss carry-forwards
in Switzerland may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, we reported tax
loss carry-forwards from financial years 2014 until 2020 for purposes of Swiss corporate income tax in the aggregate amount of
CHF 121.9 million, which could be available to offset future taxable income. If not used, these tax losses will expire 7 years
after the year in which they were incurred. Due to our limited income, there is a high risk that the tax loss carry-forwards will
expire</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">partly
or entirely and we will not be able to use them to offset future taxable income thereafter for Swiss corporate income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Exchange rate fluctuations may materially affect
our results of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under our existing agreements, we receive
and make a significant amount of payments in Swiss Franc, USD and EUR. As a result, changes and fluctuations in currency exchange
rates between the Swiss Franc and other currencies, especially the USD and EUR, could have a materially adverse effect on our operating
results. As our reporting currency is the Swiss Franc, financial line items are converted into Swiss Francs at the applicable exchange
rates. We also expect that in the future, a significant portion of our revenues and expenses will be denominated in Swiss Franc,
USD and EUR. Therefore, unfavorable developments in the value of the Swiss Franc as compared to the USD and EUR or any other currency
could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to the regulatory environment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We cannot give any assurance that any of our
product candidates will receive regulatory approval, which is necessary before they can be commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our future success is dependent on our
and our collaboration partners&rsquo; ability to successfully develop, obtain regulatory approval for, and then successfully commercialize
one or more product candidates. We currently have one product candidate that has completed Phase 2 clinical studies and five that
are in a Phase 2 clinical study. We are not permitted to market or promote any of our product candidates before we receive regulatory
approval from the FDA, EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for
any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We cannot be certain that any of our product
candidates will be successful in clinical studies or receive regulatory approval. Applications for our product candidates could
fail to receive regulatory approval for many reasons, including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full
population for which we seek approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or
clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an NDA
or other submission or to obtain regulatory approval in the US or elsewhere;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&rsquo;s
benefit-risk ratio for its proposed indication is acceptable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA, EMA or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications,
or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may change significantly
in a manner rendering our clinical data insufficient for approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We generally plan to seek regulatory approval
to commercialize our product candidates in the US, the EU and in additional foreign countries where we have commercial and typically
IP rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of
such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing,
marketing and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot
ensure that we will obtain approval in any other jurisdictions. Failure to obtain marketing authorization for our product candidates
will result in our being unable to market and sell such products, which would materially adversely affect our business, financial
condition and results of operations. If we fail to obtain approval in any jurisdiction, the geographic market for our product candidates
could be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Similarly,
regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of
our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Clinical drug development involves a lengthy
and expensive process with uncertain timelines and uncertain outcomes. If clinical studies of our product candidates are prolonged
or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates
on a timely basis or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To obtain the necessary regulatory approvals
to market and sell any of our product candidates, we must demonstrate through extensive preclinical and clinical studies that our
products are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is
inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical and early clinical
studies of our product candidates may not be predictive of the results of later-stage clinical studies. For example, the positive
results generated to date in clinical studies for our product candidates do not ensure that later clinical studies will demonstrate
similar results. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits
despite having progressed through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical
or biopharmaceutical industry, including us, have suffered significant setbacks in advanced clinical studies due to lack of efficacy
or adverse safety profiles, notwithstanding promising results in earlier studies. Our future clinical study results may not be
successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical studies must be conducted in
accordance with the legal requirements, regulations or guidelines of the FDA, EMA and comparable foreign regulatory authorities,
and are subject to oversight by these governmental agencies and Institutional Review Boards (IRBs) at the medical institutions
where the clinical studies are conducted. In addition, clinical studies must be conducted with supplies of our product candidates
produced under cGMP and other requirements. We depend on medical institutions and CROs to conduct our clinical studies in compliance
with cGCP standards. To the extent the CROs fail to enroll participants for our clinical studies, fail to conduct the study to
cGCP standards or are delayed for a significant time in the execution of studies, including achieving full enrollment, we may
be affected by increased costs, program delays or both, which may harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, neither we nor our collaboration
partners have completed all clinical studies required for the approval of any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The completion of clinical studies for
our clinical product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the delay or refusal of regulators or IRBs to authorize us to commence or amend a clinical study at a prospective study site
or changes in regulatory requirements, policies and guidelines;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays or failure to reach agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and study sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in patient enrollment and variability in the number and types of patients available for clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically
significant treatment effects;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negative or inconclusive results, which may require us to conduct additional preclinical or clinical studies or to abandon
projects that we expected to be promising;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>safety or tolerability concerns, which could cause us to suspend or terminate a study if we find that the participants are
being exposed to unacceptable health risks;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including
noncompliance with regulatory requirements or safety concerns, among others;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lower than anticipated retention rates of patients and volunteers in clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to us
in a timely manner, or at all, deviating from the protocol or dropping out of a study;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays relating to adding new clinical study sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in establishing the appropriate dosage levels;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the quality or stability of the product candidate falling below acceptable standards;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical studies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any delays in completing our clinical studies
will increase our costs, slow our product candidate development and approval process, and jeopardize our ability to commence product
sales and generate sales revenues. Any of these occurrences may significantly harm our business, financial condition and prospects.
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also
ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Even if we obtain and maintain approval for
our drug candidates from one jurisdiction, we may never obtain approval for our drug candidates in other jurisdictions, which would
limit our market opportunities and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales by us of our approved drugs will
be subject to US and non-US regulatory requirements governing clinical studies and regulatory approval, and we plan to seek regulatory
approval to commercialize our drug candidates in the US, the EEA, and other countries. Clinical studies conducted in one country
may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not ensure approval
in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the
regulatory approval process in others. For example, approval in the US by the FDA does not ensure approval by the regulatory authorities
in other countries or jurisdictions, and similarly, approval by a non-US regulatory authority, such as the EMA, does not ensure
approval by regulatory authorities in other countries, including by the FDA. However, the failure to obtain approval in one jurisdiction
may have a negative impact on our ability to obtain approval elsewhere. Approval processes and regulatory requirements vary among
countries and can involve additional drug testing and validation and additional administrative review periods. Even if a drug is
approved, the FDA or EMA, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings
on the drug labeling, or require expensive and time-consuming clinical studies or reporting as conditions of approval. In many
countries outside the US, a drug candidate must be approved for reimbursement before it can be approved for sale in that country.
In some cases, the price that would be charged for a drug is also subject to approval. Regulatory authorities in other countries
also have their own requirements for approval of drug candidates with which we must comply prior to marketing in those countries.
Obtaining non-US regulatory approvals and compliance with such non-US regulatory requirements could result in significant delays,
difficulties and costs for us and could delay or prevent the introduction of our current and any future drugs, in certain countries.
If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if
regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full
market potential of our drug candidates will be unrealized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Even if our product candidates obtain
regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant
additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and
market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated
problems with our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If marketing authorization is obtained
for any of our product candidates, the product will remain subject to continual regulatory review and therefore authorization could
be subsequently withdrawn or restricted. Any regulatory approvals that we receive for our product candidates may also be subject
to limitations on the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">approved
indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially
costly post-marketing testing, including Phase 4 clinical studies and surveillance to monitor the safety and efficacy of the product
candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will
be subject to ongoing regulatory obligations and oversight by regulatory authorities, including with respect to the manufacturing
processes, labeling, packing, distribution, adverse event reporting, storage, advertising and marketing restrictions, and record-keeping
and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our or our collaboration
partners&rsquo; ability to commercialize such products. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMP and cGCP requirements for any clinical studies
that we conduct post-approval. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity
or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
may result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory
product recalls;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines, warning letters or holds on clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation
of product license approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory constraints in promotion and distribution of drug products in various markets;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product seizure or detention, or refusal to permit the import or export of products; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any of these events occurs, our ability
to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which
could materially adversely affect our business, financial condition and results of operations. The FDA&rsquo;s policies may change
and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely
affect our business, prospects and ability to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We have conducted and may in the future conduct
clinical studies for our drug candidates outside the US, and the FDA and applicable foreign regulatory authorities may not accept
data from such studies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have conducted and may in the future
choose to conduct one or more of our clinical studies outside the US, including in Germany, Austria, Denmark, Sweden, Finland,
the UK, Poland and the Netherlands. The acceptance of study data from clinical studies conducted outside the US or another jurisdiction
by the FDA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical
studies are intended to serve as the basis for marketing approval in the US, the FDA will not approve the application on the basis
of foreign data alone unless the following are true: the data are applicable to the US population and US medical practice; the
studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for
an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data
through an on-site inspection or other appropriate means. Additionally, the FDA&rsquo;s clinical study requirements, including
sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar requirements.
In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions in which the studies
are conducted. There can be no assurance that the FDA or any applicable foreign regulatory authority will accept data from studies
conducted outside of the US or the applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not
accept such data, it would result in the need for additional studies, which would be costly and time-consuming and delay aspects
of our business plan, and which may result in our drugs or drug candidates not receiving approval or clearance for commercialization
in the applicable jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Enacted and future legislation may increase
the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices
we may set.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the US and the EU, there have been a
number of legislative and regulatory changes and proposed changes regarding the healthcare system. These changes could prevent
or delay marketing approval of our product candidates and restrict or regulate post-approval activities and affect our ability
to profitably sell any products for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the US, the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (Medicare Modernization Act), changed the way Medicare covers and pays for pharmaceutical
and biopharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
reimbursement methodology based on average sale prices for physician-administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. Cost-reduction initiatives and other
provisions of this legislation could decrease the coverage and price that we receive for any approved products. Although the Medicare
Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the
Medicare Modernization Act may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2010, former President Obama
signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
(HCERA) (collectively, the Health Care Reform Law), a sweeping law intended to broaden access to health insurance, reduce or constrain
the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care
and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.
The Health Care Reform Law, among other things, increased the rebates a manufacturer must pay to the Medicaid program; addressed
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that
are inhaled, infused, instilled, implanted or injected; established a new Medicare Part D coverage gap discount program, in which
manufacturers must provide 50% point-of-sale discounts on products covered under Part D; and implemented payment system reforms,
including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination,
quality and efficiency of certain healthcare services through bundled payment models. Further, the new law imposed a significant
annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance
were enacted, which may affect our business practices with healthcare practitioners. On July 24, 2020 and September 13, 2020,
the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several
of the administration&rsquo;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November
30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20,
2020, the US Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price
reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers,
unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale,
as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20,
2020, CMS issued an interim final rule implementing former President Trump&rsquo;s Most Favored Nation executive order, which
would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced
countries, effective January 1, 2021. On December 28, 2020, the US District Court in Northern California issued a nationwide preliminary
injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse
these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2020, we continued to face uncertainties
because of continued US federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all
of the provisions of the Health Care Reform Law. In January 2017, Congress voted to adopt a budget resolution for the fiscal year
2017 that authorized the implementation of legislation that would repeal portions of the Health Care Reform Law. On December 14,
2018, a federal judge in Texas ruled that the Health Care Reform Law is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress as part of the 2017 Tax Act. While the judge, as well as the Trump administration and CMS,
have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent
appeals, and other efforts to repeal and replace the ACA, will impact our business. On December 18, 2019, the Fifth Circuit Court
of Appeals upheld the lower court&rsquo;s decision that the Health Care Reform Law was unconstitutional. On March 2, 2020, the
US Supreme Court granted certiorari to review the case and oral arguments were held on November 10, 2020. Although the US</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Supreme
Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate
a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through
the Health Care Reform Law marketplace. The executive order also instructs certain governmental agencies to review and reconsider
their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access
to health insurance coverage through Medicaid or the ACA. Pending review, the Health Care Reform Law remains in effect, but it
is unclear what effect this litigation, other efforts to repeal and replace the Health Care Reform Law and the healthcare reform
measures of the Biden administration will have on the status of the ACA. Litigation and legislation over the Health Care Reform
Law are likely to continue, with unpredictable and uncertain results. Congress also could consider subsequent legislation to replace
elements of the Health Care Reform Law that are repealed. There is no assurance that the Health Care Reform Law, as currently
enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future
federal or state legislative or administrative changes relating to healthcare reform will affect our business<FONT STYLE="color: blue">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Moreover, other legislative changes have
also been proposed and adopted in the US since the Health Care Reform Law was enacted. On August&nbsp;2, 2011, the Budget Control
Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction,
tasked with recommending a targeted deficit reduction of at least USD 1.2 trillion for the years 2013 through 2021, was unable
to reach the required goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs. This
includes aggregate reductions in Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1,
2013 and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action
is taken. The Coronavirus Aid, Relief, and Economic Security Act suspended the 2% Medicare sequester from May 1, 2020 through
December 31, 2020, and extended the sequester reductions by one year, through 2030. On January&nbsp;2, 2013, former President
Obama signed into law the American Taxpayer Relief Act of 2012 which, among other things, further reduced Medicare payments to
several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations
period for the government to recover overpayments to providers from 3 to 5 years. These new laws may result in additional reductions
in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Our business is subject to complex
and evolving US and international laws and regulations regarding clinical trials reimbursement and privacy and data protection.
Many of these laws and regulations are subject to change and uncertain interpretation and could result in claims, changes to our
business practices, penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regulatory authorities around the world
have adopted laws and regulations, and are continuing to consider a number of legislative and regulatory proposals, concerning
privacy and data protection, including measures to ensure that encryption of users&rsquo; data does not hinder access of law enforcement
agencies to that data. In addition, the interpretation and application of consumer and data protection laws in the US, Europe and
elsewhere are often uncertain and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent
with our data practices. These laws and regulations, and legislative and regulatory proposals, if adopted, and such interpretations
could, in addition to the possibility of fines, result in an order requiring that we change our data practices, which could have
an adverse effect on our business and results of operations. Complying with these various laws could cause us to incur substantial
costs or require us to change our business practices in a manner adverse to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">In the EU, new clinical trial regulations
are scheduled to come into force in 2021. This new legislation will enforce the centralization of clinical trial applications and
approvals, which will eliminate redundancy, but in some cases, this may extend timelines for clinical study approvals, due to potentially
longer wait times. The GDPR, which became effective in May 2018 in all EU Member States, created a range of new compliance obligations
for companies that process the personal data of EU residents. Although it is expected that the GDPR will provide consistency across
the territory of the EU, it imposes more onerous requirements concerning consent and the obligations of sponsors of clinical trials
(acting as Data Controllers), among other measures, which may increase the costs and extend the timelines of our product development
efforts. Austerity measures in certain European nations may also affect the prices we are able to seek if our products are approved,
as discussed below. Furthermore, the Brexit vote and the impact of the withdrawal of the UK may adversely affect business activity,
political stability and economic conditions in the UK, the Eurozone, the EU and elsewhere. Specifically, Brexit and ongoing developments
in the UK have created uncertainty with regard to data protection regulation in the UK. We may be required to comply with both
the GDPR and the UK GDPR to the extent of our operations in the UK, exposing us to two parallel regimes with potentially divergent
interpretations and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">enforcement
actions for certain violations. The relationship between the UK and the EU in relation to certain aspects of data protection law
remains unclear, for example, how data transfers between EU member states and the UK will be treated and the role of the UK&rsquo;s
Information Commissioner&rsquo;s Office with respect to the EU following the end of the transitional period. Although we do not
have material operations in the UK, we cannot rule out potential disruptions in relation to the clinical regulatory framework
applicable to our clinical studies in the UK, and to data privacy and security rules with respect to personal data sharing with
vendors and clinical investigators in the UK, and we cannot predict future implications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Both in the US and in the EU, legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical and biopharmaceutical products. We do not know whether additional legislative changes will be enacted, whether the
regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We could be subject to liabilities under environmental,
health and safety laws or regulations, or fines, penalties or other sanctions, if we fail to comply with such laws or regulations
or otherwise incur costs that could have a material adverse effect on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to numerous environmental,
health and safety laws, regulations, and permitting requirements, including those governing laboratory procedures, decontamination
activities, and the handling, transportation, use, remediation, storage, treatment and disposal of hazardous materials, human
substances and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological
materials that produce hazardous waste products. We generally contract with third parties for the disposal of these materials
and wastes. We cannot eliminate the risk of contamination or injury from these materials or wastes either at our sites or at third-party
disposal sites. In the event of such contamination or injury, we could be held liable for any resulting damages, and any liability
could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials, human substances or other work-related injuries, this insurance may not provide
adequate coverage against potential liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we may incur substantial costs
in order to comply with current or future environmental, health and safety laws, regulations or permitting requirements. Such laws,
regulations and requirements are becoming increasingly more stringent and may impair our research, development or production efforts.
Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other
sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our relationships with clinical centers, customers
and payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, if violated,
could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational
harm and diminished profits and future earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Healthcare providers, physicians and others
play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements
with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations,
primarily in the US, which may constrain the business or financial arrangements and relationships through which we market, sell
and distribute our products for which we obtain marketing approval. Restrictions under applicable healthcare laws and regulations
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the US healthcare Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an
individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under US government
healthcare programs such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the US False Claims Act imposes criminal and civil penalties, including civil whistleblower or <I>qui tam</I> actions, against
individuals or entities for knowingly presenting, or causing to be presented, to the US government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the US HIPAA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making
false statements relating to healthcare matters;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes obligations, including
mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the transparency requirements under the Health Care Reform Law require manufacturers of drugs, devices, biologics and medical
supplies to report to the US Department of Health and Human Services information related to payments and other transfers of value
made by such manufacturers to physicians and teaching hospitals, and ownership and investment interests held by physicians or their
immediate family members; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in various other jurisdictions, analogous laws and regulations, such as state anti-kickback and false claims laws, will apply
to sales or marketing arrangements, consultancy and service agreements, and claims involving healthcare items or services reimbursed
by nongovernmental third-party payors, including private insurers, and some state laws require pharmaceutical and biopharmaceutical
companies to comply with the pharmaceutical and biopharmaceutical industries&rsquo; voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related
to payments to physicians and other healthcare providers or marketing expenditures.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because of the breadth of these laws and
the narrowness of the statutory exceptions and safe harbors available under the US federal Anti-Kickback Statute, it is possible
that some of our future business activities could be subject to challenge under one or more of such laws. In addition, recent
healthcare-reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends
the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs
to have actual knowledge of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that
the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute
constitutes a false or fraudulent claim for purposes of the False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, exclusion from US government-funded healthcare programs, such as Medicare
and Medicaid, other foreign healthcare reimbursement and procurement programs, and the curtailment or restructuring of our operations.
If any of the physicians or other providers or entities with whom we expect to do business with is found to be not in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded
healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Risks from the improper conduct of employees,
agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and
financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We cannot ensure that our compliance controls,
policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators,
which would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare,
employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations.
Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely
impact our operating results, our ability to conduct business and our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are exposed to the risk of employee
fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA or EMA regulations, to
provide accurate information to the FDA or the EMA, or intentional failures to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in
the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. In June 2016, we
adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take
to detect and prevent this activity may not be effective in controlling unknown or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant
fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our business activities may be subject to the
Foreign Corrupt Practices Act (FCPA), and similar anti-bribery and anti-corruption laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business activities may be subject
to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including
the UK Bribery Act. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value,
either directly or indirectly, to a non-US government official in order to influence official action, or otherwise obtain or retain
business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions
of the corporation, and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated
and therefore involves significant interaction with public officials, including officials of non-US governments. Additionally,
in many other countries, the healthcare providers who prescribe pharmaceuticals or biopharmaceuticals and the investigators who
perform our studies are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore,
our dealings with these prescribers and purchasers are subject to regulation under the FCPA. The Securities and Exchange Commission
(SEC) and the Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies.
There is no certainty that all of our employees, agents, contractors or collaborators, or those of our affiliates, will comply
with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws
and regulations could result in fines, criminal sanctions against us, our officers or our employees, the closing down of our facilities,
requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance
programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer
our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts,
our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to our common shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>The price of our common shares may be volatile
and may fluctuate due to factors beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The share prices of publicly traded emerging
pharmaceutical, biopharmaceutical and drug discovery and development companies have been highly volatile and are likely to remain
highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>positive or negative results of testing and clinical studies by us, strategic partners, or competitors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates
or entry into strategic relationships on terms that are not deemed to be favorable to us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>technological innovations or commercial product introductions by us or competitors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in government regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments concerning proprietary rights, including patents and litigation matters;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>public concern relating to the commercial value or safety of any of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>financing or other corporate transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publication of research reports or comments by securities or industry analysts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general market conditions in the pharmaceutical or biopharmaceutical industry or in the economy as a whole; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other events and factors beyond our control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Broad market and industry factors may materially
affect the market price of companies&rsquo; stock, including ours, regardless of actual operating performance. Furthermore, issuers
such as ourselves, whose securities have historically had limited trading volumes and/or have been susceptible to relatively high
volatility levels, can be particularly vulnerable to short-seller attacks and trading in our common shares by non-fundamental investors
such as hedge funds and others who may enter and exit positions in our common shares frequently and suddenly, causing increased
volatility of our share price. Short selling is the practice of selling securities that the seller does not own but rather has
borrowed or intends to borrow from a third party with the intention of buying identical securities at a later date to return to
the lender, and profit from a decline in the value of the securities in the process. The publication of any commentary by short
sellers with the intent of creating negative market momentum may bring about a temporary, or possibly long-term, decline in the
market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>There is only a limited free float of our common
shares; this may have a negative impact on the liquidity of and the market price for our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date hereof, certain principal
shareholders controlling 5% or more of our common shares as well as our executive officers and directors together beneficially
own approximately 69.2% of our common shares. The limited free float may have a negative impact on the liquidity of our common
shares and result in a low trading volume of our common shares, which could adversely affect the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Certain of our existing shareholders exercise
significant control over us, and your interests may conflict with the interests of our existing shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain principal shareholders as well
as our executive officers and directors together beneficially own approximately 69.2% of our common shares. Depending on the level
of attendance at our general meetings of shareholders, these shareholders may be in a position to determine the outcome of decisions
taken at any such general meeting. To the extent that the interests of these shareholders may differ from the interests of the
Company&rsquo;s other shareholders, the latter may be disadvantaged by any action that these shareholders may seek to pursue.
Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and
might therefore negatively affect the market price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Future sales, or the possibility of future
sales, of a substantial number of our common shares could adversely affect the price of our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Future sales of a substantial number of
our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares.
If certain of our shareholders sell substantial amounts of common shares in the public market, or the market perceives that such
sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in
the future could be adversely affected. We also entered into a registration rights agreement in connection with the Series E Private
Placement with certain investors in the Series E Private Placement, pursuant to which we agreed under certain circumstances to
file a registration statement to register the resale of the common shares held by certain of our existing shareholders, as well
as to cooperate in certain public offerings of such common shares. In October 2020 and August 2018, we filed registration statements
on Form F-3 to register the resale of two of our shareholder&rsquo;s common shares pursuant to the requirements of their registration
rights agreements. In addition, in 2019, we adopted a new omnibus equity incentive plan under which we have the discretion to grant
a broad range of equity-based awards to eligible participants. These shares were registered pursuant to the registration statement
on Form S-8 that we filed with the SEC and, therefore, can be freely sold in the public market upon issuance, subject to volume
limitations applicable to affiliates. If a large number of our common shares are sold in the public market after they become eligible
for sale, the sales could reduce the trading price of our common shares and impede our ability to raise future capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We have broad discretion in the use of our
cash and cash equivalents and short-term financial assets (liquidity) and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our management will have broad discretion
in the application of our cash and cash equivalents and short-term financial assets. Our or our collaboration partners&rsquo; decisions
concerning the allocation of research, development, collaboration, management and financial resources toward particular product
candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away
from better opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs
or product candidates or misread trends in the pharmaceutical or biopharmaceutical industry, in particular for neurodegenerative
diseases, our business, financial condition and results of operations could be materially adversely affected. As a result, we may
fail to capitalize on viable commercial products or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">profitable
market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases
and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable
rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have
been advantageous for us to invest additional resources to retain sole development and commercialization rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We do not expect to pay dividends
in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have not paid any dividends since our
incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings
will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing
dividends. Under our articles of association, the declaration of dividends requires a resolution passed by a simple majority of
the votes cast at a shareholders&rsquo; meeting regardless of abstentions and empty or invalid votes. The proposal to pay future
dividends to shareholders will in addition effectively be at the discretion of our board of directors after considering various
factors including our business prospects, liquidity requirements, financial performance and new product development. In addition,
payment of future dividends is subject to certain limitation pursuant to Swiss law or by our articles of association. Accordingly,
investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares will likely
depend entirely upon any future appreciation in the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are a Swiss corporation. The rights of our
shareholders may be different from the rights of shareholders in companies governed by the laws of US jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss corporation. Our corporate
affairs are governed by our articles of association and by the laws governing companies, including listed companies, incorporated
in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different
from the rights and obligations of shareholders and directors of companies governed by the laws of US jurisdictions. In the performance
of its duties, our board of directors is required by Swiss law to consider the interests of our Company, our shareholders, our
employees and other stakeholders in all cases, with due observation of the principles of reasonableness and fairness. It is possible
that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. Swiss
corporate law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors
in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of
directors but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder
claims against a member of our board of directors for breach of fiduciary duty would have to be brought in Lausanne, Switzerland,
or the country in which the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by
our shareholders against us must be brought exclusively in Lausanne, Switzerland (except for certain US securities and other claims
that may be brought in US federal court).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our common shares are issued under the laws
of Switzerland, which may not protect investors in a similar fashion afforded by incorporation in a US state.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized under the laws of Switzerland.
There can be no assurance that Swiss law will not change in the future in a way detrimental to shareholders or that it will serve
to protect investors in a similar fashion afforded under corporate law principles in the US, which could adversely affect the rights
of investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our status as a Swiss corporation may limit
our flexibility with respect to certain aspects of capital management and may cause us to be unable to make distributions without
subjecting our shareholders to Swiss withholding tax.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law allows our shareholders to authorize
share capital that can be issued by the board of directors without additional shareholder approval. This authorization is limited
to 50% of the existing registered share capital and must be renewed by the shareholders every 2 years. Additionally, as a principle,
Swiss law grants pre-emptive subscription rights to existing shareholders to subscribe to any new issuance of shares. Any ordinary
share capital increase resolution preserving pre-emptive subscription rights expires after 3 months and requires a simple majority
of the votes cast at the shareholder&rsquo;s meeting regardless of abstentions and empty or invalid votes. Swiss law also does
not provide as much flexibility in the various terms that can attach to different classes of shares as do the laws of some other
jurisdictions. Swiss law also reserves for approval by shareholders certain corporate actions over which a board of directors would
have authority in some other jurisdictions. For example, dividends must be approved by shareholders. These Swiss law requirements
relating to our capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">management
may limit our flexibility, and situations may arise in which greater flexibility would have provided substantial benefits to our
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, a Swiss corporation may
pay dividends only if the corporation has sufficient distributable profits from previous fiscal years, or if the corporation has
distributable reserves, each as evidenced by its audited statutory balance sheet. Freely distributable reserves are generally booked
either as &ldquo;free reserves&rdquo; or as &ldquo;capital contributions&rdquo; (<I>apports de capital</I>, contributions received
from shareholders) in the &ldquo;reserve from capital contributions.&rdquo; Distributions may be made out of issued share capital&mdash;the
aggregate nominal value of a company&rsquo;s issued shares&mdash;only by way of a capital reduction. As of December 31, 2020, the
Company has CHF 341.5 million of reserves from capital contributions and CHF 1,537,748 of issued share capital (consisting of 76,887,449
common shares each with a nominal value of CHF 0.02 and no preferred shares) on its audited statutory balance sheet. Of the total
issued shares and issued share capital, the Company holds 5,000,000 fully paid-in treasury shares representing CHF 100,000 of issued
share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect the aggregate of these amounts
(less the lowest legally possible issued share capital and legal reserve of together CHF 150,000) to represent the amount available
for future dividends or capital reductions on a Swiss withholding tax-free basis. We will not be able to pay dividends or make
other distributions to shareholders on a Swiss withholding tax-free basis in excess of that amount unless the Company increases
its share capital or its reserves from capital contributions. We would also be able to pay dividends out of distributable profits
or freely distributable reserves but such dividends would be subject to Swiss withholding taxes. There can be no assurance that
we will have sufficient distributable profits, free reserves, reserves from capital contributions or registered share capital to
pay a dividend or effect a capital reduction, that our shareholders will approve dividends or capital reductions proposed by us,
or that we will be able to meet the other legal requirements for dividend payments or distributions as a result of capital reductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Generally, Swiss withholding tax of 35%
is due on dividends and similar distributions to our shareholders, regardless of the place of residency of the shareholder, unless
the distribution is made to shareholders out of (i) a reduction of nominal value or (ii) assuming certain conditions are met,
reserves from capital contributions accumulated on or after January&nbsp;1, 1997. A US Holder who qualifies for benefits under
the Convention Between the United States of America and the Swiss Confederation for the Avoidance of Double Taxation with Respect
to Taxes on Income, which we refer to as the &ldquo;US-Swiss Treaty,&rdquo; may apply for a refund of the tax withheld in excess
of the 15% treaty rate (or in excess of the 5% reduced treaty rate for qualifying corporate shareholders with at least 10% participation
in our voting stock, or for a full refund in the case of qualified pension funds). There can be no assurance that we will have
sufficient reserves from capital contributions to pay dividends free from Swiss withholding tax, or that Swiss withholding tax
rules will not be changed in the future. In addition, we cannot provide assurance that the current Swiss law with respect to distributions
out of reserves from capital contributions will not be changed or that a change in Swiss law will not adversely affect us or our
shareholders, in particular as a result of distributions out of reserves from capital contributions becoming subject to additional
corporate law or other restrictions. In addition, over the long term, the amount of par value available to us for nominal value
reductions or reserves from capital contributions available to us to pay out as distributions is limited. If we are unable to
make a distribution through a reduction in nominal value or out of reserves from capital contributions, we may not be able to
make distributions without subjecting our shareholders to Swiss withholding taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, the Company held
5,000,000 fully paid-in treasury shares issued initially as part of an ATM offering established in September 2020. These shares
were not sold before December 31, 2020 and are held by the Company for future subscription (or, possibly, as part of a future share-dividend
program, should the Company become profitable and have enough earnings carried forward to cover such distribution). Under present
Swiss tax laws, repurchases of shares for the purposes of cancellation are treated as a partial liquidation and are subject to
35% Swiss withholding tax on the difference between the repurchase price and the nominal value of the shares except, since January&nbsp;1,
2011, to the extent attributable to reserves from capital contributions (<I>apports de capital</I>) if any, and to the extent that
the repurchase of shares is out of retained earnings or other taxable reserves. No partial liquidation treatment applies and no
withholding tax is triggered if the shares are not repurchased for cancellation but held by the Company as treasury shares, provided
the limitations imposed by corporate law are respected (the nominal value of such shares does not exceed 10% of the outstanding
share capital and the purchase price is covered by freely disposable equity). Regarding the above-mentioned 5,000,000 treasury
shares and given the specificities of the ATM offering, the Company has obtained a tax ruling from the Swiss Federal Tax Administration
confirming that their acquisition by the Company did not constitute a direct partial liquidation and therefore does not trigger
withholding tax. A second tax ruling request is pending with the concerned Cantonal Tax Authority at our place of incorporation,
to obtain confirmation that the future placement of these treasury shares for a subscription price superior to their nominal value
will not trigger any corporate income tax for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>US shareholders may not be able to obtain judgments
or enforce civil liabilities against us or our executive officers or members of our board of directors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized under the laws of Switzerland
and our registered office and domicile is located in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Moreover, a number of
our directors and executive officers are not residents of the US, and all or a substantial portion of the assets of such persons
are located outside the US. As a result, it may not be possible for investors to effect service of process within the US upon us
or upon such persons or to enforce against them judgments obtained in US courts, including judgments in actions predicated upon
the civil liability provisions of the federal securities laws of the US. We have been advised by our Swiss counsel that there is
doubt as to the enforceability in Switzerland of original actions, or of actions for enforcement of judgments of US courts, for
civil liabilities to the extent solely predicated upon the federal and state securities laws of the US. Original actions against
persons in Switzerland based solely upon the US federal or state securities laws are governed, among other things, by the principles
set forth in the Swiss Federal Act on Private International Law. This statute provides that the application of provisions of non-Swiss
law by the courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Additionally, certain
mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Switzerland and the US do not have a treaty
providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. The recognition and enforcement
of a judgment of the courts of the US in Switzerland is governed by the principles set forth in the Swiss Federal Act on Private
International Law. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland
only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment of such non-Swiss court has become final and non-appealable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment does not contravene Swiss public policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland,
or was earlier adjudicated in a third state for which the decision is recognizable in Switzerland.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our status as a Swiss corporation means that
our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing
capital needs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law reserves for approval by shareholders
certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment
of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders
themselves resolve, or authorize our board of directors, to increase our share capital. Although our shareholders may authorize
share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization
to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of
up to 2 years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital.
Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss
law grants pre-emptive subscription rights to existing shareholders to subscribe for new issuances of shares. Swiss law also does
not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the
laws of some other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and
situations may arise where greater flexibility would have provided benefits to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Swiss law restricts our ability to pay dividends.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The proposal to pay future dividends to
shareholders will effectively be at the discretion of our board of directors and subject to approval by, at their discretion, our
shareholders after considering various factors including our business prospects, liquidity requirements, financial performance
and new product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">In
addition, payment of future dividends is subject to certain limitations pursuant to Swiss law or our articles of association.
Investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares will likely
depend entirely upon any future appreciation in the price of our common shares. Dividends paid on our common shares are subject
to Swiss Federal withholding tax, except if paid out of reserves from capital contributions (<I>apports de capital</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 10. Additional information-
E. Taxation&mdash;Swiss tax considerations&rdquo; for a summary of certain Swiss tax consequences regarding dividends distributed
to holders of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Shareholders in countries with a currency other
than Swiss Francs face additional investment risks from currency exchange rate fluctuations in connection with their holding of
our common shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any future payments of dividends, if any,
will likely be denominated in Swiss Francs. The foreign currency equivalent of any dividend, if any, paid on our common shares
or received in connection with any sale of our common shares could be adversely affected by the depreciation of the Swiss Franc
against such other currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are a foreign private issuer and, as a result,
we are not subject to US proxy rules and are subject to Exchange Act reporting obligations that, to some extent, are more lenient
and less frequent than those of a US domestic public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are reporting under the Exchange Act
as a non-US company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act
and although we are subject to Swiss laws and regulations with regard to such matters and intend to furnish quarterly financial
information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to US domestic public companies,
including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect
of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public
reports of their stock ownership and trading activities and their liability for insiders who profit from trades made in a short
period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form
10-Q containing unaudited financial and other specified information, or of current reports on Form 8-K, upon the occurrence of
specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until
4 months after the end of each financial year, whereas US domestic issuers that are accelerated filers are required to file their
annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the
Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result
of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>As a foreign private issuer and as permitted
by the listing requirements of Nasdaq, we rely on certain home country governance practices rather than the corporate governance
requirements of Nasdaq.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a foreign private issuer. As a result,
in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country (in this case, Swiss) governance requirements and
certain exemptions thereunder rather than complying with certain of the corporate governance requirements of Nasdaq. Swiss law
does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore may
include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we
are not subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings
at which only independent directors are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although Swiss law also requires that we
adopt a compensation committee, we follow home country requirements with respect to such committee and our compensation, nomination
and corporate governance committee is tasked with certain director nomination and governance responsibilities as described under
&ldquo;Item 6. Directors, senior management and employees.&rdquo; As a result, our practice varies from the requirements of Nasdaq
Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation
committees, and from the independent director oversight of director nominations requirements of Nasdaq Listing Rule 5605(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, in accordance with Swiss law
and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable
to general meetings of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires
an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the
outstanding voting stock. Our articles of association provide for an independent proxy holder elected by our shareholders, who
may represent our shareholders at a general meeting of shareholders, and we must provide</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">shareholders
with an agenda and other relevant documents for the general meeting of shareholders. Our practice varies from the requirement
of Nasdaq Listing Rule 5620(b), which sets forth certain requirements regarding the solicitation of proxies. In addition, we have
opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition
of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a
change of control of us, and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Listing
Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with
such events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For an overview of our corporate governance
principles, see &ldquo;Item 16G. Corporate governance.&rdquo; As a result of the above, you may not have the same protections afforded
to shareholders of companies that are not foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may lose our foreign private issuer status,
which would then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to incur significant
legal, accounting and other expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a foreign private issuer and therefore
we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to US domestic issuers. We may no longer be a foreign private issuer as of June&nbsp;30, 2021 (or the end of our second fiscal
quarter in any subsequent fiscal year), which would require us to comply with all of the periodic disclosure and current reporting
requirements of the Exchange Act applicable to US domestic issuers as of January&nbsp;1, 2022 (or the first day of the fiscal
year immediately succeeding the end of such second quarter). In order to maintain our current status as a foreign private issuer,
either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the
US or (b) (i) a majority of our executive officers or directors may not be US citizens or residents, (ii)&nbsp;more than 50 percent
of our assets cannot be located in the US and (iii)&nbsp;our business must be administered principally outside the US. If we lost
this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to US domestic issuers,
which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes
in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs
to us under US securities laws if we are required to comply with the reporting requirements applicable to a US domestic issuer
may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign
private issuer status would increase our legal and financial compliance costs and would make some activities highly time-consuming
and costly. We also expect that if we were required to comply with the rules and regulations applicable to US domestic issuers,
it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required
to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make
it more difficult for us to attract and retain qualified members of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are an &ldquo;emerging growth company,&rdquo;
and we cannot be certain if the reduced reporting requirements applicable to &ldquo;emerging growth companies&rdquo; will make
our common shares less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart our Business Startups Act of 2012, (JOBS Act). For as long as we continue to be an &ldquo;emerging
growth company,&rdquo; we may take advantage of exemptions from various reporting requirements that are applicable to other public
companies that are not &ldquo;emerging growth companies,&rdquo; including not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act of 2002, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an
&ldquo;emerging growth company&rdquo; until the end of our fiscal year 2021, although circumstances could cause us to lose that
status earlier, including if the market value of our common shares held by non-affiliates exceeds USD 700 million as of any June
30 (the end of our second fiscal quarter) before the end of our fiscal year 2021, in which case we would no longer be an &ldquo;emerging
growth company&rdquo; as of the following December&nbsp;31 (our fiscal year end). We cannot predict if investors will find our
common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive
as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we fail to maintain an effective system
of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As
a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the
trading price of our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective internal controls over financial
reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
are designed to prevent fraud, among other objectives. Any failure to implement required new or improved controls, or difficulties
encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted
in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public
accounting firm, may reveal deficiencies in our internal controls over financial reporting, which are deemed to be material weaknesses
or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention
or improvement. Inferior internal controls could also subject us to regulatory scrutiny and sanctions, impair our ability to raise
revenue and cause investors to lose confidence in our reported financial information, which could have a negative effect on the
trading price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are required to disclose changes made
in our internal controls and procedures and our management is required to assess the effectiveness of these controls annually.
However, for as long as we are an &ldquo;emerging growth company&rdquo; under the JOBS Act, our independent registered public accounting
firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section
404. We could be an &ldquo;emerging growth company&rdquo; until the end of our fiscal year 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, in March 2020, the SEC approved
amendments to exempt from the requirements of Section 404(b) any companies with less than USD 100 million of revenue and less than
USD 700 million of public float. These amendments provide that such companies are no longer required to obtain an attestation of
their internal controls over financial reporting from an independent outside auditor, even if such companies are no longer &ldquo;emerging
growth companies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For as long as we remain an &ldquo;emerging
growth company&rdquo; or are exempt from the requirement of Section 404(b) per the aforementioned SEC amendments adopted in March
2020, we may not be able to detect problems that an independent assessment of the effectiveness of our internal controls could.
Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur
the expense of remediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If securities or industry analysts do not publish
research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our trading volume
could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The trading market for our common shares
will depend in part on the research and reports that securities or industry analysts publish about us or our business. If no or
too few securities or industry analysts cover our company, the trading price for our common shares would likely be negatively affected.
In addition, if one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research
about our business, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our
company or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of
our common shares and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0in"><FONT STYLE="background-color: white"><B><I>We
believe that it is likely that we were a &ldquo;passive foreign investment company,&rdquo; (PFIC) for US federal income tax purposes
in 2020, and may also be a PFIC in 2021 or later years. If we were a PFIC in 2020 or are a PFIC in 2021 or any later year, US shareholders
could be subject to adverse US federal income tax consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Under
the Internal Revenue Code of 1986, as amended Code, we will be a PFIC for any taxable year in which, after the application of certain
look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of passive income or (ii)
50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive
income. Passive income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. Although
we have not obtained independent valuations of our assets during 2020 and thus are not in a position to make a definitive determination
as to whether we were a PFIC in 2020, based on the composition of our income and assets during 2020 and certain estimates and assumptions,
including as to both the total value and the relative value of our assets as implied by our market capitalization during 2019,
we believe that it is likely that we were a PFIC in 2020. In addition, it is possible that we may also be a PFIC in 2021 or one
or more future years because, among other things, (i) we may not generate a substantial amount of non-passive gross income, for
US federal income tax purposes, in any year, (ii) we currently own, and expect to continue to own, a substantial amount of passive
assets, including cash, and (iii) the estimated valuation, for PFIC purposes, of our assets that generate non-passive income for
PFIC purposes, including our intangible assets, is likely to be dependent in large part on our market capitalization and is therefore
uncertain and may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC in 2021 or any
future taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">If
we were a PFIC in 2020 or in any future year during which a US investor held or holds common shares, we generally would continue
to be treated as a PFIC with respect to that US investor for all succeeding years during which the US investor holds common shares,
even if we ceased to meet the threshold requirements for PFIC status. Such a US investor may be subject to adverse US federal income
tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application
of a deferred interest charge on such gain and the receipt of certain dividends and (iii) compliance with certain reporting requirements.
We do not intend to provide the information that would enable investors to take a qualified electing fund election that could mitigate
the adverse US federal income tax consequences should we be classified as a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">For
further discussion, see &ldquo;Item 10. Additional information&mdash;Section E. Taxation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item04"></A>ITEM 4. INFORMATION ON THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item04a"></A>A.</TD><TD>History and development of the company</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss stock corporation (<I>soci&eacute;t&eacute;
anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute;
&agrave; responsabilit&eacute; limit&eacute;e</I>) on February&nbsp;13, 2003 with our registered office and domicile in Basel,
Switzerland. We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on
August 25, 2003. Our Swiss enterprise identification number is CHE-109.878.825. Our domicile and registered office is in Ecublens,
at the &Eacute;cole Polytechnique F&eacute;d&eacute;rale Lausanne (EPFL) Innovation Park Building B, 1015 Lausanne, Vaud, Switzerland.
Our ordinary shares were admitted to trading on Nasdaq Global Market on September&nbsp;23, 2016, and trade under the symbol ACIU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our registered and principal executive
offices are located in Ecublens, at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number
is (41) 21 345 91 21 and our internet address is www.acimmune.com. Our website and the information contained on or accessible through
our website are not part of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item04b"></A>B.</TD><TD>Business overview</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune is a leading, clinical stage
biopharmaceutical company advancing one of the broadest portfolios focused on pioneering precision medicine for neurodegenerative
diseases. Our highly differentiated approach integrates novel therapeutics and diagnostics to overcome the fundamental challenge
in this therapeutic area &ndash; the high number of co-pathologies driving disease and the urgent need for more tailored therapeutic
regimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Leveraging our dual proprietary technology
platforms, we have built a comprehensive pipeline of first-in-class or best-in-class candidates spanning multiple treatment modalities
and targeting both established and emerging neurodegenerative pathologies. We are currently advancing nine therapeutic and three
diagnostic product candidates, with six currently in clinical trials, targeting five different types of misfolded pathological
proteins related to AD and other neurodegenerative disorders. Our pipeline assets are further validated by the multiple partnerships
we have established with leading global pharmaceutical companies. We believe our validated technology platforms and personalized
medicine approach position AC Immune to revolutionize the treatment of neurodegenerative disease in the way precision diagnostics
and targeted therapies are revolutionizing the treatment of cancer.<BR>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 1: AC Immune
investment highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 242.25pt; width: 450.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our Team </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have assembled an outstanding management
team with relevant scientific, clinical and regulatory expertise. Our scientific founders, Dr.&nbsp;Jean-Marie Lehn, Dr.&nbsp;Claude
Nicolau, and Dr.&nbsp;Fred van Leuven, are regarded as pioneers in their respective scientific domains, including in the study
of AD. Our co-founder and Chief Executive Officer, Dr.&nbsp;Andrea Pfeifer, a Pharmacologist with a Ph.D. in cancer research and
a former National Institute of Health researcher, has a 30-year track record in product innovation and implementation, and was
formerly Head of Nestl&eacute; Global Research and the co-founder of Nestl&eacute; Venture Fund. Dr. Marie Kosco-Vilbois, our Chief
Scientific Officer, brings more than 20 years of experience in various aspects of discovery research and drug development, including
work on multiple drug development programs. In January 2021, Prof. Johannes Rolf Streffer joined AC Immune as our Chief Medical Officer.
Prof. Streffer is a Neurologist and Psychiatrist with extensive expertise in AD including biomolecular modalities such as PET,
volumetric and functional MRI, genetics, cognition and cerebrospinal fluid (CSF) marker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unmet need in neurodegenerative diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 2: The World Health Organization
recognizes dementia as a global public health priority</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 212.25pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neurodegenerative diseases, including dementias
and other diseases associated with protein misfolding, are prevalent, but there is currently an absence of reliable, early-stage
diagnosis and disease-modifying treatments for these diseases. The growth in the number of people with neurodegenerative diseases
has been significant, as evidenced by the prevalence of people affected by AD and PD, two of the most common neurodegenerative
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The World Health Organization recognizes dementia as a global public health priority<B>. </B>Worldwide, there is a new case
of dementia every 3 seconds, with an estimated global patient population of approximately 50&nbsp;million in 2020. This is predicted
to increase to 152&nbsp;million by 2050 (Alzheimer&rsquo;s Disease International).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The estimated total healthcare costs for the treatment of Alzheimer disease in the United States in 2020 is estimated to be
USD 305 billion per the Alzheimer&rsquo;s Association, with the cost expected to increase to more than USD 1 trillion by 2050 as
the population ages. In fact, if the estimated global costs of dementia were a country, it would be the 18<SUP>th</SUP> largest
economy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Current diagnostic and treatment paradigms
for neurodegenerative diseases are suboptimal. Diagnosis typically takes the form of observation of cognitive, functional and behavioral
impairment and other symptoms of the diseases, which are generally only apparent after irreversible neuronal damage has already
occurred. These symptoms are treated with medicines capable of providing cognitive benefit and functional improvement but fail
to affect the progression of the disease. For AD, there are currently five approved therapies, all of which only provide modest
efficacy in treating the symptoms of AD, while having significant side effect risks, and fail to address the progression of the
disease. Despite these shortcomings, marketed therapies, such as Eisai and Pfizer&rsquo;s Aricept, have achieved peak annual global
sales of approximately USD 4&nbsp;billion prior to loss of exclusivity. Similarly, in the treatment of PD, the current standard
of care is intended only to alleviate physical symptoms. In both AD and PD, there are no approved disease-modifying treatments
that slow or stop the course of disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neurodegenerative disease overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Folding and unfolding of proteins are important
ways of regulating the biological activity and cellular location of those proteins. Misfolding of proteins occurs due to a breakdown
of cellular quality control systems and is a common feature of many neurodegenerative diseases. Misfolded proteins are unable to
carry out their normal functions and aggregate to form insoluble deposits in the brain, which eventually lead to neuronal damage
and cell death. The progression of neurodegenerative diseases, such as AD and PD, is linked to the spread of misfolded, pathological
protein aggregates throughout the brain. Figure 3 shows how misfolded proteins play a key role in the pathology of neurodegenerative
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Figure 3: Misfolded proteins key impact
on the pathology of neurodegenerative diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 157.5pt; width: 411.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Typically, protein misfolding occurs in
response to cellular stress, which can be triggered by many different, largely unknown, causes. A cascade of molecular events begins
with the misfolding of single proteins within a cell, which then aggregate and ultimately form larger aggregates including plaques
and tangles. These misfolded proteins are then exported or shed from dying neurons where they can spread to healthy cells nearby.
Once inside, misfolded proteins can interact with normal proteins and cause them to misfold in a process known as &ldquo;seeding,&rdquo;
leading to spreading of the disease pathology throughout the brain, increased neuronal death and a progressive decline in cognitive
function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Figure 3 also shows how our therapies are
designed to intervene and prevent key pathological steps in the progression of neurodegenerative diseases. They are designed to
(i) prevent initial misfolding; (ii) promote disaggregation of misfolded proteins; (iii) inhibit spreading of pathological protein
to healthy cells; (iv) prevent seeding of new misfolded protein aggregates inside healthy cells; and (v) inhibit downstream neurodegeneration.
This robust approach to targeting neurodegenerative diseases is enabled by our two validated technology platforms, SupraAntigen
and Morphomer, which generate highly specific biologics and small molecule inhibitors that can distinguish normal from misfolded
proteins and inhibit key disease pathways both inside and outside of cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our strategic vision</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our goal is to continue leveraging our
proprietary discovery platforms, SupraAntigen and Morphomer, to become a global leader in precision medicine for the diagnosis
and treatment of neurodegenerative diseases. We are executing a clear business strategy built on three pillars: (i) accelerate
development of novel therapeutics in AD with our partners; (ii) expand our strategic focus in non-AD neurodegenerative diseases,
including NeuroOrphan indications, Parkinson&rsquo;s disease (PD) and limbic-predominant age-related TDP-43 encephalopathy (LATE);
and (iii) a continued focus on diagnostics enabling precision medicine to be an ultimate differentiator for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>Figure 4: AC Immune&rsquo;s
three-pillar strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 192.75pt; width: 420pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our three-pillar execution strategy reflects
our unique precision medicine approach, which ultimately creates differentiation due to our ability to address the high levels
of co-pathologies present in AD and other neurodegenerative diseases. Much like cancer, neurodegenerative diseases are heterogeneous
and may require multiple therapeutic interventions tailored to patients&rsquo; specific disease drivers, to be used in concert
in order to slow or stop the disease course. Ultimately, it is our belief that precision medicine will increase the chance of treatment
success by enabling clinical trial participants to be better defined by their various proteinopathies, affording treatment with
the right therapies at the right time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.25in">AC Immune has established itself
as a leader in developing precision medicines for neurodegenerative diseases by utilizing our diagnostic capabilities to enable
improved diagnosis of co-pathologies, patient selection and assessment of clinical trial outcomes. Our dual technology platforms
allow for a multi-modal approach encompassing a portfolio of vaccines, antibodies and small molecules tailored to the underlying
pathology driving patients&rsquo; disease. In addition to generating targeted monotherapies, this approach creates the potential
for combination regimens, which may treat a broader spectrum of disease and offer greater efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune&rsquo;s <I>Roadmap to Successful Therapies for
Neurodegenerative Diseases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Precision medicine is a key element of
our five-point framework for developing successful therapies in neurodegenerative diseases, building on one of the broadest pipelines
in the field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 5: AC Immune&rsquo;s roadmap to
successful therapies for neurodegenerative diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 192pt; width: 407.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Treat earlier</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Identifying patients at risk or in early
stages of disease when pathological burden is low and neuronal health is preserved offers the best chance of intercepting pathological
spread in neurodegenerative diseases. For example, it is now believed that treatments targeting beta-amyloid (Abeta) may be most
effective before</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">symptoms
become apparent. The Alzheimer&rsquo;s Prevention Initiative (API) trial of crenezumab aims to answer this fundamental question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Target Tau</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Tau plays a very important role in neurodegeneration.
Understanding whether the aggregation and spreading of pathological Tau throughout the brain can be stopped by therapies targeting
Tau is a critical question that we are examining. This is being addressed through AC Immune&rsquo;s multiple Tau research programs
in early and late-stage diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>More homogeneous populations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Multiple pathologies are thought to contribute
to the development of AD, including genetic, lifestyle and environmental factors. To understand if a candidate drug has therapeutic
potential, it is important to first engage more genetically homogeneous patient populations to minimize variability with respect
to pathophysiology. We are developing these efforts with our prevention studies in genetically defined populations such as familial
AD and DS-related AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Precision medicine</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Building on the understanding that multiple
pathologies contribute to AD, there is a need to accurately diagnose and target the underlying pathology. We are developing an
integrated diagnostic and therapeutic strategy to deliver, for the first time, precision medicine for patients with neurodegenerative
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Target neuroinflammation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">It is well established that microglia maintain
a healthy brain environment by clearing debris, including misfolded and aggregated Abeta, Tau and alpha-synuclein (a-syn). Chronic
hyper-stimulation of microglial cells by these protein aggregates is now emerging as a hallmark of AD &ndash; and potentially all
neurodegenerative diseases &ndash; that leads to unwanted inflammation and further damage to brain cells. We focus on the NOD-like
receptor pyrin domain-containing protein 3 (NLRP3) inflammasome pathway, based on emerging evidence showing its particular relevance
for neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key elements of our approach include:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Execution
on advancing our product candidates, in partnership or alone, from clinical development to regulatory approval and potential commercialization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 6: Our broad and robust established
targets pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 163.5pt; width: 366pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our clinical stage product candidates include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>ACI-35.030</I>.</B> Janssen and AC Immune are evaluating the anti-phosphorylated-Tau (anti-pTau) vaccine candidate ACI-35.030
in a Phase 1b/2a study in early AD. Interim results show that ACI-35.030 vaccination generated a potent antigen-specific antibody
response against pTau in 100% of older patients, achieving antibody levels several orders of magnitude higher than pre-vaccination
levels. No</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">vaccine relevant adverse events
were observed. These results support plans to further develop the Alzheimer Vaccine into Phase 2/3. ACI-35.030 specifically targets
pathological pTau and is intended as a disease-modifying treatment for AD and other Tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Semorinemab</I>.</B><I>&nbsp;</I>Our collaboration partner, Genentech, a member of the Roche Group, is currently completing
a Phase 2 clinical program for our anti-Tau monoclonal antibody semorinemab. A Phase 2 study (Tauriel) conducted in patients with
prodromal-to-mild AD was completed in Q3 2020 and <FONT STYLE="background-color: white">did not meet its primary efficacy endpoint
of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. A</FONT> second Phase 2 study (Lauriet)
conducted in patients with moderate AD remains ongoing with primary completion estimated in Q2 2021. Semorinemab is designed to
slow the prion-like propagation of Tau pathology, which coincides with both clinical symptoms and disease progression in AD.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Morphomer Tau. </I></B>In collaboration with our partner, Lilly, we are researching and developing small molecule Tau
aggregation inhibitors with plans to evaluate candidates in AD and NeuroOrphan indications. We completed a Phase 1 clinical study
in healthy volunteers with ACI-3024, in Q2 2020, which showed a dose-dependent exposure and brain penetration, achieving the desired
levels of ACI-3024 in the cerebrospinal fluid. In addition to AD, the program was expanded to NeuroOrphan indications and ACI-3024
will be further evaluated for efficacy in models of rare Tauopathies. Continued candidate characterization across the research
program has also identified new and highly differentiated candidates with excellent cerebrospinal fluid exposure and selectivity
for pathological aggregated Tau. These will be broadly developed in Tau-dependent neurodegenerative diseases.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>ACI-24.</I></B> We currently own the global rights to our anti-Abeta vaccine candidate ACI-24, and we continue to develop
this asset in-house for AD and DS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>ACI-24 for AD. </I></B>A Phase 2 study commenced in October 2018 and is currently ongoing to assess the safety, tolerability,
immunogenicity and target engagement of ACI-24 formulations using intramuscular injections, and to analyze the effects of ACI-24
on brain amyloid as assessed by PET imaging. Encouraging 12-month interim results were reported and results from the 18-month interim
analysis are expected in Q2 2021. The previous Phase 1/2 study was completed and the clinical study report finalized in 2019.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>ACI-24 for DS. </I></B>Our Phase 1b clinical study of ACI-24 for individuals with DS, intended to assess safety, tolerability
and immunogenicity at two doses, was completed and results reported in Q1 2021. The results support a favorable safety and tolerability
profile of ACI-24 in this vulnerable patient population and the advancement of this program into Phase 2 studies, the initiation
of which will be determined by appropriate public safety measures related to Covid-19.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Crenezumab.</I></B> The parent of our collaboration partner discontinued, as of January 2019, the Phase 3 clinical trials
in AD but is continuing in a landmark prevention trial in Columbia, in a population of genetically predisposed people at risk of
developing familial AD. The overall beneficial safety profile was confirmed in the CREAD studies, supporting use of crenezumab
in healthy individuals with risk of developing AD.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Diagnostic candidates</I>.</B> In addition to the above product candidates, we will continue to develop our complementary
diagnostic product candidates for Tau (with LMI), a-syn and TDP-43 to advance these through clinical development, either independently
or with collaboration partners.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expand
product development into NeuroOrphan and additional neurodegenerative diseases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Beyond AD, we aim to pursue NeuroOrphan
indications, specifically Tau- and TDP-43-driven diseases, such as FTLD-Tau (e.g., PSP, CBD, FTLD-MAPT), and ALS and FTLD-TDP,
respectively. Pursuing NeuroOrphan indications may enable us to obtain a streamlined regulatory approval pathway and favorable
reimbursement for any approved products. In addition, we are accelerating our novel therapeutic and diagnostic candidates targeting
a-syn as a primary pathology in Parkinson&rsquo;s disease and other a-synucleinopathies. A summary of our diversified novel targets
pipeline including non-AD neurodegenerative diseases, with an in-house focus on NeuroOrphan indications, is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 7: Robust
novel targets pipeline: diversification into non-AD and non-CNS diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_007.jpg" ALT="" STYLE="height: 201pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B><I>3.</I></B></TD><TD><B><I>Accelerating the advancement of our diagnostic portfolio</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To realize our vision for precision medicine
in neurodegenerative disease, we are developing a suite of companion diagnostics designed to be first-in-class or best-in-class,
which will enable improved diagnosis of co-pathologies, patient selection and assessment of clinical trial outcomes. We currently
have three families of diagnostic candidates in our pipeline, developed using our Morphomer platform; each addresses a key therapeutic
target: Tau, a-syn and TDP-43.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The most advanced clinical candidate is
PI-2620, our Tau-PET imaging agent. We are working with our partner, LMI, to advance PI-2620 as a highly differentiated, best-in-class
Tau diagnostic for AD as well as non-AD Tauopathies such as PSP. A study published in <I>JAMA Neurology</I> showed that PI-2620
could facilitate earlier and more reliable diagnosis of PSP, where previous Tau tracers and other biomarkers failed. Further, results
demonstrated PI-2620&rsquo;s excellent characteristics as a diagnostic tool for studying Tau-related diseases following recent
publications about its capabilities in early and more advanced AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also developing proprietary PET
imaging diagnostics for diseases resulting from the misfolding of a-syn and TDP-43 proteins. No such diagnostics are currently
available for these important pathologies and AC Immune has identified promising compounds with high affinity and target specificity,
as well as favorable central nervous system (CNS) pharmacokinetic properties. In 2020, the a-syn-PET tracer won the Ken Griffin
Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation for Parkinson&rsquo;s Research. Our novel TDP-43-PET tracer
and our antibody-based immuno-assay for biofluid detection of TDP-43 also were awarded highly competitive grants from the EU Joint
Programme &ndash; Neurodegenerative Disease Research&rsquo; (JPND) and The Target ALS Foundation, respectively, in 2020. Our diagnostics
for a-syn and TDP-43, if validated clinically, will be the first in the world to effectively diagnose these proteinopathies, which
are highly relevant for multiple neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B><I>4.</I></B></TD><TD><B><I>Continuing to optimize our long-term growth by selectively partnering product candidates for global development and commercialization</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a strong track record of establishing
value-driving collaboration agreements with leading pharmaceutical companies, including two collaborations with Genentech, one
with Janssen and one with Lilly. This strategy allows us to leverage our partners&rsquo; scientific, development, manufacturing
and commercialization expertise and other resources while partially monetizing our investments, de-risking and accelerating the
development of our product candidates. This strategy also enables us to use non-dilutive partnership revenue to bolster our investment
into our early-stage proprietary programs and fuel our continued growth. We have five current collaboration agreements with leading
global pharmaceutical companies, summarized in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 8: External
validation and cash generation through external collaborations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_008.jpg" ALT="" STYLE="height: 194.25pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For any additional product candidates targeting
large markets, we may selectively partner with leading companies that we believe can contribute development, manufacturing and
marketing expertise, geographic reach and/or other resources that can enhance the value of our wholly-owned products. We will continue
to seek to retain certain indications (e.g., NeuroOrphan) and/or geographies, such that we can begin to grow our own marketing
capabilities as we develop AC Immune into a fully integrated pharmaceutical company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, in this respect, we established
a strategic partnership with WuXi Biologics for its expertise in manufacturing biologicals as well as the application of our vaccine
portfolio in China and potential collaborations regarding AC Immune&rsquo;s SupraAntigen platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The benefits of our clinically validated, proprietary technology
platforms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The engines that drive our growth are our
two unique proprietary and versatile technology platforms: our SupraAntigen platform, which is our biological and immunological
platform, and our Morphomer platform, which is our chemical platform. These platforms generate biologics (vaccines and antibodies)
and small molecules, respectively, which are designed to selectively interact with the misfolded proteins that are common in a
broad range of neurodegenerative diseases. These clinically validated platforms form the basis of our ongoing pipeline development
and the value-driving strategic partnerships we have established to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The key aspect of both our SupraAntigen
and Morphomer technology platforms is conformational specificity, which we believe is central to the development of effective and
safe therapeutics for neurodegenerative diseases. Our SupraAntigen platform targets misfolded proteins through antigens displayed
on the surface of liposomes, which mimic the targeted pathological form of the protein. In a complementary approach, our Morphomer
platform uses small molecular weight compounds to target the aggregation and seeding process, which prevents the misfolded proteins
from aggregating inside the cell and prevents the formation of new misfolded proteins in healthy neighboring cells through a seeding
mechanism. Small molecules derived from our Morphomer platform, which we refer to as Morphomers, not only reduce aggregation of
pathological proteins, but also promote disaggregation of already formed aggregates, thereby potentially enhancing their therapeutic
potential even in established disease states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 17.85pt"><B>Figure 9: Morphomer
and SupraAntigen platforms: an integrated approach to CNS-specific therapies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_009.jpg" ALT="" STYLE="height: 178.5pt; width: 411.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SupraAntigen platform was first developed
by AC Immune&rsquo;s scientific co-founders to overcome a challenge common to neurodegenerative diseases: the lack of immunogenicity
of disease-causing self-proteins. The SupraAntigen platform uses liposomes (small spherical vesicles formed by a lipid bilayer)
to present specific antigens designed to evoke an immune response. SupraAntigen is used to generate conformation-specific antibodies
for immunotherapy in neurodegenerative diseases. The overarching idea behind the platform is that antibodies, which are large in
size, are well-suited to target extracellular proteins, interrupt spreading of pathological proteins, and break up and clear aggregates
of misfolded proteins through phagocytosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune has acquired advanced mastery
of the design and manipulation of liposomes to develop either passive or active immunization techniques to generate antibodies
targeting neurodegenerative diseases. When pursuing active immunization approaches, we use liposomes carrying a specific antigen
as a vaccine. After vaccination with a liposome, antigen and confirmation specific antibodies are produced naturally by the host
with very high affinity without further optimization. This immune response can be long-lasting and may be ideal to prevent the
onset of a disease, as the immune system is now primed to rapidly identify disease-causing misfolded proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Product candidates generated utilizing
the SupraAntigen platform include vaccines ACI-35 in Phase 1b/2a for AD and ACI-24 in Phase 2 for AD and Phase 1b for DS, as well
as antibodies semorinemab in Phase 2 for AD, crenezumab in Phase 2 for AD and the preclinical candidates targeting a-syn and TDP-43
for PD and NeuroOrphan indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Morphomer platform is designed to enable
the development of small molecules (Morphomers) able to bind/interact with beta-sheets containing fibrillary aggregates from candidate
selection through preclinical proof-of-concept. Morphomers can target pathological protein aggregates in any brain compartment
and are equally well suited for therapeutic and diagnostic applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The first key component of the Morphomer
platform is its library of rationally designed, CNS-optimized non-dye compounds. AC Immune&rsquo;s extensive know-how has enabled
the identification of CNS compounds that penetrate the brain and demonstrate high selectivity for the target. This knowledge has
been used to focus the Morphomer library to approximately 12,000 compounds that display these favorable characteristics, making
this library an ideal starting point when developing molecules to target human proteinopathies of the CNS. Thus, rather than using
the non-directed trial and error strategy of the typical drug development process, the Morphomer platform utilizes its bias for
successful CNS candidates to improve efficiency and accelerate the early stages of the drug development process. Extensive expertise
in medicinal chemistry and a suite of proprietary assays developed to screen and validate candidate compounds enables AC Immune
to rapidly optimize multiple, highly diversified lead compounds for further preclinical and clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Therapeutic product candidates generated
by the Morphomer platform include our lead Morphomer Tau candidates, Morphomer a-syn in PD (preclinical stage) and the diagnostic
programs PI-2620 in Phase 2 and Phase 1 in AD and PSP, respectively, and a-syn-PET and TDP-43-PET imaging agents in the preclinical
stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shifting the current treatment paradigm for neurodegenerative
diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Modifying the progression of the disease
requires targeting the specific underlying biological processes that drive disease progression. Unfortunately, these processes
evolve over the course of many years prior to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">manifestation
of symptoms and a high percentage of neurons may be lost prior to clinical manifestation. Earlier intervention could have a major
impact, but it requires accurate disease detection prior to developing symptoms. Thus, in addition to highly targeted therapeutics,
new precision diagnostics are critical to the clinical development and effective deployment of potentially disease-modifying therapies.
This early, and potentially preventative, precision medicine approach may ultimately lead to better disease management for patients
with neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 10: Treatment
and diagnosis of AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_010.jpg" ALT="" STYLE="height: 183pt; width: 417.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Due to the high level of co-pathologies
involved in neurodegenerative diseases, future treatment paradigms for may involve different combinations of disease modifiers
at various stages of a disease. Therefore, combination therapies may include combinations of immunotherapies or combinations of
small and large molecules targeting proteinopathies and neuroinflammation. Our therapeutic product candidates seek to modify the
course of AD by intervening at an earlier stage of the disease progression, prior to irreversible neuronal damage. Beyond AD, we
believe that we can leverage our proprietary platforms to generate additional molecules that address the pathologies of other neurodegenerative
diseases (Figure 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 11: Market
opportunities targeting key primary and co-pathologies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_011.jpg" ALT="" STYLE="height: 171.75pt; width: 424.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, we believe that we are a leader
in discovering new PET imaging agents to improve the timing and accuracy of diagnoses in neurodegenerative diseases. In our pipeline,
we have three families of diagnostic candidates that were developed through our Morphomer platform, which target Tau, a-syn and
TDP-43. We believe our Tau-PET imaging program has received external validation through our partnership with LMI, a leader in imaging
agents. We are also developing a-syn and TDP-43 PET imaging agents for PD and other neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With our unique integrated approach focused
on precision medicine, we believe that our diagnostic product candidate pipeline will complement our disease-modifying treatment
product candidate pipeline and potentially reshape the clinical course and treatment of neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><IMG SRC="image_012.jpg" ALT="" STYLE="height: 195.75pt; width: 450.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-pTau vaccine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In collaboration with Janssen, we are advancing
an anti-pTau vaccine program directed against a key component of the pathology of AD: phosphorylated Tau proteins, found in Tau
tangles. Developed using our SupraAntigen technology, our vaccine is designed to stimulate a patient&rsquo;s immune system to produce
antibodies against misfolded and phosphorylated, pathological Tau protein, which aggregate to create the neurofibrillary tangles
that characterize AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Advantages of Tau vaccination over other therapeutic approaches</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Tau vaccines which are able to induce a
long-lasting and boost-able antibody response have the potential to be even more advantageous than other anti-Tau therapeutic modalities
such as small molecules or monoclonal antibodies, which typically show much shorter half-lives <I>in vivo</I>, requiring more frequent
administration. Tau vaccines such as ACI-35.030 may thus offer a more cost effective, and less invasive approach for the treatment
or prevention of Tau pathology, which may be particularly relevant for addressing slow-progressing chronic neurodegenerative Tauopathies
such as AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACI-35</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">ACI-35 is a liposomal anti-pTau active
investigational vaccine designed to elicit antibodies against extracellular pTau protein in order to prevent and reduce the spread
and development of Tau pathology within the brain. In preclinical testing, the vaccine candidate induced an antibody response that
was highly specific to phosphorylated Tau. This antibody response resulted in a significant reduction of pTau and an improvement
in clinical parameters. ACI-35 was the first vaccine candidate against pathological pTau to be tested in a clinical study involving
patients with mild-to-moderate AD. The Phase 1b study was completed in June 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Mechanism of action</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ACI-35 is composed of a human pTau synthetic peptide T3 as the antigen, derived from Tau sequence 393-408 and phosphorylated
at serine residues S396 and S404. Lipidation of the peptide enables it to embed itself into the lipid bi-layer of the liposome
and confers a specific conformation to the peptide (Theunis <I>et al.</I>, PLoS ONE 2013).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In wild-type and transgenic mice, immunization with ACI-35 generated a specific antibody response to phosphorylated vs. non-phosphorylated
Tau protein (Vukicevic <I>et. al.</I> AAT-AD/PD 2020).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In transgenic mice, immunization with ACI-35 led to a significant decrease of soluble and insoluble total Tau protein and insoluble
pTau species in brain (Figure 12).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 12: Immunization
of hTauP301L mice leads to a reduction of the levels of pS396 and HT7 in the Sarkosyl insoluble forebrain of Tau.P301L mice </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_013.jpg" ALT="" STYLE="height: 186.75pt; width: 324.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Theunis <I>et al.</I>, PLoS ONE 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Clinical development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Phase 1b study design</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The safety, tolerability and immunogenicity
of ACI-35 were tested in a Phase 1b study in patients with mild-to-moderate AD. It was a randomized, placebo-controlled, double-blind
study. Different doses and dosing schedules were investigated in an ascending dose design. Multiple injections of ACI-35 were administered
per cohort for active or placebo treatment in a three-to-one ratio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Safety</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The ACI-35 vaccine is considered to be
safe and well tolerated with no events related to CNS inflammation. As previously reported, five SAEs were observed in three patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Antibody response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-35 elicited a rapid induction of anti-pTau
antibodies after the first immunization in all study cohorts, indicating a T-cell-independent antibody response. However, this
response lacked the boosting effect desired for optimal long-term and potentially preventive application. Therefore, in a collaborative
effort, AC Immune and Janssen successfully developed an optimized anti-Tau vaccine, ACI-35.030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACI-35.030</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-35.030 is an optimized liposomal anti-pTau
vaccine formulation designed to elicit an enhanced antibody response. In preclinical studies, ACI-35.030 showed that it retains
the excellent non-clinical safety profile and the highly specific antibody response against pTau observed with ACI-35, while demonstrating
an enhanced and more homogeneous antibody response with a significant, long-lasting boosting effect. We are developing ACI-35.030
with Janssen in accordance with our collaboration agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Mechanism of Action</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ACI-35.030 comprises a pTau peptide and a T-cell epitope capable of binding to human leukocyte antigen-major histocompatibility
complex, class II (HLA-DR) molecules.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In rhesus monkeys, ACI-35.030 induced a specific response to pTau over non-phosphorylated Tau, similar to that observed with
ACI-35 (Vukicevic <I>et. al.</I> AAT-AD/PD 2020). This is significant as Tau hyper-phosphorylation is considered an early event
in the development of Tau pathology, occurring even several decades before the onset of Tau deposits.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Sera from rhesus monkeys immunized with ACI-35.030 binds specifically to pathological Tau in brain sections with AD as compared
to healthy human brain tissue (Kosco-Vilbois, KOL event</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&lsquo;Untangling&rsquo; Tau
Pathology to Treat Alzheimer&rsquo;s and Neurodegenerative Diseases NYC, Nov 2019)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In nonclinical studies, immunization with ACI-35.030 elicits an enhanced and homogeneous antibody response with boosting effect.
In non-human primates (NHPs), immunization with ACI-35.030 lead to an increased level of specific anti-pTau IgG titers compared
to ACI-35 (Figure 13).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 13: pTau-specific IgG titers in
NHP induced by ACI-35.030 and ACI-35</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_014.jpg" ALT="" STYLE="height: 149.25pt; width: 367.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Dr. Marie Kosco-Vilbois, KOL event
&lsquo;Untangling&rsquo; Tau Pathology to Treat Alzheimer&rsquo;s and Neurodegenerative Diseases 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>JACI-35.054</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">JACI-35.054 is an investigational exploratory
alternative pTau vaccine, which is developed with Janssen in accordance with our collaboration agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Mechanism of action</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>JACI-35.054 is an alternative anti-pTau vaccine.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Immunization of rhesus macaques with JACI-35.054 generates an immune response that specifically binds to pathological tau structures
in human AD brain sections.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Clinical development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Phase 1b/2a study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Phase 1b/2a study is a randomized,
multicenter, double-blind, placebo-controlled clinical study with a primary objective to assess the safety, tolerability and immunogenicity
of different doses of ACI-35.030 and JACI-35.054 in patients with early AD. Secondary objectives will assess additional immunogenicity
parameters, while exploratory endpoints will include notable biomarkers of progression of AD as well as clinical assessments. This
Phase 1b/2a study evaluating ACI-35.030 and JACI-35.054 was initiated in Q3 2019 and is currently ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Safety</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, a total of
16 patients (six on active vaccination and two on placebo per sub-cohort) have been randomized in the first two dose-level cohorts
with ACI-35.030 and vaccination has commenced in the 3rd dose-level sub-cohort. In addition, a further eight subjects (six subjects
on active vaccination and two on placebo) have been randomized to the first dose-level sub-cohort with JACI-35.054 in the Phase
1b/2a study, and the recruitment will be pursued in the subsequent sub-cohorts. Two SAEs have been reported to date, an episode
of acute diverticulitis and one sick sinus syndrome, both of them are considered unlikely related to the study treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><I>Antibody response
(interim)</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Based on interim results from the first
two dose-level sub-cohorts, ACI-35.030 vaccination resulted in an anti-Tau IgG response that preferentially targets phosphorylated
Tau in all patients. 100% of patients demonstrated an anti-pTau IgG response after the 1st injection for both lowest and second
highest dosages. Very high anti-pTau IgG titers were observed following injection. An anti-pTau IgM response was also elicited
in all patients for both doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Semorinemab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Semorinemab is a humanized high-affinity
IgG4 isotype antibody candidate discovered using our SupraAntigen technology that binds all forms of Tau. Semorinemab is designed
to intercept extracellular Tau, stopping or slowing cell-to-cell spread and propagation of pathological Tau in the brain. Semorinemab
is in Phase 2 clinical development for AD as part of an ongoing collaboration, which was established in 2012, with Genentech.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Lead characterization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our anti-Tau monoclonal antibody program
successfully generated multiple humanized antibodies for potential use as passive immunotherapies, which are highly specific for
pathological forms of Tau found in AD and other Tauopathies. Results from preclinical studies demonstrated a reduction in pathological
Tau and improvement of long-term spatial memory. Efficacy studies run in mouse models of AD and other Tauopathies exhibited dose&ndash;response
alleviation of Tau pathology with behavioral improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 14: Alleviation
of Tau pathology in models of AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_015.jpg" ALT="" STYLE="height: 105pt; width: 408.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 32.6pt 0pt 17.85pt">Ref: Ayalon <I>et al.,</I> AD/PD 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 32.6pt 0pt 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 32.65pt 0pt 0.25in">Representative images of hippocampal coronal
sections from human Tau-P301L transgenic mice treated with (<B>A</B>) control antibody or (<B>B</B>) semorinemab, and immunostained
for pathological Tau deposits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 32.65pt 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Clinical development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A Phase 1 clinical trial involving 75 subjects
evaluated the safety, tolerability, pharmacokinetics and preliminary data on therapeutic activity of semorinemab in people with
AD and in healthy volunteers. This trial was completed in the second quarter of 2017. Semorinemab was administered at single doses
of up to 16,800 mg to healthy volunteers, and at multiple doses of 8,400 mg to healthy volunteers and patients with mild-to-moderate
AD. No dose-limiting toxicities and no SAEs were observed. No participant withdrawals, modifications or interruptions due to an
adverse event were reported. Results were presented at multiple conferences, including the 13<SUP>th</SUP> International Conference
on Alzheimer's &amp; Parkinson's Diseases and Related Neurological Disorders (AD/PD) in 2017, the AAIC in 2017, and the 10<SUP>th</SUP>
international CTAD conference in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Semorinemab exhibited a dose-proportional
pharmacokinetic profile and CNS exposure, with a median half-life of 32.3 days. Plasma total Tau concentration increased with increasing
drug doses and was doubled in participants with AD compared with healthy volunteers, suggesting a pharmacodynamic signal as shown
in the figure below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 15: Phase
1 pharmacokinetic and plasma Tau results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_016.jpg" ALT="" STYLE="height: 106.5pt; width: 468pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ref: Kerchner <I>et al.,</I> CTAD 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A Phase 2 clinical trial (Tauriel) commenced
in Q4 2017 with the dosing of the first patient. This multicenter trial, which enrolled 457 participants, assessed the safety,
tolerability and efficacy of semorinemab in people with prodromal-to-mild AD. Participants received one of three active doses or
a placebo for 72 weeks, followed by a 96-week optional open-label extension (OLE) (Figure 16). Primary endpoints included safety
assessment and the composite functional and cognitive endpoint CDR (Clinical Dementia Rating scale) CDR-SB score.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 16: Phase
2 (Tauriel) study design</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_017.jpg" ALT="" STYLE="height: 207pt; width: 430.5pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Kerchner <I>et al.</I>, CTAD 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">On
September 23, 2020, the Company reported that Genentech informed us of top line results which showed that semorinemab did not meet
its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. Two secondary
endpoints, Alzheimer&rsquo;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer&rsquo;s Disease Cooperative
Study Group &ndash; Activities of Daily Living Inventory (ADCS-ADL), were also not met. The primary safety endpoint was however
met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Further analyses revealed a dose-dependent
increase in serum pharmacokinetics and evidence of target engagement, measured by an increase in plasma Tau levels, which is consistent
with previous Phase 1 study results (Figure 17). Semorinemab did not show a dose-dependent effect on Tau PET signal in the brain.
Additional biomarker data are being analyzed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 17: Phase
2 (Tauriel) study pharmacokinetic and pharmacodynamic results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_018.jpg" ALT="" STYLE="height: 168.75pt; width: 414pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Teng <I>et al.</I>, CTAD 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">A second Phase 2 trial (Lauriet) was initiated
in Q1 2019. This is a multicenter study enrolling 260 participants, and is designed to evaluate the clinical efficacy, safety,
pharmacokinetics and pharmacodynamics of semorinemab in patients with moderate AD [Mini Mental State Examination (MMSE) 16&ndash;21,
CDR-GS 1 or 2]. The study consists of a screening period, a double-blind treatment period of 49 weeks, an optional OLE period,
and a follow-up period, with the 11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog11) and Alzheimer's Disease
Cooperative Study-Activities of Daily Living tools as the primary endpoints, and CDR-SB, MMSE and safety as secondary endpoints.
Primary completion (last patient, last visit) is estimated in Q2 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Morphomer Tau</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Approximately 1,600 compounds were screened
so far for the Morphomer Tau program. This allowed the identification of several chemical series of orally bioavailable small molecules
with suitable CNS properties. The lead compounds displayed selectivity for binding to pathological Tau aggregates in preference
to other protein aggregates. In addition, the lead compounds were able to prevent Tau aggregation and promote its disaggregation.
Further characterization using multiple orthogonal <I>in vitro</I>, <I>ex vivo</I> and <I>in vivo</I> tests addressing pharmacology,
absorption, distribution, metabolism, and excretion (ADME), and safety properties led to the identification of the first clinical
candidate ACI-3024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>ACI-3024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-3024 is a potent inhibitor of Tau aggregation
that acts not only on the Tau native form, but also on synthetic fibers derived from the six human Tau isoforms as well as from
the four mutants containing common point mutations associated with human Tauopathies, such as FTLD-Tau (e.g. PSP, Pick&rsquo;s
disease, corticobasal degeneration). ACI-3024 selectively binds to aggregated Tau and does not bind to the monomeric forms of Tau.
Moreover, the binding to Tau aggregates is selective, with no cross-reactivity to aggregates of Abeta and a-syn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-3024 showed a potent and dose-dependent
reduction in spontaneous intracellular Tau aggregation and misfolding as measured by immunocytochemistry in human neuronal-like
cells over-expressing Tau. Furthermore, ACI-3024 promoted <I>ex vivo</I> disaggregation of Tau neurofibrillary tangles on human
AD brain sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The <I>in vivo</I> efficacy of ACI-3024
was evaluated in the Tg4510 mouse model (Ramsden <I>et al.</I>, 2005). <I>In vivo</I> treatment of Tg4510 transgenic mice with
ACI-3024 reduced aggregated and insoluble hyper-phosphorylated Tau. Immunohistochemistry analysis of misfolded Tau using an MC1
antibody in Tg4510 brain sections of the same mice treated with ACI-3024 showed reduction of misfolded Tau. These effects were
proportional to the plasma concentration of ACI-3024 (Figure 18).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Total Tau concentration in
cerebrospinal fluid (CSF) was inversely correlated with ACI-3024 exposure in plasma, suggesting the
possibility of exploring CSF Tau concentrations as a biomarker of target engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-3024 further assessment is ongoing
in rare NeuroOrphan indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 18: Dose-dependent
reduction in Tau misfolding <I>in vivo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_019.jpg" ALT="" STYLE="height: 168.75pt; width: 402pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Ref: AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Preclinical safety</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-3024 has a good <I>in vitro</I> and
<I>in vivo</I> ADME profile, including low clearance, long half-life and good CNS disposition as assessed by brain and CSF concentrations.
ACI-3024 was negative in <I>in vitro</I> and <I>in vivo</I> genotoxicity assays [Ames, micronucleus test (MNT) and mouse lymphoma
cell mutagenesis (MLY)] and has undergone an extensive toxicology and safety pharmacology assessment. The no observed adverse effect
level has been established at 300 mg/kg in rodent and at 450 mg/kg in non-rodent animals after 4 weeks of treatment (Poli, CTAD
2018).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Effect on neuroinflammation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-3024 efficacy on pathological Tau-induced
neuroinflammation was assessed <I>in vitro</I> and <I>in vivo</I>. <I>In vitro</I>, ACI-3024 induced a potent reduction of Tau-induced
neuroinflammation markers (Figure 19, below). <I>In vivo,</I> in Tg4510 mice, treatment with ACI-3024 overall reduced microgliosis, most
likely as a downstream consequence of reducing Tau pathology, by reducing the derived pathological Tau-induced microglial activation
(Figure 19).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 19: ACI-3024
significantly reduces Tau-induced neuroinflammation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_020.jpg" ALT="" STYLE="height: 166.5pt; width: 349.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Ref: AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Clinical development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase 1 study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Phase 1 study was a
first-in-human (FiH), randomized, placebo-controlled, double-blind, sequential single and multiple ascending dose study. The
study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024. Part I included five single
ascending doses in healthy volunteers, with a food effect assessment in the fourth dose cohort. In Part II, three escalating
multiple dose regimens were evaluated; regimen two was assessed in different populations of healthy volunteers. CSF samples
were collected from the highest multiple dose group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The study was executed as planned
and all single and multiple dosing regimens were completed in healthy young, elderly, and Japanese subjects. ACI-3024 was
administered following single or multiple oral doses and dose-dependent plasma exposure was observed. ACI-3024 showed a long
half-life (47.5 to 101 h), with steady state reached after 12-13 days. Low renal clearance was shown. After multiple doses,
ACI-3024 concentrations in CSF exceeded target concentrations based on animal studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Plans to conduct additional clinical trials with ACI-3024 in AD have been suspended. The Companies have decided to pursue other promising
Tau Morphomer candidates from AC Immune&rsquo;s research platform for potential clinical development in AD. ACI-3024 will be further evaluated
for efficacy in models of rare Tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 20: Morphomer
Tau therapeutic program: summary and outlook</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_021.jpg" ALT="" STYLE="height: 217.5pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACI-24</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-24 is an anti-amyloid-beta vaccine
candidate that is currently in parallel clinical development for AD and Down syndrome-related AD. ACI-24 was developed utilizing
our SupraAntigen platform and is designed to stimulate a patient&rsquo;s immune system to produce antibodies that specifically
target the misfolded Abeta conformer to prevent plaque accumulation and to enhance plaque clearance. Preclinical data demonstrated
significant activity in plaque reduction and memory restoration. ACI-24 has a favorable safety profile, characterized by a lack
of observed local and CNS inflammation and a mechanism of action independent of inflammatory T cells. ACI-24 is fully owned by
AC Immune and has been developed in-house.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt"><B>Clinical development in AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Phase 1/2 study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To be considered a Phase 1/2 study, a study,
or part of it, must include as a primary goal the assessment of efficacy in a patient population, assessed using either clinical
endpoints or biomarkers. This is in contrast to a Phase&nbsp;1 study, for which the primary goal typically includes only safety
and pharmacokinetic or pharmacodynamic measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Phase 1 part of the combined Phase
1/2 study is completed, and the clinical study report was finalized in 2019. The efficacy, tolerability and immunogenicity of ACI-24
were tested in patients with mild-to-moderate AD with four different doses in a randomized, placebo-controlled, double-blind study.
The different doses were tested via an ascending dose design in four consecutive cohorts with 12 patients each (nine on active,
three on placebo treatment). ACI-24 was administered with multiple injections per cohort. The initial safety follow-up period for
two years was shortened to one year mainly for the patients of the last cohort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Phase 1 study data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Safety and tolerability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Due to the observed favorable safety profile,
the treatment-free safety follow-up period of the Phase 1 part of the study was shortened to one year using a protocol amendment.
Fifteen non-drug related SAEs were observed in the Phase 1/2 study. In the current Phase 2 study in patients with mild AD, seven
SAEs have been reported. Six of them were assessed as not related to study treatment and one SAE (transient ischemic attack) was
considered unlikely to be related to the study treatment. Currently, the ACI-24 vaccine is considered safe and well tolerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Antibody response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Antibody responses were observed only in
the two higher-dose groups of cohorts 3 and 4, indicating a dose-dependent effect of the vaccine. No IgG antibody response was
observed in placebo-treated patients of those cohorts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>PET Imaging and cognitive measures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the study
was not powered to examine efficacy, a tendency for reduction in accumulation in brain amyloid measured by PET imaging was observed
in cohorts 3 and 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to the safety
profile and potential dose-dependent reduction of amyloid plaques as measured by PET imaging, we have moved this program forward
into a Phase 2 clinical trial, which is currently ongoing. In order to optimize the immune response, the route of administration
has been switched to intramuscular, as this route was associated with a better antibody response in a non-clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Phase 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Phase 2 study design</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The aim of the Phase 2 double-blind, randomized,
placebo-controlled adaptive design study is to assess the safety, tolerability, immunogenicity and target engagement of ACI-24
formulations in patients with mild AD. The trial will seek to confirm the positive trends on Abeta PET imaging observed in the
previous Phase 1/2 study. The currently ongoing Phase 2 trial is being conducted in several European countries and the first dosing
occurred in October 2018 via the intramuscular route of administration. A 12-month interim analysis was completed, and a further
18-month interim analysis is planned for Q2 2021. AC Immune will complete the Phase 2 study with the 24-month analysis on the basis of currently enrolled patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase 2
results (interim)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">Treatment has
been safe and well tolerated to date. There have been no safety concerns nor evidence for central nervous system (CNS)
inflammation or  amyloid-related imaging abnormalities (ARIA) related to ACI-24 in any subject in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACI-24 for Down syndrome-related AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The AD dementia that commonly develops
in people with DS bears remarkable clinical and pathological similarity to familial and sporadic forms of AD and is characterized
by progressive changes in Abeta and a number of other relevant biomarkers, making this genetically defined population an excellent
model for the disease. AC immune is pioneering this approach with ACI-24.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Individuals with DS have an extra copy
of chromosome 21, which is where the gene for amyloid precursor protein (APP) resides. These individuals develop AD at a rate that
is three to five times that of the general population and develop the disease at a much younger age. At autopsy, AD pathology has
been reported in 80% of people with DS over the age of 40 and 100% over the age of 60 years. The prevalence of AD in people with
DS is more than 50% over the age of 50 and 75&ndash;100% over the age of 60 years (Strydom, 2018). It is estimated that there are
six million people with DS worldwide, with 250,000 in the US Preclinical results published by AC Immune in collaboration with Dr.&nbsp;Mobley
of the University of California, San Diego in March 2016, showed, in a DS mouse model (Ts65Dn), a significant 20% memory improvement&nbsp;and
a 27% reduction of Abeta in the brain following vaccination with ACI-DS-01, the mouse equivalent of ACI-24.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt"><B>Clinical development in DS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase 1b study
design</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A Phase 1b clinical trial was completed
in 2020 and evaluated the safety and tolerability of ACI-24, its effect on induction of antibodies against Abeta and changes in
biomarkers such as Abeta levels in blood and CSF, in adult participants with DS. The study was primarily funded by the Company
with additional partial funding provided by a grant from the US National Institute on Aging, a part of the US National Institutes
of Health (NIH) and an additional grant from the LuMind Research Down Syndrome Foundation. This dose-escalation study included
16 participants across all cohorts, aged 25&minus;45 years and treated for 12 months, with a 12-month safety follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase 1b results (top line)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-24 was safe and well tolerated in adults with DS, with no serious adverse events (SAEs) or evidence for CNS inflammation, meningoencephalitis,
or ARIA. There have been no early subject withdrawals at any dose. ACI-24 vaccination in adults with DS resulted in encouraging immunogenicity
(generation of anti-Abeta antibodies) and a positive pharmacodynamic response as measured by an increase in plasma Abeta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Due to the high
vulnerability of people with DS to severe COVID-19 sequelae, initiation of the next clinical trial will be delayed to ensure the safety
of study participants. In the interim, AC Immune is taking advantage of this time to accelerate development of its optimized anti-Abeta
vaccine formulation, which demonstrated encouraging safety and superior immunogenicity results in mouse and non-human primate (NHP) studies.
The optimized vaccine formulation primes, boosts and maintains a strong antibody response against key pathological Abeta species (including
oligomeric and pyroglutamate Abeta). The antibodies elicited by the vaccine in NHPs showed clear target engagement by binding to human
Abeta plaques on AD patient-derived brain tissue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC immune is in discussion with the Food and Drug Administration on a potentially accelerated
development pathway for the optimized Abeta vaccine and expects to file an Investigational New Drug (IND) application in Q4 2021. The
Company then plans to initiate a follow-on clinical trial in DS with the optimized vaccine formulation as soon as possible, depending
on Covid-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Crenezumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Crenezumab is a humanized, conformation-specific
monoclonal antibody that targets misfolded Abeta and has a broad binding profile. Crenezumab was developed using our proprietary
SupraAntigen platform. In 2006, we licensed crenezumab to Genentech, a company with a long history of developing and commercializing
innovative biologics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Mechanism of action</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Crenezumab binds to multiple forms of Abeta, particularly oligomeric forms, which it binds to with ten times higher affinity
than to monomers. This is a desirable property since oligomeric forms of Abeta are believed to be principally responsible for neurotoxicity
in AD.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Crenezumab localizes to brain regions rich in oligomers, including the halo around plaques and hippocampal mossy fibers, but
not to vascular Abeta (Maloney <I>et al.</I>, 2019).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Crenezumab has been designed with an IgG4 backbone to reduce effector function on microglia compared with an IgG1 backbone,
and to clear Abeta from the brain while limiting inflammation by minimizing Fc&gamma;R-mediated inflammatory activation of microglia
(Adolfsson <I>et al</I>., J. Neurosci 2012).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 14.2pt"><B>Figure 21: Crenezumab&rsquo;s
IgG4 backbone balances efficacy with safety</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 14.2pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_022.jpg" ALT="" STYLE="height: 189pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Data reported in Adolfsson <I>et al</I>.,
J. Neurosci 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The potential for a better safety profile
derived from a human IgG4 rather than a IgG1 backbone has been born out in practice by the safety findings from the Phase 1, 2
and 3 clinical studies of crenezumab, in which, following either single or multiple doses, no increase in ARIA-E was reported (Cummings
<I>et al.</I>, 2014 and Cummings <I>et al.</I>, 2018).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Due to its capacity to bind to multiple forms of Abeta, with 10-fold higher specificity to oligomers, which are thought to
be the most toxic species, crenezumab also protects against oligomer-induced neurotoxicity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Linked to its unique epitope, crenezumab has been shown to promote disaggregation of existing Abeta aggregates and to disrupt
their assembly, preventing amyloid plaque formation. The crystal structure reveals binding interactions that are consistent with
this flexible binding profile and provides further explanation for crenezumab&rsquo;s ability to block aggregation and to promote
disaggregation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Signal of activity in patients with
milder AD (MMSE 22&ndash;26) in Phase 2 clinical trials</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In the proof-of-concept Phase 2 studies of crenezumab, a positive trend in cognition was observed, with a greater effect on
cognition in patients with a milder stage of AD (MMSE 22&ndash;26).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In the ABBY cognition study, there, was a statistically significant 35% reduction in the rate of cognitive decline in the non-pre-specified
milder AD patient population (MMSE 22&ndash;26) for the high-dose arm.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In the BLAZE biomarker study, the high-dose arm showed a consistent trend of reduced Abeta accumulation in the brain over time,
as shown in two independent exploratory analyses of florbetapir-PET data. In addition, results have shown that crenezumab has the
ability to enhance the removal of these proteins from the brain as evidenced by a significant increase in CSF Abeta, confirming
target engagement by crenezumab.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Favorable safety profile allowing for
higher dosing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Phase 2 data from ABBY and BLAZE studies suggested that there were no imbalances in overall rate of AEs, and these were not
dose-related, with only one case of asymptomatic ARIA-E (0.4% in ABBY, 0.3% on active pooled) in patients treated with crenezumab.
AEs also included inflammation of the throat and nasal passages, urinary tract infections and upper respiratory infections. However,
no patients in the studies experienced SAEs that were believed related to the administration of crenezumab.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A Phase 1 study with higher doses of crenezumab up to 120 mg/kg showed good tolerability with no investigator assessed drug-related
SAEs and no events of ARIA-E, supporting the dose of 60 mg/kg in the Phase 3 CREAD clinical trials.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The good safety profile and lack of induction of ARIA-E was confirmed in the Phase 3 CREAD and CREAD 2 studies, in which there
was no increase in incidence of SAEs compared with placebo.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Crenezumab is currently being evaluated in a Phase 2 clinical prevention trial in Colombia, which has enrolled 300 cognitively
healthy individuals of whom 200 are genetically predisposed to develop early AD. As of January 2019, two Phase 3 clinical trials,
CREAD and CREAD 2, in patients with prodromal-to-mild AD were discontinued after an interim analysis of the CREAD study conducted
by our collaboration partner Genentech.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Phase 2 studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Phase 2 study design overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Crenezumab has been studied in two Phase
2 clinical studies, the ABBY proof-of-concept study and the BLAZE biomarker study. These two studies enrolled a total of 522 patients.
The purpose of these studies was to investigate whether crenezumab could delay cognitive and functional decline and reduce the
accumulation of brain amyloid in patients with mild-to-moderate AD. The sample size of the studies was not expected to have adequate
power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level
(as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across different endpoints and dose dependencies
were considered indicators of a response in this learning phase of development, with confirmation to then be sought in Phase 3.
Both studies had two active arms: a low-dose arm receiving 300 mg subcutaneous injection, every 2 weeks and a higher-dose arm receiving
15 mg/kg intravenously every 4 weeks. The primary analysis was conducted at 73 weeks, after 68 weeks of treatment. Safety and tolerability
measures included repeated MRI scans to assess for the development of ARIA, both vasogenic edema (E) and hemorrhages (H).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>ABBY study results</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the ABBY study, a positive trend in
cognition was observed with a greater effect on cognition in patients with a milder stage of AD (MMSE 22&ndash;26), although the
study did not meet its co-primary endpoints in patients with mild-to-moderate AD (MMSE 18&ndash;26). There was no significant change
in cognition in patients who received low-dose subcutaneous crenezumab. Results of an exploratory analysis of the high-dose intravenous
arm demonstrated that patients with the mildest cognitive impairment at screening (MMSE 22&ndash;26) showed a statistically significant
35% slowing of the rate of cognitive decline over 73 weeks. The effect became greater over time, as shown by the increasing separation
of the crenezumab (solid line) and placebo (dashed line) curves in the figure below. The milder group was not pre-specified, meaning
the group of patients with milder AD was not identified before commencing the Phase 2 clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 22: ABBY
high-dose arm: Change in ADAS-Cog 12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_023.jpg" ALT="" STYLE="height: 139.5pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ref: Cummings <I>et al.</I>, AAIC, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An exploratory subanalysis in a non-pre-specified
subgroup of patients with milder symptoms (MMSE&nbsp;22&ndash;26) showed a 35.4% reduction in cognitive decline. The sample size
of the study was not expected to have adequate power to detect a modest but clinically significant difference between active medication
and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">different
endpoints and dose dependency are considered indicators of a response in this learning phase of development, with confirmation
then sought in Phase&nbsp;3. In the pre-specified subgroup analysis in patients with mild AD (MMSE 20&ndash;26), treatment with
high-dose intravenous crenezumab led to a 23.8% reduction in cognitive decline. In patients with mild-to-moderate AD (MMSE 18&ndash;26)
treated with high-dose intravenous crenezumab, there was a 16.8% reduction in cognitive decline. Effect sizes and p-values for
exploratory analyses were not adjusted for multiplicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>BLAZE study design</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The BLAZE study was a randomized, double-blind,
parallel-group, placebo-controlled study to evaluate the effects of crenezumab on brain amyloid burden as assessed by amyloid PET
imaging and other biomarker endpoints in patients with mild-to-moderate AD. The primary endpoint was the change in brain amyloid
load using florbetapir-PET. The terms &ldquo;brain amyloid burden&rdquo; and &ldquo;brain amyloid load&rdquo; refer to the total
amount of amyloid deposited in the brain. In total, 91 patients were included in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>BLAZE study results</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The primary endpoint of change in brain
amyloid load by florbetapir-PET was not met, but the study was not powered to detect statistically significant results. However,
positive trends were observed as shown below in exploratory analyses of the BLAZE amyloid PET results using a white matter reference
region, which is considered a more sensitive approach for longitudinal studies. These analyses, conducted independently by two
laboratories, the Banner Alzheimer&rsquo;s Institute and MNI Laboratories, produced analogous results, with a trend in the reduction
of Abeta accumulation observed in the high-dose arm (Figure 23). As described below, a similar result was obtained in the Phase
3 studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 23: Blaze
high-dose arm: amyloid PET results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_043.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Honigberg <I>et al.</I>, CTAD 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The BLAZE biomarker study high-dose intravenous
cohort showed a consistent trend of reduced Abeta accumulation in the brain over time as shown by two independent exploratory analyses
of florbetapir-PET data. Using white matter rather than cerebellum as the key reference region in the brain is generally considered
a more robust method of showing treatment effects of AD therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the BLAZE study, patients also showed
a statistically significant increase in CSF Abeta<SUB>1&ndash;42</SUB>, which we believe confirms target engagement by crenezumab.
Similar results were observed in the ABBY study, which assessed CSF Abeta<SUB>1-42</SUB> level in 49 patients. These results suggest
that Abeta is being eliminated from the brain when treated with crenezumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 24: BLAZE
high-dose arm: crenezumab increases CSF total Abeta levels relative to placebo</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;<IMG SRC="image_044.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-indent: 17.85pt">Ref: Honigberg <I>et al.</I>,
CTAD 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The BLAZE study results suggest that Abeta
is being eliminated from the brain as patients showed a statistically significant increase in CSF Abeta<SUB>1&ndash;42</SUB>, which
confirms target engagement by crenezumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Safety data from ABBY and BLAZE studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Crenezumab demonstrated favorable safety
and tolerability in Phase 2 clinical studies even at high doses. Crenezumab&rsquo;s safety profile is especially reflected in a
low incidence of ARIA-E (0.3%) in Phase 2 clinical studies. ARIA-E was observed in only one patient who received high-dose intravenous
crenezumab in the ABBY study. No case of ARIA-E was reported in the placebo arm or the BLAZE study. Favorable pharmacokinetic properties
coupled with a favorable safety and tolerability profile enables crenezumab to penetrate the brain more readily at therapeutically
relevant doses. As dose-limiting toxicities are a potential reason for the failure of other antibodies to demonstrate efficacy,
crenezumab&rsquo;s potential safety at high doses is a distinguishing product feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At AAIC in 2014, it was reported that in
the combined Phase 2 study populations, SAEs occurred at similar rates in patients treated with crenezumab (16.5%) and in patients
given a placebo (11.9%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 1b study to explore higher doses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To explore safety at higher doses, crenezumab
was tested in a Phase 1b dose-escalation clinical study (NCT02353598) conducted in the US. This randomized, placebo-controlled,
double-blind, four parallel-arm study evaluated the safety and tolerability of at least four doses of intravenous crenezumab in
77 patients with mild-to-moderate AD (MMSE 18&ndash;28) between the ages of 50 and 90 years. An optional OLE stage was offered
to patients after completion of the double-blind stage of the study. At the 2017 AAIC meeting, Genentech presented the results
of the four cohorts with mild-to-moderate AD. No dose-limiting toxicities were observed at crenezumab doses of 30, 45, 60 and 120
mg/kg. No events of ARIA-E were observed and only few patients (6 of 75) showed asymptomatic ARIA-H. The pharmacokinetic profile
of crenezumab was dose-proportional up to the 120 mg/kg dose, with the 60mg/kg dose being selected for the Phase 3 CREAD and CREAD
2 studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 2 AD prevention study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is increasing understanding from
studies in patients at risk of AD due to genetic mutations that the build-up of Abeta in the brain is a very early event in the
condition, starting around 25 years before symptoms develop (McDade <I>et al.</I> 2018). To treat the underlying amyloid pathology
effectively it may therefore be necessary to use anti-amyloid therapies in a preventive mode, starting in patients in whom symptoms
have not yet emerged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2012, crenezumab was independently selected
from among 25 product candidates for use in the first-ever such AD prevention study. The study, a collaboration worth USD 100 million
between the NIH, Banner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Alzheimer&rsquo;s
Institute and Genentech, is the cornerstone of the global Alzheimer&rsquo;s Prevention Initiative. Crenezumab is being administered
pre-symptomatically to 300 members of an extended Colombian family, of which 200 members carry a mutation that causes early-onset
AD. Family members usually develop symptoms before the age of 45 years. The 5-year study has cognitive endpoints. An interim analysis
is possible according to the protocol, but the data and results of that analysis may not be made public due to patient sensitivity.
The study commenced Q4 2013 and the data for the primary outcome measures are expected in Q1 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 25: Crenezumab
AD prevention trial (Alzheimer's Prevention Initiative AD/AD): unique population to study prevention treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_025.jpg" ALT="" STYLE="height: 190.5pt; width: 426pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD>Mild cognitive impairment; (2) Alzheimer&rsquo;s disease; (3) Presenilin-1</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">Ref: McDade <I>et al.</I>, Neurology
2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 3 studies (CREAD and CREAD 2)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The randomized, double-blind, placebo-controlled,
parallel-group Phase 3 CREAD study enrolled about 750 participants with prodromal or mild AD at the age of 50&minus;85 years. A
high dose of crenezumab (60 mg/kg) was administered intravenously once every 4 weeks for 100 weeks. The primary outcome measure
was the change from baseline to week 105 in CDR-SB score. An exposure&ndash;response model to evaluate the best dose of crenezumab
for the treatment of AD was established, which predicted an improved outcome of the Phase 3 CREAD study by using the higher dose
of 60 mg/kg relative to the Phase 2 trials (Polhamus <I>et al.</I>, CTAD 2016).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 30, 2019, we announced that
Roche, the parent company of our collaboration partner, is discontinuing the CREAD and CREAD 2 (BN29552 and BN29553) Phase 3 studies
of crenezumab in people with prodromal-to-mild sporadic AD. The decision came after an interim analysis of the first CREAD study
conducted by the IDMC, which indicated that crenezumab was unlikely to meet its primary endpoint of change from baseline in CDR-SB
score.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As presented at CTAD 2019, target engagement
was observed with increases in levels of Abeta<SUB>1&ndash;42</SUB> in blood and CSF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 26: CSF total
Abeta42 and total Abeta change from baseline, pooled CREAD/CREAD2 results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_026.jpg" ALT="" STYLE="height: 179.25pt; width: 436.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Bittner <I>et al.,</I> Roche CTAD
2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Reduced accumulation of Abeta in the brain
on florebetapir amyloid PET scans was observed, with a pattern very similar to that observed in the Phase 2 BLAZE studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 27: [18F]
Florbetapir amyloid PET SUVR change from baseline, pooled CREAD/CREAD2 (SUVR standard uptake value ratio)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_027.jpg" ALT="" STYLE="height: 196.5pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Bittner <I>et al.,</I> Roche CTAD
2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A numerical trend to reduction in level
of total Tau and phospho-Tau 181 (pTau181) in the CSF in patients on crenezumab compared with placebo was observed although the
small numbers in the analysis due to early termination of the studies preclude firm conclusions from being drawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 28: CFS total
Tau and pTau181 change from baseline, polled CREAD/CREAD2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_028.jpg" ALT="" STYLE="height: 189pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Bittner <I>et al.,</I> Roche CTAD
2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Positive trends on a range of biomarkers
associated with AD in CSF including neurogranin, neurofilament light chain (NFL), Glial fibrillary acidic protein (GFAP), soluble
Triggering receptor expressed on myeloid cells 2 (sTREM2), Chitinase-3-like protein 1(YKL-40) and a-syn were reported by Roche
at the CTAD 2019 conference, although again the small numbers due to early termination of the studies limit interpretability of
the results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 29: Exploratory
biomarkers: Roche NeuroToolkit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_029.jpg" ALT="" STYLE="height: 207pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Bittner <I>et al.,</I> Roche CTAD
2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><B>Safety in the CREAD and CREAD 2 studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The decision to terminate the CREAD and
CREAD 2 was not related to safety. No safety signals for crenezumab were observed in this analysis and the overall safety profile
was similar to that seen in previous trials. There was no difference in the rate of newly developing ARIA-E (0.3%) between the
active and placebo arms and the rates of ARIA-H were also similar (8.8% on crenezumab vs 6.8% on placebo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><B>Prevention trial in familial AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As described above crenezumab continues
to be studied under the Alzheimer's Prevention Initiative in a preventive trial in Colombia, which began in 2013, of cognitively
healthy individuals with an autosomal-dominant mutation who are at risk of developing familial AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discovery therapeutic programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Using our SupraAntigen and Morphomer platforms,
we have generated additional discovery and preclinical stage molecules targeting key pathologies that drive a range of neurodegenerative
diseases, including TDP-43, a-syn, and NLRP3. We are accelerating the development of several therapeutic product candidates currently
in preclinical development, including several programs focused on indications outside of AD as a critical part of our expansion
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 30: Key pathologies
for further pipeline expansion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_030.jpg" ALT="" STYLE="height: 219.75pt; width: 450.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on the data to date, our technology
platforms can be applied to misfolded proteins across a broad range of indications. Five of our preclinical programs are outlined
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border: black 1pt solid; text-align: center"><B>Product candidate</B></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Target</B></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Lead application</B></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Partner</B></TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Platform</B></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">a-syn antibody</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">a-syn</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">PD, NeuroOrphan</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Proprietary</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">SupraAntigen</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Morphomer a-syn</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">a-syn</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">PD, NeuroOrphan</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Proprietary</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Morphomer</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Anti-TDP-43 antibody</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">TDP-43</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">NeuroOrphan</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Proprietary</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">SupraAntigen</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Morphomer inflammasome</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">NLRP3-ASC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">CNS, non-CNS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Proprietary</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Morphomer</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Anti-inflammasome antibody</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">NLRP3-ASC</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">CNS</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Proprietary</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">SupraAntigen</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune&rsquo;s proprietary SupraAntigen
platform is used to generate antibodies that can be used as therapeutic and diagnostic products. Such antibodies are generated
by injecting the full-length protein and/or corresponding peptide constructs in mice and by selecting the antibodies for their
ability to bind to and break up aggregated forms of misfolded proteins. The a-syn and TDP-43 antibodies were discovered using the
SupraAntigen technology platform. Both antibodies have unique binding properties allowing them to bind to unique epitopes of the
pathological forms of a-syn and TDP-43, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A-syn antibody</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The a-syn antibodies generated in our SupraAntigen
program have unique binding properties allowing them to bind preferentially to the pathological forms of a-syn. A-syn aggregation
and spreading are established targets for PD, MSA and other synucleinopathy diseases. Antibodies that interfere with the aggregation
and spreading mechanisms of a-syn provide a therapeutic option for the treatment of PD. The a-syn antibodies were able to significantly
delay the seeded aggregation of pathological a-syn in an <I>in vitro</I> aggregation assay, and were able to significantly decrease
pathological a-syn spreading in an <I>in vivo</I> animal model of PD. Characterization using</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">multiple
orthogonal <I>in vitro</I> and <I>in vivo</I> tests addressing binding, specificity, functionality and pharmacological properties
has led to the identification of the lead candidate ACI-5755.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Lead characterization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ACI-5755 selectively binds to pathological
forms of a-syn with low-nanomolar affinity and shows a significant preference over monomeric a-syn. Additionally, ACI-5755 shows
strong recognition for pathological a-syn in patient-derived tissues in both PD and MSA. ACI-5755 showed a potent and dose-dependent
reduction in the seeding capacity of pathological a-syn in a proprietary <I>in vitro</I> aggregation assay. Moreover, ACI-5755
substantially reduced the propagation of a-syn aggregates in a cell-based model. The <I>in vivo</I> efficacy of ACI-5755 was evaluated
in the M83 propagation mouse model (Luk <I>et al</I>., 2012). Treatment of mice with ACI-5755 significantly decreased pathological
a-syn spreading <I>in vivo</I>. Furthermore, a significant reduction in the rate of body weight loss compared with the vehicle-treated
control group was observed for mice treated with ACI-5755.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 31: Key results for the anti-a-syn
antibody program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_031.jpg" ALT="" STYLE="height: 208.5pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: 17.85pt">Ref: AC Immune data presented
at AD/PD 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Morphomer a-Syn</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Leveraging our Morphomer platform, we
identified and characterized the first biologically active small molecule inhibitors targeting intracellular alpha-synuclein aggregates.
Initial compounds, from several distinct chemical series, significantly decrease alpha-synuclein aggregate formation in cellular
assays by interfering with the fibrillation process. Iterative medicinal chemistry optimization led to the identification of compounds
with favorable CNS-penetrant pharmacokinetic properties, which will be progressed into <I>in vivo</I> proof-of-concept studies
in models of alpha-synucleinopathies, expected to begin in Q3 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TDP-43 antibody</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">TDP-43 is a recently identified target
of growing interest for NeuroOrphan indications such as frontotemporal dementia (FTD) and ALS. Interestingly, TDP-43 also plays
an important role in other significant neurodegenerative indications such as AD or LATE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Anti-TDP-43 antibodies binding to various
regions of TDP-43 were generated by our SupraAntigen platform. A subset displayed conformational selectivity to misfolded TDP-43,
while others recognized all TDP-43 isoforms. Multiple antibodies were generated and characterized <I>in vitro</I>, from which two
pan-TDP-43 antibodies (ACI-5891 and ACI-5886) were selected for the evaluation of their efficacy in mitigating TDP-43 aggregation
<I>in vitro</I> and <I>in vivo</I>. ACI-5891 showed a high binding affinity for TDP-43 and ability to inhibit TDP-43 aggregation
<I>in vitro</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Lead characterization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To evaluate the functional efficacy of
TDP-43 antibodies <I>in vitro</I>, the ability of ACI-5891 to inhibit TDP-43 aggregation was tested. In an <I>in vitro</I> assay
with recombinant TDP-43, ACI-5891 significantly inhibited TDP-43 aggregation by 98% compared with the isotype control and significantly
promoted their phagocytosis by mouse primary microglia. Moreover, ACI-5891 significantly reduced templated aggregation of TDP-43
induced by FTLD-TDP brain extracts in a cell model of TDP-43 proteinopathy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To further characterize functional efficacy
of ACI-5891 <I>in vivo</I>, its ability to mitigate TDP-43 neuropathology in a transgenic Tg(rNLS8) mouse model of TDP-43 proteinopathies
was evaluated (Walker <I>et al.</I>, Acta Neuropath, 2015). In the Tg(rNLS8) mice, systemic administration of ACI-5891 led to a
significant reduction in the density of phosphorylated TDP-43 and insoluble TDP-43 in the brain compared with the vehicle-treated
control mice (Figure 32). <I>In vitro and in vivo</I> data demonstrates that microglia promote the phagocytic clearance of TDP-43
neuropathology. These characteristics demonstrated for the first time that an antibody targeting TDP-43 ameliorates TDP-43-mediated
pathology <I>in vivo</I> providing validation for further development to target TDP-43-mediated neuropathology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>ACI-5891 humanization and manufacturability
assessment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">ACI-5891 was successfully humanized on
a VH2-VK1 human framework. Several variants had a similar binding capacity for TDP-43 as well as potency for inhibition of TDP-43
aggregation as compared to the chimeric monoclonal antibody. The target values were achieved for the clinical lead (ACI-5891.1)
in terms of target affinity, functional efficacy and percentage humanness. Developability of clinical lead (ACI-5891.1) was further
confirmed in manufacturability assessment studies and cell line development for the lead initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 32: Key results
for TDP-43 antibodies program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_032.jpg" ALT="" STYLE="height: 178.5pt; width: 450.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Pfeifer <I>et al</I>., AC Immune
Key Opinion Leader event, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neuroinflammation and the NLRP3 inflammasome pathway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Microglial cells (microglia) are the main
resident immune cells in the brain, which maintain a healthy environment by removing damaged cells and misfolded protein aggregates.
When overstimulated, microglia can drive neuroinflammation, leading to increased neuronal death and disease progression. A key
molecular pathway that is activated by misfolded proteins related to neurodegenerative and other diseases, is the NLRP3 (NOD-like
receptor pyrin domain-containing protein 3) inflammasome, a multi-protein complex that forms within microglia leading to production
of pro-inflammatory factors that exacerbate neuronal atrophy. NLRP3 inflammasome activation also leads to increased production,
truncation and/or aggregation of the pathological misfolded proteins, setting up a vicious, chronic cycle of neuroinflammation,
pathology and cell death. A critical component of the NLRP3 pathway is ASC (apoptosis-associated speck-like protein containing
a C-terminal caspase recruitment domain), which is formed and released by activated microglia. Intracellularly, ASC specks participate
in the production of <FONT STYLE="background-color: white">pro-inflammatory cytokines, whereas extracellular ASC specks cause acute
inflammatory reactions. ASC specks have been identified in microglia within the CNS of patients with NDD (Venegas, 2017) as well
in the body fluids of patients.</FONT> As illustrated in Figure 33, pathological species of Abeta, Tau, a-syn and TDP-43 have been
found to induce NLRP3 inflammasome activation and ASC speck formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 33: Activation of the NLRP3-ASC
inflammasome pathway exacerbates neuronal damage and promotes further neurodegeneration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_033.jpg" ALT="" STYLE="height: 272.25pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Adapted from Ransohoff et al. Nature
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Aberrant activation of the NLRP3 pathway
contributes to numerous neurodegenerative diseases, as well as atherosclerosis, asthma, cryopyrin-associated periodic syndromes,
gout, inflammatory bowel disease, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, and multiple sclerosis. Because
of the broad role of this pathway across a number of diseases, NLRP3 and ASC have emerged as attractive and highly valued molecular
targets to modulate certain pathological inflammatory responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">AC Immune is developing multiple small
molecule and antibody-based candidates with the potential to inhibit the NLRP3 pathway. Recent <I>in vitro</I> studies and <I>in
vivo</I> experiments in animal models of AD, PD and ALS have validated this approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Targeting NLRP3-ASC in neurodegenerative diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Alzheimer&rsquo;s disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Abeta peptides, which accumulate to form
the characteristic plaques in AD, activate the NLRP3 inflammasome (Halle, 2008). Expression of NLRP3 and downstream pro-inflammatory
factors IL-1b and IL-18 are increased in cells from AD patients and patients with mild cognitive impairment (Saresella, 2016).
NLRP3-deficiency or pharmaceutical inhibition in a mouse model decreases neuroinflammation and Abeta accumulation and improves
neuronal function (Heneka, 2013; Demspey, 2017). ASC specks purified from mouse macrophages accelerate Abeta aggregation, and crossing
AD and ASC knockout mouse strains lowers the load of Abeta significantly and rescues memory loss (Venegas, 2017). Recently, ASC
speck and IL-18 levels were shown to be higher in human MCI and AD brain samples, with data comparable to that of established biomarkers
soluble amyloid precursor protein (sAPP) and neurofilament light chain (Nfl), indicating that ASC is a promising biomarker of MCI
and AD (Scott, 2020).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Tauopathies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Extracellular Tau activates NLRP3 and ASC
formation in microglia. Intracerebral injection of fibrillar Abeta-containing brain homogenates induces Tau pathology in an NLRP3-dependent
manner (Ising, 2019). Elevated cleavage of caspase-1, increased ASC levels and mature IL-1b are indicative of NLRP3 activation
in patients with frontotemporal dementia (Ising, 2019). ASC deficiency decreases exogenously- and non-exogenously-seeded Tau in
a mouse model of Tauopathy. Inhibition of NLRP3 also inhibits exogenously-seeded Tau pathology in primary microglia (Stancu, 2019).
Finally, NLRP3 inhibition improved inflammation and ER stress signaling, both peripherally and centrally, in a mouse Tauopathy
model, alongside a partial normalization of phospho-tau levels (Hull, 2020).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Parkinson&rsquo;s disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">NLRP3 is activated and ASC formation is
upregulated in postmortem brains of PD patients (Gordon, 2018 and Anderson, 2021). In addition, NLRP3 inhibition mitigated pathological
hyper-phosphorylated a-syn accumulation in the substantia nigra and rescued dopaminergic neurons in the mouse model of a-syn propagation
using preformed fibrils (Gordon, 2018). Furthermore, exome sequencing analysis of NLRP3 identified multiple single-nucleotide polymorphisms
(SNPs), including rs7525979, which was associated with a significantly reduced risk of developing PD (von Herrmann, 2018). NLRP3
inhibition decreases fibrillar <FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>-synuclein-mediated inflammasome
activation in mouse microglial cells and extracellular ASC release <I>in vitro</I> and in multiple rodent PD models effectively
mitigates motor deficits, nigrostriatal dopaminergic degeneration and accumulation of <FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>-synuclein
aggregates (Gordon 2018). Taken together, NLRP3 is responsible for driving neuroinflammation that results in progressive dopaminergic
neuropathology, highlighting NLRP3 as a potential target for disease-modifying treatments for PD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>TDP-43 proteinopathies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">TDP-43-mediated activation of microglia
causes motor neuron cell death <I>in vitro</I> (Zhao, 2015). Recently, studies demonstrated that TDP-43 activates microglia via
CD14, with downstream activation of NF-kB and NLRP3 (Clark, 2020). This finding is clinically relevant as increased microglial
CD14 expression is observed in postmortem spinal cord tissue from patients with ALS, a TDP-43-driven disease (Clark, 2020). Furthermore,
wildtype and mutant forms of TDP-43 activate microglia to generate IL-1b, which is abolished by NLRP3 inhibition (Deora, 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Amyotrophic Lateral Sclerosis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Microglia isolated from the ALS mouse model,
SOD1G93A, express elevated levels of NLRP3 when in the pathological stage of disease (Deora, 2019). When microglia are incubated
with soluble or aggregated SOD1G93A, NLRP3 is activated, ASC specks are formed, and IL-1b is secreted. This effect is abolished
by pre-treatment with an NLRP3 inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our strategy for targeting the NLRP3-ASC inflammasome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune is aggressively pursuing this
key pathway in order to reduce the unwanted progression of inflammation in diseases and syndromes caused by the hyper-activation
of the NLRP3 inflammasome. Our aim is to develop therapeutics that decrease production of pro-inflammatory factors yet maintain
normal phagocytosis of debris and misfolded proteins as well as allow the function of other pathogen-sensing pathways. Currently,
AC Immune is targeting the NLRP3-ASC pathway using two complementary approaches, derived from our two technology platforms (Figure
34):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 34: Strategy to use dual proprietary
technology platforms to target NLRP3-ASC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_034.jpg" ALT="" STYLE="height: 228pt; width: 450.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Adapted from Ransohoff <I>et al.</I>
Nature 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Small molecule inhibitors of NLRP3</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Leveraging the know-how of our proprietary
Morphomer&trade; platform, which generated AC Immune&rsquo;s small molecule Tau aggregation inhibitors, the Company has successfully
identified and filed patent applications for various chemical series of potent small molecule NLRP3 inhibitors. The Company has
established biological activity for these compounds in multiple functional assays (Figures 35 and 36), and initial animal studies
show highly potent target inhibition in a model of peripheral inflammation (Figure 37), providing the first evidence of <I>in vivo</I>
activity. AC immune is currently evaluating potential lead compounds for further <I>in vivo</I> efficacy and optimization for CNS
delivery. The Company expects to initiate <I>in vivo</I> proof-of-concept studies in animal models of AD and other key neurodegenerative
diseases by year end, as well as evaluate the potential of a second lead molecule in a clinically relevant non-CNS disease model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 35: Screening assay to quantify
the compound-mediated inhibition of IL-1&beta; production <I>in vitro </I>using human microglia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_035.jpg" ALT="" STYLE="height: 173.25pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Adapted from Choi <I>et al.,</I>
Mol Cell 2014; AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 36: Secondary assays involving
human whole blood demonstrate potent hit compounds active <I>in vitro</I> using multiple donors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.7pt; text-align: center; text-indent: 0.15pt"><IMG SRC="image_036.jpg" ALT="" STYLE="height: 255.75pt; width: 420.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.7pt; text-align: center; text-indent: 0.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.7pt">Ref: AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 37: In a mouse model of peritonitis,
several of the initial hits targeting NLRP3 show significant inhibition of IL-1&beta; production <I>in vivo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_037.jpg" ALT="" STYLE="height: 243.75pt; width: 242.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ref: AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Therapeutic antibodies for neuroinflammation
(mAb-ASC)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">It has been shown in the APP/PSI mouse
model of AD, intracellular and extracellular ASC specks are present and treatment using an anti-ASC antibody decreases the Abeta
load in these mice (Figure 38).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 38: ASC specks in AD patients
and mouse model of AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_038.jpg" ALT="" STYLE="height: 231pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Vanegas&nbsp;<I>et al.</I>&nbsp;Nature
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Using our proprietary and validated SupraAntigen
platform, AC Immune generated neutralizing anti-ASC antibodies that bind extracellular human ASC and potently inhibit inflammation-mediated
formation of ASC specks (Figure 39). Selected antibodies will be further evaluated in <I>in vivo</I> proof-of-concept studies using
animal models of human disease, which AC Immune expects to start by year end. These innovative, potentially disease-modifying antibodies
are designed to have the highest potential to prevent inflammation and modify the downstream exacerbation of various proteinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 39: Inhibition of ASC speck formation
<I>in vitro</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(human ASC transfected cells or microglia
activated by monosodium urate (MSU) crystals)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_039.jpg" ALT="" STYLE="height: 176.25pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: AC Immune unpublished data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Early detection of neurodegenerative diseases
may be critical to enhancing the effectiveness of both symptomatic and disease-modifying therapies. As a result, therapeutic development
for AD increasingly focuses on treating early-stage disease to delay or prevent progression and to preserve the maximum amount
of cognitive function before it is irreversibly lost. Most clinical studies now target mild or even preclinical stages of the disease
increasing the need for accurate diagnosis that is independent of potentially subjective cognitive metrics. At least one study
estimates that as many as one-third of patients in previous AD studies did not in fact have AD. Accurate and early diagnosis of
AD is thus a substantial unmet market need, and diagnostic products will have a key role in generating a new treatment paradigm,
including by selecting more uniform and stage-specific clinical study subjects, tracking patient progress and results, managing
patients who are receiving treatment, and ultimately diagnosing disease at its earliest stage for immediate treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 40: The need for precision medicine
in AD: high level of other proteinopathies and co-pathologies in AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_040.jpg" ALT="" STYLE="height: 150pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Ref: Adapted from Robinson <I>et al</I>.,
Brain, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing three diagnostic product
candidates derived from our Morphomer technology platform. These product candidates are PET ligands, which are highly specific
chemical tracers that can be used to image the extent and location of Tau, a-syn and TDP-43 pathology in the brains of living patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tau diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The severity of cognitive impairment in
patients with AD is correlated with the presence of Tau protein tangles, leading us to believe that an imaging agent for Tau is
equally, if not more important than Abeta-PET to assess spreading of pathology in the brain. In May 2020, Eli Lilly received FDA
approval for the first Tau PET tracer TAUVID (flortaucipir F18 injection). However, TAUVID received approval only for a pathology
indication (i.e., correlation with histopathology findings in Braak 5 and 6 patients), but has not received a prognostic label
(i.e., prediction of cognitive deterioration based on a positive Tau PET scan.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Tau-PET tracers are designed to bind
specifically to the pathological forms of human Tau in AD and other Tauopathies. They have demonstrated an excellent PET tracer
profile with their ability to cross the blood brain barrier and a high selectivity to pathological Tau even in the early-stage
disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May 2014, we established a license and
collaboration agreement for our Tau-PET imaging program with LMI. The Phase 1 clinical study of our clinical candidate PI-2620
in AD was completed in Q1 2018. LMI commenced a Phase 2 longitudinal study in AD of the program in Q3 2019. A second Phase 2 longitudinal
study in AD was launched in South Korea (Asan Medical Center) in Q2 2019 (NCT03903211).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PI-2620 is selective for Tau over Abeta
and other &ldquo;off-target&rdquo; binding compared with current published Tau-PET agents in development, as no binding to Abeta
<I>in vivo </I>and no &ldquo;off-target&rdquo; retention in basal ganglia or choroid plexus was observed. In addition, PI-2620
can be readily radiolabeled with fluorine 18. A major differentiator for PI-2620 is its ability to bind 4-repeat (4R) Tau isoforms,
which are present in varying amounts in different neurodegenerative diseases. Most Tau PET tracers in development are not able
to bind 4R Tau and are of limited use for certain diseases driven by these Tau species.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 41: PI-2620
&ndash; a surrogate marker of neuronal injury</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_045.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Beyer <I>et al</I>., EJNMMI 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Figure 41 shows that PI-2620 early-phase
imaging can serve as a surrogate biomarker for neuronal injury, as it shows excellent semi-quantitative and visual agreement with
metabolic imaging using FDG PET. Dynamic imaging or a dual time-point protocol for Tau PET could supersede additional FDG PET imaging
by indexing both the distribution of Tau and the extent of neuronal injury. The shorter time required for recording the images
for PI-2620 (0.5 to 2.5 min) is an advantage for patient comfort, examination time, radiation safety and cost-effectiveness compared
to FDG (30 to 50 min).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Figure 42: PI-2620 &ndash; a tool to
assess early AD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_046.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Mormino <I>et al.</I>, EJNMMI. 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The PI-2620 Tau-PET data displayed in Figure
42 showed the mean regional PI-2620 Standardized Uptake Value Ratio (SUVR) values corresponding to 60 to 90 min post-injection
for the medial temporal lobe (MTL, a), posterior cingulate (b), and lateral parietal (c). The data revealed strong differences
in the MTL and cortical regions known to be impacted in AD using PI-2620 Tau PET in patients along the AD trajectory. The data
highlights the promise of PI-2620 to measure Tau aggregates throughout the course of AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 43: PI-2620
&ndash; a potential game-changer for PSP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><IMG SRC="image_041.jpg" ALT="" STYLE="height: 243.75pt; width: 390.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: Brendel <I>et al.</I>, JAMA Neurology
2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The PI-2620 Tau-PET data displayed in Figure
43 showed that PI-2620 PET imaging can detect and assess PSP (4R Tau) pathology <I>in vivo</I> to establish an earlier and more
reliable diagnosis. Differentiation at the single patient level by semiquantitative and visual classification (sensitivity/specificity.
for PSP-RS &gt;80%). Statistically significant signal in PSP target regions was observed by PI-2620 Tau PET compared to healthy
controls (HC) and disease controls (&alpha;-synucleinopathies, AD (3R/4R Tau)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Data from the Tau-PET imaging program was
presented at multiple conferences in 2020, including the Human Amyloid Imaging (HAI) conference 2020, AD/PD 2020, AAIC 2020, European
Association of Nuclear Medicine Meeting (EANM) 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Tau diagnostics are a major market opportunity
that will be driven by the growth in the aging population and the testing and availability of disease-modifying drugs. We believe
a best-in-class Tau tracer has the potential to achieve a substantial global market share in this large and growing market, which
includes AD as well as other important Tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A-syn diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also developing PET imaging agents
to detect a-syn, which progressively accumulates in the brains of PD patients and is believed to be central to the neurodegenerative
process of PD, as well as several other disorders, including Lewy body dementia and MSA, making it a priority target for development
of therapeutics and diagnostics. We have identified molecules leveraging our Morphomer technology that selectively bind to a-syn
pathological structures from human PD brain with affinity in the low-nanomolar range.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Our second-generation clinical candidate,
ACI-3847, shows low-nanomolar binding to pathological a-syn from PD brain homogenates, good selectivity and a strong preclinical
pharmacokinetic (PK) profile, with minimal background. It was evaluated in an FiH study in a small cohort of patients with idiopathic
PD and healthy volunteers. Although no statistically significant differences between PD and healthy volunteers were observed, overall,
PD patients showed higher tracer retention in the substantia nigra and surrounding brain regions, where a-syn deposits start accumulating
in PD. These encouraging data support further evaluation of <FONT STYLE="font-size: 10pt">[<SUP>18</SUP>F]</FONT>ACI-3847 in a-syn
indications with expected higher a-syn load than idiopathic PD, and these studies are currently ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May 2020, we received an additional
substantial grant from the Michael J. Fox Foundation for Parkinson&rsquo;s Disease Research to support the clinical development
of the second-generation candidate in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">different
a-synucleinopathies and the initial clinical evaluation of the third-generation candidate. The current status of the program was
presented at the HAI 2020 and AAIC 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In 2020, we advanced
a third-generation candidate, ACI-12589. Compared to the second-generation tracer, ACI-12589 retained the good selectivity and
pharmacokinetic profile while also showing a significantly increased signal specificity in PD versus non-diseased human tissues
(Figure 44). The Phase 1-enabling preclinical and manufacturing activities for ACI-12589 were completed in 2020 and the IND was
accepted in early 2021. The FiH clinical evaluation of the third-generation tracer began in February 2021 and is expected to be
completed in Q3 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Figure 44: 3<SUP>rd</SUP>
generation alpha-synuclein tracers with improved properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_042.jpg" ALT="" STYLE="height: 187.5pt; width: 451.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Ref: AC Immune, AAIC Conference, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Currently there are no imaging products
in the market that target a-syn. This provides us with the opportunity to become the market leader in a-syn PET imaging. We believe
the ability to image a-syn deposits in the brain will enable a fundamental change in the approach toward treating PD and other
a-syn-associated diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TDP-43 imaging diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To complement our pipeline of PET imaging
tracers, we also selected TDP-43 as a third target. TDP-43 in its physiological function is a protein participating in nucleic
acid transport. Similar to Tau, Abeta and a-syn, TDP-43 misfolds in TDP-43-mediated proteinopathies into insoluble aggregates predominantly
in the cytoplasm of neurons, leading to cellular dysfunction and eventually clinical symptoms. TDP-43 pathology often appears in
other neurodegenerative diseases (e.g., AD) as a part of mixed pathologies, and it has been proposed that misfolded TDP-43 contributes
to the observed clinical phenotype in addition to the primary pathology. The precise molecular diagnosis and differentiation of
early stages of such diseases is of critical importance. Using proprietary assays, a set of small molecular weight compounds from
four chemically distinct series were identified, which bind to patient-derived pathological TDP-43. Several of these compounds
demonstrated favorable pharmacokinetic profiles in rodents suggesting suitable properties for further development as PET ligands.
We identified candidates showing nanomolar affinities on tissues from patients with TDP-43 proteinopathies. Affinity and selectivity
are being further optimized to deliver a potential first-in-class PET tracer for TDP-43.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are no imaging products in the market
today targeting TDP-43. This provides us with a unique opportunity to become the first company to provide a TDP-43-PET tracer to
the market. We believe the ability to image TDP-43 deposits in the brain will enable fundamental change in the approach toward
treating primary and secondary TDP-43 proteinopathies including improved design for AD clinical trials to provide the best outcome
for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>License agreements and collaborations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our SupraAntigen and Morphomer platforms
have generated large numbers of clinical assets that address multiple diseases related to protein misfolding. Selected key assets
in the product pipeline have been licensed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">for
upfront payments, milestones and royalties to help offset the cost of our research and internal product development. Discussions
with other companies are ongoing. We have signed a number of licensing agreements with leading pharmaceutical companies to assist
and accelerate the development of our product pipeline, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a worldwide licensing agreement with Genentech signed in November 2006 (and amended in March 2009, January 2013, May 2014 and
May 2015) for crenezumab for AD, under which we may become eligible to receive payments potentially greater than USD 340 (CHF 303)
million, excluding royalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a worldwide licensing agreement with Genentech signed in June 2012 (and amended in December 2015) for semorinemab to treat
AD and potentially other indications, under which we may become eligible to receive payments potentially greater than CHF 400 million,
excluding royalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a worldwide licensing agreement with Janssen signed in December 2014 (and amended in April 2016, July 2017, January 2019 and
November 2019) for therapeutic anti-Tau vaccines for AD, and potentially other Tauopathies, under which we may become eligible
to receive payments totaling up to CHF 500&nbsp;million, excluding royalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a worldwide licensing and collaboration agreement (LCA) with LMI (formerly Piramal Imaging SA) signed in May 2014 for small-molecule
Tau ligands for use as PET tracers under which we may become eligible to receive payments totaling up to EUR 159 (CHF 175)&nbsp;million,
excluding royalties; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a worldwide license agreement with Lilly to research and develop Morphomer Tau small molecules for the treatment of AD and
other neurodegenerative diseases, which was entered into in December 2018 (and amended in September 2019 and March 2020). The agreement
was deemed effective on January 23, 2019. Under this, we may become eligible to receive payments up to approximately CHF 1.9 billion,
excluding royalties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Further information concerning details
of our agreements and collaborations can be found under &ldquo;Item 5: Operating and financial review and prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The pharmaceutical and biopharmaceutical
industries are highly competitive across all therapeutic fields. In the field of neurodegenerative diseases, there are many public
and private companies or institutions that are actively engaged in the discovery and development of therapeutic and diagnostic
products. Some of these products may have a similar target to our product candidates or address similar markets. The industry is
still in its infancy in terms of defining the pathology of neurodegenerative diseases. As disease understanding progresses, the
number of novel product candidates may well increase and broaden the therapeutic and diagnostic options in our product markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Currently, there are no approved disease-modifying
products for AD or any other neurodegenerative disease. Current approved therapies seek to treat the symptoms of AD, such as cognitive
decline, but do not slow or stop the progression of the disease. In addition, commonly, there is off-label prescription of antidepressant
and antipsychotic agents for more patients with advanced AD who may have agitation, aggressive behaviors, psychosis and depression.
No new drugs have been approved for the treatment of AD since 2003.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect there to be several classes of
disease-modifying agents that will enter the AD market. One target for monoclonal antibodies is pathological Tau protein. Therapeutic
vaccines are a second class of disease-modifying therapies, and include our candidate products ACI-35.030, which targets aggregated,
phosphorylated Tau protein and ACI-24, which targets pathological Abeta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The availability of novel diagnostic agents
to visualize the disease development in patients with AD is critical for successful clinical development of disease-modifying products
in AD. At the forefront of this new diagnostic effort are PET agents for in-life imaging of disease, and in particular, Tau-targeting
PET agents, which we believe will allow precise assessment of disease in patients with AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>ACI-35.030.</I></B> ACI-35.030, if
approved, would compete with other approved Tau-targeting therapeutic vaccines. This includes the AADvac1 vaccine developed by
Axon Neuroscience, which completed a Phase 2 study in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Semorinemab.</I></B> Semorinemab
is one of several Tau-targeting monoclonal antibodies in development to potentially act as disease-modifying agents. Biogen is
evaluating gosuranemab (licensed from Bristol-Myers Squibb) in a Phase 2 clinical trial in AD. AbbVie is currently investigating
tilavonemab in AD in Phase 2 studies. Zagotenemab (Lilly) is currently in a Phase 2 study in AD. Bepranemab (UCB/Roche), BIIB076
(Biogen/Neuroimmune), JNJ3657 (Janssen), Lu AF87908 (Lundbeck), PNT001 (Pinteon Therapeutics) and E-2814 (Eisai) are being evaluated
in Phase 1 studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Morphomer Tau. </I></B>AC Immune
has developed the first small molecule targeting aggregated Tau with high selectivity for the target. In collaboration with Lilly,
this molecule (ACI-3024) was studied in a Phase 1 clinical trial which was completed in 2020 as a first-in-class, Tau-specific,
disease-modifying, Tau aggregation inhibitor small molecule for the treatment of neurodegenerative diseases characterized by misfolded
Tau. Together with our partner Eli Lilly, we have identified optimized candidates that will now be prioritized for Alzheimer&rsquo;s
disease development. The optimized candidates have been shown to have enhanced brain uptake, good safety profiles and high affinity
for Tau. These new candidates are being further characterized in in vivo preclinical models and will be advanced into investigational
new drug (IND)-enabling studies, and one of them is expected to advance into development in 2021. ACI-3024 will continue to be
investigated in Orphan indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>ACI-24 for AD.</I></B> ACI-24, if
approved, would compete with other approved anti-Abeta-targeting therapeutic vaccines. This includes the ABvac 40 (Araclon Biotech),
which is currently being evaluated in a Phase 2 study and UB-311(Vaxxinity), which has completed a Phase 2 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>ACI-24 for DS.</I></B> ACI-24 is
the first disease-modifying vaccine candidate addressing DS-related AD, with a potential preventive and therapeutic application.
Although there are symptomatic treatments of DS in clinical development, to our knowledge there are currently no other disease-modifying
treatments in clinical development for AD in DS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Crenezumab. </I></B>Crenezumab is
the first monoclonal antibody candidate that targets Abeta in cognitively healthy individuals at risk of developing familial AD.
However, Lilly&rsquo;s solanezumab, Roche&rsquo;s gantenerumab and Eisai&rsquo;s lecanemab are being evaluated in studies of presymptomatic
AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>A-syn and TDP-43 antibodies.</I></B>
Several a-syn antibodies are currently in development; Roche/Prothena entered a Phase 2 with prasinezumab in June 2017; Biogen
entered a Phase 2 with cinpanemab in January 2018; Astra Zeneca/Takeda started a Phase 1 study in patients with Parkinson&rsquo;s
disease with MEDI1341 in August 2020; Lundbeck/Genmab entered a Phase 1 with Lu AF82422 in July 2018; and BAN0805 (AbbVie/BioArctic)
is currently in a Phase 1 study. To our knowledge, there are no TDP-43 antibodies in the clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Diagnostics.</I></B> Tauvid (previously
known as Flortaucipir), which was developed by Eli Lilly and approved by FDA in May 2020. However, should PI-2620 be approved,
it would also compete with (i)&nbsp;APN-1607 (previously known as 18F-PM-PBB3), a product candidate in a Phase 2 study and being
advanced by Aprinoia; (ii) THK-5351 (FluoroTau), a product candidate in a Phase 2 study&nbsp;being advanced by GE Healthcare; (iii)
18F-MK-6240, which is being evaluated by Cerveau/Merck in a Phase 2 clinical trial in patients with ADAD; (iv) 18F-GTP1, which
is being developed by Genentech and is in a Phase 2 study in subjects at risk of developing ADAD, (v) 18F-RO6958948, for which
Roche has completed a Phase 1 study in patients with AD and (vi)18F-JNJ-067, for which Janssen has completed a Phase 1 study in
patients with AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Many of our competitors have significantly
greater financial, technical and human resources than we have available. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity
and our success will be based in part on our ability to identify, develop and manage a portfolio of product candidates that are
safer and more effective than competing products. However, this opportunity could be eroded or even eliminated if our competitors
develop and/or market products that are novel and have superior safety and efficacy profiles, that may be brought to the market
more rapidly due to greater available resources, or that are less costly than our current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Commercialization strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our strategy to date has been to focus
on identifying partnerships for our early-stage product candidates as both a way to secure non-dilutive capital to fund our other
research and development programs and also as a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">way
to accelerate the development of these partnered products by leveraging our partners&rsquo; extensive knowledge in clinical studies,
drug development, manufacturing and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With greater financial resources at our
disposal and the significant knowledge acquired by our scientists and scientific leadership, we intend to retain selected promising
product candidates in-house for a longer period of time and fund their development from our own resources. This will allow us to
generate greater value from these product candidates, allowing us to demand more significant terms from a prospective partner.
For example, while we plan to seek a strategic partner for our Abeta vaccine program in AD, our current plan is to retain full
control of this asset for development in the DS population. We will complete the ongoing Phase 2 study for AD before partnering
this program and intend to fund further clinical development in DS from our own financial resources. In the field of diagnostics,
the parallel development of therapeutic compounds and companion diagnostics is of growing importance to the pharmaceutical and
biopharmaceutical industries. The development timeframe of a PET diagnostic agent is significantly shorter than for a therapeutic
product, providing the prospect for potential diagnostic product revenues to be realized quicker than potential therapeutic product
revenues. Our Morphomer platform is particularly well suited to generate molecules for use in the development of companion diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Given our current stage of product development,
we currently do not have a commercialization infrastructure. If any of our product candidates is granted marketing approval, we
intend to focus our initial commercial efforts in the US and select European markets, which we believe represent the largest market
opportunities for us. In those markets, we expect our commercial operations to include our own specialty sales force that will
target Neurologists and Gerontologists, both in hospitals and in private practice. In other markets, we expect to seek partnerships
that would maximize our products&rsquo; commercial potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Intellectual property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We strive to protect the proprietary technology
that we believe is important to our business, including seeking and maintaining US and foreign patents intended to cover our products
and compositions, their methods of use and processes for their manufacture, and our proprietary technology platforms, diagnostic
candidates and any other inventions that are commercially important to the development of our business. We also rely on trade secrets
and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our success will significantly depend on
our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and
know-how related to our business, to defend and enforce patents, to preserve the confidentiality of our trade secrets and to operate
our business without infringing any patents and other intellectual property or proprietary rights of third parties. See the section
titled &ldquo;Risk factors&mdash; Risks related to intellectual property&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020 we owned or co-owned
approximately 40 issued US patents and 323 issued patents in other jurisdictions, as well as 26 pending US patent applications
and 354 pending foreign patent applications. As of December 31, 2020 we licensed approximately 25 issued US patents and 20 pending
US patent applications, as well as 236 issued patents in other jurisdictions and 238 pending foreign patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The patent portfolios for our most advanced
product candidates as of December 31, 2020 are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Anti-Tau vaccines</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio for anti-Tau vaccines
includes a patent family with composition-of-matter claims (including claims directed to the ACI-35 antigenic peptide and a pharmaceutical
composition comprising such an antigenic peptide), claims directed to treating certain indications using ACI-35 including AD, and
claims directed to using ACI-35 to induce an immune response. This patent family currently contains approximately 27 issued patents
and four pending patent applications in 27 countries. The issued patents in this patent family, if the appropriate maintenance,
renewal, annuity or other governmental fees are paid, are expected to expire in 2030, excluding any additional term for patent
term adjustments or patent term extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio for anti-Tau vaccines
also includes a patent family relating to therapeutic Tau vaccine claims (including claims directed to a pharmaceutical composition
comprising an antigenic Tau peptide), claims directed to using such vaccines to induce an immune response in a subject, and claims
directed to methods for preventing or treating a neurodegenerative disease or disorder, including AD, among others. Any patents
issuing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">in
this patent family, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to expire
in 2038, excluding any additional term for patent term adjustments or patent term extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt"><B><I>Semorinemab</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our global patent portfolio relating to
semorinemab includes patents and patent applications with claims directed to compositions of matter, methods of treatment for certain
indications including AD, and methods of use, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Morphomer Tau</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to Morphomer
Tau therapeutics includes patent applications with claims directed to composition of matter (including claims directed to the molecule,
a pharmaceutical composition comprising such molecule and a mixture comprising such molecule), and claims directed to prevention
and treatment of certain indications using such molecules including AD and PSP, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to the Morphomer
Tau therapeutic program includes patent applications that we own or co-own in four different patent families. As of December 31,
2020, we owned or co-owned approximately 51 pending patent applications and one US issued patent in our main patent family directed
to the ACI-3024 small molecule Tau aggregation inhibitor. If the appropriate maintenance, renewal, annuity, or other governmental
fees are paid, national-stage applications issuing from this PCT patent application are expected to expire in 2039, excluding any
additional term for patent term adjustments or patent term extensions, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>ACI-24</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio for ACI-24 includes
composition-of-matter claims (including claims directed to the ACI-24 antigenic construct), claims directed to treating certain
indications using ACI-24 including AD, and claims directed to using ACI-24 to induce an immune response. Our patent portfolio for
ACI-24 consists of approximately 25 issued patents and 9 pending patent applications in 30 countries. With respect to the US, we
own two issued US patents. The issued patents in this patent portfolio, if the appropriate maintenance, renewal, annuity or other
governmental fees are paid, are expected to expire in 2026, excluding any additional term for patent term adjustments or patent
term extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio for ACI-24 also consists
of an additional patent family directed to the use of the ACI-24 vaccine in the treatment and/or prevention of memory and/or cognitive
impairments or abnormalities in the DS subpopulation, among others. As of December 31, 2020, in this patent family, we owned approximately
10 patents and 8 pending patent applications in 18 countries. The issued patents in this patent family, if the appropriate maintenance,
renewal, annuity or other governmental fees are paid, are expected to expire in 2032, excluding any additional term for patent
term adjustments or patent term extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio for ACI-24 also includes
a patent family related to therapeutic anti-Abeta vaccine claims (including claims directed to a pharmaceutical composition comprising
an antigenic peptide), and claims directed to using such vaccines in treating, preventing, inducing a protective immune response
against or alleviating the symptoms associated with an Abeta-associated disease in a subject, among others. This patent family
currently contains approximately 29 pending patent applications in 31 countries and one issued US patent. Any issued patents in
this patent family, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to expire
in 2039, excluding any additional term for patent term adjustments or patent term extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Crenezumab</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to crenezumab
includes patents and patent applications with claims directed to composition of matter (including claims directed to the crenezumab
antibody or a fragment thereof, a polynucleotide encoding the crenezumab antibody or a fragment thereof, a cell line used to produce
the crenezumab antibody as well as pharmaceutical compositions comprising the crenezumab antibody), claims directed to treating
certain indications using the crenezumab antibody including AD, claims directed to a method of manufacturing the crenezumab antibody
and claims directed to diagnostic and prognostic uses of the crenezumab antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to crenezumab
includes patents and patent applications that we own or co-own in four different patent families. As of December 31, 2020, we owned
or co-owned approximately 45 patents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">(not
including the patents in the individual countries where the issued European patent was validated) and 19 patent applications in
34 countries in our main patent family directed to the crenezumab antibody and methods of using the crenezumab antibody to treat
certain indications, including AD. This patent portfolio includes three issued US patents and one pending US patent applications,
which, if the appropriate maintenance or other governmental fees are paid, are expected to expire in 2027, excluding any additional
term for patent term adjustments or patent term extensions. This patent portfolio also includes a PCT patent application that
was filed on July 13, 2007. If the appropriate maintenance, renewal, annuity, or other governmental fees are paid, national-stage
applications issuing from this PCT patent application are expected to expire in 2027, excluding any additional term for patent
term adjustments or patent term extensions, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>PI-2620</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to PI-2620
includes patent applications with claims directed to composition of matter (including claims directed to the molecule, its precursor
and a diagnostic composition comprising such molecule), claims directed to diagnosis of certain indications using PI-2620 including
AD and PSP, and claims directed to a method of manufacturing PI-2620, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our patent portfolio relating to PI-2620
includes patent applications that we own or co-own in three different patent families. As of December 31, 2020, we owned or co-owned
approximately 16 patent applications in 16 countries in our main patent family directed to the PI-2620 molecule, its precursor
and methods of using the PI-2620 to diagnose certain indications, including AD and PSP. If the appropriate maintenance, renewal,
annuity, or other governmental fees are paid, national-stage applications issuing from this PCT patent application are expected
to expire in 2037, excluding any additional term for patent term adjustments or patent term extensions, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Manufacturing and supply</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not own or operate facilities for
the manufacture, packaging, labeling, storage, testing or distribution of preclinical or clinical supplies of any of our drug candidates.
We instead contract with and rely on third-party CMOs to manufacture, package, label, store, test and distribute all preclinical
development and clinical supplies of our drug candidates, and we plan to continue to do so for the foreseeable future. We have
established relationships with CMOs such as WuXi AppTec (WuXi STA), Bachem AG, Polymun GmbH, Syngene International Limited and
Avecia among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Compliance with governing
rules and quality requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The facilities used by our collaboration
partners and CMOs to manufacture our product candidates are systematically audited by local authorities and occasionally inspected
by competent authorities where the clinical studies are ongoing. The facilities where the commercial productions are performed
must be approved by the FDA or other relevant regulatory authorities, pursuant to inspections that are conducted after we submit
our NDA or comparable marketing applications. We perform periodic quality audits of the manufacturing facilities and CMOs to monitor
their compliance with the regional laws, regulations and applicable cGMP standards and other laws and regulations, such as those
related to environmental health and safety matters. The scope of our audits also involves monitoring the ability of our providers
to maintain adequate QCs and QA systems including personnel qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">After manufacturing, our products are submitted
to extensive characterization and QC testing plans performed by using properly developed analytical methods that are qualified
or validated; this ensures the accuracy of the results generated and provides evidence of the quality of our products. In addition,
our products are submitted to detailed and standardized stability programs aimed at demonstrating product stability during the
storage period; this, in addition to guaranteeing the safety of the products, supports the definition of a suitable supply chain
that may encompass the distribution of the products in different continents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Contractual framework</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have established, with CMOs supplying
drug substances or drug products under cGMP, quality agreements and master service agreements. Quality agreements define the quality
standards required to develop, produce and supply the product, and also define the responsibilities related to the collaboration
with regards to the quality related aspects. Manufacturing service agreements define the commercial and financial framework under
which product manufacturing under cGMP is performed. Any failure to achieve and maintain compliance with the laws, regulations
and standards, suspension of the manufacturing of our product candidates or revoke of cGMP permissions, which would adversely affect
our business and reputation, are defined in the master service</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">agreements
and quality agreements. The risk that any third-party providers may breach the agreements they have with us because of factors
beyond our control and the possibility that they may also terminate or refuse to renew their agreements because of their own financial
difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for us, is managed by us with
constant investments toward maintaining reserve stocks and in-depth process know-how. The latter is supported by continuous in-house
process development and production activities of small-scale/research grade materials, which may offer the chance to rapidly identify
alternative contract manufacturers to whom the manufacturing process could be transferred providing continuity for the clinical
study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Interaction with collaboration
partners and CMOs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Finally, our partnership with CMOs is managed
through an efficient project management platform in which teams are formed with the representatives of each key function from both
parties. Meetings occur either through telephone conferences aimed at updating short-term actions or face-to-face conferences when
mid- to long-term development plans are discussed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Government regulation and our regulatory
department</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our regulatory department has a strong
culture of regulatory compliance, operating under three guiding principles, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide constructive regulatory input for development products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ensure smooth regulatory approvals by anticipating hurdles; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>build confidence with regulators by continuous communication.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The QA group is included within the regulatory department with
the mission to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>create and maintain a corporate quality management system; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>ensure cGCP, cGMP, cGLP and current Good Distribution Practice (cGDP) compliance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A science-driven approach is the cornerstone
of our interactions and this has helped us to build and maintain a high level of trust with regulators. Besides informal conversations
with the authorities, our regulatory department has conducted several pre-Investigational New Drug (pre-IND) meetings with the
FDA (ACI-24 for AD and DS, and PI-2620) and Scientific Advice meetings, which are the European equivalent of pre-IND meetings (with
the German Paul-Ehrlich-Institut, Swedish Medical Products Agency; UK Medicine &amp; Healthcare Products Regulatory Agency, Finnish
Medicines Agency, the Spanish Agency of Medicines and Medical Devices and the EMA). Since 2008, our regulatory department has filed
a total of 18 clinical trial applications in the EU (one each in Austria, Denmark, the Netherlands and Poland, two in Germany,
three in Sweden, four in Finland and five in the UK) and 4 INDs in the US. Given the seriousness of AD and public pressure for
new therapeutics, we consider regulatory agencies to be important stakeholders in our product development strategies. We are committed
to working closely with global regulatory authorities to adhere to and achieve the highest levels of safety and quality of our
product candidates in the most timely and efficient manner. The transparency we have achieved and our goal of a close working relationship
with the regulatory agencies, in particular the FDA, are intended to facilitate expeditious execution through the regulatory approval
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our regulatory department contains a QA
group. As every quality issue ultimately requires regulatory involvement and input, this approach is intended to lead to rapid
resolution of issues and ensure full compliance to satisfy both the reviewers and the inspectors at the government health authorities.
Our regulatory department is charged with keeping our entire organization, directly or indirectly involved in the clinical study
application process, in a state of &ldquo;inspection readiness.&rdquo; To that end, we ensure that the Trial Master Files are complete
and regularly updated. Our regulatory department is also tasked with generating our annual quality plan. The personnel tasked with
QA have issued a set of approximately 77 standard operating procedures and working instructions and continuously train the relevant
staff. Our QA personnel conduct regular audits, including in-person audits of the contract manufacturers, contract research organizations
and laboratories conducting primary endpoint analysis. In addition, we have a full-time QA documentation assistant to ensure good
documentation practice and archiving.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Product approval process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The clinical studies, manufacturing, labeling,
storage, distribution, record-keeping, advertising, promotion, import, export and marketing, among other things, of our product
candidates are subject to extensive regulation by governmental authorities in the US and other countries. The US FDA, under the
Federal Food, Drug, and Cosmetic Act (FDCA), regulates pharmaceutical products in the US. The steps required before a drug may
be approved for marketing in the US generally include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the completion of preclinical laboratory tests and animal tests conducted under cGLP regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical
studies commence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining a positive opinion from the ethics committee (Europe)/institutional review board (US) to commence study on human
subjects;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the product
candidate for each proposed indication and conducted in accordance with cGCP requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pre-NDA submission meeting with FDA (highly recommended);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the submission to the FDA of an NDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA&rsquo;s acceptance of the NDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>satisfactory completion of an FDA Pre-Approval Inspection (PAI) of the manufacturing facilities at which the product is made
to assess compliance with cGMP requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA&rsquo;s review and approval of an NDA prior to any commercial marketing or sale of the drug in the US; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>having parallel scientific advice from the EMA or Health Technology Assessment body whereby the payors are involved at the
outset (Phase 2), which is intended to facilitate the design of clinical studies to target primarily populations with a high chance
of obtaining reimbursement and accelerate the process of time to reimbursement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA has various programs, including
Fast Track, Priority review, Accelerated Approval and Breakthrough Therapy designation, which are intended to increase agency interactions,
expedite or facilitate the process for reviewing drug candidates, and/or provide for initial approval based on surrogate endpoints.
We believe that one or more of our product candidates may qualify for some of these expedited development and review programs.
However, even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate
no longer meets the conditions for qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Fast Track program is intended to expedite
or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track
designation if they are designed to treat a serious or life-threatening condition and demonstrate the potential to address unmet
medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for
which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product at any time
during the clinical development of the product. AD, for example, meets both pre-requisites&mdash;it is life-threatening and constitutes
an unmet medical need. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on
a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections
of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the
sponsor pays any required user fees upon submission of the first section of the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any product submitted to the FDA for marketing,
including under a Fast Track program may be eligible for other types of FDA programs intended to expedite development and review,
such as Priority Review and Accelerated Approval. Any product is eligible for priority review if it has the potential to provide
safe and effective therapy where no satisfactory alternative therapy exists or it provides a significant improvement in the treatment,
diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">direct
additional resources to the evaluation of an application for a new drug designated for Priority Review to facilitate the review.
Additionally, a product may be eligible for the Accelerated Approval program. Drug candidates that are studied for their safety
and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing
treatments may receive Accelerated Approval, which means that they may be approved on the basis of adequate and well-controlled
clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of
approval, the FDA may require that a sponsor of a drug receiving Accelerated Approval perform adequate and well-controlled post-marketing
clinical studies. Failure to conduct required post-approval trials, or the inability to confirm a clinical benefit during post-marketing
trials, may allow the FDA to withdraw the drug from the market on an expedited basis. In addition, as a condition for Accelerated
Approval the FDA currently requires pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product. The Fast Track, Priority Review and Accelerated Approval programs do not change the standards for approval
but may expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Food and Drug Administration Safety
and Innovation Act of 2012 also amended the FDCA to require the FDA to expedite the development and review of a breakthrough therapy.
A drug can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies in one or more
clinically significant endpoints. A sponsor may request that a drug be designated as a breakthrough therapy at any time during
the clinical development of the product. If so designated, the FDA shall act to expedite the development and review of the product&rsquo;s
marketing application, including by meeting with the sponsor throughout the product&rsquo;s development, providing timely advice
to the sponsor to ensure that the development program to gather nonclinical and clinical data is as efficient as practicable, involving
senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the
FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review
team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The testing and approval process requires
substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain. Given this paradigm,
AD has been given Life-Threatening Disease status by the FDA and therefore AD therapies are eligible for the expanded access program
for investigational drugs and other pathways such as Breakthrough Therapy, Accelerated Approval and Priority Review. Additionally,
a single well-designed, well-conducted, pivotal clinical study could be sufficient to trigger market approval pending a successful
PAI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Preclinical studies include laboratory
evaluations of the product candidate, as well as animal studies to assess the potential safety and efficacy of the product candidate.
The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as
part of the IND, which must become effective before clinical studies may be commenced. The IND will automatically become effective
30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the studies as outlined in the
IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical studies
can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical studies involve the administration
of the product candidates to healthy volunteers or patients with the disease to be treated under the supervision of a qualified
principal investigator. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study,
the parameters to be used in monitoring safety and the efficacy criteria to be evaluated. A protocol for each clinical study and
any subsequent protocol amendments must be submitted to the FDA as part of the IND. Further, each clinical study must be reviewed
and approved by an independent IRB, either centrally or individually at each institution at which the clinical study will be conducted.
The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution.
There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.
The FDA, the IRB or the clinical study sponsor may suspend or terminate clinical studies at any time on various grounds, including
a finding that the subjects or patients are being exposed to an unacceptable health risk. Additionally, some clinical studies are
overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a Data Safety Monitoring
Board/Committee. This group provides authorization for whether or not a study may move forward at designated checkpoints based
on access to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives
and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical studies are typically conducted
in three sequential phases prior to approval, but the phases may overlap. These phases generally include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Phase 1. Phase 1 clinical studies represent
the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase 1, the product candidate
is usually tested for safety, including adverse effects, dosage tolerance, absorption, distribution, metabolism, excretion and
pharmacodynamics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Phase&nbsp;2. Phase 2 clinical studies
usually involve studies in a limited patient population to (i) evaluate the efficacy of the product candidate for specific indications,
(ii) determine dosage tolerance and optimal dosage, and (iii) identify possible adverse effects and safety risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Phase&nbsp;3. If a product candidate is
found to be potentially effective and to have an acceptable safety profile in Phase 2 studies, the clinical study program will
be expanded to Phase 3 clinical studies to further demonstrate clinical efficacy, optimal dosage and safety within an expanded
patient population at geographically dispersed clinical study sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Phase 4. Phase 4 clinical studies are conducted
after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document
a clinical benefit in the case of drugs approved under Accelerated Approval regulations, or when otherwise requested by the FDA
in the form of post-marketing requirements or commitments. Failure to conduct any required Phase 4 clinical studies promptly could
result in withdrawal of approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The results of preclinical studies and
clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information on the
manufacture, composition and quality of the product, are submitted to the FDA in the form of an NDA requesting approval to market
the product. The NDA must be accompanied by a significant user-fee payment. The FDA has substantial discretion in the approval
process and may refuse to accept any application or decide that the data is insufficient for approval and require additional preclinical,
clinical or other studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate that it generally takes 10
to 15 years, or possibly longer, to discover, develop and bring to market a new pharmaceutical or biopharmaceutical product in
the US. Several years may be needed to complete each phase, including discovery, preclinical, Phase 1, 2 or 3, or marketing authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under the Pediatric Research
Equity Act, an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the drug for the claimed
indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the product is safe and effective. Recently, the Food and Drug Administration Safety and Innovation Act (FDASIA), which
was signed into law on July&nbsp;9, 2012, amended the FDCA. The FDASIA requires that a sponsor who is planning to submit a marketing
application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing
regimen or new route of administration submit an initial Pediatric Study Plan within 60 days of an end-of-Phase-2 meeting or as
may be agreed between the sponsor and the FDA. The initial Pediatric Study Plan must include an outline of the pediatric study
or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical
approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments
or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA
and the sponsor must reach agreement on the Pediatric Study Plan. A sponsor can submit amendments to an agreed-upon initial Pediatric
Study Plan at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies,
early-phase clinical trials, and/or other clinical development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The cost of preparing and submitting an
NDA is substantial. Under federal law, NDAs are subject to substantial application user fees and the sponsor of an approved NDA
is also subject to annual product and establishment user fees. Under the Prescription Drug User Fee Act (PDUFA), as amended, each
NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA VI eliminates fees for supplements
as well as for establishments, although applicants will be assessed for annual prescription drug program fees for prescription
drug products, rather than the prescription drug product fee assessed under the previous iteration of PDUFA. According to the FDA&rsquo;s
fee schedule for the 2021 FY, the user fee for each NDA application requiring clinical data is USD 2,875,842 and the annual program
fee is USD 336,432. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee
for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as
orphan drugs, unless the product also includes a non-orphan indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Once the NDA submission has been submitted,
the FDA has 60 days after submission of the NDA to conduct an initial review to determine whether it is sufficient to accept for
filing. Under the PDUFA, the FDA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">sets
a goal date by which it plans to complete its review. This is typically 12 months from the date of submission of the NDA application.
The review process is often extended by FDA requests for additional information or clarification. Before approving an NDA, the
FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing
facility complies with cGMP regulations and may also inspect clinical study sites for integrity of the data supporting safety
and efficacy. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating
to risk, benefit and interpretation of clinical study data. The FDA is not bound by the recommendations of an advisory committee,
but generally follows such recommendations in making its decisions. The FDA may delay approval of an NDA if applicable regulatory
criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing
and surveillance to monitor safety or efficacy of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">After the FDA evaluates the NDA and conducts
inspections of the manufacturing facilities where the drug product and/or its API will be produced, it may issue an Approval Letter
or a Complete Response Letter. An Approval Letter authorizes commercial marketing of the drug with specific prescribing information
for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application
is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3
clinical study or studies, and/or other significant, expensive and time-consuming requirements related to clinical studies, preclinical
studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not
satisfy the criteria for approval. The FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategy (REMS), plan
to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as
restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on,
among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct
one or more post-marketing studies or clinical studies. Such post-marketing testing may include Phase 4 clinical studies and surveillance
to further assess and monitor the product&rsquo;s safety and effectiveness after commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Special protocol assessment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA and an IND sponsor may agree in
writing on the design and size of clinical studies intended to form the primary basis of a claim of effectiveness in an NDA. This
process is known as a special protocol assessment (SPA). Upon a specific request for a SPA by an IND sponsor, the FDA will evaluate
the protocol. If an SPA agreement is reached, however, it is not a guarantee of product approval by the FDA or approval of any
permissible claims about the product. The FDA retains significant latitude and discretion in interpreting the terms of the SPA
agreement and the data and results from any study that is the subject of the SPA agreement. In particular, the SPA agreement is
not binding on the FDA if previously unrecognized public health concerns later come to light, other new scientific concerns regarding
product safety or efficacy arise, the IND sponsor fails to comply with the agreed-upon protocol, or the relevant data, assumptions,
or information provided by the IND sponsor when requesting a SPA agreement change, are found to be false statements or misstatements,
or are found to omit relevant facts. An SPA agreement may not be changed by the sponsor or the FDA after the study begins except
with the written agreement of the sponsor and the FDA, or if the FDA determines that a substantial scientific issue essential to
determining the safety or effectiveness of the drug was identified after the testing began.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Orphan-drug designation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is a disease or condition
that either affects fewer than 200,000 individuals in the US, or affects more than 200,000 individuals in the US but there is no
reasonable expectation that the cost of developing and making a drug product available in the US for this type of disease or condition
will be recovered from sales of the product in the US. Orphan-product designation must be requested before submitting an NDA. After
the FDA grants orphan-product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly
by the FDA. Orphan-product designation does not convey any advantage in or shorten the duration of the regulatory review and approval
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If a product that has orphan designation
subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled
to orphan-product exclusivity, which means that the FDA cannot approve any other applications to market the same drug or biological
product for the same indication for 7 years, except in limited circumstances, such as a showing of clinical superiority to the
product with orphan exclusivity. The designation of such drug also entitles a party to financial incentives such as opportunities
for grant funding toward clinical study costs, tax advantages and user-fee waivers. Competitors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">however,
may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval
for the same product but for a different indication for which the orphan product has exclusivity. Orphan-product exclusivity also
could block the approval of one of our products for 7 years if a competitor obtains approval of the same drug or biological product
as defined by the FDA or if our drug candidate is determined to be contained within the competitor&rsquo;s product for the same
indication or disease. If a drug product designated as an orphan product receives marketing approval for an indication broader
than what is designated, it may not be entitled to orphan-product exclusivity. Orphan-drug status in the EU has similar but not
identical benefits in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Disclosure of clinical trial information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sponsors of clinical trials (other than
Phase 1 trials) of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, comparator, patient population, phase of investigation, trial sites and investigators and other
aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of
their clinical trials after completion. Disclosure of the results of certain trials may be delayed until the new product or new
indication being studied has been approved. However, there are evolving rules and increasing requirements for publication of trial-related
information, and it is possible that data and other information from trials involving drugs that never garner approval could be
required to be disclosed in the future. In addition, publication policies of major medical journals mandate certain registration
and disclosures as a pre-condition for potential publication, even when this is not presently mandated as a matter of law. Competitors
may use this publicly available information to gain knowledge regarding the progress of development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Post-approval requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Drugs manufactured or distributed pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating
to record-keeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with
the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are
subject to prior FDA review and approval. There also are continuing, annual user-fee requirements for any marketed products and
the establishments at which such products are manufactured, as well as new application fees for supplemental applications with
clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, drug manufacturers and other
entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the
FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the areas of production and QC to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Once an approval is granted, the FDA may
withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the
approved labeling to add new safety information, imposition of post-marketing studies or clinical studies to assess new safety
risks, or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other
things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product
recalls;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines, warning letters or holds on post-approval clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license
approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product seizure or detention, or refusal to permit the import or export of products; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The FDA strictly regulates marketing, labeling,
advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and
in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Patent term restoration and marketing
exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Depending upon the timing, duration, and
specifics of FDA approval of the use of our drug candidates, some of our US patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman
Act permits a patent term to be extended up to 5 years as compensation for patent term effectively lost due to the FDA&rsquo;s
pre-market approval requirements. However, patent term restoration cannot extend the remaining term of a patent beyond a total
of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally one-half of the time between
the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval
of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence.
Only one patent applicable to an approved drug is eligible for the extension. Extensions are not granted as a matter of right and
the extension must be applied for prior to expiration of the patent and within a 60-day period from the date the product is first
approved for commercial marketing. The USPTO, in consultation with the FDA, reviews and approves the application for any patent
term extension or restoration. Where a product contains multiple active ingredients, if any one active ingredient has not been
previously approved, it can form the basis of an extension of patent term provided the patent claims that ingredient or the combination
containing it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the future, we may apply for patent
term restoration for some of our presently owned patents to add patent life beyond their current expiration date, depending on
the expected length of clinical studies and other factors involved in the submission of the relevant NDA; however, there can be
no assurance that any such extension will be granted to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Biologics Price Competition and Innovation
Act of 2009 provides up to 12 years of non-patent data exclusivity within the US to the first applicant to gain approval of a Biologics
License Application for a new biologic product that has not previously been approved by the FDA, which we refer to as a reference
product. This 12-year data exclusivity does prohibit the FDA from approving a biosimilar or interchangeable product of such reference
product until 12 years after the licensure of such reference product. In addition, the FDA will not accept a biosimilar or interchangeable
product application for review until 4 years after the date of first licensure of such reference product. Under 21CFR314.108, 5
years&rsquo; exclusivity is also granted to new chemical entities that contain no active moiety that has been approved by the FDA
under section 505(b). This market exclusivity bars the FDA from accepting for review any ANDA or 505(b)(2) application for a drug
containing the same active moiety for (i) 5 years if an ANDA or 505(b)(2) application does not contain a paragraph IV certification
to a listed patent, or (ii) 4 years if an ANDA or 505(b)(2) is submitted containing a paragraph IV certification to a listed patent.
Moreover, pediatric exclusivity, if granted, may add 6 months of exclusivity if the reference product has been studied with respect
to a pediatric indication in accordance with certain regulatory requirements. A reference product may also be granted 7 years of
orphan-drug exclusivity for the treatment of a rare disease or condition under section 527(a) of FDCA, which would run in parallel
with the 12 years of data exclusivity of the reference product, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Non-US regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to market any product outside
of the US, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy, and governing, among other things, clinical studies, marketing authorization, commercial sales and
distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals
by the comparable foreign regulatory authorities before we can commence clinical studies or marketing of the product in foreign
countries and jurisdictions. Although many of the issues discussed above with respect to the US apply similarly in the context
of the EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional
administrative review periods, as described in greater detail below. The time required to obtain approval in other countries and
jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or
jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country
or jurisdiction may negatively impact the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>EU drug review approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EEA, which is comprised of the 27
Member States of the EU plus Norway, Iceland and Liechtenstein medicinal products can only be commercialized after obtaining a
marketing authorization. There are two types of marketing authorization: the Community Marketing Authorization, which is issued
by the EC through the Centralized Procedure based on the opinion of the Committee for Medicinal Products for Human Use (CHMP),
a body of the EMA, and which is valid throughout the entire territory of the EEA; and the National Marketing Authorization, which
is issued by the competent authorities of the Member States of the EEA and authorizes marketing only in that Member State&rsquo;s
national territory and not the EEA as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Centralized Procedure is compulsory
for human medicines for the treatment of human immunodeficiency virus or acquired immune deficiency syndrome (AIDS), cancer, diabetes,
neurodegenerative diseases, autoimmune and other immune dysfunctions, and viral diseases; for veterinary medicines for use as growth
or yield enhancers; for medicines derived from biotechnology processes, such as genetic engineering; for advanced-therapy medicines,
such as gene-therapy, somatic cell-therapy or tissue-engineered medicines; and for officially designated &lsquo;orphan medicines&rsquo;
(medicines used for rare human diseases). The Centralized Procedure is optional for products containing a new active substance
not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation, or
for products that are in the interest of public health in the EU. The National Marketing Authorization is for products not falling
within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member
State of the EEA, this National Marketing Authorization can be recognized in another Member State through the Mutual Recognition
Procedure. If the product has not received a National Marketing Authorization in any Member State at the time of application, it
can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure,
an identical dossier is submitted to the competent authorities of each of the Member States in which the marketing authorization
is sought, one of which is selected by the applicant as the Reference Member State (RMS). If the RMS proposes to authorize the
product, and the other Member States do not raise objections, the product is granted a National Marketing Authorization in all
the Member States in which the authorization was sought. Before granting the marketing authorization, the EMA or the competent
authorities of the Member States of the EEA assesses the risk&ndash;benefit balance of the product on the basis of scientific criteria
concerning its quality, safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Regulation in the EU</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Product development, the regulatory approval
process, and safety monitoring of medicinal products and their manufacturers in the EU proceed in much the same manner as they
do in the US. Therefore, many of the issues discussed above apply similarly in the context of the EU. In addition, drugs are subject
to the extensive price and reimbursement regulations of the various EU Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Clinical studies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As is the case in the US, the various phases
of preclinical and clinical research in the EU are subject to significant regulatory controls. The Clinical Trials Directive 2001/20/EC,
as amended and which will be replaced in 2021 or later by Regulation (EU) No 536/2014) provides a system for the approval of clinical
studies in the European Union via implementation through national legislation of the Member States. Under this system, approval
must be obtained from the competent national authorities of the EU Member States in which the clinical trial is to be conducted.
Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical
trial application, which must be supported by an investigational medicinal product dossier with supporting information prescribed
by the Clinical Trials Directive and corresponding national laws of the Member States, and further detailed in applicable guidance
documents. A clinical trial may only be undertaken if provision has been made for insurance or indemnity to cover the liability
of the investigator or sponsor. In certain countries, the sponsor of a clinical trial has a strict (faultless) liability for any
(direct or indirect) damage suffered by trial subjects. The sponsor of a clinical trial, or its legal representative, must be based
in the EEA. European regulators and ethics committees also require the submission of AE reports during a study and a copy of the
final study report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Marketing approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Marketing approvals under the EU regulatory
system may be obtained through a centralized or decentralized procedure. The centralized procedure results in the grant of a single
marketing authorization, which is valid for all (currently 27) EU Member States and the three European Free Trade Association (EFTA)
members (Norway, Iceland and Liechtenstein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Regulation (EC) No. 726/2004,
as amended, the centralized procedure is mandatory for drugs developed by means of specified biotechnological processes, advanced-therapy
medicinal products, drugs for human use containing a new active substance for which the therapeutic indication is the treatment
of specified diseases, including but not limited to AIDS, neurodegenerative disorders, auto-immune diseases and other immune dysfunctions,
as well as drugs designated as orphan drugs. The CHMP also has the discretion to permit other products to use the centralized procedure
if it considers them sufficiently innovative or they contain a new active substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the marketing authorization application,
the applicant has to properly and sufficiently demonstrate the quality, safety and efficacy of the drug. Under the centralized
approval procedure, the CHMP, possibly in conjunction with other committees, is responsible for drawing up the opinion of the EMA
on any matter concerning the admissibility of the files submitted in accordance with the centralized procedure, such as an opinion
on the granting, variation, suspension or revocation of a marketing authorization, and pharmacovigilance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The CHMP and other committees are also
responsible for providing guidelines and have published numerous guidelines that may apply to our product candidates. These guidelines
provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of drug products
and may include, among other things, the preclinical studies required in specific cases, the manufacturing and control information
that should be submitted in a marketing authorization application, and the post-approval measures required to monitor patients
and evaluate the long-term efficacy and potential adverse reactions. Although these guidelines are not legally binding, we believe
that our compliance with them is likely to be necessary to gain approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maximum timeframe for the evaluation
of a marketing authorization application by the CHMP under the centralized procedure is 210 days after receipt of a valid application.
This period will be suspended until such time as the supplementary information requested by the CHMP has been provided by the applicant.
Likewise, this time limit will be suspended for the time allowed for the applicant to prepare oral or written explanations. When
an application is submitted for a marketing authorization in respect of a drug that is of major interest from the viewpoint of
public health and in particular therapeutic innovation, the applicant may request an accelerated assessment procedure. If the CHMP
accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP can revert to
the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated
assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the CHMP concludes that the quality,
safety and efficacy of the product are sufficiently proven, it adopts a positive opinion. This is sent to the EC, which drafts
a decision within approximately 67 days following the CHMP opinion. After consulting with the Member States, the EC adopts a decision
and grants a marketing authorization, which is valid for the whole of the EEA. The marketing authorization may be subject to certain
conditions, which may include, without limitation, the performance of post-authorization safety and/or efficacy studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The EMA has various programs, including
accelerated assessment, conditional approval and PRIority MEdicines (PRIME), which are intended to increase agency interactions,
expedite or facilitate the process for reviewing drug candidates, and/or provide for initial approval on the basis of surrogate
endpoints. One or more of our product candidates may qualify for some of these expedited development and review programs. However,
even if a drug candidate qualifies for one or more of these programs, the EMA may later decide that the drug candidate no longer
meets the conditions for qualification. Eligibility to the PRIME scheme is limited to products considered to offer a major therapeutic
advantage in populations with high unmet need. PRIME is a voluntary scheme aimed at enhancing interaction and early dialogue with
developers of promising medicines through achieving the early appointment of the Rapporteur for the product, optimizing development
plans and speeding up evaluation so these medicines can reach patients earlier. Products benefiting from PRIME can expect to be
eligible for accelerated assessment at the time of application for a marketing authorization application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">EU legislation also provides for a system
of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No.&nbsp;726/2004, as amended, and Article
10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved on the basis
of a complete independent data package benefit from 8 years of data exclusivity and an additional 2 years of market exclusivity.
Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&rsquo;s data to assess a generic (abbreviated)
application. During the additional 2-year period of market exclusivity, a generic marketing authorization can be submitted, and
the innovator&rsquo;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market
exclusivity. The overall 10-year period will be extended to a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">maximum
of 11 years if, during the first 8 years of those 10 years, the marketing authorization holder (MAH) obtains an authorization
for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are held to bring
a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity
and the innovator can gain the period of data exclusivity, another company nevertheless could also market another version of the
drug if such company obtained marketing authorization based on a marketing authorization application with a completely independent
data package of pharmaceutical test, preclinical tests and clinical studies. However, products designated as orphan medicinal
products enjoy, upon receiving marketing authorization, a period of 10 years of orphan market exclusivity. See also &ldquo;&mdash;Orphan
drug regulation&rdquo; below. Depending upon the timing and duration of the EU marketing authorization process, products may be
eligible for an SPC of up to 5 years&rsquo;, pursuant to Regulation (EC) No.&nbsp;469/2009. Such SPCs extend the rights under
the basic patent for the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, the pediatric regulation [Regulation
(EC) No 1901/2006 as amended] requires sponsors to submit a pediatric investigation plan at the end of Phase 1. This plan will
provide the details of the quality, non-clinical and clinical studies required to support the authorization of a pediatric indication.
Additional rules apply to medicinal products for pediatric use under Regulation (EC) No.&nbsp;1901/2006. Potential incentives include
a six-month extension of any supplementary protection certificate granted pursuant to Regulation (EC) No.&nbsp;469/2009, but not
in cases in which the relevant product is designated as an orphan medicinal product pursuant to Regulation (EC) No.&nbsp;141/2000,
as amended. Instead, a medicinal product designated as an orphan medicinal product may enjoy an extension of the 10-year market
exclusivity period granted under Regulation (EC) No.&nbsp;141/2000 to 12 years subject to the conditions applicable to orphan drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Orphan drug regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, Regulation (EC) No.&nbsp;141/2000,
as amended, states that a drug will be designated as an orphan drug if its sponsor can establish:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than 5 in 10,000 persons in the EU when the application is made, or that it is intended for the diagnosis, prevention
or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives
it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized
in the EU or, if such method exists, that the drug will be of significant benefit to those affected by that condition.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regulation (EC) No.&nbsp;847/2000 sets
out further provisions for implementation of the criteria for designation of a drug as an orphan drug. An application for the designation
of a drug as an orphan drug must be submitted at any stage of development of the drug before filing of a marketing authorization
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If a EU-wide community marketing authorization
in respect of an orphan drug is granted or if all the EU Member States have granted marketing authorizations in accordance with
the procedures for mutual recognition, the EU and the Member States will not, for a period of 10 years, accept another application
for a marketing authorization, or grant a marketing authorization or accept an application to extend an existing marketing authorization,
for the same therapeutic indication, in respect of a similar drug. This period may, however, be reduced to 6 years if, at the end
of the fifth year, it is established, with respect to the drug concerned, that the criteria for orphan-drug designation are no
longer met; in other words, when it is shown on the basis of available evidence that the product is sufficiently profitable not
to justify maintenance of market exclusivity. Notwithstanding the foregoing, a marketing authorization may be granted, for the
same therapeutic indication, to a similar drug if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holder of the marketing authorization for the original orphan drug has given its consent to the second applicant;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holder of the marketing authorization for the original orphan drug is unable to supply sufficient quantities of the drug;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the second applicant can establish in the application that the second drug, although similar to the orphan drug already authorized,
is safer, more effective or otherwise clinically superior.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other incentives available to orphan drugs
in the EU include financial incentives such as a reduction of fees or fee waivers and protocol assistance. Orphan-drug designation
does not shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Manufacturing and manufacturers&rsquo;
license</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Directive 2003/94/EC, as transposed
into the national laws of the Member States, the manufacturing of investigational medicinal products and approved drugs is subject
to a separate manufacturer&rsquo;s license and must be conducted in strict compliance with cGMP requirements, which mandate the
methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Manufacturers
must have at least one qualified person permanently and continuously at their disposal. The qualified person is ultimately responsible
for certifying that each batch of finished product released onto the market has been manufactured in accordance with cGMP and the
specifications set out in the marketing authorization or investigational medicinal product dossier. cGMP requirements are enforced
through mandatory registration of facilities and inspections of those facilities. Failure to comply with these requirements could
interrupt supply and result in delays, unanticipated costs and lost revenues, and subject the applicant to potential legal or regulatory
action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action, or possible
civil and criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Wholesale distribution and license</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Directive 2001/83/EC, the wholesale
distribution of medicinal products is subject to the possession of an authorization to engage in activity as a wholesaler in medicinal
products. Possession of a manufacturing authorization includes authorization to distribute by wholesale the medicinal products
covered by that authorization. The distribution of medicinal products must comply with the principles and guidelines of cGDP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Advertising</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, the promotion of prescription
medicines is subject to intense regulation and control, including EU and national legislation as well as self-regulatory codes
(industry codes). Advertising legislation <I>inter alia</I> includes a prohibition on direct-to-consumer advertising. All advertising
of prescription medicines must be consistent with the product&rsquo;s approved Summary of Product Characteristics, and must be
factual, accurate, balanced and not misleading. Advertising of prescription medicines pre-approval or off-label is not allowed.
Some jurisdictions require that all promotional materials for prescription medicines be subjected to prior review and approval,
either internal or regulatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Other regulatory requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An MAH for a medicinal product is legally
obliged to fulfill a number of obligations by virtue of its status as an MAH. The MAH can delegate the performance of related tasks
to third parties, such as distributors or marketing partners, provided that this delegation is appropriately documented and the
MAH maintains legal responsibility and liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>The obligations of an MAH include the
following:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Manufacturing and batch release</I>&mdash;MAHs should guarantee that all manufacturing operations comply with relevant laws
and regulations, applicable GMPs, and the product specifications and manufacturing conditions set out in the marketing authorization,
and that each batch of product is subject to appropriate release formalities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Availability and continuous supply</I>&mdash;Pursuant to Directive 2001/83/EC, as transposed into the national laws of the
Member States, the MAH for a medicinal product and the distributors of the said medicinal product actually placed on the market
in a Member State shall, within the limits of their responsibilities, ensure appropriate and continued supplies of that medical
product to pharmacies and persons authorized to supply medicinal products so that the needs of patients in the Member State in
question are covered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Pharmacovigilance</I>&mdash;MAHs are obliged to establish and maintain a pharmacovigilance system, including a qualified
person responsible for oversight, to submit safety reports to the regulators and to comply with the good pharmacovigilance practice
guidelines adopted by the EMA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Advertising and promotion</I>&mdash;MAHs remain responsible for all advertising and promotion of their products, including
promotional activities by other companies or individuals on their behalf, and in some cases must conduct internal or regulatory
pre-approval of promotional materials. Regulation in this area also covers interactions with healthcare practitioners and/or patient
groups, and in some jurisdictions legal or self-regulatory obligations to disclose such interactions exist.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Medical affairs/scientific service</I>&mdash;MAHs are required to disseminate scientific and medical information on their
medicinal products to healthcare professionals, regulators and patients.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Legal representation and distributor issues</I>&mdash;MAHs are responsible for regulatory actions or inactions of their
distributors and agents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Preparation, filing and maintenance of the application and subsequent marketing authorization</I>&mdash; MAHs must maintain
appropriate records, comply with the marketing authorization&rsquo;s terms and conditions, fulfill reporting obligations to regulators,
submit renewal applications and pay all appropriate fees to the authorities. We may hold any future marketing authorizations granted
for our product candidates in our own name, or appoint an affiliate or a collaboration partner to hold marketing authorizations
on our behalf. Any failure by an MAH to comply with these obligations may result in regulatory action against an MAH and ultimately
threaten our ability to commercialize our products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Pricing and reimbursement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the EU, the pricing and reimbursement
mechanisms by private and public health insurers vary largely by country and even within countries. The public systems reimbursement
for standard drugs is determined by guidelines established by the legislator or responsible national authority. The approach taken
varies by Member State. Some jurisdictions operate positive and negative list systems under which products may only be marketed
once a reimbursement price has been agreed. Other Member States allow companies to fix their own prices for medicines, but monitor
and control company profits and may limit or restrict reimbursement. The downward pressure on healthcare costs in general, particularly
prescription drugs, has become very intense. As a result, increasingly high barriers to the entry of new products are being erected
and some EU countries require the completion of studies that compare the cost-effectiveness of a particular product candidate with
that of currently available therapies in order to obtain reimbursement or pricing approval. Special pricing and reimbursement rules
may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality
and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement
may come with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement
may apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Other US healthcare laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to FDA restrictions on marketing
of pharmaceutical or biopharmaceutical products, federal and state healthcare laws restrict certain business practices in the pharmaceutical
and biopharmaceutical industries. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security,
and transparency statutes and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The US federal Anti-Kickback Statute prohibits,
among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, to
induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item
or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &ldquo;remuneration&rdquo; has
been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment,
credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market
value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical and biopharmaceutical manufacturers
on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions
and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly,
and our practices may not in all cases meet all the criteria for a statutory exception or safe harbor protection. Practices involving
remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny
if they do not qualify for an exception or safe harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Failure to meet all the requirements of
a particular applicable statutory exception or regulatory safe harbor does not make the conduct <I>per se</I> illegal under the
Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative
review of all its facts and circumstances. Several courts have interpreted the statute&rsquo;s intent requirement to mean that
if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare-covered business, the
statute has been violated. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation
Act (collectively, the PPACA), amended the intent requirement under the Anti-Kickback Statute and criminal healthcare fraud statutes
(discussed below) such that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to
violate it in order to have committed a violation. In addition, the PPACA provides that the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the civil False Claims Act (discussed below). Further, the Civil Monetary Penalties Law imposes penalties against
any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health
program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The federal false claims laws prohibit,
among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for
payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement
material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement
and Recovery Act of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the US government.
Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things,
allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.
Other companies have been prosecuted for causing false claims to be submitted because of the companies&rsquo; marketing of the
product for unapproved, and thus non-covered, uses. The federal HIPAA created new federal criminal statutes that prohibit knowingly
and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party
payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious
or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, the PPACA also included the
federal Physician Payments Sunshine Act, which requires that certain manufacturers of drugs, devices, biologicals and medical supplies
for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions)
to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals,
or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report
annually certain ownership and investment interests held by physicians and their immediate family members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, many states have similar
healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor. Certain states require the posting of information relating to clinical studies,
and require pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for,
or payments to, individual medical or health professionals and to track and report gifts and other payments made to physicians
and other healthcare providers. If our operations are found to be in violation of any of the health regulatory laws described above
or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion of products from reimbursement under government programs,
contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
To the extent that any of our products will be sold in a foreign country, we may be subject to similar foreign laws and regulations,
which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws,
implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Data privacy and security laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we may be subject to international,
federal and state data privacy and security laws, regulations, rules and standards. Internationally, laws, regulations and standards
in many jurisdictions, such as the GDPR and the UK GDPR, apply broadly to the collection, use, retention, security, disclosure,
transfer and other processing of personal information. At the federal level, HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (HITECH), and its implementing regulations, imposes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">certain
requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things,
HITECH makes HIPAA&rsquo;s privacy and security standards directly applicable to business associates&mdash;independent contractors
or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf
of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for
damages or injunctions in federal courts to enforce the federal HIPAA laws and to seek attorneys&rsquo; fees and costs associated
with pursuing federal civil actions. In addition, state laws, [such as the CCPA and the CPRA,] govern the privacy and security
of health and other personal information in certain circumstances, many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts. Non-compliance with these laws, regulations, rules and standards
could result in significant penalties or legal liability. Although we take steps to comply with applicable laws, rules and regulations,
we cannot ensure that we will not be subject to regulatory or private actions, investigations, disputes and litigation, which
may include substantial fines or other legal liability for noncompliance of data privacy and security laws, rules and regulations,
including in the event of a cybersecurity breach or other security incident. We could be adversely affected if legislation or
regulations are expanded to require changes in our or our third-party service providers&rsquo; business practices or if governing
jurisdictions interpret or implement their legislation or regulations in ways that negatively affect our business, results of
operations or financial condition. See &ldquo;Risk Factors&mdash; <I>Changes in laws, rules or regulations relating to data privacy
and security, or any actual or perceived failure by us to comply with such laws, rules, regulations and standards, or contractual
or other obligations relating to data privacy and security, could have a material adverse effect on our reputation, results of
operations, financial condition and cash flows.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Pharmaceutical coverage, pricing and
reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In both domestic and foreign markets, our
or our collaboration partners&rsquo; sales of any approved products will depend in part on the availability of coverage and adequate
reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health
insurers and other organizations. Patients who are prescribed treatments for their conditions and providers performing the prescribed
services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely
to use our products, if approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of the
cost of our products. Sales of our products will therefore depend substantially, both domestically and abroad, on the extent to
which the costs of our products will be paid by third-party payors. These third-party payors are increasingly focused on containing
healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, significant uncertainty exists
as to the coverage and reimbursement status of newly approved healthcare product candidates. The market for our product candidates
for which we may receive regulatory approval will depend significantly on access to third-party payors&rsquo; drug formularies,
or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included
in such formularies often leads to downward pricing pressures on pharmaceutical or biopharmaceutical companies. Additionally, third-party
payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug
when a less costly generic equivalent or another alternative is available. Because each third-party payor individually approves
coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming, costly and sometimes unpredictable
process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately
with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative
effect on our future revenues and operating results. We cannot be certain that our product candidates will be considered cost-effective.
Because coverage and reimbursement determinations are made on a payor-by-payor basis, obtaining acceptable coverage and reimbursement
from one payor does not guarantee we will obtain similar acceptable coverage or reimbursement from another payor. If we are unable
to obtain coverage of, and adequate reimbursement and payment levels for, our product candidates from third-party payors, physicians
may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them.
This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations,
financial condition and future success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, in many foreign countries,
particularly the countries of the EU, the pricing of prescription drugs is subject to government control. In some non-US jurisdictions,
the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">products
for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human
use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product
candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical or biopharmaceutical
products. In addition, there may be importation of foreign products that compete with our own products, which could negatively
impact our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Healthcare reform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the US and other jurisdictions, there
have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that
could affect our future results of operations as we begin to commercialize our products directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In particular, there have been and continue
to be a number of initiatives at the US federal and state level that seek to reduce healthcare costs. Initiatives to reduce the
federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures
and the private sector will continue to review and assess alternative benefits, controls on healthcare spending through limitations
on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing
groups, price controls on pharmaceuticals and other fundamental changes to the healthcare delivery system. Any proposed or actual
changes could limit or eliminate our spending on development projects and affect our ultimate profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2010, the PPACA, as amended by
the HCERA (collectively, the Health Care Reform Law) was signed into law. The Health Care Reform Law has the potential to substantially
change the way healthcare is financed by both governmental and private insurers. The Health Care Reform Law among other things,
established an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic
agents; revised the methodology by which rebates owed by manufacturers for covered outpatient drugs under the Medicaid Drug Rebate
Program are calculated; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program;
extended the Medicaid Drug Rebate program to utilization of certain injectable outpatient drugs, as well as prescriptions of individuals
enrolled in Medicaid managed care organizations; required manufacturers to offer 50% point-of-sale discounts on negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s
outpatient drugs to be covered under Medicare Part D; and implemented payment system reforms including a national pilot program
on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency
of certain healthcare services through bundled payment models. On July 24, 2020 and September 13, 2020, the Trump administration
announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&rsquo;s
proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for
states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the US Department of Health
and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers
to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by
law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for
certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim
final rule implementing former President Trump&rsquo;s Most Favored Nation executive order, which would tie Medicare Part B payments
for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1,
2021. On December 28, 2020, the US District Court in Northern California issued a nationwide preliminary injunction against implementation
of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar
policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The future of the Health Care Reform Law
remains uncertain. In January 2017, Congress voted to adopt a budget resolution for the fiscal year 2017 that authorized the implementation
of legislation that would repeal portions of the Health Care Reform Law. On December 14, 2018, a federal judge in Texas ruled that
the Health Care Reform Law is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress
as part of the 2017 Tax Act. While the judge, as well as the Trump administration and CMS, have stated that the ruling will have
no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">appeals,
and other efforts to repeal and replace the ACA, will impact our business. On December 18, 2019, the Fifth Circuit Court of Appeals
upheld the lower court&rsquo;s decision that the Health Care Reform Law was unconstitutional. On March 2, 2020, the US Supreme
Court granted certiorari to review the case and oral arguments were held on November 10, 2020. Although the US Supreme Court has
yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special
enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the
Health Care Reform Law marketplace. The executive order also instructs certain governmental agencies to review and reconsider
their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access
to health insurance coverage through Medicaid or the ACA. Pending review, the Health Care Reform Law remains in effect, but it
is unclear what effect this litigation, other efforts to repeal and replace the Health Care Reform Law and the healthcare reform
measures of the Biden administration will have on the status of the ACA. Litigation and legislation over the Health Care Reform
Law are likely to continue, with unpredictable and uncertain results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the future, there may continue to be
additional proposals relating to the reform of the US healthcare system, some of which could further limit the prices we are able
to charge for our products candidates, or the amounts of reimbursement available for our product candidates. If future legislation
were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business.
Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. Some states have
implemented, and other states are considering, price controls or patient access constraints under the Medicaid program, and some
states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible.
Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown
legislative, regulatory, payor or policy actions, which may include cost-containment and healthcare-reform measures. Such policy
actions could have a material adverse impact on our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Moreover, the recently enacted federal
Drug Supply Chain Security Act imposes new obligations on manufacturers of pharmaceutical or biopharmaceutical products, among
others, related to product tracking and tracing. Among the requirements of this new federal legislation, manufacturers will be
required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred,
label drug product with a product identifier, and keep certain records regarding the drug product. Further, under this new legislation,
manufacturers will have drug product investigation, quarantine, disposition and notification responsibilities related to counterfeit,
diverted, stolen and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or
that are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or
death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in"><B><I>Physician Payment Sunshine
Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Physician Payment Sunshine Act requires
most pharmaceutical and biopharmaceutical manufacturers to report annually to the Secretary of Health and Human Services any and
all financial arrangements, payments, or other transfers of value made by that entity to physicians and teaching hospitals. The
payment information is made publicly available in a searchable format on a content management system (CMS) website. Over the next
several years, we will need to dedicate significant resources to establish and maintain systems and processes in order to comply
with these regulations. Failure to comply with the reporting requirements can result in significant civil monetary penalties. Similar
laws have been enacted or are under consideration in foreign jurisdictions, including France, which has adopted the Loi Bertrand,
or French Sunshine Act, which became effective in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Environmental, health and safety laws
and regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to numerous environmental,
health and safety laws and regulations and permitting requirements, including those governing laboratory procedures, decontamination
activities, and the handling, transportation, use, remediation, storage, treatment, and disposal of hazardous materials and wastes.
Our operations involve the use of hazardous and flammable materials, and the risk of injury, contamination or noncompliance with
environmental, health and safety requirements cannot be eliminated. Although compliance with such laws and regulations and permitting
requirements has not had a material effect on our capital expenditures, earnings or competitive position, environmental, health
and safety laws, and regulations and permitting requirements have tended to become increasingly stringent and, to the extent that
legal or regulatory changes may occur in the future, they could result in, among other things, increased costs to us or the impairment
of our research, development or production efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item04c"></A>C.</TD><TD>Organizational structure</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss stock corporation (<I>soci&eacute;t&eacute;
anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute;
&agrave; responsabilit&eacute; limit&eacute;e</I>) on February 13, 2003 with our registered office and domicile in Basel, Switzerland.
We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August 25, 2003.
Our Swiss enterprise identification number is CHE-109.878.825. Prior to our initial public offering, we were a privately owned
company. Our domicile and registered office is in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our registered and principal
executive offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number is
(41) 21 345 91 21 and our internet address is www.acimmune.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We did not have any subsidiaries as of
December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item04d"></A>D.</TD><TD>Property, plant and equipment</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s capital expenditures
were CHF 2 million in 2020 with CHF 1.6 million for laboratory equipment and leasehold improvements. These investments are to enhance
our research facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We lease approximately 23,600 square feet
of space at the Innovation Park of the EPFL, Switzerland as of December 31, 2020. This property serves as our corporate headquarters,
our research facility and laboratories. We believe that using the EPFL facilities instead of building our own infrastructure helps
us to maximize the value of our research and development capital and make efficient use of our funds as we continue to build and
develop our pipeline. We believe that the space of our existing facilities is sufficient to meet our current needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item04aunresolvedstaffcomments"></A>ITEM 4A. UNRESOLVED STAFF COMMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item05"></A>ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read the following discussion
and analysis of our financial condition and results of operations together our audited financial statements, including the notes
thereto, included in this Annual Report. The following discussion is based on our financial information prepared in accordance
with IFRS as issued by the IASB, which might differ in material respects from generally accepted accounting principles in other
jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors,
including but not limited to those described under &ldquo;Item 3. Key information&mdash;D. Risk factors&rdquo; and elsewhere in
this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05a"></A>A.</TD><TD>Operating results</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, we have primarily financed our
operations through the proceeds from our public offerings, share issuances, contract revenues from license and collaboration agreements
and grants. We have no products approved for commercialization and have never generated any revenues from product sales. Pharmaceutical
and biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. It may
be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a product candidate
approved for commercialization, and we begin to generate revenue and royalties from product sales. Since our inception, we have
received upfront and milestone payments from our collaboration partners and certain other revenue. However, we have also incurred
significant operating losses. We incurred net losses of CHF 61.9&nbsp;million for the fiscal year ended December 31, 2020 and have
an accumulated losses balance of CHF&nbsp;132.9 million as of December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategic collaborations and licensing agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since our inception, we have entered into
strategic collaboration agreements with a range of partners covering a number of our product candidates. We entered into a strategic
collaboration with Genentech in November 2006 (as amended in March 2009, January 2013, May 2014 and May 2015) regarding the development,
manufacture and commercialization of crenezumab, and we refer to this agreement as the 2006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Agreement.
In June 2012, we entered into an additional strategic collaboration agreement with Genentech regarding the development, manufacture
and commercialization of anti-Tau antibodies, and we refer to this agreement as the 2012 Agreement. We expect to capitalize on
Genentech&rsquo;s drug development and regulatory expertise and commercial capabilities to bring our partnered therapeutic products
to market. In May 2014, we entered into a license and collaboration agreement with LMI (formerly Piramal Imaging SA) covering
our Tau-PET Imaging tracer. In December 2014 (as amended in April 2016, July 2017, January 2019 and November 2019), we entered
into a strategic collaboration agreement with Janssen regarding the development, manufacture and commercialization of ACI-35,
an anti-Tau vaccine. We expect to capitalize on Janssen and Johnson&nbsp;&amp; Johnson&rsquo;s extensive regulatory expertise
and experience in developing, manufacturing and, if approved, commercializing vaccines to bring ACI-35 to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We entered into a license agreement with
Lilly in December 2018 (as amended in September 2019 and March 2020) to research and develop Morphomer Tau small molecules for
the treatment of AD and other neurodegenerative diseases. Under the terms of this agreement, we have completed a Phase 1 clinical
study with ACI-3024. Lilly is responsible for leading and funding further clinical development and will retain global commercialization
rights for all indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Genentech, a member of the Roche Group</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have two partnership agreements with
Genentech, a company with a reputation for scientific excellence and a history of bringing innovative protein therapeutics to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Anti-Abeta antibody in AD &ndash; 2006 agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In November 2006, we signed an exclusive,
worldwide licensing agreement for crenezumab, our humanized monoclonal therapeutic antibody targeting misfolded Abeta. The agreement
was amended March 2009, January 2013, May 2014 and May 2015. The agreement also provides for the development of a second therapeutic
product for a non-AD indication based on the same intellectual property and anti-Abeta antibody compound. The value of this partnership
is potentially greater than USD 340 (CHF 303) million. The structure of the collaboration agreement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A right-of-use license;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Clinical milestone payments</I>: payable upon commencement of each of Phase 1 and Phase 2 of clinical developments, and
upon the earlier of Genentech&rsquo;s decision to authorize Phase 3 or the commencement of Phase 3 of clinical developments. In
addition, for a second indication, clinical milestone payments would be payable upon commencement of Phase 2 of clinical developments
and upon the earlier of Genentech&rsquo;s decision to authorize Phase 3 or the commencement of Phase 3 of clinical developments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Regulatory milestone payments</I>: payable upon making regulatory filings in the US and Europe, respectively, and milestone
payments upon obtaining marketing approval in each of the US and Europe. In addition, for a second indication, additional regulatory
and approval milestones would be payable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Royalties</I>: payable on sales, with different royalty rates applicable in the US and Europe. Royalty levels are tied
                                                                                                               to annual sales volumes. We may receive royalties on sales of crenezumab with the percentage rates ranging from the
                                                                                                               mid-single digits to mid-teens.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, we have received total milestone
payments of USD 65 (CHF 70.1) million comprised of an upfront payment of USD 25 (CHF 31.6) million and of USD 40 (CHF 38.2) million
for clinical development milestones achieved all-in prior to January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the agreement, Genentech
bears all the costs of developing crenezumab through the clinical phases. In addition, Genentech is responsible for the costs associated
with seeking and obtaining regulatory and marketing approvals, along with manufacturing sales and marketing costs. Intellectual
property costs related to any crenezumab-related intellectual property filed solely by us and any costs associated with filing,
maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate by its terms
on the date on which all obligations between the parties with respect to the payment of milestones or royalties for licensed products
have passed or expired. Either party may terminate the agreement for any material breach by the other Party, provided a cure period
of 90 days from the date when that notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 30, 2019, we announced that
Roche, the parent of Genentech, is discontinuing the CREAD and CREAD 2 (BN29552 and BN29553) Phase 3 studies of crenezumab in people
with prodromal-to-mild sporadic AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Crenezumab continues to be studied in the
Phase 2 preventive trial, which began in 2013 in Columbia, of cognitively healthy individuals who carry the PSEN1 E280A autosomal-dominant
mutation and are in a preclinical phase of ADAD. This study will determine if treating people carrying this mutation with crenezumab
prior to the onset of AD symptoms will slow or prevent the decline of cognitive and functional abilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Anti-Tau antibody in AD &ndash; 2012 agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June 2012, we entered into a second
agreement with Genentech to research, develop and commercialize our anti-Tau antibodies for use as immunotherapeutics and diagnostics.
The agreement was amended in December 2015. The value of this exclusive, worldwide alliance is potentially greater than CHF 400
million and includes upfront and clinical, regulatory and commercial milestone payments. In addition to milestones, we will be
eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to low-double digits. The agreement
also provides for collaboration on at least one additional therapeutic indication outside of AD built on the same anti-Tau antibody
program as well an anti-Tau diagnostic product for AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, we have received payments totaling
CHF 59 million, including a milestone payment of CHF 14 million received and recognized in Q4 2017 associated with the first patient
dosing in a Phase 2 clinical trial for AD with an anti-Tau monoclonal body known as semorinemab, a milestone payment of CHF 14
million recognized in Q2 2016 and received in July 2016, associated with the announcement of the commencement of the Phase 1 clinical
study of semorinemab, and a milestone payment of CHF 14 million received in 2015 in connection with the ED-GO decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The structure of the collaboration agreement
is as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A right-of-use license.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Preclinical and clinical milestone payments</I>: payable upon selection of a lead candidate and commencement of each of
Phase 1, 2 and 3 of clinical development. In addition, for a second indication, clinical milestone payments would be payable upon
commencement of each of Phase 2 and 3 of clinical development.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Regulatory milestone payments</I>: payable upon making regulatory filings for marketing approvals in each of the US, Europe
and Japan. In addition, for a second indication, similar regulatory milestones would be payable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Commercialization milestones</I>: payable upon making a first commercial sale in each of the US, Europe and Japan. For a
second indication, commercialization milestones exist for each of the US, Europe and Japan, which are triggered by the first commercial
sale for the second indication in each of those jurisdictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Royalties</I>: payable on sales with royalty rates differing based on the source of the intellectual property underlying
the commercial product.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the agreement, Genentech
bears all the costs of developing semorinemab through the clinical phases. In addition, Genentech is responsible for the costs
associated with seeking and obtaining regulatory and marketing approvals, along with manufacturing, sales and marketing costs.
Intellectual property costs related to any anti-Tau antibody-related intellectual property filed solely by us and any costs associated
with filing, maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate
by its terms on the date on which all obligations between the parties with respect to the payment of milestones or royalties for
licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other Party,
provided a cure period of 90 days from the date when that notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">On
September 23, 2020, the Company reported that Genentech informed us of top line results from a Phase 2 trial of the anti-Tau antibody,
semorinemab, in early (prodromal to mild) Alzheimer&rsquo;s disease (AD) which show that semorinemab did not meet its primary efficacy
endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. The primary safety endpoint
was however met. Two secondary endpoints, Alzheimer&rsquo;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><FONT STYLE="background-color: white">Alzheimer&rsquo;s
Disease Cooperative Study Group &ndash; Activities of Daily Living Inventory (ADCS-ADL), were not met. A second Phase 2 study
of semorinemab in patients with moderate AD remains ongoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Janssen Pharmaceuticals, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><I>Tau Vaccine in AD &ndash; 2014 agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2014, we entered into an agreement
with Janssen Pharmaceuticals, Inc. (Janssen) one of The Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and
commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership
is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones,
we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. In
April 2016, July 2017, January 2019 and November 2019, the companies entered into the first, second, third and fourth amendments,
respectively. These amendments allow for the alignment of certain payment and activity provisions with the Development Plan and
Research Plan activities. We and Janssen are co-developing the second-generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054,
through Phase 1b/2a completion. AC Immune and Janssen will jointly share research and development costs until the completion of
the first Phase 2b (AC Immune&rsquo;s contribution to the first Phase 2b trial is capped). From Phase 2b and onwards, Janssen will
assume responsibility for the clinical development, manufacturing and commercialization of the second-generation vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company received an upfront, non-refundable
license fee of CHF 25.9 million, which we recognized as revenue in 2014. In May 2016, we received a payment of CHF 4.9 million
for reaching a clinical milestone in the Phase 1b study. As we met all performance obligations on reaching the milestone, we recognized
this milestone as revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The structure of the collaboration agreement
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A right-of-use license.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Clinical milestone payments</I>: payable upon completion of Phase 1b, commencement of the first Phase 2b or 2b/3 of clinical
development, upon reaching enrollment thresholds in the first Phase 2b or Phase 2b part of the first Phase 2b/3, commencement of
the first Phase 3 or Phase 3 part of a Phase 2b/3 study. In addition, for a second indication, clinical milestone payments would
be payable upon commencement of a Phase 3 clinical study, which would be payable concurrently with the first regulatory milestone,
if Janssen were to file for regulatory approval based on Phase 2 clinical data.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Regulatory milestone payments</I>: payable upon making regulatory filings in the US, Europe, and Japan, respectively. In
addition, for a second indication, similar regulatory milestones would be payable. For a second indication, additional regulatory
milestone payments are payable by Janssen to us upon receipt of each of the regulatory approvals in the US, Europe and Japan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Commercialization milestones</I>: payable upon making a first commercial sale in each of the US, Europe and Japan, and upon
achieving certain commercial milestones.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Royalties</I>: payable on sales, with royalty rates differing based on the level of annual sales.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">Under the terms of the agreement, Janssen
may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days&rsquo;
notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined
in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>LMI (formerly Piramal Imaging SA)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><I>Tau-PET imaging agent in AD &ndash; 2014 agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May 2014, we entered into an agreement,
our first diagnostic partnership, with LMI, the former Piramal Imaging SA. The partnership with LMI is an exclusive, worldwide
licensing agreement for the research, development and commercialization of the Company&rsquo;s Tau protein PET tracers supporting
the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments
totaling up to EUR 159 (CHF 175) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low-teens.
LMI may terminate the LCA at any time by providing 3 months&rsquo; notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The structure of the collaboration agreement
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A right-of-use license.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Clinical milestone payments</I>: payable upon the commencement of the Phase 1, 2 and 3 studies for generation of data intended
to support a regulatory submission in the US or the EU. We would be entitled to further clinical milestone payments for the commencement
of a Phase 2 and 3 study for a second indication.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Regulatory milestone payments</I>: payable upon acceptance of Regulatory filing (NDA) and Regulatory approval for Commercialization
in the US or the EU.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Commercialization milestones</I>: tied to specific annual net sales amounts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Royalties: </I>payable on sales with royalty rates differing based on the level of annual sales.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Eli Lilly and Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><I>Morphomer Tau small molecule &ndash; 2018 license
agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2018, we entered into an exclusive,
worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the
treatment of AD and other neurodegenerative diseases. Per the terms of the agreement, the Company received an initial upfront payment
of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly. To date, the Company has completed a Phase 1 clinical
study with ACI-3024. The program will be expanded to NeuroOrphan indications and ACI-3024 will be further evaluated for efficacy
in models of rare Tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, the Company and Lilly have
continued candidate characterization across the research program, identifying new and highly differentiated candidates with desired
cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent
neurodegenerative diseases by Lilly. Lilly is responsible for leading and funding further clinical development and will retain
global commercialization rights for all indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Per the terms of the agreement, the Company
may become eligible to receive additional milestone payments totaling up to approximately CHF 1.9 billion.&nbsp;In addition to
milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low double-digits to the mid-teens.
The agreement became effective on January 23, 2019 (the &ldquo;effective date&rdquo;) when the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, expired. In Q3 2019, the Company and Lilly entered into the first amendment to
divide the first discretionary milestone payment under the agreement of CHF 60 million into two installments. with the first CHF
30 million paid in Q3 2019 and the second CHF 30 million to be paid on or before March 31, 2020 unless Lilly terminated the agreement
earlier. In Q1 2020, the Company and Lilly entered into a second amendment to replace the second CHF 30 million to be paid on or
before March 31, 2020 with two milestone payments, one of CHF 10 million to be paid on or before March 31, 2020 and the other of
CHF 60 million following the first patient dosed in a Phase 2 clinical study of a licensed product in the US or the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company received an initial upfront
payment of CHF 80 million in February 2019. We used the residual approach to estimate the selling price for the right-of-use license
and an expected cost plus margin approach for estimating the research and development activities. The right-of-use license was
delivered on the effective date. The research and development activities were delivered over time as the services were performed.
For these services, revenue was recognized over time using the input method, based on costs incurred to perform the services, as
the level of costs incurred over time is thought to best reflect the transfer of services to Lilly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The structure of the collaboration agreement
is as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>A</I>n <I>exclusive license: </I>granted by us to Lilly under certain of our intellectual property to develop,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">manufacture and commercialize products containing
Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases throughout the world in any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Clinical milestone payment</I>s: payable upon completion of the Lilly preclinical activities period and following the first
patient dosed in a Phase 2 and Phase 3 clinical study of a licensed product in the US or the EU.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Regulatory milestone payments</I>: payable within 60 days after obtaining regulatory approval for any licensed product in
the first indication and any licensed product in certain additional indications in the US, Europe and Japan, respectively.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Commercialization milestones</I>: payable upon achieving certain commercial sales milestones.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Royalties</I>: payable on sales with royalty rates differing based on the level of annual sales of licensed products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The agreement will terminate by the date
of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly may terminate
the agreement at any time after March 31, 2020 by providing 3 months&rsquo; notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We and Lilly also entered into a convertible
note agreement that became effective on January 23, 2019 for USD 50 (CHF 50.3) million from Lilly. In Q2 2019, the Convertible
Note Agreement with Lilly automatically converted in line with the terms of the agreement. As a result of this conversion, 3,615,328
of our common shares were issued to Lilly. This note is now fully settled and there is no further equity or cash consideration
due to Lilly thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Grants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Michael J. Fox Foundation for Parkinson&rsquo;s
Research</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In Q3 2017, we
formally signed a grant continuation with the Michael J. Fox Foundation for Parkinson&rsquo;s disease research (MJFF). This grant
provides funds for the development of PET tracers for pathological forms of the protein alpha-synuclein, to support the early diagnosis
and clinical management of Parkinson&rsquo;s disease. We subsequently signed two additional grants that facilitated the <FONT STYLE="background-color: white">execution
of a first-in-human study for a potential alpha-synuclein-PET tracer (PET tracer) with the current lead compound and to further
develop the PET tracer.&nbsp;</FONT>The Company retains its intellectual property rights for these alpha-synuclein-PET tracers.
These grants concluded in Q2 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In May 2020, the
Company, as part of a joint arrangement with Sk&aring;ne University Hospital (Sk&aring;ne) in Sweden, was awarded a USD 3.2 (CHF
2.9) million grant from the MJFF&rsquo;s Ken Griffin Alpha-synuclein Imaging Competition. As part of this grant, AC Immune is eligible
to receive USD 2.5 (CHF 2.2) million directly from the MJFF. Sk&aring;ne will receive USD 0.7 (CHF 0.7) million of the total grant
directly from the MJFF over two years to conduct and support the clinical arm of the project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical accounting policies and significant judgments and
estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Revenue recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May 2014, the IASB issued IFRS 15 (<I>Revenue
from Contracts with Customers</I>)<I>, </I>which amends the guidance for accounting for revenues from contracts with customers.
This IFRS replaces all current revenue standards in IFRS including IAS 11 (<I>Construction Contracts</I>), IAS 18 (<I>Revenue</I>)
and various interpretations. The Company adopted this new standard on January 1, 2018, and would have recognized the cumulative
effect of initially applying the new revenue standard as an adjustment to the opening balance of accumulated losses; however, the
Company did not deem that any adjustments were required in the transition to the new standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This standard applies to all contracts
with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements
and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following
five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is
probable that the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">entity
will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract
inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised
within each contract, and determines those that are performance obligations, and assesses whether each promised good or service
is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation when (or as) the performance obligation is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Contract revenue</I>. The Company enters
into LCAs, which are within the scope of IFRS 15, under which it licenses certain proprietary rights to its product candidates
and intellectual property to third parties. The terms of these arrangements typically include payment to the Company of one or
more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments,&nbsp;payments
for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties
on net sales of licensed commercialized products depending on the Company&rsquo;s intellectual property. Each of these payments
results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Licenses of intellectual property</I>.&nbsp;If
the license to the Company&rsquo;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license
is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction
with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether
the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over
time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance
and related revenue recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Milestone payments</I>.&nbsp;At the
inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates
whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction
price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future
periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under
the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the
probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall
transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Research and development services</I>.&nbsp;The
Company has certain arrangements with our collaboration partners that include contracting our employees for research and development
programs. The Company assesses if these services are considered distinct in the context of each contract and, if so, they are accounted
for as separate performance obligations. These revenues are recorded in contract revenue as the services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Sublicense revenues</I>.&nbsp;The Company
has certain arrangements with our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense
revenues at the point in time it is highly probable to obtain and not subject to reversal in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Contract balances:</I>&nbsp;The Company
receives payments and determines credit terms from its customers for its various performance obligations based on billing schedules
established in each contract. The timing of revenue recognition, billings and cash collections results in billed other current
receivables, accrued income (contract assets), and deferred income (contract liabilities) on the balance sheets. Amounts are recorded
as other current receivables when the Company&rsquo;s right to consideration is unconditional. The Company does not assess whether
a contract has a significant financing component if the expectation at contract inception is such that the period between payment
by the licensees and the transfer of the promised goods or services to the licensees will be 1 year or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Accrued research and development costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We record accrued expenses for estimated
costs of our research and development activities conducted by third-party service providers, which include among others the conduct
of preclinical studies and clinical studies and contract manufacturing activities. We record accrued expenses for estimated costs
of our research and development activities based upon the estimated amount of services provided but not yet invoiced, and we include
these costs in accrued expenses on the balance sheets and within research and development expenses in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">the
statements of income/(loss). These costs are a significant component of our research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We record accrued expenses for these costs
based on the estimated amount of work completed in accordance with agreements established with these third parties, which involves
the following process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the
level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified
of actual costs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>estimating and accruing expenses in our financial statements as of each balance sheet date based on facts and circumstances
known to us at the time; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>periodically confirming the accuracy of our estimates with selected providers and adjusting, if necessary.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of estimated research and development expenses that
we accrue include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fees paid to CROs in connection with preclinical and toxicology studies and clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fees paid to investigative sites in connection with clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fees paid to CMOs in connection with the production of our product candidates prior to qualifying for capitalization as inventory;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>professional service fees for consulting and related services.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We base our expense accruals related to
clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions
and clinical CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract
to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical study milestones. Our service providers invoice us monthly in arrears for
services performed. In accruing service fees, we estimate the time period over which the services will be performed and the level
of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate
the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, we have not experienced significant
changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates,
we may be required to make changes to our estimates in the future as we become aware of additional information about the status
or conduct of our clinical studies and other research activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Share-based compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company operates an equity-settled,
share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards
is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value
of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included
in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company
revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision
of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding adjustment to equity over
the remaining vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate the fair value of all time-vested
options as of the date of grant using the Black-Scholes option-pricing model. Key assumptions in determining the fair value of
share options granted utilizing the Black-Scholes valuation method include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 77%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><B>Assumption</B></TD>
    <TD STYLE="width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center"><B>Method of estimation</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&#9679;</TD>
    <TD>Estimated expected term of options</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Simplified method</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&#9679;</TD>
    <TD>Expected volatility</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Estimate based on average historical volatilities of common shares of comparable publicly traded companies. We will continue to apply this process to grants made as a public company until a sufficient amount of historical information regarding the volatility of our own stock price becomes available </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&#9679;</TD>
    <TD>Risk-free interest rate</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Yields of long-dated Swiss government zero coupon bond issues </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&#9679;</TD>
    <TD>Forfeiture rates</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Historical and expected forfeiture data</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt">&#9679;</TD>
    <TD>Expected dividends</TD>
    <TD STYLE="text-align: center">&#9679;</TD>
    <TD>Zero percent as dividends have not been paid</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Historically, for all periods prior to
the initial public offering (IPO), the fair value of the common shares underlying our share-based awards was estimated on each
grant date by our management and approved by our board of directors. In order to determine the fair value of our common shares
underlying option grants, our board of directors considered, among other things, the breadth of our product candidate portfolio,
the stages of development of our various product candidates and major changes to stage of development, the progress and additions
to our collaboration agreements, risks inherent in our activities, the lack of liquidity of our Company&rsquo;s securities, and
the valuations and sentiment toward biotech companies. Given the absence of a public trading market for our common shares, our
board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best
estimate of the fair value of our common shares, including our stage of development, progress of our research and development efforts,
the strength of our balance sheets and capital base, equity market conditions affecting comparable public companies, and the lack
of liquidity of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Restricted shares and restricted share
units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate the fair value of non-vested
stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on
the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common
stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation
costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period
of the award using the graded method. We reclassify that portion of vested awards to share premium as the awards vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Right-of-use assets and lease liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective January 1, 2019, the Company
adopted IFRS 16 (<I>Leases</I>), which provides a new model for lessee accounting in which all leases, other than short-term and
low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and
the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company
applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially applying IFRS
16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets
at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting,
see &ldquo;Note 5. Right-of-use assets and lease liabilities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Covid-19 global
pandemic has impacted various countries where we currently operate our clinical trials and business operations. The extent to which
Covid-19 may impact us will depend on future developments, which are highly uncertain and cannot be predicted with confidence,
such as the duration of the outbreak, the severity of Covid-19, or the effectiveness of actions to contain and treat for Covid-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company effected
its business continuity plan during the interim period ended September 30, 2020. The Company implemented its plan quickly and continues
to adapt as the situation evolves. Currently, we have mostly resumed normal operations at full capacity with minimal disruptions
to our business. We are continuously assessing and adapting our working practices and business operations to ensure compliance
with official guidance and orders related to the pandemic, and are working proactively with our partners and other</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">stakeholders
to take steps intended to mitigate and minimize any negative impact to our research, clinical programs and other business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">Many of our key
trials are already fully enrolled and patient follow-up can continue remotely in most cases. However, the current pandemic may
impact certain clinical trials as long as the pandemic is ongoing. Most notably:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>ACI-35.030
for AD:</B> The Company continues to collect data from the Phase 1b/2a study. The interim analysis of ACI-35.030 at the lowest
dose (safety, tolerability and immunogenicity) was obtained in Q2 2020 and led to the initiation of the second highest dosing group
in the Phase 1b/2a clinical trial. The interim analysis of this second highest dosing group (safety, tolerability and immunogenicity)
was obtained in Q4 2020 and led to the initiation of the highest dosing group in the Phase 1b/2a clinical trial in Q1 2021. The
initiation of these dosing groups of ACI-35.030 commenced in accordance with the underlying development plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>ACI-3024</B>:
Our Phase 1 study for ACI-3024 in healthy young, elderly non-Japanese and Japanese volunteers was completed in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>ACI-24 for
DS</B>: The Company&rsquo;s ACI-24 Phase 1b trial has been completed and the final analysis is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Regulatory
submission of the ACI-24-DS Phase 2 trial was initiated as planned. The initiation of the clinical trial will be dependent on the
evolving Covid-19 situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>ACI-24 for
AD:</B> The Company continues to collect safety, immunogenicity and biomarker data from patients in the ongoing Phase 2 study of
ACI-24. The 18-month interim data analysis is anticipated for the ongoing study in Q2 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>crenezumab:
</B>In response to the government-imposed stay at home order in Colombia related to the Covid-19 pandemic, the dosing of participants
in the Colombian API study was temporarily interrupted in H1 2020.&nbsp;The dosing restarted on May 18, 2020. Participants are
receiving crenezumab or placebo for at least five years as part of the long-term prevention study, and, despite the interruption,
we continue to expect data from the study in Q1 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><B>PI-2620: </B>The
longitudinal Phase 2 study in AD and the Phase 1 test/re-test study in PSP enrolling patients in the UK were impacted by Covid-19
and Brexit and have been suspended. An investigator-initiated Phase 2 study in AD in Korea continues with a potential data analysis
in Q2 2021. The Phase 1 PSP study may resume in Q2 2021 in the UK, depending on the ongoing Covid-19 pandemic, but a backup study
is being also prepared in Germany which could begin in H2 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company has drug supplies that are expected to be sufficient to complete ongoing trials as well as additional drug substance supplies
expected to be sufficient to support ongoing cohorts of clinical trials for a period of at least three to six months. The Company will
refrain from starting new clinical trials if a minimum of a six-months supply on hand cannot be secured. Finally, the Company currently
does not expect delays to its clinical trials due to manufacturing or supply-chain issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial operations overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Contract Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Given our stage of development, we have
not generated any revenue from product sales. Our contract revenues to date have been derived primarily from separate license and
collaboration agreements on some of our product candidates in various stages of preclinical and clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our contract revenues have experienced
fluctuations over the past 3 years as a result of securing new collaboration agreements, the timing of milestone achievement and
the size of each milestone payment. We expect that any revenue we generate from our collaboration agreements with each of Lilly,
Genentech, Janssen and LMI and/or from any other current or future collaboration partners will fluctuate from year to year as a
result of the timing and amount of milestones and other payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Research and development expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development costs are expensed
as incurred, and consist of salaries and benefits, laboratory supplies, materials, intellectual property and facility costs, as
well as fees paid to other non-employees and entities that conduct certain research and development activities on our behalf. Amounts
incurred in connection with license and collaboration agreements are also included in research and development expense. Payments
made prior to the receipt of goods or services to be used in research and development are capitalized until those goods or services
are received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical trial costs are a component of
research and development expenses. We accrue and expense clinical trial activities performed by third parties based upon actual
work completed in accordance with agreements established with clinical CROs and clinical sites. We determine the actual costs through
monitoring patient enrollment and discussions with internal personnel and external service providers as to the progress or stage
of completion of trials or services and the agreed-upon fee to be paid for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Manufacturing start-up costs are a component
of research and development expenses. Additionally, manufacturing costs incurred after regulatory approval but in connection with
significant changes and/or enhancements to the approved manufacturing process are recorded as research and development expenses.
We accrue and expense the manufacturing activities performed by third parties based upon actual work completed in accordance with
agreements established with contract manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our investment in research and development
activities, including the clinical development of our product candidates has historically been and is projected to be more than
75% of our total annual operating costs. Research and development expenses represent costs incurred to conduct research, such as
the discovery and development of our product candidates, as well as development of new product candidates from our SupraAntigen
and Morphomer platforms and the development of product candidates pursuant to our collaboration agreements with Lilly, Genentech,
Janssen and LMI. We recognize all research and development costs as they are incurred. Clinical study costs, contract manufacturing
and other development costs incurred by third parties are expensed as the contracted work is performed. At present, our research
activities comprise three major areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>AD;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>focused non-Alzheimer&rsquo;s neurodegenerative diseases including NeuroOrphan indications; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>diagnostics.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect our research and development
expenses to increase substantially in the future and expect to fund a broader number of projects, which will impact our research
strategy in four key ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i) we expect to undertake later-stage
research and development of our product candidates and, if approved, to take some of those product candidates into commercialization;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ii) we will allocate more funding to existing
programs to advance the development of these programs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(iii) we will increase our research and
development efforts on non-AD indications including NeuroOrphans and diagnostics; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(iv) we will initiate a number of new research
initiatives that are complementary to our existing and planned research initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect that our total future research
and development costs will continue to increase over current levels in line with our three-pillar strategy that focuses on (i)
AD, (ii) focused non-Alzheimer&rsquo;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>General and administrative expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses include
personnel costs, expenses for outside professional services and all other allocated expenses. Personnel costs consist of salaries,
cash bonuses, benefits and share-based compensation. Outside professional services consist of legal, accounting and audit services,
information technology (IT) and other consulting fees. Allocated expenses consist of depreciation expense related to our office
and research and development facility. We continue to incur additional expenses as a result of operating as a public company, including
expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which
our securities are traded (Nasdaq), additional insurance expenses, investor relations activities and other administrative and professional
services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Finance Result, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial income and expenses include bank
fees associated with charges levied by banks on foreign payments, interest income and expense associated with our cash balances
and interest expense associated with</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">lease
liabilities. Additionally, for the year ended December 31, 2019, we incurred effective interest to amortize the host debt for
the convertible loan due to Lilly and accrue interest for our financing obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Exchange differences consist of foreign
exchange transactions and re-measurement gains and losses that arise from our cash being held in currency other than Swiss Francs,
certain collaboration agreements such as the collaboration agreements with Genentech and LMI being denominated in currencies other
than Swiss Francs, and selected purchases, which we effect in foreign currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Finally, the Company recorded a gain on
the conversion feature of the convertible loan due to Lilly for the year ended December 31, 2019 that did not repeat in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Taxation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune is subject to corporate Swiss
federal, cantonal and communal taxation, respectively, in Switzerland, Canton of Vaud, Commune of Ecublens, near Lausanne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are entitled under Swiss laws to carry
forward any losses incurred for a period of 7 years and can offset our losses carried forward against future taxes. As of December
31, 2020, we had tax loss carry-forwards totaling CHF 121.9 million. There is no certainty that we will make sufficient profits
to be able to utilize these tax loss carry-forwards in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The effective corporate income tax rate
(federal, cantonal and communal) where we are domiciled is currently 13.63%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of January 1, 2020, the Company may
request for 2020 and future tax years a tax relief of 60%, which would be applied to income from patents and similar rights at
the communal and cantonal levels. This relief would first require the reintegration of all expensed and deducted research and development
costs related to the concerned patents and similar rights for consideration in our taxable results from the prior ten years. The
Company has not currently made any decision to enter this patent box system. Additionally, a &ldquo;super-deduction&rdquo; may
be granted for payroll and other expenses of research and development of Swiss origins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">However, the aforementioned tax relief
based on the patent box and deductions for research and development may not exceed 50% of the overall taxable profit before these
tax relief and deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Notwithstanding the corporate income tax,
the corporate capital is taxed at a rate of 0.13% (cantonal and communal tax only, as there is no federal tax on capital).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Value added tax (VAT) is charged on all
qualifying goods and services supplied by VAT-registered businesses. Rates vary based on category, but the Company applies a standard
rate of 7.7% on the value of the goods or services to all sales invoices, which is payable to the Swiss tax authorities. Similarly,
VAT paid on purchase invoices is reclaimable from the Swiss tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The numbers below have been derived from
our audited financial statements included elsewhere in this Annual Report. The discussion below should be read along with these
financial statements and it is qualified in its entirety by reference to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of the years ended December 31, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Contract revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our contract
revenues during the years ended December&nbsp;31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt">Contract revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">15,431</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">110,456</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">(95,025</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,431</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,456</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(95,025</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our contract revenues experience fluctuations
as a result of securing new collaboration agreements, the timing of milestone achievements and the size of each milestone payment.
For the year ended December 31, 2020, the decrease of CHF 95 million in contract revenues compared to the year ended December 31,
2019 was primarily a result of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a decrease of CHF 91.3 million in our agreement with Lilly. The Company recognized a CHF 10 million milestone and CHF 4.3 million
for research and development activities in 2020. These were offset by an upfront payment of CHF 73.1 million for a right-of-use
license fee, CHF 30 million for the first installment of the first milestone achieved and CHF 2.6 million for research and development
activities in 2019;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a decrease of CHF 0.1 million for research and development activities associated with our collaboration agreement with Janssen;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a decrease of CHF 3.6 million from non-recurring revenues for a CHF 2.2 million Phase 2 milestone earned in 2019 from LMI,
CHF 1.1 million earned in our Biogen collaboration which ended in April 2019 and CHF 0.4 million in other contract revenues.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Research and development expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development activities are
essential to our business and represent the majority of our costs incurred. Costs for certain development activities, such as clinical
trials, are recognized based on an evaluation of the progress to completion of specific tasks using information from the clinical
sites and our vendors. Our collaboration arrangements share costs for the development of our product candidates differently. We
have completed our research and development spending in both of our Genentech collaborations. We and Janssen are co-developing
the second-generation lead therapeutic vaccines through the Phase 1b/2a completion. AC Immune and Janssen will jointly share research
and development costs until the completion of the first Phase 2b. From Phase 2b and onwards, Janssen will assume responsibility
for the clinical development, manufacturing and commercialization of the second-generation vaccines. We expect to incur additional
research and development expenditures associated with the expansion of our Morphomer Tau program into NeuroOrphan indications as
well as an expansion of ACI-3024 to be evaluated in other rare Tauopathies. In addition to these arrangements, we expect that our
total future research and development costs will continue to increase over current levels in line with our three-pillar strategy
that focuses on (i) AD, (ii) focused non-Alzheimer&rsquo;s neurodegenerative diseases including NeuroOrphan indications and (iii)
diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below provides a breakdown of
our research and development costs, including direct research and development costs and manufacturing costs related to research
and development, by major development categories of our programs for the periods covered by this Annual Report. The research and
development costs not allocated to specific programs include employment costs, regulatory, QA and intellectual property costs.
We do not assign our internal costs, such as salary and benefits, share-based compensation expenses, laboratory supplies and other
direct expenses and infrastructure costs to individual research and development projects, because the employees within our research
and development groups are typically deployed across multiple research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our research
and development expenses during the years ended December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Detailed research and development expenditures
by major development category</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Discovery and preclinical expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">20,408</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">17,809</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,599</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Clinical expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,124</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,806</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Group function expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">904</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,025</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(121</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Direct R&amp;D</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">38,436</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,640</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,796</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Payroll expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,424</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,382</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,042</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,276</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">691</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other non-allocated</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,351</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,825</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">526</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total R&amp;D</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">59,487</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,432</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,055</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%">Operating expenses<SUP>1</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">43,787</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">37,465</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,322</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Salaries and related costs<SUP>2</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,700</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,967</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,733</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">59,487</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,432</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,055</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><SUP>1</SUP>Includes depreciation
expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><SUP>2</SUP>Includes share-based
compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Discovery and preclinical expenses increased
CHF 2.6 million, primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase in ACI-24 for DS of CHF 3.6 million for development costs associated with the second generation, CHF 1.2 million
for <FONT STYLE="background-color: white">preclinical and manufacturing costs to advance our a-syn projects</FONT>, CHF 0.9 million
for certain neuroinflammation investments, CHF 0.9 million for the <FONT STYLE="background-color: white">development of our anti-TDP-43
antibody with the initiation of IND-enabling studies</FONT>, CHF 0.8 million for preclinical and manufacturing activities for our
a-syn Imaging program, CHF 0.4 million for the expansion of our Morphomer Tau program into NeuroOrphan indications, and CHF 0.6
million in other discovery programs,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">partially offset by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a decrease of CHF 4.2 million in ACI-24 for AD based on completion of manufacturing process development and CHF 1.5 million
in our collaboration with Janssen due to the completion of the majority of the preclinical safety evaluation for JACI-35.054 in
the prior period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical expenses increased by CHF 3.3
million, primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase of CHF 2.2 million in ACI-24 for DS related to <FONT STYLE="background-color: white">scaling up activities for
a Phase 2 clinical study</FONT>, CHF 0.8 million for the full year Phase 1 activities of our Morphomer Tau compound and CHF 0.9
million for ACI-35.030 related to the current Phase 1b/2a including enrollment of additional subjects and other clinical activities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">partially offset by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a decrease of CHF 0.5 million for ACI-24 for AD as the 18-month treatment completes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">The variances in Group function expenses
relate to regulatory and quality assurance, IP and other non-allocated costs. The variances in Other non-allocated expenses relate
to administrative R&amp;D and certain non-allocated functional expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">Total salaries and related costs increased
by CHF 2.7 million, primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase in salary- and benefit-related costs of CHF 2.0 million due to the hiring of 13 additional full-time equivalent
employees and annualization of 2019 hires; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>higher share-based compensation expense of CHF 0.7 million related predominantly to an increase of stock options issued to
employees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>General and administrative expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our general
and administrative expenses during the years ended December&nbsp;31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%">Operating expenses<SUP>1</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,471</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,637</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">834</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Salaries and related costs<SUP>2</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,086</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,421</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,665</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,557</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,058</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,499</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><SUP>1</SUP>Includes depreciation
expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><SUP>2</SUP>Includes share-based
compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December 31, 2020, our
general and administrative expenses totaled CHF 18.6 million, an increase of CHF 2.5 million from CHF 16.1 million incurred during
the year ended December 31, 2019. This increase is primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase in salary- and benefit-related costs of CHF 1.1 million due to the hiring of 3 additional full-time equivalent
employees and annualization of 2019 hires;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase in share-based compensation expense of CHF 0.6 million related predominantly to an increase of stock options issued
to executive officers and directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 0.5 million increase in administrative expenditures, predominantly driven by a CHF 0.4 million increase in our directors
and officers insurance and CHF 0.1 million in other miscellaneous items;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 0.6 million increase in depreciation expense <FONT STYLE="background-color: white">of our right-of-use assets and capital
equipment; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 0.2 million increase in legal fees, driven by an increase for <FONT STYLE="background-color: white">professional services
associated with our at the market offering issuance costs,</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">partially offset by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 0.3 million decrease in travel and entertainment expenditures; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 0.2 million decrease in investor relations expenditures.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Finance result, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our financial
income and expenses during the years ended December&nbsp;31, 2020 and 2019:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Financial income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">78</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">303</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(225</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financial expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,926</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,742</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Change in fair value of conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,542</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,542</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exchange differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(555</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,013</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,458</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Finance result, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(661</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">906</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,567</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net finance result was a loss primarily
increased related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the non-repetition of a CHF 4.5 million&nbsp;gain on the conversion feature related to the Company&rsquo;s convertible loan
due to Lilly. This gain was mainly related to the change in value of the shares between the share price determined in the convertible
loan and the share price at the date of the conversion,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">partially offset by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 1.7 million decrease in financial expense, of which CHF 1.4 million was effective interest recorded to amortize the host
debt per the convertible loan due to Lilly; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 1.5 million decrease in exchange differences predominantly related to a CHF 1.2 million remeasurement loss related to
the settlement of the convertible loan that did not repeat in the current period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05b"></A>B.</TD><TD>Liquidity and capital resources</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cash flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Comparison of the years ended December&nbsp;31,
2020 and 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our cash
flows for the years ended December 31, 2020 and 2019, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Net cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(59,517</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">55,220</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(114,737</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,329</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,885</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,214</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(803</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,616</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,419</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net change in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(31,991</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,951</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(69,942</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Operating activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in operating activities was
CHF 59.5 million for the year ended December 31, 2020 compared with net cash provided by operating activities of CHF 55.2 million
for the year ended December 31, 2019. The change in cash provided by operating activities for the year ended December 31, 2020
was due to the Company incurring a net loss of CHF 61.9 million for the year ended December 31, 2020 compared with net income of
CHF 45.4 million for the same period in 2019, which was driven by (i) a decrease of CHF 95 million in contract revenues principally
due to the recognition of a CHF 10 million milestones which was offset by an upfront payment of CHF 73.1 million for a right-of-use
license fee and CHF 30 million for the first installment of the first milestone achieved in 2019 and (ii) offset by the increase
in research and development costs in the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Investing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by investing activities
was CHF 28.3 million for the year ended December 31, 2020 compared with net cash used in investing activities of CHF 66.9 million
for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">A net of CHF 30 million
worth of short-term financial assets matured for the year ended December 31, 2020, compared to a CHF 65 million increase in investments
in short-term financial assets for the prior period</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Financing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in financing activities was
CHF 0.8 million for the year ended December 31, 2020 compared with net cash provided by financing activities of CHF 49.6 million
for the year ended December 31, 2019. The decrease of CHF 50.4 million is predominantly related to CHF 50.3 million received from
Lilly for a convertible loan, offset by CHF 0.5 million for transaction costs associated with loan settlement in 2019 which did
not repeat in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Operating capital requirements and plan of operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We do not expect to generate revenues from
royalties based on product sales unless and until our partners obtain regulatory approval of, and successfully commercialize, our
current or any future product candidates. As of December 31, 2020, we had cash and cash equivalents of CHF 160.9 million and short-term
financial assets of CHF 65 million, resulting in CHF 225.9 million of liquidity. The decrease relative to December 31, 2019 is
due to a decrease in contract revenues of CHF 95 million in 2020 as discussed above. The Company also increased its research and
development spending on our major discovery, research and development programs and the strengthening of the Company&rsquo;s infrastructure,
systems and organization. There can be no certainty as to the exact timing, or in fact, whether any future milestone payments will
ever be made given that these milestone payments are contingent on clear milestones being reached. Accordingly, assuming we do
not receive potential milestone payments and based upon our currently contemplated research and development strategy, we believe
that our existing capital resources will be sufficient to meet our projected operating requirements through Q1 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect to generate losses for the foreseeable
future, and these losses could increase as we continue product development until we successfully achieve regulatory approvals for
our product candidates and begin to commercialize any approved products. We are subject to all the risks pertinent to the development
of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may
harm our business. We expect to incur additional costs associated with operating a public company and we anticipate that we will
need substantial additional funding in connection with our continuing operations. If we need to raise additional capital to fund
our operations and complete our ongoing and planned clinical studies, funding may not be available to us on acceptable terms, or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our future funding requirements will depend
on many factors, including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope, rate of progress, results and cost of our preclinical and clinical studies and other related activities, according
to our long-term strategic plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any other products
we may develop;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost, timing and outcomes of regulatory approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs and timing of establishing sales, marketing and distribution capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone
and royalty payments thereunder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the emergence of competing technologies or other adverse market developments; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the potential cost and timing of managing, protecting, defending and enforcing our portfolio of intellectual property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Contractual obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the Company has been a tenant
at our current location in the EPFL Innovation Park since shortly after our inception in 2003. We have entered into long-term rental
lease agreements with respect to these facilities. However, our lease agreements are structured such that we can exit these lease
agreements without penalty provided we give the owner of our premises sufficient notice. We have capitalized a portion of our lease
liabilities in accordance with IFRS 16. See &ldquo;Note 5. Right-of-use assets and lease liabilities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company currently projects CHF 0.8
million in undiscounted short-term lease obligations and CHF 1.9 million in undiscounted long-term lease obligations. Additionally,
the Company projects CHF 24.7 million in short-term purchase commitments and CHF 9.3 million in long-term purchase commitments
predominantly driven by R&amp;D activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>ATM program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2020, the Company established
an &ldquo;at the market offering&rdquo; for the sale of up to USD 80 (CHF 71.3) million worth of our common shares from time to
time by entering into a Sales Agreement with Jefferies. As of December 31, 2020, 5,000,000 shares have been issued and are held
as treasury shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of the years ended December&nbsp;31, 2019 and
2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For a discussion of the financial results
and condition for the fiscal year ended December 31, 2018, please refer to &ldquo;Item 5. Operating and financial review and prospects&mdash;A.
Operating results &ndash; comparison of the years ended December 31, 2019 and 2018&rdquo; of our Annual Report on Form 20-F for
the year ended December 31, 2019 filed on March 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05c"></A>C.</TD><TD>Research and development, patents and licenses, etc.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 4. Information on the Company
&ndash; B. Business overview&rdquo; and &ldquo;Item 5. Operating and financial review and prospects &ndash;A. Operating results
&ndash; results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05d"></A>D.</TD><TD>Trend information</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 5. Operating and financial
review and prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05e"></A>E.</TD><TD>Safe harbor</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item05f"></A>F.</TD><TD>Non-IFRS financial measures</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to our operating results, as
calculated in accordance with IFRS, as adopted by the IASB, we use adjusted income/(loss) and adjusted earnings/(loss) per share
when monitoring and evaluating our operational performance. Adjusted income/(loss) is defined as income/(loss) for the relevant
period, as adjusted for certain items that we believe are not indicative of our ongoing operating performance. Adjusted earnings/(loss)
per share is defined as adjusted income/(loss) for the relevant period divided by the weighted-average number of shares for such
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 128 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that these measures assist our
shareholders because they enhance the comparability of our results each period and provide more useful insight into operational
results for the period. The Company&rsquo;s executive management uses these non-IFRS measures to evaluate our operational performance.
These non-IFRS financial measures are not meant to be considered alone or as substitutes for our IFRS financial measures, and should
be read in conjunction with our financial statements prepared in accordance with IFRS. The most directly comparable IFRS measure
to these non-IFRS measures is net income/(loss). The following table reconciles net income/(loss) to adjusted income/(loss) and
adjusted earnings/(loss) per share for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Reconciliation of income/(loss) to
adjusted income/(loss) and<BR>
earnings/(loss) per share to adjusted earnings/(loss) per share</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands, except for share and per share data</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; font-weight: bold; padding-bottom: 1pt">Income/(loss)</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">Adjustments:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Non-cash share-based payments<SUP>1</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,088</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,834</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,518</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Foreign currency (gains)/losses<SUP>2</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">826</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,179</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Effective interest expenses<SUP>3</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,355</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">Change in fair value of conversion feature<SUP>4</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,542</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Adjusted income/(loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,130</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,915</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(47,254</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Earnings/(loss) per share &ndash; basic</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.64</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Earnings/(loss) per share &ndash; diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.64</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Adjustment to earnings/(loss) per share &ndash; basic</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.07</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.01</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.06</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Adjustment to earnings/(loss) per share &ndash; diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.07</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.00</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.06</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Adjusted earnings/(loss) per share &ndash; basic</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.79</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.65</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.76</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Adjusted earnings/(loss) per share &ndash; diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.79</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.64</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.76</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Weighted-average number of shares used to compute adjusted loss per share &ndash; basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,900,212</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,603,611</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,838,228</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted-average number of shares used to compute adjusted loss per share &ndash; diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,900,212</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,103,341</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,838,228</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>1</SUP>Reflects non-cash expenses associated
with share-based compensation for equity awards issued to directors, management and employees of the Company. This expense reflects
the awards&rsquo; fair value recognized for the portion of the equity award which is vesting over the period.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>2</SUP>Reflects foreign currency re-measurement
gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss
Franc.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><SUP>3</SUP>Effective interest expense for
the period relates to the accretion of the Company&rsquo;s convertible loan in accordance with the effective interest method.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><SUP>4</SUP>Change in fair value
of conversion feature that is bifurcated from the convertible loan host debt with Lilly.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Adjustments for the years ended December
31, 2020, 2019 and 2018 decreased net loss by CHF 4.8 million, increased net income by CHF 0.5 million and decreased net loss
by CHF 3.7 million, respectively. The Company recorded share-based compensation expenses of CHF 4.1 million, CHF 2.8 million and
CHF 2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. There were foreign currency re-measurement
losses of CHF 0.7 million, CHF 0.8 million and CHF 1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively,
predominantly related to the cash balance of the Company as a result of fluctuations of the US Dollar against the Swiss Franc.
Related to the Company&rsquo;s convertible note settled with Lilly in 2019, we recorded CHF 1.4 million for amortization of effective
interest for the year ended December 31, 2019 and recognized a CHF 4.5 million gain for the change in fair value of the liability
related to the conversion feature in 2019. There were no comparable expenses or gains in 2020 nor 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company also discloses liquidity, which
is defined as a financial indicator comprised of cash and cash equivalents and short-term financial assets. See &ldquo;Note 3.
Summary of significant accounting policies<B>&rdquo; </B>to our Financial Statements for further definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item06"></A>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item06a"></A>A.</TD><TD>Directors and senior management</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Officers, other key employees and board of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table presents information
about our executive officers, other key employees, and directors and director nominees, including their ages, as of March 1, 2021.
The term of each of our directors is 1 year and, accordingly, will expire at our 2021 annual shareholder meeting to be held in
June 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5pt; width: 28%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Name</B></P>
</TD>
    <TD STYLE="padding-right: 5pt; width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Position</B></P>
</TD>
    <TD STYLE="padding-right: 5pt; width: 6%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Age</B></P>
</TD>
    <TD STYLE="padding-right: 5pt; width: 14%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Initial
        year of appointment</B></P>
</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt"><B>Executive Officers</B></TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Andrea Pfeifer, Ph.D. </TD>
    <TD STYLE="padding-right: 5pt">Chief Executive Officer and Director </TD>
    <TD STYLE="padding-right: 5pt; text-align: center">63</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2003</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Marie Kosco-Vilbois, Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">Chief Scientific Officer</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">63</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2019</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Johannes Rolf Streffer, M.D.</TD>
    <TD STYLE="padding-right: 5pt">Chief Medical Officer </TD>
    <TD STYLE="padding-right: 5pt; text-align: center">52</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2020</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Piergiorgio Donati</TD>
    <TD STYLE="padding-right: 5pt">Chief Technical Operations Officer</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">50</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2019</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Joerg Hornstein</TD>
    <TD STYLE="padding-right: 5pt">Chief Financial Officer</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">43</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Jean-Fabien Monin</TD>
    <TD STYLE="padding-right: 5pt">Chief Administrative Officer</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">50</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2009</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt"><B>Other Key Employees</B></TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Julien Rong&egrave;re, Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">VP Regulatory Affairs and Quality Assurance</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">43</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Alexandre Caratsch</TD>
    <TD STYLE="padding-right: 5pt">General Counsel</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">55</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2018</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Olivier Sol, M.D. </TD>
    <TD STYLE="padding-right: 5pt">AVP Medical Sciences and Clinical Operations </TD>
    <TD STYLE="padding-right: 5pt; text-align: center">54</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2016</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Bojana Portmann, Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">AVP IP and Business Development</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">41</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2011</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Julian Gray, M.D., Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">Clinical Advisor</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">63</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2007</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Mark Danton</TD>
    <TD STYLE="padding-right: 5pt">VP Information Systems, Security and Digital Technologies</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">57</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2019</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt"><B>Non-Executive Directors</B></TD>
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Douglas Williams, Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">Chairman and Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">62</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2018</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Martin Velasco </TD>
    <TD STYLE="padding-right: 5pt">Vice-Chairman and Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">66</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2003</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Peter Bollmann, Ph.D. </TD>
    <TD STYLE="padding-right: 5pt">Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">67</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2015</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Thomas Graney </TD>
    <TD STYLE="padding-right: 5pt">Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">56</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2016</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Werner Lanthaler, Ph.D.</TD>
    <TD STYLE="padding-right: 5pt">Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">52</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2018</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="padding-right: 5pt">Roy Twyman, M.D.</TD>
    <TD STYLE="padding-right: 5pt">Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">64</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2019</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5pt">Carl June, M.D.</TD>
    <TD STYLE="padding-right: 5pt">Director</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">67</TD>
    <TD STYLE="padding-right: 5pt; text-align: center">2020</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The current business addresses for our
executive officers, other key employees, directors and director nominee is AC Immune SA, EPFL Innovation Park, Building B, 1015
Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Andrea Pfeifer, Ph.D., Co-Founder, Chief
Executive Officer and Director:</B> Prof. Andrea Pfeifer co-founded AC Immune SA in 2003, successfully leading it to an IPO in
2016, since when she has served as a Director on the Board. Under her leadership, multiple transformative partnerships have been
established with leading pharmaceutical companies, yielding a potential value of up to CHF 3.3 billion plus additional royalties.
Before founding the Company, she was the Head of Nestl&eacute; Research Centre in Lausanne, Switzerland where she played a major
role in connecting science and business. Whilst at Nestl&eacute; she led the scientific development of a number of highly innovative,
critically acclaimed products from laboratory to market, established the microbiome as a major cross-category product development
platform and co-founded the Life Science focused Nestl&eacute; Venture Capital Fund. Prior to this she was a Visiting Fellow at
the Human Carcinogenesis Branch of The National Institute of Health, Bethesda, USA. She currently serves as the Chair of Investment
Fund BioMedInvest, Basel and AB2 Bio SA, Lausanne, and is a member of the Supervisory Board of Symrise AG, Holzminden, Germany.
She is also a key member of the CEOi initiative on Alzheimer&rsquo;s Disease and the Davos Alzheimer&rsquo;s Collaborative (DAC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prof. Pfeifer holds a Ph.D. in Toxicology
(Cancer Research) from the University of W&uuml;rzburg, Germany and is a registered Toxicologist and Pharmacist. She received her
Habilitation from the University of Lausanne, Switzerland and is an Honorary Professor at the Ecole Polytechnique F&eacute;d&eacute;rale
de Lausanne (EPFL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Marie Kosco-Vilbois, Ph.D., Chief Scientific
Officer</B>: A US citizen, Dr. Kosco-Vilbois has extensive experience in the biopharmaceutical industry and served as Chief Scientific
Officer of Novimmune since 2005. Prior to joining Novimmune in 2002, Dr. Kosco-Vilbois was Head of Immunology and Preclinical Pharmacology
at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of Immunology at the Glaxo Wellcome Research
Institute in Geneva, and a Scientific Member of the Basel Institute for Immunology. During her career, she has taken numerous biologicals
from discovery into preclinical studies and clinical development, most notably filing market applications of a biological for an
orphan indication. Dr. Kosco-Vilbois gained her Bachelor's Degree in Biology from Rutgers University, New Jersey,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">US,
and a PhD in Anatomy and Immunology from the Medical College of Virginia/Virginia Commonwealth University School of Medicine,
US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt; background-color: white"><B>Johannes
Rolf Streffer, M.D., Chief Medical Officer: </B>Prof. Johannes Streffer joined AC Immune SA in January 2021 as Chief Medical
Officer from UCB Biopharma SPRL where he was VP, Head of Translational Medicine Neuroscience. Prior to this he was a member
of the Alzheimer Disease Area Leadership Team at Janssen R&amp;D and the industrial lead for EMIF-AD, where 14 countries are
combined to foster understanding of early biomarkers and change in the predementia AD spectrum. His recognized expertise and
standing in the scientific and medical community provide an invaluable asset as we work to develop innovative treatments for
neurodegenerative diseases based on our proprietary technology platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt; background-color: white">Prof. Streffer
graduated from the University of T&uuml;bingen, Germany with a medical degree. He completed graduate studies on neuro-oncology
and is Board certified in Psychiatry and Neurology. Currently he is a visiting Professor in the Department of Biomedical Sciences,
University of Antwerp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Piergiorgio Donati, Chief Technical
Operations Officer: </B>Mr. Donati joined AC Immune in June 2018 as Director, Global Program Management, having previously worked
for AC Immune from 2011 to 2015 as Head of Manufacturing and Project Management. Between 2015 and 2018, Mr. Donati was Head of
CMC program development at Glenmark Pharmaceuticals and Biotech CMC Lead at Merck KGaA. Prior to 2011, he held R&amp;D positions
at Abiogen, Merck Group and Serono. Mr. Donati holds a degree in Analytical Chemistry from the Technical Institute G.L. Bernini.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Joerg Hornstein, Chief Financial Officer:
</B>Mr. Hornstein has served as our Chief Financial Officer since April 2017. Prior to joining AC Immune, Mr. Hornstein served
as Senior Vice President Group Controlling for Unternehmensgruppe Theo M&uuml;ller based in Luxembourg from January 2014 to March
2017. Between 2002 and 2013 he worked for Merck KGaA, a leading science and technology company in healthcare, life science and
performance materials, where he held various senior finance roles. Among other appointments, he was CFO for Merck&rsquo;s operations
in Indonesia and Merck Serono&rsquo;s operations in China. Furthermore, he served as Vice President Group Controlling for Merck
Group Headquarters in Germany and as Divisional CFO for Merck Millipore in the US. Mr. Hornstein holds an MBA with Distinction
from London Business School, UK, and a Bachelor of Business Administration from Baylor University in the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Jean-Fabien Monin, Chief Administrative
Officer:</B> Mr.&nbsp;Monin was nominated Chief Administrative Officer in July 2015 following his role as our Chief Financial Officer
from March 2009 to July 2015. Prior to AC Immune, he held several positions during his tenure of 14 years at bioM&eacute;rieux,
a leading international <I>in vitro</I> diagnostics group, culminating in his nomination as Chief Financial Officer. His last position
was CFO of bioM&eacute;rieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr.&nbsp;Monin holds a Masters
in Finance and International Business from the University of Paris-Dauphine, France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other key employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Julien Rong&egrave;re, Ph.D., VP Regulatory
Affairs and Quality Assurance</B>: Dr. Rong&egrave;re joined AC Immune in July 2017 as Head of European Regulatory Affairs and
Quality Assurance. Prior to joining AC Immune, Dr. Rong&egrave;re held positions of increasing responsibility at Celgene in Switzerland.
Most recently, he served as Director, Regulatory Affairs, leading the development of regulatory strategies for small molecules
and CAR-T cell therapies and contributed to the development and approval of Revlimid in multiple myeloma and mantle cell lymphoma.
Prior to Celgene, Dr. Rong&egrave;re served as a Regulatory Expert at Apoxis, SA in Switzerland. During his career, Dr. Rong&egrave;re
gained specific expertise in the development of regulatory strategies for taking products from Phase 1 through to commercialization
in the field of hematology/oncology and immunology/inflammation, including fast-to-market approaches, orphan drugs and pediatric
development. Dr. Rong&egrave;re gained his Master&rsquo;s Degree in Medical Genetics from the University of Aberdeen, UK, and holds
a Ph.D. in Molecular Biology from the University of Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Alexandre Caratsch, General Counsel:
</B>Alexandre Caratsch is a Swiss-qualified attorney with 30 years&rsquo; experience in private practice, multinational companies
and in ventures. He initially worked as an in-house lawyer for E&amp;Y and the SGS Group before specializing in healthcare, holding
senior legal positions at Novartis and Medtronic. Before joining AC Immune, he led the Corporate Legal Affairs and Intellectual
Property group for Medtronic&rsquo;s Europe, Middle East and Africa (EMEA) region. Mr. Caratsch has also co-founded two start-up
companies in the field of information technology and medical technology, respectively, and has supported other start-up companies
with strategic, transactional and general counsel. Mr. Caratsch holds a Master&rsquo;s degree in Law from the University of Neuch&acirc;tel,
Switzerland and is admitted to the Bar of Geneva, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Oliver Sol, M.D., AVP Medical Sciences
and Clinical Operations</B>: Prior to joining AC Immune, Dr. Olivier Sol was Clinical Director of Exonhit (Paris) and thereafter
Medical &amp; Regulatory Affairs Director for Diaxonhit, where he was responsible for the development and medical validation of
<I>in vitro</I> diagnostic products in cancer, infectious diseases and Alzheimer's disease. Dr. Sol spent his over 20-year career
as a Medical Expert in several therapeutic areas with a strong focus on central nervous system diseases, within pharmaceutical
companies as Janssen, UCB-Pharma, GlaxoSmithKline and Sanofi. He contributed to the clinical development of currently marketed
drugs in epilepsy (topiramate and levetiracetam) and galantamine in Alzheimer&rsquo;s disease. He has also gained significant experience
in the field of biological biomarkers. Dr. Sol holds an M.D. from the Paris-Sud University (Paris-Saclay) with a specialization
in Medical Biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Bojana Portmann, Ph.D., AVP IP and Business
Development</B>: Dr. Portmann joined AC Immune in 2011 as Intellectual Property Manager and has held multiple roles within the
IP department with increasing responsibility over the past years, during which her work was mainly focused on creating and strengthening
patent portfolios for biologicals, small molecules and liposomal technology. Dr. Portmann holds a Ph.D. degree from the EPFL University
in Switzerland, and a LL.M. degree, Master of Intellectual Property Law and Management (MIPLM), from the CEIPI in France. She also
received a M.Sc. (Dipl. Ing.) degree in Polymer and Chemical Engineering from the University of Belgrade in Serbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Julian Gray, M.D., Ph.D., Clinical Advisor</B>:
Dr. Gray has served as Clinical Advisor to our programs in neurodegenerative diseases since January 2007 and works in this function
exclusively for AC Immune. He has previously held the position of Head of CNS Therapeutics at Eisai Ltd in London leading the global
development of early and late-stage CNS projects in Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and other CNS areas. Prior
to this he served as Head of Alzheimer Clinical Research at Hoffmann-La Roche in Basel where he conducted large-scale clinical
trials in the US and Europe. After his studies he was Medical Expert at Sandoz Pharmaceuticals in Basel undertaking clinical studies
of different compounds in dementia and Parkinson&rsquo;s disease. Dr. Gray holds the title of a Specialist in Pharmaceutical Medicine
(Switzerland). He received his medical degree (MBBS) from the University of London, a B.A. and Ph.D. from the University of Oxford
and an MBA from Oxford Brookes University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Mark Danton, VP Information Systems,
Security and Digital Technologies: </B>Mr. Mark Danton is a globally recognized and experienced executive in Information Systems/Information
Technology (IS/IT) with extensive experience in developing, launching and managing business-relevant IS, cybersecurity and digital
technology solutions and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to joining AC Immune, Mr. Danton
served as IS/IT Global Manager at Nestl&eacute; and held a number of global roles at BT Global Services and in Dimension Data PLC.
Mr. Danton holds an Executive MBA from the Business School Lausanne, graduating&nbsp;cum laude&nbsp;and as the Executive MBA Student
of the Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Executive Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Douglas Williams, Ph.D., Chairman and
Director:</B> Douglas E. Williams, Ph.D., is currently the President, CEO and member of the Board of Directors of Codiak BioSciences.
He was previously Biogen&rsquo;s Executive Vice President, Research and Development, serving in this role from January 2011 to
July 2015. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. ZymoGenetics
was purchased for USD 985 million by Bristol Myers Squibb during Dr. Williams&rsquo; tenure. Previously, he held leadership positions
within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development
at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific
and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a
member of the Board of Directors. During his 30+ year career in the biotechnology industry he has played a role in the development
of several novel drugs including Enbrel, Tecfidera, and Spinraza. He has served on the board of numerous biotechnology companies
and is currently a member of the Board of Directors of Ovid Pharmaceuticals, and Chairman of the Board of AC Immune, and is a Director
for private companies Cygnal Therapeutics, and Xenikos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Martin Velasco, Vice-Chairman and Director:</B>
Mr.&nbsp;Velasco has served on our board of directors since December 2003.&nbsp;Martin Velasco is an entrepreneur and business
angel with extensive experience in the IT, medical and biotech areas.&nbsp;He serves on the board of directors or advisory board
of several other high-tech companies including as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive
technology (ART) company and World Economic Forum Technology Pioneer 2008, as Chairman of the Supervisory Board of Cocomore, a
digital communications agency&nbsp;and information technology services firm, and as a Board Member of Aridhia, a health informatics
company. Martin is also the Founder of Infantia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">Foundation,
a philanthropic organization aiding children in the developing world. He is an Ambassador of BlueOrchard, the leading private
microfinance investment advisory company and a member of the Strategic Advisory Board of the &Eacute;cole Polytechnique F&eacute;d&eacute;rale
de Lausanne (EPFL)..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Peter Bollmann, Ph.D., Director:</B>
Dr. Bollmann has joined our board in December 2015. He has extensive management and finance experience in Switzerland and abroad
as CEO, CFO and Board Member. His broad industry experience embraces biotechnology and medical technology firms, including previous
Board positions with Cytos Biotechnology and Prionics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Thomas Graney, Director: </B>Thomas
Graney is currently the Chief Financial Officer of Oxurion NV. Prior to Oxurion, he was CFO of Generation Bio, Senior Vice President
and Chief Financial Officer at Vertex Pharmaceuticals Inc. and Chief Financial Officer and Senior Vice President of Finance &amp;
Corporate Strategy at Ironwood Pharmaceuticals. Prior to Ironwood Pharmaceuticals, Mr. Graney spent 20 years working with J&amp;J
and its affiliates, serving for 4 years as worldwide Vice President of Finance and Chief Financial Officer of Ethicon. Mr. Graney
has extensive global experience that spans corporate development, commercial strategy, portfolio management and supply chain management,
communication and investor relations. A Chartered Financial Analyst charterholder, Mr. Graney holds a B.S. in accounting from the
University of Delaware and an MBA in Marketing, Finance and International Business from the Leonard N. Stern School of Business
at New York University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Werner Lanthaler, Ph.D., Director: </B>Dr.
Werner Lanthaler is the CEO of Evotec AG, a drug discovery alliance and development partnership company focused on rapidly progressing
innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture
capitalists. Since joining Evotec in 2009, Dr. Lanthaler has focused the company on collaborating with biotech and pharma companies
and academia, supporting biotech innovation. He previously served as Chief Financial Officer at Intercell AG where he played a
key role in many of that company's major milestones. During his tenure, Intercell undertook an IPO and developed from a venture-backed
biotechnology company into a global vaccine player. Dr. Lanthaler has also served as Director of the Federation of Austrian Industry,
and from 1995 to 1998 was a Senior Management Consultant at McKinsey &amp; Company. Dr. Lanthaler is a Non-Executive Member of
the Board of Directors of arGEN-X and is a member of the Supervisory Board of Topas Therapeutics GmbH. He holds a Doctorate in
Economics from Vienna University, a Master's degree in Business Administration from Harvard University, and a degree in Psychology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Roy Twyman, M.D., Director</B>: Dr.
Twyman is a Neurologist and is founder and current CEO of Amron Neuroscience, LLC, a private consulting company focused on neuroscience
drug development. Prior to this, Dr. Twyman spent almost 20 years at Janssen Research &amp; Development, LLC (a Johnson &amp; Johnson
company) and was a member of the Neuroscience Therapeutic Area Leadership team responsible for clinical R&amp;D and strategic planning
of CNS neurology and psychiatry pipeline products. From 2012 to March 2018, Dr. Twyman was a Senior Vice President in the Neuroscience
Therapeutic Area overseeing the Alzheimer&rsquo;s Disease Area. He currently participates as an independent Board Member or as
a Scientific Advisory Board Member for a number of small biotech or pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Carl June, M.D., Director: </B>Prof.
June is Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker
Institute for Cancer Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania. Due to his lifelong work
on lymphocyte activation, Prof. June is considered a world authority on mechanisms related to immune tolerance and adoptive immunotherapy
in the fields of chronic inflammation and cancer. He and his team pioneered the groundbreaking work in immunotherapy in which patients
with refractory and relapsed chronic lymphocytic leukemia are treated with genetically engineered versions of their own T cells.
This CAR-T therapy approach, which trains the immune system to attack and destroy cancer cells, has opened a new era of innovative
treatments and personalized medicine for cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prof. June is a graduate of the Naval
Academy in Annapolis, USA, and Baylor College of Medicine in Houston, USA, where he received his medical degree. Prof. June also
completed graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland,
and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research
Center in Seattle, USA. He has published more than 500 manuscripts and is the recipient of numerous honors and prizes.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item06b"></A>B.</TD><TD>Compensation</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation of directors and executive officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December&nbsp;31, 2020,
the aggregate compensation accrued or paid to the members of our board of directors and our executive officers for services in
all capacities was CHF 6.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December&nbsp;31,
2020, the total fair value of stock options granted to directors and executive officers was CHF 2.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The amount set aside or accrued by us to
provide pension, retirement or similar benefits to members of our board of directors and executive officers amounted to a total
of CHF 0.2 million in the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We incorporate by reference into this Annual
Report the information in &ldquo;Item 1. C&mdash;2020 Board Compensation&rdquo; and &ldquo;Item 2. C&mdash;2020 Executive Compensation&rdquo;
of Exhibit 99.3 to our report on Form 6-K filed with the SEC on March 23, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity incentive plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2016, we ceased issuing new grants under
our prior equity incentive plans, which we refer to as the Prior Plans, and adopted a new omnibus equity incentive plan under which
we have the discretion to grant a broad range of equity-based awards to eligible participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Prior plan: C1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since our inception in 2003, we have had
four separate Prior Plans under which stock options were granted (Prior Plans A, B and C2 have terminated): Options granted under
Plan C1 from 2013 through the adoption of the current 2016 Stock Option and Incentive Plan (SOIP) were taxed upon exercise instead
of at grant due to a change in taxation rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Plan administration</I>. Under Plan
C1, an option, which can only be granted with the approval of our board of directors, is evidenced by an option agreement signed
by the participant to indicate his or her acceptance of the option and is subject to the terms and conditions of the applicable
Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Eligibility</I>. Under Plan C1, options
were granted to our directors, employees, advisors and agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Options exercise price</I>. The exercise
price of all options issued under the Prior Plan is CHF 0.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: 0.15pt"><I>Vesting period</I>. Under
Plan C1, the options vesting period was 4 years with 25% of the options vesting each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: 0.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Expiration period. </I>The expiry dates
for each plan are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plan C1: 10 years</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Amendment</I>. Our board of directors
has the authority to amend each of the Prior Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>2016 SOIP</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the November 15, 2016 AGM of the Company,
our board of directors approved the 2016 SOIP (as amended and restated the &ldquo;2016 SOIP&rdquo;). The maximum number of shares
available for issuance under the 2016 SOIP is 3,523,000 common shares.&nbsp;The shares available for issuance under the 2016 SOIP
were initially registered with the SEC on a Form S-8 on March 8, 2017, and additional shares were registered on a Form S-8 on August
5, 2019. As of December&nbsp;31, 2020, there were a total of 1,099,015 shares underlying options that were exercisable and 2,900,667
shares underlying outstanding options and 19,494 shares underlying outstanding restricted share units issued from both our Prior
Plans and the 2016 SOIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Plan Administration</I>. The 2016 SOIP
is administered by either our board of directors or the compensation committee, or a similar committee performing the functions
of the compensation committee. Approval of the plan administrator is required for all grants of awards under the 2016 SOIP, but
the administrator may delegate to our CEO the authority to grant awards, subject to certain limitations set forth on the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Awards. </I>Awards may be granted in
the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted share units, restricted
share awards, unrestricted share awards, performance share awards and dividend equivalent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Eligibility. </I>Under the 2016 SOIP,
full or part-time officers and other employees, non-employee directors and consultants of the Company and its subsidiaries who
are selected by the administrator are eligible to participate in the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Options exercise price. </I>Under the
2016 SOIP, the option exercise price is determined by the plan administrator at the time of grant, but will not be less than fair
market value (as defined in the 2016 SOIP) on the grant date, and for incentive stock options granted to any employee who is a
10 percent owner in the Company, will not be less than 110 percent of the fair market value on the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Vesting period. </I>Vesting conditions
are determined by the administrator at the time of grant and are specified in the applicable award certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Accelerated vesting. </I>The administrator
may accelerate the exercisability or vesting of all or any portion of any award in circumstances involving the grantee&rsquo;s
death, disability, retirement or termination of employment, or a change in control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Amendment</I>. Our board of directors
has the authority to amend the 2016 SOIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Amendment and restatement to the
2016 SOIP</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June 2019, the Board authorized, and
the shareholders approved, an increase in the maximum number of shares reserved for issuance under the 2016 SOIP. In October 2019,
the Board authorized a second amendment and restatement to the 2016 SOIP. These amendments were made to align certain elements
with Swiss statutory requirements and had no financial impact for the Company in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Equity compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the fiscal year ended December 31,
2020, the Company has granted our directors and executive officers, in the aggregate, options for the right to acquire 689,700
shares at exercise prices ranging from USD 5.04 to USD 6.95 per share, which vest either over a 1 year, 3 year or 4 year period
with vesting to occur quarterly or annually depending on the nature of the award. The Company did not grant restricted share units
to its directors and executive officers in 2020 or 2019. Previous restricted share units granted to directors vested over a 1 year
period. Restricted share units granted to executives have a 4 year vesting life with vesting to occur quarterly. Please see &ldquo;Note
17. Share-based compensation&rdquo; for further detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item06c"></A>C.</TD><TD>Board practices</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Composition of board of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors is composed of eight
directors. Each director is elected for a 1-year term. The current members of our board of directors were appointed at a shareholders&rsquo;
meetings held on June 26, 2020 and November 20, 2020 to serve until the 2021 shareholders&rsquo; meeting to be held in June 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a foreign private issuer. As a result,
in accordance with the Nasdaq stock exchange listing requirements, we rely on home country governance requirements and certain
exemptions thereunder rather than relying on the stock exchange corporate governance requirements. For an overview of our corporate
governance principles, see &ldquo;Item 16G. Corporate governance.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Our Board of Directors met in accordance
with their respective mandate both physically, by video-conference and telephonically throughout 2020. The Board members analyzed
the scientific, business, financial and organizational risks of the Company based on the external factors and internal changes
that could potentially impact the risks for the Company in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a foreign private issuer, under the
listing requirements and rules of Nasdaq, we are not required to have independent directors on our board of directors, except to
the extent that our audit and finance committee is required to comply with independence requirements, subject to certain phase-in
schedules. However, our board of directors has determined that, under current listing requirements and rules of Nasdaq (which we
are not subject to) and considering any applicable committee independence standards, Douglas Williams, Martin Velasco, Peter Bollmann,
Thomas Graney, Werner Lanthaler, Roy Twyman and Carl June are &ldquo;independent directors.&rdquo; In making such determination,
our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances
our board of directors deemed relevant in determining the director&rsquo;s independence, including the number of ordinary shares
beneficially owned by the director and his or her affiliated entities, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Committees of the board of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors established two
separate committees: an audit and finance committee and a compensation, nomination and corporate governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Audit and finance committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The audit and finance committee, which
consists of Peter Bollmann (Chair), Thomas Graney, Werner Lanthaler and Martin Velasco, assists our board of directors in overseeing
our accounting and financial reporting processes and the audits of our financial statements. In addition, the audit and finance
committee is directly responsible for the appointment, compensation, retention and oversight of the work of our independent registered
public accounting firm. The audit and finance committee consists exclusively of members of our board who are financially literate,
and Peter Bollmann, Thomas Graney, Werner Lanthaler and Martin Velasco are considered to be &ldquo;audit committee financial experts&rdquo;
as defined by the SEC. Our board of directors has determined that Peter Bollmann, Thomas Graney, Werner Lanthaler and Martin Velasco
satisfy the &ldquo;independence&rdquo; requirements set forth in Rule 10A-3 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The audit and finance committee is governed
by a charter that complies with Nasdaq rules. The audit and finance committee has the responsibility to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review and assess the qualifications, independence, performance and effectiveness of the independent auditor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review the scope of the prospective audit by the independent auditor, the estimated fees, and any other matters pertaining
to the audit;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approve any audit and non-audit services proposed to be provided by the independent auditor to ensure independent auditor independence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review and assess the independent auditor&rsquo;s report and management letters and take notice of all comments of the independent
auditor on accounting procedures and systems of control, and review the independent auditor&rsquo;s reports with management;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>be responsible for the resolution of disagreements between the management and the independent auditor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review and evaluate the lead audit partner of the independent audit team and confirm and evaluate their rotation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review and discuss all (i) financial statements, (ii)&nbsp;reports intended for publication and (iii)&nbsp;any other financial
statements intended for publication to consider significant financial reporting issues and judgments made in connection with the
preparation of our financial statements, including any significant changes in our selection or application of accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approve the quarterly financial statements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review with the management, personnel responsible for the design and implementation of the internal audit function, and the
independent auditor in separate meetings any analysis or other written communication prepared by the management and/or the independent
auditor setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">statements, including critical
accounting policies, the effect of regulatory and accounting initiatives, and off-balance sheet transactions and structures on
our financial statements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review in cooperation with the independent auditor and the management whether the accounting principles applied are appropriate
in view of our size and complexity;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>periodically review our policies and procedures for risk management and assess the effectiveness thereof, including discussing
with management our major financial risk exposures and the steps that have been taken to monitor and control such exposure;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>discuss with management and external advisors any legal matters that may have a material impact on our financial statements
and any material reports or inquiries from regulatory or governmental agencies that could materially impact our contingent liabilities
and risks;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review our disclosure controls and procedures and internal control over financial reporting, including significant deficiencies
and material weaknesses in the design or operation of internal controls over financial reporting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting
controls or auditing matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting
or auditing matters; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review and approve or ratify any related-person transaction in accordance with our related-person transaction policy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The audit and finance committee will meet
as often as it determines is appropriate to carry out its responsibilities, but in any event will meet at least four times per
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Compensation, nomination and corporate governance
committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The compensation, nomination and corporate
governance committee, consists of Douglas Williams (Chair), Martin Velasco and Thomas Graney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The compensation, nomination and corporate
governance committee is governed by a charter that complies with Nasdaq rules. The compensation, nomination and corporate governance
committee has the responsibility to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recommend to the board the guidelines for the overall compensation and equity awards for the board of directors and executive
officers along with the rationale for such recommendations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recommend to the board the compensation of executive officers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 0.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>propose the maximum total compensation of the board of directors and executive officers for approval at the Annual General
Meeting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 0.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>periodically review policies and principles for the Company&rsquo;s corporate governance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish the process for assessment of the performance of members of the board, its committees and individual members;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prepare and reviews the Company&rsquo;s succession plan for members of the board and the executive committee;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>periodically review the Company&rsquo;s code of conduct and recommends changes as needed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recommend for presentation to our shareholders the compensation report for shareholder vote; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>define guidelines for the selection of candidates for election or re-election as members of the board and our executive officers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law requires that we adopt a compensation
committee, so in accordance with Nasdaq Listing Rule 5615(a)(3), we will follow home country requirements with respect to the compensation,
nomination and corporate governance committee. As a result, our practice will vary from the requirements of Nasdaq Listing Rule
5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees,
and from the independent director oversight of director nomination requirements of Nasdaq Listing Rule 5605(e). We will be subject
to the Swiss Ordinance Against Executive Compensation (Say on Pay) Rule. In addition, this committee will also be responsible for
director and board committee nominations as well as reviewing and amending, if required, our corporate governance framework and
guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item06d"></A>D.</TD><TD>Employees</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, we employed 149
employees, 24 of whom were part-time employees. 69 of our employees hold Ph.D. degrees and 50 hold M.Sc. degrees. Our 149 employees
are from more than 25 countries. The average number of employees (calculated on full-time equivalents) in 2020 was 134.4. As of
December 31, 2019 and 2018 we had 132 and 104 employees, respectively. We have never had a work stoppage, and none of our employees
is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be
good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item06e"></A>E.</TD><TD>Share ownership</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 7. Major shareholders and
related-party transactions-A. Major shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item07"></A>ITEM 7. MAJOR SHAREHOLDERS AND RELATED-PARTY TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item07a"></A>A.</TD><TD>Major shareholders</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents information relating to the beneficial
ownership of our common shares as of the date of this Annual Report by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our executive officers and directors; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all executive officers and directors as a group.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The number of common shares beneficially
owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC, and the information
is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any
common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the
individual has the right to acquire within 60 days of March 1, 2021 through the exercise of any option, warrant or other right.
Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting
and investment power with respect to all common shares held by that person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The percentage of outstanding common shares
is computed on the basis of 72,701,715 common shares outstanding as of March 1, 2021. Common shares that a person has the right
to acquire within 60&nbsp;days of March 1, 2021 are deemed outstanding for purposes of computing the percentage ownership of the
person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person,
except with respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated
below, the address for each beneficial owner is AC Immune, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shareholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares beneficially owned (%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>5% Shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">dievini Hopp BioTech holding GmbH &amp; Co KG<SUP>1</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,041,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">24.8</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Varuma AG<SUP>2</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,999,999</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.5</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Biotechnology Value Fund (BVF) Inc.<SUP>3</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,916,658</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.9</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>EcoR1 Capital, LLC<SUP>4</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,702,160</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Eli Lilly and Company<SUP>5 </SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,615,328</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Executive Officers and Directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-indent: -9.35pt; padding-left: 18.15pt">Andrea Pfeifer<SUP>6</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,675,887</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.7</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Marie Kosco-Vilbois<SUP>7</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.15pt">Johannes Rolf Streffer<SUP>8</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Piergiorgio Donati<SUP>9</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Joerg Hornstein<SUP>10</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Jean-Fabien Monin<SUP>11</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Douglas Williams<SUP>12</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Martin Velasco<SUP>13</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Peter Bollmann<SUP>14</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Thomas Graney<SUP>15</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Werner Lanthaler<SUP>16</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Roy Twyman<SUP>17</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Carl June<SUP>18</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">All executive officers and directors as a group (13 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,048,942</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.6</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">_______________</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">* Indicates beneficial ownership of less than 1% of the total
issued and outstanding common shares.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>Represents 18,041,000 shares held by dievini Hopp
BioTech holding GmbH &amp; Co KG. Dietmar Hopp controls the voting and investment decisions of the ultimate parent company of dievini
Hopp BioTech holding GmbH &amp; Co KG. The address for dievini Hopp BioTech holding GmbH &amp; Co KG is Johann-Jakob-Astor Str.
57, 69190 Walldorf, Germany.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP>Represents 11,999,999 shares held by Varuma AG set
forth in a Schedule 13G/A filed with the SEC on February 12, 2019. The address for Varuma AG is Aeschenvorstadt 55, CH-4051 Basel,
Switzerland. Rudolf Maag controls the voting and investment decisions of Varuma AG.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP><FONT STYLE="background-color: white">Based on information
set forth in a Schedule 13G filed with the SEC by BVF on January 14, 2021, these shares consist of 7,916,658 shares held of record
by BVF Inc. The address of BVF Inc. is 44 Montgomery St., 40<SUP>th</SUP> Floor, San Francisco, California 94104.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP><FONT STYLE="background-color: white">Based on information
set forth in a Schedule 13G filed with the SEC by EcoR1 Capital on January 22, 2021, these shares consist of 4,702,160 shares held
of record by EcoR1 Capital, LLC. The address of EcoR1 Capital, LLC is 357 Tehama Street #3, San Francisco, California 94103.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP>Represents 3,615,328 shares that Lilly obtained as
part of its conversion in April 2019 of the Convertible Note Agreement, which was deemed effective in January 2019. See &ldquo;Note
9. Share Capital&rdquo; in our financial statements.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP>Consists of 2,365,066 of our common shares and options
to purchase 310,821 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP>Consists of 20,661 of our common shares and options
to purchase 32,777 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>8</SUP>Dr. Streffer holds neither common shares nor non-vested
equity instruments exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>9</SUP>Consists of 4,500 of our common shares and options
to purchase 28,158 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>10</SUP>Consists of 0 of our common shares and options to
purchase 303,950 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>11</SUP>Consists of 291,593 of our common shares and options
to purchase 24,759 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>12</SUP>Consists of 12,818 of our common shares and options
to purchase 23,295 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>13</SUP>Consists of 456,078 of our common shares and options
to purchase 21,023 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>14</SUP>Consists of 46,609 of our common shares and options
to purchase 18,750 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>15</SUP>Consists of 15,851 of our common shares and options
to purchase 18,750 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>16</SUP>Consists of 9,922 of our common shares and options
to purchase 18,750 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>17</SUP>Consists of 0 of our common shares and options to
purchase 24,811 of our common shares exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>18</SUP>Dr. June holds neither common shares nor non-vested
equity instruments exercisable within 60 days of March 1, 2021.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 1, 2021, we had approximately
229 shareholders of record of our common stock. The actual number of stockholders is greater than this number of record holders
and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This
number of holders of record also does not include stockholders whose shares may be held in trust or by other entities.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Significant changes in ownership by major shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have experienced significant changes
in the percentage ownership held by major shareholders as a result of our IPO. Prior to our IPO in September 2016, our principal
shareholders were dievini Hopp BioTech holding GmbH &amp; Co KG and Varuma AG, which held shares representing 36.5% and 23.1% prior
to our IPO, respectively. As of March 1, 2021, dievini Hopp BioTech holding GmbH &amp; Co KG and Varuma AG held 24.8% and 16.5%
of our common shares, respectively. BVF Inc. decreased its holdings from 15.8% to 10.9% of our outstanding common shares and EcoR1
Capital, LLC held 6.5% of our outstanding common shares in 2020. Finally, Lilly continued to hold shares representing 5% beneficial
ownership as of March 1, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July 2018, we completed three offerings
of our common shares. In these offerings, we issued and sold 10,000,000 common shares, including 1,108,695 sold to the underwriters
pursuant to the underwriters&rsquo; over-allotment option. The percentage ownership held by certain shareholders decreased as a
result of the issuance of the common shares sold by us in these offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2016, we completed our IPO
and listed our common shares on the Nasdaq Global Market. In the IPO, we issued and sold 6,900,000 common shares, including 900,000
common shares sold to the underwriters pursuant to the underwriters&rsquo; over-allotment option. While none of our existing shareholders
sold common shares in the IPO, the percentage ownership held by certain shareholders decreased as a result of the issuance of the
common shares sold by us in the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item07b"></A>B.</TD><TD>Related-party transactions</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July 2018, as part of the Company&rsquo;s
previously announced second subscription rights offering, a major shareholder and members of the board and executive management
purchased an aggregate of 614,147 of the Company&rsquo;s common shares on the same basis and otherwise on the same terms as the
other participants in such rights offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The above transaction represents the only
related-party transactions we have entered into since January&nbsp;1, 2018 with any of our executive officers, directors and holders
of more than 10% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons,
other than the compensation arrangements we describe under &ldquo;Item 6. Directors, senior management and employees&ndash;B. Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration rights agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We entered into a registration rights agreement
in connection with the Series E Private Placement with certain investors in the Series E Private Placement pursuant to which we
granted them certain demand and piggyback registration rights for the resale of the common shares held by them, as described below.
The registration rights described below will expire on the earlier to occur of (i)&nbsp;the fifth anniversary of the completion
of our IPO and (ii)&nbsp;the date on which there are no remaining registrable securities held by the parties to the registration
rights agreement. The registration rights agreement provides that we must pay certain registration expenses in connection with
any demand, piggyback or shelf registration. The registration rights agreement contains customary indemnification and contribution
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Demand registration rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the registration
rights agreement, a shareholder or group of shareholders holding at least 10% of our outstanding common shares may request that
we effect a registration under the Securities Act of all or any portion of such requesting shareholders&rsquo; registrable securities.
As of March 1, 2021 dievini Hopp BioTech holding GmbH &amp; Co KG and Varuma AG were our only shareholders party to the registration
rights agreement who held at least 10% of our outstanding commons shares, and together they beneficially held 30,040,999 of our
common shares, representing approximately 41.3% of the voting power of our common shares outstanding as of March 1, 2021. At least
10 business days prior to the anticipated filing date of the registration statement relating to such demand registration, we must
give all other shareholders party to the registration rights agreement notice of such requested registration. Within 5 business
days of such notice, any of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">the
other shareholders party to the registration rights agreement may request that we also effect the registration of the registrable
securities held by them. We will not be required to effect a registration of all such registrable securities unless the aggregate
proceeds expected to be received from the sale of such registrable securities equals or exceeds USD 10&nbsp;million or such lesser
amount that constitutes all of the requesting shareholders&rsquo; registrable securities (<I>provided</I> that such lesser amount
is at least USD 5&nbsp;million). In no event will we be required to effect more than two demand registrations or underwritten
take downs referred to under &ldquo;Shelf registration rights&rdquo; below. Depending on certain conditions, we may postpone a
demand registration on two occasions during any period of 12 consecutive months for up to 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>&ldquo;Piggyback&rdquo; registration rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the registration
rights agreement, at any time after the trigger date, if we propose to register any of our securities, whether or not for sale
for our own account, we must give notice to the shareholders party to the registration rights agreement, and they will be entitled
to certain piggyback registration rights allowing them to add any of their remaining registrable securities in the registration,
subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the
Securities Act, the holders of these shares are entitled to notice of the registration and to request that we include their shares
in the registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Shelf registration rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the registration
rights agreement, if we are eligible to use a shelf registration statement, then a shareholder or group of shareholders holding
at least 10% of our outstanding common shares may request that we effect a shelf registration on similar terms as the demand registrations
described above, except that offerings will be conducted as underwritten takedowns. As of March 1, 2021 dievini Hopp BioTech holding
GmbH &amp; Co KG and Varuma AG were our only shareholders party to the registration rights agreement who held at least 10% of our
outstanding commons shares, representing approximately 41.3% of the voting power of our common shares outstanding. We will only
be required to effect one public offering from such shelf registration statement within any six-month period, each of which shall
be deemed to constitute a demand registration for purposes of the number of demand registrations we are required to effect as described
under &ldquo;Demand registration rights&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2020 and August 2018, respectively,
we filed registration statements on Form F-3 to register the resale of two of our shareholder&rsquo;s common shares pursuant to
the requirements of the registration rights agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related-person transaction policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to our IPO, we entered into a new
related-person transaction policy under which any such transaction must be approved or ratified by the audit and finance committee.
The board of directors reviews the policy on a yearly basis and has, lastly, determined that it adequately covers the requirements
of Sarbanes-Oxley control mechanisms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification of directors and executive management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with our IPO, our articles
of association require us to indemnify our directors and executive management to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item07c"></A>C.</TD><TD>Interests of experts and counsel</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item08"></A>ITEM 8. FINANCIAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item08a"></A>A.</TD><TD>Consolidated statements and other financial information</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 18. Financial statements,&rdquo;
which contains our financial statements prepared in accordance with IFRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time we may become involved
in legal proceedings that arise in the ordinary course of business. During the period covered by the financial statements contained
herein, we have not been a party to or paid any damages in connection with litigation that has had a material adverse effect on
our financial position. No assurance can be given that future litigation will not have a material adverse effect on our financial
position. When appropriate in the management&rsquo;s estimation, we may record reserves in our financial statements for pending
litigation and other claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends and dividend policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">We have never declared or paid cash dividends
on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion
of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related
to dividend policy will be made at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Under Swiss law, any dividend must be approved
by our shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss
statutory law and our articles of incorporation. A Swiss corporation may pay dividends only if it has sufficient distributable
profits brought forward from the previous business years (<I>report des b&eacute;n&eacute;fices</I>) or if it has distributable
reserves (<I>r&eacute;serves &agrave; libre disposition</I>), each as evidenced by its audited standalone statutory balance sheet
prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association have been
deducted. Distributable reserves are generally booked either as &ldquo;free reserves&rdquo; (<I>r&eacute;serves libres</I>) or
as &ldquo;reserve from capital contributions&rdquo; (<I>apports de capita</I>&rdquo;). Distributions out of nominal share capital,
which is the aggregate nominal value of a corporation&rsquo;s issued shares, may be made only by way of a share capital reduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item08b"></A>B.</TD><TD>Significant changes</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A discussion of the significant changes
in our business can be found under &ldquo;Item&nbsp;4. Information on the Company&ndash;A. History and development of the Company&rdquo;
and &ldquo;Item 4. Information on the Company&ndash;B. Business overview.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item09"></A>ITEM 9. THE OFFER AND LISTING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09a"></A>A.</TD><TD>Offering and listing details</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;Item 9&ndash;C. Markets&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09b"></A>B.</TD><TD>Plan of distribution</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09c"></A>C.</TD><TD>Markets</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common shares trade on the Nasdaq Global
Market under the symbol &ldquo;ACIU.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09d"></A>D.</TD><TD>Selling shareholders</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09e"></A>E.</TD><TD>Dilution</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item09f"></A>F.</TD><TD>Expenses of the issue</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item10"></A>ITEM 10. ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10a"></A>A.</TD><TD>Share capital</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10b"></A>B.</TD><TD>Memorandum and articles of association</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Please see the Articles of Association of AC Immune SA (Exhibit 3.1 to this Form 20-F).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10c"></A>C.</TD><TD>Material contracts</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise disclosed in this Annual
Report on Form 20-F (including the Exhibits), we are not currently, and have not been in the past 2 years, party to any material
contract, other than contracts entered into in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10d"></A>D.</TD><TD>Exchange controls</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are no Swiss governmental laws, decrees
or regulations that restrict, in a manner material to us, the export or import of capital, including any foreign exchange controls,
or that generally affect the remittance of dividends or other payments to non-residents or non-citizens of Switzerland who hold
our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10e"></A>E.</TD><TD>Taxation</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following summary contains a description
of the material Swiss and US federal income tax consequences of the acquisition, ownership and disposition of common shares, but
it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to purchase
common shares. The summary is based upon the tax laws of Switzerland and regulations thereunder and on the tax laws of the US and
regulations thereunder as of the date hereof, which are subject to change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Swiss tax considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This summary of material Swiss tax consequences
is based on Swiss law and regulations and the practice of the Swiss tax administration as in effect on the date hereof, all of
which are subject to change (or subject to changes in interpretation), possibly with retroactive effect. The summary does not purport
to consider the specific circumstances of any particular shareholder or potential investor and does not relate to persons in the
business of buying and selling common shares or other securities. The summary is not intended to be, and should not be interpreted
as, legal or tax advice to any particular potential shareholder, and no representation with respect to the tax consequences to
any particular shareholder is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Current and prospective shareholders are
advised to consult their own tax advisors in light of their particular circumstances as to the Swiss tax laws, regulations and
regulatory practices that could be relevant to them in connection with the acquiring, owning and selling or otherwise disposing
of common shares and receiving dividends and similar cash or in-kind distributions on common shares (including dividends on liquidation
proceeds and stock dividends) or distributions on common shares based upon a capital reduction (<I>remboursements de la valeur
nominale</I>) or reserves paid out of capital contributions (<I>r&eacute;serves sur les apports en capital</I>) and the consequences
thereof under the tax laws, regulations and regulatory practices of Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation of AC Immune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune is subject to corporate Swiss
federal, cantonal and communal taxation in Switzerland, Canton of Vaud, Commune of Ecublens, near Lausanne, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are entitled under Swiss laws to carry
forward any losses incurred for a period of 7 years and can offset our losses carried forward against future taxes. As of December
31, 2020, we had tax loss carry-forwards totaling CHF 121.9 million. There is no certainty that we will make sufficient profits
to be able to utilize these tax loss carry-forwards in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The effective corporate income tax rate
(federal, cantonal and communal) where we are domiciled is currently 13.63%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of January 1, 2020, the Company may
request a tax relief of 60%, which would be applied to income from patents and similar rights at communal and cantonal levels.
Additionally, a so-called &ldquo;super-deduction&rdquo; may be granted for payroll and other expenses of research and development
of Swiss origins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">However, the aforementioned tax relief
based on the patent box and deductions for research and development may not exceed 50% of the overall taxable profit before these
tax relief and deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Notwithstanding the corporate income tax,
the corporate capital is taxed at a rate of 0.13% (cantonal and communal tax only, as there is no federal tax on capital). As of
January 1, 2020 the capital attributable to patents and similar rights is considered with 50% relief in the capital tax calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Federal, cantonal and communal individual income
tax and corporate income tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Non-resident shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shareholders who are not resident in Switzerland
for tax purposes, and who, during the relevant taxation year, have not engaged in a trade or business carried on through a permanent
establishment or fixed place of business situated in Switzerland for tax purposes (all such shareholders for purposes of this section
termed, &ldquo;Non-resident shareholders&rdquo;), will not be subject to any Swiss federal, cantonal and communal income tax on
dividends and similar cash or in-kind distributions on Shares (including liquidation proceeds and stock dividends) (for the purposes
of this section, &ldquo;dividends&rdquo;), distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave;
la r&eacute;duction de la valeur nominale des actions</I>) and distributions paid out of reserves from capital contributions (<I>apports
de capital</I>) on shares, or capital gains realized on the sale or other disposition of shares (see, however, &ldquo;&mdash;<I>Swiss
federal withholding tax&rdquo;</I> below for a summary of Swiss federal withholding tax on dividends.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Resident private shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss-resident individuals who hold their
shares as private assets are required to include dividends, but not distributions based upon a capital reduction (<I>remboursements
li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and distributions paid out of reserves from capital
contributions (<I>apports de capital</I>), in their personal income tax return and are subject to Swiss federal, cantonal and communal
income tax on any net taxable income for the relevant taxation period, including the dividends, but not the distributions based
upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and
distributions paid out of reserves from capital contributions (<I>apports de capital)</I>. Shareholders holding at least 10% of
the share capital of the Company may be able to deduct their taxable dividends at 30% at the federal level and up to 50% at the
cantonal level, depending on their respective cantonal rates, as partial relief from economic double taxation. Capital gains resulting
from the sale or other disposition of shares are, subject to a few exceptions, not subject to Swiss federal, cantonal and communal
income tax, and conversely, capital losses are not tax-deductible for resident private shareholders (the shareholders referred
to in this paragraph for the purposes of this section, &ldquo;Resident private shareholders&rdquo;). See &ldquo;<I>Domestic commercial
shareholders</I>&rdquo; below for a summary of the taxation treatment applicable to Swiss-resident individuals, who, for income
tax purposes, are classified as &ldquo;professional securities dealers&rdquo; or are otherwise deemed to hold Company shares in
their commercial wealth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Domestic commercial shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Corporate and individual shareholders who
are resident in Switzerland for tax purposes, and corporate and individual shareholders who are not resident in Switzerland, and
who, in each case, hold their shares as part of a trade or business carried on in Switzerland, in the case of corporate and individual
shareholders not resident in Switzerland, through a permanent establishment or fixed place of business situated, for tax purposes,
in Switzerland, are required to recognize dividends, distributions based upon a capital reduction (<I>remboursements li&eacute;s
&agrave; la r&eacute;duction de la valeur nominale des actions</I>) and distributions paid out of reserves from capital contributions
(<I>apports de capital</I>) received on shares and capital gains or losses realized on the sale or other disposition of shares
in their income statement for the relevant taxation period and are subject to Swiss federal, cantonal and communal individual or
corporate income tax, as the case may be, on any net taxable earnings for such taxation period. The same taxation treatment also
applies to Swiss-resident private individuals who, for income tax purposes, are classified as &ldquo;professional securities dealers&rdquo;
for reasons of, <I>inter alia</I>, frequent dealing, or leveraged investments, in shares and other securities (the shareholders
referred to in this paragraph for purposes of this section, &ldquo;Domestic commercial shareholders&rdquo;). Domestic commercial
shareholders who are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">corporate taxpayers may be eligible for
tax relief (<I>r&eacute;duction pour participations</I>) in respect of dividends and distributions based upon a capital reduction
(<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and distributions paid out of
reserves from capital contributions (<I>apports de capital</I>), as well as capital gains on sales of shares, if the Shares held
by them as part of a Swiss business have an aggregate market value of at least CHF&nbsp;1 million or represent 10% or more of the
outstanding share capital of the Company (in the case of capital gains, if the shares have been held for at least one year).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Swiss cantonal and communal private wealth
tax and capital tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Non-resident shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Non-resident shareholders are not subject
to Swiss cantonal and communal private wealth tax or capital tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Resident private shareholders and domestic commercial
shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Resident private shareholders and domestic
commercial shareholders who are individuals are required to report their shares as part of their private wealth or their Swiss
business assets, as the case may be, and will be subject to Swiss cantonal and communal private wealth tax on any net taxable wealth
(including shares), in the case of domestic commercial shareholders to the extent the aggregate taxable wealth is allocable to
Switzerland. Domestic commercial shareholders who are corporate taxpayers are subject to Swiss cantonal and communal capital tax
on taxable capital to the extent the aggregate taxable capital is allocable to Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Swiss federal withholding tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dividends that the Company pays on the
shares are subject to Swiss Federal withholding tax <I>(imp&ocirc;t anticip&eacute;)</I> at a rate of 35% on the gross amount of
the dividend. The Company is required to withhold the Swiss federal withholding tax from the dividend and remit it to the Swiss
Federal Tax Administration. Distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction
de la valeur nominale des actions</I>) and distributions paid out of reserves from contributions (<I>apports de capital</I>) are
not subject to Swiss federal withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Swiss federal withholding tax on a
dividend will be refundable in full to a resident private shareholder and to a domestic commercial shareholder, who, in each case,
<I>inter alia,</I> as a condition to a refund, duly reports the dividend in his individual income tax return as income or recognizes
the dividend in his income statement as earnings, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A Non-resident shareholder may be entitled
to a partial or full refund, as the case may be, of the Swiss federal withholding tax on a dividend if the country of his or her
residence for tax purposes has entered into a bilateral treaty for the avoidance of double taxation with Switzerland and the conditions
of such treaty are met. Such shareholders should be aware that the procedures for claiming treaty benefits (and the time required
for obtaining a refund) might differ from country to country. For example, a shareholder who is a resident of the US for the purposes
of the bilateral tax treaty between the US and Switzerland is eligible for a partial refund of the amount of the withholding tax
in excess of the 15% treaty rate, provided such shareholder: (i)&nbsp;qualifies for benefits under this treaty and qualifies as
beneficial owner of the dividends; (ii)&nbsp;holds, directly or indirectly, less than 10% of the voting stock of the Company; (iii)&nbsp;does
not qualify as a pension scheme or retirement arrangement for the purpose of the bilateral treaty; and (iv)&nbsp;does not conduct
business through a permanent establishment or fixed base in Switzerland to which the shares are attributable. Such an eligible
US shareholder may apply for a refund of the amount of the withholding tax in excess of the 15% treaty rate. The applicable refund
request form may be filed with the Swiss Federal Tax Administration following receipt of the dividend and the relevant deduction
certificate, however no later than 31&nbsp;December of the third year following the calendar year in which the dividend was payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Swiss federal stamp taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company will be subject to and pay
to the Swiss Federal Tax Administration a 1% Swiss federal issuance stamp duty (droit de timbre <I>d&rsquo;&eacute;missions</I>)
on the consideration received for the issuance of the shares less certain costs incurred in connection with the issuance. The issuance
and delivery of the shares to the initial shareholders at the offering price is not subject to Swiss federal securities transfer
stamp duty (<I>droit de timbre de n&eacute;gociation</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any subsequent dealings in the shares,
for which a bank or another securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act, acts as an intermediary,
or is a party, to the transaction, are, subject</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">to
certain exemptions provided for in the Swiss Federal Stamp Tax Act, subject to Swiss securities transfer stamp duty tax at an
aggregate tax rate of up to 0.15% of the consideration paid for such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material US federal income tax considerations for US Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a description of the material
US federal income tax consequences to US Holders, as defined below, of owning and disposing of our common shares. It does not describe
all tax considerations that may be relevant to a particular person&rsquo;s decision to acquire common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion applies only to a US Holder
that holds common shares as capital assets for US federal income tax purposes. In addition, it does not describe all of the US
federal income tax consequences that may be relevant in light of a US Holder&rsquo;s particular circumstances, including alternative
minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution tax and tax
consequences applicable to US Holders subject to special rules, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>certain financial institutions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>dealers or traders in securities who use a mark-to-market method of tax accounting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated
transaction or persons entering into a constructive sale with respect to the common shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>US Holders whose functional currency for US federal income tax purposes is not the US dollar;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>entities classified as partnerships for US federal income tax purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>tax-exempt entities, including an &ldquo;individual retirement account&rdquo; or &ldquo;Roth IRA;&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons that own or are deemed to own 10% or more of our shares, by vote or value; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons holding common shares in connection with a trade or business conducted outside of the US.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If an entity that is classified as a partnership
for US federal income tax purposes holds common shares, the US federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships
should consult their tax advisors as to the particular US federal income tax consequences of owning and disposing of the common
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;This discussion is based on the Code,
administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty
between Switzerland and the US (the &ldquo;Treaty&rdquo;) all as of the date hereof, any of which is subject to change or differing
interpretations, possibly with retroactive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A &ldquo;US Holder&rdquo; is a holder who,
for US federal income tax purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty and
who is any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a citizen or individual resident of the US;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the US, any state therein
or the District of Columbia; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an estate or trust the income of which is subject to US federal income taxation regardless of its source.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">US
Holders should be aware that the Company has determined that it was likely a PFIC for 2019, and may be a PFIC in 2020 or one or
more future years, which could result in adverse US federal income tax consequences for US Holders. See &ldquo;&mdash;PFIC rules&rdquo;
below. US Holders should consult their tax advisors concerning the US federal, state, local and non-US tax consequences of owning
and disposing of common shares in their particular circumstances, including the consequences to them under the PFIC rules discussed
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><FONT STYLE="background-color: white"><B><I>Taxation
of distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As discussed above under &ldquo;Dividends
and dividend policy,&rdquo; we do not currently expect to make distributions on our common shares. In the event that we do make
distributions of cash or other property, subject to the PFIC rules described below, distributions paid on common shares, other
than certain pro rata distributions of common shares, will generally be treated as dividends to the extent paid out of our current
or accumulated earnings and profits (as determined under US federal income tax principles). Because we do not maintain calculations
of our earnings and profits under US federal income tax principles, we expect that distributions generally will be reported to
US Holders as dividends. For so long as our common shares are listed on Nasdaq or we are eligible for benefits under the Treaty,
dividends paid to certain non-corporate US Holders will be eligible for taxation as &ldquo;qualified dividend income&rdquo; and
therefore, subject to applicable limitations, will be taxable at rates not in excess of the long-term capital gain rate applicable
to such US Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">US Holders should consult their tax advisors
regarding the availability of the reduced tax rate on dividends in their particular circumstances. The amount of a dividend will
include any amounts withheld by us in respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source
dividend income to US Holders and will not be eligible for the dividends-received deduction generally available to US corporations
under the Code. Dividends will be included in a US Holder&rsquo;s income on the date of the US Holder&rsquo;s receipt of the dividend.
The amount of any dividend income paid in Swiss Francs will be the US dollar amount calculated by reference to the exchange rate
in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into US dollars
at that time. If the dividend is converted into US dollars on the date of receipt, a US Holder should not be required to recognize
foreign currency gain or loss in respect of the dividend income. A US Holder may have foreign currency gain or loss if the dividend
is converted into US dollars after the date of receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to applicable limitations, some
of which vary depending upon the US Holder&rsquo;s particular circumstances, Swiss income taxes withheld from dividends on common
shares at a rate not exceeding the rate provided by the Treaty will be creditable against the US Holder&rsquo;s US federal income
tax liability. The rules governing foreign tax credits are complex and US Holders should consult their tax advisors regarding the
creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, US Holders may, at
their election, deduct foreign taxes, including any Swiss income tax, in computing their taxable income, subject to generally applicable
limitations under US law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes
paid or accrued in the taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Sale or other disposition of common shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the PFIC rules described below,
gain or loss realized on the sale or other disposition of common shares will be capital gain or loss, and will be long-term capital
gain or loss if the US Holder held the common shares for more than 1 year. The amount of the gain or loss will equal the difference
between the US Holder&rsquo;s tax basis in the common shares disposed of and the amount realized on the disposition, in each case
as determined in US dollars. This gain or loss will generally be US-source gain or loss for foreign tax credit purposes. The deductibility
of capital losses is subject to various limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white"><B><I>Passive
foreign investment company (PFIC) rules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">Under
the Code, we will be a PFIC for any taxable year in which, after the application of certain &ldquo;look-through&rdquo; rules with
respect to subsidiaries, either (i) 75% or more of our gross income consists of &ldquo;passive income,&rdquo; or (ii) 50% or more
of the average quarterly value of our assets consists of assets that produce, or are held for the production of, &ldquo;passive
income.&rdquo; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of,
and directly receive our proportionate share of the income of, any other corporation in which we directly or indirectly own at
least 25%, by value, of the shares of such corporation. Passive income generally includes interest, dividends, rents, certain non-active
royalties and capital gains. Although we have not obtained independent valuations of our assets during 2020 and thus are not in
a position to make a definitive determination as to whether we were a PFIC in 2020, based on our income and assets during 2020
and certain estimates and assumptions, including as to both the total value and the relative value of our assets as implied by
our market capitalization during 2019, we believe that it is likely that we were a PFIC in 2020. In addition, it is possible that
we may also be a PFIC in 2021 or one or more future years because, among other things, (i) we may not generate a substantial amount
of non-passive gross income, for US federal income tax purposes, in any year, (ii) we currently own, and expect to continue to
own, a substantial amount of passive assets, including cash, and (iii) the estimated valuation, for PFIC purposes, of our assets
that generate non-passive income for PFIC purposes, including our intangible assets, is likely to be dependent in </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><FONT STYLE="background-color: white">large
part on our market capitalization and is therefore uncertain and may vary substantially over time. Accordingly, there can be no
assurance that we will not be a PFIC in 2021 or any future taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">If
we were a PFIC in 2020 or in any future year during which a US investor held or holds common shares, we generally would continue
to be treated as a PFIC with respect to that US Holder for all succeeding years during which the US Holder holds common shares,
even if we ceased to meet the threshold requirements for PFIC status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">If
we were a PFIC in 2020 or in any future year during which a US investor held or holds common shares (assuming such US Holder has
not made a timely mark-to-market election, as further described below), any gain recognized by a US Holder on a sale or other disposition
(including certain pledges) of the common shares would be allocated ratably over the US Holder&rsquo;s holding period for the common
shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would
be taxed as ordinary income. The amount allocated to any other taxable year would be subject to tax at the highest rate in effect
for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated
to that taxable year. Further, to the extent that any distribution received by a US Holder on its common shares exceeds 125% of
the average of the annual distributions on the common shares received during the preceding 3 years or the US Holder&rsquo;s holding
period, whichever is shorter, that distribution would be subject to taxation in the same manner as gain, described immediately
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A US Holder can avoid certain of the adverse
rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are
&ldquo;marketable.&rdquo; Common shares will be marketable if they are &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo;
or other market within the meaning of applicable Treasury regulations. If a US Holder makes the mark-to-market election, it generally
will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over
their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common
shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the mark-to-market election). If a US Holder makes this election, the holder&rsquo;s tax basis in the common
shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition
of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss
(but only to the extent of the net amount of income previously included as a result of the mark-to-market election).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, in order to avoid the application
of the foregoing rules, a US person who owns stock in a PFIC for US federal income tax purposes may make a &ldquo;qualified electing
fund&rdquo; (QEF) election with respect to such PFIC if the PFIC provides the information necessary for such election to be made.
If a US person makes a QEF election with respect to a PFIC, the US person will be currently taxable on their pro rata share of
the PFIC&rsquo;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable
year that the entity is classified as a PFIC, and will not be required to include such amounts in income when actually distributed
by the PFIC. We do not intend to provide the information necessary for US Holders to make QEF elections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, if we were a PFIC or, with
respect to particular US Holder, were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable
year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate US Holders would
not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If a US Holder owns common shares during
any year in which we are a PFIC, the holder generally must file annual reports containing such information as the US Treasury may
require on Internal Revenue Service (IRS) Form 8621 (or any successor form) with respect to us, generally with the holder&rsquo;s
federal income tax return for that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">US Holders should consult their tax advisors
concerning our potential PFIC status and the potential application of the PFIC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Information reporting and backup withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Payments of dividends and sales proceeds
that are made within the US or through certain US-related financial intermediaries generally are subject to information reporting,
and may be subject to backup withholding, unless (i)&nbsp;the US Holder is a corporation or other exempt recipient or (ii)&nbsp;in
the case of backup withholding, the US Holder provides a correct taxpayer identification number and certifies that they are not
subject to backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The amount of any backup withholding from
a payment to a US Holder will be allowed as a credit against the holder&rsquo;s US federal income tax liability and may entitle
the Holder to a refund, provided that the required information is furnished in a timely manner to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Information with respect to foreign financial
assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain US Holders who are individuals
(and, under proposed regulations, certain entities) may be required to report information relating to an interest in our common
shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain US financial
institutions). US Holders should consult their tax advisors regarding the effect, if any, of this legislation on their ownership
and disposition of the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10f"></A>F.</TD><TD>Dividends and paying agents</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B>Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10g"></A>G.</TD><TD>Statement by experts</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10h"></A>H.</TD><TD>Documents on display</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B>We are subject to the informational
requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual
reports on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other information filed with the SEC at the
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room
may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website that contains reports
and other information about issuers, such as us, that file electronically with the SEC. The address of that website is www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, pursuant to Swiss law, any
shareholder of record has the right to receive a free copy of this Annual Report and to inspect this Annual Report at any time
at our registered office in Ecublens, near Lausanne, Canton of Vaud, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our
executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions
contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports
and financial statements with the SEC as frequently or as promptly as US companies whose securities are registered under the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item10i"></A>I.</TD><TD>Subsidiary information</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item11"></A>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B>The Company&rsquo;s activities
expose it to the following financial risks: market risk (currency and interest rate risk), credit risk and liquidity risk. The
Company&rsquo;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential
adverse effects on the Company&rsquo;s financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Market risk arises from our exposure to
fluctuation in currency exchange rates. We are exposed to market risks in the ordinary course of our business, which are principally
limited to foreign currency exchange rate fluctuations and to a lesser degree, interest rate fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Market risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Foreign exchange risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is exposed to foreign exchange
risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency
exposure is not hedged. However,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">the
Company has the policy of matching its cash holdings to the currency structure of its expenses. As of December 31, 2020, the Company
holds almost 95% of its overall cash and cash equivalents balance in CHF with the remainder predominantly in EUR and USD (see
&ldquo;Note 6. Cash and cash equivalents and financial assets&rdquo; of the financial statements). The Company holds almost 96%
of its liquidity (cash and cash equivalents plus short-term financial assets) in CHF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a number of collaboration agreements
for which the upfront payments, milestone payments and future royalty payments are not denominated in Swiss Francs, our reporting
currency. Furthermore, many of our research and development activities are subcontracted to parties outside of Switzerland and
we purchase materials from suppliers outside of Switzerland. As a result, we are exposed to foreign exchange risk. Approximately
39% of our total costs are incurred in currencies other than the Swiss Franc. Due to the size of some of the income received from
collaboration agreements and also the high percentage of our costs indirectly being in foreign currencies, a hypothetical 10% change
in exchange rates relative to the Swiss Franc could have a material impact on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Interest rate risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We maintain financial instruments in accordance
with our treasury management policy. The primary objectives of our policy are to preserve principal, maintain proper liquidity
and meet operating needs. Our financial assets are subject to interest rate risk and will decrease in value if market interest
rates increase. Due to the current negative interest rates in Switzerland and our policy to maintain the majority of our cash and
cash equivalents in our functional currency. However, due to the conservative nature of our investments and relatively short duration,
interest rate risk is mitigated. We do not own derivative financial instruments. Accordingly, we do not believe that there is any
material market risk exposure with respect to derivative or other financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Credit risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company maintains a formal treasury
risk and investment management policy to limit counterparty credit risk. As of December 31, 2020, the Company&rsquo;s cash and
cash equivalents and short-term financial assets are held with four financial institutions, each with a high credit rating assigned
by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Receivables
are fully performing, not past due and not impaired (see &ldquo;Note 6. Cash and cash equivalents and financial assets&rdquo; and
&ldquo;Note 8. Other current receivables&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Liquidity risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inherent in the Company&rsquo;s business
are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts
will succeed. AC Immune&rsquo;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent
position and protection, (ii)&nbsp;enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries,
(iii)&nbsp;acquire and keep key personnel employed, and (iv)&nbsp;acquire additional capital to support its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s approach of managing
liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position
on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on the Company&rsquo;s current liquidity
position, comprised of cash and cash equivalents and short-term financial assets, the Company is well financed through Q1 2024,
excluding any potential milestones</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item12"></A>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item12a"></A>A.</TD><TD>Debt securities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item12b"></A>B.</TD><TD>Warrants and rights</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item12c"></A>C.</TD><TD>Other securities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item12d"></A>D.</TD><TD>American depositary shares</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="part02"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item13"></A>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item13a"></A>A.</TD><TD>Defaults</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No matters to report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item13b"></A>B.</TD><TD>Arrears and delinquencies</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No matters to report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item14"></A>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY
HOLDERS AND USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item14e"></A>E.</TD><TD>Use of proceeds</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item15"></A>ITEM 15. CONTROLS AND PROCEDURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item15a"></A>A.</TD><TD>Disclosure controls and procedures</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, under the supervision
and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we performed an
evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)
under the Exchange Act). There are inherent limitations to the effectiveness of any disclosure controls and procedures system,
including the possibility of human error and circumventing or overriding them. Even if effective, disclosure controls and procedures
can provide only reasonable assurance of achieving their control objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on such evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in recording, processing,
summarizing and reporting on a timely basis the information required to be included in periodic filings under the Exchange Act
and that such information is accumulated and communicated to management, including our Chief Executive and Chief Financial Officers,
as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item15b"></A>B.</TD><TD>Management&rsquo;s Annual Report on internal control
over financial reporting</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,
we conducted an evaluation of the effectiveness of our internal control over financial reporting based upon criteria established
in&nbsp;<I>Internal Control &ndash; Integrated Framework&nbsp;</I>(2013) by the Committee of Sponsoring Organizations of the Treadway
Commission. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our internal control
over financial reporting was effective as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item15c"></A>C.</TD><TD>Attestation report of the registered public accounting
firm</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Annual Report does not include an
attestation report of our registered public accounting firm, due to an exemption provided to emerging growth companies under the
JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><A NAME="item15d"></A>D.</TD><TD>Changes in internal control over financial reporting</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">There
have been no changes in the Company&rsquo;s internal control over financial reporting during the year ended December 31, 2020 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16"></A>ITEM 16. [RESERVED]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16a"></A>ITEM 16A. Audit committee financial experts</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors has determined that
Peter Bollmann, Thomas Graney, Werner Lanthaler and Martin Velasco are audit committee financial experts, as that term is defined
by the SEC, and are independent for the purposes of SEC and Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16b"></A>ITEM 16B. Code of Ethics</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have adopted a Code of Business Conduct
and Ethics, which covers a broad range of matters including the handling of conflicts of interest, compliance issues and other
corporate policies such as insider trading and equal opportunity and non-discrimination standards. Our Code of Business Conduct
applies to all of our directors, executive officers and employees. We have published our Code of Business Conduct and Ethics on
our website, <I>www.acimmune.com</I>. The information contained on our website is not a part of this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16c"></A>ITEM 16C. Principal accountant fees and services</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Audit fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">480</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">300</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Audit-related fees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">44</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total fees</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">498</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">344</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December 31, 2020, PricewaterhouseCoopers
SA (PwC) was the Company&rsquo;s auditor for the IFRS and statutory accounts. At the ordinary Annual General Meeting on June 26,
2020, the shareholders appointed PwC as the Company&rsquo;s auditor for a term of office of 1 year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #0D0E00">Audit fees for services
provided by PwC in 2020 include the standard audit work performed each fiscal year that is necessary to allow the auditor to issue
an opinion on our financial statements and to issue an opinion on the local statutory financial statements. Audit fees also include
services that can be provided only by the external auditor such as reviews of quarterly financial results and review of our shelf
registration statements and prospectus offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #0D0E00">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Audit-related fees consisted of fees billed
for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements
or for services that were traditionally performed by the external auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pre-approval policies and procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #0D0E00">In accordance with the
requirements of the US Sarbanes-Oxley Act of 2002 and rules issued by the SEC, we review and pre-approve any services performed
by PwC. The procedure requires that all proposed future engagements of PwC for audit and permitted non-audit services are submitted
to the Audit and Finance Committee for approval prior to the beginning of any such services. In accordance with this policy, all
services performed by and fees paid to PwC in this Item&nbsp;16C, were approved by the Audit and Finance Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #0D0E00">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16d"></A>ITEM 16D. Exemptions from the listing standards for audit
committees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B>Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16e"></A>ITEM 16E. Purchases of equity securities by the issuer
and affiliated purchasers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2020, no purchases of our equity securities
were made by or on behalf of AC Immune SA or any affiliated purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16f"></A>ITEM 16F. Change in registrant&rsquo;s certifying accountant</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16g"></A>ITEM 16G. Corporate governance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Summary of significant corporate governance
differences from Nasdaq listing standards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common shares are listed on the Nasdaq
Global Market. We are therefore required to comply with certain of the Nasdaq&rsquo;s corporate governance listing standards (Nasdaq
Standards). As a foreign private issuer, we may follow our home country&rsquo;s corporate governance practices in lieu of certain
of the Nasdaq Standards. Our corporate governance practices differ in certain respects from those that US companies must adopt
in order to maintain a Nasdaq listing. A brief, general summary of those differences is provided as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Independent directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law does not require that a majority
of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors
than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing
Rule 5605(b)(2), which requires that independent directors must regularly have scheduled meetings at which only independent directors
are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Compensation, nomination and corporate governance
committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As Swiss law requires that we have a compensation,
nomination and corporate governance committee, we will follow home country requirements with respect to such committee. As a result,
our practice will vary from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities,
composition and independence of compensation, nomination and corporate governance committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Quorum requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings
of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide
in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Solicitation of proxies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our articles of association provide for
an independent proxy holder elected by our shareholders, who may represent our shareholders at a general meeting of shareholders,
and we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders. However,
Swiss law does not have a regulatory regime for the solicitation of proxies, and company solicitation of proxies is prohibited
for public companies in Switzerland. Thus, our practice will vary from the requirement of Nasdaq Listing Rule 5620(b), which sets
forth certain requirements regarding the solicitation of proxies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Shareholder approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have opted out of shareholder approval
requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another
company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain
private placements. To this extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally requires
an issuer to obtain shareholder approval for the issuance of securities in connection with such events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item16h"></A>ITEM 16H. Mine safety disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="part03"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item17"></A>ITEM 17. Financial statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>We have responded to Item 18 in lieu of this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item18"></A>ITEM 18. Financial statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial Statements are filed as part
of this Annual Report, see page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="item19"></A>ITEM 19. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) The following documents are filed as
part of Annual Report on Form 20-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">2.1</TD>
    <TD STYLE="width: 88%"><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex41.htm">Registration Rights Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex0301.htm">3.1*</A></TD>
    <TD><A HREF="dp148007_ex0301.htm">Articles of Association of AC Immune SA</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex101.htm">Research
    Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated November 6, 2006 (incorporated
    herein by reference to Exhibit 10.1 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed
    with the SEC on May 31, 2016)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.2</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex102.htm">Amendment to the Research Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated May 7, 2015 (incorporated herein by reference to Exhibit 10.2 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.3</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex103.htm">Research Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated June 15, 2012 (incorporated herein by reference to Exhibit 10.3 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.4</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex104.htm">License and Collaboration Agreement between Piramal Imaging Ltd., Piramal Imaging SA and AC Immune SA, dated May 9, 2014 (incorporated herein by reference to Exhibit 10.4 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.5</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex105.htm">License, Development and Commercialization Agreement between Janssen Pharmaceuticals, Inc. and AC Immune SA, dated December 24, 2014 (incorporated herein by reference to Exhibit 10.5 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.6</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex106.htm">Form of Indemnity Agreement (incorporated herein by reference to Exhibit 10.6 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.7</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex107.htm">AC Immune SA 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.8</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex108.htm">Subscription Agreement among Fidelity entities and AC Immune SA, dated October 16, 2015 (incorporated herein by reference to Exhibit 10.8 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.9</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex109.htm">Subscription Agreement among Temasek entities and AC Immune SA, dated October&nbsp;16, 2015 (incorporated herein by reference to Exhibit 10.9 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on May 31, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.10</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010316016688/dp68999_ex9903.htm">Stock Option Plan - AC Immune of December 31, 2004 (incorporated herein by reference to Exhibit 99.03 to the Company&rsquo;s Registration Statement on Form S-8, filed with the SEC on September 29, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.11</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010316016688/dp68999_ex9902.htm">Employee Stock Option and Share Plan of AC Immune (2005 Plan) (incorporated herein by reference to Exhibit 99.02 to the Company&rsquo;s Registration Statement on Form S-8, filed with the SEC on September 29, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.12</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000119312516607922/d16439dex107.htm">AC Immune SA 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company&rsquo;s Registration Statement on Form F-1, filed with the SEC on May 31, 2016)</A></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">4.13</TD>
    <TD STYLE="width: 88%"><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010316017052/dp69421_ex9908.htm">AC Immune SA 2016 Stock Option and Incentive Plan (incorporated herein by reference to Exhibit 99.08 to the Company&rsquo;s Report on Form 6-K, filed with the SEC on October 13, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.14</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010319004949/dp105140_ex0414.htm">License Agreement between AC Immune SA and Eli Lilly and Company, dated December 11, 2018 (incorporated herein by reference to Exhibit 4.14 to the Amendment No. 1 to the Company&rsquo;s Annual Report on Form 20-F/A, filed with the SEC on April 19, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.15</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010319012523/dp112992_6k.htm">First Amendment to License Agreement between AC Immune SA and Eli Lilly and Company, dated September 19, 2019 (incorporated herein by reference to Exhibit 10.1 to the Company&rsquo;s Report on Form 6-K, filed with the SEC on September 20, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.16</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010319003578/dp103711_ex0415.htm">Convertible Note Agreement between AC Immune SA and Eli Lilly and Company, dated December 11, 2018 (incorporated herein by reference to Exhibit 4.15 to the Company&rsquo;s Annual Report on Form 20-F, filed with the SEC on March 21, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010320005734/dp124366_ex1001.htm">4.17</A></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1651625/000095010320005734/dp124366_ex1001.htm">Second Amendment to License Agreement between AC Immune SA and Eli Lilly and Company, dated March 23, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company&rsquo;s Report in Form 6-K, filed with the SEC on September 8, 2020)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1651625/000095010320017581/dp136167_ex0101.htm">4.18</A></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1651625/000095010320017581/dp136167_ex0101.htm">Open Market Sale Agreement between AC Immune SA and Jefferies LLC (incorporated herein by reference to Exhibit 1.1 to the Company's Report on 6-K, filed with the SEC on September 8, 2020)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex0419.htm">4.19*</A></TD>
    <TD><A HREF="dp148007_ex0419.htm">Description of Securities</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex1201.htm">12.1*</A></TD>
    <TD><A HREF="dp148007_ex1201.htm">Certification of Andrea Pfeifer pursuant to 17 CFR 240.13a-14(a)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex1202.htm">12.2*</A></TD>
    <TD><A HREF="dp148007_ex1202.htm">Certification of Joerg Hornstein pursuant to 17 CFR 240.13a-14(a).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex1301.htm">13.1*</A></TD>
    <TD><A HREF="dp148007_ex1301.htm">Certification of Andrea Pfeifer pursuant to 17 CFR 240.13a-14(b) and 18 USC.1350</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex1302.htm">13.2*</A></TD>
    <TD><A HREF="dp148007_ex1302.htm">Certification of Joerg Hornstein pursuant to 17 CFR 240.13a-14(b) and 18 USC.1350</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="dp148007_ex1501.htm">15.1*</A></TD>
    <TD><A HREF="dp148007_ex1501.htm">Consent of PricewaterhouseCoopers SA</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>XBRL Instance Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">_______________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Filed herewith</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) Financial Statement Schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Signatures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The registrant hereby certifies that it
meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual
Report on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC IMMUNE SA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1 solid"><P>/s/ Andrea Pfeifer</P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 25%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Andrea Pfeifer</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1 solid"><P>/s/ Joerg Hornstein</P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 25%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Joerg Hornstein</P>


<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>ChiefFinancial  Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Audited financial statements &mdash; AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; width: 95%; padding-bottom: 1pt"><A HREF="#auditorsreport">Report of independent registered public accounting firm</A></TD>
    <TD STYLE="padding-top: 1pt; width: 5%; padding-bottom: 1pt"><A HREF="#auditorsreport">F-2</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#balancesheet">Balance Sheets as of December 31, 2020 and 2019</A></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#balancesheet">F-3</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">
        <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><A HREF="#statementsofincomeloss">Statements of Income/(Loss) and Statements of Comprehensive Income/(Loss) for the fiscal years ended December 31, 2020, 2019 and 2018</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="padding-top: 1pt; text-align: left; vertical-align: bottom; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#statementsofincomeloss">F-4</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#statementsofchanges">Statements of Changes in Equity for the fiscal years ended December 31, 2020, 2019 and 2018</A></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#statementsofchanges">F-5</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#statementsofcashflow">Statements of Cash Flows for the fiscal years ended December 31, 2020, 2019 and 2018</A></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#statementsofcashflow">F-6</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#notestofinancialstatements">Notes to the Financial Statements</A></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><A HREF="#notestofinancialstatements">F-7</A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 157; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="auditorsreport"></A>Report of Independent Registered Public
Accounting Firm </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders of AC Immune SA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Opinion on the Financial Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheets of AC Immune
SA (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019 and the related statements of income/(loss), comprehensive income/(loss),
changes in equity and cash flows for each of the three years in the period ended December 31, 2020, including the related notes
(collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations
and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with the International Financial
Reporting Standards as issued by the International Accounting Standards Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Change in Accounting Principle</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As discussed in Notes 3 and 5 to the financial statements, the
Company changed the manner in which it accounts for leases in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis for Opinion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audits. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits of these financial statements in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess the risks
of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers SA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lausanne, Switzerland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Statements (IFRS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="balancesheet"></A>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(In CHF thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 65%; text-align: left">Property, plant and equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">4</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,416</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,917</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,223</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,255</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Long-term financial assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">6</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">334</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">304</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total non-current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,973</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,476</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,954</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,788</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,591</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,095</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Other current receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Short-term financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">6</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">231,767</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">292,774</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">238,740</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">299,250</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">SHAREHOLDERS&rsquo; EQUITY AND LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,538</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,437</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,890</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,526</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Treasury shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated losses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(132,850</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(75,521</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">215,478</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">272,442</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Long-term lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,780</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,813</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net employee defined benefit liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,464</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,485</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total non-current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,244</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,298</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,184</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,085</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,797</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Deferred income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,477</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Short-term financing obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">652</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Short-term lease liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">5</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">442</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,018</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,510</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23,262</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,808</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total shareholders&rsquo; equity and liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">238,740</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">299,250</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying notes are an integral
part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="statementsofincomeloss"></A>Statements of Income/(Loss)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<B>In CHF thousands, except for per-share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1pt">Contract revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; padding-bottom: 1pt">12</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">15,431</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">110,456</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">6,912</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,431</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,456</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,912</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Research &amp; development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(59,487</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,432</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,277</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General &amp; administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,557</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,058</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,467</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other operating income/(expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">12.2</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,353</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">570</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">282</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(76,691</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(65,920</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(56,462</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Operating income/(loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,260</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,536</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,550</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financial income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Financial expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,926</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,542</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exchange differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(555</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,013</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,194</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Finance result, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(661</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">906</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,401</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Income/(loss) before tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,442</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income/(loss) for the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Earnings/(loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Basic income/(loss) for the period attributable to equity holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Diluted income/(loss) for the period attributable to equity holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Statements of Comprehensive Income/(Loss)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(In CHF thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 48%; text-align: left">Income/(loss) for the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Remeasurement income/(losses) on defined benefit plans (net of tax)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">16</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,304</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(302</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive income/(loss), net of tax</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(61,195</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,138</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(51,253</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying notes are an integral
part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="statementsofchanges"></A>Statements of Changes in Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(In CHF thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share premium</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated losses</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 38%; font-weight: bold">Balance as of January 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,147</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">188,299</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(72,607</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">116,839</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(302</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(302</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(51,253</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(51,253</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from public offerings, net of underwriting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9 <BR></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,329</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,529</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Transaction offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,015</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,015</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,518</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,518</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Issuance of shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Restricted share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(535</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">17</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,351</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">298,149</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(121,877</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">177,623</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share premium</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated losses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 38%; font-weight: bold">Balance as of January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,351</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">298,149</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(121,877</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">177,623</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net income for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,442</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,442</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,304</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,304</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,138</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,138</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,834</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,834</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Issuance of shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversion note agreement, net of transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9 <BR></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,705</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,778</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Restricted share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(616</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">17</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,437</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">346,526</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(75,521</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">272,442</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share premium</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated losses</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 38%; font-weight: bold">Balance as of January 1, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,437</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">346,526</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(75,521</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">272,442</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(61,195</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(61,195</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,088</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,088</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Issuance of shares:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 0.25in">Held as treasury shares, net of transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Restricted share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">222</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(222</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">17</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">142</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">143</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,538</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">346,890</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(100</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(132,850</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">215,478</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying notes are an integral
part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="statementsofcashflow"></A>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(In CHF thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Net income/(loss) for the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Adjustments to reconcile net income/(loss) for the period to net cash flows:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,535</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,274</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">961</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Depreciation of right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">432</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance result, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">376</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,739</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,401</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Share-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,088</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,834</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,518</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in net employee defined benefit liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">16</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">705</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">437</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Change in fair value of conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,542</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/11/13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,894</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">(Gain)/loss on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Changes in working capital:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">(Increase) in prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,304</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(424</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(924</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Increase)/decrease in accrued income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(507</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,572</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(868</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">(Increase)/decrease in other current receivables </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">698</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Decrease)/increase in accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(757</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,289</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,113</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">(Decrease)/increase in deferred income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,157</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,126</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Decrease in financing obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Increase/(decrease) in trade and other payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">10</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,177</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,845</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">864</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash (used in)/provided by operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(59,247</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,227</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,772</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/11/13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(339</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(296</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(335</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net cash flows (used in)/provided by operating activities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(59,517</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">55,220</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(44,078</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Short-term financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(65,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchases of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,706</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,885</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,858</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Proceeds from sale of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Rental deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">6</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(178</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net cash flows provided by/(used in) investing activities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,329</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(66,885</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(32,036</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Repayment of short-term financing obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(514</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(339</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Principal payments of lease obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(432</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(420</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of common shares &ndash; option plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Proceeds from issuance of treasury shares, net of transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payment for the issuance of treasury shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Proceeds from issuance of convertible loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,278</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transaction costs on issuance of shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(510</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Proceeds from public offerings of common shares, net of underwriting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,529</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transaction costs on public offerings of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,015</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from long-term financing obligation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">11</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">199</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">198</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net cash flows (used in)/provided by financing activities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(803</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">49,616</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">109,378</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (decrease)/increase in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(31,991</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,951</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,264</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Cash and cash equivalents at January 1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193,587</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,462</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,377</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exchange gains on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(703</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(826</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,179</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at December 31</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,462</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (decrease)/increase in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(31,991</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,951</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,264</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Supplementary non-cash activity includes the following:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December 31, 2020, the
acquisition of CHF 0.3 million of property, plant and equipment was non-cash. For the year ended December 31, 2019, the Company
settled its convertible loan via equity for CHF 48.3 million, gross of CHF 0.5 million for transaction costs.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying notes are an integral
part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="notestofinancialstatements"></A><B>Notes to the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(In CHF thousands except for share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD><B>General information</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">AC Immune SA (the
&ldquo;Company,&rdquo; &ldquo;AC Immune,&rdquo; &ldquo;ACIU,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours,&rdquo; or
&ldquo;us&rdquo;) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover,
design and develop novel, proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases associated
with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as
Alzheimer&rsquo;s disease, or AD, and Parkinson&rsquo;s disease, or PD, with common mechanisms and drug targets, such as Abeta,
Tau, alpha-synuclein and TDP-43. Our corporate strategy is founded upon a three-pillar approach that targets (i) AD, (ii) focused
non-Alzheimer&rsquo;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics. We use our two unique
proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules),
to discover, design and develop novel medicines and diagnostics to target misfolded proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company was initially incorporated
as a limited liability company on February&nbsp;13, 2003 in Basel, and effective August&nbsp;25, 2003 was transitioned into a stock
company. The Company&rsquo;s corporate headquarters are located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD><B>Basis of preparation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Going concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements have been prepared
on the basis that the Company will continue as a going concern after considering the Company&rsquo;s cash position of CHF 160.9
million and short-term financial assets of CHF 65 million as of December 31, 2020. This total derives from multiple capital raising
efforts and revenues from license and collaboration agreements (LCAs). In 2020, the Company received CHF 10 million for a development
milestone from its licensing agreement with Lilly. In 2019, the&nbsp;Company received CHF 80 million for an upfront payment, CHF
30 million for a development milestone and USD 50 (CHF 50.3) million from a convertible loan with Lilly. In 2018, the Company completed
three offerings, raising USD 117.5 (CHF 116.3) million in gross proceeds before underwriting discounts and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">To date, the Company
has financed its cash requirements primarily from its public offerings, share issuances, contract revenues from license and collaboration
agreements and grants. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business.
Inherent to the Company&rsquo;s business are various risks and uncertainties, including the substantial uncertainty as to whether
current projects will succeed. The Company&rsquo;s success may depend in part upon its ability to (i) establish and maintain a
strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical
industries, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel
and (v) acquire capital to support its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In addition to
the foregoing, based on the Company&rsquo;s current assessment, the Company does not expect any material impact on its long-term
development timeline, its liquidity or ability to remain a going concern due to the worldwide spread of the Covid-19 virus. The
Company continues to assess the effect on its operations by carefully monitoring the spread of Covid-19 and taking appropriate
steps intended to offset any negative impacts from the Covid-19 virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Statement of compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements have been prepared
in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board
(IASB). These financial statements have been approved for issue by the Board of Directors on March 19, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of measurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements have been prepared
under the historical cost convention except for items that are required to be accounted for at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Functional currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements of the Company
are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial information presented
in Swiss Francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands),
unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>3.</B></TD><TD><B>Summary of significant accounting policies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The principal accounting policies adopted
in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years
presented, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Current vs. non-current classification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company presents assets and liabilities
in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled
within 12 months after the reporting period to be current and all other amounts to be non-current.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Foreign currency transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Foreign currency transactions are translated
into the functional currency, CHF, using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities
denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses
from these translations are included in the statements of income/(loss) in the period in which they arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Revenue recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has adopted IFRS 15&nbsp;(<I>Revenue
from Contracts with Customers</I>). This standard applies to all contracts with customers, except for contracts that are within
the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under IFRS 15, an
entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that
an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate
the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies
a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception,
once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each
contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation
when (or as) the performance obligation is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company enters into LCAs which are
within the scope of IFRS 15, under which it licenses certain rights to its product candidates and IP to third parties. The terms
of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license
fees, development, regulatory and/or commercial milestone payments;&nbsp;payments for research and clinical services the Company
provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized
from the Company&rsquo;s IP. Each of these payments results in license, collaboration and other revenues, which are classified
as contract revenue on the statements of income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Licenses of intellectual property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the license to the Company&rsquo;s intellectual
property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes
revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer
is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses
judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate
method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure
of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Milestone payments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the inception of each arrangement that
includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered
highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount
method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone
value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as
they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of
such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments
recorded would affect contract revenues and earnings in the period of adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Research and development services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has certain arrangements with
our collaboration partners that include contracting our employees for research and development programs. The Company assesses if
these services are considered distinct in the context of each contract and, if so, they are accounted for as separate performance
obligations. These revenues are recorded in contract revenue as the services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Sublicense revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has certain arrangements with
our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense revenues at the point
in time it is highly probable to obtain and not subject to reversal in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Contract balances</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company receives
payments and determines credit terms from its customers for its various performance obligations based on billing schedules established
in each contract. The timing of revenue recognition, billings and cash collections results in billed other current receivables,
accrued income (contract assets), and deferred income (contract liabilities) on the balance sheets. Amounts are recorded as other
current receivables when the Company&rsquo;s right to consideration is unconditional. The Company does not assess whether a contract
has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees
and the transfer of the promised goods or services to the licensees will be 1 year or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a complete discussion
of accounting for contract revenue, see &ldquo;Note 12. Contract revenues.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Research and development expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Given the stage of development of the Company&rsquo;s
products, all research expenditure is expensed as incurred. Research and development expenditures include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not
received regulatory approval, clinical trial materials and other research and development materials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in
connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management
and laboratory services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fees and costs related to regulatory filings and activities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>costs associated with preclinical and clinical activities; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">For external research contracts, expenses
include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing
from CROs or CMOs for services rendered do not always align with work performed. We accrue the cost of services rendered in connection
with CRO or CMO activities based on our estimate of the &ldquo;stage of completion&rdquo; for such contracted services. We maintain
regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and accrue expenses as of the balance
sheet date in the financial statements based on facts and circumstances known at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Registration costs for patents are part
of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred
as long as the research and development project concerned does not meet the criteria for capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Grant income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company has
received grants, from time to time, from the Michael J. Fox Foundation (MJFF) and other institutions to support certain research
projects. Grants are recorded at their fair value in the statements of income/(loss) within other operating income/(expenses) when
there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In
certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent
required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize
the related expenses for which the grants are intended to compensate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective January 1, 2019, the Company
adopted IFRS 16 (<I>Leases</I>), which provides a new model for lessee accounting in which all leases, other than short-term and
low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and
the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company
applied the modified retrospective approach, which required the recognition of the cumulative effect of initially applying IFRS
16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets
at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting,
see &ldquo;Note 5. Right-of-use assets and lease liabilities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Right-of-use assets and lease liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At inception of a leasing contract, the
Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use
of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease
liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments
that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be
readily determined, the Company&rsquo;s incremental borrowing rate. The lease liabilities are classified as current or non-current
based on the due dates of the underlying principal payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Lease payments generally are fixed for
the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is
re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index
or rate, a change in the Company&rsquo;s estimate of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">the
amount expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase,
extension or termination option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At inception, the right-of-use asset comprises
the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term
or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted
for certain re-measurements of the lease liability. When the lease liability is re-measured, a corresponding adjustment is made
to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset
has been reduced to zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The estimated lease term by right-of-use
asset categories are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="width: 51%">Buildings</TD>
    <TD STYLE="width: 49%; text-align: right">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Office equipment</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>IT equipment</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Both the right-of-use-assets and lease
liabilities are recognized in the balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Property, plant and equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Equipment is shown at historical acquisition
cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly
attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to
write off the cost of each asset to its residual value over its estimated useful life as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="width: 50%">IT equipment</TD>
    <TD STYLE="width: 50%; text-align: right">3 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Laboratory equipment</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Leasehold improvements/furniture</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The assets&rsquo; residual values and useful
lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&rsquo;s carrying amount is greater
than its estimated recoverable amount, it is written down to its recoverable amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Gains and losses on disposals are determined
by comparing the disposal proceeds with the carrying amount and are included in the statements of income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair value of financial assets&nbsp;and liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s financial assets and
liabilities are comprised of receivables, short-term financial assets, cash and cash equivalents, trade payables and financing
obligations. The fair value of these financial instruments approximates their respective carrying values due to the short-term
maturity of these instruments and are held at their amortized cost in accordance with IFRS 9 (<I>Financial Instruments</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Receivables</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Receivables are recognized at their billing
value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor&rsquo;s
inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with
these receivables held at amortized cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Short-term financial assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Short-term financial assets are held with
external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in
duration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Cash and cash equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Cash and cash equivalents include deposits
held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with
original duration of less than 3 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company assesses at each period whether
there is objective evidence that financial assets are impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Trade payables</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Trade payables are amounts due to third
parties in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Financing obligation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The Company&rsquo;s financing obligation
related to its agreement with a third party. This financing obligation has been fully repaid as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share capital and public offerings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Common shares are
classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax,
from the proceeds received from existing or future offerings. <FONT STYLE="background-color: white">Should a planned equity offering
not be assessed as probable, the issuance costs would be expensed immediately. </FONT>See &ldquo;Note 9. Share capital.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employee benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Post-employment benefits</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company operates the mandatory pension
schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company
has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan
is classified as a defined benefit plan under IAS 19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The net defined benefit liability is the
present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates
are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input
from independent actuaries. The defined benefit obligation is calculated annually with the assistance of an independent actuary
using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions
concerning employees&rsquo; projected salaries and pension increases as well as discount rates of highly liquid corporate bonds
that have terms to maturity approximating the terms of the related liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Re-measurements of the net defined benefit
liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately
in the statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized
immediately as a split in research and development and general and administrative expenses within the operating results. Settlement
gains or losses are recognized in either research and development and/or general and administrative expenses within the operating
results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying
the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant
events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit
liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses
related to defined benefit plans are recognized in the statements of income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Share-based compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company operates an equity-settled,
share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards
is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value
of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included
in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company
revises its estimates of the number of instruments that are expected to become exercisable. It</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 168 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">recognizes
the impact of the revision of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding
adjustment to equity over the remaining vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stock options granted under the Company&rsquo;s
stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model
(see &ldquo;Note 17. Share-based compensation&rdquo;). This valuation model as well as parameters used such as expected volatility
and expected term of the stock options are partially based on management&rsquo;s estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The proceeds received net of any directly
attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate the fair value of non-vested
stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on
the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common
stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation
costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period
of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards
vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Provisions are recognized when the Company
has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources
will be required to settle the obligation, and a reliable estimate of the amount can be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Current income tax assets and liabilities
for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and
tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance
with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is
provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying
amounts for financial reporting purposes at the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deferred tax assets and liabilities are
measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based
on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation
is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax
rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates
(and laws) that have been enacted or substantively enacted at the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deferred income tax assets are recognized
to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.
Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related
tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that
the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets as the probability
for use is low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Income taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As disclosed in &ldquo;Note 15. Income
taxes,&rdquo; the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss
was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable
profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these
tax losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 169 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Earnings per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company presents basic earnings per
share for each period in the financial statements. The earnings per share are calculated by dividing the earnings of the period
by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution
that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into
common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded
from basic and dilutive earnings per share calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical judgments and accounting estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting
policies and the reported amounts of assets, liabilities, income and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The areas where AC Immune has had to make
judgments, estimates and assumptions relate to (i)&nbsp;revenue recognition on LCAs, (ii)&nbsp;clinical development accruals, (iii)&nbsp;net
employee defined benefit liability, (iv)&nbsp;income taxes, (v)&nbsp;share-based compensation and (vi) right-of-use assets and
lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Segment reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has one segment. The Company
currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is managed and operated as
one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business.
Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located
in and revenue is attributable to the Company&rsquo;s country of domicile, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting policies, new standards, interpretations and
amendments adopted by the Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company has
not adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not
currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant
and equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following tables show the movements
in the net book values of property, plant and equipment for the years ended December 31, 2020 and 2019, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">IT equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Laboratory equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold improvements</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Acquisition cost:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; font-weight: bold">Balance at December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">158</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,187</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,698</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">402</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,445</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">310</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,566</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,034</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Disposals</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(306</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(346</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,497</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,958</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">464</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,133</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Accumulated depreciation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(627</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,619</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(214</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,528</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Depreciation expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(343</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,092</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,535</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Disposals</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">306</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">346</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(970</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,405</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(281</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,717</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Carrying amount:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">560</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,079</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,917</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">527</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,553</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,416</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 170 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">IT equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Laboratory equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold improvements</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Acquisition cost:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; font-weight: bold">Balance at December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">126</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,025</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,367</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">350</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,868</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">291</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,470</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,885</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Disposals</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(129</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(139</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(308</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,187</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,698</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">402</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,445</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Accumulated depreciation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(455</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,857</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(155</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,544</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Depreciation expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(285</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(899</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,274</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Disposals</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">137</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">290</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(627</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,619</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(214</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,528</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Carrying amount:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">570</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,510</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,324</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">560</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,079</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,917</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, the Company incurred CHF 1.5 million, 1.3 million and CHF 1.0 million in depreciation expenses, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>5.</B></TD><TD><B>Right-of-use assets and lease liabilities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company recognized
additions of right-of-use of leased assets for buildings or for office equipment totaling CHF 0.4 and CHF 0.5 million for the years
ended December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regarding lease liabilities, the amortization
depends on the rate implicit in the contract or the incremental borrowing rate for the respective lease component. The weighted
averages of the incremental borrowing rates as of December 31, 2020 are 2.5% for buildings, 4.2% for office equipment and 2.6%
for IT equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following tables show the movements
in the net book values of right-of-use of leased assets for the years ended December 31, 2020 and 2019, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Buildings</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Office equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">IT equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 48%; font-weight: bold">Balance as of December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,106</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">81</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">68</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,255</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Disposals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(400</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(432</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance as of December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,106</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,223</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Buildings</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Office equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">IT equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 48%; font-weight: bold">Balance as of January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,106</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">79</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,185</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Disposals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(400</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(420</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Balance as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,106</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,255</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are no variable lease payments which
are not included in the measurement of lease obligations. All extension options have been included in the measurement of lease
obligations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 171 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">For the years
ended December 31, 2020, and 2019, the impact on the Company&rsquo;s statements of income/(loss) and statements of cash flows is
detailed in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">Statements of income/(loss)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Depreciation of right-of-use assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">432</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">420</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense on lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expense for short-term leases and leases of low value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">603</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">565</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,088</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,037</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-style: italic; text-align: left; text-indent: 0in">Statements of cash flows</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash outflow for leases</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,088</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,037</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table presents the contractual
undiscounted cash flows for lease liabilities as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Within 1 year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">485</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">485</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Between 1 and 3 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">970</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">970</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Between 3 and 5 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">912</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">948</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,367</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,403</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD><B>Cash and cash equivalents and financial assets</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s cash and cash equivalents
are maintained in the following respective currencies as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">By currency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">CHF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,537</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,173</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">EUR</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,215</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,169</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">USD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,141</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,245</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the balance sheet dates, Company funds
were held in CHF, EUR and USD currencies. As of December 31, 2020 and 2019, funds in EUR and USD were translated into CHF at a
rate of 1.095 and 0.891 and 1.096 and 0.978, respectively, for each currency and year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the Company&rsquo;s
short-term financial assets as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt">Short-term financial assets due in 1 year or less</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">65,000</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">95,000</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">65,000</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">95,000</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company also has two deposits in escrow
accounts totaling CHF 0.3 million and CHF 0.3 million for the lease of the Company&rsquo;s premises as of December 31, 2020 and
2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 172 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD><B>Prepaid expenses and accrued income</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Prepaid expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,954</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,788</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,591</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,095</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,545</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,883</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prepaid expenses relate mainly to research
contracts with down-payments at contract signature and the related activities will start or continue into 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued income consists of CHF 1.1 million
as of December 31, 2020 associated with our Janssen collaboration (see &ldquo;Note 12. Contract revenues&rdquo;). This amount represents
68.1% of our total accrued income as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>8.</B></TD><TD><B>Other current receivables</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Swiss VAT</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">309</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">234</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Withholding tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">329</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">304</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maturity of these assets is less than
3 months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate
their fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>9.</B></TD><TD><B>Share capital</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December&nbsp;31, 2020 and 2019,
the issued share capital amounted to CHF 1,538,896 and CHF 1,437,351, respectively, and is composed of common shares of 71,936,738
and 71,859,431, respectively, and treasury shares of 5,000,000 and nil, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below summarizes the Company&rsquo;s
capital structure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share premium</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Treasury shares</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 40%; font-weight: bold">December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">67,562,333</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,351</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">298,149</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Issuance of shares &ndash; incentive plans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">681,770</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">672</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Conversion of note agreement, net of transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,615,328</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,705</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,859,431</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,437</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,526</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of shares &ndash; incentive plans, net of RSU expiration and forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,307</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">364</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Issuance of shares to be held as treasury shares, net of transaction costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,000,000</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,000,000</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">76,936,738</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,000,000</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,538</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">346,890</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(100</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 173 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The common shares and treasury shares have
nominal values of CHF 0.02 per share. All shares have been fully paid. These treasury shares are held by the Company and are not
considered outstanding shares as of December 31, 2020. Finally, as of December 31, 2020 the Company has an additional 9,500,000
authorized shares for issuance which have not been issued nor are outstanding. Additionally, 19,632 RSUs either expired or were
forfeited in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>At the market equity offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">In September 2020, the Company established
an &ldquo;at the market offering program&rdquo; for the sale of up to USD 80 (CHF 71.3) million worth of our common shares issued
from time to time by entering into an Open Market Sale Agreement (Sales Agreement) with Jefferies LLC (Jefferies) as the sales
agent. Issuance costs incurred in connection with establishing this facility and execution of the Sales Agreement with Jefferies
primarily consist of legal, printing and accounting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">No common shares have been sold pursuant
to the Sales Agreement as of December 31, 2020. For the years ended December 31,&nbsp;2020, 2019 and 2018, the Company has expensed
issuance costs of CHF 0.5 million, nil and nil, respectively, in the statement of income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Convertible note agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">The Company and Lilly entered into a convertible
note agreement effective January 23, 2019 for USD 50 (CHF 50.3) million. In April 2019, the convertible note agreement with Lilly
automatically converted in line with the terms of the agreement. As a result of this conversion, 3,615,328 of our common shares
were issued to Lilly. This note is now fully settled and there is no further equity or cash consideration due to Lilly thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Follow-on offerings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July 24, 2018, the Company announced
that it had closed the first subscription rights offering and underwritten the primary offering of its common shares, and that
the underwriters had exercised in full their option to purchase an additional 1,108,695 shares at a price per share of USD 11.75.
The underwriters&rsquo; exercise of the option to purchase additional shares brought the total number of common shares sold by
the Company to 8,500,000 shares, resulting in total gross proceeds raised in these offerings, before underwriting discounts and
estimated expenses of the offering, to approximately USD 99.9 (CHF 98.9) million. On July 20, 2018, the Company commenced a second
subscription rights offering of up to 1,500,000 shares. At closing of the second subscription rights offering on July 31, 2018,
the Company issued 1,500,000 additional common shares, resulting in gross proceeds of approximately USD 17.6 (CHF 17.4) million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the conclusion of these three offerings,
the Company raised gross proceeds of USD 117.5 (CHF 116.3) million. Net underwriting fees and transaction costs totaled CHF 6.8
million for a net total of CHF 109.5 million. Transaction costs associated with these offerings and related to the issuance of
new shares were charged directly against the share premium account thereby reducing the total equity reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Shelf registration statement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On May 4, 2018, the Company filed a Shelf
Registration Statement on Form F-3 (Reg. No. 333-2246694) (the &ldquo;Shelf Registration Statement&rdquo;) with the SEC. The Shelf
Registration Statement was declared effective by the SEC on June 8, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Shelf Registration Statement allows
the Company to offer and sell, from time to time, up to USD 350,000,000 of common stock, debt securities, warrants, purchase contracts,
units, subscription rights or any combination of the foregoing in one or more future public offerings. The terms of any future
offering would be determined at the time of the offering and would be subject to market conditions and approval by the Company&rsquo;s
Board of Directors. Any offering of securities covered by the Shelf Registration Statement will be made only by means of a written
prospectus and prospectus supplement authorized and filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As the Company raised USD 117.5 (CHF 116.3)
million in its three offerings completed in July 2018, the Company may execute one or more future offering of securities covered
by the Shelf Registration Statement up to USD 232.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 174 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>10.</B></TD><TD><B>Trade payables and accrued liabilities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt">Trade and other payables</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,184</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">142</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total trade and other payables</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,184</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">142</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,298</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,228</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Accrued payroll expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,494</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,896</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,293</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,673</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,085</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,797</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An accrual of CHF 2.1 million and CHF 1.8
million was recognized for performance-related remuneration within accrued payroll expenses for 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>11.</B></TD><TD><B>Financing obligation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 4, 2016, September 13, 2016
and January 26, 2018 for the fiscal years 2016, 2017 and 2018, respectively, AC Immune obtained separate funding commitment notices
from the LuMind Research Down Syndrome Foundation (LuMind) totaling USD 200 thousand in each instance. Per the Research Grant Agreement,
AC Immune has an obligation to reimburse LuMind for an amount equal to 125% of the then funding commitment made by LuMind to AC
Immune.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On October 31, 2018, LuMind and the Company
modified the repayment terms in an effort to fund a Down Syndrome Clinical Trials Network. The repayment terms were modified such
that the Company will repay the outstanding balance in three installments in 2018, 2019 and 2020, with the total repayment to equal
the total the Company is to receive in funding plus the additional 25% interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, the Company has
fully repaid this financing obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>12.</B></TD><TD><B>Contract revenues</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">For the years
ended December 31, 2020, 2019 and 2018, AC Immune generated contract revenues of CHF 15.4 million, CHF 110.5 million and CHF 6.9
million, respectively. For comparability, the Company reclassified CHF 0.3 million, CHF 0.6 million and CHF 0.3 million from contract
revenues to other income/(expense) for the years ended December 31, 2020, 2019 and 2018, respectively for prior grants from the
MJFF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal">The
following tables provide contract revenue amounts from its LCAs for the years ended December 31, 2020, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%">Lilly</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">14,348</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">105,662</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Genentech</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Janssen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,083</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,173</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,157</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Life Molecular Imaging</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,206</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Biogen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,063</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,024</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">352</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">731</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total contract revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,431</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,456</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,912</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Lilly accounted for 93% and 96% of our
contract revenues in 2020 and 2019, respectively. Biogen and Janssen accounted for 58% and 31% of our contract revenues in 2018,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
presents changes in the Company&rsquo;s contract assets and liabilities during the years ended December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF Thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at the beginning of the reporting period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deductions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at the end of the reporting period</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Twelve months ended December 31, 2020:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left">Accrued income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,095</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,354</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,858</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,591</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Deferred income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,477</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,467</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,638</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Twelve months ended December 31, 2019:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,667</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,211</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,783</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,095</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Deferred income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">351</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,686</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,560</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,477</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the years ended December 31, 2020,
2019 and 2018, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract
liability balances in the respective periods:&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Revenues recognized in the period from:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Amounts included in the contract liability at the beginning of the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,477</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">351</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,551</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Performance obligations satisfied in previous periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,206</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><B>12.1
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensing and collaboration agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Morphomer Tau small molecule &ndash; 2018
license agreement with Eli Lilly and Company</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2018, we entered into an exclusive,
worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the
treatment of AD and other neurodegenerative diseases. More specifically, this is an exclusive license with the right to Lilly to
grant sublicenses under the ACIU Patents, the ACIU know-how, and ACIU&rsquo;s interests in the Joint Patents and the joint know-how
to Exploit the Licensed Compounds and Licensed Products. The agreement became effective on January 23, 2019 (the &ldquo;effective
date&rdquo;) when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. In Q3
2019, the Company and Lilly entered into the first amendment to divide the first discretionary milestone payment under the agreement
of CHF 60 million into two installments, with the first CHF 30 million paid in Q3 2019 and the second CHF 30 million to be paid
on or before March 31, 2020 unless Lilly terminated the agreement earlier. In Q1 2020, the Company and Lilly entered into a second
amendment to replace the second CHF 30 million to be paid on or before March 31, 2020 with two milestone payments, one of CHF 10
million to be paid on or before March 31, 2020 and the other of CHF 60 million following the first patient dosed in a Phase 2 clinical
study of a licensed product in the US or EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Per the terms of the agreement, the Company
received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly. To date, the Company
has completed a Phase 1 clinical study with ACI-3024. The program will be expanded to NeuroOrphan indications and ACI-3024 will
be further evaluated for efficacy in models of rare Tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additionally, the Company and Lilly have
continued candidate characterization across the research program, identifying new and highly differentiated candidates with desired
cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent
neurodegenerative diseases by Lilly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 176 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Lilly is responsible for leading and funding
further clinical development and will retain global commercialization rights for all indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Per the terms of the agreement, the Company
may become eligible to receive additional milestone payments totaling up to approximately CHF 880 million for clinical and regulatory
milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible
to receive royalties on sales at a percentage rate ranging from the low double-digits to the mid-teens. The agreement will terminate
by the date of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly
may terminate the agreement at any time by providing 3 months&rsquo; prior notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations
under the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. Per
the agreement, the Company was responsible for the preclinical and Phase 1 activities for the first clinical candidate, ACI-3024,
which the Company determined was distinct and capable of being completed by Lilly or a third party. Preclinical activities for
which AC Immune was responsible prior to their completion in Q2 2019 included final manufacturing of materials for use in the regulatory
submission of the protocol and in the Phase 1 study. For the completed Phase 1, AC Immune was responsible for leading the study
design, obtaining relevant regulatory agency approvals, arranging necessary third-party contracts, completing patient selection,
ensuring patient treatment, following up with patients, drafting the clinical study report development and other relevant clinical
activities to ensure that the primary objective of the study was completed. The Company used CMOs for certain of its preclinical
activities and CROs to complete certain Phase 1 activities and to issue the final clinical study report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s preclinical and Phase
1 activities did not represent integrated services with the licensed IP for which Lilly contracted. Lilly purchased a license to
the Company&rsquo;s Tau therapeutic small-molecule program, which was delivered at commencement of the agreement, and AC Immune&rsquo;s
preclinical and Phase 1 activities did not affect the form or functionality of this license. The Company&rsquo;s objective for
the Phase 1 activity was to assess safety and tolerability and did not modify or customize ACI-3024. The completion of these preclinical
and Phase 1 activities does not affect the licensed IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Finally, per the agreement, each party
has three representatives on a joint steering committee (JSC); depending upon the agenda, additional field experts can attend the
JSC to provide the technical and scientific contribution required. The JSC meets on a regular basis depending on agreements between
the representatives. The JSC is responsible for serving as the forum to (i) discuss, review and approve certain activities by reviewing
and discussing the development progress with updates on back-up candidates, (ii) discuss, review and approve all amendments to
the global development plan, (iii) periodically discuss and review commercialization of licensed products and (iv) review and approve
reports related to development costs among other activities. The JSC is intended to ensure that communication between the parties
remains consistent and that the development plan is progressing as intended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The valuation of each performance obligation
involves estimates and assumptions with revenue recognition timing to be determined by either delivery or the provision of services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company used the residual approach
to estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research
and development activities. The right-of-use license was delivered on the effective date. The research and development activities
were delivered over time as the services were performed. For these services, revenue was recognized over time using the input method,
based on costs incurred to perform the services, as the level of costs incurred over time is thought to best reflect the transfer
of services to Lilly. The Company determined the value of the research and development activities to be CHF 6.9 million and deferred
this balance from the effective date. As of December 31, 2020, the Company has cumulatively recognized CHF 6.9 million in contract
revenue, resulting in no deferred income (contract liability) on the balance sheets. The remaining CHF 73.1 million from the upfront
payment was allocated to the right-of-use license and recognized on the effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At inception of the agreement, none of
the clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully
constrained. Through December 31, 2020, the Company has recognized CHF 40 million from milestone payments triggered in Q3 2019
and Q1 2020 related to the right-of-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 177 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">use
license for IP as there were no further constraints related to these milestones. In assessing that future clinical, regulatory
or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are
not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon
success in future clinical trials and the licensee&rsquo;s efforts. Any consideration related to sales-based milestones (including
royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted
to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price
in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, we have recognized CHF 14.3 million, CHF 105.7 million and nil, respectively from this arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Anti-Abeta antibody in AD &ndash; 2006 agreement
with Genentech, a member of the Roche Group</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In November 2006, we signed an exclusive,
worldwide licensing agreement for crenezumab, our humanized monoclonal therapeutic antibody targeting misfolded Abeta. The agreement
was amended March 2009, January 2013, May 2014 and May 2015. The agreement also provides for the development of a second therapeutic
product for a non-AD indication based on the same intellectual property and anti-Abeta antibody compound. The value of this partnership
is potentially greater than USD 340 (CHF 303) million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The term of the agreement commenced on
the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates
on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to
licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party,
provided a cure period of 90 days from the date when that notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Genentech commenced a first Phase 3 clinical
study in March 2016 for crenezumab&nbsp;(CREAD). In March&nbsp;2017, Genentech started a second Phase 3 clinical trial (CREAD 2).
Since 2013, crenezumab has also been studied in a Phase 2 trial in individuals who carry the PSEN1 E280A autosomal-dominant mutation
and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase
of&nbsp;AD&nbsp;(autosomal dominant AD (ADAD)). In 2019, Genentech initiated a Tau Positron Emission Tomography (PET) substudy
to the ongoing Phase 2 trial in ADAD to evaluate the effect of crenezumab on Tau burden, which may also increase the understanding
of disease progression in the preclinical stage of ADAD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If crenezumab receives regulatory
approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates
applicable in the US and Europe ranging from the mid-single digits to mid-teens. To date, we have received total milestone
payments of USD 65 million (CHF 70.1 million) comprised of an upfront payment of USD 25 (CHF 31.6) million and of USD 40 (CHF
38.2) million for clinical development milestones achieved all-in prior to January 1, 2017. Genentech may terminate the
agreement at any time by providing 3 months&rsquo; notice to us. In such event all costs incurred are still refundable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations
under the contract: (i) a right-of-use license and (ii) conducting of research under a research plan. The Company considered the
research and development capabilities of Genentech and Genentech&rsquo;s right to sublicense to conclude that the license has stand-alone
functionality and is distinct. The Company&rsquo;s obligation to perform research does not significantly impact or modify the licenses&rsquo;
granted functionality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At execution of the agreement, the transaction
price included the upfront consideration received of USD 25 (CHF 31.6) million. At inception, none of the clinical or regulatory
milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received
three milestone payments since inception, totaling USD 40 (CHF 38.2) million. The Company could receive greater than USD 275 (CHF
245) million or more for further regulatory milestones for this exclusive, worldwide alliance. In assessing that future regulatory
milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside
the control of the Company and contingent upon success in future clinical trials and the licensee&rsquo;s efforts. Any consideration
related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license
granted to Genentech and therefore have also been excluded from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 178 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">the
transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved
or other changes in circumstances occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 30, 2019, we announced that
Roche, the parent of Genentech, is discontinuing the CREAD and CREAD 2 (BN29552 and BN29553) Phase 3 studies of crenezumab in people
with prodromal-to-mild sporadic AD. The decision came after an interim analysis conducted by the Independent Data Monitoring Center
(IDMC) indicated that crenezumab was unlikely to meet its primary endpoint of change from baseline in Clinical Dementia Rating-Sum
of Boxes (CDR-SB) Score. This decision was not related to the safety of the investigational product. No safety signals for crenezumab
were observed in this analysis and the overall safety profile was similar to that seen in previous trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Crenezumab continues to be studied in the
Phase 2 preventive trial, which began in 2013 in Columbia, of cognitively healthy individuals who carry the PSEN1 E280A autosomal-dominant
mutation and are in a preclinical phase of ADAD. This study will determine if treating people carrying this mutation with crenezumab
prior to the onset of AD symptoms will slow or prevent the decline of cognitive and functional abilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, we have recognized no revenues from this arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Anti-Tau antibody in AD &ndash; 2012 agreement
with Genentech, a member of the Roche Group</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June 2012, we entered into a second
agreement with Genentech to research, develop and commercialize our anti-Tau antibodies for use as immunotherapeutics and diagnostics.
The agreement was amended in December 2015. The value of this exclusive, worldwide alliance is potentially greater than CHF 400
million and includes upfront and clinical, regulatory and commercial milestone payments. In addition to milestones, we will be
eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to low-double digits. The agreement
also provides for collaboration on at least one additional therapeutic indication outside of AD built on the same anti-Tau antibody
program as well an anti-Tau diagnostic product for AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The term of the agreement commenced on
the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates
on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to
licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party,
provided a cure period of 90 days from the date when that notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To date, we have received payments totaling
CHF 59 million, including a milestone payment of CHF 14 million received and recognized in Q4 2017 associated with the first patient
dosing in a Phase 2 clinical trial for AD with an anti-Tau monoclonal body known as semorinemab, a milestone payment of CHF 14
million recognized in Q2 2016 and received in July 2016, associated with the announcement of the commencement of the Phase 1 clinical
study of semorinemab, and a milestone payment of CHF 14 million received in 2015 in connection with the ED-GO decision. As we met
all performance obligations on reaching these milestones, we have recognized revenue in the respective periods. Genentech may terminate
the agreement at any time by providing 3 months&rsquo; notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations
under the contract: (i) a right-of-use license and (ii) conduct of research under a research plan. The Company considered the research
and development capabilities of Genentech and Genentech&rsquo;s right to sublicense to conclude that the license has stand-alone
functionality and is distinct. The Company&rsquo;s obligation to perform research does not significantly impact or modify the licenses&rsquo;
granted functionality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At execution of the agreement, the transaction
price included an upfront consideration received of CHF 17 million. At inception, none of the clinical or regulatory milestones
had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestones
since inception totaling CHF 42 million. The Company could also receive up to an additional CHF 368.5 million in clinical, regulatory
and commercial milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company
considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon
success in future clinical trials. Any consideration related to sales-based milestones (including royalties) will be recognized
when the related sales occur as they were determined to relate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 179 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">predominantly
to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate
the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">On
September 23, 2020, the Company reported that Genentech informed us of top line results from a Phase 2 trial of the anti-Tau antibody,
semorinemab, in early (prodromal to mild) Alzheimer&rsquo;s disease (AD) which show that semorinemab did not meet its primary efficacy
endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. The primary safety endpoint
was however met. Two secondary endpoints, Alzheimer&rsquo;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer&rsquo;s
Disease Cooperative Study Group &ndash; Activities of Daily Living Inventory (ADCS-ADL), were not met. A second Phase 2 study of
semorinemab in patients with moderate AD remains ongoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, we have recognized no revenues from this arrangement, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Tau vaccine in AD &ndash; 2014 agreement with
Janssen Pharmaceuticals, Inc.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2014, we entered into an agreement
with Janssen Pharmaceuticals, Inc. (Janssen) one of The Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and
commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership
is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones,
we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. In
April 2016, July 2017, January 2019 and November 2019, the companies entered into the first, second, third and fourth amendments,
respectively. These amendments allow for the alignment of certain payment and activity provisions with the Development Plan and
Research Plan activities. We and Janssen are co-developing the second-generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054,
through Phase 1b/2a completion. AC Immune and Janssen will jointly share research and development costs until the completion of
the first Phase 2b (AC Immune&rsquo;s contribution to the first Phase 2b trial is capped). From Phase 2b and onwards, Janssen will
assume responsibility for the clinical development, manufacturing and commercialization of the second-generation vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the agreement, Janssen
may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days&rsquo;
notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined
in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The agreement also allows for the expansion
to a second indication based on the same anti-Tau vaccine program and based on intellectual property related to this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company received an upfront, non-refundable
license fee of CHF 25.9 million, which we recognized as revenue in 2014. In May 2016, we received a payment of CHF 4.9 million
for reaching a clinical milestone in the first Phase 1b study. As we met all performance obligations on reaching the milestone,
we have recognized this income as revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Janssen is a customer. The Company identified the following performance obligations
under the contract: (i) a right-of-use license and (ii) research and development services including a development and chemistry,
manufacturing and controls work plan. The Company considered the research and development capabilities of Janssen, Janssen&rsquo;s
right to sublicense, and the fact that the research and development services are not proprietary and can be provided by other vendors,
to conclude that the license has stand-alone functionality and is distinct. The Company&rsquo;s obligation to perform research
and development services does not significantly impact or modify the licenses&rsquo; granted functionality. Based on these assessments,
the Company identified the license and the research and development services as the performance obligations at the inception of
the arrangement, which were deemed to be distinct in the context of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At execution of the agreement, the transaction
price included only the upfront consideration received of CHF 25.9 million. At inception, none of the clinical, regulatory or commercial
milestones has been included in the transaction price, as all milestone amounts were fully constrained. The Company did receive
a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study in May 2016. The Company could also
receive up to more than CHF 458 million in clinical, regulatory and commercial milestones as well as tiered, low-double digit to
mid-teen royalties on aggregate net sales of products. In assessing that future clinical, regulatory or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 180 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">commercial
milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable
to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future
clinical trials and the licensee&rsquo;s efforts. Any consideration related to sales-based milestones (including royalties) will
be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and
therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting
period and as uncertain events are resolved or other changes in circumstances occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, we have recognized revenues totaling CHF 1.1 million, CHF 1.2 million and CHF 2.2 million, respectively from this
arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Tau-PET imaging agent in AD &ndash;2014 agreement
with Life Molecular Imaging (LMI) (formerly Piramal Imaging SA)</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In May 2014, we entered into an agreement,
our first diagnostic partnership, with LMI, the former Piramal Imaging SA. The partnership with LMI is an exclusive, worldwide
licensing agreement for the research, development and commercialization of the Company&rsquo;s Tau protein PET tracers supporting
the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments
totaling up to EUR 159 (CHF 175) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low-teens.
LMI may terminate the LCA at any time by providing 3 months&rsquo; notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with this agreement, AC Immune
received a payment of EUR 500 (CHF 664) thousand, which was fully recognized in 2015. In Q1 2017, we recorded a milestone payment
of EUR 1 (CHF 1.1) million related to the initiation of &ldquo;Part B&rdquo; of the first-in-man Phase 1 study. In Q3 2019, the
Company recognized EUR 2 (CHF 2.2) million in connection with the initiation of a Phase 2 trial of Tau-PET tracer in patients with
mild cognitive impairment and mild&ndash;to-moderate AD in comparison with non-demented control participants. The Company is eligible
to receive variable consideration related to the achievement of certain clinical milestones totaling EUR 8 (CHF 9) million should
the compound make it through Phase 3 clinical studies. We are also eligible to receive potential regulatory and sales-based milestones
totaling EUR 148 (CHF 162) million. Finally, the Company is eligible for royalties from the mid-single digits to low-double digits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that LMI is a customer. The Company has identified that the right-of-use license as the only
performance obligation. The Company determined that transaction price based on the defined terms allocated to each performance
obligation specified in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The upfront payment constitutes the amount
of consideration to be included in the transaction price and has been allocated to the license. None of the clinical, regulatory
or commercial milestones has been included in the transaction price as these variable consideration elements are considered fully
constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the
milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&rsquo;s
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any consideration related to sales-based
milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate
predominantly to the license granted to LMI and therefore are recognized at the later of when the performance obligation is satisfied
or the related sales occur. The Company considered LMI&rsquo;s right to sublicense and develop the Tau protein PET tracers, and
the fact that LMI could perform the research and development work themselves within the license term without AC Immune, to conclude
that the license has stand-alone functionality and is distinct. The Company believes that the contracted amount represents the
fair value. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or
other changes in circumstances occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, the Company has recognized nil, CHF 2.2 million and nil, respectively, from this arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">A-syn and TDP-43 PET tracers &ndash; 2016
agreement with Biogen</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 13, 2016, we entered into a non-exclusive
research collaboration agreement with Biogen International GmbH, (Biogen). Under the agreement, we and Biogen have agreed to collaborate
in the research and early clinical</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 181 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">development
of our a-syn PET tracer program for PD and other synucleinopathies, and a second program for the identification, research and
development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic
lateral sclerosis (ALS). In addition, we have agreed to share the costs of the collaboration, with Biogen primarily funding the
majority of research costs, subject to a cap, which includes an upfront technology access fee and funding toward research and
development personnel. We own all intellectual property rights to any invention relating to a-syn or TDP-43 PET tracers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Biogen is a customer. The Company has identified two performance obligations in our
Biogen collaboration: (i) technology access fee and (ii) research and development services. The Company determined the transaction
price based on the defined terms allocated to each performance obligation specified in the contract. In instances where the Company
is reimbursed for research and development contributions procured from third parties such as negotiated terms with clinical CROs,
AC Immune records revenues for such services as it is acting as a principal in procuring the goods or services. The Company has
the primary responsibility for fulfilling the promise to provide the specified good or service, it has inventory risk before transfer
to the customer and it has discretion in negotiating the price with third parties. For other research and development services,
revenues are recognized as work is performed, which correspond with and best depict the transfer of control to the customer in
line with the terms outlined in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, the Company has recognized nil, CHF 1.1 million and CHF 4.0 million, respectively, from this arrangement. This collaboration
ended in April 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><B>12.2
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Grants from the Michael J. Fox Foundation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In Q3 2017, we
formally signed a grant continuation with the MJFF. This grant provides funds for the development of PET tracers for pathological
forms of the protein alpha-synuclein, to support the early diagnosis and clinical management of Parkinson&rsquo;s disease. We subsequently
signed two additional grants which facilitated the <FONT STYLE="background-color: white">execution of a first-in-human study for
a potential alpha-synuclein-PET tracer (PET tracer) with the current lead compound and to further develop the PET tracer.&nbsp;</FONT>The
Company retains its intellectual property rights for these alpha-synuclein-PET tracers. These grants concluded in Q2 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In May 2020, the
Company, as part of a joint arrangement with Sk&aring;ne University Hospital (Sk&aring;ne) in Sweden, was awarded a USD 3.2 (CHF
2.9) million grant from the MJFF&rsquo;s Ken Griffin Alpha-synuclein Imaging Competition. As part of this grant, AC Immune is eligible
to receive USD 2.5 (CHF 2.2) million directly from the MJFF. Sk&aring;ne will receive USD 0.7 (CHF 0.7) million of the total grant
directly from the MJFF over two years to conduct and support the clinical arm of the project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The MJFF expects
that AC Immune and Sk&aring;ne will complete tasks according to the agreed timelines. AC Immune&rsquo;s funding is variable depending
on the satisfactory achievement of these specific tasks within a specific period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the years ended December 31, 2020,
2019 and 2018, the Company has recognized CHF 1.3 million, CHF 0.6 million and CHF 0.3 million, respectively, from these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><B>13.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses by category</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Operating expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">43,787</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">37,465</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">32,921</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,424</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,382</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,662</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,276</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">585</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">694</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">59,487</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,432</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,277</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 182 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended December 31, 2020, 2019
and 2018, the Company incurred CHF 59.5 million, CHF 50.4 million and CHF 44.3 million in research and development expenses, respectively.
These increases are predominantly driven by increases in investments in our research and development projects and full-time equivalents
(FTEs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended December 31, 2020, 2019
and 2018, the Company had 115.3, 102.7 and 87 FTEs in research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>General and administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Operating expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,471</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,637</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,903</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,274</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,172</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,740</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,812</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,249</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,824</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,557</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,058</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,467</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended December 31, 2020, 2019
and 2018, the Company incurred CHF 18.6 million, CHF 16.1 million and CHF 12.5 million in general and administrative expenses,
respectively. These increases are predominantly driven by increases in full-time equivalents (FTEs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended December 31, 2020, 2019
and 2018, the Company had 26.7, 24.1 and 17 FTEs general and administrative functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Financial result, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Financial income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">78</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">303</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">127</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financial expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,926</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Change in fair value of conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,542</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exchange differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(555</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,013</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,194</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Finance result, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(661</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">906</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,401</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.3pt">Our financial income and expense primarily
consist of interest income and interest expense associated with our lease liabilities and prior convertible debt instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.3pt">For the year ended December 31, 2020, the
following items from 2019 did not repeat:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the CHF 4.5 million gain on the conversion feature
related to the Company&rsquo;s convertible loan due to Lilly in 2019;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>CHF 1.4 million in interest expenses related to effective
interest recorded to amortize the host debt per the convertible loan due to Lilly; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a CHF 1.2 million remeasurement loss related to the
settlement of the convertible loan.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related-party
transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For key management, including the board
of directors (seven individuals excluding the CEO) and the executive management (five individuals including the CEO), compensation
was as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 183 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Short-term employee benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,497</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,526</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,681</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Post-employment benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,578</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,155</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,683</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,289</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,896</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,524</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2018, as part of the Company&rsquo;s
subscription rights offering, a major shareholder and members of the board and executive management purchased an aggregate of 614,147
of the Company&rsquo;s common shares on the same basis and otherwise on the same terms as the other participants in such rights
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company recognized no income tax expense
or deferred tax asset or liability positions for the years ended December 31, 2020, 2019, and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The income tax expense for each year can
be reconciled to loss before tax as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Income/(loss) before income tax</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,441</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,194</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,507</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Income not subject to tax/(expenses) not deductible for tax purposes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">462</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(62</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">334</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effect of unused tax losses and tax offsets not recognized as deferred tax assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,979</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,132</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,173</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Effective income tax rate benefit/(expense)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The tax rate used for the 2020 reconciliations
above is the corporate tax rate of 13.6% (13.6% in 2019 and 20.6% in 2018) payable by corporate entities in the Canton of Vaud,
Switzerland on taxable profits under tax law in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Tax losses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">121,948</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">64,125</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">109,294</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Deductible temporary differences related to:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -19.85pt; padding-left: 39.7pt">Right-of-use assets and lease liabilities, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -19.85pt; padding-left: 39.7pt">Retirement benefit plan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,464</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,485</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,665</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">129,412</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">71,610</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">114,959</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 184 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Tax losses expiry dates are shown in the
table below:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Tax losses split by expiry date:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">16,566</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,338</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,628</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,231</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,231</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,868</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,894</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,894</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,894</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">December 31, 2027</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,824</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">121,948</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64,125</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">109,294</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The tax losses available for future offset
against taxable profits have increased by CHF 57.8&nbsp;million from 2019, representing the amount of tax losses that are additionally
available as an offset, subject to expiration as disclosed in the table above, against future taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Consistent with prior years, the Company
has not recorded any deferred tax assets in relation to the past tax losses available for offset against future profits as the
recognition criteria were not met at the balance sheet date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retirement benefit
plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company participates in a collective
foundation covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides
death or long-term disability benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contributions paid to the plan are computed
as a percentage of salary, adjusted for the age of the employee and shared approximately 47% and 53% by employee and employer,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This plan is governed by the Swiss Law
on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a separately
administered fund. The fund has the legal form of a foundation and it is governed by the board of trustees, which consists of an
equal number of employer and employee representatives. The board of trustees is responsible for the administration of the plan
assets and for the definition of the investment strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The collective foundation is governed by
a foundation board. The board is made up of an equal number of employee and employer representatives of the different affiliated
companies. The Company has no direct influence on the investment strategy of the foundation board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The assets are invested by the pension
plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore,
disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those
assets is not possible. Under the plan, both the Company and the employee share the costs equally. The structure of the plan and
the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest
risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized
these risks, as they are shared between a much greater number of participants. On leaving the Company, a departing employee&rsquo;s
retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This transfer
mechanism may result in pension payments varying considerably from year to year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The pension plan is exposed to Swiss inflation,
interest rate risks and changes in the life expectancy for pensioners. For accounting purposes under IFRS, the plan is treated
as a defined benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of January 1, 2019 the Company changed
from a fully insured plan to a plan for which the Company now bears investment and old age risks. The new plan has a higher statutory
coverage ratio, which led to an increase in plan assets of 10% (CHF 1.2 million) for the year ended December 31, 2019. The increase
is presented in Table B as part of the line &ldquo;Return on plan assets excluding interest income.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the status
of the defined benefit pension plan and the amount that is recognized in the balance sheet:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 185 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Defined benefit obligation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(30,213</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(26,624</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(17,942</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Fair value of plan assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,749</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,139</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,277</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liability</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,464</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,485</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,665</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following amounts have been recorded
as net pension cost in the statement of income:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Service cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,626</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,313</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,095</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(42</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(133</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net pension cost</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,655</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,375</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,130</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The changes in defined benefit obligation,
fair value of plan assets and unrecognized gains/(losses) are as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD><B>Change in defined benefit obligation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; font-weight: bold">Defined benefit obligation as of January 1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(26,624</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(17,942</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(14,278</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Service cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,626</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,313</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,095</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Interest cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(195</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in demographic assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,138</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Change in financial assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,171</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in experience assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(931</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,003</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(888</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Benefits deposited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,467</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,382</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,710</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Employees&rsquo; contributions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(851</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(756</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(621</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Defined benefit obligation as of December 31</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(30,213</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(26,624</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(17,942</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD><B>Change in fair value of plan assets</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; font-weight: bold">Fair value of plan assets as of January 1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">19,139</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">12,277</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9,352</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Employees&rsquo; contributions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">851</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">756</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Employer&rsquo;s contributions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">859</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">693</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Benefits deposited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,467</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,382</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,710</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Return on plan assets excluding interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">300</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,732</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(164</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Fair value of plan assets as of December 31</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,749</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,139</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,277</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Expected contributions by the employer
to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount
to approximately CHF 1.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 186 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: left; width: 0.25in"><B>C.</B></TD><TD><B>Change in net defined benefit liability</B></TD>
</TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; font-weight: bold">Net defined benefit liabilities as of January 1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,485</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,665</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,926</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net pension cost through statement of income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,655</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,375</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,130</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Remeasurement through other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(726</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,304</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Employer&rsquo;s contribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(950</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(859</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(693</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Net defined benefit liabilities as of December 31</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,464</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,485</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,665</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>D.</B></TD><TD><B>Change in other comprehensive loss</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; font-weight: bold">Other comprehensive loss as of January 1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(5,587</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(4,283</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(3,981</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of changes in demographic assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,138</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Effect of changes in financial assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,171</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of changes in experience assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(931</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,003</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(888</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Return on plan assets excluding interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">300</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,732</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(164</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Other comprehensive loss as of December 31</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,861</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,283</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The fair value of the plan assets is the
cash surrender value of the insurance with the insurance company (AXA). The investment strategy defined by the board of trustees
follows a conservative profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The plan assets are primarily held within
instruments with quoted market prices in an active market, with the exception of real estate and mortgages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The weighted-average duration of the defined
benefit obligation is 17.6 years and 19.3 years as of December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The actuarial assumptions used for the
calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December
31, 2020, 2019 and 2018, respectively, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.20</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.20</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.90</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate of future increase in compensations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Rate of future increase in current pensions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest rate on retirement savings capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Mortality and disability rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">BVG 2020-CMI</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">BVG 2015-CMI</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">BVG 2015G</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In defining the benefits, the minimum requirements
of the Swiss BVG and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum
retirement credits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A quantitative sensitivity analysis for
significant assumptions as of December&nbsp;31, 2020 is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Discount rate</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Future salary increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Future pension cost</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Interest rate on savings capital</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Assumptions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="31" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 9pt">In CHF thousands</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 20%; text-align: left">Potential defined benefit obligation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">27,740</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">33,080</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">30,912</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">29,519</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">31,652</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">28,916</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">31,070</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">29,405</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Decrease/(increase) from actual defined benefit obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,473</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,867</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(699</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">694</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,439</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,297</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(857</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">808</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 187 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A quantitative sensitivity analysis for
significant assumptions as of December&nbsp;31, 2019 is shown below:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Discount rate</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Future salary increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Future pension cost</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Interest rate on savings capital</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Assumptions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% increase</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">0.5% decrease</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="31" STYLE="font-size: 10pt; font-weight: bold; text-align: center">in CHF thousands</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 20%; text-align: left">Potential defined benefit obligation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">24,248</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">29,396</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">27,317</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">25,930</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">27,993</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">25,393</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">27,447</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">25,848</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Decrease/(increase) from actual defined benefit obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,376</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,772</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(693</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">694</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,369</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,231</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(823</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">776</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The sensitivity analyses above are subject
to limitations and have been determined based on a method that extrapolates the impact on net defined benefit obligation as a result
of reasonable changes in key assumptions occurring at the end of the reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>17.</B></TD><TD><B>Share-based compensation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Share-based option awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Through the year ended December 31, 2020,
there are equity-based instruments outstanding that the Company has granted under four different plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s 2016 Share Option and
Incentive Plan (SOIP) was approved by the shareholders at the ordinary shareholders' meeting in November 2016. The 2016 Plan authorizes
the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units,
unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.
The Company only grants equity-based instruments from the SOIP as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes equity-settled
share option grants since inception under each plan type:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">PLAN</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of options awarded (since inception)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting conditions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contractual life of options</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 21%; text-align: left">Share option plan A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">362,750</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 52%; text-align: left">At grant</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">15.5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share option plan B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">819,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">At grant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Share option plan C1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,775,250</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">4 years&rsquo; service from grant date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2016 SOIP:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Executives and directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,898,222</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">1 year, 3 year and 4 years&rsquo; service from the date of grant, quarterly and annually</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">Employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">989,279</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">4 years&rsquo; service from the date of grant, annually</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 188 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The number and weighted-average exercise
prices (in CHF) of options under the share option programs for Plans A, B, C1 and the 2016 SOIP are as follows:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average exercise price (CHF)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average remaining<BR> term (years)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%">Outstanding at January 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,359,891</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.09</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.8</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73,624</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.16</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Exercised during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(151,814</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">484,403</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.79</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Outstanding at December 31, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,618,856</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.25</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.3</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Exercisable at December 31, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">932,175</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.25</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.4</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Outstanding at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,618,856</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.25</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73,699</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.71</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Exercised during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(616,833</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,053,305</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.24</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Outstanding at December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,981,629</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.3</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Exercisable at December 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">602,218</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.94</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.5</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Outstanding at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,981,629</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.93</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.3</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53,591</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.03</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Expired during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,729</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.38</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exercised during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73,669</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,073,027</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.29</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Outstanding at December 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,900,667</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.90</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.2</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Exercisable at December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,099,015</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.49</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The outstanding stock options as of December
31, 2020 have the following range of exercise prices. In fiscal year 2018, we began to grant awards solely with USD denominated
exercise prices and discontinued granting awards with a CHF denominated exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Range of expiration dates</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Range of exercise prices</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-indent: -8.8pt; padding-left: 17.6pt">CHF 0.15</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">243,125</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2020&ndash;2026</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -8.8pt; padding-left: 17.6pt">CHF 9.53</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,646</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2027</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">USD 5.04 to USD 12.30</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,433,896</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">2028&ndash;2030</P></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding options</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,900,667</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The weighted-average exercise price for
options granted in 2020, 2019 and 2018 is USD 7.11 (CHF 6.29), USD 5.41 (CHF 5.24) and USD 9.97 (CHF 9.79), respectively. The range
of exercise prices for outstanding options was CHF 0.15 to CHF 9.53 for awards previously granted in CHF and USD 5.04 to USD 12.30
for awards granted in USD as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prior to the IPO, the exercise price was
set by the board of directors. The volatility is based on the historical trend of an appropriate sample of companies operating
in the pharmaceutical and biopharmaceutical industries. The risk-free interest rate is based on the CHF swap rate for the expected
life of the option. The weighted-average share price of common share options exercised in 2020 is USD 6.86 (CHF 6.07).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The weighted-average grant date fair values
of the options granted in 2020, 2019 and 2018 are USD 5.25 (CHF 4.65), USD 3.71 (CHF 3.59) and USD 6.66 (CHF 6.54), respectively.
The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining
the fair value of these awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Exercise price</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">USD 5.04-9.16</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">USD 5.15&ndash;5.54</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">USD 8.33&ndash;12.30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%">Share price (weighted average)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7.11</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.41</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9.87</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6 years</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6 years</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6 years</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 189 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Restricted share awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A summary of non-vested share awards (restricted
share and restricted share units) activity as of&nbsp;December&nbsp;31, 2020&nbsp;and changes during the year then ended is presented
below:&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Grantee type</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of non-vested share awards granted</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting conditions</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contractual life of non-vested share awards</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Restricted share units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 31%; text-indent: -9.35pt; padding-left: 18.15pt">Directors</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">83,864</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">1 year service from date of grant, annually</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.15pt">Executives</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,839</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">4 years&rsquo; service from the date of grant, quarterly</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Restricted share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,023</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">2.75 years&rsquo; service from date of grant, quarterly</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> non-vested shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average<BR> grant date fair value (CHF)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%">Non-vested at December 31, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">122,014</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9.59</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,673</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.48</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,371</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.43</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Vested during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56,671</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.60</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Non-vested at December 31, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">109,041</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9.51</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64,012</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.65</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Non-vested at December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,041</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.51</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Vested during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,278</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.51</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Non-vested at December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,763</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9.52</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">130,290</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.58</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Non-vested at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,763</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.52</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeited during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,828</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.47</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Expired during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,804</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.52</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exercised during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(84,638</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.51</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Granted during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Vested during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,269</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.52</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Non-vested at December 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,494</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9.51</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Vested and exercisable at December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">49,289</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.47</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company did not grant restricted share
awards in 2020 or 2019, respectively. The weighted-average grant date fair value of the restricted share awards granted (restricted
shares and restricted share units) was CHF 9.43 for the year ended December 31, 2018. The weighted-average grant date fair values
of the remaining non-vested share awards as of the respective year end (restricted shares and restricted share units) was CHF 9.51,
CHF 9.52 and CHF 9.51 for the years ended December 31, 2020, 2019 and 2018, respectively. These fair values of non-vested share
awards granted have been determined using a reasonable estimate of market value of the common stock on the date of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The expense charged against the income
statement was CHF 4.1 million, CHF 2.8 million and CHF 2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively.
The expense is revised by the Company based on the number of instruments that are expected to become exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>18.</B></TD><TD><B>Commitments and contingencies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the normal course of business,&nbsp;we
conduct product research and development programs through collaborative programs that include, among others, arrangements with
universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations.
As of December&nbsp;31, 2020, external research projects included in the schedule below for 2021 total CHF 24.7&nbsp;million that
have been committed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We lease our corporate, laboratory and
other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our
lease agreements have no termination clauses longer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 190 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">than a 12-month contractual notice period.
Since January 1, 2019, the Company has applied IFRS 16 and recognized a right-of-use asset for its leases, except for short-term
and low-value leases as indicated in Note 3<I>.</I> See &ldquo;Note 5. Right-of-use assets and lease liabilities&rdquo; for the
contractual undiscounted cash flows for lease obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 74%; text-align: left">Within 1 year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">25,072</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">19,907</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Between 1 and 3 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,885</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,993</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Between 3 and 5 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,816</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">More than 5 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,193</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,355</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">39,909</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>19.</B></TD><TD><B>Earnings per share</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands, except for share and per share data</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Basic income/(loss) per share (EPS):</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Net income/(loss) attributable to equity holders of the Company</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">45,442</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">Weighted-average number of shares outstanding to equity holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,900,212</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,603,611</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,838,228</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.8pt; padding-left: 17.6pt">Basic income/(loss) for the period attributable to equity holders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.64</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Diluted income/(loss) per share (EPS):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Numerator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Net income/(loss) attributable to equity holders of the Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,921</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,442</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,951</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Weighted-average number of shares outstanding to equity holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,900,212</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,603,611</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,838,228</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; text-indent: -8.8pt; padding-left: 17.6pt">Effect of dilutive securities from equity incentive plans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499,730</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.8pt; padding-left: 17.6pt">Weighted-average number of shares outstanding &ndash; diluted to equity holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,900,212</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,103,341</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,838,228</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.8pt; padding-left: 17.6pt">Diluted income/(loss) for the period attributable to equity holders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.86</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.64</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.82</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In periods for which we have a loss, basic
net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all
potentially dilutive in-the-money (i)&nbsp;share options and (ii) shares that were issued upon conversion of the convertible note
as their inclusion would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share
calculations because they would be anti-dilutive were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 61%; text-align: left">Share options issued and outstanding (in-the-money)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">412,191</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,081,836</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,472,589</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted share awards subject to future vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,418</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,041</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Convertible shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">911,261</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">440,609</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,993,097</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,581,630</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>20.</B></TD><TD><B>Financial instruments and risk management</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s activities expose it
to the following financial risks: market risk (foreign exchange and interest rate risk), credit risk and liquidity risk. The Company&rsquo;s
overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects
on the Company&rsquo;s financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 191 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table shows the carrying
amounts of financial assets and financial liabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Long-term financial assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">334</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">304</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Other current receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">329</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Short-term financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">160,893</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">193,587</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total financial assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">226,556</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">289,195</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Financial liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Long-term lease liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,780</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,813</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,184</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,085</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,797</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Short-term financing obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">652</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Short-term lease liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">442</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total financial liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,492</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,846</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Foreign exchange risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">The Company is exposed to foreign exchange
risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency
exposure is not hedged. However, the Company has a policy of matching its cash holdings to the currency structure of its expenses,
which means that the Company holds predominately CHF, with lesser balances of EUR and USD (see &ldquo;Note 6. Cash and cash equivalents
and financial assets&rdquo;). The Company recognized a loss of CHF 0.7 million, CHF 0.8 million and CHF 1.2 million for the years
ended December 31, 2020, 2019 and 2018, respectively, within &ldquo;Finance result, net.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2020, if the CHF had
strengthened/weakened by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would
have been lower/higher by CHF 0.8 million (2019: CHF 3.5 million), mainly as a result of foreign exchange gains/losses on predominantly
EUR/USD denominated cash and cash equivalents and short-term financial assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Interest rates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s CHF cash holdings (inclusive
of those held in short-term financial assets) are subject to negative interest rates at certain counterparty thresholds. As of
December&nbsp;31, 2020 if the interest rates charged by the counterparties had increased/decreased by 10%, the net income for the
period would have been higher/lower by less than CHF 0.1 million. Interest income and interest expense are recorded within finance
results, net in our statements of income/(loss).&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Credit risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company maintains a formal treasury
risk and investment management policy to limit counterparty credit risk. As of December 31, 2020, the Company&rsquo;s cash and
cash equivalents and short-term financial assets are held with four financial institutions, each with a high credit rating assigned
by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Trade
and other receivables are fully performing, not past due and not impaired (see &ldquo;Note 6. Cash and cash equivalents and financial
assets&rdquo; and &ldquo;Note 8. Other current receivables&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 192 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt"><A HREF="#toc" STYLE="font-weight: bold">Table of Contents</A></P><P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Liquidity risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inherent in the Company&rsquo;s business
are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts
will succeed. AC Immune&rsquo;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent
position and protection, (ii)&nbsp;enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries,
(iii)&nbsp;acquire and keep key personnel employed and (iv)&nbsp;acquire additional capital to support its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s approach of managing
liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position
on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 18 months. The Company
has CHF 2.2 million in trade and other payables, which are due within 12 months from the reporting date. Finally, as it relates
to the Company&rsquo;s lease liabilities please see &ldquo;Note 5. Right-of-use assets and lease liabilities&rdquo; for detail
of when corresponding lease liabilities are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital risk
management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s objectives when managing
capital are to safeguard the Company&rsquo;s ability to continue as a going concern and to preserve the capital on the required
statutory level in order to succeed in developing a cure against (i) AD, (ii) focused non-Alzheimer&rsquo;s neurodegenerative diseases
including NeuroOrphan indications and (iii) diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">Management has
evaluated subsequent events after the balance sheet date, through the issuance of these financial statements, for appropriate accounting
and disclosures. We raised USD 8.8 (CHF 8.0) million, net of sales agent commissions, from the sale 764,977 of our ordinary shares
pursuant to our ATM program in February 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 193; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>dp148007_ex0301.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit 3.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 2%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt; width: 47%">
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Articles
        of Association</P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: none">of</FONT></P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AC Immune SA<BR>
        (AC Immune AG)<BR>
        (AC Immune Ltd)</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>with registered office in </B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Ecublens (VD)</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The French version of these articles of
        association shall prevail.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 1%; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt; width: 47%">
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">STATUTS</P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>de</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AC Immune SA<BR>
        (AC Immune AG)<BR>
        (AC Immune Ltd)</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>avec si&egrave;ge &agrave;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Ecublens (VD)</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">La version fran&ccedil;aise de ces
statuts fait foi.&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 2%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 4pt 0pt 4pt 0.25in; text-indent: -0.25in; text-align: left; vertical-align: top; font-weight: bold; font-size: 10pt; text-transform: uppercase">I.&#9;&nbsp;&nbsp;&nbsp;Corporate Name, Principal Office, Duration and Purpose of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; vertical-align: top; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding: 4pt 0pt">
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-transform: uppercase; text-indent: -46.65pt">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rAISON
        socialE, Si&egrave;ge,</P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-transform: uppercase; text-indent: -46.65pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dur&eacute;e et BUT de la soci&eacute;t&eacute;</P>
        <P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-transform: uppercase; text-indent: -46.65pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        1&#9;Corporate Name and Duration </B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the name</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">AC Immune SA<BR>
        (AC Immune AG)<BR>
        (AC Immune Ltd)</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">there exists a Company pursuant to the provisions
        of Articles 620 <I>et seq.</I> of the Swiss Code of Obligations (CO) with registered office in Ecublens (VD). The duration of the
        Company is unlimited.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        1&#9;Raison sociale et dur&eacute;e</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sous la raison sociale</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">AC Immune SA<BR>
        (AC Immune AG)<BR>
        (AC Immune Ltd)</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">il existe une soci&eacute;t&eacute; conform&eacute;ment
        aux articles 620 ss. du Code des Obligations suisse (CO) ayant son si&egrave;ge &agrave; Ecublens (VD). La dur&eacute;e de la soci&eacute;t&eacute;
        est illimit&eacute;e.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 4pt 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        2&#9;Purpose</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The purpose of the Company is the research,
        study, development, manufacture, promotion, sale and marketing of products and substances within the pharmaceutical and nutrition
        industry as well as the purchase, sale and exploitation of patents and licenses in this field.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding: 4pt 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        2&#9;But</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le but de la soci&eacute;t&eacute; est la
        recherche, les &eacute;tudes, le d&eacute;veloppement, la fabrication, la promotion, la vente et le marketing des produits et des
        substances au sein de l'industrie pharmaceutique et de la nutrition ainsi que l'achat, la vente et l'exploitation de brevets et
        de licences dans ce domaine.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt; text-align: justify; font-size: 10pt">The Company may engage in any activities which are apt to favor the purpose of the Company directly or indirectly. The Company may also acquire and sell real estate.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 4pt 0pt; text-align: justify; font-size: 10pt">La soci&eacute;t&eacute; peut se livrer &agrave; des activit&eacute;s qui sont de nature &agrave; favoriser directement ou indirectement le but de la soci&eacute;t&eacute;. La soci&eacute;t&eacute; peut &eacute;galement acqu&eacute;rir et vendre des biens immobiliers.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 4pt 0pt; text-align: justify; font-size: 10pt">The Company may open branch offices in Switzerland and abroad and may also acquire participations in other companies.</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-weight: bold; text-indent: 0in; font-size: 10pt; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 4pt 0pt; text-align: justify; font-size: 10pt">La soci&eacute;t&eacute; peut ouvrir des succursales en Suisse et &agrave; l'&eacute;tranger et peut &eacute;galement acqu&eacute;rir des participations dans d'autres soci&eacute;t&eacute;s.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Company may provide securities to its subsidiaries and supply guarantees.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">La soci&eacute;t&eacute; peut fournir des titres &agrave; ses filiales et des garanties d'approvisionnement.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 4pt 0pt 4pt 0.25in; text-indent: -0.25in; text-align: left; vertical-align: top; font-weight: bold; font-size: 10pt; text-transform: uppercase">II.&#9;&nbsp;&nbsp;Share Capital and Shares </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">II.&#9;&nbsp;&nbsp;&nbsp;Capital-actions et actions </TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        3&#9;Share Capital and Shares</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Share Capital of the Company is CHF&nbsp;1'537'748.98.
        It is divided into 76'887'449 registered shares with a nominal value of CHF 0.02 each, fully paid-in.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        3&#9;Capital-actions et actions</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le capital-actions de la soci&eacute;t&eacute;
        se monte &agrave; CHF&nbsp;1'537'748.98. Il est divis&eacute; en 76'887'449 actions nominatives d'une valeur nominale de CHF 0.02
        chacune, enti&egrave;rement lib&eacute;r&eacute;es.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt"><B>Art. 3a&#9;Authorized Capital Increase of Share Capital</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-left: 0.25in; text-indent: -0.25in; text-align: left; padding-bottom: 4pt"><B>Art.
    3a&#9;Augmentation autoris&eacute;e du capital-actions</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Board of Directors is authorized to increase the share capital, in one or several steps until 27 June 2022, by a maximum amount of CHF 190'000 by issuing a maximum of 9'500'000 registered shares with a par value of CHF 0.02 each, to be fully paid up. An increase of the share capital (i) by means of an offering underwritten by a financial institution, a syndicate or another third party or third parties, followed by an offer to the then-existing shareholders of the Company and (ii) in partial amounts shall also be permissible.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le conseil d'administration est autoris&eacute; &agrave; augmenter le capital-actions, en une ou plusieurs &eacute;tapes jusqu'au 27 juin 2022, d'un montant maximum de CHF 190'000 par l'&eacute;mission d'un nombre maximum de 9'500'000 actions nominatives d'une valeur nominale de CHF 0.02 chacune, &agrave; lib&eacute;rer enti&egrave;rement. Une augmentation de capital (i)&nbsp;par souscription d'actions par une institution financi&egrave;re, un syndicat ou un tiers ou des tiers, suivie par une souscription d'actions par les actionnaires de la soci&eacute;t&eacute; alors existants et (ii) par montants partiels, est &eacute;galement autoris&eacute;e.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Board of Directors shall determine the time of the issuance, the issue price, the manner in which the new registered shares have to be paid up, the date from which the registered shares carry the right to dividends, the conditions for the exercise of the preemptive rights and the allotment of preemptive rights that have not been exercised. The Board of Directors may allow the preemptive rights that have not been exercised to expire, or it may place with third parties such rights or registered shares, the preemptive rights of which have not been exercised, at market conditions or use them otherwise in the interest of the Company.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le conseil d'administration fixe la date d'&eacute;mission, le prix d'&eacute;mission, la mani&egrave;re de lib&eacute;rer les nouvelles actions nominatives, la date &agrave; partir de laquelle les actions nominatives donnent droit &agrave; un dividende, les conditions pour l'exercice des droits de souscription pr&eacute;f&eacute;rentiels et l'attribution des droits de souscription pr&eacute;f&eacute;rentiels qui n'ont pas &eacute;t&eacute; exerc&eacute;s. Le conseil d'administration peut autoriser que des droits de souscription pr&eacute;f&eacute;rentiels qui n'ont pas &eacute;t&eacute; exerc&eacute;s expirent ou attribuer &agrave; des tiers ces droits ou actions nominatives, dont les droits de souscription pr&eacute;f&eacute;rentiels n'ont pas &eacute;t&eacute; exerc&eacute;s, aux conditions du march&eacute; ou les utiliser autrement dans l'int&eacute;r&ecirc;t de la soci&eacute;t&eacute;.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Board of Directors is authorized to withdraw or limit the preemptive rights of the</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le conseil d'administration est autoris&eacute; &agrave; retirer ou de limiter les droits de souscription</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-left: 0pt; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">shareholders and to allot them to third
        parties:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">a)&nbsp;&nbsp;&nbsp;&nbsp;if
        the issue price of the new registered shares is determined by reference to the market price; or</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">b)&nbsp;&nbsp;&nbsp;&nbsp;for
        the acquisition of an enterprise, part of an enterprise or participations, or for the financing or refinancing of any of such acquisition,
        or in the event of share placement for the financing or refinancing of such placement; or</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">c)&nbsp;&nbsp;&nbsp;&nbsp;for
        purposes of broadening the shareholder constituency of the Company in certain financial or investor markets, for purposes of the
        participation of strategic partners, or in connection with the listing or registration of new registered shares on domestic or
        foreign stock exchanges; or</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">d)&nbsp;&nbsp;&nbsp;&nbsp;for
        purposes of granting an over-allotment option (Greenshoe) of up to 20% of the total number of registered shares in a placement
        or sale of registered shares to the respective initial purchaser(s) or underwriter(s); or<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">e)&#9;&#9;&nbsp;&nbsp;&nbsp;for
        raising of capital (including private placements) in a fast and flexible which probably could not be reached without the exclusion
        of the statutory pre-emptive right of the existing shareholders; or&#9;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
        other valid grounds in the sense of Article 652b para. 2 CO; or</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">g)&nbsp;&nbsp;&nbsp;&nbsp;following
        a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 33 <SUP>1</SUP>/<SUB>3
        </SUB>% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover
        offer recommended by the Board of Directors, or for the defense of an actual, threatened or potential takeover bid, in relation
        to which the Board of Directors, upon consultation with an independent financial adviser</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">pr&eacute;f&eacute;rentiels des actionnaires
        et de les attribuer &agrave; des tiers:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">a)&nbsp;&nbsp;&nbsp;&nbsp;si
        le prix d'&eacute;mission des nouvelles actions nominatives est d&eacute;termin&eacute; avec une r&eacute;f&eacute;rence au prix
        de march&eacute;; ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">b)&nbsp;&nbsp;&nbsp;&nbsp;pour
        l'acquisition d'une entreprise, part d'entreprise ou participation, ou pour le financement ou le refinancement de ladite acquisition,
        ou en cas de placement d'actions pour le financement ou le refinancement dudit placement; ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">c)&nbsp;&nbsp;&nbsp;&nbsp;pour
        l'&eacute;largissement de la base des actionnaires de la soci&eacute;t&eacute; dans certains march&eacute;s financiers ou d'investissement,
        afin de permettre une participation de partenaires strat&eacute;giques, ou dans le cas de cotation ou d'enregistrement de nouvelles
        actions nominatives aux bourses nationales ou &eacute;trang&egrave;res; ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">d)&nbsp;&nbsp;&nbsp;&nbsp;pour
        octroyer une option de surallocation (Greenshoe) d'un maximum de 20% du nombre total d'actions nominatives dans un placement ou
        une vente d'actions nominatives &agrave; l'/des acheteur(s) initial(s) ou du/des souscripteur(s) respectif(s); ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">e)&#9;&#9;&nbsp;&nbsp;pour
        lever des capitaux (y compris des placements priv&eacute;s) dans un d&eacute;lai rapide et flexible, ce qui ne pourrait probablement
        pas &ecirc;tre r&eacute;alis&eacute; sans l'exclusion du droit pr&eacute;f&eacute;rentiel de souscription statuaire des actionnaires
        existants; ou&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pour
        d'autres motifs valables au sens de l'article 652b al. 2 CO; ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">g)&nbsp;&nbsp;&nbsp;&nbsp;suite
        &agrave; l'accumulation par un actionnaire ou un groupe d'actionnaires agissant de concert de participations sup&eacute;rieures
        &agrave; 33 <SUP>1</SUP>/<SUB>3 </SUB>% du capital-actions inscrit au registre du commerce sans avoir soumis aux autres actionnaires
        une offre publique d'achat recommand&eacute;e par le conseil d'administration, ou pour la d&eacute;fense d'une offre publique d'achat
        r&eacute;elle, imminente ou potentielle, pour laquelle le conseil d'administration, apr&egrave;s consultation avec un conseiller
        financier</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-left: 0.25in; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt">retained by it, has not recommended to the shareholders acceptance on the basis that the Board of Directors has not found the takeover bid to be financially fair to the shareholders.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0in; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-left: 0.25in; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt">ind&eacute;pendant retenu par lui, n'a pas recommand&eacute; l'acceptation aux actionnaires car il a estim&eacute; que l'offre publique d'achat n'&eacute;tait pas financi&egrave;rement &eacute;quitable pour les actionnaires.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">The acquisition of registered shares out of authorized capital increase of share capital for general purposes and any transfers of registered shares shall be subject to the restrictions specified in Article 4 of the Articles of Association.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0in; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">L'acquisition d'actions nominatives dans le cadre d'une augmentation autoris&eacute;e du capital-actions &agrave; des fins g&eacute;n&eacute;rales et les transferts d'actions nominatives sont soumis aux restrictions pr&eacute;vues &agrave; l'article 4 des statuts.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 49.65pt; text-indent: -49.65pt; text-align: left; padding-bottom: 4pt"><B>Art. 3b &#9;&nbsp;&nbsp;&nbsp;&nbsp;Conditional Capital Increase for Bonds and Similar Debt Instruments</B></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0in; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 46.65pt; text-indent: -46.65pt; text-align: justify; padding-bottom: 4pt"><B>Art. 3b &#9;Augmentation conditionnelle du capital-actions pour les obligations et instruments de dettes similaire</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">The share capital of the Company shall be increased by a maximum amount of <BR>
CHF 91'560.94 through the issue of a maximum of 4'578'047 registered shares, payable in full, each with a nominal value of CHF&nbsp;0.02 through the exercise of conversion and/or option or warrant rights granted in connection with bonds or similar instruments, issued or to be issued by the Company or by subsidiaries of the Company, including convertible debt instruments. </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0in; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">Le capital-actions de la soci&eacute;t&eacute; peut &ecirc;tre augment&eacute; d'un montant maximum de CHF 91'560.94 par l'&eacute;mission d'un maximum de 4'578'047 actions nominatives, d'une valeur nominale de CHF&nbsp;0.02 chacune, &agrave; lib&eacute;rer enti&egrave;rement, suite &agrave; l'exercice de droits de conversion et/ou d'option ou de bons de souscription accord&eacute;s en relation avec des obligations ou d'instruments similaires, &eacute;mis ou devant &ecirc;tre &eacute;mis par la soci&eacute;t&eacute; ou par des filiales de la soci&eacute;t&eacute;, y compris les instruments d'emprunt convertibles.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">Shareholders' subscription rights are excluded. Shareholders' advance subscription rights with regard to the new bonds or similar instruments may be restricted or excluded by decision of the Board of Directors in order to finance or re-finance the acquisition of companies, parts of companies or holdings, or new investments planned by the Company, or in order to issue convertible bonds and warrants on the international capital markets or through private placement. If advance subscription rights are excluded, then (1) the instruments are to be placed at market conditions, (2) the exercise period is not to exceed ten years from the date of issue for warrants and twenty years for conversion rights and (3) the conversion or exercise price for the new shares is to be set at least in line </TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0in; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt">Le droit de souscription pr&eacute;f&eacute;rentiel des actionnaires est exclu. Les droits de souscription pr&eacute;f&eacute;rentiels pr&eacute;alables des actionnaires &agrave; l'&eacute;gard des nouvelles obligations ou instruments similaires peuvent &ecirc;tre limit&eacute;s ou exclus par d&eacute;cision du conseil d'administration afin de financer ou de refinancer l'acquisition d'entreprises, parts d'entreprises ou de holdings, ou de nouveaux investissements pr&eacute;vus par la soci&eacute;t&eacute;, ou en vue d'&eacute;mettre des obligations convertibles et des bons de souscription sur les march&eacute;s internationaux de capitaux ou par placement priv&eacute;. Si les droits de souscription pr&eacute;f&eacute;rentiels pr&eacute;alables sont exclus, (1) les instruments doivent &ecirc;tre attribu&eacute;s aux conditions du march&eacute;, (2) la p&eacute;riode d'exercice ne doit pas d&eacute;passer dix ans &agrave; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">with the market conditions prevailing at the date on which the instruments are issued. The respective holders of conversion and/or option or warrant rights are entitled to subscribe the new shares.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">partir de la date d'&eacute;mission des bons de souscription et vingt ans pour les droits de conversion et (3) le prix de conversion ou d'exercice des actions nouvelles doit &ecirc;tre fix&eacute; au moins aux conditions du march&eacute; pr&eacute;valant &agrave; la date &agrave; laquelle les instruments sont &eacute;mis. Les d&eacute;tenteurs respectifs de droits de conversion et/ou option ou de bons de souscription ont le droit de souscrire les nouvelles actions.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The acquisition of registered shares through the exercise of conversion rights or warrants and any transfers of registered shares shall be subject to the restrictions specified in Article 4 of the Articles of Association.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">L'acquisition d'actions nominatives par l'exercice de droits ou de bons de conversion et les transferts d'actions nominatives sont assujetties aux restrictions pr&eacute;vues par l'article 4 des statuts.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt"><B>Art. 3c&#9;Conditional Share Capital Increase for Employee Benefit Plans</B></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt"><B>Art. 3c&#9;Augmentation conditionnelle du capital-actions pour les plans d'avantages sociaux </B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The share capital of the Company shall be increased by an amount not exceeding CHF&nbsp;65'954.32 through the issue of a maximum of 3'297'716 &nbsp;registered shares, payable in full, each with a nominal value of CHF 0.02, in connection with the exercise of option rights granted to any employee of the Company or a subsidiary, and any consultant, members of the Board of Directors, or other person providing services to the Company or a subsidiary.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le capital social de la soci&eacute;t&eacute; sera augment&eacute; d'un montant ne d&eacute;passant pas CHF&nbsp;65'954.32 par l'&eacute;mission d'un maximum de 3'297'716 actions nominatives, enti&egrave;rement lib&eacute;r&eacute;es, chacune avec une valeur nominale de CHF 0.02, dans le cadre de l'exercice de droits d'option accord&eacute;s &agrave; tout employ&eacute; de la Soci&eacute;t&eacute; ou d'une succursale, et &agrave; tout consultant, aux membres du conseil d'administration, ou &agrave; d'autres personnes fournissant des services en faveur de la Soci&eacute;t&eacute; ou d'une filiale.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Shareholders' subscription rights shall be excluded with regard to these shares. These new registered shares may be issued at a price below the current market price. The Board of Directors shall specify the precise conditions of issue including the issue price of the shares.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le droit de souscription pr&eacute;f&eacute;rentiel des actionnaires est exclu &agrave; l'&eacute;gard de ces actions. Ces nouvelles actions nominatives peuvent &ecirc;tre &eacute;mises &agrave; un prix inf&eacute;rieur au prix du march&eacute; actuel. Le conseil d'administration doit pr&eacute;ciser les conditions pr&eacute;cises d'&eacute;mission, y compris le prix d'&eacute;mission des actions.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The acquisition of registered shares in connection with employee participation and any further transfers of registered shares shall be subject to the restrictions specified in Article 4 of the Articles of Association.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">L'acquisition d'actions nominatives dans le cadre de la participation des employ&eacute;s et d'autres transferts d'actions nominatives sont soumis aux restrictions pr&eacute;vues &agrave; l'article 4 des statuts.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        4&#9;Share Register</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company shall maintain a share register
        in which it shall register the name, first name and place of residence (in case of legal persons the place of incorporation) of
        the owners and usufructuaries of its registered shares. Natural and legal persons as well as legal representatives of minors etc.
        entitled by law to the voting rights of a share which they do not own will be noted in the share register upon request.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        4&#9;Registre des actions</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La soci&eacute;t&eacute; tient un registre
        des actions nominatives, dans lequel sont inscrits le nom, le pr&eacute;nom et l'adresse (dans le cas d'une personne morale, le
        si&egrave;ge) des propri&eacute;taires et des usufruitiers des actions. Les personnes physiques et morales ainsi que les repr&eacute;sentants
        l&eacute;gaux des mineurs etc. autoris&eacute;s par la loi &agrave; voter alors qu'ils ne sont pas propri&eacute;taires des actions
        seront, sur demande, inscrits dans le registre des actions.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Upon request, acquirers of shares will be registered in the share register without limitation as shareholders if they expressly certify that they acquired the shares in their own name and for their own account.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Sur demande, les acqu&eacute;reurs d'actions seront inscrits dans le registre des actions sans limitation comme actionnaires s'ils attestent express&eacute;ment qu'ils ont acquis les actions en leur propre nom et pour leur propre compte.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Persons who do not expressly declare in the registration application that they are holding the shares on their own account (thereafter: nominees) shall forthwith be entered on the share register as shareholders with voting rights up to a maximum of 3 percent of the share capital. Beyond that limit, registered shares of nominees shall only be entered as voting if the nominees in question confirm in writing that they are willing to disclose the names, addresses and shareholdings of the persons on whose account they hold 0.5 percent or more of the share capital. The Board of Directors concludes agreements with nominees that among other things govern the representation of shareholders and the voting rights.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Les personnes qui ne d&eacute;clarent pas express&eacute;ment dans la demande d'inscription qu'ils d&eacute;tiennent les actions pour leur propre compte (par la suite: les candidats) doivent imm&eacute;diatement &ecirc;tre inscrits dans le registre des actions comme actionnaires avec droit de vote pour un maximum de 3 pour cent du capital-actions. Au-del&agrave; de cette limite, les actions nominatives des candidats ne sont inscrites avec droit de vote que si les candidats en question confirment par &eacute;crit qu'ils sont pr&ecirc;ts &agrave; divulguer les noms, adresses et participations des personnes pour le compte desquelles ils d&eacute;tiennent 0,5 pour cent ou plus du capital-actions. Le conseil d'administration conclut des accords avec les candidats qui, entre autres choses, r&eacute;gissent la repr&eacute;sentation des actionnaires et des droits de vote.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">After hearing the registered shareholder or nominee, the Board of Directors may remove entries in the share register with retroactive effect as per the date of entry, if such entry was based on false information. The party affected must be informed of such removal immediately.</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Apr&egrave;s avoir entendu l'actionnaire enregistr&eacute; ou le candidat, le conseil d'administration peut supprimer des inscriptions dans le registre des actions avec effet r&eacute;troactif &agrave; la date d'inscription, si cette inscription &eacute;tait bas&eacute;e sur de fausses informations. La partie touch&eacute;e doit &ecirc;tre imm&eacute;diatement inform&eacute;e de cette suppression. </TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No individual or legal entity may, directly
        or indirectly, formally, constructively or beneficially own (as defined in the next paragraph below) or otherwise control voting
        rights (&quot;Controlled Shares&quot;) with respect to 33 <SUP>1</SUP>/<SUB>3</SUB> % or more of the registered share capital recorded
        in the Commercial Register except if such individual or legal entity has submitted prior to the acquisition of such Controlled
        Shares an orderly tender offer to all shareholders with a minimum price of the higher of (i) the volume weighted average price
        of the last 60 trading days prior to the publication of the tender offer or (ii) the highest price paid by such individual or legal
        entity in the 12 months preceding to the publication of the tender offer. Those associated through capital, voting power, joint
        management or in any other way, or joining for the acquisition of shares, shall be regarded as one person. The registered shares
        exceeding the limit of 33 <SUP>1</SUP>/<SUB>3</SUB> % and not benefiting from the exemption regarding a tender offer shall be entered
        in the share register as shares without voting rights.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Aucune personne physique ou morale ne peut, directement ou indirectement, formellement ou implicitement d&eacute;tenir &agrave; son profit (comme d&eacute;fini dans le paragraphe ci-dessous) ou, d'une autre mani&egrave;re, contr&ocirc;ler le droit de vote (les &quot;Actions Contr&ocirc;l&eacute;es&quot;) de 33 <SUP>1</SUP>/<SUB>3</SUB> % ou plus du capital-actions nominatif tel qu'inscrit au registre du commerce sauf si cette personne physique ou morale a pr&eacute;sent&eacute; avant l'acquisition de ces Actions Contr&ocirc;l&eacute;e une offre publique d'achat en bonne et due forme &agrave; tous les actionnaires &agrave; un prix minimum &eacute;quivalent au montant le plus &eacute;lev&eacute; entre (i) le cours moyen pond&eacute;r&eacute; en fonction du volume des 60 derniers jours de bourse pr&eacute;c&eacute;dant la publication de l'offre publique d'achat et (ii) le plus haut prix pay&eacute; par cette personne physique ou morale dans les 12 mois pr&eacute;c&eacute;dant la publication de l'offre publique d'achat. Les personnes associ&eacute;es par le capital, les droits de vote, une gestion commune ou de toute autre mani&egrave;re, ou qui se joignent pour une acquisition d'actions, sont consid&eacute;r&eacute;es comme une personne. Les actions nominatives d&eacute;passant la limite de 33 <SUP>1</SUP>/<SUB>3</SUB> % et ne b&eacute;n&eacute;ficiant pas de l'exemption relative &agrave; une offre publique d'achat sont inscrites dans le registre des actions comme des actions sans droit de vote. </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the purposes of this Article 4, &quot;Controlled
        Shares&quot; in reference to any individual or entity means:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">(a)&nbsp;&nbsp;&nbsp;all
        shares of the Company directly, indirectly or constructively owned by such individual or entity; provided that<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i) &#9;&nbsp;&nbsp;shares
        owned, directly or indirectly, by or for a partnership, or trust or estate will be considered as being owned proportionately by
        its partners, or beneficiaries; and&#9;<BR></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;shares
        owned, directly or indirectly, by or for a corporation will be considered as being owned proportionately by any shareholder</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Aux fins du pr&eacute;sent article 4, Actions
        Contr&ocirc;l&eacute;es signifie en r&eacute;f&eacute;rence &agrave; toute personne physique ou morale:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">(a)&nbsp;&nbsp;&nbsp;toutes
        actions directement, indirectement ou implicitement d&eacute;tenues par cette personne physique ou morale, &agrave; condition que</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i) &nbsp;&nbsp;&nbsp;les
        actions d&eacute;tenues, directement ou indirectement, par ou pour un partenariat, une fiducie ou une communaut&eacute; d'h&eacute;ritiers
        sont consid&eacute;r&eacute;es comme &eacute;tant d&eacute;tenues proportionnellement par leurs partenaires ou b&eacute;n&eacute;ficiaires;
        et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;les
        actions d&eacute;tenues, directement ou indirectement, par ou pour une soci&eacute;t&eacute; seront consid&eacute;r&eacute;es comme
        &eacute;tant d&eacute;tenues proportionnellement</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;owning
        50% or more of the outstanding voting shares of such corporation; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;shares
        subject to options, warrants or other similar rights shall be deemed to be owned; and<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">(b)&nbsp;&nbsp;&nbsp;all
        shares of the Company directly, indirectly beneficially owned by such individual or entity; provided that<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i)&nbsp;&nbsp;&nbsp;a
        beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding,
        relationship, or otherwise alone or together with other such persons has or shares:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">(1)&nbsp;&nbsp;&nbsp;voting
        power which includes the power to vote, or to direct the voting of, such security; and/or</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">(2)&nbsp;&nbsp;&nbsp;investment
        power which includes the power to dispose, or to direct the disposition of, such security.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&nbsp;&nbsp;&nbsp;Any
        person who, directly or indirectly, creates or uses a trust, proxy, power of attorney, pooling arrangement or any other contract,
        arrangement, or device with the purpose or effect of divesting such person of beneficial ownership of shares of the Company or
        preventing the vesting of such beneficial ownership as part of a plan or scheme to evade the provisions of these articles of association
        shall be deemed to be the beneficial owner of such shares.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;A
        person shall be deemed to be the beneficial owner of shares if that person has the right to acquire beneficial ownership of such
        shares within 60 days, including but not limited to any right acquired: (A) through the exercise of any option, warrant or right;
        (B) through the</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;par tout
        actionnaire d&eacute;tenant 50% ou plus des actions avec droit de vote en circulation de cette soci&eacute;t&eacute;; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&#9;&nbsp;&nbsp;les
        actions sujettes &agrave; des options, des bons de souscription ou autres droits semblables sont r&eacute;put&eacute;es &ecirc;tre
        d&eacute;tenues; et&#9;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">(b)&nbsp;&nbsp;&nbsp;toutes
        actions de la soci&eacute;t&eacute; d&eacute;tenues directement, indirectement ou &agrave; son profit par cette personne physique
        ou morale, &agrave; condition que</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i)&#9;&nbsp;&nbsp;&nbsp;un
        b&eacute;n&eacute;ficiaire effectif d'un titre comprend toute personne qui, directement ou indirectement, par le biais d'un contrat,
        d'un accord, d'une entente, d'une relation, ou autrement, seul ou avec d'autres personnes a ou partage:&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">(1)&nbsp;&nbsp;&nbsp;le
        pouvoir de voter, y compris le pouvoir de voter ou de diriger le vote d'un tel titre; et/ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">(2)&nbsp;&nbsp;&nbsp;le
        pouvoir d'investir, y compris le pouvoir de disposer ou de diriger la disposition d'un tel titre.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&#9;&nbsp;&nbsp;Toute
        personne qui, directement ou indirectement, cr&eacute;e ou utilise une fiducie, une procuration, un pooling ou tout autre contrat,
        accord, ou un dispositif ayant pour objet ou pour effet de priver cette personne de la propri&eacute;t&eacute; effective des actions
        de la soci&eacute;t&eacute; ou d'en emp&ecirc;cher l'acquisition effective au moyen d'un plan ou programme visant &agrave; se soustraire
        aux dispositions de ces statuts est r&eacute;put&eacute;e &ecirc;tre le propri&eacute;taire effectif de ces actions.&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;Une
        personne est r&eacute;put&eacute;e &ecirc;tre propri&eacute;taire effective d'actions si cette personne a le droit d'acqu&eacute;rir
        la propri&eacute;t&eacute; effective de ces actions dans les 60 jours, y compris, mais pas limit&eacute; &agrave; un droit acquis:
        (A) au moyen de l'exercice d'une option, d'un bon ou d'un droit de</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;conversion
        of a security; (C) pursuant to the power to revoke a trust, discretionary account, or similar arrangement; or (D) pursuant to the
        automatic termination of a trust, discretionary account or similar arrangement.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The limit of 33 <SUP>1</SUP>/<SUB>3</SUB>
        % of the registered share capital also applies to the subscription for, or acquisition of, registered shares by exercising option
        or convertible rights arising from registered or bearer securities or any other securities issued by the Company or third parties,
        as well as by means of exercising purchased preemptive rights arising from either registered or bearer shares. The registered shares
        exceeding the limit of 33 <SUP>1</SUP>/<SUB>3</SUB> % shall be entered in the share register as shares without voting rights.&#9;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Board
        of Directors may in special cases approve exceptions to the above regulations. The Board of Directors is in addition authorized,
        after due consultation with the person concerned, to delete with retroactive effect entries in the share register which were effected
        on the basis of false information.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;souscription;
        (B) par la conversion d'un titre; (C) en vertu du pouvoir de r&eacute;voquer une fiducie, compte discr&eacute;tionnaire ou accord
        semblable; ou (D) conform&eacute;ment &agrave; la r&eacute;siliation automatique d'une fiducie, compte discr&eacute;tionnaire ou
        accord semblable.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La limite de 33 <SUP>1</SUP>/<SUB>3</SUB>
        % du capital-actions nominatif s'applique &eacute;galement &agrave; la souscription ou l'acquisition d'actions nominatives par
        l'exercice d'options ou de droits convertibles d&eacute;coulant de titres nominatifs ou au porteur ou d'autres titres &eacute;mis
        par la soci&eacute;t&eacute; ou par des tiers, ainsi que par le biais de l'exercice de droits de souscription pr&eacute;f&eacute;rentiels
        achet&eacute;s d&eacute;coulant d'actions nominatives ou au porteur. Les actions nominatives d&eacute;passant la limite de 33 <SUP>1</SUP>/<SUB>3</SUB>
        % sont inscrites dans le registre des actions comme des actions sans droit de vote.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Le conseil
        d'administration peut dans des cas particuliers approuver des exceptions aux r&egrave;gles pr&eacute;cit&eacute;es. Il est en outre
        autoris&eacute;, apr&egrave;s consultation avec la personne concern&eacute;e, de supprimer avec effet r&eacute;troactif des inscriptions
        du registre des actions qui ont &eacute;t&eacute; effectu&eacute;es sur la base de fausses informations.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
5&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Certificates and</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intermediated Securities</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company may issue registered shares
        in the form of single certificates, global certificates and uncertificated securities. Under the conditions set forth by statutory
        law, the Company may convert its registered shares from one form into another form at any time and without the approval of the
        shareholders.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        5&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificats d'actions et titres<BR>
        interm&eacute;di&eacute;s</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La soci&eacute;t&eacute; peut &eacute;mettre
        des actions nominatives sous forme de certificats individuels, de certificats globaux et de titres d&eacute;mat&eacute;rialis&eacute;s.
        Dans les conditions pr&eacute;vues par la loi, la soci&eacute;t&eacute; peut convertir ses actions nominatives d'une forme en une
        autre forme, &agrave; tout moment et sans l'approbation des actionnaires.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">The shareholder has no right to demand a conversion of the registered shares. Each shareholder may, however, at any time request a written confirmation from the Company of the registered shares held by such shareholder, as reflected in the share register.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">L'actionnaire n'a pas le droit d'exiger une conversion d'actions nominatives. Chaque actionnaire peut toutefois, &agrave; tout moment, demander une confirmation &eacute;crite de la soci&eacute;t&eacute; du nombres d'actions nominatives d&eacute;tenues par cet actionnaire telles qu'inscrites au registre du commerce.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The transfer of intermediated securities and the pledging of these intermediated securities shall be based on the provisions of the Swiss Federal Intermediated Securities Act. Transfer of propriety as collateral by means of written assignment are not permitted.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le transfert des titres interm&eacute;di&eacute;s et la mise en gage de ces titres interm&eacute;di&eacute;s suivent les dispositions de la Loi f&eacute;d&eacute;rale sur les titres interm&eacute;di&eacute;s. Le transfert de propri&eacute;t&eacute; &agrave; titre de s&ucirc;ret&eacute; par cession &eacute;crite n'est pas autoris&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        6&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Shareholders Right</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The shares are indivisible and the Company
        recognizes only one single representative per share.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: justify; text-indent: -46.65pt"><B>Art.
        6&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercice des droits des actionnaires</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: justify; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les actions sont indivisibles et la soci&eacute;t&eacute;
        ne reconna&icirc;t qu'un seul repr&eacute;sentant par action.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The right to vote and the other rights pertaining
        to a registered share may only be exercised by a shareholder, a usufructuary or a nominee who is registered with the right to vote
        in the share register and by persons who are entitled by law to the voting rights of a share.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le droit de vote et les autres droits relatifs &agrave; une action nominative ne peut &ecirc;tre exerc&eacute; que par un actionnaire, un usufruitier ou un candidat qui est inscrit avec le droit de vote dans le registre des actions et par des personnes autoris&eacute;es par la loi &agrave; exercer les droits de vote d'une action.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">III.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate structure</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">III.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sTRUCTURE DE LA SOCI&Eacute;T&Eacute;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        7&#9;&nbsp;&nbsp;Organization</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The corporate bodies are:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        General Meeting;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        Board of Directors;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        Auditors.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        7&#9;&nbsp;&nbsp;Organisation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les organes de la soci&eacute;t&eacute;
        sont:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;L'assembl&eacute;
        g&eacute;n&eacute;rale;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Le
        conseil d'administration;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l'organe
        de r&eacute;vision.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">IV.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THe General Meeting</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;L'assembl&eacute;e G&eacute;n&eacute;rale</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        8&#9;&nbsp;&nbsp;Powers</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The General Meeting is the supreme body
        of the Company. It has the following non delegable powers:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: justify; text-indent: -67.85pt"><B>Art.
        8&#9;&nbsp;&nbsp;Pouvoirs</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: justify; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'assembl&eacute;e g&eacute;n&eacute;rale
        des actionnaires est le pouvoir supr&ecirc;me de la soci&eacute;t&eacute;. Elle a les droits intransmissibles suivants:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; border-bottom: Black 1pt solid">a)&#9;&nbsp;&nbsp;&nbsp;to adopt and amend the Articles of Association (Articles 651a, 652g, 653g und 653i CO remain reserved);</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; border-bottom: Black 1pt solid">a)&#9;&nbsp;&nbsp;adapter et modifier les statuts (articles 651a, 652g, 653g et 653i CO sont r&eacute;serv&eacute;s); </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; width: 47%; padding-bottom: 4pt">b)&#9;&nbsp;&nbsp;to elect and remove the members of the Board of Directors, the Chairman of the Board of Directors, the members of the Compensation Committee, the Auditors and the Independent Proxy;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; width: 47%; padding-bottom: 4pt">b)&#9;&nbsp;&nbsp;nommer et r&eacute;voquer les membres du conseil d'administration, le pr&eacute;sident du conseil d'administration, les membres du comit&eacute; de r&eacute;mun&eacute;ration, l'organe de r&eacute;vision et le mandataire ind&eacute;pendant;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">c)&#9;&nbsp;&nbsp;to approve the management report and the annual accounts and to determine the allocation of profits, in particular with regard to dividends and bonus payments;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">c)&#9;&nbsp;&nbsp;approuver le rapport de gestion et les comptes annuels et d&eacute;terminer la r&eacute;partition des b&eacute;n&eacute;fices, en particulier en ce qui concerne les dividendes et les bonus;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">d)&#9;&nbsp;&nbsp;to discharge the members of the Board of Directors and of the Executive Committee;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">d)&#9;&nbsp;&nbsp;donner d&eacute;charge aux membres du conseil d'administration et au comit&eacute; ex&eacute;cutif;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">e)&#9;&nbsp;&nbsp;to approve the total compensation paid to the Board of Directors and the Executive Committee as per Articles 32 and 33 below;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">e)&#9;&nbsp;&nbsp;approuver la r&eacute;mun&eacute;ration totale vers&eacute;e au conseil d'administration et au comit&eacute; ex&eacute;cutif conform&eacute;ment aux l'articles 32 et 33 ci-dessous;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">f)&#9;&nbsp;&nbsp;&nbsp;to pass resolutions concerning all matters which are reserved to the authority of the General Meeting by law or by the Articles of Association.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.25pt; text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">f)&#9;&nbsp;&nbsp;&nbsp;prendre les d&eacute;cisions sur toutes les affaires qui sont attribu&eacute;es &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale par la loi ou les statuts.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt"><B>Art.
        9&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary General Meeting</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Ordinary General Meeting shall be held
        annually within six months after the close of the business year at such time and at such location, which may be within or outside
        Switzerland, as determined by the Board of Directors.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt"></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt"><B>Art.
        9&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assembl&eacute;e g&eacute;n&eacute;rale ordinaire</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt">L'assembl&eacute;e g&eacute;n&eacute;rale
        ordinaire aura lieu chaque ann&eacute;e dans les six mois qui suivent la cl&ocirc;ture de l'exercice &agrave; la date et &agrave;
        l'endroit, qui peut &ecirc;tre en ou hors de la Suisse, tel que d&eacute;termin&eacute; par le conseil d'administration.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        10&#9;&nbsp;&nbsp;&nbsp;&nbsp;Extraordinary General Meeting<BR>
        </B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Extraordinary General Meetings may be called
        by resolution of the General Meeting, the Auditors or the Board of Directors, or by shareholders with voting powers, provided they
        represent at least 10% of the share capital and who submit (a)(1) a request signed by such shareholder(s) that specifies the item(s)
        to be included on the agenda, (2) the respective proposals of the shareholders and (3) evidence of the required shareholdings recorded
        in the share register and (b) such other information as would be required to be included in a proxy statement</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        10&#9;&nbsp;&nbsp;&nbsp;&nbsp;Assembl&eacute;e g&eacute;n&eacute;rale extraordinaire</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les assembl&eacute;es g&eacute;n&eacute;rales
        extraordinaires peuvent &ecirc;tre convoqu&eacute;es par d&eacute;cision de l'assembl&eacute;e g&eacute;n&eacute;rale, l'organe
        de r&eacute;vision ou le conseil d'administration, ou par des actionnaires avec droit de vote, &agrave; condition qu'ils repr&eacute;sentent
        au moins 10% du capital-actions et qu'ils soumettent (a) (1) une demande sign&eacute;e par le(s)dit(s) actionnaire(s) qui sp&eacute;cifie
        les objets &agrave; faire figurer sur l'ordre du jour, (2) les propositions respectives de ces actionnaires et (3) la preuve des
        participations requises inscrites dans le registre des actions et (b) les autres</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt">pursuant to the rules of the country where the Company's shares are primarily listed.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt">informations qui doivent &ecirc;tre mentionn&eacute;es dans une d&eacute;claration (proxy statement) conform&eacute;ment aux r&egrave;gles du pays o&ugrave; les actions de la soci&eacute;t&eacute; sont principalement cot&eacute;es.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -49.65pt"><B>Art.
        11&#9;&nbsp;&nbsp;&nbsp;Notice and Agenda of Shareholders' Meetings</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Notice of a General Meeting of
Shareholders shall be given by the Board of Directors or, if necessary, by the Auditor, not later than twenty calendar days prior
to the date of the General Meeting of Shareholders. Notice of the General Meeting of Shareholders shall be given by way of a one-time
announcement in the official means of publication of the Company pursuant to Article 46 of these Articles of Association. The
notice period shall be deemed to have been observed if notice of the General Meeting of Shareholders is published in such official
means of publication, it being understood that the date of publication shall not be computed in the notice period. Shareholders
of record may in addition be informed of the General Meeting of Shareholders by ordinary mail or e-mail.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt"></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: justify; text-indent: -46.65pt"><B>Art.
        11&#9;&nbsp;&nbsp;&nbsp;Convocations et ordres du jour des assembl&eacute;es g&eacute;n&eacute;rales</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: justify; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt">L'assembl&eacute;e g&eacute;n&eacute;rale
        est convoqu&eacute;e par le conseil d'administration ou, si n&eacute;cessaire, par l'organe de r&eacute;vision, au moins 20 jours
        avant la tenue de l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires. La convocation &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale
        des actionnaires doit &ecirc;tre faite au moyen d'une seule publication conform&eacute;ment &agrave; l'article 46 de ces statuts.
        La p&eacute;riode de pr&eacute;avis sera r&eacute;put&eacute;e avoir &eacute;t&eacute; respect&eacute;e si la convocation &agrave;
        l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires est publi&eacute;e conform&eacute;ment &agrave; l'article 46 de ces
        statuts, &eacute;tant entendu que la date de publication ne doit pas &ecirc;tre calcul&eacute;e dans la p&eacute;riode de pr&eacute;avis.
        Les actionnaires inscrits peuvent en outre &ecirc;tre inform&eacute;s de l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires
        par courrier ordinaire ou par e-mail.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The notice of a General Meeting of Shareholders shall specify the items on the agenda and the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting of Shareholders be held or an item be included on the agenda, and, in the event of elections, the name(s) of the candidate(s) that has or have been put on the ballot for election.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">La convocation &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires doit pr&eacute;ciser les objets de l'ordre du jour et les propositions du conseil d'administration et l'/les actionnaire(s) qui a/ont demand&eacute; que l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires ait lieu ou qu'un objet soit inscrit &agrave; l'ordre du jour, et, dans le cas d'&eacute;lections, le/les nom(s) du/des candidat(s) qui a ou ont &eacute;t&eacute; mis sur le bulletin de vote pour l'&eacute;lection.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The Board of Directors shall state the matters on the agenda.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le conseil d'administration doit indiquer les objets de l'ordre du jour.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Shareholders who represent an aggregate of at least 10 percent of the share capital or together representing shares with a nominal value of 1 million Swiss francs may demand that an item be placed on the agenda of a General Meeting of Shareholders. A request for inclusion of an item on the agenda must be requested in writing delivered to or mailed and received at the registered office of the</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Les actionnaires qui repr&eacute;sentent un total d'au moins 10 pour cent du capital-actions ou qui repr&eacute;sentent ensemble une valeur nominale de CHF 1 million d'actions peuvent exiger qu'un objet soit inscrit &agrave; l'ordre du jour d'une assembl&eacute;e g&eacute;n&eacute;rale des actionnaires. Une demande d'inscription d'un objet &agrave; l'ordre du jour doit &ecirc;tre faite par &eacute;crit et remise ou envoy&eacute;e et re&ccedil;ue au si&egrave;ge de la soci&eacute;t&eacute; au</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Company at least 120 calendar days before the first anniversary of the date that the Company's proxy statement was released to shareholders in connection with the previous year's ordinary General Meeting of Shareholders. However, if no ordinary General Meeting of Shareholders was held in the previous year or if the date of the ordinary General Meeting of Shareholders has been changed by more than 30 calendar days from the date contemplated at the time of the previous year's proxy statement, request for inclusion of an item on the agenda must be requested not fewer than the later of (i) 150 calendar days prior to the date of the contemplated annual General Meeting or (ii) the date which is ten calendar days after the date of the first public announcement or other notification to the shareholders of the date of the contemplated annual General Meeting. To be timely for an extraordinary General Meeting, a shareholder's notice to the Secretary must be delivered to or mailed and received at the registered office of the Company not fewer than the later of (i) 120 calendar days before the date of the extraordinary General Meeting of Shareholders or (ii) the date which is ten calendar days after the date of the first public announcement or other notification to the shareholders of the date of the contemplated extraordinary General Meeting of Shareholders. </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">moins 120 jours avant le premier anniversaire de la date &agrave; laquelle la d&eacute;claration (proxy statement) de la Soci&eacute;t&eacute; a &eacute;t&eacute; communiqu&eacute;e aux actionnaires lors de l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire des actionnaires de l'ann&eacute;e pr&eacute;c&eacute;dente. Toutefois, si aucune assembl&eacute;e g&eacute;n&eacute;rale ordinaire des actionnaires n'a eu lieu l'ann&eacute;e pr&eacute;c&eacute;dente ou si la date de l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire des actionnaires a &eacute;t&eacute; modifi&eacute;e de plus de 30 jours calendaires &agrave; compter de la date pr&eacute;vue au moment de la d&eacute;claration (proxy statement) de l'ann&eacute;e pr&eacute;c&eacute;dente, une demande d'inscription d'un objet &agrave; l'ordre du jour doit &ecirc;tre demand&eacute;e au moins &agrave; la date la plus tardive entre (i) 150 jours calendaires avant la date de l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire envisag&eacute;e ou (ii) la date qui est dix jours calendaires plus tard que la date de la premi&egrave;re annonce publique ou autre notification aux actionnaires de la date envisag&eacute;e de l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire. Pour &ecirc;tre dans les d&eacute;lais pour une assembl&eacute;e g&eacute;n&eacute;rale extraordinaire, l'avis d'un actionnaire au secr&eacute;taire doit &ecirc;tre livr&eacute; ou envoy&eacute; et re&ccedil;u au si&egrave;ge de la soci&eacute;t&eacute; au moins &agrave; la date la plus tardive entre (i) 120 jours calendaires avant la date de l'assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires ou (ii) la date qui est dix jours calendaires plus tard que la date de la premi&egrave;re annonce publique ou autre notification aux actionnaires de la date envisag&eacute;e de l'assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">Each request for inclusion of an item on the agenda must include (i) a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting; (ii) the name and address, as they appear on the Company's register of shareholders, of the shareholder proposing such business; (iii) the number of shares of the Company which are beneficially owned by such shareholder; (iv) the dates upon which the shareholder acquired such shares; (v) documentary support for any claim of beneficial ownership; (vi) any material interest of such shareholder in such</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid"><FONT STYLE="color: #222222">Chaque demande d'inscription d'un objet &agrave; l'ordre du jour doit inclure (i) une br&egrave;ve description de l'affaire qui sera soumise &agrave; l'assembl&eacute;e et les raisons pour lesquelles cette affaire est soumise &agrave; l'assembl&eacute;e; (ii) le nom et l'adresse, tels qu'ils apparaissent dans le registre des actionnaires de la soci&eacute;t&eacute;, de l'/des actionnaire(s) proposant un tel objet; (iii) le nombre d'actions de la soci&eacute;t&eacute; effectivement d&eacute;tenues par (un) tel(s) actionnaire(s); (iv) les dates auxquelles l'/les actionnaire(s) a/ont acquis ces actions; (v) l'appui documentaire pour toute revendication de propri&eacute;t&eacute; effective; (vi) un</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">business; and (vii) a statement in support of the matter and, for proposals sought to be included in the Company's proxy statement, any other information required by Securities and Exchange Commission Rule &quot;14a-8&quot;.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt"><FONT STYLE="color: #222222">int&eacute;r&ecirc;t important de cet/ces actionnaire(s) par rapport &agrave; cet objet; et (vii) une d&eacute;claration &agrave; l'appui de cet objet et, pour les propositions devant &ecirc;tre incluses dans la d&eacute;claration (proxy statement) de la soci&eacute;t&eacute;, toute autre information requise par la Securities and Exchange Commission r&egrave;gle &quot;14a-8&quot;.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">In addition, if the shareholder intends to solicit proxies from the shareholders of the Company, such shareholder shall notify the Company of this intent in accordance with Securities and Exchange Commission Rule &quot;14a-4&quot; and/or Rule &quot;14a-8&quot;.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt"><FONT STYLE="color: #222222">En outre, si un actionnaire a l'intention de solliciter des procurations des actionnaires de la soci&eacute;t&eacute;, cet actionnaire doit en informer la soci&eacute;t&eacute; conform&eacute;ment aux dispositions de la Securities and Exchange Commission r&egrave;gle &quot;14a-4&quot; et &quot;14a-8&quot;.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">No resolution may be passed at a General Meeting of Shareholders concerning an item in relation to which due notice was not given. Proposals made during a General Meeting of Shareholders to (i) convene a extraordinary General Meeting or (ii) initiate a special investigation in accordance with article 697a of the Swiss Code of Obligations are not subject to the due notice requirement set forth herein.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Aucune d&eacute;cision ne peut &ecirc;tre adopt&eacute;e lors d'une assembl&eacute;e g&eacute;n&eacute;rale des actionnaires si un objet n'a pas &eacute;t&eacute; inscrit &agrave; l'ordre du jour dans le d&eacute;lai de pr&eacute;avis. Les propositions faites au cours d'une assembl&eacute;e g&eacute;n&eacute;rale des actionnaires pour (i) convoquer une assembl&eacute;e g&eacute;n&eacute;rale extraordinaire ou (ii) instituer un contr&ocirc;le sp&eacute;cial au sens de l'article 697a CO ne sont pas soumises &agrave; l'obligation d'inscription pr&eacute;vue dans ces statuts.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">No advance notice is required to propose motions on duly notified agenda items and to debate items without passing resolutions.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; text-indent: 0pt">Aucun pr&eacute;avis n'est n&eacute;cessaire pour proposer des motions sur les objets inscrits &agrave; l'ordre du jour ou d&eacute;battre desdits objets sans prendre de d&eacute;cisions.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 12&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Documentation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The annual business report, the compensation
        report and the Auditor's report must be submitted for examination by the shareholders at the registered office of the Company at
        least 20 days prior to the date of the Ordinary General Meeting. Each shareholder may request that a copy of this documentation
        be sent to him promptly by e-mail. Such right shall be included in the invitation to the General Meeting.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 12&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Documents</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le rapport de gestion annuel, le rapport
        de r&eacute;mun&eacute;ration et le rapport du r&eacute;viseur doivent &ecirc;tre pr&eacute;sent&eacute;s aux actionnaires pour
        examen au si&egrave;ge de la soci&eacute;t&eacute; au moins 20 jours avant la date de l'assembl&eacute;e g&eacute;n&eacute;rale
        ordinaire. Chaque actionnaire peut demander une copie de ces documents qui doivent lui &ecirc;tre envoy&eacute;s promptement par
        e-mail. Ce droit doit &ecirc;tre mentionn&eacute; dans l'invitation &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        13&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meeting of All Shareholders</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Shareholders or their proxies representing
        all shares issued may hold a General Meeting without observing the formalities required for calling a meeting, unless objection
        is raised. At such a meeting, discussions may be held and resolutions passed on all matters within the scope of the powers of a
        General Meeting for so long as the shareholders or proxies representing all shares issued are present.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        13&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assembl&eacute;e universelle</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les propri&eacute;taires ou les repr&eacute;sentants
        de la totalit&eacute; des actions peuvent, s'il n'y a pas d'opposition, tenir une assembl&eacute;e g&eacute;n&eacute;rale sans
        observer les formes pr&eacute;vues pour sa convocation. Aussi longtemps que les propri&eacute;taires ou les repr&eacute;sentants
        de la totalit&eacute; des actions sont pr&eacute;sents, cette assembl&eacute;e a le droit de d&eacute;lib&eacute;rer et de statuer
        valablement sur tous les objets qui sont du ressort de l'assembl&eacute;e g&eacute;n&eacute;rale.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        14&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chairman and Scrutineers</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Chairman of the Board of Directors shall
        preside over the General Meeting. In his absence, a member of the Board of Directors or another Chairman of the Meeting designated
        by the General Meeting shall preside.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        14&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pr&eacute;sident et scrutateurs</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'assembl&eacute;e g&eacute;n&eacute;rale
        est pr&eacute;sid&eacute;e par le pr&eacute;sident du conseil d'administration. En cas d'emp&ecirc;chement, un autre membre du
        conseil d'administration ou un pr&eacute;sident ad hoc nomm&eacute; par l'assembl&eacute;e g&eacute;n&eacute;rale pr&eacute;side
        celle-ci.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Chairman of the Meeting shall designate a Secretary and the scrutineers who need not be shareholders.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le pr&eacute;sident de l'assembl&eacute;e g&eacute;n&eacute;rale d&eacute;signe un secr&eacute;taire et les scrutateurs qui ne doivent pas n&eacute;cessairement &ecirc;tre actionnaires.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 15&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minutes</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Board of Directors is responsible for
        the keeping of the minutes of the Meeting, which shall state the number, kind, nominal value of shares represented by the shareholders,
        by the corporate bodies and by the independent proxy and gives information on resolutions passed, elections, requests for information
        and information as well as declarations given by the shareholders. The minutes shall be signed by the Chairman and the Secretary.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 15&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proc&egrave;s-verbal</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration est responsable
        de la tenue du proc&egrave;s-verbal de l'assembl&eacute;e, qui doit indiquer le nombre, le type, la valeur nominale des actions
        repr&eacute;sent&eacute;es par les actionnaires, par les organes sociaux et par le repr&eacute;sentant ind&eacute;pendant et donne
        des informations sur les d&eacute;cisions adopt&eacute;es, les &eacute;lections, les demandes de renseignements et les informations
        ainsi que les d&eacute;clarations faites par les actionnaires. Le proc&egrave;s-verbal est sign&eacute; par le pr&eacute;sident
        et le secr&eacute;taire.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The shareholders are entitled to inspect the minutes.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Les actionnaires ont le droit d'examiner le proc&egrave;s-verbal.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 16&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right to Vote</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Each share entitles to one vote.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 16&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Droit de vote</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Chaque action donne droit &agrave; une voix.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Each shareholder may be represented at a General Meeting by any person who is so authorized by a written proxy. A proxy need not be a shareholder.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Chaque actionnaire peut se faire repr&eacute;senter &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale par toute personne qui est autoris&eacute;e par une procuration &eacute;crite. Le repr&eacute;sentant ne doit pas n&eacute;cessairement &ecirc;tre un actionnaire.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Each shareholder may be represented by the Independent Proxy. The requirements regarding proxies and instructions are determined by the Board of Directors. </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Chaque actionnaire peut se faire repr&eacute;senter par le repr&eacute;sentant ind&eacute;pendant. Les exigences en mati&egrave;re de procurations et les instructions sont d&eacute;termin&eacute;es par le conseil d'administration.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Art. 17&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolutions and Elections</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All voting and elections are held openly
        or electronically. A written voting or election shall be held if instructed so by the Chairman or if decided by the General Meeting.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Art. 17&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D&eacute;cisions and &eacute;lections</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Tous votes et &eacute;lections sont tenus
        ouvertement ou par voie &eacute;lectronique. Sur instruction du pr&eacute;sident ou de l'assembl&eacute;e g&eacute;n&eacute;rale,
        un vote ou une &eacute;lection doit &ecirc;tre tenu par &eacute;crit.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The General Meeting shall pass its resolutions and carry out its elections with the simple majority of the votes cast regardless of abstentions and empty or invalid votes, unless statutory law or articles of association state otherwise. In the event of tie votes, the request shall be refused. The Chairman shall not have a casting vote.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Sous r&eacute;serve des dispositions imp&eacute;ratives de la loi ou des statuts, l'assembl&eacute;e g&eacute;n&eacute;rale prend ses d&eacute;cisions et proc&egrave;de aux &eacute;lections &agrave; la majorit&eacute; simple des voix &eacute;mises. En cas de partage &eacute;gal des voix, la requ&ecirc;te sera refus&eacute;e. Le pr&eacute;sident n'a pas voix pr&eacute;pond&eacute;rante.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A resolution of the General Meeting passed
        by at least two thirds of the represented share votes and the absolute majority of the represented shares par value is required
        for:<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;The
        cases listed in art. 704 para. 1 CO, i.e.:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        change of the company purpose;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        creation of shares with privileged voting rights;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the
        restriction of the transferability of registered shares;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iv)&#9;&nbsp;&nbsp;&nbsp;an
        increase of capital, authorized or subject to a condition;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;an
        increase of capital out of equity, against contribution in kind, or for the purpose of acquisition of assets and the granting of
        special benefits;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Une d&eacute;cision de l'assembl&eacute;e
        g&eacute;n&eacute;rale recueillant au moins les deux tiers des voix attribu&eacute;es aux actions repr&eacute;sent&eacute;es et
        la majorit&eacute; absolue des valeurs nominales repr&eacute;sent&eacute;es est n&eacute;cessaire pour:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;les
        cas &eacute;num&eacute;r&eacute;s dans l'art. 704 al. 1 CO, i.e.:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;la
        modification du but social;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;l'introduction
        d'actions &agrave; droit de vote privil&eacute;gi&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;la
        restriction de la transmissibilit&eacute; des actions nominatives;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(iv)&nbsp;&nbsp;&nbsp;l'augmentation
        autoris&eacute;e ou conditionnelle du capital-actions;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;l'augmentation
du capital-actions au moyen des fonds propres, contre apport en nature ou en vue d'une reprise de biens et l'octroi d'avantages
particuliers;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Each shareholder may be represented at a General Meeting by any person who is so authorized by a written proxy. A proxy need not be a shareholder.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Chaque actionnaire peut se faire repr&eacute;senter &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale par toute personne qui est autoris&eacute;e par une procuration &eacute;crite. Le repr&eacute;sentant ne doit pas n&eacute;cessairement &ecirc;tre un actionnaire.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Each shareholder may be represented by the Independent Proxy. The requirements regarding proxies and instructions are determined by the Board of Directors. </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Chaque actionnaire peut se faire repr&eacute;senter par le repr&eacute;sentant ind&eacute;pendant. Les exigences en mati&egrave;re de procurations et les instructions sont d&eacute;termin&eacute;es par le conseil d'administration.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Art. 17&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolutions and Elections</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All voting and elections are held openly
        or electronically. A written voting or election shall be held if instructed so by the Chairman or if decided by the General Meeting.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Art. 17&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D&eacute;cisions and &eacute;lections</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Tous votes et &eacute;lections sont tenus
        ouvertement ou par voie &eacute;lectronique. Sur instruction du pr&eacute;sident ou de l'assembl&eacute;e g&eacute;n&eacute;rale,
        un vote ou une &eacute;lection doit &ecirc;tre tenu par &eacute;crit.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The General Meeting shall pass its resolutions and carry out its elections with the simple majority of the votes cast regardless of abstentions and empty or invalid votes, unless statutory law or articles of association state otherwise. In the event of tie votes, the request shall be refused. The Chairman shall not have a casting vote.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Sous r&eacute;serve des dispositions imp&eacute;ratives de la loi ou des statuts, l'assembl&eacute;e g&eacute;n&eacute;rale prend ses d&eacute;cisions et proc&egrave;de aux &eacute;lections &agrave; la majorit&eacute; simple des voix &eacute;mises. En cas de partage &eacute;gal des voix, la requ&ecirc;te sera refus&eacute;e. Le pr&eacute;sident n'a pas voix pr&eacute;pond&eacute;rante.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A resolution of the General Meeting passed
        by at least two thirds of the represented share votes and the absolute majority of the represented shares par value is required
        for:<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;The
        cases listed in art. 704 para. 1 CO, i.e.:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        change of the company purpose;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        creation of shares with privileged voting rights;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the
        restriction of the transferability of registered shares;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(iv)&#9;&nbsp;&nbsp;&nbsp;an
        increase of capital, authorized or subject to a condition;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(v)&nbsp;&nbsp;&nbsp;
        an increase of capital out of equity, against contribution in kind, or for the purpose of acquisition of assets and the
        granting of special benefits;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Une d&eacute;cision de l'assembl&eacute;e
        g&eacute;n&eacute;rale recueillant au moins les deux tiers des voix attribu&eacute;es aux actions repr&eacute;sent&eacute;es et
        la majorit&eacute; absolue des valeurs nominales repr&eacute;sent&eacute;es est n&eacute;cessaire pour:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;les
        cas &eacute;num&eacute;r&eacute;s dans l'art. 704 al. 1 CO, i.e.:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;la
        modification du but social;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">(ii)&nbsp;&nbsp;&nbsp;l'introduction
        d'actions &agrave; droit de vote privil&eacute;gi&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 61.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(iii)&nbsp;&nbsp;&nbsp;la
        restriction de la transmissibilit&eacute; des actions nominatives;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(iv)&nbsp;&nbsp;&nbsp;l'augmentation
        autoris&eacute;e ou conditionnelle du capital-actions;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;l'augmentation
du capital-actions au moyen des fonds propres, contre apport en nature ou en vue d'une reprise de biens et l'octroi d'avantages
particuliers;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(vi)&nbsp;&nbsp;&nbsp;the
        limitation or withdrawal of subscription rights;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(vii)&nbsp;&nbsp;the
        change of the domicile of the Company; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">(viii)&nbsp;the
        liquidation of the Company;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;the
        merger, de-merger or conversion of the Company (subject to mandatory law);</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&#9;&nbsp;&nbsp;&nbsp;the
        alleviating or withdrawal of restrictions upon the transfer of registered shares;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">d)&nbsp;&nbsp;&nbsp;&nbsp;the
        conversion of registered shares into bearer shares and vice versa; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">the amendment or elimination of the provisions
        of Article 4 and 29 of the Articles of Association as well as those contained in this Article 17.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(vi)&nbsp;&nbsp;&nbsp;la
        limitation ou la suppression du droit de souscription pr&eacute;f&eacute;rentiel;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(vii)&nbsp;&nbsp;le
        transfert du si&egrave;ge de la soci&eacute;t&eacute;; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt">(viii)&nbsp;la
        dissolution de la soci&eacute;t&eacute;;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.6pt; text-align: justify; text-indent: -21.25pt"></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;la
        fusion, la scission ou la conversion de la soci&eacute;t&eacute; (sous r&eacute;serve des dispositions imp&eacute;ratives);</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l'att&eacute;nuation
        ou la suppression des restrictions sur le transfert des actions nominatives;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;la
        conversion d'actions nominatives en actions au porteur et vice versa; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">la modification ou la suppression des dispositions
        des articles 4 et 29 des statuts ainsi que ceux contenues dans le pr&eacute;sent article 17.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 18&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes on Compensation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Each year, the General Meeting separately
        approves the total maximum amounts proposed by the Board of Directors pursuant to Articles 32 and 33 of the Articles of Association
        for:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">a)&nbsp;&nbsp;&nbsp;the
        non-performance-related compensation of the Board of Directors for the next term of office;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">b)&#9;&nbsp;&nbsp;a
        possible additional compensation of the Board of Directors for the preceding business year;&#9;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">c)&nbsp;&nbsp;&nbsp;the
        non-performance-related compensation of the Executive Committee for the 12-month period starting on 1 July following the Ordinary
        General Meeting;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">d)&nbsp;&nbsp;&nbsp;the
        variable compensation for the Executive Committee for the current year;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in">e)&nbsp;&nbsp;&nbsp;the
        grant of options or shares in the Company to the Board of Directors and the Executive Committee.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: -0.25in"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 18&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes sur la r&eacute;mun&eacute;ration</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Chaque ann&eacute;e, l'assembl&eacute;e
        g&eacute;n&eacute;rale approuve s&eacute;par&eacute;ment les montants totaux maximaux propos&eacute;s par le conseil d'administration
        conform&eacute;ment aux articles 32 et 33 des statuts pour:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">a)&nbsp;&nbsp;&nbsp;la
        r&eacute;mun&eacute;ration non li&eacute;e &agrave; la performance du conseil d'administration pour le prochain mandat;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">b)&nbsp;&nbsp;&nbsp;une
        &eacute;ventuelle r&eacute;mun&eacute;ration suppl&eacute;mentaire du conseil d'administration pour l'exercice pr&eacute;c&eacute;dent;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">c)&nbsp;&nbsp;&nbsp;la
        r&eacute;mun&eacute;ration non li&eacute;e &agrave; la performance du comit&eacute; ex&eacute;cutif pour la p&eacute;riode de 12
        mois commen&ccedil;ant le 1er juillet apr&egrave;s chaque assembl&eacute;e g&eacute;n&eacute;rale ordinaire;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">d)&nbsp;&nbsp;&nbsp;la
r&eacute;mun&eacute;ration variable pour le comit&eacute; ex&eacute;cutif pour l'ann&eacute;e en cours;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 19.65pt; text-align: justify; text-indent: -0.25in">e)&nbsp;&nbsp;&nbsp;l'octroi
d'options ou d'actions de la soci&eacute;t&eacute; au conseil d'administration et au comit&eacute; ex&eacute;cutif.</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The respective total compensation amounts include social security and occupational pension contributions for the benefit of the members of the Board of Directors, the Executive Committee and the Company.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Les montants totaux de r&eacute;mun&eacute;ration respectifs comprennent la s&eacute;curit&eacute; sociale et les cotisations de retraite professionnelle au profit des membres du conseil d'administration, du comit&eacute; ex&eacute;cutif et de la soci&eacute;t&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">If the General Meeting refuses to approve a respective motion by the Board of Directors, the Board of Directors may either submit a new motion at the same meeting or determine a maximum total remuneration or several maximum partial remunerations, subject to the relevant principles of the compensation, or submit a new motion to the next General Meeting for approval. The Company may pay remunerations within the framework of the maximum total or partial remuneration and subject to the approval by the General Meeting.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Si l'assembl&eacute;e g&eacute;n&eacute;rale refuse d'approuver une motion soumise par le conseil d'administration, le conseil d'administration peut, soit pr&eacute;senter une nouvelle motion &agrave; la m&ecirc;me s&eacute;ance ou d&eacute;terminer une r&eacute;mun&eacute;ration maximale totale ou plusieurs r&eacute;mun&eacute;rations maximales partielles, sous r&eacute;serve des principes concernant la r&eacute;mun&eacute;ration, soit soumettre une nouvelle motion &agrave; la prochaine assembl&eacute;e g&eacute;n&eacute;rale pour approbation. La soci&eacute;t&eacute; peut verser des r&eacute;mun&eacute;rations dans le cadre de la r&eacute;mun&eacute;ration maximale totale ou partielle et sous r&eacute;serve de l'approbation par l'assembl&eacute;e g&eacute;n&eacute;rale.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 19&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent Proxy</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Independent Proxy shall be
elected by the Ordinary General Meeting for a term of one year until the end of the next Ordinary General Meeting. Re-election
is permitted. The Independent Proxy informs the Company about number, type, par value and category of the represented shares.
The Chairman of the Board discloses the information to the General Meeting. The other duties of the Independent Proxy are determined
by the applicable statutory provisions.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 19&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repr&eacute;sentant ind&eacute;pendant</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le repr&eacute;sentant ind&eacute;pendant
        est &eacute;lu par l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire pour une dur&eacute;e d'un an jusqu'&agrave; la fin de la
        prochaine assembl&eacute;e g&eacute;n&eacute;rale ordinaire. Une r&eacute;&eacute;lection est possible. Le repr&eacute;sentant
        ind&eacute;pendant informe la soci&eacute;t&eacute; sur le nombre, le type, la valeur nominale et la cat&eacute;gorie des actions
        repr&eacute;sent&eacute;es. Le pr&eacute;sident du conseil d'administration communique ces informations &agrave; l'assembl&eacute;e
        g&eacute;n&eacute;rale. Les autres fonctions du repr&eacute;sentant ind&eacute;pendant sont d&eacute;termin&eacute;es par les dispositions
        statutaires applicables.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; vertical-align: top; width: 47%; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">V.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board of directors</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; vertical-align: top; width: 1%; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">V.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conseil d'administration</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        20&#9;Number of Members, Term of Office</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Board of Directors shall consist of
        at least 3 and not more than 9 members. The chairman and the members of the Board of Directors are individually elected by the
        General Meeting for a term of one year until the end of the next Ordinary General Meeting, provided that he/she does not resign
        or is not replaced during his term.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        20&#9;Nombre de membres, dur&eacute;e de la fonction</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration se compose d'au
        minimum 3 et au maximum 9 membres. Le pr&eacute;sident et les membres du conseil d'administration sont &eacute;lus individuellement
        par l'assembl&eacute;e g&eacute;n&eacute;rale pour un mandat d'un an jusqu'&agrave; la fin de la prochaine assembl&eacute;e g&eacute;n&eacute;rale
        ordinaire, &agrave; condition qu'il/elle ne d&eacute;missionne pas ou ne soit pas remplac&eacute;(e) durant son mandat.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The members of the Board of Directors may be re-elected without limitation. The maximum age limit of members of the Board shall be 75 years. When a member of the Board of Directors reaches this age limit during his term of office, such term shall automatically extend to the next ordinary shareholders' meeting. The shareholders' meeting may resolve to grant an exception to the age limit.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Les membres du conseil d'administration peuvent &ecirc;tre r&eacute;&eacute;lus sans limitation. La limite d&rsquo;&acirc;ge des membres du conseil d'administration est fix&eacute;e &agrave; 75 ans. Lorsqu'un membre du conseil d'administration atteint cette limite d'&acirc;ge durant son mandat, ledit mandat sera automatiquement prolong&eacute; jusqu'&agrave; la prochaine assembl&eacute;e g&eacute;n&eacute;rale ordinaire. L'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires peut d&eacute;cider d'accorder une d&eacute;rogation &agrave; la limite d'&acirc;ge.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 21&#9;Constitution</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Subject to the powers of the General Meeting,
        the Board of Directors determines its own organization. It appoints a Secretary who needs not be a member of the Board of Directors.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 21&#9;Constitution</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sous r&eacute;serve des pouvoirs de l'assembl&eacute;e
        g&eacute;n&eacute;rale, le conseil d'administration d&eacute;termine sa propre organisation. Il nomme un secr&eacute;taire qui
        ne doit pas n&eacute;cessairement &ecirc;tre un membre du conseil d'administration.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 22&#9;Function, Organization</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">It is the Board of Director's duty to lead
        the Company and to supervise the management. The Board of Director represents the Company and may take decisions on all affairs
        which are not assigned to any other body of the Company by law, the Articles of Association or the organizational regulations.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 22&#9;Fonction, organisation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration exerce la direction
        de la soci&eacute;t&eacute; et en supervise la gestion. Le conseil d'administration repr&eacute;sente la soci&eacute;t&eacute;
        et peut prendre les d&eacute;cisions sur toutes les affaires qui ne sont pas attribu&eacute;es &agrave; un autre organe de la soci&eacute;t&eacute;
        par la loi, les statuts ou le r&egrave;glement d'organisation.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The Board of Directors shall enact the organizational regulations and arrange for the appropriate contractual relationships.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Le conseil d'administration &eacute;dicte le r&egrave;glement d'organisation et s'occupe des relations contractuelles appropri&eacute;es.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 23&#9;Powers</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Board of Directors has the following
        non-</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 23&#9;Pouvoirs</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration a les attributions</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">delegable and inalienable duties:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;the
        overall management of the company and the issuing of all necessary directives;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;determination
        of the company's organisation;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&nbsp;&nbsp;&nbsp;&nbsp;the
        organisation of the accounting, financial control and financial planning systems as required for management of the company;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">d)&nbsp;&nbsp;&nbsp;&nbsp;the
        appointment and dismissal of persons entrusted with managing and representing the company;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">e)&nbsp;&nbsp;&nbsp;&nbsp;overall
        supervision of the persons entrusted with managing the company, in particular with regard to compliance with the law, articles
        of association, operational regulations and directives;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compilation
        of the annual report, preparation for the general meeting and implementation of its resolutions;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">g)&nbsp;&nbsp;&nbsp;&nbsp;the
        preparation of the compensation report and to request approval by the General Meeting regarding compensation of the Board of Directors
        and the Executive Committee; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">h)&nbsp;&nbsp;&nbsp;&nbsp;notification
        of the court in the event that the company is overindebted.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">intransmissibles et inali&eacute;nables
        suivantes:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">a)&nbsp;&nbsp;&nbsp;exercer
        la haute direction de la soci&eacute;t&eacute; et &eacute;tablir les instructions n&eacute;cessaires;<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: left; text-indent: -18.25pt">b)&nbsp;&nbsp;&nbsp;fixer
        l'organisation;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: left; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">c)&nbsp;&nbsp;&nbsp;fixer
        les principes de la comptabilit&eacute; et du contr&ocirc;le financier ainsi que le plan financier pour autant que celui-ci soit
        n&eacute;cessaire &agrave; la gestion de la soci&eacute;t&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">d)&nbsp;&nbsp;&nbsp;nommer
        et r&eacute;voquer les personnes charg&eacute;es de la gestion et de la repr&eacute;sentation;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">e)&nbsp;&nbsp;&nbsp;exercer
        la haute surveillance sur les personnes charg&eacute;es de la gestion pour s'assurer notamment qu'elles observent la loi, les statuts,
        les r&egrave;glements et les instructions donn&eacute;es;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&eacute;tablir
        le rapport de gestion, pr&eacute;parer l'assembl&eacute;e g&eacute;n&eacute;rale et ex&eacute;cuter ses d&eacute;cisions;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">g)&nbsp;&nbsp;&nbsp;la
        pr&eacute;paration du rapport de r&eacute;mun&eacute;ration et de demander l'approbation par l'assembl&eacute;e g&eacute;n&eacute;rale
        en ce qui concerne la r&eacute;mun&eacute;ration du conseil d'administration et du comit&eacute; ex&eacute;cutif; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt">h)&nbsp;&nbsp;&nbsp;informer
        le juge en cas de surendettement.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify; text-indent: -18.25pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The board of directors may assign responsibility for preparing and implementing its resolutions or monitoring transactions to committees or individual members. It must ensure appropriate reporting to its members.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le conseil d'administration peut d&eacute;l&eacute;guer &agrave; un ou plusieurs membres, regroup&eacute;s en comit&eacute;s, la charge de pr&eacute;parer et d'ex&eacute;cuter ses d&eacute;cisions ou de surveiller certaines affaires. Il veille &agrave; ce que ses membres soient convenablement inform&eacute;s.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        24&#9;Representation of the Company</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Board of Directors shall assign the
        persons with signatory power for the company and the kind of signatory power.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        24&#9;Repr&eacute;sentation de la soci&eacute;t&eacute;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration nomme les personnes
        pouvant repr&eacute;senter la soci&eacute;t&eacute; ainsi que le mode de signature.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 25&#9;Delegation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Moreover, the Board of Directors is authorized
        to delegate, in part or entirely, the management and the representation of the Company, within the limits of the law, to one or
        more individual directors (Delegates) or to third parties pursuant to organizational regulations.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 25&#9;D&eacute;l&eacute;gation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">En outre, le conseil d'administration peut,
        dans les limites de la loi, d&eacute;l&eacute;guer, en partie ou enti&egrave;rement, la gestion et la repr&eacute;sentation de
        la soci&eacute;t&eacute; &agrave; un ou plusieurs administrateurs (d&eacute;l&eacute;gu&eacute;s) ou &agrave; des tiers conform&eacute;ment
        au r&egrave;glement d'organisation.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        26&#9;Meetings, Resolutions and Minutes</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The organization of the meetings, the presence
        quorum and the passing of resolutions of the Board of Directors is determined by the organizational regulations. No presence quorum
        is required for the approval of the capital increase.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        26&#9;R&eacute;unions, d&eacute;cisions et proc&egrave;s-verbal</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: -0.3pt">L'organisation
        des r&eacute;unions, le quorum de pr&eacute;sence et l'adoption de d&eacute;cisions du conseil d'administration sont pr&eacute;vus
        dans le r&egrave;glement d'organisation. Aucun quorum de pr&eacute;sence n'est n&eacute;cessaire pour l'approbation d'un rapport
        d'augmentation de capital.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: -0.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Resolutions may be passed via telephone or videoconference. Resolutions may also be passed by way of circulation, provided that no member requests oral deliberation.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; text-indent: 0pt"><FONT STYLE="color: #222222">Les d&eacute;cisions peuvent &ecirc;tre prises par t&eacute;l&eacute;phone ou par vid&eacute;oconf&eacute;rence. Les d&eacute;cisions peuvent &eacute;galement &ecirc;tre prises par voie de circulation, &agrave; condition qu'aucun membre ne demande une d&eacute;lib&eacute;ration orale.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Minutes are kept of the board's discussions and resolutions and signed by the chairman and the minute-taker.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; text-indent: 0pt">Les d&eacute;lib&eacute;rations et les d&eacute;cisions du conseil d'administration sont consign&eacute;es dans un proc&egrave;s-verbal sign&eacute; par le pr&eacute;sident et le r&eacute;dacteur du proc&egrave;s-verbal.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        27&#9;Right to information and inspection</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Any member of the board of directors
may request information on any company business.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        27&#9;Droit aux renseignements et &agrave; la consultation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt">Chaque membre du conseil
        d'administration a le droit d'obtenir des renseignements sur toutes les affaires de la soci&eacute;t&eacute;.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left; text-indent: -0.2pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Outside meetings, any member may request information from the persons entrusted with managing the company's business concerning the company's business performance and, with the chairman's authorisation, specific transactions.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; text-indent: 0pt">En dehors des s&eacute;ances, chaque membre du conseil d'administration peut exiger des personnes charg&eacute;es de la gestion des renseignements sur la marche de l'entreprise et, avec l'autorisation du pr&eacute;sident, sur des affaires d&eacute;termin&eacute;es.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">Where required for the performance of his duties, any member may request the chairman to have books of account and documents made available to him for inspection.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: left; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">Dans la mesure o&ugrave; cela est n&eacute;cessaire &agrave; l'accomplissement de ses t&acirc;ches, chaque membre du conseil d'administration peut demander au pr&eacute;sident la production des livres ou des dossiers.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">If the chairman refuses a request for information, a request to be heard or an application to inspect documents, the board of directors rules on the matter.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Si le pr&eacute;sident rejette une demande de renseignement, d'audition ou de consultation, le conseil d'administration tranche.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 28&#9;Compensation Committee</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Compensation Committee shall comprise
        at least 2 members. The members of the Compensation Committee shall be individually elected by the Ordinary General Meeting from
        among the members of the Board of Directors for a term of one year until the next Ordinary General Meeting. Re-election is permitted.
        The Compensation Committee has the following duties:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;to
        draw up principles for compensation of members of the Board of Directors and the Executive Committee and to submit them to the
        Board of Directors for approval;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&#9;&nbsp;&nbsp;&nbsp;&nbsp;to
        propose to the Board of Directors the resolution to be submitted to the Ordinary General Meeting for the maximum total compensation
        of the Board of Directors and Executive Committee;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&#9;&nbsp;&nbsp;&nbsp;&nbsp;subject
        to and within the bounds of the maximum compensation approved by the Ordinary General Meeting, to request approval by the Board
        of Directors of the individual remuneration packages to be paid to members of the Board of Directors and members of the Executive
        Committee;&#9;<BR>
        <BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        request approval by the Board of Directors regarding the determination of the compensation-related targets for the Executive Committee;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        request approval by the Board of Directors regarding the adjustments to the Articles of Association relating to remuneration; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        prepare the Compensation Report and submit it to the Board of Directors.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 28&#9;Comit&eacute; de r&eacute;mun&eacute;ration</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le comit&eacute; de r&eacute;mun&eacute;ration
        se compose d'au moins 2 membres. Les membres du comit&eacute; de r&eacute;mun&eacute;ration sont &eacute;lus par l'assembl&eacute;e
        g&eacute;n&eacute;rale ordinaire parmi les membres du conseil d'administration pour un mandat d'un an jusqu'&agrave; la prochaine
        assembl&eacute;e g&eacute;n&eacute;rale ordinaire. Une r&eacute;&eacute;lection est possible. Le comit&eacute; de r&eacute;mun&eacute;ration
        a les fonctions suivantes:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&eacute;laborer
        des principes de r&eacute;mun&eacute;ration des membres du conseil d'administration et du comit&eacute; ex&eacute;cutif et de les
        soumettre au conseil d'administration pour approbation;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;proposer
        au conseil d'administration la d&eacute;cision sera soumise &agrave; l'assembl&eacute;e g&eacute;n&eacute;rale ordinaire pour la
        r&eacute;mun&eacute;ration totale maximale du conseil d'administration et du comit&eacute; ex&eacute;cutif;<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sous
        r&eacute;serve et dans les limites de la r&eacute;mun&eacute;ration maximale approuv&eacute;e par l'assembl&eacute;e g&eacute;n&eacute;rale
        ordinaire, demander l'approbation du conseil d'administration quant aux paquets de r&eacute;mun&eacute;ration individuels devant
        &ecirc;tre vers&eacute;s aux membres du conseil d'administration et aux membres du comit&eacute; ex&eacute;cutif;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requ&eacute;rir
        l'approbation du conseil d'administration sur la fixation d'objectifs li&eacute;s &agrave; la r&eacute;mun&eacute;ration pour le
        comit&eacute; ex&eacute;cutif;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requ&eacute;rir
        l'approbation du conseil d'administration sur les adaptations des statuts relatives &agrave; la r&eacute;mun&eacute;ration; et<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pr&eacute;parer
le rapport de r&eacute;mun&eacute;ration et de le soumettre au conseil d'administration.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt"></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The Board of Directors shall set out any further duties and responsibilities vested on the Compensation Committee in the Company's Organizational Rules.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Le conseil d'administration fixe toutes les autres fonctions et responsabilit&eacute;s d&eacute;volues au comit&eacute; de r&eacute;mun&eacute;ration dans le r&egrave;glement d'organisation de la soci&eacute;t&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt"><B>Art. 29&#9;Indemnification</B></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt"><B>Art. 29&#9;Indemnisation</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">As far as is permissible under applicable law, the Company shall indemnify any current or former member of the Board of Directors, former members of the Executive Committee, or any person who is serving or has served at the request of the Company as a member of the Board of Directors or member of the Executive Committee (each individually, a &quot;Covered Person&quot;), against any expenses, including attorneys' fees, judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with any threatened, pending, or completed action, suit or proceeding, whether civil, criminal or administrative, to which he or she was, is, or is threatened to be made a party, or is otherwise involved (a &quot;Proceeding&quot;). This provision shall not indemnify any Covered Person against any liability arising out of (a) any fraud or dishonesty in the performance of such Covered Person's duty to the Company, or (b) such Covered Party's conscious, intentional or willful or grossly negligent breach of the obligation to act honestly and in good faith with a view to the best interests of the Company. Notwithstanding the preceding sentence, this section shall not extend to any person holding the office of auditor or special auditor of the Company.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Dans la mesure permise par la loi applicable, la soci&eacute;t&eacute; indemnisera tout membre actuel ou ancien du conseil d'administration, les anciens membres du comit&eacute; ex&eacute;cutif, ou toute personne qui sert ou a servi &agrave; la demande de la soci&eacute;t&eacute; en tant que membre du conseil d'administration ou membre du comit&eacute; ex&eacute;cutif (chacun individuellement, une &quot;Personne Couverte&quot;), pour toutes les d&eacute;penses, y compris les honoraires d'avocat, jugements, amendes, et montants vers&eacute;s effectivement et raisonnablement &agrave; titre de r&egrave;glement dans le cadre de toute action, poursuite ou proc&eacute;dure imminente, pendante ou termin&eacute;e, qu'elle soit civile, p&eacute;nale ou administrative, &agrave; laquelle il ou elle a &eacute;t&eacute;, est, ou est menac&eacute; d'&ecirc;tre partie, ou est impliqu&eacute; de toute autre mani&egrave;re (une &quot;Proc&eacute;dure&quot;). Cette disposition ne doit pas indemniser une Personne Couverte contre une responsabilit&eacute; d&eacute;coulant de (a) une fraude ou une malhonn&ecirc;tet&eacute; de cette Personne Couverte dans l'exercice de ses fonctions vis-&agrave;-vis de la soci&eacute;t&eacute;, ou (b) une violation consciente, intentionnelle ou volontaire ou gravement n&eacute;gligente de l'obligation de cette Personne Couverte d'agir avec honn&ecirc;tet&eacute; en tenant compte du meilleur int&eacute;r&ecirc;t de la soci&eacute;t&eacute;. Nonobstant ce qui pr&eacute;c&egrave;de, cette disposition ne s'&eacute;tend pas aux personnes qui occupent le poste de r&eacute;viseur ou de r&eacute;viseur sp&eacute;cial de la soci&eacute;t&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">In the case of any Proceeding by or in the name of the Company, the Company shall indemnify each Covered Person against expenses, including attorneys' fees, actually and reasonably incurred in connection with the defense or settlement thereof, except no indemnification shall be made in respect of any claim, issue or matter as to which a Covered Person shall have been adjudged to be liable for fraud or dishonesty in the</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Dans le cas de toute Proc&eacute;dure intent&eacute;e par ou au nom de la soci&eacute;t&eacute;, la soci&eacute;t&eacute; doit indemniser chaque Personne Couverte pour les d&eacute;penses, y compris les honoraires d'avocat, effectivement et raisonnablement encourus dans le cadre de la d&eacute;fense ou du r&egrave;glement dans le cadre de la Proc&eacute;dure. Aucune indemnisation ne sera octroy&eacute;e pour une r&eacute;clamation, probl&egrave;me ou affaire pour laquelle une Personne Couverte est tenue</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">performance of his or her duty to the Company, or for conscious, intentional or willful or grossly negligent breach of his or her obligation to act honestly and in good faith with a view to the best interests of the Company, unless and only to the extent that a court in which such action or suit was brought shall determine upon application that despite the adjudication of liability, but in view of all the circumstances of the case, such Covered Person is fairly and reasonably entitled to indemnity for such expenses as the court shall deem proper. Notwithstanding the preceding sentence, this section shall not extend to any person holding the office of auditor or special auditor of the Company. </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">responsable &agrave; la suite de fraude ou de malhonn&ecirc;tet&eacute; dans l'exercice de ses fonctions vis-&agrave;-vis de la soci&eacute;t&eacute;, ou &agrave; cause d'une violation consciente, intentionnelle ou volontaire ou gravement n&eacute;gligente de l'obligation de la Personne Couverte d'agir avec honn&ecirc;tet&eacute; en tenant compte du meilleur int&eacute;r&ecirc;t de la soci&eacute;t&eacute;, sauf et uniquement si un tribunal auquel une telle action ou poursuite a &eacute;t&eacute; port&eacute; d&eacute;termine que, malgr&eacute; la reconnaissance de la responsabilit&eacute;, mais compte tenu de toutes les circonstances du cas d'esp&egrave;ce, cette Personne Couverte a &eacute;quitablement et raisonnablement droit &agrave; une indemnisation de ces d&eacute;penses, mais uniquement &agrave; hauteur du montant que le tribunal jugera convenable. Nonobstant la phrase pr&eacute;c&eacute;dente, cette disposition ne s'&eacute;tend pas aux personnes qui occupent le poste de r&eacute;viseur ou de r&eacute;viseur sp&eacute;cial de la soci&eacute;t&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Any indemnification under this Article 29 (unless ordered by a court) shall be made by the Company only as authorized in the specific case upon a determination that indemnification of the Covered Person is proper in the circumstances because such person has met the applicable Standard of conduct set forth in this Article 29. Such determination shall be made, with respect to a Covered Person (a) by a majority vote of the members of the Board of Directors who are not parties to such proceeding, even though less than a quorum; (b) by a committee of such members of the Board of Directors designated by a majority vote of such the Board of Directors, even though less than a quorum; (c) if there are no such member of the Board of Directors, or if such member of the Board of Directors so direct, by independent legal counsel in a written opinion; or (d) by the General Meeting of Shareholders. Such determination shall be made, with respect to any other Covered Person, by any person or persons having the authority to act on the matter on behalf of the Company. To the extent, however, that any Covered Person has been successful on the merits or otherwise in defense of any </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Toute indemnisation en vertu du pr&eacute;sent article 29 (sauf si ordonn&eacute;e par un tribunal) doit &ecirc;tre octroy&eacute;e par la soci&eacute;t&eacute; dans chaque cas dans les limites de l'autorisation sur la base d'une d&eacute;termination que l'indemnisation de la Personne Couverte est appropri&eacute;e dans les circonstances parce que cette personne a satisfait au standard de conduite applicable &eacute;nonc&eacute; dans le pr&eacute;sent article 29. Une telle d&eacute;cision concernant une Personne Couverte doit &ecirc;tre prise (a) par la majorit&eacute; des votes des membres du conseil d'administration qui ne sont pas parties &agrave; cette proc&eacute;dure, m&ecirc;me si le quorum requis n'est pas r&eacute;uni; (b) par un comit&eacute; de membres du conseil d'administration d&eacute;sign&eacute;s par une majorit&eacute; des votes du conseil d'administration, m&ecirc;me si le quorum requis n'est pas r&eacute;uni; (c) s'il n'y a pas de tel membre du conseil d'administration, ou si ce membre du conseil d'administration l'ordonne, par un conseiller juridique ind&eacute;pendant dans un avis &eacute;crit; ou (d) par l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires. Une telle d&eacute;cision concernant une Personne Couverte doit &ecirc;tre prise par une personne ou des personnes ayant le pouvoir d'agir dans cet affaire au nom de la soci&eacute;t&eacute;. Dans la mesure, cependant, o&ugrave; une Personne </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">proceeding, or in defense of any claim, issue or matter therein, such Covered Person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Couverte a gagn&eacute; sur le fond ou autrement dans la d&eacute;fense d'une proc&eacute;dure, ou dans la d&eacute;fense de toute r&eacute;clamation, probl&egrave;me ou affaire dans cette proc&eacute;dure, cette Personne Couverte doit &ecirc;tre indemnis&eacute;e pour les d&eacute;penses (y compris les honoraires d'avocat) effectivement et raisonnablement encourus dans le cadre de l'affaire en question sans qu'il soit n&eacute;cessaire d'avoir une autorisation dans le cas sp&eacute;cifique.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">As far as is permissible under applicable law, expenses, including attorneys' fees, incurred in defending any proceeding for which indemnification is permitted pursuant to this Article 29 shall be paid by the Company in advance of the final disposition of such proceeding upon receipt by the Board of Directors of an undertaking by or on behalf of the Covered Person to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Company under these Articles of Association.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Dans la mesure permise par la loi applicable, les d&eacute;penses, y compris les honoraires d'avocats, encourus dans la d&eacute;fense de toute proc&eacute;dure pour laquelle l'indemnisation est permise en vertu du pr&eacute;sent article 29, doivent &ecirc;tre pay&eacute;es par la soci&eacute;t&eacute; avant la d&eacute;cision finale dans cette proc&eacute;dure &agrave; r&eacute;ception par le conseil d'administration d'une promesse faite par ou au nom de la Personne Couverte de rembourser ce montant s'il s'av&egrave;re finalement que cette Personne Couverte n'a pas droit &agrave; l'indemnisation par la soci&eacute;t&eacute; en vertu de ces statuts.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">It being the policy of the Company that indemnification of the persons specified in this Article 29 shall be made to the fullest extent permitted by law and the indemnification provided by this Article 29 shall not be deemed exclusive (a) of any other rights to which those seeking indemnification or advancement of expenses may be entitled under these Articles of Association, any agreement, any insurance purchased by the Company, vote of shareholders or disinterested members of the Board of Directors, or pursuant to the decision of any court of competent jurisdiction, or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office, or (b) of the power of the Company to indemnify any person who is or was an employee or agent of the Company or of another corporation, joint venture, trust or other enterprise which he or she is serving or has served at the request of the Company, to the same extent and in the same situations and subject to the same determinations as are hereinabove set forth with respect to a </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">La politique de la soci&eacute;t&eacute; pr&eacute;voit que l'indemnisation des personnes vis&eacute;es au pr&eacute;sent article 29 doit &ecirc;tre pay&eacute;e dans toute la mesure autoris&eacute;e par la loi et l'indemnisation pr&eacute;vue par cet article 29 ne sera pas consid&eacute;r&eacute;e comme exclusive (a) d'autres droits auxquels les personnes demandant une indemnisation ou une avance des d&eacute;penses ont droit en vertu de ces statuts, d'un accord, d'une assurance souscrite par la soci&eacute;t&eacute;, d'un vote d'actionnaires ou de membres du conseil d'administration n'ayant pas d'int&eacute;r&ecirc;t direct, ou en vertu d'une d&eacute;cision d'un tribunal comp&eacute;tent, ou autrement, soit &agrave; l'&eacute;gard d'actions faites en sa capacit&eacute; officielle, soit &agrave; l'&eacute;gard d'actions faites &agrave; un autre titre tout en ayant une telle fonction, ou (b) du pouvoir de la soci&eacute;t&eacute; d'indemniser toute personne qui est ou &eacute;tait un employ&eacute; ou un mandataire de la soci&eacute;t&eacute; ou d'une autre soci&eacute;t&eacute;, d'une joint venture, d'une fiducie ou d'une autre entreprise pour laquelle il ou elle travaille ou a travaill&eacute; &agrave; la demande de la soci&eacute;t&eacute;, dans la m&ecirc;me mesure et dans les m&ecirc;mes situations </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Covered Person.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><BR>
        As used in this Article 29, references to the &quot;Company&quot; include all constituent corporations in a consolidation or merger
        in which the Company or a predecessor to the Company by consolidation or merger was involved.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The indemnification provided by this Article
        29 shall continue as to a person who has ceased to be a member of the Board of Directors or the Executive Committee and shall inure
        to the benefit of their heirs, executors, and administrators.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">et sous r&eacute;serve des m&ecirc;mes principes
        concernant une Personne Couverte &eacute;voqu&eacute;es ci-dessus.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Tel qu'utilis&eacute; dans le pr&eacute;sent
        article 29, les r&eacute;f&eacute;rences &agrave; la &quot;soci&eacute;t&eacute;&quot; comprennent toutes les soci&eacute;t&eacute;s
        ayant fait l'objet d'un regroupement ou d'une fusion dans laquelle la soci&eacute;t&eacute; ou un pr&eacute;d&eacute;cesseur &agrave;
        la soci&eacute;t&eacute; a &eacute;t&eacute; impliqu&eacute;.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'indemnisation pr&eacute;vue par cet article
        29 est maintenue &agrave; l'&eacute;gard d'une personne qui a cess&eacute; d'&ecirc;tre un membre du conseil d'administration ou
        le comit&eacute; ex&eacute;cutif et sera en vigueur au b&eacute;n&eacute;fice de ses h&eacute;ritiers, ex&eacute;cuteurs et administrateurs.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; vertical-align: top; font-weight: bold; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">VI.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Auditors</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">VI.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;organe de r&eacute;vision</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 30&#9;Election, Term</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The General Meeting shall elect one or more
        accountants as its Auditors in terms of Articles 727 <I>et seq.</I> CO every year with the rights and duties determined by law.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 30&#9;&Eacute;lection, dur&eacute;e</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'assembl&eacute;e g&eacute;n&eacute;rale
        nomme chaque ann&eacute;e un ou plusieurs r&eacute;viseurs comme organe de r&eacute;vision selon les articles 727 ss. CO avec les
        droits et les devoirs d&eacute;termin&eacute;s par la loi.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">The General Meeting may appoint Special Auditors for a term of up to three years who provide the attestations required for capital increases.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">L'assembl&eacute;e g&eacute;n&eacute;rale peut nommer des r&eacute;viseurs sp&eacute;ciaux pour une dur&eacute;e de trois ans au maximum qui fournissent les attestations requises pour les augmentations de capital.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 31&#9;Duties</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Auditors shall perform their duties
        to audit and report whether the accounting, the annual accounts and the proposal regarding allocation of profits are in accordance
        with law and the Articles of Association.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 31&#9;Fonctions</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'organe de r&eacute;vision v&eacute;rifie
        et rapporte si la comptabilit&eacute;, les comptes annuels et la proposition relative &agrave; la r&eacute;partition des b&eacute;n&eacute;fices
        sont en conformit&eacute; avec la loi et les statuts.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">VII.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compensation and related provisions </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">VII.&#9;&nbsp;&nbsp;&nbsp;&nbsp;R&eacute;mun&eacute;ration et dispositions analogues </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        32&#9;Principles of the Compensation of the Board of Directors</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The compensation payable to the members
        of the Board of Directors comprises, subject to and within the bounds of the approval by the General Meeting of the total compensation,
        the following elements:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        32&#9;Principes de r&eacute;mun&eacute;ration du conseil d'administration</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La r&eacute;mun&eacute;ration des membres
        du conseil d'administration comprend, sous r&eacute;serve et dans les limites de l'approbation de la r&eacute;mun&eacute;ration
        totale par l'assembl&eacute;e g&eacute;n&eacute;rale, les &eacute;l&eacute;ments suivants:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
        fixed basic remuneration;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.25pt; text-align: justify; text-indent: -25.25pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
        fixed committee fee for work in a committee of the Board of Directors;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.25pt; text-align: justify; text-indent: -25.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.25pt; text-align: justify; text-indent: -25.25pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
        lump sum compensation for expenses;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
        number of options or shares in the Company, as further outlined in Art. 41.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">a)&nbsp;&nbsp;&nbsp;une
        r&eacute;mun&eacute;ration fixe de base;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">b)&nbsp;&nbsp;&nbsp;des
        frais de commission fixes pour le travail dans un comit&eacute; du conseil d'administration;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">c)&nbsp;&nbsp;&nbsp;une
        compensation forfaitaire pour les d&eacute;penses;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">d)&nbsp;&nbsp;&nbsp;un
        nombre d'actions ou d'options dans la soci&eacute;t&eacute;, comme d&eacute;taill&eacute;e &agrave; l'art. 41.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The compensation is paid in cash and in form of options or shares in the Company. The board of directors or, to the extent delegated to it, the compensation committee shall determine grant, exercise and forfeiture conditions. In particular, they may provide for continuation, acceleration or removal of vesting, exercise and forfeiture conditions, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of pre-determined events such as a change-of-control or termination of an employment or mandate agreement. The Company may procure the required shares through purchases in the market, from treasury shares or by using contingent or authorized share capital.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">La r&eacute;mun&eacute;ration est vers&eacute;e en esp&egrave;ces et sous forme d'options ou d'actions de la soci&eacute;t&eacute;. Le conseil d'administration ou, en cas de d&eacute;l&eacute;gation des fonctions, le comit&eacute; de r&eacute;mun&eacute;ration doit fixer les conditions de l'octroi, de l'exercice et de la p&eacute;remption. En particulier, il peut pr&eacute;voir la poursuite, l'acc&eacute;l&eacute;ration ou la suppression des conditions d'acquisition, d'exercice et de p&eacute;remption, pour le paiement ou l'octroi d'une r&eacute;mun&eacute;ration bas&eacute;e sur la r&eacute;alisation des objectifs suppos&eacute;s, ou pour la p&eacute;remption, dans chaque cas, dans le cas d'&eacute;v&eacute;nements pr&eacute;d&eacute;termin&eacute;s tels qu'un changement de contr&ocirc;le ou la r&eacute;siliation d'un contrat de travail ou d'un mandat. La soci&eacute;t&eacute; peut fournir les actions n&eacute;cessaires par des achats sur le march&eacute;, par ses actions propres ou en utilisant du capital conditionnel ou autoris&eacute;.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Subject to the approval by the General Meeting, the members of the Board of Directors may receive remuneration in cash at customary conditions for advisory services rendered outside their capacity as Board member for the benefit of the Company or companies under its control. The General Meeting may approve an additional bonus for the members of the Board of Directors in exceptional cases.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Sous r&eacute;serve de l'approbation par l'assembl&eacute;e g&eacute;n&eacute;rale, les membres du conseil d'administration peuvent recevoir une r&eacute;mun&eacute;ration en esp&egrave;ces dans les conditions habituelles pour des services consultatifs rendus en-dehors de leur qualit&eacute; de membre du conseil pour le b&eacute;n&eacute;fice de la soci&eacute;t&eacute; ou des soci&eacute;t&eacute;s sous son contr&ocirc;le. L'assembl&eacute;e g&eacute;n&eacute;rale peut approuver un bonus suppl&eacute;mentaire pour les membres du conseil d'administration dans des cas exceptionnels.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">The compensation may also be paid for activities in companies that are directly or indirectly controlled by the Company and may be paid by the Company or by a company controlled by it.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">La r&eacute;mun&eacute;ration peut &eacute;galement &ecirc;tre accord&eacute;e pour des activit&eacute;s dans des entreprises qui sont contr&ocirc;l&eacute;es directement ou indirectement par la soci&eacute;t&eacute; et peuvent &ecirc;tre vers&eacute;es par la soci&eacute;t&eacute; ou par une soci&eacute;t&eacute; contr&ocirc;l&eacute;e par elle.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        33&#9;Principles of the Compensation of the Executive Committee</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The compensation payable to the members
        of the Executive Committee is subject to the approval by the General Meeting and comprises the following elements:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;a
        fixed remuneration payable in cash;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;a
        performance-related remuneration payable in cash (variable);</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&nbsp;&nbsp;&nbsp;&nbsp;a
        number of options or shares in the Company, as further outlined in Art. 41.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        33&#9;Principe de r&eacute;mun&eacute;ration du comit&eacute; ex&eacute;cutif</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La r&eacute;mun&eacute;ration des membres
        du comit&eacute; ex&eacute;cutif est soumis &agrave; l'approbation l'assembl&eacute;e g&eacute;n&eacute;rale et comprend les &eacute;l&eacute;ments
        suivants</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;une
        r&eacute;mun&eacute;ration fixe payable en esp&egrave;ces;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;une
        r&eacute;mun&eacute;ration li&eacute;e &agrave; la performance payable en esp&egrave;ces (variable);</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;un
nombre d'actions ou d'options dans la soci&eacute;t&eacute;, comme d&eacute;taill&eacute;e &agrave; l'art. 41.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The performance-related remuneration depends on the Company's business success and the individual performance of the member of the Executive Committee based on the achievement of pre-determined targets during a business year. The Board of Directors determines annually at the beginning of each relevant business year the decisive targets and their weighting upon proposal by the Compensation Committee. The amount of the performance-related remuneration for each member of the Executive Committee is determined by the Board of Directors and may not exceed 100 percent of the respective individual fixed remuneration for the same year.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">La r&eacute;mun&eacute;ration li&eacute;e &agrave; la performance d&eacute;pend de la r&eacute;ussite &eacute;conomique de la soci&eacute;t&eacute; et de la performance individuelle du membre du comit&eacute; ex&eacute;cutif sur la base de la r&eacute;alisation des objectifs pr&eacute;d&eacute;termin&eacute;s au cours d'une ann&eacute;e d'activit&eacute;. Le conseil d'administration d&eacute;termine au d&eacute;but de chaque exercice les objectifs d&eacute;cisifs et leur pond&eacute;ration sur proposition du comit&eacute; de r&eacute;mun&eacute;ration. Le montant de la r&eacute;mun&eacute;ration li&eacute;e &agrave; la performance pour chaque membre du comit&eacute; ex&eacute;cutif est d&eacute;termin&eacute; par le conseil d'administration et ne peut d&eacute;passer 100 pour cent de la r&eacute;mun&eacute;ration fixe individuelle respective pour la m&ecirc;me ann&eacute;e.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">The compensation may also be paid for activities in companies that are directly or indirectly controlled by the Company and may be paid by the Company or by a company controlled by it.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">La r&eacute;mun&eacute;ration peut &eacute;galement &ecirc;tre vers&eacute;e pour activit&eacute;s dans des entreprises qui sont contr&ocirc;l&eacute;es directement ou indirectement par la soci&eacute;t&eacute; et peut &ecirc;tre vers&eacute;e par la soci&eacute;t&eacute; ou par une soci&eacute;t&eacute; contr&ocirc;l&eacute;e par elle.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        34&#9;Compensation for new Members of the Executive Committee</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If new members of the Executive Committee
        are appointed and take up their position in the Company after the General Meeting has approved the maximum total compensation for
        members of the Executive Committee for the year in question, the new members may be paid an additional amount for the period until
        the next Ordinary Meeting of Shareholder. The additional amount payable</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        34&#9;R&eacute;mun&eacute;ration pour les nouveaux membres du comit&eacute; ex&eacute;cutif</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Si de nouveaux membres du comit&eacute;
        ex&eacute;cutif sont nomm&eacute;s et prennent leur position dans la soci&eacute;t&eacute; apr&egrave;s que l'assembl&eacute;e
        g&eacute;n&eacute;rale a approuv&eacute; la r&eacute;mun&eacute;ration totale maximale pour les membres du comit&eacute; ex&eacute;cutif
        pour l'ann&eacute;e en question, les nouveaux membres peuvent &ecirc;tre pay&eacute;s au moyen d'un montant additionnel pour la
        p&eacute;riode allant jusqu'&agrave; la prochaine assembl&eacute;e ordinaire des</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-left: 0pt; text-indent: 0pt; text-align: left; padding-bottom: 4pt">to all new members of the Executive Committee may not exceed 50 percent of the respective total compensation already approved by the General Meeting. The additional compensation may only be paid if the total compensation amount that has been approved by the General Meeting for the compensation of the members of the Executive Committee is insufficient to compensate the newly appointed members. The General Meeting is not required to vote on this additional amount.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-left: 0pt; text-indent: 0pt; text-align: justify; padding-bottom: 4pt">actionnaires. Le montant additionnel payable &agrave; tous les nouveaux membres du comit&eacute; ex&eacute;cutif ne peut pas d&eacute;passer 50 pour cent de la r&eacute;mun&eacute;ration totale respective d&eacute;j&agrave; approuv&eacute; par l'assembl&eacute;e g&eacute;n&eacute;rale. La r&eacute;mun&eacute;ration additionnelle ne peut &ecirc;tre vers&eacute;e que si le montant total de la r&eacute;mun&eacute;ration qui a &eacute;t&eacute; approuv&eacute; par l'assembl&eacute;e g&eacute;n&eacute;rale pour la r&eacute;mun&eacute;ration des membres du comit&eacute; ex&eacute;cutif est insuffisant pour r&eacute;mun&eacute;rer les membres nouvellement nomm&eacute;s. L'assembl&eacute;e g&eacute;n&eacute;rale n'a pas &agrave; se prononcer sur ce montant suppl&eacute;mentaire.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">This additional overall compensation is understood to include any settlements for any disadvantage suffered as a result of the change of job.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Cette r&eacute;mun&eacute;ration additionnelle globale est sens&eacute;e comprendre tous les r&egrave;glements pour tout inconv&eacute;nient subi &agrave; la suite du changement de travail.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 35&#9;Expenses</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Expenses which are not covered by the lump
        sum compensation pursuant to the Company's expense regulations shall be reimbursed following presentation of the supporting receipts.
        This additional remuneration is not subject to a separate vote by the General Meeting.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 35&#9;D&eacute;penses</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les d&eacute;penses qui ne sont pas couvertes
        par l'indemnit&eacute; forfaitaire conform&eacute;ment aux r&egrave;glements de frais de la soci&eacute;t&eacute; sont rembours&eacute;es
        &agrave; la suite de la pr&eacute;sentation des re&ccedil;us correspondants. Cette r&eacute;mun&eacute;ration additionnelle n'est
        pas soumise &agrave; un vote s&eacute;par&eacute; par l'assembl&eacute;e g&eacute;n&eacute;rale.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt"><B>Art.
        36&#9;Compensation Agreements</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Agreements on compensation with members of
        the Board of Directors may not exceed the term of maximal one year.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt"><B>Art.
        36&#9;Accords sur la r&eacute;mun&eacute;ration</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.75pt; text-align: left; text-indent: -67.75pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les accords sur la r&eacute;mun&eacute;ration
        des membres du conseil d'administration ne peuvent pas exc&eacute;der la dur&eacute;e maximale d'une ann&eacute;e.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Employment agreements of the members of the Executive Committee are principally concluded for an indefinite period of time whereas a notice period may not exceed 12 months. If an employment agreement is concluded for a fixed term such term may not exceed one year.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Les contrats de travail des membres du comit&eacute; ex&eacute;cutif sont principalement conclus pour une dur&eacute;e ind&eacute;termin&eacute;e. Un d&eacute;lai de pr&eacute;avis ne peut pas exc&eacute;der 12 mois. Si un accord de travail est conclu pour une dur&eacute;e d&eacute;termin&eacute;e, telle dur&eacute;e ne peut pas exc&eacute;der un an.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.6pt; text-align: left; text-indent: -49.6pt"><B>Art. 37&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mandates
        of a Member of the Board of Directors outside the Company</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.6pt; text-align: left; text-indent: -49.6pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A member of the Board of Directors may cumulatively
        assume not more than the following number of mandates in the board of directors, the superior management or an administrative body
        of a legal entity which is obliged to be registered in the Swiss commercial register or an equivalent foreign register:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&#9;&nbsp;&nbsp;&nbsp;&nbsp;7
        mandates for publicly traded companies pursuant to art. 727 para. 1 number 1 CO; and&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8
        mandates for companies pursuant to art. 727 para. 1 number 2 CO; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5
        mandates for companies which do not fulfil the criteria under a) and b) above.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        37&#9;&nbsp;&nbsp;&nbsp;&nbsp;Mandats d'un membre du conseil d'administration de la soci&eacute;t&eacute;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Un membre du conseil d'administration ne
        peut pas cumuler plus que le nombre suivant de mandats dans un conseil d'administration, une direction sup&eacute;rieure ou un
        organisme administratif d'une personne morale qui est oblig&eacute;e d'&ecirc;tre inscrite au registre du commerce suisse ou un
        registre &eacute;tranger &eacute;quivalent:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7
        mandats pour les entreprises cot&eacute;es en bourse selon l'art. 727 al. 1 chiffre 1 CO; et&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8
        mandats pour des entreprises selon l'art. 727 al. 1 chiffre 2 CO; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5
        mandats pour les entreprises qui ne remplissent pas les crit&egrave;res sous a) et b) ci-dessus.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Mandates held in several legal entities each operating under the same management or same beneficial owner (group) are deemed to be a single mandate.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Les mandats exerc&eacute;s dans plusieurs entit&eacute;s juridiques op&eacute;rant chacune sous la m&ecirc;me direction ou le m&ecirc;me b&eacute;n&eacute;ficiaire effectif (groupe) sont r&eacute;put&eacute;s &ecirc;tre un seul mandat.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If a legal entity fulfills several of the
        above mentioned criteria, it can be freely counted towards any category. The following mandates are excepted from these restrictions:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;mandates
        in legal entities which are controlled by the Company or which control the Company;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;honorary
        mandates in charitable legal entities.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Si une entit&eacute; juridique remplit plusieurs
        des crit&egrave;res mentionn&eacute;s ci-dessus, elle peut &ecirc;tre librement plac&eacute;e dans une cat&eacute;gorie. Les mandats
        suivants sont except&eacute;s de ces restrictions:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;les
        mandats dans des entit&eacute;s juridiques qui sont contr&ocirc;l&eacute;es par la soci&eacute;t&eacute; ou qui contr&ocirc;lent
        la soci&eacute;t&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;des
        mandats d'honneur &agrave; des personnes morales de bienfaisance.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"><B>Art.
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38&#9;Mandates of a Member of the Executive Committee outside the Company</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Each member
        of the Executive Committee may, with approval of the Board of Directors, cumulatively assume not more than the following number
        of mandates in the board of directors, the superior management or an administrative body of a legal entity which is obliged to
        be registered in the Swiss commercial register or an equivalent foreign</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -49.65pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"><B>Art.
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38&#9;Mandats d'un membre du comit&eacute; ex&eacute;cutif en-dehors de la soci&eacute;t&eacute;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Chaque membre
        du comit&eacute; ex&eacute;cutif peut, avec l'approbation du conseil d'administration, cumuler pas plus que le nombre suivant de
        mandats dans un conseil d'administration, une direction sup&eacute;rieure ou un organisme administratif d'une personne morale qui
        est oblig&eacute;e d'&ecirc;tre inscrite dans le registre du commerce suisse ou un registre</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 46.65pt; text-align: left; text-indent: -46.65pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">register:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;2
        mandates for publicly traded companies pursuant to Art. 727 para. 1 number 1 CO; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;3
        mandates for companies pursuant to Art.&nbsp;727 para. 1 number 2 CO; and</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&nbsp;&nbsp;&nbsp;&nbsp;5
        mandates for companies which do not fulfil the criteria under litera a) and b) above.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Mandates held in several legal entities
        each operating under the same management or same beneficial owner (group) are deemed to be a single mandate.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If a legal entity fulfills several of the
        above mentioned criteria, it can be freely counted towards any category. The following mandates are excepted from this restrictions:&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&#9;&nbsp;&nbsp;&nbsp;mandates
        in legal entities which are controlled by the Company or which control the Company;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;honorary
        mandates in charitable legal entities.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&eacute;tranger &eacute;quivalent:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2
        mandats pour les entreprises cot&eacute;es en bourse selon l'art. 727 al. 1 chiffre 1 CO; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3
        mandats pour des entreprises selon l'art. 727 al. 1 chiffre 2 CO; et</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5
        mandats pour les entreprises qui ne remplissent pas les crit&egrave;res sous a) et b) ci-dessus.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les mandats exerc&eacute;s dans plusieurs
        entit&eacute;s juridiques op&eacute;rant chacun sous la m&ecirc;me direction ou m&ecirc;me b&eacute;n&eacute;ficiaire effectif
        (groupe) sont r&eacute;put&eacute;s &ecirc;tre un seul mandat.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Si une entit&eacute; juridique remplit plusieurs
        des crit&egrave;res mentionn&eacute;s ci-dessus, elle peut &ecirc;tre librement plac&eacute;e dans une cat&eacute;gorie. Les mandats
        suivants sont except&eacute;s de ces restrictions:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;les
        mandats dans des entit&eacute;s juridiques qui sont contr&ocirc;l&eacute;es par la soci&eacute;t&eacute; ou qui contr&ocirc;lent
        la soci&eacute;t&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mandats
        d'honneur dans des entit&eacute;s juridiques de bienfaisance.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 39&#9;Loans and Credits </B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The members of the Board of Directors
and the Executive Committee may not be granted any loans, credits or securities. Excepted from the above are advances in the maximum
amount of CHF 500'000 per person for attorneys' fees, court and other similar costs required for the defence of third-party liability
claims permitted by Article 29.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 39&#9;Pr&ecirc;ts et cr&eacute;dits
        </B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les membres du conseil d'administration
        et du comit&eacute; ex&eacute;cutif ne peuvent pas souscrire des pr&ecirc;ts, des cr&eacute;dits ou des titres. Sont except&eacute;es
        les avances d'un montant maximum de CHF 500'000 par personne pour les frais d'avocat, des co&ucirc;ts de tribunaux et d'autres
        co&ucirc;ts similaires n&eacute;cessaires &agrave; la d&eacute;fense contre des actions en responsabilit&eacute; civile autoris&eacute;s
        par l'article 29.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 40&#9;Pension Funds</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company shall remunerate members of
        the Board of Directors only in respect of the employer's mandatory contributions to social insurance. Above and beyond this, the
        Company shall not make any contributions to pension funds or other such pension plans. In exceptional cases, contributions such
        as these may be made subject to a request by the Compensation Committee and the approval of the General Meeting.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 40&#9;Fonds de pension</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La soci&eacute;t&eacute; ne doit r&eacute;mun&eacute;rer
        les membres du conseil d'administration que du montant d&ucirc; au titre de contributions obligatoire de l'employeur &agrave; l'assurance
        sociale. Au-del&agrave; de ce montant, la soci&eacute;t&eacute; ne doit pas verser de cotisations &agrave; des institutions de
        pr&eacute;voyance ou &agrave; d'autres r&eacute;gimes de retraite. Dans des cas exceptionnels, des contributions comme celles-ci
        peuvent &ecirc;tre faites sur demande au comit&eacute; de r&eacute;mun&eacute;ration et sous r&eacute;serve de</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">l'approbation de l'assembl&eacute;e g&eacute;n&eacute;rale.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Members of the Executive Committee participate in the Company's pension plans (the Company's pension fund and the management pension plan). The pension plans conform to the legal requirements. For members of the Executive Committee, the insured income is defined as the fixed remuneration plus 50 percent of the target performance-related remuneration, up to the legal maximum. Equity-linked income components are not included.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Les membres du comit&eacute; ex&eacute;cutif participent aux r&eacute;gimes de retraite de la soci&eacute;t&eacute; (le fond de pension de la soci&eacute;t&eacute; et le r&eacute;gime de retraite du management). Les r&eacute;gimes de retraite sont conformes aux exigences l&eacute;gales (LPP). Pour les membres du comit&eacute; ex&eacute;cutif, le revenu assur&eacute; est d&eacute;fini comme la r&eacute;mun&eacute;ration fixe plus les 50 pour cent de la r&eacute;mun&eacute;ration li&eacute;e &agrave; la performance, jusqu'au maximum l&eacute;gal. Les composantes du revenu li&eacute;es au capital propre ne sont pas inclus.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Within the overall compensation approved by the General Meeting, the Company may make additional payments into the Company's pension funds for the benefit of members of the Executive Committee in order to cover any disadvantage suffered as a result of the change of jobs or to purchase additional pension entitlements. In this context the Company may conclude life insurance policies on behalf of members of the Executive Committee and pay the insurance premiums either fully or in part.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Dans la r&eacute;mun&eacute;ration globale approuv&eacute;e par l'assembl&eacute;e g&eacute;n&eacute;rale, la soci&eacute;t&eacute; pourra effectuer des paiements suppl&eacute;mentaires dans les caisses de retraite de la soci&eacute;t&eacute; pour le b&eacute;n&eacute;fice des membres du comit&eacute; ex&eacute;cutif afin de couvrir tout d&eacute;savantage subi par suite de la modification de l'emploi ou pour acheter des droits de pension suppl&eacute;mentaires. Dans ce contexte, la soci&eacute;t&eacute; peut conclure des contrats d'assurance-vie au nom des membres du comit&eacute; ex&eacute;cutif et payer en totalit&eacute; ou en partie les primes d'assurance.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">Upon retirement, the Company may also grant members of the Executive Committee a bridging pension to cover the period between early retirement at 62 and the ordinary age of retirement, if such bridging pension does not exceed 100 percent of the total annual compensation of the respective member last paid.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt">&Agrave; la retraite, la soci&eacute;t&eacute; peut &eacute;galement accorder aux membres du comit&eacute; ex&eacute;cutif, une pension de transition pour couvrir la p&eacute;riode entre la retraite anticip&eacute;e &agrave; 62 ans et l'&acirc;ge ordinaire de la retraite, si cette rente transitoire ne d&eacute;passe pas 100 pour cent du dernier montant de la r&eacute;mun&eacute;ration annuelle totale pay&eacute;e au membre respectif.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 41&#9;Option and Share Plans</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the Company's Option Plan, the Board
        of Directors, upon proposal of the Compensation Committee, allocates the participating members of the Executive Committee and the
        Board of Directors a fixed number of options or shares with a vesting for a period of at least three years (the vesting period).
        At the end of the vesting period, participants in the Option Plan are entitled to exercise the options granted against payment
        of the strike price. These options to acquire shares in the Company or allocated shares are</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 41&#9;Options et plan d'actions</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">En vertu du r&eacute;gime d'options de la
        soci&eacute;t&eacute;, le conseil d'administration, sur proposition du comit&eacute; de r&eacute;mun&eacute;ration, attribue aux
        membres participants du comit&eacute; ex&eacute;cutif et du conseil d'administration un nombre fixe d'options ou d'actions avec
        une p&eacute;riode de blocage d'une p&eacute;riode d'au moins trois ans (la &quot;P&eacute;riode de Blocage&quot;). &Agrave; la
        fin de la P&eacute;riode de Blocage, les participants au r&eacute;gime d'options sont habilit&eacute;s &agrave; exercer les options
        attribu&eacute;es contre paiement du prix d'exercice. Ces options d'achat d'actions de la soci&eacute;t&eacute; ou</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">subject to the basic principles set out
        in the following:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">a)&nbsp;&nbsp;&nbsp;&nbsp;it
        is the sole discretion of the Board of Directors to decide whether to allocate options or shares and to whom;<BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">b)&nbsp;&nbsp;&nbsp;&nbsp;each
        year, the Board of Directors, upon proposal of the Compensation Committee, stipulates the number of options and shares to be allocated,
        the date of allocation and the strike price;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">c)&nbsp;&nbsp;&nbsp;&nbsp;each
        option incorporates a non-transferable, pre-emptive, and contingent right to acquire a certain number of Company's shares;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">d)&#9;&nbsp;&nbsp;&nbsp;&nbsp;in
        the case of a change of control (as defined in the Option Plan) or delisting of the Company's shares, the vesting period shall
        end (accelerated vesting) and the participant shall be entitled to exercise the options on a pro rata basis on the day the transaction
        that led to the change of control or delisting was executed. It is at the sole discretion of the Board of Directors to decide upon
        proposal of the Compensation Committee whether the financial objectives have been met;&#9;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><BR>
        </P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">e)&nbsp;&nbsp;&nbsp;&nbsp;the
        individual members of the Executive Committee or the Board of Directors participating in the Option Plan are responsible for paying
        any taxes or social security contributions and for declaring income correctly to the authorities;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">f)&#9;&nbsp;&nbsp;&nbsp;&nbsp;it
        is at the sole discretion of the Board of Directors to decide whether to supplement the Option Plan within the bounds of the principles
        set out above or to discontinue it.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; padding-bottom: 4pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">d'actions attribu&eacute;es sont soumises
        aux principes de base suivants:</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;il
        rel&egrave;ve de la libre appr&eacute;ciation du conseil d'administration de d&eacute;cider si des options ou actions sont attribu&eacute;es
        et &agrave; qui;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chaque
        ann&eacute;e, le conseil d'administration, sur proposition du comit&eacute; de r&eacute;mun&eacute;ration, fixe le nombre d'options
        et d'actions &agrave; attribuer, la date d'attribution et le prix d'exercice;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chaque
        option comporte un droit non transf&eacute;rable, de souscription pr&eacute;f&eacute;rentielle et optionnel d'acqu&eacute;rir un
        certain nombre d'actions de la soci&eacute;t&eacute;;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dans
        le cas d'un changement de contr&ocirc;le (tel que d&eacute;fini dans le r&eacute;gime d'options) ou la radiation des actions de
        la soci&eacute;t&eacute;, la P&eacute;riode de Blocage prend fin (acquisition acc&eacute;l&eacute;r&eacute;e) et le participant
        est en droit d'exercer les options sur une base pro rata le jour de la transaction qui a conduit &agrave; un changement de contr&ocirc;le
        ou le jour o&ugrave; la radiation a &eacute;t&eacute; ex&eacute;cut&eacute;e. Il rel&egrave;ve de la libre appr&eacute;ciation
        du conseil d'administration de d&eacute;cider, sur proposition du comit&eacute; de r&eacute;mun&eacute;ration, si les objectifs
        financiers ont &eacute;t&eacute; atteints;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;les
        membres individuels du comit&eacute; ex&eacute;cutif ou du conseil d'administration qui participent au r&eacute;gime d'options
        sont responsables du paiement de tous les imp&ocirc;ts ou cotisations de s&eacute;curit&eacute; sociale et de d&eacute;clarer correctement
        le revenu aux autorit&eacute;s;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 25.35pt; text-align: justify; text-indent: -25.35pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;il
rel&egrave;ve de la libre appr&eacute;ciation du conseil d'administration de d&eacute;cider si le r&eacute;gime d'options est
compl&eacute;t&eacute; dans les limites des principes &eacute;nonc&eacute;s ci-dessus ou de l'interrompre.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">The Company may periodically offer shares in the Company to important and long-term employees for a price being at maximum ten percent below the average volume-weighted price of the last 30 trading days at the stock </TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; border-bottom: Black 1pt solid">La soci&eacute;t&eacute; peut p&eacute;riodiquement offrir des actions de la soci&eacute;t&eacute; aux salari&eacute;s importants et &agrave; long terme pour un prix &eacute;tant au maximum dix pour cent au-dessous du prix moyen pond&eacute;r&eacute; par les volumes des 30 </TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">exchange. Members of the Board of Directors and the Executive Committee may be included in this program. The shares acquired thereby shall be blocked for a period of at least 3 years.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">derniers jours &agrave; la bourse. Les membres du conseil d'administration et du comit&eacute; ex&eacute;cutif peuvent &ecirc;tre inclus dans ce programme. Les actions ainsi acquises seront bloqu&eacute;es pour une p&eacute;riode d'au moins 3 ans.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">VIII.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business Year, Accounting, Allocation of Profits</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; vertical-align: top; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">VIII.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercice, comptabilit&eacute;, R&eacute;partition des b&eacute;n&eacute;fices</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 42&#9;&nbsp;&nbsp;Business Year</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Board of Directors shall determine the
        start and the end of the Company's business year.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 42&#9;&nbsp;&nbsp;&nbsp;Exercice</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Le conseil d'administration d&eacute;termine
le d&eacute;but et la fin de l'exercice de la soci&eacute;t&eacute;.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 43&#9;&nbsp;&nbsp;Accounting</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The annual accounts consist of the profit
        and loss statement, the balance sheet, the cash flow statement, the annex and the management report, and shall be drawn up pursuant
        to the provisions of the CO, particularly of Articles 958 <I>et seq.</I> CO, and the generally accepted commercial principles and
        customary rules in that business area.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 43&#9;&nbsp;&nbsp;Comptabilit&eacute;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Les comptes annuels se composent du compte
        de profits et pertes, du bilan, du tableau des flux de tr&eacute;sorerie, de l'annexe et du rapport de gestion, et sont &eacute;tablis
        conform&eacute;ment aux dispositions du CO, en particulier des articles 958 ss. CO, et aux principes commerciaux g&eacute;n&eacute;ralement
        reconnus et aux r&egrave;gles coutumi&egrave;res dans ce secteur d'activit&eacute;.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">If required by law, the consolidated financial statements shall be drawn in accordance with the provisions of Article 962 CO.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Si requis par la loi, les &eacute;tats financiers consolid&eacute;s sont &eacute;tablis en conformit&eacute; avec les dispositions de l'article 962 CO.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 44&#9;&nbsp;&nbsp;Allocation of Profits</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Subject to the legal provisions
regarding distribution of profits, the profit as shown on the balance sheet shall be allocated by the General Meeting at its discretion
after receipt of the proposals of the Board of Directors and the Auditors.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 44&#9;&nbsp;&nbsp;R&eacute;partition des b&eacute;n&eacute;fices</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sous r&eacute;serve des dispositions l&eacute;gales
        en mati&egrave;re de r&eacute;partition des b&eacute;n&eacute;fices, le b&eacute;n&eacute;fice comme indiqu&eacute; sur le bilan
        doit &ecirc;tre allou&eacute; &agrave; la libre appr&eacute;ciation de l'assembl&eacute;e g&eacute;n&eacute;rale apr&egrave;s r&eacute;ception
        des propositions du conseil d'administration et de l'organe de r&eacute;vision.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">In addition to the legal reserves, the General Meeting may create supplemental reserves.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">En plus des r&eacute;serves l&eacute;gales, l'assembl&eacute;e g&eacute;n&eacute;rale peut cr&eacute;er des r&eacute;serves suppl&eacute;mentaires.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Dividends not claimed within five years after the due date shall remain with the Company and be allocated to the general reserves.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 1%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; width: 1%; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; width: 47%; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Les dividendes non r&eacute;clam&eacute;s dans les cinq ans apr&egrave;s la date d'&eacute;ch&eacute;ance restent avec la soci&eacute;t&eacute; et sont attribu&eacute;s aux r&eacute;serves g&eacute;n&eacute;rales.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; width: 2%; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">Ix.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dissolution and Liquidation</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">Ix.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dissolution et Liquidation</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        45&#9;Dissolution and Liquidation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The dissolution and liquidation
of the Company shall take place in accordance with the provisions of the CO.</P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt"><B>Art.
        45&#9;Dissolution et Liquidation</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 67.85pt; text-align: left; text-indent: -67.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">La dissolution et la liquidation de la soci&eacute;t&eacute;
        ont lieu en conformit&eacute; avec les dispositions du CO.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">X.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices and Publications</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-left: 0pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt">X.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;avis et Publications</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 46&#9;Notices and Publications&#9;</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Swiss Official Gazette of Commerce is
        the official publication medium.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; font-weight: bold; text-indent: 0pt; text-transform: uppercase; padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Art. 46&#9;Avis et Publications</B></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'organe de publication l&eacute;gal est
        la Feuille officielle suisse du commerce.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Shareholder communications and notices to the shareholders shall be made by publication in the Swiss Official Gazette of Commerce or sent by mail or e-mail to the addresses registered in the share register.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">Les communications et avis aux actionnaires sont effectu&eacute;s par publication dans la Feuille officielle suisse du commerce ou envoy&eacute;s par courrier ou e-mail aux adresses enregistr&eacute;es dans le registre des actions.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Unless the law provides otherwise, notices shall be given to creditors by publication in the Swiss Official Gazette of Commerce. The Board of Directors may assign further means of communication.</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 4pt; text-align: justify; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt; border-bottom: Black 1pt solid">Sauf si la loi en dispose autrement, les avis seront envoy&eacute;s aux cr&eacute;anciers par publication dans la Feuille officielle suisse du commerce. Le conseil d'administration peut pr&eacute;voir d'autres moyens de communication.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Statuts modifi&eacute;s lors de la s&eacute;ance
du conseil d'administration du 23 f&eacute;vrier 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">L'atteste:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>3
<FILENAME>dp148007_ex0419.htm
<DESCRIPTION>EXHIBIT 4.19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EXCHANGE
ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>The following is a summary of the material
terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
as of March 22, 2021. The following description of the terms of our common shares is not meant to be complete and is qualified
by reference to our articles of association (&ldquo;articles of association&rdquo;), which is incorporated by reference as an exhibit
to our Annual Report on Form 20-F, of which this exhibit is a part. We encourage you to read our articles of association and the
applicable provisions of Swiss law for additional information.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss stock corporation (<I>soci&eacute;t&eacute;
anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute;
&agrave; responsabilit&eacute; limit&eacute;e</I>) on February 13, 2003 with our registered office and domicile in Basel, Switzerland.
We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August 4, 2003.
Our domicile and registered office is in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our head office is currently located
at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 22, 2021, our issued share
capital is CHF 1,537,748.98, consisting of 76,887,449 common shares with a nominal value of CHF 0.02 each. We have no dividend
rights certificates (<I>bons de jouissance</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Articles of Association</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 23, 2021, we adopted the articles
of association and when we refer to our articles of association, we refer to the articles of association as filed as Exhibit 3.1
to our Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Purpose</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under our articles of association, our
purpose is the research, study, development, manufacture, promotion, sale and marketing of products and substances within the pharmaceutical
and nutrition industry as well as the purchase, sale and exploitation of patents and licenses in this field. We may engage in any
activities which are apt to favor our purpose directly or indirectly. We may also acquire and sell real estate. We may open branch
offices in Switzerland and abroad and may also acquire participations in other companies. We may provide securities to our subsidiaries
and supply guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Ordinary Capital Increase, Authorized and Conditional
Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, we may increase our share
capital (<I>capital-actions</I>) with a resolution of the general meeting of shareholders (ordinary capital increase) that must
be carried out by the board of directors within three months of the general meeting of shareholders in order to become effective.
Under our articles of association, in the case of an increase of capital against payment of contributions in cash, a resolution
passed by a simple majority of the votes cast at the general meeting of shareholders regardless of abstentions and empty or invalid
votes is required. In the case of the limitation or withdrawal of subscription rights or in the case of an increase of capital
out of equity, against contribution in kind, or for the purpose of acquisition of assets and the granting of special benefits,
a resolution passed by at least two-thirds of the shares represented at a general meeting of shareholders and the absolute majority
of the nominal amount of the shares represented is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, under the Swiss Code of Obligations,
or the CO, our shareholders, by a resolution passed by at least two-thirds of the shares represented at a general meeting of shareholders
and the absolute majority of the nominal amount of the shares represented, may empower our board of directors to issue shares of
a specific aggregate nominal amount up to a maximum of 50% of the share capital in the form of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">conditional capital (<I>capital conditionnel</I>) for the purpose
of issuing shares in connection with, among other things, (i) the exercise of conversion and/or option or warrant rights granted
in connection with bonds or similar instruments, issued or to be issued by the Company or by one of our subsidiaries or (ii) the
exercise of option rights granted to employees of the Company or a subsidiary, members of our board of directors or any consultant
of the Company, or other persons providing services to the Company or a subsidiary; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">authorized capital (<I>capital-actions autoris&eacute;</I>) to be
utilized by the board of directors within a period determined by the shareholders but not exceeding two years from the date of
the shareholder approval.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Pre-Emptive Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the CO, shareholders have in
principle pre-emptive subscription rights (<I>droit pr&eacute;f&eacute;rentiel de souscription</I>). With respect to conditional
capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have
in principle advance subscription rights (<I>droit de souscrire pr&eacute;alablement</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A resolution passed at a general meeting
of shareholders by at least two-thirds of the shares represented and the absolute majority of the nominal value of the shares represented
may authorize our board of directors to withdraw or limit pre-emptive subscription rights or advance subscription rights in certain
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If pre-emptive subscription rights are
granted, but not exercised, the board of directors may allocate the non-exercised pre-emptive subscription rights as it elects
but has to follow the principle of equal treatment of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our Authorized Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3a of our articles of association,
board of directors is authorized to increase the share capital, in one or several steps until 27 June 2022, by a maximum amount
of CHF 190,000 by issuing a maximum of 9,500,000 registered shares with a par value of CHF 0.02 each, to be fully paid up. An increase
of the share capital (i) by means of an offering underwritten by a financial institution, a syndicate or another third party or
third parties, followed by an offer to the then-existing shareholders of the Company and (ii) in partial amounts shall also be
permissible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors is authorized to
determine the time of the issuance, the issue price, the manner in which the new registered shares have to be paid up, the date
from which the registered shares carry the right to dividends, the conditions for the exercise of the preemptive rights and the
allotment of preemptive rights that have not been exercised. The board of directors may allow the pre-emptive rights that have
not been exercised to expire, or it may place with third parties such rights or registered shares, the pre-emptive rights of which
have not been exercised, at market conditions or use them otherwise in the interest of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors is authorized to
withdraw or limit the pre-emptive rights of the shareholders and to allot them to third parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if the issue price of the new registered shares is determined by reference
to the market price; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for the acquisition of an enterprise, part of an enterprise or participations,
or for the financing or refinancing of any of such acquisition, or in the event of share placement for the financing or refinancing
of such placement; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for purposes of broadening the shareholder constituency of the Company
in certain financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing
or registration of new registered shares on domestic or foreign stock exchanges; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for purposes of granting an over-allotment option (Greenshoe) of up
to 20% of the total number of registered shares in a placement or sale of registered shares to the respective initial purchaser(s)
or underwriter(s); </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for raising of capital (including private placements) in a fast and
flexible which probably could not be reached without the exclusion of the statutory pre-emptive right of the existing shareholders;
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for other valid grounds in the sense of Article 652b para. 2 CO; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">following a shareholder or a group of shareholders acting in concert
having accumulated shareholdings in excess of 33 1/3 % of the share capital registered in the commercial register without having
submitted to the other shareholders a takeover offer recommended by the board of directors, or for the defense of an actual, threatened
or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial adviser
retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover
bid to be financially fair to the shareholders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our Conditional Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Conditional Share Capital for Bonds and Similar
Debt Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3b of our articles of
association, our share capital may be increased by a maximum aggregate amount of CHF 91,560.94 through the issue of a maximum
of 4,578,047 common shares, payable in full, each with a nominal value of CHF 0.02, through the exercise of conversion and/or
option or warrant rights granted in connection with bonds or similar instruments, issued or to be issued by the Company or by
one of our subsidiaries, including convertible debt instruments. Shareholders do not have pre-emptive subscription rights in
such circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shareholders&rsquo; subscription rights
are excluded. Shareholders&rsquo; advance subscription rights with regards to new bonds or similar instruments may be restricted
or excluded by decision of the board of directors in order to finance or re-finance the acquisition of companies or holdings, or
new investments planned by the Company, or in order to issue convertible bonds and warrants on the international capital markets
or through private placement. If advance subscription rights are excluded, then (i) the instruments are to be placed at market
conditions; (ii) the exercise period is not to exceed ten years from the date of issue for warrants and twenty years for conversion
rights; and (iii) the conversion or exercise price for the new shares is to be set at least in line with the market conditions
prevailing at the date on which the instruments are issued. The respective holders of conversion and/or option or warrant rights
are entitled to subscribe the new shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Conditional Share Capital for Employee Benefit
Plans</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3c of our articles of association,
our share capital may, to the exclusion of the pre-emptive subscription rights of shareholders, be increased by a maximum aggregate
amount of CHF 65,954.32 through the issue of a maximum of 3,297,716 common shares, payable in full, each with a nominal value of
CHF 0.02, in connection with the exercise of option rights granted to employees of the Company or one of our subsidiaries, members
of the board of directors or any consultant, or other persons providing services to the Company or one of our subsidiaries. The
board of directors specifies the precise conditions of issue including the issue price of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Uncertificated Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our shares are uncertificated securities
(<I>droits-valeurs</I>, within the meaning of Article 973c of the CO) and, when administered by a financial intermediary (<I>d&eacute;positaire</I>,
within the meaning of the Federal Act on Intermediated Securities, &ldquo;FISA&rdquo;), qualify as intermediated securities (<I>titres
interm&eacute;di&eacute;s</I>, within the meaning of the FISA). In accordance with Article 973c of the CO, we maintain a non-public
register of uncertificated securities (<I>registre des droits-valeurs</I>). We may at any time convert uncertificated securities
into share certificates (including global certificates), one kind of certificate into another, or share certificates (including
global certificates) into uncertificated securities. Following entry in our share register, a shareholder may at any time request
from us a written confirmation in respect of the shares held by such shareholder, as reflected in the share register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>General Meeting of Shareholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Ordinary/Extraordinary Meetings, Powers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The general meeting of shareholders is
our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders may be held. Under Swiss
law, an ordinary general meeting of shareholders must be held annually within six months after the end of a Company&rsquo;s financial
year. In our case, this generally means on or before June 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following powers are vested exclusively
in the general meeting of shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adopting and amending the articles of association, including change
of a company&rsquo;s purpose or domicile;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">electing and removal of the members of the board of directors, the
chairman of the board of directors, the members of the compensation committee, the auditors and the independent proxy;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">approving the management report and the consolidated accounts;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">approving the annual accounts and resolutions on the allocation of
the disposable profits, and in particular setting the dividend and the shares of profit to board members;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">approving the total compensation paid to members of the board of directors
and executive management;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">discharging the members of the board of directors and executive management
from liability with respect to their tenure in the previous financial year;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">dissolving a company with or without liquidation; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">passing resolutions concerning all matters which are reserved to the
authority of the general meeting of shareholders by law or by the articles of association.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An extraordinary general meeting of shareholders
may be called by a resolution of the general meeting, the board of directors or, under certain circumstances, by a company&rsquo;s
auditor, liquidator or the representatives of convertible bond holders, if any. In addition, the board of directors is required
to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of the share capital request
such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be
acted upon. The board of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring
measures if, based on a company&rsquo;s stand-alone annual statutory balance sheet, half of the share capital and reserves are
not covered by its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Voting and Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shareholder resolutions and elections (including
elections of members of the board of directors) require the affirmative vote of the simple majority of the votes cast at the general
meeting of shareholders regardless of abstentions or empty or invalid votes, unless statutory law or the articles of association
state otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A resolution of the general meeting of
the shareholders passed by at least two-thirds of the shares represented at the meeting, and the absolute majority of the nominal
value of the shares represented is required for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">amending a company&rsquo;s corporate purpose;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">creating shares with privileged voting rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">restricting the transferability of common shares;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">creating authorized or conditional share capital;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">increasing the share capital out of equity, against contributions
in-kind or for the purpose of acquiring assets and granting of special benefits;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">limiting or withdrawing shareholder&rsquo;s pre-emptive subscription
rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">changing a company&rsquo;s domicile;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">alleviating or withdrawing of restrictions upon the transfer of common
shares and the removal of the voting cap of 33 1&#8725;3% as contained in article 4 of the articles of association;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">removing the indemnification provision for the board of directors
and executive management as contained in article 29 of the articles of association;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">converting common shares into bearer shares and vice versa;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">dissolving or liquidating a company; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">amending or eliminating article 17 (<I>resolutions and elections</I>)
of the articles of association.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The same voting requirements apply, subject
to mandatory law, to resolutions regarding transactions among corporations (including a merger, demerger or conversion of a corporation)
based on Switzerland&rsquo;s Federal Act on Mergers, Demergers, Transformations and Transfer of Assets, or the Merger Act, see
&ldquo;&mdash;Compulsory Acquisitions; Appraisal Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings
of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer
to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding
voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Notice</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General meetings of shareholders must be
convened by the board of directors or, if necessary, by the auditors at least 20 days before the date of the meeting. The general
meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official
Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or e-mail. The notice of a general meeting of
shareholders must state the items on the agenda, the proposals to be acted upon and, in case of elections, the names of the nominated
candidates. Except in the limited circumstances listed below, a resolution may not be passed at a general meeting without proper
notice. This limitation does not apply to proposals to convene an extraordinary general meeting of shareholders or to initiate
a special investigation. No previous notification is required for proposals concerning items included in the agenda or for debates
that do not result in a vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of the owners or representatives of
our shares may, if no objection is raised, hold a general meeting of shareholders without complying with the formal requirements
for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass
binding resolutions on all matters within the purview of the ordinary general meeting of shareholders, provided that the owners
or representatives of all the shares are present at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Agenda Requests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Swiss law, one or more shareholders,
whose combined shareholdings represent the lower of (i) at least one tenth of the share capital or (ii) an aggregate nominal value
of at least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders.
A request for inclusion of an item on the agenda must in principle be requested in writing delivered to or mailed and received
at the registered office of the Company at least 120 calendar days before the first anniversary of the date that the Company's
proxy statement was released to shareholders in connection with the previous year's ordinary general meeting of shareholders. The
request must contain, for each of the agenda items, the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a brief description of the business desired to be brought before the
ordinary general meeting of shareholders and the reasons for conducting such business at the ordinary general meeting of shareholders;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the name and address, as they appear in our share register, of the
shareholder proposing such business;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of shares of the Company which are beneficially owned by
such shareholder; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the dates upon which the shareholder acquired such shares;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">documentary support for any claim of beneficial ownership;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any material interest of such shareholder in such business; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a statement in support of the matter and, for proposals sought to
be included in the Company's proxy statement, any other information required by Securities and Exchange Commission Rule 14a-8.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, if the shareholder intends
to solicit proxies from the shareholders of the Company, such shareholder shall notify the Company of this intent in accordance
with Securities and Exchange Commission Rule 14a-4 and/or Rule 14a-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our annual business report, the compensation
report and the auditor&rsquo;s report must be made available for inspection by the shareholders at our registered office no later
than 20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of our shares entitles its holder
to one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the other rights of share ownership
may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off
date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by
the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third
person with written authorization to act as proxy or the shareholder&rsquo;s legal representative. The chairman has the power to
decide whether to recognize a power of attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our articles of association state that
no individual or legal entity may, directly or indirectly, formally, constructively or beneficially own or otherwise control voting
rights (&ldquo;Controlled Shares&rdquo;) with respect to 33 1&#8725;3% or more of the registered share capital recorded in the
Commercial Register except if such individual or legal entity submits prior to the acquisition of such Controlled Shares an orderly
tender offer to all shareholders with a minimum price of the higher of (i) the volume weighted average price of the last 60 trading
days prior to the publication of the tender offer or (ii) the highest price paid by such individual or legal entity in the 12 months
preceding to the publication of the tender offer. Those associated through capital, voting power, joint management or in any other
way, or joining for the acquisition of shares, will be regarded as one person. The common shares exceeding the limit of 33 1/3%
and not benefitting from the exemption regarding a tender offer will be entered in our share registered as shares without voting
rights. The board of directors may in special cases approve exceptions to the above regulations. Additional voting caps apply to
shareholders acquiring shares for other persons (nominees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Dividends and Other Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors may propose to shareholders
that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution
passed by a simple majority of the votes cast at a general meeting of shareholders regardless of abstentions or empty or invalid
votes. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss statutory
law and our articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, we may pay dividends only
from the disposable profit and from reserves formed for this purpose, each as evidenced by our audited stand-alone statutory balance
sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have
been deducted. We are not permitted to pay interim dividends out of profit of the current business year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Distributable reserves are generally booked
either as &ldquo;free reserves&rdquo; (<I>r&eacute;serves libres</I>) or as &ldquo;reserve from capital contributions&rdquo; (<I>apports
de capital</I>). Under the CO, if our general reserves (<I>r&eacute;serve g&eacute;n&eacute;rale</I>) amount to less than 20% of
our share capital recorded in the Commercial Register (i.e., 20% of the aggregate nominal value of our issued capital), then at
least 5% of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further,
a purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the
purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which
are not distributable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Distributions out of issued share capital
(i.e. the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a share capital reduction.
Such a capital reduction requires a resolution passed by a simple majority of the votes cast at a general meeting of shareholders
regardless of abstentions or empty or invalid votes. The resolution of the shareholders must be recorded in a public deed and a
special audit report must confirm that claims of our creditors remain fully covered despite the reduction in the share capital
recorded in the Commercial Register. The share capital may be reduced below CHF 100,000 only if and to the extent that at the same
time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval
by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital
reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two
months of the third publication, satisfaction of or security for their claims. The reduction of the share capital may be implemented
only after expiration of this time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors determines the date
on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the
resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends
in quarterly or other installments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Transfer of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shares in uncertificated form (<I>droits-valeurs</I>)
may only be transferred by way of assignment. Shares that constitute intermediated securities (<I>titres interm&eacute;di&eacute;s</I>)
may only be transferred when a credit of the relevant intermediated securities to the acquirer&rsquo;s securities account is made
in accordance with the relevant provisions of the FISA. Article 5 of our articles of association provides that the transfer of
intermediated securities and the pledging of these intermediated securities are based on the provisions of the FISA and that transfer
of propriety as collateral by means of written assignment are not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Voting rights may be exercised only after
a shareholder (or usufructuaries) has been entered in our share register (<I>registre des actions</I>) with his or her name, first
name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. Our articles of association
state that no individual or legal entity may, directly or indirectly, formally, constructively or beneficially own or otherwise
control voting rights (&quot;Controlled Shares&quot;) with respect to 33 1&#8725;3% or more of the registered share capital recorded
in the Commercial Register except if such individual or legal entity submits prior to the acquisition of such Controlled Shares
an orderly tender offer to all shareholders with a minimum price of the higher of (i) the volume weighted average price of the
last 60 trading days prior to the publication of the tender offer or (ii) the highest price paid by such individual or legal entity
in the 12 months preceding to the publication of the tender offer. Those associated through capital, voting power, joint management
or in any other way, or joining for the acquisition of shares, will be regarded as one person. The common shares exceeding the
limit of 33 1/3% and not benefitting from the exemption regarding a tender offer will be entered in our share registered as shares
without voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Additional voting caps apply to shareholders
acquiring shares for other persons (nominees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Inspection of Books and Records</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the CO, a shareholder has a right
to inspect our share register with respect to his own shares and otherwise to the extent necessary to exercise his shareholder
rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express
authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding
of our business secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Special Investigation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the shareholders&rsquo; inspection rights
as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting
of shareholders that specific facts be examined by a special commissioner in a special investigation. If the general meeting of
shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders,
request the competent court sitting in Lausanne, Switzerland, our registered office, to appoint a special commissioner. If the
general meeting of shareholders rejects the request, one or more shareholders representing at least 10 percent of the share capital
or holders of shares in an aggregate nominal value of at least CHF 2,000,000 may request that the court appoint a special commissioner.
The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors
or our executive management infringed the law or our articles of association and thereby caused damages to the Company or the shareholders.
The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Compulsory Acquisitions; Appraisal Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Business combinations and other similar
transactions (i.e. mergers, demergers, transformations and certain asset transfers) that are governed by the Swiss Merger Act are,
if approved in accordance with the applicable provisions of the Swiss Merger Act, binding on all shareholders of the involved companies.
A statutory merger or demerger requires approval by at least two-thirds of the shares represented at a general meeting of shareholders
and the absolute majority of the nominal value of the shares represented. If the merger agreement provides, however, only for a
compensation payment, or in the event of an asymmetrical demerger, at least 90 percent of all shareholders of the transferring
company who are entitled to vote must approve the merger agreement and the asymmetrical demerger, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss corporations may be acquired by an
acquirer through the direct acquisition of shares of the Swiss corporation. The Swiss Merger Act provides for the possibility of
a so-called &ldquo;cash-out&rdquo; or &ldquo;squeeze-out&rdquo; merger if the acquirer controls 90% of the outstanding shares.
If such a squeeze-out merger under the Swiss Merger Act occurs, a minority shareholder subject to the squeeze-out merger could
seek to claim, within two months of the publication of the squeeze-out merger, that the consideration offered is &ldquo;inadequate&rdquo;
and petition a Swiss competent court to determine what &ldquo;adequate&rdquo; consideration is.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under Swiss law, the sale
of &ldquo;all or substantially all of our assets&rdquo; by us may require the approval of at least two-thirds of the number of
shares represented at a general meeting shareholders and the absolute majority of the nominal value of the shares represented.
Whether a shareholder resolution is required depends on the particular transaction, including whether the following test is satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a core part of our business is sold without which it is economically
impracticable or unreasonable to continue to operate the remaining business;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our assets, after the divestment, are not invested in accordance with
our statutory business purpose; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the proceeds of the divestment are not earmarked for reinvestment
in accordance with our business purpose but, instead, are intended for distribution to our shareholders or for financial investments
unrelated to our business.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If in a merger, demerger or transformation,
equity or shareholder rights are not adequately preserved or the compensation paid is unreasonable, within two months after the
publication of the merger, demerger or transformation resolution, each shareholder may demand that the competent court determines
what is a reasonable amount of compensation. The decision of the court is legally binding on all shareholders of the company involved,
provided that they are in the same legal position as the plaintiff. The costs of proceedings shall be borne by the acquiring company.
If the particular circumstances justify it, the court may decide that the plaintiff shall bear all or part of the cost. An action
to obtain a review of the protection of equity or shareholder rights does not affect the legal validity of the merger, demerger
or transformation resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our articles of association provide that
the board of directors shall consist of at least three and not more than nine members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The members of the board of directors and
the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent ordinary
general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Powers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors has the following
non-delegable and inalienable powers and duties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the overall management of the Company and the issuing of all necessary
directives;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the determination of the Company's organization;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the organization of the accounting, financial control and financial
planning systems are required for management of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the appointment an dismissal of persons entrusted with managing and
representing the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the overall supervision of the persons entrusted with managing the
Company, in particular with regard to compliance with the law, articles of association, operational regulations and directives;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the compilation of the annual report, and the preparation for the
general meeting of shareholders and implementing its resolutions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the preparation of the compensation report and to request approval
by the general meeting of shareholders regarding the compensation of the board of directors and the executive committee; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the notification of the court in the event that the Company is over-indebted.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors may assign responsibility
for preparing and implementing its resolutions or monitoring transactions to committees or individual members. It must ensure appropriate
reporting to its members. Furthermore, the board of directors may, while retaining such non-delegable and inalienable powers and
duties, delegate, in part or entirely, the management and the representation of the Company, within the limits of the law, to a
one or more individual directors (Delegates) or to third parties pursuant to the organizational regulations issued by the board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Swiss law and Article 25 of
our articles of association, details of the delegation and other procedural rules such as quorum requirements must be set in the
organizational rules issued by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors assigns the persons
with signatory power for the Company and the kind of signatory power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>Indemnification of Executive Management and Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to Swiss law, Article 29 of our
articles of association provides for indemnification of the current and former members of the board of directors, executive management
and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in
such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and members of
the executive management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under general principles of
Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee
in the proper execution of their duties under the employment agreement with the employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Conflict of Interest, Management Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law does not have a general provision
regarding conflicts of interest. However, the CO contains a provision that requires our directors and the members of the executive
management to safeguard the Company&rsquo;s interests and imposes a duty of loyalty and duty of care on our directors and the members
of the executive management. This rule is generally understood to disqualify directors and members of the executive management
from participating in decisions that directly affect them. Our directors and executive officers are personally liable to us for
any breach of these provisions. In addition, Swiss law contains provisions under which directors and all persons engaged in the
Company&rsquo;s management are liable to the Company, each shareholder and the Company&rsquo;s creditors for damages caused by
an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments made to
any of the Company&rsquo;s shareholders or directors or any person associated with any such shareholder or director, other than
payments made at arm&rsquo;s length, must be repaid to the Company if such shareholder or director acted in bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors has adopted a Code
of Business Conduct and Ethics that covers a broad range of matters, including the handling of conflicts of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Principles of the Compensation of the Board
of Directors and the Executive Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Swiss law, our shareholders
must annually approve the compensation of the board of directors and the persons whom the board of directors has, fully or partially,
entrusted with the management of the Company. The board of directors must issue, on an annual basis, a written compensation report
that must be reviewed together with a report on our business by our auditor. The compensation report must disclose all compensation
(as defined in section 14 of the Swiss Ordinance against Excessive Compensation in Listed Companies) granted by the Company, directly
or indirectly, to current members of the board of directors and executive management as well as to former members of the board
of directors and executive management but in the latter case only to the extent if such compensation is related to their former
role within the Company or if such compensation is not on customary market terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The disclosure concerning compensation
must in particular include the aggregate amount for the board of directors and the aggregate amount for the executive management,
as well as the particular amount of compensation for each member of the board of directors and the highest paid member of the executive
management, specifying the name and function of each person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain forms of compensation are prohibited
for members of our board of directors and executive management, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">severance payments provided for either contractually or in the articles
of association (compensation due until the termination of a contractual relationship does not qualify as severance payment);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">advance compensation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">incentive fees for the acquisition or transfer of corporations, or
parts thereof, by the Company or by companies being, directly or indirectly, controlled by the us;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">loans, other forms of indebtedness, pension benefits not based on
occupational pension schemes and performance-based compensation not provided for in the articles of association; and </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">equity securities and conversion and option rights awards not provided
for in the articles of association.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Compensation to members of the board of
directors and executive management for activities in entities that are, directly or indirectly, controlled by the Company is prohibited
if the compensation (i) would have been prohibited if it was paid directly by the Company, (ii) is not provided for in the articles
of association or (iii) has not been approved by the general meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The general meeting of shareholders annually
votes on the proposals of the board of directors with respect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum aggregate amount of non-performance-related compensation
of the board of directors for the next term of office;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum aggregate amount of a possible additional compensation
of the board of directors for the preceding business year;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum aggregate amount of non-performance-related compensation
of the executive management for the 12-month period starting on 1 July following the ordinary general meeting of shareholders;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum aggregate amount of variable compensation for the executive
management for the current year; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maximum aggregate amount of options or shares in the Company granted
to the board of directors and the executive management.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The respective total compensation amounts
include social security and occupational pension contributions for the benefit of the members of the board of directors, the executive
management and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the general meeting of shareholders
refuses to approve a respective motion by the board of directors, the board of directors may either submit a new motion at the
same meeting or determine a maximum total remuneration or several maximum partial remunerations, subject to the relevant principles
of the compensation, or submit a new motion to the next general meeting of shareholders for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to fixed compensation, members
of the executive management may be paid in cash a variable compensation, depending on the achievement of certain performance criteria.
The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation to the
market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient
of the variable compensation. The board of directors or, where delegated to it, the compensation committee determines the relative
weight of the performance criteria and the respective target values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Compensation may be paid in cash or granted
in form of options or shares in the Company. The board of directors or, to the extent delegated to it, the compensation committee
determines grant, vesting, exercise and forfeiture conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Borrowing Powers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neither Swiss law nor our articles of association
restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our
board of directors, and no approval by the shareholders is required in relation to any such borrowing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Repurchases of Shares and Purchases of Own
Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The CO limits our right to purchase and
hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (i) we have freely distributable
reserves in the amount of the purchase price; and (ii) the aggregate nominal value of all shares held by us does not exceed 10
percent of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out
in the articles of association, the foregoing upper limit is 20 percent. If we own shares that exceed the threshold of 10 percent
of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently hold 4,235,023 fully paid
up common shares of par value CHF 0.02 each, as treasury shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shares of the Company held by us or our
subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable
to the shares generally, including dividends and pre-emptive subscription rights in the case of share capital increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, selective share repurchases
are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may purchase
and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out
variances in the market price of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Notification and Disclosure of Substantial
Share Interests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The disclosure obligations generally applicable
to shareholders of Swiss corporations under the Swiss Financial Market Infrastructure Act, FinMIA, do not apply to us since our
shares are not listed on a Swiss stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Article 663c of the CO, Swiss
corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in
the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common shares are listed on the NASDAQ
Global Market under the symbol &ldquo;ACIU.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Computershare Trust Company, N.A. acts
as transfer agent and registrar for our common shares. The share register reflects only record owners of our shares. Swiss law
does not recognize fractional share interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>dp148007_ex1201.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Andrea Pfeifer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this annual report on Form 20-F of AC Immune
SA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and
the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">/s/ Andrea Pfeifer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Andrea Pfeifer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>dp148007_ex1202.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joerg Hornstein, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this annual report on Form 20-F of AC Immune
SA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and
the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) All significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">/s/ Joerg Hornstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joerg Hornstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>dp148007_ex1301.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The certification set forth below is being submitted in connection
with AC Immune SA&rsquo;s annual report on Form 20-F for the year ended December 31, 2020 (the &ldquo;Report&rdquo;) for the purpose
of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) and
Section 1350 of Chapter 63 of Title 18 of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrea Pfeifer, the Chief Executive Officer of AC Immune SA,
certifies that, to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of AC Immune SA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">/s/ Andrea Pfeifer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;Andrea Pfeifer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>dp148007_ex1302.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The certification set forth below is being submitted in connection
with AC Immune SA&rsquo;s annual report on Form 20-F for the year ended December 31, 2020 (the &ldquo;Report&rdquo;) for the purpose
of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) and
Section 1350 of Chapter 63 of Title 18 of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joerg Hornstein, the Chief Financial Officer of AC Immune SA,
certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of AC Immune SA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">/s/ Joerg Hornstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 43%"><FONT STYLE="font-size: 10pt">&nbsp;Joerg Hornstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></P>
                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>dp148007_ex1501.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statements on Form F-3 (No. 333-224694,  No. 333-227016, and  No. 333-249655) and on Form S-8 (No. 333-233019) of AC Immune
SA of our report dated March 23, 2021 relating to the financial statements, which appears in this Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers SA<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lausanne, Switzerland<BR>
March 23, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>aciu-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:aciu="http://acimume.com/20201231" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="aciu-20201231.xsd" />
  <xbrli:context id="c20200101to20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ComponentsOfEquityAxis_TreasurySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ComponentsOfEquityAxis_IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ComponentsOfEquityAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ComponentsOfEquityAxis_SharePremiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">aciu:ConvertibleNoteAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ClassesOfShareCapitalAxis_InitialPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:InitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsAndFixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LeaseholdImprovementsAndFixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">aciu:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfAssetsAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfAssetsAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfAssetsAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfAssetsAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfAssetsAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfAssetsAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfAssetsAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfAssetsAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfAssetsAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfAssetsAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfAssetsAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ClassesOfAssetsAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ClassesOfAssetsAxis_OfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ClassesOfAssetsAxis_BuildingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfAssetsAxis_ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CurrencyAxis_USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CurrencyAxis_EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CurrencyAxis_USD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CurrencyAxis_CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CurrencyAxis_CHF">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CurrencyAxis_EUR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_ClassesOfShareCapitalAxis_OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ClassesOfShareCapitalAxis_OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ClassesOfShareCapitalAxis_OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200901to20200930_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_RangeAxis_TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190425to20190425">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-25</xbrli:startDate>
      <xbrli:endDate>2019-04-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180731to20180731_ClassesOfShareCapitalAxis_SecondSubscriptionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:SecondSubscriptionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-31</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180724to20180724_ClassesOfShareCapitalAxis_OptionForOverAllotmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:OptionForOverAllotmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-24</xbrli:startDate>
      <xbrli:endDate>2018-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180724to20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:FirstSubscriptionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-24</xbrli:startDate>
      <xbrli:endDate>2018-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:FirstSubscriptionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:FollowOnOfferingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180504">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsLuMindResearchDownSyndromeFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsLuMindResearchDownSyndromeFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsLuMindResearchDownSyndromeFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsLuMindResearchDownSyndromeFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_OtherAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:OtherAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_OtherAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:OtherAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_OtherAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:OtherAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyFirstAmendmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyFirstAmendmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillySecondAmendmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillySecondAmendmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_PerformanceObligationsAxis_PhaseTwoClinicalStudyLicensedProductMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:PhaseTwoClinicalStudyLicensedProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillySecondAmendmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyFirstAmendmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_PerformanceObligationsAxis_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:MilestonePaymentsClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_PerformanceObligationsAxis_RightOfUseLicenseMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:RightOfUseLicenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_PerformanceObligationsAxis_MilestonePaymentsCommercialMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:MilestonePaymentsCommercialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_PerformanceObligationsAxis_ResearchAndDevelopmentMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_PerformanceObligationsAxis_ResearchAndDevelopmentMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">aciu:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauMorphomerSmallMoleculeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementWithLillyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170331_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2006GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiAbetaAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160401to20160630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160701to20160731_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171001to20171231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2012GenentechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AntiTauAntibodyInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_ProductsAndServicesAxis_TauVaccineInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160501to20160531_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>
      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_TauVaccineInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauVaccineInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20140531_ProductsAndServicesAxis_TauPETImagingAgentInADMember_RangeAxis_TopOfRangeMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190701to20190930_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20170331_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:TauPETImagingAgentInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AlphaSynucleinAndTDP43PETTracerInADMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AlphaSynucleinAndTDP43PETTracerInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:CollaborationAgreementOf2016BiogenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">aciu:AlphaSynucleinAndTDP43PETTracerInADMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200531_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200531_CounterpartiesAxis_SkaneUniversityHospitalMember_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">aciu:SkaneUniversityHospitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">aciu:GrantsMichaelJFoxFoundationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">aciu:ConvertibleNoteAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180731to20180731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-31</xbrli:startDate>
      <xbrli:endDate>2018-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRetirementBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRetirementBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRetirementBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">aciu:UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanSevenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_NotLaterThanPriorYearEndMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:NotLaterThanPriorYearEndMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_NotLaterThanPriorYearEndMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:NotLaterThanPriorYearEndMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanEightYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanEightYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanEightYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_NotLaterThanPriorYearEndMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:NotLaterThanPriorYearEndMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_MaturityAxis_NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanSevenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">aciu:LaterThanSixYearsAndNotLaterThanSevenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">aciu:DefinedBenefitsPlanEmployerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployeeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">aciu:DefinedBenefitsPlanEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">aciu:ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:OtherMaterialActuarialAssumptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:OtherMaterialActuarialAssumptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:OtherMaterialActuarialAssumptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:OtherMaterialActuarialAssumptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:StockOptionPlanAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:Two016ShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanC1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:StockOptionPlanC1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_EmployeesMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">aciu:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:Two016ShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:StockOptionPlanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:Two016ShareOptionAndIncentivePlanVestingTrancheOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">aciu:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_RangeAxis_BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_RangeAxis_TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_RangeAxis_TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_RangeAxis_BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_ExecutiveManagementMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">aciu:ExecutiveManagementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfRelatedPartiesAxis_BoardOfDirectorsMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">aciu:BoardOfDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">aciu:RestrictedSharesAndRestrictedShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_MaturityAxis_LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialAssetsAxis_CashOnHandAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:CashOnHandAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialAssetsAxis_ShortTermFinancialAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:ShortTermFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialAssetsAxis_CashOnHandAndCashEquivalentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:CashOnHandAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialAssetsAxis_ShortTermFinancialAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:ShortTermFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialAssetsAxis_OtherReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:OtherReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialAssetsAxis_OtherReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:OtherReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialAssetsAxis_LongTermFinancialAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:LongTermFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialAssetsAxis_LongTermFinancialAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">aciu:LongTermFinancialAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialLiabilitiesAxis_ShorttermBorrowingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialLiabilitiesAxis_ShortTermLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:ShortTermLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialLiabilitiesAxis_ShortTermLeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:ShortTermLeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialLiabilitiesAxis_AccruedExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:AccruedExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialLiabilitiesAxis_ShorttermBorrowingsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20191231_CategoriesOfFinancialLiabilitiesAxis_AccruedExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:AccruedExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_TypesOfRisksAxis_CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20190101to20191231_TypesOfRisksAxis_CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfRisksAxis_CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20201231_TypesOfRisksAxis_CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfRisksAxis_InterestRateRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_RangeAxis_TopOfRangeMember_TypesOfRisksAxis_InterestRateRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfRisksAxis_CreditRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember_RangeAxis_BottomOfRangeMember_TypesOfRisksAxis_LiquidityRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">aciu:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20200101to20201231_TypesOfRisksAxis_LiquidityRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20210201to20210228_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_NonadjustingEventsAfterReportingPeriodAxis_SubsequentEventsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">aciu:SubsequentEventsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20210228_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_NonadjustingEventsAfterReportingPeriodAxis_SubsequentEventsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001651625</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">aciu:SubsequentEventsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">aciu:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:CHF</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CHF</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>aciu:Platform</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>aciu:Offering</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>aciu:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>iso4217:CHF</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U010">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:EUR</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>iso4217:CHF</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U011">
    <xbrli:measure>aciu:Deposit</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U012">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U013">
    <xbrli:measure>aciu:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U014">
    <xbrli:measure>aciu:Representative</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U015">
    <xbrli:measure>aciu:Payment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U016">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U017">
    <xbrli:measure>aciu:Obligation</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U018">
    <xbrli:measure>aciu:Grant</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U019">
    <xbrli:measure>aciu:Employee</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U020">
    <xbrli:measure>aciu:Individual</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U021">
    <xbrli:measure>aciu:Plan</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U022">
    <xbrli:measure>utr:Y</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U023">
    <xbrli:measure>aciu:Institution</xbrli:measure>
  </xbrli:unit>
  <!--Actuarial assumption of discount rates-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfDiscountRates id="Fact_09042d522a7e47ada05fe1c637cc2f1e" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0020</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <!--Actuarial assumption of discount rates-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfDiscountRates id="Fact_2c034c5061574372ac0c82da73cc4dc1" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0020</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <!--Actuarial assumption of discount rates-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfDiscountRates id="Fact_b3e90e8c31aa4042a4e26f259bd8e8b4" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0090</ifrs-full:ActuarialAssumptionOfDiscountRates>
  <!--Actuarial assumption of expected rates of pension increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases id="Fact_41ec7620192844d8a7a263f17fda83c7" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0000</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <!--Actuarial assumption of expected rates of pension increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases id="Fact_7bdded41068b46eeb5566652f62d61a0" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0000</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <!--Actuarial assumption of expected rates of pension increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases id="Fact_88bbc3c575cf4cab84f8bbdae83e120b" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0050</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
  <!--Actuarial assumption of expected rates of salary increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases id="Fact_6546016ec29647b9b72bc6a8095d4732" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0175</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <!--Actuarial assumption of expected rates of salary increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases id="Fact_b2c46c8566b14447bea05f297c8f071e" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0150</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <!--Actuarial assumption of expected rates of salary increases-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases id="Fact_12af0bb5d2de4d22a81697071875932b" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0175</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
  <!--Effect of changes in demographic assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_9dc36624ca6e4a23b3ba45195819e864" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in demographic assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_a89d3b539c664973bfdbfa3638afc858" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">1138000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in demographic assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_d882d3a77ded41fe9cfcbf5caee972d2" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">1428000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in demographic assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_330c7599772a49f1ad55232a7726433c" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">1428000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in demographic assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_5ed7a9380eee422092d58f58071d7b9a" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">1138000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in demographic assumptions-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_659e13b2f79848df9a8d15a968f26240" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_287bd097f6124613b2c09a3b0127faf3" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-71000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_8647037c8fd645fe927e187f6f60cc77" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">750000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_d9648a566aa743fda841fa79a3d02f58" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-2171000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_ba0003bcaa574bfb8f2e4657ced9b2e4" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-2171000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_c082524c069e43039d65a0d30c8b6ea7" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">750000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Effect of changes in financial assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset id="Fact_edb4023c13a04dee8df6825bfbb139a7" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-71000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_514b6e44dddf4b7e86687949fd621df9" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-888000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_617df79956d84e88bca5a648bc98fec7" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-2003000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_8ce67334d2e5442b8b0de9756786770a" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-931000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_6b1dfc73da624aa583f4798d1f9db917" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-2003000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_7b26b02ca4a34e5288c0e1e3c0f1438b" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-888000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Change in experience assumptions-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset id="Fact_eb15614c9ab141ee9ed7678cecd5f654" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-931000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Computer equipment [member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_2290148b65644c7d8a0df2471ee2b3e1" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">310000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Leasehold Improvements [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_36cf108f4e104c6c8fe6b1f9e58eeddb" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">59000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Furniture [Member]-Acquisition Cost [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_55ffac9b0d2b437db7553b0b97830088" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">96000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Leasehold Improvements [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_6bdbd508a0f64affbeda87e561c72fb1" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">62000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_877606b3f19e414dbf7605174d38fa15" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">1885000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Laboratory equipment [Member]-Acquisition Cost [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_8ab01a0d7a994fb396d427b7e3d066f8" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">1566000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Furniture [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_cba4d2cbe7a04a57983b8616173b2a01" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">65000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Computer equipment [member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_eb6022393e35478298058bf76cdf1208" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">291000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-Laboratory equipment [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_f6bc76dc70e8439a8cb77f03244fd91a" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">1470000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions other than through business combinations, property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment id="Fact_0dd23beb412241998b87d905cda8aa91" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">2034000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <!--Additions-Office equipment [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_025ea8a8cd2740e08d0af97d180574f1" contextRef="c20200101to20201231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">0</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_3193e00353a24b55989d4ae52f3c6e0e" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">400000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-Buildings [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_4ef711375c31470cadbe12cce0827070" contextRef="c20200101to20201231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">400000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-Computer equipment [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_72fd3704884d45ae87152f037d82b23c" contextRef="c20190101to20191231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">71000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-Office equipment [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_74e727ea28664c8fb79022770021fe77" contextRef="c20190101to20191231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">29000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-Buildings [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_ae1c8c61f5d14a3784bf7091b3b6e6a7" contextRef="c20190101to20191231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">400000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_e6a81508a4be4304b17dc66c3b85718c" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">500000</ifrs-full:AdditionsToRightofuseAssets>
  <!--Additions-Computer equipment [member]-->
  <ifrs-full:AdditionsToRightofuseAssets id="Fact_fc0ba6371dae4370beddc7258e1f0c73" contextRef="c20200101to20201231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</ifrs-full:AdditionsToRightofuseAssets>
  <!--Adjusted weighted average number of ordinary shares outstanding-->
  <ifrs-full:AdjustedWeightedAverageShares id="Fact_244354675c254884ae045d2ad92a55f4" contextRef="c20200101to20201231" unitRef="U001" decimals="0">71900212</ifrs-full:AdjustedWeightedAverageShares>
  <!--Adjusted weighted average number of ordinary shares outstanding-->
  <ifrs-full:AdjustedWeightedAverageShares id="Fact_94618baf1fd94ae4ab817aec37996d8e" contextRef="c20180101to20181231" unitRef="U001" decimals="0">61838228</ifrs-full:AdjustedWeightedAverageShares>
  <!--Adjusted weighted average number of ordinary shares outstanding-->
  <ifrs-full:AdjustedWeightedAverageShares id="Fact_9fc3d8e8598d43edb3eaf240bc81455f" contextRef="c20190101to20191231" unitRef="U001" decimals="0">71103341</ifrs-full:AdjustedWeightedAverageShares>
  <!--Adjustments for decrease (increase) in other operating receivables-->
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables id="Fact_4bd3c6a766414df3a1ee0970870a53ec" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-68000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
  <!--Adjustments for decrease (increase) in other operating receivables-->
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables id="Fact_53b0e71f8aa74d659a52c440d77df7c3" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">698000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
  <!--Adjustments for decrease (increase) in other operating receivables-->
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables id="Fact_78791b219c0344229d3c331fb24ab71c" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-25000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
  <!--Adjustments for depreciation expense-->
  <ifrs-full:AdjustmentsForDepreciationExpense id="Fact_b205fc17b85c405584ea32514954bbf3" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1535000</ifrs-full:AdjustmentsForDepreciationExpense>
  <!--Adjustments for depreciation expense-->
  <ifrs-full:AdjustmentsForDepreciationExpense id="Fact_d3ad0f4f34e5463ca5928d159deac492" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">1274000</ifrs-full:AdjustmentsForDepreciationExpense>
  <!--Adjustments for depreciation expense-->
  <ifrs-full:AdjustmentsForDepreciationExpense id="Fact_e05c0070af694f17b2c5e53f89dab853" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">961000</ifrs-full:AdjustmentsForDepreciationExpense>
  <!--Adjustments for fair value losses (gains)-->
  <ifrs-full:AdjustmentsForFairValueGainsLosses id="Fact_441bdd6630f54040b6b38f5bf5bc195f" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:AdjustmentsForFairValueGainsLosses>
  <!--Adjustments for fair value losses (gains)-->
  <ifrs-full:AdjustmentsForFairValueGainsLosses id="Fact_61817339f9f1400dae35c8b4106e3964" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-4542000</ifrs-full:AdjustmentsForFairValueGainsLosses>
  <!--Adjustments for fair value losses (gains)-->
  <ifrs-full:AdjustmentsForFairValueGainsLosses id="Fact_f425f5ec77dc4aa9a0c14e147b0200e1" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</ifrs-full:AdjustmentsForFairValueGainsLosses>
  <!--Adjustments for finance income (cost)-->
  <ifrs-full:AdjustmentsForFinanceIncomeCost id="Fact_00629e35cfae447481dfce5d2c0f7202" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-1401000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <!--Adjustments for finance income (cost)-->
  <ifrs-full:AdjustmentsForFinanceIncomeCost id="Fact_0523ba26e309482394914e9be924e14c" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-376000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <!--Adjustments for finance income (cost)-->
  <ifrs-full:AdjustmentsForFinanceIncomeCost id="Fact_ad03b58b5d8240ca92ba952d08aafe55" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-1739000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <!--Adjustments for gain (loss) on disposals, property, plant and equipment-->
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="Fact_a30ad54af8cc4fe093c43bd13df0d0c3" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <!--Adjustments for gain (loss) on disposals, property, plant and equipment-->
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="Fact_b4ab28fb825943548d56b895044e7f29" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">64000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <!--Adjustments for gain (loss) on disposals, property, plant and equipment-->
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment id="Fact_c3cfec2b96274e0d97ceda1d3de82a27" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <!--Adjustments for increase (decrease) in deferred income-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome id="Fact_333e6b4a7b254bc8946ee2bc108250e8" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-18000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <!--Adjustments for increase (decrease) in deferred income-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome id="Fact_4ac87d8999a448d9952f5a21aa980cc8" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-4157000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <!--Adjustments for increase (decrease) in deferred income-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome id="Fact_85e7a146468c4168806929e2fc0a6ccf" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">4126000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <!--Adjustments for increase (decrease) in employee benefit liabilities-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities id="Fact_734ee2bf639645ad914bdf786bb49b96" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">437000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
  <!--Adjustments for increase (decrease) in employee benefit liabilities-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities id="Fact_81a5697868744592b564bf3dcb1db087" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">705000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
  <!--Adjustments for increase (decrease) in employee benefit liabilities-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities id="Fact_919d218b3d1a49c9afdde0d80763d0e8" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">516000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
  <!--Adjustments for increase (decrease) in trade accounts payable-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable id="Fact_3f2de05808e74a9d8a091809b0b1bb5e" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-1845000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <!--Adjustments for increase (decrease) in trade accounts payable-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable id="Fact_b28089ccf83943009f972cebe44a1fa4" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">864000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <!--Adjustments for increase (decrease) in trade accounts payable-->
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable id="Fact_b43ae00443e84a768b20f1844c03cc7e" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">2177000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
  <!--Adjustments for interest expense-->
  <ifrs-full:AdjustmentsForInterestExpense id="Fact_059c47e329654ae68da0b2a65a8162c6" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">50000</ifrs-full:AdjustmentsForInterestExpense>
  <!--Adjustments for interest expense-->
  <ifrs-full:AdjustmentsForInterestExpense id="Fact_bee070d5aa0b42b5a52ba94e1ee2a772" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">1894000</ifrs-full:AdjustmentsForInterestExpense>
  <!--Adjustments for interest expense-->
  <ifrs-full:AdjustmentsForInterestExpense id="Fact_d5d0543b658241f1834fa57d42ca9e88" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">175000</ifrs-full:AdjustmentsForInterestExpense>
  <!--Adjustments for share-based payments-->
  <ifrs-full:AdjustmentsForSharebasedPayments id="Fact_2cb77bc440da4cf0973911fabd3df61c" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">4088000</ifrs-full:AdjustmentsForSharebasedPayments>
  <!--Adjustments for share-based payments-->
  <ifrs-full:AdjustmentsForSharebasedPayments id="Fact_80ccdb5dc1b54e82bffa3995dfa438d8" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2834000</ifrs-full:AdjustmentsForSharebasedPayments>
  <!--Adjustments for share-based payments-->
  <ifrs-full:AdjustmentsForSharebasedPayments id="Fact_fd3b488d1678435fb074c3ed62776e4b" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2518000</ifrs-full:AdjustmentsForSharebasedPayments>
  <!--Applicable tax rate-->
  <ifrs-full:ApplicableTaxRate id="Fact_47ec3563d8c74855bacb84849c0743f0" contextRef="c20180101to20181231" unitRef="U008" decimals="INF">0.206</ifrs-full:ApplicableTaxRate>
  <!--Applicable tax rate-->
  <ifrs-full:ApplicableTaxRate id="Fact_9ebd1cffcde84bd1844eb4ed05b48f4c" contextRef="c20190101to20191231" unitRef="U008" decimals="INF">0.136</ifrs-full:ApplicableTaxRate>
  <!--Applicable tax rate-->
  <ifrs-full:ApplicableTaxRate id="Fact_b3a5a031d707481fa88f438f0f8e2e63" contextRef="c20200101to20201231" unitRef="U008" decimals="INF">0.136</ifrs-full:ApplicableTaxRate>
  <!--Assets-->
  <ifrs-full:Assets id="Fact_a7c5467c6a6541b4bf8e8e3a6a3207b0" contextRef="c20201231" unitRef="U002" decimals="-3">238740000</ifrs-full:Assets>
  <!--Assets-->
  <ifrs-full:Assets id="Fact_e6ccd71ae0384ecfa2a2d2d3190d093a" contextRef="c20191231" unitRef="U002" decimals="-3">299250000</ifrs-full:Assets>
  <!--Basic earnings (loss) per share-->
  <ifrs-full:BasicEarningsLossPerShare id="Fact_021943d5228f4cf5b9aea8cd2267940f" contextRef="c20190101to20191231" unitRef="U003" decimals="2">0.64</ifrs-full:BasicEarningsLossPerShare>
  <!--Basic earnings (loss) per share-->
  <ifrs-full:BasicEarningsLossPerShare id="Fact_15342f62aed74e36a709b836f16ba407" contextRef="c20200101to20201231" unitRef="U003" decimals="2">-0.86</ifrs-full:BasicEarningsLossPerShare>
  <!--Basic earnings (loss) per share-->
  <ifrs-full:BasicEarningsLossPerShare id="Fact_decf592658224163adae8dc9409e03ff" contextRef="c20180101to20181231" unitRef="U003" decimals="2">-0.82</ifrs-full:BasicEarningsLossPerShare>
  <!--Cash and cash equivalents-->
  <ifrs-full:CashAndCashEquivalents id="Fact_39a52170aaea4224a098e29cc978e4d5" contextRef="c20201231" unitRef="U002" decimals="-3">160893000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-->
  <ifrs-full:CashAndCashEquivalents id="Fact_a48bc62d5b78473f9bcae68fef81fa79" contextRef="c20191231" unitRef="U002" decimals="-3">193587000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-->
  <ifrs-full:CashAndCashEquivalents id="Fact_94e9f42aa25e4e51897f7577e7d74b1a" contextRef="c20171231" unitRef="U002" decimals="-3">124377000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-->
  <ifrs-full:CashAndCashEquivalents id="Fact_a6773f65b43b4a2e94a501952aa549cb" contextRef="c20181231" unitRef="U002" decimals="-3">156462000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-United States of America, Dollars-->
  <ifrs-full:CashAndCashEquivalents id="Fact_2500985373924291a73519829a828fbb" contextRef="c20191231_CurrencyAxis_USD" unitRef="U002" decimals="-3">25245000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-Euro Member Countries, Euro-->
  <ifrs-full:CashAndCashEquivalents id="Fact_4e582fd141734f9ca850a1975932233c" contextRef="c20191231_CurrencyAxis_EUR" unitRef="U002" decimals="-3">10169000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-United States of America, Dollars-->
  <ifrs-full:CashAndCashEquivalents id="Fact_5500cdf3d2574310b5e64c648475957b" contextRef="c20201231_CurrencyAxis_USD" unitRef="U002" decimals="-3">4141000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-Switzerland, Francs-->
  <ifrs-full:CashAndCashEquivalents id="Fact_64b0ea96a2d946a491bf9de63cbf5efe" contextRef="c20201231_CurrencyAxis_CHF" unitRef="U002" decimals="-3">152537000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-Switzerland, Francs-->
  <ifrs-full:CashAndCashEquivalents id="Fact_9899f23b900e465bb739521a4106a2b8" contextRef="c20191231_CurrencyAxis_CHF" unitRef="U002" decimals="-3">158173000</ifrs-full:CashAndCashEquivalents>
  <!--Cash and cash equivalents-Euro Member Countries, Euro-->
  <ifrs-full:CashAndCashEquivalents id="Fact_e9d24ea2fc3f40b08967af50aa0d7fcd" contextRef="c20201231_CurrencyAxis_EUR" unitRef="U002" decimals="-3">4215000</ifrs-full:CashAndCashEquivalents>
  <!--Cash flows from (used in) financing activities-->
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="Fact_1c56f8cb82a54096a9bcb93d146abd5d" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-803000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <!--Cash flows from (used in) financing activities-->
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="Fact_7a9cabd968284ca2a2ca9e744e283159" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">49616000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <!--Cash flows from (used in) financing activities-->
  <ifrs-full:CashFlowsFromUsedInFinancingActivities id="Fact_cd69ee078bfa47c8a74ae87b22479474" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">109378000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <!--Cash flows from (used in) investing activities-->
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="Fact_d8de0198da7c47b3b5cfdad9fa2b3271" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-32036000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <!--Cash flows from (used in) investing activities-->
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="Fact_e714e21c54d043d0a2407e448ada0c64" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">28329000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <!--Cash flows from (used in) investing activities-->
  <ifrs-full:CashFlowsFromUsedInInvestingActivities id="Fact_ef5540e68bff4c36a94e354d4caf7885" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-66885000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <!--Cash flows from (used in) operating activities-->
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="Fact_4a530c374ec44d599e37f7f5a7a29b01" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-59517000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <!--Cash flows from (used in) operating activities-->
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="Fact_57973db7e8484fd7bb436c02ee2b3daf" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">55220000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <!--Cash flows from (used in) operating activities-->
  <ifrs-full:CashFlowsFromUsedInOperatingActivities id="Fact_8692d715a72e48adb3f8f59ab4c7a90d" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-44078000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <!--Cash flows from (used in) operations-->
  <ifrs-full:CashFlowsFromUsedInOperations id="Fact_58d4da3d9e124eaeb62970fc47bf1933" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">55227000</ifrs-full:CashFlowsFromUsedInOperations>
  <!--Cash flows from (used in) operations-->
  <ifrs-full:CashFlowsFromUsedInOperations id="Fact_ccc831016cd349f5b2b91ad7ef9ada52" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-43772000</ifrs-full:CashFlowsFromUsedInOperations>
  <!--Cash flows from (used in) operations-->
  <ifrs-full:CashFlowsFromUsedInOperations id="Fact_cd6b6cda21a64e0c9d9ce97571b9681b" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-59247000</ifrs-full:CashFlowsFromUsedInOperations>
  <!--Cash outflow for leases-->
  <ifrs-full:CashOutflowForLeases id="Fact_2cce372adf48453aafa5e7ea4215ffc5" contextRef="c20200101to20201231" unitRef="U005" decimals="-3">1088000</ifrs-full:CashOutflowForLeases>
  <!--Cash outflow for leases-->
  <ifrs-full:CashOutflowForLeases id="Fact_bd4494eb52db4dabadc7aebd4508c541" contextRef="c20190101to20191231" unitRef="U005" decimals="-3">1037000</ifrs-full:CashOutflowForLeases>
  <!--Closing foreign exchange rate-United States of America, Dollars-->
  <ifrs-full:ClosingForeignExchangeRate id="Fact_4ce3ea21ac2e4055a043a1445455a6db" contextRef="c20191231_CurrencyAxis_USD" unitRef="U009" decimals="INF">0.978</ifrs-full:ClosingForeignExchangeRate>
  <!--Closing foreign exchange rate-Euro Member Countries, Euro-->
  <ifrs-full:ClosingForeignExchangeRate id="Fact_6eb692641b264f32924098a812c2a761" contextRef="c20191231_CurrencyAxis_EUR" unitRef="U010" decimals="INF">1.096</ifrs-full:ClosingForeignExchangeRate>
  <!--Closing foreign exchange rate-Euro Member Countries, Euro-->
  <ifrs-full:ClosingForeignExchangeRate id="Fact_71b465c8686743d5b92b3a921b218bb8" contextRef="c20201231_CurrencyAxis_EUR" unitRef="U010" decimals="INF">1.095</ifrs-full:ClosingForeignExchangeRate>
  <!--Closing foreign exchange rate-United States of America, Dollars-->
  <ifrs-full:ClosingForeignExchangeRate id="Fact_8a5685129502472b98b0d652dc117ca9" contextRef="c20201231_CurrencyAxis_USD" unitRef="U009" decimals="INF">0.891</ifrs-full:ClosingForeignExchangeRate>
  <!--Comprehensive income-->
  <ifrs-full:ComprehensiveIncome id="Fact_30582d761a3f4254a09b1ee02006080e" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-61195000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-->
  <ifrs-full:ComprehensiveIncome id="Fact_6a21844ebb274a4ebd4220150e496ac5" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">44138000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-->
  <ifrs-full:ComprehensiveIncome id="Fact_f82c88fd274e46dc96355284955cf9da" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-51253000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Treasury shares [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_4aeeb2ab7b0f4cbd8f107753aeb5b949" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Issued capital [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_506e4381e3384544bf12fedc0182e357" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Retained earnings [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_537f034ac2214c78984c33cd1803abb9" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-51253000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Share Premium [Member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_56790177ddd0454e8b9d76e183c2d6f6" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Issued capital [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_58c54d5227e241fa8e59d0988555c55f" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Treasury shares [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_7c05bec6a2914f488390751fbb9c3de9" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Retained earnings [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_8b74a8fd8d884671b251cf9fd5a46c1e" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-61195000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Issued capital [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_a4e1ed908bdd4867a68989f0e9e12d0f" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Treasury shares [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_afa19c3d30df403e82eeddfdee9b5533" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Share Premium [Member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_b73bd6c18bb64b9299dab223557b1ecb" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Retained earnings [member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_dd8254069d1c43819018b9dc3db467e8" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">44138000</ifrs-full:ComprehensiveIncome>
  <!--Comprehensive income-Share Premium [Member]-->
  <ifrs-full:ComprehensiveIncome id="Fact_0f0990c20aca41dba22269d296a926bd" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ComprehensiveIncome>
  <!--Contract assets-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-Research and development [Member]-->
  <ifrs-full:ContractAssets id="Fact_e5f514b8a20a46e2ba1fcd000903dea9" contextRef="c20201231_PerformanceObligationsAxis_ResearchAndDevelopmentMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-5">6900000</ifrs-full:ContractAssets>
  <!--Contract liabilities-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_417add4a8e924f8d82f3815978bbb54e" contextRef="c20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">80000000</ifrs-full:ContractLiabilities>
  <!--Contract liabilities-Collaboration Agreement with Lilly [Member]-Tau Morphomer Small Molecule [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_279745f5ec1f453d9b9d458f1fee0414" contextRef="c20190331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">80000000</ifrs-full:ContractLiabilities>
  <!--Contract liabilities-Anti-Abeta antibody in AD [Member]-Collaboration agreement of 2006, Genentech [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_79f0084653294414ba15f17135cc1824" contextRef="c20170331_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-5">31600000</ifrs-full:ContractLiabilities>
  <!--Contract liabilities-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_adc9881ddb9e4b00af15862cca3a6106" contextRef="c20170331_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">25000000</ifrs-full:ContractLiabilities>
  <!--Contract liabilities-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_42a2e3f6e3d149498fdad27d3cb04d61" contextRef="c20120630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">17000000</ifrs-full:ContractLiabilities>
  <!--Contract liabilities-Tau Vaccine in AD [Member]-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:ContractLiabilities id="Fact_4698ce42949144b68ec2225994726331" contextRef="c20141231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">25900000</ifrs-full:ContractLiabilities>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_1de658af73c3402aad1e40100f11fce4" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">693000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_54d9a1adb8054d1ba73a1de306214523" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">859000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_f3c8e57c73a948629d46cf1112155927" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">950000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_492ee374071c42bf830352dde42ca270" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">950000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_7e8ab156b8b54dd3af6817146f4518ba" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">693000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by employer, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset id="Fact_c677a1fa6fe94b25822481d013ede917" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">859000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_5b8e0c5b34e44633b2eb357956df6719" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-756000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_8015f87c1045413e83d7823e3da5e4cc" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-621000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_ec94112c50a4412c94b997b34a301303" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-851000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_57b8ec44aff74ea2b7e5ada234ed11a4" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">621000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_9f42b7ace7744d49bb8f2ab63026e489" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">756000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Contributions to plan by plan participants, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset id="Fact_ead36466fdc14696b901758f5270ac53" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">851000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
  <!--Current accrued expenses and other current liabilities-->
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities id="Fact_d637db30225848338dabd2f150412548" contextRef="c20201231" unitRef="U002" decimals="-3">11085000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <!--Current accrued expenses and other current liabilities-->
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities id="Fact_ecfcc8e0428647e09ba7e8b8252ae3e6" contextRef="c20191231" unitRef="U002" decimals="-3">11797000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <!--Current assets-->
  <ifrs-full:CurrentAssets id="Fact_5a502fc49b6840b990cba1ceb7f58584" contextRef="c20201231" unitRef="U002" decimals="-3">231767000</ifrs-full:CurrentAssets>
  <!--Current assets-->
  <ifrs-full:CurrentAssets id="Fact_c167d6acac2e42fa9f5cf4e71855bd8e" contextRef="c20191231" unitRef="U002" decimals="-3">292774000</ifrs-full:CurrentAssets>
  <!--Current contract assets-->
  <ifrs-full:CurrentContractAssets id="Fact_2a42edf674084482807c9ac1af75c8bf" contextRef="c20191231" unitRef="U002" decimals="-3">1095000</ifrs-full:CurrentContractAssets>
  <!--Current contract assets-->
  <ifrs-full:CurrentContractAssets id="Fact_bd1da714eea54920a8a1ab1e192e67ba" contextRef="c20201231" unitRef="U002" decimals="-3">1591000</ifrs-full:CurrentContractAssets>
  <!--Current contract assets-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:CurrentContractAssets id="Fact_7dd49ba62abf4094b5bf0d1082713207" contextRef="c20201231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">1100000</ifrs-full:CurrentContractAssets>
  <!--Current contract assets-->
  <ifrs-full:CurrentContractAssets id="Fact_44db604fbd3a49fba7fb576530dab795" contextRef="c20181231" unitRef="U002" decimals="-3">3667000</ifrs-full:CurrentContractAssets>
  <!--Current contract liabilities-->
  <ifrs-full:CurrentContractLiabilities id="Fact_02c772f8c71345f8a852abaec4063aba" contextRef="c20191231" unitRef="U002" decimals="-3">4477000</ifrs-full:CurrentContractLiabilities>
  <!--Current contract liabilities-->
  <ifrs-full:CurrentContractLiabilities id="Fact_dad8ae49016b41908682dacf57486181" contextRef="c20201231" unitRef="U002" decimals="-3">306000</ifrs-full:CurrentContractLiabilities>
  <!--Current contract liabilities-->
  <ifrs-full:CurrentContractLiabilities id="Fact_1a21f80f6fb0458d88a5fb40f61a9d8b" contextRef="c20181231" unitRef="U002" decimals="-3">351000</ifrs-full:CurrentContractLiabilities>
  <!--Current contract liabilities-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:CurrentContractLiabilities id="Fact_b5482c46f9224e7caa9856c204ba5264" contextRef="c20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">0</ifrs-full:CurrentContractLiabilities>
  <!--Short-term financial assets-->
  <ifrs-full:CurrentFinancialAssets id="Fact_8a80fc5d0d1648af90709e66108507e6" contextRef="c20191231" unitRef="U002" decimals="-3">95000000</ifrs-full:CurrentFinancialAssets>
  <!--Short-term financial assets-->
  <ifrs-full:CurrentFinancialAssets id="Fact_d66543b5134045fba93115b9d636d3bb" contextRef="c20201231" unitRef="U002" decimals="-3">65000000</ifrs-full:CurrentFinancialAssets>
  <!--Short-term financing obligation-->
  <ifrs-full:CurrentFinancialLiabilities id="Fact_714eaa0c984044db82d266634b469a36" contextRef="c20201231" unitRef="U002" decimals="-3">0</ifrs-full:CurrentFinancialLiabilities>
  <!--Short-term financing obligation-->
  <ifrs-full:CurrentFinancialLiabilities id="Fact_f9f733238a5f4857b33d3e1832cc70d7" contextRef="c20191231" unitRef="U002" decimals="-3">652000</ifrs-full:CurrentFinancialLiabilities>
  <!--Current lease liabilities-->
  <ifrs-full:CurrentLeaseLiabilities id="Fact_1a364c9fe0444a19bd4351a319910089" contextRef="c20201231" unitRef="U002" decimals="-3">443000</ifrs-full:CurrentLeaseLiabilities>
  <!--Current lease liabilities-->
  <ifrs-full:CurrentLeaseLiabilities id="Fact_2e558992bdfd4e9aaf57e53d94844859" contextRef="c20191231" unitRef="U002" decimals="-3">442000</ifrs-full:CurrentLeaseLiabilities>
  <!--Current liabilities-->
  <ifrs-full:CurrentLiabilities id="Fact_26b141710afa4ab384482d3d1957c360" contextRef="c20201231" unitRef="U002" decimals="-3">14018000</ifrs-full:CurrentLiabilities>
  <!--Current liabilities-->
  <ifrs-full:CurrentLiabilities id="Fact_57d11526868e44c5a0a93f12e1f38492" contextRef="c20191231" unitRef="U002" decimals="-3">17510000</ifrs-full:CurrentLiabilities>
  <!--Current prepayments-->
  <ifrs-full:CurrentPrepayments id="Fact_9e5ebcf6a8c4448dbcfbf0917a2ce34f" contextRef="c20201231" unitRef="U002" decimals="-3">3954000</ifrs-full:CurrentPrepayments>
  <!--Current prepayments-->
  <ifrs-full:CurrentPrepayments id="Fact_a680602e7c5f49428cb383c57678e145" contextRef="c20191231" unitRef="U002" decimals="-3">2788000</ifrs-full:CurrentPrepayments>
  <!--Current prepayments and current accrued income-->
  <ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome id="Fact_386c677b23da46de9bd1c80747fe1169" contextRef="c20191231" unitRef="U002" decimals="-3">3883000</ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome>
  <!--Current prepayments and current accrued income-->
  <ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome id="Fact_9e2e6052bd4440e1b5409ecfecb7fce6" contextRef="c20201231" unitRef="U002" decimals="-3">5545000</ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome>
  <!--Current provisions for employee benefits-->
  <ifrs-full:CurrentProvisionsForEmployeeBenefits id="Fact_beaca5ff2eaa4c8886e7bfbc429c8573" contextRef="c20201231" unitRef="U002" decimals="-3">3494000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
  <!--Current provisions for employee benefits-->
  <ifrs-full:CurrentProvisionsForEmployeeBenefits id="Fact_c1c13f2771434b23959aa6e2906db7d3" contextRef="c20191231" unitRef="U002" decimals="-3">2896000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
  <!--Current receivables from taxes other than income tax-->
  <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax id="Fact_521a7800b92448b7ba727146807b7709" contextRef="c20191231" unitRef="U002" decimals="-3">70000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
  <!--Current receivables from taxes other than income tax-->
  <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax id="Fact_fa5e562caf1f4e6e8b76355bd71edf59" contextRef="c20201231" unitRef="U002" decimals="-3">20000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_2ab3c7e495404c24944e7f8e4c361ae8" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1626000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_3cf8e6ca657f43c2a22dbfa56ba33abb" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1095000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_9527949bb4084c26b117d8f6a4aabfc0" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1313000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_7485abdb82524a5a80b4d7b32587a9dc" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">1626000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_eb24a04be6444826a075a1df41f930d0" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">1313000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current service cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset id="Fact_f92f1c73490a46419fc61f8fb62aade0" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">1095000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
  <!--Current value added tax receivables-->
  <ifrs-full:CurrentValueAddedTaxReceivables id="Fact_73de363003bf4b9ab0ba65e40d732c33" contextRef="c20201231" unitRef="U002" decimals="-3">309000</ifrs-full:CurrentValueAddedTaxReceivables>
  <!--Current value added tax receivables-->
  <ifrs-full:CurrentValueAddedTaxReceivables id="Fact_0c596571a5a4430e99a5d032d8c6ebc3" contextRef="c20191231" unitRef="U002" decimals="-3">234000</ifrs-full:CurrentValueAddedTaxReceivables>
  <!--Deferred tax assets-->
  <ifrs-full:DeferredTaxAssets id="Fact_e94a600b3b9b4bb6bc15d9e02eb1a6ad" contextRef="c20201231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-->
  <ifrs-full:DeferredTaxAssets id="Fact_65af1a3cd4874a90971d0209d887eb50" contextRef="c20191231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-->
  <ifrs-full:DeferredTaxAssets id="Fact_6f331216d13c40449656f4bc7793be6c" contextRef="c20181231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax losses [member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_1c07c26400c949999fba93ad45a8af4a" contextRef="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember" unitRef="U002" decimals="-3">64125000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Retirement benefit plan [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_2f4dc2f70c9948c0947833211e3f9152" contextRef="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember" unitRef="U002" decimals="-3">7485000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Right-of-use assets and lease liabilities net [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_4736cc8374d2498fadfa3f9ccb26055a" contextRef="c20191231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Retirement benefit plan [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_67e4eb96ebab463486e2fb809fcbe4f5" contextRef="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember" unitRef="U002" decimals="-3">7464000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Retirement benefit plan [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_94d3c53458bc4a41938c39dd883efdd6" contextRef="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRetirementBenefitPlanMember" unitRef="U002" decimals="-3">5665000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax losses [member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_bcd45b68f4ea4e7f85b46606f7ff928e" contextRef="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember" unitRef="U002" decimals="-3">109294000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Right-of-use assets and lease liabilities net [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_c47875b7076642198b5fafd2884b179a" contextRef="c20181231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax losses [member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_e89d1b3248794b3eb983da57dc91a7b0" contextRef="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxLossesMember" unitRef="U002" decimals="-3">121948000</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax assets-Unused tax credits, Right-of-use assets and lease liabilities net [Member]-->
  <ifrs-full:DeferredTaxAssets id="Fact_1011d910defa4c87b32d82065b5882a8" contextRef="c20201231_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <!--Deferred tax liabilities-->
  <ifrs-full:DeferredTaxLiabilities id="Fact_50028e214fdb41d0837da9f768a8f7fa" contextRef="c20181231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxLiabilities>
  <!--Deferred tax liabilities-->
  <ifrs-full:DeferredTaxLiabilities id="Fact_a97bbf94560f431db8a65d4a22f354be" contextRef="c20191231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxLiabilities>
  <!--Deferred tax liabilities-->
  <ifrs-full:DeferredTaxLiabilities id="Fact_bbbf9c559e4b467faca12bc73bd08f82" contextRef="c20201231" unitRef="U002" decimals="-3">0</ifrs-full:DeferredTaxLiabilities>
  <!--Deferred tax liability (asset)-->
  <ifrs-full:DeferredTaxLiabilityAsset id="Fact_e489c8afcbbb45859eeb88cc88db254b" contextRef="c20181231" unitRef="U002" decimals="-3">114959000</ifrs-full:DeferredTaxLiabilityAsset>
  <!--Deferred tax liability (asset)-->
  <ifrs-full:DeferredTaxLiabilityAsset id="Fact_f42eca3375a14de8b1cd6b66a6b133d8" contextRef="c20201231" unitRef="U002" decimals="-3">129412000</ifrs-full:DeferredTaxLiabilityAsset>
  <!--Deferred tax liability (asset)-->
  <ifrs-full:DeferredTaxLiabilityAsset id="Fact_f7dd9e71ef384f8eb7fbb4ed18271436" contextRef="c20191231" unitRef="U002" decimals="-3">71610000</ifrs-full:DeferredTaxLiabilityAsset>
  <!--Defined benefit obligation, at present value-Present value of defined benefit obligation [member]-->
  <ifrs-full:DefinedBenefitObligationAtPresentValue id="Fact_093d66ec3a694bf7805c6da444980c64" contextRef="c20191231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">26624000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <!--Defined benefit obligation, at present value-Present value of defined benefit obligation [member]-->
  <ifrs-full:DefinedBenefitObligationAtPresentValue id="Fact_7283c3a27cd44017bb5345f409f5733c" contextRef="c20201231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">30213000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <!--Defined benefit obligation, at present value-Present value of defined benefit obligation [member]-->
  <ifrs-full:DefinedBenefitObligationAtPresentValue id="Fact_d43f545232324d2e896a33ea26029a79" contextRef="c20181231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">17942000</ifrs-full:DefinedBenefitObligationAtPresentValue>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_31d11c928cf3402199bd22f1cac10cfa" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">285000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_5245f6f70afc42c69a15bfe5ee05b00d" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">343000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Leasehold Improvements [Member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_7dde01b990d141abb53ce7797df73105" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">66000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Laboratory equipment [Member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_97ec65469d0d4a74b69e048b92f78317" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">899000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Laboratory equipment [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_a684845da6114bcaa51768e26bbb2c2d" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">1092000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Leasehold Improvements [Member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_b5240e86c2d04a38a148c611c19ac46e" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">67000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_d2db9df6db35480786aa5eb4a404e090" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">1274000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_dfea9af7ac154699a7e0587b03c005f7" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">1535000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_e86b581eb5584d63b939054b9600f08f" contextRef="c20180101to20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">961000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Furniture [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_f335330cbd114089a1d1b480e11adbfd" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">33000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, property, plant and equipment-Accumulated depreciation and amortisation [member]-Furniture [Member]-->
  <ifrs-full:DepreciationPropertyPlantAndEquipment id="Fact_13baf64c1714402a900240f04e771873" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">24000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <!--Depreciation, right-of-use assets-Buildings [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_034474f149a843daa5b5eb62ca6e5805" contextRef="c20190101to20191231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">400000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-Office equipment [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_20aadb3be8654cbc903d896536a89ba8" contextRef="c20200101to20201231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">18000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_244fdf9118ac4cc490d606b417ac7dd9" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">420000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-Computer equipment [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_466e6d6c14ea4312814b7f39511df719" contextRef="c20200101to20201231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">14000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-Computer equipment [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_b03b62a87e2f4fa78748ecc8af855b52" contextRef="c20190101to20191231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">3000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-Office equipment [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_bfc447e576b9406d8b9e83e537aacb19" contextRef="c20190101to20191231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">17000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_c07b376f52b74335bc7cd4e26f799a3a" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">432000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-Buildings [member]-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_cea955a265144cb7b5f831b236c296d3" contextRef="c20200101to20201231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">400000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_57021b669b204dd181aaa2572daf2c23" contextRef="c20200101to20201231" unitRef="U005" decimals="-3">432000</ifrs-full:DepreciationRightofuseAssets>
  <!--Depreciation, right-of-use assets-->
  <ifrs-full:DepreciationRightofuseAssets id="Fact_8afc1ee82fe34ce99d608336d3c7889c" contextRef="c20190101to20191231" unitRef="U005" decimals="-3">420000</ifrs-full:DepreciationRightofuseAssets>
  <!--Description of accounting policy for earnings per share [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory id="Fact_47d4aacca1654ea2b83c5635c6083d7c" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Earnings per share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company presents basic earnings per share for each period in the financial statements. The earnings per share are calculated by dividing the earnings of the period by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
  <!--Description of accounting policy for employee benefits [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory id="Fact_2ea5ee3711f9471c999ceb865ab43cb7" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Employee benefits&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Post-employment benefits&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. The&lt;font style="color: #000000;"&gt; defined benefit obligation is calculated annually with the assistance of an independent actuary&lt;/font&gt; using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&amp;#8217; projected salaries and pension increases as well as discount rates of highly liquid corporate bonds that have terms to maturity approximating the terms of the related liability.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately in the statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized immediately as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses are recognized in either research and development and/or general and administrative expenses within the operating results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses related to defined benefit plans are recognized in the statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Share-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding adjustment to equity over the remaining vesting period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Stock options granted under the Company&amp;#8217;s stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model (see &amp;#8220;Note 17. Share-based compensation&amp;#8221;). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management&amp;#8217;s estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;We estimate the fair value of non-vested stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards vest.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <!--Description of accounting policy for foreign currency translation [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory id="Fact_eaf82c3e3a704a9a98681425940b1026" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Foreign currency transactions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Foreign currency transactions are translated into the functional currency, CHF, using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of income/(loss) in the period in which they arise.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <!--Description of accounting policy for income tax [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory id="Fact_01579e32d38f4b259e2bccf778e5745e" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Taxation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets as the probability for use is low.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As disclosed in &amp;#8220;Note 15. Income taxes,&amp;#8221; the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <!--Description of accounting policy for issued capital [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory id="Fact_608a36488d36480880ee2248119e62dd" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Share capital and public offerings&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt;"&gt;Common shares are classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax, from the proceeds received from existing or future offerings. &lt;font style="color: #000000;"&gt;Should a planned equity offering not be assessed as probable, the issuance costs would be expensed immediately. &lt;/font&gt;See &amp;#8220;Note 9. Share capital.&amp;#8221;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
  <!--Leases-->
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory id="Fact_734bca2f206d416e8e5bac0692d215d3" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Leases&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Effective January 1, 2019, the Company adopted IFRS 16 (&lt;font style="font-style: italic;"&gt;Leases&lt;/font&gt;), which provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company applied the modified retrospective approach, which required the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting, see &amp;#8220;Note 5. Right-of-use assets and lease liabilities.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; font-style: italic; font-weight: bold;"&gt;Right-of-use assets and lease liabilities&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&amp;#8217;s incremental borrowing rate. The lease liabilities are classified as current or non-current based on the due dates of the underlying principal payments.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company&amp;#8217;s estimate of the amount expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase, extension or termination option.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability. When the lease liability is re-measured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The estimated lease term by right-of-use asset categories are as follows:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Both the right-of-use-assets and lease liabilities are recognized in the balance sheets.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <!--Description of accounting policy for property, plant and equipment [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory id="Fact_fb1fe791e9ca4d1a9ff6128c821a1c41" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Property, plant and equipment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;3 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Leasehold improvements/furniture&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The assets&amp;#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&amp;#8217;s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the statements of income/(loss).&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <!--Description of accounting policy for provisions [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory id="Fact_82109a58fb204ad0a20c41822f17227f" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Provisions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <!--Description of accounting policy for recognition of revenue [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue id="Fact_38a11f3fc622438895fdadde554d40a8" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Company has adopted IFRS 15 (&lt;font style="font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Company enters into LCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and IP to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized from the Company&amp;#8217;s IP. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Licenses of intellectual property&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Milestone payments&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <!--Description of accounting policy for research and development expense [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory id="Fact_43ba7faaef514936b28818020d7928a2" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt; font-weight: bold;"&gt;Research and development expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Given the stage of development of the Company&amp;#8217;s products, all research expenditure is expensed as incurred. Research and development expenditures include:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management and laboratory services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;fees and costs related to regulatory filings and activities;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;costs associated with preclinical and clinical activities; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;For external research contracts, &lt;font style="color: #000000;"&gt;expenses include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing from CROs or CMOs for services rendered do not always align with work performed. We accrue the cost of services rendered in connection with CRO or CMO activities based on our estimate of the &amp;#8220;stage of completion&amp;#8221; for such contracted services. We maintain regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and&lt;/font&gt; accrue expenses as of the balance sheet date in the financial statements based on facts and circumstances known at the time.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
  <!--Description of accounting policy for segment reporting [text block]-->
  <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory id="Fact_213e730cd0c744a584eed5ce1fad07b2" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Segment reporting&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located in and revenue is attributable to the Company&amp;#8217;s country of domicile, Switzerland.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
  <!--Expected volatility, share options granted-->
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="Fact_4c16a8b61d1f454c90df9faaf4185732" contextRef="c20200101to20201231" unitRef="U008" decimals="1">0.8</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <!--Expected volatility, share options granted-->
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="Fact_71e17457b32c4a6a94d32cb0b0be9c6c" contextRef="c20190101to20191231" unitRef="U008" decimals="1">0.8</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <!--Expected volatility, share options granted-->
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted id="Fact_73d2c6cf2c8045aa901f3a67a8992bed" contextRef="c20180101to20181231" unitRef="U008" decimals="1">0.8</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <!--Option life, share options granted-->
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="Fact_05aa8652aebd42b3a124a3be3d17fe2c" contextRef="c20200101to20201231" unitRef="U022" decimals="0">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <!--Option life, share options granted-->
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="Fact_5d834a1d0abc450e9b9181c2e922f34e" contextRef="c20180101to20181231" unitRef="U022" decimals="0">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <!--Option life, share options granted-->
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted id="Fact_fa103edb990a41db8043f77ba95ab755" contextRef="c20190101to20191231" unitRef="U022" decimals="0">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <!--Risk free interest rate, share options granted-->
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="Fact_bfb94c21796644fe8b6daa3a91435edb" contextRef="c20200101to20201231" unitRef="U008" decimals="0">0</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <!--Risk free interest rate, share options granted-->
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="Fact_c9e3c63c96cd4ec396ba19182a00773c" contextRef="c20190101to20191231" unitRef="U008" decimals="0">0</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <!--Risk free interest rate, share options granted-->
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted id="Fact_de84230071de4775b490c8f7b399a853" contextRef="c20180101to20181231" unitRef="U008" decimals="0">0</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <!--Diluted earnings (loss) per share-->
  <ifrs-full:DilutedEarningsLossPerShare id="Fact_af759f035d6440ecad0cd49d4d80e52e" contextRef="c20180101to20181231" unitRef="U003" decimals="2">-0.82</ifrs-full:DilutedEarningsLossPerShare>
  <!--Diluted earnings (loss) per share-->
  <ifrs-full:DilutedEarningsLossPerShare id="Fact_cbfc0765c1714e76a853968fd3a632fa" contextRef="c20200101to20201231" unitRef="U003" decimals="2">-0.86</ifrs-full:DilutedEarningsLossPerShare>
  <!--Diluted earnings (loss) per share-->
  <ifrs-full:DilutedEarningsLossPerShare id="Fact_eed4f8e9486947f7b3af19651a11141c" contextRef="c20190101to20191231" unitRef="U003" decimals="2">0.64</ifrs-full:DilutedEarningsLossPerShare>
  <!--Dilutive effect of convertible instruments on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_21507596ae154bf89b45da246c698c70" contextRef="c20190101to20191231" unitRef="U001" decimals="0">911261</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of convertible instruments on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_68e8d0e0fb6f48c2ad3b7cc124a006a4" contextRef="c20200101to20201231" unitRef="U001" decimals="0">0</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of convertible instruments on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_6be8ae1a08d64c658f8ee4ce1b06c21f" contextRef="c20180101to20181231" unitRef="U001" decimals="0">0</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of share options on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares id="Fact_1c3a20bc6424441281729f2b14a30a47" contextRef="c20200101to20201231" unitRef="U001" decimals="0">0</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of share options on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares id="Fact_3d9b1112374b490b87baa7cb8fb21a21" contextRef="c20190101to20191231" unitRef="U001" decimals="0">499730</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of share options on number of ordinary shares-->
  <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares id="Fact_f4d0410cf80b4eea81c14db0cb3984dc" contextRef="c20180101to20181231" unitRef="U001" decimals="0">0</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
  <!--Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]-->
  <ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory id="Fact_ebe40e29586f4687849d667793f86a0a" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;For key management, including the board of directors (seven individuals excluding the CEO) and the executive management (five individuals including the CEO), compensation was as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,497&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,526&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,681&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Post-employment benefits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;215&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;160&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,578&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,155&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,683&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;6,289&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;5,896&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4,524&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory>
  <!--Disclosure of basis of preparation of financial statements [text block]-->
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory id="Fact_307634cb16a741f287c1ae6998319629" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;2.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Basis of preparation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Going concern&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company&amp;#8217;s cash position of CHF 160.9 million and short-term financial assets of CHF 65 million as of December 31, 2020. This total derives from multiple capital raising efforts and revenues from license and collaboration agreements (LCAs). In 2020, the Company received CHF 10 million for a development milestone from its licensing agreement with Lilly. In 2019, the&lt;font style="color: #000000;"&gt; Company received CHF 80 million for an upfront payment, CHF 30 million for a development milestone and USD 50 (CHF 50.3) million from a convertible loan with Lilly. &lt;/font&gt;In 2018, the Company completed three offerings, raising USD 117.5 (CHF 116.3) million in gross proceeds b&lt;font style="color: #000000;"&gt;efore underwriting discounts and expenses.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;To date, the Company has financed its cash requirements primarily from its public offerings, share issuances, contract revenues from license and collaboration agreements and grants. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&amp;#8217;s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company&amp;#8217;s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel and (v) acquire capital to support its operations.&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;In addition to the foregoing, based on the Company&amp;#8217;s current assessment, the Company does not expect any material impact on its long-term development timeline, its liquidity or ability to remain a going concern due to the worldwide spread of the Covid-19 virus. The Company continues to assess the effect on its operations by carefully monitoring the spread of Covid-19 and taking appropriate steps intended to offset any negative impacts from the Covid-19 virus.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Statement of compliance&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These financial statements have been approved for issue by the Board of Directors on March 19, 2021.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Basis of measurement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The financial statements have been prepared under the historical cost convention except for items that are required to be accounted for at fair value.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Functional currency&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The financial statements of the Company are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial information presented in Swiss Francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands), unless otherwise indicated.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <!--Disclosure of classes of share capital [text block]-->
  <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory id="Fact_57f38a5f41f341568887a0362fb0d5d6" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The table below summarizes the Company&amp;#8217;s capital structure:&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Common &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Treasury &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;premium&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Treasury &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;67,562,333&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;298,149&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares &amp;#8211; incentive plans&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;681,770&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;13&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;672&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion of note agreement, net of transaction costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,615,328&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;73&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;47,705&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;71,859,431&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,437&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;346,526&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares &amp;#8211; incentive plans, net of RSU expiration and forfeiture&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;77,307&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;364&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares to be held as treasury shares, net of transaction costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;76,936,738&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;346,890&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
  <!--Disclosure of commitments and contingent liabilities [text block]-->
  <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory id="Fact_fe1673e924f2486283c3db9bfc9f152a" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;18.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Commitments and contingencies&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;In the normal course of business, we conduct product research and development programs through collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations&lt;/font&gt;. As of December 31, 2020, external research projects included in the schedule below for 2021 total CHF 24.7 million that have been committed.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;We lease our corporate, laboratory and other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. &lt;/font&gt;Since January 1, 2019, the Company has applied IFRS 16 and recognized a right-of-use asset for its leases, except for short-term and low-value leases as indicated in Note 3&lt;font style="font-style: italic;"&gt;.&lt;/font&gt; See &amp;#8220;Note 5. Right-of-use assets and lease liabilities&amp;#8221; for the contractual undiscounted cash flows for lease obligations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Within 1 year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;25,072&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;19,907&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 1 and 3 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,885&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;12,993&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 3 and 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;341&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,816&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;More than 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,193&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;34,355&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;39,909&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
  <!--Disclosure of contingent liabilities [text block]-->
  <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory id="Fact_12a448b304984f6c87a248d6e14e9134" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;We lease our corporate, laboratory and other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. &lt;/font&gt;Since January 1, 2019, the Company has applied IFRS 16 and recognized a right-of-use asset for its leases, except for short-term and low-value leases as indicated in Note 3&lt;font style="font-style: italic;"&gt;.&lt;/font&gt; See &amp;#8220;Note 5. Right-of-use assets and lease liabilities&amp;#8221; for the contractual undiscounted cash flows for lease obligations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Within 1 year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;25,072&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;19,907&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 1 and 3 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,885&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;12,993&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 3 and 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;341&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,816&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;More than 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,193&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;34,355&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;39,909&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
  <!--Disclosure of debt instruments [text block]-->
  <ifrs-full:DisclosureOfDebtSecuritiesExplanatory id="Fact_58ccef3b3e8f4303b823890fbf44b467" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;11.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Financing obligation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;On January 4, 2016, September 13, 2016 and January 26, 2018 for the fiscal years 2016, 2017 and 2018, respectively, AC Immune obtained separate funding commitment notices from the LuMind Research Down Syndrome Foundation (LuMind) totaling USD 200 thousand in each instance. Per the Research Grant Agreement, AC Immune has an obligation to reimburse LuMind for an amount equal to 125% of the then funding commitment made by LuMind to AC Immune.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;On October 31, 2018, LuMind and the Company modified the repayment terms in an effort to fund a Down Syndrome Clinical Trials Network. The repayment terms were modified such that the Company will repay the outstanding balance in three installments in 2018, 2019 and 2020, with the total repayment to equal the total the Company is to receive in funding plus the additional 25% interest.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As of December 31, 2020, the Company has fully repaid this financing obligation.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDebtSecuritiesExplanatory>
  <!--Disclosure of detailed information about property, plant and equipment [text block]-->
  <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory id="Fact_fa45c20e9f8b4df4884f60759aa2883e" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following tables show the movements in the net book values of property, plant and equipment for the years ended December 31, 2020 and 2019, respectively:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Acquisition cost:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;158&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,187&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,698&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;402&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;8,445&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Acquisitions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;96&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;310&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,566&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;62&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,034&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,497&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,958&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;464&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,133&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Accumulated depreciation:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(627&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,619&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,528&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(33&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(343&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,092&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(67&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,535&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(61&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(4,405&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(281&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(5,717&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Carrying amount:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,079&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;188&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,917&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;153&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;527&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,553&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;183&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,416&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Acquisition cost:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;126&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,025&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5,367&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;350&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,868&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Acquisitions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;65&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;291&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,470&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;59&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,885&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(129&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(139&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(308&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;158&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,187&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6,698&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;402&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,445&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Accumulated depreciation:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(77&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(455&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,857&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(155&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,544&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(24&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(899&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(66&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,274&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;137&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(627&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(3,619&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(4,528&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Carrying amount:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;49&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;570&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,510&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,324&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,079&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;188&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,917&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
  <!--Disclosure of earnings per share [text block]-->
  <ifrs-full:DisclosureOfEarningsPerShareExplanatory id="Fact_ebdbacc3eef744f8a1be1821f131055b" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;19.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Earnings per share&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands, except for share and per share data&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Basic income/(loss) per share (EPS):&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net income/(loss) attributable to equity holders of the Company&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;70,603,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Basic income/(loss) for the period attributable to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(0.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;0.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(0.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Diluted income/(loss) per share (EPS):&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net income/(loss) attributable to equity holders of the Company&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;70,603,611&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of dilutive securities from equity incentive plans&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;499,730&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding &amp;#8211; diluted to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;71,103,341&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Diluted income/(loss) for the period attributable to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(0.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;0.64&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(0.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;In periods for which we have a loss, basic net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all potentially dilutive in-the-money (i) share options and (ii) shares that were issued upon conversion of the convertible note as their inclusion would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share options issued and outstanding (in-the-money)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;412,191&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,081,836&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,472,589&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Restricted share awards subject to future vesting&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;28,418&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Convertible shares&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;911,261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;440,609&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,993,097&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,581,630&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
  <!--Disclosure of employee benefits [text block]-->
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory id="Fact_d8cc42cc1b2641d9884db03917a66a24" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;16.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Retirement benefit plan&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company participates in a collective foundation covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee and shared approximately 47% and 53% by employee and employer, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;This plan is governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a separately administered fund. The fund has the legal form of a foundation and it is governed by the board of trustees, which consists of an equal number of employer and employee representatives. The board of trustees is responsible for the administration of the plan assets and for the definition of the investment strategy.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the different affiliated companies. The Company has no direct influence on the investment strategy of the foundation board.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, as they are shared between a much greater number of participants. On leaving the Company, a departing employee&amp;#8217;s retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This transfer mechanism may result in pension payments varying considerably from year to year.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners. For accounting purposes under IFRS, the plan is treated as a defined benefit plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As of January 1, 2019 the Company changed from a fully insured plan to a plan for which the Company now bears investment and old age risks. The new plan has a higher statutory coverage ratio, which led to an increase in plan assets of 10% (CHF 1.2 million) for the year ended December 31, 2019. The increase is presented in Table B as part of the line &amp;#8220;Return on plan assets excluding interest income.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table sets forth the status of the defined benefit pension plan and the amount that is recognized in the balance sheet:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(30,213&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair value of plan assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;22,749&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total liability&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7,464&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7,485&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(5,665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following amounts have been recorded as net pension cost in the statement of income:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Service cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,626&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,313&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;100&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(133&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net pension cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,655&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,375&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,130&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The changes in defined benefit obligation, fair value of plan assets and unrecognized gains/(losses) are as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;A.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Defined benefit obligation as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(14,278&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Service cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,626&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,313&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in demographic assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,428&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,138&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in financial assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,171&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in experience assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(931&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(2,003&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(888&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Benefits deposited&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,710&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&amp;#8217; contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(851&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(621&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Defined benefit obligation as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(30,213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;B.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in fair value of plan assets&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Fair value of plan assets as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9,352&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;42&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;133&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;65&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&amp;#8217; contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;851&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;756&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;621&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employer&amp;#8217;s contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;950&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;859&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;693&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Benefits deposited&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,710&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Return on plan assets excluding interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(164&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Fair value of plan assets as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;22,749&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Expected contributions by the employer to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount to approximately CHF 1.1 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;C.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in net defined benefit liability&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net defined benefit liabilities as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,926&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net pension cost through statement of income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,655&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,375&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,130&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Remeasurement through other comprehensive loss&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(726&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;302&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employer&amp;#8217;s contribution&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(950&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(693&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net defined benefit liabilities as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7,464&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;D.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in other comprehensive loss&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Other comprehensive loss as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(5,587&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,283&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,981&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in demographic assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,428&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,138&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in financial assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,171&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in experience assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(931&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(2,003&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(888&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Return on plan assets excluding interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(164&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Other comprehensive loss as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(4,861&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(5,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(4,283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The fair value of the plan assets is the cash surrender value of the insurance with the insurance company (AXA). The investment strategy defined by the board of trustees follows a conservative profile.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The plan assets are primarily held within instruments with quoted market prices in an active market, with the exception of real estate and mortgages.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The weighted-average duration of the defined benefit obligation is 17.6 years and 19.3 years as of December 31, 2020 and 2019, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December 31, 2020, 2019 and 2018, respectively, are as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.20&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.20&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Rate of future increase in compensations&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.75&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.75&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Rate of future increase in current pensions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest rate on retirement savings capital&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Mortality and disability rates&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2020-CMI&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2015-CMI&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2015G&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In defining the benefits, the minimum requirements of the Swiss BVG and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;A quantitative sensitivity analysis for significant assumptions as of December 31, 2020 is shown below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Discount rate&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future salary increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future pension cost&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Interest rate on &lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;savings capital&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot; font-weight: bold;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="30" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Potential defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,740&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;33,080&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;30,912&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,519&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;31,652&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;28,916&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;31,070&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,405&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Decrease/(increase) from actual defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;2,473&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(2,867&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(699&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;694&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(1,439&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;1,297&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(857&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;808&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;A quantitative sensitivity analysis for significant assumptions as of December 31, 2019 is shown below:&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Discount rate&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future salary increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future pension cost&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Interest rate on &lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;savings capital&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot; font-weight: bold;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="30" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;in CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Potential defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;24,248&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,396&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,317&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,930&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,993&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,393&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,447&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,848&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Decrease/(increase) from actual defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;2,376&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(2,772&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(693&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;694&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(1,369&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;1,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(823&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;776&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The sensitivity analyses above are subject to limitations and have been determined based on a method that extrapolates the impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <!--Subsequent events-->
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory id="Fact_1515c0cfa73a4145b98fa07b0f8ca826" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;22.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Subsequent events&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Management has evaluated subsequent events after the balance sheet date, through the issuance of these financial statements, for appropriate accounting and disclosures. &lt;/font&gt;We raised USD 8.8 (CHF 8.0) million, net of sales agent commissions, from the sale &lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;764,977 &lt;/font&gt;of our ordinary shares pursuant to our ATM program in February 2021.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <!--Disclosure of expenses [text block]-->
  <ifrs-full:DisclosureOfExpensesExplanatory id="Fact_ca7970eb3c6f4af6988d0936907dd8f1" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="vertical-align: top; width: 18pt; font-weight: bold;"&gt;13.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Expenses by category&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Research and Development&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;43,787&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;37,465&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;32,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;14,424&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;12,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,662&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,276&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;694&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total research and development expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;59,487&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;50,432&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;44,277&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the year ended December 31, 2020, 2019 and 2018, the Company incurred CHF 59.5 million, CHF 50.4 million and CHF 44.3 million in research and development expenses, respectively. These increases are predominantly driven by increases in investments in our research and development projects and full-time equivalents (FTEs).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company had 115.3, 102.7 and 87 FTEs in research and development.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;General and administrative&lt;/div&gt;&lt;div style="margin-left: 9.35pt;"&gt;&lt;font style="font-weight: bold; font-style: italic;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,471&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,637&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,903&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,274&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,172&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5,740&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,812&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,249&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total general and administrative expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;18,557&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;16,058&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;12,467&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the year ended December 31, 2020, 2019 and 2018, the Company incurred CHF 18.6 million, CHF 16.1 million and CHF 12.5 million in general and administrative expenses, respectively. These increases are predominantly driven by increases in full-time equivalents (FTEs).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company had 26.7, 24.1 and 17 FTEs general and administrative functions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Financial result, net&lt;/div&gt;&lt;div style="margin-left: 9.35pt;"&gt;&lt;font style="font-weight: bold; font-style: italic;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Financial income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;78&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;303&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;127&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Financial expense&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(184&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,926&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in fair value of conversion feature&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,542&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exchange differences&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(2,013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Finance result, net&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;906&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(1,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Our financial income and expense primarily consist of interest income and interest expense associated with our lease liabilities and prior convertible debt instrument.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the year ended December 31, 2020, the following items from 2019 did not repeat:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;the CHF 4.5 million gain on the conversion feature related to the Company&amp;#8217;s convertible loan due to Lilly in 2019;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;CHF 1.4 million in interest expenses related to effective interest recorded to amortize the host debt per the convertible loan due to Lilly; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;a CHF 1.2 million remeasurement loss related to the settlement of the convertible loan.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfExpensesExplanatory>
  <!--Disclosure of fair value of plan assets [text block]-->
  <ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory id="Fact_44203aeadb6f4393ae1057bc3a3f10d9" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The changes in defined benefit obligation, fair value of plan assets and unrecognized gains/(losses) are as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;A.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Defined benefit obligation as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(14,278&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Service cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,626&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,313&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in demographic assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,428&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,138&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in financial assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,171&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in experience assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(931&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(2,003&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(888&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Benefits deposited&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,710&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&amp;#8217; contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(851&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(621&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Defined benefit obligation as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(30,213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;B.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in fair value of plan assets&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Fair value of plan assets as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9,352&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;42&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;133&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;65&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&amp;#8217; contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;851&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;756&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;621&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employer&amp;#8217;s contributions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;950&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;859&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;693&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Benefits deposited&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,710&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Return on plan assets excluding interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(164&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Fair value of plan assets as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;22,749&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Expected contributions by the employer to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount to approximately CHF 1.1 million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;C.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in net defined benefit liability&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net defined benefit liabilities as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,926&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net pension cost through statement of income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,655&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,375&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,130&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Remeasurement through other comprehensive loss&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(726&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;302&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employer&amp;#8217;s contribution&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(950&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(859&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(693&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net defined benefit liabilities as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7,464&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;D.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Change in other comprehensive loss&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Other comprehensive loss as of January 1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(5,587&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,283&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,981&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in demographic assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,428&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,138&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in financial assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,171&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of changes in experience assumptions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(931&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(2,003&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(888&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Return on plan assets excluding interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;300&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(164&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Other comprehensive loss as of December 31&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(4,861&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(5,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(4,283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory>
  <!--Financial Result, net-->
  <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory id="Fact_cb3207bf79954763aa18edcbb31d7845" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Financial result, net&lt;/div&gt;&lt;div style="margin-left: 9.35pt;"&gt;&lt;font style="font-weight: bold; font-style: italic;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Financial income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;78&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;303&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;127&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Financial expense&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(184&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,926&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Change in fair value of conversion feature&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,542&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exchange differences&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(555&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(2,013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(1,194&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Finance result, net&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(661&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;906&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(1,401&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
  <!--Cash and cash equivalents and short-term financial assets-->
  <ifrs-full:DisclosureOfFinancialAssetsExplanatory id="Fact_7a046d455b154d529d671d39bee36e7d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;By currency&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;152,537&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;158,173&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;EUR&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,215&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;10,169&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;USD&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;4,141&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;25,245&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table summarizes the Company&amp;#8217;s short-term financial assets as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financial assets due in 1 year or less&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
  <!--Disclosure of financial risk management [text block]-->
  <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory id="Fact_4af1a713780a4e1b9297f4be3a3ee4f6" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;20.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Financial instruments and risk management&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s activities expose it to the following financial risks: market risk (foreign exchange and interest rate risk), credit risk and liquidity risk. The Company&amp;#8217;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company&amp;#8217;s financial performance.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table shows the carrying amounts of financial assets and financial liabilities:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Long-term financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other current receivables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;329&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;226,556&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;289,195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Financial liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Long-term lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,780&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,813&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;142&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;11,085&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;11,797&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financing obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;652&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total financial liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;15,492&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;14,846&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Foreign exchange risk&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 9.35pt;"&gt;The Company is exposed to foreign exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency exposure is not hedged. However, the Company has a policy of matching its cash holdings to the currency structure of its expenses, which means that the Company holds predominately CHF, with lesser balances of EUR and USD (see &amp;#8220;Note 6. Cash and cash equivalents and financial assets&amp;#8221;). The Company recognized a loss of CHF 0.7 million, CHF 0.8 million and CHF 1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively, within &amp;#8220;Finance result, net.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As of December 31, 2020, if the CHF had strengthened/weakened by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would have been lower/higher by CHF 0.8 million (2019: CHF 3.5 million), mainly as a result of foreign exchange gains/losses on predominantly EUR/USD denominated cash and cash equivalents and short-term financial assets.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Interest rates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s CHF cash holdings (inclusive of those held in short-term financial assets) are subject to negative interest rates at certain counterparty thresholds. As of December 31, 2020 if the interest rates charged by the counterparties had increased/decreased by 10%, the net income for the period would have been higher/lower by less than CHF 0.1 million. Interest income and interest expense are recorded within finance results, net in our statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Credit risk&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company maintains a formal treasury risk and investment management policy to limit counterparty credit risk. As of December 31, 2020, the Company&amp;#8217;s cash and cash equivalents and short-term financial assets are held with four financial institutions, each with a high credit rating assigned by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Trade and other receivables are fully performing, not past due and not impaired (see &amp;#8220;Note 6. Cash and cash equivalents and financial assets&amp;#8221; and &amp;#8220;Note 8. Other current receivables&amp;#8221;).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Liquidity risk&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Inherent in the Company&amp;#8217;s business are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts will succeed. AC Immune&amp;#8217;s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) acquire and keep key personnel employed and (iv) acquire additional capital to support its operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 18 months. The Company has CHF 2.2 million in trade and other payables, which are due within 12 months from the reporting date. Finally, as it relates to the Company&amp;#8217;s lease liabilities please see &amp;#8220;Note 5. Right-of-use assets and lease liabilities&amp;#8221; for detail of when corresponding lease liabilities are due.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
  <!--Disclosure of general and administrative expense [text block]-->
  <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory id="Fact_794cbd34fb674510b9da51744f69e6a5" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;General and administrative&lt;/div&gt;&lt;div style="margin-left: 9.35pt;"&gt;&lt;font style="font-weight: bold; font-style: italic;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,471&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,637&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,903&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,274&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,172&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5,740&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,812&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,249&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total general and administrative expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;18,557&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;16,058&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;12,467&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
  <!--Income taxes-->
  <ifrs-full:DisclosureOfIncomeTaxExplanatory id="Fact_58e2cf502a654f879376d08d54a87ce3" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;15.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Income taxes&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company recognized no income tax expense or deferred tax asset or liability positions for the years ended December 31, 2020, 2019, and 2018.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The income tax expense for each year can be reconciled to loss before tax as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Income/(loss) before income tax&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(8,441&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6,194&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(10,507&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Income not subject to tax/(expenses) not deductible for tax purposes&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;462&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(62&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of unused tax losses and tax offsets not recognized as deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,979&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(6,132&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;10,173&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Effective income tax rate benefit/(expense)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The tax rate used for the 2020 reconciliations above is the corporate tax rate of 13.6% (13.6% in 2019 and 20.6% in 2018) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Unrecognized deductible temporary differences, unused tax losses and unused tax credits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax losses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;121,948&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;64,125&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;109,294&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deductible temporary differences related to:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Right-of-use assets and lease liabilities, net&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Retirement benefit plan&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,464&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;129,412&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;71,610&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;114,959&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Tax losses expiry dates are shown in the table below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Tax losses split by expiry date:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;16,566&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,338&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2023&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,628&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2024&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;15,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;15,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;25,868&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2025&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2026&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;57,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;121,948&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;64,125&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;109,294&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The tax losses available for future offset against taxable profits have increased by CHF 57.8 million from 2019, re&lt;font style="color: #000000;"&gt;presenting the amount of tax losses that are additionally available as an offset, subject to expiration as disclosed in the table above, against future taxable income.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Consistent with prior years, the Company has not recorded any deferred tax assets in relation to the past tax losses available for offset against future profits as the recognition criteria were not met at the balance sheet date.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <!--Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]-->
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory id="Fact_87f70c5b492141edb4da5353c4200273" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The weighted-average grant date fair values of the options granted in 2020, 2019 and 2018 are USD 5.25 (CHF 4.65), USD 3.71 (CHF 3.59) and USD 6.66 (CHF 6.54), respectively. &lt;font style="color: #000000;"&gt;The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of these awards:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 5.04-9.16&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 5.15&amp;#8211;5.54&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 8.33&amp;#8211;12.30&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share price (weighted average)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7.11&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.41&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.87&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <!--Right-of-use assets and lease liabilities-->
  <ifrs-full:DisclosureOfLeasesExplanatory id="Fact_b4552f04c43947b9a9aec015e9982a47" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;5.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Right-of-use assets and lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company recognized additions of right-of-use of leased assets for buildings or for office equipment totaling CHF 0.4 and CHF 0.5 million for the years ended December 31, 2020 and 2019, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Regarding lease liabilities, the amortization depends on the rate implicit in the contract or the incremental borrowing rate for the respective lease component. The weighted averages of the incremental borrowing rates as of December 31, 2020 are 2.5% for buildings, 4.2% for office equipment and 2.6% for IT equipment.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following tables show the movements in the net book values of right-of-use of leased assets for the years ended December 31, 2020 and 2019, respectively:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;81&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,255&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(432&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;63&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;54&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,223&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;79&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,185&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;29&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;500&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(10&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(10&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(420&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;81&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,255&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;There are no variable lease payments which are not included in the measurement of lease obligations. All extension options have been included in the measurement of lease obligations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, and 2019, the impact on the Company&amp;#8217;s statements of income/(loss) and statements of cash flows is detailed in the table below.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;"&gt;Statements of income/(loss)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation of right-of-use assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;432&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;420&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest expense on lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;53&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expense for short-term leases and leases of low value&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;603&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;565&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,088&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,037&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;"&gt;Statements of cash flows&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total cash outflow for leases&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,088&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,037&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table presents the contractual undiscounted cash flows for lease liabilities as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Within 1 year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 1 and 3 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 3 and 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;912&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;948&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,367&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
  <!--Disclosure of net defined benefit liability (asset) [text block]-->
  <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory id="Fact_b6160eeef9ea4c5093fb249c3ffebeba" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following table sets forth the status of the defined benefit pension plan and the amount that is recognized in the balance sheet:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(30,213&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(17,942&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Fair value of plan assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;22,749&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;19,139&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;12,277&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total liability&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7,464&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7,485&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(5,665&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following amounts have been recorded as net pension cost in the statement of income:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Service cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,626&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,313&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;100&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(133&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(65&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Net pension cost&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,655&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,375&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,130&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
  <!--Disclosure of number and weighted average exercise prices of other equity instruments [text block]-->
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory id="Fact_d6f6b6aa9400457695907c53d013ae13" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;A summary of non-vested share awards (restricted share and restricted share units) activity as of December 31, 2020 and changes during the year then ended is presented below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Grantee type&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;awards &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;granted&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Vesting conditions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;life of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Restricted share units&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Directors&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;83,864&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;1 year service from date of grant, annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Executives&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;110,839&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from the date of grant, quarterly&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Restricted share awards&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,023&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;2.75 years&amp;#8217; service from date of grant, quarterly&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested shares&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;grant date fair value (CHF)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;122,014&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.59&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(25,673&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.48&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;69,371&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.43&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(56,671&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.60&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;64,012&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.65&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(66,278&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;42,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;130,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.58&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;42,763&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(11,828&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.47&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(7,804&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(84,638&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(23,269&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;19,494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;49,289&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.47&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
  <!--Disclosure of number and weighted average exercise prices of share options [text block]-->
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory id="Fact_98b33b7b134444c2972025803f188074" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The number and weighted-average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and the 2016 SOIP are as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of options&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average exercise price (CHF)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average remaining&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;term (years)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,359,891&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2.09&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.8&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.16&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(151,814&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;484,403&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.79&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,618,856&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;4.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;6.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;932,175&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1.25&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4.4&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,618,856&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4.25&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6.3&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,699&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6.71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(616,833&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,053,305&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5.24&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,981,629&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5.93&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;8.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;602,218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,981,629&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.93&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;8.3&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(53,591&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6.03&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,729&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4.38&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,669&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,073,027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6.29&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,900,667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;5.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;8.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,099,015&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5.49&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7.0&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <!--Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]-->
  <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory id="Fact_797b4fb8f03a4f3e94ad472b67c7e992" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The outstanding stock options as of December 31, 2020 have the following range of exercise prices. In fiscal year 2018, we began to grant awards solely with USD denominated exercise prices and discontinued granting awards with a CHF denominated exercise price.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total options&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Range of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;expiration &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;dates&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Range of exercise prices&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF 0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;243,125&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2020&amp;#8211;2026&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF 9.53&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;223,646&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;USD 5.04 to USD 12.30&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,433,896&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2028&amp;#8211;2030&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total outstanding options&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,900,667&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
  <!--Disclosure of objectives, policies and processes for managing capital [text block]-->
  <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory id="Fact_c8e22796d6bf4450a6dc1768e355efd4" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;21.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Capital risk management&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s objectives when managing capital are to safeguard the Company&amp;#8217;s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against (i) AD, (ii) focused non-Alzheimer&amp;#8217;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
  <!--Disclosure of property, plant and equipment [text block]-->
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory id="Fact_a1028b30e0d944359bc0d0b40c0ddc8d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;4.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following tables show the movements in the net book values of property, plant and equipment for the years ended December 31, 2020 and 2019, respectively:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Acquisition cost:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;158&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,187&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,698&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;402&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;8,445&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Acquisitions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;96&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;310&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,566&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;62&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,034&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,497&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,958&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;464&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,133&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Accumulated depreciation:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(627&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,619&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,528&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(33&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(343&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,092&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(67&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,535&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(61&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(4,405&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(281&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(5,717&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Carrying amount:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,079&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;188&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,917&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;153&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;527&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,553&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;183&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,416&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Acquisition cost:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;126&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,025&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5,367&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;350&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,868&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Acquisitions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;65&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;291&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,470&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;59&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,885&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(129&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(139&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(308&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;158&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,187&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6,698&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;402&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;8,445&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Accumulated depreciation:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(77&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(455&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(2,857&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(155&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(3,544&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(24&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(285&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(899&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(66&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(1,274&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;33&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;137&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(627&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(3,619&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(4,528&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Carrying amount:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;49&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;570&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,510&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;195&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,324&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,079&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;188&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;3,917&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company incurred CHF 1.5 million, 1.3 million and CHF 1.0 million in depreciation expenses, respectively.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <!--Disclosure of quantitative information about right-of-use assets [text block]-->
  <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory id="Fact_6635b67bc2094eb59391182db39c800a" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following tables show the movements in the net book values of right-of-use of leased assets for the years ended December 31, 2020 and 2019, respectively:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;81&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,255&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(432&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;63&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;54&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,223&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Buildings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;IT equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;79&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,185&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Additions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;400&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;29&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;500&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Disposals&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(10&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(10&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(420&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Balance as of December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,106&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;81&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,255&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
  <!--Disclosure of related party [text block]-->
  <ifrs-full:DisclosureOfRelatedPartyExplanatory id="Fact_f8536c15ea6c445597b39d44219118e3" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;14.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Related-party transactions&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For key management, including the board of directors (seven individuals excluding the CEO) and the executive management (five individuals including the CEO), compensation was as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,497&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,526&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,681&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Post-employment benefits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;214&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;215&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;160&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,578&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,155&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,683&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;6,289&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;5,896&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4,524&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;In 2018, as part of the Company&amp;#8217;s subscription rights offering, a major shareholder and members of the board and executive management purchased an aggregate of 614,147 of the Company&amp;#8217;s common shares on the same basis and otherwise on the same terms as the other participants in such rights offering.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <!--Disclosure of research and development expense [text block]-->
  <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory id="Fact_b3650b28579a407a884d6b3a4498c4ce" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Research and Development&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;43,787&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;37,465&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;32,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;14,424&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;12,382&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,662&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,276&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;694&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total research and development expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;59,487&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;50,432&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;44,277&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
  <!--Cash and cash equivalents and financial assets-->
  <ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory id="Fact_308e9cd47bdf4d7db5370e17eddd7fe7" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;6.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Cash and cash equivalents and financial assets&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;By currency&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;152,537&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;158,173&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;EUR&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,215&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;10,169&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;USD&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;4,141&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;25,245&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At the balance sheet dates, Company funds were held in CHF, EUR and USD currencies. As of December 31, 2020 and 2019, funds in EUR and USD were translated into CHF at a rate of 1.095 and 0.891 and 1.096 and 0.978, respectively, for each currency and year.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table summarizes the Company&amp;#8217;s short-term financial assets as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financial assets due in 1 year or less&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company also has two deposits in escrow accounts totaling CHF 0.3 million and CHF 0.3 million for the lease of the Company&amp;#8217;s premises as of December 31, 2020 and 2019, respectively.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory>
  <!--Disclosure of revenue [text block]-->
  <ifrs-full:DisclosureOfRevenueExplanatory id="Fact_1278b56a55f74607bfff010d8958e688" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;12.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Contract revenues&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, AC Immune generated contract revenues of CHF 15.4 million, CHF 110.5 million and CHF 6.9 million, respectively. For comparability, the Company reclassified CHF 0.3 million, CHF 0.6 million and CHF 0.3 million from contract revenues to other income/(expense) for the years ended December 31, 2020, 2019 and 2018, respectively for prior grants from the MJFF.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The following tables provide contract revenue amounts from its LCAs for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Lilly&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;14,348&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;105,662&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Genentech&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Janssen&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,083&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,173&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,157&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Life Molecular Imaging&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,206&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Biogen&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,063&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,024&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;352&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;731&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total contract revenue&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;15,431&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;110,456&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;6,912&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Lilly accounted for 93% and 96% of our contract revenues in 2020 and 2019, respectively. Biogen and Janssen accounted for 58% and 31% of our contract revenues in 2018, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt; color: #000000;"&gt;The following table presents changes in the Company&amp;#8217;s contract assets and liabilities during the years ended December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF Thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Balance at &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;the beginning &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;of the &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;reporting period&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Additions&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Deductions&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Balance at &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;the end &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;of the&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;reporting period&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Twelve months ended December 31, 2020:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,354&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,858&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,591&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(5,638&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;306&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Twelve months ended December 31, 2019:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,667&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,211&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,783&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,686&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(3,560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;During the years ended December 31, 2020, 2019 and 2018, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Revenues recognized in the period from:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Amounts included in the contract liability at the beginning of the period&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;1,551&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Performance obligations satisfied in previous periods&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,206&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 22pt; vertical-align: top; font-weight: bold;"&gt;12.1&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Licensing and collaboration agreements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;Morphomer Tau small molecule &amp;#8211; 2018 license agreement with Eli Lilly and Company&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. More specifically, this is an exclusive license with the right to Lilly to grant sublicenses under the ACIU Patents, the ACIU know-how, and ACIU&amp;#8217;s interests in the Joint Patents and the joint know-how to Exploit the Licensed Compounds and Licensed Products. The agreement became effective on January 23, 2019 (the &amp;#8220;effective date&amp;#8221;) when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. In Q3 2019, the Company and Lilly entered into the first amendment to divide the first discretionary milestone payment under the agreement of CHF 60 million into two installments, with the first CHF 30 million paid in Q3 2019 and the second CHF 30 million to be paid on or before March 31, 2020 unless Lilly terminated the agreement earlier. In Q1 2020, the Company and Lilly entered into a second amendment to replace the second CHF 30 million to be paid on or before March 31, 2020 with two milestone payments, one of CHF 10 million to be paid on or before March 31, 2020 and the other of CHF 60 million following the first patient dosed in a Phase 2 clinical study of a licensed product in the US or EU.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly. To date, the Company has completed a Phase 1 clinical study with ACI-3024. The program will be expanded to NeuroOrphan indications and ACI-3024 will be further evaluated for efficacy in models of rare Tauopathies.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Additionally, the Company and Lilly have continued candidate characterization across the research program, identifying new and highly differentiated candidates with desired cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent neurodegenerative diseases by Lilly.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Lilly is responsible for leading and funding further clinical development and will retain global commercialization rights for all indications.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Per the terms of the agreement, the Company may become eligible to receive additional milestone payments totaling up to approximately CHF 880 million for clinical and regulatory milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low double-digits to the mid-teens. The agreement will terminate by the date of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly may terminate the agreement at any time by providing 3 months&amp;#8217; prior notice to us.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations under the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. Per the agreement, the Company was responsible for the preclinical and Phase 1 activities for the first clinical candidate, ACI-3024, which the Company determined was distinct and capable of being completed by Lilly or a third party. Preclinical activities for which AC Immune was responsible prior to their completion in Q2 2019 included final manufacturing of materials for use in the regulatory submission of the protocol and in the Phase 1 study. For the completed Phase 1, AC Immune was responsible for leading the study design, obtaining relevant regulatory agency approvals, arranging necessary third-party contracts, completing patient selection, ensuring patient treatment, following up with patients, drafting the clinical study report development and other relevant clinical activities to ensure that the primary objective of the study was completed. The Company used CMOs for certain of its preclinical activities and CROs to complete certain Phase 1 activities and to issue the final clinical study report.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s preclinical and Phase 1 activities did not represent integrated services with the licensed IP for which Lilly contracted. Lilly purchased a license to the Company&amp;#8217;s Tau therapeutic small-molecule program, which was delivered at commencement of the agreement, and AC Immune&amp;#8217;s preclinical and Phase 1 activities did not affect the form or functionality of this license. The Company&amp;#8217;s objective for the Phase 1 activity was to assess safety and tolerability and did not modify or customize ACI-3024. The completion of these preclinical and Phase 1 activities does not affect the licensed IP.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Finally, per the agreement, each party has three representatives on a joint steering committee (JSC); depending upon the agenda, additional field experts can attend the JSC to provide the technical and scientific contribution required. The JSC meets on a regular basis depending on agreements between the representatives. The JSC is responsible for serving as the forum to (i) discuss, review and approve certain activities by reviewing and discussing the development progress with updates on back-up candidates, (ii) discuss, review and approve all amendments to the global development plan, (iii) periodically discuss and review commercialization of licensed products and (iv) review and approve reports related to development costs among other activities. The JSC is intended to ensure that communication between the parties remains consistent and that the development plan is progressing as intended.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The valuation of each performance obligation involves estimates and assumptions with revenue recognition timing to be determined by either delivery or the provision of services.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company used the residual approach to estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research and development activities. The right-of-use license was delivered on the effective date. The research and development activities were delivered over time as the services were performed. For these services, revenue was recognized over time using the input method, based on costs incurred to perform the services, as the level of costs incurred over time is thought to best reflect the transfer of services to Lilly. The Company determined the value of the research and development activities to be CHF 6.9 million and deferred this balance from the effective date. As of December 31, 2020, the Company has cumulatively recognized CHF 6.9 million in contract revenue, resulting in no deferred income (contract liability) on the balance sheets. The remaining CHF 73.1 million from the upfront payment was allocated to the right-of-use license and recognized on the effective date.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At inception of the agreement, none of the clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully constrained. Through December 31, 2020, the Company has recognized CHF 40 million from milestone payments triggered in Q3 2019 and Q1 2020 related to the right-of-use license for IP as there were no further constraints related to these milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&amp;#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, we have recognized CHF 14.3 million, CHF 105.7 million and nil, respectively from this arrangement.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;Anti-Abeta antibody in AD &amp;#8211; 2006 agreement with Genentech, a member of the Roche Group&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In November 2006, we signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal therapeutic antibody targeting misfolded Abeta. The agreement was amended March 2009, January 2013, May 2014 and May 2015. The agreement also provides for the development of a second therapeutic product for a non-AD indication based on the same intellectual property and anti-Abeta antibody compound. The value of this partnership is potentially greater than USD 340 (CHF 303) million.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The term of the agreement commenced on the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party, provided a cure period of 90 days from the date when that notice is given.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Genentech commenced a first Phase 3 clinical study in March 2016 for crenezumab (CREAD). In March 2017, Genentech started a second Phase 3 clinical trial (CREAD 2). Since 2013, crenezumab has also been studied in a Phase 2 trial in individuals who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD (autosomal dominant AD (ADAD)). In 2019, Genentech initiated a Tau Positron Emission Tomography (PET) substudy to the ongoing Phase 2 trial in ADAD to evaluate the effect of crenezumab on Tau burden, which may also increase the understanding of disease progression in the preclinical stage of ADAD.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the US and Europe ranging from the mid-single digits to mid-teens. To date, we have received total milestone payments of USD 65 million (CHF 70.1 million) comprised of an upfront payment of USD 25 (CHF 31.6) million and of USD 40 (CHF 38.2) million for clinical development milestones achieved all-in prior to January 1, 2017. Genentech may terminate the agreement at any time by providing 3 months&amp;#8217; notice to us. In such event all costs incurred are still refundable.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conducting of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech&amp;#8217;s right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company&amp;#8217;s obligation to perform research does not significantly impact or modify the licenses&amp;#8217; granted functionality.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At execution of the agreement, the transaction price included the upfront consideration received of USD 25 (CHF 31.6) million. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestone payments since inception, totaling USD 40 (CHF 38.2) million. The Company could receive greater than USD 275 (CHF 245) million or more for further regulatory milestones for this exclusive, worldwide alliance. In assessing that future regulatory milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&amp;#8217;s efforts. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;On January 30, 2019, we announced that Roche, the parent of Genentech, is discontinuing the CREAD and CREAD 2 (BN29552 and BN29553) Phase 3 studies of crenezumab in people with prodromal-to-mild sporadic AD. The decision came after an interim analysis conducted by the Independent Data Monitoring Center (IDMC) indicated that crenezumab was unlikely to meet its primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score. This decision was not related to the safety of the investigational product. No safety signals for crenezumab were observed in this analysis and the overall safety profile was similar to that seen in previous trials.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Crenezumab continues to be studied in the Phase 2 preventive trial, which began in 2013 in Columbia, of cognitively healthy individuals who carry the PSEN1 E280A autosomal-dominant mutation and are in a preclinical phase of ADAD. This study will determine if treating people carrying this mutation with crenezumab prior to the onset of AD symptoms will slow or prevent the decline of cognitive and functional abilities.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, we have recognized no revenues from this arrangement.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;Anti-Tau antibody in AD &amp;#8211; 2012 agreement with Genentech, a member of the Roche Group&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In June 2012, we entered into a second agreement with Genentech to research, develop and commercialize our anti-Tau antibodies for use as immunotherapeutics and diagnostics. The agreement was amended in December 2015. The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million and includes upfront and clinical, regulatory and commercial milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to low-double digits. The agreement also provides for collaboration on at least one additional therapeutic indication outside of AD built on the same anti-Tau antibody program as well an anti-Tau diagnostic product for AD.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The term of the agreement commenced on the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party, provided a cure period of 90 days from the date when that notice is given.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;To date, we have received payments totaling CHF 59 million, including a milestone payment of CHF 14 million received and recognized in Q4 2017 associated with the first patient dosing in a Phase 2 clinical trial for AD with an anti-Tau monoclonal body known as semorinemab, a milestone payment of CHF 14 million recognized in Q2 2016 and received in July 2016, associated with the announcement of the commencement of the Phase 1 clinical study of semorinemab, and a milestone payment of CHF 14 million received in 2015 in connection with the ED-GO decision. As we met all performance obligations on reaching these milestones, we have recognized revenue in the respective periods. Genentech may terminate the agreement at any time by providing 3 months&amp;#8217; notice to us.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conduct of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech&amp;#8217;s right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company&amp;#8217;s obligation to perform research does not significantly impact or modify the licenses&amp;#8217; granted functionality.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At execution of the agreement, the transaction price included an upfront consideration received of CHF 17 million. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestones since inception totaling CHF 42 million. The Company could also receive up to an additional CHF 368.5 million in clinical, regulatory and commercial milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;On September 23, 2020, the Company reported that Genentech informed us of top line results from a Phase 2 trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer&amp;#8217;s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. The primary safety endpoint was however met. Two secondary endpoints, Alzheimer&amp;#8217;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer&amp;#8217;s Disease Cooperative Study Group &amp;#8211; Activities of Daily Living Inventory (ADCS-ADL), were not met. A second Phase 2 study of semorinemab in patients with moderate AD remains ongoing.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, we have recognized no revenues from this arrangement, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;Tau vaccine in AD &amp;#8211; 2014 agreement with Janssen Pharmaceuticals, Inc.&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen) one of The Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. In April 2016, July 2017, January 2019 and November 2019, the companies entered into the first, second, third and fourth amendments, respectively. These amendments allow for the alignment of certain payment and activity provisions with the Development Plan and Research Plan activities. We and Janssen are co-developing the second-generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054, through Phase 1b/2a completion. AC Immune and Janssen will jointly share research and development costs until the completion of the first Phase 2b (AC Immune's contribution to the first Phase 2b trial capped). From Phase 2b and onwards, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of the second-generation vaccines.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days&amp;#8217; notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined in the contract.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The agreement also allows for the expansion to a second indication based on the same anti-Tau vaccine program and based on intellectual property related to this program.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company received an upfront, non-refundable license fee of CHF 25.9 million, which we recognized as revenue in 2014. In May 2016, we received a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study. As we met all performance obligations on reaching the milestone, we have recognized this income as revenue.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Janssen is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) research and development services including a development and chemistry, manufacturing and controls work plan. The Company considered the research and development capabilities of Janssen, Janssen&amp;#8217;s right to sublicense, and the fact that the research and development services are not proprietary and can be provided by other vendors, to conclude that the license has stand-alone functionality and is distinct. The Company&amp;#8217;s obligation to perform research and development services does not significantly impact or modify the licenses&amp;#8217; granted functionality. Based on these assessments, the Company identified the license and the research and development services as the performance obligations at the inception of the arrangement, which were deemed to be distinct in the context of the contract.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At execution of the agreement, the transaction price included only the upfront consideration received of CHF 25.9 million. At inception, none of the clinical, regulatory or commercial milestones has been included in the transaction price, as all milestone amounts were fully constrained. The Company did receive a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study in May 2016. The Company could also receive up to more than CHF 458 million in clinical, regulatory and commercial milestones as well as tiered, low-double digit to mid-teen royalties on aggregate net sales of products. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&amp;#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, we have recognized revenues totaling CHF 1.1 million, CHF 1.2 million and CHF 2.2 million, respectively from this arrangement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;Tau-PET imaging agent in AD &amp;#8211;2014 agreement with Life Molecular Imaging (LMI) (formerly Piramal Imaging SA)&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In May 2014, we entered into an agreement, our first diagnostic partnership, with LMI, the former Piramal Imaging SA. The partnership with LMI is an exclusive, worldwide licensing agreement for the research, development and commercialization of the Company&amp;#8217;s Tau protein PET tracers supporting the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments totaling up to EUR 159 (CHF 175) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low-teens. LMI may terminate the LCA at any time by providing 3 months&amp;#8217; notice to us.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In connection with this agreement, AC Immune received a payment of EUR 500 (CHF 664) thousand, which was fully recognized in 2015. In Q1 2017, we recorded a milestone payment of EUR 1 (CHF 1.1) million related to the initiation of &amp;#8220;Part B&amp;#8221; of the first-in-man Phase 1 study. In Q3 2019, the Company recognized EUR 2 (CHF 2.2) million in connection with the initiation of a Phase 2 trial of Tau-PET tracer in patients with mild cognitive impairment and mild&amp;#8211;to-moderate AD in comparison with non-demented control participants. The Company is eligible to receive variable consideration related to the achievement of certain clinical milestones totaling EUR 8 (CHF 9) million should the compound make it through Phase 3 clinical studies. We are also eligible to receive potential regulatory and sales-based milestones totaling EUR 148 (CHF 162) million. Finally, the Company is eligible for royalties from the mid-single digits to low-double digits.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that LMI is a customer. The Company has identified that the right-of-use license as the only performance obligation. The Company determined that transaction price based on the defined terms allocated to each performance obligation specified in the contract.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The upfront payment constitutes the amount of consideration to be included in the transaction price and has been allocated to the license. None of the clinical, regulatory or commercial milestones has been included in the transaction price as these variable consideration elements are considered fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&amp;#8217;s efforts.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to LMI and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. The Company considered LMI&amp;#8217;s right to sublicense and develop the Tau protein PET tracers, and the fact that LMI could perform the research and development work themselves within the license term without AC Immune, to conclude that the license has stand-alone functionality and is distinct. The Company believes that the contracted amount represents the fair value. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company has recognized nil, CHF 2.2 million and nil, respectively, from this arrangement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 18pt; font-style: italic;"&gt;A-syn and TDP-43 PET tracers &amp;#8211; 2016 agreement with Biogen&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;On April 13, 2016, we entered into a non-exclusive research collaboration agreement with Biogen International GmbH, (Biogen). Under the agreement, we and Biogen have agreed to collaborate in the research and early clinical development of our a-syn PET tracer program for PD and other synucleinopathies, and a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic lateral sclerosis (ALS). In addition, we have agreed to share the costs of the collaboration, with Biogen primarily funding the majority of research costs, subject to a cap, which includes an upfront technology access fee and funding toward research and development personnel. We own all intellectual property rights to any invention relating to a-syn or TDP-43 PET tracers.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Biogen is a customer. The Company has identified two performance obligations in our Biogen collaboration: (i) technology access fee and (ii) research and development services. The Company determined the transaction price based on the defined terms allocated to each performance obligation specified in the contract. In instances where the Company is reimbursed for research and development contributions procured from third parties such as negotiated terms with clinical CROs, AC Immune records revenues for such services as it is acting as a principal in procuring the goods or services. The Company has the primary responsibility for fulfilling the promise to provide the specified good or service, it has inventory risk before transfer to the customer and it has discretion in negotiating the price with third parties. For other research and development services, revenues are recognized as work is performed, which correspond with and best depict the transfer of control to the customer in line with the terms outlined in the contract.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company has recognized nil, CHF 1.1 million and CHF 4.0 million, respectively, from this arrangement. &lt;font style="color: #000000;"&gt;This collaboration ended in April 2019.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 22pt; vertical-align: top; font-weight: bold;"&gt;12.2 &lt;br /&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Grant income&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; font-style: italic;"&gt;Grants from the Michael J. Fox Foundation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In Q3 2017, we formally signed a grant continuation with the MJFF. This grant provides funds for the development of PET tracers for pathological forms of the protein alpha-synuclein, to support the early diagnosis and clinical management of Parkinson&amp;#8217;s disease. We subsequently signed two additional grants which facilitated the &lt;font style="color: #000000;"&gt;execution of a first-in-human study for a potential alpha-synuclein-PET tracer (PET tracer) with the current lead compound and to further develop the PET tracer. &lt;/font&gt;The Company retains its intellectual property rights for these alpha-synuclein-PET tracers. These grants concluded in Q2 2020.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;In May 2020, the Company, as part of a joint arrangement with Sk&amp;#229;ne University Hospital (Sk&amp;#229;ne) in Sweden, was awarded a USD 3.2 (CHF 2.9) million grant from the MJFF&amp;#8217;s Ken Griffin Alpha-synuclein Imaging Competition. As part of this grant, AC Immune is eligible to receive USD 2.5 (CHF 2.2) million directly from the MJFF. Sk&amp;#229;ne will receive USD 0.7 (CHF 0.7) million of the total grant directly from the MJFF over two years to conduct and support the clinical arm of the project.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The MJFF expects that AC Immune and Sk&amp;#229;ne will complete tasks according to the agreed timelines. AC Immune&amp;#8217;s funding is variable depending on the satisfactory achievement of these specific tasks within a specific period of time.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company has recognized CHF 1.3 million, CHF 0.6 million and CHF 0.3 million, respectively, from these grants.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
  <!--Disclosure of revenue from contracts with customers [text block]-->
  <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory id="Fact_7cd0610615884d5ebfb308f3ae24c57a" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The following tables provide contract revenue amounts from its LCAs for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Lilly&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;14,348&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;105,662&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Genentech&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Janssen&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,083&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,173&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,157&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Life Molecular Imaging&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,206&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Biogen&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,063&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,024&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;352&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;731&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total contract revenue&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;15,431&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;110,456&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;6,912&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;During the years ended December 31, 2020, 2019 and 2018, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the years ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Revenues recognized in the period from:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Amounts included in the contract liability at the beginning of the period&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;1,551&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Performance obligations satisfied in previous periods&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,206&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
  <!--Disclosure of sensitivity analysis for actuarial assumptions [text block]-->
  <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory id="Fact_9757179d4bf043bc8686a06f8ef6bf4e" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December 31, 2020, 2019 and 2018, respectively, are as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.20&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.20&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Rate of future increase in compensations&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.75&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.75&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Rate of future increase in current pensions&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest rate on retirement savings capital&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.50&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0.90&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Mortality and disability rates&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2020-CMI&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2015-CMI&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"&gt;&lt;div style="text-align: right;"&gt;BVG 2015G&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;A quantitative sensitivity analysis for significant assumptions as of December 31, 2020 is shown below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Discount rate&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future salary increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future pension cost&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Interest rate on &lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;savings capital&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot; font-weight: bold;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="30" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Potential defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,740&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;33,080&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;30,912&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,519&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;31,652&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;28,916&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;31,070&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,405&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Decrease/(increase) from actual defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;2,473&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(2,867&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(699&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;694&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(1,439&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;1,297&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(857&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;808&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;A quantitative sensitivity analysis for significant assumptions as of December 31, 2019 is shown below:&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Discount rate&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future salary increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Future pension cost&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;Interest rate on &lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;savings capital&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot; font-weight: bold;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% increase&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;0.5% decrease&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="30" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-align: center; font-family: &amp;amp;quot; font-weight: bold;"&gt;in CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Potential defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;24,248&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;29,396&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,317&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,930&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,993&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,393&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;27,447&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;25,848&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 20%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;amp;quot;"&gt;Decrease/(increase) from actual defined benefit obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;2,376&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(2,772&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(693&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;694&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(1,369&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;1,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;(823&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"&gt;&lt;div style="font-family: &amp;amp;quot;"&gt;776&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
  <!--Disclosure of share capital, reserves and other equity interest [text block]-->
  <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory id="Fact_24ed52c9ea7740abb92abedc689f35d6" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;9.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Share capital&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As of December 31, 2020 and 2019, the issued share capital amounted to CHF 1,538,896 and CHF 1,437,351, respectively, and is composed of common shares of 71,936,738 and 71,859,431, respectively, and treasury shares of 5,000,000 and nil, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The table below summarizes the Company&amp;#8217;s capital structure:&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Common &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Treasury &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;premium&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Treasury &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;67,562,333&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;298,149&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares &amp;#8211; incentive plans&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;681,770&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;13&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;672&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Conversion of note agreement, net of transaction costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,615,328&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;73&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;47,705&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;71,859,431&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,437&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;346,526&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares &amp;#8211; incentive plans, net of RSU expiration and forfeiture&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;77,307&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;364&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Issuance of shares to be held as treasury shares, net of transaction costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;76,936,738&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(5,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;346,890&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The common shares and treasury shares have nominal values of CHF 0.02 per share. All shares have been fully paid. These treasury shares are held by the Company and are not considered outstanding shares as of December 31, 2020. Finally, as of December 31, 2020 the Company has an additional 9,500,000 authorized shares for issuance which have not been issued nor are outstanding. Additionally, 19,632 RSUs either expired or were forfeited in 2020.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;At the market equity offering&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;In September 2020, the Company&lt;font style="color: #000000;"&gt; established an &amp;#8220;at the market offering program&amp;#8221; for the sale of up to USD 80 (CHF 71.3) million worth of our common shares issued from time to time by entering into an Open Market Sale Agreement&lt;/font&gt;&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;&amp;#160;&lt;/sup&gt;&lt;font style="color: #000000;"&gt;(Sales Agreement) with &lt;/font&gt;Jefferies LLC (Jefferies) as the sales agent. Issuance costs incurred in connection with establishing this facility and execution of the Sales Agreement with Jefferies primarily consist of legal, printing and accounting fees.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;No common shares have been sold pursuant to the Sales Agreement as of December 31, 2020. For the years ended December 31, 2020, 2019 and 2018, the Company has expensed issuance costs of CHF 0.5 million, nil and nil, respectively, in the statement of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Convertible note agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 21.3pt; color: #000000;"&gt;The Company and Lilly entered into a convertible note agreement effective January 23, 2019 for USD 50 (CHF 50.3) million. In April 2019, the convertible note agreement with Lilly automatically converted in line with the terms of the agreement. As a result of this conversion, 3,615,328 of our common shares were issued to Lilly. This note is now fully settled and there is no further equity or cash consideration due to Lilly thereunder.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Follow-on offerings&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;On July 24, 2018, the Company announced that it had closed the first subscription rights offering and underwritten the primary offering of its common shares, and that the underwriters had exercised in full their option to purchase an additional 1,108,695 shares at a price per share of USD 11.75. The underwriters&amp;#8217; exercise of the option to purchase additional shares brought the total number of common shares sold by the Company to 8,500,000 shares, resulting in total gross proceeds raised in these offerings, before underwriting discounts and estimated expenses of the offering, to approximately USD 99.9 (CHF 98.9) million. On July 20, 2018, the Company commenced a second subscription rights offering of up to 1,500,000 shares. At closing of the second subscription rights offering on July 31, 2018, the Company issued 1,500,000 additional common shares, resulting in gross proceeds of approximately USD 17.6 (CHF 17.4) million.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;At the conclusion of these three offerings, the Company raised gross proceeds of USD 117.5 (CHF 116.3) million. Net underwriting fees and transaction costs totaled CHF 6.8 million for a net total of CHF 109.5 million. &lt;/font&gt;Transaction costs associated with these offerings and related to the issuance of new shares were charged directly against the share premium account thereby reducing the total equity reported.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Shelf registration statement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;On May 4, 2018, the Company filed a Shelf Registration Statement on Form F-3 (Reg. No. 333-2246694) (the &amp;#8220;Shelf Registration Statement&amp;#8221;) with the SEC. The Shelf Registration Statement was declared effective by the SEC on June 8, 2018.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Shelf Registration Statement allows the Company to offer and sell, from time to time, up to USD 350,000,000 of common stock, debt securities, warrants, purchase contracts, units, subscription rights or any combination of the foregoing in one or more future public offerings. The terms of any future offering would be determined at the time of the offering and would be subject to market conditions and approval by the Company&amp;#8217;s Board of Directors. Any offering of securities covered by the Shelf Registration Statement will be made only by means of a written prospectus and prospectus supplement authorized and filed by the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;As the Company raised USD 117.5 (CHF 116.3) million in its three offerings completed in July 2018, the Company may execute one or more future offering of securities covered by the Shelf Registration Statement up to USD 232.5 million.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
  <!--Disclosure of share-based payment arrangements [text block]-->
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory id="Fact_05f5eb13574543ad9f5d4ef66cf86a73" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;17.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; font-style: italic;"&gt;Share-based option awards&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Through the year ended December 31, 2020, there are equity-based instruments outstanding that the Company has granted under four different plans.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s 2016 Share Option and Incentive Plan (SOIP) was approved by the shareholders at the ordinary shareholders' meeting in November 2016. The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights. The Company only grants equity-based instruments from the SOIP as of December 31, 2020.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The following table summarizes equity-settled share option grants since inception under each plan type:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;PLAN&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;options awarded &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;(since inception)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Vesting conditions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;life of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan A&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;362,750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;At grant&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;15.5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan B&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;819,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;At grant&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10.5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan C1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,775,250&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from grant date&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;2016 SOIP:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Executives and directors&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,898,222&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;1 year, 3 year and 4 years&amp;#8217; service from the date of grant, quarterly and annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;989,279&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from the date of grant, annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The number and weighted-average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and the 2016 SOIP are as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of options&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average exercise price (CHF)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average remaining&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;term (years)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,359,891&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2.09&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.8&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,624&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.16&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(151,814&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;484,403&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.79&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,618,856&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;4.25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;6.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;932,175&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1.25&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4.4&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,618,856&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4.25&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6.3&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,699&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6.71&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(616,833&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,053,305&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5.24&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,981,629&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5.93&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;8.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;602,218&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;6.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at January 1, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,981,629&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.93&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;8.3&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(53,591&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6.03&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(26,729&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4.38&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(73,669&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2.00&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,073,027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6.29&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Outstanding at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,900,667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;5.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;8.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Exercisable at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;1,099,015&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5.49&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;7.0&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The outstanding stock options as of December 31, 2020 have the following range of exercise prices. In fiscal year 2018, we began to grant awards solely with USD denominated exercise prices and discontinued granting awards with a CHF denominated exercise price.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Total options&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Range of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;expiration &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;dates&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Range of exercise prices&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF 0.15&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;243,125&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2020&amp;#8211;2026&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;CHF 9.53&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;223,646&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;USD 5.04 to USD 12.30&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,433,896&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2028&amp;#8211;2030&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total outstanding options&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,900,667&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The weighted-average exercise price for options granted in 2020, 2019 and 2018 is USD 7.11 (CHF 6.29), USD 5.41 (CHF 5.24) and USD 9.97 (CHF 9.79), respectively. The range of exercise prices for outstanding options was CHF 0.15 to CHF 9.53 for awards previously granted in CHF and USD 5.04 to USD 12.30 for awards granted in USD as of December 31, 2020.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Prior to the IPO, the exercise price was set by the board of directors. The volatility is based on the historical trend of an appropriate sample of companies operating in the pharmaceutical and biopharmaceutical industries. The risk-free interest rate is based on the CHF swap rate for the expected life of the option. The weighted-average share price of common share options exercised in 2020 is USD 6.86 (CHF 6.07).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The weighted-average grant date fair values of the options granted in 2020, 2019 and 2018 are USD 5.25 (CHF 4.65), USD 3.71 (CHF 3.59) and USD 6.66 (CHF 6.54), respectively. &lt;font style="color: #000000;"&gt;The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of these awards:&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 5.04-9.16&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 5.15&amp;#8211;5.54&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;USD 8.33&amp;#8211;12.30&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share price (weighted average)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7.11&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;5.41&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.87&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;0&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: right;"&gt;6 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000; font-style: italic;"&gt;Restricted share awards&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;A summary of non-vested share awards (restricted share and restricted share units) activity as of December 31, 2020 and changes during the year then ended is presented below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Grantee type&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;awards &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;granted&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Vesting conditions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;life of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;share &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Restricted share units&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Directors&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;83,864&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;1 year service from date of grant, annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Executives&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;110,839&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from the date of grant, quarterly&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Restricted share awards&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;4,023&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;2.75 years&amp;#8217; service from date of grant, quarterly&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;non-vested shares&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Weighted-average&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;grant date fair value (CHF)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;122,014&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.59&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(25,673&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.48&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;69,371&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.43&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(56,671&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.60&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;64,012&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.65&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(66,278&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;42,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;130,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.58&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;42,763&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Forfeited during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(11,828&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.47&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(7,804&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(84,638&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Vested during the year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(23,269&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;9.52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Non-vested at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;19,494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;9.51&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Vested and exercisable at December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;49,289&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;9.47&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company did not grant restricted share awards in 2020 or 2019, respectively. The weighted-average grant date fair value of the restricted share awards granted (restricted shares and restricted share units) was CHF 9.43 for the year ended December 31, 2018. The weighted-average grant date fair values of the remaining non-vested share awards as of the respective year end (restricted shares and restricted share units) was CHF 9.51, CHF 9.52 and CHF 9.51 for the years ended December 31, 2020, 2019 and 2018, respectively. These fair values of non-vested share awards granted have been determined using a reasonable estimate of market value of the common stock on the date of the award.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The expense charged against the income statement was CHF 4.1 million, CHF 2.8 million and CHF 2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. The expense is revised by the Company based on the number of instruments that are expected to become exercisable.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <!--Disclosure of significant accounting policies [text block]-->
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory id="Fact_55985bd937ce46ce9c1bfd5858bc5459" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="vertical-align: top; width: 18pt;"&gt;&lt;div style="text-align: left;"&gt;&lt;font style="font-weight: bold;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="align: left; vertical-align: top; width: auto;"&gt;&lt;div style="text-align: left;"&gt;&lt;font style="font-weight: bold;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Current vs. non-current classification&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be non-current.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Foreign currency transactions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Foreign currency transactions are translated into the functional currency, CHF, using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of income/(loss) in the period in which they arise.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Company has adopted IFRS 15 (&lt;font style="font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Company enters into LCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and IP to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized from the Company&amp;#8217;s IP. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Licenses of intellectual property&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Milestone payments&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Research and development services&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;The Company has certain arrangements with our collaboration partners that include contracting our employees for research and development programs. The Company assesses if these services are considered distinct in the context of each contract and, if so, they are accounted for as separate performance obligations. These revenues are recorded in contract revenue as the services are performed.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Sublicense revenues&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company has certain arrangements with our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense revenues at the point in time it is highly probable to obtain and not subject to reversal in the future.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Contract balances&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt; color: #000000;"&gt;The Company receives payments and determines credit terms from its customers for its various performance obligations based on billing schedules established in each contract. The timing of revenue recognition, billings and cash collections results in billed other current receivables, accrued income (contract assets), and deferred income (contract liabilities) on the balance sheets. Amounts are recorded as other current receivables when the Company&amp;#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be 1 year or less.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt; color: #000000;"&gt;For a complete discussion of accounting for contract revenue, see &amp;#8220;Note 12. Contract revenues.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; font-weight: bold;"&gt;Research and development expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Given the stage of development of the Company&amp;#8217;s products, all research expenditure is expensed as incurred. Research and development expenditures include:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management and laboratory services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;fees and costs related to regulatory filings and activities;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;costs associated with preclinical and clinical activities; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt;"&gt;&lt;br /&gt;&lt;/td&gt;&lt;td style="width: 18pt; vertical-align: top; align: right;"&gt;&lt;font style="font-family: Times New Roman;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div&gt;employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;For external research contracts, &lt;font style="color: #000000;"&gt;expenses include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing from CROs or CMOs for services rendered do not always align with work performed. We accrue the cost of services rendered in connection with CRO or CMO activities based on our estimate of the &amp;#8220;stage of completion&amp;#8221; for such contracted services. We maintain regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and&lt;/font&gt; accrue expenses as of the balance sheet date in the financial statements based on facts and circumstances known at the time.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Grant income&lt;/div&gt;&lt;div&gt;&lt;font style="font-weight: bold;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;The Company has received grants, from time to time, from the Michael J. Fox Foundation (MJFF) and other institutions to support certain research projects.&lt;/font&gt; Grants are recorded at their fair value in the statements of income/(loss) within other operating income/(expenses) when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Leases&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Effective January 1, 2019, the Company adopted IFRS 16 (&lt;font style="font-style: italic;"&gt;Leases&lt;/font&gt;), which provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company applied the modified retrospective approach, which required the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting, see &amp;#8220;Note 5. Right-of-use assets and lease liabilities.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; font-style: italic; font-weight: bold;"&gt;Right-of-use assets and lease liabilities&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&amp;#8217;s incremental borrowing rate. The lease liabilities are classified as current or non-current based on the due dates of the underlying principal payments.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company&amp;#8217;s estimate of the amount expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase, extension or termination option.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability. When the lease liability is re-measured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The estimated lease term by right-of-use asset categories are as follows:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Both the right-of-use-assets and lease liabilities are recognized in the balance sheets.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Property, plant and equipment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;3 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Leasehold improvements/furniture&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The assets&amp;#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&amp;#8217;s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Fair value of financial assets and liabilities&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s financial assets and liabilities are comprised of receivables, short-term financial assets, cash and cash equivalents, trade payables and financing obligations. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments and&lt;font style="color: #000000;"&gt; are held at their amortized cost in accordance with IFRS 9 (&lt;/font&gt;&lt;font style="font-style: italic; color: #000000;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="color: #000000;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Receivables&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor&amp;#8217;s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Short-term financial assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company assesses at each period whether there is objective evidence that financial assets are impaired.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Trade payables&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Trade payables are amounts &lt;font style="color: #000000;"&gt;due to third parties in the ordinary course of business.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Financing obligation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;The Company&amp;#8217;s financing obligation related to its agreement with a third party. This financing obligation has been fully repaid as of December 31, 2020.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Share capital and public offerings&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 18pt;"&gt;Common shares are classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax, from the proceeds received from existing or future offerings. &lt;font style="color: #000000;"&gt;Should a planned equity offering not be assessed as probable, the issuance costs would be expensed immediately. &lt;/font&gt;See &amp;#8220;Note 9. Share capital.&amp;#8221;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Employee benefits&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Post-employment benefits&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. The&lt;font style="color: #000000;"&gt; defined benefit obligation is calculated annually with the assistance of an independent actuary&lt;/font&gt; using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&amp;#8217; projected salaries and pension increases as well as discount rates of highly liquid corporate bonds that have terms to maturity approximating the terms of the related liability.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt; color: #000000;"&gt;Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately in the statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized immediately as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses are recognized in either research and development and/or general and administrative expenses within the operating results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses related to defined benefit plans are recognized in the statements of income/(loss).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Share-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding adjustment to equity over the remaining vesting period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Stock options granted under the Company&amp;#8217;s stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model (see &amp;#8220;Note 17. Share-based compensation&amp;#8221;). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management&amp;#8217;s estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;We estimate the fair value of non-vested stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards vest.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Provisions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Taxation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets as the probability for use is low.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;As disclosed in &amp;#8220;Note 15. Income taxes,&amp;#8221; the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Earnings per share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company presents basic earnings per share for each period in the financial statements. The earnings per share are calculated by dividing the earnings of the period by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Critical judgments and accounting estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on LCAs, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation and (vi) right-of-use assets and lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Segment reporting&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located in and revenue is attributable to the Company&amp;#8217;s country of domicile, Switzerland.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Accounting policies, new standards, interpretations and amendments adopted by the Company&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <!--Disclosure of temporary difference, unused tax losses and unused tax credits [text block]-->
  <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory id="Fact_fcbe302acf454c0e91c4b72d7a3f7d20" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The tax rate used for the 2020 reconciliations above is the corporate tax rate of 13.6% (13.6% in 2019 and 20.6% in 2018) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Unrecognized deductible temporary differences, unused tax losses and unused tax credits&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax losses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;121,948&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;64,125&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;109,294&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deductible temporary differences related to:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Right-of-use assets and lease liabilities, net&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Retirement benefit plan&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,464&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,485&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;5,665&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;129,412&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;71,610&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;114,959&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
  <!--Disclosure of terms and conditions of share-based payment arrangement [text block]-->
  <ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory id="Fact_f69eda5dec634c7d823b58b91e8742d4" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following table summarizes equity-settled share option grants since inception under each plan type:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;PLAN&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Number of &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;options awarded &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;(since inception)&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-weight: bold;"&gt;Vesting conditions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;life of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan A&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;362,750&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;At grant&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;15.5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan B&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;819,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;At grant&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10.5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share option plan C1&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;6,775,250&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from grant date&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;2016 SOIP:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Executives and directors&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,898,222&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;1 year, 3 year and 4 years&amp;#8217; service from the date of grant, quarterly and annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Employees&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;989,279&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;4 years&amp;#8217; service from the date of grant, annually&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"&gt;&lt;div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;"&gt;10 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory>
  <!--Disclosure of trade and other payables [text block]-->
  <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory id="Fact_511b8e24218c40e59dd0f8f5495a6418" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;10.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Trade payables and accrued liabilities&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;font style="font-weight: bold;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;&amp;#160;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;"&gt;Total trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5,298&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,228&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Accrued payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,494&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,896&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,293&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,673&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;"&gt;Total accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;11,085&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;11,797&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;An accrual of CHF 2.1 million and CHF 1.8 million was recognized for performance-related remuneration within accrued payroll expenses for 2020 and 2019, respectively.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_050e9c9534844e8fa403ec1e4dd9f067" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">-113000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Laboratory equipment [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_08217252464d433db38a7622d52cc501" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">-306000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Laboratory equipment [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_0c322b88611b489babc4da7d6b65d26d" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">-137000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Leasehold Improvements [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_2ea24d599b0b46da8161b5a59d57569b" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">7000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Furniture [Member]-Acquisition Cost [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_3b137c467a9e457f9ff582d290e40a50" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">40000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Furniture [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_5245c55b63b2432aa24a8e32b7b023a7" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">-40000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_5b713dc146174be38d1f933b0c430a1c" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Computer equipment [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_937c084719f44558a7aa334909790e1c" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_bad13f99742f4f9683c8b297e7a08f85" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">-290000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Leasehold Improvements [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_c9f5113479e948cd9f4261defed4399e" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Leasehold Improvements [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_cae5674a9a7a4b7abc90e959995a4c8a" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Furniture [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_cf13865115eb4c68af40e6ae575cdd2d" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">33000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_d63044c7bddd4098ac50f35745b693c6" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">-346000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_d91b8bb6aab44450a31f1a2b8f9c59f3" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">346000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Furniture [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_da776621caed48a9a69118dec1a23eaa" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">-33000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Accumulated depreciation and amortisation [member]-Leasehold Improvements [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_e740897dcdfd41d3bd48df0153dd8d45" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">-7000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Computer equipment [member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_ea6ff514b1524803910eaedf443a3cf5" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">129000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-Laboratory equipment [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_f40f8c6345c147bd81660061fbea7820" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">139000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_fb70edb575524a2da97ca985abffe882" contextRef="c20190101to20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">308000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Disposals, property, plant and equipment-Laboratory equipment [Member]-Acquisition Cost [Member]-->
  <ifrs-full:DisposalsPropertyPlantAndEquipment id="Fact_fd0a2e40718e46ea8df636fb556fa46e" contextRef="c20200101to20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">306000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <!--Earnings per share [text block]-->
  <ifrs-full:EarningsPerShareExplanatory id="Fact_5fe70952db3a449dad9f89c919465d69" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands, except for share and per share data&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Basic income/(loss) per share (EPS):&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net income/(loss) attributable to equity holders of the Company&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;70,603,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Basic income/(loss) for the period attributable to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(0.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;0.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;(0.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Diluted income/(loss) per share (EPS):&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Net income/(loss) attributable to equity holders of the Company&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;70,603,611&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of dilutive securities from equity incentive plans&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;499,730&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Weighted-average number of shares outstanding &amp;#8211; diluted to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;71,900,212&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;71,103,341&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;61,838,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Diluted income/(loss) for the period attributable to equity holders&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(0.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;0.64&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;(0.82&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="Fact_4b022d7001a3430ea324dc0b2acf9901" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-703000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="Fact_cfaa77b169c44ad182c26c5c4f33df31" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-1179000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents id="Fact_d0efdd24088745d8aefdc6c882931362" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-826000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <!--Equity-->
  <ifrs-full:Equity id="Fact_42e8c0cc35cb49fdbe73629a3962ca4f" contextRef="c20191231" unitRef="U002" decimals="-3">272442000</ifrs-full:Equity>
  <!--Equity-->
  <ifrs-full:Equity id="Fact_d26a3ee5d6d0487c9eb5b5abed824243" contextRef="c20201231" unitRef="U002" decimals="-3">215478000</ifrs-full:Equity>
  <!--Equity-Share Premium [Member]-->
  <ifrs-full:Equity id="Fact_3267ec20b26549fe83b5d682d9c87c42" contextRef="c20171231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">188299000</ifrs-full:Equity>
  <!--Equity-Issued capital [member]-->
  <ifrs-full:Equity id="Fact_50b57556ef8d4aae8b66be24712450b3" contextRef="c20171231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1147000</ifrs-full:Equity>
  <!--Equity-Treasury shares [member]-->
  <ifrs-full:Equity id="Fact_683efc19dc7241089336a9e16db90080" contextRef="c20171231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:Equity>
  <!--Equity-->
  <ifrs-full:Equity id="Fact_96611d26bfbb48edbeaffe570e37c7af" contextRef="c20171231" unitRef="U002" decimals="-3">116839000</ifrs-full:Equity>
  <!--Equity-Retained earnings [member]-->
  <ifrs-full:Equity id="Fact_e6a5fe929a5a476bb9f53a58123b3119" contextRef="c20171231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-72607000</ifrs-full:Equity>
  <!--Equity-Treasury shares [member]-->
  <ifrs-full:Equity id="Fact_20736e9a493d43558760f1e7b0a49c33" contextRef="c20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">-100000</ifrs-full:Equity>
  <!--Equity-Treasury shares [member]-->
  <ifrs-full:Equity id="Fact_235362cc2d224af88fe42f2159d9d27b" contextRef="c20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:Equity>
  <!--Equity-Retained earnings [member]-->
  <ifrs-full:Equity id="Fact_282182c74a0c4e688c105d3d3b707243" contextRef="c20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-132850000</ifrs-full:Equity>
  <!--Equity-Issued capital [member]-->
  <ifrs-full:Equity id="Fact_4adb6b2caf5a41998b688f1edec7defe" contextRef="c20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1351000</ifrs-full:Equity>
  <!--Equity-Share Premium [Member]-->
  <ifrs-full:Equity id="Fact_852b254cfa5f45228f41d3f6fd31ba9a" contextRef="c20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">346890000</ifrs-full:Equity>
  <!--Equity-Issued capital [member]-->
  <ifrs-full:Equity id="Fact_901f75a45cc04e8c99cfe51179b35bde" contextRef="c20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1538000</ifrs-full:Equity>
  <!--Equity-Retained earnings [member]-->
  <ifrs-full:Equity id="Fact_a5ca6c7e13e14cae9aab744e3f275a3c" contextRef="c20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-75521000</ifrs-full:Equity>
  <!--Equity-Treasury shares [member]-->
  <ifrs-full:Equity id="Fact_bbbf8225653b48e28f4d0ef00378c4e5" contextRef="c20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:Equity>
  <!--Equity-Share Premium [Member]-->
  <ifrs-full:Equity id="Fact_be6b3a355e3a438f8dee088aa7edcc1e" contextRef="c20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">298149000</ifrs-full:Equity>
  <!--Equity-Issued capital [member]-->
  <ifrs-full:Equity id="Fact_cc43831bf29c4a7f8d696a9ddce7fac6" contextRef="c20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1437000</ifrs-full:Equity>
  <!--Equity-->
  <ifrs-full:Equity id="Fact_d3f0932440284fd69c99366bad209f1b" contextRef="c20181231" unitRef="U002" decimals="-3">177623000</ifrs-full:Equity>
  <!--Equity-Retained earnings [member]-->
  <ifrs-full:Equity id="Fact_dc61f37b51cb42daa75fc013c09601e0" contextRef="c20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-121877000</ifrs-full:Equity>
  <!--Equity-Share Premium [Member]-->
  <ifrs-full:Equity id="Fact_12db80d022d64893be712ae45d4a228d" contextRef="c20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">346526000</ifrs-full:Equity>
  <!--Equity-Issued capital [member]-->
  <!--Equity and liabilities-->
  <ifrs-full:EquityAndLiabilities id="Fact_5544865d3e374e70ac0aa3436d853d17" contextRef="c20201231" unitRef="U002" decimals="-3">238740000</ifrs-full:EquityAndLiabilities>
  <!--Equity and liabilities-->
  <ifrs-full:EquityAndLiabilities id="Fact_9b8cef8b34fd45308f830112bbbef8ad" contextRef="c20191231" unitRef="U002" decimals="-3">299250000</ifrs-full:EquityAndLiabilities>
  <!--Exercise price (in USD per share)-Top of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_4c4ec7e4da6b4cccb6967c7794e52568" contextRef="c20190101to20191231_RangeAxis_TopOfRangeMember" unitRef="U012" decimals="2">5.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Exercise price (in USD per share)-Bottom of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_4fe3ee0247484845a3988ebd09ea253e" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember" unitRef="U012" decimals="2">5.04</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Exercise price (in USD per share)-Bottom of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_9610c7fc637f428cb05b3a07cd9418bc" contextRef="c20180101to20181231_RangeAxis_BottomOfRangeMember" unitRef="U012" decimals="2">8.33</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Exercise price (in USD per share)-Top of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_a03a389737f0444e9e4b50191ad15503" contextRef="c20180101to20181231_RangeAxis_TopOfRangeMember" unitRef="U012" decimals="2">12.30</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Exercise price (in USD per share)-Bottom of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_a95ac4aaf9b841628166666afeafae65" contextRef="c20190101to20191231_RangeAxis_BottomOfRangeMember" unitRef="U012" decimals="2">5.15</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Exercise price (in USD per share)-Top of range [member]-->
  <ifrs-full:ExercisePriceShareOptionsGranted2019 id="Fact_fb906082e6e24d4fa992d23853c6689e" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember" unitRef="U012" decimals="2">9.16</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <!--Dividend yield-->
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted id="Fact_0a8949cdec384570b5628bd6266f8c11" contextRef="c20190101to20191231" unitRef="U008" decimals="0">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <!--Dividend yield-->
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted id="Fact_b0341e9818eb402480c005cb1b1bd20f" contextRef="c20200101to20201231" unitRef="U008" decimals="0">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <!--Dividend yield-->
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted id="Fact_bc8d7fd2d28143919e701b0092f821af" contextRef="c20180101to20181231" unitRef="U008" decimals="0">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <!--Expense from share-based payment transactions with employees-->
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="Fact_306bce0a2c2e4ade8b610e53d2197c71" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2834000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <!--Expense from share-based payment transactions with employees-->
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="Fact_47b42a1f9c384c9f9ec12c0ab4835ab7" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2518000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <!--Expense from share-based payment transactions with employees-->
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees id="Fact_a5ef527b4bc1470bb836df30e6408bc3" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">4088000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <!--Expense relating to short-term leases for which recognition exemption has been used-->
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed id="Fact_7b6e8b8b736d4897bf3b2a0949fee671" contextRef="c20190101to20191231" unitRef="U005" decimals="-3">565000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <!--Expense relating to short-term leases for which recognition exemption has been used-->
  <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed id="Fact_9ad1599d618c418f9f7add0d562daf20" contextRef="c20200101to20201231" unitRef="U005" decimals="-3">603000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <!--Changes in Contract Assets and Contract Liabilities-->
  <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory id="Fact_e046811a7c0f47659c217f01c7889245" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 18pt; color: #000000;"&gt;The following table presents changes in the Company&amp;#8217;s contract assets and liabilities during the years ended December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: 2px solid #000000;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF Thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Balance at &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;the beginning &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;of the &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;reporting period&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Additions&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Deductions&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;Balance at &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;the end &lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;of the&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;reporting period&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Twelve months ended December 31, 2020:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,354&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(1,858&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,591&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;1,467&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(5,638&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;306&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Twelve months ended December 31, 2019:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,667&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,211&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(4,783&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Deferred income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;351&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,686&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(3,560&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;4,477&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
  <!--Finance costs-->
  <ifrs-full:FinanceCosts id="Fact_777ecd60e4fe4889b9f3378bc4faff46" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">334000</ifrs-full:FinanceCosts>
  <!--Finance costs-->
  <ifrs-full:FinanceCosts id="Fact_99429302e4544324b3c380b4532fcbc2" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">1926000</ifrs-full:FinanceCosts>
  <!--Finance costs-->
  <ifrs-full:FinanceCosts id="Fact_c6ea3a98c2ce45cc8c030c548840a730" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">184000</ifrs-full:FinanceCosts>
  <!--Finance costs paid, classified as operating activities-->
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities id="Fact_073de6a5c0244c8cbc19291594c97475" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">9000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <!--Finance costs paid, classified as operating activities-->
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities id="Fact_eae82446614647cda7cfad12360564dc" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">335000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <!--Finance costs paid, classified as operating activities-->
  <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities id="Fact_11a2fd5cd7054fa7afd6d2af2ee0159f" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">15000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
  <!--Financial income-->
  <ifrs-full:FinanceIncome id="Fact_79393b5244064fef909f301fc756c8f6" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">78000</ifrs-full:FinanceIncome>
  <!--Financial income-->
  <ifrs-full:FinanceIncome id="Fact_7a2ab6a6b43343aa8dc875da9e133956" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">303000</ifrs-full:FinanceIncome>
  <!--Financial income-->
  <ifrs-full:FinanceIncome id="Fact_b2dab921e5ee4b5fbb66803d67706618" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">127000</ifrs-full:FinanceIncome>
  <!--Finance income (cost)-->
  <ifrs-full:FinanceIncomeCost id="Fact_379576e3c17d45108d5902800e08531b" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-1401000</ifrs-full:FinanceIncomeCost>
  <!--Finance income (cost)-->
  <ifrs-full:FinanceIncomeCost id="Fact_9b0c7127de314b35a5142d88d88395ef" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-661000</ifrs-full:FinanceIncomeCost>
  <!--Finance income (cost)-->
  <ifrs-full:FinanceIncomeCost id="Fact_f87688fd41e34a678b4c9265b7abf235" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">906000</ifrs-full:FinanceIncomeCost>
  <!--Finance income received, classified as operating activities-->
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities id="Fact_8cf88f6c93d9404e9b558cbd5052b1a3" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">78000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <!--Finance income received, classified as operating activities-->
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities id="Fact_9d1f300544544f03bbb74602667bd2ed" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">304000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <!--Finance income received, classified as operating activities-->
  <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities id="Fact_d7d971dfa6d1419bb35d37cfcfb08e89" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">29000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
  <!--Financial assets-Cash on hand and cash equivalents [Member]-->
  <ifrs-full:FinancialAssets id="Fact_1b7468bd319148e1a41d072c109dfbc6" contextRef="c20191231_CategoriesOfFinancialAssetsAxis_CashOnHandAndCashEquivalentsMember" unitRef="U002" decimals="-3">193587000</ifrs-full:FinancialAssets>
  <!--Financial assets-Short-term Financial Assets [Member]-->
  <ifrs-full:FinancialAssets id="Fact_1cd8ff033e01437f809cf5dc83a88551" contextRef="c20191231_CategoriesOfFinancialAssetsAxis_ShortTermFinancialAssetsMember" unitRef="U002" decimals="-3">95000000</ifrs-full:FinancialAssets>
  <!--Financial assets-Cash on hand and cash equivalents [Member]-->
  <ifrs-full:FinancialAssets id="Fact_200c2aee31c145a5891cc1cf957fbef3" contextRef="c20201231_CategoriesOfFinancialAssetsAxis_CashOnHandAndCashEquivalentsMember" unitRef="U002" decimals="-3">160893000</ifrs-full:FinancialAssets>
  <!--Financial assets-Short-term Financial Assets [Member]-->
  <ifrs-full:FinancialAssets id="Fact_255f55e608554f1c9d0df58a36d89dcc" contextRef="c20201231_CategoriesOfFinancialAssetsAxis_ShortTermFinancialAssetsMember" unitRef="U002" decimals="-3">65000000</ifrs-full:FinancialAssets>
  <!--Financial assets-->
  <ifrs-full:FinancialAssets id="Fact_2e1de65662974b53a0f75169f54ff560" contextRef="c20201231" unitRef="U002" decimals="-3">226556000</ifrs-full:FinancialAssets>
  <!--Financial assets-Other receivables [Member]-->
  <ifrs-full:FinancialAssets id="Fact_4623de24563342ab83da723d62852d86" contextRef="c20191231_CategoriesOfFinancialAssetsAxis_OtherReceivablesMember" unitRef="U002" decimals="-3">304000</ifrs-full:FinancialAssets>
  <!--Financial assets-Other receivables [Member]-->
  <ifrs-full:FinancialAssets id="Fact_4c264163258143fa86d5c51e947812c4" contextRef="c20201231_CategoriesOfFinancialAssetsAxis_OtherReceivablesMember" unitRef="U002" decimals="-3">329000</ifrs-full:FinancialAssets>
  <!--Financial assets-Long-term Financial Assets [Member]-->
  <ifrs-full:FinancialAssets id="Fact_9fa23ca7ebdc4bd1930c53676eaaa8a4" contextRef="c20191231_CategoriesOfFinancialAssetsAxis_LongTermFinancialAssetsMember" unitRef="U002" decimals="-3">304000</ifrs-full:FinancialAssets>
  <!--Financial assets-->
  <ifrs-full:FinancialAssets id="Fact_e05dff37606c4a768f39943363d7ec2e" contextRef="c20191231" unitRef="U002" decimals="-3">289195000</ifrs-full:FinancialAssets>
  <!--Financial assets-Long-term Financial Assets [Member]-->
  <ifrs-full:FinancialAssets id="Fact_e761979a622b49869341af7b30f5c5ad" contextRef="c20201231_CategoriesOfFinancialAssetsAxis_LongTermFinancialAssetsMember" unitRef="U002" decimals="-3">334000</ifrs-full:FinancialAssets>
  <!--Financial liabilities-Short-term Financing Obligation [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_241b868faf564f4da2ec0d500eabcf3b" contextRef="c20201231_CategoriesOfFinancialLiabilitiesAxis_ShorttermBorrowingsMember" unitRef="U002" decimals="-3">0</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Trade and Other Payables [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_5ae5170ece57489588ddf754fe0cbf80" contextRef="c20191231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember" unitRef="U002" decimals="-3">142000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Lease liabilities [member]-->
  <ifrs-full:FinancialLiabilities id="Fact_5cf09d78faa34169ba9550dac004c12a" contextRef="c20191231_CategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMember" unitRef="U002" decimals="-3">1813000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Short-term lease liabilities [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_810af594dcfd4e6f96728c1f9f13fa9a" contextRef="c20191231_CategoriesOfFinancialLiabilitiesAxis_ShortTermLeaseLiabilitiesMember" unitRef="U002" decimals="-3">442000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Short-term lease liabilities [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_8362e56b7c0c482db41eebe666320a0c" contextRef="c20201231_CategoriesOfFinancialLiabilitiesAxis_ShortTermLeaseLiabilitiesMember" unitRef="U002" decimals="-3">443000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Accrued Expenses [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_841ed1a056b541cdbe1b90212988d6b7" contextRef="c20201231_CategoriesOfFinancialLiabilitiesAxis_AccruedExpensesMember" unitRef="U002" decimals="-3">11085000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-->
  <ifrs-full:FinancialLiabilities id="Fact_86c5351c167540eca767df4aac2cbb3f" contextRef="c20191231" unitRef="U002" decimals="-3">14846000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-->
  <ifrs-full:FinancialLiabilities id="Fact_c14c105932d44a76b5f564cf7a2b72e6" contextRef="c20201231" unitRef="U002" decimals="-3">15492000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Lease liabilities [member]-->
  <ifrs-full:FinancialLiabilities id="Fact_cddde6d0f34847eb920d90dddd710931" contextRef="c20201231_CategoriesOfFinancialLiabilitiesAxis_LeaseLiabilitiesMember" unitRef="U002" decimals="-3">1780000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Trade and Other Payables [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_f12d4058193d4fd7a5150f5f54f25a91" contextRef="c20201231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember" unitRef="U002" decimals="-3">2184000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Short-term Financing Obligation [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_f217a36456124f3ca1a90b4036ecf25e" contextRef="c20191231_CategoriesOfFinancialLiabilitiesAxis_ShorttermBorrowingsMember" unitRef="U002" decimals="-3">652000</ifrs-full:FinancialLiabilities>
  <!--Financial liabilities-Accrued Expenses [Member]-->
  <ifrs-full:FinancialLiabilities id="Fact_ff6a7dd4446e49f195ceaa50a32872b4" contextRef="c20191231_CategoriesOfFinancialLiabilitiesAxis_AccruedExpensesMember" unitRef="U002" decimals="-3">11797000</ifrs-full:FinancialLiabilities>
  <!--Gain (loss) on remeasurement, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset id="Fact_032f119fb6f0409b9bb10dc559b8ba01" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1304000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <!--Gain (loss) on remeasurement, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset id="Fact_3622f352a10a448cb7eaa86e93026611" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">-726000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <!--Gain (loss) on remeasurement, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset id="Fact_fef4eff44a0145e1a60331a04ed6a63d" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">302000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
  <!--Exchange differences-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_6361e0b285944ef187419b204885c058" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-555000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Exchange differences-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_a4b523c6e4004475a86328a8a6af09e9" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-2013000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Exchange differences-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_f78972e719ff4433854bb49c51e81a60" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-1194000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Exchange differences-Currency risk [member]-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_386aa738323a4b70b9b1eadbc941484a" contextRef="c20180101to20181231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U002" decimals="-5">-1200000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Exchange differences-Currency risk [member]-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_70bde9124a2f4a9e8a32a5bb953f0f6a" contextRef="c20190101to20191231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U002" decimals="-5">-800000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Exchange differences-Currency risk [member]-->
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss id="Fact_aa34cf830a834c52a2e4426d3f78e46b" contextRef="c20200101to20201231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U002" decimals="-5">-700000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <!--Income tax expense-->
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="Fact_605c9409a1fe4319b49af5687498d0cc" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <!--Income tax expense-->
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="Fact_7888d39f80a74b8b840d50b76b49789e" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <!--Income tax expense-->
  <ifrs-full:IncomeTaxExpenseContinuingOperations id="Fact_e6ecc76bda6448a898629db7c71ac2d8" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <!--Increase (decrease) in cash and cash equivalents-->
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents id="Fact_01f1b1b4eaf0485a957b532dde6ca269" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">37951000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <!--Increase (decrease) in cash and cash equivalents-->
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents id="Fact_780051550b9844a89f86b7f4599b7e23" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-31991000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <!--Increase (decrease) in cash and cash equivalents-->
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents id="Fact_e70bd897ef324a1cb119b18289b7448e" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">33264000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <!--Increase in tax losses available as an offset-->
  <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset id="Fact_85af35de787140329e3ef9fff11c23d1" contextRef="c20200101to20201231" unitRef="U002" decimals="-5">57800000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
  <!--Decrease/(increase) from actual defined benefit obligation-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of expected rates of salary increases [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_040e257176ac4ebdb0382bd6c6e8cf34" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">694000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-Actuarial assumption of expected rates of pension increases [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_5c69c0cc62da4f40a2cf0a516e663e33" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">1231000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_8164cfe616a14438a57b2b6ad50a4095" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-2867000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Actuarial assumption of expected rates of pension increases [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_84bd1db9dcf14e44bfde5d6bee2aed7f" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">1297000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-Other material actuarial assumptions [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_a7de49b1d1ae4109bc25808b04707312" contextRef="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">776000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_ac20e50db9ce471daecc8c86e3950df0" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-2772000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Actuarial assumption of expected rates of salary increases [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_b3d7d7ad078241db9fdfce782bb604f8" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">694000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Decrease/(increase) from actual defined benefit obligation-Percentage of reasonably possible decrease in actuarial assumption [Member]-Other material actuarial assumptions [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption id="Fact_c2e07c42a74a49a1968a4fdbe3c0fa1f" contextRef="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">808000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Percentage of reasonably possible increase in actuarial assumption [Member]-Other material actuarial assumptions [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_270d683aad664b85a8a04bd7b54c7135" contextRef="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-857000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of expected rates of pension increases [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_488a9eb07d7e42bf820851b7a728954c" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-1369000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_4e67e3faa74b4d269dd1ad974ea974d0" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">2473000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Actuarial assumption of expected rates of salary increases [member]-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_89fb4ab0a8304c2ebfa754d95ab71275" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-693000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_89fd617a42c845378f8342f854de9646" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">2376000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Defined benefit plans that share risks between entities under common control [member]-Actuarial assumption of expected rates of pension increases [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_dbc9ff5fe45c4d22bc2446594024e0a7" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-1439000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of expected rates of salary increases [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_e6ef5e1548f449e286a3a2a3a4ed1f92" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-699000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption-Other material actuarial assumptions [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption id="Fact_f0a2da2b3d434772b215b9d283117ee1" contextRef="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">-823000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Increase (decrease) in net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset id="Fact_7862811f85eb419a8e4c6ea8d856f049" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1655000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset>
  <!--Increase (decrease) in net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset id="Fact_c153d51a48d44f019e6feedaf3ea4dd1" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1130000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset>
  <!--Increase (decrease) in net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset id="Fact_c88c07e11da64a8faa9b3736faacc526" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1375000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset>
  <!--Increase (decrease) in number of ordinary shares issued-Second Subscription Rights [Member]-->
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued id="Fact_01c020ea88394281ac406367315b95a7" contextRef="c20180731to20180731_ClassesOfShareCapitalAxis_SecondSubscriptionRightsMember" unitRef="U001" decimals="INF">1500000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <!--Increase (decrease) in number of ordinary shares issued-Option for Over-Allotment [Member]-->
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued id="Fact_0c0028e30e454b158fcc59eb53813792" contextRef="c20180724to20180724_ClassesOfShareCapitalAxis_OptionForOverAllotmentMember" unitRef="U001" decimals="INF">1108695</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <!--Increase (decrease) in number of ordinary shares issued-First Subscription Rights [Member]-->
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued id="Fact_9cd2d830415a4ca1b2438e027dad42c3" contextRef="c20180724to20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember" unitRef="U001" decimals="INF">8500000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <!--Conversion of note agreement, net of transaction costs-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments id="Fact_27812ec8837c4c78a0712a9b9ce217b6" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">73000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <!--Conversion of note agreement, net of transaction costs-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments id="Fact_4dfb8c67e3b54e6798a4daa9395b4648" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">47705000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <!--Conversion of note agreement, net of transaction costs-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments id="Fact_71a453a3676c41c7a7601d238d1af1bd" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <!--Conversion of note agreement, net of transaction costs-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments id="Fact_89d662a4e1f64a11b3540e88b797de97" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <!--Conversion of note agreement, net of transaction costs-->
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments id="Fact_96df53a40d5d433a88e79e9e702b6e60" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">47778000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <!--Increase (decrease) through exercise of options, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_04f91166abc3486f86186e23bd39d29f" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">12000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_16077b92ae134cf69b5a3a6b050b8eca" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_183f638cbea04f29967bde08016ff532" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_25295810ba904f52a2d4459db7785d97" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_2d7e2d40e1124c26bf888d30dcdc8efe" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_5c8c455a72f441d6978f7c2107bc8577" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">142000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_5d4c5a55d5a044918095fdae5a2f609a" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_73a7e4efcba64e689ac7275ad4b04ace" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_a596cd726acd42f8bafb5289e0f423c0" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_a93ea00d9cfd4eb3958c7ef760b90f29" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">56000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_b30ee04c6e9546449e24980981f84c33" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">68000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_c8518a67c8e24db49a1c63339cac148f" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_e89c611c75eb42988924574a3a9534c6" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">4000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_100a9b72156e4b638665797650b27056" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through exercise of options, equity-->
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions id="Fact_1039a0f8b2954923b40d477a30b9f0a5" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">143000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <!--Increase (decrease) through share-based payment transactions, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_083c76ca68ee4db6b81c59b015816d50" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_35e71a1e60a64183812baeba4df871ae" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_35eabc8a0c104946977a4208c5743077" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2518000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_748d62f8f1954de0a25eb4c24d4bd4ca" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">4088000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_7a97842906a440f292889a62fd4aa996" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">2834000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_7cfe2d578a5442dea0c657347dcb0391" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_9c0e6afa913840dab3f34ddbf9ba70df" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_a2e86090cddd4e27b9f8a8610cbb9ba1" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_ad1475a963324e5e8701b13880778492" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_af455e8b1e314a1a8005d19ff0101fa3" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_be5df13dab494a8299a5b9425b7a4c86" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_c3ea38be4e214954828bc0f186e8dac7" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">4088000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_ef9f8eb0892c436f991b95b6bd8051e7" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">2518000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_f389f7721bfe4ccbb2762fdb58093396" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2834000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Increase (decrease) through share-based payment transactions, equity-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions id="Fact_fb6a345ccb70494c8072cd6f2f04fbd7" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <!--Held as treasury shares, net of transaction costs-Issued capital [member]-->
  <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions id="Fact_21c00191b88f42ac943657d17ba72c3c" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">100000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
  <!--Held as treasury shares, net of transaction costs-Treasury shares [member]-->
  <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions id="Fact_286728e2bb234b38acc53a0537b49102" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">-100000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
  <!--Held as treasury shares, net of transaction costs-Share Premium [Member]-->
  <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions id="Fact_31b3da741e334509b534d55c0a82f8bb" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
  <!--Held as treasury shares, net of transaction costs-Retained earnings [member]-->
  <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions id="Fact_a6efe84ada6a44f88ca83a03833a1009" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
  <!--Held as treasury shares, net of transaction costs-->
  <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions id="Fact_d24e055f0a0347d6a56d3b034a661851" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
  <!--Interest expense-Convertible Note Agreement [Member]-->
  <ifrs-full:InterestExpense id="Fact_cce27875b9bd4c6db48cc60248e9d485" contextRef="c20200101to20201231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember" unitRef="U002" decimals="-5">1400000</ifrs-full:InterestExpense>
  <!--Effective interest recorded to amortize the host debt-Convertible Note Agreement [Member]-->
  <ifrs-full:InterestExpenseOnDebtInstrumentsIssued id="Fact_48b0301d4c324db18fc61bf421be9317" contextRef="c20200101to20201231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember" unitRef="U002" decimals="-5">1200000</ifrs-full:InterestExpenseOnDebtInstrumentsIssued>
  <!--Interest expense on lease liabilities-->
  <ifrs-full:InterestExpenseOnLeaseLiabilities id="Fact_b4c0c9c9468245f48a31901c9e865204" contextRef="c20200101to20201231" unitRef="U005" decimals="-3">53000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <!--Interest expense on lease liabilities-->
  <ifrs-full:InterestExpenseOnLeaseLiabilities id="Fact_ee8ef34d7265477e8aaf171e31ea1a67" contextRef="c20190101to20191231" unitRef="U005" decimals="-3">52000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <!--Interest paid, classified as operating activities-->
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="Fact_60e1f99ab84c46e1a96aff7d3b28f66b" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <!--Interest paid, classified as operating activities-->
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="Fact_f75936d76e5c4eacb106295e007d1453" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">339000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <!--Interest paid, classified as operating activities-->
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities id="Fact_fadb3acd706b4648af4c8b8ba27a0d08" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">296000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <!--Issued capital-->
  <ifrs-full:IssuedCapital id="Fact_81046c5e462549708526a814c5e0135b" contextRef="c20201231" unitRef="U002" decimals="-3">1538000</ifrs-full:IssuedCapital>
  <!--Issued capital-->
  <ifrs-full:IssuedCapital id="Fact_8555d4ce8b114eefbc64b0d83151a186" contextRef="c20191231" unitRef="U002" decimals="-3">1437000</ifrs-full:IssuedCapital>
  <!--Key management personnel compensation-->
  <ifrs-full:KeyManagementPersonnelCompensation id="Fact_64d8e3f6042441788f3285e9aac8b1a2" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">6289000</ifrs-full:KeyManagementPersonnelCompensation>
  <!--Key management personnel compensation-->
  <ifrs-full:KeyManagementPersonnelCompensation id="Fact_b1ee29a8b1af4e5bb239d125b7dcbe20" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">5896000</ifrs-full:KeyManagementPersonnelCompensation>
  <!--Key management personnel compensation-->
  <ifrs-full:KeyManagementPersonnelCompensation id="Fact_b231e0802beb4e35ad48729d2336d386" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">4524000</ifrs-full:KeyManagementPersonnelCompensation>
  <!--Post-employment benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits id="Fact_7047d08d97a44a50836df8c767d3b8e2" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">215000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <!--Post-employment benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits id="Fact_7374bc64f1a94245ad49b033e160aa43" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">214000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <!--Post-employment benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits id="Fact_da6dd22872d84248b16bdade91a705ad" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">160000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <!--Share-based compensation-->
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="Fact_3690ed75f76d43a796f316df6db87264" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">2578000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <!--Share-based compensation-->
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="Fact_7752274fbcff494e87cd6486d4b9db3d" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">1683000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <!--Share-based compensation-->
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment id="Fact_f2d03a5a4d6c4af0b565a49528ace005" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2155000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <!--Short-term employee benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="Fact_44b20324c80846ac99d6caf3f846a067" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2681000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <!--Short-term employee benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="Fact_91c416048bfd4e48a8199bc5416549d5" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">3526000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <!--Short-term employee benefits-->
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits id="Fact_d3767414fe434df0aeedfb66be1b9672" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">3497000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <!--Liabilities-->
  <ifrs-full:Liabilities id="Fact_21c2dcbaca754ea48b6679eb1f20eee6" contextRef="c20191231" unitRef="U002" decimals="-3">26808000</ifrs-full:Liabilities>
  <!--Liabilities-->
  <ifrs-full:Liabilities id="Fact_ad8b774e32d84a8c8484916f11e7d0f1" contextRef="c20201231" unitRef="U002" decimals="-3">23262000</ifrs-full:Liabilities>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_2c52729d8ee4483f91989e098664f545" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">26624000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Present value of defined benefit obligation [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_67bb8b7b6c7841f3b7febbd35195f42a" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">17942000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_7665b9fc95a64e3fa1ab0cca7a78b98b" contextRef="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">14278000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_3b9dc1a57de24ca7938cb9816d652ba2" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">30213000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_45e4ba984c0d4e6b93693c796cbdaad3" contextRef="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">4926000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_935686ce510e4a2d88de484de9e052d8" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">7485000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_c969ca1b7aa74220af7fedab4111b225" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">5665000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_be4643fe281943ea95e41ff061938270" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">7464000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-Actuarial assumption of discount rates [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_02972ca6e2b94419845c1a93ac97fbde" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">29396000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Actuarial assumption of expected rates of pension increases [member]-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_089ed7cb0ee1439884ee135cbedba570" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">28916000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of expected rates of pension increases [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_1917b754bbfa41c5891741f3921cd3c9" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">25393000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Actuarial assumption of expected rates of pension increases [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_1a52d77ef7b5402ea8b2d898bc530da2" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">27993000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Actuarial assumption of expected rates of salary increases [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_2491bc7f6bfe47c1adf63d6e534cc56b" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">27317000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of expected rates of salary increases [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_2e50917f77894b72b53679a7d40bbae6" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">25930000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible decrease in actuarial assumption [Member]-Actuarial assumption of expected rates of salary increases [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_31c6aaca013948f1bfdf82198e3a6a1b" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">29519000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Actuarial assumption of expected rates of pension increases [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_471f17d646f047c1994ca2358a281e34" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">31652000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of expected rates of salary increases [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_7d95a77738244dbebb27a289071ffa3a" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">30912000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_9738fec236ad4dc3a6a3bacaa446075a" contextRef="c20191231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">24248000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Actuarial assumption of discount rates [member]-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible decrease in actuarial assumption [Member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_a4b157cdab71412982f688763f2b3e5d" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">33080000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Other material actuarial assumptions [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_b053ce4a875b4bb1927732034da310b6" contextRef="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">31070000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-Other material actuarial assumptions [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_bfbbbc79befd44ffa54d34a1fe7cbc46" contextRef="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">25848000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Other material actuarial assumptions [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_d08cdcccd0c24549a93df84535e65c1d" contextRef="c20191231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">27447000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Percentage of reasonably possible increase in actuarial assumption [Member]-Actuarial assumption of discount rates [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_d6dfc2d48ccd47efa796068b6da19996" contextRef="c20201231_ActuarialAssumptionsAxis_ActuarialAssumptionOfDiscountRatesMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">27740000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Net defined benefit liability (asset)-Percentage of reasonably possible decrease in actuarial assumption [Member]-Other material actuarial assumptions [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:LiabilityAssetOfDefinedBenefitPlans id="Fact_f867d6737c9041dc87882f5719b669e4" contextRef="c20201231_ActuarialAssumptionsAxis_OtherMaterialActuarialAssumptionsMember_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U002" decimals="-3">29405000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
  <!--Non-current assets-->
  <ifrs-full:NoncurrentAssets id="Fact_7dfb6877236e497e925fe873cd20aa6d" contextRef="c20201231" unitRef="U002" decimals="-3">6973000</ifrs-full:NoncurrentAssets>
  <!--Non-current assets-->
  <ifrs-full:NoncurrentAssets id="Fact_0c91f0e02f75487cbfb8e966f1869cb5" contextRef="c20191231" unitRef="U002" decimals="-3">6476000</ifrs-full:NoncurrentAssets>
  <!--Non-current lease liabilities-->
  <ifrs-full:NoncurrentLeaseLiabilities id="Fact_6b16ef09b91944428fe42a8534e72c37" contextRef="c20201231" unitRef="U002" decimals="-3">1780000</ifrs-full:NoncurrentLeaseLiabilities>
  <!--Non-current lease liabilities-->
  <ifrs-full:NoncurrentLeaseLiabilities id="Fact_d2f9fb61dc6443a7b3890d98fef0c356" contextRef="c20191231" unitRef="U002" decimals="-3">1813000</ifrs-full:NoncurrentLeaseLiabilities>
  <!--Non-current liabilities-->
  <ifrs-full:NoncurrentLiabilities id="Fact_3ae0def71df845528951efa38817f648" contextRef="c20201231" unitRef="U002" decimals="-3">9244000</ifrs-full:NoncurrentLiabilities>
  <!--Non-current liabilities-->
  <ifrs-full:NoncurrentLiabilities id="Fact_77a41f320c534e05a16e00503b21b472" contextRef="c20191231" unitRef="U002" decimals="-3">9298000</ifrs-full:NoncurrentLiabilities>
  <!--Non-current provisions for employee benefits-->
  <ifrs-full:NoncurrentProvisionsForEmployeeBenefits id="Fact_4d66a206dd4f4074a80c3ce388d7b574" contextRef="c20201231" unitRef="U002" decimals="-3">7464000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
  <!--Non-current provisions for employee benefits-->
  <ifrs-full:NoncurrentProvisionsForEmployeeBenefits id="Fact_93f62c92326a4293870045ae98ad4f81" contextRef="c20191231" unitRef="U002" decimals="-3">7485000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
  <!--Deposits in escrow accounts-->
  <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents id="Fact_a2d6f5a1f0e04b91a48e9914a71ea75a" contextRef="c20201231" unitRef="U002" decimals="-3">334000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
  <!--Deposits in escrow accounts-->
  <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents id="Fact_ff2db50821044b85a4e2ee64f2684f73" contextRef="c20191231" unitRef="U002" decimals="-3">304000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
  <!--Number of other equity instruments granted in share-based payment arrangement-Executive Management [Member]-Restricted Stock Units [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_3518ac2fb4514848be960a9019d2824e" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_ExecutiveManagementMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember" unitRef="U001" decimals="INF">110839</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments granted in share-based payment arrangement-Restricted Stock Units [Member]-Board of Directors [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_4bad1d7bef784909a167483224606fdf" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_BoardOfDirectorsMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember" unitRef="U001" decimals="INF">83864</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments granted in share-based payment arrangement-Restricted shares [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_5def0a07441246b9b7116a7101b64c99" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesMember" unitRef="U001" decimals="INF">4023</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_4a843eb8eb1841abb09f1fd069ffa8b3" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_86a0d260455a4ef89ea470fcfa383e51" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted id="Fact_0ce25942e48b434cb9da4eb34b1de9b6" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">69371</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <!--Number of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement id="Fact_326b27c45dc043cd8546ddea462ed46b" contextRef="c20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">130290</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
  <!--Number of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement id="Fact_83837869adad4f4897602780f4345269" contextRef="c20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">49289</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
  <!--Number of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement id="Fact_d8a28a6baa664e6392dd263be03d9ccc" contextRef="c20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">64012</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
  <!--Number of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement id="Fact_08aaea1a7c0e41bfafd876019296397d" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">23269</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement id="Fact_cb3ae9779cf8439aa0c7b2b3fb9d59f7" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">66278</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement id="Fact_dd1223fab10b4e0da1fe3ddc9dea5d53" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">56671</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments expired in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement id="Fact_4fd766177d784c10ab6c236acca4ded5" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">7804</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
  <!--Number of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement id="Fact_1992ad31cdbe4280aa81c867aa69f845" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">25673</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement id="Fact_6675a101591641beb5d11c7863060373" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement id="Fact_a96bac182dcc4cdfbd8b2c6b76a70d69" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">11828</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <!--Number of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement id="Fact_06b28f86ee834191a441d2c1241adad2" contextRef="c20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">42763</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <!--Number of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement id="Fact_2e79aebbd99c44099790e5a6e069207d" contextRef="c20171231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">122014</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <!--Number of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement id="Fact_eee702133c884160b88478170e83fd64" contextRef="c20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">109041</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <!--Number of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement id="Fact_aa4837d33ee247a288158d250ceef3b7" contextRef="c20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">19494</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <!--Outstanding Options (in shares)-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_82d046a469c444ea95de4b11b46c0300" contextRef="c20191231" unitRef="U001" decimals="INF">1981629</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_8dd57bcda1834322ae51f1407e03ff44" contextRef="c20181231" unitRef="U001" decimals="INF">1618856</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_ba0af87dd5da47428bf17f7fccefe8ea" contextRef="c20171231" unitRef="U001" decimals="INF">1359891</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_dbc7042f6090488c98ffba28be9e90de" contextRef="c20201231" unitRef="U001" decimals="INF">2900667</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-Range of Exercise Prices one [Member]-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_1c2b3baa2ae44e168160c41a62dff957" contextRef="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember" unitRef="U001" decimals="INF">243125</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-Range Of Exercise Prices Two [Member]-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_368482938ca443a08d1735262c3fb5e2" contextRef="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesTwoMember" unitRef="U001" decimals="INF">223646</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Outstanding Options (in shares)-Range Of Exercise Prices Three [Member]-->
  <ifrs-full:NumberOfOutstandingShareOptions id="Fact_5565e0ae94564e7dbc8e149f4ea8d38a" contextRef="c20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember" unitRef="U001" decimals="INF">2433896</ifrs-full:NumberOfOutstandingShareOptions>
  <!--Number of share options exercisable in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement id="Fact_40b5dd8dcf7549f7b9e7fa62eef16ab2" contextRef="c20191231" unitRef="U001" decimals="INF">602218</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <!--Number of share options exercisable in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement id="Fact_80b499ef1fe349d59308a8a3c6f06293" contextRef="c20201231" unitRef="U001" decimals="INF">1099015</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <!--Number of share options exercisable in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement id="Fact_b093d11d9ea04a9c883194aaf62a7cf8" contextRef="c20181231" unitRef="U001" decimals="INF">932175</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <!--Number of share options exercised in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement id="Fact_5e8b938a78d74ab8a97630cc8ed9aa00" contextRef="c20180101to20181231" unitRef="U001" decimals="INF">151814</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <!--Number of share options exercised in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement id="Fact_b5c53760f887425e8543f812fb29b3cd" contextRef="c20200101to20201231" unitRef="U001" decimals="INF">73669</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <!--Number of share options exercised in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement id="Fact_e7b774d1426c498aa30ece82930dae0a" contextRef="c20190101to20191231" unitRef="U001" decimals="INF">616833</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <!--Number of share options expired in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement id="Fact_d1faf5ed0acd4869a7754b7f0fcaa029" contextRef="c20200101to20201231" unitRef="U001" decimals="INF">26729</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <!--Number of share options forfeited in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="Fact_2cafb826a0a0421584b301fa2ff6ee1b" contextRef="c20180101to20181231" unitRef="U001" decimals="INF">73624</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <!--Number of share options forfeited in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="Fact_6aaf1b72274744719f2a9baedc4104bf" contextRef="c20190101to20191231" unitRef="U001" decimals="INF">73699</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <!--Number of share options forfeited in share-based payment arrangement-->
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement id="Fact_6b199438e280441fb95dd10e804bb73f" contextRef="c20200101to20201231" unitRef="U001" decimals="INF">53591</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-Stock option plan A [Member]-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_002e2457bdd14fe1a959d9c637393342" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanAMember" unitRef="U001" decimals="INF">362750</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-2016 Share Option and Incentive Plan [Member]-Executives and Directors [Member]-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_38343185818b40de88228079d8c1f86b" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember" unitRef="U001" decimals="INF">1898222</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-Stock option plan C1 [Member]-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_66b2a80bd49846b7bbbe5266ef2953a0" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanC1Member" unitRef="U001" decimals="INF">6775250</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-Employees [Member]-2016 Share Option and Incentive Plan [Member]-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_6e87c55e4ed74de8b851a728e64fb809" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_EmployeesMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember" unitRef="U001" decimals="INF">989279</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-Stock option plan B [Member]-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_b24f782977f2429a970c972173b35262" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanBMember" unitRef="U001" decimals="INF">819000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_91a9f166ec5b4c21b41bd5cce793b029" contextRef="c20200101to20201231" unitRef="U001" decimals="INF">1073027</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_9c6ce7b7065a4b26ae0e0e9c8254dc61" contextRef="c20190101to20191231" unitRef="U001" decimals="INF">1053305</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Granted during the year (in shares)-->
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement id="Fact_f23fcde4db3f40ed97335c93bf2ba0be" contextRef="c20180101to20181231" unitRef="U001" decimals="INF">484403</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <!--Number of shares authorised-->
  <ifrs-full:NumberOfSharesAuthorised id="Fact_1b7ecfafefc049d09763410c388806c0" contextRef="c20201231" unitRef="U001" decimals="INF">9500000</ifrs-full:NumberOfSharesAuthorised>
  <!--Number of shares issued-At the Market Equity Offering [Member]-->
  <ifrs-full:NumberOfSharesIssued id="Fact_0e18684e71494ae983c63c3eb4091187" contextRef="c20201231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember" unitRef="U001" decimals="INF">0</ifrs-full:NumberOfSharesIssued>
  <!--Number of shares issued-Subsequent events [Member]-At the Market Equity Offering [Member]-->
  <ifrs-full:NumberOfSharesIssued id="Fact_7e3c50f8c0204e28992c0cbbcdc7d624" contextRef="c20210228_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_NonadjustingEventsAfterReportingPeriodAxis_SubsequentEventsMember" unitRef="U001" decimals="INF">764977</ifrs-full:NumberOfSharesIssued>
  <!--Number of shares outstanding-Ordinary shares [member]-->
  <ifrs-full:NumberOfSharesOutstanding id="Fact_a7bb0f49571c46aabcd0a69f6b62d8d1" contextRef="c20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">71936738</ifrs-full:NumberOfSharesOutstanding>
  <!--Operating expense-->
  <ifrs-full:OperatingExpense id="Fact_581c9da6a5ac4bc3a5bb6d72c9346eed" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">65920000</ifrs-full:OperatingExpense>
  <!--Operating expense-->
  <ifrs-full:OperatingExpense id="Fact_f14da73a498c4172a952c0dd58ef8240" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">76691000</ifrs-full:OperatingExpense>
  <!--Operating expense-->
  <ifrs-full:OperatingExpense id="Fact_0e33b27880364336a54769b15c179f0a" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">56462000</ifrs-full:OperatingExpense>
  <!--Other comprehensive income-Retained earnings [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_1da25884275840c694ac2ba1d7dba23c" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-302000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_23408c7a2f0443a1a4352d6c5d23785a" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-302000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Treasury shares [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_2adbd4e4c9784a14837e211e305cb421" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_34cd8b63d4d84fa18151eadb9bb8b715" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-1304000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Retained earnings [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_4bb29797e96e49138b6d5f4abd062ec5" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">726000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Issued capital [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_4edb1c39b9f347ad8d2f07efc1e52ba4" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Retained earnings [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_6bbf2913c547400d8016c31b8658e3b2" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-1304000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Issued capital [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_7112bf8029a64217a16a796de3e7b497" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Treasury shares [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_838dc5125dca4cb6943c9ee315788ddd" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_84b78178bf99444eae359b73138b1c3b" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">726000</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Treasury shares [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_8c34ae52eacc4f0481689ba6c80c5cd4" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Share Premium [Member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_981f4ff704e941278d40cbb273b6c241" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Share Premium [Member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_bc10a37d446d4d4fa9ac8d0739dae8e3" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Issued capital [member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_dfd3afaae5ec43b29171985d4a9cd596" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income-Share Premium [Member]-->
  <ifrs-full:OtherComprehensiveIncome id="Fact_e8d79717f3c34c689bb2c0dd97efd59a" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <!--Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans-->
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans id="Fact_040af086908c4d53a8359ca01a2410dd" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-302000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <!--Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans-->
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans id="Fact_2abf7d751156493792775057e7c62d0e" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-1304000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <!--Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans-->
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans id="Fact_a70a30caee23443c987978045aee4da0" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">726000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
  <!--Other current liabilities-->
  <ifrs-full:OtherCurrentLiabilities id="Fact_1509312c1d7546c287bf6976ab333f02" contextRef="c20201231" unitRef="U002" decimals="-3">2293000</ifrs-full:OtherCurrentLiabilities>
  <!--Other current liabilities-->
  <ifrs-full:OtherCurrentLiabilities id="Fact_8b607be153494e68b76ce767708d216e" contextRef="c20191231" unitRef="U002" decimals="-3">1673000</ifrs-full:OtherCurrentLiabilities>
  <!--Other material actuarial assumptions-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:OtherMaterialActuarialAssumptions id="Fact_31cd841d5afd4eb694663f9fc23ac871" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0050</ifrs-full:OtherMaterialActuarialAssumptions>
  <!--Other material actuarial assumptions-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:OtherMaterialActuarialAssumptions id="Fact_70661593c8a74650977f2146a6ac7d57" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0050</ifrs-full:OtherMaterialActuarialAssumptions>
  <!--Other material actuarial assumptions-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:OtherMaterialActuarialAssumptions id="Fact_e252788bde684636bedd546ac62e1f5e" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U008" decimals="4">0.0090</ifrs-full:OtherMaterialActuarialAssumptions>
  <!--Other operating income/(expense)-->
  <ifrs-full:OtherOperatingIncomeExpense id="Fact_b44ea95e151f42568bc15440d3ef0052" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">282000</ifrs-full:OtherOperatingIncomeExpense>
  <!--Other operating income/(expense)-->
  <ifrs-full:OtherOperatingIncomeExpense id="Fact_d5b750df175847c4a90554db8f7d8072" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1353000</ifrs-full:OtherOperatingIncomeExpense>
  <!--Other operating income/(expense)-->
  <ifrs-full:OtherOperatingIncomeExpense id="Fact_e9b6177b3bb9419bb2f79ab4d3db3647" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">570000</ifrs-full:OtherOperatingIncomeExpense>
  <!--Par value per share-Treasury shares [member]-->
  <ifrs-full:ParValuePerShare id="Fact_c02071ea407648968edcfa698862a431" contextRef="c20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U003" decimals="INF">0.02</ifrs-full:ParValuePerShare>
  <!--Past service cost and gains (losses) arising from settlements, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset id="Fact_23b6062fb7fe4e338c1bf3e05d22b84e" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1375000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <!--Past service cost and gains (losses) arising from settlements, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset id="Fact_3567ff0695f04fe785e8972131489718" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1130000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <!--Past service cost and gains (losses) arising from settlements, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset id="Fact_a2d9037fbd964d54aa15c28c0211afa7" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">1655000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
  <!--Payments for share issue costs-->
  <ifrs-full:PaymentsForShareIssueCosts id="Fact_3a050882325d478181099dbcbcdfb788" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">510000</ifrs-full:PaymentsForShareIssueCosts>
  <!--Payments for share issue costs-->
  <ifrs-full:PaymentsForShareIssueCosts id="Fact_6f36b1790e1048968d0c7bb1a0106f7f" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</ifrs-full:PaymentsForShareIssueCosts>
  <!--Payments for share issue costs-->
  <ifrs-full:PaymentsForShareIssueCosts id="Fact_b0f62a0bc493409a9da5137ed16f5fc1" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:PaymentsForShareIssueCosts>
  <!--Payments from plan, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_00250cf928414cea86b009b9d41b1020" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-1710000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments from plan, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_1cf4f58804354c97987c6bc99e428715" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-3382000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments from plan, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_3622e2f499084349975777489d4f0279" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-1467000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments from plan, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_0463478a25fa4568800393a2301a3dd5" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">3382000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments from plan, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_7890839cfd3245ba9656ddb47f2c3cac" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">1710000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments from plan, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset id="Fact_0f8f1acd814e4ea1807431e428a9805d" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">1467000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
  <!--Payments of lease liabilities, classified as financing activities-->
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="Fact_045ca14cf8914298bf663dee23a95746" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">420000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <!--Payments of lease liabilities, classified as financing activities-->
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="Fact_1ec76ad29a1b49b69069a5c4e4ed6945" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">432000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <!--Payments of lease liabilities, classified as financing activities-->
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities id="Fact_94558eff45824667a4817cf66b9d5e7e" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <!--Payments to acquire or redeem entity's shares-->
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares id="Fact_cb00c79789db47a788707aeca872c059" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <!--Payments to acquire or redeem entity's shares-->
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares id="Fact_d1791483de8446e787278b1ba61a491a" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">100000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <!--Payments to acquire or redeem entity's shares-->
  <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares id="Fact_ee0f9cf8675b484d8c43de8e18e91649" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
  <!--Percentage of entity's revenue-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:PercentageOfEntitysRevenue id="Fact_02cef3802fc0424c84beb89045add791" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U008" decimals="2">0.93</ifrs-full:PercentageOfEntitysRevenue>
  <!--Percentage of entity's revenue-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:PercentageOfEntitysRevenue id="Fact_3a910049e2e54073810b05d6658f73be" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U008" decimals="2">0.31</ifrs-full:PercentageOfEntitysRevenue>
  <!--Percentage of entity's revenue-Collaboration agreement of 2016, Biogen [Member]-->
  <ifrs-full:PercentageOfEntitysRevenue id="Fact_5e9ede380e964fefa104e73e2b17e366" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U008" decimals="2">0.58</ifrs-full:PercentageOfEntitysRevenue>
  <!--Percentage of entity's revenue-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:PercentageOfEntitysRevenue id="Fact_ce21e978b22640ebb508aa3fa6f5569d" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U008" decimals="2">0.96</ifrs-full:PercentageOfEntitysRevenue>
  <!--Percentage of reasonably possible decrease in actuarial assumption-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption id="Fact_b67327e20d0d4502bb2762fc2bebdbe8" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U008" decimals="INF">0.005</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Percentage of reasonably possible decrease in actuarial assumption-Percentage of reasonably possible decrease in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption id="Fact_bbecc5288a9449de9c7b51456fd22696" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" unitRef="U008" decimals="INF">0.005</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
  <!--Percentage of reasonably possible increase in actuarial assumption-Percentage of reasonably possible increase in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption id="Fact_b8acc163ddeb47a4aa8d3ae0bd69d328" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U008" decimals="3">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Percentage of reasonably possible increase in actuarial assumption-Percentage of reasonably possible increase in actuarial assumption [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption id="Fact_fb261c1c9fc14db38e89626ae9cf904f" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_TypesOfRisksAxis_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" unitRef="U008" decimals="3">0.005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
  <!--Plan assets, at fair value-Present value of defined benefit obligation [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_43cf1bcc1d3a4dbe910a519cb73df4ea" contextRef="c20181231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">12277000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Present value of defined benefit obligation [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_a707a8615d1e43029f0229bad19aa744" contextRef="c20191231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">19139000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Present value of defined benefit obligation [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_e9478235fc6844fa888767a414c8ccd8" contextRef="c20201231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">22749000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Defined benefit plans that share risks between entities under common control [member]-Plan assets [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_4c7b5816fd3b4255854c3e686d20da2f" contextRef="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">9352000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_e41189d4543d472398dfdb256eb9b666" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">12277000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_f3bede3b8a54410790fdfca771c1be25" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">19139000</ifrs-full:PlanAssetsAtFairValue>
  <!--Plan assets, at fair value-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PlanAssetsAtFairValue id="Fact_b2e461509daf43878b6c3b8b5b284109" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">22749000</ifrs-full:PlanAssetsAtFairValue>
  <!--Expected contribution by employer to be paid to post-retirement benefit plans-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans id="Fact_b06dd25a531e4a14837b815db918b492" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-5">1100000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
  <!--Proceeds from long-term financing obligation-->
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="Fact_810aa8a81f474ddba02589c27b9f3ac9" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">199000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <!--Proceeds from long-term financing obligation-->
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="Fact_8448ac3696c34f0b86aa0ab28d63f942" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <!--Proceeds from long-term financing obligation-->
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities id="Fact_c4d4907b364a4ac1a846951b5159de28" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">198000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <!--Proceeds from exercise of options-->
  <ifrs-full:ProceedsFromExerciseOfOptions id="Fact_05edac0cfa394994a5386cbacde1911d" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">143000</ifrs-full:ProceedsFromExerciseOfOptions>
  <!--Proceeds from exercise of options-->
  <ifrs-full:ProceedsFromExerciseOfOptions id="Fact_99fdda54e1504c4690a9abcf7e8a46e1" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">5000</ifrs-full:ProceedsFromExerciseOfOptions>
  <!--Proceeds from exercise of options-->
  <ifrs-full:ProceedsFromExerciseOfOptions id="Fact_f295f2939c6644a4828194313bc7f0e5" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">69000</ifrs-full:ProceedsFromExerciseOfOptions>
  <!--Proceeds from issue of ordinary shares-Initial Public Offering [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_675a6777a4e04a06a1be095e0abe63ba" contextRef="c20180101to20181231_ClassesOfShareCapitalAxis_InitialPublicOfferingMember" unitRef="U005" decimals="-5">117500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-Initial Public Offering [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_dc431fb8ddfa4027b727748e846893f1" contextRef="c20180101to20181231_ClassesOfShareCapitalAxis_InitialPublicOfferingMember" unitRef="U002" decimals="-5">116300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-Second Subscription Rights [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_2297e0d2e84741b2afb1aef3102bd3a4" contextRef="c20180731to20180731_ClassesOfShareCapitalAxis_SecondSubscriptionRightsMember" unitRef="U002" decimals="-5">17400000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-First Subscription Rights [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_231a7e29db6f4b00bdc433f56a86fa36" contextRef="c20180724to20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember" unitRef="U002" decimals="-5">98900000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-First Subscription Rights [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_4662f45e44504209ad081cb5eea02d44" contextRef="c20180724to20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember" unitRef="U005" decimals="-5">99900000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-Follow-on Offerings [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_89208a0ea36a4e2e9213483e642f8d51" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember" unitRef="U002" decimals="-5">116300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-Second Subscription Rights [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_bb9c1bf5d6cf439ab5c7eee3035e245a" contextRef="c20180731to20180731_ClassesOfShareCapitalAxis_SecondSubscriptionRightsMember" unitRef="U005" decimals="-5">17600000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-Follow-on Offerings [Member]-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_e81137fbd8d74c0fae009b230b49e10c" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember" unitRef="U005" decimals="-5">117500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_0b719403b2d442b9ad6f7d3b72bc7c79" contextRef="c20200101to20201231" unitRef="U005" decimals="-5">117500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issue of ordinary shares-->
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares id="Fact_2dadae14fc794f35bd546b44e5ef429e" contextRef="c20200101to20201231" unitRef="U002" decimals="-5">116300000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <!--Proceeds from issuance of treasury shares, net of transaction costs-->
  <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares id="Fact_42516c9e86fe47e3b18e9e3391615c92" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">100000</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
  <!--Proceeds from issuance of treasury shares, net of transaction costs-->
  <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares id="Fact_7126c463db304f64919198ec74577930" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
  <!--Proceeds from issuance of treasury shares, net of transaction costs-->
  <ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares id="Fact_7eaf1af9e785452c9626e208a979d0f9" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:ProceedsFromSaleOrIssueOfTreasuryShares>
  <!--Proceeds from sales of property, plant and equipment, classified as investing activities-->
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_38edab3366204d79ae9f048aab80f2bc" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">64000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Proceeds from sales of property, plant and equipment, classified as investing activities-->
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_61427c1cf6ff435eb74e2d63b80f517b" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Proceeds from sales of property, plant and equipment, classified as investing activities-->
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_b2a0a8544c444df296cfe7f50d5ef025" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Income/(loss) for the period-->
  <ifrs-full:ProfitLoss id="Fact_4402dbb14f9b499492e3c02116a011cf" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">45442000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-->
  <ifrs-full:ProfitLoss id="Fact_57512a633ed145dc84045f532ad190a0" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-61921000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-->
  <ifrs-full:ProfitLoss id="Fact_bc8748b270ec49499447f4f81dabae22" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-50951000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Retained earnings [member]-->
  <ifrs-full:ProfitLoss id="Fact_190859a5b1c74deebfbcc76100399866" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-50951000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Issued capital [member]-->
  <ifrs-full:ProfitLoss id="Fact_42d86b98bbad41229214fc7de997c82f" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Issued capital [member]-->
  <ifrs-full:ProfitLoss id="Fact_4e15ae438304481980ba7f72861388fd" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Retained earnings [member]-->
  <ifrs-full:ProfitLoss id="Fact_aaf5cbbe830940e9b8b43c9ce40d8b49" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">45442000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Retained earnings [member]-->
  <ifrs-full:ProfitLoss id="Fact_b31c07297d2d4fdd817a1cceed5bbf38" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-61921000</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Share Premium [Member]-->
  <ifrs-full:ProfitLoss id="Fact_b33d6d319d9145738e156f8c3bd805fd" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Share Premium [Member]-->
  <ifrs-full:ProfitLoss id="Fact_bf434eb5cb8e40f4a6cfbb19d3f89506" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Treasury shares [member]-->
  <ifrs-full:ProfitLoss id="Fact_cbeebf2480ce49bdb21df64f22db0938" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Share Premium [Member]-->
  <ifrs-full:ProfitLoss id="Fact_d5e5df1c125642478cb3e12a84f5371f" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Treasury shares [member]-->
  <ifrs-full:ProfitLoss id="Fact_dad015d3e9454cb98a4a2cd1c8cad4d2" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Issued capital [member]-->
  <ifrs-full:ProfitLoss id="Fact_f1fc566f88ca46beb39ab1484720567a" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) for the period-Treasury shares [member]-->
  <ifrs-full:ProfitLoss id="Fact_f3983caa7ec044e0a2930b2d686d7c8f" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ProfitLoss>
  <!--Income/(loss) before income tax-->
  <ifrs-full:ProfitLossBeforeTax id="Fact_6ed45bd070624067becfe6513f6b4874" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">45442000</ifrs-full:ProfitLossBeforeTax>
  <!--Income/(loss) before income tax-->
  <ifrs-full:ProfitLossBeforeTax id="Fact_7a59d33cd2f841ee9020a5b702025483" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-50951000</ifrs-full:ProfitLossBeforeTax>
  <!--Income/(loss) before income tax-->
  <ifrs-full:ProfitLossBeforeTax id="Fact_7be493c5c12d4d6b8776398dd3144d3d" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-61921000</ifrs-full:ProfitLossBeforeTax>
  <!--Profit (loss) from operating activities-->
  <ifrs-full:ProfitLossFromOperatingActivities id="Fact_3d00ebfda2da46d69af09f8fc3486736" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-49550000</ifrs-full:ProfitLossFromOperatingActivities>
  <!--Profit (loss) from operating activities-->
  <ifrs-full:ProfitLossFromOperatingActivities id="Fact_bd490cc689f7485abdbb1718299862f3" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">44536000</ifrs-full:ProfitLossFromOperatingActivities>
  <!--Profit (loss) from operating activities-->
  <ifrs-full:ProfitLossFromOperatingActivities id="Fact_e428c63d1db2465da13e7f71d20895e5" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-61260000</ifrs-full:ProfitLossFromOperatingActivities>
  <!--Property, plant and equipment-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_ac0f6f386e0648eaaca2ac3c064b459c" contextRef="c20201231" unitRef="U002" decimals="-3">4416000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_1027dece249f4d408b34db9ecf90de58" contextRef="c20191231" unitRef="U002" decimals="-3">3917000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_005d11cbeb684a9c9a3a9085e78fc561" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">6868000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_16632cbf5768451292f1f7842030a0ab" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">-4528000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_191844130ea7466e90b9154ab106f380" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">-77000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_20797d3f8b2c43a0a31e927fcdebf141" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">350000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_26e9e028a4db4b76b0400cfb95a9e86f" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">-3544000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_2e042117ba5f445caa28923df861292e" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">-68000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_3b78ce79175c46ccba9882557016a4e3" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">5367000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_4aedc9d1df334fa9a0031cb75f372e71" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">126000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_64d1c199a97d453ab3bb84525ede61d5" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">-455000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Computer equipment [member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_66352405ae114962b65ada93d402f9d6" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">1187000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_80aaea07d81b481fb901dcc7b8f87539" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">-627000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-Furniture [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_8b6ac289a1d7474e935ff926e78cc4a6" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">158000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_9f38a02610984e13a0650a15e661c211" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">6698000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Computer equipment [member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_ac40c5ab6f5044d2afcd23dea9d2b980" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">1025000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-Leasehold Improvements [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_bec83d644aba4993acffadef5e0f5475" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">402000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_c6e6cba5c26f4fbfa2a49c8e5c1e04d7" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">-2857000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_d766487202674db68efb904dbab3166b" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">8445000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_e4820dcbf52d48c0bdeceb23cab04db2" contextRef="c20181231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">-155000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Laboratory equipment [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_104b3e58f4014d2ea4979ccf4476ba9a" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">-3619000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Leasehold Improvements [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_10ab4a840792412d9ce5bb1a98852b5c" contextRef="c20191231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">-214000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_18ba2bb09b294d1797304d9c4e1a39d5" contextRef="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">3553000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Furniture [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_40dc769649d34c82845696230742450a" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">-61000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_4743c0e186474007bde2574e2cc2676b" contextRef="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">188000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_4bf2998ef854419fb7f5cb936447966a" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">-281000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_545d9c676c584d76b3e117169a7654be" contextRef="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">3079000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_5475be2959104096ae32d3415d59b0fc" contextRef="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">527000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_5f7a4fd2b7164a5eb7a1e1eedffc0fed" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">-4405000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_6cdc85c180164f8abe45c1f11e2f1278" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">-970000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_741c99f92049446dae488c2b25473268" contextRef="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">49000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_7b507120e0ff4da49a64bea40205de9d" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">464000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_861ff7f740964bae8c08f059806ba888" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">214000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-Laboratory equipment [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_8c4ea630fac14665b51ae79840fea842" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">7958000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_9260b048f4d046c6949586c173ec139a" contextRef="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">153000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_9a03519cfbbb426faacfa1abe90489d0" contextRef="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">570000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Accumulated depreciation and amortisation [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_9ad9882b3fbb4718b705772aac1b50cf" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_AccumulatedDepreciationAndAmortisationMember" unitRef="U002" decimals="-3">-5717000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_a57107387ee84cc3afeb2875ab235499" contextRef="c20201231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">183000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Furniture [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_deef6fb904624bca9ff60220b2b0384c" contextRef="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_FixturesAndFittingsMember" unitRef="U002" decimals="-3">90000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_e3733e21bc8647c2a986f9d5373ece72" contextRef="c20181231" unitRef="U002" decimals="-3">3324000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Laboratory equipment [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_e9115ad4d1b148d09ec7b46f7c896b1d" contextRef="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember" unitRef="U002" decimals="-3">2510000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_ea4a134215594258b2494812d42639a3" contextRef="c20191231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">560000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_ebdbc5e20c8d4b5badb4ce5302131562" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember" unitRef="U002" decimals="-3">10133000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Leasehold Improvements [Member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_0cf2610479e940888aba0c29b0822b8a" contextRef="c20181231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3">195000</ifrs-full:PropertyPlantAndEquipment>
  <!--Property, plant and equipment-Acquisition Cost [Member]-Computer equipment [member]-->
  <ifrs-full:PropertyPlantAndEquipment id="Fact_1457a9d45c1c4ccc8f415c265b2c9897" contextRef="c20201231_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">1497000</ifrs-full:PropertyPlantAndEquipment>
  <!--Provisions-Loss Expiry, December 31, 2020 [Member]-->
  <ifrs-full:Provisions id="Fact_4a321707333d457ebc3e335f56a53695" contextRef="c20201231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U002" decimals="-3">25072000</ifrs-full:Provisions>
  <!--Provisions-Between 1 and 3 Years [Member]-->
  <ifrs-full:Provisions id="Fact_91a61f18f02a46dc82cb7601533ae8ed" contextRef="c20201231_MaturityAxis_LaterThanOneYearAndNotLaterThanThreeYearsMember" unitRef="U002" decimals="-3">8885000</ifrs-full:Provisions>
  <!--Provisions-->
  <ifrs-full:Provisions id="Fact_9f86e341ada24c4e945e9a0e99d6975f" contextRef="c20191231" unitRef="U002" decimals="-3">39909000</ifrs-full:Provisions>
  <!--Provisions-Between 3 and 5 Years [Member]-->
  <ifrs-full:Provisions id="Fact_a3e0be7674e147279bc689d4a410f6ca" contextRef="c20191231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" unitRef="U002" decimals="-3">4816000</ifrs-full:Provisions>
  <!--Provisions-More Than 5 Years [Member]-->
  <ifrs-full:Provisions id="Fact_a52d47e6cf484175befed825a481c3c7" contextRef="c20191231_MaturityAxis_LaterThanFiveYearsMember" unitRef="U002" decimals="-3">2193000</ifrs-full:Provisions>
  <!--Provisions-->
  <ifrs-full:Provisions id="Fact_c613372fbcd0487e99a75c5aac82fdd2" contextRef="c20201231" unitRef="U002" decimals="-3">34355000</ifrs-full:Provisions>
  <!--Provisions-Between 1 and 3 Years [Member]-->
  <ifrs-full:Provisions id="Fact_cecc6c5ff54345ff81a17a2812ef0c54" contextRef="c20191231_MaturityAxis_LaterThanOneYearAndNotLaterThanThreeYearsMember" unitRef="U002" decimals="-3">12993000</ifrs-full:Provisions>
  <!--Provisions-More Than 5 Years [Member]-->
  <ifrs-full:Provisions id="Fact_d8ad70961a9f4834802178a2872e383b" contextRef="c20201231_MaturityAxis_LaterThanFiveYearsMember" unitRef="U002" decimals="-3">57000</ifrs-full:Provisions>
  <!--Provisions-Between 3 and 5 Years [Member]-->
  <ifrs-full:Provisions id="Fact_f6e0fd17f60b484495be668274f888c8" contextRef="c20201231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" unitRef="U002" decimals="-3">341000</ifrs-full:Provisions>
  <!--Provisions-Loss Expiry, December 31, 2020 [Member]-->
  <ifrs-full:Provisions id="Fact_fa5ab4daaf7a4b93856e310533edf745" contextRef="c20191231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U002" decimals="-3">19907000</ifrs-full:Provisions>
  <!--Purchase of financial instruments, classified as investing activities-->
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities id="Fact_047fbb3795334f91a6fc4202d6f332ee" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">65000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <!--Purchase of financial instruments, classified as investing activities-->
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities id="Fact_57972fc9372440a39b6e9410e7e1207e" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">30000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <!--Purchase of financial instruments, classified as investing activities-->
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities id="Fact_5f401c58b8cb43b3af878ed074043fbf" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-30000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <!--Purchase of property, plant and equipment, classified as investing activities-->
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_6b2b608b8d3342309c9983dfde001bd7" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">1885000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Purchase of property, plant and equipment, classified as investing activities-->
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_75346d90a80a47ec82115cf2c765a32a" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1706000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Purchase of property, plant and equipment, classified as investing activities-->
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities id="Fact_8bc567d565384cefa52a7de820b4fde6" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">1858000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <!--Receivables from contracts with customers-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly, Second Amendment [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_0901134b38844ceb8268b766b3db9b6d" contextRef="c20200331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember" unitRef="U002" decimals="-6">10000000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly, First Amendment [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_8eecf2507c114d07bdafe7aaded68019" contextRef="c20190331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember" unitRef="U002" decimals="-6">30000000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Phase two clinical study, licensed product [Member]-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly, Second Amendment [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_a58997d699e3431b92228befccfe4c96" contextRef="c20201231_PerformanceObligationsAxis_PhaseTwoClinicalStudyLicensedProductMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember" unitRef="U002" decimals="-6">60000000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Collaboration Agreement with Lilly, First Amendment [Member]-Tau Morphomer Small Molecule [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_d75ff398b081446989c16ab2ffd8790e" contextRef="c20200331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember" unitRef="U002" decimals="-6">30000000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_48568584c5654185a849a12b9961f580" contextRef="c20200531_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">2200000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Skane University Hospital [Member]-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_6d4616bd35664a8faa5eab1f5f2a9112" contextRef="c20200531_CounterpartiesAxis_SkaneUniversityHospitalMember_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">700000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_7492128972314fdf97b8febf2d413016" contextRef="c20200531_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U005" decimals="-5">2500000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Receivables from contracts with customers-Skane University Hospital [Member]-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:ReceivablesFromContractsWithCustomers id="Fact_12118d4bdf1b4ecba17f9612c4a51341" contextRef="c20200531_CounterpartiesAxis_SkaneUniversityHospitalMember_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U005" decimals="-5">700000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <!--Repayments of current borrowings-->
  <ifrs-full:RepaymentsOfCurrentBorrowings id="Fact_4b60676ae1804974bcc84b550b52f260" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</ifrs-full:RepaymentsOfCurrentBorrowings>
  <!--Repayments of current borrowings-->
  <ifrs-full:RepaymentsOfCurrentBorrowings id="Fact_9b6593a7339e4251b29cc82ee968d1e5" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">339000</ifrs-full:RepaymentsOfCurrentBorrowings>
  <!--Repayments of current borrowings-->
  <ifrs-full:RepaymentsOfCurrentBorrowings id="Fact_d5c83706ee40437788678db68f0027ad" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">514000</ifrs-full:RepaymentsOfCurrentBorrowings>
  <!--Research and development expense-->
  <ifrs-full:ResearchAndDevelopmentExpense id="Fact_5a1ce4a06d2d4321a01e09d6f5ae2ae3" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">50432000</ifrs-full:ResearchAndDevelopmentExpense>
  <!--Research and development expense-->
  <ifrs-full:ResearchAndDevelopmentExpense id="Fact_66f8c262112b495aab1787c7a1161884" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">44277000</ifrs-full:ResearchAndDevelopmentExpense>
  <!--Research and development expense-->
  <ifrs-full:ResearchAndDevelopmentExpense id="Fact_c498ee50e6e14de68e5e14eb3ed12f2d" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">59487000</ifrs-full:ResearchAndDevelopmentExpense>
  <!--Retained earnings-->
  <ifrs-full:RetainedEarnings id="Fact_320e007732924bd09ef2477d69db015d" contextRef="c20191231" unitRef="U002" decimals="-3">-75521000</ifrs-full:RetainedEarnings>
  <!--Retained earnings-->
  <ifrs-full:RetainedEarnings id="Fact_73ad296f22a545c2aa150dfb06356ef4" contextRef="c20201231" unitRef="U002" decimals="-3">-132850000</ifrs-full:RetainedEarnings>
  <!--Return on plan assets excluding interest income-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_1e3d9ecc6d584295b9ed915763911f29" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">-164000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Return on plan assets excluding interest income-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_2f89416d90d742de87cb6d1859020c71" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">300000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Return on plan assets excluding interest income-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_615a69e6e53c4227835e159758de8bfb" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">1732000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Return on plan assets excluding interest income-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_4c13fefed93e4e92819956440eef8bfe" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">-164000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Return on plan assets excluding interest income-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_6302896e34e44de4904297e8d86f2fca" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">300000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Return on plan assets excluding interest income-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset id="Fact_ce47bdc0c583443b98e2c4c3de0f6bcd" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">1732000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
  <!--Revenue-->
  <ifrs-full:Revenue id="Fact_3800ec247aa34f659ba79f6cdbe4aa83" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">15431000</ifrs-full:Revenue>
  <!--Revenue-->
  <ifrs-full:Revenue id="Fact_a279e4f8ed04424c8f2fd0866a1b2529" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">110456000</ifrs-full:Revenue>
  <!--Revenue-->
  <ifrs-full:Revenue id="Fact_f4cd5781566443dcaead96b0f12120e9" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">6912000</ifrs-full:Revenue>
  <!--Recognized revenues-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_55dbbdbf81814d43ab1387e7e04884a8" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">6912000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_5a7636a81b3e4f0ea92f9bedd0ff495f" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">15431000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_7c702fad583843e9bcc433b5e76367d7" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">110456000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_14c2ac2115de407fbf28f817c1ab311d" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-3">2157000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_1e2eade20a004b39abd381f3ad6d300e" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_239623106fa442e2ba83993fd1826ac8" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-3">105662000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_38f5ef8b9312402ca27b1483288b4b30" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_3a8a10b640c344958211c393bd36c8cf" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Other agreement [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_4ad4e9db6c88465d856e3367287f68e5" contextRef="c20190101to20191231_TypesOfContractsAxis_OtherAgreementMember" unitRef="U002" decimals="-3">352000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Other agreement [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_567c4975c8d54439b3796c01a3980df6" contextRef="c20180101to20181231_TypesOfContractsAxis_OtherAgreementMember" unitRef="U002" decimals="-3">731000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2016, Biogen [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_759027a2bb6c4f6c90dff456c9350586" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-3">1063000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_8136286d29a54dd1817409d9ce95b3fe" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-3">1083000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2016, Biogen [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_9a0b7dec67164c44883b14944d4aab58" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_c26a63959dc54893be49cdd6e6fab045" contextRef="c20190101to20191231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-3">2206000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_cd790a80b276458e8d77ff49e6a59e3a" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-3">1173000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_d17177f128fa4af1bb108b0d229a06e9" contextRef="c20180101to20181231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_d37399db9e224a128df319e1326040e7" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-3">14348000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_d67f71d7f2904853914edbf4bb9f8070" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_ea31e4f9b9e647068946f874f94adcf2" contextRef="c20200101to20201231_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Other agreement [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_ebf92d22352447b8906c1215f332f0ca" contextRef="c20200101to20201231_TypesOfContractsAxis_OtherAgreementMember" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2016, Biogen [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_f643f37279cb4e9c977187e1b5987560" contextRef="c20180101to20181231_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-3">4024000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Tau Morphomer Small Molecule [Member]-Research and development [Member]-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_416f2b5d55b841dc9cf35a600ecc927f" contextRef="c20200101to20201231_PerformanceObligationsAxis_ResearchAndDevelopmentMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-5">6900000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration Agreement with Lilly [Member]-Tau Morphomer Small Molecule [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_82037613e28b4636917c3a92510b8319" contextRef="c20190101to20191231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-5">105700000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_8a4767003c9e40bb8a9d52bf61d9c900" contextRef="c20180101to20181231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_b89e2bb07350438b84ddf5ae3c9856ff" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-5">14300000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_3e5a07c4b3a14d7b9ab8402f62d73660" contextRef="c20190101to20191231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_5204b0988325433598101dbb0b17ef93" contextRef="c20180101to20181231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_56f6ac88ffc840c8a1f8245eb4bfc764" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_317617a8f4854d3bbb4d89a9955e2cb8" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_8382d5cebbca4d8cb972dc82d7424cf4" contextRef="c20190101to20191231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_d40030aa5a454fee8de00a64ee6298da" contextRef="c20180101to20181231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_79529fbb3fe141fc89103b823f4c1592" contextRef="c20190101to20191231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">1200000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_815e09ff5bea4f049a70e287a59abcd6" contextRef="c20180101to20181231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">2200000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_8b44b7f86dca4b7090163e349159dae7" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">1100000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_7e47e996683e480f8b4a88b253b0a3bc" contextRef="c20180101to20181231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_9cf1bab5d1994d2797798630f3209a58" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_ab36a81290ef4077a176e959b9047ce5" contextRef="c20190101to20191231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-5">2200000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2016, Biogen [Member]-Alpha-synuclein and TDP-43 PET tracer in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_71861e1bbfbf4f8fb2aa67076ec36830" contextRef="c20180101to20181231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-5">4000000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Alpha-synuclein and TDP-43 PET tracer in AD [Member]-Collaboration agreement of 2016, Biogen [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_7dc9e8d2e8154908b8ca91ac280c44b6" contextRef="c20200101to20201231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-6">0</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Collaboration agreement of 2016, Biogen [Member]-Alpha-synuclein and TDP-43 PET tracer in AD [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_10b82da823e74cb4bc8a72c69e7c9ab7" contextRef="c20190101to20191231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U002" decimals="-5">1100000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_031d24a037f4418e9ac3ea5fa8801c02" contextRef="c20190101to20191231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">600000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_063342396c124fe9a9e2808f3adca934" contextRef="c20200101to20201231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">1300000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Recognized revenues-Grants, Michael J. Fox Foundation [Member]-->
  <ifrs-full:RevenueFromContractsWithCustomers id="Fact_acca8ee32c3442d197dee1573ca80df4" contextRef="c20180101to20181231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">300000</ifrs-full:RevenueFromContractsWithCustomers>
  <!--Performance obligations satisfied in previous periods-->
  <ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods id="Fact_1fd0c3c5c6cd43d7a09e364aa10320cf" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2206000</ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods>
  <!--Performance obligations satisfied in previous periods-->
  <ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods id="Fact_390df2f8f284494a928022f78e13065a" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">10000000</ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods>
  <!--Performance obligations satisfied in previous periods-->
  <ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods id="Fact_82b663d88bee45a5a68b5e3029a54410" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods>
  <!--Amounts included in the contract liability at the beginning of the period-->
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod id="Fact_4760dbd233f145eaa64e4197c7eade1b" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">4477000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <!--Amounts included in the contract liability at the beginning of the period-->
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod id="Fact_bd0394f6ea5c44529a14bcd9aba0d891" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">1551000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <!--Amounts included in the contract liability at the beginning of the period-->
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod id="Fact_f7df1632617b4a9b878e02662af14084" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">351000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <!--Right-of-use assets-->
  <ifrs-full:RightofuseAssets id="Fact_9b7e359c4e0b4d8a9f3c35ca88532fb8" contextRef="c20201231" unitRef="U002" decimals="-3">2223000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-->
  <ifrs-full:RightofuseAssets id="Fact_bbb9bfcb6d754600a384628ae862fabe" contextRef="c20191231" unitRef="U002" decimals="-3">2255000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Office equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_02236d135dad4c1ab0ecc852f1955719" contextRef="c20191231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">81000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-->
  <ifrs-full:RightofuseAssets id="Fact_28877fdd06cb4a6d8810fc5048c9a59e" contextRef="c20181231" unitRef="U002" decimals="-3">2185000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Buildings [member]-->
  <ifrs-full:RightofuseAssets id="Fact_5b412219f901439195ff75ce2cf93571" contextRef="c20181231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">2106000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Office equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_5d395e2b64154b1399e06046df7cf922" contextRef="c20181231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">79000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Computer equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_b21d90999c9e4db1b55de87701674a95" contextRef="c20191231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">68000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Computer equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_ea8143f688ab45cd820c2e3b254b7926" contextRef="c20181231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Buildings [member]-->
  <ifrs-full:RightofuseAssets id="Fact_103f96e9d15c4996b4b3a95050f940d4" contextRef="c20191231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">2106000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Buildings [member]-->
  <ifrs-full:RightofuseAssets id="Fact_20723b67c6c44e538ecca9748f2cbe78" contextRef="c20201231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">2106000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Computer equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_4acde2c3f763420d8f3c2becef50d75d" contextRef="c20201231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">54000</ifrs-full:RightofuseAssets>
  <!--Right-of-use assets-Office equipment [member]-->
  <ifrs-full:RightofuseAssets id="Fact_c25b07075e734627808dc0e635a3dee0" contextRef="c20201231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">63000</ifrs-full:RightofuseAssets>
  <!--Selling, general and administrative expense-->
  <ifrs-full:SellingGeneralAndAdministrativeExpense id="Fact_36205f3ae53249be88284463c334238e" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">16058000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general and administrative expense-->
  <ifrs-full:SellingGeneralAndAdministrativeExpense id="Fact_b6c006c5bec6463582430c27df0bd8ba" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">18557000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general and administrative expense-->
  <ifrs-full:SellingGeneralAndAdministrativeExpense id="Fact_d6d261ee9f1f4e5c900bd4dffcc8d3d2" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">12467000</ifrs-full:SellingGeneralAndAdministrativeExpense>
  <!--Share issue related cost-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_0992249c2d6c45cc925b3da7d96588c1" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2015000</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Treasury shares [member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_4960d998e869465cb2c5a7d6772b8b77" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Issued capital [member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_7b7352b38930439c8e3e49b06704c25f" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Share Premium [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_acdd5ac3192f49a2bb986a2450f2b44e" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">2015000</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Retained earnings [member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_0d551ec06e9f4485a53d6aa7a91b6239" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Convertible Note Agreement [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_796107ba05c3400e92d29f112544a113" contextRef="c20190101to20191231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember" unitRef="U002" decimals="-5">500000</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-Follow-on Offerings [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_21d5179b533140bc8e10119b766cfa68" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember" unitRef="U002" decimals="-5">6800000</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-At the Market Equity Offering [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_9726dda950d742caa81066e346d8615d" contextRef="c20190101to20191231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember" unitRef="U002" decimals="-6">0</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-At the Market Equity Offering [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_b2dc05830d0c4777bd984c71aefc0909" contextRef="c20180101to20181231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember" unitRef="U002" decimals="-6">0</ifrs-full:ShareIssueRelatedCost>
  <!--Share issue related cost-At the Market Equity Offering [Member]-->
  <ifrs-full:ShareIssueRelatedCost id="Fact_f85203555b8a483a81dbe977bc665408" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember" unitRef="U002" decimals="-5">500000</ifrs-full:ShareIssueRelatedCost>
  <!--Share premium-->
  <ifrs-full:SharePremium id="Fact_9900e8c15f544927a7cd6c44b8c3d5e0" contextRef="c20191231" unitRef="U002" decimals="-3">346526000</ifrs-full:SharePremium>
  <!--Share premium-->
  <ifrs-full:SharePremium id="Fact_ea3c25dea5d944e888b4fc0580dfbc1e" contextRef="c20201231" unitRef="U002" decimals="-3">346890000</ifrs-full:SharePremium>
  <!--Short-term employee benefits accruals-->
  <ifrs-full:ShorttermEmployeeBenefitsAccruals id="Fact_5bee615fef83402fbb531f0fd7b14d03" contextRef="c20191231" unitRef="U002" decimals="-5">1800000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <!--Short-term employee benefits accruals-->
  <ifrs-full:ShorttermEmployeeBenefitsAccruals id="Fact_7056975973d641f193be700e8794ebeb" contextRef="c20201231" unitRef="U002" decimals="-5">2100000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <!--Surplus (deficit) in plan-Present value of defined benefit obligation [member]-->
  <ifrs-full:SurplusDeficitInPlan id="Fact_01747828503842d3982f02b0137316e8" contextRef="c20191231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-7485000</ifrs-full:SurplusDeficitInPlan>
  <!--Surplus (deficit) in plan-Present value of defined benefit obligation [member]-->
  <ifrs-full:SurplusDeficitInPlan id="Fact_4401bd45511e4242a83ead4567f91dc3" contextRef="c20181231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-5665000</ifrs-full:SurplusDeficitInPlan>
  <!--Surplus (deficit) in plan-Present value of defined benefit obligation [member]-->
  <ifrs-full:SurplusDeficitInPlan id="Fact_7191b51a825d48d09c7087699f1d0d2c" contextRef="c20201231_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">-7464000</ifrs-full:SurplusDeficitInPlan>
  <!--Tax effect of expense not deductible in determining taxable profit (tax loss)-->
  <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss id="Fact_2e4168e8602249c790c962c6f274dbad" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">334000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <!--Tax effect of expense not deductible in determining taxable profit (tax loss)-->
  <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss id="Fact_ffb6d44f15b94b48bcab67de427b373c" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">462000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
  <!--Tax effect of revenues exempt from taxation-->
  <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011 id="Fact_ff57cec99b544d669ecbc10c2c36815a" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">62000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
  <!--Tax effect of tax losses-->
  <ifrs-full:TaxEffectOfTaxLosses id="Fact_b9ffdc9b4a444754914831c395141365" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">7979000</ifrs-full:TaxEffectOfTaxLosses>
  <!--Tax effect of tax losses-->
  <ifrs-full:TaxEffectOfTaxLosses id="Fact_d7346787f79641089fcacae1afd00230" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">10173000</ifrs-full:TaxEffectOfTaxLosses>
  <!--Tax effect of tax losses-->
  <ifrs-full:TaxEffectOfTaxLosses id="Fact_116aa7be1aaa4759a1ea2d83161c376d" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-6132000</ifrs-full:TaxEffectOfTaxLosses>
  <!--Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)-->
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="Fact_a593660aea3b492e94f69679a6ab62fd" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-10507000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <!--Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)-->
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="Fact_c814ecae804c40c2ad420635385b0df0" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">6194000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <!--Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)-->
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate id="Fact_11be326364fd4b379356743c754bc09a" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-8441000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <!--Trade and other current payables-->
  <ifrs-full:TradeAndOtherCurrentPayables id="Fact_2a85be971b4a45d8835f5a025cd520cc" contextRef="c20201231" unitRef="U002" decimals="-3">2184000</ifrs-full:TradeAndOtherCurrentPayables>
  <!--Trade and other current payables-->
  <ifrs-full:TradeAndOtherCurrentPayables id="Fact_8ca5134665d041858915656846c1e5a8" contextRef="c20191231" unitRef="U002" decimals="-3">142000</ifrs-full:TradeAndOtherCurrentPayables>
  <!--Transaction price allocated to remaining performance obligations-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-Milestone payments, clinical and regulatory milestones [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_590a4c4733bb4a159e3fa5bbe06298d0" contextRef="c20201231_PerformanceObligationsAxis_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">880000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Right-of-use license [Member]-Collaboration Agreement with Lilly [Member]-Tau Morphomer Small Molecule [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_75f42b3a9b5f4243b9fff4156bafdb2d" contextRef="c20201231_PerformanceObligationsAxis_RightOfUseLicenseMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-5">73100000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Collaboration Agreement with Lilly [Member]-Milestone payments, commercial [Member]-Tau Morphomer Small Molecule [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_847455cfb70b45db837871a427f93027" contextRef="c20201231_PerformanceObligationsAxis_MilestonePaymentsCommercialMember_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">900000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-Bottom of range [member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_0b813c45d5894aeca130f060e065b536" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">275000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Anti-Abeta antibody in AD [Member]-Bottom of range [member]-Collaboration agreement of 2006, Genentech [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_2532e9011e894e6093d61972ac01d805" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-6">245000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Anti-tau antibody in AD [Member]-Bottom of range [member]-Collaboration agreement of 2012, Genentech [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_4dfd7bc8d98344e5832c3cf79fdfd87d" contextRef="c20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-5">368500000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Transaction price allocated to remaining performance obligations-Bottom of range [member]-Tau Vaccine in AD [Member]-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations id="Fact_1faff601df174ee0b79c5d5fbef21d77" contextRef="c20201231_ProductsAndServicesAxis_TauVaccineInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-6">458000000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <!--Treasury shares-->
  <ifrs-full:TreasuryShares id="Fact_7b564c2d0770499496abf4d297f31eb6" contextRef="c20201231" unitRef="U002" decimals="-3">100000</ifrs-full:TreasuryShares>
  <!--Treasury shares-->
  <ifrs-full:TreasuryShares id="Fact_b3744f718f3d4e66bbe8c60df109394d" contextRef="c20191231" unitRef="U002" decimals="-3">0</ifrs-full:TreasuryShares>
  <!--Unused tax losses for which no deferred tax asset recognised-Loss Expiry, December 31, 2020 [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_005d640b3484459889164a676a0ba70a" contextRef="c20201231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than six years and not later than seven years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_014164663f134ec3b054c02c5c1e440f" contextRef="c20181231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Not later than prior year end [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_1645c2cf60804d7cbe7a1c9216a2c914" contextRef="c20201231_MaturityAxis_NotLaterThanPriorYearEndMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than two years and not later than three years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_18e069c78cb648baba496813587bcea3" contextRef="c20181231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Not later than prior year end [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_19b80dcbb72d4883be13b92b49d343c2" contextRef="c20191231_MaturityAxis_NotLaterThanPriorYearEndMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later Than Six Years And Not Later Than Eight Years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_1cd9576f1de24cc9afe5909636e4567b" contextRef="c20191231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than five years and not later than six years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_1effd5a027d548818e6f221cfb526927" contextRef="c20201231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember" unitRef="U002" decimals="-3">48894000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_25f7ca70a7e541a094ca42a358872810" contextRef="c20181231" unitRef="U002" decimals="-3">109294000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than three years and not later than four years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_35bdea81dea64bf89245fbd2d907539d" contextRef="c20191231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_3ab4992d50e74aaeab772dc937d32923" contextRef="c20201231" unitRef="U002" decimals="-3">121948000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than four years and not later than five years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_45fcbe14a18843eea29bc26d00644c30" contextRef="c20181231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="U002" decimals="-3">25868000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than one year and not later than two years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_4ad07045983e48f9af79e2387fca151a" contextRef="c20201231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_52040921afb34e299548740651db3d52" contextRef="c20191231" unitRef="U002" decimals="-3">64125000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than four years and not later than five years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_8c076bab7aaf4af8b76dbdb99e99d084" contextRef="c20201231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="U002" decimals="-3">15231000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later Than Six Years And Not Later Than Eight Years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_93325afcec2e4da3943391aa23cc0bd2" contextRef="c20201231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember" unitRef="U002" decimals="-3">57824000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than one year and not later than two years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_a2cefddef73e469baa72c3e5cadcd40a" contextRef="c20181231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than one year and not later than two years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_a80b4f36fc5e4617a830a7ffc0e7b78b" contextRef="c20191231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than five years and not later than six years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_a9774064a8c3481bbc49724174ab6f26" contextRef="c20181231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember" unitRef="U002" decimals="-3">48894000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than two years and not later than three years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_b67decebdd324ffc8ab36b4d96ccd4f0" contextRef="c20191231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later Than Six Years And Not Later Than Eight Years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_be9cca675c824ceaa2d95828fad475a0" contextRef="c20181231_MaturityAxis_LaterThanSixYearsAndNotLaterThanEightYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than three years and not later than four years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_d9d8747575724305b30f2af5c6e0845a" contextRef="c20181231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="U002" decimals="-3">7628000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Not later than prior year end [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_dab1cd08df46469fba57ea6f6bbefe0b" contextRef="c20181231_MaturityAxis_NotLaterThanPriorYearEndMember" unitRef="U002" decimals="-3">16566000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than three years and not later than four years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_e19b92fb7cf74f9fb69479d790aa1e65" contextRef="c20201231_MaturityAxis_LaterThanThreeYearsAndNotLaterThanFourYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Loss Expiry, December 31, 2020 [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_e406e6fa0b624f4a9e9fff7d58874014" contextRef="c20181231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U002" decimals="-3">10338000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than two years and not later than three years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_e856319c23d840e19ee345d6155f8f81" contextRef="c20201231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than four years and not later than five years [member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_e9f7de10b42746d29728b8c2efdcc1a9" contextRef="c20191231_MaturityAxis_LaterThanFourYearsAndNotLaterThanFiveYearsMember" unitRef="U002" decimals="-3">15231000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than six years and not later than seven years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_edd14e2f72fc4c999f72cb46a907d79d" contextRef="c20191231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than five years and not later than six years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_ef5d98ea120843b5867a7f3ffa5ece10" contextRef="c20191231_MaturityAxis_LaterThanFiveYearsAndNotLaterThanSixYearsMember" unitRef="U002" decimals="-3">48894000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Later than six years and not later than seven years [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_f9701f7c5dca4002ba618bffbde814b6" contextRef="c20201231_MaturityAxis_LaterThanSixYearsAndNotLaterThanSevenYearsMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Unused tax losses for which no deferred tax asset recognised-Loss Expiry, December 31, 2020 [Member]-->
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised id="Fact_fc4d975206454659858cd1077ed23d5b" contextRef="c20191231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U002" decimals="-3">0</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <!--Useful life measured as period of time, property, plant and equipment-Leasehold improvements and fixtures and fittings [Member]-->
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="Fact_29d31480573e4a5fada8680e8c59954c" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_LeaseholdImprovementsAndFixturesAndFittingsMember">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <!--Useful life measured as period of time, property, plant and equipment-Computer equipment [member]-->
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="Fact_4332395768964a6492bab0023f582346" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <!--Useful life measured as period of time, property, plant and equipment-Laboratory equipment [Member]-->
  <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment id="Fact_a34c6b8ee86b48eb8a9ebd0c48ba335d" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_LaboratoryEquipmentMember">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
  <!--Weighted average duration period for defined benefit obligation-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 id="Fact_37b8953d1d9e49a78e135b121cd963c2" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">P19Y3M18D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
  <!--Weighted average duration period for defined benefit obligation-Defined benefit plans that share risks between entities under common control [member]-->
  <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 id="Fact_737ed652751b405189bff0fd4a00c396" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">P17Y7M6D</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
  <!--Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 id="Fact_4f62ee51893a4a8493db566e8d7decc3" contextRef="c20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.65</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 id="Fact_7368bcc7a754448ca218a934e781046e" contextRef="c20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.58</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 id="Fact_9e1668cd610549b391f1a16d4c7092c1" contextRef="c20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.47</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 id="Fact_31f157108aea436290a0fc46feafc747" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.60</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 id="Fact_465b3fed7aec4399a9a4f36cb09ff713" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.51</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 id="Fact_cd64f955cfa74540992809e9b14531a0" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.52</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments expired in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019 id="Fact_45317f5f6cda43bfb6e3c0cf40b223b4" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.52</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 id="Fact_60e6d9c0962046d4ab590aa9b00c584d" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="0">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 id="Fact_7e57cee7be324df781dda0a7fc8229fd" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.48</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 id="Fact_13f5c9b9727d46ff82f1ecce484144c0" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.47</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_0510fa8512a44b9db18cfd93a9f6cf57" contextRef="c20180101to20181231" unitRef="U003" decimals="2">9.43</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_3385999616584bbc9e9883e9a2121f36" contextRef="c20190101to20191231" unitRef="U003" decimals="0">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_46fec699054b4972ac07e273cd7e0316" contextRef="c20200101to20201231" unitRef="U003" decimals="0">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_0965b259e52c41ada4ed2a58e03ce517" contextRef="c20180101to20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.43</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_982644516b444ae789710f0e86f0735d" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="0">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments granted in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 id="Fact_d1636cdcc8244b938447e3b1fd4556e9" contextRef="c20190101to20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="0">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 id="Fact_2a31b8d51bd749d789f870e3f9b68b07" contextRef="c20191231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.52</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 id="Fact_faf503236be946119c157d2a8b23107d" contextRef="c20171231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.59</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 id="Fact_fbd63ebfd5f048788a4c068ad6941c12" contextRef="c20181231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.51</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 id="Fact_b6230e4862124726b6427d9012cbf49c" contextRef="c20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.51</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options exercisable in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 id="Fact_4c56f887c01b4f86abea9f56c9361e92" contextRef="c20191231" unitRef="U003" decimals="2">4.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options exercisable in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 id="Fact_62e2d522122b44fba346ba69e3a40c9d" contextRef="c20201231" unitRef="U003" decimals="2">5.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options exercisable in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 id="Fact_d77af25dcdd2479cb940c4efba1f339d" contextRef="c20181231" unitRef="U003" decimals="2">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
  <!--Exercised during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 id="Fact_37a8bff43a5943f5a8db5e3cdb5d01bf" contextRef="c20200101to20201231" unitRef="U003" decimals="2">2.00</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <!--Exercised during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 id="Fact_abb2978084ac4afab72d1d7933865b9e" contextRef="c20180101to20181231" unitRef="U003" decimals="2">0.15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <!--Exercised during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 id="Fact_f1c4d1f43ea24718b11e00eba2d6cd4d" contextRef="c20190101to20191231" unitRef="U003" decimals="2">0.15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
  <!--Expired during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 id="Fact_fc2c36fb75674cd1bd9e268cba7d7264" contextRef="c20200101to20201231" unitRef="U003" decimals="2">4.38</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
  <!--Forfeited during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 id="Fact_0c3ad033899f4bb69cb90c5c142d7eec" contextRef="c20180101to20181231" unitRef="U003" decimals="2">9.16</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
  <!--Forfeited during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 id="Fact_a460bddf2d5e47e0a55a55dc5afedfda" contextRef="c20200101to20201231" unitRef="U003" decimals="2">6.03</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
  <!--Forfeited during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 id="Fact_11551f699d3c4bc3a58e5a5aa93de565" contextRef="c20190101to20191231" unitRef="U003" decimals="2">6.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_032a1472ce9f4733ac061b9bb7e6ad80" contextRef="c20200101to20201231" unitRef="U003" decimals="2">6.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_694fd905a861499f9410ab6a034e8b36" contextRef="c20190101to20191231" unitRef="U003" decimals="2">5.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_8fe50c784cca4f7cbca03dcb750821a8" contextRef="c20180101to20181231" unitRef="U003" decimals="2">9.79</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-Bottom of range [member]-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_0806091b186b438b8a92789737b093a1" contextRef="c20180101to20181231_RangeAxis_BottomOfRangeMember" unitRef="U003" decimals="2">9.79</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-Bottom of range [member]-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_2d2d7dfb45f34da5b83683e6877312f5" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember" unitRef="U012" decimals="2">5.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_5fbda1b29d72425dade81b5299d4cbea" contextRef="c20180101to20181231" unitRef="U012" decimals="2">9.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_68a7888014c546ce8eddaa5509529fa4" contextRef="c20190101to20191231" unitRef="U012" decimals="2">5.41</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-Top of range [member]-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_b8ccdb4b95184c86b4ab3a2643230c20" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember" unitRef="U003" decimals="2">9.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-Bottom of range [member]-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_c537160286d34e5f9d7a14b7f689a019" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember" unitRef="U003" decimals="2">0.15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_cd244073154447dbb3cea1869c041a06" contextRef="c20200101to20201231" unitRef="U012" decimals="2">7.11</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Granted during the year (in CHF per share)-Top of range [member]-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 id="Fact_d02799d7a59649a6b63c0c42fddcdf28" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember" unitRef="U012" decimals="2">12.30</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
  <!--Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 id="Fact_02c36042cfd141deb68606717082d40b" contextRef="c20200101to20201231" unitRef="U003" decimals="2">6.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <!--Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 id="Fact_6b4a4a1cfa5f48e681cbc0fe0935bc10" contextRef="c20200101to20201231" unitRef="U012" decimals="2">6.86</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
  <!--Weighted average exercise price of share options outstanding in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="Fact_49a286e450884c66b102aee43a658468" contextRef="c20171231" unitRef="U003" decimals="2">2.09</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options outstanding in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="Fact_65bbc78f0f6e40459ff357e385b1c76d" contextRef="c20181231" unitRef="U003" decimals="2">4.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options outstanding in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="Fact_7399498d78bc4e108e325b5c64504a3c" contextRef="c20191231" unitRef="U003" decimals="2">5.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average exercise price of share options outstanding in share-based payment arrangement-->
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 id="Fact_afa209c09c334125857c64bf141f0f8d" contextRef="c20201231" unitRef="U003" decimals="2">5.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
  <!--Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16-Office equipment [member]-->
  <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 id="Fact_56e11ec6821746398b601f35cbd78fed" contextRef="c20201231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U008" decimals="INF">0.042</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
  <!--Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16-Buildings [member]-->
  <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 id="Fact_b4fedb14f76f422089ca04203b7fb2c6" contextRef="c20201231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U008" decimals="INF">0.025</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
  <!--Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16-Computer equipment [member]-->
  <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 id="Fact_c5a1fc18fc8547b4afcdd1de762beffd" contextRef="c20201231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U008" decimals="INF">0.026</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
  <!--Weighted average remaining contractual life of outstanding share options-->
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="Fact_09371c4a79fc4230a87c525dd8933049" contextRef="c20200101to20201231">P8Y2M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <!--Weighted average remaining contractual life of outstanding share options-->
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="Fact_3658915b621540ee9289236da6169e43" contextRef="c20170101to20171231">P5Y9M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <!--Weighted average remaining contractual life of outstanding share options-->
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="Fact_4c12d78c70434cdf847d0e1944c0b41d" contextRef="c20180101to20181231">P6Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <!--Weighted average remaining contractual life of outstanding share options-->
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 id="Fact_6a4f5f67e30f48e3b67c5c16a2831963" contextRef="c20190101to20191231">P8Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <!--Weighted average share price-->
  <ifrs-full:WeightedAverageSharePrice2019 id="Fact_59f5b42b92a24d2bab9a707eebc0e305" contextRef="c20190101to20191231" unitRef="U012" decimals="2">5.41</ifrs-full:WeightedAverageSharePrice2019>
  <!--Weighted average share price-->
  <ifrs-full:WeightedAverageSharePrice2019 id="Fact_5bdb0f6bd09f4dd488add76f8b7e6a75" contextRef="c20200101to20201231" unitRef="U012" decimals="2">7.11</ifrs-full:WeightedAverageSharePrice2019>
  <!--Weighted average share price-->
  <ifrs-full:WeightedAverageSharePrice2019 id="Fact_fdade5f55626443d8d88972da58a7642" contextRef="c20180101to20181231" unitRef="U012" decimals="2">9.87</ifrs-full:WeightedAverageSharePrice2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_3d4e5f6adf4b47219423597c3d604aeb" contextRef="c20200101to20201231" unitRef="U003" decimals="2">4.65</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_5af5835bf51d4ac0918deb1f94216553" contextRef="c20180101to20181231" unitRef="U012" decimals="2">6.66</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_6a14a9785ced4b668707adc97b159510" contextRef="c20190101to20191231" unitRef="U003" decimals="2">3.59</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_b41f5d6e2a3141738ed3a5b289ab731d" contextRef="c20200101to20201231" unitRef="U012" decimals="2">5.25</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_e23cdecf4b21469c8e0aec3155524e8e" contextRef="c20180101to20181231" unitRef="U003" decimals="2">6.54</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average share price, share options granted-->
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019 id="Fact_f0b557e3e1c142c7af0f84ff803eb22e" contextRef="c20190101to20191231" unitRef="U012" decimals="2">3.71</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
  <!--Weighted average number of ordinary shares outstanding-->
  <ifrs-full:WeightedAverageShares id="Fact_45bee4f600084b8689e56fc23c89f003" contextRef="c20180101to20181231" unitRef="U001" decimals="0">61838228</ifrs-full:WeightedAverageShares>
  <!--Weighted average number of ordinary shares outstanding-->
  <ifrs-full:WeightedAverageShares id="Fact_45c5476d3b83406ebe2c98057c73e067" contextRef="c20190101to20191231" unitRef="U001" decimals="0">70603611</ifrs-full:WeightedAverageShares>
  <!--Weighted average number of ordinary shares outstanding-->
  <ifrs-full:WeightedAverageShares id="Fact_7ea6244575254c5f81c4485f7cd76489" contextRef="c20200101to20201231" unitRef="U001" decimals="0">71900212</ifrs-full:WeightedAverageShares>
  <!--Amendment Flag-->
  <dei:AmendmentFlag id="Fact_6ac29e2c2fc340f9b345a281961cb387" contextRef="c20200101to20201231">false</dei:AmendmentFlag>
  <!--Entity Address, Country-->
  <dei:EntityAddressCountry id="Fact_7ff3935fbf27409e9738d28199a7196c" contextRef="c20200101to20201231">CH</dei:EntityAddressCountry>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate id="Fact_7087292761784d1ca150615b5a06cb52" contextRef="c20200101to20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate id="Fact_09e8de33b3f2445f89ea966ff7456c07" contextRef="c20200101to20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer id="Fact_c001eb7305dc4cef851bf641b147686e" contextRef="c20200101to20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers id="Fact_c02d51c4d08842fab22631df0252637a" contextRef="c20200101to20201231">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus id="Fact_0c44b98f58a840a4bdb5ff282ce49ebc" contextRef="c20200101to20201231">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory id="Fact_dff0775c2669440eb3411021adc6f256" contextRef="c20200101to20201231">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName id="Fact_afa3cb83805e4d2199878158f4ad6fe8" contextRef="c20200101to20201231">AC Immune SA</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey id="Fact_50a57b1d278f41bebdc068cd75aa5e71" contextRef="c20200101to20201231">0001651625</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding id="Fact_7d41c7dd733d417789a14fd8dfa661c5" contextRef="c20201231" unitRef="U001" decimals="INF">71936738</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus id="Fact_7695089714d8470dad8de9ac4feb3a52" contextRef="c20200101to20201231">2020</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus id="Fact_4f0dbc7cb43d4a669740b213175ff221" contextRef="c20200101to20201231">FY</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType id="Fact_6a89fdbec8ed43e9b022f9dd6fceec64" contextRef="c20200101to20201231">20-F</dei:DocumentType>
  <!--Document Annual Report-->
  <dei:DocumentAnnualReport id="Fact_7930d538aa71440aa05dcd2708f75bc4" contextRef="c20200101to20201231">true</dei:DocumentAnnualReport>
  <!--Document Transition Report-->
  <dei:DocumentTransitionReport id="Fact_e0a214c93fb04cb3ab8d74453c17d176" contextRef="c20200101to20201231">false</dei:DocumentTransitionReport>
  <!--Document Shell Company Report-->
  <dei:DocumentShellCompanyReport id="Fact_abce18210dfa40b4bac77d3d15e1b768" contextRef="c20200101to20201231">false</dei:DocumentShellCompanyReport>
  <!--Document Accounting Standard-->
  <dei:DocumentAccountingStandard id="Fact_13f9ab8db6cd4b8781726b9a0c659499" contextRef="c20200101to20201231">International Financial Reporting Standards</dei:DocumentAccountingStandard>
  <!--Entity Interactive Data Current-->
  <dei:EntityInteractiveDataCurrent id="Fact_0819f46c425047dea0471ae80190064d" contextRef="c20200101to20201231">Yes</dei:EntityInteractiveDataCurrent>
  <!--Entity Shell Company-->
  <dei:EntityShellCompany id="Fact_fc20d1c7b1ed49bc95dbc5105c1a4c93" contextRef="c20200101to20201231">false</dei:EntityShellCompany>
  <!--Entity Emerging Growth Company-->
  <dei:EntityEmergingGrowthCompany id="Fact_07257e26049d40ac9e48ccbd7f2ed2d6" contextRef="c20200101to20201231">true</dei:EntityEmergingGrowthCompany>
  <!--Entity Ex Transition Period-->
  <dei:EntityExTransitionPeriod id="Fact_80171dcb04b4415a9defe7b54fe97f53" contextRef="c20200101to20201231">false</dei:EntityExTransitionPeriod>
  <!--Current receivables classified as other and value added and withholding taxes-->
  <aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes id="Fact_5c2b8e3eaeab453b93bd555db93f77bc" contextRef="c20191231" unitRef="U002" decimals="-3">304000</aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes>
  <!--Current receivables classified as other and value added and withholding taxes-->
  <aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes id="Fact_d3af5a3e7c3442669ec22802bc25817a" contextRef="c20201231" unitRef="U002" decimals="-3">329000</aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes>
  <!--Gain (loss) arising from change in fair value of convertible instrument-->
  <aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument id="Fact_d76a5639a5d940289b4fdda7e8c75a63" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">4542000</aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument>
  <!--Gain (loss) arising from change in fair value of convertible instrument-->
  <aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument id="Fact_d9f871331d314ef191e18e977b171299" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument>
  <!--Gain (loss) arising from change in fair value of convertible instrument-->
  <aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument id="Fact_e30157d9fe104d089db45035f33884f4" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:GainLossArisingFromChangeInFairValueOfConvertibleInstrument>
  <!--Proceeds from issuing shares, net of underwriting fees-Retained earnings [member]-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_75de8f411df34059ae1f37a27c9a0db5" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-Issued capital [member]-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_bedfe029f48b47feb0f1b058a70c13b1" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">200000</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-Treasury shares [member]-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_bf518e8cc725449d874277e67a31383b" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-Share Premium [Member]-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_f400dbe0d0544f1ea2b99294a1f86809" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">111329000</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_f82005a2e8b345ceae634c6f5b2321a9" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">111529000</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_6c765e86462042d68001a36a0565c358" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Proceeds from issuing shares, net of underwriting fees-->
  <aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees id="Fact_78cb791c442a434c8c40eda1b63ca05d" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees>
  <!--Issue of Equity, Restricted Share Awards-Issued capital [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_34e57016cdd4412b830f14731f98ca72" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Retained earnings [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_3ae195cab323493f84b940af3a8cc86d" contextRef="c20180101to20181231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-535000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Treasury shares [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_409d2314eef045d0b18d57a2a9423a89" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_5620f44098f546b292ed12d0ff1c7bab" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">1000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Share Premium [Member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_664dfd9c6036468fb96301df44ba4936" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">616000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_7789ba51afbe4891a6befb9fea7fbc15" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Share Premium [Member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_8b938f93e88e4fd8b3b5cc1fe0a4eb0d" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">222000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Treasury shares [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_8cbf3f91bca44cd5898520f4517f2c3c" contextRef="c20180101to20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Retained earnings [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_8e80e450736543409810493c935d8d24" contextRef="c20190101to20191231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-616000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Share Premium [Member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_8ee7da7eebcd49f596954194d8f1dea5" contextRef="c20180101to20181231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">535000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Treasury shares [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_9056b3de121841058c9b5aa3c063b9ec" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_9abd6ab95be0499bafbd2e7c9c8063b7" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">1000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Issued capital [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_9bde09e3c1674117879e46d5401dca1c" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">0</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Issued capital [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_ab1d165060b042a78b594048db1aa035" contextRef="c20180101to20181231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Issue of Equity, Restricted Share Awards-Retained earnings [member]-->
  <aciu:IssueOfEquityRestrictedShareAwards id="Fact_e2dac6a111ec45ca9656cb465ae28d85" contextRef="c20200101to20201231_ComponentsOfEquityAxis_RetainedEarningsMember" unitRef="U002" decimals="-3">-222000</aciu:IssueOfEquityRestrictedShareAwards>
  <!--Cash Advances for Rent Deposit-->
  <aciu:CashAdvancesForRentDeposit id="Fact_2e7da1ba68ab47f2902052e1a69e8271" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">29000</aciu:CashAdvancesForRentDeposit>
  <!--Cash Advances for Rent Deposit-->
  <aciu:CashAdvancesForRentDeposit id="Fact_92d859d088ca449eac6af2fabccb0a55" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">178000</aciu:CashAdvancesForRentDeposit>
  <!--Cash Advances for Rent Deposit-->
  <aciu:CashAdvancesForRentDeposit id="Fact_ba8258579f84481e969a542de1183d2f" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</aciu:CashAdvancesForRentDeposit>
  <!--Payments for share issue costs on public offering-->
  <aciu:PaymentsForShareIssueCostsOnPublicOffering id="Fact_6bc868faafe84688a3a6c9b574091a05" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:PaymentsForShareIssueCostsOnPublicOffering>
  <!--Payments for share issue costs on public offering-->
  <aciu:PaymentsForShareIssueCostsOnPublicOffering id="Fact_c148444881424bbe937aff6b45640a4c" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">2015000</aciu:PaymentsForShareIssueCostsOnPublicOffering>
  <!--Payments for share issue costs on public offering-->
  <aciu:PaymentsForShareIssueCostsOnPublicOffering id="Fact_fff3416d635149c3bdec9689877234a2" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</aciu:PaymentsForShareIssueCostsOnPublicOffering>
  <!--Proceeds from issue of convertible debt-->
  <aciu:ProceedsFromIssueOfConvertibleDebt id="Fact_024fac4cff9f4743b2434de6223ef88c" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssueOfConvertibleDebt>
  <!--Proceeds from issue of convertible debt-->
  <aciu:ProceedsFromIssueOfConvertibleDebt id="Fact_525b966358504f8e98d13fcb33a1b228" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">50278000</aciu:ProceedsFromIssueOfConvertibleDebt>
  <!--Proceeds from issue of convertible debt-->
  <aciu:ProceedsFromIssueOfConvertibleDebt id="Fact_895ba4c293a742f881fcedd9ff834caa" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:ProceedsFromIssueOfConvertibleDebt>
  <!--Proceeds from issue of convertible debt-->
  <aciu:ProceedsFromIssueOfConvertibleDebt id="Fact_81f92bd2a1c541cbbb7d96f1493042c9" contextRef="c20190101to20191231" unitRef="U005" decimals="-6">50000000</aciu:ProceedsFromIssueOfConvertibleDebt>
  <!--Adjustments for Increase (Decrease) Long-term Financial Liabilities-->
  <aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities id="Fact_268ea1589d194fb9bf9f2751595435aa" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities>
  <!--Adjustments for Increase (Decrease) Long-term Financial Liabilities-->
  <aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities id="Fact_9fc8a5c624924e91b0300a4e6751605e" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">0</aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities>
  <!--Adjustments for Increase (Decrease) Long-term Financial Liabilities-->
  <aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities id="Fact_a2306753c7584814b731d06df01f67ad" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">53000</aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities>
  <!--Adjustments for decrease (increase) in accrued income-->
  <aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome id="Fact_3f1e22da6b51427b89a7c7ec38cf9969" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2572000</aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome>
  <!--Adjustments for decrease (increase) in accrued income-->
  <aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome id="Fact_62b7dc2598aa435e88366a3cd6236e93" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">-507000</aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome>
  <!--Adjustments for decrease (increase) in accrued income-->
  <aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome id="Fact_0ca7101782be4567b85b2355cc288a6e" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-868000</aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome>
  <!--Adjustments for increase (decrease) in accrued expenses-->
  <aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses id="Fact_031f10797efd44459c1f5e1577adc61c" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">-2113000</aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
  <!--Adjustments for increase (decrease) in accrued expenses-->
  <aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses id="Fact_c503bba57bd146209b25b28610be30eb" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">-1289000</aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
  <!--Adjustments for increase (decrease) in accrued expenses-->
  <aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses id="Fact_d03d0da6b511447e8ff63cd5ad3a1437" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">757000</aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses>
  <!--Adjustments for decrease (increase) in prepaid expense-->
  <aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense id="Fact_2282d03dd8c242fca119002ae30b9c28" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">924000</aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense>
  <!--Adjustments for decrease (increase) in prepaid expense-->
  <aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense id="Fact_a41c0d9f9cc3423d9c86aca95d11a01d" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">424000</aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense>
  <!--Adjustments for decrease (increase) in prepaid expense-->
  <aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense id="Fact_e0c158482e3844bb8a580de8ce1fd37d" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1304000</aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense>
  <!--Adjustments for depreciation expense, right-of-use assets-->
  <aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets id="Fact_3aaac2a17d6d463dbf36646163debeff" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">432000</aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets>
  <!--Adjustments for depreciation expense, right-of-use assets-->
  <aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets id="Fact_652378efdcbf489bbafbd30f30d26619" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">0</aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets>
  <!--Adjustments for depreciation expense, right-of-use assets-->
  <aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets id="Fact_beec2a06f84f4deb80b3bddc33beb789" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">420000</aciu:AdjustmentsForDepreciationExpenseRightOfUseAssets>
  <!--Disclosure of prepaid expenses and accrued income [Text Block]-->
  <aciu:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock id="Fact_8a6f3298f7664d1c948c103d31192626" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;7.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Prepaid expenses and accrued income&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;font style="font-weight: bold;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,954&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,788&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,591&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,545&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;3,883&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The prepaid expenses relate mainly to research contracts with down-payments at contract signature and the related activities will start or continue into 2021.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Accrued income consists of CHF 1.1 million as of December 31, 2020 associated with our Janssen collaboration (see &amp;#8220;Note 12. Contract revenues&amp;#8221;). This amount represents 68.1% of our total accrued income as of December 31, 2020.&lt;/div&gt;&lt;/div&gt;</aciu:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock>
  <!--Percentage of Accrued Income-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-->
  <aciu:PercentageOfAccruedIncome id="Fact_e60118b2ac8b434aa21bda332c5b5066" contextRef="c20201231_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U008" decimals="3">0.681</aciu:PercentageOfAccruedIncome>
  <!--Issued Actuarial Tables, Switzerland-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:IssuedActuarialTablesSwitzerland id="Fact_260eaed203f741bda2ce985250ab51d7" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">BVG 2015-CMI</aciu:IssuedActuarialTablesSwitzerland>
  <!--Issued Actuarial Tables, Switzerland-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:IssuedActuarialTablesSwitzerland id="Fact_b44f607141e642aebb0130408df063d5" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">BVG 2020-CMI</aciu:IssuedActuarialTablesSwitzerland>
  <!--Issued Actuarial Tables, Switzerland-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:IssuedActuarialTablesSwitzerland id="Fact_0db630afa46c477ea46e69f61e2b0d56" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">BVG 2015G</aciu:IssuedActuarialTablesSwitzerland>
  <!--Other comprehensive income (loss}, defined benefit plan, gain (loss)-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss id="Fact_3efdf401d2df44d18914da43aed86afe" contextRef="c20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">5587000</aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss>
  <!--Other comprehensive income (loss}, defined benefit plan, gain (loss)-Change in other comprehensive loss, defined benefit plan [Member]-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss id="Fact_3f1c1cc2fdd14cdfaedbfc2f8c902d3e" contextRef="c20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">4283000</aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss>
  <!--Other comprehensive income (loss}, defined benefit plan, gain (loss)-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss id="Fact_64110284515141c490eb29695290e750" contextRef="c20171231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">3981000</aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss>
  <!--Other comprehensive income (loss}, defined benefit plan, gain (loss)-Defined benefit plans that share risks between entities under common control [member]-Change in other comprehensive loss, defined benefit plan [Member]-->
  <aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss id="Fact_4ca0085f900149928395fe9431a8ac8d" contextRef="c20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" unitRef="U002" decimals="-3">4861000</aciu:OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss>
  <!--Number of Equity-based Instrument Plans-->
  <aciu:NumberOfEquityBasedInstrumentPlans id="Fact_65648052a9d24108ab887358a111a0e5" contextRef="c20200101to20201231" unitRef="U021" decimals="INF">4</aciu:NumberOfEquityBasedInstrumentPlans>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-2016 Share Option and Incentive Plan, Vesting Tranche Three [Member]-Executives and Directors [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_2cefed1a7a584f47a52cad6e1c25af4f" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember">P4Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Employees [Member]-2016 Share Option and Incentive Plan [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_436851996b9f40ffb764885fad541dfc" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_EmployeesMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember">P4Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Stock option plan C1 [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_678eebd8e65841ba8a7fc6d6aa1d94dd" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanC1Member">P4Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-2016 Share Option and Incentive Plan, Vesting Tranche One [Member]-Executives and Directors [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_cc2d8381e846437ea93665718f5cef68" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember">P1Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Executives and Directors [Member]-2016 Share Option and Incentive Plan, Vesting Tranche Two [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_d337a0288456438ea8e11e6f82420d9a" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember">P3Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Restricted Stock Units [Member]-Board of Directors [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_a7743a3a7234412694751b131658442c" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_BoardOfDirectorsMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">P1Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Restricted shares [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_b13e7571a8ec4dad9db3c22da1421d3e" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesMember">P2Y9M</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Vesting requirements for share-based payment arrangement, award vesting period-Executive Management [Member]-Restricted Stock Units [Member]-->
  <aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod id="Fact_e03a059c70624959b4e19d9d71e9017a" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_ExecutiveManagementMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">P4Y</aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod>
  <!--Maximum term of options granted for share-based payment arrangement-2016 Share Option and Incentive Plan [Member]-Executives and Directors [Member]-->
  <aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement id="Fact_9d61862161374266993d35efd7428841" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_KeyManagementPersonnelOfEntityOrParentMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember">P10Y</aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
  <!--Maximum term of options granted for share-based payment arrangement-Stock option plan B [Member]-->
  <aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement id="Fact_a4e2483a328f4806b8ad45b158c202a9" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanBMember">P10Y6M</aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
  <!--Maximum term of options granted for share-based payment arrangement-Employees [Member]-2016 Share Option and Incentive Plan [Member]-->
  <aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement id="Fact_c28eb197960949559e486eb8626a6c09" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_EmployeesMember_TypesOfSharebasedPaymentArrangementsAxis_Two016ShareOptionAndIncentivePlanMember">P10Y</aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
  <!--Maximum term of options granted for share-based payment arrangement-Stock option plan A [Member]-->
  <aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement id="Fact_cb3053e738c7487fbd4e10ce1568760a" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanAMember">P15Y6M</aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
  <!--Maximum term of options granted for share-based payment arrangement-Stock option plan C1 [Member]-->
  <aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement id="Fact_ee62ca89c9ca495c9ceeb2c3b715a210" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_StockOptionPlanC1Member">P10Y</aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
  <!--Disclosure of other current receivables [Text Block]-->
  <aciu:DisclosureOfOtherCurrentReceivablesTextBlock id="Fact_c73bf2bb0f1548cb81fa610a61b9f227" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;8.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;Other current receivables&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;font style="font-weight: bold;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Swiss VAT&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;309&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;234&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Withholding tax&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;329&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;304&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The maturity of these assets is less than 3 months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate their fair value.&lt;/div&gt;&lt;/div&gt;</aciu:DisclosureOfOtherCurrentReceivablesTextBlock>
  <!--Schedule of information about property, plant and equipment useful life [Table Text Block]-->
  <aciu:ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock id="Fact_0ac6c102b85848bea0c2bacc833b219d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div&gt;Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;3 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Leasehold improvements/furniture&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <!--Schedule of information about contract lease term by right-of-use asset categories [Table Text Block]-->
  <aciu:ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock id="Fact_bf43c24d2f2b4b558ba7fec42182b3d5" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The estimated lease term by right-of-use asset categories are as follows:&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top;"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;IT equipment&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;5 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock>
  <!--Undiscounted operating lease payments due-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_1545e9a6fdea4f0ab72e4144025d8465" contextRef="c20191231" unitRef="U005" decimals="-3">2403000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Later than one year and not later than two years [member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_1c0a74e9a8d24ffbacd236876a6df09e" contextRef="c20191231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="U005" decimals="-3">970000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Later than two years and not later than three years [member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_4761c0c0d5654432b52d16c7cab0907e" contextRef="c20201231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="U005" decimals="-3">912000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Later than one year and not later than two years [member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_538220a137544f0991ea9aef01d1a40d" contextRef="c20201231_MaturityAxis_LaterThanOneYearAndNotLaterThanTwoYearsMember" unitRef="U005" decimals="-3">970000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Later than two years and not later than three years [member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_76189de7a26644c99dfb15d5ec837140" contextRef="c20191231_MaturityAxis_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" unitRef="U005" decimals="-3">948000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_a8bfe21693ca492596623553b2b49866" contextRef="c20201231" unitRef="U005" decimals="-3">2367000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Loss Expiry, December 31, 2020 [Member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_cf33b8e36d2e4cf2a785698381676436" contextRef="c20191231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U005" decimals="-3">485000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Undiscounted operating lease payments due-Loss Expiry, December 31, 2020 [Member]-->
  <aciu:UndiscountedOperatingLeasePaymentsDue id="Fact_0fbfe146609a44a4b74155fc196b2fe3" contextRef="c20201231_MaturityAxis_NotLaterThanOneYearMember" unitRef="U005" decimals="-3">485000</aciu:UndiscountedOperatingLeasePaymentsDue>
  <!--Expense relating to leases-->
  <aciu:ExpenseRelatingToLeases id="Fact_7061cc05bd7b431ba95a33ac7786a6a8" contextRef="c20200101to20201231" unitRef="U005" decimals="-3">1088000</aciu:ExpenseRelatingToLeases>
  <!--Expense relating to leases-->
  <aciu:ExpenseRelatingToLeases id="Fact_c56d140fb97b48b1905926876684772e" contextRef="c20190101to20191231" unitRef="U005" decimals="-3">1037000</aciu:ExpenseRelatingToLeases>
  <!--Disposal of right-of-use assets-Buildings [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_1edc572776304aec97153442b97087a0" contextRef="c20200101to20201231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-Office equipment [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_4d0a0879928b4fa5adc2ff21c51f07a1" contextRef="c20190101to20191231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">10000</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-Computer equipment [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_84ae8d5982c145e89f317c4e93f9f2c3" contextRef="c20190101to20191231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-Office equipment [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_8ced14fbd3fc455189bd088546470867" contextRef="c20200101to20201231_ClassesOfAssetsAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_943d2a4e6bfe4eceb6ae91b505c33bac" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-Computer equipment [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_9941f76c0f094de48434a39118efe3c6" contextRef="c20200101to20201231_ClassesOfAssetsAxis_ComputerEquipmentMember" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_dc55d9bfb07b4b5aa878bb857871d67c" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">10000</aciu:DisposalOfRightOfUseAssets>
  <!--Disposal of right-of-use assets-Buildings [member]-->
  <aciu:DisposalOfRightOfUseAssets id="Fact_fe8ec4950d7f456cbc5c275f41f01de3" contextRef="c20190101to20191231_ClassesOfAssetsAxis_BuildingsMember" unitRef="U002" decimals="-3">0</aciu:DisposalOfRightOfUseAssets>
  <!--Number of other equity instruments exercised in share-based payment arrangement-Restricted Shares and Restricted Share Units [Member]-->
  <aciu:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement id="Fact_5e512ce901964417a84dd541ccc6f35a" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U001" decimals="INF">84638</aciu:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement>
  <!--Weighted average exercise price of other equity instruments exercised in sharebased payment arrangement2019-Restricted Shares and Restricted Share Units [Member]-->
  <aciu:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019 id="Fact_aa47752e73924c3ab4951a8c4fe83bd5" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesAndRestrictedShareUnitsMember" unitRef="U003" decimals="2">9.51</aciu:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019>
  <!--Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement-Restricted shares [Member]-->
  <aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement id="Fact_582c8150897e443bb7171ac941c5438b" contextRef="c20200101to20201231_TypesOfSharebasedPaymentArrangementsAxis_RestrictedSharesMember">P10Y</aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement>
  <!--Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement-Restricted Stock Units [Member]-Board of Directors [Member]-->
  <aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement id="Fact_ba4f1fb0f29e4be099b5ae1a049d6142" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_BoardOfDirectorsMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">P10Y</aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement>
  <!--Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement-Executive Management [Member]-Restricted Stock Units [Member]-->
  <aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement id="Fact_d4a6a0c2873645ceafad379f7fd3f462" contextRef="c20200101to20201231_CategoriesOfRelatedPartiesAxis_ExecutiveManagementMember_TypesOfSharebasedPaymentArrangementsAxis_RestrictedStockUnitsMember">P10Y</aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement>
  <!--Weighted average exercise price of non-vested other equity instruments granted in share-based payment arrangement-->
  <aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement id="Fact_4f65c132f6b74612896d12e820c75341" contextRef="c20190101to20191231" unitRef="U003" decimals="2">9.52</aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
  <!--Weighted average exercise price of non-vested other equity instruments granted in share-based payment arrangement-->
  <aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement id="Fact_8b23836d10c94c4c8b9c08a31e969538" contextRef="c20200101to20201231" unitRef="U003" decimals="2">9.51</aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
  <!--Weighted average exercise price of non-vested other equity instruments granted in share-based payment arrangement-->
  <aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement id="Fact_deb1e783ff3743cc901bda4e8afdcad3" contextRef="c20180101to20181231" unitRef="U003" decimals="2">9.51</aciu:WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
  <!--Estimated lease term-Buildings [member]-->
  <aciu:EstimatedLeaseTerm id="Fact_8ff5123d0bba4a879e12b296284b9905" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_BuildingsMember">P5Y</aciu:EstimatedLeaseTerm>
  <!--Estimated lease term-Computer equipment [member]-->
  <aciu:EstimatedLeaseTerm id="Fact_cc015d7b73ce4b7bb47b832a484944cc" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_ComputerEquipmentMember">P5Y</aciu:EstimatedLeaseTerm>
  <!--Estimated lease term-Office equipment [member]-->
  <aciu:EstimatedLeaseTerm id="Fact_10907d31355849d4a3c685c93c646357" contextRef="c20200101to20201231_ClassesOfPropertyPlantAndEquipmentAxis_OfficeEquipmentMember">P5Y</aciu:EstimatedLeaseTerm>
  <!--Disclosure of detailed information about other current receivables [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock id="Fact_2a2440a3bc034824854fd6961c30d5e4" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Swiss VAT&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;309&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;234&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Withholding tax&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;329&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;304&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock>
  <!--Share Options Date of Expiry-Range Of Exercise Prices Three [Member]-Bottom of range [member]-->
  <aciu:ShareOptionsDateOfExpiry id="Fact_59da51570e8349bd9d0a49bb89bfe837" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember">2028</aciu:ShareOptionsDateOfExpiry>
  <!--Share Options Date of Expiry-Range Of Exercise Prices Three [Member]-Top of range [member]-->
  <aciu:ShareOptionsDateOfExpiry id="Fact_8bb933ed0545419fb3fc6676aaa787d6" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesThreeMember">2030</aciu:ShareOptionsDateOfExpiry>
  <!--Share Options Date of Expiry-Range of Exercise Prices one [Member]-Bottom of range [member]-->
  <aciu:ShareOptionsDateOfExpiry id="Fact_b27d7d9cd8774d5db109852c811877c3" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember">2020</aciu:ShareOptionsDateOfExpiry>
  <!--Share Options Date of Expiry-Top of range [member]-Range of Exercise Prices one [Member]-->
  <aciu:ShareOptionsDateOfExpiry id="Fact_f134e52e8eac4ed588268944c666fa8f" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesOneMember">2026</aciu:ShareOptionsDateOfExpiry>
  <!--Share Options Date of Expiry-Range Of Exercise Prices Two [Member]-->
  <aciu:ShareOptionsDateOfExpiry id="Fact_fbffc9856b894ab1adb46ffcae2bd204" contextRef="c20200101to20201231_RangesOfExercisePricesForOutstandingShareOptionsAxis_RangeOfExercisePricesTwoMember">2027</aciu:ShareOptionsDateOfExpiry>
  <!--Current accrued research and development costs-->
  <aciu:CurrentAccruedResearchAndDevelopmentCosts id="Fact_77b853a2c0b943c49f05c93100d2a77f" contextRef="c20201231" unitRef="U002" decimals="-3">5298000</aciu:CurrentAccruedResearchAndDevelopmentCosts>
  <!--Current accrued research and development costs-->
  <aciu:CurrentAccruedResearchAndDevelopmentCosts id="Fact_f2df7bafcb204d18b2f395714b9ff557" contextRef="c20191231" unitRef="U002" decimals="-3">7228000</aciu:CurrentAccruedResearchAndDevelopmentCosts>
  <!--Period of maturity, receivables fair value carrying amount-Top of range [member]-->
  <aciu:PeriodOfMaturityReceivablesFairValueCarryingAmount id="Fact_91da15bfbfb746bf9abb5aec894738c7" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember">P3M</aciu:PeriodOfMaturityReceivablesFairValueCarryingAmount>
  <!--Number of escrow deposit accounts-->
  <aciu:NumberOfEscrowDepositAccounts id="Fact_d7f2c01380254ed5bc8d9e06de42f301" contextRef="c20200101to20201231" unitRef="U011" decimals="INF">2</aciu:NumberOfEscrowDepositAccounts>
  <!--Disclosure of detailed information about prepaid expenses and accrued income [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock id="Fact_dd0cfea5b571499b9f6139e915c056cc" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,954&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,788&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued income&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,591&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;5,545&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;3,883&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock>
  <!--Collaborative agreement, Milestone payment received-Collaboration Agreement with Lilly [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_44280edf816c4e83bcf0221a8bb28c9e" contextRef="c20190101to20191231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">30000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration Agreement with Lilly [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_b4580572f0b0400c8f4883eb33bff996" contextRef="c20200101to20201231_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">10000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_7d183a0b0c80471dadd91c2f43688d17" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U002" decimals="-6">40000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_2ce0413c11e54010ae1326699b7d9241" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">40000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_88abe8d1efcd4ff0927ca80fe6912dcd" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-5">38200000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Anti-tau antibody in AD [Member]-Collaboration agreement of 2012, Genentech [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_575eacc49c0148f9b0d245a3c60632ed" contextRef="c20160701to20160731_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">14000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_62db78dfb4824b8199e471a42a0faa89" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">42000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_6308dd06609045fa858da68606e53fda" contextRef="c20150101to20151231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">14000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Anti-tau antibody in AD [Member]-Collaboration agreement of 2012, Genentech [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_e0dc7636b50a4574931b147fa4d684ca" contextRef="c20171001to20171231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">14000000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Collaborative agreement, Milestone payment received-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentReceived id="Fact_1dd99439f4344d628e101f565b39a519" contextRef="c20160501to20160531_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">4900000</aciu:CollaborativeAgreementMilestonePaymentReceived>
  <!--Number of Public Offerings-->
  <aciu:NumberOfPublicOfferings id="Fact_e38bbd12dd594b7ea82d674e9b5d4805" contextRef="c20180101to20181231" unitRef="U006" decimals="INF">3</aciu:NumberOfPublicOfferings>
  <!--Grant income [Policy Text Block]-->
  <aciu:GrantIncomePolicyTextBlock id="Fact_d343454af1bf4e4bacce9cab25c6fe2b" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Grant income&lt;/div&gt;&lt;div&gt;&lt;font style="font-weight: bold;"&gt;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="color: #000000;"&gt;The Company has received grants, from time to time, from the Michael J. Fox Foundation (MJFF) and other institutions to support certain research projects.&lt;/font&gt; Grants are recorded at their fair value in the statements of income/(loss) within other operating income/(expenses) when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.&lt;/div&gt;&lt;/div&gt;</aciu:GrantIncomePolicyTextBlock>
  <!--Description of accounting policy for classification of assets and liabilities [Policy Text Block]-->
  <aciu:DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock id="Fact_4d31d07085944913bf0f9086d112801d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Current vs. non-current classification&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be non-current.&lt;/div&gt;&lt;/div&gt;</aciu:DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock>
  <!--Description of accounting policy for accounting judgments and estimates [Policy Text Block]-->
  <aciu:DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock id="Fact_56800fef2fe54cdb9ab6b72c7a4ce61d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Critical judgments and accounting estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on LCAs, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation and (vi) right-of-use assets and lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/div&gt;&lt;/div&gt;</aciu:DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock>
  <!--Fair value of financial assets and liabilities [Policy Text Block]-->
  <aciu:FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock id="Fact_1a2a12dbc490410093d6b79a76e8d8c0" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Fair value of financial assets and liabilities&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company&amp;#8217;s financial assets and liabilities are comprised of receivables, short-term financial assets, cash and cash equivalents, trade payables and financing obligations. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments and&lt;font style="color: #000000;"&gt; are held at their amortized cost in accordance with IFRS 9 (&lt;/font&gt;&lt;font style="font-style: italic; color: #000000;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="color: #000000;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Receivables&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor&amp;#8217;s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Short-term financial assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company assesses at each period whether there is objective evidence that financial assets are impaired.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Trade payables&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;Trade payables are amounts &lt;font style="color: #000000;"&gt;due to third parties in the ordinary course of business.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;"&gt;Financing obligation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 17.85pt;"&gt;The Company&amp;#8217;s financing obligation related to its agreement with a third party. This financing obligation has been fully repaid as of December 31, 2020.&lt;/div&gt;&lt;/div&gt;</aciu:FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock>
  <!--Disclosure Of Accounting Policy For Changes In Accounting Policies Recently Adopted [Text Block]-->
  <aciu:DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock id="Fact_35fd635a78244194b159a1610a3305ee" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-weight: bold;"&gt;Accounting policies, new standards, interpretations and amendments adopted by the Company&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/div&gt;&lt;/div&gt;</aciu:DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_395242df45e54748a2761ef84b9d33b0" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">100000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_8b5a3c2c31224f6b94a1a60fd069627b" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">195000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_b7d16722d0db49b483e93f34d440d774" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">71000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_3a22dbc138014d7e839455b3088b5234" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">71000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_58c8320edc604597ad27021b86db1037" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">195000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Interest cost, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-Present value of defined benefit obligation [member]-->
  <aciu:InterestCostNetDefinedBenefitLiabilityAsset id="Fact_9df9b85d23c0418098809b8c413ab646" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PresentValueOfDefinedBenefitObligationMember" unitRef="U002" decimals="-3">100000</aciu:InterestCostNetDefinedBenefitLiabilityAsset>
  <!--Disclosure of general information about the entity explanatory [Text Block]-->
  <aciu:DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock id="Fact_f2017d3e83f74ee8a8f53bb9ddd8103a" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;&lt;tr&gt;&lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;1.&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="font-weight: bold;"&gt;General information&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;AC Immune SA (the &amp;#8220;Company,&amp;#8221; &amp;#8220;AC Immune,&amp;#8221; &amp;#8220;ACIU,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;ours,&amp;#8221; or &amp;#8220;us&amp;#8221;) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&amp;#8217;s disease, or AD, and Parkinson&amp;#8217;s disease, or PD, with common mechanisms and drug targets, such as Abeta, Tau, alpha-synuclein and TDP-43. Our corporate strategy is founded upon a three-pillar approach that targets (i) AD, (ii) focused non-Alzheimer&amp;#8217;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop novel medicines and diagnostics to target misfolded proteins.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;The Company was initially incorporated as a limited liability company on February 13, 2003 in Basel, and effective August 25, 2003 was transitioned into a stock company. The Company&amp;#8217;s corporate headquarters are located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.&lt;/div&gt;&lt;/div&gt;</aciu:DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock>
  <!--Number of technology platforms-->
  <aciu:NumberOfTechnologyPlatforms id="Fact_72d5a761daa24de1be89b5d1d2a7e60b" contextRef="c20201231" unitRef="U004" decimals="INF">2</aciu:NumberOfTechnologyPlatforms>
  <!--Share issued price per share-First Subscription Rights [Member]-->
  <aciu:ShareIssuedPricePerShare id="Fact_763dcac40b3f48b198a3f9b9a9bd6a89" contextRef="c20180724_ClassesOfShareCapitalAxis_FirstSubscriptionRightsMember" unitRef="U012" decimals="INF">11.75</aciu:ShareIssuedPricePerShare>
  <!--Number of offerings-Follow-on Offerings [Member]-->
  <aciu:NumberOfOfferings id="Fact_de8ff219964b466db88d0c4cac7c45a1" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember" unitRef="U006" decimals="INF">3</aciu:NumberOfOfferings>
  <!--Common shares authorized for issuance sales in in open market-Top of range [member]-At the Market Equity Offering [Member]-->
  <aciu:CommonSharesAuthorizedForIssuanceSalesInInOpenMarket id="Fact_265e62280aee41f1a4d747390d7b4527" contextRef="c20200901to20200930_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_RangeAxis_TopOfRangeMember" unitRef="U002" decimals="-2">71300</aciu:CommonSharesAuthorizedForIssuanceSalesInInOpenMarket>
  <!--Common shares authorized for issuance sales in in open market-Top of range [member]-At the Market Equity Offering [Member]-->
  <aciu:CommonSharesAuthorizedForIssuanceSalesInInOpenMarket id="Fact_1012979e2e224372bbd5c98356773849" contextRef="c20200901to20200930_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_RangeAxis_TopOfRangeMember" unitRef="U005" decimals="-3">80000</aciu:CommonSharesAuthorizedForIssuanceSalesInInOpenMarket>
  <!--Convertible borrowings-->
  <aciu:ConvertibleBorrowings id="Fact_2d85ede779eb4ff4a828395bbb1dee5a" contextRef="c20190123" unitRef="U005" decimals="-5">50000000</aciu:ConvertibleBorrowings>
  <!--Convertible borrowings-->
  <aciu:ConvertibleBorrowings id="Fact_ca66dd94273a444dbd9ffc551aa45410" contextRef="c20190123" unitRef="U002" decimals="-5">50300000</aciu:ConvertibleBorrowings>
  <!--Increase in number of ordinary shares issued under conversion of convertible debt-Treasury shares [member]-->
  <aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt id="Fact_6d046a1aac1f4afa8e3fa589c89fd8fa" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">0</aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt>
  <!--Increase in number of ordinary shares issued under conversion of convertible debt-Ordinary shares [member]-->
  <aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt id="Fact_9c5ab70316794c4eba948bfd48d7b6d7" contextRef="c20190101to20191231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">3615328</aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt>
  <!--Increase in number of ordinary shares issued under conversion of convertible debt-->
  <aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt id="Fact_c46ff8cf73194575b1ac6d2a9ea58fe0" contextRef="c20190425to20190425" unitRef="U001" decimals="INF">3615328</aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt>
  <!--Proceeds from issue of ordinary shares, net issuance costs-Follow-on Offerings [Member]-->
  <aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts id="Fact_a900b5a891034d42aaa47082e5a577c7" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_FollowOnOfferingsMember" unitRef="U002" decimals="-5">109500000</aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts>
  <!--Proceeds from issue of ordinary shares, net issuance costs-Subsequent events [Member]-At the Market Equity Offering [Member]-->
  <aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts id="Fact_750750fd35d648b59d02ab16e5655c8d" contextRef="c20210201to20210228_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_NonadjustingEventsAfterReportingPeriodAxis_SubsequentEventsMember" unitRef="U002" decimals="-5">8000000</aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts>
  <!--Proceeds from issue of ordinary shares, net issuance costs-Subsequent events [Member]-At the Market Equity Offering [Member]-->
  <aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts id="Fact_116847bf95f148378100c8e2216c00fd" contextRef="c20210201to20210228_ClassesOfShareCapitalAxis_AtTheMarketEquityOfferingMember_NonadjustingEventsAfterReportingPeriodAxis_SubsequentEventsMember" unitRef="U005" decimals="-5">8800000</aciu:ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts>
  <!--Repayment of convertible debt, Equity Settlement, Amount-Convertible Note Agreement [Member]-->
  <aciu:RepaymentOfConvertibleDebtEquitySettlementAmount id="Fact_1a244d7f8bb34e88a005670e52b6dea7" contextRef="c20190101to20191231_BorrowingsByNameAxis_ConvertibleNoteAgreementMember" unitRef="U002" decimals="-5">48300000</aciu:RepaymentOfConvertibleDebtEquitySettlementAmount>
  <!--Purchase of property, plant and equipment, classified as noncash investing activities-->
  <aciu:PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities id="Fact_a958c88e39c24fa1a94414e1dc4b6f58" contextRef="c20200101to20201231" unitRef="U002" decimals="-5">300000</aciu:PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities>
  <!--Increase (decrease) in plan assets of defined benefit plan, percentage-Defined benefits plan, Employer [Member]-->
  <aciu:IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage id="Fact_1411f9870a1c4f818c6f7f431da2987f" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployerMember" unitRef="U008" decimals="1">0.1</aciu:IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage>
  <!--Defined benefit plan, percentage of contribution-Defined benefits plan, Employer [Member]-->
  <aciu:DefinedBenefitPlanPercentageOfContribution id="Fact_2cc2f81e5b274b56b849ae1c1aef4f34" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployerMember" unitRef="U008" decimals="INF">0.53</aciu:DefinedBenefitPlanPercentageOfContribution>
  <!--Defined benefit plan, percentage of contribution-Defined benefits plan, Employee [Member]-->
  <aciu:DefinedBenefitPlanPercentageOfContribution id="Fact_89f363dd0c0b4eb7a10ec04c476e3011" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployeeMember" unitRef="U008" decimals="INF">0.47</aciu:DefinedBenefitPlanPercentageOfContribution>
  <!--Increase (decrease) in plan assets of defined benefit plan, amount-Defined benefits plan, Employer [Member]-->
  <aciu:IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount id="Fact_bc306ac6b1884571b82ac9f2415834b9" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitsPlanEmployerMember" unitRef="U002" decimals="-5">1200000</aciu:IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount>
  <!--Interest income, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_2df7065422414853b2b7b9b0c7bbe582" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">133000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Interest income, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_8c3bfd401fa54513bd1df995459fa7f5" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">42000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Interest income, net defined benefit liability (asset)-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_0da39df23efa4cd58e826438e82a4aaa" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" unitRef="U002" decimals="-3">65000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Interest income, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_56a01a44978845b187ba7236566e7a65" contextRef="c20200101to20201231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">42000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Interest income, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_b30d2e9dea014092b1bd381c3a122bce" contextRef="c20190101to20191231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">133000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Interest income, net defined benefit liability (asset)-Plan assets [member]-Defined benefit plans that share risks between entities under common control [member]-->
  <aciu:InterestIncomeNetDefinedBenefitLiabilityAsset id="Fact_cb1b68e01930435bafee171bc7233bf8" contextRef="c20180101to20181231_DefinedBenefitPlansAxis_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_NetDefinedBenefitLiabilityAssetAxis_PlanAssetsMember" unitRef="U002" decimals="-3">65000</aciu:InterestIncomeNetDefinedBenefitLiabilityAsset>
  <!--Weighted average remaining contractual life of exercisable share options-->
  <aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions id="Fact_2ea7dfdb77e24a17955667b1707d3095" contextRef="c20191231" unitRef="U022" decimals="1">6.5</aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions>
  <!--Weighted average remaining contractual life of exercisable share options-->
  <aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions id="Fact_a193a7f4cd274f4896db1fa9bf8ad081" contextRef="c20201231" unitRef="U022" decimals="1">7.0</aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions>
  <!--Weighted average remaining contractual life of exercisable share options-->
  <aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions id="Fact_e8868c2abfcf4461a2fb621eab52a5a4" contextRef="c20181231" unitRef="U022" decimals="1">4.4</aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions>
  <!--Research and development expense allocation, operating expense-->
  <aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense id="Fact_15948e5526ba4cefb03dbd47c558614a" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">37465000</aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense>
  <!--Research and development expense allocation, operating expense-->
  <aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense id="Fact_936ec196e7704d1288eb41b4673779b3" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">43787000</aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense>
  <!--Research and development expense allocation, operating expense-->
  <aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense id="Fact_a77252ef28544197b1f1353118b01f1d" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">32921000</aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense>
  <!--Research and development expense allocation, wages and salaries-->
  <aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries id="Fact_517b307bdc544357ad321d80b54f7dbc" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">12382000</aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries>
  <!--Research and development expense allocation, wages and salaries-->
  <aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries id="Fact_55fcc79647354891a419c9efe74fe57c" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">10662000</aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries>
  <!--Research and development expense allocation, wages and salaries-->
  <aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries id="Fact_7d9fd7b495994da39137743bbdb12823" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">14424000</aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries>
  <!--Employee, full-time equivalents in research and development-->
  <aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment id="Fact_2701cd7cb4d64489ab07d46974a0dda4" contextRef="c20180101to20181231" unitRef="U019" decimals="0">87</aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment>
  <!--Employee, full-time equivalents in research and development-->
  <aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment id="Fact_bde290ef3e65499e9340b65965d22a46" contextRef="c20190101to20191231" unitRef="U019" decimals="1">102.7</aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment>
  <!--Employee, full-time equivalents in research and development-->
  <aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment id="Fact_d3a434d227b44686b424326bf2e86891" contextRef="c20200101to20201231" unitRef="U019" decimals="1">115.3</aciu:EmployeeFullTimeEquivalentsInResearchAndDevelopment>
  <!--General and administrative expense allocation, wages and salaries-->
  <aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries id="Fact_0869688cfde94faa9f68ed9fd2e5932f" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">8274000</aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries>
  <!--General and administrative expense allocation, wages and salaries-->
  <aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries id="Fact_08ace87c0ad74e789bf1b0c60052a202" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">5740000</aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries>
  <!--General and administrative expense allocation, wages and salaries-->
  <aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries id="Fact_3a2425cce9314c8fb03a5a9931271d77" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">7172000</aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries>
  <!--General and administrative expense allocation, operating expense-->
  <aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense id="Fact_58bf9e14573f494b9dd758771a4f3cca" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">4903000</aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense>
  <!--General and administrative expense allocation, operating expense-->
  <aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense id="Fact_61aa8aba267a4ac1818e01f4c772c0bd" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">6637000</aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense>
  <!--General and administrative expense allocation, operating expense-->
  <aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense id="Fact_ed63cb089e32462597fde480bce7a995" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">7471000</aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense>
  <!--General and administrative expense allocation, expense from share-based payment transactions with employees-->
  <aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_3a1c69e711a845ec90ee6486c4bcfdc8" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2249000</aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--General and administrative expense allocation, expense from share-based payment transactions with employees-->
  <aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_76949e6d13c74603b0b3faf730dfbc29" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">2812000</aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--General and administrative expense allocation, expense from share-based payment transactions with employees-->
  <aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_c2a7d4087336470289a6099bc0095ecb" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">1824000</aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--Employee, full-time equivalents in general and administrative expenses-->
  <aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses id="Fact_4659aeb0728e4a68ba16715bb3f9596f" contextRef="c20180101to20181231" unitRef="U019" decimals="0">17</aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses>
  <!--Employee, full-time equivalents in general and administrative expenses-->
  <aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses id="Fact_61d12022a4f0484bb2dd11468b1b530c" contextRef="c20200101to20201231" unitRef="U019" decimals="1">26.7</aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses>
  <!--Employee, full-time equivalents in general and administrative expenses-->
  <aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses id="Fact_87aee9ba57294c2881de102b168ed9d2" contextRef="c20190101to20191231" unitRef="U019" decimals="1">24.1</aciu:EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses>
  <!--Research and development expense allocation, expense from share-based payment transactions with employees-->
  <aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_9eb52a708dca43fda8ce0b49168c4cb0" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1276000</aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--Research and development expense allocation, expense from share-based payment transactions with employees-->
  <aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_f37b05b58aa14da4bb8e31ba869e3ae1" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">585000</aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--Research and development expense allocation, expense from share-based payment transactions with employees-->
  <aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees id="Fact_fe207d9805fc46cfabf62d1e796f8155" contextRef="c20180101to20181231" unitRef="U002" decimals="-3">694000</aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees>
  <!--Rental contract, period for notice of cancellation-->
  <aciu:RentalContractPeriodForNoticeOfCancellation id="Fact_ef4d19660f474a7cb13493dafd7006ac" contextRef="c20200101to20201231">P12M</aciu:RentalContractPeriodForNoticeOfCancellation>
  <!--Provisions, research contracts-->
  <aciu:ProvisionsResearchContracts id="Fact_fb41b32b9547450393d069e667cc593c" contextRef="c20201231" unitRef="U002" decimals="-5">24700000</aciu:ProvisionsResearchContracts>
  <!--Number of future offerings of securities authorized under Shelf Registration Statement-Bottom of range [member]-->
  <aciu:NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement id="Fact_8c14d13046204a6f87894432632a1f8c" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember" unitRef="U006" decimals="INF">1</aciu:NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement>
  <!--Potential additional proceeds, sale of equity instruments, Shelf Registration Statement-Top of range [member]-->
  <aciu:PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement id="Fact_481fc775e66e412f983f23179f7cf397" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember" unitRef="U005" decimals="-5">232500000</aciu:PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement>
  <!--Shelf Registration Statement, shares authorized-->
  <aciu:ShelfRegistrationStatementSharesAuthorized id="Fact_8cd08aa28a664ddc886de1f8294b56d3" contextRef="c20180504" unitRef="U001" decimals="INF">350000000</aciu:ShelfRegistrationStatementSharesAuthorized>
  <!--Increase through shares issued under incentive plans-Treasury shares [member]-->
  <aciu:IncreaseThroughSharesIssuedUnderIncentivePlans id="Fact_301045f3443f48879520dbed9d155a71" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:IncreaseThroughSharesIssuedUnderIncentivePlans>
  <!--Increase through shares issued under incentive plans-Issued capital [member]-->
  <aciu:IncreaseThroughSharesIssuedUnderIncentivePlans id="Fact_b8c78c397aa64bc79868466007982f67" contextRef="c20190101to20191231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">13000</aciu:IncreaseThroughSharesIssuedUnderIncentivePlans>
  <!--Increase through shares issued under incentive plans-Share Premium [Member]-->
  <aciu:IncreaseThroughSharesIssuedUnderIncentivePlans id="Fact_e6514bde31544cea962a3daf01baaf66" contextRef="c20190101to20191231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">672000</aciu:IncreaseThroughSharesIssuedUnderIncentivePlans>
  <!--Increase (decrease) through treasury share transactions, equity, shares-Ordinary shares [member]-->
  <aciu:IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares id="Fact_476c1c4a62264e64a71f6be330278443" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">5000000</aciu:IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares>
  <!--Increase (decrease) through treasury share transactions, equity, shares-Treasury shares [member]-->
  <aciu:IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares id="Fact_dff323dba6304441996b86c16cd8c15e" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">-5000000</aciu:IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares>
  <!--Increase in number of ordinary shares issued under incentive plans-Ordinary shares [member]-->
  <aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans id="Fact_20b0fa1cf10e4a3a8b40133017df3e8b" contextRef="c20190101to20191231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">681770</aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans>
  <!--Increase in number of ordinary shares issued under incentive plans-Treasury shares [member]-->
  <aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans id="Fact_ded739fb40954065ab1e81a7147d8ad9" contextRef="c20190101to20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">0</aciu:IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans>
  <!--Increase through shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture-Treasury shares [member]-->
  <aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture id="Fact_746d07f5a2a7415c85d968605c7ada49" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U002" decimals="-3">0</aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture>
  <!--Increase through shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture-Share Premium [Member]-->
  <aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture id="Fact_8c78c0e800af4016bd1d1ca87f6247a9" contextRef="c20200101to20201231_ComponentsOfEquityAxis_SharePremiumMember" unitRef="U002" decimals="-3">364000</aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture>
  <!--Increase through shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture-Issued capital [member]-->
  <aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture id="Fact_bfed8b9482484d0f862372133834192e" contextRef="c20200101to20201231_ComponentsOfEquityAxis_IssuedCapitalMember" unitRef="U002" decimals="-3">1000</aciu:IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture>
  <!--Number of shares outstanding including treasury shares-Treasury shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_6043ca60734f48f8bc2b09a79967be40" contextRef="c20181231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">0</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of shares outstanding including treasury shares-Ordinary shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_d860a39eadf74eaa92794c63c1a0ebec" contextRef="c20181231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">67562333</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of shares outstanding including treasury shares-Treasury shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_592f147dcb344188a08a4f549e825874" contextRef="c20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">-5000000</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of shares outstanding including treasury shares-Ordinary shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_5f15bbd010f944cb9c1f34813d1033c7" contextRef="c20191231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">71859431</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of shares outstanding including treasury shares-Treasury shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_807fbc81b05b446aa9b2b70b6d368cb9" contextRef="c20191231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">0</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of shares outstanding including treasury shares-Ordinary shares [member]-->
  <aciu:NumberOfSharesOutstandingIncludingTreasuryShares id="Fact_a3bfa32b03bc411ba6cd5aa6b8fa1a1e" contextRef="c20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">76936738</aciu:NumberOfSharesOutstandingIncludingTreasuryShares>
  <!--Number of other equity instruments expired or forfeited in share-based payment arrangement-->
  <aciu:NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement id="Fact_c64d436cae814430bb8684b702d79691" contextRef="c20201231" unitRef="U001" decimals="INF">19632</aciu:NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement>
  <!--Increase in number of shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture-Ordinary shares [member]-->
  <aciu:IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture id="Fact_2b100a522fbf4f398eb9156f2d4540e1" contextRef="c20200101to20201231_ClassesOfShareCapitalAxis_OrdinarySharesMember" unitRef="U001" decimals="INF">77307</aciu:IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture>
  <!--Increase in number of shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture-Treasury shares [member]-->
  <aciu:IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture id="Fact_bd5650cfd3c64bccb54db0d1c331c061" contextRef="c20200101to20201231_ComponentsOfEquityAxis_TreasurySharesMember" unitRef="U001" decimals="INF">0</aciu:IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture>
  <!--Schedule of contractual undiscounted cash flows [Table Text Block]-->
  <aciu:ScheduleOfContractualUndiscountedCashFlowsTableTextBlock id="Fact_f861bd3f7a8e4b6fbeea1ac2c4a479ae" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following table presents the contractual undiscounted cash flows for lease liabilities as of December 31, 2020 and 2019:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Within 1 year&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 1 and 3 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;970&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Between 3 and 5 years&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;912&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;948&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,367&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,403&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:ScheduleOfContractualUndiscountedCashFlowsTableTextBlock>
  <!--Disclosure of right-of-use assets impact on statements [Text Block]-->
  <aciu:DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock id="Fact_cdce7f8607ee4a7fa89bf8fc323011f6" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;For the years ended December 31, 2020, and 2019, the impact on the Company&amp;#8217;s statements of income/(loss) and statements of cash flows is detailed in the table below.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;"&gt;Statements of income/(loss)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Depreciation of right-of-use assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;432&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;420&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Interest expense on lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;53&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;52&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expense for short-term leases and leases of low value&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;603&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;565&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,088&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,037&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;"&gt;Statements of cash flows&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total cash outflow for leases&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,088&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,037&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock>
  <!--Disclosure of detailed information about trade payables and accrued liabilities [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock id="Fact_3e6f52e898fc4c6e9a5a3b030c0c6779" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;&amp;#160;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;"&gt;Total trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;142&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;5,298&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;7,228&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Accrued payroll expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;3,494&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;2,896&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;2,293&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;1,673&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;"&gt;Total accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;11,085&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;11,797&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock>
  <!--Contract liabilities, addition-->
  <aciu:ContractLiabilitiesAddition id="Fact_4880db13d3e942dfbb34dead619bdcd5" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1467000</aciu:ContractLiabilitiesAddition>
  <!--Contract liabilities, addition-->
  <aciu:ContractLiabilitiesAddition id="Fact_59f4b8c373164cd9840387b31b2c6bc5" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">7686000</aciu:ContractLiabilitiesAddition>
  <!--Contract assets, deductions-->
  <aciu:ContractAssetsDeductions id="Fact_015b4b3f587846e39099568f2148d3cc" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">1858000</aciu:ContractAssetsDeductions>
  <!--Contract assets, deductions-->
  <aciu:ContractAssetsDeductions id="Fact_c1d44e20702d486594f97ab4c85d989d" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">4783000</aciu:ContractAssetsDeductions>
  <!--Contract assets, additions-->
  <aciu:ContractAssetsAdditions id="Fact_b2d906c712f04bc7a5ec81c69d58d65e" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">2354000</aciu:ContractAssetsAdditions>
  <!--Contract assets, additions-->
  <aciu:ContractAssetsAdditions id="Fact_b6eb3c7292c9417888f117b0e87cd83e" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">2211000</aciu:ContractAssetsAdditions>
  <!--Contract liabilities, deductions-->
  <aciu:ContractLiabilitiesDeductions id="Fact_3922b5b91b79438b9d549e23be5e9896" contextRef="c20200101to20201231" unitRef="U002" decimals="-3">5638000</aciu:ContractLiabilitiesDeductions>
  <!--Contract liabilities, deductions-->
  <aciu:ContractLiabilitiesDeductions id="Fact_6f1c779e105140ee828dbf29a4152aec" contextRef="c20190101to20191231" unitRef="U002" decimals="-3">3560000</aciu:ContractLiabilitiesDeductions>
  <!--Number of common shares sold, related party transactions-->
  <aciu:NumberOfCommonSharesSoldRelatedPartyTransactions id="Fact_8657e6436fba44628d9c11c880a359be" contextRef="c20180731to20180731" unitRef="U001" decimals="INF">614147</aciu:NumberOfCommonSharesSoldRelatedPartyTransactions>
  <!--Number of persons, key management, Board of Directors-->
  <aciu:NumberOfPersonsKeyManagementBoardOfDirectors id="Fact_e595d1a677744067ad4b11993698145a" contextRef="c20200101to20201231" unitRef="U020" decimals="INF">7</aciu:NumberOfPersonsKeyManagementBoardOfDirectors>
  <!--Number of persons, key management, Executive Management-->
  <aciu:NumberOfPersonsKeyManagementExecutiveManagement id="Fact_59371ead9f6747cdbf744d32c76e7e26" contextRef="c20200101to20201231" unitRef="U020" decimals="INF">5</aciu:NumberOfPersonsKeyManagementExecutiveManagement>
  <!--Disclosure of detailed information about income tax losses expiry [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock id="Fact_7c6dcb8520dd4081984a21c867df847d" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;Tax losses expiry dates are shown in the table below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Tax losses split by expiry date:&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;16,566&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2020&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;10,338&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2023&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;7,628&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2024&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;15,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;15,231&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;25,868&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2025&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;48,894&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2026&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;December 31, 2027&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;57,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;121,948&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;64,125&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;109,294&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock>
  <!--Disclosure of detailed information about income tax reconciliation [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock id="Fact_8be9ea100c314896903294e9e218d86b" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The income tax expense for each year can be reconciled to loss before tax as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;For the Years Ended&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Income/(loss) before income tax&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(61,921&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;45,442&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(50,951&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(8,441&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;6,194&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;(10,507&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Income not subject to tax/(expenses) not deductible for tax purposes&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;462&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;(62&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&lt;div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Effect of unused tax losses and tax offsets not recognized as deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;7,979&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;(6,132&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&lt;div&gt;&lt;div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;10,173&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Effective income tax rate benefit/(expense)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock>
  <!--Revenue reclassified to other income (expense)-->
  <aciu:RevenueReclassifiedToOtherIncomeExpense id="Fact_4897f08ff8e544f3b003bd8579c3000c" contextRef="c20180101to20181231" unitRef="U002" decimals="-5">300000</aciu:RevenueReclassifiedToOtherIncomeExpense>
  <!--Revenue reclassified to other income (expense)-->
  <aciu:RevenueReclassifiedToOtherIncomeExpense id="Fact_816461c1f9654e86aa09b5ddd2522a69" contextRef="c20200101to20201231" unitRef="U002" decimals="-5">300000</aciu:RevenueReclassifiedToOtherIncomeExpense>
  <!--Revenue reclassified to other income (expense)-->
  <aciu:RevenueReclassifiedToOtherIncomeExpense id="Fact_cfea61c87eb04120b1f5b9a827ac622e" contextRef="c20190101to20191231" unitRef="U002" decimals="-5">600000</aciu:RevenueReclassifiedToOtherIncomeExpense>
  <!--Collaborative Agreement, Milestone Payment Recognized-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_4beb7ddb0d8f4b9baccd40a330dafafb" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-5">31600000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_ea1ab30f5e4f4cfc85de9d798fae3fb1" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">25000000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_a85035379d2b4827a2d9dd6d15b96910" contextRef="c20160401to20160630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">14000000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_0524b0f125aa4dc9afaf2b0910441446" contextRef="c20190701to20190930_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-5">2200000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_29f3c3d1f1ca43dd805f1cb03456b0c1" contextRef="c20190701to20190930_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-6">2000000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_6e2a946575124c2d8398427f4d3244cc" contextRef="c20170101to20170331_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-5">1100000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative Agreement, Milestone Payment Recognized-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentRecognized id="Fact_facad373a15d445aa366edebf14acf05" contextRef="c20170101to20170331_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-6">1000000</aciu:CollaborativeAgreementMilestonePaymentRecognized>
  <!--Collaborative agreement, Cumulative payments received-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_665525604df94f16bd355ba0314c3c93" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">65000000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Cumulative payments received-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_e6cd1e3124e1487092fb06b30610ec1b" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-5">70100000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Cumulative payments received-Anti-tau antibody in AD [Member]-Collaboration agreement of 2012, Genentech [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_2240a3691d9f4699970a85ca48da972a" contextRef="c20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">59000000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Cumulative payments received-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_fa5abf18eea64f19a54e6a5fcc4ad0cc" contextRef="c20141231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-5">25900000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Cumulative payments received-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_401f920ecadd4a59a9183a3f1e18ad44" contextRef="c20151231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-3">500000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Cumulative payments received-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementCumulativePaymentsReceived id="Fact_ad22b88692294906b69ef3d28791713a" contextRef="c20151231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-3">664000</aciu:CollaborativeAgreementCumulativePaymentsReceived>
  <!--Collaborative agreement, Notice of contract termination period-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod id="Fact_6104dc3999704a2a8ab64eea1f81410c" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember">P3M</aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod>
  <!--Collaborative agreement, Notice of contract termination period-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod id="Fact_a7a68bba41114c4a9e6447649d20f990" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember">P90D</aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod>
  <!--Collaborative agreement, Notice of contract termination period-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod id="Fact_4e3fba22709340cbab295254dfbe20d9" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember">P90D</aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod>
  <!--Collaborative agreement, Notice of contract termination period-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod id="Fact_b136dc666ef24e72a6afd8b0619b57d1" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauVaccineInADMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">P90D</aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod>
  <!--Collaborative agreement, Notice of contract termination period-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod id="Fact_456da21b9ad14147a8ae4a1e77db7b98" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">P3M</aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod>
  <!--Number of milestone payments received-Collaboration agreement of 2006, Genentech [Member]-Anti-Abeta antibody in AD [Member]-->
  <aciu:NumberOfMilestonePaymentsReceived id="Fact_4c3bc05a86c240b2ba7c12469c38f9e4" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U015" decimals="INF">3</aciu:NumberOfMilestonePaymentsReceived>
  <!--Number of milestone payments received-Collaboration agreement of 2012, Genentech [Member]-Anti-tau antibody in AD [Member]-->
  <aciu:NumberOfMilestonePaymentsReceived id="Fact_0a5a57b3adf04b05b10ede6aeeabb291" contextRef="c20200101to20201231_ProductsAndServicesAxis_AntiTauAntibodyInADMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U015" decimals="INF">3</aciu:NumberOfMilestonePaymentsReceived>
  <!--Collaborative agreement, potential value-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly, First Amendment [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_25be3a4eb96b4d8ca92a3b23bbcab1b7" contextRef="c20190331_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember" unitRef="U002" decimals="-6">60000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Anti-Abeta antibody in AD [Member]-Collaboration agreement of 2006, Genentech [Member]-Bottom of range [member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_a0ea8d584490404f8d0a1cc95d7f3a35" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U002" decimals="-6">303000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Anti-Abeta antibody in AD [Member]-Bottom of range [member]-Collaboration agreement of 2006, Genentech [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_e5d6096dc69f4ef1849e7d4d19a28b78" contextRef="c20201231_ProductsAndServicesAxis_AntiAbetaAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2006GenentechMember" unitRef="U005" decimals="-6">340000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Anti-tau antibody in AD [Member]-Collaboration agreement of 2012, Genentech [Member]-Bottom of range [member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_999c55a0da1149acb4930602b522f9ac" contextRef="c20120630_ProductsAndServicesAxis_AntiTauAntibodyInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2012GenentechMember" unitRef="U002" decimals="-6">400000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Bottom of range [member]-Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]-Tau Vaccine in AD [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_88bd1f5002f047118d84853e89b47e0a" contextRef="c20141231_ProductsAndServicesAxis_TauVaccineInADMember_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" unitRef="U002" decimals="-6">500000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-Top of range [member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_36f229fb6a50414787f59574b4d9e580" contextRef="c20140531_ProductsAndServicesAxis_TauPETImagingAgentInADMember_RangeAxis_TopOfRangeMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-6">175000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Top of range [member]-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_5a6237dd119042a49b426673e1736de4" contextRef="c20140531_ProductsAndServicesAxis_TauPETImagingAgentInADMember_RangeAxis_TopOfRangeMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-6">159000000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Grants, Michael J. Fox Foundation [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_b2fe0d0bb3394053836f933f7908f448" contextRef="c20200531_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U002" decimals="-5">2900000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, potential value-Grants, Michael J. Fox Foundation [Member]-->
  <aciu:CollaborativeAgreementPotentialValue id="Fact_e6f3f12697d1492d8b410abab7eb3e95" contextRef="c20200531_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U005" decimals="-5">3200000</aciu:CollaborativeAgreementPotentialValue>
  <!--Collaborative agreement, milestone payment, number of installments-Collaboration Agreement with Lilly, First Amendment [Member]-Tau Morphomer Small Molecule [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentNumberOfInstallments id="Fact_3bb615e83be9454683cf48bed7d4edcb" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyFirstAmendmentMember" unitRef="U013" decimals="INF">2</aciu:CollaborativeAgreementMilestonePaymentNumberOfInstallments>
  <!--Collaborative agreement, milestone payment, number of installments-Collaboration Agreement with Lilly, Second Amendment [Member]-Tau Morphomer Small Molecule [Member]-->
  <aciu:CollaborativeAgreementMilestonePaymentNumberOfInstallments id="Fact_d89c82ea9aca482a9986139c99cc0511" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillySecondAmendmentMember" unitRef="U013" decimals="INF">2</aciu:CollaborativeAgreementMilestonePaymentNumberOfInstallments>
  <!--Number of representatives in joint steering committee by each party-Tau Morphomer Small Molecule [Member]-Collaboration Agreement with Lilly [Member]-->
  <aciu:NumberOfRepresentativesInJointSteeringCommitteeByEachParty id="Fact_d2941d0237da435b8b6bead7593724ef" contextRef="c20200101to20201231_ProductsAndServicesAxis_TauMorphomerSmallMoleculeMember_TypesOfContractsAxis_CollaborationAgreementWithLillyMember" unitRef="U014" decimals="INF">3</aciu:NumberOfRepresentativesInJointSteeringCommitteeByEachParty>
  <!--Number of performance obligations identified-Alpha-synuclein and TDP-43 PET tracer in AD [Member]-Collaboration agreement of 2016, Biogen [Member]-->
  <aciu:NumberOfPerformanceObligationsIdentified id="Fact_edc7ff20fa06474cb533d1d32e5cb9e2" contextRef="c20200101to20201231_ProductsAndServicesAxis_AlphaSynucleinAndTDP43PETTracerInADMember_TypesOfContractsAxis_CollaborationAgreementOf2016BiogenMember" unitRef="U017" decimals="INF">2</aciu:NumberOfPerformanceObligationsIdentified>
  <!--Dilutive effect of convertible instruments [Text Block]-->
  <aciu:DilutiveEffectOfConvertibleInstrumentsTextBlock id="Fact_d85688f8b3f34a368cc984bab226d953" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Share options issued and outstanding (in-the-money)&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;412,191&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,081,836&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,472,589&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Restricted share awards subject to future vesting&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;28,418&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;109,041&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Convertible shares&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;911,261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;440,609&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,993,097&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;1,581,630&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DilutiveEffectOfConvertibleInstrumentsTextBlock>
  <!--Funding commitment-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:FundingCommitment id="Fact_4fcb0c0d40b84ce090b686f963b891dd" contextRef="c20161231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U005" decimals="-3">200000</aciu:FundingCommitment>
  <!--Funding commitment-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:FundingCommitment id="Fact_7c8fad778ede46579f8f1e473e1e50a3" contextRef="c20171231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U005" decimals="-3">200000</aciu:FundingCommitment>
  <!--Funding commitment-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:FundingCommitment id="Fact_104fa70bfa5a462c85da9db724bcdda4" contextRef="c20181231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U005" decimals="-3">200000</aciu:FundingCommitment>
  <!--Reimbursement percentage of funding commitment.-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:ReimbursementPercentageOfFundingCommitment id="Fact_8ed6309fe9e942babc169a32e84cbd15" contextRef="c20200101to20201231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U008" decimals="INF">1.25</aciu:ReimbursementPercentageOfFundingCommitment>
  <!--Percentage of additional interest on total repayment-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:PercentageOfAdditionalInterestOnTotalRepayment id="Fact_431efb76aba44da2822f95355efd5d73" contextRef="c20200101to20201231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U008" decimals="2">0.25</aciu:PercentageOfAdditionalInterestOnTotalRepayment>
  <!--Debt instrument, number of installments-Grants, LuMind Research Down Syndrome Foundation [Member]-->
  <aciu:DebtInstrumentNumberOfInstallments id="Fact_f16f4cfc0e08443cb0357f1b2bb1cf26" contextRef="c20200101to20201231_TypesOfContractsAxis_GrantsLuMindResearchDownSyndromeFoundationMember" unitRef="U013" decimals="INF">3</aciu:DebtInstrumentNumberOfInstallments>
  <!--Number of grants-Grants, Michael J. Fox Foundation [Member]-->
  <aciu:NumberOfGrants id="Fact_d8ac1d2c86b645e18dde9e87a1003f3b" contextRef="c20200101to20201231_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember" unitRef="U018" decimals="INF">2</aciu:NumberOfGrants>
  <!--Collaborative agreement, Joint research collaboration period-Grants, Michael J. Fox Foundation [Member]-Bottom of range [member]-->
  <aciu:CollaborativeAgreementJointResearchCollaborationPeriod id="Fact_79cdec6e7a0d447ba1d0a0c5c258b655" contextRef="c20200101to20201231_RangeAxis_BottomOfRangeMember_TypesOfContractsAxis_GrantsMichaelJFoxFoundationMember">P2Y</aciu:CollaborativeAgreementJointResearchCollaborationPeriod>
  <!--Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <aciu:CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones id="Fact_47a0c9d6cad748bda908da0f37bde094" contextRef="c20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-6">162000000</aciu:CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones>
  <!--Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <aciu:CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones id="Fact_6be0331ac1cc4c4e9ce8720f5c4781d7" contextRef="c20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-6">148000000</aciu:CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones>
  <!--Collaborative agreement, Collaboration contract receivable for clinical milestones-Tau-PET imaging agent in AD [Member]-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-->
  <aciu:CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones id="Fact_56dc99fe53e64d61b268b7565d739db5" contextRef="c20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U016" decimals="-6">8000000</aciu:CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones>
  <!--Collaborative agreement, Collaboration contract receivable for clinical milestones-License and collaboration agreement of 2014, Life Molecular Imaging [Member]-Tau-PET imaging agent in AD [Member]-->
  <aciu:CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones id="Fact_bef3687b712e4ef2b0f06da30d4d814d" contextRef="c20201231_ProductsAndServicesAxis_TauPETImagingAgentInADMember_TypesOfContractsAxis_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" unitRef="U002" decimals="-6">9000000</aciu:CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones>
  <!--Disclosure of detailed information about carrying amounts of financial assets and financial liabilities [Table Text Block]-->
  <aciu:DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock id="Fact_632c4db01bb240c3b0b67aeebce685c9" contextRef="c20200101to20201231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="text-indent: 18pt;"&gt;The following table shows the carrying amounts of financial assets and financial liabilities:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Long-term financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;334&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Other current receivables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;329&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;304&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;65,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;95,000&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;160,893&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;193,587&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;226,556&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;289,195&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;div&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;In CHF thousands&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Financial liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Long-term lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,780&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;1,813&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Trade and other payables&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;2,184&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;142&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;11,085&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"&gt;&lt;div&gt;11,797&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term financing obligation&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"&gt;&lt;div&gt;652&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Short-term lease liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"&gt;&lt;div&gt;&lt;div&gt;442&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"&gt;&lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"&gt;Total financial liabilities&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;15,492&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"&gt;&lt;div&gt;&lt;div&gt;14,846&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aciu:DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
  <!--Percentage of increase in interest rates-Interest rate risk [member]-->
  <aciu:PercentageOfIncreaseInInterestRates id="Fact_fe568a9c68d54b7aba21f71dd11a6c59" contextRef="c20200101to20201231_TypesOfRisksAxis_InterestRateRiskMember" unitRef="U008" decimals="1">0.1</aciu:PercentageOfIncreaseInInterestRates>
  <!--Liquidity management, rolling forecast period-Liquidity risk [member]-->
  <aciu:LiquidityManagementRollingForecastPeriod id="Fact_325b0f3e1cfe4a4c981e495176c107c5" contextRef="c20200101to20201231_TypesOfRisksAxis_LiquidityRiskMember">P18M</aciu:LiquidityManagementRollingForecastPeriod>
  <!--Number of financial institutions holding, cash and cash equivalents and short-term financial assets-Credit risk [member]-->
  <aciu:NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets id="Fact_263300e51d5842b0b9a9b46ca9c690a7" contextRef="c20200101to20201231_TypesOfRisksAxis_CreditRiskMember" unitRef="U023" decimals="INF">4</aciu:NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets>
  <!--Borrowings, debt extinguishment period-Liquidity risk [member]-Trade and Other Payables [Member]-Bottom of range [member]-->
  <aciu:BorrowingsDebtExtinguishmentPeriod id="Fact_5790ef66bbbe43f9b772d1565ab349a0" contextRef="c20200101to20201231_CategoriesOfFinancialLiabilitiesAxis_TradeAndOtherPayablesMember_RangeAxis_BottomOfRangeMember_TypesOfRisksAxis_LiquidityRiskMember">P12M</aciu:BorrowingsDebtExtinguishmentPeriod>
  <!--Decrease in net loss, interest rate decrease-Top of range [member]-Interest rate risk [member]-->
  <aciu:DecreaseInNetLossInterestRateDecrease id="Fact_813ad322cea148c9844c6fb23de00269" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember_TypesOfRisksAxis_InterestRateRiskMember" unitRef="U002" decimals="-5">100000</aciu:DecreaseInNetLossInterestRateDecrease>
  <!--Closing foreign exchange rate, increase-Currency risk [member]-->
  <aciu:ClosingForeignExchangeRateIncrease id="Fact_29f8897e48ca4b399b8cc68f3c9ee9c6" contextRef="c20201231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U008" decimals="1">0.1</aciu:ClosingForeignExchangeRateIncrease>
  <!--Closing foreign exchange rate, decrease-Currency risk [member]-->
  <aciu:ClosingForeignExchangeRateDecrease id="Fact_b7b68334cdec4509af89ae13748d6605" contextRef="c20201231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U008" decimals="1">0.1</aciu:ClosingForeignExchangeRateDecrease>
  <!--Decrease in net loss, foreign exchange rate increase-Currency risk [member]-->
  <aciu:DecreaseInNetLossForeignExchangeRateIncrease id="Fact_a04388e515db48d0a511743724e7aa9f" contextRef="c20190101to20191231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U002" decimals="-5">3500000</aciu:DecreaseInNetLossForeignExchangeRateIncrease>
  <!--Decrease in net loss, foreign exchange rate increase-Currency risk [member]-->
  <aciu:DecreaseInNetLossForeignExchangeRateIncrease id="Fact_c9c486ad48f44e4aa18df0260e19365d" contextRef="c20200101to20201231_TypesOfRisksAxis_CurrencyRiskMember" unitRef="U002" decimals="-5">800000</aciu:DecreaseInNetLossForeignExchangeRateIncrease>
  <!--Percentage of decrease in interest rates-Interest rate risk [member]-->
  <aciu:PercentageOfDecreaseInInterestRates id="Fact_8c0f1458af0a4a6a95346c7f9f788544" contextRef="c20200101to20201231_TypesOfRisksAxis_InterestRateRiskMember" unitRef="U008" decimals="1">0.1</aciu:PercentageOfDecreaseInInterestRates>
  <!--Increase in net loss, interest rate increase-Top of range [member]-Interest rate risk [member]-->
  <aciu:IncreaseInNetLossInterestRateIncrease id="Fact_69ef2c740bac4a9e8bb35fb756cff4dd" contextRef="c20200101to20201231_RangeAxis_TopOfRangeMember_TypesOfRisksAxis_InterestRateRiskMember" unitRef="U002" decimals="-5">100000</aciu:IncreaseInNetLossInterestRateIncrease>
  <!--Dilutive effect of share options and convertible instruments on number of ordinary shares-->
  <aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_51f3b3e4b61343f58a7fe83c40d18e3d" contextRef="c20190101to20191231" unitRef="U001" decimals="0">1993097</aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of share options and convertible instruments on number of ordinary shares-->
  <aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_cab45be5ec434887b23ef359ff30b06a" contextRef="c20180101to20181231" unitRef="U001" decimals="0">1581630</aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of share options and convertible instruments on number of ordinary shares-->
  <aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares id="Fact_ff3d1b832f0341568a3ed7eacb113fca" contextRef="c20200101to20201231" unitRef="U001" decimals="0">440609</aciu:DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <!--Dilutive effect of Restricted share awards subject to future vesting-->
  <aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting id="Fact_36b84ff471564b1ab7b74f24f87da628" contextRef="c20200101to20201231" unitRef="U001" decimals="0">28418</aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting>
  <!--Dilutive effect of Restricted share awards subject to future vesting-->
  <aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting id="Fact_60485a71745542859522db062c4e0a89" contextRef="c20190101to20191231" unitRef="U001" decimals="0">0</aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting>
  <!--Dilutive effect of Restricted share awards subject to future vesting-->
  <aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting id="Fact_a612d067011143dab15a15401c6e035e" contextRef="c20180101to20181231" unitRef="U001" decimals="0">109041</aciu:DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting>
  <!--Dilutive effect of share options issued and outstanding-->
  <aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding id="Fact_3994a66432b34f2eaf03ff86dba67c9e" contextRef="c20190101to20191231" unitRef="U001" decimals="0">1081836</aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding>
  <!--Dilutive effect of share options issued and outstanding-->
  <aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding id="Fact_9732273cdf364caeaecea2dab9d93496" contextRef="c20200101to20201231" unitRef="U001" decimals="0">412191</aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding>
  <!--Dilutive effect of share options issued and outstanding-->
  <aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding id="Fact_9df2283867314becbf5b5fa5ce26c3ce" contextRef="c20180101to20181231" unitRef="U001" decimals="0">1472589</aciu:DilutiveEffectOfShareOptionsIssuedAndOutstanding>
  <!--Income tax loss, Carryforward period-->
  <aciu:IncomeTaxLossCarryforwardPeriod id="Fact_11704447ceda488180b97db0fee04ebd" contextRef="c20200101to20201231">P7Y</aciu:IncomeTaxLossCarryforwardPeriod>
  <!--Reportable segments, number-->
  <aciu:ReportableSegmentsNumber id="Fact_35729ec41c5240368544cd0044b615d9" contextRef="c20200101to20201231" unitRef="U007" decimals="INF">1</aciu:ReportableSegmentsNumber>
  <!--Operating segments, number-->
  <aciu:OperatingSegmentsNumber id="Fact_dd606db2fada4591a63708be082af8cb" contextRef="c20200101to20201231" unitRef="U007" decimals="INF">1</aciu:OperatingSegmentsNumber>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>aciu-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://acimume.com/20201231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:aciu="http://acimume.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="aciu-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aciu-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aciu-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aciu-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://acimume.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>010000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/StatementsOfIncomeLoss" id="StatementsOfIncomeLoss">
        <link:definition>020000 - Statement - Statements of Income/(Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss" id="StatementsOfComprehensiveIncomeLoss">
        <link:definition>030000 - Statement - Statements of Comprehensive Income/(Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>040000 - Statement - Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>050000 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
        <!--Parent Role: Statements of Cash Flows-->
        <link:definition>050100 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/GeneralInformation" id="GeneralInformation">
        <link:definition>060100 - Disclosure - General information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/BasisOfPreparation" id="BasisOfPreparation">
        <link:definition>060200 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060300 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
        <link:definition>060400 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities" id="RightofuseAssetsAndLeaseLiabilities">
        <link:definition>060500 - Disclosure - Right-of-use assets and lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets" id="CashAndCashEquivalentsAndFinancialAssets">
        <link:definition>060600 - Disclosure - Cash and cash equivalents and financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncome" id="PrepaidExpensesAndAccruedIncome">
        <link:definition>060700 - Disclosure - Prepaid expenses and accrued income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/OtherCurrentReceivables" id="OtherCurrentReceivables">
        <link:definition>060800 - Disclosure - Other current receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ShareCapital" id="ShareCapital">
        <link:definition>060900 - Disclosure - Share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilities" id="TradePayablesAndAccruedLiabilities">
        <link:definition>061000 - Disclosure - Trade payables and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/FinancingObligation" id="FinancingObligation">
        <link:definition>061100 - Disclosure - Financing obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenues" id="ContractRevenues">
        <link:definition>061200 - Disclosure - Contract revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ExpensesByCategory" id="ExpensesByCategory">
        <link:definition>061300 - Disclosure - Expenses by category</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RelatedpartyTransactions" id="RelatedpartyTransactions">
        <link:definition>061400 - Disclosure - Related-party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061500 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlan" id="RetirementBenefitPlan">
        <link:definition>061600 - Disclosure - Retirement benefit plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensation" id="SharebasedCompensation">
        <link:definition>061700 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061800 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/EarningsPerShare" id="EarningsPerShare">
        <link:definition>061900 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagement" id="FinancialInstrumentsAndRiskManagement">
        <link:definition>062000 - Disclosure - Financial instruments and risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CapitalRiskManagement" id="CapitalRiskManagement">
        <link:definition>062100 - Disclosure - Capital risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>062200 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>070300 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>080300 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
        <!--Parent Role: Property, plant and equipment-->
        <link:definition>080400 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables" id="RightofuseAssetsAndLeaseLiabilitiesTables">
        <!--Parent Role: Right-of-use assets and lease liabilities-->
        <link:definition>080500 - Disclosure - Right-of-use assets and lease liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables" id="CashAndCashEquivalentsAndFinancialAssetsTables">
        <!--Parent Role: Cash and cash equivalents and financial assets-->
        <link:definition>080600 - Disclosure - Cash and cash equivalents and financial assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables" id="PrepaidExpensesAndAccruedIncomeTables">
        <!--Parent Role: Prepaid expenses and accrued income-->
        <link:definition>080700 - Disclosure - Prepaid expenses and accrued income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/OtherCurrentReceivablesTables" id="OtherCurrentReceivablesTables">
        <!--Parent Role: Other current receivables-->
        <link:definition>080800 - Disclosure - Other current receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <!--Parent Role: Share capital-->
        <link:definition>080900 - Disclosure - Share capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables" id="TradePayablesAndAccruedLiabilitiesTables">
        <!--Parent Role: Trade payables and accrued liabilities-->
        <link:definition>081000 - Disclosure - Trade payables and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesTables" id="ContractRevenuesTables">
        <!--Parent Role: Contract revenues-->
        <link:definition>081200 - Disclosure - Contract revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ExpensesByCategoryTables" id="ExpensesByCategoryTables">
        <!--Parent Role: Expenses by category-->
        <link:definition>081300 - Disclosure - Expenses by category (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RelatedpartyTransactionsTables" id="RelatedpartyTransactionsTables">
        <!--Parent Role: Related-party transactions-->
        <link:definition>081400 - Disclosure - Related-party transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income taxes-->
        <link:definition>081500 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanTables" id="RetirementBenefitPlanTables">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>081600 - Disclosure - Retirement benefit plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationTables" id="SharebasedCompensationTables">
        <!--Parent Role: Share-based compensation-->
        <link:definition>081700 - Disclosure - Share-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <!--Parent Role: Commitments and contingencies-->
        <link:definition>081800 - Disclosure - Commitments and contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
        <!--Parent Role: Earnings per share-->
        <link:definition>081900 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables" id="FinancialInstrumentsAndRiskManagementTables">
        <!--Parent Role: Financial instruments and risk management-->
        <link:definition>082000 - Disclosure - Financial instruments and risk management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/GeneralInformationDetails" id="GeneralInformationDetails">
        <!--Parent Role: General information-->
        <link:definition>090100 - Disclosure - General information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/BasisOfPreparationDetails" id="BasisOfPreparationDetails">
        <!--Parent Role: Basis of preparation-->
        <link:definition>090200 - Disclosure - Basis of preparation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails" id="SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>090300 - Disclosure - Summary of significant accounting policies, Right-of-use assets and lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>090302 - Disclosure - Summary of significant accounting policies, Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>090304 - Disclosure - Summary of significant accounting policies, Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" id="SummaryOfSignificantAccountingPoliciesSegmentReportingDetails">
        <!--Parent Role: Summary of significant accounting policies-->
        <link:definition>090306 - Disclosure - Summary of significant accounting policies, Segment reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
        <!--Parent Role: Property, plant and equipment-->
        <link:definition>090400 - Disclosure - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails" id="RightofuseAssetsAndLeaseLiabilitiesDetails">
        <!--Parent Role: Right-of-use assets and lease liabilities-->
        <link:definition>090500 - Disclosure - Right-of-use assets and lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails" id="CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails">
        <!--Parent Role: Cash and cash equivalents and financial assets-->
        <link:definition>090600 - Disclosure - Cash and cash equivalents and financial assets, Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" id="CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails">
        <!--Parent Role: Cash and cash equivalents and financial assets-->
        <link:definition>090602 - Disclosure - Cash and cash equivalents and financial assets, Cash and cash equivalents and short-term financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails" id="PrepaidExpensesAndAccruedIncomeDetails">
        <!--Parent Role: Prepaid expenses and accrued income-->
        <link:definition>090700 - Disclosure - Prepaid expenses and accrued income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/OtherCurrentReceivablesDetails" id="OtherCurrentReceivablesDetails">
        <!--Parent Role: Other current receivables-->
        <link:definition>090800 - Disclosure - Other current receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ShareCapitalDetails" id="ShareCapitalDetails">
        <!--Parent Role: Share capital-->
        <link:definition>090900 - Disclosure - Share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails" id="ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails">
        <!--Parent Role: Share capital-->
        <link:definition>090902 - Disclosure - Share capital, Convertible Note Agreement an Follow-On Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails" id="ShareCapitalShelfRegistrationStatementDetails">
        <!--Parent Role: Share capital-->
        <link:definition>090904 - Disclosure - Share capital, Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails" id="TradePayablesAndAccruedLiabilitiesDetails">
        <!--Parent Role: Trade payables and accrued liabilities-->
        <link:definition>091000 - Disclosure - Trade payables and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/FinancingObligationDetails" id="FinancingObligationDetails">
        <!--Parent Role: Financing obligation-->
        <link:definition>091100 - Disclosure - Financing obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails" id="ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091200 - Disclosure - Contract revenues, Contract Revenue Attributable to Licensing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" id="ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091202 - Disclosure - Contract revenues, Changes in Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails" id="ContractRevenuesRecognizedRevenuesDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091204 - Disclosure - Contract revenues, Recognized Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails" id="ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091206 - Disclosure - Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails" id="ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091208 - Disclosure - Contract revenues, Anti-Abeta Antibody in AD - 2006 Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails" id="ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091210 - Disclosure - Contract revenues, Anti-Tau Antibody in AD - 2012 Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails" id="ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091212 - Disclosure - Contract revenues, Tau Vaccine in AD - 2014 Agreement with Janssen Pharmaceuticals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails" id="ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091214 - Disclosure - Contract revenues, Tau-PET imaging agent in AD -2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails" id="ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091216 - Disclosure - Contract revenues, A-syn and TDP-43 PET tracers - 2016 agreement with Biogen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails" id="ContractRevenuesGrantsFromMichaelJFoxFoundationDetails">
        <!--Parent Role: Contract revenues-->
        <link:definition>091218 - Disclosure - Contract revenues, Grants from the Michael J. Fox Foundation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/ExpensesByCategoryDetails" id="ExpensesByCategoryDetails">
        <!--Parent Role: Expenses by category-->
        <link:definition>091300 - Disclosure - Expenses by category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RelatedpartyTransactionsDetails" id="RelatedpartyTransactionsDetails">
        <!--Parent Role: Related-party transactions-->
        <link:definition>091400 - Disclosure - Related-party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income taxes-->
        <link:definition>091500 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails" id="IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails">
        <!--Parent Role: Income taxes-->
        <link:definition>091502 - Disclosure - Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanDetails" id="RetirementBenefitPlanDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091600 - Disclosure - Retirement benefit plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails" id="RetirementBenefitPlanChangesInDefinedBenefitObligationDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091602 - Disclosure - Retirement benefit plan, Changes in Defined Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails" id="RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091604 - Disclosure - Retirement benefit plan, Changes in Fair Value of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails" id="RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091606 - Disclosure - Retirement benefit plan, Change in Net Defined Benefit Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails" id="RetirementBenefitPlanChangeInOtherComprehensiveLossDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091608 - Disclosure - Retirement benefit plan, Change in Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails" id="RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails">
        <!--Parent Role: Retirement benefit plan-->
        <link:definition>091610 - Disclosure - Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails" id="SharebasedCompensationPlansOutstandingDetails">
        <!--Parent Role: Share-based compensation-->
        <link:definition>091700 - Disclosure - Share-based compensation, Plans Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails" id="SharebasedCompensationWeightedAverageExercisePricesDetails">
        <!--Parent Role: Share-based compensation-->
        <link:definition>091702 - Disclosure - Share-based compensation, Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails" id="SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails">
        <!--Parent Role: Share-based compensation-->
        <link:definition>091704 - Disclosure - Share-based compensation, Outstanding Options, Range of Exercise prices and Expiration Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails" id="SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails">
        <!--Parent Role: Share-based compensation-->
        <link:definition>091706 - Disclosure - Share-based compensation, Weighted Average Grant date Fair Value and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails" id="SharebasedCompensationNonvestedShareAwardsDetails">
        <!--Parent Role: Share-based compensation-->
        <link:definition>091708 - Disclosure - Share-based compensation, Non-vested Share Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and contingencies-->
        <link:definition>091800 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/EarningsPerShareDetails" id="EarningsPerShareDetails">
        <!--Parent Role: Earnings per share-->
        <link:definition>091900 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
        <!--Parent Role: Financial instruments and risk management-->
        <link:definition>092000 - Disclosure - Financial instruments and risk management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://acimume.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent events-->
        <link:definition>092200 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd" />
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <xs:element name="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" id="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ExpensesOperatingAbstract" id="aciu_ExpensesOperatingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" id="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssuingSharesNetOfUnderwritingFees" id="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IssueOfEquityRestrictedShareAwards" id="aciu_IssueOfEquityRestrictedShareAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CashAdvancesForRentDeposit" id="aciu_CashAdvancesForRentDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsForShareIssueCostsOnPublicOffering" id="aciu_PaymentsForShareIssueCostsOnPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssueOfConvertibleDebt" id="aciu_ProceedsFromIssueOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ChangesInWorkingCapitalAbstract" id="aciu_ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" id="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AdjustmentsForDecreaseIncreaseInAccruedIncome" id="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AdjustmentsForIncreaseDecreaseInAccruedExpenses" id="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AdjustmentsForDecreaseIncreaseInPrepaidExpense" id="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AdjustmentsForDepreciationExpenseRightOfUseAssets" id="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" id="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidExpensesAndAccruedIncomeTable" id="aciu_PrepaidExpensesAndAccruedIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidExpensesAndAccruedIncomeLineItems" id="aciu_PrepaidExpensesAndAccruedIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfAccruedIncome" id="aciu_PercentageOfAccruedIncome" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" id="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SensitivityAnalysisActuarialAssumptionsAbstract" id="aciu_SensitivityAnalysisActuarialAssumptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IssuedActuarialTablesSwitzerland" id="aciu_IssuedActuarialTablesSwitzerland" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" id="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" id="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" id="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChangeInOtherComprehensiveLossAbstract" id="aciu_ChangeInOtherComprehensiveLossAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" id="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfEquityBasedInstrumentPlans" id="aciu_NumberOfEquityBasedInstrumentPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPlansOutstandingAbstract" id="aciu_ShareBasedPlansOutstandingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" id="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlanBMember" id="aciu_StockOptionPlanBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Two016ShareOptionAndIncentivePlanMember" id="aciu_Two016ShareOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlanC1Member" id="aciu_StockOptionPlanC1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EmployeesMember" id="aciu_EmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" id="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlanAMember" id="aciu_StockOptionPlanAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherCurrentReceivablesAbstract" id="aciu_OtherCurrentReceivablesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfOtherCurrentReceivablesTextBlock" id="aciu_DisclosureOfOtherCurrentReceivablesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" id="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" id="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaboratoryEquipmentMember" id="aciu_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LeaseholdImprovementsAndFixturesAndFittingsMember" id="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" id="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" id="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UndiscountedOperatingLeasePaymentsDue" id="aciu_UndiscountedOperatingLeasePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ExpenseRelatingToLeases" id="aciu_ExpenseRelatingToLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RightOfUseLeasedAssetsAbstract" id="aciu_RightOfUseLeasedAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalOfRightOfUseAssets" id="aciu_DisposalOfRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ExecutiveManagementMember" id="aciu_ExecutiveManagementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RestrictedSharesAndRestrictedShareUnitsMember" id="aciu_RestrictedSharesAndRestrictedShareUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockUnitsMember" id="aciu_RestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BoardOfDirectorsMember" id="aciu_BoardOfDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RestrictedSharesMember" id="aciu_RestrictedSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfNonVestedSharesAbstract" id="aciu_NumberOfNonVestedSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" id="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageExercisePriceAbstract" id="aciu_WeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" id="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPaymentArrangementAbstract" id="aciu_ShareBasedPaymentArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" id="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" id="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageAssumptionsAbstract" id="aciu_WeightedAverageAssumptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FormerChiefExecutiveFinancialOfficerMember" id="aciu_FormerChiefExecutiveFinancialOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EstimatedLeaseTerm" id="aciu_EstimatedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CashAndCashEquivalentsTable" id="aciu_CashAndCashEquivalentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashAndCashEquivalentLineItems" id="aciu_CashAndCashEquivalentLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommitmentsAndContingenciesAbstract" id="aciu_CommitmentsAndContingenciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" id="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareOptionsDateOfExpiry" id="aciu_ShareOptionsDateOfExpiry" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RangeOfExercisePricesTwoMember" id="aciu_RangeOfExercisePricesTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeOfExercisePricesThreeMember" id="aciu_RangeOfExercisePricesThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RangeOfExercisePricesOneMember" id="aciu_RangeOfExercisePricesOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CurrentAccruedResearchAndDevelopmentCosts" id="aciu_CurrentAccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DisclosureOfOtherCurrentReceivablesTable" id="aciu_DisclosureOfOtherCurrentReceivablesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfOtherCurrentReceivablesLineItems" id="aciu_DisclosureOfOtherCurrentReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodOfMaturityReceivablesFairValueCarryingAmount" id="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfEscrowDepositAccounts" id="aciu_NumberOfEscrowDepositAccounts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BasisOfPreparationAbstract" id="aciu_BasisOfPreparationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfGoingConcernTable" id="aciu_DisclosureOfGoingConcernTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfClassesOfGoingConcernLineItems" id="aciu_DisclosureOfClassesOfGoingConcernLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InitialPublicOfferingMember" id="aciu_InitialPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GoingConcernAbstract" id="aciu_GoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementMilestonePaymentReceived" id="aciu_CollaborativeAgreementMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfPublicOfferings" id="aciu_NumberOfPublicOfferings" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborationAndLicenseRevenueAgreementsMember" id="aciu_CollaborationAndLicenseRevenueAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementWithLillyMember" id="aciu_CollaborationAgreementWithLillyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GrantIncomePolicyTextBlock" id="aciu_GrantIncomePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" id="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" id="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" id="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" id="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InterestCostNetDefinedBenefitLiabilityAsset" id="aciu_InterestCostNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="GeneralInformationAbstract" id="aciu_GeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" id="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfTechnologyPlatforms" id="aciu_NumberOfTechnologyPlatforms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AtTheMarketEquityOfferingMember" id="aciu_AtTheMarketEquityOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" id="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareIssuedPricePerShare" id="aciu_ShareIssuedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfOfferings" id="aciu_NumberOfOfferings" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" id="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ConvertibleBorrowings" id="aciu_ConvertibleBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" id="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="FollowOnOfferingsMember" id="aciu_FollowOnOfferingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecondSubscriptionRightsMember" id="aciu_SecondSubscriptionRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OptionForOverAllotmentMember" id="aciu_OptionForOverAllotmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstSubscriptionRightsMember" id="aciu_FirstSubscriptionRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StatementOfCashFlowsTable" id="aciu_StatementOfCashFlowsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleNoteAgreementMember" id="aciu_ConvertibleNoteAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StatementOfCashFlowsLineItems" id="aciu_StatementOfCashFlowsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SupplementaryNonCashActivityAbstract" id="aciu_SupplementaryNonCashActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RepaymentOfConvertibleDebtEquitySettlementAmount" id="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" id="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DefinedBenefitPlanPercentageOfContribution" id="aciu_DefinedBenefitPlanPercentageOfContribution" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DefinedBenefitsPlanEmployeeMember" id="aciu_DefinedBenefitsPlanEmployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NetPensionCostInStatementOfIncomeAbstract" id="aciu_NetPensionCostInStatementOfIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InterestIncomeNetDefinedBenefitLiabilityAsset" id="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DefinedBenefitsPlanEmployerMember" id="aciu_DefinedBenefitsPlanEmployerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExpensesByCategoryAbstract" id="aciu_ExpensesByCategoryAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageRemainingAbstract" id="aciu_WeightedAverageRemainingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" id="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfOptionsAbstract" id="aciu_NumberOfOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FinancialResultNetAbstract" id="aciu_FinancialResultNetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentExpensesAbstract" id="aciu_ResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentExpenseAllocationOperatingExpense" id="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" id="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EmployeeFullTimeEquivalentsInResearchAndDevelopment" id="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" id="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GeneralAndAdministrativeExpenseAllocationOperatingExpense" id="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" id="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" id="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" id="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommitmentsAbstract" id="aciu_CommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RentalContractPeriodForNoticeOfCancellation" id="aciu_RentalContractPeriodForNoticeOfCancellation" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProvisionsResearchContracts" id="aciu_ProvisionsResearchContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TaxLossesSplitByExpiryDateAbstract" id="aciu_TaxLossesSplitByExpiryDateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaterThanSixYearsAndNotLaterThanSevenYearsMember" id="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NotLaterThanPriorYearEndMember" id="aciu_NotLaterThanPriorYearEndMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaterThanSixYearsAndNotLaterThanEightYearsMember" id="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UnusedTaxCreditsRetirementBenefitPlanMember" id="aciu_UnusedTaxCreditsRetirementBenefitPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" id="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaterThanFiveYearsAndNotLaterThanSixYearsMember" id="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChangesInFairValueOfPlanAssetsAbstract" id="aciu_ChangesInFairValueOfPlanAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShelfRegistrationStatementAbstract" id="aciu_ShelfRegistrationStatementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" id="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" id="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ShelfRegistrationStatementSharesAuthorized" id="aciu_ShelfRegistrationStatementSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IncreaseThroughSharesIssuedUnderIncentivePlans" id="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" id="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" id="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfSharesOutstandingIncludingTreasuryShares" id="aciu_NumberOfSharesOutstandingIncludingTreasuryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" id="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" id="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" id="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" id="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FinancingObligationAbstract" id="aciu_FinancingObligationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContractLiabilitiesAddition" id="aciu_ContractLiabilitiesAddition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ContractAssetsDeductions" id="aciu_ContractAssetsDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ContractAssetsAdditions" id="aciu_ContractAssetsAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ContractLiabilitiesDeductions" id="aciu_ContractLiabilitiesDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NumberOfCommonSharesSoldRelatedPartyTransactions" id="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPersonsKeyManagementBoardOfDirectors" id="aciu_NumberOfPersonsKeyManagementBoardOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPersonsKeyManagementExecutiveManagement" id="aciu_NumberOfPersonsKeyManagementExecutiveManagement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RevenueReclassifiedToOtherIncomeExpense" id="aciu_RevenueReclassifiedToOtherIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ContractRevenueAbstract" id="aciu_ContractRevenueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" id="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementOf2012GenentechMember" id="aciu_CollaborationAgreementOf2012GenentechMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementOf2016BiogenMember" id="aciu_CollaborationAgreementOf2016BiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OtherAgreementMember" id="aciu_OtherAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementMilestonePaymentRecognized" id="aciu_CollaborativeAgreementMilestonePaymentRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CollaborativeAgreementCumulativePaymentsReceived" id="aciu_CollaborativeAgreementCumulativePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CollaborativeAgreementNoticeOfContractTerminationPeriod" id="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AntiTauAntibodyInADMember" id="aciu_AntiTauAntibodyInADMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfMilestonePaymentsReceived" id="aciu_NumberOfMilestonePaymentsReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementPotentialValue" id="aciu_CollaborativeAgreementPotentialValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="RightOfUseLicenseMember" id="aciu_RightOfUseLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsCommercialMember" id="aciu_MilestonePaymentsCommercialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementMilestonePaymentNumberOfInstallments" id="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" id="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PhaseTwoClinicalStudyLicensedProductMember" id="aciu_PhaseTwoClinicalStudyLicensedProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" id="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TauMorphomerSmallMoleculeMember" id="aciu_TauMorphomerSmallMoleculeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentMember" id="aciu_ResearchAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementWithLillyFirstAmendmentMember" id="aciu_CollaborationAgreementWithLillyFirstAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementWithLillySecondAmendmentMember" id="aciu_CollaborationAgreementWithLillySecondAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AlphaSynucleinAndTDP43PETTracerInADMember" id="aciu_AlphaSynucleinAndTDP43PETTracerInADMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPerformanceObligationsIdentified" id="aciu_NumberOfPerformanceObligationsIdentified" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DilutiveEffectOfConvertibleInstrumentsTextBlock" id="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PostBalanceSheetEventsAbstract" id="aciu_PostBalanceSheetEventsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubsequentEventsMember" id="aciu_SubsequentEventsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermFinancingObligationTable" id="aciu_LongTermFinancingObligationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermFinancingObligationLineItems" id="aciu_LongTermFinancingObligationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FundingCommitment" id="aciu_FundingCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ReimbursementPercentageOfFundingCommitment" id="aciu_ReimbursementPercentageOfFundingCommitment" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfAdditionalInterestOnTotalRepayment" id="aciu_PercentageOfAdditionalInterestOnTotalRepayment" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentNumberOfInstallments" id="aciu_DebtInstrumentNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="GrantsLuMindResearchDownSyndromeFoundationMember" id="aciu_GrantsLuMindResearchDownSyndromeFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GrantRevenueMember" id="aciu_GrantRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GrantsMichaelJFoxFoundationMember" id="aciu_GrantsMichaelJFoxFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfGrants" id="aciu_NumberOfGrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementJointResearchCollaborationPeriod" id="aciu_CollaborativeAgreementJointResearchCollaborationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SkaneUniversityHospitalMember" id="aciu_SkaneUniversityHospitalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TauVaccineInADMember" id="aciu_TauVaccineInADMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" id="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" id="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TauPETImagingAgentInADMember" id="aciu_TauPETImagingAgentInADMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" id="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementOf2006GenentechMember" id="aciu_CollaborationAgreementOf2006GenentechMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AntiAbetaAntibodyInADMember" id="aciu_AntiAbetaAntibodyInADMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FinancialAssetsAndLiabilitiesAbstract" id="aciu_FinancialAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FinancialRisksAbstract" id="aciu_FinancialRisksAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfIncreaseInInterestRates" id="aciu_PercentageOfIncreaseInInterestRates" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LiquidityManagementRollingForecastPeriod" id="aciu_LiquidityManagementRollingForecastPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" id="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BorrowingsDebtExtinguishmentPeriod" id="aciu_BorrowingsDebtExtinguishmentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DecreaseInNetLossInterestRateDecrease" id="aciu_DecreaseInNetLossInterestRateDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ClosingForeignExchangeRateIncrease" id="aciu_ClosingForeignExchangeRateIncrease" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ClosingForeignExchangeRateDecrease" id="aciu_ClosingForeignExchangeRateDecrease" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShortTermLeaseLiabilitiesMember" id="aciu_ShortTermLeaseLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TradeAndOtherPayablesMember" id="aciu_TradeAndOtherPayablesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DecreaseInNetLossForeignExchangeRateIncrease" id="aciu_DecreaseInNetLossForeignExchangeRateIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PercentageOfDecreaseInInterestRates" id="aciu_PercentageOfDecreaseInInterestRates" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedExpensesMember" id="aciu_AccruedExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncreaseInNetLossInterestRateIncrease" id="aciu_IncreaseInNetLossInterestRateIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OtherReceivablesMember" id="aciu_OtherReceivablesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashOnHandAndCashEquivalentsMember" id="aciu_CashOnHandAndCashEquivalentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermFinancialAssetsMember" id="aciu_LongTermFinancialAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShortTermFinancialAssetsMember" id="aciu_ShortTermFinancialAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AntidilutiveSecuritiesAbstract" id="aciu_AntidilutiveSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" id="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" id="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DilutiveEffectOfShareOptionsIssuedAndOutstanding" id="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncomeTaxLossCarryforwardPeriod" id="aciu_IncomeTaxLossCarryforwardPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ReportableSegmentsNumber" id="aciu_ReportableSegmentsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingSegmentsNumber" id="aciu_OperatingSegmentsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>aciu-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShareDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanDetails" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactionsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactionsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategoryDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategoryDetails" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivablesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivablesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncomeDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfChangesInEquity" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfChangesInEquity" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/BalanceSheets" xlink:type="simple" xlink:href="aciu-20201231.xsd#BalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="NoncurrentAssets" xlink:title="NoncurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="NoncurrentRestrictedCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NoncurrentAssets" xlink:to="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="calculation: NoncurrentAssets to NoncurrentRestrictedCashAndCashEquivalents" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment" xlink:title="PropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NoncurrentAssets" xlink:to="PropertyPlantAndEquipment" xlink:title="calculation: NoncurrentAssets to PropertyPlantAndEquipment" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets" xlink:title="RightofuseAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NoncurrentAssets" xlink:to="RightofuseAssets" xlink:title="calculation: NoncurrentAssets to RightofuseAssets" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="NoncurrentAssets" xlink:title="calculation: Assets to NoncurrentAssets" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="CurrentAssets" xlink:title="CurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAssets" xlink:to="CashAndCashEquivalents" xlink:title="calculation: CurrentAssets to CashAndCashEquivalents" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAssets" xlink:to="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="calculation: CurrentAssets to CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAssets" xlink:to="CurrentContractAssets" xlink:title="calculation: CurrentAssets to CurrentContractAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAssets" xlink:to="CurrentPrepayments" xlink:title="calculation: CurrentAssets to CurrentPrepayments" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAssets" xlink:to="CurrentFinancialAssets" xlink:title="calculation: CurrentAssets to CurrentFinancialAssets" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="CurrentAssets" xlink:title="calculation: Assets to CurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" xlink:title="EquityAndLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="IssuedCapital" xlink:title="IssuedCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Equity" xlink:to="IssuedCapital" xlink:title="calculation: Equity to IssuedCapital" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="SharePremium" xlink:title="SharePremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Equity" xlink:to="SharePremium" xlink:title="calculation: Equity to SharePremium" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="RetainedEarnings" xlink:title="RetainedEarnings" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Equity" xlink:to="RetainedEarnings" xlink:title="calculation: Equity to RetainedEarnings" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="TreasuryShares" xlink:title="TreasuryShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Equity" xlink:to="TreasuryShares" xlink:title="calculation: Equity to TreasuryShares" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="Equity" xlink:title="calculation: EquityAndLiabilities to Equity" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="NoncurrentLiabilities" xlink:title="NoncurrentLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="NoncurrentProvisionsForEmployeeBenefits" xlink:title="NoncurrentProvisionsForEmployeeBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NoncurrentLiabilities" xlink:to="NoncurrentProvisionsForEmployeeBenefits" xlink:title="calculation: NoncurrentLiabilities to NoncurrentProvisionsForEmployeeBenefits" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="NoncurrentLeaseLiabilities" xlink:title="NoncurrentLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NoncurrentLiabilities" xlink:to="NoncurrentLeaseLiabilities" xlink:title="calculation: NoncurrentLiabilities to NoncurrentLeaseLiabilities" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="NoncurrentLiabilities" xlink:title="calculation: Liabilities to NoncurrentLiabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="CurrentLiabilities" xlink:title="CurrentLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentLiabilities" xlink:to="CurrentContractLiabilities" xlink:title="calculation: CurrentLiabilities to CurrentContractLiabilities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="TradeAndOtherCurrentPayables" xlink:title="TradeAndOtherCurrentPayables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentLiabilities" xlink:to="TradeAndOtherCurrentPayables" xlink:title="calculation: CurrentLiabilities to TradeAndOtherCurrentPayables" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="CurrentAccruedExpensesAndOtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentLiabilities" xlink:to="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="calculation: CurrentLiabilities to CurrentAccruedExpensesAndOtherCurrentLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="CurrentFinancialLiabilities" xlink:title="CurrentFinancialLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentLiabilities" xlink:to="CurrentFinancialLiabilities" xlink:title="calculation: CurrentLiabilities to CurrentFinancialLiabilities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="CurrentLeaseLiabilities" xlink:title="CurrentLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentLiabilities" xlink:to="CurrentLeaseLiabilities" xlink:title="calculation: CurrentLiabilities to CurrentLeaseLiabilities" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="CurrentLiabilities" xlink:title="calculation: Liabilities to CurrentLiabilities" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="Liabilities" xlink:title="calculation: EquityAndLiabilities to Liabilities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ProfitLossBeforeTax" xlink:title="ProfitLossBeforeTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="FinanceCosts" xlink:title="calculation: FinanceIncomeCost to FinanceCosts" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="FinanceIncome" xlink:title="calculation: FinanceIncomeCost to FinanceIncome" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="calculation: FinanceIncomeCost to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="calculation: FinanceIncomeCost to GainLossArisingFromChangeInFairValueOfConvertibleInstrument" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLossBeforeTax" xlink:to="FinanceIncomeCost" xlink:title="calculation: ProfitLossBeforeTax to FinanceIncomeCost" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ProfitLossFromOperatingActivities" xlink:title="ProfitLossFromOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="Revenue" xlink:title="Revenue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenue" xlink:to="RevenueFromContractsWithCustomers" xlink:title="calculation: Revenue to RevenueFromContractsWithCustomers" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLossFromOperatingActivities" xlink:to="Revenue" xlink:title="calculation: ProfitLossFromOperatingActivities to Revenue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="OperatingExpense" xlink:title="OperatingExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpense" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpense to ResearchAndDevelopmentExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpense" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpense to SellingGeneralAndAdministrativeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="OtherOperatingIncomeExpense" xlink:title="OtherOperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpense" xlink:to="OtherOperatingIncomeExpense" xlink:title="calculation: OperatingExpense to OtherOperatingIncomeExpense" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLossFromOperatingActivities" xlink:to="OperatingExpense" xlink:title="calculation: ProfitLossFromOperatingActivities to OperatingExpense" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLossBeforeTax" xlink:to="ProfitLossFromOperatingActivities" xlink:title="calculation: ProfitLossBeforeTax to ProfitLossFromOperatingActivities" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ProfitLossBeforeTax" xlink:title="calculation: ProfitLoss to ProfitLossBeforeTax" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="IncomeTaxExpenseContinuingOperations" xlink:title="IncomeTaxExpenseContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeTaxExpenseContinuingOperations" xlink:title="calculation: ProfitLoss to IncomeTaxExpenseContinuingOperations" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ProfitLoss" xlink:title="calculation: ComprehensiveIncome to ProfitLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:title="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:title="calculation: ComprehensiveIncome to OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfChangesInEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ProfitLoss" xlink:title="calculation: ComprehensiveIncome to ProfitLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="OtherComprehensiveIncome" xlink:title="OtherComprehensiveIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="OtherComprehensiveIncome" xlink:title="calculation: ComprehensiveIncome to OtherComprehensiveIncome" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="IncreaseDecreaseInCashAndCashEquivalents" xlink:title="IncreaseDecreaseInCashAndCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="CashFlowsFromUsedInInvestingActivities" xlink:title="CashFlowsFromUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAdvancesForRentDeposit" xlink:label="CashAdvancesForRentDeposit" xlink:title="CashAdvancesForRentDeposit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="CashAdvancesForRentDeposit" xlink:title="calculation: CashFlowsFromUsedInInvestingActivities to CashAdvancesForRentDeposit" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="calculation: CashFlowsFromUsedInInvestingActivities to PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="calculation: CashFlowsFromUsedInInvestingActivities to ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:title="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:title="calculation: CashFlowsFromUsedInInvestingActivities to PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="CashFlowsFromUsedInInvestingActivities" xlink:title="calculation: IncreaseDecreaseInCashAndCashEquivalents to CashFlowsFromUsedInInvestingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="CashFlowsFromUsedInFinancingActivities" xlink:title="CashFlowsFromUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:title="ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfConvertibleDebt" xlink:label="ProceedsFromIssueOfConvertibleDebt" xlink:title="ProceedsFromIssueOfConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ProceedsFromIssueOfConvertibleDebt" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to ProceedsFromIssueOfConvertibleDebt" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PaymentsForShareIssueCostsOnPublicOffering" xlink:label="PaymentsForShareIssueCostsOnPublicOffering" xlink:title="PaymentsForShareIssueCostsOnPublicOffering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="PaymentsForShareIssueCostsOnPublicOffering" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to PaymentsForShareIssueCostsOnPublicOffering" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:label="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="ProceedsFromIssuingSharesNetOfUnderwritingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to ProceedsFromIssuingSharesNetOfUnderwritingFees" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="PaymentsForShareIssueCosts" xlink:title="PaymentsForShareIssueCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="PaymentsForShareIssueCosts" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to PaymentsForShareIssueCosts" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:title="ProceedsFromSaleOrIssueOfTreasuryShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to ProceedsFromSaleOrIssueOfTreasuryShares" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="PaymentsToAcquireOrRedeemEntitysShares" xlink:title="PaymentsToAcquireOrRedeemEntitysShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="PaymentsToAcquireOrRedeemEntitysShares" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to PaymentsToAcquireOrRedeemEntitysShares" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ProceedsFromExerciseOfOptions" xlink:title="ProceedsFromExerciseOfOptions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ProceedsFromExerciseOfOptions" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to ProceedsFromExerciseOfOptions" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:title="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="RepaymentsOfCurrentBorrowings" xlink:title="RepaymentsOfCurrentBorrowings" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="RepaymentsOfCurrentBorrowings" xlink:title="calculation: CashFlowsFromUsedInFinancingActivities to RepaymentsOfCurrentBorrowings" order="8.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="CashFlowsFromUsedInFinancingActivities" xlink:title="calculation: IncreaseDecreaseInCashAndCashEquivalents to CashFlowsFromUsedInFinancingActivities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="CashFlowsFromUsedInOperatingActivities" xlink:title="CashFlowsFromUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="InterestPaidClassifiedAsOperatingActivities" xlink:title="InterestPaidClassifiedAsOperatingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="InterestPaidClassifiedAsOperatingActivities" xlink:title="calculation: CashFlowsFromUsedInOperatingActivities to InterestPaidClassifiedAsOperatingActivities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="CashFlowsFromUsedInOperations" xlink:title="CashFlowsFromUsedInOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="AdjustmentsForFinanceIncomeCost" xlink:title="AdjustmentsForFinanceIncomeCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForFinanceIncomeCost" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForFinanceIncomeCost" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="AdjustmentsForInterestExpense" xlink:title="AdjustmentsForInterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForInterestExpense" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForInterestExpense" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="AdjustmentsForDepreciationExpense" xlink:title="AdjustmentsForDepreciationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForDepreciationExpense" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForDepreciationExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:title="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="16.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:label="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:title="AdjustmentsForIncreaseDecreaseInAccruedExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForIncreaseDecreaseInAccruedExpenses" order="13.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="AdjustmentsForFairValueGainsLosses" xlink:title="AdjustmentsForFairValueGainsLosses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForFairValueGainsLosses" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForFairValueGainsLosses" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:title="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:label="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:title="AdjustmentsForDepreciationExpenseRightOfUseAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForDepreciationExpenseRightOfUseAssets" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:label="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:title="AdjustmentsForDecreaseIncreaseInAccruedIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForDecreaseIncreaseInAccruedIncome" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="AdjustmentsForSharebasedPayments" xlink:title="AdjustmentsForSharebasedPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForSharebasedPayments" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForSharebasedPayments" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:title="AdjustmentsForIncreaseDecreaseInDeferredIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForIncreaseDecreaseInDeferredIncome" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:label="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:title="AdjustmentsForDecreaseIncreaseInPrepaidExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForDecreaseIncreaseInPrepaidExpense" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:title="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:title="calculation: CashFlowsFromUsedInOperations to AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" order="15.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperations" xlink:to="ProfitLoss" xlink:title="calculation: CashFlowsFromUsedInOperations to ProfitLoss" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="CashFlowsFromUsedInOperations" xlink:title="calculation: CashFlowsFromUsedInOperatingActivities to CashFlowsFromUsedInOperations" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:title="FinanceIncomeReceivedClassifiedAsOperatingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:title="calculation: CashFlowsFromUsedInOperatingActivities to FinanceIncomeReceivedClassifiedAsOperatingActivities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:title="FinanceCostsPaidClassifiedAsOperatingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:title="calculation: CashFlowsFromUsedInOperatingActivities to FinanceCostsPaidClassifiedAsOperatingActivities" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="CashFlowsFromUsedInOperatingActivities" xlink:title="calculation: IncreaseDecreaseInCashAndCashEquivalents to CashFlowsFromUsedInOperatingActivities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpenseRelatingToLeases" xlink:label="ExpenseRelatingToLeases" xlink:title="ExpenseRelatingToLeases" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:title="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRelatingToLeases" xlink:to="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:title="calculation: ExpenseRelatingToLeases to ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="DepreciationRightofuseAssets" xlink:title="DepreciationRightofuseAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRelatingToLeases" xlink:to="DepreciationRightofuseAssets" xlink:title="calculation: ExpenseRelatingToLeases to DepreciationRightofuseAssets" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="InterestExpenseOnLeaseLiabilities" xlink:title="InterestExpenseOnLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseRelatingToLeases" xlink:to="InterestExpenseOnLeaseLiabilities" xlink:title="calculation: ExpenseRelatingToLeases to InterestExpenseOnLeaseLiabilities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome" xlink:label="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="CurrentPrepaymentsAndCurrentAccruedIncome" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:to="CurrentPrepayments" xlink:title="calculation: CurrentPrepaymentsAndCurrentAccruedIncome to CurrentPrepayments" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:to="CurrentContractAssets" xlink:title="calculation: CurrentPrepaymentsAndCurrentAccruedIncome to CurrentContractAssets" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivablesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="calculation: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to CurrentReceivablesFromTaxesOtherThanIncomeTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="CurrentValueAddedTaxReceivables" xlink:title="CurrentValueAddedTaxReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="CurrentValueAddedTaxReceivables" xlink:title="calculation: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to CurrentValueAddedTaxReceivables" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="CurrentAccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentAccruedResearchAndDevelopmentCosts" xlink:label="CurrentAccruedResearchAndDevelopmentCosts" xlink:title="CurrentAccruedResearchAndDevelopmentCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="CurrentAccruedResearchAndDevelopmentCosts" xlink:title="calculation: CurrentAccruedExpensesAndOtherCurrentLiabilities to CurrentAccruedResearchAndDevelopmentCosts" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="CurrentProvisionsForEmployeeBenefits" xlink:title="CurrentProvisionsForEmployeeBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="CurrentProvisionsForEmployeeBenefits" xlink:title="calculation: CurrentAccruedExpensesAndOtherCurrentLiabilities to CurrentProvisionsForEmployeeBenefits" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="OtherCurrentLiabilities" xlink:title="OtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="OtherCurrentLiabilities" xlink:title="calculation: CurrentAccruedExpensesAndOtherCurrentLiabilities to OtherCurrentLiabilities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategoryDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="FinanceIncome" xlink:title="calculation: FinanceIncomeCost to FinanceIncome" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="calculation: FinanceIncomeCost to GainLossArisingFromChangeInFairValueOfConvertibleInstrument" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="InterestExpense" xlink:title="calculation: FinanceIncomeCost to InterestExpense" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="calculation: FinanceIncomeCost to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceIncomeCost" xlink:to="FinanceCosts" xlink:title="calculation: FinanceIncomeCost to FinanceCosts" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:label="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:label="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="ResearchAndDevelopmentExpenseAllocationOperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentExpenseAllocationOperatingExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:label="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="calculation: SellingGeneralAndAdministrativeExpense to GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="calculation: SellingGeneralAndAdministrativeExpense to GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:label="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="GeneralAndAdministrativeExpenseAllocationOperatingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="calculation: SellingGeneralAndAdministrativeExpense to GeneralAndAdministrativeExpenseAllocationOperatingExpense" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="KeyManagementPersonnelCompensation" xlink:title="KeyManagementPersonnelCompensation" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:title="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:title="calculation: KeyManagementPersonnelCompensation to KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:title="KeyManagementPersonnelCompensationPostemploymentBenefits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:title="calculation: KeyManagementPersonnelCompensation to KeyManagementPersonnelCompensationPostemploymentBenefits" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="KeyManagementPersonnelCompensationSharebasedPayment" xlink:title="KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="KeyManagementPersonnelCompensation" xlink:to="KeyManagementPersonnelCompensationSharebasedPayment" xlink:title="calculation: KeyManagementPersonnelCompensation to KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="IncomeTaxExpenseContinuingOperations" xlink:title="IncomeTaxExpenseContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="TaxEffectOfTaxLosses" xlink:title="TaxEffectOfTaxLosses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="TaxEffectOfTaxLosses" xlink:title="calculation: IncomeTaxExpenseContinuingOperations to TaxEffectOfTaxLosses" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:title="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:title="calculation: IncomeTaxExpenseContinuingOperations to TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="TaxExpenseIncomeAtApplicableTaxRate" xlink:title="TaxExpenseIncomeAtApplicableTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="TaxExpenseIncomeAtApplicableTaxRate" xlink:title="calculation: IncomeTaxExpenseContinuingOperations to TaxExpenseIncomeAtApplicableTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:label="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:title="TaxEffectOfRevenuesExemptFromTaxation2011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:title="calculation: IncomeTaxExpenseContinuingOperations to TaxEffectOfRevenuesExemptFromTaxation2011" order="4.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:label="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="calculation: IncreaseDecreaseInNetDefinedBenefitLiabilityAsset to CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="calculation: IncreaseDecreaseInNetDefinedBenefitLiabilityAsset to InterestIncomeNetDefinedBenefitLiabilityAsset" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="calculation: IncreaseDecreaseInNetDefinedBenefitLiabilityAsset to InterestCostNetDefinedBenefitLiabilityAsset" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="SurplusDeficitInPlan" xlink:title="SurplusDeficitInPlan" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="DefinedBenefitObligationAtPresentValue" xlink:title="DefinedBenefitObligationAtPresentValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SurplusDeficitInPlan" xlink:to="DefinedBenefitObligationAtPresentValue" xlink:title="calculation: SurplusDeficitInPlan to DefinedBenefitObligationAtPresentValue" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SurplusDeficitInPlan" xlink:to="PlanAssetsAtFairValue" xlink:title="calculation: SurplusDeficitInPlan to PlanAssetsAtFairValue" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:label="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:title="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:title="calculation: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:label="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:title="DilutiveEffectOfShareOptionsIssuedAndOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:title="calculation: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to DilutiveEffectOfShareOptionsIssuedAndOutstanding" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="calculation: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" order="2.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>aciu-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://acimume.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagementDetails" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShareDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationNonvestedShareAwardsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationWeightedAverageExercisePricesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationPlansOutstandingDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangeInOtherComprehensiveLossDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangesInDefinedBenefitObligationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanDetails" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactionsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactionsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategoryDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategoryDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesGrantsFromMichaelJFoxFoundationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesRecognizedRevenuesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancingObligationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancingObligationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalShelfRegistrationStatementDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalDetails" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivablesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivablesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncomeDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/BasisOfPreparationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#BasisOfPreparationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/GeneralInformationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#GeneralInformationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagementTables" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShareTables" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationTables" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanTables" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactionsTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactionsTables" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategoryTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategoryTables" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTables" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalTables" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivablesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivablesTables" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncomeTables" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsTables" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilitiesTables" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipmentTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipmentTables" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://acimume.com/role/SubsequentEvents" xlink:type="simple" xlink:href="aciu-20201231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://acimume.com/role/CapitalRiskManagement" xlink:type="simple" xlink:href="aciu-20201231.xsd#CapitalRiskManagement" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagement" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagement" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShare" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShare" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensation" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlan" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlan" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxes" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactions" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactions" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategory" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategory" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenues" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenues" />
  <link:roleRef roleURI="http://acimume.com/role/FinancingObligation" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancingObligation" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilities" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilities" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapital" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapital" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivables" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivables" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncome" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncome" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssets" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilities" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipment" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipment" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://acimume.com/role/BasisOfPreparation" xlink:type="simple" xlink:href="aciu-20201231.xsd#BasisOfPreparation" />
  <link:roleRef roleURI="http://acimume.com/role/GeneralInformation" xlink:type="simple" xlink:href="aciu-20201231.xsd#GeneralInformation" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfChangesInEquity" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfChangesInEquity" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/BalanceSheets" xlink:type="simple" xlink:href="aciu-20201231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://acimume.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="aciu-20201231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/BalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfIncomeLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfChangesInEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="StatementOfChangesInEquityLineItems" xlink:title="StatementOfChangesInEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="Equity" xlink:title="definition: StatementOfChangesInEquityLineItems to Equity" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ProfitLoss" xlink:title="definition: StatementOfChangesInEquityLineItems to ProfitLoss" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="OtherComprehensiveIncome" xlink:title="OtherComprehensiveIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="OtherComprehensiveIncome" xlink:title="definition: StatementOfChangesInEquityLineItems to OtherComprehensiveIncome" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ComprehensiveIncome" xlink:title="definition: StatementOfChangesInEquityLineItems to ComprehensiveIncome" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:label="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="ProceedsFromIssuingSharesNetOfUnderwritingFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="definition: StatementOfChangesInEquityLineItems to ProceedsFromIssuingSharesNetOfUnderwritingFees" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ShareIssueRelatedCost" xlink:title="definition: StatementOfChangesInEquityLineItems to ShareIssueRelatedCost" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:title="IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:title="definition: StatementOfChangesInEquityLineItems to IncreaseDecreaseThroughSharebasedPaymentTransactions" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAbstract" xlink:label="NumberOfSharesIssuedAbstract" xlink:title="NumberOfSharesIssuedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="NumberOfSharesIssuedAbstract" xlink:title="definition: StatementOfChangesInEquityLineItems to NumberOfSharesIssuedAbstract" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="definition: StatementOfChangesInEquityLineItems to IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="definition: StatementOfChangesInEquityLineItems to IncreaseDecreaseThroughTreasuryShareTransactions" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssueOfEquityRestrictedShareAwards" xlink:label="IssueOfEquityRestrictedShareAwards" xlink:title="IssueOfEquityRestrictedShareAwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IssueOfEquityRestrictedShareAwards" xlink:title="definition: StatementOfChangesInEquityLineItems to IssueOfEquityRestrictedShareAwards" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="IncreaseDecreaseThroughExerciseOfOptions" xlink:title="IncreaseDecreaseThroughExerciseOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughExerciseOfOptions" xlink:title="definition: StatementOfChangesInEquityLineItems to IncreaseDecreaseThroughExerciseOfOptions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="StatementOfChangesInEquityTable" xlink:title="StatementOfChangesInEquityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="StatementOfChangesInEquityTable" xlink:title="definition: StatementOfChangesInEquityLineItems to StatementOfChangesInEquityTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementOfChangesInEquityTable" xlink:to="ComponentsOfEquityAxis" xlink:title="definition: StatementOfChangesInEquityTable to ComponentsOfEquityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember_2" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember_2" xlink:title="definition: ComponentsOfEquityAxis to EquityMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="IssuedCapitalMember" xlink:title="IssuedCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="IssuedCapitalMember" xlink:title="definition: EquityMember to IssuedCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="SharePremiumMember" xlink:title="SharePremiumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="SharePremiumMember" xlink:title="definition: EquityMember to SharePremiumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:label="TreasurySharesMember" xlink:title="TreasurySharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="TreasurySharesMember" xlink:title="definition: EquityMember to TreasurySharesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityMember to RetainedEarningsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsLineItems" xlink:label="StatementOfCashFlowsLineItems" xlink:title="StatementOfCashFlowsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SupplementaryNonCashActivityAbstract" xlink:label="SupplementaryNonCashActivityAbstract" xlink:title="SupplementaryNonCashActivityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfCashFlowsLineItems" xlink:to="SupplementaryNonCashActivityAbstract" xlink:title="definition: StatementOfCashFlowsLineItems to SupplementaryNonCashActivityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfCashFlowsLineItems" xlink:to="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:title="definition: StatementOfCashFlowsLineItems to PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:label="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:title="RepaymentOfConvertibleDebtEquitySettlementAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfCashFlowsLineItems" xlink:to="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:title="definition: StatementOfCashFlowsLineItems to RepaymentOfConvertibleDebtEquitySettlementAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementOfCashFlowsLineItems" xlink:to="ShareIssueRelatedCost" xlink:title="definition: StatementOfCashFlowsLineItems to ShareIssueRelatedCost" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsTable" xlink:label="StatementOfCashFlowsTable" xlink:title="StatementOfCashFlowsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementOfCashFlowsLineItems" xlink:to="StatementOfCashFlowsTable" xlink:title="definition: StatementOfCashFlowsLineItems to StatementOfCashFlowsTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementOfCashFlowsTable" xlink:to="BorrowingsByNameAxis" xlink:title="definition: StatementOfCashFlowsTable to BorrowingsByNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember_2" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember_2" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementMember" xlink:label="ConvertibleNoteAgreementMember" xlink:title="ConvertibleNoteAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BorrowingsByNameMember" xlink:to="ConvertibleNoteAgreementMember" xlink:title="definition: BorrowingsByNameMember to ConvertibleNoteAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/GeneralInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/BasisOfPreparation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncome" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapital" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancingObligation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenues" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategory" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CapitalRiskManagement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivablesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategoryTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactionsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingenciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/GeneralInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/BasisOfPreparationDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfClassesOfGoingConcernLineItems" xlink:label="DisclosureOfClassesOfGoingConcernLineItems" xlink:title="DisclosureOfClassesOfGoingConcernLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GoingConcernAbstract" xlink:label="GoingConcernAbstract" xlink:title="GoingConcernAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="GoingConcernAbstract" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to GoingConcernAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="CashAndCashEquivalents" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to CashAndCashEquivalents" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="CurrentFinancialAssets" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to CurrentFinancialAssets" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="ContractLiabilities" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to ContractLiabilities" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to CollaborativeAgreementMilestonePaymentReceived" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfConvertibleDebt" xlink:label="ProceedsFromIssueOfConvertibleDebt" xlink:title="ProceedsFromIssueOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="ProceedsFromIssueOfConvertibleDebt" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to ProceedsFromIssueOfConvertibleDebt" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPublicOfferings" xlink:label="NumberOfPublicOfferings" xlink:title="NumberOfPublicOfferings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="NumberOfPublicOfferings" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to NumberOfPublicOfferings" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to ProceedsFromIssueOfOrdinaryShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfGoingConcernTable" xlink:label="DisclosureOfGoingConcernTable" xlink:title="DisclosureOfGoingConcernTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="DisclosureOfGoingConcernTable" xlink:title="definition: DisclosureOfClassesOfGoingConcernLineItems to DisclosureOfGoingConcernTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfGoingConcernTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="definition: DisclosureOfGoingConcernTable to ClassesOfShareCapitalAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember_2" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember_2" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InitialPublicOfferingMember" xlink:label="InitialPublicOfferingMember" xlink:title="InitialPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfShareCapitalMember" xlink:to="InitialPublicOfferingMember" xlink:title="definition: ClassesOfShareCapitalMember to InitialPublicOfferingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfGoingConcernTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfGoingConcernTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EstimatedLeaseTerm" xlink:label="EstimatedLeaseTerm" xlink:title="EstimatedLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="EstimatedLeaseTerm" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to EstimatedLeaseTerm" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember_2" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember_2" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="BuildingsMember" xlink:title="BuildingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="BuildingsMember" xlink:title="definition: PropertyPlantAndEquipmentMember to BuildingsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:title="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:title="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to DisclosureOfPropertyPlantAndEquipmentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentTable to ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember_2" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember_2" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to LaboratoryEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:label="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:title="LeaseholdImprovementsAndFixturesAndFittingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:title="definition: PropertyPlantAndEquipmentMember to LeaseholdImprovementsAndFixturesAndFittingsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:title="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment" xlink:title="PropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipment" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:title="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="DepreciationPropertyPlantAndEquipment" xlink:title="DepreciationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="DepreciationPropertyPlantAndEquipment" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to DepreciationPropertyPlantAndEquipment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="DisposalsPropertyPlantAndEquipment" xlink:title="DisposalsPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="DisposalsPropertyPlantAndEquipment" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to DisposalsPropertyPlantAndEquipment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentLineItems to DisclosureOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentTable to ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember_2" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember_2" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="FixturesAndFittingsMember" xlink:title="FixturesAndFittingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="FixturesAndFittingsMember" xlink:title="definition: PropertyPlantAndEquipmentMember to FixturesAndFittingsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to LaboratoryEquipmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentMember to LeaseholdImprovementsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="definition: DisclosureOfPropertyPlantAndEquipmentTable to CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember_2" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember_2" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="GrossCarryingAmountMember" xlink:title="GrossCarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CarryingAmountMember" xlink:to="GrossCarryingAmountMember" xlink:title="definition: CarryingAmountMember to GrossCarryingAmountMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="AccumulatedDepreciationAndAmortisationMember" xlink:title="AccumulatedDepreciationAndAmortisationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CarryingAmountMember" xlink:to="AccumulatedDepreciationAndAmortisationMember" xlink:title="definition: CarryingAmountMember to AccumulatedDepreciationAndAmortisationMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:label="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:title="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:title="definition: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems to ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UndiscountedOperatingLeasePaymentsDue" xlink:label="UndiscountedOperatingLeasePaymentsDue" xlink:title="UndiscountedOperatingLeasePaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="UndiscountedOperatingLeasePaymentsDue" xlink:title="definition: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems to UndiscountedOperatingLeasePaymentsDue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:title="definition: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems to DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="MaturityAxis" xlink:title="definition: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable to MaturityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember_2" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember_2" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="definition: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanTwoYearsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:title="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLeasedAssetsAbstract" xlink:label="RightOfUseLeasedAssetsAbstract" xlink:title="RightOfUseLeasedAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="RightOfUseLeasedAssetsAbstract" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to RightOfUseLeasedAssetsAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets" xlink:title="RightofuseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="RightofuseAssets" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to RightofuseAssets" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="AdditionsToRightofuseAssets" xlink:title="AdditionsToRightofuseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="AdditionsToRightofuseAssets" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to AdditionsToRightofuseAssets" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisposalOfRightOfUseAssets" xlink:label="DisposalOfRightOfUseAssets" xlink:title="DisposalOfRightOfUseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisposalOfRightOfUseAssets" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisposalOfRightOfUseAssets" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="DepreciationRightofuseAssets" xlink:title="DepreciationRightofuseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DepreciationRightofuseAssets" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DepreciationRightofuseAssets" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ClassesOfAssetsAxis" xlink:title="definition: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to ClassesOfAssetsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember_2" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember_2" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfAssetsMember" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfAssetsMember to PropertyPlantAndEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="BuildingsMember" xlink:title="BuildingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="BuildingsMember" xlink:title="definition: PropertyPlantAndEquipmentMember to BuildingsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentLineItems" xlink:label="CashAndCashEquivalentLineItems" xlink:title="CashAndCashEquivalentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAbstract" xlink:label="CashAbstract" xlink:title="CashAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentLineItems" xlink:to="CashAbstract" xlink:title="definition: CashAndCashEquivalentLineItems to CashAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentLineItems" xlink:to="CashAndCashEquivalents" xlink:title="definition: CashAndCashEquivalentLineItems to CashAndCashEquivalents" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ClosingForeignExchangeRate" xlink:title="ClosingForeignExchangeRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentLineItems" xlink:to="ClosingForeignExchangeRate" xlink:title="definition: CashAndCashEquivalentLineItems to ClosingForeignExchangeRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentsTable" xlink:label="CashAndCashEquivalentsTable" xlink:title="CashAndCashEquivalentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CashAndCashEquivalentLineItems" xlink:to="CashAndCashEquivalentsTable" xlink:title="definition: CashAndCashEquivalentLineItems to CashAndCashEquivalentsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="CashAndCashEquivalentsTable" xlink:to="CurrencyAxis" xlink:title="definition: CashAndCashEquivalentsTable to CurrencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain_2" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain_2" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF" xlink:label="CHF" xlink:title="CHF" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllCurrenciesDomain" xlink:to="CHF" xlink:title="definition: AllCurrenciesDomain to CHF" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="EUR" xlink:title="EUR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllCurrenciesDomain" xlink:to="EUR" xlink:title="definition: AllCurrenciesDomain to EUR" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="USD" xlink:title="USD" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllCurrenciesDomain" xlink:to="USD" xlink:title="definition: AllCurrenciesDomain to USD" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeLineItems" xlink:label="PrepaidExpensesAndAccruedIncomeLineItems" xlink:title="PrepaidExpensesAndAccruedIncomeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentPrepayments" xlink:title="definition: PrepaidExpensesAndAccruedIncomeLineItems to CurrentPrepayments" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentContractAssets" xlink:title="definition: PrepaidExpensesAndAccruedIncomeLineItems to CurrentContractAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome" xlink:label="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="CurrentPrepaymentsAndCurrentAccruedIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="definition: PrepaidExpensesAndAccruedIncomeLineItems to CurrentPrepaymentsAndCurrentAccruedIncome" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAccruedIncome" xlink:label="PercentageOfAccruedIncome" xlink:title="PercentageOfAccruedIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="PercentageOfAccruedIncome" xlink:title="definition: PrepaidExpensesAndAccruedIncomeLineItems to PercentageOfAccruedIncome" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeTable" xlink:label="PrepaidExpensesAndAccruedIncomeTable" xlink:title="PrepaidExpensesAndAccruedIncomeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="PrepaidExpensesAndAccruedIncomeTable" xlink:title="definition: PrepaidExpensesAndAccruedIncomeLineItems to PrepaidExpensesAndAccruedIncomeTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="PrepaidExpensesAndAccruedIncomeTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: PrepaidExpensesAndAccruedIncomeTable to TypesOfContractsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivablesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesLineItems" xlink:label="DisclosureOfOtherCurrentReceivablesLineItems" xlink:title="DisclosureOfOtherCurrentReceivablesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="TradeAndOtherReceivablesAbstract" xlink:title="TradeAndOtherReceivablesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="TradeAndOtherReceivablesAbstract" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to TradeAndOtherReceivablesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:label="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:title="PeriodOfMaturityReceivablesFairValueCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to PeriodOfMaturityReceivablesFairValueCarryingAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="CurrentValueAddedTaxReceivables" xlink:title="CurrentValueAddedTaxReceivables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="CurrentValueAddedTaxReceivables" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to CurrentValueAddedTaxReceivables" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to CurrentReceivablesFromTaxesOtherThanIncomeTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesTable" xlink:label="DisclosureOfOtherCurrentReceivablesTable" xlink:title="DisclosureOfOtherCurrentReceivablesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="DisclosureOfOtherCurrentReceivablesTable" xlink:title="definition: DisclosureOfOtherCurrentReceivablesLineItems to DisclosureOfOtherCurrentReceivablesTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfOtherCurrentReceivablesTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfOtherCurrentReceivablesTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" xlink:title="DisclosureOfClassesOfShareCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="DisclosureOfClassesOfShareCapitalAbstract" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to DisclosureOfClassesOfShareCapitalAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="Equity" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to Equity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfSharesOutstandingIncludingTreasuryShares" xlink:label="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:title="NumberOfSharesOutstandingIncludingTreasuryShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfSharesOutstandingIncludingTreasuryShares" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:label="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:title="IncreaseThroughSharesIssuedUnderIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseThroughSharesIssuedUnderIncentivePlans" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseDecreaseThroughTreasuryShareTransactions" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="NumberOfSharesOutstanding" xlink:title="NumberOfSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfSharesOutstanding" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfSharesOutstanding" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ParValuePerShare" xlink:title="ParValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ParValuePerShare" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ParValuePerShare" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="NumberOfSharesAuthorised" xlink:title="NumberOfSharesAuthorised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfSharesAuthorised" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfSharesAuthorised" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to DisclosureOfClassesOfShareCapitalTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ComponentsOfEquityAxis" xlink:title="definition: DisclosureOfClassesOfShareCapitalTable to ComponentsOfEquityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember_2" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember_2" xlink:title="definition: ComponentsOfEquityAxis to EquityMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="IssuedCapitalMember" xlink:title="IssuedCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="IssuedCapitalMember" xlink:title="definition: EquityMember to IssuedCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="SharePremiumMember" xlink:title="SharePremiumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="SharePremiumMember" xlink:title="definition: EquityMember to SharePremiumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:label="TreasurySharesMember" xlink:title="TreasurySharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMember" xlink:to="TreasurySharesMember" xlink:title="definition: EquityMember to TreasurySharesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="definition: DisclosureOfClassesOfShareCapitalTable to ClassesOfShareCapitalAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember_2" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember_2" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="OrdinarySharesMember" xlink:title="OrdinarySharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfShareCapitalMember" xlink:to="OrdinarySharesMember" xlink:title="definition: ClassesOfShareCapitalMember to OrdinarySharesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:label="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:title="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:label="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:title="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="NumberOfSharesIssued" xlink:title="NumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfSharesIssued" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleBorrowings" xlink:label="ConvertibleBorrowings" xlink:title="ConvertibleBorrowings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ConvertibleBorrowings" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ConvertibleBorrowings" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:title="IncreaseDecreaseInNumberOfOrdinarySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareIssuedPricePerShare" xlink:label="ShareIssuedPricePerShare" xlink:title="ShareIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ShareIssuedPricePerShare" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ShareIssuedPricePerShare" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ProceedsFromIssueOfOrdinaryShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOfferings" xlink:label="NumberOfOfferings" xlink:title="NumberOfOfferings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfOfferings" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfOfferings" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ShareIssueRelatedCost" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ShareIssueRelatedCost" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:label="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to DisclosureOfClassesOfShareCapitalTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="definition: DisclosureOfClassesOfShareCapitalTable to ClassesOfShareCapitalAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember_2" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember_2" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AtTheMarketEquityOfferingMember" xlink:label="AtTheMarketEquityOfferingMember" xlink:title="AtTheMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfShareCapitalMember" xlink:to="AtTheMarketEquityOfferingMember" xlink:title="definition: ClassesOfShareCapitalMember to AtTheMarketEquityOfferingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FollowOnOfferingsMember" xlink:label="FollowOnOfferingsMember" xlink:title="FollowOnOfferingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfShareCapitalMember" xlink:to="FollowOnOfferingsMember" xlink:title="definition: ClassesOfShareCapitalMember to FollowOnOfferingsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OptionForOverAllotmentMember" xlink:label="OptionForOverAllotmentMember" xlink:title="OptionForOverAllotmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FollowOnOfferingsMember" xlink:to="OptionForOverAllotmentMember" xlink:title="definition: FollowOnOfferingsMember to OptionForOverAllotmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FirstSubscriptionRightsMember" xlink:label="FirstSubscriptionRightsMember" xlink:title="FirstSubscriptionRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FollowOnOfferingsMember" xlink:to="FirstSubscriptionRightsMember" xlink:title="definition: FollowOnOfferingsMember to FirstSubscriptionRightsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SecondSubscriptionRightsMember" xlink:label="SecondSubscriptionRightsMember" xlink:title="SecondSubscriptionRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FollowOnOfferingsMember" xlink:to="SecondSubscriptionRightsMember" xlink:title="definition: FollowOnOfferingsMember to SecondSubscriptionRightsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfClassesOfShareCapitalTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementAbstract" xlink:label="ShelfRegistrationStatementAbstract" xlink:title="ShelfRegistrationStatementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ShelfRegistrationStatementAbstract" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ShelfRegistrationStatementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementSharesAuthorized" xlink:label="ShelfRegistrationStatementSharesAuthorized" xlink:title="ShelfRegistrationStatementSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ShelfRegistrationStatementSharesAuthorized" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ShelfRegistrationStatementSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to ProceedsFromIssueOfOrdinaryShares" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:label="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:title="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:label="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:title="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="definition: DisclosureOfClassesOfShareCapitalLineItems to DisclosureOfClassesOfShareCapitalTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfClassesOfShareCapitalTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancingObligationDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationLineItems" xlink:label="LongTermFinancingObligationLineItems" xlink:title="LongTermFinancingObligationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" xlink:title="BorrowingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermFinancingObligationLineItems" xlink:to="BorrowingsAbstract" xlink:title="definition: LongTermFinancingObligationLineItems to BorrowingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FundingCommitment" xlink:label="FundingCommitment" xlink:title="FundingCommitment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermFinancingObligationLineItems" xlink:to="FundingCommitment" xlink:title="definition: LongTermFinancingObligationLineItems to FundingCommitment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ReimbursementPercentageOfFundingCommitment" xlink:label="ReimbursementPercentageOfFundingCommitment" xlink:title="ReimbursementPercentageOfFundingCommitment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermFinancingObligationLineItems" xlink:to="ReimbursementPercentageOfFundingCommitment" xlink:title="definition: LongTermFinancingObligationLineItems to ReimbursementPercentageOfFundingCommitment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermFinancingObligationLineItems" xlink:to="DebtInstrumentNumberOfInstallments" xlink:title="definition: LongTermFinancingObligationLineItems to DebtInstrumentNumberOfInstallments" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAdditionalInterestOnTotalRepayment" xlink:label="PercentageOfAdditionalInterestOnTotalRepayment" xlink:title="PercentageOfAdditionalInterestOnTotalRepayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermFinancingObligationLineItems" xlink:to="PercentageOfAdditionalInterestOnTotalRepayment" xlink:title="definition: LongTermFinancingObligationLineItems to PercentageOfAdditionalInterestOnTotalRepayment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationTable" xlink:label="LongTermFinancingObligationTable" xlink:title="LongTermFinancingObligationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LongTermFinancingObligationLineItems" xlink:to="LongTermFinancingObligationTable" xlink:title="definition: LongTermFinancingObligationLineItems to LongTermFinancingObligationTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermFinancingObligationTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: LongTermFinancingObligationTable to TypesOfContractsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsLuMindResearchDownSyndromeFoundationMember" xlink:label="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:title="GrantsLuMindResearchDownSyndromeFoundationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:title="definition: TypesOfContractsMember to GrantsLuMindResearchDownSyndromeFoundationMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractRevenueAbstract" xlink:label="ContractRevenueAbstract" xlink:title="ContractRevenueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractRevenueAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractRevenueAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RevenueReclassifiedToOtherIncomeExpense" xlink:label="RevenueReclassifiedToOtherIncomeExpense" xlink:title="RevenueReclassifiedToOtherIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueReclassifiedToOtherIncomeExpense" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueReclassifiedToOtherIncomeExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="PercentageOfEntitysRevenue" xlink:title="PercentageOfEntitysRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="PercentageOfEntitysRevenue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to PercentageOfEntitysRevenue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2012GenentechMember" xlink:label="CollaborationAgreementOf2012GenentechMember" xlink:title="CollaborationAgreementOf2012GenentechMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2012GenentechMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2012GenentechMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:label="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2016BiogenMember" xlink:label="CollaborationAgreementOf2016BiogenMember" xlink:title="CollaborationAgreementOf2016BiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2016BiogenMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2016BiogenMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherAgreementMember" xlink:label="OtherAgreementMember" xlink:title="OtherAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="OtherAgreementMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to OtherAgreementMember" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:label="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:title="CollaborativeAgreementMilestonePaymentNumberOfInstallments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentNumberOfInstallments" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ReceivablesFromContractsWithCustomers" xlink:title="ReceivablesFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ReceivablesFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ReceivablesFromContractsWithCustomers" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractLiabilities" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractLiabilities" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to TransactionPriceAllocatedToRemainingPerformanceObligations" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:label="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:title="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to NumberOfRepresentativesInJointSteeringCommitteeByEachParty" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ContractAssets" xlink:title="ContractAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractAssets" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractAssets" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CurrentContractLiabilities" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CurrentContractLiabilities" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauMorphomerSmallMoleculeMember" xlink:label="TauMorphomerSmallMoleculeMember" xlink:title="TauMorphomerSmallMoleculeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="TauMorphomerSmallMoleculeMember" xlink:title="definition: ProductsAndServicesMember to TauMorphomerSmallMoleculeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyFirstAmendmentMember" xlink:label="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:title="CollaborationAgreementWithLillyFirstAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:title="definition: CollaborationAgreementWithLillyMember to CollaborationAgreementWithLillyFirstAmendmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillySecondAmendmentMember" xlink:label="CollaborationAgreementWithLillySecondAmendmentMember" xlink:title="CollaborationAgreementWithLillySecondAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="CollaborationAgreementWithLillySecondAmendmentMember" xlink:title="definition: CollaborationAgreementWithLillyMember to CollaborationAgreementWithLillySecondAmendmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="PerformanceObligationsAxis" xlink:title="PerformanceObligationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="PerformanceObligationsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to PerformanceObligationsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="PerformanceObligationsMember" xlink:title="PerformanceObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PerformanceObligationsAxis" xlink:to="PerformanceObligationsMember" xlink:title="definition: PerformanceObligationsAxis to PerformanceObligationsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="PerformanceObligationsMember_2" xlink:title="PerformanceObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PerformanceObligationsAxis" xlink:to="PerformanceObligationsMember_2" xlink:title="definition: PerformanceObligationsAxis to PerformanceObligationsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:label="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:title="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PerformanceObligationsMember" xlink:to="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:title="definition: PerformanceObligationsMember to MilestonePaymentsClinicalAndRegulatoryMilestonesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsCommercialMember" xlink:label="MilestonePaymentsCommercialMember" xlink:title="MilestonePaymentsCommercialMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PerformanceObligationsMember" xlink:to="MilestonePaymentsCommercialMember" xlink:title="definition: PerformanceObligationsMember to MilestonePaymentsCommercialMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentMember" xlink:label="ResearchAndDevelopmentMember" xlink:title="ResearchAndDevelopmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PerformanceObligationsMember" xlink:to="ResearchAndDevelopmentMember" xlink:title="definition: PerformanceObligationsMember to ResearchAndDevelopmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLicenseMember" xlink:label="RightOfUseLicenseMember" xlink:title="RightOfUseLicenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PerformanceObligationsMember" xlink:to="RightOfUseLicenseMember" xlink:title="definition: PerformanceObligationsMember to RightOfUseLicenseMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PhaseTwoClinicalStudyLicensedProductMember" xlink:label="PhaseTwoClinicalStudyLicensedProductMember" xlink:title="PhaseTwoClinicalStudyLicensedProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PerformanceObligationsMember" xlink:to="PhaseTwoClinicalStudyLicensedProductMember" xlink:title="definition: PerformanceObligationsMember to PhaseTwoClinicalStudyLicensedProductMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCumulativePaymentsReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentRecognized" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentReceived" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractLiabilities" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractLiabilities" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfMilestonePaymentsReceived" xlink:label="NumberOfMilestonePaymentsReceived" xlink:title="NumberOfMilestonePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="NumberOfMilestonePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to NumberOfMilestonePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to TransactionPriceAllocatedToRemainingPerformanceObligations" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiAbetaAntibodyInADMember" xlink:label="AntiAbetaAntibodyInADMember" xlink:title="AntiAbetaAntibodyInADMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="AntiAbetaAntibodyInADMember" xlink:title="definition: ProductsAndServicesMember to AntiAbetaAntibodyInADMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2006GenentechMember" xlink:label="CollaborationAgreementOf2006GenentechMember" xlink:title="CollaborationAgreementOf2006GenentechMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2006GenentechMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2006GenentechMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCumulativePaymentsReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentRecognized" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentReceived" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractLiabilities" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractLiabilities" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfMilestonePaymentsReceived" xlink:label="NumberOfMilestonePaymentsReceived" xlink:title="NumberOfMilestonePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="NumberOfMilestonePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to NumberOfMilestonePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to TransactionPriceAllocatedToRemainingPerformanceObligations" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiTauAntibodyInADMember" xlink:label="AntiTauAntibodyInADMember" xlink:title="AntiTauAntibodyInADMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="AntiTauAntibodyInADMember" xlink:title="definition: ProductsAndServicesMember to AntiTauAntibodyInADMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2012GenentechMember" xlink:label="CollaborationAgreementOf2012GenentechMember" xlink:title="CollaborationAgreementOf2012GenentechMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2012GenentechMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2012GenentechMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCumulativePaymentsReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentReceived" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractLiabilities" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractLiabilities" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to TransactionPriceAllocatedToRemainingPerformanceObligations" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauVaccineInADMember" xlink:label="TauVaccineInADMember" xlink:title="TauVaccineInADMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="TauVaccineInADMember" xlink:title="definition: ProductsAndServicesMember to TauVaccineInADMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCumulativePaymentsReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementMilestonePaymentRecognized" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauPETImagingAgentInADMember" xlink:label="TauPETImagingAgentInADMember" xlink:title="TauPETImagingAgentInADMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="TauPETImagingAgentInADMember" xlink:title="definition: ProductsAndServicesMember to TauPETImagingAgentInADMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:label="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPerformanceObligationsIdentified" xlink:label="NumberOfPerformanceObligationsIdentified" xlink:title="NumberOfPerformanceObligationsIdentified" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="NumberOfPerformanceObligationsIdentified" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to NumberOfPerformanceObligationsIdentified" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember_2" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember_2" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AlphaSynucleinAndTDP43PETTracerInADMember" xlink:label="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:title="AlphaSynucleinAndTDP43PETTracerInADMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesMember" xlink:to="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:title="definition: ProductsAndServicesMember to AlphaSynucleinAndTDP43PETTracerInADMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="definition: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2016BiogenMember" xlink:label="CollaborationAgreementOf2016BiogenMember" xlink:title="CollaborationAgreementOf2016BiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2016BiogenMember" xlink:title="definition: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2016BiogenMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfGrants" xlink:label="NumberOfGrants" xlink:title="NumberOfGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="NumberOfGrants" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to NumberOfGrants" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementPotentialValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ReceivablesFromContractsWithCustomers" xlink:title="ReceivablesFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ReceivablesFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ReceivablesFromContractsWithCustomers" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementJointResearchCollaborationPeriod" xlink:label="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:title="CollaborativeAgreementJointResearchCollaborationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to CollaborativeAgreementJointResearchCollaborationPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="RevenueFromContractsWithCustomers" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to RevenueFromContractsWithCustomers" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember_2" xlink:title="TypesOfContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember_2" xlink:title="definition: TypesOfContractsAxis to TypesOfContractsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantRevenueMember" xlink:label="GrantRevenueMember" xlink:title="GrantRevenueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfContractsMember" xlink:to="GrantRevenueMember" xlink:title="definition: TypesOfContractsMember to GrantRevenueMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsMichaelJFoxFoundationMember" xlink:label="GrantsMichaelJFoxFoundationMember" xlink:title="GrantsMichaelJFoxFoundationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="GrantRevenueMember" xlink:to="GrantsMichaelJFoxFoundationMember" xlink:title="definition: GrantRevenueMember to GrantsMichaelJFoxFoundationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="CounterpartiesAxis" xlink:title="CounterpartiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="CounterpartiesAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to CounterpartiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="CounterpartiesMember" xlink:title="CounterpartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartiesAxis" xlink:to="CounterpartiesMember" xlink:title="definition: CounterpartiesAxis to CounterpartiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="CounterpartiesMember_2" xlink:title="CounterpartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartiesAxis" xlink:to="CounterpartiesMember_2" xlink:title="definition: CounterpartiesAxis to CounterpartiesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SkaneUniversityHospitalMember" xlink:label="SkaneUniversityHospitalMember" xlink:title="SkaneUniversityHospitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CounterpartiesMember" xlink:to="SkaneUniversityHospitalMember" xlink:title="definition: CounterpartiesMember to SkaneUniversityHospitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategoryDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpensesAbstract" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:title="ResearchAndDevelopmentExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpensesAbstract" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpensesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="SellingGeneralAndAdministrativeExpenseAbstract" xlink:title="SellingGeneralAndAdministrativeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="SellingGeneralAndAdministrativeExpenseAbstract" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to SellingGeneralAndAdministrativeExpenseAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialResultNetAbstract" xlink:label="FinancialResultNetAbstract" xlink:title="FinancialResultNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="FinancialResultNetAbstract" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to FinancialResultNetAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="FinanceIncome" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to FinanceIncome" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="FinanceCosts" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to FinanceCosts" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to GainLossArisingFromChangeInFairValueOfConvertibleInstrument" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="FinanceIncomeCost" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to FinanceIncomeCost" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="InterestExpense" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to InterestExpense" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="InterestExpenseOnDebtInstrumentsIssued" xlink:title="InterestExpenseOnDebtInstrumentsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="InterestExpenseOnDebtInstrumentsIssued" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to InterestExpenseOnDebtInstrumentsIssued" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:label="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="GeneralAndAdministrativeExpenseAllocationOperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to GeneralAndAdministrativeExpenseAllocationOperatingExpense" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:label="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to SellingGeneralAndAdministrativeExpense" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:label="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:title="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:label="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="ResearchAndDevelopmentExpenseAllocationOperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpenseAllocationOperatingExpense" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:label="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpense" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:label="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:title="EmployeeFullTimeEquivalentsInResearchAndDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to EmployeeFullTimeEquivalentsInResearchAndDevelopment" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsLineItems to DisclosureOfDetailedInformationAboutBorrowingsTable" order="21.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="BorrowingsByNameAxis" xlink:title="definition: DisclosureOfDetailedInformationAboutBorrowingsTable to BorrowingsByNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember_2" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember_2" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementMember" xlink:label="ConvertibleNoteAgreementMember" xlink:title="ConvertibleNoteAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BorrowingsByNameMember" xlink:to="ConvertibleNoteAgreementMember" xlink:title="definition: BorrowingsByNameMember to ConvertibleNoteAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactionsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TaxLossesSplitByExpiryDateAbstract" xlink:label="TaxLossesSplitByExpiryDateAbstract" xlink:title="TaxLossesSplitByExpiryDateAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="TaxLossesSplitByExpiryDateAbstract" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to TaxLossesSplitByExpiryDateAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:title="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:title="IncreaseDecreaseInDeferredTaxLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to IncreaseDecreaseInDeferredTaxLiabilityAsset" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="DeferredTaxAssets" xlink:title="DeferredTaxAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="DeferredTaxAssets" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to DeferredTaxAssets" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="DeferredTaxLiabilityAsset" xlink:title="DeferredTaxLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="DeferredTaxLiabilityAsset" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to DeferredTaxLiabilityAsset" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="UnusedTaxLossesMember" xlink:title="UnusedTaxLossesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxLossesMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxLossesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:label="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:title="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRetirementBenefitPlanMember" xlink:label="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:title="UnusedTaxCreditsRetirementBenefitPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxCreditsRetirementBenefitPlanMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="MaturityAxis" xlink:title="definition: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to MaturityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember_2" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember_2" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NotLaterThanPriorYearEndMember" xlink:label="NotLaterThanPriorYearEndMember" xlink:title="NotLaterThanPriorYearEndMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanPriorYearEndMember" xlink:title="definition: AggregatedTimeBandsMember to NotLaterThanPriorYearEndMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="definition: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanTwoYearsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFourYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanThreeYearsAndNotLaterThanFourYearsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanFourYearsAndNotLaterThanFiveYearsMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:title="LaterThanFiveYearsAndNotLaterThanSixYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanFiveYearsAndNotLaterThanSixYearsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanSevenYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanSixYearsAndNotLaterThanSevenYearsMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanEightYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanSixYearsAndNotLaterThanEightYearsMember" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitPlanPercentageOfContribution" xlink:label="DefinedBenefitPlanPercentageOfContribution" xlink:title="DefinedBenefitPlanPercentageOfContribution" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DefinedBenefitPlanPercentageOfContribution" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DefinedBenefitPlanPercentageOfContribution" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlanAbstract" xlink:label="SurplusDeficitInPlanAbstract" xlink:title="SurplusDeficitInPlanAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="SurplusDeficitInPlanAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to SurplusDeficitInPlanAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NetPensionCostInStatementOfIncomeAbstract" xlink:label="NetPensionCostInStatementOfIncomeAbstract" xlink:title="NetPensionCostInStatementOfIncomeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="NetPensionCostInStatementOfIncomeAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to NetPensionCostInStatementOfIncomeAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to InterestCostNetDefinedBenefitLiabilityAsset" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to InterestIncomeNetDefinedBenefitLiabilityAsset" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:label="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="DefinedBenefitObligationAtPresentValue" xlink:title="DefinedBenefitObligationAtPresentValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DefinedBenefitObligationAtPresentValue" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DefinedBenefitObligationAtPresentValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PlanAssetsAtFairValue" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PlanAssetsAtFairValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="SurplusDeficitInPlan" xlink:title="SurplusDeficitInPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="SurplusDeficitInPlan" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to SurplusDeficitInPlan" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployeeMember" xlink:label="DefinedBenefitsPlanEmployeeMember" xlink:title="DefinedBenefitsPlanEmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="DefinedBenefitsPlanEmployeeMember" xlink:title="definition: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to DefinedBenefitsPlanEmployeeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployerMember" xlink:label="DefinedBenefitsPlanEmployerMember" xlink:title="DefinedBenefitsPlanEmployerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="DefinedBenefitsPlanEmployerMember" xlink:title="definition: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to DefinedBenefitsPlanEmployerMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="PresentValueOfDefinedBenefitObligationMember" xlink:title="PresentValueOfDefinedBenefitObligationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PresentValueOfDefinedBenefitObligationMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetMember to PresentValueOfDefinedBenefitObligationMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:label="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="ChangesInNetDefinedBenefitLiabilityAssetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInNetDefinedBenefitLiabilityAssetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to LiabilityAssetOfDefinedBenefitPlans" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to InterestCostNetDefinedBenefitLiabilityAsset" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PaymentsFromPlanNetDefinedBenefitLiabilityAsset" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="PresentValueOfDefinedBenefitObligationMember" xlink:title="PresentValueOfDefinedBenefitObligationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PresentValueOfDefinedBenefitObligationMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetMember to PresentValueOfDefinedBenefitObligationMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangesInFairValueOfPlanAssetsAbstract" xlink:label="ChangesInFairValueOfPlanAssetsAbstract" xlink:title="ChangesInFairValueOfPlanAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInFairValueOfPlanAssetsAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInFairValueOfPlanAssetsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PlanAssetsAtFairValue" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PlanAssetsAtFairValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to InterestIncomeNetDefinedBenefitLiabilityAsset" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PaymentsFromPlanNetDefinedBenefitLiabilityAsset" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:title="PostemploymentBenefitExpenseDefinedContributionPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PostemploymentBenefitExpenseDefinedContributionPlans" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsMember" xlink:label="PlanAssetsMember" xlink:title="PlanAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PlanAssetsMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetMember to PlanAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="MaturityAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to MaturityAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember_2" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember_2" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="definition: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:label="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="ChangesInNetDefinedBenefitLiabilityAssetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInNetDefinedBenefitLiabilityAssetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to LiabilityAssetOfDefinedBenefitPlans" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:title="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:title="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossAbstract" xlink:label="ChangeInOtherComprehensiveLossAbstract" xlink:title="ChangeInOtherComprehensiveLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangeInOtherComprehensiveLossAbstract" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangeInOtherComprehensiveLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:label="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:title="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:label="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:title="WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to WeightedAverageDurationOfDefinedBenefitObligation2019" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="definition: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember_2" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:label="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:title="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetMember to ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SensitivityAnalysisActuarialAssumptionsAbstract" xlink:label="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:title="SensitivityAnalysisActuarialAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to SensitivityAnalysisActuarialAssumptionsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to LiabilityAssetOfDefinedBenefitPlans" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="ActuarialAssumptionOfDiscountRates" xlink:title="ActuarialAssumptionOfDiscountRates" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ActuarialAssumptionOfDiscountRates" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to ActuarialAssumptionOfDiscountRates" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to ActuarialAssumptionOfExpectedRatesOfPensionIncreases" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptions" xlink:label="OtherMaterialActuarialAssumptions" xlink:title="OtherMaterialActuarialAssumptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="OtherMaterialActuarialAssumptions" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to OtherMaterialActuarialAssumptions" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssuedActuarialTablesSwitzerland" xlink:label="IssuedActuarialTablesSwitzerland" xlink:title="IssuedActuarialTablesSwitzerland" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="IssuedActuarialTablesSwitzerland" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to IssuedActuarialTablesSwitzerland" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to DefinedBenefitPlansAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember_2" xlink:title="DefinedBenefitPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember_2" xlink:title="definition: DefinedBenefitPlansAxis to DefinedBenefitPlansMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="definition: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="ActuarialAssumptionsAxis" xlink:title="ActuarialAssumptionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ActuarialAssumptionsAxis" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to ActuarialAssumptionsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="ActuarialAssumptionsMember" xlink:title="ActuarialAssumptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ActuarialAssumptionsAxis" xlink:to="ActuarialAssumptionsMember" xlink:title="definition: ActuarialAssumptionsAxis to ActuarialAssumptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="ActuarialAssumptionsMember_2" xlink:title="ActuarialAssumptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ActuarialAssumptionsAxis" xlink:to="ActuarialAssumptionsMember_2" xlink:title="definition: ActuarialAssumptionsAxis to ActuarialAssumptionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="ActuarialAssumptionOfDiscountRatesMember" xlink:title="ActuarialAssumptionOfDiscountRatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfDiscountRatesMember" xlink:title="definition: ActuarialAssumptionsMember to ActuarialAssumptionOfDiscountRatesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:title="definition: ActuarialAssumptionsMember to ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:title="definition: ActuarialAssumptionsMember to ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptionsMember" xlink:label="OtherMaterialActuarialAssumptionsMember" xlink:title="OtherMaterialActuarialAssumptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActuarialAssumptionsMember" xlink:to="OtherMaterialActuarialAssumptionsMember" xlink:title="definition: ActuarialAssumptionsMember to OtherMaterialActuarialAssumptionsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="TypesOfRisksAxis" xlink:title="definition: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to TypesOfRisksAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember_2" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember_2" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:title="definition: TypesOfRisksMember to PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:title="definition: TypesOfRisksMember to PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPlansOutstandingAbstract" xlink:label="ShareBasedPlansOutstandingAbstract" xlink:title="ShareBasedPlansOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ShareBasedPlansOutstandingAbstract" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to ShareBasedPlansOutstandingAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:label="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to TypesOfSharebasedPaymentArrangementsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember_2" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember_2" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanAMember" xlink:label="StockOptionPlanAMember" xlink:title="StockOptionPlanAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanAMember" xlink:title="definition: SharebasedPaymentArrangementsMember to StockOptionPlanAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanBMember" xlink:label="StockOptionPlanBMember" xlink:title="StockOptionPlanBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanBMember" xlink:title="definition: SharebasedPaymentArrangementsMember to StockOptionPlanBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanC1Member" xlink:label="StockOptionPlanC1Member" xlink:title="StockOptionPlanC1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanC1Member" xlink:title="definition: SharebasedPaymentArrangementsMember to StockOptionPlanC1Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanMember" xlink:label="Two016ShareOptionAndIncentivePlanMember" xlink:title="Two016ShareOptionAndIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="Two016ShareOptionAndIncentivePlanMember" xlink:title="definition: SharebasedPaymentArrangementsMember to Two016ShareOptionAndIncentivePlanMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:title="definition: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:title="definition: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:title="definition: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to CategoriesOfRelatedPartiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember_2" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember_2" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="KeyManagementPersonnelOfEntityOrParentMember" xlink:title="KeyManagementPersonnelOfEntityOrParentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="KeyManagementPersonnelOfEntityOrParentMember" xlink:title="definition: EntitysTotalForRelatedPartiesMember to KeyManagementPersonnelOfEntityOrParentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="EmployeesMember" xlink:title="definition: EntitysTotalForRelatedPartiesMember to EmployeesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:label="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:title="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="NumberOfOutstandingShareOptions" xlink:title="NumberOfOutstandingShareOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="NumberOfOutstandingShareOptions" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to NumberOfOutstandingShareOptions" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareOptionsDateOfExpiry" xlink:label="ShareOptionsDateOfExpiry" xlink:title="ShareOptionsDateOfExpiry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ShareOptionsDateOfExpiry" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to ShareOptionsDateOfExpiry" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to RangesOfExercisePricesForOutstandingShareOptionsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:title="definition: RangesOfExercisePricesForOutstandingShareOptionsAxis to RangesOfExercisePricesForOutstandingShareOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsMember_2" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangesOfExercisePricesForOutstandingShareOptionsMember_2" xlink:title="definition: RangesOfExercisePricesForOutstandingShareOptionsAxis to RangesOfExercisePricesForOutstandingShareOptionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesOneMember" xlink:label="RangeOfExercisePricesOneMember" xlink:title="RangeOfExercisePricesOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesOneMember" xlink:title="definition: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesTwoMember" xlink:label="RangeOfExercisePricesTwoMember" xlink:title="RangeOfExercisePricesTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesTwoMember" xlink:title="definition: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesThreeMember" xlink:label="RangeOfExercisePricesThreeMember" xlink:title="RangeOfExercisePricesThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesThreeMember" xlink:title="definition: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesThreeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="WeightedAverageSharePriceShareOptionsGranted2019" xlink:title="WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageSharePriceShareOptionsGranted2019" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to WeightedAverageSharePriceShareOptionsGranted2019" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:title="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageAssumptionsAbstract" xlink:label="WeightedAverageAssumptionsAbstract" xlink:title="WeightedAverageAssumptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageAssumptionsAbstract" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to WeightedAverageAssumptionsAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPaymentArrangementAbstract" xlink:label="ShareBasedPaymentArrangementAbstract" xlink:title="ShareBasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ShareBasedPaymentArrangementAbstract" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to ShareBasedPaymentArrangementAbstract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:title="ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ExercisePriceShareOptionsGranted2019" xlink:title="ExercisePriceShareOptionsGranted2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ExercisePriceShareOptionsGranted2019" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to ExercisePriceShareOptionsGranted2019" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="WeightedAverageSharePrice2019" xlink:title="WeightedAverageSharePrice2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="WeightedAverageSharePrice2019" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to WeightedAverageSharePrice2019" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:title="DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:title="DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DescriptionOfExpectedVolatilityShareOptionsGranted" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="DescriptionOfOptionLifeShareOptionsGranted" xlink:title="DescriptionOfOptionLifeShareOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DescriptionOfOptionLifeShareOptionsGranted" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DescriptionOfOptionLifeShareOptionsGranted" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ExpectedDividendAsPercentageShareOptionsGranted" xlink:title="ExpectedDividendAsPercentageShareOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ExpectedDividendAsPercentageShareOptionsGranted" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to ExpectedDividendAsPercentageShareOptionsGranted" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to CategoriesOfRelatedPartiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember_2" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember_2" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FormerChiefExecutiveFinancialOfficerMember" xlink:label="FormerChiefExecutiveFinancialOfficerMember" xlink:title="FormerChiefExecutiveFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="FormerChiefExecutiveFinancialOfficerMember" xlink:title="definition: EntitysTotalForRelatedPartiesMember to FormerChiefExecutiveFinancialOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPaymentArrangementAbstract" xlink:label="ShareBasedPaymentArrangementAbstract" xlink:title="ShareBasedPaymentArrangementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ShareBasedPaymentArrangementAbstract" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to ShareBasedPaymentArrangementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfNonVestedSharesAbstract" xlink:label="NumberOfNonVestedSharesAbstract" xlink:title="NumberOfNonVestedSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfNonVestedSharesAbstract" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfNonVestedSharesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceAbstract" xlink:label="WeightedAverageExercisePriceAbstract" xlink:title="WeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceAbstract" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfInstrumentsOtherEquityInstrumentsGranted" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:label="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="20.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to TypesOfSharebasedPaymentArrangementsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember_2" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember_2" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesAndRestrictedShareUnitsMember" xlink:label="RestrictedSharesAndRestrictedShareUnitsMember" xlink:title="RestrictedSharesAndRestrictedShareUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedSharesAndRestrictedShareUnitsMember" xlink:title="definition: SharebasedPaymentArrangementsMember to RestrictedSharesAndRestrictedShareUnitsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesMember" xlink:label="RestrictedSharesMember" xlink:title="RestrictedSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedSharesMember" xlink:title="definition: SharebasedPaymentArrangementsMember to RestrictedSharesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedStockUnitsMember" xlink:label="RestrictedStockUnitsMember" xlink:title="RestrictedStockUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedStockUnitsMember" xlink:title="definition: SharebasedPaymentArrangementsMember to RestrictedStockUnitsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="definition: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to CategoriesOfRelatedPartiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember_2" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember_2" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BoardOfDirectorsMember" xlink:label="BoardOfDirectorsMember" xlink:title="BoardOfDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="BoardOfDirectorsMember" xlink:title="definition: EntitysTotalForRelatedPartiesMember to BoardOfDirectorsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExecutiveManagementMember" xlink:label="ExecutiveManagementMember" xlink:title="ExecutiveManagementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="ExecutiveManagementMember" xlink:title="definition: EntitysTotalForRelatedPartiesMember to ExecutiveManagementMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAbstract" xlink:label="CommitmentsAbstract" xlink:title="CommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="CommitmentsAbstract" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to CommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProvisionsResearchContracts" xlink:label="ProvisionsResearchContracts" xlink:title="ProvisionsResearchContracts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="ProvisionsResearchContracts" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to ProvisionsResearchContracts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RentalContractPeriodForNoticeOfCancellation" xlink:label="RentalContractPeriodForNoticeOfCancellation" xlink:title="RentalContractPeriodForNoticeOfCancellation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="RentalContractPeriodForNoticeOfCancellation" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to RentalContractPeriodForNoticeOfCancellation" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Provisions" xlink:label="Provisions" xlink:title="Provisions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="Provisions" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to Provisions" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to DisclosureOfInformationAboutCommitmentsAndContingenciesTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:to="MaturityAxis" xlink:title="definition: DisclosureOfInformationAboutCommitmentsAndContingenciesTable to MaturityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember_2" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember_2" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="definition: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanThreeYearsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanThreeYearsAndNotLaterThanFiveYearsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="LaterThanFiveYearsMember" xlink:title="LaterThanFiveYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFiveYearsMember" xlink:title="definition: AggregatedTimeBandsMember to LaterThanFiveYearsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShareDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialAssetsAndLiabilitiesAbstract" xlink:label="FinancialAssetsAndLiabilitiesAbstract" xlink:title="FinancialAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialAssetsAndLiabilitiesAbstract" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialAssetsAndLiabilitiesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialRisksAbstract" xlink:label="FinancialRisksAbstract" xlink:title="FinancialRisksAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialRisksAbstract" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialRisksAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateIncrease" xlink:label="ClosingForeignExchangeRateIncrease" xlink:title="ClosingForeignExchangeRateIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ClosingForeignExchangeRateIncrease" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to ClosingForeignExchangeRateIncrease" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateDecrease" xlink:label="ClosingForeignExchangeRateDecrease" xlink:title="ClosingForeignExchangeRateDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ClosingForeignExchangeRateDecrease" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to ClosingForeignExchangeRateDecrease" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossForeignExchangeRateIncrease" xlink:label="DecreaseInNetLossForeignExchangeRateIncrease" xlink:title="DecreaseInNetLossForeignExchangeRateIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="DecreaseInNetLossForeignExchangeRateIncrease" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to DecreaseInNetLossForeignExchangeRateIncrease" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfIncreaseInInterestRates" xlink:label="PercentageOfIncreaseInInterestRates" xlink:title="PercentageOfIncreaseInInterestRates" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="PercentageOfIncreaseInInterestRates" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to PercentageOfIncreaseInInterestRates" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfDecreaseInInterestRates" xlink:label="PercentageOfDecreaseInInterestRates" xlink:title="PercentageOfDecreaseInInterestRates" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="PercentageOfDecreaseInInterestRates" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to PercentageOfDecreaseInInterestRates" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNetLossInterestRateIncrease" xlink:label="IncreaseInNetLossInterestRateIncrease" xlink:title="IncreaseInNetLossInterestRateIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="IncreaseInNetLossInterestRateIncrease" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to IncreaseInNetLossInterestRateIncrease" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossInterestRateDecrease" xlink:label="DecreaseInNetLossInterestRateDecrease" xlink:title="DecreaseInNetLossInterestRateDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="DecreaseInNetLossInterestRateDecrease" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to DecreaseInNetLossInterestRateDecrease" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:label="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:title="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BorrowingsDebtExtinguishmentPeriod" xlink:label="BorrowingsDebtExtinguishmentPeriod" xlink:title="BorrowingsDebtExtinguishmentPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="BorrowingsDebtExtinguishmentPeriod" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to BorrowingsDebtExtinguishmentPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LiquidityManagementRollingForecastPeriod" xlink:label="LiquidityManagementRollingForecastPeriod" xlink:title="LiquidityManagementRollingForecastPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="LiquidityManagementRollingForecastPeriod" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to LiquidityManagementRollingForecastPeriod" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="FinancialAssets" xlink:title="FinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialAssets" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialAssets" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="FinancialLiabilities" xlink:title="FinancialLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialLiabilities" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialLiabilities" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="CategoriesOfFinancialAssetsAxis" xlink:title="CategoriesOfFinancialAssetsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="CategoriesOfFinancialAssetsAxis" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to CategoriesOfFinancialAssetsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="FinancialAssetsCategoryMember" xlink:title="FinancialAssetsCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CategoriesOfFinancialAssetsAxis" xlink:to="FinancialAssetsCategoryMember" xlink:title="definition: CategoriesOfFinancialAssetsAxis to FinancialAssetsCategoryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="FinancialAssetsCategoryMember_2" xlink:title="FinancialAssetsCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfFinancialAssetsAxis" xlink:to="FinancialAssetsCategoryMember_2" xlink:title="definition: CategoriesOfFinancialAssetsAxis to FinancialAssetsCategoryMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancialAssetsMember" xlink:label="LongTermFinancialAssetsMember" xlink:title="LongTermFinancialAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialAssetsCategoryMember" xlink:to="LongTermFinancialAssetsMember" xlink:title="definition: FinancialAssetsCategoryMember to LongTermFinancialAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherReceivablesMember" xlink:label="OtherReceivablesMember" xlink:title="OtherReceivablesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialAssetsCategoryMember" xlink:to="OtherReceivablesMember" xlink:title="definition: FinancialAssetsCategoryMember to OtherReceivablesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermFinancialAssetsMember" xlink:label="ShortTermFinancialAssetsMember" xlink:title="ShortTermFinancialAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialAssetsCategoryMember" xlink:to="ShortTermFinancialAssetsMember" xlink:title="definition: FinancialAssetsCategoryMember to ShortTermFinancialAssetsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashOnHandAndCashEquivalentsMember" xlink:label="CashOnHandAndCashEquivalentsMember" xlink:title="CashOnHandAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialAssetsCategoryMember" xlink:to="CashOnHandAndCashEquivalentsMember" xlink:title="definition: FinancialAssetsCategoryMember to CashOnHandAndCashEquivalentsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="CategoriesOfFinancialLiabilitiesAxis" xlink:title="CategoriesOfFinancialLiabilitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="CategoriesOfFinancialLiabilitiesAxis" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to CategoriesOfFinancialLiabilitiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="FinancialLiabilitiesCategoryMember" xlink:title="FinancialLiabilitiesCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilitiesCategoryMember" xlink:title="definition: CategoriesOfFinancialLiabilitiesAxis to FinancialLiabilitiesCategoryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="FinancialLiabilitiesCategoryMember_2" xlink:title="FinancialLiabilitiesCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilitiesCategoryMember_2" xlink:title="definition: CategoriesOfFinancialLiabilitiesAxis to FinancialLiabilitiesCategoryMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="LeaseLiabilitiesMember" xlink:title="LeaseLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="LeaseLiabilitiesMember" xlink:title="definition: FinancialLiabilitiesCategoryMember to LeaseLiabilitiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TradeAndOtherPayablesMember" xlink:label="TradeAndOtherPayablesMember" xlink:title="TradeAndOtherPayablesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="TradeAndOtherPayablesMember" xlink:title="definition: FinancialLiabilitiesCategoryMember to TradeAndOtherPayablesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AccruedExpensesMember" xlink:label="AccruedExpensesMember" xlink:title="AccruedExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="AccruedExpensesMember" xlink:title="definition: FinancialLiabilitiesCategoryMember to AccruedExpensesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ShorttermBorrowingsMember" xlink:title="ShorttermBorrowingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="ShorttermBorrowingsMember" xlink:title="definition: FinancialLiabilitiesCategoryMember to ShorttermBorrowingsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermLeaseLiabilitiesMember" xlink:label="ShortTermLeaseLiabilitiesMember" xlink:title="ShortTermLeaseLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="ShortTermLeaseLiabilitiesMember" xlink:title="definition: FinancialLiabilitiesCategoryMember to ShortTermLeaseLiabilitiesMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="TypesOfRisksAxis" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to TypesOfRisksAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember_2" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember_2" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="CurrencyRiskMember" xlink:title="CurrencyRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="CurrencyRiskMember" xlink:title="definition: TypesOfRisksMember to CurrencyRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="CreditRiskMember" xlink:title="CreditRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="CreditRiskMember" xlink:title="definition: TypesOfRisksMember to CreditRiskMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="LiquidityRiskMember" xlink:title="LiquidityRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="LiquidityRiskMember" xlink:title="definition: TypesOfRisksMember to LiquidityRiskMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="InterestRateRiskMember" xlink:title="InterestRateRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypesOfRisksMember" xlink:to="InterestRateRiskMember" xlink:title="definition: TypesOfRisksMember to InterestRateRiskMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="RangeAxis" xlink:title="definition: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember_2" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember_2" xlink:title="definition: RangeAxis to RangesMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="definition: RangesMember to BottomOfRangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="definition: RangesMember to TopOfRangeMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://acimume.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PostBalanceSheetEventsAbstract" xlink:label="PostBalanceSheetEventsAbstract" xlink:title="PostBalanceSheetEventsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PostBalanceSheetEventsAbstract" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to PostBalanceSheetEventsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:label="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="NumberOfSharesIssued" xlink:title="NumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="NumberOfSharesIssued" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to NumberOfSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to DisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to NonadjustingEventsAfterReportingPeriodAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember_2" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember_2" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SubsequentEventsMember" xlink:label="SubsequentEventsMember" xlink:title="SubsequentEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonadjustingEventsMember" xlink:to="SubsequentEventsMember" xlink:title="definition: NonadjustingEventsMember to SubsequentEventsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="definition: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to ClassesOfShareCapitalAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember_2" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember_2" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AtTheMarketEquityOfferingMember" xlink:label="AtTheMarketEquityOfferingMember" xlink:title="AtTheMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassesOfShareCapitalMember" xlink:to="AtTheMarketEquityOfferingMember" xlink:title="definition: ClassesOfShareCapitalMember to AtTheMarketEquityOfferingMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>aciu-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="AccumulatedDepreciationAndAmortisationMember" xlink:title="AccumulatedDepreciationAndAmortisationMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US" id="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl">Accumulated Depreciation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xlink:title="label: AccumulatedDepreciationAndAmortisationMember to ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl1" xml:lang="en-US" id="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl1">Accumulated depreciation and amortisation [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl1" xlink:title="label: AccumulatedDepreciationAndAmortisationMember to ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="ActuarialAssumptionOfDiscountRates" xlink:title="ActuarialAssumptionOfDiscountRates" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl">Discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xlink:title="label: ActuarialAssumptionOfDiscountRates to ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl1">Actuarial assumption of discount rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl1" xlink:title="label: ActuarialAssumptionOfDiscountRates to ifrs-full_ActuarialAssumptionOfDiscountRates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="ActuarialAssumptionOfDiscountRatesMember" xlink:title="ActuarialAssumptionOfDiscountRatesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl">Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfDiscountRatesMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" xlink:title="label: ActuarialAssumptionOfDiscountRatesMember to ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl1">Actuarial assumption of discount rates [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfDiscountRatesMember" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl1" xlink:title="label: ActuarialAssumptionOfDiscountRatesMember to ifrs-full_ActuarialAssumptionOfDiscountRatesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl">Rate of future increase in current pensions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfPensionIncreases to ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl1">Actuarial assumption of expected rates of pension increases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl1" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfPensionIncreases to ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl">Future Pension Cost [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember to ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl1">Actuarial assumption of expected rates of pension increases [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl1" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember to ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl">Rate of future increase in compensations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfSalaryIncreases to ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl1">Actuarial assumption of expected rates of salary increases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl1" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfSalaryIncreases to ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl">Future Salary Increase [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember to ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl1">Actuarial assumption of expected rates of salary increases [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl1" xlink:title="label: ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember to ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="ActuarialAssumptionsAxis" xlink:title="ActuarialAssumptionsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionsAxis_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionsAxis_lbl">Actuarial assumptions [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionsAxis" xlink:to="ifrs-full_ActuarialAssumptionsAxis_lbl" xlink:title="label: ActuarialAssumptionsAxis to ifrs-full_ActuarialAssumptionsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="ActuarialAssumptionsMember" xlink:title="ActuarialAssumptionsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialAssumptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialAssumptionsMember_lbl" xml:lang="en-US" id="ifrs-full_ActuarialAssumptionsMember_lbl">Actuarial assumptions [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialAssumptionsMember" xlink:to="ifrs-full_ActuarialAssumptionsMember_lbl" xlink:title="label: ActuarialAssumptionsMember to ifrs-full_ActuarialAssumptionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl">Effect of changes in demographic assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl1">Change in demographic assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl">Effect of changes in financial assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl1">Change in financial assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl">Effect of changes in experience assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl1">Change in experience assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset to ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:title="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl">Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:title="label: AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment to ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl1">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl1" xlink:title="label: AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment to ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="AdditionsToRightofuseAssets" xlink:title="AdditionsToRightofuseAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" id="ifrs-full_AdditionsToRightofuseAssets_lbl">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:title="label: AdditionsToRightofuseAssets to ifrs-full_AdditionsToRightofuseAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="AdjustedWeightedAverageShares" xlink:title="AdjustedWeightedAverageShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" id="ifrs-full_AdjustedWeightedAverageShares_lbl">Weighted-average number of shares outstanding - diluted to equity holders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:title="label: AdjustedWeightedAverageShares to ifrs-full_AdjustedWeightedAverageShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustedWeightedAverageShares_lbl1" xml:lang="en-US" id="ifrs-full_AdjustedWeightedAverageShares_lbl1">Adjusted weighted average number of ordinary shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl1" xlink:title="label: AdjustedWeightedAverageShares to ifrs-full_AdjustedWeightedAverageShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:title="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl">(Increase)/decrease in other current receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xlink:title="label: AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables to ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl1">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl1" xlink:title="label: AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables to ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="AdjustmentsForDepreciationExpense" xlink:title="AdjustmentsForDepreciationExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForDepreciationExpense_lbl">Depreciation of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:title="label: AdjustmentsForDepreciationExpense to ifrs-full_AdjustmentsForDepreciationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForDepreciationExpense_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForDepreciationExpense_lbl1">Adjustments for depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl1" xlink:title="label: AdjustmentsForDepreciationExpense to ifrs-full_AdjustmentsForDepreciationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="AdjustmentsForFairValueGainsLosses" xlink:title="AdjustmentsForFairValueGainsLosses" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl">Change in fair value of conversion feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xlink:title="label: AdjustmentsForFairValueGainsLosses to ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl1">Adjustments for fair value losses (gains)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl1" xlink:title="label: AdjustmentsForFairValueGainsLosses to ifrs-full_AdjustmentsForFairValueGainsLosses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="AdjustmentsForFinanceIncomeCost" xlink:title="AdjustmentsForFinanceIncomeCost" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl">Finance result, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xlink:title="label: AdjustmentsForFinanceIncomeCost to ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl1">Adjustments for finance income (cost)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl1" xlink:title="label: AdjustmentsForFinanceIncomeCost to ifrs-full_AdjustmentsForFinanceIncomeCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:title="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl">(Gain)/loss on sale of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xlink:title="label: AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment to ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl1">Adjustments for gain (loss) on disposals, property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl1" xlink:title="label: AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment to ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:title="AdjustmentsForIncreaseDecreaseInDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl">(Decrease)/increase in deferred income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xlink:title="label: AdjustmentsForIncreaseDecreaseInDeferredIncome to ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl1">Adjustments for increase (decrease) in deferred income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl1" xlink:title="label: AdjustmentsForIncreaseDecreaseInDeferredIncome to ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl">Changes in net employee defined benefit liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xlink:title="label: AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities to ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl1">Adjustments for increase (decrease) in employee benefit liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl1" xlink:title="label: AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities to ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:title="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl">Increase/(decrease) in trade and other payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:title="label: AdjustmentsForIncreaseDecreaseInTradeAccountPayable to ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl1">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl1" xlink:title="label: AdjustmentsForIncreaseDecreaseInTradeAccountPayable to ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="AdjustmentsForInterestExpense" xlink:title="AdjustmentsForInterestExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForInterestExpense_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForInterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForInterestExpense" xlink:to="ifrs-full_AdjustmentsForInterestExpense_lbl" xlink:title="label: AdjustmentsForInterestExpense to ifrs-full_AdjustmentsForInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForInterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForInterestExpense_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForInterestExpense_lbl1">Adjustments for interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForInterestExpense" xlink:to="ifrs-full_AdjustmentsForInterestExpense_lbl1" xlink:title="label: AdjustmentsForInterestExpense to ifrs-full_AdjustmentsForInterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="AdjustmentsForReconcileProfitLossAbstract" xlink:title="AdjustmentsForReconcileProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl">Adjustments to reconcile net income/(loss) for the period to net cash flows:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:title="label: AdjustmentsForReconcileProfitLossAbstract to ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xlink:title="label: AdjustmentsForReconcileProfitLossAbstract to ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="AdjustmentsForSharebasedPayments" xlink:title="AdjustmentsForSharebasedPayments" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" id="ifrs-full_AdjustmentsForSharebasedPayments_lbl">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:title="label: AdjustmentsForSharebasedPayments to ifrs-full_AdjustmentsForSharebasedPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US" id="ifrs-full_AdjustmentsForSharebasedPayments_lbl1">Adjustments for share-based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xlink:title="label: AdjustmentsForSharebasedPayments to ifrs-full_AdjustmentsForSharebasedPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" id="ifrs-full_AggregatedTimeBandsMember_lbl">Aggregated time bands [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xlink:title="label: AggregatedTimeBandsMember to ifrs-full_AggregatedTimeBandsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ApplicableTaxRate" xlink:title="ApplicableTaxRate" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" id="ifrs-full_ApplicableTaxRate_lbl">Corporate tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xlink:title="label: ApplicableTaxRate to ifrs-full_ApplicableTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ApplicableTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ApplicableTaxRate_lbl1" xml:lang="en-US" id="ifrs-full_ApplicableTaxRate_lbl1">Applicable tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl1" xlink:title="label: ApplicableTaxRate to ifrs-full_ApplicableTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_Assets_lbl" xml:lang="en-US" id="ifrs-full_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="ifrs-full_Assets_lbl" xlink:title="label: Assets to ifrs-full_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_Assets_lbl1" xml:lang="en-US" id="ifrs-full_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="ifrs-full_Assets_lbl1" xlink:title="label: Assets to ifrs-full_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" id="ifrs-full_AssetsAbstract_lbl">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to ifrs-full_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_AssetsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_AssetsAbstract_lbl1">Assets [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to ifrs-full_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="BasicEarningsLossPerShare" xlink:title="BasicEarningsLossPerShare" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" id="ifrs-full_BasicEarningsLossPerShare_lbl">Basic income/(loss) for the period attributable to equity holders (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:title="label: BasicEarningsLossPerShare to ifrs-full_BasicEarningsLossPerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BasicEarningsLossPerShare_lbl1" xml:lang="en-US" id="ifrs-full_BasicEarningsLossPerShare_lbl1">Basic earnings (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl1" xlink:title="label: BasicEarningsLossPerShare to ifrs-full_BasicEarningsLossPerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="BasicEarningsPerShareAbstract" xlink:title="BasicEarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BasicEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_BasicEarningsPerShareAbstract_lbl" xml:lang="en-US" id="ifrs-full_BasicEarningsPerShareAbstract_lbl">Basic income/(loss) per share (EPS) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasicEarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsPerShareAbstract_lbl" xlink:title="label: BasicEarningsPerShareAbstract to ifrs-full_BasicEarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BasicEarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BasicEarningsPerShareAbstract_lbl1" xml:lang="en-US" id="ifrs-full_BasicEarningsPerShareAbstract_lbl1">Basic earnings per share [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasicEarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsPerShareAbstract_lbl1" xlink:title="label: BasicEarningsPerShareAbstract to ifrs-full_BasicEarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" xlink:title="BorrowingsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_BorrowingsAbstract_lbl" xml:lang="en-US" id="ifrs-full_BorrowingsAbstract_lbl">Financing obligation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl" xlink:title="label: BorrowingsAbstract to ifrs-full_BorrowingsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BorrowingsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_BorrowingsAbstract_lbl1">Borrowings [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl1" xlink:title="label: BorrowingsAbstract to ifrs-full_BorrowingsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" id="ifrs-full_BorrowingsByNameAxis_lbl">Borrowings by name [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xlink:title="label: BorrowingsByNameAxis to ifrs-full_BorrowingsByNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" id="ifrs-full_BorrowingsByNameMember_lbl">Borrowings by name [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xlink:title="label: BorrowingsByNameMember to ifrs-full_BorrowingsByNameMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" id="ifrs-full_BottomOfRangeMember_lbl">Bottom of Range [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xlink:title="label: BottomOfRangeMember to ifrs-full_BottomOfRangeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US" id="ifrs-full_BottomOfRangeMember_lbl1">Bottom of range [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1" xlink:title="label: BottomOfRangeMember to ifrs-full_BottomOfRangeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="BuildingsMember" xlink:title="BuildingsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BuildingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" id="ifrs-full_BuildingsMember_lbl">Buildings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" xlink:title="label: BuildingsMember to ifrs-full_BuildingsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_BuildingsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_BuildingsMember_lbl1" xml:lang="en-US" id="ifrs-full_BuildingsMember_lbl1">Buildings [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl1" xlink:title="label: BuildingsMember to ifrs-full_BuildingsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" id="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl">Carrying amount, accumulated depreciation, amortization and impairment and gross carrying amount [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:title="label: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" id="ifrs-full_CarryingAmountMember_lbl">Carrying amount [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" xlink:title="label: CarryingAmountMember to ifrs-full_CarryingAmountMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAbstract" xlink:label="CashAbstract" xlink:title="CashAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashAbstract_lbl" xml:lang="en-US" id="ifrs-full_CashAbstract_lbl">Cash and cash equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl" xlink:title="label: CashAbstract to ifrs-full_CashAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CashAbstract_lbl1">Cash [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl1" xlink:title="label: CashAbstract to ifrs-full_CashAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="ifrs-full_CashAndCashEquivalents_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:title="label: CashAndCashEquivalents to ifrs-full_CashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US" id="ifrs-full_CashAndCashEquivalents_lbl1">Cash and cash equivalents, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1" xlink:title="label: CashAndCashEquivalents to ifrs-full_CashAndCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US" id="ifrs-full_CashAndCashEquivalents_lbl2">Cash and cash equivalents, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2" xlink:title="label: CashAndCashEquivalents to ifrs-full_CashAndCashEquivalents_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US" id="ifrs-full_CashAndCashEquivalents_lbl3">Company's cash position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3" xlink:title="label: CashAndCashEquivalents to ifrs-full_CashAndCashEquivalents_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="CashFlowsFromUsedInFinancingActivities" xlink:title="CashFlowsFromUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl">Net cash flows (used in)/provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:title="label: CashFlowsFromUsedInFinancingActivities to ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1">Cash flows from (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1" xlink:title="label: CashFlowsFromUsedInFinancingActivities to ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:title="CashFlowsFromUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: CashFlowsFromUsedInFinancingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl1">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: CashFlowsFromUsedInFinancingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="CashFlowsFromUsedInInvestingActivities" xlink:title="CashFlowsFromUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl">Net cash flows provided by/(used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:title="label: CashFlowsFromUsedInInvestingActivities to ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl1">Cash flows from (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl1" xlink:title="label: CashFlowsFromUsedInInvestingActivities to ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:title="CashFlowsFromUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: CashFlowsFromUsedInInvestingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl1">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl1" xlink:title="label: CashFlowsFromUsedInInvestingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="CashFlowsFromUsedInOperatingActivities" xlink:title="CashFlowsFromUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl">Net cash flows (used in)/provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:title="label: CashFlowsFromUsedInOperatingActivities to ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1">Cash flows from (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xlink:title="label: CashFlowsFromUsedInOperatingActivities to ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:title="CashFlowsFromUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: CashFlowsFromUsedInOperatingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: CashFlowsFromUsedInOperatingActivitiesAbstract to ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="CashFlowsFromUsedInOperations" xlink:title="CashFlowsFromUsedInOperations" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperations_lbl">Cash (used in)/provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:title="label: CashFlowsFromUsedInOperations to ifrs-full_CashFlowsFromUsedInOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashFlowsFromUsedInOperations_lbl1" xml:lang="en-US" id="ifrs-full_CashFlowsFromUsedInOperations_lbl1">Cash flows from (used in) operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl1" xlink:title="label: CashFlowsFromUsedInOperations to ifrs-full_CashFlowsFromUsedInOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases" xlink:label="CashOutflowForLeases" xlink:title="CashOutflowForLeases" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US" id="ifrs-full_CashOutflowForLeases_lbl">Total cash outflow for leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl" xlink:title="label: CashOutflowForLeases to ifrs-full_CashOutflowForLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CashOutflowForLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CashOutflowForLeases_lbl1" xml:lang="en-US" id="ifrs-full_CashOutflowForLeases_lbl1">Cash outflow for leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl1" xlink:title="label: CashOutflowForLeases to ifrs-full_CashOutflowForLeases_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="CategoriesOfFinancialAssetsAxis" xlink:title="CategoriesOfFinancialAssetsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl">Categories of financial assets [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xlink:title="label: CategoriesOfFinancialAssetsAxis to ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="CategoriesOfFinancialLiabilitiesAxis" xlink:title="CategoriesOfFinancialLiabilitiesAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" id="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl">Categories of financial liabilities [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:title="label: CategoriesOfFinancialLiabilitiesAxis to ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" id="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl">Categories of related parties [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:title="label: CategoriesOfRelatedPartiesAxis to ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ChangesInEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ChangesInEquityAbstract_lbl" xml:lang="en-US" id="ifrs-full_ChangesInEquityAbstract_lbl">Share capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInEquityAbstract" xlink:to="ifrs-full_ChangesInEquityAbstract_lbl" xlink:title="label: ChangesInEquityAbstract to ifrs-full_ChangesInEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:label="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="ChangesInNetDefinedBenefitLiabilityAssetAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl" xml:lang="en-US" id="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl">Change in net defined benefit liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl" xlink:title="label: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl1" xml:lang="en-US" id="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl1">Changes in defined benefit obligation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl1" xlink:title="label: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl2" xml:lang="en-US" id="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl2">Changes in net defined benefit liability (asset) [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl2" xlink:title="label: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" id="ifrs-full_ClassesOfAssetsAxis_lbl">Classes of assets [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:title="label: ClassesOfAssetsAxis to ifrs-full_ClassesOfAssetsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" id="ifrs-full_ClassesOfAssetsMember_lbl">Assets [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xlink:title="label: ClassesOfAssetsMember to ifrs-full_ClassesOfAssetsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" id="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl">Classes of property, plant and equipment [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:title="label: ClassesOfPropertyPlantAndEquipmentAxis to ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" id="ifrs-full_ClassesOfShareCapitalAxis_lbl">Classes of share capital [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:title="label: ClassesOfShareCapitalAxis to ifrs-full_ClassesOfShareCapitalAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" id="ifrs-full_ClassesOfShareCapitalMember_lbl">Share capital [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:title="label: ClassesOfShareCapitalMember to ifrs-full_ClassesOfShareCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClassesOfShareCapitalMember_lbl1" xml:lang="en-US" id="ifrs-full_ClassesOfShareCapitalMember_lbl1">Share Capital [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl1" xlink:title="label: ClassesOfShareCapitalMember to ifrs-full_ClassesOfShareCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ClosingForeignExchangeRate" xlink:title="ClosingForeignExchangeRate" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" id="ifrs-full_ClosingForeignExchangeRate_lbl">Translation rate into CHF</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl" xlink:title="label: ClosingForeignExchangeRate to ifrs-full_ClosingForeignExchangeRate_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ClosingForeignExchangeRate_lbl1" xml:lang="en-US" id="ifrs-full_ClosingForeignExchangeRate_lbl1">Closing foreign exchange rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl1" xlink:title="label: ClosingForeignExchangeRate to ifrs-full_ClosingForeignExchangeRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" id="ifrs-full_ComponentsOfEquityAxis_lbl">Components of equity [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:title="label: ComponentsOfEquityAxis to ifrs-full_ComponentsOfEquityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:title="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" id="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl">Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:title="label: ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract to ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl1" xml:lang="en-US" id="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl1">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl1" xlink:title="label: ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract to ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="ifrs-full_ComprehensiveIncome_lbl">Total comprehensive income/(loss), net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xlink:title="label: ComprehensiveIncome to ifrs-full_ComprehensiveIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US" id="ifrs-full_ComprehensiveIncome_lbl1">Comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1" xlink:title="label: ComprehensiveIncome to ifrs-full_ComprehensiveIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US" id="ifrs-full_ComputerEquipmentMember_lbl">IT Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl" xlink:title="label: ComputerEquipmentMember to ifrs-full_ComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ComputerEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ComputerEquipmentMember_lbl1" xml:lang="en-US" id="ifrs-full_ComputerEquipmentMember_lbl1">Computer equipment [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl1" xlink:title="label: ComputerEquipmentMember to ifrs-full_ComputerEquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ContractAssets" xlink:title="ContractAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContractAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="ifrs-full_ContractAssets_lbl">Deferred research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssets" xlink:to="ifrs-full_ContractAssets_lbl" xlink:title="label: ContractAssets to ifrs-full_ContractAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContractAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ContractAssets_lbl1" xml:lang="en-US" id="ifrs-full_ContractAssets_lbl1">Contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssets" xlink:to="ifrs-full_ContractAssets_lbl1" xlink:title="label: ContractAssets to ifrs-full_ContractAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="ifrs-full_ContractLiabilities_lbl">Upfront payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xlink:title="label: ContractLiabilities to ifrs-full_ContractLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ContractLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_ContractLiabilities_lbl1">Up-front consideration received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl1" xlink:title="label: ContractLiabilities to ifrs-full_ContractLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContractLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ContractLiabilities_lbl2" xml:lang="en-US" id="ifrs-full_ContractLiabilities_lbl2">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl2" xlink:title="label: ContractLiabilities to ifrs-full_ContractLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl">Employer's contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset to ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl1">Employer's contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset to ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl2" xml:lang="en-US" id="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl2">Contributions to plan by employer, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl2" xlink:title="label: ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset to ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl">Employees' contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset to ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl1">Contributions to plan by plan participants, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset to ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="CounterpartiesAxis" xlink:title="CounterpartiesAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" id="ifrs-full_CounterpartiesAxis_lbl">Counterparties [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:title="label: CounterpartiesAxis to ifrs-full_CounterpartiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="CounterpartiesMember" xlink:title="CounterpartiesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CounterpartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" id="ifrs-full_CounterpartiesMember_lbl">Counterparties [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl" xlink:title="label: CounterpartiesMember to ifrs-full_CounterpartiesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="CreditRiskMember" xlink:title="CreditRiskMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CreditRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" id="ifrs-full_CreditRiskMember_lbl">Credit Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl" xlink:title="label: CreditRiskMember to ifrs-full_CreditRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CreditRiskMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CreditRiskMember_lbl1" xml:lang="en-US" id="ifrs-full_CreditRiskMember_lbl1">Credit risk [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl1" xlink:title="label: CreditRiskMember to ifrs-full_CreditRiskMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="CurrencyRiskMember" xlink:title="CurrencyRiskMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" id="ifrs-full_CurrencyRiskMember_lbl">Foreign Currency Exchange Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xlink:title="label: CurrencyRiskMember to ifrs-full_CurrencyRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrencyRiskMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrencyRiskMember_lbl1" xml:lang="en-US" id="ifrs-full_CurrencyRiskMember_lbl1">Currency risk [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl1" xlink:title="label: CurrencyRiskMember to ifrs-full_CurrencyRiskMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="CurrentAccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:title="label: CurrentAccruedExpensesAndOtherCurrentLiabilities to ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl1">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl1" xlink:title="label: CurrentAccruedExpensesAndOtherCurrentLiabilities to ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl2" xml:lang="en-US" id="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl2">Current accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl2" xlink:title="label: CurrentAccruedExpensesAndOtherCurrentLiabilities to ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="CurrentAssets" xlink:title="CurrentAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" id="ifrs-full_CurrentAssets_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:title="label: CurrentAssets to ifrs-full_CurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US" id="ifrs-full_CurrentAssets_lbl1">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1" xlink:title="label: CurrentAssets to ifrs-full_CurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="CurrentAssetsAbstract" xlink:title="CurrentAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" id="ifrs-full_CurrentAssetsAbstract_lbl">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:title="label: CurrentAssetsAbstract to ifrs-full_CurrentAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentAssetsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CurrentAssetsAbstract_lbl1">Current assets [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl1" xlink:title="label: CurrentAssetsAbstract to ifrs-full_CurrentAssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" id="ifrs-full_CurrentContractAssets_lbl">Accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl" xlink:title="label: CurrentContractAssets to ifrs-full_CurrentContractAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_CurrentContractAssets_lbl1" xml:lang="en-US" id="ifrs-full_CurrentContractAssets_lbl1">Accrued income, ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl1" xlink:title="label: CurrentContractAssets to ifrs-full_CurrentContractAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_CurrentContractAssets_lbl2" xml:lang="en-US" id="ifrs-full_CurrentContractAssets_lbl2">Accrued income, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl2" xlink:title="label: CurrentContractAssets to ifrs-full_CurrentContractAssets_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractAssets_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentContractAssets_lbl3" xml:lang="en-US" id="ifrs-full_CurrentContractAssets_lbl3">Current contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl3" xlink:title="label: CurrentContractAssets to ifrs-full_CurrentContractAssets_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" id="ifrs-full_CurrentContractLiabilities_lbl">Deferred income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xlink:title="label: CurrentContractLiabilities to ifrs-full_CurrentContractLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_CurrentContractLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_CurrentContractLiabilities_lbl1">Deferred income, ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl1" xlink:title="label: CurrentContractLiabilities to ifrs-full_CurrentContractLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_CurrentContractLiabilities_lbl2" xml:lang="en-US" id="ifrs-full_CurrentContractLiabilities_lbl2">Deferred income, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl2" xlink:title="label: CurrentContractLiabilities to ifrs-full_CurrentContractLiabilities_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_CurrentContractLiabilities_lbl3" xml:lang="en-US" id="ifrs-full_CurrentContractLiabilities_lbl3">Deferred income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl3" xlink:title="label: CurrentContractLiabilities to ifrs-full_CurrentContractLiabilities_lbl3" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentContractLiabilities_lbl4" xml:lang="en-US" id="ifrs-full_CurrentContractLiabilities_lbl4">Current contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl4" xlink:title="label: CurrentContractLiabilities to ifrs-full_CurrentContractLiabilities_lbl4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US" id="ifrs-full_CurrentFinancialAssets_lbl">Short-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl" xlink:title="label: CurrentFinancialAssets to ifrs-full_CurrentFinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_CurrentFinancialAssets_lbl1" xml:lang="en-US" id="ifrs-full_CurrentFinancialAssets_lbl1">Short-term financial assets due in one year or less</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl1" xlink:title="label: CurrentFinancialAssets to ifrs-full_CurrentFinancialAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="CurrentFinancialLiabilities" xlink:title="CurrentFinancialLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentFinancialLiabilities_lbl" xml:lang="en-US" id="ifrs-full_CurrentFinancialLiabilities_lbl">Short-term financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:title="label: CurrentFinancialLiabilities to ifrs-full_CurrentFinancialLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="CurrentLeaseLiabilities" xlink:title="CurrentLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" id="ifrs-full_CurrentLeaseLiabilities_lbl">Short-term lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:title="label: CurrentLeaseLiabilities to ifrs-full_CurrentLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentLeaseLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_CurrentLeaseLiabilities_lbl1">Current lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl1" xlink:title="label: CurrentLeaseLiabilities to ifrs-full_CurrentLeaseLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="CurrentLiabilities" xlink:title="CurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" id="ifrs-full_CurrentLiabilities_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:title="label: CurrentLiabilities to ifrs-full_CurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_CurrentLiabilities_lbl1">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1" xlink:title="label: CurrentLiabilities to ifrs-full_CurrentLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="CurrentLiabilitiesAbstract" xlink:title="CurrentLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_CurrentLiabilitiesAbstract_lbl">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:title="label: CurrentLiabilitiesAbstract to ifrs-full_CurrentLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentLiabilitiesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_CurrentLiabilitiesAbstract_lbl1">Current liabilities [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl1" xlink:title="label: CurrentLiabilitiesAbstract to ifrs-full_CurrentLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US" id="ifrs-full_CurrentPrepayments_lbl">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl" xlink:title="label: CurrentPrepayments to ifrs-full_CurrentPrepayments_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentPrepayments_lbl1" xml:lang="en-US" id="ifrs-full_CurrentPrepayments_lbl1">Current prepayments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl1" xlink:title="label: CurrentPrepayments to ifrs-full_CurrentPrepayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome" xlink:label="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="CurrentPrepaymentsAndCurrentAccruedIncome" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl" xml:lang="en-US" id="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:to="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl" xlink:title="label: CurrentPrepaymentsAndCurrentAccruedIncome to ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl1" xml:lang="en-US" id="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl1">Current prepayments and current accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:to="ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl1" xlink:title="label: CurrentPrepaymentsAndCurrentAccruedIncome to ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="CurrentProvisionsForEmployeeBenefits" xlink:title="CurrentProvisionsForEmployeeBenefits" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US" id="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl">Accrued payroll expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xlink:title="label: CurrentProvisionsForEmployeeBenefits to ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl1" xml:lang="en-US" id="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl1">Current provisions for employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl1" xlink:title="label: CurrentProvisionsForEmployeeBenefits to ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" id="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl">Withholding tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xlink:title="label: CurrentReceivablesFromTaxesOtherThanIncomeTax to ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl1" xml:lang="en-US" id="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl1">Current receivables from taxes other than income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl1" xlink:title="label: CurrentReceivablesFromTaxesOtherThanIncomeTax to ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl">Service cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: CurrentServiceCostNetDefinedBenefitLiabilityAsset to ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl1">Service cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: CurrentServiceCostNetDefinedBenefitLiabilityAsset to ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl2" xml:lang="en-US" id="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl2">Current service cost, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl2" xlink:title="label: CurrentServiceCostNetDefinedBenefitLiabilityAsset to ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="CurrentValueAddedTaxReceivables" xlink:title="CurrentValueAddedTaxReceivables" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US" id="ifrs-full_CurrentValueAddedTaxReceivables_lbl">Swiss VAT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xlink:title="label: CurrentValueAddedTaxReceivables to ifrs-full_CurrentValueAddedTaxReceivables_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_CurrentValueAddedTaxReceivables_lbl1" xml:lang="en-US" id="ifrs-full_CurrentValueAddedTaxReceivables_lbl1">Current value added tax receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl1" xlink:title="label: CurrentValueAddedTaxReceivables to ifrs-full_CurrentValueAddedTaxReceivables_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="DeferredTaxAssets" xlink:title="DeferredTaxAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" id="ifrs-full_DeferredTaxAssets_lbl">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xlink:title="label: DeferredTaxAssets to ifrs-full_DeferredTaxAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DeferredTaxAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DeferredTaxAssets_lbl1" xml:lang="en-US" id="ifrs-full_DeferredTaxAssets_lbl1">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl1" xlink:title="label: DeferredTaxAssets to ifrs-full_DeferredTaxAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" xlink:title="DeferredTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="ifrs-full_DeferredTaxLiabilities_lbl">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" xlink:title="label: DeferredTaxLiabilities to ifrs-full_DeferredTaxLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="DeferredTaxLiabilityAsset" xlink:title="DeferredTaxLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DeferredTaxLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_DeferredTaxLiabilityAsset_lbl">Unused tax losses and tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_lbl" xlink:title="label: DeferredTaxLiabilityAsset to ifrs-full_DeferredTaxLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DeferredTaxLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_DeferredTaxLiabilityAsset_lbl1">Deferred tax liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilityAsset_lbl1" xlink:title="label: DeferredTaxLiabilityAsset to ifrs-full_DeferredTaxLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="DefinedBenefitObligationAtPresentValue" xlink:title="DefinedBenefitObligationAtPresentValue" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xml:lang="en-US" id="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl">Defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitObligationAtPresentValue" xlink:to="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xlink:title="label: DefinedBenefitObligationAtPresentValue to ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl1" xml:lang="en-US" id="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl1">Defined benefit obligation, at present value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitObligationAtPresentValue" xlink:to="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl1" xlink:title="label: DefinedBenefitObligationAtPresentValue to ifrs-full_DefinedBenefitObligationAtPresentValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US" id="ifrs-full_DefinedBenefitPlansAxis_lbl">Defined benefit plans [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:title="label: DefinedBenefitPlansAxis to ifrs-full_DefinedBenefitPlansAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DefinedBenefitPlansMember_lbl" xml:lang="en-US" id="ifrs-full_DefinedBenefitPlansMember_lbl">Defined benefit plans [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlansMember" xlink:to="ifrs-full_DefinedBenefitPlansMember_lbl" xlink:title="label: DefinedBenefitPlansMember to ifrs-full_DefinedBenefitPlansMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl" xml:lang="en-US" id="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl">Defined Benefit Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl" xlink:title="label: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl1" xml:lang="en-US" id="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl1">Defined benefit plans that share risks between entities under common control [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl1" xlink:title="label: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="DepreciationPropertyPlantAndEquipment" xlink:title="DepreciationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:title="label: DepreciationPropertyPlantAndEquipment to ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl1">Depreciation, property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl1" xlink:title="label: DepreciationPropertyPlantAndEquipment to ifrs-full_DepreciationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="DepreciationRightofuseAssets" xlink:title="DepreciationRightofuseAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" id="ifrs-full_DepreciationRightofuseAssets_lbl">Depreciation of right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:title="label: DepreciationRightofuseAssets to ifrs-full_DepreciationRightofuseAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_DepreciationRightofuseAssets_lbl1" xml:lang="en-US" id="ifrs-full_DepreciationRightofuseAssets_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl1" xlink:title="label: DepreciationRightofuseAssets to ifrs-full_DepreciationRightofuseAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DepreciationRightofuseAssets_lbl2" xml:lang="en-US" id="ifrs-full_DepreciationRightofuseAssets_lbl2">Depreciation, right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl2" xlink:title="label: DepreciationRightofuseAssets to ifrs-full_DepreciationRightofuseAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:title="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl">Earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForEarningsPerShareExplanatory to ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl1">Description of accounting policy for earnings per share [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForEarningsPerShareExplanatory to ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:title="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl">Employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory to ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl1">Description of accounting policy for employee benefits [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory to ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:title="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl">Foreign currency transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory to ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl1">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory to ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:title="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl">Taxation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForIncomeTaxExplanatory to ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl1">Description of accounting policy for income tax [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForIncomeTaxExplanatory to ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:title="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl">Share capital and public offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForIssuedCapitalExplanatory to ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl1">Description of accounting policy for issued capital [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForIssuedCapitalExplanatory to ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:title="DescriptionOfAccountingPolicyForLeasesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForLeasesExplanatory to ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:title="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory to ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl1">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory to ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:title="DescriptionOfAccountingPolicyForProvisionsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl">Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForProvisionsExplanatory to ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl1">Description of accounting policy for provisions [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForProvisionsExplanatory to ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:title="DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl">Revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xlink:title="label: DescriptionOfAccountingPolicyForRecognitionOfRevenue to ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl1">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForRecognitionOfRevenue to ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:title="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory to ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl1">Description of accounting policy for research and development expense [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory to ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:title="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl">Segment reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xlink:title="label: DescriptionOfAccountingPolicyForSegmentReportingExplanatory to ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl1">Description of accounting policy for segment reporting [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForSegmentReportingExplanatory to ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:title="DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:title="label: DescriptionOfExpectedVolatilityShareOptionsGranted to ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1">Expected volatility, share options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xlink:title="label: DescriptionOfExpectedVolatilityShareOptionsGranted to ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="DescriptionOfOptionLifeShareOptionsGranted" xlink:title="DescriptionOfOptionLifeShareOptionsGranted" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xlink:title="label: DescriptionOfOptionLifeShareOptionsGranted to ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl1">Option life, share options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl1" xlink:title="label: DescriptionOfOptionLifeShareOptionsGranted to ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:title="DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" id="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:title="label: DescriptionOfRiskFreeInterestRateShareOptionsGranted to ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xml:lang="en-US" id="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1">Risk free interest rate, share options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xlink:title="label: DescriptionOfRiskFreeInterestRateShareOptionsGranted to ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="DilutedEarningsLossPerShare" xlink:title="DilutedEarningsLossPerShare" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="ifrs-full_DilutedEarningsLossPerShare_lbl">Diluted income/(loss) for the period attributable to equity holders (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:title="label: DilutedEarningsLossPerShare to ifrs-full_DilutedEarningsLossPerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DilutedEarningsLossPerShare_lbl1" xml:lang="en-US" id="ifrs-full_DilutedEarningsLossPerShare_lbl1">Diluted earnings (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl1" xlink:title="label: DilutedEarningsLossPerShare to ifrs-full_DilutedEarningsLossPerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="DilutedEarningsPerShareAbstract" xlink:title="DilutedEarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="ifrs-full_DilutedEarningsPerShareAbstract_lbl">Diluted income/(loss) per share (EPS) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutedEarningsPerShareAbstract" xlink:to="ifrs-full_DilutedEarningsPerShareAbstract_lbl" xlink:title="label: DilutedEarningsPerShareAbstract to ifrs-full_DilutedEarningsPerShareAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US" id="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl">Convertible shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:title="label: DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares to ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xml:lang="en-US" id="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1">Dilutive effect of convertible instruments on number of ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xlink:title="label: DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares to ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US" id="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl">Effect of dilutive securities from equity incentive plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xlink:title="label: DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares to ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl1" xml:lang="en-US" id="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl1">Dilutive effect of share options on number of ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl1" xlink:title="label: DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares to ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:label="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:title="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl">Key management compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl" xlink:title="label: DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory to ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl1">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl1" xlink:title="label: DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory to ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:title="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl">Basis of preparation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:title="label: DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory to ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl1">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl1" xlink:title="label: DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory to ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" xlink:title="DisclosureOfClassesOfShareCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl">Capital structure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:title="label: DisclosureOfClassesOfShareCapitalAbstract to ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="DisclosureOfClassesOfShareCapitalExplanatory" xlink:title="DisclosureOfClassesOfShareCapitalExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl">Summary of capital structure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:title="label: DisclosureOfClassesOfShareCapitalExplanatory to ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl1">Disclosure of classes of share capital [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl1" xlink:title="label: DisclosureOfClassesOfShareCapitalExplanatory to ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl">Disclosure of classes of share capital [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xlink:title="label: DisclosureOfClassesOfShareCapitalLineItems to ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl">Disclosure of classes of share capital [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xlink:title="label: DisclosureOfClassesOfShareCapitalTable to ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:title="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:title="label: DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory to ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl1">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl1" xlink:title="label: DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory to ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="DisclosureOfContingentLiabilitiesExplanatory" xlink:title="DisclosureOfContingentLiabilitiesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl">Maturity of commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xlink:title="label: DisclosureOfContingentLiabilitiesExplanatory to ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl1">Disclosure of contingent liabilities [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl1" xlink:title="label: DisclosureOfContingentLiabilitiesExplanatory to ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="DisclosureOfDebtSecuritiesExplanatory" xlink:title="DisclosureOfDebtSecuritiesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl">Financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDebtSecuritiesExplanatory" xlink:to="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" xlink:title="label: DisclosureOfDebtSecuritiesExplanatory to ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl1">Disclosure of debt instruments [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDebtSecuritiesExplanatory" xlink:to="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl1" xlink:title="label: DisclosureOfDebtSecuritiesExplanatory to ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_lbl">Retirement benefit plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_lbl" xlink:title="label: DisclosureOfDefinedBenefitPlansAbstract to ifrs-full_DisclosureOfDefinedBenefitPlansAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl">Disclosure of detailed information about borrowings [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutBorrowingsTable to ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:title="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory to ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl1">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory to ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl">Contract revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xlink:title="label: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl1">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl1" xlink:title="label: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xlink:title="label: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:title="label: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="DisclosureOfEarningsPerShareExplanatory" xlink:title="DisclosureOfEarningsPerShareExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl">Earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xlink:title="label: DisclosureOfEarningsPerShareExplanatory to ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl1">Disclosure of earnings per share [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl1" xlink:title="label: DisclosureOfEarningsPerShareExplanatory to ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="DisclosureOfEmployeeBenefitsExplanatory" xlink:title="DisclosureOfEmployeeBenefitsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl">Retirement benefit plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:title="label: DisclosureOfEmployeeBenefitsExplanatory to ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl1">Disclosure of employee benefits [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl1" xlink:title="label: DisclosureOfEmployeeBenefitsExplanatory to ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:title="DisclosureOfEventsAfterReportingPeriodExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl">Subsequent events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:title="label: DisclosureOfEventsAfterReportingPeriodExplanatory to ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:label="DisclosureOfExpensesExplanatory" xlink:title="DisclosureOfExpensesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfExpensesExplanatory_lbl">Expenses by category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfExpensesExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xlink:title="label: DisclosureOfExpensesExplanatory to ifrs-full_DisclosureOfExpensesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfExpensesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfExpensesExplanatory_lbl1">Disclosure of expenses [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfExpensesExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory_lbl1" xlink:title="label: DisclosureOfExpensesExplanatory to ifrs-full_DisclosureOfExpensesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:label="DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:title="DisclosureOfFairValueOfPlanAssetsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl">Changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl" xlink:title="label: DisclosureOfFairValueOfPlanAssetsExplanatory to ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl1">Disclosure of fair value of plan assets [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl1" xlink:title="label: DisclosureOfFairValueOfPlanAssetsExplanatory to ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="DisclosureOfFinanceIncomeExpenseExplanatory" xlink:title="DisclosureOfFinanceIncomeExpenseExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl">Financial Result, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xlink:title="label: DisclosureOfFinanceIncomeExpenseExplanatory to ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" xlink:title="DisclosureOfFinancialAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl">Cash and cash equivalents and financial assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xlink:title="label: DisclosureOfFinancialAssetsAbstract to ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="DisclosureOfFinancialAssetsExplanatory" xlink:title="DisclosureOfFinancialAssetsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl">Cash and cash equivalents and short-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xlink:title="label: DisclosureOfFinancialAssetsExplanatory to ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="DisclosureOfFinancialRiskManagementExplanatory" xlink:title="DisclosureOfFinancialRiskManagementExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl">Financial instruments and risk management</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xlink:title="label: DisclosureOfFinancialRiskManagementExplanatory to ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl1">Disclosure of financial risk management [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl1" xlink:title="label: DisclosureOfFinancialRiskManagementExplanatory to ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:title="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xlink:title="label: DisclosureOfGeneralAndAdministrativeExpenseExplanatory to ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl1">Disclosure of general and administrative expense [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl1" xlink:title="label: DisclosureOfGeneralAndAdministrativeExpenseExplanatory to ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="DisclosureOfIncomeTaxExplanatory" xlink:title="DisclosureOfIncomeTaxExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:title="label: DisclosureOfIncomeTaxExplanatory to ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:title="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl">Weighted-average assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:title="label: DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory to ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl1">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl1" xlink:title="label: DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory to ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl">Summary of significant accounting policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" xlink:title="label: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="DisclosureOfLeasesExplanatory" xlink:title="DisclosureOfLeasesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfLeasesExplanatory_lbl">Right-of-use assets and lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:title="label: DisclosureOfLeasesExplanatory to ifrs-full_DisclosureOfLeasesExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl" xlink:title="label: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems to ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_lbl">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_lbl" xlink:title="label: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable to ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl">Financial instruments and risk management [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xlink:title="label: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract to ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xlink:title="label: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xlink:title="label: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl">Defined benefit pension plan amounts recognized in the balance sheet and statement of income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" xlink:title="label: DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory to ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl1">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl1" xlink:title="label: DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory to ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_lbl">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_lbl" xlink:title="label: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_lbl">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_lbl" xlink:title="label: DisclosureOfNetDefinedBenefitLiabilityAssetTable to ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl">Subsequent events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:title="label: DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract to ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xlink:title="label: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:title="label: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl">Summary of non-vested share awards (restricted share and restricted share units)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl1">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl1" xlink:title="label: DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl">Number and weighted average exercise prices of options under share option programs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl1">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl1" xlink:title="label: DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl">Number and weighted average exercise prices of options under the share option programs [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl1">Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl1" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl">Outstanding options, exercise price range and expiry dates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl1">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl1" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_lbl">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_lbl" xlink:title="label: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:label="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:title="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl">Capital risk management [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl" xlink:title="label: DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract to ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:title="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl">Capital risk management</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl" xlink:title="label: DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory to ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl1">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl1" xlink:title="label: DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory to ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="DisclosureOfOperatingSegmentsAbstract" xlink:title="DisclosureOfOperatingSegmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl">Segment reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xlink:title="label: DisclosureOfOperatingSegmentsAbstract to ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl1">Disclosure of operating segments [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl1" xlink:title="label: DisclosureOfOperatingSegmentsAbstract to ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:title="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl">Property, plant and equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: DisclosureOfPropertyPlantAndEquipmentAbstract to ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:title="DisclosureOfPropertyPlantAndEquipmentExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:title="label: DisclosureOfPropertyPlantAndEquipmentExplanatory to ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl1">Disclosure of property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl1" xlink:title="label: DisclosureOfPropertyPlantAndEquipmentExplanatory to ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: DisclosureOfPropertyPlantAndEquipmentLineItems to ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: DisclosureOfPropertyPlantAndEquipmentTable to ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl">Right-of-use assets and lease liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" xlink:title="label: DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract to ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl1">Disclosure of quantitative information about leases for lessee [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl1" xlink:title="label: DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract to ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl">Information about Right-of-Use Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:title="label: DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory to ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl1">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl1" xlink:title="label: DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory to ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xlink:title="label: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xlink:title="label: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xlink:title="label: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_lbl">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_lbl" xlink:title="label: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="DisclosureOfRelatedPartyExplanatory" xlink:title="DisclosureOfRelatedPartyExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl">Related-party transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:title="label: DisclosureOfRelatedPartyExplanatory to ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl1">Disclosure of related party [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl1" xlink:title="label: DisclosureOfRelatedPartyExplanatory to ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:title="DisclosureOfResearchAndDevelopmentExpenseExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xlink:title="label: DisclosureOfResearchAndDevelopmentExpenseExplanatory to ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl1">Disclosure of research and development expense [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl1" xlink:title="label: DisclosureOfResearchAndDevelopmentExpenseExplanatory to ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:label="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:title="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl">Cash and cash equivalents and financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl" xlink:title="label: DisclosureOfRestrictedCashAndCashEquivalentsExplanatory to ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="DisclosureOfRevenueExplanatory" xlink:title="DisclosureOfRevenueExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRevenueExplanatory_lbl">Contract revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:title="label: DisclosureOfRevenueExplanatory to ifrs-full_DisclosureOfRevenueExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRevenueExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfRevenueExplanatory_lbl1">Disclosure of revenue [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl1" xlink:title="label: DisclosureOfRevenueExplanatory to ifrs-full_DisclosureOfRevenueExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:title="DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl">Contract Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xlink:title="label: DisclosureOfRevenueFromContractsWithCustomersExplanatory to ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl1">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl1" xlink:title="label: DisclosureOfRevenueFromContractsWithCustomersExplanatory to ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl">Actuarial assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl1">Disclosure of sensitivity analysis for actuarial assumptions [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl1" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl">Actuarial assumptions and sensitivity analysis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl1">Disclosure of sensitivity analysis for actuarial assumptions [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl1" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" xlink:title="label: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:title="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl">Share capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:title="label: DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory to ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl1">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl1" xlink:title="label: DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory to ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:title="DisclosureOfSharebasedPaymentArrangementsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:title="label: DisclosureOfSharebasedPaymentArrangementsExplanatory to ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl1">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl1" xlink:title="label: DisclosureOfSharebasedPaymentArrangementsExplanatory to ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:title="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl">Summary of significant accounting policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:title="label: DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory to ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl1">Disclosure of significant accounting policies [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl1" xlink:title="label: DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory to ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl">Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl1">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl1" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl1">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl1" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xlink:title="label: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl">Share-based compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:title="label: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl">Share-based compensation plans outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xlink:title="label: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory to ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl1">Disclosure of terms and conditions of share-based payment arrangement [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl1" xlink:title="label: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory to ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:title="label: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:title="label: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="DisclosureOfTradeAndOtherPayablesExplanatory" xlink:title="DisclosureOfTradeAndOtherPayablesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl">Trade payables and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xlink:title="label: DisclosureOfTradeAndOtherPayablesExplanatory to ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl1">Disclosure of trade and other payables [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl1" xlink:title="label: DisclosureOfTradeAndOtherPayablesExplanatory to ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:title="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl">Related-party transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xlink:title="label: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="DisposalsPropertyPlantAndEquipment" xlink:title="DisposalsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl">Disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:title="label: DisposalsPropertyPlantAndEquipment to ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl1">Disposals, property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl1" xlink:title="label: DisposalsPropertyPlantAndEquipment to ifrs-full_DisposalsPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="ifrs-full_EarningsPerShareAbstract_lbl">Earnings/(loss) per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to ifrs-full_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EarningsPerShareAbstract_lbl1" xml:lang="en-US" id="ifrs-full_EarningsPerShareAbstract_lbl1">Earnings per share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl1" xlink:title="label: EarningsPerShareAbstract to ifrs-full_EarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="EarningsPerShareExplanatory" xlink:title="EarningsPerShareExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" id="ifrs-full_EarningsPerShareExplanatory_lbl">Earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:title="label: EarningsPerShareExplanatory to ifrs-full_EarningsPerShareExplanatory_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EarningsPerShareExplanatory_lbl1" xml:lang="en-US" id="ifrs-full_EarningsPerShareExplanatory_lbl1">Earnings per share [text block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl1" xlink:title="label: EarningsPerShareExplanatory to ifrs-full_EarningsPerShareExplanatory_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl">Exchange gains on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:title="label: EffectOfExchangeRateChangesOnCashAndCashEquivalents to ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl1" xml:lang="en-US" id="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl1">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl1" xlink:title="label: EffectOfExchangeRateChangesOnCashAndCashEquivalents to ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" id="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl">Entity's total for related parties [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xlink:title="label: EntitysTotalForRelatedPartiesMember to ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_Equity_lbl" xml:lang="en-US" id="ifrs-full_Equity_lbl">Total shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Equity" xlink:to="ifrs-full_Equity_lbl" xlink:title="label: Equity to ifrs-full_Equity_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Equity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_Equity_lbl1" xml:lang="en-US" id="ifrs-full_Equity_lbl1">Balance, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Equity" xlink:to="ifrs-full_Equity_lbl1" xlink:title="label: Equity to ifrs-full_Equity_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Equity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_Equity_lbl2" xml:lang="en-US" id="ifrs-full_Equity_lbl2">Balance, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Equity" xlink:to="ifrs-full_Equity_lbl2" xlink:title="label: Equity to ifrs-full_Equity_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Equity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_Equity_lbl3" xml:lang="en-US" id="ifrs-full_Equity_lbl3">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Equity" xlink:to="ifrs-full_Equity_lbl3" xlink:title="label: Equity to ifrs-full_Equity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" id="ifrs-full_EquityAbstract_lbl">Shareholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:title="label: EquityAbstract to ifrs-full_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" xlink:title="EquityAndLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" id="ifrs-full_EquityAndLiabilities_lbl">Total shareholders' equity and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:title="label: EquityAndLiabilities to ifrs-full_EquityAndLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EquityAndLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_EquityAndLiabilities_lbl1">Equity and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl1" xlink:title="label: EquityAndLiabilities to ifrs-full_EquityAndLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="EquityAndLiabilitiesAbstract" xlink:title="EquityAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_EquityAndLiabilitiesAbstract_lbl">SHAREHOLDERS' EQUITY AND LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:title="label: EquityAndLiabilitiesAbstract to ifrs-full_EquityAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_EquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_EquityMember_lbl" xml:lang="en-US" id="ifrs-full_EquityMember_lbl">Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xlink:title="label: EquityMember to ifrs-full_EquityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ExercisePriceShareOptionsGranted2019" xlink:title="ExercisePriceShareOptionsGranted2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US" id="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl">Exercise price (in USD per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xlink:title="label: ExercisePriceShareOptionsGranted2019 to ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ExpectedDividendAsPercentageShareOptionsGranted" xlink:title="ExpectedDividendAsPercentageShareOptionsGranted" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US" id="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xlink:title="label: ExpectedDividendAsPercentageShareOptionsGranted to ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:title="ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl">Expense charged against the income statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:title="label: ExpenseFromSharebasedPaymentTransactionsWithEmployees to ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl1" xml:lang="en-US" id="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl1">Expense from share-based payment transactions with employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl1" xlink:title="label: ExpenseFromSharebasedPaymentTransactionsWithEmployees to ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:title="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" id="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl">Expense for short-term leases and leases of low value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:title="label: ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed to ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl1" xml:lang="en-US" id="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl1">Expense relating to short-term leases for which recognition exemption has been used</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl1" xlink:title="label: ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed to ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:title="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" id="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl">Changes in Contract Assets and Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xlink:title="label: ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory to ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="ifrs-full_FinanceCosts_lbl">Financial expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xlink:title="label: FinanceCosts to ifrs-full_FinanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinanceCosts_lbl1" xml:lang="en-US" id="ifrs-full_FinanceCosts_lbl1">Finance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl1" xlink:title="label: FinanceCosts to ifrs-full_FinanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:title="FinanceCostsPaidClassifiedAsOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl">Finance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:title="label: FinanceCostsPaidClassifiedAsOperatingActivities to ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl1" xml:lang="en-US" id="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl1">Finance costs paid, classified as operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl1" xlink:title="label: FinanceCostsPaidClassifiedAsOperatingActivities to ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="ifrs-full_FinanceIncome_lbl">Financial income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xlink:title="label: FinanceIncome to ifrs-full_FinanceIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_FinanceIncome_lbl1" xml:lang="en-US" id="ifrs-full_FinanceIncome_lbl1">Financial income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl1" xlink:title="label: FinanceIncome to ifrs-full_FinanceIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" id="ifrs-full_FinanceIncomeCost_lbl">Finance result, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xlink:title="label: FinanceIncomeCost to ifrs-full_FinanceIncomeCost_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinanceIncomeCost_lbl1" xml:lang="en-US" id="ifrs-full_FinanceIncomeCost_lbl1">Finance income (cost)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl1" xlink:title="label: FinanceIncomeCost to ifrs-full_FinanceIncomeCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:title="FinanceIncomeReceivedClassifiedAsOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:title="label: FinanceIncomeReceivedClassifiedAsOperatingActivities to ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl1" xml:lang="en-US" id="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl1">Finance income received, classified as operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl1" xlink:title="label: FinanceIncomeReceivedClassifiedAsOperatingActivities to ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="FinancialAssets" xlink:title="FinancialAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" id="ifrs-full_FinancialAssets_lbl">Financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl" xlink:title="label: FinancialAssets to ifrs-full_FinancialAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="FinancialAssetsCategoryMember" xlink:title="FinancialAssetsCategoryMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinancialAssetsCategoryMember_lbl" xml:lang="en-US" id="ifrs-full_FinancialAssetsCategoryMember_lbl">Financial assets, category [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsCategoryMember_lbl" xlink:title="label: FinancialAssetsCategoryMember to ifrs-full_FinancialAssetsCategoryMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="FinancialLiabilities" xlink:title="FinancialLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" id="ifrs-full_FinancialLiabilities_lbl">Financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" xlink:title="label: FinancialLiabilities to ifrs-full_FinancialLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="FinancialLiabilitiesCategoryMember" xlink:title="FinancialLiabilitiesCategoryMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US" id="ifrs-full_FinancialLiabilitiesCategoryMember_lbl">Financial liabilities, category [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xlink:title="label: FinancialLiabilitiesCategoryMember to ifrs-full_FinancialLiabilitiesCategoryMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="FixturesAndFittingsMember" xlink:title="FixturesAndFittingsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_FixturesAndFittingsMember_lbl" xml:lang="en-US" id="ifrs-full_FixturesAndFittingsMember_lbl">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl" xlink:title="label: FixturesAndFittingsMember to ifrs-full_FixturesAndFittingsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:title="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl">Remeasurement through other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset to ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl1">Gain (loss) on remeasurement, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset to ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl">Exchange differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xlink:title="label: GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss to ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1" xml:lang="en-US" id="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1">Loss in finance results, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1" xlink:title="label: GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss to ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="GrossCarryingAmountMember" xlink:title="GrossCarryingAmountMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" id="ifrs-full_GrossCarryingAmountMember_lbl">Acquisition Cost [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xlink:title="label: GrossCarryingAmountMember to ifrs-full_GrossCarryingAmountMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" id="ifrs-full_IncomeStatementAbstract_lbl">Statements of Income/(Loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to ifrs-full_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="IncomeTaxExpenseContinuingOperations" xlink:title="IncomeTaxExpenseContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:title="label: IncomeTaxExpenseContinuingOperations to ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US" id="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1">Effective income tax rate benefit/(expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xlink:title="label: IncomeTaxExpenseContinuingOperations to ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl2" xml:lang="en-US" id="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl2">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl2" xlink:title="label: IncomeTaxExpenseContinuingOperations to ifrs-full_IncomeTaxExpenseContinuingOperations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="IncreaseDecreaseInCashAndCashEquivalents" xlink:title="IncreaseDecreaseInCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl">Net (decrease)/increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:title="label: IncreaseDecreaseInCashAndCashEquivalents to ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl1">Net (decrease)/increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl1" xlink:title="label: IncreaseDecreaseInCashAndCashEquivalents to ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl2" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl2">Increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl2" xlink:title="label: IncreaseDecreaseInCashAndCashEquivalents to ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:title="IncreaseDecreaseInDeferredTaxLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl">Increase in tax losses available as an offset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:title="label: IncreaseDecreaseInDeferredTaxLiabilityAsset to ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl">Decrease/(increase) from actual defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:title="label: IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption to ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl">Decrease/(increase) from actual defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:title="label: IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption to ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl1">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xlink:title="label: IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption to ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:label="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl">Net pension cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: IncreaseDecreaseInNetDefinedBenefitLiabilityAsset to ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl1">Increase (decrease) in net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: IncreaseDecreaseInNetDefinedBenefitLiabilityAsset to ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:title="IncreaseDecreaseInNumberOfOrdinarySharesIssued" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl">Shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:title="label: IncreaseDecreaseInNumberOfOrdinarySharesIssued to ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1">Increase (decrease) in number of ordinary shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xlink:title="label: IncreaseDecreaseInNumberOfOrdinarySharesIssued to ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl">Conversion note agreement, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xlink:title="label: IncreaseDecreaseThroughConversionOfConvertibleInstruments to ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl1">Conversion of note agreement, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl1" xlink:title="label: IncreaseDecreaseThroughConversionOfConvertibleInstruments to ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="IncreaseDecreaseThroughExerciseOfOptions" xlink:title="IncreaseDecreaseThroughExerciseOfOptions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl">Exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xlink:title="label: IncreaseDecreaseThroughExerciseOfOptions to ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl1">Increase (decrease) through exercise of options, equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl1" xlink:title="label: IncreaseDecreaseThroughExerciseOfOptions to ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:title="IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl">Share-based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:title="label: IncreaseDecreaseThroughSharebasedPaymentTransactions to ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl1">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl1" xlink:title="label: IncreaseDecreaseThroughSharebasedPaymentTransactions to ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl">Issuance of shares to be held as treasury shares, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xlink:title="label: IncreaseDecreaseThroughTreasuryShareTransactions to ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl1" xml:lang="en-US" id="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl1">Held as treasury shares, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl1" xlink:title="label: IncreaseDecreaseThroughTreasuryShareTransactions to ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_InterestExpense_lbl" xml:lang="en-US" id="ifrs-full_InterestExpense_lbl">Net interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl" xlink:title="label: InterestExpense to ifrs-full_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_InterestExpense_lbl1" xml:lang="en-US" id="ifrs-full_InterestExpense_lbl1">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl1" xlink:title="label: InterestExpense to ifrs-full_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="InterestExpenseOnDebtInstrumentsIssued" xlink:title="InterestExpenseOnDebtInstrumentsIssued" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestExpenseOnDebtInstrumentsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_InterestExpenseOnDebtInstrumentsIssued_lbl" xml:lang="en-US" id="ifrs-full_InterestExpenseOnDebtInstrumentsIssued_lbl">Effective interest recorded to amortize the host debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOnDebtInstrumentsIssued" xlink:to="ifrs-full_InterestExpenseOnDebtInstrumentsIssued_lbl" xlink:title="label: InterestExpenseOnDebtInstrumentsIssued to ifrs-full_InterestExpenseOnDebtInstrumentsIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="InterestExpenseOnLeaseLiabilities" xlink:title="InterestExpenseOnLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" id="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl">Interest expense on lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:title="label: InterestExpenseOnLeaseLiabilities to ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1">Interest expense on lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1" xlink:title="label: InterestExpenseOnLeaseLiabilities to ifrs-full_InterestExpenseOnLeaseLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="InterestPaidClassifiedAsOperatingActivities" xlink:title="InterestPaidClassifiedAsOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xlink:title="label: InterestPaidClassifiedAsOperatingActivities to ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl1" xml:lang="en-US" id="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl1">Interest paid, classified as operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl1" xlink:title="label: InterestPaidClassifiedAsOperatingActivities to ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="InterestRateRiskMember" xlink:title="InterestRateRiskMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_InterestRateRiskMember_lbl" xml:lang="en-US" id="ifrs-full_InterestRateRiskMember_lbl">Interest Rate [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl" xlink:title="label: InterestRateRiskMember to ifrs-full_InterestRateRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_InterestRateRiskMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_InterestRateRiskMember_lbl1" xml:lang="en-US" id="ifrs-full_InterestRateRiskMember_lbl1">Interest rate risk [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl1" xlink:title="label: InterestRateRiskMember to ifrs-full_InterestRateRiskMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="IssuedCapital" xlink:title="IssuedCapital" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" id="ifrs-full_IssuedCapital_lbl">Share capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:title="label: IssuedCapital to ifrs-full_IssuedCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IssuedCapital_lbl1" xml:lang="en-US" id="ifrs-full_IssuedCapital_lbl1">Issued capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl1" xlink:title="label: IssuedCapital to ifrs-full_IssuedCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="IssuedCapitalMember" xlink:title="IssuedCapitalMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" id="ifrs-full_IssuedCapitalMember_lbl">Share Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:title="label: IssuedCapitalMember to ifrs-full_IssuedCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_IssuedCapitalMember_lbl1" xml:lang="en-US" id="ifrs-full_IssuedCapitalMember_lbl1">Issued capital [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl1" xlink:title="label: IssuedCapitalMember to ifrs-full_IssuedCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="KeyManagementPersonnelCompensation" xlink:title="KeyManagementPersonnelCompensation" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelCompensation_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:title="label: KeyManagementPersonnelCompensation to ifrs-full_KeyManagementPersonnelCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_KeyManagementPersonnelCompensation_lbl1" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelCompensation_lbl1">Key management personnel compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl1" xlink:title="label: KeyManagementPersonnelCompensation to ifrs-full_KeyManagementPersonnelCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:title="KeyManagementPersonnelCompensationPostemploymentBenefits" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl">Post-employment benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xlink:title="label: KeyManagementPersonnelCompensationPostemploymentBenefits to ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="KeyManagementPersonnelCompensationSharebasedPayment" xlink:title="KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:title="label: KeyManagementPersonnelCompensationSharebasedPayment to ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:title="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl">Short-term employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xlink:title="label: KeyManagementPersonnelCompensationShorttermEmployeeBenefits to ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="KeyManagementPersonnelOfEntityOrParentMember" xlink:title="KeyManagementPersonnelOfEntityOrParentMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" id="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl">Executives and Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:title="label: KeyManagementPersonnelOfEntityOrParentMember to ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="LaterThanFiveYearsMember" xlink:title="LaterThanFiveYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanFiveYearsMember_lbl">More Than 5 Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl" xlink:title="label: LaterThanFiveYearsMember to ifrs-full_LaterThanFiveYearsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl">Loss Expiry, December 31, 2024 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl" xlink:title="label: LaterThanFourYearsAndNotLaterThanFiveYearsMember to ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl1" xml:lang="en-US" id="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl1">Later than four years and not later than five years [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl1" xlink:title="label: LaterThanFourYearsAndNotLaterThanFiveYearsMember to ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanThreeYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl">Between 1 and 3 Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xlink:title="label: LaterThanOneYearAndNotLaterThanThreeYearsMember to ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl">Between 1 and 3 Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xlink:title="label: LaterThanOneYearAndNotLaterThanTwoYearsMember to ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl1" xml:lang="en-US" id="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl1">Loss Expiry, December 31, 2021 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl1" xlink:title="label: LaterThanOneYearAndNotLaterThanTwoYearsMember to ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl2" xml:lang="en-US" id="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl2">Later than one year and not later than two years [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl2" xlink:title="label: LaterThanOneYearAndNotLaterThanTwoYearsMember to ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl">Between 3 and 5 Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:title="label: LaterThanThreeYearsAndNotLaterThanFiveYearsMember to ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFourYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl">Loss Expiry, December 31, 2023 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl" xlink:title="label: LaterThanThreeYearsAndNotLaterThanFourYearsMember to ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl1" xml:lang="en-US" id="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl1">Later than three years and not later than four years [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl1" xlink:title="label: LaterThanThreeYearsAndNotLaterThanFourYearsMember to ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" id="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl">Between 3 and 5 Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" xlink:title="label: LaterThanTwoYearsAndNotLaterThanThreeYearsMember to ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl1" xml:lang="en-US" id="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl1">Loss Expiry, December 31, 2022 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl1" xlink:title="label: LaterThanTwoYearsAndNotLaterThanThreeYearsMember to ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl2" xml:lang="en-US" id="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl2">Later than two years and not later than three years [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl2" xlink:title="label: LaterThanTwoYearsAndNotLaterThanThreeYearsMember to ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="LeaseLiabilitiesMember" xlink:title="LeaseLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" id="ifrs-full_LeaseLiabilitiesMember_lbl">Long-term Lease Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:title="label: LeaseLiabilitiesMember to ifrs-full_LeaseLiabilitiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LeaseLiabilitiesMember_lbl1" xml:lang="en-US" id="ifrs-full_LeaseLiabilitiesMember_lbl1">Lease liabilities [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl1" xlink:title="label: LeaseLiabilitiesMember to ifrs-full_LeaseLiabilitiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="ifrs-full_LeaseholdImprovementsMember_lbl">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to ifrs-full_LeaseholdImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_Liabilities_lbl" xml:lang="en-US" id="ifrs-full_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:title="label: Liabilities to ifrs-full_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_Liabilities_lbl1" xml:lang="en-US" id="ifrs-full_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="ifrs-full_Liabilities_lbl1" xlink:title="label: Liabilities to ifrs-full_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl">Potential defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl1" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl1">Net defined benefit liabilities, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl1" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl2" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl2">Net defined benefit liabilities, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl2" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl3" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl3">Defined benefit obligation, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl3" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl3" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl4" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl4" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl4">Defined benefit obligation, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl4" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl4" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl5" xml:lang="en-US" id="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl5">Net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl5" xlink:title="label: LiabilityAssetOfDefinedBenefitPlans to ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="LiquidityRiskMember" xlink:title="LiquidityRiskMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_LiquidityRiskMember_lbl" xml:lang="en-US" id="ifrs-full_LiquidityRiskMember_lbl">Liquidity Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl" xlink:title="label: LiquidityRiskMember to ifrs-full_LiquidityRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_LiquidityRiskMember_lbl1" xml:lang="en-US" id="ifrs-full_LiquidityRiskMember_lbl1">Liquidity risk [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl1" xlink:title="label: LiquidityRiskMember to ifrs-full_LiquidityRiskMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" id="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl">Income taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xlink:title="label: MajorComponentsOfTaxExpenseIncomeAbstract to ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl1" xml:lang="en-US" id="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl1">Income taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl1" xlink:title="label: MajorComponentsOfTaxExpenseIncomeAbstract to ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" id="ifrs-full_MaturityAxis_lbl">Maturity [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xlink:title="label: MaturityAxis to ifrs-full_MaturityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl" xml:lang="en-US" id="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl">Net defined benefit liability (asset) [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl" xlink:title="label: NetDefinedBenefitLiabilityAssetAxis to ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xml:lang="en-US" id="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl">Net defined benefit liability (asset) [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xlink:title="label: NetDefinedBenefitLiabilityAssetMember to ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" id="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl">Non-adjusting events after reporting period [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:title="label: NonadjustingEventsAfterReportingPeriodAxis to ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" id="ifrs-full_NonadjustingEventsMember_lbl">Non-adjusting events after reporting period [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xlink:title="label: NonadjustingEventsMember to ifrs-full_NonadjustingEventsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="NoncurrentAssets" xlink:title="NoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentAssets_lbl">Total non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:title="label: NoncurrentAssets to ifrs-full_NoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentAssets_lbl1">Non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1" xlink:title="label: NoncurrentAssets to ifrs-full_NoncurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="NoncurrentAssetsAbstract" xlink:title="NoncurrentAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentAssetsAbstract_lbl">Non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:title="label: NoncurrentAssetsAbstract to ifrs-full_NoncurrentAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentAssetsAbstract_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentAssetsAbstract_lbl1">Non-current assets [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl1" xlink:title="label: NoncurrentAssetsAbstract to ifrs-full_NoncurrentAssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="NoncurrentLeaseLiabilities" xlink:title="NoncurrentLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentLeaseLiabilities_lbl">Long-term lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:title="label: NoncurrentLeaseLiabilities to ifrs-full_NoncurrentLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentLeaseLiabilities_lbl1">Non-current lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xlink:title="label: NoncurrentLeaseLiabilities to ifrs-full_NoncurrentLeaseLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="NoncurrentLiabilities" xlink:title="NoncurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentLiabilities_lbl">Total non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xlink:title="label: NoncurrentLiabilities to ifrs-full_NoncurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentLiabilities_lbl1">Non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl1" xlink:title="label: NoncurrentLiabilities to ifrs-full_NoncurrentLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="NoncurrentLiabilitiesAbstract" xlink:title="NoncurrentLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentLiabilitiesAbstract_lbl">Non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:title="label: NoncurrentLiabilitiesAbstract to ifrs-full_NoncurrentLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1">Non-current liabilities [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1" xlink:title="label: NoncurrentLiabilitiesAbstract to ifrs-full_NoncurrentLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="NoncurrentProvisionsForEmployeeBenefits" xlink:title="NoncurrentProvisionsForEmployeeBenefits" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl">Net employee defined benefit liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xlink:title="label: NoncurrentProvisionsForEmployeeBenefits to ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl1">Non-current provisions for employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl1" xlink:title="label: NoncurrentProvisionsForEmployeeBenefits to ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="NoncurrentRestrictedCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl">Long-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xlink:title="label: NoncurrentRestrictedCashAndCashEquivalents to ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl1" xml:lang="en-US" id="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl1">Deposits in escrow accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl1" xlink:title="label: NoncurrentRestrictedCashAndCashEquivalents to ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" id="ifrs-full_NotLaterThanOneYearMember_lbl">Within 1 Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:title="label: NotLaterThanOneYearMember to ifrs-full_NotLaterThanOneYearMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NotLaterThanOneYearMember_lbl1" xml:lang="en-US" id="ifrs-full_NotLaterThanOneYearMember_lbl1">Loss Expiry, December 31, 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl1" xlink:title="label: NotLaterThanOneYearMember to ifrs-full_NotLaterThanOneYearMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_NotLaterThanOneYearMember_lbl2" xml:lang="en-US" id="ifrs-full_NotLaterThanOneYearMember_lbl2">2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl2" xlink:title="label: NotLaterThanOneYearMember to ifrs-full_NotLaterThanOneYearMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl">Granted during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:title="label: NumberOfInstrumentsOtherEquityInstrumentsGranted to ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1">Number of non-vested share awards granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" xlink:title="label: NumberOfInstrumentsOtherEquityInstrumentsGranted to ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl2" xml:lang="en-US" id="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl2">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl2" xlink:title="label: NumberOfInstrumentsOtherEquityInstrumentsGranted to ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl">Vested and exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl1">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl">Vested during the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl1">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl">Expired during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl1">Number of other equity instruments expired in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl">Forfeited during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl1">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl">Non-vested at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1">Non-vested at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl2" xml:lang="en-US" id="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl2">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl2" xlink:title="label: NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement to ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="NumberOfOutstandingShareOptions" xlink:title="NumberOfOutstandingShareOptions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="ifrs-full_NumberOfOutstandingShareOptions_lbl">Outstanding Options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:title="label: NumberOfOutstandingShareOptions to ifrs-full_NumberOfOutstandingShareOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfOutstandingShareOptions_lbl1">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xlink:title="label: NumberOfOutstandingShareOptions to ifrs-full_NumberOfOutstandingShareOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_NumberOfOutstandingShareOptions_lbl2" xml:lang="en-US" id="ifrs-full_NumberOfOutstandingShareOptions_lbl2">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl2" xlink:title="label: NumberOfOutstandingShareOptions to ifrs-full_NumberOfOutstandingShareOptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfShareOptionsExercisableInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl1">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfShareOptionsExercisableInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl">Exercised during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfShareOptionsExercisedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1">Number of share options exercised in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfShareOptionsExercisedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl">Expired during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfShareOptionsExpiredInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1">Number of share options expired in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfShareOptionsExpiredInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl">Forfeited during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl">Number of options awarded (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:title="label: NumberOfShareOptionsGrantedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1">Granted during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" xlink:title="label: NumberOfShareOptionsGrantedInSharebasedPaymentArrangement to ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="NumberOfSharesAuthorised" xlink:title="NumberOfSharesAuthorised" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" id="ifrs-full_NumberOfSharesAuthorised_lbl">Number of additional authorized shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xlink:title="label: NumberOfSharesAuthorised to ifrs-full_NumberOfSharesAuthorised_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfSharesAuthorised_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfSharesAuthorised_lbl1">Number of shares authorised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl1" xlink:title="label: NumberOfSharesAuthorised to ifrs-full_NumberOfSharesAuthorised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="NumberOfSharesIssued" xlink:title="NumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" id="ifrs-full_NumberOfSharesIssued_lbl">Number of common shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:title="label: NumberOfSharesIssued to ifrs-full_NumberOfSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfSharesIssued_lbl1">Number of shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1" xlink:title="label: NumberOfSharesIssued to ifrs-full_NumberOfSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAbstract" xlink:label="NumberOfSharesIssuedAbstract" xlink:title="NumberOfSharesIssuedAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfSharesIssuedAbstract_lbl" xml:lang="en-US" id="ifrs-full_NumberOfSharesIssuedAbstract_lbl">Issuance of shares:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssuedAbstract_lbl" xlink:title="label: NumberOfSharesIssuedAbstract to ifrs-full_NumberOfSharesIssuedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="NumberOfSharesOutstanding" xlink:title="NumberOfSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" id="ifrs-full_NumberOfSharesOutstanding_lbl">Shares outstanding, excluding treasury shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:title="label: NumberOfSharesOutstanding to ifrs-full_NumberOfSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US" id="ifrs-full_NumberOfSharesOutstanding_lbl1">Number of shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1" xlink:title="label: NumberOfSharesOutstanding to ifrs-full_NumberOfSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US" id="ifrs-full_OfficeEquipmentMember_lbl">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl" xlink:title="label: OfficeEquipmentMember to ifrs-full_OfficeEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OfficeEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OfficeEquipmentMember_lbl1" xml:lang="en-US" id="ifrs-full_OfficeEquipmentMember_lbl1">Office equipment [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl1" xlink:title="label: OfficeEquipmentMember to ifrs-full_OfficeEquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="OperatingExpense" xlink:title="OperatingExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="ifrs-full_OperatingExpense_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl" xlink:title="label: OperatingExpense to ifrs-full_OperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OperatingExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OperatingExpense_lbl1" xml:lang="en-US" id="ifrs-full_OperatingExpense_lbl1">Operating expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl1" xlink:title="label: OperatingExpense to ifrs-full_OperatingExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="OrdinarySharesMember" xlink:title="OrdinarySharesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" id="ifrs-full_OrdinarySharesMember_lbl">Common Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xlink:title="label: OrdinarySharesMember to ifrs-full_OrdinarySharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US" id="ifrs-full_OrdinarySharesMember_lbl1">Ordinary shares [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1" xlink:title="label: OrdinarySharesMember to ifrs-full_OrdinarySharesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="OtherComprehensiveIncome" xlink:title="OtherComprehensiveIncome" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="ifrs-full_OtherComprehensiveIncome_lbl">Other comprehensive income/(loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xlink:title="label: OtherComprehensiveIncome to ifrs-full_OtherComprehensiveIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherComprehensiveIncome_lbl1" xml:lang="en-US" id="ifrs-full_OtherComprehensiveIncome_lbl1">Other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl1" xlink:title="label: OtherComprehensiveIncome to ifrs-full_OtherComprehensiveIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:title="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xml:lang="en-US" id="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl">Remeasurement income/(losses) on defined benefit plans (net of tax)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xlink:title="label: OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans to ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl1" xml:lang="en-US" id="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl1">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl1" xlink:title="label: OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans to ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="OtherCurrentLiabilities" xlink:title="OtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" id="ifrs-full_OtherCurrentLiabilities_lbl">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xlink:title="label: OtherCurrentLiabilities to ifrs-full_OtherCurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherCurrentLiabilities_lbl1" xml:lang="en-US" id="ifrs-full_OtherCurrentLiabilities_lbl1">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl1" xlink:title="label: OtherCurrentLiabilities to ifrs-full_OtherCurrentLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptions" xlink:label="OtherMaterialActuarialAssumptions" xlink:title="OtherMaterialActuarialAssumptions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherMaterialActuarialAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OtherMaterialActuarialAssumptions_lbl" xml:lang="en-US" id="ifrs-full_OtherMaterialActuarialAssumptions_lbl">Interest rate on retirement savings capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherMaterialActuarialAssumptions" xlink:to="ifrs-full_OtherMaterialActuarialAssumptions_lbl" xlink:title="label: OtherMaterialActuarialAssumptions to ifrs-full_OtherMaterialActuarialAssumptions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherMaterialActuarialAssumptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherMaterialActuarialAssumptions_lbl1" xml:lang="en-US" id="ifrs-full_OtherMaterialActuarialAssumptions_lbl1">Other material actuarial assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherMaterialActuarialAssumptions" xlink:to="ifrs-full_OtherMaterialActuarialAssumptions_lbl1" xlink:title="label: OtherMaterialActuarialAssumptions to ifrs-full_OtherMaterialActuarialAssumptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptionsMember" xlink:label="OtherMaterialActuarialAssumptionsMember" xlink:title="OtherMaterialActuarialAssumptionsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl" xml:lang="en-US" id="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl">Interest Rate on Savings Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherMaterialActuarialAssumptionsMember" xlink:to="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl" xlink:title="label: OtherMaterialActuarialAssumptionsMember to ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl1" xml:lang="en-US" id="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl1">Other material actuarial assumptions [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherMaterialActuarialAssumptionsMember" xlink:to="ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl1" xlink:title="label: OtherMaterialActuarialAssumptionsMember to ifrs-full_OtherMaterialActuarialAssumptionsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="OtherOperatingIncomeExpense" xlink:title="OtherOperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" id="ifrs-full_OtherOperatingIncomeExpense_lbl">Other operating income/(expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl" xlink:title="label: OtherOperatingIncomeExpense to ifrs-full_OtherOperatingIncomeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ParValuePerShare" xlink:title="ParValuePerShare" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" id="ifrs-full_ParValuePerShare_lbl">Nominal value per share (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xlink:title="label: ParValuePerShare to ifrs-full_ParValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US" id="ifrs-full_ParValuePerShare_lbl1">Par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1" xlink:title="label: ParValuePerShare to ifrs-full_ParValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:title="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl">Net pension cost through statement of income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset to ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl1">Past service cost and gains (losses) arising from settlements, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset to ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="PaymentsForShareIssueCosts" xlink:title="PaymentsForShareIssueCosts" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" id="ifrs-full_PaymentsForShareIssueCosts_lbl">Transaction costs on issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:title="label: PaymentsForShareIssueCosts to ifrs-full_PaymentsForShareIssueCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PaymentsForShareIssueCosts_lbl1" xml:lang="en-US" id="ifrs-full_PaymentsForShareIssueCosts_lbl1">Payments for share issue costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl1" xlink:title="label: PaymentsForShareIssueCosts to ifrs-full_PaymentsForShareIssueCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl">Benefits deposited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: PaymentsFromPlanNetDefinedBenefitLiabilityAsset to ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl1">Benefits deposited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: PaymentsFromPlanNetDefinedBenefitLiabilityAsset to ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl2" xml:lang="en-US" id="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl2">Payments from plan, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl2" xlink:title="label: PaymentsFromPlanNetDefinedBenefitLiabilityAsset to ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:title="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl">Principal payments of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:title="label: PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities to ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1" xml:lang="en-US" id="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1">Payments of lease liabilities, classified as financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1" xlink:title="label: PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities to ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="PaymentsToAcquireOrRedeemEntitysShares" xlink:title="PaymentsToAcquireOrRedeemEntitysShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xml:lang="en-US" id="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl">Payment for the issuance of treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireOrRedeemEntitysShares" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:title="label: PaymentsToAcquireOrRedeemEntitysShares to ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl1" xml:lang="en-US" id="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl1">Payments to acquire or redeem entity's shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireOrRedeemEntitysShares" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl1" xlink:title="label: PaymentsToAcquireOrRedeemEntitysShares to ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="PercentageOfEntitysRevenue" xlink:title="PercentageOfEntitysRevenue" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PercentageOfEntitysRevenue_lbl" xml:lang="en-US" id="ifrs-full_PercentageOfEntitysRevenue_lbl">Percentage of contract revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:title="label: PercentageOfEntitysRevenue to ifrs-full_PercentageOfEntitysRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PercentageOfEntitysRevenue_lbl1" xml:lang="en-US" id="ifrs-full_PercentageOfEntitysRevenue_lbl1">Percentage of entity's revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl1" xlink:title="label: PercentageOfEntitysRevenue to ifrs-full_PercentageOfEntitysRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" xml:lang="en-US" id="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl">Percentage decrease in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" xlink:title="label: PercentageOfReasonablyPossibleDecreaseInActuarialAssumption to ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl1" xml:lang="en-US" id="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl1">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl1" xlink:title="label: PercentageOfReasonablyPossibleDecreaseInActuarialAssumption to ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" xml:lang="en-US" id="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl">Percentage increase in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" xlink:title="label: PercentageOfReasonablyPossibleIncreaseInActuarialAssumption to ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xml:lang="en-US" id="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl1">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl1" xlink:title="label: PercentageOfReasonablyPossibleIncreaseInActuarialAssumption to ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="PerformanceObligationsAxis" xlink:title="PerformanceObligationsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PerformanceObligationsAxis_lbl" xml:lang="en-US" id="ifrs-full_PerformanceObligationsAxis_lbl">Performance obligations [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl" xlink:title="label: PerformanceObligationsAxis to ifrs-full_PerformanceObligationsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="PerformanceObligationsMember" xlink:title="PerformanceObligationsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PerformanceObligationsMember_lbl" xml:lang="en-US" id="ifrs-full_PerformanceObligationsMember_lbl">Performance obligations [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsMember_lbl" xlink:title="label: PerformanceObligationsMember to ifrs-full_PerformanceObligationsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PlanAssetsAtFairValue_lbl" xml:lang="en-US" id="ifrs-full_PlanAssetsAtFairValue_lbl">Fair value of plan assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl" xlink:title="label: PlanAssetsAtFairValue to ifrs-full_PlanAssetsAtFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_PlanAssetsAtFairValue_lbl1" xml:lang="en-US" id="ifrs-full_PlanAssetsAtFairValue_lbl1">Fair value of plan assets, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl1" xlink:title="label: PlanAssetsAtFairValue to ifrs-full_PlanAssetsAtFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_PlanAssetsAtFairValue_lbl2" xml:lang="en-US" id="ifrs-full_PlanAssetsAtFairValue_lbl2">Fair value of plan assets, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl2" xlink:title="label: PlanAssetsAtFairValue to ifrs-full_PlanAssetsAtFairValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PlanAssetsAtFairValue_lbl3" xml:lang="en-US" id="ifrs-full_PlanAssetsAtFairValue_lbl3">Plan assets, at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl3" xlink:title="label: PlanAssetsAtFairValue to ifrs-full_PlanAssetsAtFairValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsMember" xlink:label="PlanAssetsMember" xlink:title="PlanAssetsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PlanAssetsMember_lbl" xml:lang="en-US" id="ifrs-full_PlanAssetsMember_lbl">Fair Value of Plan Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsMember" xlink:to="ifrs-full_PlanAssetsMember_lbl" xlink:title="label: PlanAssetsMember to ifrs-full_PlanAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PlanAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PlanAssetsMember_lbl1" xml:lang="en-US" id="ifrs-full_PlanAssetsMember_lbl1">Plan assets [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanAssetsMember" xlink:to="ifrs-full_PlanAssetsMember_lbl1" xlink:title="label: PlanAssetsMember to ifrs-full_PlanAssetsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:title="PostemploymentBenefitExpenseDefinedContributionPlans" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xml:lang="en-US" id="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl">Expected contribution by employer to be paid to post-retirement benefit plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xlink:title="label: PostemploymentBenefitExpenseDefinedContributionPlans to ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrepaymentsAndAccruedIncomeAbstract" xlink:label="PrepaymentsAndAccruedIncomeAbstract" xlink:title="PrepaymentsAndAccruedIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PrepaymentsAndAccruedIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PrepaymentsAndAccruedIncomeAbstract_lbl" xml:lang="en-US" id="ifrs-full_PrepaymentsAndAccruedIncomeAbstract_lbl">Prepaid expenses and accrued income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsAndAccruedIncomeAbstract" xlink:to="ifrs-full_PrepaymentsAndAccruedIncomeAbstract_lbl" xlink:title="label: PrepaymentsAndAccruedIncomeAbstract to ifrs-full_PrepaymentsAndAccruedIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="PresentValueOfDefinedBenefitObligationMember" xlink:title="PresentValueOfDefinedBenefitObligationMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl" xml:lang="en-US" id="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl">Defined Benefit Obligation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresentValueOfDefinedBenefitObligationMember" xlink:to="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl" xlink:title="label: PresentValueOfDefinedBenefitObligationMember to ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl1" xml:lang="en-US" id="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl1">Present value of defined benefit obligation [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresentValueOfDefinedBenefitObligationMember" xlink:to="ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl1" xlink:title="label: PresentValueOfDefinedBenefitObligationMember to ifrs-full_PresentValueOfDefinedBenefitObligationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" xlink:title="PresentationOfLeasesForLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US" id="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl">Right-of-use assets and lease liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xlink:title="label: PresentationOfLeasesForLesseeAbstract to ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:title="ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl">Proceeds from long-term financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:title="label: ProceedsFromBorrowingsClassifiedAsFinancingActivities to ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ProceedsFromExerciseOfOptions" xlink:title="ProceedsFromExerciseOfOptions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" id="ifrs-full_ProceedsFromExerciseOfOptions_lbl">Proceeds from issuance of common shares - option plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xlink:title="label: ProceedsFromExerciseOfOptions to ifrs-full_ProceedsFromExerciseOfOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProceedsFromExerciseOfOptions_lbl1" xml:lang="en-US" id="ifrs-full_ProceedsFromExerciseOfOptions_lbl1">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl1" xlink:title="label: ProceedsFromExerciseOfOptions to ifrs-full_ProceedsFromExerciseOfOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" id="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl">Gross proceeds received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:title="label: ProceedsFromIssueOfOrdinaryShares to ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl1" xml:lang="en-US" id="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl1">Proceeds from issue of ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl1" xlink:title="label: ProceedsFromIssueOfOrdinaryShares to ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:title="ProceedsFromSaleOrIssueOfTreasuryShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US" id="ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_lbl">Proceeds from issuance of treasury shares, net of transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_lbl" xlink:title="label: ProceedsFromSaleOrIssueOfTreasuryShares to ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl">Proceeds from sale of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:title="label: ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities to ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xml:lang="en-US" id="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1">Proceeds from sales of property, plant and equipment, classified as investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xlink:title="label: ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities to ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" id="ifrs-full_ProductsAndServicesAxis_lbl">Products and services [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xlink:title="label: ProductsAndServicesAxis to ifrs-full_ProductsAndServicesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" id="ifrs-full_ProductsAndServicesMember_lbl">Products and services [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xlink:title="label: ProductsAndServicesMember to ifrs-full_ProductsAndServicesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="ifrs-full_ProfitLoss_lbl">Income/(loss) for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:title="label: ProfitLoss to ifrs-full_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US" id="ifrs-full_ProfitLoss_lbl1">Income/(loss) for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1" xlink:title="label: ProfitLoss to ifrs-full_ProfitLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US" id="ifrs-full_ProfitLoss_lbl2">Net income/(loss) for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2" xlink:title="label: ProfitLoss to ifrs-full_ProfitLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US" id="ifrs-full_ProfitLoss_lbl3">Net income/(loss) attributable to equity holders of the Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3" xlink:title="label: ProfitLoss to ifrs-full_ProfitLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:label="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:title="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl" xml:lang="en-US" id="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl">Numerator [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl" xlink:title="label: ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract to ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl1" xml:lang="en-US" id="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl1">Profit (loss), attributable to ordinary equity holders of parent entity [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl1" xlink:title="label: ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract to ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ProfitLossBeforeTax" xlink:title="ProfitLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" id="ifrs-full_ProfitLossBeforeTax_lbl">Income/(loss) before tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:title="label: ProfitLossBeforeTax to ifrs-full_ProfitLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProfitLossBeforeTax_lbl1" xml:lang="en-US" id="ifrs-full_ProfitLossBeforeTax_lbl1">Income/(loss) before income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl1" xlink:title="label: ProfitLossBeforeTax to ifrs-full_ProfitLossBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ProfitLossFromOperatingActivities" xlink:title="ProfitLossFromOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="ifrs-full_ProfitLossFromOperatingActivities_lbl">Operating income/(loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:title="label: ProfitLossFromOperatingActivities to ifrs-full_ProfitLossFromOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xml:lang="en-US" id="ifrs-full_ProfitLossFromOperatingActivities_lbl1">Profit (loss) from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xlink:title="label: ProfitLossFromOperatingActivities to ifrs-full_ProfitLossFromOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment" xlink:title="PropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_PropertyPlantAndEquipment_lbl">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:title="label: PropertyPlantAndEquipment to ifrs-full_PropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_PropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_PropertyPlantAndEquipment_lbl1">Property, plant and equipment, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl1" xlink:title="label: PropertyPlantAndEquipment to ifrs-full_PropertyPlantAndEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_PropertyPlantAndEquipment_lbl2" xml:lang="en-US" id="ifrs-full_PropertyPlantAndEquipment_lbl2">Property, plant and equipment, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl2" xlink:title="label: PropertyPlantAndEquipment to ifrs-full_PropertyPlantAndEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" id="ifrs-full_PropertyPlantAndEquipmentMember_lbl">Property, plant and equipment [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xlink:title="label: PropertyPlantAndEquipmentMember to ifrs-full_PropertyPlantAndEquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Provisions" xlink:label="Provisions" xlink:title="Provisions" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Provisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_Provisions_lbl" xml:lang="en-US" id="ifrs-full_Provisions_lbl">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Provisions" xlink:to="ifrs-full_Provisions_lbl" xlink:title="label: Provisions to ifrs-full_Provisions_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Provisions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_Provisions_lbl1" xml:lang="en-US" id="ifrs-full_Provisions_lbl1">Provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Provisions" xlink:to="ifrs-full_Provisions_lbl1" xlink:title="label: Provisions to ifrs-full_Provisions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:title="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl">Short-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:title="label: PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities to ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl1" xml:lang="en-US" id="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl1">Purchase of financial instruments, classified as investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl1" xlink:title="label: PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities to ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl">Purchases of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:title="label: PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities to ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xml:lang="en-US" id="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" xlink:title="label: PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities to ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RangeAxis_lbl" xml:lang="en-US" id="ifrs-full_RangeAxis_lbl">Range [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:title="label: RangeAxis to ifrs-full_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RangesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RangesMember_lbl" xml:lang="en-US" id="ifrs-full_RangesMember_lbl">Ranges [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xlink:title="label: RangesMember to ifrs-full_RangesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl" xml:lang="en-US" id="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl" xlink:title="label: RangesOfExercisePricesForOutstandingShareOptionsAxis to ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl" xml:lang="en-US" id="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl" xlink:title="label: RangesOfExercisePricesForOutstandingShareOptionsMember to ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ReceivablesFromContractsWithCustomers" xlink:title="ReceivablesFromContractsWithCustomers" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xml:lang="en-US" id="ifrs-full_ReceivablesFromContractsWithCustomers_lbl">Milestone payment receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xlink:title="label: ReceivablesFromContractsWithCustomers to ifrs-full_ReceivablesFromContractsWithCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_ReceivablesFromContractsWithCustomers_lbl1" xml:lang="en-US" id="ifrs-full_ReceivablesFromContractsWithCustomers_lbl1">Eligible grant amount receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl1" xlink:title="label: ReceivablesFromContractsWithCustomers to ifrs-full_ReceivablesFromContractsWithCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ReceivablesFromContractsWithCustomers_lbl2" xml:lang="en-US" id="ifrs-full_ReceivablesFromContractsWithCustomers_lbl2">Receivables from contracts with customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl2" xlink:title="label: ReceivablesFromContractsWithCustomers to ifrs-full_ReceivablesFromContractsWithCustomers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:title="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xml:lang="en-US" id="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl">Income tax expense reconciled to Income / (loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xlink:title="label: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl1">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl1" xlink:title="label: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:title="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl">Property, plant and equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl1" xml:lang="en-US" id="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl1">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl1" xlink:title="label: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="RepaymentsOfCurrentBorrowings" xlink:title="RepaymentsOfCurrentBorrowings" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xml:lang="en-US" id="ifrs-full_RepaymentsOfCurrentBorrowings_lbl">Repayment of short-term financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfCurrentBorrowings" xlink:to="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xlink:title="label: RepaymentsOfCurrentBorrowings to ifrs-full_RepaymentsOfCurrentBorrowings_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RepaymentsOfCurrentBorrowings_lbl1" xml:lang="en-US" id="ifrs-full_RepaymentsOfCurrentBorrowings_lbl1">Repayments of current borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfCurrentBorrowings" xlink:to="ifrs-full_RepaymentsOfCurrentBorrowings_lbl1" xlink:title="label: RepaymentsOfCurrentBorrowings to ifrs-full_RepaymentsOfCurrentBorrowings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="ifrs-full_ResearchAndDevelopmentExpense_lbl">Research &amp; development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to ifrs-full_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="ifrs-full_ResearchAndDevelopmentExpense_lbl1">Total research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to ifrs-full_ResearchAndDevelopmentExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US" id="ifrs-full_ResearchAndDevelopmentExpense_lbl2">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl2" xlink:title="label: ResearchAndDevelopmentExpense to ifrs-full_ResearchAndDevelopmentExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="RetainedEarnings" xlink:title="RetainedEarnings" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RetainedEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" id="ifrs-full_RetainedEarnings_lbl">Accumulated losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:title="label: RetainedEarnings to ifrs-full_RetainedEarnings_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RetainedEarnings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RetainedEarnings_lbl1" xml:lang="en-US" id="ifrs-full_RetainedEarnings_lbl1">Retained earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl1" xlink:title="label: RetainedEarnings to ifrs-full_RetainedEarnings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" id="ifrs-full_RetainedEarningsMember_lbl">Accumulated Losses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to ifrs-full_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RetainedEarningsMember_lbl1" xml:lang="en-US" id="ifrs-full_RetainedEarningsMember_lbl1">Retained earnings [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to ifrs-full_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl">Return on plan assets excluding interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset to ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl1">Return on plan assets excluding interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset to ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="Revenue" xlink:title="Revenue" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_Revenue_lbl" xml:lang="en-US" id="ifrs-full_Revenue_lbl">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenue" xlink:to="ifrs-full_Revenue_lbl" xlink:title="label: Revenue to ifrs-full_Revenue_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_Revenue_lbl1" xml:lang="en-US" id="ifrs-full_Revenue_lbl1">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenue" xlink:to="ifrs-full_Revenue_lbl1" xlink:title="label: Revenue to ifrs-full_Revenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" id="ifrs-full_RevenueAbstract_lbl">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" xlink:title="label: RevenueAbstract to ifrs-full_RevenueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RevenueAbstract_lbl1" xml:lang="en-US" id="ifrs-full_RevenueAbstract_lbl1">Contract revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl1" xlink:title="label: RevenueAbstract to ifrs-full_RevenueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" id="ifrs-full_RevenueFromContractsWithCustomers_lbl">Contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:title="label: RevenueFromContractsWithCustomers to ifrs-full_RevenueFromContractsWithCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_RevenueFromContractsWithCustomers_lbl1" xml:lang="en-US" id="ifrs-full_RevenueFromContractsWithCustomers_lbl1">Total contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl1" xlink:title="label: RevenueFromContractsWithCustomers to ifrs-full_RevenueFromContractsWithCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RevenueFromContractsWithCustomers_lbl2" xml:lang="en-US" id="ifrs-full_RevenueFromContractsWithCustomers_lbl2">Recognized revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl2" xlink:title="label: RevenueFromContractsWithCustomers to ifrs-full_RevenueFromContractsWithCustomers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:title="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" xml:lang="en-US" id="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl">Performance obligations satisfied in previous periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:to="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" xlink:title="label: RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods to ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:title="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" id="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl">Amounts included in the contract liability at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xlink:title="label: RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod to ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets" xlink:title="RightofuseAssets" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" id="ifrs-full_RightofuseAssets_lbl">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xlink:title="label: RightofuseAssets to ifrs-full_RightofuseAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_RightofuseAssets_lbl1" xml:lang="en-US" id="ifrs-full_RightofuseAssets_lbl1">Balance, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl1" xlink:title="label: RightofuseAssets to ifrs-full_RightofuseAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_RightofuseAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_RightofuseAssets_lbl2" xml:lang="en-US" id="ifrs-full_RightofuseAssets_lbl2">Balance, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl2" xlink:title="label: RightofuseAssets to ifrs-full_RightofuseAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl">General &amp; administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1">Total general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpense to ifrs-full_SellingGeneralAndAdministrativeExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl2" xml:lang="en-US" id="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl2">Selling, general and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl2" xlink:title="label: SellingGeneralAndAdministrativeExpense to ifrs-full_SellingGeneralAndAdministrativeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="SellingGeneralAndAdministrativeExpenseAbstract" xlink:title="SellingGeneralAndAdministrativeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" id="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl">General and administrative [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpenseAbstract to ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl1" xml:lang="en-US" id="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl1">Selling, general and administrative expense [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpenseAbstract to ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" id="ifrs-full_ShareIssueRelatedCost_lbl">Transaction offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xlink:title="label: ShareIssueRelatedCost to ifrs-full_ShareIssueRelatedCost_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ShareIssueRelatedCost_lbl1" xml:lang="en-US" id="ifrs-full_ShareIssueRelatedCost_lbl1">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl1" xlink:title="label: ShareIssueRelatedCost to ifrs-full_ShareIssueRelatedCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ShareIssueRelatedCost_lbl2" xml:lang="en-US" id="ifrs-full_ShareIssueRelatedCost_lbl2">Share issue related cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl2" xlink:title="label: ShareIssueRelatedCost to ifrs-full_ShareIssueRelatedCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="SharePremium" xlink:title="SharePremium" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SharePremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SharePremium_lbl" xml:lang="en-US" id="ifrs-full_SharePremium_lbl">Share premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xlink:title="label: SharePremium to ifrs-full_SharePremium_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="SharePremiumMember" xlink:title="SharePremiumMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SharePremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" id="ifrs-full_SharePremiumMember_lbl">Share Premium [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xlink:title="label: SharePremiumMember to ifrs-full_SharePremiumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" id="ifrs-full_SharebasedPaymentArrangementsMember_lbl">Share-based payment arrangements [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:title="label: SharebasedPaymentArrangementsMember to ifrs-full_SharebasedPaymentArrangementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ShorttermBorrowingsMember" xlink:title="ShorttermBorrowingsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ShorttermBorrowingsMember_lbl" xml:lang="en-US" id="ifrs-full_ShorttermBorrowingsMember_lbl">Short-term Financing Obligation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermBorrowingsMember" xlink:to="ifrs-full_ShorttermBorrowingsMember_lbl" xlink:title="label: ShorttermBorrowingsMember to ifrs-full_ShorttermBorrowingsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ShorttermEmployeeBenefitsAccruals" xlink:title="ShorttermEmployeeBenefitsAccruals" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US" id="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl">Accrual of performance-related remuneration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xlink:title="label: ShorttermEmployeeBenefitsAccruals to ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl1" xml:lang="en-US" id="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl1">Short-term employee benefits accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl1" xlink:title="label: ShorttermEmployeeBenefitsAccruals to ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="ifrs-full_StatementOfCashFlowsAbstract_lbl">Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to ifrs-full_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" xlink:title="StatementOfChangesInEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" id="ifrs-full_StatementOfChangesInEquityAbstract_lbl">Statements of Changes in Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:title="label: StatementOfChangesInEquityAbstract to ifrs-full_StatementOfChangesInEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="StatementOfChangesInEquityLineItems" xlink:title="StatementOfChangesInEquityLineItems" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" id="ifrs-full_StatementOfChangesInEquityLineItems_lbl">Statement of changes in equity [line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:title="label: StatementOfChangesInEquityLineItems to ifrs-full_StatementOfChangesInEquityLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="StatementOfChangesInEquityTable" xlink:title="StatementOfChangesInEquityTable" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" id="ifrs-full_StatementOfChangesInEquityTable_lbl">Statement of changes in equity [table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:title="label: StatementOfChangesInEquityTable to ifrs-full_StatementOfChangesInEquityTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" xlink:title="StatementOfComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl">Statements of Comprehensive Income/(Loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:title="label: StatementOfComprehensiveIncomeAbstract to ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="ifrs-full_StatementOfFinancialPositionAbstract_lbl">Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to ifrs-full_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="SurplusDeficitInPlan" xlink:title="SurplusDeficitInPlan" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SurplusDeficitInPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ifrs-full_SurplusDeficitInPlan_lbl" xml:lang="en-US" id="ifrs-full_SurplusDeficitInPlan_lbl">Total liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SurplusDeficitInPlan" xlink:to="ifrs-full_SurplusDeficitInPlan_lbl" xlink:title="label: SurplusDeficitInPlan to ifrs-full_SurplusDeficitInPlan_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SurplusDeficitInPlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SurplusDeficitInPlan_lbl1" xml:lang="en-US" id="ifrs-full_SurplusDeficitInPlan_lbl1">Surplus (deficit) in plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SurplusDeficitInPlan" xlink:to="ifrs-full_SurplusDeficitInPlan_lbl1" xlink:title="label: SurplusDeficitInPlan to ifrs-full_SurplusDeficitInPlan_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlanAbstract" xlink:label="SurplusDeficitInPlanAbstract" xlink:title="SurplusDeficitInPlanAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SurplusDeficitInPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_SurplusDeficitInPlanAbstract_lbl" xml:lang="en-US" id="ifrs-full_SurplusDeficitInPlanAbstract_lbl">Defined benefit pension plan amount recognized in balance sheet [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SurplusDeficitInPlanAbstract" xlink:to="ifrs-full_SurplusDeficitInPlanAbstract_lbl" xlink:title="label: SurplusDeficitInPlanAbstract to ifrs-full_SurplusDeficitInPlanAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_SurplusDeficitInPlanAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_SurplusDeficitInPlanAbstract_lbl1" xml:lang="en-US" id="ifrs-full_SurplusDeficitInPlanAbstract_lbl1">Surplus (deficit) in plan [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SurplusDeficitInPlanAbstract" xlink:to="ifrs-full_SurplusDeficitInPlanAbstract_lbl1" xlink:title="label: SurplusDeficitInPlanAbstract to ifrs-full_SurplusDeficitInPlanAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:title="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xml:lang="en-US" id="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl">Income not subject to tax/(expenses) not deductible for tax purposes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:title="label: TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss to ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl1" xml:lang="en-US" id="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl1">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl1" xlink:title="label: TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss to ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:label="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:title="TaxEffectOfRevenuesExemptFromTaxation2011" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl" xml:lang="en-US" id="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl">Income not subject to tax/(expenses) not deductible for tax purposes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:to="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl" xlink:title="label: TaxEffectOfRevenuesExemptFromTaxation2011 to ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl1" xml:lang="en-US" id="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl1">Tax effect of revenues exempt from taxation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:to="ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl1" xlink:title="label: TaxEffectOfRevenuesExemptFromTaxation2011 to ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="TaxEffectOfTaxLosses" xlink:title="TaxEffectOfTaxLosses" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US" id="ifrs-full_TaxEffectOfTaxLosses_lbl">Effect of unused tax losses and tax offsets not recognized as deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:title="label: TaxEffectOfTaxLosses to ifrs-full_TaxEffectOfTaxLosses_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TaxEffectOfTaxLosses_lbl1" xml:lang="en-US" id="ifrs-full_TaxEffectOfTaxLosses_lbl1">Tax effect of tax losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl1" xlink:title="label: TaxEffectOfTaxLosses to ifrs-full_TaxEffectOfTaxLosses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="TaxExpenseIncomeAtApplicableTaxRate" xlink:title="TaxExpenseIncomeAtApplicableTaxRate" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" id="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl">Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:title="label: TaxExpenseIncomeAtApplicableTaxRate to ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" id="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xlink:title="label: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" id="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xlink:title="label: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" id="ifrs-full_TopOfRangeMember_lbl">Top of Range [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xlink:title="label: TopOfRangeMember to ifrs-full_TopOfRangeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US" id="ifrs-full_TopOfRangeMember_lbl1">Top of range [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1" xlink:title="label: TopOfRangeMember to ifrs-full_TopOfRangeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="TradeAndOtherCurrentPayables" xlink:title="TradeAndOtherCurrentPayables" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" id="ifrs-full_TradeAndOtherCurrentPayables_lbl">Trade and other payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:title="label: TradeAndOtherCurrentPayables to ifrs-full_TradeAndOtherCurrentPayables_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US" id="ifrs-full_TradeAndOtherCurrentPayables_lbl1">Total trade and other payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xlink:title="label: TradeAndOtherCurrentPayables to ifrs-full_TradeAndOtherCurrentPayables_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TradeAndOtherCurrentPayables_lbl2" xml:lang="en-US" id="ifrs-full_TradeAndOtherCurrentPayables_lbl2">Trade and other current payables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl2" xlink:title="label: TradeAndOtherCurrentPayables to ifrs-full_TradeAndOtherCurrentPayables_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" xlink:title="TradeAndOtherCurrentPayablesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US" id="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl">Trade payables and accrued liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xlink:title="label: TradeAndOtherCurrentPayablesAbstract to ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="TradeAndOtherReceivablesAbstract" xlink:title="TradeAndOtherReceivablesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US" id="ifrs-full_TradeAndOtherReceivablesAbstract_lbl">Other current receivables [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xlink:title="label: TradeAndOtherReceivablesAbstract to ifrs-full_TradeAndOtherReceivablesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TradeAndOtherReceivablesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_TradeAndOtherReceivablesAbstract_lbl1">Trade and other receivables [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl1" xlink:title="label: TradeAndOtherReceivablesAbstract to ifrs-full_TradeAndOtherReceivablesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xml:lang="en-US" id="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl">Total potential collaboration agreement value remaining</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xlink:title="label: TransactionPriceAllocatedToRemainingPerformanceObligations to ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl1" xml:lang="en-US" id="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl1">Expected transaction price allocation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl1" xlink:title="label: TransactionPriceAllocatedToRemainingPerformanceObligations to ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl2" xml:lang="en-US" id="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl2">Transaction price allocated to remaining performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl2" xlink:title="label: TransactionPriceAllocatedToRemainingPerformanceObligations to ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="TreasuryShares" xlink:title="TreasuryShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" id="ifrs-full_TreasuryShares_lbl">Treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xlink:title="label: TreasuryShares to ifrs-full_TreasuryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TreasuryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TreasuryShares_lbl1" xml:lang="en-US" id="ifrs-full_TreasuryShares_lbl1">Treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl1" xlink:title="label: TreasuryShares to ifrs-full_TreasuryShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:label="TreasurySharesMember" xlink:title="TreasurySharesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" id="ifrs-full_TreasurySharesMember_lbl">Treasury Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" xlink:title="label: TreasurySharesMember to ifrs-full_TreasurySharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TreasurySharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TreasurySharesMember_lbl1" xml:lang="en-US" id="ifrs-full_TreasurySharesMember_lbl1">Treasury shares [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl1" xlink:title="label: TreasurySharesMember to ifrs-full_TreasurySharesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" id="ifrs-full_TypesOfContractsAxis_lbl">Types of contracts [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl" xlink:title="label: TypesOfContractsAxis to ifrs-full_TypesOfContractsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" id="ifrs-full_TypesOfContractsMember_lbl">Types of contracts [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl" xlink:title="label: TypesOfContractsMember to ifrs-full_TypesOfContractsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" id="ifrs-full_TypesOfRisksAxis_lbl">Types of risks [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xlink:title="label: TypesOfRisksAxis to ifrs-full_TypesOfRisksAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" id="ifrs-full_TypesOfRisksMember_lbl">Risks [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xlink:title="label: TypesOfRisksMember to ifrs-full_TypesOfRisksMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" id="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl">Types of share-based payment arrangements [axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:title="label: TypesOfSharebasedPaymentArrangementsAxis to ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:title="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US" id="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl">Unused tax losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xlink:title="label: UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised to ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl1" xml:lang="en-US" id="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl1">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl1" xlink:title="label: UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised to ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="UnusedTaxLossesMember" xlink:title="UnusedTaxLossesMember" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" id="ifrs-full_UnusedTaxLossesMember_lbl">Tax Losses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl" xlink:title="label: UnusedTaxLossesMember to ifrs-full_UnusedTaxLossesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_UnusedTaxLossesMember_lbl1" xml:lang="en-US" id="ifrs-full_UnusedTaxLossesMember_lbl1">Unused tax losses [member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl1" xlink:title="label: UnusedTaxLossesMember to ifrs-full_UnusedTaxLossesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:title="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:title="label: UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment to ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl1">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl1" xlink:title="label: UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment to ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:label="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:title="WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl">Weighted average duration period for defined benefit obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:to="ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" xlink:title="label: WeightedAverageDurationOfDefinedBenefitObligation2019 to ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl">Vested and exercisable (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl">Vested during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl">Expired during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of other equity instruments expired in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl">Forfeited during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl">Granted during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl1">Weighted average fair value, restricted share awards granted (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl2" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl2">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl2" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl">Non-vested at beginning of period (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl1">Non-vested at end of period (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl2" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl2">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl2" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl">Exercisable (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl">Exercised during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl">Expired during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl">Forfeited during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl">Weighted average exercise price for options granted (in CHF/USD per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl1">Granted during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl">Weighted average share price of common share options exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl1">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl">Outstanding at beginning of period (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1">Outstanding at end of period (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2" xml:lang="en-US" id="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2" xlink:title="label: WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 to ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:title="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl">Weighted average incremental borrowing rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" xlink:title="label: WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 to ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl1">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl1" xlink:title="label: WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 to ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:title="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl">Weighted average remaining term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:title="label: WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 to ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" xlink:title="label: WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 to ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="WeightedAverageSharePrice2019" xlink:title="WeightedAverageSharePrice2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageSharePrice2019_lbl">Share price, weighted average (in USD per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xlink:title="label: WeightedAverageSharePrice2019 to ifrs-full_WeightedAverageSharePrice2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageSharePrice2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageSharePrice2019_lbl1">Weighted average share price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl1" xlink:title="label: WeightedAverageSharePrice2019 to ifrs-full_WeightedAverageSharePrice2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="WeightedAverageSharePriceShareOptionsGranted2019" xlink:title="WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl">Weighted average fair value, options granted (in USD/CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xlink:title="label: WeightedAverageSharePriceShareOptionsGranted2019 to ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1">Weighted average share price, share options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xlink:title="label: WeightedAverageSharePriceShareOptionsGranted2019 to ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="WeightedAverageShares" xlink:title="WeightedAverageShares" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageShares_lbl">Weighted-average number of shares outstanding to equity holders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:title="label: WeightedAverageShares to ifrs-full_WeightedAverageShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageShares_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageShares_lbl1">Weighted average number of ordinary shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl1" xlink:title="label: WeightedAverageShares to ifrs-full_WeightedAverageShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:title="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US" id="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl">Denominator [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:title="label: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl1" xml:lang="en-US" id="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl1">Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl1" xlink:title="label: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport_lbl" xml:lang="en-US" id="dei_DocumentAnnualReport_lbl">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="DocumentShellCompanyReport" xlink:title="DocumentShellCompanyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentShellCompanyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" id="dei_DocumentShellCompanyReport_lbl">Document Shell Company Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:title="label: DocumentShellCompanyReport to dei_DocumentShellCompanyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="DocumentAccountingStandard" xlink:title="DocumentAccountingStandard" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAccountingStandard_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" id="dei_DocumentAccountingStandard_lbl">Document Accounting Standard</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:title="label: DocumentAccountingStandard to dei_DocumentAccountingStandard_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="dei_EntityExTransitionPeriod_lbl">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:title="label: EntityExTransitionPeriod to dei_EntityExTransitionPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF" xlink:label="CHF" xlink:title="CHF" />
    <link:label xlink:type="resource" xlink:label="currency_CHF_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="currency_CHF_lbl" xml:lang="en-US" id="currency_CHF_lbl">CHF [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CHF" xlink:to="currency_CHF_lbl" xlink:title="label: CHF to currency_CHF_lbl" />
    <link:label xlink:type="resource" xlink:label="currency_CHF_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="currency_CHF_lbl1" xml:lang="en-US" id="currency_CHF_lbl1">Switzerland, Francs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CHF" xlink:to="currency_CHF_lbl1" xlink:title="label: CHF to currency_CHF_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="EUR" xlink:title="EUR" />
    <link:label xlink:type="resource" xlink:label="currency_EUR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="currency_EUR_lbl" xml:lang="en-US" id="currency_EUR_lbl">EUR [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUR" xlink:to="currency_EUR_lbl" xlink:title="label: EUR to currency_EUR_lbl" />
    <link:label xlink:type="resource" xlink:label="currency_EUR_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="currency_EUR_lbl1" xml:lang="en-US" id="currency_EUR_lbl1">Euro Member Countries, Euro</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUR" xlink:to="currency_EUR_lbl1" xlink:title="label: EUR to currency_EUR_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="USD" xlink:title="USD" />
    <link:label xlink:type="resource" xlink:label="currency_USD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="currency_USD_lbl" xml:lang="en-US" id="currency_USD_lbl">USD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USD" xlink:to="currency_USD_lbl" xlink:title="label: USD to currency_USD_lbl" />
    <link:label xlink:type="resource" xlink:label="currency_USD_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="currency_USD_lbl1" xml:lang="en-US" id="currency_USD_lbl1">United States of America, Dollars</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USD" xlink:to="currency_USD_lbl1" xlink:title="label: USD to currency_USD_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:label xlink:type="resource" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" id="currency_AllCurrenciesDomain_lbl">All Currencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xlink:title="label: AllCurrenciesDomain to currency_AllCurrenciesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CurrencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CurrencyAxis_lbl" xml:lang="en-US" id="srt_CurrencyAxis_lbl">Currency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:title="label: CurrencyAxis to srt_CurrencyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl" xml:lang="en-US" id="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl">The amount of current other receivables and receivables from value added taxes and withholding taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl" xlink:title="label: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl1" xml:lang="en-US" id="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl1">Current receivables classified as other and value added and withholding taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl1" xlink:title="label: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl2" xml:lang="en-US" id="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl2">Other current receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl2" xlink:title="label: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl3" xml:lang="en-US" id="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl3">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:to="aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl3" xlink:title="label: CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes to aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesOperatingAbstract" xlink:label="ExpensesOperatingAbstract" xlink:title="ExpensesOperatingAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpensesOperatingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ExpensesOperatingAbstract_lbl1" xml:lang="en-US" id="aciu_ExpensesOperatingAbstract_lbl1">Expenses, Operating [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpensesOperatingAbstract" xlink:to="aciu_ExpensesOperatingAbstract_lbl1" xlink:title="label: ExpensesOperatingAbstract to aciu_ExpensesOperatingAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpensesOperatingAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ExpensesOperatingAbstract_lbl2" xml:lang="en-US" id="aciu_ExpensesOperatingAbstract_lbl2">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpensesOperatingAbstract" xlink:to="aciu_ExpensesOperatingAbstract_lbl2" xlink:title="label: ExpensesOperatingAbstract to aciu_ExpensesOperatingAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:label xlink:type="resource" xlink:label="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl" xml:lang="en-US" id="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl">The gain (loss) arising from the change in fair value of a convertible instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:to="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl" xlink:title="label: GainLossArisingFromChangeInFairValueOfConvertibleInstrument to aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl1" xml:lang="en-US" id="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl1">Gain (loss) arising from change in fair value of convertible instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:to="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl1" xlink:title="label: GainLossArisingFromChangeInFairValueOfConvertibleInstrument to aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl2" xml:lang="en-US" id="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl2">Change in fair value of conversion feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:to="aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl2" xlink:title="label: GainLossArisingFromChangeInFairValueOfConvertibleInstrument to aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:label="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="ProceedsFromIssuingSharesNetOfUnderwritingFees" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl" xml:lang="en-US" id="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl">The cash inflow from issuing ordinary shares net of underwriting fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:to="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl" xlink:title="label: ProceedsFromIssuingSharesNetOfUnderwritingFees to aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl1" xml:lang="en-US" id="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl1">Proceeds from issuing shares, net of underwriting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:to="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl1" xlink:title="label: ProceedsFromIssuingSharesNetOfUnderwritingFees to aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl2" xml:lang="en-US" id="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl2">Proceeds from public offerings, net of underwriting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:to="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl2" xlink:title="label: ProceedsFromIssuingSharesNetOfUnderwritingFees to aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl3" xml:lang="en-US" id="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl3">Proceeds from public offerings of common shares, net of underwriting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:to="aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl3" xlink:title="label: ProceedsFromIssuingSharesNetOfUnderwritingFees to aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssueOfEquityRestrictedShareAwards" xlink:label="IssueOfEquityRestrictedShareAwards" xlink:title="IssueOfEquityRestrictedShareAwards" />
    <link:label xlink:type="resource" xlink:label="aciu_IssueOfEquityRestrictedShareAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IssueOfEquityRestrictedShareAwards_lbl" xml:lang="en-US" id="aciu_IssueOfEquityRestrictedShareAwards_lbl">The increase in equity through the issue of restricted share awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssueOfEquityRestrictedShareAwards" xlink:to="aciu_IssueOfEquityRestrictedShareAwards_lbl" xlink:title="label: IssueOfEquityRestrictedShareAwards to aciu_IssueOfEquityRestrictedShareAwards_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IssueOfEquityRestrictedShareAwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IssueOfEquityRestrictedShareAwards_lbl1" xml:lang="en-US" id="aciu_IssueOfEquityRestrictedShareAwards_lbl1">Issue of Equity, Restricted Share Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssueOfEquityRestrictedShareAwards" xlink:to="aciu_IssueOfEquityRestrictedShareAwards_lbl1" xlink:title="label: IssueOfEquityRestrictedShareAwards to aciu_IssueOfEquityRestrictedShareAwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IssueOfEquityRestrictedShareAwards_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IssueOfEquityRestrictedShareAwards_lbl2" xml:lang="en-US" id="aciu_IssueOfEquityRestrictedShareAwards_lbl2">Restricted share awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssueOfEquityRestrictedShareAwards" xlink:to="aciu_IssueOfEquityRestrictedShareAwards_lbl2" xlink:title="label: IssueOfEquityRestrictedShareAwards to aciu_IssueOfEquityRestrictedShareAwards_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAdvancesForRentDeposit" xlink:label="CashAdvancesForRentDeposit" xlink:title="CashAdvancesForRentDeposit" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAdvancesForRentDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CashAdvancesForRentDeposit_lbl" xml:lang="en-US" id="aciu_CashAdvancesForRentDeposit_lbl">The cash outflow for deposit of rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAdvancesForRentDeposit" xlink:to="aciu_CashAdvancesForRentDeposit_lbl" xlink:title="label: CashAdvancesForRentDeposit to aciu_CashAdvancesForRentDeposit_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAdvancesForRentDeposit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CashAdvancesForRentDeposit_lbl1" xml:lang="en-US" id="aciu_CashAdvancesForRentDeposit_lbl1">Cash Advances for Rent Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAdvancesForRentDeposit" xlink:to="aciu_CashAdvancesForRentDeposit_lbl1" xlink:title="label: CashAdvancesForRentDeposit to aciu_CashAdvancesForRentDeposit_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAdvancesForRentDeposit_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_CashAdvancesForRentDeposit_lbl2" xml:lang="en-US" id="aciu_CashAdvancesForRentDeposit_lbl2">Rental deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAdvancesForRentDeposit" xlink:to="aciu_CashAdvancesForRentDeposit_lbl2" xlink:title="label: CashAdvancesForRentDeposit to aciu_CashAdvancesForRentDeposit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PaymentsForShareIssueCostsOnPublicOffering" xlink:label="PaymentsForShareIssueCostsOnPublicOffering" xlink:title="PaymentsForShareIssueCostsOnPublicOffering" />
    <link:label xlink:type="resource" xlink:label="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl" xml:lang="en-US" id="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl">The cash outflow for share issue costs for public offerings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForShareIssueCostsOnPublicOffering" xlink:to="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl" xlink:title="label: PaymentsForShareIssueCostsOnPublicOffering to aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl1" xml:lang="en-US" id="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl1">Payments for share issue costs on public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForShareIssueCostsOnPublicOffering" xlink:to="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl1" xlink:title="label: PaymentsForShareIssueCostsOnPublicOffering to aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl2" xml:lang="en-US" id="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl2">Transaction costs on public offerings of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForShareIssueCostsOnPublicOffering" xlink:to="aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl2" xlink:title="label: PaymentsForShareIssueCostsOnPublicOffering to aciu_PaymentsForShareIssueCostsOnPublicOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfConvertibleDebt" xlink:label="ProceedsFromIssueOfConvertibleDebt" xlink:title="ProceedsFromIssueOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ProceedsFromIssueOfConvertibleDebt_lbl" xml:lang="en-US" id="aciu_ProceedsFromIssueOfConvertibleDebt_lbl">The cash inflow from the issuing of convertible debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfConvertibleDebt" xlink:to="aciu_ProceedsFromIssueOfConvertibleDebt_lbl" xlink:title="label: ProceedsFromIssueOfConvertibleDebt to aciu_ProceedsFromIssueOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ProceedsFromIssueOfConvertibleDebt_lbl1" xml:lang="en-US" id="aciu_ProceedsFromIssueOfConvertibleDebt_lbl1">Proceeds from issue of convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfConvertibleDebt" xlink:to="aciu_ProceedsFromIssueOfConvertibleDebt_lbl1" xlink:title="label: ProceedsFromIssueOfConvertibleDebt to aciu_ProceedsFromIssueOfConvertibleDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfConvertibleDebt_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ProceedsFromIssueOfConvertibleDebt_lbl2" xml:lang="en-US" id="aciu_ProceedsFromIssueOfConvertibleDebt_lbl2">Proceeds from issuance of convertible loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfConvertibleDebt" xlink:to="aciu_ProceedsFromIssueOfConvertibleDebt_lbl2" xlink:title="label: ProceedsFromIssueOfConvertibleDebt to aciu_ProceedsFromIssueOfConvertibleDebt_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangesInWorkingCapitalAbstract" xlink:label="ChangesInWorkingCapitalAbstract" xlink:title="ChangesInWorkingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangesInWorkingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ChangesInWorkingCapitalAbstract_lbl1" xml:lang="en-US" id="aciu_ChangesInWorkingCapitalAbstract_lbl1">Changes in working capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="aciu_ChangesInWorkingCapitalAbstract_lbl1" xlink:title="label: ChangesInWorkingCapitalAbstract to aciu_ChangesInWorkingCapitalAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangesInWorkingCapitalAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ChangesInWorkingCapitalAbstract_lbl2" xml:lang="en-US" id="aciu_ChangesInWorkingCapitalAbstract_lbl2">Changes in working capital:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="aciu_ChangesInWorkingCapitalAbstract_lbl2" xlink:title="label: ChangesInWorkingCapitalAbstract to aciu_ChangesInWorkingCapitalAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl">Adjustments for increase (decrease) in long-term financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:to="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl" xlink:title="label: AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities to aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl1" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl1">Adjustments for Increase (Decrease) Long-term Financial Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:to="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl1" xlink:title="label: AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities to aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl2" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl2">Decrease in financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:to="aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl2" xlink:title="label: AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities to aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:label="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:title="AdjustmentsForDecreaseIncreaseInAccruedIncome" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl">Adjustments for decrease (increase) in accrued income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl" xlink:title="label: AdjustmentsForDecreaseIncreaseInAccruedIncome to aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl1" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl1">Adjustments for decrease (increase) in accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl1" xlink:title="label: AdjustmentsForDecreaseIncreaseInAccruedIncome to aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl2" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl2">(Increase)/decrease in accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl2" xlink:title="label: AdjustmentsForDecreaseIncreaseInAccruedIncome to aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:label="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:title="AdjustmentsForIncreaseDecreaseInAccruedExpenses" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl">Adjustments for increase (decrease) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:to="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl" xlink:title="label: AdjustmentsForIncreaseDecreaseInAccruedExpenses to aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl1" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl1">Adjustments for increase (decrease) in accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:to="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl1" xlink:title="label: AdjustmentsForIncreaseDecreaseInAccruedExpenses to aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl2" xml:lang="en-US" id="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl2">(Decrease)/increase in accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:to="aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl2" xlink:title="label: AdjustmentsForIncreaseDecreaseInAccruedExpenses to aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:label="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:title="AdjustmentsForDecreaseIncreaseInPrepaidExpense" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl">Adjustments for decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl" xlink:title="label: AdjustmentsForDecreaseIncreaseInPrepaidExpense to aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl1" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl1">Adjustments for decrease (increase) in prepaid expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl1" xlink:title="label: AdjustmentsForDecreaseIncreaseInPrepaidExpense to aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl2" xml:lang="en-US" id="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl2">(Increase) in prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:to="aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl2" xlink:title="label: AdjustmentsForDecreaseIncreaseInPrepaidExpense to aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:label="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:title="AdjustmentsForDepreciationExpenseRightOfUseAssets" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl" xml:lang="en-US" id="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl">Adjustments for depreciation expense for right-of-use assets to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:to="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl" xlink:title="label: AdjustmentsForDepreciationExpenseRightOfUseAssets to aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl1" xml:lang="en-US" id="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl1">Adjustments for depreciation expense, right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:to="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl1" xlink:title="label: AdjustmentsForDepreciationExpenseRightOfUseAssets to aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl2" xml:lang="en-US" id="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl2">Depreciation of right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:to="aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl2" xlink:title="label: AdjustmentsForDepreciationExpenseRightOfUseAssets to aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:label="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:title="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl">The disclosure of prepayments and accrued income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:to="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl" xlink:title="label: DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock to aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl1">Disclosure of prepaid expenses and accrued income [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:to="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl1" xlink:title="label: DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock to aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl2">Prepaid expenses and accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:to="aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl2" xlink:title="label: DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock to aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeTable" xlink:label="PrepaidExpensesAndAccruedIncomeTable" xlink:title="PrepaidExpensesAndAccruedIncomeTable" />
    <link:label xlink:type="resource" xlink:label="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl" xml:lang="en-US" id="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl">Schedule disclosing information related to details of Prepaid expenses and accrued income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndAccruedIncomeTable" xlink:to="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl" xlink:title="label: PrepaidExpensesAndAccruedIncomeTable to aciu_PrepaidExpensesAndAccruedIncomeTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl1" xml:lang="en-US" id="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl1">Prepaid Expenses and Accrued Income [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndAccruedIncomeTable" xlink:to="aciu_PrepaidExpensesAndAccruedIncomeTable_lbl1" xlink:title="label: PrepaidExpensesAndAccruedIncomeTable to aciu_PrepaidExpensesAndAccruedIncomeTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeLineItems" xlink:label="PrepaidExpensesAndAccruedIncomeLineItems" xlink:title="PrepaidExpensesAndAccruedIncomeLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl" xml:lang="en-US" id="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl" xlink:title="label: PrepaidExpensesAndAccruedIncomeLineItems to aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl1" xml:lang="en-US" id="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl1">Prepaid Expenses and Accrued Income [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl1" xlink:title="label: PrepaidExpensesAndAccruedIncomeLineItems to aciu_PrepaidExpensesAndAccruedIncomeLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAccruedIncome" xlink:label="PercentageOfAccruedIncome" xlink:title="PercentageOfAccruedIncome" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAccruedIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfAccruedIncome_lbl" xml:lang="en-US" id="aciu_PercentageOfAccruedIncome_lbl">Percentage that represents the percentage of total accrued income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAccruedIncome" xlink:to="aciu_PercentageOfAccruedIncome_lbl" xlink:title="label: PercentageOfAccruedIncome to aciu_PercentageOfAccruedIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAccruedIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfAccruedIncome_lbl1" xml:lang="en-US" id="aciu_PercentageOfAccruedIncome_lbl1">Percentage of Accrued Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAccruedIncome" xlink:to="aciu_PercentageOfAccruedIncome_lbl1" xlink:title="label: PercentageOfAccruedIncome to aciu_PercentageOfAccruedIncome_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAccruedIncome_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfAccruedIncome_lbl2" xml:lang="en-US" id="aciu_PercentageOfAccruedIncome_lbl2">Percentage of accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAccruedIncome" xlink:to="aciu_PercentageOfAccruedIncome_lbl2" xlink:title="label: PercentageOfAccruedIncome to aciu_PercentageOfAccruedIncome_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl">The 2014 contractual research agreement associated with collaboration with Janssen Pharmaceuticals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:to="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl" xlink:title="label: CollaborationAgreementOf2014JanssenPharmaceuticalsMember to aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl1">Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:to="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl1" xlink:title="label: CollaborationAgreementOf2014JanssenPharmaceuticalsMember to aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl2">Janssen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:to="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl2" xlink:title="label: CollaborationAgreementOf2014JanssenPharmaceuticalsMember to aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl3" xml:lang="en-US" id="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl3">2014 Agreement with Janssen Pharmaceuticals [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:to="aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl3" xlink:title="label: CollaborationAgreementOf2014JanssenPharmaceuticalsMember to aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SensitivityAnalysisActuarialAssumptionsAbstract" xlink:label="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:title="SensitivityAnalysisActuarialAssumptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl1" xml:lang="en-US" id="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl1">Sensitivity analysis, actuarial assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl1" xlink:title="label: SensitivityAnalysisActuarialAssumptionsAbstract to aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl2" xml:lang="en-US" id="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl2">Sensitivity analysis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl2" xlink:title="label: SensitivityAnalysisActuarialAssumptionsAbstract to aciu_SensitivityAnalysisActuarialAssumptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssuedActuarialTablesSwitzerland" xlink:label="IssuedActuarialTablesSwitzerland" xlink:title="IssuedActuarialTablesSwitzerland" />
    <link:label xlink:type="resource" xlink:label="aciu_IssuedActuarialTablesSwitzerland_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IssuedActuarialTablesSwitzerland_lbl" xml:lang="en-US" id="aciu_IssuedActuarialTablesSwitzerland_lbl">Published actuarial tables that detail assumptions about mortality and disability rates which are used to determine benefit obligations for defined benefit plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedActuarialTablesSwitzerland" xlink:to="aciu_IssuedActuarialTablesSwitzerland_lbl" xlink:title="label: IssuedActuarialTablesSwitzerland to aciu_IssuedActuarialTablesSwitzerland_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IssuedActuarialTablesSwitzerland_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IssuedActuarialTablesSwitzerland_lbl1" xml:lang="en-US" id="aciu_IssuedActuarialTablesSwitzerland_lbl1">Issued Actuarial Tables, Switzerland</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedActuarialTablesSwitzerland" xlink:to="aciu_IssuedActuarialTablesSwitzerland_lbl1" xlink:title="label: IssuedActuarialTablesSwitzerland to aciu_IssuedActuarialTablesSwitzerland_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IssuedActuarialTablesSwitzerland_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IssuedActuarialTablesSwitzerland_lbl2" xml:lang="en-US" id="aciu_IssuedActuarialTablesSwitzerland_lbl2">Mortality and disability rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuedActuarialTablesSwitzerland" xlink:to="aciu_IssuedActuarialTablesSwitzerland_lbl2" xlink:title="label: IssuedActuarialTablesSwitzerland to aciu_IssuedActuarialTablesSwitzerland_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl">The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl" xlink:title="label: PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl1" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl1">Percentage of reasonably possible increase in actuarial assumption [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl1" xlink:title="label: PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl2" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl2">+0.5% Increase [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl2" xlink:title="label: PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl">The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl" xlink:title="label: PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl1" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl1">Percentage of reasonably possible decrease in actuarial assumption [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl1" xlink:title="label: PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl2" xml:lang="en-US" id="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl2">-0.5% Decrease [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:to="aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl2" xlink:title="label: PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember to aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:label="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:title="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl" xml:lang="en-US" id="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl">This member stands for defined benefit plans change in other comprehensive loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:to="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl" xlink:title="label: ChangeInOtherComprehensiveLossDefinedBenefitPlanMember to aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl1" xml:lang="en-US" id="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl1">Change in other comprehensive loss, defined benefit plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:to="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl1" xlink:title="label: ChangeInOtherComprehensiveLossDefinedBenefitPlanMember to aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl2" xml:lang="en-US" id="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl2">Change in Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:to="aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl2" xlink:title="label: ChangeInOtherComprehensiveLossDefinedBenefitPlanMember to aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossAbstract" xlink:label="ChangeInOtherComprehensiveLossAbstract" xlink:title="ChangeInOtherComprehensiveLossAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangeInOtherComprehensiveLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ChangeInOtherComprehensiveLossAbstract_lbl1" xml:lang="en-US" id="aciu_ChangeInOtherComprehensiveLossAbstract_lbl1">Change in other comprehensive loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="aciu_ChangeInOtherComprehensiveLossAbstract_lbl1" xlink:title="label: ChangeInOtherComprehensiveLossAbstract to aciu_ChangeInOtherComprehensiveLossAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangeInOtherComprehensiveLossAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ChangeInOtherComprehensiveLossAbstract_lbl2" xml:lang="en-US" id="aciu_ChangeInOtherComprehensiveLossAbstract_lbl2">Change in other comprehensive loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="aciu_ChangeInOtherComprehensiveLossAbstract_lbl2" xlink:title="label: ChangeInOtherComprehensiveLossAbstract to aciu_ChangeInOtherComprehensiveLossAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:label="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:title="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl" xml:lang="en-US" id="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl">The amount of gain (loss) for the (increase) decrease in value of benefit obligation for the change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:to="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl" xlink:title="label: OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss to aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl1" xml:lang="en-US" id="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl1">Other comprehensive income (loss}, defined benefit plan, gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:to="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl1" xlink:title="label: OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss to aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:title="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl2" xml:lang="en-US" id="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl2">Other comprehensive loss, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:to="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl2" xlink:title="label: OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss to aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:title="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl3" xml:lang="en-US" id="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl3">Other comprehensive loss, end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:to="aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl3" xlink:title="label: OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss to aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfEquityBasedInstrumentPlans" xlink:label="NumberOfEquityBasedInstrumentPlans" xlink:title="NumberOfEquityBasedInstrumentPlans" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEquityBasedInstrumentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfEquityBasedInstrumentPlans_lbl" xml:lang="en-US" id="aciu_NumberOfEquityBasedInstrumentPlans_lbl">Number of equity-based instrument plans approved by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityBasedInstrumentPlans" xlink:to="aciu_NumberOfEquityBasedInstrumentPlans_lbl" xlink:title="label: NumberOfEquityBasedInstrumentPlans to aciu_NumberOfEquityBasedInstrumentPlans_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEquityBasedInstrumentPlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfEquityBasedInstrumentPlans_lbl1" xml:lang="en-US" id="aciu_NumberOfEquityBasedInstrumentPlans_lbl1">Number of Equity-based Instrument Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityBasedInstrumentPlans" xlink:to="aciu_NumberOfEquityBasedInstrumentPlans_lbl1" xlink:title="label: NumberOfEquityBasedInstrumentPlans to aciu_NumberOfEquityBasedInstrumentPlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEquityBasedInstrumentPlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfEquityBasedInstrumentPlans_lbl2" xml:lang="en-US" id="aciu_NumberOfEquityBasedInstrumentPlans_lbl2">Number of equity-based instrument plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityBasedInstrumentPlans" xlink:to="aciu_NumberOfEquityBasedInstrumentPlans_lbl2" xlink:title="label: NumberOfEquityBasedInstrumentPlans to aciu_NumberOfEquityBasedInstrumentPlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPlansOutstandingAbstract" xlink:label="ShareBasedPlansOutstandingAbstract" xlink:title="ShareBasedPlansOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareBasedPlansOutstandingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShareBasedPlansOutstandingAbstract_lbl1" xml:lang="en-US" id="aciu_ShareBasedPlansOutstandingAbstract_lbl1">Share-based plans outstanding [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPlansOutstandingAbstract" xlink:to="aciu_ShareBasedPlansOutstandingAbstract_lbl1" xlink:title="label: ShareBasedPlansOutstandingAbstract to aciu_ShareBasedPlansOutstandingAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareBasedPlansOutstandingAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShareBasedPlansOutstandingAbstract_lbl2" xml:lang="en-US" id="aciu_ShareBasedPlansOutstandingAbstract_lbl2">Share-based plans outstanding [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPlansOutstandingAbstract" xlink:to="aciu_ShareBasedPlansOutstandingAbstract_lbl2" xlink:title="label: ShareBasedPlansOutstandingAbstract to aciu_ShareBasedPlansOutstandingAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:label="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl" xml:lang="en-US" id="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl">For vesting requirements for a type of share-based payment arrangement that existed at any time during the period, this element represents the period which an employees' right to exercise an award is no longer contingent on satisfaction of a service condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:to="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl" xlink:title="label: VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod to aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl1" xml:lang="en-US" id="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl1">Vesting requirements for share-based payment arrangement, award vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:to="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl1" xlink:title="label: VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod to aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl2" xml:lang="en-US" id="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl2">Vesting conditions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:to="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl2" xlink:title="label: VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod to aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl3" xml:lang="en-US" id="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl3">Vesting conditions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:to="aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl3" xlink:title="label: VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod to aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanBMember" xlink:label="StockOptionPlanBMember" xlink:title="StockOptionPlanBMember" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_StockOptionPlanBMember_lbl" xml:lang="en-US" id="aciu_StockOptionPlanBMember_lbl">A share-based payment arrangement that existed at any time during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanBMember" xlink:to="aciu_StockOptionPlanBMember_lbl" xlink:title="label: StockOptionPlanBMember to aciu_StockOptionPlanBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_StockOptionPlanBMember_lbl1" xml:lang="en-US" id="aciu_StockOptionPlanBMember_lbl1">Stock option plan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanBMember" xlink:to="aciu_StockOptionPlanBMember_lbl1" xlink:title="label: StockOptionPlanBMember to aciu_StockOptionPlanBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_StockOptionPlanBMember_lbl2" xml:lang="en-US" id="aciu_StockOptionPlanBMember_lbl2">Stock Option Plan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanBMember" xlink:to="aciu_StockOptionPlanBMember_lbl2" xlink:title="label: StockOptionPlanBMember to aciu_StockOptionPlanBMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanMember" xlink:label="Two016ShareOptionAndIncentivePlanMember" xlink:title="Two016ShareOptionAndIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_Two016ShareOptionAndIncentivePlanMember_lbl" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanMember_lbl">The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanMember_lbl" xlink:title="label: Two016ShareOptionAndIncentivePlanMember to aciu_Two016ShareOptionAndIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_Two016ShareOptionAndIncentivePlanMember_lbl1" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanMember_lbl1">2016 Share Option and Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanMember_lbl1" xlink:title="label: Two016ShareOptionAndIncentivePlanMember to aciu_Two016ShareOptionAndIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_Two016ShareOptionAndIncentivePlanMember_lbl2" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanMember_lbl2">2016 SOIP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanMember_lbl2" xlink:title="label: Two016ShareOptionAndIncentivePlanMember to aciu_Two016ShareOptionAndIncentivePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanC1Member" xlink:label="StockOptionPlanC1Member" xlink:title="StockOptionPlanC1Member" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanC1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_StockOptionPlanC1Member_lbl" xml:lang="en-US" id="aciu_StockOptionPlanC1Member_lbl">A share-based payment arrangement that existed at any time during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanC1Member" xlink:to="aciu_StockOptionPlanC1Member_lbl" xlink:title="label: StockOptionPlanC1Member to aciu_StockOptionPlanC1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanC1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_StockOptionPlanC1Member_lbl1" xml:lang="en-US" id="aciu_StockOptionPlanC1Member_lbl1">Stock option plan C1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanC1Member" xlink:to="aciu_StockOptionPlanC1Member_lbl1" xlink:title="label: StockOptionPlanC1Member to aciu_StockOptionPlanC1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanC1Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_StockOptionPlanC1Member_lbl2" xml:lang="en-US" id="aciu_StockOptionPlanC1Member_lbl2">Stock Option Plan C1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanC1Member" xlink:to="aciu_StockOptionPlanC1Member_lbl2" xlink:title="label: StockOptionPlanC1Member to aciu_StockOptionPlanC1Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_EmployeesMember_lbl" xml:lang="en-US" id="aciu_EmployeesMember_lbl">Refers to personnel employed by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="aciu_EmployeesMember_lbl" xlink:title="label: EmployeesMember to aciu_EmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_EmployeesMember_lbl1" xml:lang="en-US" id="aciu_EmployeesMember_lbl1">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="aciu_EmployeesMember_lbl1" xlink:title="label: EmployeesMember to aciu_EmployeesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl">The maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl" xlink:title="label: MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl1" xml:lang="en-US" id="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl1">Maximum term of options granted for share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl1" xlink:title="label: MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl2" xml:lang="en-US" id="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl2">Contractual life of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl2" xlink:title="label: MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanAMember" xlink:label="StockOptionPlanAMember" xlink:title="StockOptionPlanAMember" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_StockOptionPlanAMember_lbl" xml:lang="en-US" id="aciu_StockOptionPlanAMember_lbl">A share-based payment arrangement that existed at any time during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanAMember" xlink:to="aciu_StockOptionPlanAMember_lbl" xlink:title="label: StockOptionPlanAMember to aciu_StockOptionPlanAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_StockOptionPlanAMember_lbl1" xml:lang="en-US" id="aciu_StockOptionPlanAMember_lbl1">Stock option plan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanAMember" xlink:to="aciu_StockOptionPlanAMember_lbl1" xlink:title="label: StockOptionPlanAMember to aciu_StockOptionPlanAMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_StockOptionPlanAMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_StockOptionPlanAMember_lbl2" xml:lang="en-US" id="aciu_StockOptionPlanAMember_lbl2">Stock Option Plan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanAMember" xlink:to="aciu_StockOptionPlanAMember_lbl2" xlink:title="label: StockOptionPlanAMember to aciu_StockOptionPlanAMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl">Vesting tranche one of the 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheOneMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl1" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl1">2016 Share Option and Incentive Plan, Vesting Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl1" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheOneMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl2" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl2">2016 SOIP, Vesting Condition 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl2" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheOneMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl">Vesting tranche two of the 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl1" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl1">2016 Share Option and Incentive Plan, Vesting Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl1" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl2" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl2">2016 SOIP, Vesting Condition 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl2" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl">Vesting tranche three of the 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl1" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl1">2016 Share Option and Incentive Plan, Vesting Tranche Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl1" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl2" xml:lang="en-US" id="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl2">2016 SOIP, Vesting Condition 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:to="aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl2" xlink:title="label: Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember to aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherCurrentReceivablesAbstract" xlink:label="OtherCurrentReceivablesAbstract" xlink:title="OtherCurrentReceivablesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherCurrentReceivablesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OtherCurrentReceivablesAbstract_lbl1" xml:lang="en-US" id="aciu_OtherCurrentReceivablesAbstract_lbl1">Other current receivables [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentReceivablesAbstract" xlink:to="aciu_OtherCurrentReceivablesAbstract_lbl1" xlink:title="label: OtherCurrentReceivablesAbstract to aciu_OtherCurrentReceivablesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesTextBlock" xlink:label="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:title="DisclosureOfOtherCurrentReceivablesTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl">The disclosure of other current receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl" xlink:title="label: DisclosureOfOtherCurrentReceivablesTextBlock to aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl1">Disclosure of other current receivables [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl1" xlink:title="label: DisclosureOfOtherCurrentReceivablesTextBlock to aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl2">Other current receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl2" xlink:title="label: DisclosureOfOtherCurrentReceivablesTextBlock to aciu_DisclosureOfOtherCurrentReceivablesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:title="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl">The disclosure of detailed information about the useful life of property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:title="label: ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock to aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl1" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl1">Schedule of information about property, plant and equipment useful life [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl1" xlink:title="label: ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock to aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl2" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl2">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl2" xlink:title="label: ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock to aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:label="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:title="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl">The disclosure of detailed information about the estimated lease term by right-of-use asset by category.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl" xlink:title="label: ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock to aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl1" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl1">Schedule of information about contract lease term by right-of-use asset categories [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl1" xlink:title="label: ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock to aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl2" xml:lang="en-US" id="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl2">Estimated Lease Term by Right-of-use Asset Categories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:to="aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl2" xlink:title="label: ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock to aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:title="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl1" xml:lang="en-US" id="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl1">Property plant and equipment estimated useful life [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:to="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract to aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl2" xml:lang="en-US" id="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl2">Estimated useful life [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:to="aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl2" xlink:title="label: PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract to aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="aciu_LaboratoryEquipmentMember_lbl">This member stands for a class of property, plant and equipment representing laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="aciu_LaboratoryEquipmentMember_lbl" xlink:title="label: LaboratoryEquipmentMember to aciu_LaboratoryEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LaboratoryEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LaboratoryEquipmentMember_lbl1" xml:lang="en-US" id="aciu_LaboratoryEquipmentMember_lbl1">Laboratory equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="aciu_LaboratoryEquipmentMember_lbl1" xlink:title="label: LaboratoryEquipmentMember to aciu_LaboratoryEquipmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LaboratoryEquipmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LaboratoryEquipmentMember_lbl2" xml:lang="en-US" id="aciu_LaboratoryEquipmentMember_lbl2">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="aciu_LaboratoryEquipmentMember_lbl2" xlink:title="label: LaboratoryEquipmentMember to aciu_LaboratoryEquipmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:label="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:title="LeaseholdImprovementsAndFixturesAndFittingsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl" xml:lang="en-US" id="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl">This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement and fixtures and fittings that are not permanently attached to real property.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:to="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl" xlink:title="label: LeaseholdImprovementsAndFixturesAndFittingsMember to aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl1" xml:lang="en-US" id="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl1">Leasehold improvements and fixtures and fittings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:to="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl1" xlink:title="label: LeaseholdImprovementsAndFixturesAndFittingsMember to aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl2" xml:lang="en-US" id="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl2">Leasehold Improvements/Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:to="aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl2" xlink:title="label: LeaseholdImprovementsAndFixturesAndFittingsMember to aciu_LeaseholdImprovementsAndFixturesAndFittingsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:label="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:title="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl1" xml:lang="en-US" id="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl1">Impact on statements of income/(loss) and cash flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl1" xlink:title="label: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl2" xml:lang="en-US" id="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl2">Impact on statements of income/(loss) and cash flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl2" xlink:title="label: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:label="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:title="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl1" xml:lang="en-US" id="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl1">Contractual undiscounted cash flows for lease liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:to="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl1" xlink:title="label: ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract to aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl2" xml:lang="en-US" id="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl2">Contractual undiscounted cash flows for lease liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:to="aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl2" xlink:title="label: ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract to aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UndiscountedOperatingLeasePaymentsDue" xlink:label="UndiscountedOperatingLeasePaymentsDue" xlink:title="UndiscountedOperatingLeasePaymentsDue" />
    <link:label xlink:type="resource" xlink:label="aciu_UndiscountedOperatingLeasePaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_UndiscountedOperatingLeasePaymentsDue_lbl" xml:lang="en-US" id="aciu_UndiscountedOperatingLeasePaymentsDue_lbl">The amount of undiscounted operating lease payments due for lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndiscountedOperatingLeasePaymentsDue" xlink:to="aciu_UndiscountedOperatingLeasePaymentsDue_lbl" xlink:title="label: UndiscountedOperatingLeasePaymentsDue to aciu_UndiscountedOperatingLeasePaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_UndiscountedOperatingLeasePaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_UndiscountedOperatingLeasePaymentsDue_lbl1" xml:lang="en-US" id="aciu_UndiscountedOperatingLeasePaymentsDue_lbl1">Undiscounted operating lease payments due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndiscountedOperatingLeasePaymentsDue" xlink:to="aciu_UndiscountedOperatingLeasePaymentsDue_lbl1" xlink:title="label: UndiscountedOperatingLeasePaymentsDue to aciu_UndiscountedOperatingLeasePaymentsDue_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_UndiscountedOperatingLeasePaymentsDue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_UndiscountedOperatingLeasePaymentsDue_lbl2" xml:lang="en-US" id="aciu_UndiscountedOperatingLeasePaymentsDue_lbl2">Contractual undiscounted cash flows for lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UndiscountedOperatingLeasePaymentsDue" xlink:to="aciu_UndiscountedOperatingLeasePaymentsDue_lbl2" xlink:title="label: UndiscountedOperatingLeasePaymentsDue to aciu_UndiscountedOperatingLeasePaymentsDue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpenseRelatingToLeases" xlink:label="ExpenseRelatingToLeases" xlink:title="ExpenseRelatingToLeases" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpenseRelatingToLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ExpenseRelatingToLeases_lbl" xml:lang="en-US" id="aciu_ExpenseRelatingToLeases_lbl">The expense for leases recognized through profit and loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseRelatingToLeases" xlink:to="aciu_ExpenseRelatingToLeases_lbl" xlink:title="label: ExpenseRelatingToLeases to aciu_ExpenseRelatingToLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpenseRelatingToLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ExpenseRelatingToLeases_lbl1" xml:lang="en-US" id="aciu_ExpenseRelatingToLeases_lbl1">Expense relating to leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseRelatingToLeases" xlink:to="aciu_ExpenseRelatingToLeases_lbl1" xlink:title="label: ExpenseRelatingToLeases to aciu_ExpenseRelatingToLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpenseRelatingToLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="aciu_ExpenseRelatingToLeases_lbl2" xml:lang="en-US" id="aciu_ExpenseRelatingToLeases_lbl2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpenseRelatingToLeases" xlink:to="aciu_ExpenseRelatingToLeases_lbl2" xlink:title="label: ExpenseRelatingToLeases to aciu_ExpenseRelatingToLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLeasedAssetsAbstract" xlink:label="RightOfUseLeasedAssetsAbstract" xlink:title="RightOfUseLeasedAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_RightOfUseLeasedAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RightOfUseLeasedAssetsAbstract_lbl1" xml:lang="en-US" id="aciu_RightOfUseLeasedAssetsAbstract_lbl1">Right-of-use leased assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="aciu_RightOfUseLeasedAssetsAbstract_lbl1" xlink:title="label: RightOfUseLeasedAssetsAbstract to aciu_RightOfUseLeasedAssetsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RightOfUseLeasedAssetsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RightOfUseLeasedAssetsAbstract_lbl2" xml:lang="en-US" id="aciu_RightOfUseLeasedAssetsAbstract_lbl2">Right-of-use of leased assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="aciu_RightOfUseLeasedAssetsAbstract_lbl2" xlink:title="label: RightOfUseLeasedAssetsAbstract to aciu_RightOfUseLeasedAssetsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisposalOfRightOfUseAssets" xlink:label="DisposalOfRightOfUseAssets" xlink:title="DisposalOfRightOfUseAssets" />
    <link:label xlink:type="resource" xlink:label="aciu_DisposalOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisposalOfRightOfUseAssets_lbl" xml:lang="en-US" id="aciu_DisposalOfRightOfUseAssets_lbl">The amount of decrease in right-of-use assets from disposals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalOfRightOfUseAssets" xlink:to="aciu_DisposalOfRightOfUseAssets_lbl" xlink:title="label: DisposalOfRightOfUseAssets to aciu_DisposalOfRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisposalOfRightOfUseAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisposalOfRightOfUseAssets_lbl1" xml:lang="en-US" id="aciu_DisposalOfRightOfUseAssets_lbl1">Disposal of right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalOfRightOfUseAssets" xlink:to="aciu_DisposalOfRightOfUseAssets_lbl1" xlink:title="label: DisposalOfRightOfUseAssets to aciu_DisposalOfRightOfUseAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisposalOfRightOfUseAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_DisposalOfRightOfUseAssets_lbl2" xml:lang="en-US" id="aciu_DisposalOfRightOfUseAssets_lbl2">Disposals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalOfRightOfUseAssets" xlink:to="aciu_DisposalOfRightOfUseAssets_lbl2" xlink:title="label: DisposalOfRightOfUseAssets to aciu_DisposalOfRightOfUseAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExecutiveManagementMember" xlink:label="ExecutiveManagementMember" xlink:title="ExecutiveManagementMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ExecutiveManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ExecutiveManagementMember_lbl" xml:lang="en-US" id="aciu_ExecutiveManagementMember_lbl">Key managers, or ranking officers of an entity, appointed to their position by the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveManagementMember" xlink:to="aciu_ExecutiveManagementMember_lbl" xlink:title="label: ExecutiveManagementMember to aciu_ExecutiveManagementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ExecutiveManagementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ExecutiveManagementMember_lbl1" xml:lang="en-US" id="aciu_ExecutiveManagementMember_lbl1">Executive Management [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveManagementMember" xlink:to="aciu_ExecutiveManagementMember_lbl1" xlink:title="label: ExecutiveManagementMember to aciu_ExecutiveManagementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ExecutiveManagementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_ExecutiveManagementMember_lbl2" xml:lang="en-US" id="aciu_ExecutiveManagementMember_lbl2">Executives [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveManagementMember" xlink:to="aciu_ExecutiveManagementMember_lbl2" xlink:title="label: ExecutiveManagementMember to aciu_ExecutiveManagementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesAndRestrictedShareUnitsMember" xlink:label="RestrictedSharesAndRestrictedShareUnitsMember" xlink:title="RestrictedSharesAndRestrictedShareUnitsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl" xml:lang="en-US" id="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl">This member stands for share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesAndRestrictedShareUnitsMember" xlink:to="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl" xlink:title="label: RestrictedSharesAndRestrictedShareUnitsMember to aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl1" xml:lang="en-US" id="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl1">Restricted Shares and Restricted Share Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesAndRestrictedShareUnitsMember" xlink:to="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl1" xlink:title="label: RestrictedSharesAndRestrictedShareUnitsMember to aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl2" xml:lang="en-US" id="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl2">Non-vested Share Awards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesAndRestrictedShareUnitsMember" xlink:to="aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl2" xlink:title="label: RestrictedSharesAndRestrictedShareUnitsMember to aciu_RestrictedSharesAndRestrictedShareUnitsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedStockUnitsMember" xlink:label="RestrictedStockUnitsMember" xlink:title="RestrictedStockUnitsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RestrictedStockUnitsMember_lbl" xml:lang="en-US" id="aciu_RestrictedStockUnitsMember_lbl">This member stands for equity instruments that are convertible to stock after a specified period of time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsMember" xlink:to="aciu_RestrictedStockUnitsMember_lbl" xlink:title="label: RestrictedStockUnitsMember to aciu_RestrictedStockUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedStockUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RestrictedStockUnitsMember_lbl1" xml:lang="en-US" id="aciu_RestrictedStockUnitsMember_lbl1">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsMember" xlink:to="aciu_RestrictedStockUnitsMember_lbl1" xlink:title="label: RestrictedStockUnitsMember to aciu_RestrictedStockUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedStockUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RestrictedStockUnitsMember_lbl2" xml:lang="en-US" id="aciu_RestrictedStockUnitsMember_lbl2">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsMember" xlink:to="aciu_RestrictedStockUnitsMember_lbl2" xlink:title="label: RestrictedStockUnitsMember to aciu_RestrictedStockUnitsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BoardOfDirectorsMember" xlink:label="BoardOfDirectorsMember" xlink:title="BoardOfDirectorsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_BoardOfDirectorsMember_lbl" xml:lang="en-US" id="aciu_BoardOfDirectorsMember_lbl">Key managers of an entity who collectively have responsibility of governing the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsMember" xlink:to="aciu_BoardOfDirectorsMember_lbl" xlink:title="label: BoardOfDirectorsMember to aciu_BoardOfDirectorsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_BoardOfDirectorsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_BoardOfDirectorsMember_lbl1" xml:lang="en-US" id="aciu_BoardOfDirectorsMember_lbl1">Board of Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsMember" xlink:to="aciu_BoardOfDirectorsMember_lbl1" xlink:title="label: BoardOfDirectorsMember to aciu_BoardOfDirectorsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_BoardOfDirectorsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_BoardOfDirectorsMember_lbl2" xml:lang="en-US" id="aciu_BoardOfDirectorsMember_lbl2">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsMember" xlink:to="aciu_BoardOfDirectorsMember_lbl2" xlink:title="label: BoardOfDirectorsMember to aciu_BoardOfDirectorsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesMember" xlink:label="RestrictedSharesMember" xlink:title="RestrictedSharesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RestrictedSharesMember_lbl" xml:lang="en-US" id="aciu_RestrictedSharesMember_lbl">This member stands for equity instruments that are prohibited for sale for a specified period of time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesMember" xlink:to="aciu_RestrictedSharesMember_lbl" xlink:title="label: RestrictedSharesMember to aciu_RestrictedSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RestrictedSharesMember_lbl1" xml:lang="en-US" id="aciu_RestrictedSharesMember_lbl1">Restricted shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesMember" xlink:to="aciu_RestrictedSharesMember_lbl1" xlink:title="label: RestrictedSharesMember to aciu_RestrictedSharesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RestrictedSharesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RestrictedSharesMember_lbl2" xml:lang="en-US" id="aciu_RestrictedSharesMember_lbl2">Restricted Share Awards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedSharesMember" xlink:to="aciu_RestrictedSharesMember_lbl2" xlink:title="label: RestrictedSharesMember to aciu_RestrictedSharesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfNonVestedSharesAbstract" xlink:label="NumberOfNonVestedSharesAbstract" xlink:title="NumberOfNonVestedSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfNonVestedSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfNonVestedSharesAbstract_lbl1" xml:lang="en-US" id="aciu_NumberOfNonVestedSharesAbstract_lbl1">Number Of Non-vested Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="aciu_NumberOfNonVestedSharesAbstract_lbl1" xlink:title="label: NumberOfNonVestedSharesAbstract to aciu_NumberOfNonVestedSharesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfNonVestedSharesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfNonVestedSharesAbstract_lbl2" xml:lang="en-US" id="aciu_NumberOfNonVestedSharesAbstract_lbl2">Number of non-vested shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="aciu_NumberOfNonVestedSharesAbstract_lbl2" xlink:title="label: NumberOfNonVestedSharesAbstract to aciu_NumberOfNonVestedSharesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl">The number of other equity instruments (ie other than share options) exercised in a share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl1" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl1">Number of other equity instruments exercised in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl2" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl2">Exercised during the year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl2" xlink:title="label: NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceAbstract" xlink:label="WeightedAverageExercisePriceAbstract" xlink:title="WeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceAbstract_lbl1">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="aciu_WeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: WeightedAverageExercisePriceAbstract to aciu_WeightedAverageExercisePriceAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_WeightedAverageExercisePriceAbstract_lbl2" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceAbstract_lbl2">Weighted Average grant date fair value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="aciu_WeightedAverageExercisePriceAbstract_lbl2" xlink:title="label: WeightedAverageExercisePriceAbstract to aciu_WeightedAverageExercisePriceAbstract_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceAbstract_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_WeightedAverageExercisePriceAbstract_lbl3" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceAbstract_lbl3">Weighted average exercise price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="aciu_WeightedAverageExercisePriceAbstract_lbl3" xlink:title="label: WeightedAverageExercisePriceAbstract to aciu_WeightedAverageExercisePriceAbstract_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl">The weighted average exercise price of other equity instruments (ie other than share options) exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:to="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019 to aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl1">Weighted average exercise price of other equity instruments exercised in sharebased payment arrangement2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:to="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl1" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019 to aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl2" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl2">Exercised during the year (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:to="aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl2" xlink:title="label: WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019 to aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPaymentArrangementAbstract" xlink:label="ShareBasedPaymentArrangementAbstract" xlink:title="ShareBasedPaymentArrangementAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareBasedPaymentArrangementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShareBasedPaymentArrangementAbstract_lbl1" xml:lang="en-US" id="aciu_ShareBasedPaymentArrangementAbstract_lbl1">Share-based payment arrangement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="aciu_ShareBasedPaymentArrangementAbstract_lbl1" xlink:title="label: ShareBasedPaymentArrangementAbstract to aciu_ShareBasedPaymentArrangementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareBasedPaymentArrangementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShareBasedPaymentArrangementAbstract_lbl2" xml:lang="en-US" id="aciu_ShareBasedPaymentArrangementAbstract_lbl2">Share-based compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="aciu_ShareBasedPaymentArrangementAbstract_lbl2" xlink:title="label: ShareBasedPaymentArrangementAbstract to aciu_ShareBasedPaymentArrangementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl">The maximum term of other equity instruments (ie other than share options) granted for a type of share-based payment arrangement that existed at any time during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl" xlink:title="label: MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl1" xml:lang="en-US" id="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl1">Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl1" xlink:title="label: MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl2" xml:lang="en-US" id="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl2">Contractual life of non-vested share awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:to="aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl2" xlink:title="label: MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement to aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:title="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl">The weighted average exercise price of non-vested other equity instruments (ie other than share options) granted in a share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xlink:title="label: WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement to aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl1" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl1">Weighted average exercise price of non-vested other equity instruments granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl1" xlink:title="label: WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement to aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl2" xml:lang="en-US" id="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl2">Weighted average fair value, non-vested restricted share awards granted (in CHF per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl2" xlink:title="label: WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement to aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageAssumptionsAbstract" xlink:label="WeightedAverageAssumptionsAbstract" xlink:title="WeightedAverageAssumptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageAssumptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageAssumptionsAbstract_lbl1" xml:lang="en-US" id="aciu_WeightedAverageAssumptionsAbstract_lbl1">Weighted Average Assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="aciu_WeightedAverageAssumptionsAbstract_lbl1" xlink:title="label: WeightedAverageAssumptionsAbstract to aciu_WeightedAverageAssumptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageAssumptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_WeightedAverageAssumptionsAbstract_lbl2" xml:lang="en-US" id="aciu_WeightedAverageAssumptionsAbstract_lbl2">Weighted average assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="aciu_WeightedAverageAssumptionsAbstract_lbl2" xlink:title="label: WeightedAverageAssumptionsAbstract to aciu_WeightedAverageAssumptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FormerChiefExecutiveFinancialOfficerMember" xlink:label="FormerChiefExecutiveFinancialOfficerMember" xlink:title="FormerChiefExecutiveFinancialOfficerMember" />
    <link:label xlink:type="resource" xlink:label="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl" xml:lang="en-US" id="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl">An former executive officer responsible for overseeing the financial activities of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerChiefExecutiveFinancialOfficerMember" xlink:to="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl" xlink:title="label: FormerChiefExecutiveFinancialOfficerMember to aciu_FormerChiefExecutiveFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl1" xml:lang="en-US" id="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl1">Former Chief Executive Financial Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerChiefExecutiveFinancialOfficerMember" xlink:to="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl1" xlink:title="label: FormerChiefExecutiveFinancialOfficerMember to aciu_FormerChiefExecutiveFinancialOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl2" xml:lang="en-US" id="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl2">Former Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerChiefExecutiveFinancialOfficerMember" xlink:to="aciu_FormerChiefExecutiveFinancialOfficerMember_lbl2" xlink:title="label: FormerChiefExecutiveFinancialOfficerMember to aciu_FormerChiefExecutiveFinancialOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EstimatedLeaseTerm" xlink:label="EstimatedLeaseTerm" xlink:title="EstimatedLeaseTerm" />
    <link:label xlink:type="resource" xlink:label="aciu_EstimatedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_EstimatedLeaseTerm_lbl" xml:lang="en-US" id="aciu_EstimatedLeaseTerm_lbl">The estimated lease term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedLeaseTerm" xlink:to="aciu_EstimatedLeaseTerm_lbl" xlink:title="label: EstimatedLeaseTerm to aciu_EstimatedLeaseTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_EstimatedLeaseTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_EstimatedLeaseTerm_lbl1" xml:lang="en-US" id="aciu_EstimatedLeaseTerm_lbl1">Estimated lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedLeaseTerm" xlink:to="aciu_EstimatedLeaseTerm_lbl1" xlink:title="label: EstimatedLeaseTerm to aciu_EstimatedLeaseTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_EstimatedLeaseTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_EstimatedLeaseTerm_lbl2" xml:lang="en-US" id="aciu_EstimatedLeaseTerm_lbl2">Estimated lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedLeaseTerm" xlink:to="aciu_EstimatedLeaseTerm_lbl2" xlink:title="label: EstimatedLeaseTerm to aciu_EstimatedLeaseTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentsTable" xlink:label="CashAndCashEquivalentsTable" xlink:title="CashAndCashEquivalentsTable" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CashAndCashEquivalentsTable_lbl" xml:lang="en-US" id="aciu_CashAndCashEquivalentsTable_lbl">Schedule of cash and cash equivalent balances, including foreign currencies in which the balances are denominated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsTable" xlink:to="aciu_CashAndCashEquivalentsTable_lbl" xlink:title="label: CashAndCashEquivalentsTable to aciu_CashAndCashEquivalentsTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAndCashEquivalentsTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CashAndCashEquivalentsTable_lbl1" xml:lang="en-US" id="aciu_CashAndCashEquivalentsTable_lbl1">Cash and cash equivalents [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsTable" xlink:to="aciu_CashAndCashEquivalentsTable_lbl1" xlink:title="label: CashAndCashEquivalentsTable to aciu_CashAndCashEquivalentsTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentLineItems" xlink:label="CashAndCashEquivalentLineItems" xlink:title="CashAndCashEquivalentLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAndCashEquivalentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CashAndCashEquivalentLineItems_lbl" xml:lang="en-US" id="aciu_CashAndCashEquivalentLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentLineItems" xlink:to="aciu_CashAndCashEquivalentLineItems_lbl" xlink:title="label: CashAndCashEquivalentLineItems to aciu_CashAndCashEquivalentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CashAndCashEquivalentLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CashAndCashEquivalentLineItems_lbl1" xml:lang="en-US" id="aciu_CashAndCashEquivalentLineItems_lbl1">Cash and cash equivalent [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentLineItems" xlink:to="aciu_CashAndCashEquivalentLineItems_lbl1" xlink:title="label: CashAndCashEquivalentLineItems to aciu_CashAndCashEquivalentLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl">The disclosure of detailed information about other current receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl1">Disclosure of detailed information about other current receivables [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl2">Other current receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAndContingenciesAbstract" xlink:label="CommitmentsAndContingenciesAbstract" xlink:title="CommitmentsAndContingenciesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_CommitmentsAndContingenciesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CommitmentsAndContingenciesAbstract_lbl1" xml:lang="en-US" id="aciu_CommitmentsAndContingenciesAbstract_lbl1">Commitments and contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesAbstract" xlink:to="aciu_CommitmentsAndContingenciesAbstract_lbl1" xlink:title="label: CommitmentsAndContingenciesAbstract to aciu_CommitmentsAndContingenciesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:label="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:title="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl1" xml:lang="en-US" id="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl1">Outstanding Options Exercise Price Range and Expiry Dates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl1" xlink:title="label: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl2" xml:lang="en-US" id="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl2">Outstanding options, exercise price range and expiry dates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl2" xlink:title="label: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareOptionsDateOfExpiry" xlink:label="ShareOptionsDateOfExpiry" xlink:title="ShareOptionsDateOfExpiry" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareOptionsDateOfExpiry_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ShareOptionsDateOfExpiry_lbl" xml:lang="en-US" id="aciu_ShareOptionsDateOfExpiry_lbl">The date on which share options will expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareOptionsDateOfExpiry" xlink:to="aciu_ShareOptionsDateOfExpiry_lbl" xlink:title="label: ShareOptionsDateOfExpiry to aciu_ShareOptionsDateOfExpiry_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareOptionsDateOfExpiry_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShareOptionsDateOfExpiry_lbl1" xml:lang="en-US" id="aciu_ShareOptionsDateOfExpiry_lbl1">Share Options Date of Expiry</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareOptionsDateOfExpiry" xlink:to="aciu_ShareOptionsDateOfExpiry_lbl1" xlink:title="label: ShareOptionsDateOfExpiry to aciu_ShareOptionsDateOfExpiry_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareOptionsDateOfExpiry_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShareOptionsDateOfExpiry_lbl2" xml:lang="en-US" id="aciu_ShareOptionsDateOfExpiry_lbl2">Expiration Dates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareOptionsDateOfExpiry" xlink:to="aciu_ShareOptionsDateOfExpiry_lbl2" xlink:title="label: ShareOptionsDateOfExpiry to aciu_ShareOptionsDateOfExpiry_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesTwoMember" xlink:label="RangeOfExercisePricesTwoMember" xlink:title="RangeOfExercisePricesTwoMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RangeOfExercisePricesTwoMember_lbl" xml:lang="en-US" id="aciu_RangeOfExercisePricesTwoMember_lbl">This member stands for exercise of price range two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesTwoMember" xlink:to="aciu_RangeOfExercisePricesTwoMember_lbl" xlink:title="label: RangeOfExercisePricesTwoMember to aciu_RangeOfExercisePricesTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RangeOfExercisePricesTwoMember_lbl1" xml:lang="en-US" id="aciu_RangeOfExercisePricesTwoMember_lbl1">Range Of Exercise Prices Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesTwoMember" xlink:to="aciu_RangeOfExercisePricesTwoMember_lbl1" xlink:title="label: RangeOfExercisePricesTwoMember to aciu_RangeOfExercisePricesTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RangeOfExercisePricesTwoMember_lbl2" xml:lang="en-US" id="aciu_RangeOfExercisePricesTwoMember_lbl2">CHF 9.53 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesTwoMember" xlink:to="aciu_RangeOfExercisePricesTwoMember_lbl2" xlink:title="label: RangeOfExercisePricesTwoMember to aciu_RangeOfExercisePricesTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesThreeMember" xlink:label="RangeOfExercisePricesThreeMember" xlink:title="RangeOfExercisePricesThreeMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RangeOfExercisePricesThreeMember_lbl" xml:lang="en-US" id="aciu_RangeOfExercisePricesThreeMember_lbl">This member stands for exercise of price range three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesThreeMember" xlink:to="aciu_RangeOfExercisePricesThreeMember_lbl" xlink:title="label: RangeOfExercisePricesThreeMember to aciu_RangeOfExercisePricesThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesThreeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RangeOfExercisePricesThreeMember_lbl1" xml:lang="en-US" id="aciu_RangeOfExercisePricesThreeMember_lbl1">Range Of Exercise Prices Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesThreeMember" xlink:to="aciu_RangeOfExercisePricesThreeMember_lbl1" xlink:title="label: RangeOfExercisePricesThreeMember to aciu_RangeOfExercisePricesThreeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesThreeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RangeOfExercisePricesThreeMember_lbl2" xml:lang="en-US" id="aciu_RangeOfExercisePricesThreeMember_lbl2">USD 5.04 to USD 12.30 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesThreeMember" xlink:to="aciu_RangeOfExercisePricesThreeMember_lbl2" xlink:title="label: RangeOfExercisePricesThreeMember to aciu_RangeOfExercisePricesThreeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesOneMember" xlink:label="RangeOfExercisePricesOneMember" xlink:title="RangeOfExercisePricesOneMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RangeOfExercisePricesOneMember_lbl" xml:lang="en-US" id="aciu_RangeOfExercisePricesOneMember_lbl">This member stands for exercise of price range one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesOneMember" xlink:to="aciu_RangeOfExercisePricesOneMember_lbl" xlink:title="label: RangeOfExercisePricesOneMember to aciu_RangeOfExercisePricesOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RangeOfExercisePricesOneMember_lbl1" xml:lang="en-US" id="aciu_RangeOfExercisePricesOneMember_lbl1">Range of Exercise Prices one [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesOneMember" xlink:to="aciu_RangeOfExercisePricesOneMember_lbl1" xlink:title="label: RangeOfExercisePricesOneMember to aciu_RangeOfExercisePricesOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RangeOfExercisePricesOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RangeOfExercisePricesOneMember_lbl2" xml:lang="en-US" id="aciu_RangeOfExercisePricesOneMember_lbl2">CHF 0.15 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeOfExercisePricesOneMember" xlink:to="aciu_RangeOfExercisePricesOneMember_lbl2" xlink:title="label: RangeOfExercisePricesOneMember to aciu_RangeOfExercisePricesOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentAccruedResearchAndDevelopmentCosts" xlink:label="CurrentAccruedResearchAndDevelopmentCosts" xlink:title="CurrentAccruedResearchAndDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl">The amount of current accrued research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedResearchAndDevelopmentCosts" xlink:to="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl" xlink:title="label: CurrentAccruedResearchAndDevelopmentCosts to aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl1" xml:lang="en-US" id="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl1">Current accrued research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedResearchAndDevelopmentCosts" xlink:to="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl1" xlink:title="label: CurrentAccruedResearchAndDevelopmentCosts to aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl2" xml:lang="en-US" id="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl2">Accrued research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentAccruedResearchAndDevelopmentCosts" xlink:to="aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl2" xlink:title="label: CurrentAccruedResearchAndDevelopmentCosts to aciu_CurrentAccruedResearchAndDevelopmentCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesTable" xlink:label="DisclosureOfOtherCurrentReceivablesTable" xlink:title="DisclosureOfOtherCurrentReceivablesTable" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl">Schedule disclosing information related to other current receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesTable" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl" xlink:title="label: DisclosureOfOtherCurrentReceivablesTable to aciu_DisclosureOfOtherCurrentReceivablesTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl1" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl1">Disclosure of other current receivables [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesTable" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesTable_lbl1" xlink:title="label: DisclosureOfOtherCurrentReceivablesTable to aciu_DisclosureOfOtherCurrentReceivablesTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesLineItems" xlink:label="DisclosureOfOtherCurrentReceivablesLineItems" xlink:title="DisclosureOfOtherCurrentReceivablesLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl" xlink:title="label: DisclosureOfOtherCurrentReceivablesLineItems to aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl1" xml:lang="en-US" id="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl1">Disclosure of other current receivables [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl1" xlink:title="label: DisclosureOfOtherCurrentReceivablesLineItems to aciu_DisclosureOfOtherCurrentReceivablesLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:label="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:title="PeriodOfMaturityReceivablesFairValueCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl" xml:lang="en-US" id="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl">Refers to the maturity period over which the entity considers carrying value of current receivables to correspond to their fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:to="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl" xlink:title="label: PeriodOfMaturityReceivablesFairValueCarryingAmount to aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl1" xml:lang="en-US" id="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl1">Period of maturity, receivables fair value carrying amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:to="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl1" xlink:title="label: PeriodOfMaturityReceivablesFairValueCarryingAmount to aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl2" xml:lang="en-US" id="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl2">Maturity period of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:to="aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl2" xlink:title="label: PeriodOfMaturityReceivablesFairValueCarryingAmount to aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfEscrowDepositAccounts" xlink:label="NumberOfEscrowDepositAccounts" xlink:title="NumberOfEscrowDepositAccounts" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEscrowDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfEscrowDepositAccounts_lbl" xml:lang="en-US" id="aciu_NumberOfEscrowDepositAccounts_lbl">The number of escrow accounts with cash deposits of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEscrowDepositAccounts" xlink:to="aciu_NumberOfEscrowDepositAccounts_lbl" xlink:title="label: NumberOfEscrowDepositAccounts to aciu_NumberOfEscrowDepositAccounts_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEscrowDepositAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfEscrowDepositAccounts_lbl1" xml:lang="en-US" id="aciu_NumberOfEscrowDepositAccounts_lbl1">Number of escrow deposit accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEscrowDepositAccounts" xlink:to="aciu_NumberOfEscrowDepositAccounts_lbl1" xlink:title="label: NumberOfEscrowDepositAccounts to aciu_NumberOfEscrowDepositAccounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfEscrowDepositAccounts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfEscrowDepositAccounts_lbl2" xml:lang="en-US" id="aciu_NumberOfEscrowDepositAccounts_lbl2">Number of deposits in escrow accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEscrowDepositAccounts" xlink:to="aciu_NumberOfEscrowDepositAccounts_lbl2" xlink:title="label: NumberOfEscrowDepositAccounts to aciu_NumberOfEscrowDepositAccounts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl">The disclosure of detailed information about prepaid expenses and accrued income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock to aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl1">Disclosure of detailed information about prepaid expenses and accrued income [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock to aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl2">Prepaid expenses and accrued income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock to aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BasisOfPreparationAbstract" xlink:label="BasisOfPreparationAbstract" xlink:title="BasisOfPreparationAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_BasisOfPreparationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_BasisOfPreparationAbstract_lbl1" xml:lang="en-US" id="aciu_BasisOfPreparationAbstract_lbl1">Basis of preparation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPreparationAbstract" xlink:to="aciu_BasisOfPreparationAbstract_lbl1" xlink:title="label: BasisOfPreparationAbstract to aciu_BasisOfPreparationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfGoingConcernTable" xlink:label="DisclosureOfGoingConcernTable" xlink:title="DisclosureOfGoingConcernTable" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfGoingConcernTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfGoingConcernTable_lbl" xml:lang="en-US" id="aciu_DisclosureOfGoingConcernTable_lbl">Schedule disclosing information related to the entity's ability to continue as a going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGoingConcernTable" xlink:to="aciu_DisclosureOfGoingConcernTable_lbl" xlink:title="label: DisclosureOfGoingConcernTable to aciu_DisclosureOfGoingConcernTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfGoingConcernTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfGoingConcernTable_lbl1" xml:lang="en-US" id="aciu_DisclosureOfGoingConcernTable_lbl1">Disclosure of going concern [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGoingConcernTable" xlink:to="aciu_DisclosureOfGoingConcernTable_lbl1" xlink:title="label: DisclosureOfGoingConcernTable to aciu_DisclosureOfGoingConcernTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfClassesOfGoingConcernLineItems" xlink:label="DisclosureOfClassesOfGoingConcernLineItems" xlink:title="DisclosureOfClassesOfGoingConcernLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl" xml:lang="en-US" id="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl" xlink:title="label: DisclosureOfClassesOfGoingConcernLineItems to aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl1" xml:lang="en-US" id="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl1">Disclosure of classes of going concern [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl1" xlink:title="label: DisclosureOfClassesOfGoingConcernLineItems to aciu_DisclosureOfClassesOfGoingConcernLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InitialPublicOfferingMember" xlink:label="InitialPublicOfferingMember" xlink:title="InitialPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="aciu_InitialPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_InitialPublicOfferingMember_lbl" xml:lang="en-US" id="aciu_InitialPublicOfferingMember_lbl">This member represents the equity instruments that are the first or initial sale of equity shares by a private company to the public.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingMember" xlink:to="aciu_InitialPublicOfferingMember_lbl" xlink:title="label: InitialPublicOfferingMember to aciu_InitialPublicOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_InitialPublicOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_InitialPublicOfferingMember_lbl1" xml:lang="en-US" id="aciu_InitialPublicOfferingMember_lbl1">Initial Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingMember" xlink:to="aciu_InitialPublicOfferingMember_lbl1" xlink:title="label: InitialPublicOfferingMember to aciu_InitialPublicOfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_InitialPublicOfferingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_InitialPublicOfferingMember_lbl2" xml:lang="en-US" id="aciu_InitialPublicOfferingMember_lbl2">Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingMember" xlink:to="aciu_InitialPublicOfferingMember_lbl2" xlink:title="label: InitialPublicOfferingMember to aciu_InitialPublicOfferingMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GoingConcernAbstract" xlink:label="GoingConcernAbstract" xlink:title="GoingConcernAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_GoingConcernAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GoingConcernAbstract_lbl1" xml:lang="en-US" id="aciu_GoingConcernAbstract_lbl1">Going Concern [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoingConcernAbstract" xlink:to="aciu_GoingConcernAbstract_lbl1" xlink:title="label: GoingConcernAbstract to aciu_GoingConcernAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GoingConcernAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GoingConcernAbstract_lbl2" xml:lang="en-US" id="aciu_GoingConcernAbstract_lbl2">Going concern [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoingConcernAbstract" xlink:to="aciu_GoingConcernAbstract_lbl2" xlink:title="label: GoingConcernAbstract to aciu_GoingConcernAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl">Payment(s) received for milestone payments associated with a collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentReceived" xlink:to="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl" xlink:title="label: CollaborativeAgreementMilestonePaymentReceived to aciu_CollaborativeAgreementMilestonePaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl1">Collaborative agreement, Milestone payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentReceived" xlink:to="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl1" xlink:title="label: CollaborativeAgreementMilestonePaymentReceived to aciu_CollaborativeAgreementMilestonePaymentReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl2">Milestone payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentReceived" xlink:to="aciu_CollaborativeAgreementMilestonePaymentReceived_lbl2" xlink:title="label: CollaborativeAgreementMilestonePaymentReceived to aciu_CollaborativeAgreementMilestonePaymentReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPublicOfferings" xlink:label="NumberOfPublicOfferings" xlink:title="NumberOfPublicOfferings" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPublicOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfPublicOfferings_lbl" xml:lang="en-US" id="aciu_NumberOfPublicOfferings_lbl">The number of public offerings issued or completed by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPublicOfferings" xlink:to="aciu_NumberOfPublicOfferings_lbl" xlink:title="label: NumberOfPublicOfferings to aciu_NumberOfPublicOfferings_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPublicOfferings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfPublicOfferings_lbl1" xml:lang="en-US" id="aciu_NumberOfPublicOfferings_lbl1">Number of Public Offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPublicOfferings" xlink:to="aciu_NumberOfPublicOfferings_lbl1" xlink:title="label: NumberOfPublicOfferings to aciu_NumberOfPublicOfferings_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPublicOfferings_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfPublicOfferings_lbl2" xml:lang="en-US" id="aciu_NumberOfPublicOfferings_lbl2">Number of public offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPublicOfferings" xlink:to="aciu_NumberOfPublicOfferings_lbl2" xlink:title="label: NumberOfPublicOfferings to aciu_NumberOfPublicOfferings_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl" xml:lang="en-US" id="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl">Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl" xlink:title="label: CollaborationAndLicenseRevenueAgreementsMember to aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl1">Collaboration and License Revenue Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl1" xlink:title="label: CollaborationAndLicenseRevenueAgreementsMember to aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl2">Collaboration and License Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl2" xlink:title="label: CollaborationAndLicenseRevenueAgreementsMember to aciu_CollaborationAndLicenseRevenueAgreementsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementWithLillyMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyMember_lbl">The collaboration agreement with Lilly for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="aciu_CollaborationAgreementWithLillyMember_lbl" xlink:title="label: CollaborationAgreementWithLillyMember to aciu_CollaborationAgreementWithLillyMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementWithLillyMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyMember_lbl1">Collaboration Agreement with Lilly [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="aciu_CollaborationAgreementWithLillyMember_lbl1" xlink:title="label: CollaborationAgreementWithLillyMember to aciu_CollaborationAgreementWithLillyMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborationAgreementWithLillyMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyMember_lbl2">2018 License Agreement with Eli Lilly and Company [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="aciu_CollaborationAgreementWithLillyMember_lbl2" xlink:title="label: CollaborationAgreementWithLillyMember to aciu_CollaborationAgreementWithLillyMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementWithLillyMember_lbl3" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyMember_lbl3">Lilly [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="aciu_CollaborationAgreementWithLillyMember_lbl3" xlink:title="label: CollaborationAgreementWithLillyMember to aciu_CollaborationAgreementWithLillyMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantIncomePolicyTextBlock" xlink:label="GrantIncomePolicyTextBlock" xlink:title="GrantIncomePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantIncomePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US" id="aciu_GrantIncomePolicyTextBlock_lbl">The description of the entity's accounting policy for grant income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantIncomePolicyTextBlock" xlink:to="aciu_GrantIncomePolicyTextBlock_lbl" xlink:title="label: GrantIncomePolicyTextBlock to aciu_GrantIncomePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantIncomePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GrantIncomePolicyTextBlock_lbl1" xml:lang="en-US" id="aciu_GrantIncomePolicyTextBlock_lbl1">Grant income [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantIncomePolicyTextBlock" xlink:to="aciu_GrantIncomePolicyTextBlock_lbl1" xlink:title="label: GrantIncomePolicyTextBlock to aciu_GrantIncomePolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantIncomePolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GrantIncomePolicyTextBlock_lbl2" xml:lang="en-US" id="aciu_GrantIncomePolicyTextBlock_lbl2">Grant income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantIncomePolicyTextBlock" xlink:to="aciu_GrantIncomePolicyTextBlock_lbl2" xlink:title="label: GrantIncomePolicyTextBlock to aciu_GrantIncomePolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:label="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:title="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl">The description of the entity's accounting policy for the basis for how the entity classifies assets and liabilities as current and non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl" xlink:title="label: DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl1">Description of accounting policy for classification of assets and liabilities [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl2" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl2">Current vs. non-current classification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl2" xlink:title="label: DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:label="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:title="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl">The description of the entity's accounting policy for judgments that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognized in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl" xlink:title="label: DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl1" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl1">Description of accounting policy for accounting judgments and estimates [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl1" xlink:title="label: DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl2" xml:lang="en-US" id="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl2">Critical judgments and accounting estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:to="aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl2" xlink:title="label: DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock to aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:label="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:title="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" id="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl">The description of the entity's accounting policy for fair value of financial assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl" xlink:title="label: FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock to aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US" id="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1">Fair value of financial assets and liabilities [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1" xlink:title="label: FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock to aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl2" xml:lang="en-US" id="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl2">Fair value of financial assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl2" xlink:title="label: FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock to aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:label="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:title="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl">The description of the entity's accounting policy for changes to accounting policies recently adopted by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:to="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl" xlink:title="label: DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock to aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl1">Disclosure Of Accounting Policy For Changes In Accounting Policies Recently Adopted [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:to="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl1" xlink:title="label: DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock to aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl2">Accounting policies, new standards, interpretations and amendments adopted by the Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:to="aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl2" xlink:title="label: DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock to aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl">The decrease in the net defined benefit liability (asset) resulting from interest costs resulting from the passage of time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestCostNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: InterestCostNetDefinedBenefitLiabilityAsset to aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl1">Interest cost, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestCostNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: InterestCostNetDefinedBenefitLiabilityAsset to aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl2" xml:lang="en-US" id="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl2">Interest cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestCostNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl2" xlink:title="label: InterestCostNetDefinedBenefitLiabilityAsset to aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl3" xml:lang="en-US" id="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl3">Interest cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestCostNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl3" xlink:title="label: InterestCostNetDefinedBenefitLiabilityAsset to aciu_InterestCostNetDefinedBenefitLiabilityAsset_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" xlink:title="GeneralInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GeneralInformationAbstract_lbl1" xml:lang="en-US" id="aciu_GeneralInformationAbstract_lbl1">General information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralInformationAbstract" xlink:to="aciu_GeneralInformationAbstract_lbl1" xlink:title="label: GeneralInformationAbstract to aciu_GeneralInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:label="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:title="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl">The entire disclosure for general information about the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:to="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl" xlink:title="label: DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock to aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl1">Disclosure of general information about the entity explanatory [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:to="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl1" xlink:title="label: DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock to aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl2">General information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:to="aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl2" xlink:title="label: DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock to aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfTechnologyPlatforms" xlink:label="NumberOfTechnologyPlatforms" xlink:title="NumberOfTechnologyPlatforms" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfTechnologyPlatforms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfTechnologyPlatforms_lbl" xml:lang="en-US" id="aciu_NumberOfTechnologyPlatforms_lbl">The number of unique proprietary platform technologies to discover, design and develop medicines and diagnostics to target misfolded proteins.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTechnologyPlatforms" xlink:to="aciu_NumberOfTechnologyPlatforms_lbl" xlink:title="label: NumberOfTechnologyPlatforms to aciu_NumberOfTechnologyPlatforms_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfTechnologyPlatforms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfTechnologyPlatforms_lbl1" xml:lang="en-US" id="aciu_NumberOfTechnologyPlatforms_lbl1">Number of technology platforms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTechnologyPlatforms" xlink:to="aciu_NumberOfTechnologyPlatforms_lbl1" xlink:title="label: NumberOfTechnologyPlatforms to aciu_NumberOfTechnologyPlatforms_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfTechnologyPlatforms_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfTechnologyPlatforms_lbl2" xml:lang="en-US" id="aciu_NumberOfTechnologyPlatforms_lbl2">Number of proprietary technology platforms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTechnologyPlatforms" xlink:to="aciu_NumberOfTechnologyPlatforms_lbl2" xlink:title="label: NumberOfTechnologyPlatforms to aciu_NumberOfTechnologyPlatforms_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AtTheMarketEquityOfferingMember" xlink:label="AtTheMarketEquityOfferingMember" xlink:title="AtTheMarketEquityOfferingMember" />
    <link:label xlink:type="resource" xlink:label="aciu_AtTheMarketEquityOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AtTheMarketEquityOfferingMember_lbl" xml:lang="en-US" id="aciu_AtTheMarketEquityOfferingMember_lbl">An "at-the-market" offering is an offering of securities into an existing trading market for outstanding shares of the same class at other than a fixed price on, or through the facilities of, a national securities exchange, or to or through a market maker otherwise than on an exchange.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketEquityOfferingMember" xlink:to="aciu_AtTheMarketEquityOfferingMember_lbl" xlink:title="label: AtTheMarketEquityOfferingMember to aciu_AtTheMarketEquityOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AtTheMarketEquityOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AtTheMarketEquityOfferingMember_lbl1" xml:lang="en-US" id="aciu_AtTheMarketEquityOfferingMember_lbl1">At the Market Equity Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketEquityOfferingMember" xlink:to="aciu_AtTheMarketEquityOfferingMember_lbl1" xlink:title="label: AtTheMarketEquityOfferingMember to aciu_AtTheMarketEquityOfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AtTheMarketEquityOfferingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_AtTheMarketEquityOfferingMember_lbl2" xml:lang="en-US" id="aciu_AtTheMarketEquityOfferingMember_lbl2">ATM Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketEquityOfferingMember" xlink:to="aciu_AtTheMarketEquityOfferingMember_lbl2" xlink:title="label: AtTheMarketEquityOfferingMember to aciu_AtTheMarketEquityOfferingMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_AtTheMarketEquityOfferingMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AtTheMarketEquityOfferingMember_lbl3" xml:lang="en-US" id="aciu_AtTheMarketEquityOfferingMember_lbl3">At the Market Equity Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketEquityOfferingMember" xlink:to="aciu_AtTheMarketEquityOfferingMember_lbl3" xlink:title="label: AtTheMarketEquityOfferingMember to aciu_AtTheMarketEquityOfferingMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:label="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:title="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl1" xml:lang="en-US" id="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl1">Convertible Note Agreement and Follow-On Offerings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl1" xlink:title="label: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl2" xml:lang="en-US" id="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl2">Convertible Note Agreement and Follow-On Offerings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl2" xlink:title="label: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareIssuedPricePerShare" xlink:label="ShareIssuedPricePerShare" xlink:title="ShareIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ShareIssuedPricePerShare_lbl" xml:lang="en-US" id="aciu_ShareIssuedPricePerShare_lbl">Price per share received for common stock issued or sold in public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssuedPricePerShare" xlink:to="aciu_ShareIssuedPricePerShare_lbl" xlink:title="label: ShareIssuedPricePerShare to aciu_ShareIssuedPricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareIssuedPricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShareIssuedPricePerShare_lbl1" xml:lang="en-US" id="aciu_ShareIssuedPricePerShare_lbl1">Share issued price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssuedPricePerShare" xlink:to="aciu_ShareIssuedPricePerShare_lbl1" xlink:title="label: ShareIssuedPricePerShare to aciu_ShareIssuedPricePerShare_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShareIssuedPricePerShare_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShareIssuedPricePerShare_lbl2" xml:lang="en-US" id="aciu_ShareIssuedPricePerShare_lbl2">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareIssuedPricePerShare" xlink:to="aciu_ShareIssuedPricePerShare_lbl2" xlink:title="label: ShareIssuedPricePerShare to aciu_ShareIssuedPricePerShare_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOfferings" xlink:label="NumberOfOfferings" xlink:title="NumberOfOfferings" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfOfferings_lbl" xml:lang="en-US" id="aciu_NumberOfOfferings_lbl">The number of offerings of subscription rights by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOfferings" xlink:to="aciu_NumberOfOfferings_lbl" xlink:title="label: NumberOfOfferings to aciu_NumberOfOfferings_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOfferings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfOfferings_lbl1" xml:lang="en-US" id="aciu_NumberOfOfferings_lbl1">Number of offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOfferings" xlink:to="aciu_NumberOfOfferings_lbl1" xlink:title="label: NumberOfOfferings to aciu_NumberOfOfferings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:label="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:title="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" />
    <link:label xlink:type="resource" xlink:label="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl" xml:lang="en-US" id="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl">The amount of common shares authorized for sale in the open market.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:to="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl" xlink:title="label: CommonSharesAuthorizedForIssuanceSalesInInOpenMarket to aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl1" xml:lang="en-US" id="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl1">Common shares authorized for issuance sales in in open market</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:to="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl1" xlink:title="label: CommonSharesAuthorizedForIssuanceSalesInInOpenMarket to aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl2" xml:lang="en-US" id="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl2">Shares authorized for sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:to="aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl2" xlink:title="label: CommonSharesAuthorizedForIssuanceSalesInInOpenMarket to aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleBorrowings" xlink:label="ConvertibleBorrowings" xlink:title="ConvertibleBorrowings" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ConvertibleBorrowings_lbl" xml:lang="en-US" id="aciu_ConvertibleBorrowings_lbl">The carrying amount of debt identified as being convertible into another form of financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleBorrowings" xlink:to="aciu_ConvertibleBorrowings_lbl" xlink:title="label: ConvertibleBorrowings to aciu_ConvertibleBorrowings_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleBorrowings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ConvertibleBorrowings_lbl1" xml:lang="en-US" id="aciu_ConvertibleBorrowings_lbl1">Convertible borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleBorrowings" xlink:to="aciu_ConvertibleBorrowings_lbl1" xlink:title="label: ConvertibleBorrowings to aciu_ConvertibleBorrowings_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleBorrowings_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ConvertibleBorrowings_lbl2" xml:lang="en-US" id="aciu_ConvertibleBorrowings_lbl2">Convertible note agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleBorrowings" xlink:to="aciu_ConvertibleBorrowings_lbl2" xlink:title="label: ConvertibleBorrowings to aciu_ConvertibleBorrowings_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl">The increase in the number of ordinary shares issued under a convertible debt arrangement upon conversion of the debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl1" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl1">Increase in number of ordinary shares issued under conversion of convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl1" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl2" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl2">Shares issued to settle Convertible Note Agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl2" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl3" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl3">Conversion of note agreement, net of transaction costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl3" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:label="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl" xml:lang="en-US" id="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl">The cash inflow from the issuing of ordinary shares net of costs to issue shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:to="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl" xlink:title="label: ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts to aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl1" xml:lang="en-US" id="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl1">Proceeds from issue of ordinary shares, net issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:to="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl1" xlink:title="label: ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts to aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl2" xml:lang="en-US" id="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl2">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:to="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl2" xlink:title="label: ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts to aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl3" xml:lang="en-US" id="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl3">Proceeds from issuance of ordinary shares, net of agent commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:to="aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl3" xlink:title="label: ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts to aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FollowOnOfferingsMember" xlink:label="FollowOnOfferingsMember" xlink:title="FollowOnOfferingsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_FollowOnOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_FollowOnOfferingsMember_lbl" xml:lang="en-US" id="aciu_FollowOnOfferingsMember_lbl">This member represents the equity instruments that are included in each offering of equity shares by a private company to the public subsequent to the initial offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FollowOnOfferingsMember" xlink:to="aciu_FollowOnOfferingsMember_lbl" xlink:title="label: FollowOnOfferingsMember to aciu_FollowOnOfferingsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_FollowOnOfferingsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FollowOnOfferingsMember_lbl1" xml:lang="en-US" id="aciu_FollowOnOfferingsMember_lbl1">Follow-on Offerings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FollowOnOfferingsMember" xlink:to="aciu_FollowOnOfferingsMember_lbl1" xlink:title="label: FollowOnOfferingsMember to aciu_FollowOnOfferingsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FollowOnOfferingsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FollowOnOfferingsMember_lbl2" xml:lang="en-US" id="aciu_FollowOnOfferingsMember_lbl2">Follow-on Offerings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FollowOnOfferingsMember" xlink:to="aciu_FollowOnOfferingsMember_lbl2" xlink:title="label: FollowOnOfferingsMember to aciu_FollowOnOfferingsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SecondSubscriptionRightsMember" xlink:label="SecondSubscriptionRightsMember" xlink:title="SecondSubscriptionRightsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_SecondSubscriptionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_SecondSubscriptionRightsMember_lbl" xml:lang="en-US" id="aciu_SecondSubscriptionRightsMember_lbl">This member represents the equity instruments that are the follow-on offering of equity shares by a private company to the public this issuance is after first follow-on offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondSubscriptionRightsMember" xlink:to="aciu_SecondSubscriptionRightsMember_lbl" xlink:title="label: SecondSubscriptionRightsMember to aciu_SecondSubscriptionRightsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_SecondSubscriptionRightsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_SecondSubscriptionRightsMember_lbl1" xml:lang="en-US" id="aciu_SecondSubscriptionRightsMember_lbl1">Second Subscription Rights [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondSubscriptionRightsMember" xlink:to="aciu_SecondSubscriptionRightsMember_lbl1" xlink:title="label: SecondSubscriptionRightsMember to aciu_SecondSubscriptionRightsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OptionForOverAllotmentMember" xlink:label="OptionForOverAllotmentMember" xlink:title="OptionForOverAllotmentMember" />
    <link:label xlink:type="resource" xlink:label="aciu_OptionForOverAllotmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_OptionForOverAllotmentMember_lbl" xml:lang="en-US" id="aciu_OptionForOverAllotmentMember_lbl">This member represents the equity instruments from the right of the underwriter to sell additional equity shares over the initial allotment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionForOverAllotmentMember" xlink:to="aciu_OptionForOverAllotmentMember_lbl" xlink:title="label: OptionForOverAllotmentMember to aciu_OptionForOverAllotmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_OptionForOverAllotmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OptionForOverAllotmentMember_lbl1" xml:lang="en-US" id="aciu_OptionForOverAllotmentMember_lbl1">Option for Over-Allotment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionForOverAllotmentMember" xlink:to="aciu_OptionForOverAllotmentMember_lbl1" xlink:title="label: OptionForOverAllotmentMember to aciu_OptionForOverAllotmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OptionForOverAllotmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_OptionForOverAllotmentMember_lbl2" xml:lang="en-US" id="aciu_OptionForOverAllotmentMember_lbl2">Over-Allotment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionForOverAllotmentMember" xlink:to="aciu_OptionForOverAllotmentMember_lbl2" xlink:title="label: OptionForOverAllotmentMember to aciu_OptionForOverAllotmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FirstSubscriptionRightsMember" xlink:label="FirstSubscriptionRightsMember" xlink:title="FirstSubscriptionRightsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_FirstSubscriptionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_FirstSubscriptionRightsMember_lbl" xml:lang="en-US" id="aciu_FirstSubscriptionRightsMember_lbl">This member represents the equity instruments that are the follow-on offering of first equity shares by a private company to the public.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstSubscriptionRightsMember" xlink:to="aciu_FirstSubscriptionRightsMember_lbl" xlink:title="label: FirstSubscriptionRightsMember to aciu_FirstSubscriptionRightsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_FirstSubscriptionRightsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FirstSubscriptionRightsMember_lbl1" xml:lang="en-US" id="aciu_FirstSubscriptionRightsMember_lbl1">First Subscription Rights [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstSubscriptionRightsMember" xlink:to="aciu_FirstSubscriptionRightsMember_lbl1" xlink:title="label: FirstSubscriptionRightsMember to aciu_FirstSubscriptionRightsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FirstSubscriptionRightsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FirstSubscriptionRightsMember_lbl2" xml:lang="en-US" id="aciu_FirstSubscriptionRightsMember_lbl2">First Subscription Rights [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstSubscriptionRightsMember" xlink:to="aciu_FirstSubscriptionRightsMember_lbl2" xlink:title="label: FirstSubscriptionRightsMember to aciu_FirstSubscriptionRightsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsTable" xlink:label="StatementOfCashFlowsTable" xlink:title="StatementOfCashFlowsTable" />
    <link:label xlink:type="resource" xlink:label="aciu_StatementOfCashFlowsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_StatementOfCashFlowsTable_lbl" xml:lang="en-US" id="aciu_StatementOfCashFlowsTable_lbl">Schedule disclosing information related to the Statement of Cash Flows.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsTable" xlink:to="aciu_StatementOfCashFlowsTable_lbl" xlink:title="label: StatementOfCashFlowsTable to aciu_StatementOfCashFlowsTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_StatementOfCashFlowsTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_StatementOfCashFlowsTable_lbl1" xml:lang="en-US" id="aciu_StatementOfCashFlowsTable_lbl1">Statement of Cash Flows [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsTable" xlink:to="aciu_StatementOfCashFlowsTable_lbl1" xlink:title="label: StatementOfCashFlowsTable to aciu_StatementOfCashFlowsTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementMember" xlink:label="ConvertibleNoteAgreementMember" xlink:title="ConvertibleNoteAgreementMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleNoteAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ConvertibleNoteAgreementMember_lbl" xml:lang="en-US" id="aciu_ConvertibleNoteAgreementMember_lbl">The member represents to convertible note agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNoteAgreementMember" xlink:to="aciu_ConvertibleNoteAgreementMember_lbl" xlink:title="label: ConvertibleNoteAgreementMember to aciu_ConvertibleNoteAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleNoteAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ConvertibleNoteAgreementMember_lbl1" xml:lang="en-US" id="aciu_ConvertibleNoteAgreementMember_lbl1">Convertible Note Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNoteAgreementMember" xlink:to="aciu_ConvertibleNoteAgreementMember_lbl1" xlink:title="label: ConvertibleNoteAgreementMember to aciu_ConvertibleNoteAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ConvertibleNoteAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ConvertibleNoteAgreementMember_lbl2" xml:lang="en-US" id="aciu_ConvertibleNoteAgreementMember_lbl2">Convertible Note Agreement with Lilly [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNoteAgreementMember" xlink:to="aciu_ConvertibleNoteAgreementMember_lbl2" xlink:title="label: ConvertibleNoteAgreementMember to aciu_ConvertibleNoteAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsLineItems" xlink:label="StatementOfCashFlowsLineItems" xlink:title="StatementOfCashFlowsLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_StatementOfCashFlowsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_StatementOfCashFlowsLineItems_lbl" xml:lang="en-US" id="aciu_StatementOfCashFlowsLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsLineItems" xlink:to="aciu_StatementOfCashFlowsLineItems_lbl" xlink:title="label: StatementOfCashFlowsLineItems to aciu_StatementOfCashFlowsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_StatementOfCashFlowsLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_StatementOfCashFlowsLineItems_lbl1" xml:lang="en-US" id="aciu_StatementOfCashFlowsLineItems_lbl1">Statement of Cash Flows [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsLineItems" xlink:to="aciu_StatementOfCashFlowsLineItems_lbl1" xlink:title="label: StatementOfCashFlowsLineItems to aciu_StatementOfCashFlowsLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SupplementaryNonCashActivityAbstract" xlink:label="SupplementaryNonCashActivityAbstract" xlink:title="SupplementaryNonCashActivityAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_SupplementaryNonCashActivityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_SupplementaryNonCashActivityAbstract_lbl1" xml:lang="en-US" id="aciu_SupplementaryNonCashActivityAbstract_lbl1">Supplementary non-cash activity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementaryNonCashActivityAbstract" xlink:to="aciu_SupplementaryNonCashActivityAbstract_lbl1" xlink:title="label: SupplementaryNonCashActivityAbstract to aciu_SupplementaryNonCashActivityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_SupplementaryNonCashActivityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_SupplementaryNonCashActivityAbstract_lbl2" xml:lang="en-US" id="aciu_SupplementaryNonCashActivityAbstract_lbl2">Supplementary non-cash activity includes the following:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementaryNonCashActivityAbstract" xlink:to="aciu_SupplementaryNonCashActivityAbstract_lbl2" xlink:title="label: SupplementaryNonCashActivityAbstract to aciu_SupplementaryNonCashActivityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:label="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:title="RepaymentOfConvertibleDebtEquitySettlementAmount" />
    <link:label xlink:type="resource" xlink:label="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl" xml:lang="en-US" id="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl">The gross value of the settlement of convertible debt that is settled via shares of entity's common shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:to="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl" xlink:title="label: RepaymentOfConvertibleDebtEquitySettlementAmount to aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl1" xml:lang="en-US" id="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl1">Repayment of convertible debt, Equity Settlement, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:to="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl1" xlink:title="label: RepaymentOfConvertibleDebtEquitySettlementAmount to aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl2" xml:lang="en-US" id="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl2">Settlement of convertible loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:to="aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl2" xlink:title="label: RepaymentOfConvertibleDebtEquitySettlementAmount to aciu_RepaymentOfConvertibleDebtEquitySettlementAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl" xml:lang="en-US" id="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl">Amount of property plant and equipment acquired through noncash investing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:to="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl" xlink:title="label: PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities to aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl1" xml:lang="en-US" id="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl1">Purchase of property, plant and equipment, classified as noncash investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:to="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl1" xlink:title="label: PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities to aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl2" xml:lang="en-US" id="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl2">Acquisition of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:to="aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl2" xlink:title="label: PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities to aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl">Percentage of increase (decrease) in plan assets of defined benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl1" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl1">Increase (decrease) in plan assets of defined benefit plan, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl1" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl2" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl2">Percentage increase in plan assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl2" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitPlanPercentageOfContribution" xlink:label="DefinedBenefitPlanPercentageOfContribution" xlink:title="DefinedBenefitPlanPercentageOfContribution" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitPlanPercentageOfContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DefinedBenefitPlanPercentageOfContribution_lbl" xml:lang="en-US" id="aciu_DefinedBenefitPlanPercentageOfContribution_lbl">The contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlanPercentageOfContribution" xlink:to="aciu_DefinedBenefitPlanPercentageOfContribution_lbl" xlink:title="label: DefinedBenefitPlanPercentageOfContribution to aciu_DefinedBenefitPlanPercentageOfContribution_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitPlanPercentageOfContribution_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DefinedBenefitPlanPercentageOfContribution_lbl1" xml:lang="en-US" id="aciu_DefinedBenefitPlanPercentageOfContribution_lbl1">Defined benefit plan, percentage of contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlanPercentageOfContribution" xlink:to="aciu_DefinedBenefitPlanPercentageOfContribution_lbl1" xlink:title="label: DefinedBenefitPlanPercentageOfContribution to aciu_DefinedBenefitPlanPercentageOfContribution_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitPlanPercentageOfContribution_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DefinedBenefitPlanPercentageOfContribution_lbl2" xml:lang="en-US" id="aciu_DefinedBenefitPlanPercentageOfContribution_lbl2">Contributions paid to the plan by computing percentage in salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlanPercentageOfContribution" xlink:to="aciu_DefinedBenefitPlanPercentageOfContribution_lbl2" xlink:title="label: DefinedBenefitPlanPercentageOfContribution to aciu_DefinedBenefitPlanPercentageOfContribution_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl">Amount of increase (decrease) in plan assets of defined benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl1" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl1">Increase (decrease) in plan assets of defined benefit plan, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl1" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl2" xml:lang="en-US" id="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl2">Increase in plan assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:to="aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl2" xlink:title="label: IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount to aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployeeMember" xlink:label="DefinedBenefitsPlanEmployeeMember" xlink:title="DefinedBenefitsPlanEmployeeMember" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DefinedBenefitsPlanEmployeeMember_lbl" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployeeMember_lbl">This member stands for the employee portion of a domestic defined benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployeeMember" xlink:to="aciu_DefinedBenefitsPlanEmployeeMember_lbl" xlink:title="label: DefinedBenefitsPlanEmployeeMember to aciu_DefinedBenefitsPlanEmployeeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployeeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DefinedBenefitsPlanEmployeeMember_lbl1" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployeeMember_lbl1">Defined benefits plan, Employee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployeeMember" xlink:to="aciu_DefinedBenefitsPlanEmployeeMember_lbl1" xlink:title="label: DefinedBenefitsPlanEmployeeMember to aciu_DefinedBenefitsPlanEmployeeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployeeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DefinedBenefitsPlanEmployeeMember_lbl2" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployeeMember_lbl2">Employee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployeeMember" xlink:to="aciu_DefinedBenefitsPlanEmployeeMember_lbl2" xlink:title="label: DefinedBenefitsPlanEmployeeMember to aciu_DefinedBenefitsPlanEmployeeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NetPensionCostInStatementOfIncomeAbstract" xlink:label="NetPensionCostInStatementOfIncomeAbstract" xlink:title="NetPensionCostInStatementOfIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl1" xml:lang="en-US" id="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl1">Net pension cost in statement of income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl1" xlink:title="label: NetPensionCostInStatementOfIncomeAbstract to aciu_NetPensionCostInStatementOfIncomeAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl2" xml:lang="en-US" id="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl2">Net pension cost in statement of income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="aciu_NetPensionCostInStatementOfIncomeAbstract_lbl2" xlink:title="label: NetPensionCostInStatementOfIncomeAbstract to aciu_NetPensionCostInStatementOfIncomeAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" id="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl">The increase in the net defined benefit liability (asset) resulting from the passage of time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl" xlink:title="label: InterestIncomeNetDefinedBenefitLiabilityAsset to aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl1" xml:lang="en-US" id="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl1">Interest income, net defined benefit liability (asset)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl1" xlink:title="label: InterestIncomeNetDefinedBenefitLiabilityAsset to aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl2" xml:lang="en-US" id="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl2">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl2" xlink:title="label: InterestIncomeNetDefinedBenefitLiabilityAsset to aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl3" xml:lang="en-US" id="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl3">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:to="aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl3" xlink:title="label: InterestIncomeNetDefinedBenefitLiabilityAsset to aciu_InterestIncomeNetDefinedBenefitLiabilityAsset_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployerMember" xlink:label="DefinedBenefitsPlanEmployerMember" xlink:title="DefinedBenefitsPlanEmployerMember" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DefinedBenefitsPlanEmployerMember_lbl" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployerMember_lbl">This member stands for the employee portion of a domestic defined benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployerMember" xlink:to="aciu_DefinedBenefitsPlanEmployerMember_lbl" xlink:title="label: DefinedBenefitsPlanEmployerMember to aciu_DefinedBenefitsPlanEmployerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DefinedBenefitsPlanEmployerMember_lbl1" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployerMember_lbl1">Defined benefits plan, Employer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployerMember" xlink:to="aciu_DefinedBenefitsPlanEmployerMember_lbl1" xlink:title="label: DefinedBenefitsPlanEmployerMember to aciu_DefinedBenefitsPlanEmployerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DefinedBenefitsPlanEmployerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DefinedBenefitsPlanEmployerMember_lbl2" xml:lang="en-US" id="aciu_DefinedBenefitsPlanEmployerMember_lbl2">Employer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitsPlanEmployerMember" xlink:to="aciu_DefinedBenefitsPlanEmployerMember_lbl2" xlink:title="label: DefinedBenefitsPlanEmployerMember to aciu_DefinedBenefitsPlanEmployerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesByCategoryAbstract" xlink:label="ExpensesByCategoryAbstract" xlink:title="ExpensesByCategoryAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ExpensesByCategoryAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ExpensesByCategoryAbstract_lbl1" xml:lang="en-US" id="aciu_ExpensesByCategoryAbstract_lbl1">Expenses by category [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExpensesByCategoryAbstract" xlink:to="aciu_ExpensesByCategoryAbstract_lbl1" xlink:title="label: ExpensesByCategoryAbstract to aciu_ExpensesByCategoryAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageRemainingAbstract" xlink:label="WeightedAverageRemainingAbstract" xlink:title="WeightedAverageRemainingAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageRemainingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageRemainingAbstract_lbl1" xml:lang="en-US" id="aciu_WeightedAverageRemainingAbstract_lbl1">Weighted Average Remaining [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingAbstract" xlink:to="aciu_WeightedAverageRemainingAbstract_lbl1" xlink:title="label: WeightedAverageRemainingAbstract to aciu_WeightedAverageRemainingAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageRemainingAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_WeightedAverageRemainingAbstract_lbl2" xml:lang="en-US" id="aciu_WeightedAverageRemainingAbstract_lbl2">Weighted average remaining term (years) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingAbstract" xlink:to="aciu_WeightedAverageRemainingAbstract_lbl2" xlink:title="label: WeightedAverageRemainingAbstract to aciu_WeightedAverageRemainingAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:label="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:title="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl" xml:lang="en-US" id="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl">The weighted average remaining contractual life of exercisable share options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:to="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl" xlink:title="label: WeightedAverageRemainingContractualLifeOfExercisableShareOptions to aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl1" xml:lang="en-US" id="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl1">Weighted average remaining contractual life of exercisable share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:to="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl1" xlink:title="label: WeightedAverageRemainingContractualLifeOfExercisableShareOptions to aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl2" xml:lang="en-US" id="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl2">Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:to="aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl2" xlink:title="label: WeightedAverageRemainingContractualLifeOfExercisableShareOptions to aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOptionsAbstract" xlink:label="NumberOfOptionsAbstract" xlink:title="NumberOfOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfOptionsAbstract_lbl1" xml:lang="en-US" id="aciu_NumberOfOptionsAbstract_lbl1">Number of Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOptionsAbstract" xlink:to="aciu_NumberOfOptionsAbstract_lbl1" xlink:title="label: NumberOfOptionsAbstract to aciu_NumberOfOptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfOptionsAbstract_lbl2" xml:lang="en-US" id="aciu_NumberOfOptionsAbstract_lbl2">Number of options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOptionsAbstract" xlink:to="aciu_NumberOfOptionsAbstract_lbl2" xlink:title="label: NumberOfOptionsAbstract to aciu_NumberOfOptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialResultNetAbstract" xlink:label="FinancialResultNetAbstract" xlink:title="FinancialResultNetAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialResultNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FinancialResultNetAbstract_lbl1" xml:lang="en-US" id="aciu_FinancialResultNetAbstract_lbl1">Financial Result, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialResultNetAbstract" xlink:to="aciu_FinancialResultNetAbstract_lbl1" xlink:title="label: FinancialResultNetAbstract to aciu_FinancialResultNetAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialResultNetAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FinancialResultNetAbstract_lbl2" xml:lang="en-US" id="aciu_FinancialResultNetAbstract_lbl2">Financial result, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialResultNetAbstract" xlink:to="aciu_FinancialResultNetAbstract_lbl2" xlink:title="label: FinancialResultNetAbstract to aciu_FinancialResultNetAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpensesAbstract" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:title="ResearchAndDevelopmentExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ResearchAndDevelopmentExpensesAbstract_lbl1" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpensesAbstract_lbl1">Research and Development Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="aciu_ResearchAndDevelopmentExpensesAbstract_lbl1" xlink:title="label: ResearchAndDevelopmentExpensesAbstract to aciu_ResearchAndDevelopmentExpensesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpensesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ResearchAndDevelopmentExpensesAbstract_lbl2" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpensesAbstract_lbl2">Research and Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="aciu_ResearchAndDevelopmentExpensesAbstract_lbl2" xlink:title="label: ResearchAndDevelopmentExpensesAbstract to aciu_ResearchAndDevelopmentExpensesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:label="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="ResearchAndDevelopmentExpenseAllocationOperatingExpense" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl">The amount of all operating expenses allocated to research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpenseAllocationOperatingExpense to aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl1" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl1">Research and development expense allocation, operating expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseAllocationOperatingExpense to aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl2" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl2">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl2" xlink:title="label: ResearchAndDevelopmentExpenseAllocationOperatingExpense to aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:label="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl">A class of employee benefits expense that represents wages and salaries that are allocated to research and development expenses. [Refer: Employee benefits expense]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl" xlink:title="label: ResearchAndDevelopmentExpenseAllocationWagesAndSalaries to aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl1" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl1">Research and development expense allocation, wages and salaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseAllocationWagesAndSalaries to aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl2" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl2">Payroll expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl2" xlink:title="label: ResearchAndDevelopmentExpenseAllocationWagesAndSalaries to aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:label="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:title="EmployeeFullTimeEquivalentsInResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl">Number of employees calculated on full-time equivalents within research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:to="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl" xlink:title="label: EmployeeFullTimeEquivalentsInResearchAndDevelopment to aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl1" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl1">Employee, full-time equivalents in research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:to="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl1" xlink:title="label: EmployeeFullTimeEquivalentsInResearchAndDevelopment to aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl2" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl2">Full-time equivalents in research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:to="aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl2" xlink:title="label: EmployeeFullTimeEquivalentsInResearchAndDevelopment to aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:label="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl">A class of employee benefits expense that represents wages and salaries that are allocated to general and administrative expense. [Refer: Employee benefits expense]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl" xlink:title="label: GeneralAndAdministrativeExpenseAllocationWagesAndSalaries to aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl1" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl1">General and administrative expense allocation, wages and salaries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseAllocationWagesAndSalaries to aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl2" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl2">Payroll expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl2" xlink:title="label: GeneralAndAdministrativeExpenseAllocationWagesAndSalaries to aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:label="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="GeneralAndAdministrativeExpenseAllocationOperatingExpense" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl">The amount of all operating expenses allocated to general and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpenseAllocationOperatingExpense to aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl1" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl1">General and administrative expense allocation, operating expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseAllocationOperatingExpense to aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl2" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl2">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl2" xlink:title="label: GeneralAndAdministrativeExpenseAllocationOperatingExpense to aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl">The amount of expense from share-based payment transactions with employees allocated to general and administrative expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xlink:title="label: GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1">General and administrative expense allocation, expense from share-based payment transactions with employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xml:lang="en-US" id="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xlink:title="label: GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:label="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:title="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl">Number of employees calculated on full-time equivalents within general and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:to="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl" xlink:title="label: EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses to aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl1">Employee, full-time equivalents in general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:to="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl1" xlink:title="label: EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses to aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl2" xml:lang="en-US" id="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl2">Full-time equivalents in general and administrative functions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:to="aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl2" xlink:title="label: EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses to aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl">The amount of expense from share-based payment transactions with employees that are allocated to research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" xlink:title="label: ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1">Research and development expense allocation, expense from share-based payment transactions with employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xml:lang="en-US" id="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:to="aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" xlink:title="label: ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees to aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl">Schedule of disclosing information related to commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:to="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl" xlink:title="label: DisclosureOfInformationAboutCommitmentsAndContingenciesTable to aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl1" xml:lang="en-US" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl1">Disclosure of information about commitments and contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:to="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl1" xlink:title="label: DisclosureOfInformationAboutCommitmentsAndContingenciesTable to aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl" xlink:title="label: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl1" xml:lang="en-US" id="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl1">Disclosure of information about commitments and contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl1" xlink:title="label: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAbstract" xlink:label="CommitmentsAbstract" xlink:title="CommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_CommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CommitmentsAbstract_lbl1" xml:lang="en-US" id="aciu_CommitmentsAbstract_lbl1">Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAbstract" xlink:to="aciu_CommitmentsAbstract_lbl1" xlink:title="label: CommitmentsAbstract to aciu_CommitmentsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CommitmentsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CommitmentsAbstract_lbl2" xml:lang="en-US" id="aciu_CommitmentsAbstract_lbl2">Commitments and contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAbstract" xlink:to="aciu_CommitmentsAbstract_lbl2" xlink:title="label: CommitmentsAbstract to aciu_CommitmentsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RentalContractPeriodForNoticeOfCancellation" xlink:label="RentalContractPeriodForNoticeOfCancellation" xlink:title="RentalContractPeriodForNoticeOfCancellation" />
    <link:label xlink:type="resource" xlink:label="aciu_RentalContractPeriodForNoticeOfCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RentalContractPeriodForNoticeOfCancellation_lbl" xml:lang="en-US" id="aciu_RentalContractPeriodForNoticeOfCancellation_lbl">The period of time required by the lessee in a lease agreement to provide notice of cancellation of a lease to the lessor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RentalContractPeriodForNoticeOfCancellation" xlink:to="aciu_RentalContractPeriodForNoticeOfCancellation_lbl" xlink:title="label: RentalContractPeriodForNoticeOfCancellation to aciu_RentalContractPeriodForNoticeOfCancellation_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RentalContractPeriodForNoticeOfCancellation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RentalContractPeriodForNoticeOfCancellation_lbl1" xml:lang="en-US" id="aciu_RentalContractPeriodForNoticeOfCancellation_lbl1">Rental contract, period for notice of cancellation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RentalContractPeriodForNoticeOfCancellation" xlink:to="aciu_RentalContractPeriodForNoticeOfCancellation_lbl1" xlink:title="label: RentalContractPeriodForNoticeOfCancellation to aciu_RentalContractPeriodForNoticeOfCancellation_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RentalContractPeriodForNoticeOfCancellation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RentalContractPeriodForNoticeOfCancellation_lbl2" xml:lang="en-US" id="aciu_RentalContractPeriodForNoticeOfCancellation_lbl2">Notice period for cancellation of rental contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RentalContractPeriodForNoticeOfCancellation" xlink:to="aciu_RentalContractPeriodForNoticeOfCancellation_lbl2" xlink:title="label: RentalContractPeriodForNoticeOfCancellation to aciu_RentalContractPeriodForNoticeOfCancellation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProvisionsResearchContracts" xlink:label="ProvisionsResearchContracts" xlink:title="ProvisionsResearchContracts" />
    <link:label xlink:type="resource" xlink:label="aciu_ProvisionsResearchContracts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ProvisionsResearchContracts_lbl" xml:lang="en-US" id="aciu_ProvisionsResearchContracts_lbl">The amount of provisions for research and development contracts with external providers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProvisionsResearchContracts" xlink:to="aciu_ProvisionsResearchContracts_lbl" xlink:title="label: ProvisionsResearchContracts to aciu_ProvisionsResearchContracts_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ProvisionsResearchContracts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ProvisionsResearchContracts_lbl1" xml:lang="en-US" id="aciu_ProvisionsResearchContracts_lbl1">Provisions, research contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProvisionsResearchContracts" xlink:to="aciu_ProvisionsResearchContracts_lbl1" xlink:title="label: ProvisionsResearchContracts to aciu_ProvisionsResearchContracts_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ProvisionsResearchContracts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ProvisionsResearchContracts_lbl2" xml:lang="en-US" id="aciu_ProvisionsResearchContracts_lbl2">External research projects</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProvisionsResearchContracts" xlink:to="aciu_ProvisionsResearchContracts_lbl2" xlink:title="label: ProvisionsResearchContracts to aciu_ProvisionsResearchContracts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TaxLossesSplitByExpiryDateAbstract" xlink:label="TaxLossesSplitByExpiryDateAbstract" xlink:title="TaxLossesSplitByExpiryDateAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_TaxLossesSplitByExpiryDateAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_TaxLossesSplitByExpiryDateAbstract_lbl1" xml:lang="en-US" id="aciu_TaxLossesSplitByExpiryDateAbstract_lbl1">Tax losses split by expiry date [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxLossesSplitByExpiryDateAbstract" xlink:to="aciu_TaxLossesSplitByExpiryDateAbstract_lbl1" xlink:title="label: TaxLossesSplitByExpiryDateAbstract to aciu_TaxLossesSplitByExpiryDateAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_TaxLossesSplitByExpiryDateAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_TaxLossesSplitByExpiryDateAbstract_lbl2" xml:lang="en-US" id="aciu_TaxLossesSplitByExpiryDateAbstract_lbl2">Tax losses split by expiry date [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxLossesSplitByExpiryDateAbstract" xlink:to="aciu_TaxLossesSplitByExpiryDateAbstract_lbl2" xlink:title="label: TaxLossesSplitByExpiryDateAbstract to aciu_TaxLossesSplitByExpiryDateAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanSevenYearsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl">This member stands for a time band of later than six years and not later than seven years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl" xlink:title="label: LaterThanSixYearsAndNotLaterThanSevenYearsMember to aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl1" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl1">Later than six years and not later than seven years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl1" xlink:title="label: LaterThanSixYearsAndNotLaterThanSevenYearsMember to aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl2" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl2">Loss Expiry, December 31, 2026 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl2" xlink:title="label: LaterThanSixYearsAndNotLaterThanSevenYearsMember to aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NotLaterThanPriorYearEndMember" xlink:label="NotLaterThanPriorYearEndMember" xlink:title="NotLaterThanPriorYearEndMember" />
    <link:label xlink:type="resource" xlink:label="aciu_NotLaterThanPriorYearEndMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NotLaterThanPriorYearEndMember_lbl" xml:lang="en-US" id="aciu_NotLaterThanPriorYearEndMember_lbl">This member stands for a time band not later than prior year end.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanPriorYearEndMember" xlink:to="aciu_NotLaterThanPriorYearEndMember_lbl" xlink:title="label: NotLaterThanPriorYearEndMember to aciu_NotLaterThanPriorYearEndMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NotLaterThanPriorYearEndMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NotLaterThanPriorYearEndMember_lbl1" xml:lang="en-US" id="aciu_NotLaterThanPriorYearEndMember_lbl1">Not later than prior year end [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanPriorYearEndMember" xlink:to="aciu_NotLaterThanPriorYearEndMember_lbl1" xlink:title="label: NotLaterThanPriorYearEndMember to aciu_NotLaterThanPriorYearEndMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NotLaterThanPriorYearEndMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NotLaterThanPriorYearEndMember_lbl2" xml:lang="en-US" id="aciu_NotLaterThanPriorYearEndMember_lbl2">Loss Expiry, December 31, 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotLaterThanPriorYearEndMember" xlink:to="aciu_NotLaterThanPriorYearEndMember_lbl2" xlink:title="label: NotLaterThanPriorYearEndMember to aciu_NotLaterThanPriorYearEndMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanEightYearsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl">This member stands for a time band of later than seven years and not later than eight years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl" xlink:title="label: LaterThanSixYearsAndNotLaterThanEightYearsMember to aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl1" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl1">Later Than Six Years And Not Later Than Eight Years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl1" xlink:title="label: LaterThanSixYearsAndNotLaterThanEightYearsMember to aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl2" xml:lang="en-US" id="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl2">Loss Expiry, December 31, 2027 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:to="aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl2" xlink:title="label: LaterThanSixYearsAndNotLaterThanEightYearsMember to aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRetirementBenefitPlanMember" xlink:label="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:title="UnusedTaxCreditsRetirementBenefitPlanMember" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl" xml:lang="en-US" id="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl">This member stands for tax credits that have been received and are carried forward for use against future taxable profit related to the retirement benefit plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:to="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl" xlink:title="label: UnusedTaxCreditsRetirementBenefitPlanMember to aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl1" xml:lang="en-US" id="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl1">Unused tax credits, Retirement benefit plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:to="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl1" xlink:title="label: UnusedTaxCreditsRetirementBenefitPlanMember to aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl2" xml:lang="en-US" id="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl2">Deductible Temporary Differences Related to Retirement Benefit Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:to="aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl2" xlink:title="label: UnusedTaxCreditsRetirementBenefitPlanMember to aciu_UnusedTaxCreditsRetirementBenefitPlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:label="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:title="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl" xml:lang="en-US" id="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl">This member stands for tax credits that have been received and are carried forward for use against future taxable profit related to right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:to="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl" xlink:title="label: UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember to aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl1" xml:lang="en-US" id="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl1">Unused tax credits, Right-of-use assets and lease liabilities net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:to="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl1" xlink:title="label: UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember to aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl2" xml:lang="en-US" id="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl2">Deductible Temporary Differences Related to Right-of-use Assets and Lease Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:to="aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl2" xlink:title="label: UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember to aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:title="LaterThanFiveYearsAndNotLaterThanSixYearsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl" xml:lang="en-US" id="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl">This member stands for a time band of later than five years and not later than six years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl" xlink:title="label: LaterThanFiveYearsAndNotLaterThanSixYearsMember to aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl1" xml:lang="en-US" id="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl1">Later than five years and not later than six years [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl1" xlink:title="label: LaterThanFiveYearsAndNotLaterThanSixYearsMember to aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl2" xml:lang="en-US" id="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl2">Loss Expiry, December 31, 2025 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl2" xlink:title="label: LaterThanFiveYearsAndNotLaterThanSixYearsMember to aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangesInFairValueOfPlanAssetsAbstract" xlink:label="ChangesInFairValueOfPlanAssetsAbstract" xlink:title="ChangesInFairValueOfPlanAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl1" xml:lang="en-US" id="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl1">Changes in fair value of plan assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl1" xlink:title="label: ChangesInFairValueOfPlanAssetsAbstract to aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl2" xml:lang="en-US" id="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl2">Changes in fair value of plan assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl2" xlink:title="label: ChangesInFairValueOfPlanAssetsAbstract to aciu_ChangesInFairValueOfPlanAssetsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementAbstract" xlink:label="ShelfRegistrationStatementAbstract" xlink:title="ShelfRegistrationStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ShelfRegistrationStatementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShelfRegistrationStatementAbstract_lbl1" xml:lang="en-US" id="aciu_ShelfRegistrationStatementAbstract_lbl1">Shelf Registration Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAbstract" xlink:to="aciu_ShelfRegistrationStatementAbstract_lbl1" xlink:title="label: ShelfRegistrationStatementAbstract to aciu_ShelfRegistrationStatementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:label="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:title="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl" xml:lang="en-US" id="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl">The number of future offerings of securities the entity may execute covered by the Shelf Registration Statement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:to="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl" xlink:title="label: NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement to aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl1" xml:lang="en-US" id="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl1">Number of future offerings of securities authorized under Shelf Registration Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:to="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl1" xlink:title="label: NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement to aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl2" xml:lang="en-US" id="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl2">Number of additional future public offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:to="aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl2" xlink:title="label: NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement to aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:label="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:title="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" />
    <link:label xlink:type="resource" xlink:label="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl" xml:lang="en-US" id="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl">The potential additional cash inflow from issuing equity instruments through a Shelf Registration Statement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:to="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl" xlink:title="label: PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement to aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl1" xml:lang="en-US" id="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl1">Potential additional proceeds, sale of equity instruments, Shelf Registration Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:to="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl1" xlink:title="label: PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement to aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl2" xml:lang="en-US" id="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl2">Additional proceeds from Shelf Registration Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:to="aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl2" xlink:title="label: PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement to aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementSharesAuthorized" xlink:label="ShelfRegistrationStatementSharesAuthorized" xlink:title="ShelfRegistrationStatementSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="aciu_ShelfRegistrationStatementSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ShelfRegistrationStatementSharesAuthorized_lbl" xml:lang="en-US" id="aciu_ShelfRegistrationStatementSharesAuthorized_lbl">The number of common stock, debt securities, warrants, purchase contracts, units, subscription rights or any combination of the foregoing in one or more future public offerings authorized for sale by the entity through a Shelf Registration Statement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementSharesAuthorized" xlink:to="aciu_ShelfRegistrationStatementSharesAuthorized_lbl" xlink:title="label: ShelfRegistrationStatementSharesAuthorized to aciu_ShelfRegistrationStatementSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ShelfRegistrationStatementSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShelfRegistrationStatementSharesAuthorized_lbl1" xml:lang="en-US" id="aciu_ShelfRegistrationStatementSharesAuthorized_lbl1">Shelf Registration Statement, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementSharesAuthorized" xlink:to="aciu_ShelfRegistrationStatementSharesAuthorized_lbl1" xlink:title="label: ShelfRegistrationStatementSharesAuthorized to aciu_ShelfRegistrationStatementSharesAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShelfRegistrationStatementSharesAuthorized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShelfRegistrationStatementSharesAuthorized_lbl2" xml:lang="en-US" id="aciu_ShelfRegistrationStatementSharesAuthorized_lbl2">Shares authorized under Shelf Registration Statement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementSharesAuthorized" xlink:to="aciu_ShelfRegistrationStatementSharesAuthorized_lbl2" xlink:title="label: ShelfRegistrationStatementSharesAuthorized to aciu_ShelfRegistrationStatementSharesAuthorized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:label="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:title="IncreaseThroughSharesIssuedUnderIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl">The increase in equity resulting from the issue of shares under incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl" xlink:title="label: IncreaseThroughSharesIssuedUnderIncentivePlans to aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl1" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl1">Increase through shares issued under incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl1" xlink:title="label: IncreaseThroughSharesIssuedUnderIncentivePlans to aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl2" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl2">Issuance of shares - incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl2" xlink:title="label: IncreaseThroughSharesIssuedUnderIncentivePlans to aciu_IncreaseThroughSharesIssuedUnderIncentivePlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl" xml:lang="en-US" id="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl">The increase (decrease) in equity shares resulting from treasury share transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:to="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl" xlink:title="label: IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares to aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl1" xml:lang="en-US" id="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl1">Increase (decrease) through treasury share transactions, equity, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:to="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl1" xlink:title="label: IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares to aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl2" xml:lang="en-US" id="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl2">Issuance of shares to be held as treasury shares, net of transaction costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:to="aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl2" xlink:title="label: IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares to aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl">The increase in the number of ordinary shares issued under incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl1" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl1">Increase in number of ordinary shares issued under incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl1" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl2" xml:lang="en-US" id="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl2">Issuance of shares - incentive plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:to="aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl2" xlink:title="label: IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans to aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl">The increase in equity resulting from the issue of shares under share-based payment arrangements equity instruments other that share options net of expirations and forfeitures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xlink:title="label: IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1">Increase through shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xlink:title="label: IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xml:lang="en-US" id="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2">Issuance of shares - incentive plans, net of RSU expiration and forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xlink:title="label: IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfSharesOutstandingIncludingTreasuryShares" xlink:label="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:title="NumberOfSharesOutstandingIncludingTreasuryShares" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl" xml:lang="en-US" id="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl">The number of shares that have been authorized and issued, including treasury shares held. [Refer: Treasury shares]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:to="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl" xlink:title="label: NumberOfSharesOutstandingIncludingTreasuryShares to aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl1" xml:lang="en-US" id="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl1">Number of shares outstanding including treasury shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:to="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl1" xlink:title="label: NumberOfSharesOutstandingIncludingTreasuryShares to aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl2" xml:lang="en-US" id="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl2">Balance, beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:to="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl2" xlink:title="label: NumberOfSharesOutstandingIncludingTreasuryShares to aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl3" xml:lang="en-US" id="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl3">Balance, end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:to="aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl3" xlink:title="label: NumberOfSharesOutstandingIncludingTreasuryShares to aciu_NumberOfSharesOutstandingIncludingTreasuryShares_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl">The number of other equity instruments (ie other than share options) expired or forfeited in a share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl" xlink:title="label: NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl1" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl1">Number of other equity instruments expired or forfeited in share-based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl1" xlink:title="label: NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl2" xml:lang="en-US" id="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl2">Number of RSUs either expired or forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:to="aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl2" xlink:title="label: NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement to aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xml:lang="en-US" id="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl">The increase in number of equity instruments issued resulting from the issue of shares under share-based payment arrangements equity instruments other that share options net of expirations and forfeitures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" xlink:title="label: IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xml:lang="en-US" id="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1">Increase in number of shares issued, share-based payment arrangement, other equity instruments net of expiration and forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" xlink:title="label: IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xml:lang="en-US" id="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2">Issuance of shares - incentive plans, net of RSU expiration and forfeiture (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:to="aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" xlink:title="label: IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture to aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:label="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:title="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl" xml:lang="en-US" id="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl">Tabular disclosure of information related to the contractual undiscounted cash flows.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:to="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl" xlink:title="label: ScheduleOfContractualUndiscountedCashFlowsTableTextBlock to aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl1" xml:lang="en-US" id="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl1">Schedule of contractual undiscounted cash flows [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:to="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl1" xlink:title="label: ScheduleOfContractualUndiscountedCashFlowsTableTextBlock to aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl2" xml:lang="en-US" id="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl2">Contractual Undiscounted Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:to="aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl2" xlink:title="label: ScheduleOfContractualUndiscountedCashFlowsTableTextBlock to aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:label="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:title="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl">The disclosure of right-of-use assets impact on the company's statements of income/(loss) and statements of cash flows.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:to="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl" xlink:title="label: DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock to aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl1">Disclosure of right-of-use assets impact on statements [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:to="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl1" xlink:title="label: DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock to aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl2">Impact on Statements of income/(loss) and Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:to="aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl2" xlink:title="label: DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock to aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl">The disclosure of detailed information about trade payables and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl1">Disclosure of detailed information about trade payables and accrued liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl2">Trade payables and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancingObligationAbstract" xlink:label="FinancingObligationAbstract" xlink:title="FinancingObligationAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancingObligationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FinancingObligationAbstract_lbl1" xml:lang="en-US" id="aciu_FinancingObligationAbstract_lbl1">Financing obligation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancingObligationAbstract" xlink:to="aciu_FinancingObligationAbstract_lbl1" xlink:title="label: FinancingObligationAbstract to aciu_FinancingObligationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractLiabilitiesAddition" xlink:label="ContractLiabilitiesAddition" xlink:title="ContractLiabilitiesAddition" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ContractLiabilitiesAddition_lbl" xml:lang="en-US" id="aciu_ContractLiabilitiesAddition_lbl">The increase in contract liabilities for the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesAddition" xlink:to="aciu_ContractLiabilitiesAddition_lbl" xlink:title="label: ContractLiabilitiesAddition to aciu_ContractLiabilitiesAddition_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesAddition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractLiabilitiesAddition_lbl1" xml:lang="en-US" id="aciu_ContractLiabilitiesAddition_lbl1">Contract liabilities, addition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesAddition" xlink:to="aciu_ContractLiabilitiesAddition_lbl1" xlink:title="label: ContractLiabilitiesAddition to aciu_ContractLiabilitiesAddition_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesAddition_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ContractLiabilitiesAddition_lbl2" xml:lang="en-US" id="aciu_ContractLiabilitiesAddition_lbl2">Deferred income, additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesAddition" xlink:to="aciu_ContractLiabilitiesAddition_lbl2" xlink:title="label: ContractLiabilitiesAddition to aciu_ContractLiabilitiesAddition_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractAssetsDeductions" xlink:label="ContractAssetsDeductions" xlink:title="ContractAssetsDeductions" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ContractAssetsDeductions_lbl" xml:lang="en-US" id="aciu_ContractAssetsDeductions_lbl">The decrease in contract assets for the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsDeductions" xlink:to="aciu_ContractAssetsDeductions_lbl" xlink:title="label: ContractAssetsDeductions to aciu_ContractAssetsDeductions_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsDeductions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractAssetsDeductions_lbl1" xml:lang="en-US" id="aciu_ContractAssetsDeductions_lbl1">Contract assets, deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsDeductions" xlink:to="aciu_ContractAssetsDeductions_lbl1" xlink:title="label: ContractAssetsDeductions to aciu_ContractAssetsDeductions_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsDeductions_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_ContractAssetsDeductions_lbl2" xml:lang="en-US" id="aciu_ContractAssetsDeductions_lbl2">Accrued income, deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsDeductions" xlink:to="aciu_ContractAssetsDeductions_lbl2" xlink:title="label: ContractAssetsDeductions to aciu_ContractAssetsDeductions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractAssetsAdditions" xlink:label="ContractAssetsAdditions" xlink:title="ContractAssetsAdditions" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ContractAssetsAdditions_lbl" xml:lang="en-US" id="aciu_ContractAssetsAdditions_lbl">The increase in contract assets for the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsAdditions" xlink:to="aciu_ContractAssetsAdditions_lbl" xlink:title="label: ContractAssetsAdditions to aciu_ContractAssetsAdditions_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsAdditions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractAssetsAdditions_lbl1" xml:lang="en-US" id="aciu_ContractAssetsAdditions_lbl1">Contract assets, additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsAdditions" xlink:to="aciu_ContractAssetsAdditions_lbl1" xlink:title="label: ContractAssetsAdditions to aciu_ContractAssetsAdditions_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractAssetsAdditions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ContractAssetsAdditions_lbl2" xml:lang="en-US" id="aciu_ContractAssetsAdditions_lbl2">Accrued income, additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetsAdditions" xlink:to="aciu_ContractAssetsAdditions_lbl2" xlink:title="label: ContractAssetsAdditions to aciu_ContractAssetsAdditions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractLiabilitiesDeductions" xlink:label="ContractLiabilitiesDeductions" xlink:title="ContractLiabilitiesDeductions" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ContractLiabilitiesDeductions_lbl" xml:lang="en-US" id="aciu_ContractLiabilitiesDeductions_lbl">The decrease in contract liabilities for the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesDeductions" xlink:to="aciu_ContractLiabilitiesDeductions_lbl" xlink:title="label: ContractLiabilitiesDeductions to aciu_ContractLiabilitiesDeductions_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesDeductions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractLiabilitiesDeductions_lbl1" xml:lang="en-US" id="aciu_ContractLiabilitiesDeductions_lbl1">Contract liabilities, deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesDeductions" xlink:to="aciu_ContractLiabilitiesDeductions_lbl1" xlink:title="label: ContractLiabilitiesDeductions to aciu_ContractLiabilitiesDeductions_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractLiabilitiesDeductions_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="aciu_ContractLiabilitiesDeductions_lbl2" xml:lang="en-US" id="aciu_ContractLiabilitiesDeductions_lbl2">Deferred income, deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractLiabilitiesDeductions" xlink:to="aciu_ContractLiabilitiesDeductions_lbl2" xlink:title="label: ContractLiabilitiesDeductions to aciu_ContractLiabilitiesDeductions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:label="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:title="NumberOfCommonSharesSoldRelatedPartyTransactions" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl" xml:lang="en-US" id="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl">The number of the entity's common shares sold to a related party in related party transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:to="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl" xlink:title="label: NumberOfCommonSharesSoldRelatedPartyTransactions to aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl1" xml:lang="en-US" id="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl1">Number of common shares sold, related party transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:to="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl1" xlink:title="label: NumberOfCommonSharesSoldRelatedPartyTransactions to aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl2" xml:lang="en-US" id="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl2">Number of shares purchased under subscription rights offering by related party (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:to="aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl2" xlink:title="label: NumberOfCommonSharesSoldRelatedPartyTransactions to aciu_NumberOfCommonSharesSoldRelatedPartyTransactions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPersonsKeyManagementBoardOfDirectors" xlink:label="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:title="NumberOfPersonsKeyManagementBoardOfDirectors" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl">The number of persons that are the included in Board of Directors excluding the Chief Executive Officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:to="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl" xlink:title="label: NumberOfPersonsKeyManagementBoardOfDirectors to aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl1" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl1">Number of persons, key management, Board of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:to="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl1" xlink:title="label: NumberOfPersonsKeyManagementBoardOfDirectors to aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl2" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl2">Number of individuals, Board of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:to="aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl2" xlink:title="label: NumberOfPersonsKeyManagementBoardOfDirectors to aciu_NumberOfPersonsKeyManagementBoardOfDirectors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPersonsKeyManagementExecutiveManagement" xlink:label="NumberOfPersonsKeyManagementExecutiveManagement" xlink:title="NumberOfPersonsKeyManagementExecutiveManagement" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl">The number of persons that comprise key management of the entity that are Executive Management.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementExecutiveManagement" xlink:to="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl" xlink:title="label: NumberOfPersonsKeyManagementExecutiveManagement to aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl1" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl1">Number of persons, key management, Executive Management</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementExecutiveManagement" xlink:to="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl1" xlink:title="label: NumberOfPersonsKeyManagementExecutiveManagement to aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl2" xml:lang="en-US" id="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl2">Number of individuals, Executive Management</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPersonsKeyManagementExecutiveManagement" xlink:to="aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl2" xlink:title="label: NumberOfPersonsKeyManagementExecutiveManagement to aciu_NumberOfPersonsKeyManagementExecutiveManagement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl">The disclosure of detailed information about the expiration of income tax losses that may be carried forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl1">Disclosure of detailed information about income tax losses expiry [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl2">Tax losses expiry dates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl">The disclosure of detailed information about income tax reconciliation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl1">Disclosure of detailed information about income tax reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl2">Income tax expense reconciled to loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock to aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RevenueReclassifiedToOtherIncomeExpense" xlink:label="RevenueReclassifiedToOtherIncomeExpense" xlink:title="RevenueReclassifiedToOtherIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl" xml:lang="en-US" id="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl">The amount of revenue reclassified to other income (expense).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueReclassifiedToOtherIncomeExpense" xlink:to="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl" xlink:title="label: RevenueReclassifiedToOtherIncomeExpense to aciu_RevenueReclassifiedToOtherIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl1" xml:lang="en-US" id="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl1">Revenue reclassified to other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueReclassifiedToOtherIncomeExpense" xlink:to="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl1" xlink:title="label: RevenueReclassifiedToOtherIncomeExpense to aciu_RevenueReclassifiedToOtherIncomeExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl2" xml:lang="en-US" id="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl2">Amount reclassified from contract revenue to other income/(expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueReclassifiedToOtherIncomeExpense" xlink:to="aciu_RevenueReclassifiedToOtherIncomeExpense_lbl2" xlink:title="label: RevenueReclassifiedToOtherIncomeExpense to aciu_RevenueReclassifiedToOtherIncomeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractRevenueAbstract" xlink:label="ContractRevenueAbstract" xlink:title="ContractRevenueAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractRevenueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ContractRevenueAbstract_lbl1" xml:lang="en-US" id="aciu_ContractRevenueAbstract_lbl1">Contract Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractRevenueAbstract" xlink:to="aciu_ContractRevenueAbstract_lbl1" xlink:title="label: ContractRevenueAbstract to aciu_ContractRevenueAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ContractRevenueAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ContractRevenueAbstract_lbl2" xml:lang="en-US" id="aciu_ContractRevenueAbstract_lbl2">Contract Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractRevenueAbstract" xlink:to="aciu_ContractRevenueAbstract_lbl2" xlink:title="label: ContractRevenueAbstract to aciu_ContractRevenueAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:label="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl" xml:lang="en-US" id="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl">The 2014 contractual research agreement associated with collaboration with Life Molecular Imaging.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:to="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl" xlink:title="label: LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember to aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl1" xml:lang="en-US" id="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl1">License and collaboration agreement of 2014, Life Molecular Imaging [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:to="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl1" xlink:title="label: LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember to aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl2" xml:lang="en-US" id="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl2">Life Molecular Imaging [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:to="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl2" xlink:title="label: LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember to aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl3" xml:lang="en-US" id="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl3">2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) Imaging [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:to="aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl3" xlink:title="label: LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember to aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2012GenentechMember" xlink:label="CollaborationAgreementOf2012GenentechMember" xlink:title="CollaborationAgreementOf2012GenentechMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2012GenentechMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementOf2012GenentechMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementOf2012GenentechMember_lbl">The 2012 contractual research agreement associated with collaboration with Genentech.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2012GenentechMember" xlink:to="aciu_CollaborationAgreementOf2012GenentechMember_lbl" xlink:title="label: CollaborationAgreementOf2012GenentechMember to aciu_CollaborationAgreementOf2012GenentechMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2012GenentechMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementOf2012GenentechMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementOf2012GenentechMember_lbl1">Collaboration agreement of 2012, Genentech [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2012GenentechMember" xlink:to="aciu_CollaborationAgreementOf2012GenentechMember_lbl1" xlink:title="label: CollaborationAgreementOf2012GenentechMember to aciu_CollaborationAgreementOf2012GenentechMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2012GenentechMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborationAgreementOf2012GenentechMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementOf2012GenentechMember_lbl2">Genentech [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2012GenentechMember" xlink:to="aciu_CollaborationAgreementOf2012GenentechMember_lbl2" xlink:title="label: CollaborationAgreementOf2012GenentechMember to aciu_CollaborationAgreementOf2012GenentechMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2012GenentechMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementOf2012GenentechMember_lbl3" xml:lang="en-US" id="aciu_CollaborationAgreementOf2012GenentechMember_lbl3">2012 Agreement with Genentech [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2012GenentechMember" xlink:to="aciu_CollaborationAgreementOf2012GenentechMember_lbl3" xlink:title="label: CollaborationAgreementOf2012GenentechMember to aciu_CollaborationAgreementOf2012GenentechMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2016BiogenMember" xlink:label="CollaborationAgreementOf2016BiogenMember" xlink:title="CollaborationAgreementOf2016BiogenMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2016BiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementOf2016BiogenMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementOf2016BiogenMember_lbl">The 2016 contractual research agreement associated with collaboration with Biogen.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2016BiogenMember" xlink:to="aciu_CollaborationAgreementOf2016BiogenMember_lbl" xlink:title="label: CollaborationAgreementOf2016BiogenMember to aciu_CollaborationAgreementOf2016BiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2016BiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementOf2016BiogenMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementOf2016BiogenMember_lbl1">Collaboration agreement of 2016, Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2016BiogenMember" xlink:to="aciu_CollaborationAgreementOf2016BiogenMember_lbl1" xlink:title="label: CollaborationAgreementOf2016BiogenMember to aciu_CollaborationAgreementOf2016BiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2016BiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborationAgreementOf2016BiogenMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementOf2016BiogenMember_lbl2">Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2016BiogenMember" xlink:to="aciu_CollaborationAgreementOf2016BiogenMember_lbl2" xlink:title="label: CollaborationAgreementOf2016BiogenMember to aciu_CollaborationAgreementOf2016BiogenMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2016BiogenMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementOf2016BiogenMember_lbl3" xml:lang="en-US" id="aciu_CollaborationAgreementOf2016BiogenMember_lbl3">2016 Agreement with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2016BiogenMember" xlink:to="aciu_CollaborationAgreementOf2016BiogenMember_lbl3" xlink:title="label: CollaborationAgreementOf2016BiogenMember to aciu_CollaborationAgreementOf2016BiogenMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherAgreementMember" xlink:label="OtherAgreementMember" xlink:title="OtherAgreementMember" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_OtherAgreementMember_lbl" xml:lang="en-US" id="aciu_OtherAgreementMember_lbl">contractual research agreement associated with collaboration with other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAgreementMember" xlink:to="aciu_OtherAgreementMember_lbl" xlink:title="label: OtherAgreementMember to aciu_OtherAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OtherAgreementMember_lbl1" xml:lang="en-US" id="aciu_OtherAgreementMember_lbl1">Other agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAgreementMember" xlink:to="aciu_OtherAgreementMember_lbl1" xlink:title="label: OtherAgreementMember to aciu_OtherAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_OtherAgreementMember_lbl2" xml:lang="en-US" id="aciu_OtherAgreementMember_lbl2">Other [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAgreementMember" xlink:to="aciu_OtherAgreementMember_lbl2" xlink:title="label: OtherAgreementMember to aciu_OtherAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl">The amount of consideration recognized for the milestone payment(s) associated with a collaborative agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentRecognized" xlink:to="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl" xlink:title="label: CollaborativeAgreementMilestonePaymentRecognized to aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl1">Collaborative Agreement, Milestone Payment Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentRecognized" xlink:to="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl1" xlink:title="label: CollaborativeAgreementMilestonePaymentRecognized to aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl2">Milestone payment recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentRecognized" xlink:to="aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl2" xlink:title="label: CollaborativeAgreementMilestonePaymentRecognized to aciu_CollaborativeAgreementMilestonePaymentRecognized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl">The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCumulativePaymentsReceived" xlink:to="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl" xlink:title="label: CollaborativeAgreementCumulativePaymentsReceived to aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl1">Collaborative agreement, Cumulative payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCumulativePaymentsReceived" xlink:to="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl1" xlink:title="label: CollaborativeAgreementCumulativePaymentsReceived to aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl2">Cumulative payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCumulativePaymentsReceived" xlink:to="aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl2" xlink:title="label: CollaborativeAgreementCumulativePaymentsReceived to aciu_CollaborativeAgreementCumulativePaymentsReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl">Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:to="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl" xlink:title="label: CollaborativeAgreementNoticeOfContractTerminationPeriod to aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl1">Collaborative agreement, Notice of contract termination period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:to="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl1" xlink:title="label: CollaborativeAgreementNoticeOfContractTerminationPeriod to aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl2">Period to provide notice of termination of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:to="aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl2" xlink:title="label: CollaborativeAgreementNoticeOfContractTerminationPeriod to aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiTauAntibodyInADMember" xlink:label="AntiTauAntibodyInADMember" xlink:title="AntiTauAntibodyInADMember" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiTauAntibodyInADMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AntiTauAntibodyInADMember_lbl" xml:lang="en-US" id="aciu_AntiTauAntibodyInADMember_lbl">The research and development of medicines for the treatment of Alzheimer's disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiTauAntibodyInADMember" xlink:to="aciu_AntiTauAntibodyInADMember_lbl" xlink:title="label: AntiTauAntibodyInADMember to aciu_AntiTauAntibodyInADMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiTauAntibodyInADMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AntiTauAntibodyInADMember_lbl1" xml:lang="en-US" id="aciu_AntiTauAntibodyInADMember_lbl1">Anti-tau antibody in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiTauAntibodyInADMember" xlink:to="aciu_AntiTauAntibodyInADMember_lbl1" xlink:title="label: AntiTauAntibodyInADMember to aciu_AntiTauAntibodyInADMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiTauAntibodyInADMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AntiTauAntibodyInADMember_lbl2" xml:lang="en-US" id="aciu_AntiTauAntibodyInADMember_lbl2">Anti-tau Antibody in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiTauAntibodyInADMember" xlink:to="aciu_AntiTauAntibodyInADMember_lbl2" xlink:title="label: AntiTauAntibodyInADMember to aciu_AntiTauAntibodyInADMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfMilestonePaymentsReceived" xlink:label="NumberOfMilestonePaymentsReceived" xlink:title="NumberOfMilestonePaymentsReceived" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfMilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfMilestonePaymentsReceived_lbl" xml:lang="en-US" id="aciu_NumberOfMilestonePaymentsReceived_lbl">Number of times payment(s) received for milestone payments associated with a collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsReceived" xlink:to="aciu_NumberOfMilestonePaymentsReceived_lbl" xlink:title="label: NumberOfMilestonePaymentsReceived to aciu_NumberOfMilestonePaymentsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfMilestonePaymentsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfMilestonePaymentsReceived_lbl1" xml:lang="en-US" id="aciu_NumberOfMilestonePaymentsReceived_lbl1">Number of milestone payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsReceived" xlink:to="aciu_NumberOfMilestonePaymentsReceived_lbl1" xlink:title="label: NumberOfMilestonePaymentsReceived to aciu_NumberOfMilestonePaymentsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfMilestonePaymentsReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfMilestonePaymentsReceived_lbl2" xml:lang="en-US" id="aciu_NumberOfMilestonePaymentsReceived_lbl2">Number of milestone payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsReceived" xlink:to="aciu_NumberOfMilestonePaymentsReceived_lbl2" xlink:title="label: NumberOfMilestonePaymentsReceived to aciu_NumberOfMilestonePaymentsReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementPotentialValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementPotentialValue_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementPotentialValue_lbl">The total potential value of the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementPotentialValue" xlink:to="aciu_CollaborativeAgreementPotentialValue_lbl" xlink:title="label: CollaborativeAgreementPotentialValue to aciu_CollaborativeAgreementPotentialValue_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementPotentialValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementPotentialValue_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementPotentialValue_lbl1">Collaborative agreement, potential value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementPotentialValue" xlink:to="aciu_CollaborativeAgreementPotentialValue_lbl1" xlink:title="label: CollaborativeAgreementPotentialValue to aciu_CollaborativeAgreementPotentialValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementPotentialValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementPotentialValue_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementPotentialValue_lbl2">Total potential collaboration agreement value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementPotentialValue" xlink:to="aciu_CollaborativeAgreementPotentialValue_lbl2" xlink:title="label: CollaborativeAgreementPotentialValue to aciu_CollaborativeAgreementPotentialValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLicenseMember" xlink:label="RightOfUseLicenseMember" xlink:title="RightOfUseLicenseMember" />
    <link:label xlink:type="resource" xlink:label="aciu_RightOfUseLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_RightOfUseLicenseMember_lbl" xml:lang="en-US" id="aciu_RightOfUseLicenseMember_lbl">Performance obligation related to right-of-use license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseLicenseMember" xlink:to="aciu_RightOfUseLicenseMember_lbl" xlink:title="label: RightOfUseLicenseMember to aciu_RightOfUseLicenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_RightOfUseLicenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_RightOfUseLicenseMember_lbl1" xml:lang="en-US" id="aciu_RightOfUseLicenseMember_lbl1">Right-of-use license [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseLicenseMember" xlink:to="aciu_RightOfUseLicenseMember_lbl1" xlink:title="label: RightOfUseLicenseMember to aciu_RightOfUseLicenseMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_RightOfUseLicenseMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_RightOfUseLicenseMember_lbl2" xml:lang="en-US" id="aciu_RightOfUseLicenseMember_lbl2">Right-of-use License [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseLicenseMember" xlink:to="aciu_RightOfUseLicenseMember_lbl2" xlink:title="label: RightOfUseLicenseMember to aciu_RightOfUseLicenseMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsCommercialMember" xlink:label="MilestonePaymentsCommercialMember" xlink:title="MilestonePaymentsCommercialMember" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_MilestonePaymentsCommercialMember_lbl" xml:lang="en-US" id="aciu_MilestonePaymentsCommercialMember_lbl">Refers to a milestone payment arrangement related to certain commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsCommercialMember" xlink:to="aciu_MilestonePaymentsCommercialMember_lbl" xlink:title="label: MilestonePaymentsCommercialMember to aciu_MilestonePaymentsCommercialMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsCommercialMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_MilestonePaymentsCommercialMember_lbl1" xml:lang="en-US" id="aciu_MilestonePaymentsCommercialMember_lbl1">Milestone payments, commercial [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsCommercialMember" xlink:to="aciu_MilestonePaymentsCommercialMember_lbl1" xlink:title="label: MilestonePaymentsCommercialMember to aciu_MilestonePaymentsCommercialMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsCommercialMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_MilestonePaymentsCommercialMember_lbl2" xml:lang="en-US" id="aciu_MilestonePaymentsCommercialMember_lbl2">Commercial [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsCommercialMember" xlink:to="aciu_MilestonePaymentsCommercialMember_lbl2" xlink:title="label: MilestonePaymentsCommercialMember to aciu_MilestonePaymentsCommercialMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:label="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:title="CollaborativeAgreementMilestonePaymentNumberOfInstallments" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl">The number of installments for satisfying a milestone payment associated with a collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:to="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl" xlink:title="label: CollaborativeAgreementMilestonePaymentNumberOfInstallments to aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl1">Collaborative agreement, milestone payment, number of installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:to="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl1" xlink:title="label: CollaborativeAgreementMilestonePaymentNumberOfInstallments to aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl2">Number of installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:to="aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl2" xlink:title="label: CollaborativeAgreementMilestonePaymentNumberOfInstallments to aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:label="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:title="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl" xml:lang="en-US" id="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl">The number of representatives in a joint steering committee by each party as per the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:to="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl" xlink:title="label: NumberOfRepresentativesInJointSteeringCommitteeByEachParty to aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl1" xml:lang="en-US" id="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl1">Number of representatives in joint steering committee by each party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:to="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl1" xlink:title="label: NumberOfRepresentativesInJointSteeringCommitteeByEachParty to aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl2" xml:lang="en-US" id="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl2">Number of representatives in joint steering committee by each party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:to="aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl2" xlink:title="label: NumberOfRepresentativesInJointSteeringCommitteeByEachParty to aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PhaseTwoClinicalStudyLicensedProductMember" xlink:label="PhaseTwoClinicalStudyLicensedProductMember" xlink:title="PhaseTwoClinicalStudyLicensedProductMember" />
    <link:label xlink:type="resource" xlink:label="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl" xml:lang="en-US" id="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl">Performance obligation related to a phase 2 clinical study of a licensed product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseTwoClinicalStudyLicensedProductMember" xlink:to="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl" xlink:title="label: PhaseTwoClinicalStudyLicensedProductMember to aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl1" xml:lang="en-US" id="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl1">Phase two clinical study, licensed product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseTwoClinicalStudyLicensedProductMember" xlink:to="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl1" xlink:title="label: PhaseTwoClinicalStudyLicensedProductMember to aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl2" xml:lang="en-US" id="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl2">Phase 2 Clinical Study Licensed Product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PhaseTwoClinicalStudyLicensedProductMember" xlink:to="aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl2" xlink:title="label: PhaseTwoClinicalStudyLicensedProductMember to aciu_PhaseTwoClinicalStudyLicensedProductMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:label="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:title="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl">Refers to a milestone payment arrangement related to clinical and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:to="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl" xlink:title="label: MilestonePaymentsClinicalAndRegulatoryMilestonesMember to aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl1" xml:lang="en-US" id="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl1">Milestone payments, clinical and regulatory milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:to="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl1" xlink:title="label: MilestonePaymentsClinicalAndRegulatoryMilestonesMember to aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl2" xml:lang="en-US" id="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl2">Clinical and Regulatory [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:to="aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl2" xlink:title="label: MilestonePaymentsClinicalAndRegulatoryMilestonesMember to aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauMorphomerSmallMoleculeMember" xlink:label="TauMorphomerSmallMoleculeMember" xlink:title="TauMorphomerSmallMoleculeMember" />
    <link:label xlink:type="resource" xlink:label="aciu_TauMorphomerSmallMoleculeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_TauMorphomerSmallMoleculeMember_lbl" xml:lang="en-US" id="aciu_TauMorphomerSmallMoleculeMember_lbl">The research and development of medicines for the treatment of Alzheimer's disease and other neurodegenerative diseases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauMorphomerSmallMoleculeMember" xlink:to="aciu_TauMorphomerSmallMoleculeMember_lbl" xlink:title="label: TauMorphomerSmallMoleculeMember to aciu_TauMorphomerSmallMoleculeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_TauMorphomerSmallMoleculeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_TauMorphomerSmallMoleculeMember_lbl1" xml:lang="en-US" id="aciu_TauMorphomerSmallMoleculeMember_lbl1">Tau Morphomer Small Molecule [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauMorphomerSmallMoleculeMember" xlink:to="aciu_TauMorphomerSmallMoleculeMember_lbl1" xlink:title="label: TauMorphomerSmallMoleculeMember to aciu_TauMorphomerSmallMoleculeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_TauMorphomerSmallMoleculeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_TauMorphomerSmallMoleculeMember_lbl2" xml:lang="en-US" id="aciu_TauMorphomerSmallMoleculeMember_lbl2">Morphomer Tau small molecule [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauMorphomerSmallMoleculeMember" xlink:to="aciu_TauMorphomerSmallMoleculeMember_lbl2" xlink:title="label: TauMorphomerSmallMoleculeMember to aciu_TauMorphomerSmallMoleculeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentMember" xlink:label="ResearchAndDevelopmentMember" xlink:title="ResearchAndDevelopmentMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="aciu_ResearchAndDevelopmentMember_lbl">Performance obligation related to research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentMember" xlink:to="aciu_ResearchAndDevelopmentMember_lbl" xlink:title="label: ResearchAndDevelopmentMember to aciu_ResearchAndDevelopmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ResearchAndDevelopmentMember_lbl1" xml:lang="en-US" id="aciu_ResearchAndDevelopmentMember_lbl1">Research and development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentMember" xlink:to="aciu_ResearchAndDevelopmentMember_lbl1" xlink:title="label: ResearchAndDevelopmentMember to aciu_ResearchAndDevelopmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ResearchAndDevelopmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ResearchAndDevelopmentMember_lbl2" xml:lang="en-US" id="aciu_ResearchAndDevelopmentMember_lbl2">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentMember" xlink:to="aciu_ResearchAndDevelopmentMember_lbl2" xlink:title="label: ResearchAndDevelopmentMember to aciu_ResearchAndDevelopmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyFirstAmendmentMember" xlink:label="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:title="CollaborationAgreementWithLillyFirstAmendmentMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl">The first amendment to the collaboration agreement with Lilly for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl" xlink:title="label: CollaborationAgreementWithLillyFirstAmendmentMember to aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl1">Collaboration Agreement with Lilly, First Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl1" xlink:title="label: CollaborationAgreementWithLillyFirstAmendmentMember to aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl2">2018 License Agreement with Eli Lilly, First Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl2" xlink:title="label: CollaborationAgreementWithLillyFirstAmendmentMember to aciu_CollaborationAgreementWithLillyFirstAmendmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillySecondAmendmentMember" xlink:label="CollaborationAgreementWithLillySecondAmendmentMember" xlink:title="CollaborationAgreementWithLillySecondAmendmentMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl">The second amendment to the collaboration agreement with Lilly for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillySecondAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl" xlink:title="label: CollaborationAgreementWithLillySecondAmendmentMember to aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl1">Collaboration Agreement with Lilly, Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillySecondAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl1" xlink:title="label: CollaborationAgreementWithLillySecondAmendmentMember to aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl2">2018 License Agreement with Eli Lilly, Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementWithLillySecondAmendmentMember" xlink:to="aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl2" xlink:title="label: CollaborationAgreementWithLillySecondAmendmentMember to aciu_CollaborationAgreementWithLillySecondAmendmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AlphaSynucleinAndTDP43PETTracerInADMember" xlink:label="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:title="AlphaSynucleinAndTDP43PETTracerInADMember" />
    <link:label xlink:type="resource" xlink:label="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl" xml:lang="en-US" id="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl">The research and development of medicines for the treatment of Alzheimer's disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:to="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl" xlink:title="label: AlphaSynucleinAndTDP43PETTracerInADMember to aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl1" xml:lang="en-US" id="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl1">Alpha-synuclein and TDP-43 PET tracer in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:to="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl1" xlink:title="label: AlphaSynucleinAndTDP43PETTracerInADMember to aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl2" xml:lang="en-US" id="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl2">A-syn and TDP-43 PET tracers - 2016 agreement with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:to="aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl2" xlink:title="label: AlphaSynucleinAndTDP43PETTracerInADMember to aciu_AlphaSynucleinAndTDP43PETTracerInADMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPerformanceObligationsIdentified" xlink:label="NumberOfPerformanceObligationsIdentified" xlink:title="NumberOfPerformanceObligationsIdentified" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPerformanceObligationsIdentified_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfPerformanceObligationsIdentified_lbl" xml:lang="en-US" id="aciu_NumberOfPerformanceObligationsIdentified_lbl">The number of performance obligations identified applicable to the entity's assessment of a specific contractual arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsIdentified" xlink:to="aciu_NumberOfPerformanceObligationsIdentified_lbl" xlink:title="label: NumberOfPerformanceObligationsIdentified to aciu_NumberOfPerformanceObligationsIdentified_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPerformanceObligationsIdentified_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfPerformanceObligationsIdentified_lbl1" xml:lang="en-US" id="aciu_NumberOfPerformanceObligationsIdentified_lbl1">Number of performance obligations identified</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsIdentified" xlink:to="aciu_NumberOfPerformanceObligationsIdentified_lbl1" xlink:title="label: NumberOfPerformanceObligationsIdentified to aciu_NumberOfPerformanceObligationsIdentified_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfPerformanceObligationsIdentified_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfPerformanceObligationsIdentified_lbl2" xml:lang="en-US" id="aciu_NumberOfPerformanceObligationsIdentified_lbl2">Number of performance obligations identified</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsIdentified" xlink:to="aciu_NumberOfPerformanceObligationsIdentified_lbl2" xlink:title="label: NumberOfPerformanceObligationsIdentified to aciu_NumberOfPerformanceObligationsIdentified_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:label="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:title="DilutiveEffectOfConvertibleInstrumentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl" xml:lang="en-US" id="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl">The disclosure of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:to="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl" xlink:title="label: DilutiveEffectOfConvertibleInstrumentsTextBlock to aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl1" xml:lang="en-US" id="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl1">Dilutive effect of convertible instruments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:to="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl1" xlink:title="label: DilutiveEffectOfConvertibleInstrumentsTextBlock to aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl2" xml:lang="en-US" id="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl2">Antidilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:to="aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl2" xlink:title="label: DilutiveEffectOfConvertibleInstrumentsTextBlock to aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PostBalanceSheetEventsAbstract" xlink:label="PostBalanceSheetEventsAbstract" xlink:title="PostBalanceSheetEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_PostBalanceSheetEventsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PostBalanceSheetEventsAbstract_lbl1" xml:lang="en-US" id="aciu_PostBalanceSheetEventsAbstract_lbl1">Post balance sheet events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostBalanceSheetEventsAbstract" xlink:to="aciu_PostBalanceSheetEventsAbstract_lbl1" xlink:title="label: PostBalanceSheetEventsAbstract to aciu_PostBalanceSheetEventsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PostBalanceSheetEventsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PostBalanceSheetEventsAbstract_lbl2" xml:lang="en-US" id="aciu_PostBalanceSheetEventsAbstract_lbl2">Subsequent events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostBalanceSheetEventsAbstract" xlink:to="aciu_PostBalanceSheetEventsAbstract_lbl2" xlink:title="label: PostBalanceSheetEventsAbstract to aciu_PostBalanceSheetEventsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SubsequentEventsMember" xlink:label="SubsequentEventsMember" xlink:title="SubsequentEventsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_SubsequentEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_SubsequentEventsMember_lbl" xml:lang="en-US" id="aciu_SubsequentEventsMember_lbl">Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsMember" xlink:to="aciu_SubsequentEventsMember_lbl" xlink:title="label: SubsequentEventsMember to aciu_SubsequentEventsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_SubsequentEventsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_SubsequentEventsMember_lbl1" xml:lang="en-US" id="aciu_SubsequentEventsMember_lbl1">Subsequent events [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsMember" xlink:to="aciu_SubsequentEventsMember_lbl1" xlink:title="label: SubsequentEventsMember to aciu_SubsequentEventsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_SubsequentEventsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_SubsequentEventsMember_lbl2" xml:lang="en-US" id="aciu_SubsequentEventsMember_lbl2">Subsequent Events [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsMember" xlink:to="aciu_SubsequentEventsMember_lbl2" xlink:title="label: SubsequentEventsMember to aciu_SubsequentEventsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationTable" xlink:label="LongTermFinancingObligationTable" xlink:title="LongTermFinancingObligationTable" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LongTermFinancingObligationTable_lbl" xml:lang="en-US" id="aciu_LongTermFinancingObligationTable_lbl">Schedule disclosing information related to details of long term financing obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationTable" xlink:to="aciu_LongTermFinancingObligationTable_lbl" xlink:title="label: LongTermFinancingObligationTable to aciu_LongTermFinancingObligationTable_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LongTermFinancingObligationTable_lbl1" xml:lang="en-US" id="aciu_LongTermFinancingObligationTable_lbl1">Long term financing obligation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationTable" xlink:to="aciu_LongTermFinancingObligationTable_lbl1" xlink:title="label: LongTermFinancingObligationTable to aciu_LongTermFinancingObligationTable_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationTable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LongTermFinancingObligationTable_lbl2" xml:lang="en-US" id="aciu_LongTermFinancingObligationTable_lbl2">Long term financing obligation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationTable" xlink:to="aciu_LongTermFinancingObligationTable_lbl2" xlink:title="label: LongTermFinancingObligationTable to aciu_LongTermFinancingObligationTable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationLineItems" xlink:label="LongTermFinancingObligationLineItems" xlink:title="LongTermFinancingObligationLineItems" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LongTermFinancingObligationLineItems_lbl" xml:lang="en-US" id="aciu_LongTermFinancingObligationLineItems_lbl">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationLineItems" xlink:to="aciu_LongTermFinancingObligationLineItems_lbl" xlink:title="label: LongTermFinancingObligationLineItems to aciu_LongTermFinancingObligationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LongTermFinancingObligationLineItems_lbl1" xml:lang="en-US" id="aciu_LongTermFinancingObligationLineItems_lbl1">Long term financing obligation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationLineItems" xlink:to="aciu_LongTermFinancingObligationLineItems_lbl1" xlink:title="label: LongTermFinancingObligationLineItems to aciu_LongTermFinancingObligationLineItems_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancingObligationLineItems_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LongTermFinancingObligationLineItems_lbl2" xml:lang="en-US" id="aciu_LongTermFinancingObligationLineItems_lbl2">Debt obligation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancingObligationLineItems" xlink:to="aciu_LongTermFinancingObligationLineItems_lbl2" xlink:title="label: LongTermFinancingObligationLineItems to aciu_LongTermFinancingObligationLineItems_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FundingCommitment" xlink:label="FundingCommitment" xlink:title="FundingCommitment" />
    <link:label xlink:type="resource" xlink:label="aciu_FundingCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_FundingCommitment_lbl" xml:lang="en-US" id="aciu_FundingCommitment_lbl">The amount of contractual commitments for funding research grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingCommitment" xlink:to="aciu_FundingCommitment_lbl" xlink:title="label: FundingCommitment to aciu_FundingCommitment_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_FundingCommitment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FundingCommitment_lbl1" xml:lang="en-US" id="aciu_FundingCommitment_lbl1">Funding commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingCommitment" xlink:to="aciu_FundingCommitment_lbl1" xlink:title="label: FundingCommitment to aciu_FundingCommitment_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FundingCommitment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FundingCommitment_lbl2" xml:lang="en-US" id="aciu_FundingCommitment_lbl2">Funding commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FundingCommitment" xlink:to="aciu_FundingCommitment_lbl2" xlink:title="label: FundingCommitment to aciu_FundingCommitment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ReimbursementPercentageOfFundingCommitment" xlink:label="ReimbursementPercentageOfFundingCommitment" xlink:title="ReimbursementPercentageOfFundingCommitment" />
    <link:label xlink:type="resource" xlink:label="aciu_ReimbursementPercentageOfFundingCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ReimbursementPercentageOfFundingCommitment_lbl" xml:lang="en-US" id="aciu_ReimbursementPercentageOfFundingCommitment_lbl">The percentage of funding commitment amount required to be reimbursed as per a research grant agreement of which the amount includes the entire funding commitment plus an additional upcharge.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursementPercentageOfFundingCommitment" xlink:to="aciu_ReimbursementPercentageOfFundingCommitment_lbl" xlink:title="label: ReimbursementPercentageOfFundingCommitment to aciu_ReimbursementPercentageOfFundingCommitment_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ReimbursementPercentageOfFundingCommitment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ReimbursementPercentageOfFundingCommitment_lbl1" xml:lang="en-US" id="aciu_ReimbursementPercentageOfFundingCommitment_lbl1">Reimbursement percentage of funding commitment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursementPercentageOfFundingCommitment" xlink:to="aciu_ReimbursementPercentageOfFundingCommitment_lbl1" xlink:title="label: ReimbursementPercentageOfFundingCommitment to aciu_ReimbursementPercentageOfFundingCommitment_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ReimbursementPercentageOfFundingCommitment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ReimbursementPercentageOfFundingCommitment_lbl2" xml:lang="en-US" id="aciu_ReimbursementPercentageOfFundingCommitment_lbl2">Reimbursement percentage of funding commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursementPercentageOfFundingCommitment" xlink:to="aciu_ReimbursementPercentageOfFundingCommitment_lbl2" xlink:title="label: ReimbursementPercentageOfFundingCommitment to aciu_ReimbursementPercentageOfFundingCommitment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAdditionalInterestOnTotalRepayment" xlink:label="PercentageOfAdditionalInterestOnTotalRepayment" xlink:title="PercentageOfAdditionalInterestOnTotalRepayment" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl" xml:lang="en-US" id="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl">Amount of the required periodic payments applied to specific interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalInterestOnTotalRepayment" xlink:to="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl" xlink:title="label: PercentageOfAdditionalInterestOnTotalRepayment to aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl1" xml:lang="en-US" id="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl1">Percentage of additional interest on total repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalInterestOnTotalRepayment" xlink:to="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl1" xlink:title="label: PercentageOfAdditionalInterestOnTotalRepayment to aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl2" xml:lang="en-US" id="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl2">Percentage of additional interest on total repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalInterestOnTotalRepayment" xlink:to="aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl2" xlink:title="label: PercentageOfAdditionalInterestOnTotalRepayment to aciu_PercentageOfAdditionalInterestOnTotalRepayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:label xlink:type="resource" xlink:label="aciu_DebtInstrumentNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DebtInstrumentNumberOfInstallments_lbl" xml:lang="en-US" id="aciu_DebtInstrumentNumberOfInstallments_lbl">Payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="aciu_DebtInstrumentNumberOfInstallments_lbl" xlink:title="label: DebtInstrumentNumberOfInstallments to aciu_DebtInstrumentNumberOfInstallments_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DebtInstrumentNumberOfInstallments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DebtInstrumentNumberOfInstallments_lbl1" xml:lang="en-US" id="aciu_DebtInstrumentNumberOfInstallments_lbl1">Debt instrument, number of installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="aciu_DebtInstrumentNumberOfInstallments_lbl1" xlink:title="label: DebtInstrumentNumberOfInstallments to aciu_DebtInstrumentNumberOfInstallments_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DebtInstrumentNumberOfInstallments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DebtInstrumentNumberOfInstallments_lbl2" xml:lang="en-US" id="aciu_DebtInstrumentNumberOfInstallments_lbl2">Number of installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="aciu_DebtInstrumentNumberOfInstallments_lbl2" xlink:title="label: DebtInstrumentNumberOfInstallments to aciu_DebtInstrumentNumberOfInstallments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsLuMindResearchDownSyndromeFoundationMember" xlink:label="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:title="GrantsLuMindResearchDownSyndromeFoundationMember" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl" xml:lang="en-US" id="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl">Funding provided for certain types of expenditures in connection with research and development activities over a contractually-defined period from the LuMind Research Down Syndrome Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:to="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl" xlink:title="label: GrantsLuMindResearchDownSyndromeFoundationMember to aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl1" xml:lang="en-US" id="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl1">Grants, LuMind Research Down Syndrome Foundation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:to="aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl1" xlink:title="label: GrantsLuMindResearchDownSyndromeFoundationMember to aciu_GrantsLuMindResearchDownSyndromeFoundationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantRevenueMember" xlink:label="GrantRevenueMember" xlink:title="GrantRevenueMember" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GrantRevenueMember_lbl" xml:lang="en-US" id="aciu_GrantRevenueMember_lbl">Revenue earned from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantRevenueMember" xlink:to="aciu_GrantRevenueMember_lbl" xlink:title="label: GrantRevenueMember to aciu_GrantRevenueMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantRevenueMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GrantRevenueMember_lbl1" xml:lang="en-US" id="aciu_GrantRevenueMember_lbl1">Grant revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantRevenueMember" xlink:to="aciu_GrantRevenueMember_lbl1" xlink:title="label: GrantRevenueMember to aciu_GrantRevenueMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantRevenueMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GrantRevenueMember_lbl2" xml:lang="en-US" id="aciu_GrantRevenueMember_lbl2">Grant revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantRevenueMember" xlink:to="aciu_GrantRevenueMember_lbl2" xlink:title="label: GrantRevenueMember to aciu_GrantRevenueMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsMichaelJFoxFoundationMember" xlink:label="GrantsMichaelJFoxFoundationMember" xlink:title="GrantsMichaelJFoxFoundationMember" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantsMichaelJFoxFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_GrantsMichaelJFoxFoundationMember_lbl" xml:lang="en-US" id="aciu_GrantsMichaelJFoxFoundationMember_lbl">Funding provided for certain types of expenditures in connection with research and development activities over a contractually-defined period from the Michael J. Fox Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsMichaelJFoxFoundationMember" xlink:to="aciu_GrantsMichaelJFoxFoundationMember_lbl" xlink:title="label: GrantsMichaelJFoxFoundationMember to aciu_GrantsMichaelJFoxFoundationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantsMichaelJFoxFoundationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_GrantsMichaelJFoxFoundationMember_lbl1" xml:lang="en-US" id="aciu_GrantsMichaelJFoxFoundationMember_lbl1">Grants, Michael J. Fox Foundation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsMichaelJFoxFoundationMember" xlink:to="aciu_GrantsMichaelJFoxFoundationMember_lbl1" xlink:title="label: GrantsMichaelJFoxFoundationMember to aciu_GrantsMichaelJFoxFoundationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_GrantsMichaelJFoxFoundationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_GrantsMichaelJFoxFoundationMember_lbl2" xml:lang="en-US" id="aciu_GrantsMichaelJFoxFoundationMember_lbl2">Grant from Michael J. Fox Foundation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrantsMichaelJFoxFoundationMember" xlink:to="aciu_GrantsMichaelJFoxFoundationMember_lbl2" xlink:title="label: GrantsMichaelJFoxFoundationMember to aciu_GrantsMichaelJFoxFoundationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfGrants" xlink:label="NumberOfGrants" xlink:title="NumberOfGrants" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfGrants_lbl" xml:lang="en-US" id="aciu_NumberOfGrants_lbl">The number of grants received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfGrants" xlink:to="aciu_NumberOfGrants_lbl" xlink:title="label: NumberOfGrants to aciu_NumberOfGrants_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfGrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfGrants_lbl1" xml:lang="en-US" id="aciu_NumberOfGrants_lbl1">Number of grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfGrants" xlink:to="aciu_NumberOfGrants_lbl1" xlink:title="label: NumberOfGrants to aciu_NumberOfGrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfGrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfGrants_lbl2" xml:lang="en-US" id="aciu_NumberOfGrants_lbl2">Number of grants received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfGrants" xlink:to="aciu_NumberOfGrants_lbl2" xlink:title="label: NumberOfGrants to aciu_NumberOfGrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementJointResearchCollaborationPeriod" xlink:label="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:title="CollaborativeAgreementJointResearchCollaborationPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl">The period over which collaborating entities are contracted to perform research, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:to="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl" xlink:title="label: CollaborativeAgreementJointResearchCollaborationPeriod to aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl1">Collaborative agreement, Joint research collaboration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:to="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl1" xlink:title="label: CollaborativeAgreementJointResearchCollaborationPeriod to aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl2">Period of joint research agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:to="aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl2" xlink:title="label: CollaborativeAgreementJointResearchCollaborationPeriod to aciu_CollaborativeAgreementJointResearchCollaborationPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SkaneUniversityHospitalMember" xlink:label="SkaneUniversityHospitalMember" xlink:title="SkaneUniversityHospitalMember" />
    <link:label xlink:type="resource" xlink:label="aciu_SkaneUniversityHospitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_SkaneUniversityHospitalMember_lbl" xml:lang="en-US" id="aciu_SkaneUniversityHospitalMember_lbl">Skane University Hospital is a university hospital in Scania, Sweden.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SkaneUniversityHospitalMember" xlink:to="aciu_SkaneUniversityHospitalMember_lbl" xlink:title="label: SkaneUniversityHospitalMember to aciu_SkaneUniversityHospitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_SkaneUniversityHospitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_SkaneUniversityHospitalMember_lbl1" xml:lang="en-US" id="aciu_SkaneUniversityHospitalMember_lbl1">Skane University Hospital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SkaneUniversityHospitalMember" xlink:to="aciu_SkaneUniversityHospitalMember_lbl1" xlink:title="label: SkaneUniversityHospitalMember to aciu_SkaneUniversityHospitalMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_SkaneUniversityHospitalMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_SkaneUniversityHospitalMember_lbl2" xml:lang="en-US" id="aciu_SkaneUniversityHospitalMember_lbl2">Skane University Hospital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SkaneUniversityHospitalMember" xlink:to="aciu_SkaneUniversityHospitalMember_lbl2" xlink:title="label: SkaneUniversityHospitalMember to aciu_SkaneUniversityHospitalMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauVaccineInADMember" xlink:label="TauVaccineInADMember" xlink:title="TauVaccineInADMember" />
    <link:label xlink:type="resource" xlink:label="aciu_TauVaccineInADMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_TauVaccineInADMember_lbl" xml:lang="en-US" id="aciu_TauVaccineInADMember_lbl">The research and development of a vaccine for the treatment of Alzheimer's disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauVaccineInADMember" xlink:to="aciu_TauVaccineInADMember_lbl" xlink:title="label: TauVaccineInADMember to aciu_TauVaccineInADMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_TauVaccineInADMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_TauVaccineInADMember_lbl1" xml:lang="en-US" id="aciu_TauVaccineInADMember_lbl1">Tau Vaccine in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauVaccineInADMember" xlink:to="aciu_TauVaccineInADMember_lbl1" xlink:title="label: TauVaccineInADMember to aciu_TauVaccineInADMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_TauVaccineInADMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_TauVaccineInADMember_lbl2" xml:lang="en-US" id="aciu_TauVaccineInADMember_lbl2">Tau Vaccine in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauVaccineInADMember" xlink:to="aciu_TauVaccineInADMember_lbl2" xlink:title="label: TauVaccineInADMember to aciu_TauVaccineInADMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl">The amount that the entity is eligible to receive for regulatory, commercialization and sales milestones from a collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl1">Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl1" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl2">Collaboration contract receivable for regulatory, commercialization and sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl2" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl">The amount that the entity is eligible to receive for clinical milestones from a collaborative agreement..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl1" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl1">Collaborative agreement, Collaboration contract receivable for clinical milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl1" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl2" xml:lang="en-US" id="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl2">Collaboration contract receivable for clinical milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:to="aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl2" xlink:title="label: CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones to aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauPETImagingAgentInADMember" xlink:label="TauPETImagingAgentInADMember" xlink:title="TauPETImagingAgentInADMember" />
    <link:label xlink:type="resource" xlink:label="aciu_TauPETImagingAgentInADMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_TauPETImagingAgentInADMember_lbl" xml:lang="en-US" id="aciu_TauPETImagingAgentInADMember_lbl">The research and development of medicines for the treatment of Alzheimer's disease through molecular imaging.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauPETImagingAgentInADMember" xlink:to="aciu_TauPETImagingAgentInADMember_lbl" xlink:title="label: TauPETImagingAgentInADMember to aciu_TauPETImagingAgentInADMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_TauPETImagingAgentInADMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_TauPETImagingAgentInADMember_lbl1" xml:lang="en-US" id="aciu_TauPETImagingAgentInADMember_lbl1">Tau-PET imaging agent in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauPETImagingAgentInADMember" xlink:to="aciu_TauPETImagingAgentInADMember_lbl1" xlink:title="label: TauPETImagingAgentInADMember to aciu_TauPETImagingAgentInADMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_TauPETImagingAgentInADMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_TauPETImagingAgentInADMember_lbl2" xml:lang="en-US" id="aciu_TauPETImagingAgentInADMember_lbl2">Tau-PET Imaging Agent in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TauPETImagingAgentInADMember" xlink:to="aciu_TauPETImagingAgentInADMember_lbl2" xlink:title="label: TauPETImagingAgentInADMember to aciu_TauPETImagingAgentInADMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl">The disclosure of detailed information about carrying amounts of financial assets and financial liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xlink:title="label: DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl1">Disclosure of detailed information about carrying amounts of financial assets and financial liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl1" xlink:title="label: DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl2" xml:lang="en-US" id="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl2">Carrying amounts of financial assets and financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl2" xlink:title="label: DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock to aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2006GenentechMember" xlink:label="CollaborationAgreementOf2006GenentechMember" xlink:title="CollaborationAgreementOf2006GenentechMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2006GenentechMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CollaborationAgreementOf2006GenentechMember_lbl" xml:lang="en-US" id="aciu_CollaborationAgreementOf2006GenentechMember_lbl">The 2006 contractual research agreement associated with collaboration with Genentech.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2006GenentechMember" xlink:to="aciu_CollaborationAgreementOf2006GenentechMember_lbl" xlink:title="label: CollaborationAgreementOf2006GenentechMember to aciu_CollaborationAgreementOf2006GenentechMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2006GenentechMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CollaborationAgreementOf2006GenentechMember_lbl1" xml:lang="en-US" id="aciu_CollaborationAgreementOf2006GenentechMember_lbl1">Collaboration agreement of 2006, Genentech [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2006GenentechMember" xlink:to="aciu_CollaborationAgreementOf2006GenentechMember_lbl1" xlink:title="label: CollaborationAgreementOf2006GenentechMember to aciu_CollaborationAgreementOf2006GenentechMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CollaborationAgreementOf2006GenentechMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="aciu_CollaborationAgreementOf2006GenentechMember_lbl2" xml:lang="en-US" id="aciu_CollaborationAgreementOf2006GenentechMember_lbl2">2006 Agreement with Genentech [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementOf2006GenentechMember" xlink:to="aciu_CollaborationAgreementOf2006GenentechMember_lbl2" xlink:title="label: CollaborationAgreementOf2006GenentechMember to aciu_CollaborationAgreementOf2006GenentechMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiAbetaAntibodyInADMember" xlink:label="AntiAbetaAntibodyInADMember" xlink:title="AntiAbetaAntibodyInADMember" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiAbetaAntibodyInADMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AntiAbetaAntibodyInADMember_lbl" xml:lang="en-US" id="aciu_AntiAbetaAntibodyInADMember_lbl">The research and development of medicines for the treatment of Alzheimer's disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiAbetaAntibodyInADMember" xlink:to="aciu_AntiAbetaAntibodyInADMember_lbl" xlink:title="label: AntiAbetaAntibodyInADMember to aciu_AntiAbetaAntibodyInADMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiAbetaAntibodyInADMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AntiAbetaAntibodyInADMember_lbl1" xml:lang="en-US" id="aciu_AntiAbetaAntibodyInADMember_lbl1">Anti-Abeta antibody in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiAbetaAntibodyInADMember" xlink:to="aciu_AntiAbetaAntibodyInADMember_lbl1" xlink:title="label: AntiAbetaAntibodyInADMember to aciu_AntiAbetaAntibodyInADMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_AntiAbetaAntibodyInADMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_AntiAbetaAntibodyInADMember_lbl2" xml:lang="en-US" id="aciu_AntiAbetaAntibodyInADMember_lbl2">Anti-Abeta Antibody in AD [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntiAbetaAntibodyInADMember" xlink:to="aciu_AntiAbetaAntibodyInADMember_lbl2" xlink:title="label: AntiAbetaAntibodyInADMember to aciu_AntiAbetaAntibodyInADMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialAssetsAndLiabilitiesAbstract" xlink:label="FinancialAssetsAndLiabilitiesAbstract" xlink:title="FinancialAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl1" xml:lang="en-US" id="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl1">Financial assets and liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialAssetsAndLiabilitiesAbstract" xlink:to="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl1" xlink:title="label: FinancialAssetsAndLiabilitiesAbstract to aciu_FinancialAssetsAndLiabilitiesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl2" xml:lang="en-US" id="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl2">Financial assets and liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialAssetsAndLiabilitiesAbstract" xlink:to="aciu_FinancialAssetsAndLiabilitiesAbstract_lbl2" xlink:title="label: FinancialAssetsAndLiabilitiesAbstract to aciu_FinancialAssetsAndLiabilitiesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialRisksAbstract" xlink:label="FinancialRisksAbstract" xlink:title="FinancialRisksAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialRisksAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_FinancialRisksAbstract_lbl1" xml:lang="en-US" id="aciu_FinancialRisksAbstract_lbl1">Financial risks [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialRisksAbstract" xlink:to="aciu_FinancialRisksAbstract_lbl1" xlink:title="label: FinancialRisksAbstract to aciu_FinancialRisksAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_FinancialRisksAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_FinancialRisksAbstract_lbl2" xml:lang="en-US" id="aciu_FinancialRisksAbstract_lbl2">Financial risks [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialRisksAbstract" xlink:to="aciu_FinancialRisksAbstract_lbl2" xlink:title="label: FinancialRisksAbstract to aciu_FinancialRisksAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfIncreaseInInterestRates" xlink:label="PercentageOfIncreaseInInterestRates" xlink:title="PercentageOfIncreaseInInterestRates" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfIncreaseInInterestRates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfIncreaseInInterestRates_lbl" xml:lang="en-US" id="aciu_PercentageOfIncreaseInInterestRates_lbl">The percentage increase to interest rate at the end of the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncreaseInInterestRates" xlink:to="aciu_PercentageOfIncreaseInInterestRates_lbl" xlink:title="label: PercentageOfIncreaseInInterestRates to aciu_PercentageOfIncreaseInInterestRates_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfIncreaseInInterestRates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfIncreaseInInterestRates_lbl1" xml:lang="en-US" id="aciu_PercentageOfIncreaseInInterestRates_lbl1">Percentage of increase in interest rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncreaseInInterestRates" xlink:to="aciu_PercentageOfIncreaseInInterestRates_lbl1" xlink:title="label: PercentageOfIncreaseInInterestRates to aciu_PercentageOfIncreaseInInterestRates_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfIncreaseInInterestRates_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfIncreaseInInterestRates_lbl2" xml:lang="en-US" id="aciu_PercentageOfIncreaseInInterestRates_lbl2">Percentage of increase in interest rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncreaseInInterestRates" xlink:to="aciu_PercentageOfIncreaseInInterestRates_lbl2" xlink:title="label: PercentageOfIncreaseInInterestRates to aciu_PercentageOfIncreaseInInterestRates_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LiquidityManagementRollingForecastPeriod" xlink:label="LiquidityManagementRollingForecastPeriod" xlink:title="LiquidityManagementRollingForecastPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_LiquidityManagementRollingForecastPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LiquidityManagementRollingForecastPeriod_lbl" xml:lang="en-US" id="aciu_LiquidityManagementRollingForecastPeriod_lbl">The periodic interval in which the entity performs a rolling forecast of the entity's cash position.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityManagementRollingForecastPeriod" xlink:to="aciu_LiquidityManagementRollingForecastPeriod_lbl" xlink:title="label: LiquidityManagementRollingForecastPeriod to aciu_LiquidityManagementRollingForecastPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LiquidityManagementRollingForecastPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LiquidityManagementRollingForecastPeriod_lbl1" xml:lang="en-US" id="aciu_LiquidityManagementRollingForecastPeriod_lbl1">Liquidity management, rolling forecast period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityManagementRollingForecastPeriod" xlink:to="aciu_LiquidityManagementRollingForecastPeriod_lbl1" xlink:title="label: LiquidityManagementRollingForecastPeriod to aciu_LiquidityManagementRollingForecastPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_LiquidityManagementRollingForecastPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_LiquidityManagementRollingForecastPeriod_lbl2" xml:lang="en-US" id="aciu_LiquidityManagementRollingForecastPeriod_lbl2">Cash position rolling forecast period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityManagementRollingForecastPeriod" xlink:to="aciu_LiquidityManagementRollingForecastPeriod_lbl2" xlink:title="label: LiquidityManagementRollingForecastPeriod to aciu_LiquidityManagementRollingForecastPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:label="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:title="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl" xml:lang="en-US" id="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl">The number of financial institutions holding the entity's deposits of cash and cash equivalents and short-term financial assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:to="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl" xlink:title="label: NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets to aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl1" xml:lang="en-US" id="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl1">Number of financial institutions holding, cash and cash equivalents and short-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:to="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl1" xlink:title="label: NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets to aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl2" xml:lang="en-US" id="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl2">Number of financial institutions holding cash and cash equivalents and short-term financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:to="aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl2" xlink:title="label: NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets to aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BorrowingsDebtExtinguishmentPeriod" xlink:label="BorrowingsDebtExtinguishmentPeriod" xlink:title="BorrowingsDebtExtinguishmentPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_BorrowingsDebtExtinguishmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_BorrowingsDebtExtinguishmentPeriod_lbl" xml:lang="en-US" id="aciu_BorrowingsDebtExtinguishmentPeriod_lbl">The expected period over which a debt obligation is expected to be extinguished in full.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsDebtExtinguishmentPeriod" xlink:to="aciu_BorrowingsDebtExtinguishmentPeriod_lbl" xlink:title="label: BorrowingsDebtExtinguishmentPeriod to aciu_BorrowingsDebtExtinguishmentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_BorrowingsDebtExtinguishmentPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_BorrowingsDebtExtinguishmentPeriod_lbl1" xml:lang="en-US" id="aciu_BorrowingsDebtExtinguishmentPeriod_lbl1">Borrowings, debt extinguishment period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsDebtExtinguishmentPeriod" xlink:to="aciu_BorrowingsDebtExtinguishmentPeriod_lbl1" xlink:title="label: BorrowingsDebtExtinguishmentPeriod to aciu_BorrowingsDebtExtinguishmentPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_BorrowingsDebtExtinguishmentPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_BorrowingsDebtExtinguishmentPeriod_lbl2" xml:lang="en-US" id="aciu_BorrowingsDebtExtinguishmentPeriod_lbl2">Expected debt obligation payoff period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BorrowingsDebtExtinguishmentPeriod" xlink:to="aciu_BorrowingsDebtExtinguishmentPeriod_lbl2" xlink:title="label: BorrowingsDebtExtinguishmentPeriod to aciu_BorrowingsDebtExtinguishmentPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossInterestRateDecrease" xlink:label="DecreaseInNetLossInterestRateDecrease" xlink:title="DecreaseInNetLossInterestRateDecrease" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossInterestRateDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DecreaseInNetLossInterestRateDecrease_lbl" xml:lang="en-US" id="aciu_DecreaseInNetLossInterestRateDecrease_lbl">The decrease in net loss arising from a decrease in the interest rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossInterestRateDecrease" xlink:to="aciu_DecreaseInNetLossInterestRateDecrease_lbl" xlink:title="label: DecreaseInNetLossInterestRateDecrease to aciu_DecreaseInNetLossInterestRateDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossInterestRateDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DecreaseInNetLossInterestRateDecrease_lbl1" xml:lang="en-US" id="aciu_DecreaseInNetLossInterestRateDecrease_lbl1">Decrease in net loss, interest rate decrease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossInterestRateDecrease" xlink:to="aciu_DecreaseInNetLossInterestRateDecrease_lbl1" xlink:title="label: DecreaseInNetLossInterestRateDecrease to aciu_DecreaseInNetLossInterestRateDecrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossInterestRateDecrease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DecreaseInNetLossInterestRateDecrease_lbl2" xml:lang="en-US" id="aciu_DecreaseInNetLossInterestRateDecrease_lbl2">Net loss for period decrease, due to decrease in interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossInterestRateDecrease" xlink:to="aciu_DecreaseInNetLossInterestRateDecrease_lbl2" xlink:title="label: DecreaseInNetLossInterestRateDecrease to aciu_DecreaseInNetLossInterestRateDecrease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateIncrease" xlink:label="ClosingForeignExchangeRateIncrease" xlink:title="ClosingForeignExchangeRateIncrease" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ClosingForeignExchangeRateIncrease_lbl" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateIncrease_lbl">The percentage increase to spot exchange rate at the end of the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateIncrease" xlink:to="aciu_ClosingForeignExchangeRateIncrease_lbl" xlink:title="label: ClosingForeignExchangeRateIncrease to aciu_ClosingForeignExchangeRateIncrease_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateIncrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ClosingForeignExchangeRateIncrease_lbl1" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateIncrease_lbl1">Closing foreign exchange rate, increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateIncrease" xlink:to="aciu_ClosingForeignExchangeRateIncrease_lbl1" xlink:title="label: ClosingForeignExchangeRateIncrease to aciu_ClosingForeignExchangeRateIncrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateIncrease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ClosingForeignExchangeRateIncrease_lbl2" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateIncrease_lbl2">Percentage exchange rate strengthened</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateIncrease" xlink:to="aciu_ClosingForeignExchangeRateIncrease_lbl2" xlink:title="label: ClosingForeignExchangeRateIncrease to aciu_ClosingForeignExchangeRateIncrease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateDecrease" xlink:label="ClosingForeignExchangeRateDecrease" xlink:title="ClosingForeignExchangeRateDecrease" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ClosingForeignExchangeRateDecrease_lbl" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateDecrease_lbl">The percentage decrease to spot exchange rate at the end of the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateDecrease" xlink:to="aciu_ClosingForeignExchangeRateDecrease_lbl" xlink:title="label: ClosingForeignExchangeRateDecrease to aciu_ClosingForeignExchangeRateDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ClosingForeignExchangeRateDecrease_lbl1" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateDecrease_lbl1">Closing foreign exchange rate, decrease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateDecrease" xlink:to="aciu_ClosingForeignExchangeRateDecrease_lbl1" xlink:title="label: ClosingForeignExchangeRateDecrease to aciu_ClosingForeignExchangeRateDecrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ClosingForeignExchangeRateDecrease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ClosingForeignExchangeRateDecrease_lbl2" xml:lang="en-US" id="aciu_ClosingForeignExchangeRateDecrease_lbl2">Percentage exchange rate weakened</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClosingForeignExchangeRateDecrease" xlink:to="aciu_ClosingForeignExchangeRateDecrease_lbl2" xlink:title="label: ClosingForeignExchangeRateDecrease to aciu_ClosingForeignExchangeRateDecrease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermLeaseLiabilitiesMember" xlink:label="ShortTermLeaseLiabilitiesMember" xlink:title="ShortTermLeaseLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ShortTermLeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ShortTermLeaseLiabilitiesMember_lbl" xml:lang="en-US" id="aciu_ShortTermLeaseLiabilitiesMember_lbl">This member stands for short-term lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLeaseLiabilitiesMember" xlink:to="aciu_ShortTermLeaseLiabilitiesMember_lbl" xlink:title="label: ShortTermLeaseLiabilitiesMember to aciu_ShortTermLeaseLiabilitiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ShortTermLeaseLiabilitiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShortTermLeaseLiabilitiesMember_lbl1" xml:lang="en-US" id="aciu_ShortTermLeaseLiabilitiesMember_lbl1">Short-term lease liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLeaseLiabilitiesMember" xlink:to="aciu_ShortTermLeaseLiabilitiesMember_lbl1" xlink:title="label: ShortTermLeaseLiabilitiesMember to aciu_ShortTermLeaseLiabilitiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ShortTermLeaseLiabilitiesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ShortTermLeaseLiabilitiesMember_lbl2" xml:lang="en-US" id="aciu_ShortTermLeaseLiabilitiesMember_lbl2">Short-term Lease Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLeaseLiabilitiesMember" xlink:to="aciu_ShortTermLeaseLiabilitiesMember_lbl2" xlink:title="label: ShortTermLeaseLiabilitiesMember to aciu_ShortTermLeaseLiabilitiesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TradeAndOtherPayablesMember" xlink:label="TradeAndOtherPayablesMember" xlink:title="TradeAndOtherPayablesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_TradeAndOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" id="aciu_TradeAndOtherPayablesMember_lbl">This member stands for trade and other payables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherPayablesMember" xlink:to="aciu_TradeAndOtherPayablesMember_lbl" xlink:title="label: TradeAndOtherPayablesMember to aciu_TradeAndOtherPayablesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_TradeAndOtherPayablesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_TradeAndOtherPayablesMember_lbl1" xml:lang="en-US" id="aciu_TradeAndOtherPayablesMember_lbl1">Trade and Other Payables [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherPayablesMember" xlink:to="aciu_TradeAndOtherPayablesMember_lbl1" xlink:title="label: TradeAndOtherPayablesMember to aciu_TradeAndOtherPayablesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossForeignExchangeRateIncrease" xlink:label="DecreaseInNetLossForeignExchangeRateIncrease" xlink:title="DecreaseInNetLossForeignExchangeRateIncrease" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl" xml:lang="en-US" id="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl">The decrease in net loss arising from a increase in the foreign exchange rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossForeignExchangeRateIncrease" xlink:to="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl" xlink:title="label: DecreaseInNetLossForeignExchangeRateIncrease to aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl1" xml:lang="en-US" id="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl1">Decrease in net loss, foreign exchange rate increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossForeignExchangeRateIncrease" xlink:to="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl1" xlink:title="label: DecreaseInNetLossForeignExchangeRateIncrease to aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl2" xml:lang="en-US" id="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl2">Net loss for period decrease, result of foreign exchange rate increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DecreaseInNetLossForeignExchangeRateIncrease" xlink:to="aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl2" xlink:title="label: DecreaseInNetLossForeignExchangeRateIncrease to aciu_DecreaseInNetLossForeignExchangeRateIncrease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfDecreaseInInterestRates" xlink:label="PercentageOfDecreaseInInterestRates" xlink:title="PercentageOfDecreaseInInterestRates" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfDecreaseInInterestRates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_PercentageOfDecreaseInInterestRates_lbl" xml:lang="en-US" id="aciu_PercentageOfDecreaseInInterestRates_lbl">The percentage decrease to interest rate at the end of the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDecreaseInInterestRates" xlink:to="aciu_PercentageOfDecreaseInInterestRates_lbl" xlink:title="label: PercentageOfDecreaseInInterestRates to aciu_PercentageOfDecreaseInInterestRates_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfDecreaseInInterestRates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_PercentageOfDecreaseInInterestRates_lbl1" xml:lang="en-US" id="aciu_PercentageOfDecreaseInInterestRates_lbl1">Percentage of decrease in interest rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDecreaseInInterestRates" xlink:to="aciu_PercentageOfDecreaseInInterestRates_lbl1" xlink:title="label: PercentageOfDecreaseInInterestRates to aciu_PercentageOfDecreaseInInterestRates_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_PercentageOfDecreaseInInterestRates_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_PercentageOfDecreaseInInterestRates_lbl2" xml:lang="en-US" id="aciu_PercentageOfDecreaseInInterestRates_lbl2">Percentage of decrease in interest rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDecreaseInInterestRates" xlink:to="aciu_PercentageOfDecreaseInInterestRates_lbl2" xlink:title="label: PercentageOfDecreaseInInterestRates to aciu_PercentageOfDecreaseInInterestRates_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AccruedExpensesMember" xlink:label="AccruedExpensesMember" xlink:title="AccruedExpensesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_AccruedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_AccruedExpensesMember_lbl" xml:lang="en-US" id="aciu_AccruedExpensesMember_lbl">This member stands for accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesMember" xlink:to="aciu_AccruedExpensesMember_lbl" xlink:title="label: AccruedExpensesMember to aciu_AccruedExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_AccruedExpensesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AccruedExpensesMember_lbl1" xml:lang="en-US" id="aciu_AccruedExpensesMember_lbl1">Accrued Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesMember" xlink:to="aciu_AccruedExpensesMember_lbl1" xlink:title="label: AccruedExpensesMember to aciu_AccruedExpensesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNetLossInterestRateIncrease" xlink:label="IncreaseInNetLossInterestRateIncrease" xlink:title="IncreaseInNetLossInterestRateIncrease" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNetLossInterestRateIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncreaseInNetLossInterestRateIncrease_lbl" xml:lang="en-US" id="aciu_IncreaseInNetLossInterestRateIncrease_lbl">The increase in net loss arising from a increase in the interest rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNetLossInterestRateIncrease" xlink:to="aciu_IncreaseInNetLossInterestRateIncrease_lbl" xlink:title="label: IncreaseInNetLossInterestRateIncrease to aciu_IncreaseInNetLossInterestRateIncrease_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNetLossInterestRateIncrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncreaseInNetLossInterestRateIncrease_lbl1" xml:lang="en-US" id="aciu_IncreaseInNetLossInterestRateIncrease_lbl1">Increase in net loss, interest rate increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNetLossInterestRateIncrease" xlink:to="aciu_IncreaseInNetLossInterestRateIncrease_lbl1" xlink:title="label: IncreaseInNetLossInterestRateIncrease to aciu_IncreaseInNetLossInterestRateIncrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncreaseInNetLossInterestRateIncrease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncreaseInNetLossInterestRateIncrease_lbl2" xml:lang="en-US" id="aciu_IncreaseInNetLossInterestRateIncrease_lbl2">Net loss for period increase, due to increase in interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInNetLossInterestRateIncrease" xlink:to="aciu_IncreaseInNetLossInterestRateIncrease_lbl2" xlink:title="label: IncreaseInNetLossInterestRateIncrease to aciu_IncreaseInNetLossInterestRateIncrease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherReceivablesMember" xlink:label="OtherReceivablesMember" xlink:title="OtherReceivablesMember" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_OtherReceivablesMember_lbl" xml:lang="en-US" id="aciu_OtherReceivablesMember_lbl">This member represents receivables classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesMember" xlink:to="aciu_OtherReceivablesMember_lbl" xlink:title="label: OtherReceivablesMember to aciu_OtherReceivablesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherReceivablesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OtherReceivablesMember_lbl1" xml:lang="en-US" id="aciu_OtherReceivablesMember_lbl1">Other receivables [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesMember" xlink:to="aciu_OtherReceivablesMember_lbl1" xlink:title="label: OtherReceivablesMember to aciu_OtherReceivablesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OtherReceivablesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_OtherReceivablesMember_lbl2" xml:lang="en-US" id="aciu_OtherReceivablesMember_lbl2">Other Current Receivables [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesMember" xlink:to="aciu_OtherReceivablesMember_lbl2" xlink:title="label: OtherReceivablesMember to aciu_OtherReceivablesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashOnHandAndCashEquivalentsMember" xlink:label="CashOnHandAndCashEquivalentsMember" xlink:title="CashOnHandAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_CashOnHandAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_CashOnHandAndCashEquivalentsMember_lbl" xml:lang="en-US" id="aciu_CashOnHandAndCashEquivalentsMember_lbl">This member represents cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashOnHandAndCashEquivalentsMember" xlink:to="aciu_CashOnHandAndCashEquivalentsMember_lbl" xlink:title="label: CashOnHandAndCashEquivalentsMember to aciu_CashOnHandAndCashEquivalentsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_CashOnHandAndCashEquivalentsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_CashOnHandAndCashEquivalentsMember_lbl1" xml:lang="en-US" id="aciu_CashOnHandAndCashEquivalentsMember_lbl1">Cash on hand and cash equivalents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashOnHandAndCashEquivalentsMember" xlink:to="aciu_CashOnHandAndCashEquivalentsMember_lbl1" xlink:title="label: CashOnHandAndCashEquivalentsMember to aciu_CashOnHandAndCashEquivalentsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_CashOnHandAndCashEquivalentsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_CashOnHandAndCashEquivalentsMember_lbl2" xml:lang="en-US" id="aciu_CashOnHandAndCashEquivalentsMember_lbl2">Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashOnHandAndCashEquivalentsMember" xlink:to="aciu_CashOnHandAndCashEquivalentsMember_lbl2" xlink:title="label: CashOnHandAndCashEquivalentsMember to aciu_CashOnHandAndCashEquivalentsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancialAssetsMember" xlink:label="LongTermFinancialAssetsMember" xlink:title="LongTermFinancialAssetsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancialAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_LongTermFinancialAssetsMember_lbl" xml:lang="en-US" id="aciu_LongTermFinancialAssetsMember_lbl">This member represents financial assets classified as long-term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancialAssetsMember" xlink:to="aciu_LongTermFinancialAssetsMember_lbl" xlink:title="label: LongTermFinancialAssetsMember to aciu_LongTermFinancialAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_LongTermFinancialAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_LongTermFinancialAssetsMember_lbl1" xml:lang="en-US" id="aciu_LongTermFinancialAssetsMember_lbl1">Long-term Financial Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermFinancialAssetsMember" xlink:to="aciu_LongTermFinancialAssetsMember_lbl1" xlink:title="label: LongTermFinancialAssetsMember to aciu_LongTermFinancialAssetsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermFinancialAssetsMember" xlink:label="ShortTermFinancialAssetsMember" xlink:title="ShortTermFinancialAssetsMember" />
    <link:label xlink:type="resource" xlink:label="aciu_ShortTermFinancialAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ShortTermFinancialAssetsMember_lbl" xml:lang="en-US" id="aciu_ShortTermFinancialAssetsMember_lbl">This member represents financial assets classified as short-term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermFinancialAssetsMember" xlink:to="aciu_ShortTermFinancialAssetsMember_lbl" xlink:title="label: ShortTermFinancialAssetsMember to aciu_ShortTermFinancialAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ShortTermFinancialAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ShortTermFinancialAssetsMember_lbl1" xml:lang="en-US" id="aciu_ShortTermFinancialAssetsMember_lbl1">Short-term Financial Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermFinancialAssetsMember" xlink:to="aciu_ShortTermFinancialAssetsMember_lbl1" xlink:title="label: ShortTermFinancialAssetsMember to aciu_ShortTermFinancialAssetsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntidilutiveSecuritiesAbstract" xlink:label="AntidilutiveSecuritiesAbstract" xlink:title="AntidilutiveSecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="aciu_AntidilutiveSecuritiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_AntidilutiveSecuritiesAbstract_lbl1" xml:lang="en-US" id="aciu_AntidilutiveSecuritiesAbstract_lbl1">Antidilutive securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesAbstract" xlink:to="aciu_AntidilutiveSecuritiesAbstract_lbl1" xlink:title="label: AntidilutiveSecuritiesAbstract to aciu_AntidilutiveSecuritiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl">The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options and potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xlink:title="label: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1">Dilutive effect of share options and convertible instruments on number of ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" xlink:title="label: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl2" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl2">Total (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl2" xlink:title="label: DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares to aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:label="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:title="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl" xml:lang="en-US" id="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl">The number of dilutive restricted share awards subject to future vesting that relate to the assumed exercise of the entity's incentive share options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:to="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl" xlink:title="label: DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting to aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl1" xml:lang="en-US" id="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl1">Dilutive effect of Restricted share awards subject to future vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:to="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl1" xlink:title="label: DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting to aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl2" xml:lang="en-US" id="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl2">Restricted share awards subject to future vesting (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:to="aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl2" xlink:title="label: DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting to aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:label="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:title="DilutiveEffectOfShareOptionsIssuedAndOutstanding" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl">The number of dilutive share options that relate to the assumed exercise of the entity's share options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:to="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl" xlink:title="label: DilutiveEffectOfShareOptionsIssuedAndOutstanding to aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl1" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl1">Dilutive effect of share options issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:to="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl1" xlink:title="label: DilutiveEffectOfShareOptionsIssuedAndOutstanding to aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl2" xml:lang="en-US" id="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl2">Share options issued and outstanding (in-the-money) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:to="aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl2" xlink:title="label: DilutiveEffectOfShareOptionsIssuedAndOutstanding to aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncomeTaxLossCarryforwardPeriod" xlink:label="IncomeTaxLossCarryforwardPeriod" xlink:title="IncomeTaxLossCarryforwardPeriod" />
    <link:label xlink:type="resource" xlink:label="aciu_IncomeTaxLossCarryforwardPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_IncomeTaxLossCarryforwardPeriod_lbl" xml:lang="en-US" id="aciu_IncomeTaxLossCarryforwardPeriod_lbl">The period or time limit over which financial losses of the entity for preceding years can be deducted from the taxable revenue for a period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxLossCarryforwardPeriod" xlink:to="aciu_IncomeTaxLossCarryforwardPeriod_lbl" xlink:title="label: IncomeTaxLossCarryforwardPeriod to aciu_IncomeTaxLossCarryforwardPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_IncomeTaxLossCarryforwardPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_IncomeTaxLossCarryforwardPeriod_lbl1" xml:lang="en-US" id="aciu_IncomeTaxLossCarryforwardPeriod_lbl1">Income tax loss, Carryforward period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxLossCarryforwardPeriod" xlink:to="aciu_IncomeTaxLossCarryforwardPeriod_lbl1" xlink:title="label: IncomeTaxLossCarryforwardPeriod to aciu_IncomeTaxLossCarryforwardPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_IncomeTaxLossCarryforwardPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_IncomeTaxLossCarryforwardPeriod_lbl2" xml:lang="en-US" id="aciu_IncomeTaxLossCarryforwardPeriod_lbl2">Tax loss carryforward period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxLossCarryforwardPeriod" xlink:to="aciu_IncomeTaxLossCarryforwardPeriod_lbl2" xlink:title="label: IncomeTaxLossCarryforwardPeriod to aciu_IncomeTaxLossCarryforwardPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ReportableSegmentsNumber" xlink:label="ReportableSegmentsNumber" xlink:title="ReportableSegmentsNumber" />
    <link:label xlink:type="resource" xlink:label="aciu_ReportableSegmentsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_ReportableSegmentsNumber_lbl" xml:lang="en-US" id="aciu_ReportableSegmentsNumber_lbl">Number of reportable segments reported by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReportableSegmentsNumber" xlink:to="aciu_ReportableSegmentsNumber_lbl" xlink:title="label: ReportableSegmentsNumber to aciu_ReportableSegmentsNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_ReportableSegmentsNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_ReportableSegmentsNumber_lbl1" xml:lang="en-US" id="aciu_ReportableSegmentsNumber_lbl1">Reportable segments, number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReportableSegmentsNumber" xlink:to="aciu_ReportableSegmentsNumber_lbl1" xlink:title="label: ReportableSegmentsNumber to aciu_ReportableSegmentsNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_ReportableSegmentsNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_ReportableSegmentsNumber_lbl2" xml:lang="en-US" id="aciu_ReportableSegmentsNumber_lbl2">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReportableSegmentsNumber" xlink:to="aciu_ReportableSegmentsNumber_lbl2" xlink:title="label: ReportableSegmentsNumber to aciu_ReportableSegmentsNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OperatingSegmentsNumber" xlink:label="OperatingSegmentsNumber" xlink:title="OperatingSegmentsNumber" />
    <link:label xlink:type="resource" xlink:label="aciu_OperatingSegmentsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="aciu_OperatingSegmentsNumber_lbl" xml:lang="en-US" id="aciu_OperatingSegmentsNumber_lbl">Number of operating segments reported by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsNumber" xlink:to="aciu_OperatingSegmentsNumber_lbl" xlink:title="label: OperatingSegmentsNumber to aciu_OperatingSegmentsNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="aciu_OperatingSegmentsNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="aciu_OperatingSegmentsNumber_lbl1" xml:lang="en-US" id="aciu_OperatingSegmentsNumber_lbl1">Operating segments, number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsNumber" xlink:to="aciu_OperatingSegmentsNumber_lbl1" xlink:title="label: OperatingSegmentsNumber to aciu_OperatingSegmentsNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="aciu_OperatingSegmentsNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="aciu_OperatingSegmentsNumber_lbl2" xml:lang="en-US" id="aciu_OperatingSegmentsNumber_lbl2">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsNumber" xlink:to="aciu_OperatingSegmentsNumber_lbl2" xlink:title="label: OperatingSegmentsNumber to aciu_OperatingSegmentsNumber_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>aciu-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://acimume.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagementDetails" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShareDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationNonvestedShareAwardsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationWeightedAverageExercisePricesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationPlansOutstandingDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangeInOtherComprehensiveLossDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanChangesInDefinedBenefitObligationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanDetails" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactionsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactionsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategoryDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategoryDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesGrantsFromMichaelJFoxFoundationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesRecognizedRevenuesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancingObligationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancingObligationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalShelfRegistrationStatementDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalDetails" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivablesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivablesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncomeDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://acimume.com/role/BasisOfPreparationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#BasisOfPreparationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/GeneralInformationDetails" xlink:type="simple" xlink:href="aciu-20201231.xsd#GeneralInformationDetails" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagementTables" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShareTables" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensationTables" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlanTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlanTables" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactionsTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactionsTables" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategoryTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategoryTables" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenuesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenuesTables" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilitiesTables" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapitalTables" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivablesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivablesTables" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncomeTables" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssetsTables" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilitiesTables" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipmentTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipmentTables" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://acimume.com/role/SubsequentEvents" xlink:type="simple" xlink:href="aciu-20201231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://acimume.com/role/CapitalRiskManagement" xlink:type="simple" xlink:href="aciu-20201231.xsd#CapitalRiskManagement" />
  <link:roleRef roleURI="http://acimume.com/role/FinancialInstrumentsAndRiskManagement" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancialInstrumentsAndRiskManagement" />
  <link:roleRef roleURI="http://acimume.com/role/EarningsPerShare" xlink:type="simple" xlink:href="aciu-20201231.xsd#EarningsPerShare" />
  <link:roleRef roleURI="http://acimume.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="aciu-20201231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://acimume.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="aciu-20201231.xsd#SharebasedCompensation" />
  <link:roleRef roleURI="http://acimume.com/role/RetirementBenefitPlan" xlink:type="simple" xlink:href="aciu-20201231.xsd#RetirementBenefitPlan" />
  <link:roleRef roleURI="http://acimume.com/role/IncomeTaxes" xlink:type="simple" xlink:href="aciu-20201231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://acimume.com/role/RelatedpartyTransactions" xlink:type="simple" xlink:href="aciu-20201231.xsd#RelatedpartyTransactions" />
  <link:roleRef roleURI="http://acimume.com/role/ExpensesByCategory" xlink:type="simple" xlink:href="aciu-20201231.xsd#ExpensesByCategory" />
  <link:roleRef roleURI="http://acimume.com/role/ContractRevenues" xlink:type="simple" xlink:href="aciu-20201231.xsd#ContractRevenues" />
  <link:roleRef roleURI="http://acimume.com/role/FinancingObligation" xlink:type="simple" xlink:href="aciu-20201231.xsd#FinancingObligation" />
  <link:roleRef roleURI="http://acimume.com/role/TradePayablesAndAccruedLiabilities" xlink:type="simple" xlink:href="aciu-20201231.xsd#TradePayablesAndAccruedLiabilities" />
  <link:roleRef roleURI="http://acimume.com/role/ShareCapital" xlink:type="simple" xlink:href="aciu-20201231.xsd#ShareCapital" />
  <link:roleRef roleURI="http://acimume.com/role/OtherCurrentReceivables" xlink:type="simple" xlink:href="aciu-20201231.xsd#OtherCurrentReceivables" />
  <link:roleRef roleURI="http://acimume.com/role/PrepaidExpensesAndAccruedIncome" xlink:type="simple" xlink:href="aciu-20201231.xsd#PrepaidExpensesAndAccruedIncome" />
  <link:roleRef roleURI="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets" xlink:type="simple" xlink:href="aciu-20201231.xsd#CashAndCashEquivalentsAndFinancialAssets" />
  <link:roleRef roleURI="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities" xlink:type="simple" xlink:href="aciu-20201231.xsd#RightofuseAssetsAndLeaseLiabilities" />
  <link:roleRef roleURI="http://acimume.com/role/PropertyPlantAndEquipment" xlink:type="simple" xlink:href="aciu-20201231.xsd#PropertyPlantAndEquipment" />
  <link:roleRef roleURI="http://acimume.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="aciu-20201231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://acimume.com/role/BasisOfPreparation" xlink:type="simple" xlink:href="aciu-20201231.xsd#BasisOfPreparation" />
  <link:roleRef roleURI="http://acimume.com/role/GeneralInformation" xlink:type="simple" xlink:href="aciu-20201231.xsd#GeneralInformation" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfChangesInEquity" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfChangesInEquity" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/StatementsOfIncomeLoss" xlink:type="simple" xlink:href="aciu-20201231.xsd#StatementsOfIncomeLoss" />
  <link:roleRef roleURI="http://acimume.com/role/BalanceSheets" xlink:type="simple" xlink:href="aciu-20201231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://acimume.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="aciu-20201231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAnnualReport" xlink:title="presentation: CoverAbstract to DocumentAnnualReport" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="DocumentShellCompanyReport" xlink:title="DocumentShellCompanyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentShellCompanyReport" xlink:title="presentation: CoverAbstract to DocumentShellCompanyReport" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: CoverAbstract to EntityWellKnownSeasonedIssuer" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: CoverAbstract to EntityVoluntaryFilers" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: CoverAbstract to EntityExTransitionPeriod" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="DocumentAccountingStandard" xlink:title="DocumentAccountingStandard" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAccountingStandard" xlink:title="presentation: CoverAbstract to DocumentAccountingStandard" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="NoncurrentAssetsAbstract" xlink:title="NoncurrentAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment" xlink:title="PropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentAssetsAbstract" xlink:to="PropertyPlantAndEquipment" xlink:title="presentation: NoncurrentAssetsAbstract to PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets" xlink:title="RightofuseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentAssetsAbstract" xlink:to="RightofuseAssets" xlink:title="presentation: NoncurrentAssetsAbstract to RightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="NoncurrentRestrictedCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentAssetsAbstract" xlink:to="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="presentation: NoncurrentAssetsAbstract to NoncurrentRestrictedCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="NoncurrentAssets" xlink:title="NoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentAssetsAbstract" xlink:to="NoncurrentAssets" xlink:title="presentation: NoncurrentAssetsAbstract to NoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="NoncurrentAssetsAbstract" xlink:title="presentation: AssetsAbstract to NoncurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="CurrentAssetsAbstract" xlink:title="CurrentAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CurrentPrepayments" xlink:title="presentation: CurrentAssetsAbstract to CurrentPrepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CurrentContractAssets" xlink:title="presentation: CurrentAssetsAbstract to CurrentContractAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="presentation: CurrentAssetsAbstract to CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CurrentFinancialAssets" xlink:title="presentation: CurrentAssetsAbstract to CurrentFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CashAndCashEquivalents" xlink:title="presentation: CurrentAssetsAbstract to CashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="CurrentAssets" xlink:title="CurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="CurrentAssets" xlink:title="presentation: CurrentAssetsAbstract to CurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="CurrentAssetsAbstract" xlink:title="presentation: AssetsAbstract to CurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="EquityAndLiabilitiesAbstract" xlink:title="EquityAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="IssuedCapital" xlink:title="IssuedCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="IssuedCapital" xlink:title="presentation: EquityAbstract to IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="SharePremium" xlink:title="SharePremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="SharePremium" xlink:title="presentation: EquityAbstract to SharePremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="TreasuryShares" xlink:title="TreasuryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="TreasuryShares" xlink:title="presentation: EquityAbstract to TreasuryShares" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="RetainedEarnings" xlink:title="RetainedEarnings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="RetainedEarnings" xlink:title="presentation: EquityAbstract to RetainedEarnings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="Equity" xlink:title="presentation: EquityAbstract to Equity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="EquityAbstract" xlink:title="presentation: EquityAndLiabilitiesAbstract to EquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="NoncurrentLiabilitiesAbstract" xlink:title="NoncurrentLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="NoncurrentLeaseLiabilities" xlink:title="NoncurrentLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentLiabilitiesAbstract" xlink:to="NoncurrentLeaseLiabilities" xlink:title="presentation: NoncurrentLiabilitiesAbstract to NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="NoncurrentProvisionsForEmployeeBenefits" xlink:title="NoncurrentProvisionsForEmployeeBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentLiabilitiesAbstract" xlink:to="NoncurrentProvisionsForEmployeeBenefits" xlink:title="presentation: NoncurrentLiabilitiesAbstract to NoncurrentProvisionsForEmployeeBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="NoncurrentLiabilities" xlink:title="NoncurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncurrentLiabilitiesAbstract" xlink:to="NoncurrentLiabilities" xlink:title="presentation: NoncurrentLiabilitiesAbstract to NoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="NoncurrentLiabilitiesAbstract" xlink:title="presentation: EquityAndLiabilitiesAbstract to NoncurrentLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="CurrentLiabilitiesAbstract" xlink:title="CurrentLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="TradeAndOtherCurrentPayables" xlink:title="TradeAndOtherCurrentPayables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="TradeAndOtherCurrentPayables" xlink:title="presentation: CurrentLiabilitiesAbstract to TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="CurrentAccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: CurrentLiabilitiesAbstract to CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="CurrentContractLiabilities" xlink:title="presentation: CurrentLiabilitiesAbstract to CurrentContractLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="CurrentFinancialLiabilities" xlink:title="CurrentFinancialLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="CurrentFinancialLiabilities" xlink:title="presentation: CurrentLiabilitiesAbstract to CurrentFinancialLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="CurrentLeaseLiabilities" xlink:title="CurrentLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="CurrentLeaseLiabilities" xlink:title="presentation: CurrentLiabilitiesAbstract to CurrentLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="CurrentLiabilities" xlink:title="CurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="CurrentLiabilities" xlink:title="presentation: CurrentLiabilitiesAbstract to CurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="CurrentLiabilitiesAbstract" xlink:title="presentation: EquityAndLiabilitiesAbstract to CurrentLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="Liabilities" xlink:title="presentation: EquityAndLiabilitiesAbstract to Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" xlink:title="EquityAndLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAndLiabilitiesAbstract" xlink:to="EquityAndLiabilities" xlink:title="presentation: EquityAndLiabilitiesAbstract to EquityAndLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="EquityAndLiabilitiesAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to EquityAndLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: RevenueAbstract to RevenueFromContractsWithCustomers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="Revenue" xlink:title="Revenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="Revenue" xlink:title="presentation: RevenueAbstract to Revenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenueAbstract" xlink:title="presentation: IncomeStatementAbstract to RevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesOperatingAbstract" xlink:label="ExpensesOperatingAbstract" xlink:title="ExpensesOperatingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesOperatingAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: ExpensesOperatingAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesOperatingAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: ExpensesOperatingAbstract to SellingGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="OtherOperatingIncomeExpense" xlink:title="OtherOperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesOperatingAbstract" xlink:to="OtherOperatingIncomeExpense" xlink:title="presentation: ExpensesOperatingAbstract to OtherOperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="OperatingExpense" xlink:title="OperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesOperatingAbstract" xlink:to="OperatingExpense" xlink:title="presentation: ExpensesOperatingAbstract to OperatingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ExpensesOperatingAbstract" xlink:title="presentation: IncomeStatementAbstract to ExpensesOperatingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ProfitLossFromOperatingActivities" xlink:title="ProfitLossFromOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ProfitLossFromOperatingActivities" xlink:title="presentation: IncomeStatementAbstract to ProfitLossFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="FinanceIncome" xlink:title="presentation: IncomeStatementAbstract to FinanceIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="FinanceCosts" xlink:title="presentation: IncomeStatementAbstract to FinanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="presentation: IncomeStatementAbstract to GainLossArisingFromChangeInFairValueOfConvertibleInstrument" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="presentation: IncomeStatementAbstract to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="FinanceIncomeCost" xlink:title="presentation: IncomeStatementAbstract to FinanceIncomeCost" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ProfitLossBeforeTax" xlink:title="ProfitLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ProfitLossBeforeTax" xlink:title="presentation: IncomeStatementAbstract to ProfitLossBeforeTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="IncomeTaxExpenseContinuingOperations" xlink:title="IncomeTaxExpenseContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseContinuingOperations" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseContinuingOperations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ProfitLoss" xlink:title="presentation: IncomeStatementAbstract to ProfitLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="BasicEarningsLossPerShare" xlink:title="BasicEarningsLossPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="BasicEarningsLossPerShare" xlink:title="presentation: EarningsPerShareAbstract to BasicEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="DilutedEarningsLossPerShare" xlink:title="DilutedEarningsLossPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="DilutedEarningsLossPerShare" xlink:title="presentation: EarningsPerShareAbstract to DilutedEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" xlink:title="StatementOfComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ProfitLoss" xlink:title="presentation: StatementOfComprehensiveIncomeAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:title="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:title="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:title="presentation: ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract to OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:title="presentation: StatementOfComprehensiveIncomeAbstract to ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncome" xlink:title="presentation: StatementOfComprehensiveIncomeAbstract to ComprehensiveIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfChangesInEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" xlink:title="StatementOfChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="StatementOfChangesInEquityTable" xlink:title="StatementOfChangesInEquityTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="IssuedCapitalMember" xlink:title="IssuedCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="IssuedCapitalMember" xlink:title="presentation: EquityMember to IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="SharePremiumMember" xlink:title="SharePremiumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="SharePremiumMember" xlink:title="presentation: EquityMember to SharePremiumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:label="TreasurySharesMember" xlink:title="TreasurySharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="TreasurySharesMember" xlink:title="presentation: EquityMember to TreasurySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="RetainedEarningsMember" xlink:title="presentation: EquityMember to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="presentation: ComponentsOfEquityAxis to EquityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityTable" xlink:to="ComponentsOfEquityAxis" xlink:title="presentation: StatementOfChangesInEquityTable to ComponentsOfEquityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="StatementOfChangesInEquityLineItems" xlink:title="StatementOfChangesInEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="Equity" xlink:title="presentation: StatementOfChangesInEquityLineItems to Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ProfitLoss" xlink:title="presentation: StatementOfChangesInEquityLineItems to ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="OtherComprehensiveIncome" xlink:title="OtherComprehensiveIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="OtherComprehensiveIncome" xlink:title="presentation: StatementOfChangesInEquityLineItems to OtherComprehensiveIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" xlink:title="ComprehensiveIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ComprehensiveIncome" xlink:title="presentation: StatementOfChangesInEquityLineItems to ComprehensiveIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:label="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="ProceedsFromIssuingSharesNetOfUnderwritingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="presentation: StatementOfChangesInEquityLineItems to ProceedsFromIssuingSharesNetOfUnderwritingFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="ShareIssueRelatedCost" xlink:title="presentation: StatementOfChangesInEquityLineItems to ShareIssueRelatedCost" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:title="IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:title="presentation: StatementOfChangesInEquityLineItems to IncreaseDecreaseThroughSharebasedPaymentTransactions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssuedAbstract" xlink:label="NumberOfSharesIssuedAbstract" xlink:title="NumberOfSharesIssuedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesIssuedAbstract" xlink:to="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="presentation: NumberOfSharesIssuedAbstract to IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesIssuedAbstract" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="presentation: NumberOfSharesIssuedAbstract to IncreaseDecreaseThroughTreasuryShareTransactions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssueOfEquityRestrictedShareAwards" xlink:label="IssueOfEquityRestrictedShareAwards" xlink:title="IssueOfEquityRestrictedShareAwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesIssuedAbstract" xlink:to="IssueOfEquityRestrictedShareAwards" xlink:title="presentation: NumberOfSharesIssuedAbstract to IssueOfEquityRestrictedShareAwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="IncreaseDecreaseThroughExerciseOfOptions" xlink:title="IncreaseDecreaseThroughExerciseOfOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesIssuedAbstract" xlink:to="IncreaseDecreaseThroughExerciseOfOptions" xlink:title="presentation: NumberOfSharesIssuedAbstract to IncreaseDecreaseThroughExerciseOfOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="NumberOfSharesIssuedAbstract" xlink:title="presentation: StatementOfChangesInEquityLineItems to NumberOfSharesIssuedAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity_2" xlink:title="Equity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityLineItems" xlink:to="Equity_2" xlink:title="presentation: StatementOfChangesInEquityLineItems to Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityTable" xlink:to="StatementOfChangesInEquityLineItems" xlink:title="presentation: StatementOfChangesInEquityTable to StatementOfChangesInEquityLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="StatementOfChangesInEquityTable" xlink:title="presentation: StatementOfChangesInEquityAbstract to StatementOfChangesInEquityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:title="CashFlowsFromUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ProfitLoss" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="AdjustmentsForReconcileProfitLossAbstract" xlink:title="AdjustmentsForReconcileProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="AdjustmentsForDepreciationExpense" xlink:title="AdjustmentsForDepreciationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForDepreciationExpense" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForDepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:label="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:title="AdjustmentsForDepreciationExpenseRightOfUseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForDepreciationExpenseRightOfUseAssets" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForDepreciationExpenseRightOfUseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="AdjustmentsForFinanceIncomeCost" xlink:title="AdjustmentsForFinanceIncomeCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForFinanceIncomeCost" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForFinanceIncomeCost" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="AdjustmentsForSharebasedPayments" xlink:title="AdjustmentsForSharebasedPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForSharebasedPayments" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForSharebasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="AdjustmentsForFairValueGainsLosses" xlink:title="AdjustmentsForFairValueGainsLosses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForFairValueGainsLosses" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForFairValueGainsLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="AdjustmentsForInterestExpense" xlink:title="AdjustmentsForInterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForInterestExpense" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForInterestExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:title="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:title="presentation: AdjustmentsForReconcileProfitLossAbstract to AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsForReconcileProfitLossAbstract" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangesInWorkingCapitalAbstract" xlink:label="ChangesInWorkingCapitalAbstract" xlink:title="ChangesInWorkingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:label="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:title="AdjustmentsForDecreaseIncreaseInPrepaidExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForDecreaseIncreaseInPrepaidExpense" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForDecreaseIncreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:label="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:title="AdjustmentsForDecreaseIncreaseInAccruedIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForDecreaseIncreaseInAccruedIncome" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForDecreaseIncreaseInAccruedIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:title="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:label="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:title="AdjustmentsForIncreaseDecreaseInAccruedExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInAccruedExpenses" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForIncreaseDecreaseInAccruedExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:title="AdjustmentsForIncreaseDecreaseInDeferredIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForIncreaseDecreaseInDeferredIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:label="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:title="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:title="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInWorkingCapitalAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:title="presentation: ChangesInWorkingCapitalAbstract to AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ChangesInWorkingCapitalAbstract" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to ChangesInWorkingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="CashFlowsFromUsedInOperations" xlink:title="CashFlowsFromUsedInOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="CashFlowsFromUsedInOperations" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to CashFlowsFromUsedInOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:title="FinanceIncomeReceivedClassifiedAsOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to FinanceIncomeReceivedClassifiedAsOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="InterestPaidClassifiedAsOperatingActivities" xlink:title="InterestPaidClassifiedAsOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="InterestPaidClassifiedAsOperatingActivities" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to InterestPaidClassifiedAsOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:title="FinanceCostsPaidClassifiedAsOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="FinanceCostsPaidClassifiedAsOperatingActivities" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to FinanceCostsPaidClassifiedAsOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="CashFlowsFromUsedInOperatingActivities" xlink:title="CashFlowsFromUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="CashFlowsFromUsedInOperatingActivities" xlink:title="presentation: CashFlowsFromUsedInOperatingActivitiesAbstract to CashFlowsFromUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:title="CashFlowsFromUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:title="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:title="presentation: CashFlowsFromUsedInInvestingActivitiesAbstract to PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="presentation: CashFlowsFromUsedInInvestingActivitiesAbstract to PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:title="presentation: CashFlowsFromUsedInInvestingActivitiesAbstract to ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAdvancesForRentDeposit" xlink:label="CashAdvancesForRentDeposit" xlink:title="CashAdvancesForRentDeposit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="CashAdvancesForRentDeposit" xlink:title="presentation: CashFlowsFromUsedInInvestingActivitiesAbstract to CashAdvancesForRentDeposit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="CashFlowsFromUsedInInvestingActivities" xlink:title="CashFlowsFromUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="CashFlowsFromUsedInInvestingActivities" xlink:title="presentation: CashFlowsFromUsedInInvestingActivitiesAbstract to CashFlowsFromUsedInInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:title="CashFlowsFromUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="RepaymentsOfCurrentBorrowings" xlink:title="RepaymentsOfCurrentBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfCurrentBorrowings" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to RepaymentsOfCurrentBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:title="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ProceedsFromExerciseOfOptions" xlink:title="ProceedsFromExerciseOfOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromExerciseOfOptions" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to ProceedsFromExerciseOfOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares" xlink:label="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:title="ProceedsFromSaleOrIssueOfTreasuryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSaleOrIssueOfTreasuryShares" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to ProceedsFromSaleOrIssueOfTreasuryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="PaymentsToAcquireOrRedeemEntitysShares" xlink:title="PaymentsToAcquireOrRedeemEntitysShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentsToAcquireOrRedeemEntitysShares" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to PaymentsToAcquireOrRedeemEntitysShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfConvertibleDebt" xlink:label="ProceedsFromIssueOfConvertibleDebt" xlink:title="ProceedsFromIssueOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssueOfConvertibleDebt" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to ProceedsFromIssueOfConvertibleDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="PaymentsForShareIssueCosts" xlink:title="PaymentsForShareIssueCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentsForShareIssueCosts" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to PaymentsForShareIssueCosts" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:label="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="ProceedsFromIssuingSharesNetOfUnderwritingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuingSharesNetOfUnderwritingFees" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to ProceedsFromIssuingSharesNetOfUnderwritingFees" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PaymentsForShareIssueCostsOnPublicOffering" xlink:label="PaymentsForShareIssueCostsOnPublicOffering" xlink:title="PaymentsForShareIssueCostsOnPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentsForShareIssueCostsOnPublicOffering" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to PaymentsForShareIssueCostsOnPublicOffering" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:title="ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="CashFlowsFromUsedInFinancingActivities" xlink:title="CashFlowsFromUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="CashFlowsFromUsedInFinancingActivities" xlink:title="presentation: CashFlowsFromUsedInFinancingActivitiesAbstract to CashFlowsFromUsedInFinancingActivities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="IncreaseDecreaseInCashAndCashEquivalents" xlink:title="IncreaseDecreaseInCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="IncreaseDecreaseInCashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to IncreaseDecreaseInCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents_2" xlink:title="CashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="IncreaseDecreaseInCashAndCashEquivalents_2" xlink:title="IncreaseDecreaseInCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="IncreaseDecreaseInCashAndCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to IncreaseDecreaseInCashAndCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/StatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsTable" xlink:label="StatementOfCashFlowsTable" xlink:title="StatementOfCashFlowsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementMember" xlink:label="ConvertibleNoteAgreementMember" xlink:title="ConvertibleNoteAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsByNameMember" xlink:to="ConvertibleNoteAgreementMember" xlink:title="presentation: BorrowingsByNameMember to ConvertibleNoteAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="presentation: BorrowingsByNameAxis to BorrowingsByNameMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsTable" xlink:to="BorrowingsByNameAxis" xlink:title="presentation: StatementOfCashFlowsTable to BorrowingsByNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StatementOfCashFlowsLineItems" xlink:label="StatementOfCashFlowsLineItems" xlink:title="StatementOfCashFlowsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SupplementaryNonCashActivityAbstract" xlink:label="SupplementaryNonCashActivityAbstract" xlink:title="SupplementaryNonCashActivityAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:label="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:title="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementaryNonCashActivityAbstract" xlink:to="PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" xlink:title="presentation: SupplementaryNonCashActivityAbstract to PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:label="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:title="RepaymentOfConvertibleDebtEquitySettlementAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementaryNonCashActivityAbstract" xlink:to="RepaymentOfConvertibleDebtEquitySettlementAmount" xlink:title="presentation: SupplementaryNonCashActivityAbstract to RepaymentOfConvertibleDebtEquitySettlementAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementaryNonCashActivityAbstract" xlink:to="ShareIssueRelatedCost" xlink:title="presentation: SupplementaryNonCashActivityAbstract to ShareIssueRelatedCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsLineItems" xlink:to="SupplementaryNonCashActivityAbstract" xlink:title="presentation: StatementOfCashFlowsLineItems to SupplementaryNonCashActivityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsTable" xlink:to="StatementOfCashFlowsLineItems" xlink:title="presentation: StatementOfCashFlowsTable to StatementOfCashFlowsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementOfCashFlowsTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementOfCashFlowsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/GeneralInformation">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" xlink:title="GeneralInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:label="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:title="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationAbstract" xlink:to="DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" xlink:title="presentation: GeneralInformationAbstract to DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/BasisOfPreparation">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BasisOfPreparationAbstract" xlink:label="BasisOfPreparationAbstract" xlink:title="BasisOfPreparationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:title="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPreparationAbstract" xlink:to="DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:title="presentation: BasisOfPreparationAbstract to DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:title="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:title="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:title="DisclosureOfPropertyPlantAndEquipmentExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentAbstract to DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" xlink:title="PresentationOfLeasesForLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="DisclosureOfLeasesExplanatory" xlink:title="DisclosureOfLeasesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfLeasesExplanatory" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" xlink:title="DisclosureOfFinancialAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:label="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:title="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrepaymentsAndAccruedIncomeAbstract" xlink:label="PrepaymentsAndAccruedIncomeAbstract" xlink:title="PrepaymentsAndAccruedIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:label="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:title="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndAccruedIncomeAbstract" xlink:to="DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" xlink:title="presentation: PrepaymentsAndAccruedIncomeAbstract to DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivables">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherCurrentReceivablesAbstract" xlink:label="OtherCurrentReceivablesAbstract" xlink:title="OtherCurrentReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesTextBlock" xlink:label="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:title="DisclosureOfOtherCurrentReceivablesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCurrentReceivablesAbstract" xlink:to="DisclosureOfOtherCurrentReceivablesTextBlock" xlink:title="presentation: OtherCurrentReceivablesAbstract to DisclosureOfOtherCurrentReceivablesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapital">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:title="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInEquityAbstract" xlink:to="DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:title="presentation: ChangesInEquityAbstract to DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" xlink:title="TradeAndOtherCurrentPayablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="DisclosureOfTradeAndOtherPayablesExplanatory" xlink:title="DisclosureOfTradeAndOtherPayablesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="DisclosureOfTradeAndOtherPayablesExplanatory" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancingObligation">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancingObligationAbstract" xlink:label="FinancingObligationAbstract" xlink:title="FinancingObligationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="DisclosureOfDebtSecuritiesExplanatory" xlink:title="DisclosureOfDebtSecuritiesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingObligationAbstract" xlink:to="DisclosureOfDebtSecuritiesExplanatory" xlink:title="presentation: FinancingObligationAbstract to DisclosureOfDebtSecuritiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenues">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="DisclosureOfRevenueExplanatory" xlink:title="DisclosureOfRevenueExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfRevenueExplanatory" xlink:title="presentation: RevenueAbstract to DisclosureOfRevenueExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategory">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesByCategoryAbstract" xlink:label="ExpensesByCategoryAbstract" xlink:title="ExpensesByCategoryAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfExpensesExplanatory" xlink:label="DisclosureOfExpensesExplanatory" xlink:title="DisclosureOfExpensesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesByCategoryAbstract" xlink:to="DisclosureOfExpensesExplanatory" xlink:title="presentation: ExpensesByCategoryAbstract to DisclosureOfExpensesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactions">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:title="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="DisclosureOfRelatedPartyExplanatory" xlink:title="DisclosureOfRelatedPartyExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="DisclosureOfRelatedPartyExplanatory" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="DisclosureOfIncomeTaxExplanatory" xlink:title="DisclosureOfIncomeTaxExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfIncomeTaxExplanatory" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="DisclosureOfEmployeeBenefitsExplanatory" xlink:title="DisclosureOfEmployeeBenefitsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfEmployeeBenefitsExplanatory" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:title="DisclosureOfSharebasedPaymentArrangementsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAndContingenciesAbstract" xlink:label="CommitmentsAndContingenciesAbstract" xlink:title="CommitmentsAndContingenciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:title="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesAbstract" xlink:to="DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:title="presentation: CommitmentsAndContingenciesAbstract to DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShare">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="DisclosureOfEarningsPerShareExplanatory" xlink:title="DisclosureOfEarningsPerShareExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="DisclosureOfEarningsPerShareExplanatory" xlink:title="presentation: EarningsPerShareAbstract to DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagement">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="DisclosureOfFinancialRiskManagementExplanatory" xlink:title="DisclosureOfFinancialRiskManagementExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="DisclosureOfFinancialRiskManagementExplanatory" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract to DisclosureOfFinancialRiskManagementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CapitalRiskManagement">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:label="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:title="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:title="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:to="DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:title="presentation: DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract to DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:title="DisclosureOfEventsAfterReportingPeriodExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract to DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:label="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:title="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:title="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:title="DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:title="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantIncomePolicyTextBlock" xlink:label="GrantIncomePolicyTextBlock" xlink:title="GrantIncomePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="GrantIncomePolicyTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to GrantIncomePolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:title="DescriptionOfAccountingPolicyForLeasesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForLeasesExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:title="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:label="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:title="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:title="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:title="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:title="DescriptionOfAccountingPolicyForProvisionsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForProvisionsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:title="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:title="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:label="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:title="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:title="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:label="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:title="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:label="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:title="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:title="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:title="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:title="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentAbstract to DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" xlink:title="PresentationOfLeasesForLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:label="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:title="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:label="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:title="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to ScheduleOfContractualUndiscountedCashFlowsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" xlink:title="DisclosureOfFinancialAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="DisclosureOfFinancialAssetsExplanatory" xlink:title="DisclosureOfFinancialAssetsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="DisclosureOfFinancialAssetsExplanatory" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to DisclosureOfFinancialAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrepaymentsAndAccruedIncomeAbstract" xlink:label="PrepaymentsAndAccruedIncomeAbstract" xlink:title="PrepaymentsAndAccruedIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndAccruedIncomeAbstract" xlink:to="DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" xlink:title="presentation: PrepaymentsAndAccruedIncomeAbstract to DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivablesTables">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherCurrentReceivablesAbstract" xlink:label="OtherCurrentReceivablesAbstract" xlink:title="OtherCurrentReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCurrentReceivablesAbstract" xlink:to="DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" xlink:title="presentation: OtherCurrentReceivablesAbstract to DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="DisclosureOfClassesOfShareCapitalExplanatory" xlink:title="DisclosureOfClassesOfShareCapitalExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInEquityAbstract" xlink:to="DisclosureOfClassesOfShareCapitalExplanatory" xlink:title="presentation: ChangesInEquityAbstract to DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" xlink:title="TradeAndOtherCurrentPayablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:title="DisclosureOfRevenueFromContractsWithCustomersExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:title="presentation: RevenueAbstract to DisclosureOfRevenueFromContractsWithCustomersExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:title="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:title="presentation: RevenueAbstract to ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategoryTables">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesByCategoryAbstract" xlink:label="ExpensesByCategoryAbstract" xlink:title="ExpensesByCategoryAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:title="DisclosureOfResearchAndDevelopmentExpenseExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesByCategoryAbstract" xlink:to="DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:title="presentation: ExpensesByCategoryAbstract to DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:title="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesByCategoryAbstract" xlink:to="DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:title="presentation: ExpensesByCategoryAbstract to DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="DisclosureOfFinanceIncomeExpenseExplanatory" xlink:title="DisclosureOfFinanceIncomeExpenseExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesByCategoryAbstract" xlink:to="DisclosureOfFinanceIncomeExpenseExplanatory" xlink:title="presentation: ExpensesByCategoryAbstract to DisclosureOfFinanceIncomeExpenseExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactionsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:title="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:label="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:title="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:label="DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:title="DisclosureOfFairValueOfPlanAssetsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfFairValueOfPlanAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:title="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:title="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAndContingenciesAbstract" xlink:label="CommitmentsAndContingenciesAbstract" xlink:title="CommitmentsAndContingenciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="DisclosureOfContingentLiabilitiesExplanatory" xlink:title="DisclosureOfContingentLiabilitiesExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesAbstract" xlink:to="DisclosureOfContingentLiabilitiesExplanatory" xlink:title="presentation: CommitmentsAndContingenciesAbstract to DisclosureOfContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShareTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="EarningsPerShareExplanatory" xlink:title="EarningsPerShareExplanatory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareExplanatory" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:label="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:title="DilutiveEffectOfConvertibleInstrumentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="DilutiveEffectOfConvertibleInstrumentsTextBlock" xlink:title="presentation: EarningsPerShareAbstract to DilutiveEffectOfConvertibleInstrumentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:title="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract to DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/GeneralInformationDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" xlink:title="GeneralInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfTechnologyPlatforms" xlink:label="NumberOfTechnologyPlatforms" xlink:title="NumberOfTechnologyPlatforms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationAbstract" xlink:to="NumberOfTechnologyPlatforms" xlink:title="presentation: GeneralInformationAbstract to NumberOfTechnologyPlatforms" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/BasisOfPreparationDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BasisOfPreparationAbstract" xlink:label="BasisOfPreparationAbstract" xlink:title="BasisOfPreparationAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfGoingConcernTable" xlink:label="DisclosureOfGoingConcernTable" xlink:title="DisclosureOfGoingConcernTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InitialPublicOfferingMember" xlink:label="InitialPublicOfferingMember" xlink:title="InitialPublicOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalMember" xlink:to="InitialPublicOfferingMember" xlink:title="presentation: ClassesOfShareCapitalMember to InitialPublicOfferingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="presentation: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGoingConcernTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="presentation: DisclosureOfGoingConcernTable to ClassesOfShareCapitalAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGoingConcernTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfGoingConcernTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfClassesOfGoingConcernLineItems" xlink:label="DisclosureOfClassesOfGoingConcernLineItems" xlink:title="DisclosureOfClassesOfGoingConcernLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GoingConcernAbstract" xlink:label="GoingConcernAbstract" xlink:title="GoingConcernAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="CashAndCashEquivalents" xlink:title="presentation: GoingConcernAbstract to CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="CurrentFinancialAssets" xlink:title="presentation: GoingConcernAbstract to CurrentFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="ContractLiabilities" xlink:title="presentation: GoingConcernAbstract to ContractLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="presentation: GoingConcernAbstract to CollaborativeAgreementMilestonePaymentReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfConvertibleDebt" xlink:label="ProceedsFromIssueOfConvertibleDebt" xlink:title="ProceedsFromIssueOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="ProceedsFromIssueOfConvertibleDebt" xlink:title="presentation: GoingConcernAbstract to ProceedsFromIssueOfConvertibleDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPublicOfferings" xlink:label="NumberOfPublicOfferings" xlink:title="NumberOfPublicOfferings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="NumberOfPublicOfferings" xlink:title="presentation: GoingConcernAbstract to NumberOfPublicOfferings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="presentation: GoingConcernAbstract to ProceedsFromIssueOfOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfGoingConcernLineItems" xlink:to="GoingConcernAbstract" xlink:title="presentation: DisclosureOfClassesOfGoingConcernLineItems to GoingConcernAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGoingConcernTable" xlink:to="DisclosureOfClassesOfGoingConcernLineItems" xlink:title="presentation: DisclosureOfGoingConcernTable to DisclosureOfClassesOfGoingConcernLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPreparationAbstract" xlink:to="DisclosureOfGoingConcernTable" xlink:title="presentation: BasisOfPreparationAbstract to DisclosureOfGoingConcernTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="BuildingsMember" xlink:title="BuildingsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="BuildingsMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to BuildingsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="presentation: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to ClassesOfPropertyPlantAndEquipmentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EstimatedLeaseTerm" xlink:label="EstimatedLeaseTerm" xlink:title="EstimatedLeaseTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="EstimatedLeaseTerm" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract to EstimatedLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:label="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:title="LeaseholdImprovementsAndFixturesAndFittingsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LeaseholdImprovementsAndFixturesAndFittingsMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to LeaseholdImprovementsAndFixturesAndFittingsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="presentation: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentTable to ClassesOfPropertyPlantAndEquipmentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:title="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:title="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:to="UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract to UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentTable to DisclosureOfPropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DisclosureOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncomeTaxLossCarryforwardPeriod" xlink:label="IncomeTaxLossCarryforwardPeriod" xlink:title="IncomeTaxLossCarryforwardPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="IncomeTaxLossCarryforwardPeriod" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to IncomeTaxLossCarryforwardPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="DeferredTaxAssets" xlink:title="DeferredTaxAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DeferredTaxAssets" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DeferredTaxAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to MajorComponentsOfTaxExpenseIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:label="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:title="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="DisclosureOfOperatingSegmentsAbstract" xlink:title="DisclosureOfOperatingSegmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OperatingSegmentsNumber" xlink:label="OperatingSegmentsNumber" xlink:title="OperatingSegmentsNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsNumber" xlink:title="presentation: DisclosureOfOperatingSegmentsAbstract to OperatingSegmentsNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ReportableSegmentsNumber" xlink:label="ReportableSegmentsNumber" xlink:title="ReportableSegmentsNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOperatingSegmentsAbstract" xlink:to="ReportableSegmentsNumber" xlink:title="presentation: DisclosureOfOperatingSegmentsAbstract to ReportableSegmentsNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract" xlink:to="DisclosureOfOperatingSegmentsAbstract" xlink:title="presentation: DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract to DisclosureOfOperatingSegmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:title="DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="DisclosureOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="FixturesAndFittingsMember" xlink:title="FixturesAndFittingsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="FixturesAndFittingsMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to FixturesAndFittingsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="presentation: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentTable to ClassesOfPropertyPlantAndEquipmentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="GrossCarryingAmountMember" xlink:title="GrossCarryingAmountMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CarryingAmountMember" xlink:to="GrossCarryingAmountMember" xlink:title="presentation: CarryingAmountMember to GrossCarryingAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="AccumulatedDepreciationAndAmortisationMember" xlink:title="AccumulatedDepreciationAndAmortisationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CarryingAmountMember" xlink:to="AccumulatedDepreciationAndAmortisationMember" xlink:title="presentation: CarryingAmountMember to AccumulatedDepreciationAndAmortisationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="presentation: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentTable to CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:title="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment" xlink:title="PropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipment" xlink:title="presentation: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:title="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:title="presentation: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="DepreciationPropertyPlantAndEquipment" xlink:title="DepreciationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="DepreciationPropertyPlantAndEquipment" xlink:title="presentation: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to DepreciationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="DisposalsPropertyPlantAndEquipment" xlink:title="DisposalsPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="DisposalsPropertyPlantAndEquipment" xlink:title="presentation: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to DisposalsPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="PropertyPlantAndEquipment_2" xlink:title="PropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipment_2" xlink:title="presentation: ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentLineItems to ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentTable to DisclosureOfPropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="DisclosureOfPropertyPlantAndEquipmentTable" xlink:title="presentation: DisclosureOfPropertyPlantAndEquipmentAbstract to DisclosureOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="PresentationOfLeasesForLesseeAbstract" xlink:title="PresentationOfLeasesForLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BuildingsMember" xlink:label="BuildingsMember" xlink:title="BuildingsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="BuildingsMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to BuildingsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentMember" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentMember to ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfAssetsMember" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="presentation: ClassesOfAssetsMember to PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="presentation: ClassesOfAssetsAxis to ClassesOfAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ClassesOfAssetsAxis" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to ClassesOfAssetsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:title="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract to WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLeasedAssetsAbstract" xlink:label="RightOfUseLeasedAssetsAbstract" xlink:title="RightOfUseLeasedAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets" xlink:title="RightofuseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="RightofuseAssets" xlink:title="presentation: RightOfUseLeasedAssetsAbstract to RightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="AdditionsToRightofuseAssets" xlink:title="AdditionsToRightofuseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="AdditionsToRightofuseAssets" xlink:title="presentation: RightOfUseLeasedAssetsAbstract to AdditionsToRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisposalOfRightOfUseAssets" xlink:label="DisposalOfRightOfUseAssets" xlink:title="DisposalOfRightOfUseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="DisposalOfRightOfUseAssets" xlink:title="presentation: RightOfUseLeasedAssetsAbstract to DisposalOfRightOfUseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="DepreciationRightofuseAssets" xlink:title="DepreciationRightofuseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="DepreciationRightofuseAssets" xlink:title="presentation: RightOfUseLeasedAssetsAbstract to DepreciationRightofuseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="RightofuseAssets_2" xlink:title="RightofuseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseLeasedAssetsAbstract" xlink:to="RightofuseAssets_2" xlink:title="presentation: RightOfUseLeasedAssetsAbstract to RightofuseAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="RightOfUseLeasedAssetsAbstract" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract to RightOfUseLeasedAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems to DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:title="presentation: DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable to DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:label="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:title="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="DepreciationRightofuseAssets" xlink:title="presentation: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to DepreciationRightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="InterestExpenseOnLeaseLiabilities" xlink:title="InterestExpenseOnLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="InterestExpenseOnLeaseLiabilities" xlink:title="presentation: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to InterestExpenseOnLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:title="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:title="presentation: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpenseRelatingToLeases" xlink:label="ExpenseRelatingToLeases" xlink:title="ExpenseRelatingToLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="ExpenseRelatingToLeases" xlink:title="presentation: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to ExpenseRelatingToLeases" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases" xlink:label="CashOutflowForLeases" xlink:title="CashOutflowForLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:to="CashOutflowForLeases" xlink:title="presentation: ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract to CashOutflowForLeases" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="presentation: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanTwoYearsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="presentation: MaturityAxis to AggregatedTimeBandsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="MaturityAxis" xlink:title="presentation: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable to MaturityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:title="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:label="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:title="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UndiscountedOperatingLeasePaymentsDue" xlink:label="UndiscountedOperatingLeasePaymentsDue" xlink:title="UndiscountedOperatingLeasePaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:to="UndiscountedOperatingLeasePaymentsDue" xlink:title="presentation: ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract to UndiscountedOperatingLeasePaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" xlink:title="presentation: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems to ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:title="presentation: DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable to DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:title="presentation: PresentationOfLeasesForLesseeAbstract to DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" xlink:title="DisclosureOfFinancialAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentsTable" xlink:label="CashAndCashEquivalentsTable" xlink:title="CashAndCashEquivalentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_CHF" xlink:label="CHF" xlink:title="CHF" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllCurrenciesDomain" xlink:to="CHF" xlink:title="presentation: AllCurrenciesDomain to CHF" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="EUR" xlink:title="EUR" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllCurrenciesDomain" xlink:to="EUR" xlink:title="presentation: AllCurrenciesDomain to EUR" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="USD" xlink:title="USD" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllCurrenciesDomain" xlink:to="USD" xlink:title="presentation: AllCurrenciesDomain to USD" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="presentation: CurrencyAxis to AllCurrenciesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsTable" xlink:to="CurrencyAxis" xlink:title="presentation: CashAndCashEquivalentsTable to CurrencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashAndCashEquivalentLineItems" xlink:label="CashAndCashEquivalentLineItems" xlink:title="CashAndCashEquivalentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAbstract" xlink:label="CashAbstract" xlink:title="CashAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="CashAndCashEquivalents" xlink:title="CashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAbstract" xlink:to="CashAndCashEquivalents" xlink:title="presentation: CashAbstract to CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ClosingForeignExchangeRate" xlink:title="ClosingForeignExchangeRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAbstract" xlink:to="ClosingForeignExchangeRate" xlink:title="presentation: CashAbstract to ClosingForeignExchangeRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentLineItems" xlink:to="CashAbstract" xlink:title="presentation: CashAndCashEquivalentLineItems to CashAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsTable" xlink:to="CashAndCashEquivalentLineItems" xlink:title="presentation: CashAndCashEquivalentsTable to CashAndCashEquivalentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="CashAndCashEquivalentsTable" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to CashAndCashEquivalentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="DisclosureOfFinancialAssetsAbstract" xlink:title="DisclosureOfFinancialAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="CurrentFinancialAssets" xlink:title="CurrentFinancialAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="CurrentFinancialAssets" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to CurrentFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfEscrowDepositAccounts" xlink:label="NumberOfEscrowDepositAccounts" xlink:title="NumberOfEscrowDepositAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="NumberOfEscrowDepositAccounts" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to NumberOfEscrowDepositAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="NoncurrentRestrictedCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialAssetsAbstract" xlink:to="NoncurrentRestrictedCashAndCashEquivalents" xlink:title="presentation: DisclosureOfFinancialAssetsAbstract to NoncurrentRestrictedCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PrepaymentsAndAccruedIncomeAbstract" xlink:label="PrepaymentsAndAccruedIncomeAbstract" xlink:title="PrepaymentsAndAccruedIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeTable" xlink:label="PrepaidExpensesAndAccruedIncomeTable" xlink:title="PrepaidExpensesAndAccruedIncomeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeTable to TypesOfContractsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PrepaidExpensesAndAccruedIncomeLineItems" xlink:label="PrepaidExpensesAndAccruedIncomeLineItems" xlink:title="PrepaidExpensesAndAccruedIncomeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepayments" xlink:label="CurrentPrepayments" xlink:title="CurrentPrepayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentPrepayments" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeLineItems to CurrentPrepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentContractAssets" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeLineItems to CurrentContractAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome" xlink:label="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="CurrentPrepaymentsAndCurrentAccruedIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="CurrentPrepaymentsAndCurrentAccruedIncome" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeLineItems to CurrentPrepaymentsAndCurrentAccruedIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAccruedIncome" xlink:label="PercentageOfAccruedIncome" xlink:title="PercentageOfAccruedIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeLineItems" xlink:to="PercentageOfAccruedIncome" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeLineItems to PercentageOfAccruedIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndAccruedIncomeTable" xlink:to="PrepaidExpensesAndAccruedIncomeLineItems" xlink:title="presentation: PrepaidExpensesAndAccruedIncomeTable to PrepaidExpensesAndAccruedIncomeLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentsAndAccruedIncomeAbstract" xlink:to="PrepaidExpensesAndAccruedIncomeTable" xlink:title="presentation: PrepaymentsAndAccruedIncomeAbstract to PrepaidExpensesAndAccruedIncomeTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/OtherCurrentReceivablesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherCurrentReceivablesAbstract" xlink:label="OtherCurrentReceivablesAbstract" xlink:title="OtherCurrentReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesTable" xlink:label="DisclosureOfOtherCurrentReceivablesTable" xlink:title="DisclosureOfOtherCurrentReceivablesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherCurrentReceivablesTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfOtherCurrentReceivablesTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfOtherCurrentReceivablesLineItems" xlink:label="DisclosureOfOtherCurrentReceivablesLineItems" xlink:title="DisclosureOfOtherCurrentReceivablesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="TradeAndOtherReceivablesAbstract" xlink:title="TradeAndOtherReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="CurrentValueAddedTaxReceivables" xlink:title="CurrentValueAddedTaxReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherReceivablesAbstract" xlink:to="CurrentValueAddedTaxReceivables" xlink:title="presentation: TradeAndOtherReceivablesAbstract to CurrentValueAddedTaxReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherReceivablesAbstract" xlink:to="CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:title="presentation: TradeAndOtherReceivablesAbstract to CurrentReceivablesFromTaxesOtherThanIncomeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:label="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherReceivablesAbstract" xlink:to="CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" xlink:title="presentation: TradeAndOtherReceivablesAbstract to CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="TradeAndOtherReceivablesAbstract" xlink:title="presentation: DisclosureOfOtherCurrentReceivablesLineItems to TradeAndOtherReceivablesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:label="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:title="PeriodOfMaturityReceivablesFairValueCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherCurrentReceivablesLineItems" xlink:to="PeriodOfMaturityReceivablesFairValueCarryingAmount" xlink:title="presentation: DisclosureOfOtherCurrentReceivablesLineItems to PeriodOfMaturityReceivablesFairValueCarryingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherCurrentReceivablesTable" xlink:to="DisclosureOfOtherCurrentReceivablesLineItems" xlink:title="presentation: DisclosureOfOtherCurrentReceivablesTable to DisclosureOfOtherCurrentReceivablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCurrentReceivablesAbstract" xlink:to="DisclosureOfOtherCurrentReceivablesTable" xlink:title="presentation: OtherCurrentReceivablesAbstract to DisclosureOfOtherCurrentReceivablesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="IssuedCapitalMember" xlink:title="IssuedCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="IssuedCapitalMember" xlink:title="presentation: EquityMember to IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="SharePremiumMember" xlink:title="SharePremiumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="SharePremiumMember" xlink:title="presentation: EquityMember to SharePremiumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasurySharesMember" xlink:label="TreasurySharesMember" xlink:title="TreasurySharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMember" xlink:to="TreasurySharesMember" xlink:title="presentation: EquityMember to TreasurySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="presentation: ComponentsOfEquityAxis to EquityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ComponentsOfEquityAxis" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to ComponentsOfEquityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="OrdinarySharesMember" xlink:title="OrdinarySharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalMember" xlink:to="OrdinarySharesMember" xlink:title="presentation: ClassesOfShareCapitalMember to OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="presentation: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" xlink:title="DisclosureOfClassesOfShareCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity" xlink:title="Equity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="Equity" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfSharesOutstandingIncludingTreasuryShares" xlink:label="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:title="NumberOfSharesOutstandingIncludingTreasuryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesOutstandingIncludingTreasuryShares" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to NumberOfSharesOutstandingIncludingTreasuryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:label="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:title="IncreaseThroughSharesIssuedUnderIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseThroughSharesIssuedUnderIncentivePlans" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseThroughSharesIssuedUnderIncentivePlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:label="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactions" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseDecreaseThroughTreasuryShareTransactions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:label="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:title="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="Equity_2" xlink:title="Equity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="Equity_2" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to Equity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfSharesOutstandingIncludingTreasuryShares" xlink:label="NumberOfSharesOutstandingIncludingTreasuryShares_2" xlink:title="NumberOfSharesOutstandingIncludingTreasuryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesOutstandingIncludingTreasuryShares_2" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to NumberOfSharesOutstandingIncludingTreasuryShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="NumberOfSharesOutstanding" xlink:title="NumberOfSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesOutstanding" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to NumberOfSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ParValuePerShare" xlink:title="ParValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ParValuePerShare" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to ParValuePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="NumberOfSharesAuthorised" xlink:title="NumberOfSharesAuthorised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesAuthorised" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to NumberOfSharesAuthorised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" xlink:title="presentation: DisclosureOfClassesOfShareCapitalAbstract to NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="DisclosureOfClassesOfShareCapitalAbstract" xlink:title="presentation: DisclosureOfClassesOfShareCapitalLineItems to DisclosureOfClassesOfShareCapitalAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to DisclosureOfClassesOfShareCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInEquityAbstract" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="presentation: ChangesInEquityAbstract to DisclosureOfClassesOfShareCapitalTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AtTheMarketEquityOfferingMember" xlink:label="AtTheMarketEquityOfferingMember" xlink:title="AtTheMarketEquityOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalMember" xlink:to="AtTheMarketEquityOfferingMember" xlink:title="presentation: ClassesOfShareCapitalMember to AtTheMarketEquityOfferingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FollowOnOfferingsMember" xlink:label="FollowOnOfferingsMember" xlink:title="FollowOnOfferingsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OptionForOverAllotmentMember" xlink:label="OptionForOverAllotmentMember" xlink:title="OptionForOverAllotmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FollowOnOfferingsMember" xlink:to="OptionForOverAllotmentMember" xlink:title="presentation: FollowOnOfferingsMember to OptionForOverAllotmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FirstSubscriptionRightsMember" xlink:label="FirstSubscriptionRightsMember" xlink:title="FirstSubscriptionRightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FollowOnOfferingsMember" xlink:to="FirstSubscriptionRightsMember" xlink:title="presentation: FollowOnOfferingsMember to FirstSubscriptionRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SecondSubscriptionRightsMember" xlink:label="SecondSubscriptionRightsMember" xlink:title="SecondSubscriptionRightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FollowOnOfferingsMember" xlink:to="SecondSubscriptionRightsMember" xlink:title="presentation: FollowOnOfferingsMember to SecondSubscriptionRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalMember" xlink:to="FollowOnOfferingsMember" xlink:title="presentation: ClassesOfShareCapitalMember to FollowOnOfferingsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="presentation: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to ClassesOfShareCapitalAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:label="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:title="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:label="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:title="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to CommonSharesAuthorizedForIssuanceSalesInInOpenMarket" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="NumberOfSharesIssued" xlink:title="NumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="NumberOfSharesIssued" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to NumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleBorrowings" xlink:label="ConvertibleBorrowings" xlink:title="ConvertibleBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="ConvertibleBorrowings" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to ConvertibleBorrowings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:label="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:title="IncreaseDecreaseInNumberOfOrdinarySharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareIssuedPricePerShare" xlink:label="ShareIssuedPricePerShare" xlink:title="ShareIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="ShareIssuedPricePerShare" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to ShareIssuedPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to ProceedsFromIssueOfOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOfferings" xlink:label="NumberOfOfferings" xlink:title="NumberOfOfferings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="NumberOfOfferings" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to NumberOfOfferings" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ShareIssueRelatedCost" xlink:title="ShareIssueRelatedCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="ShareIssueRelatedCost" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to ShareIssueRelatedCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:label="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:to="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="presentation: ConvertibleNoteAgreementAndFollowOnOfferingsAbstract to ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" xlink:title="presentation: DisclosureOfClassesOfShareCapitalLineItems to ConvertibleNoteAgreementAndFollowOnOfferingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to DisclosureOfClassesOfShareCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInEquityAbstract" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="presentation: ChangesInEquityAbstract to DisclosureOfClassesOfShareCapitalTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquityAbstract" xlink:label="ChangesInEquityAbstract" xlink:title="ChangesInEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="DisclosureOfClassesOfShareCapitalTable" xlink:title="DisclosureOfClassesOfShareCapitalTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="DisclosureOfClassesOfShareCapitalLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementAbstract" xlink:label="ShelfRegistrationStatementAbstract" xlink:title="ShelfRegistrationStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShelfRegistrationStatementSharesAuthorized" xlink:label="ShelfRegistrationStatementSharesAuthorized" xlink:title="ShelfRegistrationStatementSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShelfRegistrationStatementAbstract" xlink:to="ShelfRegistrationStatementSharesAuthorized" xlink:title="presentation: ShelfRegistrationStatementAbstract to ShelfRegistrationStatementSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ProceedsFromIssueOfOrdinaryShares" xlink:title="ProceedsFromIssueOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShelfRegistrationStatementAbstract" xlink:to="ProceedsFromIssueOfOrdinaryShares" xlink:title="presentation: ShelfRegistrationStatementAbstract to ProceedsFromIssueOfOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:label="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:title="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShelfRegistrationStatementAbstract" xlink:to="NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" xlink:title="presentation: ShelfRegistrationStatementAbstract to NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:label="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:title="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShelfRegistrationStatementAbstract" xlink:to="PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" xlink:title="presentation: ShelfRegistrationStatementAbstract to PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ShelfRegistrationStatementAbstract" xlink:title="presentation: DisclosureOfClassesOfShareCapitalLineItems to ShelfRegistrationStatementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalTable" xlink:to="DisclosureOfClassesOfShareCapitalLineItems" xlink:title="presentation: DisclosureOfClassesOfShareCapitalTable to DisclosureOfClassesOfShareCapitalLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInEquityAbstract" xlink:to="DisclosureOfClassesOfShareCapitalTable" xlink:title="presentation: ChangesInEquityAbstract to DisclosureOfClassesOfShareCapitalTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" xlink:title="TradeAndOtherCurrentPayablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="TradeAndOtherCurrentPayables" xlink:title="TradeAndOtherCurrentPayables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="TradeAndOtherCurrentPayables" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CurrentAccruedResearchAndDevelopmentCosts" xlink:label="CurrentAccruedResearchAndDevelopmentCosts" xlink:title="CurrentAccruedResearchAndDevelopmentCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="CurrentAccruedResearchAndDevelopmentCosts" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to CurrentAccruedResearchAndDevelopmentCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="CurrentProvisionsForEmployeeBenefits" xlink:title="CurrentProvisionsForEmployeeBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="CurrentProvisionsForEmployeeBenefits" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to CurrentProvisionsForEmployeeBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="OtherCurrentLiabilities" xlink:title="OtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="OtherCurrentLiabilities" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to OtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="CurrentAccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to CurrentAccruedExpensesAndOtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ShorttermEmployeeBenefitsAccruals" xlink:title="ShorttermEmployeeBenefitsAccruals" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ShorttermEmployeeBenefitsAccruals" xlink:title="presentation: TradeAndOtherCurrentPayablesAbstract to ShorttermEmployeeBenefitsAccruals" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancingObligationDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancingObligationAbstract" xlink:label="FinancingObligationAbstract" xlink:title="FinancingObligationAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationTable" xlink:label="LongTermFinancingObligationTable" xlink:title="LongTermFinancingObligationTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsLuMindResearchDownSyndromeFoundationMember" xlink:label="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:title="GrantsLuMindResearchDownSyndromeFoundationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="GrantsLuMindResearchDownSyndromeFoundationMember" xlink:title="presentation: TypesOfContractsMember to GrantsLuMindResearchDownSyndromeFoundationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermFinancingObligationTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: LongTermFinancingObligationTable to TypesOfContractsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancingObligationLineItems" xlink:label="LongTermFinancingObligationLineItems" xlink:title="LongTermFinancingObligationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsAbstract" xlink:label="BorrowingsAbstract" xlink:title="BorrowingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FundingCommitment" xlink:label="FundingCommitment" xlink:title="FundingCommitment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="FundingCommitment" xlink:title="presentation: BorrowingsAbstract to FundingCommitment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ReimbursementPercentageOfFundingCommitment" xlink:label="ReimbursementPercentageOfFundingCommitment" xlink:title="ReimbursementPercentageOfFundingCommitment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="ReimbursementPercentageOfFundingCommitment" xlink:title="presentation: BorrowingsAbstract to ReimbursementPercentageOfFundingCommitment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="DebtInstrumentNumberOfInstallments" xlink:title="presentation: BorrowingsAbstract to DebtInstrumentNumberOfInstallments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfAdditionalInterestOnTotalRepayment" xlink:label="PercentageOfAdditionalInterestOnTotalRepayment" xlink:title="PercentageOfAdditionalInterestOnTotalRepayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsAbstract" xlink:to="PercentageOfAdditionalInterestOnTotalRepayment" xlink:title="presentation: BorrowingsAbstract to PercentageOfAdditionalInterestOnTotalRepayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermFinancingObligationLineItems" xlink:to="BorrowingsAbstract" xlink:title="presentation: LongTermFinancingObligationLineItems to BorrowingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermFinancingObligationTable" xlink:to="LongTermFinancingObligationLineItems" xlink:title="presentation: LongTermFinancingObligationTable to LongTermFinancingObligationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingObligationAbstract" xlink:to="LongTermFinancingObligationTable" xlink:title="presentation: FinancingObligationAbstract to LongTermFinancingObligationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2012GenentechMember" xlink:label="CollaborationAgreementOf2012GenentechMember" xlink:title="CollaborationAgreementOf2012GenentechMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2012GenentechMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2012GenentechMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:label="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2016BiogenMember" xlink:label="CollaborationAgreementOf2016BiogenMember" xlink:title="CollaborationAgreementOf2016BiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2016BiogenMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2016BiogenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherAgreementMember" xlink:label="OtherAgreementMember" xlink:title="OtherAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="OtherAgreementMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to OtherAgreementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractRevenueAbstract" xlink:label="ContractRevenueAbstract" xlink:title="ContractRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractRevenueAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: ContractRevenueAbstract to RevenueFromContractsWithCustomers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RevenueReclassifiedToOtherIncomeExpense" xlink:label="RevenueReclassifiedToOtherIncomeExpense" xlink:title="RevenueReclassifiedToOtherIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractRevenueAbstract" xlink:to="RevenueReclassifiedToOtherIncomeExpense" xlink:title="presentation: ContractRevenueAbstract to RevenueReclassifiedToOtherIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="PercentageOfEntitysRevenue" xlink:title="PercentageOfEntitysRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractRevenueAbstract" xlink:to="PercentageOfEntitysRevenue" xlink:title="presentation: ContractRevenueAbstract to PercentageOfEntitysRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ContractRevenueAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to ContractRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets" xlink:title="CurrentContractAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="CurrentContractAssets" xlink:title="presentation: RevenueAbstract to CurrentContractAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractAssetsAdditions" xlink:label="ContractAssetsAdditions" xlink:title="ContractAssetsAdditions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ContractAssetsAdditions" xlink:title="presentation: RevenueAbstract to ContractAssetsAdditions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractAssetsDeductions" xlink:label="ContractAssetsDeductions" xlink:title="ContractAssetsDeductions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ContractAssetsDeductions" xlink:title="presentation: RevenueAbstract to ContractAssetsDeductions" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractAssets" xlink:label="CurrentContractAssets_2" xlink:title="CurrentContractAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="CurrentContractAssets_2" xlink:title="presentation: RevenueAbstract to CurrentContractAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="CurrentContractLiabilities" xlink:title="presentation: RevenueAbstract to CurrentContractLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractLiabilitiesAddition" xlink:label="ContractLiabilitiesAddition" xlink:title="ContractLiabilitiesAddition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ContractLiabilitiesAddition" xlink:title="presentation: RevenueAbstract to ContractLiabilitiesAddition" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ContractLiabilitiesDeductions" xlink:label="ContractLiabilitiesDeductions" xlink:title="ContractLiabilitiesDeductions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="ContractLiabilitiesDeductions" xlink:title="presentation: RevenueAbstract to ContractLiabilitiesDeductions" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities_2" xlink:title="CurrentContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="CurrentContractLiabilities_2" xlink:title="presentation: RevenueAbstract to CurrentContractLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:title="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:title="presentation: RevenueAbstract to RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:title="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:title="presentation: RevenueAbstract to RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauMorphomerSmallMoleculeMember" xlink:label="TauMorphomerSmallMoleculeMember" xlink:title="TauMorphomerSmallMoleculeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="TauMorphomerSmallMoleculeMember" xlink:title="presentation: ProductsAndServicesMember to TauMorphomerSmallMoleculeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyMember" xlink:label="CollaborationAgreementWithLillyMember" xlink:title="CollaborationAgreementWithLillyMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillyFirstAmendmentMember" xlink:label="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:title="CollaborationAgreementWithLillyFirstAmendmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="CollaborationAgreementWithLillyFirstAmendmentMember" xlink:title="presentation: CollaborationAgreementWithLillyMember to CollaborationAgreementWithLillyFirstAmendmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementWithLillySecondAmendmentMember" xlink:label="CollaborationAgreementWithLillySecondAmendmentMember" xlink:title="CollaborationAgreementWithLillySecondAmendmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAgreementWithLillyMember" xlink:to="CollaborationAgreementWithLillySecondAmendmentMember" xlink:title="presentation: CollaborationAgreementWithLillyMember to CollaborationAgreementWithLillySecondAmendmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementWithLillyMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementWithLillyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="PerformanceObligationsAxis" xlink:title="PerformanceObligationsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="PerformanceObligationsMember" xlink:title="PerformanceObligationsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:label="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:title="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsMember" xlink:to="MilestonePaymentsClinicalAndRegulatoryMilestonesMember" xlink:title="presentation: PerformanceObligationsMember to MilestonePaymentsClinicalAndRegulatoryMilestonesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MilestonePaymentsCommercialMember" xlink:label="MilestonePaymentsCommercialMember" xlink:title="MilestonePaymentsCommercialMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsMember" xlink:to="MilestonePaymentsCommercialMember" xlink:title="presentation: PerformanceObligationsMember to MilestonePaymentsCommercialMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentMember" xlink:label="ResearchAndDevelopmentMember" xlink:title="ResearchAndDevelopmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsMember" xlink:to="ResearchAndDevelopmentMember" xlink:title="presentation: PerformanceObligationsMember to ResearchAndDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RightOfUseLicenseMember" xlink:label="RightOfUseLicenseMember" xlink:title="RightOfUseLicenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsMember" xlink:to="RightOfUseLicenseMember" xlink:title="presentation: PerformanceObligationsMember to RightOfUseLicenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PhaseTwoClinicalStudyLicensedProductMember" xlink:label="PhaseTwoClinicalStudyLicensedProductMember" xlink:title="PhaseTwoClinicalStudyLicensedProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsMember" xlink:to="PhaseTwoClinicalStudyLicensedProductMember" xlink:title="presentation: PerformanceObligationsMember to PhaseTwoClinicalStudyLicensedProductMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PerformanceObligationsAxis" xlink:to="PerformanceObligationsMember" xlink:title="presentation: PerformanceObligationsAxis to PerformanceObligationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="PerformanceObligationsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to PerformanceObligationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:label="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:title="CollaborativeAgreementMilestonePaymentNumberOfInstallments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentNumberOfInstallments" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentNumberOfInstallments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ReceivablesFromContractsWithCustomers" xlink:title="ReceivablesFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ReceivablesFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ReceivablesFromContractsWithCustomers" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ContractLiabilities" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ContractLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to TransactionPriceAllocatedToRemainingPerformanceObligations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:label="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:title="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="NumberOfRepresentativesInJointSteeringCommitteeByEachParty" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to NumberOfRepresentativesInJointSteeringCommitteeByEachParty" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ContractAssets" xlink:title="ContractAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ContractAssets" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ContractAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="CurrentContractLiabilities" xlink:title="CurrentContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CurrentContractLiabilities" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CurrentContractLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiAbetaAntibodyInADMember" xlink:label="AntiAbetaAntibodyInADMember" xlink:title="AntiAbetaAntibodyInADMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="AntiAbetaAntibodyInADMember" xlink:title="presentation: ProductsAndServicesMember to AntiAbetaAntibodyInADMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2006GenentechMember" xlink:label="CollaborationAgreementOf2006GenentechMember" xlink:title="CollaborationAgreementOf2006GenentechMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2006GenentechMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2006GenentechMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCumulativePaymentsReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ContractLiabilities" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ContractLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfMilestonePaymentsReceived" xlink:label="NumberOfMilestonePaymentsReceived" xlink:title="NumberOfMilestonePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="NumberOfMilestonePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to NumberOfMilestonePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to TransactionPriceAllocatedToRemainingPerformanceObligations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntiTauAntibodyInADMember" xlink:label="AntiTauAntibodyInADMember" xlink:title="AntiTauAntibodyInADMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="AntiTauAntibodyInADMember" xlink:title="presentation: ProductsAndServicesMember to AntiTauAntibodyInADMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2012GenentechMember" xlink:label="CollaborationAgreementOf2012GenentechMember" xlink:title="CollaborationAgreementOf2012GenentechMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2012GenentechMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2012GenentechMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCumulativePaymentsReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ContractLiabilities" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ContractLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfMilestonePaymentsReceived" xlink:label="NumberOfMilestonePaymentsReceived" xlink:title="NumberOfMilestonePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="NumberOfMilestonePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to NumberOfMilestonePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to TransactionPriceAllocatedToRemainingPerformanceObligations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauVaccineInADMember" xlink:label="TauVaccineInADMember" xlink:title="TauVaccineInADMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="TauVaccineInADMember" xlink:title="presentation: ProductsAndServicesMember to TauVaccineInADMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:label="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2014JanssenPharmaceuticalsMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2014JanssenPharmaceuticalsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCumulativePaymentsReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentReceived" xlink:label="CollaborativeAgreementMilestonePaymentReceived" xlink:title="CollaborativeAgreementMilestonePaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ContractLiabilities" xlink:title="ContractLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ContractLiabilities" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ContractLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to TransactionPriceAllocatedToRemainingPerformanceObligations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TauPETImagingAgentInADMember" xlink:label="TauPETImagingAgentInADMember" xlink:title="TauPETImagingAgentInADMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="TauPETImagingAgentInADMember" xlink:title="presentation: ProductsAndServicesMember to TauPETImagingAgentInADMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:label="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:label="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="CollaborativeAgreementNoticeOfContractTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementNoticeOfContractTerminationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementNoticeOfContractTerminationPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCumulativePaymentsReceived" xlink:label="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="CollaborativeAgreementCumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCumulativePaymentsReceived" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCumulativePaymentsReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementMilestonePaymentRecognized" xlink:label="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="CollaborativeAgreementMilestonePaymentRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementMilestonePaymentRecognized" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementMilestonePaymentRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:label="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:title="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AlphaSynucleinAndTDP43PETTracerInADMember" xlink:label="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:title="AlphaSynucleinAndTDP43PETTracerInADMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesMember" xlink:to="AlphaSynucleinAndTDP43PETTracerInADMember" xlink:title="presentation: ProductsAndServicesMember to AlphaSynucleinAndTDP43PETTracerInADMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="presentation: ProductsAndServicesAxis to ProductsAndServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ProductsAndServicesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to ProductsAndServicesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAndLicenseRevenueAgreementsMember" xlink:label="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="CollaborationAndLicenseRevenueAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborationAgreementOf2016BiogenMember" xlink:label="CollaborationAgreementOf2016BiogenMember" xlink:title="CollaborationAgreementOf2016BiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseRevenueAgreementsMember" xlink:to="CollaborationAgreementOf2016BiogenMember" xlink:title="presentation: CollaborationAndLicenseRevenueAgreementsMember to CollaborationAgreementOf2016BiogenMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="CollaborationAndLicenseRevenueAgreementsMember" xlink:title="presentation: TypesOfContractsMember to CollaborationAndLicenseRevenueAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPerformanceObligationsIdentified" xlink:label="NumberOfPerformanceObligationsIdentified" xlink:title="NumberOfPerformanceObligationsIdentified" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="NumberOfPerformanceObligationsIdentified" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to NumberOfPerformanceObligationsIdentified" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="RevenueAbstract" xlink:title="RevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="TypesOfContractsAxis" xlink:title="TypesOfContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="TypesOfContractsMember" xlink:title="TypesOfContractsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantRevenueMember" xlink:label="GrantRevenueMember" xlink:title="GrantRevenueMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GrantsMichaelJFoxFoundationMember" xlink:label="GrantsMichaelJFoxFoundationMember" xlink:title="GrantsMichaelJFoxFoundationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GrantRevenueMember" xlink:to="GrantsMichaelJFoxFoundationMember" xlink:title="presentation: GrantRevenueMember to GrantsMichaelJFoxFoundationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsMember" xlink:to="GrantRevenueMember" xlink:title="presentation: TypesOfContractsMember to GrantRevenueMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfContractsAxis" xlink:to="TypesOfContractsMember" xlink:title="presentation: TypesOfContractsAxis to TypesOfContractsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="TypesOfContractsAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to TypesOfContractsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="CounterpartiesAxis" xlink:title="CounterpartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="CounterpartiesMember" xlink:title="CounterpartiesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SkaneUniversityHospitalMember" xlink:label="SkaneUniversityHospitalMember" xlink:title="SkaneUniversityHospitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartiesMember" xlink:to="SkaneUniversityHospitalMember" xlink:title="presentation: CounterpartiesMember to SkaneUniversityHospitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartiesAxis" xlink:to="CounterpartiesMember" xlink:title="presentation: CounterpartiesAxis to CounterpartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="CounterpartiesAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to CounterpartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfGrants" xlink:label="NumberOfGrants" xlink:title="NumberOfGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="NumberOfGrants" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to NumberOfGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementPotentialValue" xlink:label="CollaborativeAgreementPotentialValue" xlink:title="CollaborativeAgreementPotentialValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementPotentialValue" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementPotentialValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ReceivablesFromContractsWithCustomers" xlink:title="ReceivablesFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ReceivablesFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to ReceivablesFromContractsWithCustomers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CollaborativeAgreementJointResearchCollaborationPeriod" xlink:label="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:title="CollaborativeAgreementJointResearchCollaborationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="CollaborativeAgreementJointResearchCollaborationPeriod" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to CollaborativeAgreementJointResearchCollaborationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="RevenueFromContractsWithCustomers" xlink:title="RevenueFromContractsWithCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="RevenueFromContractsWithCustomers" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract to RevenueFromContractsWithCustomers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:title="presentation: DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:title="presentation: RevenueAbstract to DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/ExpensesByCategoryDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExpensesByCategoryAbstract" xlink:label="ExpensesByCategoryAbstract" xlink:title="ExpensesByCategoryAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ConvertibleNoteAgreementMember" xlink:label="ConvertibleNoteAgreementMember" xlink:title="ConvertibleNoteAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsByNameMember" xlink:to="ConvertibleNoteAgreementMember" xlink:title="presentation: BorrowingsByNameMember to ConvertibleNoteAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="presentation: BorrowingsByNameAxis to BorrowingsByNameMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="BorrowingsByNameAxis" xlink:title="presentation: DisclosureOfDetailedInformationAboutBorrowingsTable to BorrowingsByNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:title="DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpensesAbstract" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:title="ResearchAndDevelopmentExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:label="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="ResearchAndDevelopmentExpenseAllocationOperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseAllocationOperatingExpense" xlink:title="presentation: ResearchAndDevelopmentExpensesAbstract to ResearchAndDevelopmentExpenseAllocationOperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:label="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" xlink:title="presentation: ResearchAndDevelopmentExpensesAbstract to ResearchAndDevelopmentExpenseAllocationWagesAndSalaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="presentation: ResearchAndDevelopmentExpensesAbstract to ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: ResearchAndDevelopmentExpensesAbstract to ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:label="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:title="EmployeeFullTimeEquivalentsInResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="EmployeeFullTimeEquivalentsInResearchAndDevelopment" xlink:title="presentation: ResearchAndDevelopmentExpensesAbstract to EmployeeFullTimeEquivalentsInResearchAndDevelopment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ResearchAndDevelopmentExpensesAbstract" xlink:title="presentation: DisclosureOfDetailedInformationAboutBorrowingsLineItems to ResearchAndDevelopmentExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="SellingGeneralAndAdministrativeExpenseAbstract" xlink:title="SellingGeneralAndAdministrativeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:label="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="GeneralAndAdministrativeExpenseAllocationOperatingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpenseAllocationOperatingExpense" xlink:title="presentation: SellingGeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeExpenseAllocationOperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:label="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" xlink:title="presentation: SellingGeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeExpenseAllocationWagesAndSalaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:label="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" xlink:title="presentation: SellingGeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: SellingGeneralAndAdministrativeExpenseAbstract to SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:label="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:title="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" xlink:title="presentation: SellingGeneralAndAdministrativeExpenseAbstract to EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="SellingGeneralAndAdministrativeExpenseAbstract" xlink:title="presentation: DisclosureOfDetailedInformationAboutBorrowingsLineItems to SellingGeneralAndAdministrativeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialResultNetAbstract" xlink:label="FinancialResultNetAbstract" xlink:title="FinancialResultNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="FinanceIncome" xlink:title="FinanceIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="FinanceIncome" xlink:title="presentation: FinancialResultNetAbstract to FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="FinanceCosts" xlink:title="FinanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="FinanceCosts" xlink:title="presentation: FinancialResultNetAbstract to FinanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:label="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="GainLossArisingFromChangeInFairValueOfConvertibleInstrument" xlink:title="presentation: FinancialResultNetAbstract to GainLossArisingFromChangeInFairValueOfConvertibleInstrument" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="presentation: FinancialResultNetAbstract to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="FinanceIncomeCost" xlink:title="FinanceIncomeCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="FinanceIncomeCost" xlink:title="presentation: FinancialResultNetAbstract to FinanceIncomeCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="InterestExpense" xlink:title="presentation: FinancialResultNetAbstract to InterestExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnDebtInstrumentsIssued" xlink:label="InterestExpenseOnDebtInstrumentsIssued" xlink:title="InterestExpenseOnDebtInstrumentsIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialResultNetAbstract" xlink:to="InterestExpenseOnDebtInstrumentsIssued" xlink:title="presentation: FinancialResultNetAbstract to InterestExpenseOnDebtInstrumentsIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="FinancialResultNetAbstract" xlink:title="presentation: DisclosureOfDetailedInformationAboutBorrowingsLineItems to FinancialResultNetAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:title="presentation: DisclosureOfDetailedInformationAboutBorrowingsTable to DisclosureOfDetailedInformationAboutBorrowingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesByCategoryAbstract" xlink:to="DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:title="presentation: ExpensesByCategoryAbstract to DisclosureOfDetailedInformationAboutBorrowingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RelatedpartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:title="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPersonsKeyManagementBoardOfDirectors" xlink:label="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:title="NumberOfPersonsKeyManagementBoardOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="NumberOfPersonsKeyManagementBoardOfDirectors" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to NumberOfPersonsKeyManagementBoardOfDirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfPersonsKeyManagementExecutiveManagement" xlink:label="NumberOfPersonsKeyManagementExecutiveManagement" xlink:title="NumberOfPersonsKeyManagementExecutiveManagement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="NumberOfPersonsKeyManagementExecutiveManagement" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to NumberOfPersonsKeyManagementExecutiveManagement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:title="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:title="KeyManagementPersonnelCompensationPostemploymentBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to KeyManagementPersonnelCompensationPostemploymentBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="KeyManagementPersonnelCompensationSharebasedPayment" xlink:title="KeyManagementPersonnelCompensationSharebasedPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="KeyManagementPersonnelCompensationSharebasedPayment" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to KeyManagementPersonnelCompensationSharebasedPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="KeyManagementPersonnelCompensation" xlink:title="KeyManagementPersonnelCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="KeyManagementPersonnelCompensation" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to KeyManagementPersonnelCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:label="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:title="NumberOfCommonSharesSoldRelatedPartyTransactions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="NumberOfCommonSharesSoldRelatedPartyTransactions" xlink:title="presentation: DisclosureOfTransactionsBetweenRelatedPartiesAbstract to NumberOfCommonSharesSoldRelatedPartyTransactions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="IncomeTaxExpenseContinuingOperations" xlink:title="IncomeTaxExpenseContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="IncomeTaxExpenseContinuingOperations" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to IncomeTaxExpenseContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="DeferredTaxAssets" xlink:title="DeferredTaxAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DeferredTaxAssets" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DeferredTaxAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" xlink:title="DeferredTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DeferredTaxLiabilities" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DeferredTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:title="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ProfitLossBeforeTax" xlink:title="ProfitLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ProfitLossBeforeTax" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="TaxExpenseIncomeAtApplicableTaxRate" xlink:title="TaxExpenseIncomeAtApplicableTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="TaxExpenseIncomeAtApplicableTaxRate" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to TaxExpenseIncomeAtApplicableTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:title="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:label="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:title="TaxEffectOfRevenuesExemptFromTaxation2011" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="TaxEffectOfRevenuesExemptFromTaxation2011" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to TaxEffectOfRevenuesExemptFromTaxation2011" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="TaxEffectOfTaxLosses" xlink:title="TaxEffectOfTaxLosses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="TaxEffectOfTaxLosses" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to TaxEffectOfTaxLosses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="IncomeTaxExpenseContinuingOperations" xlink:title="presentation: ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract to IncomeTaxExpenseContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ApplicableTaxRate" xlink:title="ApplicableTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ApplicableTaxRate" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to ApplicableTaxRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:title="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="UnusedTaxLossesMember" xlink:title="UnusedTaxLossesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxLossesMember" xlink:title="presentation: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxLossesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:label="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:title="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" xlink:title="presentation: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_UnusedTaxCreditsRetirementBenefitPlanMember" xlink:label="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:title="UnusedTaxCreditsRetirementBenefitPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="UnusedTaxCreditsRetirementBenefitPlanMember" xlink:title="presentation: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember to UnusedTaxCreditsRetirementBenefitPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="presentation: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NotLaterThanPriorYearEndMember" xlink:label="NotLaterThanPriorYearEndMember" xlink:title="NotLaterThanPriorYearEndMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanPriorYearEndMember" xlink:title="presentation: AggregatedTimeBandsMember to NotLaterThanPriorYearEndMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="presentation: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanTwoYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFourYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanThreeYearsAndNotLaterThanFourYearsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanFourYearsAndNotLaterThanFiveYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanFourYearsAndNotLaterThanFiveYearsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:title="LaterThanFiveYearsAndNotLaterThanSixYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanFiveYearsAndNotLaterThanSixYearsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanSevenYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanSixYearsAndNotLaterThanSevenYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanSixYearsAndNotLaterThanSevenYearsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:label="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:title="LaterThanSixYearsAndNotLaterThanEightYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanSixYearsAndNotLaterThanEightYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanSixYearsAndNotLaterThanEightYearsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="presentation: MaturityAxis to AggregatedTimeBandsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="MaturityAxis" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to MaturityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:title="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="DeferredTaxAssets" xlink:title="DeferredTaxAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="DeferredTaxAssets" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract to DeferredTaxAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="DeferredTaxLiabilityAsset" xlink:title="DeferredTaxLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="DeferredTaxLiabilityAsset" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract to DeferredTaxLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TaxLossesSplitByExpiryDateAbstract" xlink:label="TaxLossesSplitByExpiryDateAbstract" xlink:title="TaxLossesSplitByExpiryDateAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:title="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxLossesSplitByExpiryDateAbstract" xlink:to="UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:title="presentation: TaxLossesSplitByExpiryDateAbstract to UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:title="IncreaseDecreaseInDeferredTaxLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxLossesSplitByExpiryDateAbstract" xlink:to="IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:title="presentation: TaxLossesSplitByExpiryDateAbstract to IncreaseDecreaseInDeferredTaxLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="TaxLossesSplitByExpiryDateAbstract" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems to TaxLossesSplitByExpiryDateAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:title="presentation: DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:title="presentation: MajorComponentsOfTaxExpenseIncomeAbstract to DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployeeMember" xlink:label="DefinedBenefitsPlanEmployeeMember" xlink:title="DefinedBenefitsPlanEmployeeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="DefinedBenefitsPlanEmployeeMember" xlink:title="presentation: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to DefinedBenefitsPlanEmployeeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitsPlanEmployerMember" xlink:label="DefinedBenefitsPlanEmployerMember" xlink:title="DefinedBenefitsPlanEmployerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:to="DefinedBenefitsPlanEmployerMember" xlink:title="presentation: DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember to DefinedBenefitsPlanEmployerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="PresentValueOfDefinedBenefitObligationMember" xlink:title="PresentValueOfDefinedBenefitObligationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PresentValueOfDefinedBenefitObligationMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetMember to PresentValueOfDefinedBenefitObligationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DefinedBenefitPlanPercentageOfContribution" xlink:label="DefinedBenefitPlanPercentageOfContribution" xlink:title="DefinedBenefitPlanPercentageOfContribution" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="DefinedBenefitPlanPercentageOfContribution" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to DefinedBenefitPlanPercentageOfContribution" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:label="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:title="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlanAbstract" xlink:label="SurplusDeficitInPlanAbstract" xlink:title="SurplusDeficitInPlanAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="DefinedBenefitObligationAtPresentValue" xlink:title="DefinedBenefitObligationAtPresentValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SurplusDeficitInPlanAbstract" xlink:to="DefinedBenefitObligationAtPresentValue" xlink:title="presentation: SurplusDeficitInPlanAbstract to DefinedBenefitObligationAtPresentValue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SurplusDeficitInPlanAbstract" xlink:to="PlanAssetsAtFairValue" xlink:title="presentation: SurplusDeficitInPlanAbstract to PlanAssetsAtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="SurplusDeficitInPlan" xlink:title="SurplusDeficitInPlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SurplusDeficitInPlanAbstract" xlink:to="SurplusDeficitInPlan" xlink:title="presentation: SurplusDeficitInPlanAbstract to SurplusDeficitInPlan" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="SurplusDeficitInPlanAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to SurplusDeficitInPlanAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NetPensionCostInStatementOfIncomeAbstract" xlink:label="NetPensionCostInStatementOfIncomeAbstract" xlink:title="NetPensionCostInStatementOfIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="presentation: NetPensionCostInStatementOfIncomeAbstract to CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="presentation: NetPensionCostInStatementOfIncomeAbstract to InterestCostNetDefinedBenefitLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="presentation: NetPensionCostInStatementOfIncomeAbstract to InterestIncomeNetDefinedBenefitLiabilityAsset" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:label="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetPensionCostInStatementOfIncomeAbstract" xlink:to="IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" xlink:title="presentation: NetPensionCostInStatementOfIncomeAbstract to IncreaseDecreaseInNetDefinedBenefitLiabilityAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="NetPensionCostInStatementOfIncomeAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to NetPensionCostInStatementOfIncomeAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:label="PresentValueOfDefinedBenefitObligationMember" xlink:title="PresentValueOfDefinedBenefitObligationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PresentValueOfDefinedBenefitObligationMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetMember to PresentValueOfDefinedBenefitObligationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:label="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="ChangesInNetDefinedBenefitLiabilityAssetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to LiabilityAssetOfDefinedBenefitPlans" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="CurrentServiceCostNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to CurrentServiceCostNetDefinedBenefitLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestCostNetDefinedBenefitLiabilityAsset" xlink:label="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="InterestCostNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="InterestCostNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to InterestCostNetDefinedBenefitLiabilityAsset" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to PaymentsFromPlanNetDefinedBenefitLiabilityAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans_2" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="LiabilityAssetOfDefinedBenefitPlans_2" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to LiabilityAssetOfDefinedBenefitPlans" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInNetDefinedBenefitLiabilityAssetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsMember" xlink:label="PlanAssetsMember" xlink:title="PlanAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="PlanAssetsMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetMember to PlanAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="presentation: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="presentation: MaturityAxis to AggregatedTimeBandsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="MaturityAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to MaturityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangesInFairValueOfPlanAssetsAbstract" xlink:label="ChangesInFairValueOfPlanAssetsAbstract" xlink:title="ChangesInFairValueOfPlanAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue" xlink:title="PlanAssetsAtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="PlanAssetsAtFairValue" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to PlanAssetsAtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:label="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="InterestIncomeNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="InterestIncomeNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to InterestIncomeNetDefinedBenefitLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to PaymentsFromPlanNetDefinedBenefitLiabilityAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="PlanAssetsAtFairValue_2" xlink:title="PlanAssetsAtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="PlanAssetsAtFairValue_2" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to PlanAssetsAtFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:title="PostemploymentBenefitExpenseDefinedContributionPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInFairValueOfPlanAssetsAbstract" xlink:to="PostemploymentBenefitExpenseDefinedContributionPlans" xlink:title="presentation: ChangesInFairValueOfPlanAssetsAbstract to PostemploymentBenefitExpenseDefinedContributionPlans" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInFairValueOfPlanAssetsAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInFairValueOfPlanAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:label="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="ChangesInNetDefinedBenefitLiabilityAssetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to LiabilityAssetOfDefinedBenefitPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:title="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:title="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans_2" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:to="LiabilityAssetOfDefinedBenefitPlans_2" xlink:title="presentation: ChangesInNetDefinedBenefitLiabilityAssetAbstract to LiabilityAssetOfDefinedBenefitPlans" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangesInNetDefinedBenefitLiabilityAssetAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangesInNetDefinedBenefitLiabilityAssetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:label="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:title="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetMember" xlink:to="ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetMember to ChangeInOtherComprehensiveLossDefinedBenefitPlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="presentation: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="NetDefinedBenefitLiabilityAssetAxis" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to NetDefinedBenefitLiabilityAssetAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ChangeInOtherComprehensiveLossAbstract" xlink:label="ChangeInOtherComprehensiveLossAbstract" xlink:title="ChangeInOtherComprehensiveLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:label="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:title="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" xlink:label="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_2" xlink:title="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss_2" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:label="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:title="WeightedAverageDurationOfDefinedBenefitObligation2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOtherComprehensiveLossAbstract" xlink:to="WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:title="presentation: ChangeInOtherComprehensiveLossAbstract to WeightedAverageDurationOfDefinedBenefitObligation2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="ChangeInOtherComprehensiveLossAbstract" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetLineItems to ChangeInOtherComprehensiveLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:title="presentation: DisclosureOfNetDefinedBenefitLiabilityAssetTable to DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfNetDefinedBenefitLiabilityAssetTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="DisclosureOfDefinedBenefitPlansAbstract" xlink:title="DisclosureOfDefinedBenefitPlansAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="DefinedBenefitPlansAxis" xlink:title="DefinedBenefitPlansAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="DefinedBenefitPlansMember" xlink:title="DefinedBenefitPlansMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:label="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansMember" xlink:to="DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" xlink:title="presentation: DefinedBenefitPlansMember to DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlansAxis" xlink:to="DefinedBenefitPlansMember" xlink:title="presentation: DefinedBenefitPlansAxis to DefinedBenefitPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="DefinedBenefitPlansAxis" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to DefinedBenefitPlansAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="ActuarialAssumptionsAxis" xlink:title="ActuarialAssumptionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="ActuarialAssumptionsMember" xlink:title="ActuarialAssumptionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="ActuarialAssumptionOfDiscountRatesMember" xlink:title="ActuarialAssumptionOfDiscountRatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfDiscountRatesMember" xlink:title="presentation: ActuarialAssumptionsMember to ActuarialAssumptionOfDiscountRatesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:title="presentation: ActuarialAssumptionsMember to ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActuarialAssumptionsMember" xlink:to="ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:title="presentation: ActuarialAssumptionsMember to ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptionsMember" xlink:label="OtherMaterialActuarialAssumptionsMember" xlink:title="OtherMaterialActuarialAssumptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActuarialAssumptionsMember" xlink:to="OtherMaterialActuarialAssumptionsMember" xlink:title="presentation: ActuarialAssumptionsMember to OtherMaterialActuarialAssumptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActuarialAssumptionsAxis" xlink:to="ActuarialAssumptionsMember" xlink:title="presentation: ActuarialAssumptionsAxis to ActuarialAssumptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="ActuarialAssumptionsAxis" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to ActuarialAssumptionsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" xlink:title="presentation: TypesOfRisksMember to PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" xlink:title="presentation: TypesOfRisksMember to PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="presentation: TypesOfRisksAxis to TypesOfRisksMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="TypesOfRisksAxis" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to TypesOfRisksAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:label="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:title="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="ActuarialAssumptionOfDiscountRates" xlink:title="ActuarialAssumptionOfDiscountRates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ActuarialAssumptionOfDiscountRates" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to ActuarialAssumptionOfDiscountRates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:title="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to ActuarialAssumptionOfExpectedRatesOfPensionIncreases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherMaterialActuarialAssumptions" xlink:label="OtherMaterialActuarialAssumptions" xlink:title="OtherMaterialActuarialAssumptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="OtherMaterialActuarialAssumptions" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to OtherMaterialActuarialAssumptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IssuedActuarialTablesSwitzerland" xlink:label="IssuedActuarialTablesSwitzerland" xlink:title="IssuedActuarialTablesSwitzerland" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:to="IssuedActuarialTablesSwitzerland" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract to IssuedActuarialTablesSwitzerland" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SensitivityAnalysisActuarialAssumptionsAbstract" xlink:label="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:title="SensitivityAnalysisActuarialAssumptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="presentation: SensitivityAnalysisActuarialAssumptionsAbstract to PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="presentation: SensitivityAnalysisActuarialAssumptionsAbstract to PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="LiabilityAssetOfDefinedBenefitPlans" xlink:title="LiabilityAssetOfDefinedBenefitPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="LiabilityAssetOfDefinedBenefitPlans" xlink:title="presentation: SensitivityAnalysisActuarialAssumptionsAbstract to LiabilityAssetOfDefinedBenefitPlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:title="presentation: SensitivityAnalysisActuarialAssumptionsAbstract to IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:to="IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:title="presentation: SensitivityAnalysisActuarialAssumptionsAbstract to IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="SensitivityAnalysisActuarialAssumptionsAbstract" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems to SensitivityAnalysisActuarialAssumptionsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:title="presentation: DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable to DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDefinedBenefitPlansAbstract" xlink:to="DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:title="presentation: DisclosureOfDefinedBenefitPlansAbstract to DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfEquityBasedInstrumentPlans" xlink:label="NumberOfEquityBasedInstrumentPlans" xlink:title="NumberOfEquityBasedInstrumentPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfEquityBasedInstrumentPlans" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to NumberOfEquityBasedInstrumentPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanAMember" xlink:label="StockOptionPlanAMember" xlink:title="StockOptionPlanAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanAMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to StockOptionPlanAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanBMember" xlink:label="StockOptionPlanBMember" xlink:title="StockOptionPlanBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanBMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to StockOptionPlanBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_StockOptionPlanC1Member" xlink:label="StockOptionPlanC1Member" xlink:title="StockOptionPlanC1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="StockOptionPlanC1Member" xlink:title="presentation: SharebasedPaymentArrangementsMember to StockOptionPlanC1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanMember" xlink:label="Two016ShareOptionAndIncentivePlanMember" xlink:title="Two016ShareOptionAndIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" xlink:title="presentation: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" xlink:title="presentation: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:label="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:title="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Two016ShareOptionAndIncentivePlanMember" xlink:to="Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" xlink:title="presentation: Two016ShareOptionAndIncentivePlanMember to Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="Two016ShareOptionAndIncentivePlanMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to Two016ShareOptionAndIncentivePlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="presentation: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to TypesOfSharebasedPaymentArrangementsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="KeyManagementPersonnelOfEntityOrParentMember" xlink:title="KeyManagementPersonnelOfEntityOrParentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="KeyManagementPersonnelOfEntityOrParentMember" xlink:title="presentation: EntitysTotalForRelatedPartiesMember to KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="EmployeesMember" xlink:title="presentation: EntitysTotalForRelatedPartiesMember to EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="presentation: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPlansOutstandingAbstract" xlink:label="ShareBasedPlansOutstandingAbstract" xlink:title="ShareBasedPlansOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPlansOutstandingAbstract" xlink:to="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="presentation: ShareBasedPlansOutstandingAbstract to NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:label="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPlansOutstandingAbstract" xlink:to="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="presentation: ShareBasedPlansOutstandingAbstract to VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPlansOutstandingAbstract" xlink:to="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:title="presentation: ShareBasedPlansOutstandingAbstract to MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ShareBasedPlansOutstandingAbstract" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to ShareBasedPlansOutstandingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOptionsAbstract" xlink:label="NumberOfOptionsAbstract" xlink:title="NumberOfOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="NumberOfOutstandingShareOptions" xlink:title="NumberOfOutstandingShareOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfOutstandingShareOptions" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="NumberOfOutstandingShareOptions_2" xlink:title="NumberOfOutstandingShareOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfOutstandingShareOptions_2" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfOutstandingShareOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:title="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfOptionsAbstract" xlink:to="NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfOptionsAbstract to NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="NumberOfOptionsAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to NumberOfOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceAbstract" xlink:label="WeightedAverageExercisePriceAbstract" xlink:title="WeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" xlink:title="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageExercisePriceAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageRemainingAbstract" xlink:label="WeightedAverageRemainingAbstract" xlink:title="WeightedAverageRemainingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:title="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingAbstract" xlink:to="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:title="presentation: WeightedAverageRemainingAbstract to WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:label="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:title="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingAbstract" xlink:to="WeightedAverageRemainingContractualLifeOfExercisableShareOptions" xlink:title="presentation: WeightedAverageRemainingAbstract to WeightedAverageRemainingContractualLifeOfExercisableShareOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageRemainingAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageRemainingAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:title="RangesOfExercisePricesForOutstandingShareOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesOneMember" xlink:label="RangeOfExercisePricesOneMember" xlink:title="RangeOfExercisePricesOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesOneMember" xlink:title="presentation: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesTwoMember" xlink:label="RangeOfExercisePricesTwoMember" xlink:title="RangeOfExercisePricesTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesTwoMember" xlink:title="presentation: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RangeOfExercisePricesThreeMember" xlink:label="RangeOfExercisePricesThreeMember" xlink:title="RangeOfExercisePricesThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="RangeOfExercisePricesThreeMember" xlink:title="presentation: RangesOfExercisePricesForOutstandingShareOptionsMember to RangeOfExercisePricesThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:title="presentation: RangesOfExercisePricesForOutstandingShareOptionsAxis to RangesOfExercisePricesForOutstandingShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to RangesOfExercisePricesForOutstandingShareOptionsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:label="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:title="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="NumberOfOutstandingShareOptions" xlink:title="NumberOfOutstandingShareOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="NumberOfOutstandingShareOptions" xlink:title="presentation: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareOptionsDateOfExpiry" xlink:label="ShareOptionsDateOfExpiry" xlink:title="ShareOptionsDateOfExpiry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="ShareOptionsDateOfExpiry" xlink:title="presentation: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to ShareOptionsDateOfExpiry" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:title="presentation: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:title="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:to="WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:title="presentation: OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract to WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems to OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FormerChiefExecutiveFinancialOfficerMember" xlink:label="FormerChiefExecutiveFinancialOfficerMember" xlink:title="FormerChiefExecutiveFinancialOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="FormerChiefExecutiveFinancialOfficerMember" xlink:title="presentation: EntitysTotalForRelatedPartiesMember to FormerChiefExecutiveFinancialOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="presentation: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="presentation: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to CategoriesOfRelatedPartiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:title="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="WeightedAverageSharePriceShareOptionsGranted2019" xlink:title="WeightedAverageSharePriceShareOptionsGranted2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageSharePriceShareOptionsGranted2019" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageSharePriceShareOptionsGranted2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:title="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageAssumptionsAbstract" xlink:label="WeightedAverageAssumptionsAbstract" xlink:title="WeightedAverageAssumptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ExercisePriceShareOptionsGranted2019" xlink:title="ExercisePriceShareOptionsGranted2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="ExercisePriceShareOptionsGranted2019" xlink:title="presentation: WeightedAverageAssumptionsAbstract to ExercisePriceShareOptionsGranted2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="WeightedAverageSharePrice2019" xlink:title="WeightedAverageSharePrice2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="WeightedAverageSharePrice2019" xlink:title="presentation: WeightedAverageAssumptionsAbstract to WeightedAverageSharePrice2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:title="DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:title="presentation: WeightedAverageAssumptionsAbstract to DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:title="DescriptionOfExpectedVolatilityShareOptionsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:title="presentation: WeightedAverageAssumptionsAbstract to DescriptionOfExpectedVolatilityShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="DescriptionOfOptionLifeShareOptionsGranted" xlink:title="DescriptionOfOptionLifeShareOptionsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="DescriptionOfOptionLifeShareOptionsGranted" xlink:title="presentation: WeightedAverageAssumptionsAbstract to DescriptionOfOptionLifeShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ExpectedDividendAsPercentageShareOptionsGranted" xlink:title="ExpectedDividendAsPercentageShareOptionsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsAbstract" xlink:to="ExpectedDividendAsPercentageShareOptionsGranted" xlink:title="presentation: WeightedAverageAssumptionsAbstract to ExpectedDividendAsPercentageShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="WeightedAverageAssumptionsAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to WeightedAverageAssumptionsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPaymentArrangementAbstract" xlink:label="ShareBasedPaymentArrangementAbstract" xlink:title="ShareBasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:title="ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:title="presentation: ShareBasedPaymentArrangementAbstract to ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ShareBasedPaymentArrangementAbstract" xlink:title="presentation: DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract to ShareBasedPaymentArrangementAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:title="presentation: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems to DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:title="presentation: DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable to DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesAndRestrictedShareUnitsMember" xlink:label="RestrictedSharesAndRestrictedShareUnitsMember" xlink:title="RestrictedSharesAndRestrictedShareUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedSharesAndRestrictedShareUnitsMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to RestrictedSharesAndRestrictedShareUnitsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedSharesMember" xlink:label="RestrictedSharesMember" xlink:title="RestrictedSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedSharesMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to RestrictedSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RestrictedStockUnitsMember" xlink:label="RestrictedStockUnitsMember" xlink:title="RestrictedStockUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedPaymentArrangementsMember" xlink:to="RestrictedStockUnitsMember" xlink:title="presentation: SharebasedPaymentArrangementsMember to RestrictedStockUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="presentation: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to TypesOfSharebasedPaymentArrangementsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BoardOfDirectorsMember" xlink:label="BoardOfDirectorsMember" xlink:title="BoardOfDirectorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="BoardOfDirectorsMember" xlink:title="presentation: EntitysTotalForRelatedPartiesMember to BoardOfDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ExecutiveManagementMember" xlink:label="ExecutiveManagementMember" xlink:title="ExecutiveManagementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntitysTotalForRelatedPartiesMember" xlink:to="ExecutiveManagementMember" xlink:title="presentation: EntitysTotalForRelatedPartiesMember to ExecutiveManagementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="presentation: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="CategoriesOfRelatedPartiesAxis" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShareBasedPaymentArrangementAbstract" xlink:label="ShareBasedPaymentArrangementAbstract" xlink:title="ShareBasedPaymentArrangementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="presentation: ShareBasedPaymentArrangementAbstract to NumberOfInstrumentsOtherEquityInstrumentsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:label="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" xlink:title="presentation: ShareBasedPaymentArrangementAbstract to VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:label="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:title="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementAbstract" xlink:to="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:title="presentation: ShareBasedPaymentArrangementAbstract to MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ShareBasedPaymentArrangementAbstract" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to ShareBasedPaymentArrangementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfNonVestedSharesAbstract" xlink:label="NumberOfNonVestedSharesAbstract" xlink:title="NumberOfNonVestedSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfInstrumentsOtherEquityInstrumentsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" xlink:title="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:title="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfNonVestedSharesAbstract" xlink:to="NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:title="presentation: NumberOfNonVestedSharesAbstract to NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfNonVestedSharesAbstract" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to NumberOfNonVestedSharesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceAbstract" xlink:label="WeightedAverageExercisePriceAbstract" xlink:title="WeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:title="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageExercisePriceAbstract" xlink:to="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:title="presentation: WeightedAverageExercisePriceAbstract to WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="WeightedAverageExercisePriceAbstract" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems to WeightedAverageExercisePriceAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:title="presentation: DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract to DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAndContingenciesAbstract" xlink:label="CommitmentsAndContingenciesAbstract" xlink:title="CommitmentsAndContingenciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="NotLaterThanOneYearMember" xlink:title="NotLaterThanOneYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="NotLaterThanOneYearMember" xlink:title="presentation: AggregatedTimeBandsMember to NotLaterThanOneYearMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:title="LaterThanOneYearAndNotLaterThanThreeYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanOneYearAndNotLaterThanThreeYearsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:title="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanThreeYearsAndNotLaterThanFiveYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="LaterThanFiveYearsMember" xlink:title="LaterThanFiveYearsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregatedTimeBandsMember" xlink:to="LaterThanFiveYearsMember" xlink:title="presentation: AggregatedTimeBandsMember to LaterThanFiveYearsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="presentation: MaturityAxis to AggregatedTimeBandsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:to="MaturityAxis" xlink:title="presentation: DisclosureOfInformationAboutCommitmentsAndContingenciesTable to MaturityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:label="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:title="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CommitmentsAbstract" xlink:label="CommitmentsAbstract" xlink:title="CommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProvisionsResearchContracts" xlink:label="ProvisionsResearchContracts" xlink:title="ProvisionsResearchContracts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAbstract" xlink:to="ProvisionsResearchContracts" xlink:title="presentation: CommitmentsAbstract to ProvisionsResearchContracts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_RentalContractPeriodForNoticeOfCancellation" xlink:label="RentalContractPeriodForNoticeOfCancellation" xlink:title="RentalContractPeriodForNoticeOfCancellation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAbstract" xlink:to="RentalContractPeriodForNoticeOfCancellation" xlink:title="presentation: CommitmentsAbstract to RentalContractPeriodForNoticeOfCancellation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Provisions" xlink:label="Provisions" xlink:title="Provisions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAbstract" xlink:to="Provisions" xlink:title="presentation: CommitmentsAbstract to Provisions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:to="CommitmentsAbstract" xlink:title="presentation: DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems to CommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:to="DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" xlink:title="presentation: DisclosureOfInformationAboutCommitmentsAndContingenciesTable to DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesAbstract" xlink:to="DisclosureOfInformationAboutCommitmentsAndContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesAbstract to DisclosureOfInformationAboutCommitmentsAndContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="BasicEarningsPerShareAbstract" xlink:title="BasicEarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:label="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:title="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:to="ProfitLoss" xlink:title="presentation: ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicEarningsPerShareAbstract" xlink:to="ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:title="presentation: BasicEarningsPerShareAbstract to ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="BasicEarningsPerShareAbstract" xlink:title="presentation: EarningsPerShareAbstract to BasicEarningsPerShareAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="DilutedEarningsPerShareAbstract" xlink:title="DilutedEarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:title="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="WeightedAverageShares" xlink:title="WeightedAverageShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="WeightedAverageShares" xlink:title="presentation: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="BasicEarningsLossPerShare" xlink:title="BasicEarningsLossPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="BasicEarningsLossPerShare" xlink:title="presentation: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to BasicEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:title="presentation: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="AdjustedWeightedAverageShares" xlink:title="AdjustedWeightedAverageShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="AdjustedWeightedAverageShares" xlink:title="presentation: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to AdjustedWeightedAverageShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="DilutedEarningsLossPerShare" xlink:title="DilutedEarningsLossPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="DilutedEarningsLossPerShare" xlink:title="presentation: WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract to DilutedEarningsLossPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DilutedEarningsPerShareAbstract" xlink:to="WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:title="presentation: DilutedEarningsPerShareAbstract to WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="DilutedEarningsPerShareAbstract" xlink:title="presentation: EarningsPerShareAbstract to DilutedEarningsPerShareAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AntidilutiveSecuritiesAbstract" xlink:label="AntidilutiveSecuritiesAbstract" xlink:title="AntidilutiveSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:label="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:title="DilutiveEffectOfShareOptionsIssuedAndOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesAbstract" xlink:to="DilutiveEffectOfShareOptionsIssuedAndOutstanding" xlink:title="presentation: AntidilutiveSecuritiesAbstract to DilutiveEffectOfShareOptionsIssuedAndOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:label="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:title="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesAbstract" xlink:to="DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" xlink:title="presentation: AntidilutiveSecuritiesAbstract to DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesAbstract" xlink:to="DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="presentation: AntidilutiveSecuritiesAbstract to DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesAbstract" xlink:to="DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:title="presentation: AntidilutiveSecuritiesAbstract to DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="AntidilutiveSecuritiesAbstract" xlink:title="presentation: EarningsPerShareAbstract to AntidilutiveSecuritiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="CategoriesOfFinancialAssetsAxis" xlink:title="CategoriesOfFinancialAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="FinancialAssetsCategoryMember" xlink:title="FinancialAssetsCategoryMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LongTermFinancialAssetsMember" xlink:label="LongTermFinancialAssetsMember" xlink:title="LongTermFinancialAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsCategoryMember" xlink:to="LongTermFinancialAssetsMember" xlink:title="presentation: FinancialAssetsCategoryMember to LongTermFinancialAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_OtherReceivablesMember" xlink:label="OtherReceivablesMember" xlink:title="OtherReceivablesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsCategoryMember" xlink:to="OtherReceivablesMember" xlink:title="presentation: FinancialAssetsCategoryMember to OtherReceivablesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermFinancialAssetsMember" xlink:label="ShortTermFinancialAssetsMember" xlink:title="ShortTermFinancialAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsCategoryMember" xlink:to="ShortTermFinancialAssetsMember" xlink:title="presentation: FinancialAssetsCategoryMember to ShortTermFinancialAssetsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_CashOnHandAndCashEquivalentsMember" xlink:label="CashOnHandAndCashEquivalentsMember" xlink:title="CashOnHandAndCashEquivalentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsCategoryMember" xlink:to="CashOnHandAndCashEquivalentsMember" xlink:title="presentation: FinancialAssetsCategoryMember to CashOnHandAndCashEquivalentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CategoriesOfFinancialAssetsAxis" xlink:to="FinancialAssetsCategoryMember" xlink:title="presentation: CategoriesOfFinancialAssetsAxis to FinancialAssetsCategoryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="CategoriesOfFinancialAssetsAxis" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to CategoriesOfFinancialAssetsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="CategoriesOfFinancialLiabilitiesAxis" xlink:title="CategoriesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="FinancialLiabilitiesCategoryMember" xlink:title="FinancialLiabilitiesCategoryMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="LeaseLiabilitiesMember" xlink:title="LeaseLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="LeaseLiabilitiesMember" xlink:title="presentation: FinancialLiabilitiesCategoryMember to LeaseLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_TradeAndOtherPayablesMember" xlink:label="TradeAndOtherPayablesMember" xlink:title="TradeAndOtherPayablesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="TradeAndOtherPayablesMember" xlink:title="presentation: FinancialLiabilitiesCategoryMember to TradeAndOtherPayablesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AccruedExpensesMember" xlink:label="AccruedExpensesMember" xlink:title="AccruedExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="AccruedExpensesMember" xlink:title="presentation: FinancialLiabilitiesCategoryMember to AccruedExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ShorttermBorrowingsMember" xlink:title="ShorttermBorrowingsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="ShorttermBorrowingsMember" xlink:title="presentation: FinancialLiabilitiesCategoryMember to ShorttermBorrowingsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ShortTermLeaseLiabilitiesMember" xlink:label="ShortTermLeaseLiabilitiesMember" xlink:title="ShortTermLeaseLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesCategoryMember" xlink:to="ShortTermLeaseLiabilitiesMember" xlink:title="presentation: FinancialLiabilitiesCategoryMember to ShortTermLeaseLiabilitiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilitiesCategoryMember" xlink:title="presentation: CategoriesOfFinancialLiabilitiesAxis to FinancialLiabilitiesCategoryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="CategoriesOfFinancialLiabilitiesAxis" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to CategoriesOfFinancialLiabilitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="CurrencyRiskMember" xlink:title="CurrencyRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="CurrencyRiskMember" xlink:title="presentation: TypesOfRisksMember to CurrencyRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="CreditRiskMember" xlink:title="CreditRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="CreditRiskMember" xlink:title="presentation: TypesOfRisksMember to CreditRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiquidityRiskMember" xlink:label="LiquidityRiskMember" xlink:title="LiquidityRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="LiquidityRiskMember" xlink:title="presentation: TypesOfRisksMember to LiquidityRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestRateRiskMember" xlink:label="InterestRateRiskMember" xlink:title="InterestRateRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksMember" xlink:to="InterestRateRiskMember" xlink:title="presentation: TypesOfRisksMember to InterestRateRiskMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="presentation: TypesOfRisksAxis to TypesOfRisksMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="TypesOfRisksAxis" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to TypesOfRisksAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="BottomOfRangeMember" xlink:title="BottomOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="BottomOfRangeMember" xlink:title="presentation: RangesMember to BottomOfRangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="TopOfRangeMember" xlink:title="TopOfRangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesMember" xlink:to="TopOfRangeMember" xlink:title="presentation: RangesMember to TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="presentation: RangeAxis to RangesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="RangeAxis" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:title="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialAssetsAndLiabilitiesAbstract" xlink:label="FinancialAssetsAndLiabilitiesAbstract" xlink:title="FinancialAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="FinancialAssets" xlink:title="FinancialAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialAssets" xlink:title="presentation: FinancialAssetsAndLiabilitiesAbstract to FinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="FinancialLiabilities" xlink:title="FinancialLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialLiabilities" xlink:title="presentation: FinancialAssetsAndLiabilitiesAbstract to FinancialLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialAssetsAndLiabilitiesAbstract" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialAssetsAndLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_FinancialRisksAbstract" xlink:label="FinancialRisksAbstract" xlink:title="FinancialRisksAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:title="presentation: FinancialRisksAbstract to GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateIncrease" xlink:label="ClosingForeignExchangeRateIncrease" xlink:title="ClosingForeignExchangeRateIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="ClosingForeignExchangeRateIncrease" xlink:title="presentation: FinancialRisksAbstract to ClosingForeignExchangeRateIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ClosingForeignExchangeRateDecrease" xlink:label="ClosingForeignExchangeRateDecrease" xlink:title="ClosingForeignExchangeRateDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="ClosingForeignExchangeRateDecrease" xlink:title="presentation: FinancialRisksAbstract to ClosingForeignExchangeRateDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossForeignExchangeRateIncrease" xlink:label="DecreaseInNetLossForeignExchangeRateIncrease" xlink:title="DecreaseInNetLossForeignExchangeRateIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="DecreaseInNetLossForeignExchangeRateIncrease" xlink:title="presentation: FinancialRisksAbstract to DecreaseInNetLossForeignExchangeRateIncrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfIncreaseInInterestRates" xlink:label="PercentageOfIncreaseInInterestRates" xlink:title="PercentageOfIncreaseInInterestRates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="PercentageOfIncreaseInInterestRates" xlink:title="presentation: FinancialRisksAbstract to PercentageOfIncreaseInInterestRates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PercentageOfDecreaseInInterestRates" xlink:label="PercentageOfDecreaseInInterestRates" xlink:title="PercentageOfDecreaseInInterestRates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="PercentageOfDecreaseInInterestRates" xlink:title="presentation: FinancialRisksAbstract to PercentageOfDecreaseInInterestRates" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_IncreaseInNetLossInterestRateIncrease" xlink:label="IncreaseInNetLossInterestRateIncrease" xlink:title="IncreaseInNetLossInterestRateIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="IncreaseInNetLossInterestRateIncrease" xlink:title="presentation: FinancialRisksAbstract to IncreaseInNetLossInterestRateIncrease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_DecreaseInNetLossInterestRateDecrease" xlink:label="DecreaseInNetLossInterestRateDecrease" xlink:title="DecreaseInNetLossInterestRateDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="DecreaseInNetLossInterestRateDecrease" xlink:title="presentation: FinancialRisksAbstract to DecreaseInNetLossInterestRateDecrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:label="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:title="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" xlink:title="presentation: FinancialRisksAbstract to NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_BorrowingsDebtExtinguishmentPeriod" xlink:label="BorrowingsDebtExtinguishmentPeriod" xlink:title="BorrowingsDebtExtinguishmentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="BorrowingsDebtExtinguishmentPeriod" xlink:title="presentation: FinancialRisksAbstract to BorrowingsDebtExtinguishmentPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_LiquidityManagementRollingForecastPeriod" xlink:label="LiquidityManagementRollingForecastPeriod" xlink:title="LiquidityManagementRollingForecastPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRisksAbstract" xlink:to="LiquidityManagementRollingForecastPeriod" xlink:title="presentation: FinancialRisksAbstract to LiquidityManagementRollingForecastPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="FinancialRisksAbstract" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems to FinancialRisksAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable to DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:title="presentation: DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract to DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://acimume.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_SubsequentEventsMember" xlink:label="SubsequentEventsMember" xlink:title="SubsequentEventsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonadjustingEventsMember" xlink:to="SubsequentEventsMember" xlink:title="presentation: NonadjustingEventsMember to SubsequentEventsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="presentation: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to NonadjustingEventsAfterReportingPeriodAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_AtTheMarketEquityOfferingMember" xlink:label="AtTheMarketEquityOfferingMember" xlink:title="AtTheMarketEquityOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalMember" xlink:to="AtTheMarketEquityOfferingMember" xlink:title="presentation: ClassesOfShareCapitalMember to AtTheMarketEquityOfferingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="presentation: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ClassesOfShareCapitalAxis" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:title="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_PostBalanceSheetEventsAbstract" xlink:label="PostBalanceSheetEventsAbstract" xlink:title="PostBalanceSheetEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="aciu-20201231.xsd#aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:label="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostBalanceSheetEventsAbstract" xlink:to="ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" xlink:title="presentation: PostBalanceSheetEventsAbstract to ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="NumberOfSharesIssued" xlink:title="NumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostBalanceSheetEventsAbstract" xlink:to="NumberOfSharesIssued" xlink:title="presentation: PostBalanceSheetEventsAbstract to NumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PostBalanceSheetEventsAbstract" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems to PostBalanceSheetEventsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodTable to DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:title="presentation: DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract to DisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" , !90# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5/5=2AT?2[C4+A9&A@7<PC +$>V2*P)/B'H,.C6VI2R3(+D,8[<H#*0&*DD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ5Q/A30+77_B!J,=ZN^WMY)9FC/1SOP ?;G/X5VWPK_Y$Q?^OB3^E<_\.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYFW^7LQE5&,9/]W]:WZ*GE7-S=398BHJ3HI^ZW>WFCE?^$-_XK[_ (2C[?\
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M_+V=0!C&3Z5NT4<JOS=1*O45)T4_=;3^:.6\3>!-+\2RBY<O;7F,&>(#YO\
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M9/6MBT:=[*!KI%2X,:F5%Z*^.0.3W]Z )J*** "BBB@ HHHH **** "BBB@
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M-'SM*@)\I]0>,_E76Q:980R!XK&VC<<AEB4$?I4.O?\ (O:G_P!>DO\ Z :
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M5)[#P=9ZK:V45DT]U*XVB"9WV'/&[Y^/_K47LB:1\1X[R[(CMKJ'8LK'"@X
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MLAU=]2T^=_+E65]SQ^X.?\XKN:X?4-.\&6%S!;?87N)YVVK';S.Y'U^>NXH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,,C#(-244 8D/A'08)Q-'IT>\'(W,S#/T)Q5[4-)L=5\G[;!YODMN3YV7!_
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MSB>UL424=&9F<CZ;B<5K44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.6L$<=S*D8$@F>/.3]T$<5N5T8*I.K0C.IN_\V98B$85'&.P4445U&(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3H^LRNG975M;:Z&'>Z?JNHVPCGFM4VD,%C#88^Y/3O5Z*SE36)[QBGER1J@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'<$2.0=H.[L3G)..<5+JL"VU^R:SXMEL;**)$M8H+O9.^!\SR'&221VXY_,
M[>L_6]7M]!TB?4KI)7AAV[EB +'+!1C) ZGUK@M/\6W-CX<\0O#J$FHBSF2.
MQN)E)9O,X&<CG'7FI/%WA[4;#P5=W$FN7UW(5C^UQ7$FZ-OG4_(/X<''X9H
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M"L#X>?\ (O7'_7]-_P"A51\9:6+KQ?X=)O;V+[1)(G[J<KY>%!RG]TG/)[T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+:***_*3[0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH GM+R>RG$L#E6'Y'V-
M=OI.MPZFFPXCN .4]?<5P-.CD>)U=&*LIR"#R*]++\SJX*6FL>J_R[/^F<F*
MP<,0M='W/4**PM$U];T+;W)"W Z'L_\ ]>MVOO,-BJ6)IJI2=U_6Y\W6HSHR
MY)K4****Z#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M1E5T9'4,K#!!&012T4;@016-I#()(K6"-QT9(P#4]%%3&$8*T5;T&Y.6K85R
M'B:QU@>*M&U?3-,^WK9QRAX_/2+EEVCEOKGIVKKZ*H1Q.IIXM\36ITR728=(
MM)L">9[I9FV9R0H7UJ_-H<\/BO0)[2W_ .)?86TL+-N'R97"C&<G\!73T4 <
M/XC\+7VH^*H);9 =-O/*_M$[@/\ 5MD<9R<C XSTK2\1Z1J+ZMI^NZ.L<MY9
MAHWMY&VB:-NH![$<_P"17344 <[83>)K_68IKRTCTO38D.^#S4FDG8].0/E
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MX=X)DNU7R&/5''?!].?Z=S7-W/@JRENKF:WO]3L5N6+S0VEQLC=CU)&#U]J
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MM+;SK<)MES(IQ@D$< GG%;G_  KCPG_T"O\ R8E_^*H_X5QX3_Z!7_DQ+_\
M%4 1ZAI&K66KV&NZ3!%<7$=H+6ZM'<(9$Z\-TR#Z^@ID6E:QK&NG6=4LX[(6
MUM)#:6JRB1BS @LS#COC_/,__"N/"?\ T"O_ "8E_P#BJ/\ A7'A/_H%?^3$
MO_Q5 $F@:5>V7@&/3+B'9>"WE0Q[E/S$M@9!QW'>N>/AG6;?3O#4QTV*_;3H
MW2?3I94 RW1@3E2?\!6[_P *X\)_] K_ ,F)?_BJ/^%<>$_^@5_Y,2__ !5
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MI-<Q6EU L+123.%595 P"??D?C7.>,KWQ%>:!%%J&DPV,0N(P[BX63SFSP$
MZ#OSZ5Z!J>FVNKZ?+8WL?F02C##.".X(/8@UC6W@NRBN[>XNK[4K_P"S-N@C
MO+CS$C;L0,#D>] %>\T[6-'\476LZ1:)?P7T:+<VIE$3!E&%8$\=/YFK-C#X
MBU&+4GU40VD5Q$8K:R5@_E9!&YG Y/TKHZ* .'TJU\66'ABTM+:SBM[FP< Q
M23(ZWD>3D C.P].M/M](U/5?%6GZK<Z)!H\=GO9V69)))V88P2G8>_O7:T4
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M"'R9B!<H.?\ ;'K6S7Z%AL13Q%-5:;NF?+U:4J4W"6X4445N9A1110 4444
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M;]24D9&89!/!R.F>_-:&OVVI:-X0;5$UK49K^=H2P:<B-6+ D*HQM'.,9Z4
M>AT5YYKMIK&@76CO:^(;^6ZO[D6LWVA@\0+\;E3&%P3D#Z?CH1P7OA_QII%F
MNK7U[::E',)$NY?,VM&N[(XX[<#WH [.BLKQ+JCZ+X<OM0B4-)#'E >FXD 9
M_$U@1>&]<.FV]_;>)+UM68)*R7$N;9LX)78!P,>GZ9X .TJ&[NHK*SGNYR5A
M@C:1R!G"J,GCZ"N2US U:9]:\4'3+,(OV:UL[KRY"<?,S\9//3'_ .O$LKR7
M6?"GBJS.KW=W;6"M);W.\J\B;&.USC++QR#UH ]'LKN._L+:\A#"*XB65-PP
M<, 1G\ZGKAK.QN[7P+I*VVNFR@G2&:ZN;N?YHD,:Y2(D84>@[5GVVKVUAXMT
MFWTCQ+>:I!<R&*YAN9C,%R.&#$<?AZ4 =QIFLV^JSW\,"2JUE.;>0N  6'<8
M)X_*M&O-1%>OIGC*73[B:"ZM]3>=&B<J6"\D''4$9XK9UG6)=7L?#UIIUQ)!
M+JTB2N\+E62)1N?D<CT_.@#L:HZKJUKH]O%-=%]LLRPH$7)+,>!7!7FI))X@
MU2WU[7]5TB59V6R6%C'"8A]UN!\Q/4Y_/T=XHL[JY\+Z!/?:H;BX^V10M+9S
M_NI 2<...6  Y^M 'I-%>>:]=-IFNVVGZKJ^K66CI;*(;J"1MTLF>?,D )S[
M5T7A%IVL+C?K$6JVHE/V:</ND"?W9#CJ/ZT :U[?_8Y;5/LEU/\ :)1'N@CW
M"//\3^B^]6ZYCQ9=7%MJ/AU8+B6)9=11) CE0Z^AQU'M659VNHZ[XL\06LFM
M7]M8VLR;8[:8JQ++T!YV@8/ ZDT =Y6=J.LV^F7FGVLR2L]]+Y410 @'&><G
MI],UC^#;N],FKZ9>W4EV=/NS%'/*<NR$< GN?\:C\6_\C#X5_P"OX_\ H- '
M6T5Q&L^6NK7;Z[XL?3X<@6MK8W7E,J8ZN,9)/XBL5?$-]+\.]>DBU.:>2QO%
MCM[T$H[Q^8F,G@YP3GZXH ]1HKA-4@U/1+:RLX-9OYM2U>=('EGDWI!W=HUQ
MA>N,>E1ZSIVI>'K_ $)K?7=2N+6YU*"&=+F<L22V>#Q\I 8%>G2@#OZ*\TOO
M$5GJ/B34X-4\1W>E6EG(8((;-F1I&'#,S 'OV_R=OP+KDFIG4[%KXW\=C(OD
MW;##21N#C=[C:: .PHK"\3B[:TMQ%JT.EVGF_P"E7#2!'V?W4)& 37*V&L6]
MEXRTNTTGQ%>:I:W6^.YBN9C+L(7*E6(]?3T]Z /1Z*X'1M/U'Q#>:Z;C7=2M
M[:WU*>&!+:<J00V>3R< $ +TJK!XBU?_ (1.&R6[+:G-JATQ+HKD@9Y?Z@''
MZT =MK6MVVA0VLMTDKK<W*6R>4 2&;."<D<<5I5YMXLT*ZTJ#2&&KWM[;G4H
M?,2\D\Q@_.&4]AR<CZ5Z+<3+;6TL[YVQH7./0#- $E%<)HVF:KXHTC^VKK7M
M0L[BZ+-;PVLNR*%02%!7^+I^59L^OZMJ^AZ"L=[):WSZD;*XEA; 8@8W8Z'@
M@XZ9H ]-HK@M;L-2TW4=!TS3-:U(M=SS!YKB8RL%V#/' .!DC/0\U99+WPMX
MGTJ%=4O;ZPU%FA>.\D\QHW R&5O3V_\ K8 .CT?6;?6X)YK9)46"=[=A( "6
M7J1@GCFM&O-_"FA76K6^K.=9O[.!=0F6*.SD\OYLC+,>I[#'M5[3-0UC5/ P
M)U6"TN(;IH+B^F.W]TK<L#C&[&!S^= '=45YF^K6NF^(-'31_%-[J7VB[2"X
MM[B<S*48XW XP,>WM6A9VNHZ[XL\06LFM7]M8VLR;8[:8JQ++T!YV@8/ ZDT
M =Y52[O_ +)<6L/V2ZF^T/LWPQ[EB]W/8>]8/@V[O3)J^F7MU)=G3[LQ1SRG
M+LA' )[G_&G>)[JXM]=\-QPW$L:37A654<@.,="!U'UH Z>BN"TZSU#7O$/B
M"";6]1M[.UNML<=M,5;)'3=SA1CH/4U57Q%JNF^&=5LS=/<7]OJ7]GVUS(,L
M0QX)]2!G]* .UUS6[;P_IXO;M)7C,BQXB )R>G4BIX[_ ,S5)K'[)=+Y2!_/
M:/$3Y[*W<CTKS_QIX?N],\.QS?VU?WJ>?&)TNY-X)SPR?W>>W/!]JV9=6N+'
MQ?XA=II9+>STQ;A("YV @9.!T!.* .RHKA;#0M;U;08=7_X2*_BU2YC%Q%&L
MNVW7<,JI0 \8(S5K6UN?M5N=:\21Z78K;KF.TN/*EEF_B.2,[?3% '7.ZQQM
M(YPJ@DGT K*C\16]QHMOJMK:WMU!.^Q$@BW/C<5W$9X'%<?HE]_:4_B#1H-<
MO+[3DMUE@NC(1*A[KO(R1GCZ50LEN-,^&FFWEKJ%ZDES=1 KYY"H/,8$*!T!
M[CO0!ZM17&S&^\3>+-1T]-2NK'3=,6-6^R/Y<DLC#/+=<#!'_P"NJ;7^HZ2_
MB309=0GN?(TR2\M+F1OWR#:1@L.I!(P?\@ [ZBO.);'5T\#IXA;Q#J(OUMDN
M519?W.W (4KW..YZFI=?UJ9KK1Y-2OK_ $[1[FQ69Y['(/G-CY68 D  C_/0
M ]"HKFO"+R.EYY>N)JVG[U-M(TF^:,8Y63CUZ?\ UZZ6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM=1CGF.Y1M0'D\GGZ#FIM6TV[N?%WAV^ABW6UG]I\]]P&S?& O!.3D^E;]%
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MA_'\\?JTWJMO3M\OR/"S3#<LO;1V>YH4445],>0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y;11
M17Y2?:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5UOA&[W0S6K'E3O7Z=_Z5R5:6@W/V;5X"3A7.P_C7H95
MB/88N$NC=GZ/3_(Y<;2]I0DOG]QZ!1117Z,?*A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45Q2:]J9U%8C<_(9@N/+7IG'I7:UP
MX+,*>,YO9IKE=M3IQ&&G0MS=0J.XN(;2WDN+B18H8U+.[' 4#O4E<=\0B9K3
M2-.9BMO?:C%#.<_P9Z?U_"NXYBR/'-G*C2VFDZS=VHS_ *3!9DQD>HR0<?A6
MWI6K66M6"WEA,)82=IXP58=01V-1ZIJ*:)8121Z=>72;A$L-C!O91@X.W(PH
MQC\17('Q7IECHWB*^TK3+JQOH71IH[N/86ED) .W<>F"2.* /0**\FN->M+#
M3%O[/QG>W>KQ@.T$I8P2G^)0A7 'IS6]<S:AKOC*QM;;4KJQL[C1X[J989,$
M N?N]@W*C.,X% '=T5PEKJ-WX:UK7+&>_N+ZTMK#[;";J3>ZD?P[N^3_ $K
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M"U^R\16L]S8>9Y,,[0;G4#<0 <CGH01UP?:M2N3\!Q1P0Z_#$@2./6KA44=
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MKS<S3$DG"!N2.<C/M^%3Z%X@BA\5P:9I>MW&KV5Y$Y NV9GAD52P^8@'! H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% 'EM%%%?E)]H%%%% !1110
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M:HT=G!&XPRQJ"/0@5Q%OX<U:/P7XCT]K3%U>7LLL$?F)\ZG9@YS@=#UKO:*
M*VG1/!IEI#(NV2.%%89S@A0#5FBB@#EKA/$FDZ[=W-E;MJ]A=!66![H1M;L!
MSMW<;3[?_KJVGAK5[FVUR_N[D6.KZH%"?9W/^CA!\HW#KG !([5V=% '#W\7
MBW6]'_L2YTJWMA*%CN+\W*NI4$994'.3CO6JW@/PW+M:?35ED"*A=I'RVT #
M.#Z"NCHH Y#P?X2AT6[U*ZEL%@G-[,MJ_F;O]&.-HX)]^O-7O&NF7FK^'6M;
M&'S9S-&VW<%X# GDD"NAHH YKQ7I5[J5YH,EI#YBVNHQSS'<HVH#R>3S]!S4
MVK:;=W/B[P[?0Q;K:S^T^>^X#9OC 7@G)R?2M^B@#SS_ (1G6/\ A#OL'V/_
M $G^U?M&SS$_U>[.<YQT[=:V)='OV\4:Y>"#_1[K3Q#"^]?F?'3&<C\:ZNB@
M#A(O#.KVVA>'KJTCB35])# P2,,2*W#+N''3I]35LV.M^(M;TVYU33H],LM/
MD\]8O/65Y9.W*\ #_/MV%% &!X6TV[T[^VOM<7E_:=5GN(OF!W1MMP>#QT/!
MYIO@_3+S2["_CO8?*>6_FF0;@V4;&#P370T4 <QXJT_4IM1T74M-LQ>-83.S
MP>:L98, ."W':JJV.NZ#KE]?Z;IJ7]IJ)666V,ZQR0RXYY/!'7_/7L:* .<\
M-Z1?0ZAJ.M:LL27]\5 AC.X0QJ,!<]STS]*=XIT>\OVT_4=,\MM0TZ8RQ1R'
M"R*>&7/;.!70T4 <+=VWB?6_$6BWESHZ65G93[WC^TI(_(Y8D=N,8'-1Z?I.
MN:)?ZBJ^'[34Y+BY>:+4))T4@-T# Y;CT'J?K7?44 >?6OA?6AX*\0:3<11_
M;+J[:>)PXV2YV'CG(^Z>N.HJY<Z9KLYTG7+;3T@U2Q1H)+*6=6$T9&.'' /4
M_C[<]K10!SMA-XFO]9BFO+2/2]-B0[X/-2:2=CTY ^4#V_\ U7M)U:34KK4H
M);40&RN3 ")0_F# (;@<9!'';O6I3(H8H0PBC2,.Q=MJ@98]2?<^M &'XITV
M[U'^Q?LD7F?9M5@N)?F VQKNR>3SU' YJ'7]*O;WQ3X<O;>'?;V<DQG?<HV!
M@H'!.3T/2M#6?#FD^(/(_M2T^T>1N\O]XZ;=V,_=(]!67_PKCPG_ - K_P F
M)?\ XJ@!=4T*YU'QBMP\7_$O?3)+624,O#,3QC.>A],50LD\7Z/HPT2WTNWN
M3$IBM]0%RJJ%[%D/S9'M_P#KO?\ "N/"?_0*_P#)B7_XJC_A7'A/_H%?^3$O
M_P 50!2B\)W6FR>%+>U031:=)*]S*"%P6&<X)R><],U?\0:3J2Z[8Z_H\<<]
MS;QM!+;2/L$L9YX;L02?\]6_\*X\)_\ 0*_\F)?_ (JC_A7'A/\ Z!7_ ),2
M_P#Q5 %C39?$M]K(N+^VCTS3HXR/LOF),\SGH2P' 'L?S[7O$-A-J?AV_LK?
M;YT\+(FXX&<5G6O@'PS9W<-U;Z9LFA=9(V\^0X8'(."V.HKI* .'33-:O(_"
MYN-+-LVFSA9AYZ/\BHH#\'N<\<GBM?7M,O+WQ%X>NK>'?!:32-.VX#8"H X)
MR?PKH:* //\ 2M*U[0Y;V%/#UG?SRW#RQZE).BYW'C<"-W'7CU_&J\7A;6X_
M"4NFO:A[H:N+@%9$"R1Y&7'/'0\'GVKTBB@#GO&&F7FJ6%A'90^:\5_#,XW!
M<(N<GDBNAHHH Y7PUHFH6?@JXTRY'V6[E\\*=P;9OSM;()]<UBZ?I'B"U\/-
MHL/ARQMIS$\+ZB9T(8$$%MH&[)!QS_\ 6KT2B@#A+#P_JL4'@\26A1M.:7[4
M#(A\L$8'0\Y]LU;NO^$F1KNSN]#M=<MWD9K>9Y8XPJGH&0CG'J*["B@#@8O!
MVJZ;HFBS64D+ZMIDDDOE$X1UD/S1@]N./SK9M;CQ3J.K6S3V,>D:?%DS(9DG
M>?T ('RC\C72T4 <7967B'PO)>V.EZ7#J%C-,TUM(;A8S"6_A8'D@>W_ .J]
MX'TK4=)T:YAU2,)<R7DDIVL&# XY&/7!]ZZ:B@#GM>TR\O?$7AZZMX=\%I-(
MT[;@-@*@#@G)_"G:3IMW;>+O$5]-%MMKS[-Y#[@=^R,AN <C!]:WZ* ..@LM
M=\,ZIJ/]F:;'J>G7L[7*H)UA:&1OO#YN".!TJA>^%=7G\):\TL4<NLZM-'*T
M,3@*@5U(4,3C@9[UZ!10!S7C/2KW5K/3([*'S6@U&*>0;E7:BALGDCU''6I-
M>TR\O?$7AZZMX=\%I-(T[;@-@*@#@G)_"NAHH S]=MI;SP]J5K;IOFFM98XU
MR!EBA &3QU-8$&B:@E[X+D:WPFFVLD=V=Z_NV,*J!UYY!'&:Z^B@#GM1TR\G
M\;Z-J,<.ZTMX9EEDW ;2PP.,Y/X5DZUX5O;WQC#-!&/[)NGBFOOF RT6[ QG
M)SD#@5V]% ',>(-)U)==L=?T>..>YMXV@EMI'V"6,\\-V()/^>LE@_B?4-4,
MUY#'I-@D3*+<.DTDCGHQ(& !UQ_/MT=% '"7UOXHO]*FTK4- LM0G8-&FHM/
M&J 'H^S&X$>U37NAZMIA\+3Z?;#4GTF.2*6/SEC+[T"Y!;C P?TKM:* ..CL
M=<\.ZUJ-QIFFIJ5CJ$GV@Q>>L3PR'KR>"#_GWI77A?5[KP[X@N;B*)]8U8QG
MR(W&(U0C:NXG'3^0KOJ* ,;4X=830[<:1)&E[#Y;-'( 5D4#YDR>F?7VZU@-
MI6K:YXATR]NM"M])%G-YTLXG2228C^$;>WUKN** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_/;I'-,61FW( [#N^2,MW%4I==M;;21J%OXTOI]:11(T#EC [=2FS;@#MG-
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MMBYNKB-I$ 7@*O4DU1;Q1;'7GTB"SOKF:)D2:6&$-%"6Z;FSQ^5<WJ6G"_\
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M+PHS^ 7T2[;9=72&2=^N)F.[)QUP<#CTJND_C9=+CTR/2[:&Y11%_:1N5:,
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MBO+]J1O.V$8"C/R] >3VK<O!XCL;F/[/81:IISVZ(]HTB1M$X')R>&!KJ**
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MIFG)>0:DB-<V9G5'BE48R&/!')_SBM;0O[>FFNKK6?*MXY"!;V495_* ZEG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM=7=K[>=_P!+V,RZE2WM&D;7)6OE7.V.7*%O3:!5W4[]O^$>A8LJRW:(H).
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M0!>HKEO^%C^$_P#H*_\ DO+_ /$U+)X^\,Q00SOJ>(Y@3&WD2?-@X/\ #ZT
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MMEQR5W?GS5^FQH(XU1>B@ 4ZOU"C3]E2C371)?@?'5)<\W+NPHHHK4@****
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M=(2TN[9T'EI+<1;$E8'(*'/*Y4<^]<SK6OZE)X(N=.GT'4(+M+;RYYI8P(%
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M]Q<$= $!^O)_E7?E='VV,IQ\[_=J<V,J<E"3_K4ZNBBBOT<^4"BBB@ HHHH
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M0O<//:3V<7F!@W\+?W2/6F&UUZYU'PM=:I#)).MS/)-Y<>5MT91M5BHP/J:
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MV2RN[FWFTU;-I[>(N$D\W)+8Z#'.:P)M*U$^!M4MQ871G?6&D6/R6W,F]?F
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M(@N60&6-6W!6[@'TJQ63X8M+VP\-6%KJ#EKJ.+#DMN(YX&?88'X5K4 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4)/)TZYD_N
MQL?TJS63XDF\K1)AW<A1^=<^+J>SP\Y]D_R-:$>>K&/=HX0=****_,3Z\***
M* "I+>%KBXCA099V"BHZW_"MGYU^UPP^6$<?4_Y-=.#P[Q%>%)=7^'7\#+$5
M52I2GV.OAB6"".)/NHH4?A4E%%?IB22LCY%N[NPHHHIB"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &/XET+_A(]'?3_ +;/:;F#;XNC<'AA_$O.<9'(%9</@7RH8X_^
M$G\1#:H7"7NU>!V&.![5UE% '+?\(3_U,_B7_P #_P#[&C_A"?\ J9_$O_@?
M_P#8UU-% '+?\(3_ -3/XE_\#_\ [&C_ (0G_J9_$O\ X'__ &-=310!RW_"
M$_\ 4S^)?_ __P"QH_X0G_J9_$O_ ('_ /V-=310!RW_  A/_4S^)?\ P/\
M_L:/^$)_ZF?Q+_X'_P#V-=310!RW_"$_]3/XE_\  _\ ^QH_X0G_ *F?Q+_X
M'_\ V-=310!RW_"$_P#4S^)?_ __ .QH_P"$)_ZF?Q+_ .!__P!C74T4 <M_
MPA/_ %,_B7_P/_\ L:/^$)_ZF?Q+_P"!_P#]C74T4 <M_P (3_U,_B7_ ,#_
M /[&C_A"?^IG\2_^!_\ ]C74T4 <M_PA/_4S^)?_  /_ /L:/^$)_P"IG\2_
M^!__ -C74T4 <M_PA/\ U,_B7_P/_P#L:/\ A"?^IG\2_P#@?_\ 8UU-% '+
M?\(3_P!3/XE_\#__ +&C_A"?^IG\2_\ @?\ _8UU-% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110
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MX:C&E'I^?5GR5>LZU1S?4****Z3(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJ&\F:WLKB9 "T<;. >F0,U,I*,7)[(:3;21-17-:1XAN]0U
M*.WEC@5&!)**0>!GUKI:Y\)C*6+A[2EM>VJL:UZ$Z$N6>X5E:SXCTGP_Y']J
M7?V?S]WE_NW?=MQG[H/J*U:XOQ???V=XN\+W?V6YNO+^U_N;6/?(V8U'"]^N
M?H#748FA:^/O#-Y=PVMOJ>^:9UCC7R)!EB< 9*XZFMFRU.SU"6ZCM9O,>UE,
M,PVD;7'4<CG\*S-,\3_VG?):_P!A:W:[@3YMU:;(Q@9Y.:P+KQ'JT>A>++E+
MO$UA>F*V;RT_=KN48QCGJ>N: .]HKAM3U+Q%HGATZM<ZE%*]T8U$?V8!+/>>
M6R.6 ''/?\JMZ/<ZTVIVS0ZU:Z[IDH/GR(D<;6YQP<*><^G7K0!TUO?VMU<7
M%O!.LDMLP695YV$C.#[U8K@O!5GJ$?B77VFU1IDBN=LRF!%\YMO#9'W<>@XK
MO: "BLO77U<6<<>BQQFYEE5&EE(VPH>KX)Y(]*YE]6U;1?$6EVL^OVVK07LW
MDR1>3'&\1/1AM.<?6@#NJ*XBTNO$FMZ[K5E;:M'96UE<[5E^S)(^".% /&!@
MDDY/-0+XPU.T\.WR7(AFU>WU#^SHW"[4D<]&(^F3CV% '9:EJMEI$$<]]-Y4
M<D@B4[6;+'H. ?2GW=_;6'D?:9-GGS+!'\I.YVZ#@>W7I7GOC&RU^TTNQ_M'
M4XM0@>]B+XMQ$8GYQC'WEZCGGI72ZD1>^-],M6*^3I\$E[+D\!C\B9^GS&@#
MIJ*XC3+GQ-XILY-6LM5ATVT=V%I;_9EDWA21EV/(R01Q5:Z\7:M<^&-.N;,1
MP:FVJ+I\Z;0R,^&XY[$[3QS[T >@5474[-]5?3%FS>1Q"9H]IX0G&<XQU]ZB
MTFTU&TMW34M3^WRELJ_D+%M&.F%Z\YYKD;^+5;CXG7$.E7,=J[Z>GFW#QARB
M;OX5/!)..OO0!WU%<;;>(=0T2]U73M=F2[:SM#>PW"1B,RQYQ@@< YP.*RQK
MNMR:.=9_X2?2DG*>>-+VQD;<9V%L[MV/UXH ]&I'=8T9W8*BC+,QP /4UPFH
M^+I[N71([:_BT>VU"W,[W<T8?#=/+&[Y1SW/M^-L?\)!/H6LV]SJ$$T(AW6N
MIPHA\U<992@.!P",^Y/I0!U5G>6^H6D=U:RB6"091P#@CI4=[J=GI\MK'=3>
M6]U*(81M)W.>@X''XU@?#V"YB\(V;SWAGCD0&*,QA?*&3QD?>_&K/B;4[S3[
M_0H[6;RTNK]89AM!W(>HY''X4 =#17$P7?B/6/$VM:=::I'9VEG*N)3;K(XW
M+PH!XQP22<]JT_">JZA>C4K'5'CEN]/N3"9D7:)%QP<=C0!T=%8GBK6I=#T4
MW%O$LMU+(L$"MTWL>,^W4U1CM?%^GW5G-)J4.J0O(%NK?R$B\I3U9&XSCWZ_
MR -^QU*TU'[3]DE\S[-.UO+\I&V1<9'(YZCD<5:KA]!EU&'2O%+Z5;)<7W]M
MW(B1V"KG*\G)'09-0:QJFN^&5MKN?Q':7Y,RI/9&".,X)P=N/FXH [^BN(U7
M7+V;Q;=:0NNV^B0P1QM$\L*N;@L,G!?@ =/7^CM1UW7]'\'R7-\MN+P7(@6[
M4!HS$3Q-M'\OIQVH [6BN1T>YUIM3MFAUJUUW3)0?/D1(XVMSC@X4\Y].O6N
MCU._CTO2[J_E!9+>)I"H[X&<?C0!;HKB8!XTO-(CUF#4K?SIE$T>F?9UV%#R
M%\P\YP?6IY=3UO7/$%QI6F7$>F16,4;7<QC69_,<9" 'CCD$^QH Z^BN)77M
M7L(_$&DW]Q'+J%C8O=VUW'&%\Q=IP2O0$''M_6A<:MXJL_"<'BB74X#&%BD:
MQ^S* Z,0 2_7)R#Q@<\4 >BT5P]WJ/B/1FTK4[W48+BUO;F.&:S2W"B(/TVM
M]XX]Z6&[\2:QXGUG3K/4TL[.SE7$QMTD897A ",'N23GM0!V]%<AINMZ])8Z
MUI[V\-WKFF,J(1A$F#C*L<X XR<<5FZWJ>O^&K./4+CQ)9WCHZ^=8&"-,@D
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M')&,>G- '<T5QDM[KUSK<?ARRU.-9K6 37NHM;J68D_*JI]T<$?YZK!XAO\
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M<[B6XP?0=J .\HK-T&75)=)C.L0QQW@)5C&P*N,\,,=,CM6E0 4444 %%%%
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MRBM9WNQ9VJF!8R7R#'D;>N1@Y^E=M10!R/BRSNKG0-&C@MII9([VW9U1"Q4
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MX,,X!#$N >,XX&>_XUC:I9+K4,*Z=X3O]-UTR(3="#R8HB#\S;@<-W]ZZ?\
MX0G_ *F?Q+_X'_\ V-'_  A/_4S^)?\ P/\ _L: (I1<V'Q)-X]A=RVMW9I;
MK-!$75&WC[Y'W1[FL6UT+59/!P,%K(E]9:NU]%!,I0R;2< 9'<'BM_\ X0G_
M *F?Q+_X'_\ V-'_  A/_4S^)?\ P/\ _L: &?VYK.L7UA;:=I=_IT8E#WL]
MY % 0=47.<D^H]JU_$W_ "*FL?\ 7C/_ .@&LO\ X0G_ *F?Q+_X'_\ V-0W
M7@/[1:30_P#"3>(#YB,F);S>AR,?,N!D>HR,T 9=IK>KW7@JWTB+0;Y[V>S6
M".?8/(*,@ <OT'RG./6KUIHMQIOBOP]$L4LD%IIKPR3JAV!OKT&3VJ:U\!_9
M[2&'_A)O$ \M%3$5YL08&/E7!P/09.*F_P"$)_ZF?Q+_ .!__P!C0!!J$=]H
M/C&76X;"XOK&]@6*=;5=TD;KT.WN,?U_&H=(N_%VL7VHW=E-I]I]@>RM4N!M
MD9FR=Y7L!GI]/>M+_A"?^IG\2_\ @?\ _8T?\(3_ -3/XE_\#_\ [&@#';5M
M:@\(R:"WA[4)-1CMC:^:D>Z%E"[=X?N<=NYI%L]2T_3?!VJ+IMS.=-CD2YMH
MXSYJB1 N0IYR,'BMG_A"?^IG\2_^!_\ ]C1_PA/_ %,_B7_P/_\ L: ,V.:_
MU?XA:3J7]CWUK8Q02QA[B(J<[3RP_AR3@9ZXI-&O-3\(Z7)HDNAW]X\#O]DF
MMH]\<BL2PW-_#R><UI_\(3_U,_B7_P #_P#[&C_A"?\ J9_$O_@?_P#8T 96
MI0ZY;KX7U+4K:XO[FUED>[%I$&9-PX 5?0<9]JGU:X%Q?7$.N^$Y[^V.&M+B
MTM#(^PC.U^<JP_"KW_"$_P#4S^)?_ __ .QH_P"$)_ZF?Q+_ .!__P!C0 _P
M-IUWINA2Q74,ENDES));V\K[FAB.-JGWX)_&NFK*T;1/[&\__B::E?>;M_X_
MKCS=F,_=X&,YY^@K5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?%.I^;,+&)ODC.9".[>E;
MNLZDNFV+.,&5_EC'OZUP#,SL68DL3DD]S7S/$&/Y(?5H/5[^G;Y_D>OE>&YI
M>VELMA****^//="IK2VDO+J."(99SCZ5#7:^'-*^QVWVF5?WTHX!_A6N_+<#
M+&5U#HM6_+_@G-B\0J%/FZ]#6LK2.RM([>,?*HY/J?6IZ**_180C"*C%62/E
M92<G=[A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5A^'9-8/VJ/4YX+R!6!M;Z':!.I'.54\$'BMR@ HHHH **** "BBB@ HHHH
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M8I@X'V<E909E/R$?>P.>*ZK_ (0G_J9_$O\ X'__ &-'_"$_]3/XE_\  _\
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MF-&^/F5ES^OT_#.O-)U/4=+\3ZU/I\T-QJ$216UF%W2A%P,E1W.!Q[&O1J*
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MK:R7;K!-NAC^\RXYQZD=<>U2+#=^*_$UM>RZ==V.FV,$R*;I/+DE>5=IPO4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "4444 %%%% !1110 4444 %
M%%% !1110 4450U;5(],M2YPTK<1IZG_  K.K5A1@ZDW9(J$)3DHQ6K*?B'6
M/L,'V>%O](D'4?P#UKB:?--)<3/-*Q:1SDDTROSS,<?/&5N=[+9>7^9]3A<-
M'#T^5;]0HHHK@.D?%&\TJQQJ6=C@ =Z[[1]+33+0*<&9^9&_I5#P[HWV6,7<
MZ_OG'R*?X1_C705]ID>6>QC]8JKWGMY+_-_D?/YCC/:/V4-EOYA1117T1Y84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5?N%;('XX%4+U+<WB/<V+3+Y9 D"&0 YZ;0#CZU-ID<L6GQ)*&##/#') R<
M_08%=M.I-UI1>WY;>777JSGE&/LTU_6_G^A;HHHKJ,0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH ****
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M#D'(Q6A136%@JGM+N]V_FU;\D#K2<>7RM^-PK+UM+^6W2&RB+JY_>E7"G;Z
MGUK4HK2O2]M3=-MJ_;<BG/DDI6O8R;&2]@$5NNC"" $ L+A3M'KCO5,Q:F=3
MDNYM,-QM.(%-PH"#Z>OO7145RRP/-&,74=HNZ^'Y:<MM.FFYLL39MJ*U]?\
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M>OL*L:+X>>[VW%T"D'4+W?\ ^M78HB1(J(H55& !T%?1Y3DKK6K8A6CT7?\
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M>:$P)Y0^\@&<-GV_K7I%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% "44R6:.",R2NJ(.I8X%<[J'BN-,QV*>8W_ #T;
MH/H.]<N*QM#"QO5E;RZ_<;4</4K.T$=!<74%I$9)Y%C0=R:Y74_%$LVZ*Q!C
M3H9#]X_3TK#N;J>\E\RXE:1O?M]*AKY+'9]6KWA1]V/XO_+Y?>>YALMIT_>J
M:O\  5F+,68EF/)).2:2BBO /2"BBI[6TFO9Q% A=CZ=J<8RFU&*NV)M15V0
MJI=@J@DG@ 5U>B^&Q'MN+Y<MU6(]OK_A5_2-"ATY1(^)+C^]V7Z5KU]AE>1*
MG:KB5=]%T7KW?X>IX>,S%S]REMW#&!@4445]*>0%%%% !1110 4444 %%%%
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ML;^ 2K);L,@%B67U4=S71>*;2YN/$OAB6"WEECANG:5T0L(QA>6(Z?C75T4
M<?KVE3ZEXSM4\F7[+)IL\$DP0E$+ C!/3//2L/3X(](TD:;?^!C>:G #&D\=
MBDD4W/RL9,<=LYKTRB@#B)]-OUOO!Y?38H&@DE:XCLH2(8"RYQQD#GWY.:T]
M:M;B7QMX8N(X)7AA^U^;(J$K'F, ;CT&3TS7244 <AX9%S8>)==L[FPNT%U>
M/<17'E$PE3T^?IGVJQXXM;B[T[3EMK>69DU&%V$:%BJC.2<=O>NGHH YC3+6
MXC^(&NW+V\JP2P0".5D(5R%Y /0XJJFGWDFN>-MMM*%N[>!+=F4A93Y+ A2>
M#@G!]*[&B@#S>"TU.?PWH5S:Z7=K?Z%( ]M<1F(S*1AMA/7H/\]=#4I;WQE<
MZ=8Q:/?V5E#<I<W4U[%Y1PO\*CN3GK7<44 07BEK&X502QC8 #J>*YOPU:7,
M'PWBM9K>6.X%K,IA="'R2V!@\]ZZNB@#S,>'[N/0_#.IOI'VUK&)HKJPFB!=
MD8GD*PZCKCZ5KZ8L5YKUJ=-\'PZ?:19>:ZO+%89 >PC YS[_ .3VM% 'GT>C
M7Z_$8P?9YO[)%T=2$NP[/-,>,9Z9W4SPKH5];>-+D7-O,EAIWG"S=T(5O,?.
M02,'Y<]*]$HH YCPK82+#XBAO+:1([C5KE@LB%?,C;:,C/4'GD5@^"=/N6\0
MS171WQ:"CV<#$_>9W8[O^^,"N[U&WNKJPEALKTV=PV-DXC$FS!!^Z>#D<?C5
M;0M&30]/:W$[W$LDC33SR<-+(W5CZ=J -.O/?[!OO^$X_L\6\HT4WG]JF38=
MF_;]S/3[W;TKT*B@#@/$=D[^,3<:OH]]JNDFW"VR6J-((G[EE!'/7GW'X5M*
MTZYC\1:O/'H,VG6ESI3K;Q"+OD##;> YP3MZUZ110!YW::;?+IO@A&LKD-;3
MDS@Q-F(>K<?+^-7;*6^\(:CJEHVD7U[975RUU:R6<?F;2V,HW]WIUKMZ* /+
M8['Q%<^&O$#BPN;>ZN=1$TD"@JSQ'EE0]^W(ZX-0:UIEO=Z,J:#X-OK5HY$D
MEEGMR), XVJ"2S=<G'85ZS10!R5ZUQ9?$6UU#[!>3VEQIPM/-@A+B-S+NR_]
MT =ZPM.TV#PTMUIVI^$7U3;*SVUW;V2S^8AZ!B1D$>__ .OTJB@#@9]%U27P
M_8:C#H]G9:A97OVQ+"U4(&CZ%3C@N0!^6.O%-UK4]2\0:AH"6^@:G!:V^I03
M3R7$!4J0?3^Z 6RW3I7H%% !7F,5MKD?A#6-%MM/OH;U+EYBWEE5EC+C(C?H
M3CT[9KTZB@#R37-*M[WP[)!H7@R_MIEVM++<6Y#@ CA,DLQ/MVS796EO<-\1
MKJ]-O,MM)IJ*LK1D*6W@[<GO[5U-% '%Q/>>%?$6JLVEWU]8:A*+B.2SB\QD
M<CYE9?Z_Y&%9Z;=^*+?QE;R0"VNYYH7CC=ON,,E5)'?  /UKK;OPU?+JUSJ&
MCZW)I[76TSQM;K,C,!@$ D8-7M!T*+0K:91/)<W-Q(9;BXE^](Y[^P]J ./W
MI+81VUO\/HQJY 5C/IZ+;JW=M_<5IZK%=:;XNT34!IL\]K%:-;O]AA+"-C_L
MCHM=G10!P.J.EU/=V_B'P?<7MPKD07-A;%ED3^'+@Y4_Y[5T'@VPOM-\+6EK
MJ)83KN.QFW&-2257/L*WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+:**FMK2
M>\E$<$;.Q]!TK\JC&4GRQ5V?9MJ*NR&M+3=%NM18,J[(>\C=/P]:W],\+Q0;
M9;PB63KL'W1_C70*H50J@ #H!VKZ7 </RG:>*T7;K\^WYGDXG-$O=HZ^92T[
M2;734_=)F0CF1NI_PJ]117UE*E"E!0IJR1XDYRF^:3NPHHHK0D***9--%;Q-
M+-(D<:]7=@ /Q- #Z*8\T4<D<;R(LDA(12P!; R<#OQ1%-%,&,4B2!6*,48'
M# X(/N#VH ?14,]W;6IB%Q<11&5Q'&)'"[V/11GJ?:IJ "BBB@ HHI"0 22
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MPW$,D*D@R(X*C'7D>E1S:E8V]FEW/>VT5M( 4F>551LC(PQ.#D4 6J*JC4K
MV'V\7ML;/_GX\U?+ZX^]G'7CZTVSU;3=0D:.RU"TN74;F6&97('J0#0!<HID
M4T5Q&)(9$DC)(#(P(.#@\CW%1-?6B2M$]U LBNJ%#( 0S?=&/4]AWH L45'#
M<0W,?F031RIDKN1@PR#@C([@\5)0 4444 %%%% !112*RN,JP89(R#GD<&@!
M:*** "BBB@ HI-RER@8;@ 2,\@'I_(_E3)YX;:%I9Y4BC7&7D8*!DX')]Z )
M***9--%;PO--(D<2#<[NP"J/4D]* 'T5#:WEK?0">TN8;B(G DA<.N?J*E)
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M>:KKK2(NJ26AMK6W.8X8V\R22,.6;<#QSC"[>_-:TWAC2)P ]LX40K 52>1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" *)!6(# 2(  A$! Q$!_\0
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M_OX*/MUE_P _D7_?P4 2T5%]NLO^?R+_ +^"C[=9?\_D7_?P4 2T5%]NLO\
MG\B_[^"C[=9?\_D7_?P4 2T5%]NLO^?R+_OX*/MUE_S^1?\ ?P4 2T5%]NLO
M^?R+_OX*/MUE_P _D7_?P4 2T5%]NLO^?R+_ +^"C[=9?\_D7_?P4 2T5%]N
MLO\ G\B_[^"C[=9?\_D7_?P4 2T4V.:*8;H958>JMFFW5Y:6,)N+VZCAC7[T
MDKA5'XF@-]$2450_X2KPQ_T,=A_X&)_C1_PE7AC_ *&.P_\  Q/\:GFCW-/8
MUOY7]S+]%4/^$J\,?]#'8?\ @8G^-'_"5>&/^ACL/_ Q/\:.:/</8UOY7]S+
M]%4/^$J\,?\ 0QV'_@8G^-'_  E7AC_H8[#_ ,#$_P :.:/</8UOY7]S+]%4
M/^$J\,?]#'8?^!B?XT?\)5X8_P"ACL/_  ,3_&CFCW#V-;^5_<R_15#_ (2K
MPQ_T,=A_X&)_C1_PE7AC_H8[#_P,3_&CFCW#V-;^5_<R_15#_A*O#'_0QV'_
M (&)_C1_PE7AC_H8[#_P,3_&CFCW#V-;^5_<R_15#_A*O#'_ $,=A_X&)_C1
M_P )5X8_Z&.P_P# Q/\ &CFCW#V-;^5_<R_15#_A*O#'_0QV'_@8G^-'_"5>
M&/\ H8[#_P #$_QHYH]P]C6_E?W,OT50_P"$J\,?]#'8?^!B?XT?\)5X8_Z&
M.P_\#$_QHYH]P]C6_E?W,OT50_X2KPQ_T,=A_P"!B?XT?\)5X8_Z&.P_\#$_
MQHYH]P]C6_E?W,OT50_X2KPQ_P!#'8?^!B?XT?\ "5>&/^ACL/\ P,3_ !HY
MH]P]C6_E?W,OT50_X2KPQ_T,=A_X&)_C1_PE7AC_ *&.P_\  Q/\:.:/</8U
MOY7]S+]%4/\ A*O#'_0QV'_@8G^-'_"5>&/^ACL/_ Q/\:.:/</8UOY7]S+]
M%4/^$J\,?]#'8?\ @8G^-'_"5>&/^ACL/_ Q/\:.:/</8UOY7]S+]%4/^$J\
M,?\ 0QV'_@8G^-'_  E7AC_H8[#_ ,#$_P :.:/</8UOY7]S+]%4/^$J\,?]
M#'8?^!B?XT?\)5X8_P"ACL/_  ,3_&CFCW#V-;^5_<R_14-G?V.HQ&?3[V&=
M VTO#(& /ID4^>YM[5/,N9TC7^](P _6JOU(Y97M8?15;^V=(_Z"MM_W_7_&
MC^V=(_Z"MM_W_7_&IYH]Q^SJ=F6:*K?VSI'_ $%;;_O^O^-']LZ1_P!!6V_[
M_K_C1S1[A[.IV99HJM_;.D?]!6V_[_K_ (T?VSI'_05MO^_Z_P"-'-'N'LZG
M9EFBJW]LZ1_T%;;_ +_K_C1_;.D?]!6V_P"_Z_XT<T>X>SJ=F6:*K?VSI'_0
M5MO^_P"O^-']LZ1_T%;;_O\ K_C1S1[A[.IV99HJM_;.D?\ 05MO^_Z_XT?V
MSI'_ $%;;_O^O^-'-'N'LZG9EFBJW]LZ1_T%;;_O^O\ C1_;.D?]!6V_[_K_
M (T<T>X>SJ=F6:*K?VSI'_05MO\ O^O^-']LZ1_T%;;_ +_K_C1S1[A[.IV9
M9HJM_;.D?]!6V_[_ *_XT?VSI'_05MO^_P"O^-'-'N'LZG9EFBJW]LZ1_P!!
M6V_[_K_C1_;.D?\ 05MO^_Z_XT<T>X>SJ=F6:*K?VSI'_05MO^_Z_P"-']LZ
M1_T%;;_O^O\ C1S1[A[.IV99HJM_;.D?]!6V_P"_Z_XT?VSI'_05MO\ O^O^
M-'-'N'LZG9EFBJW]LZ1_T%;;_O\ K_C1_;.D?]!6V_[_ *_XT<T>X>SJ=F6:
M*K?VSI'_ $%;;_O^O^-']LZ1_P!!6V_[_K_C1S1[A[.IV99HJM_;.D?]!6V_
M[_K_ (T?VSI'_05MO^_Z_P"-'-'N'LZG9EFBJW]LZ1_T%;;_ +_K_C1_;.D?
M]!6V_P"_Z_XT<T>X>SJ=F6:*9!<6]U'YMM.LB_WHV!%/9E12[MA1R2>U42%%
M5_[5TL]-2M_^_P O^-']JZ9_T$;?_O\ +_C6?MJ/\R^]%>SJ=F6**K_VKIG_
M $$;?_O\O^-']JZ9_P!!&W_[_+_C1[:C_,OO0_9U.S+%%5_[5TS_ *"-O_W^
M7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,
M_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]
M_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1
M_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U
M.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[
M5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-
MO_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C
M^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@
MC;_]_E_QH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_Q
MH]M1_F7WH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7W
MH/9U.S+%%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%
M%5_[5TS_ *"-O_W^7_&C^U=,_P"@C;_]_E_QH]M1_F7WH/9U.S+%%1PWEI<D
MBWNHY,==C@X_*DNKZRL5#WUY%"K'"M+(%S^=7&49*ZU(::T9+15/_A(= _Z#
MEG_X%)_C1_PD.@?]!RS_ / I/\:8%RBJ?_"0Z!_T'+/_ ,"D_P :/^$AT#_H
M.6?_ (%)_C0!<HJG_P )#H'_ $'+/_P*3_&C_A(= _Z#EG_X%)_C0!<HJG_P
MD.@?]!RS_P# I/\ &C_A(= _Z#EG_P"!2?XT 7**I_\ "0Z!_P!!RS_\"D_Q
MH_X2'0/^@Y9_^!2?XT 7**I_\)#H'_0<L_\ P*3_ !H_X2'0/^@Y9_\ @4G^
M- %RBJ?_  D.@?\ 0<L__ I/\:/^$AT#_H.6?_@4G^- %RBJ?_"0Z!_T'+/_
M ,"D_P :/^$AT#_H.6?_ (%)_C0!<HJG_P )#H'_ $'+/_P*3_&C_A(= _Z#
MEG_X%)_C0!<HJG_PD.@?]!RS_P# I/\ &C_A(= _Z#EG_P"!2?XT 7**I_\
M"0Z!_P!!RS_\"D_QH_X2'0/^@Y9_^!2?XT 7**I_\)#H'_0<L_\ P*3_ !H_
MX2'0/^@Y9_\ @4G^- %RBJ?_  D.@?\ 0<L__ I/\:/^$AT#_H.6?_@4G^-
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M2BCFEW#EB+YDO_/9_P#OJCS)?^>S_P#?5)11S2[ARQ%\R7_GL_\ WU1YDO\
MSV?_ +ZI*"<4<TNX<L1?,E_Y[/\ ]]4>9+_SV?\ [ZIN\8S2YHYI=Q6B+YDO
M_/9_^^J/,E_Y[/\ ]]4E%'-+N/EB+YDO_/9_^^J/,E_Y[/\ ]]4E%'-+N'+$
M7S)?^>S_ /?5'F2_\]G_ .^J2BCFEW#EB+YDO_/9_P#OJCS)?^>S_P#?5)11
MS2[ARQ%\R7_GL_\ WU1YDO\ SV?_ +ZI**.:7<.6(OF2_P#/9_\ OJCS)?\
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MWV:/M=W_ ,_,G_?9J.B@"3[7=_\ /S)_WV:/M=W_ ,_,G_?9J.B@"3[7=_\
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MBB@ HHHH **** "BBB@#Z"_9#_Y$G4_^PI_[32O+?^"U_P#RC@\>?]=M-_\
M2^"O4OV0_P#D2=3_ .PI_P"TTKRW_@M?_P HX/'G_7;3?_2^"O/S7_D65O\
M!+\F?9^'/_)P,I_[":'_ *<B?@?1117XN?ZLA1110 4444 %%%% !117U=_P
M3J_X)6?%C]M_5HO&>O/<>&_AY;7&V\\020_O;\J?FAM%;[[=C(?D0_WB-M=&
M%PN(QE94J,;R?]?(\7B#B+)N%\KGF.:5E2I0W;ZOHHK>4GT23;/ ?@E\!/C!
M^T;XWA^'?P5\!:AK^K3<M#9Q?) F<>9*YPL2#^\Y ]Z_2O\ 9R_X(2?!+X->
M%O\ A;O[?GQ4LYX;.(37FBVFI_8M+M!Z3W3%7E^B&,9[N#7=_'O]NO\ 8K_X
M)+> 9/V<OV4_ FG:SXOA7%YI]G+N2"?&/.U&Z&6DE_Z9 E@./W:[:_+G]IO]
ML?\ :'_:[\5-XG^-_P 0[K48TD+6.CPL8K&Q![10*=J\<;CESW8U] Z.4Y+I
M5M6K=E\$?7N_ZLC\5IYEXF>*WOY:WE662VJ25\35CW@KKDBULTUW4IK0_2GX
MD?\ !:']A7]D?0I/AC^Q7\%;?7?LN4631[--+TO<.-QD*&6<^^SYO[_>OD3X
MT?\ !<']OGXLRS6_A_QYI_@K3Y"0MGX5TU4<+VS/-YDN?=64>PKY!HKAQ6?Y
MGB%RJ?)'M'W5^&OXGV&0>#'A_D4O;3POUFL]74Q#]K*3[M2]Q/S44_,ZWQW\
M?/CC\3[EKOXC?&'Q1KLC-ECJVNW%Q^CN17)%F9MS')]316EX.\&>,/B'XFL_
M!?@+POJ&M:OJ$GEV.EZ79O/<3MC.$1 68X!/ Z#->0Y5*LM;MOYL_2J='!Y?
MAVH1C3A%7T2C%)=>B21FUN>%/B9\1_ EVM_X(\?ZUH\R?=FTO5)K=A^*,*I^
M*_"7BGP)XCO/!_C;PY?:1JVGS&*^TW4K5X)[>0?PNC@,I]B*SZ5Y4Y=FC24<
M/C**NE.$E?HTT_O33/IOX0?\%@O^"@7P>EBCM/CK=>(K./&[3_%UNFH(X'8R
M/B8#_=D%?8/P5_X. O@[\4--7P!^V;\ X;2TO%\J\U#2(1J&GR9ZF2UFRZK[
M!I3[5^4=%>KA<]S3"Z1J-KM+5?C^EC\ZX@\(?#WB-.5; QI5-U4HKV4T^]X6
M3:_O*1^O_P 3?^"3?_!/W]N_PC-\6/V'?B?IOAZ^D^9ET*;[1IID/(2>T8B2
MT8XZ+L &3Y;5^;G[5O[#G[1W[&?B3^Q/C3X&DALYIBFG^(+$F;3[W_<E P&Q
MSL<*X'5:XKX2_&?XJ_ CQC;^/_@]X]U+P[J]N?DO--N#&67/W''W9$/=&!4]
MP:_3W]C_ /X+._!G]ISPX/V</^"@WA'1+=]6B%HVO75JK:3J.> +F-LBV?.#
MY@_=@\YCP*]&,\GSGW9I4*KZKX&_-=/ZU9\15POBCX6_O</5EFV71WA/_>:<
M>\9:^T2737LHQ7O'Y-T5^A'_  4A_P""+6M?!O3[SX]?LCQW.O\ @T1FYU+P
MZLAGN]+B(W>;"W)N+<#ZNHY.\98?GOSZ5X>.P.*R^M[*M&SZ=FNZ9^M<)<89
M!QME*S#*JO/':2>DX2_EG'>+7W/=-K4****XSZ@**** "BBB@ HHHH _:[_@
MWE_Y,9U3_LH%]_Z36E>Z?\%(/^39;O\ ["]I_P"AFO"_^#>7_DQG5/\ LH%]
M_P"DUI7NG_!2#_DV6[_["]I_Z&:_3U_R2+_Z]O\ (_S=XN_Y/KB/^PI?FC\\
M:***_)#]Z"BBB@ HHHH **** "BBB@ HHHH **** "OLCX;?\$P?#>L>#+#5
M_'GQ"U*'4KJW2::WTV&+RX=P!V9<$L1GD\#/05\;@$G %?KUX8&/#FG\?\N4
M7_H K['A'+,%F%2J\1#FY4K;VUOV]#\K\4.(<WR/#X58&KR<[E=I*_NJ-EJG
MW9\:?M ?\$Y=$^&WPRU/Q]X$\=7UY-H]LUU=6>I0QXDA49<JR 88+D\@YQCB
MOE"OU1_:5C:7]GOQLD<99F\+7P55')_</7Y7$%3AA67%F78/+\736'CRJ4;M
M:[W\SI\,L^S3/,KK2QU3GE"=DVDG9I.VB74****^3/TL**** "BBB@ HHHH
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M"<O_ "9'\.O^P&?_ $=)7ME>)_\ !.7_ ),C^'7_ & S_P"CI*]LKG ****
M"N2^.O\ R237/^O4?^AK76UR7QU_Y))KG_7J/_0UH ^4**** "BBB@ HHHH
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MXT?_ (**>'2R*2N@ZJ5)'0_96&:^.Z^Q?^"$G_*1/P]_V =4_P#29J]+)_\
MD:T/\<?S/A?%#_DW.;?]@]7_ -(9D_\ !;= G_!2GQ]M'_+OI!/O_P 2NUKY
M0KZP_P""W7_*2KQ]_P!>VC_^FNUKY/J<V_Y&E?\ QR_-FWAO_P F]RC_ +!J
M'_IJ(4445YY]H%%;'@'P!XS^*7C/3OA[\/?#EUJVM:M=+;Z?I]G'NDFD;L/0
M=R3@  DD $UZY^VC_P $]_CK^PI_PC3?&*ZT6XC\3VTKV<FC7C2B*2+9YD+[
MD4[E\Q>0"I['BMHX?$5*,JT8MQC:[Z*YY6(SS)\'FE'+:U>,<164G"#:YI**
MO)I;V23^YVV9[A_P2_\ ^"NOB[]EK4['X*?'G4;K6OAS<2+#;7,C&2Y\/Y.-
M\?4O;_WHNJCE.A1O6/\ @JW_ ,$M?"OBGPM/^V]^QC:6MYI=]:_VEXDT'1</
M!/"R[SJ%F$XVX^:2,<8RRXPPK\PZ^]O^"-__  4SNOV>?%]K^S/\;M?+> =>
MN]FD7UY)\NA7DC>I^[;R,?F'1&._@%R?>RW,*.,HK 8YWB_AEU@^FO;^MMOQ
M[CG@S-.&<TEQEPA'EQ$=<107P8BFM9/E7_+Q;W2O)ZKW_B^":*^[/^"T/_!.
M:W_9G\?K^T-\'=#\KP+XIO2+ZQM8_P!WHVH-EB@ ^[#)\S)V5@R<#8#\)UXV
M.P=;+\5*A56J_%=&O)GZGPGQ3E?&60T<VR^5Z=1;/>,E\4)=I1>C[Z-733"B
MBBN0^C"BBB@ HHHH _:[_@WE_P"3&=4_[*!??^DUI7NG_!2#_DV6[_["]I_Z
M&:\+_P"#>7_DQG5/^R@7W_I-:5[I_P %(/\ DV6[_P"PO:?^AFOT_P#YI%_]
M>W^1_F[Q=_R?7$?]A2_-'YXT445^2'[T%%%% !1110 4444 %%%% !1110 5
MZA^S;^ROX[_:,UIAI/\ Q+]%M9 NH:S-&65#UV(O&]\=L@#J2.,\K\'/AAK7
MQC^)&E?#O0\K)J%QMDFVY$,0^9Y#[*H)]SQWK]1OAQ\/?"_PM\&V/@CP?IZV
M]C8P!(U'5VZL['NS'))[DU]3PUD*S:JZM;^''\7V]._]6_.?$#C27#6'CAL+
M9XBHKJ^JA';FMU;>D5MHV]K/C_A#^R/\#_@W:1'0/"$-YJ"J/,U;5(UGN&;U
M!(PGT4"O2T4(-JBEHW#UK]5P^'P^%IJ%&*BNR5C^;,9C\;F-9UL54E.3ZR;;
M_KR!AD8KSGXM_LJ?!+XQVD@\3^#;>&]=?EU338Q!<H?7<H^?Z,&'M7HH92<
MTM%?#T,53<*L5)=FKBP>.QF7UE6PU24)+K%M/\#\U_VFOV//'G[/-T=85VU;
MP[-)MM]6ABVF(GHDR\[&]#G:>V#P/'Z_7KQ'X>T7Q9H5UX;\1Z9%>6-["T5U
M:S+E9$(P0?\ .17YF_M2_ >\_9]^*MUX20R2:9<+]IT:YDZR6[$_*3_>4@J?
M7 />OR_B7AV.6-8C#_PV[-?RO_)]#^BO#_CJ?$,7@L;;V\5=-:*:6[MTDNJ6
MC6J6C/-Z***^1/U **** "BBB@ HHHH **** "BBB@#]$O\ @G+_ ,FPZ?\
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MO'A91XY_99N])C&^:QAE7;WW1/YJC_OG%>#T =9\#M1&E_%C0[EFVAKORO\
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MO]+^T1J%FM6D0HS+_<<=USVZ<>A.0#Q'X1_ '6O'VS6]<:2QTGJ),?O+@?[
M/0?[1X],U[EX1U#PG;:!>>%?AK=03'1HS$D8=G59"&8 MGYLMG.#Z]*\I_:$
M^,'B*/4Y_AYHEG-I=G;C9.VW8]PN/X<=(\=,=?TJ/]D75S!XLU/16;Y;BQ64
M#U9'Q_)S0!Y_XP^(OC/QQ<M+XFUJ:5=WRVR_+$GT0<?UKT[]D#3RLNNZW)\J
MK'#$K'I_$S?E@?G7E_Q'TH:)X^UC2U7:L.I3!!Z*6)'Z$5[#X.B_X5=^S9>:
MW<#R[K4H7ECSUW2@)'_X[AOSH \0\0W_ /:NOWVJ#_EYO))?^^G)_K5.BB@
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MO]E+_HX_QA_WW8__ !JOR!4E3E3BG>9)_?;\ZTP>89;0PZA5PJG)7O+F:O\
M*QR<3<%\=YQG%3%9=Q#/"T96Y:2H0FHV23M)RBW=IRU6E[7LD?KY_P 0[?[*
M7_1Q_C#_ +[L?_C5>#_\%%/^"07P!_8\_9UN_C/X%_:&U&^U*TO[>&'1]<:V
M/V\2.%9(O*"MO4'?T8;4;..M?GWYDG]]OSII9F^\Q-77S+*ZE&4(811;6CYF
M[/OL<>3\!^(F S2CB<7Q-.M2A).5-X>$5.*>L7+G=KK2Z3:Z:@3CM7]*O['_
M (9T?P?^RK\-_#N@1JMK;>!]+$6S&#FUC8MQZDD_4U_-4>1BOW>_X(N?M5Z)
M^T+^QWH_@J\U1&\2> ((]&UBU9_WAMT&+6?'=6B 7/\ ?B?VKU.#:U.&-G3E
MO):?)ZK]?D?G_P!*;*\?BN$\'C*2;IT:KY[=.>-HR?DFN6_>274^OJ***_1S
M^$PHHHH SO%^@Z/XI\*:EX8\11))I^HV$UK?1R?=:&1"C@Y[%2:_EVF54E9%
MZ!B!7]!7_!4S]K70OV3?V2?$.LC4T3Q'XBLY=(\*VH;]X]S,A5I@/[L2$R$]
M,A1U85_/GSWK\\XTK4I8BE27Q13;^=K?D?V[]%7*<PPV2YCF%5-4JTZ<87ZN
MFI\[7E[Z5^Z:Z'UU_P $M/\ @G?\)/V[[CQ9_P +-^--QX=D\/BV%GI.F& 7
M5RLN_=-^]S^[78%X4\L,D< _8G_$.W^RE_T<?XP_[[L?_C5?D""0<J<4[S)/
M[[?G7B83,,MH8=0JX53DMWS-7U[6/UOB3@KCS-\YJ8K+N(9X6C*W+25"$U&R
M2=I.<6[M.6JTO;9'Z^?\0[?[*7_1Q_C#_ONQ_P#C5?/W_!2'_@D=\!OV,_V?
MF^,7@']H+4-0U&/5(+6/1=<-L6OED;#>3Y05MR#YSP1M!Z<5\">9)_?;\Z0L
MS?>8FKQ&9974HRA#"*+:T?,W;SM8Y<EX#\0LOS6CB<7Q+.O2A).5-X>$5-+>
M+ESNU]KI77342OHK_@DWXPE\%?\ !0WX8:BDNU;O7'T^3W%S!+!C\W%?.M>M
M?L&SRVW[:WPIFA#;A\0-*'R]>;J,5YF!DZ>.I2724?S1]YQ?AX8OA/,*$]I4
M*J?SIR1],?\ !PQX3BT;]M31O$L,6W^VO MJ\K8^_)%<7$>?^^0@_"O@VOTA
M_P"#D*UBC^.7PWO%^_)X3ND;Z+<Y'_H1K\WJ[N((\N<5EYW^])GR7@OB)8KP
MORN<NE/E^492BOP04445XY^GA1110!^UW_!O+_R8SJG_ &4"^_\ 2:TKW3_@
MI!_R;+=_]A>T_P#0S7A?_!O+_P F,ZI_V4"^_P#2:TKW3_@I!_R;+=_]A>T_
M]#-?I_\ S2+_ .O;_(_S=XN_Y/KB/^PI?FC\\:***_)#]Z"BBB@ HHHH ***
M* "BBB@ HHHH ]C_ &'OC?;?!;XV6\NN78AT?6X?L&I2,?EBRP,<I_W7 !/9
M6:OTCCD21%=&#!AD$=Z_'FOJ/]DO]OR7X>Z?:_#GXRO-=:3"HCL-913)-:)V
M21>KH!T(RP'&", ?;\*\04<%%X3$NT6[Q?1-[I^3WOT=[GX_XD\$XK-IK,\!
M'FJ)6G%;R2V:[M;-;M6MJK/[EKG/B!\)/AO\5--_LKX@^#['5(0,1M<0_O(_
M]QQAD/\ ND5H^%?&/A7QQHT7B#PAXAM-2LIES'<V<PD4^W'0^QY%:5?I,HT<
M13LTI1?S3_0_ XSQ6!Q'-%RA.+Z7C)/\&F?)/Q:_X)>:%>^9J7P:\9264A^9
M=+UC,D7T651N4?[P8^]?,OQ4_9Q^,OP9E9O'?@>[M[56PNHPKYMLWI^\3(&?
M1L'VK]4*CNK.UOH'M;R!)(Y%*R1R*&5E/4$'J*^7Q_!^68J\J-Z<O+5?<_T:
M/T3)?%+B#+;0Q5J\/[VDK>4E_P"W)GX]T5]Q?M4_\$^_#OB:PNO'7P/TR/3M
M5C5I9]#APMO>=R(QTB?T PIZ<=:^(+FWN+.XDM+N!XI8G*21R*59&!P00>A!
M[5^=YIE.+RFM[.LM'LUL_P"NJ/W;ASB;*^)L'[;"/5?%%_%%^?D^C6C];I,H
MHHKRSZ(**** "BBB@ HHHH **** "BBB@#]$O^"<O_)L.G_]A2\_]&5ZQ\4O
M^29^(O\ L!W?_HEJ\G_X)R_\FPZ?_P!A2\_]&5ZQ\4O^29^(O^P'=_\ HEJ_
M7H_\DB_^O+_](9_)'$'_ "6V(_Z_/_TL_-6BBBO\H3^OPHHHH **** "BBB@
M HHHH *FTS3Y]6U*WTJU3=)<SI%&H[LS  ?F:AKN?V:= 'B;X]>%M+9-RKJJ
M7#+CJL(,I_1*]3),OEFV=8; QWJU(07_ &_)1_4X\PQ4<#E];$O:$92_\!3?
MZ'K_ .W]J,'A[0?!OPMTY\0V=J\S1CLJ(D49_+S*^9Z]E_;N\0'6?C[<:>'R
MNEZ9;VR^V093^LE>-5]QXQ9A',?$C,'#X:<U2BNB5**IV7SBW\SYS@/"O"\)
MX52WG'G;[N;<K_<T%%%%?F9]>>P?L+WHM?VA;&'=_P ?&GW4?_D,O_[+7-_M
M061L?C]XJMR,;M4:3_OL!OZU:_9&O_[-_:,\,W!.-]S+%_WW!(G_ +-5_P#;
M5L?L'[1NN$+\MQ%:RK[Y@0']0:_7I_[1X$P?6EF#7RGAT_S1\+']SXD27\^%
M3^<:MOR9U/[,W[4&G:=I@^#'QH\N\\/7<?V>UN[Q=PME/'E29ZQ>AZI].FSX
MI_X)\:CJ/B_[;X!\96,/AVZ<21_:F=Y;=#SM7 (D'H2PSW]3\T$9KZD_9R\-
M:!\+_@0WQI^+GBC5FTRXS]AT>/4)OLXCWE%'DJP61W;/#?*!SZD?4^'>;X;Q
M P\,AXEPJQ%+"0=2.(E4=*5&E&W-&<TFY4]4DMUTT2<?&XIP-;ABM+,LHK.E
M.O)0=)0YU4G+9QC=)2W;>S]7KB?MP^-O"=EH'ASX&>%]06Z;0%5KR17#>5LB
M\J-&(_CQN)';BOG:OK"/P)^SA^UIX.U23X5>&5T#Q!IT>Z-1:K;MN(.S>J$H
MZ,003]X>W?Y1EBF@F>WGCVO&Q5E/8CJ*^8\9,'F5;/Z>>3G2J8;%1M0E1;E!
M0I)0Y-4GS0TYKK5O2VJ7K\ XC"T\MEET8SA6HO\ >*HDI<T[RYM&U:6MO)?-
MMHHHK\?/O HHHH **** "BBB@ HHHH ^G/\ @FY_R%/%G_7O:?\ H4M</_P7
M6_Y(-X-_[&YO_266NX_X)N?\A3Q9_P!>]I_Z%+7#_P#!=;_D@W@W_L;F_P#2
M66O](/H^_P#)J\!ZU?\ T]4/Y1\3O^2TQ/I#_P!-Q/R_HHHK]L/@0HHHH **
M** "BBB@ HHHH **** "OW:_8Z\;6OQ"_97^'WBJWNUF:;PC8QW$BMG]_'"L
M4H^HD1@?<5^$M>Q?LZ?MW?M)?LN:3/X<^%OC*,:3<2&5M)U.T6XMTD/5T#<H
M3WVD ]P:F4>;8#[C_P""Z4^C#]GOPC;SW:+J#>,=UK#D;GB%K,)2!Z F+)]6
M'K7T)^P=X/L? W['/PYT33X519/"MK>RA1UEN4^T2'_ON5J_'#X]?M(?&+]I
M?Q:OC+XP^+Y-3NH8S'9PK&L<%K&3DK'&H"J">IQDX&2<5^O7_!.;XJZ!\5?V
M.? ]WI&H1RSZ+HL.C:E"&R\$]J@BPP[%E5''J'!J)*T0/<****@ S5?3M6TS
M5A,VF:A#<"WN'@G\F0-Y<JG#(<=&!ZCJ*\7_ &^?VMM*_9)^!MUXGMIHI/$F
MJ[K/PO8O@[[@KS,P_N1@[CV)VKQNKYE_X(F?M&ZKX@UKQI\%/&>N275[J%PW
MB*PFNI2SS2L0EWDGJ23"_P#WV?6JY=+@?9/[4OP'T;]I3X$^(/A!J_EI)J5F
M3IMU(O\ QZWB?-#+ZX#@9QU4L.]>3_L2_P#!-'X5?LK6MOXP\3+#XD\;&/,F
ML7$/[FQ)'*6R'[OIYA^<]MH)6OIFFS30V\33SRJB(I9F9L!0.I)]*5^@#N@K
MY3_X*Y_'CP%\/?V6-9^%NI:I;R^(/%BPV^FZ6'#2"-9DD>=EZJBA" QZL0!W
MQQ'[;?\ P5\\(_#C[9\-?V99[77M=7=%=^)&7S+&Q;H1%VN''K_JP>[\@?FI
MXV\<^,/B1XGO/&GCWQ)>:MJM])YEW?7TQDDD;ZGH!T & !P !Q51CU R:***
MU **** "BBB@ HHHH _;C_@G+_R9'\.O^P&?_1TE>V5XG_P3E_Y,C^'7_8#/
M_HZ2O;*YP"BBB@ KDOCK_P DDUS_ *]1_P"AK76UR7QU_P"22:Y_UZC_ -#6
M@#Y0HHHH **** "BBB@ HHHH ]B_9+\2PKJ&J>";QLQW<(N(4;NR_*X_%2/P
M6O-_B%X7E\&>--1\-R*0MO<-Y)_O1GE#^*D5#X*\3W7@WQ38^);3):UG#,H_
MC7HR_BI(_&O6OVF?"EKXET#3_BOX>Q+&8$2Y9!]Z%N4?\"<'ZCTH \1KW3]G
MO7=/\?\ P^U#X3Z^^YH8F$.?O&%CU'NCG/XKZ5X76IX.\5ZIX)\1VOB727Q-
M;29*GI(O\2'V(XH C\4^'-2\(^(+KP[JL6V:UF*-QPP[,/8C!'UJYX!\ Z[\
M1->30]$B_P!JXN&'R0)_>;^@ZFO;/&W@#P_^T-X?T_QIX1OH[>\^5)GD'\&?
MFC<#^)<DCU^A!J'Q?XO\(_L[^%%\&^#(XY]7E3+,P!96(_ULOOZ+_3J .\2^
M*_!W[-WA5?"GA.!+K6)TW-YG+%O^>LN.WHO_ -<TW1O%WPU_:+T2/P[XLMH[
M+6(U_=@-M<-W:)CU![J<_0XS7@NJ:IJ&M:A-JNJW<EQ<7$A>::1LLS5#'))$
MZR1.RLIRK*<$&@#M_B+\ _&G@.22[@MFU'3UY6[M8R2J_P"VO5?KR/>N&KTS
MX?\ [3?C#PNB:=XEC_M:T7@-(VV=1_O_ ,7_  +GWKM8$_9X^-]PL4=NMEJD
M^?E1?L\[-C)Z?)(?S- 'GOP%^$S?$/7CJFK0G^R;!P;C_IN_41C^9]OJ*[7Q
MO^TNGAOQQ!HWA:SAN-)T]O*O=H \[L1&>P7MV)]L&NXU+X>:EH7PR;P+\-+N
M&TF,?E_:;IB&(;[[94??/KCC/'05X;JG[./Q:TYF\OP^ETH_CM;I&S^!(/Z4
M >R>,_!G@WX^^#8=9T:\C^T>638WRK\R-WC<>F>HZ@\CW\O^!NC:WX&^.=OX
M>UZS:WN##-$ZMT8;"P(/<';P:C^&;_&/X1ZWYX\"ZQ-83,!?6:V;LK#^\I (
M##U[]#7NZ:-X=\77&E>-/[/D2YL\R6LDD1CD0,I5D8$9QR>#W% 'C/C+X;W'
MCC]I&\T..,K;,T-S?2 <)%Y:;OQ)X'N:D_:G\:VTMY9_#K2&40Z>HENECZ!\
M81/^ KS_ ,"'I7I?Q.\7>'/A/I=]XM6WC;5=258X$)^:9E7"Y_V%')^OJ17R
MWJ6HWNKW\VJ:C<-+<7$K232-U9B<DT 0T444 %%%% !1110 4444 ?07[(?_
M ").I_\ 84_]II7EO_!:_P#Y1P>//^NVF_\ I?!7J7[(?_(DZG_V%/\ VFE>
M6_\ !:__ )1P>//^NVF_^E\%>?FO_(LK?X)?DS[/PY_Y.!E/_830_P#3D3\#
MZ***_%S_ %9"BBB@ KZ+_P""2VN1^'_^"BGPNO9FVK+KDMM^,UK-$/U<5\Z5
MW7[+_CY?A9^TCX"^(\DFR/0_&&G7DS>D<=RC-_XZ#73@ZGL<93J/I)/[FCPN
M*,#+,N&<=@XJ[JT:L%ZRA)+\SZU_X.&M!DTS]N+1]7V?N]2^'MC*K=BR75W&
M1]0%7\Q7PA7ZB?\ !R)\/':]^%WQ>M(MT4EOJ&DW4R],@Q30C/N&F/X5^7=>
MCQ#3=+.*R[N_WI,^(\$\?',/"[+)Q?PP<'Y.$Y0_2_H%%%%>*?J@4444 %>G
M?LD_M7_%+]C;XR6/QA^%M\/.A_<ZGID['[/J5J2"\$H'8XR&'*L PZ5PO@CP
M1XN^)/BW3_ ?@+P[=:MK&JW2V^GZ=8PEY9Y&/"@#\R>@ ). *WOCG^S]\9/V
M:?')^&WQR\!W7A[6OLD=TMG=21OYD+DA9$>-F1U)5AE6(!5@>016]'ZQ1M7I
MW7*_B71^O<\G,EDN9*648UPFZT)7I2:O*&TGRWNXJ]FTM';5,_H*_8S_ &U_
M@U^VS\+X_B#\+]6\N[@5$USP_=2#[7I<Y'*2*.JD@[9!\K =B"![!7\SO[.G
M[1_Q;_97^*-C\6_@WXGDT[5+-@)HVRT%Y#D;H)DSB2-L<CJ.""& (_>?]@/]
MOKX7?MV_"L>*O"\J:?XCTU4C\3^&9)09;&4CAU[O"Y!V/CL0<$$5^FY%Q!3S
M./LJNE1?=+S7GW7S7E_ ?C!X+XW@&L\QRZ]3 2>^\J3;TC/O%[1GU^&5G9R]
M[KRS]KC]L#X-?L9?"RX^)OQ<UY8\[H])T>W8&ZU.XQD10H3SVW,?E4<DCC.3
M^W)^V[\+?V&OA%+\1?'LWVS4KK=#X<\/0RA9]3N0,[1UVQKP7DP0H/=BJG\$
M?VH/VI?C#^UW\4[OXL?&3Q$UY>392RLH<K;:?!G*P0)D[$'XECRQ))-//<^I
MY7'V=/6H^G1>;_1&/A!X,X[Q Q"Q^.O3P$'K+:51K>$/+I*>RV5W>VO^VC^V
M7\5?VW/C%<?%3XDW(@MXE:#0=#MY";?2[7=D1I_>8]7<C+MZ !1Y'17HWQ:_
M9&_:3^!7@30?B=\6_A!JVAZ#XEC5]'U*Z5"DNY-ZJX1B87*_,$D"L0"0.#C\
MRJ/$XJ4ZTKR>\GOOW['^@&#IY'P[A\-E=!PHQMR4J=U&_*KM03=Y-+5VN]V^
MYYS1117.>P%%%% !7M?_  3AT*7Q)^W?\)]+B3=_Q6UC.V/[L4GFL?P"$UXI
M7V%_P0P^'4OCK_@H+H.M&WWP^%]&U#5)FQ]W]R;=#_WW<+7=EM-ULPI0762_
M,^2X^Q\,KX(S+%2=N6A5:]>1I+YMI'IG_!QIKD=W^TYX'T!),M9^!_-=?3S+
MN8?^TZ_/&OKS_@N1\0HO'/\ P4,\2:9;S^9'X;TG3])5@> 1 )W'X/.P/N#7
MR'6V>5%5S:M)?S-?=I^AY'A+@9Y?X:Y51DM71C+_ ,#]_P#]N"BBBO+/T0**
M** /VN_X-Y?^3&=4_P"R@7W_ *36E>Z?\%(/^39;O_L+VG_H9KPO_@WE_P"3
M&=4_[*!??^DUI7NG_!2#_DV6[_["]I_Z&:_3_P#FD7_U[?Y'^;O%W_)]<1_V
M%+\T?GC1117Y(?O04444 %%%% !1110 4444 %%%% !1110!N>!?B7X^^&>J
M?VSX"\6WVEW&?F:TG*K)[,OW7'L017TI\)/^"H'B?2A%I7QC\)1ZG",!M4TG
M$4X'JT1^1S]"GTKY/HKT<#FV89=+]Q4:7;=?<]#P<XX9R//HVQM!2?\ ,M)+
M_MY6?RV\C]4/A-^T5\'_ (TVP?P%XSM[BXV[I-/F_=7,?UC;!('J,CWKN 01
MD5^/NG:EJ.D7T6J:5?36MS!('AN+>0H\;#H01R#]*_13]A7X^Z[\<_A5*/%U
MSYVL:'="UO+CC=<1E<QRM_M'Y@?4KGO7Z+D'$_\ :E7ZO6CRSM=-;.V^G1_>
M?A/&WAY_JWAOKV$J.=&Z34OBC?;5:-7TV36F^Y[<0",&O@K_ (*3_!VR\$_$
M^R^(VA62PVOB6.0W:QKA1=QXW-[;E93[D,:^]:^=_P#@ICX<@U7]GF'6C$/,
MTO7[>4/W"NKQD?0EU_(5W<3X6.*R:I=:Q]Y?+?\ "YXWAWF57+N*Z"B_=J/D
MDNZEM]TK,_/^BBBOQL_JT**** "BBB@ HHHH **** "BBB@#]$O^"<O_ ";#
MI_\ V%+S_P!&5ZQ\4O\ DF?B+_L!W?\ Z):O)_\ @G+_ ,FPZ?\ ]A2\_P#1
ME>L?%+_DF?B+_L!W?_HEJ_7H_P#)(O\ Z\O_ -(9_)'$'_);8C_K\_\ TL_-
M6BBBO\H3^OPHHHH **** "BBB@ HHHH *]L_8&T3^U/CO_:3)QINCW$RMZ,Q
M2/\ D[5XG7TI_P $[-.CMKWQ=XKG&%MK*WB#'L"7=O\ T 5^G>#>!CF'B;EL
M);1J.;_[AQE4O]\3X_C[$/"\(8N2W<>7_P ":C^IX[^T+KG_  D7QO\ %&J!
MMRMK,T:'_9C;RQ^BBN-JQJ^H2:MJUUJLI.ZYN))6SZLQ/]:KU\'G&.EFF;XC
M&2WJU)S_ / I-_J?2Y?AU@\#2H+[$8Q^Y)?H%%%%>:=9V'[/EPUM\<_",BGK
MX@M4_P"^I O]:[O]OJV6'X]^;M_UVBVS?7EQ_2N ^ O_ "6[PC_V,EE_Z/2O
M1O\ @H)_R72V_P"Q?M__ $9-7Z]E?O>".8)],91:]73DOR/A<;IXA85]Z%3_
M -*1X;7=^(?VA?&7B7X/V/P4O=)TU-+T]HS#<11R"=MA)&27*_Q'HHKA**_,
M\OSC,\JIUZ>$JN"K0=.:7VH-IN+\FTCZ[%8#!XV=.5>"DZ<N:-^DELUYGT9_
MP3E&?''B('_H%Q?^C*\#\6(L7BK4XT'RKJ$P'_?PU[Y_P3E8?\)UXB7//]E1
MG'_;6O!?&'_(VZI_V$I__1C5^F<3?\F?X??_ $]Q?_I<3Y')_P#DNLS_ ,%#
M_P!)9FT445^0GW04444 %%%% !1110 4444 ?3G_  3<_P"0IXL_Z][3_P!"
MEKA_^"ZW_)!O!O\ V-S?^DLM=Q_P3<_Y"GBS_KWM/_0I:X?_ (+K?\D&\&_]
MC<W_ *2RU_I!]'W_ )-7@/6K_P"GJA_*/B=_R6F)](?^FXGY?T445^V'P(44
M44 %%%% !1110 4444 %%%% !1179? #X(>,OVBOBSH_PD\#6I:\U2X"R3LI
M,=K".9)W]%1<GW. ,D@% >__ /!+;]ANT_:<\>77Q%^)NC--X)\//Y<UO)N5
M=3O"ORP C!VH"'<@]T'\1QZC\1O@U\<O^"3?Q=;XZ? LW7B+X7:I<*NN:/-(
M2;>,MQ%.1G!7/[NXQP3M8')#_>WP/^#?@WX _"W1_A/X#L_*T_2;41JY4;YY
M.KS/CJ[L2Q]SQP!72:OI.E:]I=QHNN:;#>6=U"T5U:W,0>.:-AAD93PP(."#
MP:RYM0.4^ WQY^''[1WPXLOB=\,=;6[L;M<2PM@36DP'S0RKGY77/3H1@@D$
M$]G7Y0?$+X[>%O\ @G-^W)K-K^RMK5QJ'A7?''XL\+7$VZU$V29+>)\D[HL_
M*Y^9&+(=P# _I;\!OCQ\./VC?AO8_$_X8ZVMY87:[98VP)K28#YH95_@=<].
MA&""0022C8#SG]NK]AOP=^V5X$C@ENQIOBG2(G/A_6.2BD\F&51]Z)B!DCYE
M/(SRK?ES\+=4^)G[ O[7FCZI\1/#]UIM_P"'-55-7M".+BRDS'*8STD5HV8J
MPX) K]OJ\9_;,_8J^&O[8?@3^QO$4,>G^(+&-CH/B**+,MJY_@?_ )Z1,>J$
M^XP>:(RZ,!OCG_@H1^R%X&^'H^(UQ\;=&U"VEAWVMCI-TMQ>3MC(00*=RMV^
M<*!W(K\W?VSO^"G/Q@_:D>X\'>&3+X7\&LQ4:3:S_O[Y>QN9!C<#_P \UP@[
M[B U>+_'7X$_$K]G7XB7GPS^*.@M9:A:G,<@RT-W$3\LT3_QHW8]0<@@$$#C
M:N,4M0#-%%%6 4444 %%%% !1110 4444 ?MQ_P3E_Y,C^'7_8#/_HZ2O;*\
M3_X)R_\ )D?PZ_[ 9_\ 1TE>V5S@%%%% !7)?'7_ )))KG_7J/\ T-:ZVN2^
M.O\ R237/^O4?^AK0!\H4444 %%%% !1110 4444 %>T?LW>/=.UG2KCX1>*
M]LD,\;_85DZ.K??B_FP_'VKQ>I;*]NM.O([^QG:*:&0/%(C8*L#D$4 ;_P 4
M?AYJ'PW\4RZ+<AGMWR]C<$?ZV//'XCH??ZBN;KZ$T/5O#/[2O@!M!UMH[?6K
M-=VY5^:-^GFJ.Z-T9>W3T->'^+O".N>"-<FT#7[0Q31'Y6_AD7LRGN#_ )YH
M UOA3\5=9^&&M?:K8-/8S,!>69;AQ_>7T8=C^!KU7QK\,_!_QXTG_A.OA]J<
M,>HLO[[=P)&Q]R4=5<>O\Q@UX!6IX3\9^)/!&IKJWAK4WMY>CJ.5D'HRG@B@
M"/Q'X7U_PEJ+:3XBTN:UG7^&1>&'J#T8>XXK/KW30_C_ /#KXB:>N@?%C0(8
M&/'G-&9(2?4'[T9_/'K1JO[,/@GQ1 =5^'/C,)&W*QLRW$?T#*01^.30!X77
MLW[+?A&TL+;4/BAK86.&UC>*UDD_A 7,C_E@9_WJP=3_ &6?BC8L?L26-XHZ
M&&ZVY_[[ KTSQ?X$\5:;\%+7X<>"-.$UU)%'#>,)53"_>D;+$?>;CZ-0!XOX
MG^+_ (SU;QC>^)M(\0WMDL\W[F&"X956,<*" <'C]<UH:9^TG\6M- 6378KI
M1VNK5#^H /ZUI:3^RE\2+U@=2N=/LE_BWSEV'X*"/UKJK+]GSX4_#^%=5^(W
MBQ;G;SY<T@@C;_@()9OP//I0!7\ ?'CXR^.M073M%\&:==8/[ZX*21QQ#U9M
MQ ^G4]A7HGCKXGZ/\-/#R7WBFXCDOGC_ '5G:]9G_P!D'D+G^(_SXKS?Q;^T
MOH'A[3SX=^$N@QQQH-J74D 2-/=8^I/NV/H:\=UO7-7\1ZE)J^N:A+=7$IS)
M-,V2?\![#@4 >^:A9^#/VF_!HOM.D6TUJS3"J[9:!C_"W]Z,]CCCZY%>#^(_
M#FL>%-8FT+7K)H+F!L,C=_0@]P>QJ3PGXLUSP5K<.O\ A^[,,\1_X"Z]U8=P
M:]^N] T#]I'X=V^O3Z;)IVH(&6"X:(_*XZ@'^.,G\OJ#0!\WT5H>*/"VM^#=
M:FT'7[-H;B%N_1U[,I[@^M9] !1110 4444 %%%% 'T%^R'_ ,B3J?\ V%/_
M &FE>6_\%K_^4<'CS_KMIO\ Z7P5ZE^R'_R).I_]A3_VFE>6_P#!:_\ Y1P>
M//\ KMIO_I?!7GYK_P BRM_@E^3/L_#G_DX&4_\ 830_].1/P/HHHK\7/]60
MHHHH * <<T44 ?L1^UU;#]NG_@B3H/QATP?:]8\.:+9:S.5Y;[19;K6^_)?/
M;_@-?CO7ZI?\&^_QVT/QQ\.?'G[%OCUH[J!HY-5TNSN&RL]G<((+R#_=!\ML
M#KYSFOSR_:T^ &N?LN_M%^+/@9KJ2'^P]5DCL;B1<?:;-OGMYO\ @43(QQT)
M([5])G2^N8/#X^/VERR_Q1_SU^2/P?PGE_JSQ-G7!]73V55XBBN]&K9V7E!\
MJ?\ >DSSJBBBOFS]X"M3P3X(\6_$GQ;I_@/P'X?NM6UC5KI;?3].LHB\D\C'
M 4#^O0#DX JOX>T#6/%>OV/A?P]8M=:AJ5Y%:V-K']Z::1PB(,]RQ _&OV,_
M97_98_9X_P"".?[/%U^T[^T]JUG>>.KRU\N::$+(\#L,KIU@IQOD;'SR<9P2
M2J*2?4RO+)YA4;;Y:<=92>R7^9^>^(/'^%X)P-.%.FZ^,KOEH48ZRJ3T5W;5
M13:N_DM7H[]EO]EO]GG_ ((V_L\7G[3?[3FK6=YX\NK3RYIK?;+)%(ZY73;!
M3C>[8P\G (!)*QJ37Y@?MK?M?>/_ -MKXZ7GQF\=VL-FHMULM%TNW.4L+%'=
MHX=W5VW2.S,>K.< # %O]MO]MWXM?MQ?%>7X@_$&Y-KIEJS1^'?#EO*3;Z9;
MD_='3?(V 7D(!8]@H51XS71FF9TZT%A<*N6C';O)_P S_K_@>/X>\ X[*L94
MXBXBJ>VS3$+WG]FC![4J:V26S:]%I=R*]!_9@_:7^)W[)7QCTOXT?"G4Q#?Z
M>VVYM)B?(O[=L>9;S $;D8#Z@A6&" :\^HKQJ=2I1J*<'9K5,_4,;@L)F6#J
M87%04Z=1.,HM7335FFO-'JW[8W[7OQ1_;5^,MU\7_B=+'"3$MOI.CVLC&WTV
MV7I%'NY.3EF8\LS$\# 'E-%%.K5J5ZCJ5'=O5LG+LNP.4X&G@L'35.E32C&*
MV26R_P"#NWJ]0K]<O^"<7_!07X2_MV_"-OV$OVS]-L;K7+C35L=-N+X!8=?A
M11L /'EWD>T,",%BH9<,"*_(VIM/U"_TF_@U72KV:VNK699;>XMY"DD4BG*L
MK#D$$9!'(-=V6YE6RVMS15XO247LU_6Q\GQYP+EO'>4K#UY.G6IOGHU8Z3I5
M%M)--.UTN975[)IJ237TE_P4?_X)O_$/]A'XA_:(!<:QX#UBX;_A'?$7E\H>
MOV6XQPDRCH>!(HW+T95^9Z_7?_@GA_P4.^%W_!0#X73_ +$?[;EE8WWB*^LO
MLMG>:AA8_$,:C@[N/+O$QN!7!8C<N&!%?"W_  4C_P""?7BS]@KXLPZ,-2;5
M/"/B!IIO"FL28$K1H5WP3 =)8]Z@L!M<$,,9*KV9GEM'V/UW!.])[KK!]GY=
MO^&;^3X!XZS;^U)<)\515/,J2O":^#$TU?\ >0>BYK)N2TV;234HQ^<:***\
M$_9 K]6/^#=_X26G@_X;?$C]J?Q6%MK2:1-)L[N;@1V]LAN+I_\ =R\//K$W
MIQ^6&C:/JGB'6+70-$L9+J\OKF.WM+>%2SRRNP54 [DD@"OV'_;/OM+_ .":
M_P#P2&TG]G/0[V.+Q)XDTU=#9H6^:6XN09M2F'<J%:5 >WF1CTKZ+AVG&G6J
M8V?PTHM_-JR7YGX?XX8RMF&48/A7"/\ ?YC6A3TW5.$E*I/T5HW\K]C\G_V@
MOBG>?&_XZ^,/B_>[@WB7Q)>:BL;'F-)9F=$^BJ54>RUQ]%%?/SG*I-REN]3]
MIPN'HX/#0P]%6A!**79)62^Y!1114FX4444 ?M=_P;R_\F,ZI_V4"^_])K2O
M=/\ @I!_R;+=_P#87M/_ $,UX7_P;R_\F,ZI_P!E OO_ $FM*]T_X*0?\FRW
M?_87M/\ T,U^G_\ -(O_ *]O\C_-WB[_ )/KB/\ L*7YH_/&BBBOR0_>@HHH
MH **** "BBB@ HHHH ***!R: "BOT@_9C^"7P>U;X >$=6U7X8:#=75UH<,M
MQ<W&E1222NRY+,Q4DDFN[_X4)\#_ /HD/AK_ ,$L'_Q-?:T>"\56HQJ*K'WD
MGL^JN?D>,\7,OP>+J4'AIODDXWYEK9V/RDHKZ$_X*.^"?"/@?XR:78^#_#5C
MI<,_A^.6:&PM5B1G\Z4;MJ@#. !GVKY[KY7'826!QD\/)W<7:Y^DY+F=/.<K
MI8V$7%5%>SW05]??\$H;N1=0\;V&?E:'3Y,>A!N!_7]*^0:^NO\ @E%$YUOQ
MM< ?*MK8*?J6G/\ 0UZO"]_[>HV_O?\ I+/F_$;E_P!2\5?^Y_Z<@?9U>-_M
M^VRW/[*7B;/6-K)U/IB[A_IFO9*\;_;]NDMOV4O$P;K*UFBCU)NX?Z9K]3S>
MW]DU[_R2_P#26?S?POS?ZRX*W_/VG_Z6C\VZ***_##^QPHHHH **** "BBB@
M HHHH **** /T2_X)R_\FPZ?_P!A2\_]&5ZQ\4O^29^(O^P'=_\ HEJ\G_X)
MR_\ )L.G_P#84O/_ $97K'Q2_P"29^(O^P'=_P#HEJ_7H_\ )(O_ *\O_P!(
M9_)'$'_);8C_ *_/_P!+/S5HHHK_ "A/Z_"BBB@ HHHH **** "BBB@ KZ>_
M93QX9_94\?>,/NLZW81O4QVHVC_OI_UKYAKUK]G3]J%O@OI5]X.\2>%EUC0]
M0E,LEN'4-&Y4*W# JZL ,J<=.M?I?A/GF3Y!Q<L1F-7V4)4JL%4LY*$YP<8R
M:CK;5IV[]%=GR/&V7X[,LC]EA(<\E.$G&Z3E&,DVDWI?3K^9Y*O2BOI\?'K]
MB?Q*AN-<^"$EJ6^\ZZ'"/_'HG%)'XI_X)X:@X+^%)XVY.T6=X,?@C&O5_P"(
M6Y36UPW$6!:>W/4G3?W.#.+_ %RQU/2ME>(3_NQC)?>I'S#17T])XE_X)V6K
M97PW-(?3[+>\>WS,*2/XO?L%Z2=NF?"22\?^%3HXDR?^VKTO^(5Y;3?[[B'
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M9-(C/;S-$S1ME25)&0>XXIMO=7-I)YMK<21MC&Z-BIQZ<5'F@ HHHH ****
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M_:/"?@99-)T-HWS'<3;O]*N5]=\BA01P4B0]Z^UO^"BG[07PX_X)@?L8Z/\
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MH ^G?AS$C?\ !/OQ!(5^;S+CM_TVCKA?V$463]H"U5A_S"[K_P!!%=Y\./\
ME'OXA_ZZW'_HZ.N$_8-_Y."M/^P7=?\ H(K^FI_\EEP1_P!@^%_].2/R"/\
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M.Y'_ -?L5_Z5 ^&RK_DO,Q_Z]T?R9DT445^1'W(4444 %%%% !1110 4444
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M6-5&\!T/RLJ1M&VTC:SRLQ''/WQ965IIUI'8:?:QPP0QA(888PJ(H& H X
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MZ!8R3'\Y>*K:I^UAH^FP?8O _@98U'"-<LL:C_@"?XBO$J* .M\7_&_XD>-
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MM_+M;>21@,[8T+']*CKLOA!\7IOA1<WLL>@17RWJH&W2[&3;G&#@\'=R/84
M<O\ V+K/_0)NO_ =O\*/[%UG_H$W7_@.W^%>Q?\ #8D__0A+_P"#$_\ Q%'_
M  V)/_T(2_\ @Q/_ ,10!X[_ &+K/_0)NO\ P';_  KW#X]6=W/\#?#MO!:R
M22*]KN1(R2/]';M5'_AL2?\ Z$)?_!B?_B*/^&Q)_P#H0E_\&)_^(H \=_L7
M6?\ H$W7_@.W^%']BZS_ - FZ_\  =O\*]B_X;$G_P"A"7_P8G_XBC_AL2?_
M *$)?_!B?_B* /'?[%UG_H$W7_@.W^%5F5D8HZX(X(/:O:_^&Q)_^A"7_P &
M)_\ B*\F\9>)9?&/BB\\3364=NUY-O\ )B^ZO&/Q/')[F@#,HHHH **** "B
MBB@ HHHH **** /H+]D/_D2=3_["G_M-*\M_X+7_ /*.#QY_UVTW_P!+X*]2
M_9#_ .1)U/\ ["G_ +32O+?^"U__ "C@\>?]=M-_]+X*\_-?^196_P $OR9]
MGX<_\G RG_L)H?\ IR)^!]%%%?BY_JR%%%% !1110 4444 %26EW=6%W%?6-
MS)#-#(LD,T+E6C8'(8$<@@\@BHZ* >JLS]&/V%?^"Z_BGP)I]M\(?VS].N/%
M/A\QBWB\5PQB2^MXR,;;F,\728ZMQ)C.?,)P/:/C7_P27_8D_;V\+2?'7]A[
MXGZ3X?OKW+NNCXFTF>4\[);<$/9R>H4#'>(FOQ_KJOA'\</B_P# 3Q3'XT^#
M7Q&U;PWJ4>/])TN\:/S!_=D7[LB^JN"I[BOH,/GG/25#'P]K!;/[2]'_ %ZG
MXKG7A']5S*><<'8MY?BI:RC%7H5/*=/97[I-+=0OJ>E_M*?\$W/VP_V5[B>?
MXD?"*^NM)A8X\1:"AO;%E_O%XQF(>TBH?:O"J_2#]G3_ (.(/BMX;AAT#]IW
MX56/BBV"A)=:T!EL[LCNSPG,,A]E\H5[1-\?O^"$W[;_ /I/Q-\-^'?#FM77
M,TVMZ7)H=WN/\3W=L5C<@_WI6^E:/*LIQFN#Q*B_Y:FC^_K]S.*/B)XC<+?N
M^)\CG5BO^7V#_>1:[NFWS1\^:4?1'X[T5^OEU_P0Q_X)[_&:%M9^ 7[2>K1Q
M2?-'_9/B*QU:W4>V%W8^KD^]<CJ__!MA"9&;P_\ M:-Y>?E^V>$!G'_ ;FLY
M<,9PM814EW4E^K1VT/I!>&,WRXC$3HRZQJ4:B:]>6,E^)^6-%?J19?\ !M?>
M";&J?M:Q^7_T[^#SN_6YKK=)_P"#?;]D/X>VG]L_&O\ :<\036T?^MD\ZRTN
M'\6D$F!^-$>&,XE\4$O62_S95?Z0/A;3TI8R5672,*55M^EX17XGY%5Z1\ _
MV0OVE/VG=433?@C\']8UM&DVR:A';>79P_[]Q)MB7Z%L^U?I[!I?_! C]C4_
M;9+WPAXIU:V^Z6N9?$TSN/\ 87S+>-@?9,'O7!_'+_@X>T'1-+;PI^R1\ 5M
MXH4\NUU/Q1MBBB';9:6[=/3,@^E:+)\OPNN-Q,?\,/>?_ ^XX9>*/&G$?[OA
M;(:K3VJXJU&FO/EO>:])I^1=_9F_X(-?#'X3Z3_PMS]O3XIZ?-:Z?']HNM T
M^^^RZ=;J.?\ 2;MRK./54"#/\3 XIW[6?_!;;X-_ CPC_P *#_X)X^#-,9;"
M$VT/B)-/$.F:>.F;6# \]\\[W 3/.) :_/;]HS]LO]I?]J_5_P"U/CG\6-2U
MB%)-]MI2N(;&V]/+MXP(U..-V"Q[DUYA2J9W1PM-TLNI^S3WD]9OY]/ZM8TP
M'A-F7$..AF7'>-^N3B[QH0O'#0?^'1S]6HWVES(V?B!\0_'/Q6\87WC_ .)'
MBJ^UK6M2F,M[J6H3F265OJ>@'0 8 '  '%8U%%?.RE*4KO5G[=2I4J%*-.E%
M1C%)))622T226B2Z(****1H%%%% !1110 4444 ?M=_P;R_\F,ZI_P!E OO_
M $FM*]T_X*0?\FRW?_87M/\ T,UX7_P;R_\ )C.J?]E OO\ TFM*]T_X*0?\
MFRW?_87M/_0S7Z?_ ,TB_P#KV_R/\W>+O^3ZXC_L*7YH_/&BBBOR0_>@HHHH
M **** "BBB@ HHHH **** "BBB@ K];?AQXAT;Q5X$TG7M U"*ZM+C3X6AFA
M8,I^0?J.A'4&OR2JW9:_KNF1>1INLW5O&>=D-PRCZX!KZ#(<\_L6I-N',I)=
M;6M?R?<^(XTX._UNHT8JM[-TW+[/,FI6OU79'Z<?M9>(]&\._L[>,)-:U".W
M%UH-S:V_F-CS)I(RB(OJ2Q'\^@K\O*LW^LZOJ@4:GJMS<;?N_:)V?'YFJU9Y
M[G/]M8B-3DY5%6M>_6_9&_!O"G^J>!J4'5]HYRYF[<J6EK6N_ON%%%%>&?8!
M1110 4444 %%%% !1110 4444 %%%% 'Z)?\$Y?^38=/_P"PI>?^C*]8^*7_
M "3/Q%_V [O_ -$M7D__  3E_P"38=/_ .PI>?\ HRO6/BE_R3/Q%_V [O\
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M.34O%\D^K-?2Q1PNWF2))(.&?<B@$$*%9L'&#L:9\3O^"7GBKQ9%\+F_9?\
M$.CZ+=7 M+?QTOBR=KV(D[1<O Q,87HQ7G _A/2BX'RC5G1M-;6=8M-(241M
M=7,<(D(SMW,%S^M?2/A__@G9X@N_VZ;K]D_6/$C)I.GJVI7GB".,!FTD(L@E
M / =@R1]PKD]0.=_3/'/_!,CQ!\3;/X2^'_@1K^AV*ZI';:;\25\2S2SF82
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M9:0MN+?G5SQEXU\4_$'7&\2>,=8DOKYHUC:XD502JC 'R@#BO-EQ%@WP_F.
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M= W(STRH]14/PXTS4/AK^RIXX\1^++.2T7Q,UO9:/;W"E6N""<NJGL S'/\
ML'VK2^+?QA\7_#GX=?"R_P#AOXR-K<?\(KY=]' Z2*<)!@21L"I(YQD<<UXW
MX_\ BG\0/BC?QZEX\\47&H21#$*R;5CCSUVHH"KGV'->YQ5G7#/#_$N(QM#V
MLL9+#0IJ-H>R3JX6$'4Y^;F=H2=J?);G5^>VAY^2Y?G&:932P]3D5!5I3;O+
MG:A6E)1Y;<JO)+WN;X?LWU/6O&>JP:'^S=\(=;NUW1V>MS3R+CJJ3%B/R%=A
M^TM\8OBUX%\81ZWX1\.:/J/AS5K.&?3-4DT5;C?E!E6D]<C(_P!EABOFO5/'
M?BW6O"^G^#-4UJ2;2]+9VT^T95VPECEB"!DYSW)K>\!_M#?&3X:Z6-$\'^.;
MBWLU_P!7:S0QSQI_NB56V_ABN7#>*&#5.KA%4KX>$Z6%2J4E%U(U,/15*2<'
M.*G3G=NW/%JT7W1M6X.Q'-"ORTZLHSK-PFY*+C5J<Z]Y1;C*.GV6G=KS.^^+
MOBWX\:Q\ X-6^(,/A[2](UG4D6WTF'3VM[R9D^82A ,;/EY)(.,>HSX;6UXY
M^(GC;XE:JNM>.?$EQJ-PB[8VF8;8QZ*H 51] *Q:_/>,N(*?$6;1KTYU9QA"
M,%*M+FG+ENVW:ZBG)MJ$6U%.UV[L^IR#*YY5@73G&$7*3DU35HJ^R5[-V22<
MFDWV04445\F>V%%%% 'TY_P3<_Y"GBS_ *][3_T*6N'_ ."ZW_)!O!O_ &-S
M?^DLM=Q_P3<_Y"GBS_KWM/\ T*6N'_X+K?\ )!O!O_8W-_Z2RU_I!]'W_DU>
M ]:O_IZH?RCXG?\ ):8GTA_Z;B?E_1117[8? A1110 4444 ?6W_  6 Y^-'
M@;'_ $3/3O\ T9-6'\:/^+-?\$Z/AI\*D_=:A\0M?O/%FK1C[WV>,""V!_V6
M4HP]T->&?%+XR_$SXU:M9ZY\4/%<VK76GZ?'8V<TT:*8K="2L8V*!@%C[\TO
MQ/\ C+\1OC'-H\_Q#U];[^P-$ATC2$CLXH4MK.+.R,+$J@XW'YB"Q[DX%38#
MT;1/V-=2\:_L?M^T_P##?Q--KU]IVMM9^(_"]GIN9=-A&[$^X.6<8\MC\HP'
M)Z*37KG_  2YT'Q=X%TGXI?$WXE6%UI_PW7P'=6^MMJ431VU]<DKY<:!\"1P
MOFKQDCS O5Q7S/\ !K]H+XR_L^:])XD^#OQ OM#NID"7'V=E:*=1T$D;@H^.
MVY3CM6W\;?VQ_P!I7]HG38]$^+WQ5O=4T^&02+IT<,5K;EQT8Q0(B,1V)!([
M4:@>9N06RHX[5]:_LPDC_@F!\?-I_P"8II7_ *.BKY)KI_#OQE^)GA/X=:W\
M)O#WBN:U\.^(I(Y-:TQ(T*731D%"25+#! Z$=*8'T[_P1Y\:QZ9\1?'OPXTJ
MZL(?$'B?P7*GAG^THPT,UY%N98F4_>4[]Q7NJ-5G2?VPOV^]6^*<?P9M_P!G
MWPK'XBDOA:MI\WP]56B?=@LQZ!!U+YVA><XYKX\T;6M8\.ZM;Z]H&J7%C?6D
MRRVMY:3-')#(#D,K*05(/<5[=<?\%-/VX[GPX?#$GQ\OA 8?+-Q'I]HMSM_Z
M[B(2Y]]V?>E;4#Z&^%6M?%W4O^"P7AS2_CCXJ\+ZQXBTG3+BRNKGPC'(MJBB
MPN'6,[U4^8H?#<8!XSP:Y/\ 98^"WPT\3^+?CY\>?&OPV3QSJ7@/4KN?0_!L
MF3'=2O/<,9'09,@'ECC!&-W!.VOE'P#\7?B1\,/B!#\4_ _BVZLO$,,DKQZK
M\LDNZ1661B9 VXL&;).>M:'PX_:&^-'PC^(%U\4?AS\0+[2M<OI)'OKRWVD7
M)=M["2-@4<%N<%2 >@HY0/M#]AS]J+]IOXZ_M#Z'X6\"_!'PAX/\)VMYYOB:
M;PSX.2U2*U52?+:9L[2[;5 &&)/IFJO[('^C?\%D_B D_P K/K'B38&_BS.Q
M'Z<_2OF?QY^WY^U[\2+K3[KQ1\;-0_XE=]'>V<-A;P6<0N(V#)(T<$:+(0P!
M&X'FN0M?VA/C)8?&%OC]8>.KJW\7-=&XDUJ".-'>0KL8LH4(0R\,"N&R<@Y-
M'*!]3_\ !+&^U_P!\</B1\(M4TM-'\5^)/"EPOANV\0611);J%W(C9' W*<E
MB.ZQMZ52TK]L']OO5_BE'\&8/V??"<?B*2^%JVGS?#U5,;;L%F/0(.I?[NWG
M.*^;OBQ^TY\<OC9\0K'XK?$3Q[-=>(=,MXX=/U2SMXK.2!49G3;]G1 "&9CN
MQGGK7>7'_!3/]N.Y\._\(Q)\?+_R##Y9N$T^U6YV_P#7<1>;GWW9]Z+ ?3GP
M>^(WC\?\%*O$7PT_:/\ 'GA2\\3ZU\/IO#-OJ7A99$M8KA@L\<)\Q5/F[=P(
MQ][:HR:^-]!_95^.]Q\=[?X%/\.]4BUY-66WFC^R.$B4/@SE\8\H#YO,SMV\
MYKSTZYK)UG_A(O[6N?[0^T_:/MWGMYWG;MWF;\[MV[G=G.>:]@UK_@HG^V?X
MA\$M\/\ 5OCQJ<FG20^5*RV\"W$D?]UKA8Q,P(ZY<Y[YHV [+_@KO";;]MC6
M+<ON\O0],7=ZXMDYKRC]D-TC_:J^'$DC!57QQI>6;M_I4=<Y\4/BM\0?C1XN
ME\=_$[Q+-JVK30QQ27DT:*S(B[4&$ ' &.E8>G:C?Z1J$&JZ7>26]U:S++;W
M$+E7BD4Y5E(Y!! (/8T= /NJ]UH_![_@M')XV\?Z7<:?I.J>(I+6UU*]@:.%
MS/8")'5V&TC>Z@D' SS7S?\ M3_LX_&'P#^TQXD\#7W@;5KJYU#Q%<S:/);V
M,D@U"&69FBDC*@[]RL,@<@Y!Y!K)^-O[7?[0O[1>A:7X<^,OQ";6K719&DT\
M2:?;Q/&Y4*6+Q1JSD@#[Q-=+X3_X*/?MJ>"O"D?@S0OCMJ'V&&'RH#>65M<S
M1)C "S31M(,#@?-P*$F@/3?^"CMK_P *P^ 'P)_9MU^XB;Q-X9\-7-WKUJL@
M9K,W'D[(R1WRDH^B ]"*^0ZT/%7BSQ/XY\077BOQEK]YJFIWTGF7=_?7#2RS
M-ZLS$D_T%9]" ****H HHHH _;C_ ()R_P#)D?PZ_P"P&?\ T=)7ME>)_P#!
M.7_DR/X=?]@,_P#HZ2O;*YP"BBB@ KDOCK_R237/^O4?^AK76UR7QU_Y))KG
M_7J/_0UH ^4**** "BBB@ HHHH ***]L\'?#SP:G@G3/ VO:5;_VYXDTVYN[
M:\DC'F0, IC /4?+SCV:@#Q.BII;"]AOVTN2W;[0LQB:';\V_.-N/7/%>S66
M@7'P[^&FC3Z9\((]8U34/,;4OMVGM(\.#P",97C&.G0T >)T5[5J>FCX9?#3
M29[#X3V^H75Y9R3ZQ=7UB7:V. 3NX^3&3Z !:\GT'PAXI\4LP\.^'[N\V?ZQ
MK> L%^I' H S:*M:OHFL:!>&PUO2[BTF SY5Q$4;'K@U-H7A;Q)XGE:'P]H=
MU>,GW_L\);;]2.E &?16A?>$_$^FZK'H>H>'[R&\F($-O);L'?Z#'/X5UWQ?
M^%O_  A=AI%WHVAWBP-I,<NI74BLP6=FQACC"G) QQ0!P-%;&C_#[QSX@LO[
M1T7PGJ%S;]IH;5BI^AQS^%9=Y97FGW+V5_:R0S1G$D4T95E/H0>E $=% ]Z]
M?\2ZK\-_A38Z+X=U7X4V.K7TNCPSWEQ+.(V#L.<_(V>0: /(**Z3Q]XM\,^+
MYK3_ (1?P!;Z)Y.X2);S^9YQ)&,_(O3!]>M=?XDG\(_!"&Q\++X(T_6-6EM$
MGU2ZU)2ZH6_Y9J.W^&.N: /+**[SXI^&?#5SX8TGXG^#-,^Q6>J,T-W8JVY;
M>=<\+['#?EVSBN9M/ OC.^O4TZS\+7\D\D F2);5LF,]'Z?=.#STH R:*TI?
M!WBN#65\.R^'+U;YN5M/L[>81Z@8Z>]-U[PIXE\+RI#XBT*ZLFD&8_M$)7=]
M,]: ,^BBB@ HHHH **** /H+]D/_ )$G4_\ L*?^TTKRW_@M?_RC@\>?]=M-
M_P#2^"O4OV0_^1)U/_L*?^TTKRW_ (+7_P#*.#QY_P!=M-_]+X*\_-?^196_
MP2_)GV?AS_R<#*?^PFA_Z<B?@?1117XN?ZL@3CK17V?^R9^S)^S?\$OV3Y/^
M"A'[:OANY\2:;?:HVG_#WP#!.85UBX4LIEF;_GGNCDX/RA8F8A\JIU?#/_!4
MS]EKQ;KL/@OXR_\ !-/X7V_@FZD$-PWAW34CU"RA)QYBR^6ID91S@>63CA@:
M]2.74XPBZ]50<E=)IMV>S=EHGTZVUL?GV(XXQM;%XBGD^6U,73P\G"I.,Z<(
M\\?CA34Y)U)1VE9*/-[JDVF?#=%?1'_!0_\ 94^&?P _:#L?#W[-_C6V\4>%
M_%UA#J'AJUL;Y;NZM#,<"TD"$L6R5*;@&974'+!B?#/&G@;QG\./$=QX/^('
MA34-%U:UV_:M-U2S>">+<H9=R. PRI!&1R"*XL1AZN'J2A-?"[-K5??Y]#ZG
M)L\R_/<OH8O#2TJQYXQDN6=MG>+U3B])=$]+[&516YXF^&?Q$\%Z7H^N>+O
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M-6)7I@(/H*L_$']C7]K#X4^%V\:_$?\ 9T\8Z+I**&EU&^T&9(8AZNVW"?\
M L5H\/5O+E3:CNTG;_@?,XJ><8"-.@L14A3J58IQA*<.9MI:*SM*S=KQNGT9
MYI1116)ZI^UW_!O+_P F,ZI_V4"^_P#2:TKW3_@I!_R;+=_]A>T_]#->%_\
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M;X9\-^'H?@UI/BSQ-K&DK?ZCJVOQ^;#'NXV1H01C.1QC@ DDGBCHGBC]GO\
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MJ#2E>27*VKI.[T;332>]SD:*ZKXD_!7XD_";R9/&WAQK>WN#BWO(95EAD/7
M="1G'8X-6O!O[/OQ9\?6.FZKX7\+-<6NJR2K:7'VB-5_=G#ELME #QD@9/3-
M;1X7XDEF4LO6#JNO&S=/V<N=)M)-QM=)N44G:S;7=&;SC*8X18IXB'LW>TN9
M<K:3;2=[723=O)]CBZ"1G!K6\;^"?$?P[\3W/A#Q79+;WUH5\Z)9ED R PY4
MD<@@UZ1^R)X4\.:OK?B/Q?K6A1:M<>&]!DOM-TF9=RW$P!P2O\6,8Q@\L#U
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M(^),?PAUKPI=6/B234HK!=)OE\F07$CA44[L  EAALXP0<XYHN!SU%>XW/\
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M_ACKVB^'M:^%%Q>3>(;G[/I$VC7,=W%-+M+;"\;$(0H+?/M&%8YP"0WXS?\
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M#6@#Y0HHHH **** "BBB@#=^&GA1_&WCC3O#H0F.:X!N,=HU^9_T!KU;Q_X
M^+VJ_%>+QKX?T6/[+ILT2Z:OVR-<QIVQGHQW<>AKC?@SXB\.^!]!\0>+[S5(
M5U7[$;;2;5F^<LW)8#TSM_)JX(W5RQW-<2<_[1H ]"_:/\*S^$_B&OB&P1H(
M]447,;(<&.88W@$=\X;C^]6M\1_&WC'3_A-X.U.Q\5ZC#<W<4QNKB.\=7EP1
MC<0<M^-8K>)= \5_ G_A'M:U>&/5M#O-^G1S-\TT1ZJ/P)X_V5J'XA^(]#U3
MX5^$=&T_4XI;JQBF%W K?-%DC&: -[XO^*/%!^'?@Z.+Q%?+_:>EN+_%T_\
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MIP8S)?[4RG,I8?GK4JT\#&7+A7AZ4W'$P<W&%W*4HP=JD^11Y5%<SY7;OO\
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M1110 4444 ?HE_P3E_Y-AT__ +"EY_Z,KUCXI?\ ),_$7_8#N_\ T2U>3_\
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M^7R9?E)/LIVM_P !KTKX<?!FQ^'7[4/B35=;M_+T/P5;S:O&S#Y3&REK=?J
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M8^.:>]&<J2IVYJM)4ZD6FK4U)*//&UVVHV32]YW.8HHHK\;/OPHHHH ****
M/IS_ ()N?\A3Q9_U[VG_ *%+7#_\%UO^2#>#?^QN;_TEEKN/^";G_(4\6?\
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M RS<<UZ?\.O"6C^/?^"U>K:9XG1;BVT_Q-J-];V\_P RF:&W9X\ ^CA6_P"
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M&.SAU"XATZY,UNLS+!,R[3(@/RMCMD<XJ&J _;C_ ()R_P#)D?PZ_P"P&?\
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M)_R;!I__ &%+S_T97K'Q2_Y)GXB_[ =W_P"B6K]>C_R2+_Z\O_TAG\D<0?\
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MBCWH *^B?A]_P4!ELOA5H_P;^/7P!\+?$C1_#D7E>'YM:WPW=C%C C$J@Y0
M  8!P "2 ,?.U>K_ +&/[-EI^U;\<+;X07WBR318[C3KFZ^W0V8G8&)-VW:6
M7KZYXJ7Y@6OVC_VR/&7Q_P##6D_#73O!VB>#_!>ARF72_"OANW,=NLI!_>R$
M\R/\S<X &XG&22?'J]/\$:!^SEX4\*ZKXB^+UWK6NZK#K[:=IOA?0[]+%Q B
MY>\FFDAE&TG"*BC.0Q) QFM^TU\(_#?PA\;Z7;>#+Z^ET?Q#X8L->TN#5E7[
M9:0W4>\03[ %+J0?F  92IP,T_(#SFBBBF 4444 ?MQ_P3E_Y,C^'7_8#/\
MZ.DKVRO$_P#@G+_R9'\.O^P&?_1TE>V5S@%%%% !7)?'7_DDFN?]>H_]#6NM
MKDOCK_R237/^O4?^AK0!\H4444 %%%% !1110 5V.@>!-$\0?"75_%EI)/\
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MCDMGD@\?@*P/B'XE\8:I\*[)[_P7H^D:3>7WF6B649CD9P&^;83T([X]/44
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M"BBB@ HHHH **** /VN_X-Y?^3&=4_[*!??^DUI7NG_!2#_DV6[_ .PO:?\
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M>YA?$OX%_"OQ'\()OCY^SQJVIMIFG72V_B#0=:VM<6#,0%<,OWER5]>#G/!
MW-/_ &?OV?/"_P  O"/QX^*.OZY'#JD<RW>EZ6R--?3^8PC2+< (U"HQ8D^F
M".[O@)I]YX,_8T^*GC'Q)"T-AX@CM;'2/.&//F4R*Q3/WN95Y'=&]#4/Q])_
MX8H^$"YX\R_/_D0U:HX6-&6)E2CS.ES<MM%+VBBFEV:UMMKV,98K,*F+AE\<
M3/DCB73YTUS.'L'-Q;MJXR]WFW5D]U<J_$7X+? KQG\!+[X]_L_3:U8KHE]'
M;:UHNM2*[*'95#*1GNZG[Q!&>A&*\'KZ"^"G_)BOQ5_["5C_ .C(Z^?:\G-(
MT^6C5C%1<X7:6BOS25TNETD?3<.5,0I8O#5*DIJE5<8N3O+E<(2LWULY.S>M
MCZN\">'_ (:ZW^P#H]Y\6M?O+'1=+\7S7D\>FQJUQ>./.C6"/=P&8R9R>@4]
M.HXW_A2_P ^.?P_USQ%^SNVNZ5KWANS-Y>:#KDR2B\ME^\\;*2<CZ]<#'S U
M<U7PSKNO?\$Y-&U#1[22:'2_&,]S?K&I.R+]ZGF'V#.N?3=FF?L V5WX?U[Q
MA\5=6C:+0M'\)W,=]=2#]VTC%66//=L(3CZ>HS[?[NOB,/AJE).,J<;RMK\+
M]Y/HH_=H[GR'[[!X''YA0Q$E.GB)\L$URM\Z]QQM[SG?=ZJZY;6UY*;X*^#]
M<_917XW>$)KQM8TC6OL7B:UDF#1K&Q^21%"Y4?/$.2>2WI4/P,^#GA/Q9\-?
M''Q9^(<MW'I?AG356Q6UF$9N+Z0_NTR5/ .T$<']X.:Z7]A[Q#INM>)_$7P#
M\1SA=-\>:+-:QAND=TB,T;CWQOQ[A:O_ +15A<_ ;]FOP?\ L]R 0ZMK%Q)K
MGB5%/S Y*Q(?;^L(KCIX;#2PL<=RKEC!J2Z.HO=C]_-&3]&>MB,PS"GF4\G5
M1^TJ58RA+JJ,KSG9_P!UPG!=N:)\\FNV\6_'+Q+XM^$GAWX.2Z?:6>E^'I99
M8_LN\-=2.<[Y<L06&7P0!]XUQ.:][_9V^!'@S1O 3?M)?'33[F[T.&;R]!\/
MVT)>35IP3R0.L8((QT.TDG:,-Y67T<5B*DJ5%V37O-[**:;;\KI>;V/I,\Q6
M7X&A3Q.*AS.,E[.*UDYM-)17=IO?1*[=K7-?X$Z)J/PG_9+^(7Q ^(9:VTOQ
M9IZV/A_3KAOFO)RKJ)E4]LL,'N$8] "<_P 3/)X+_P"">GA^UTMC"WBSQ9-+
MJ3IP9DB,BJA]LQ(<?[-</\?_ (M?%?XZ^(O[=\3^'[RQTNQ0II>DPVKK;V,(
M_  M@#+'T[  #N-5@N?B+_P3[TDZ)$UQ-X*\53#4XHQEHH)?,;S"!VS*O/U]
M#7LTZU.I&I0HWM3I246]'+WDY.W1-.5ET6_4^2K8/$49T,9C'%2K8FG*<8N\
M8)0E&G&_5IJ%Y=9;:)#?V"V?Q+>^._A3J3E]-USP7</) WW1-&RJCX]0)&Y^
MGI7ENC?%_P =Z1\,=0^">CSP1Z3K&H)<7BI;CSI9 5PN_J5^1?EZ?F:]5_87
MM[GP?:^/OC3JD+1:7HWA&XMEN9/E5[B0JRQJ>Y^3&/\ :7U%>>:#\ /$/BCX
M%ZG\=-!UF"ZCT?4!;ZAI4,;&XA3"GSCVVC<#],GC!KFE'%2RV@J5^;EJ-VWY
M+J_R^+\3T:=3+H9]C7B;<G/02NKKVMG;TE\&KVTU/:? 'PF\:?LK_L__ !!\
M4?%>QW'Q'I/]F6>CV#_:E60AQYLSQ;HXU7=P2WJ.I /,?!=Y/!G[#_Q*\=:8
MS17VJ:M;:2;A.&6']WN7/;(F8'ZU-_P3TNO$]U\2-8M-2FEE\(_V!<'Q/'=,
M6M0FWY2V?EW9S[[=W;-'P9A3X@?LC?%#X7>%HFGO-/U:'6;&T09DEMPR;B .
M20L/;N1ZUZ-#V=2E2G132]G6C%/5W2;;OI>]]+)6::/!QBK8?%8FEBY*;]MA
M9U)Q7+'D<E%1<;OEY>1-WE*Z:;=M#G_V!->N]+_:5T?10Y:SUJUN[+4+?^&:
M,P.X!'?YT4US?A32%\*_M2Z;X3M)&^SV/Q"MX%CW<$1WH521ZX_G74?L!^&;
MW4?VAK'Q=)$R:;X<L[J^U2\;B.%/(D1<MT!W.#]%;TKRWQUXE;Q%\0-7\7V,
MK1F^UBXNX75B&7?*S@@]B,UY//[+*:$Y+55)->EH7^5_QN?3^R6)XFQE.F]'
M0IJ792<JEK^:B_NL3?%G_DJ?B;_L8+S_ -'O7/TZ666>5III&=V8LS,V2Q/4
MDTVO(J2YZCEW;9]10I^QHQIWO9)?<K!1114&I^B7_!.7_DV'3_\ L*7G_HRO
M6/BE_P DS\1?]@.[_P#1+5Y/_P $Y?\ DV'3_P#L*7G_ *,KUCXI?\DS\1?]
M@.[_ /1+5^O1_P"21?\ UY?_ *0S^2.(/^2VQ'_7Y_\ I9^:M%%%?Y0G]?A1
M110 4444 %>S>%/"WPU^#OP8TWXN_$3P;'XCU?Q%<2)HFDW4Q6WAA0X,C@?>
M['H?O*!CDUXS7NWB_0-7^-7[+O@W5? EC)J%WX/>XLM6TZU4O,BOLQ)L')&(
MU/']X^AQ^B>'^'4_[1Q-"E&KBJ-!SHPE%37-[2G&<U"2:E*%)SDDT[6YK>Z?
M*\45.7ZI2J3<*-2KRU))N.G))QBY)II2FHIM-;VOJ=+\+O%GPR\9?!;XE:UX
M0\$Q^'=4_P"$;=-2T^UG+6TB!)-DL8/W3]X%>G />O.-&\"^$KG]D+6/B!/H
MD3:Q;^)H[:&^);<D1$65QG&.3V[UUGP$^%GC#PE\$_B1XP\5:-<:?'?>&9H+
M*"\C,<DH56+/L;D*#M )&#FLGP__ ,F(:]_V.$/\H:_3,3#%9CD^$J9KAHQJ
M?V=C9J/LXP5U4FXU%!12C)_%=)7;YEN?'T94<+CJ\<%5<H?6L/&_,Y:<L4X\
MUVVEM9M]NAG:+XG_ &??AAX T>\M_!]GXU\3:BIDU)=0>1(-/Z8BV8PQYQD9
MR03G&!6SXU\,_#OXG?L]ZK\8M"^%P\)ZKH-]#%-#:L_V>\CD=$RH( X,@/ X
MV]3GCIO%%SXE^!?PS\(R_ 3X<V=ZFKZ2EQJ7B-=)^US/<,JG9G!V]3@$$=AC
M!JYXENOC+K?['OC+5_C+=S-J%U<6<MG8SPI#);VXN8<,8U"[,D,<$ X6N^GD
ML(8/&Y5BJ<9>RP-2?)3PD%1A*.']I"?UJ4O;2J.5GS)-2DVD^167-+,)2Q&'
MQM&37/B(QYIUY.<HNKRRC[%+DC%*ZLVFE9M<QPUCX?\ AE\!/A1H/C7QUX$@
M\3>(O%,;7-C8WTI6WL[88P2H^\Q#*>1W/3;SLVF@_ ?XG? +QE\4/#OPYBTG
M6M-M8TGL8[AGAMI-V5EAY& X)!!X!7@=S5^*/A77OCM\$/ _CCX<Z;)JDV@Z
M:=+UK3[-=\T$B! K;!R0=I/'9E/3.-3X>?"CQ7\./V4OB%J?C'39+&ZU:UA:
M&QN.)4B1L!V7JNXLV >?EK'!9?BHYM4P%# 4YY9' SJ0J.C!KF^J.7MO;<O,
MZCJMQ:YO==XI+E5M,1BJ,L%#$U<3*.,>)C&454DM/;)<GL[V45"S7NZ[W=W?
M%\ >#O@QI/[,,/Q=\?\ @YM0O+3Q%)%'##<-&U[\I5(';/RH"=Y(&?D[]#-I
M]E\(?V@/A-XKU31?A99^%]<\*Z?]MAFTV8F.>,!CM88&3A".03R"#U%9]]_R
M8;:_]CP?_1;T[]E$9^'?Q6X_YDZ3_P! FK@P-;#2S3+,C>&H^PKX#FJ?NJ?/
M.?L*LE/VCCSJ2<8M.,EJK[MWZL13JK!8S,?:S]K2Q-H>_+EC'VL(N/+?E::;
MO=/>W1%'X6^ _ASX,^#\_P ?/BMH+:TLVH?8=!T/SC''/(,Y=R.<##>H&P\$
MD8VO ]I\'_VGX]0\#:?\,;+PGXFALY+G1;O2IF\BX*CF-U./;GDXR<C&"S1]
M$U#XR?L?6GA;P7 ;O6/"6N23W6F0\RR02>8=ZKU;[_X[&QS@4O[(OP\\3>!O
M&]U\8_'VBW6BZ+X?TVX>:XU&W:'S79"FQ0X!8X)Z=\#J11DN!J1S/)LKH8.$
M\NQ%&G*O-TH2YN9/ZQ4E6<7*$J+YDK3C[/D6FKNLPQ$7@\?C*N(E'%TJDE3B
MIR5K->RBJ::C)5%:]XOFYGKII4^ GPO\.#X5>(OBQK/P^D\6ZII.H"TM?#H=
M@J<*6E=5!+8W'C!X4\=QG>*_%/P'\>_#_5CJ?@&W\%>+-/96TV'3XYC%?>L;
M)MPA&.K8Y*G/458^#^C_ !=E\+^(/C+\$_&<RZE;ZH1?^&[.W\R26)CN$A0Y
M5Q\QP-I/#8Z5Z!I?B3Q/\:_A3XKO/VBOAA:6$>CZ.\VF^(I=-:UF^T ':J[^
MI)Q]W _A(.:TR?+\/C^'</E^'H*E*>'JR7M</"I1KI>T?MOK,'[6C4BEM+2$
MHQ3M%M.<=BJF&S:KBJM1S4:L%[E64*E._(O9^RDN2<7?IK)2;W5UP?@CP+\/
M_A=\'-/^,?Q%\&2>)=2UZYDCT+16D988HD)!EEV@YR1G'(P5]21>TSP]\.OV
MC/"VMVWA[X5Q^$_%&BZ:U_9_V>S_ &6^B0C=&58#:W( QSD@YP"*ZSP_\0/B
MYJ'[+7AO5/@#J9:_\/M)9^(--M[&*XFVY.QPDB,>F#\HYW'KM.,_PMX\_; \
M1^$=<\7^,?'_ /PC6D:78,[W&K>&[:/[4W3RD4Q*Q)Z9'<@=3QZ5'+^'\/3P
M>7PP]6KAJF%C.4882A*,VZ7-4J_6YUH3C.$^;7W53<>2S7Q<E3%9I6E7Q3JP
MA6C6<4Y5ZB<;3M"'L8TY1<91MIJY*7->^W'_  S\&?#OX?\ P7;X]_$[PU_;
MDE]J367A[1I)BD,C+G=)(1U&5<8P1\OOQZ#^SQXU^%OCBR\9:CX=^'L'AK7(
MO"ETD]KI\Y:VNK<C[X4CY&5@ <<$-W[<E8:-J/QD_8_TWP[X*MVO-6\'ZU*]
M[IL'S2R02&1@ZKU/WQTZ[6J]^R9\*/&OA^U\7^._$NA76FVK>$KRTM8[Z$Q/
M.S ,2JL 2%"<G&,L/PQX5CF67Y_D^%RS"1E@ZF&C4E/V49-SE2DZTW6Y7.,J
M=2\$E-)**A:TFGIG4L)BLMQU;%UY*O&JXJ/.TE%37)%4[\K4HVE?E;;;E?33
MSOX8>&/&,>DV_C?X1>/8;?6TGEM]3L6OHK26UB^4I(&D<"2-N=W'RE<$'K6?
M\<[[PWJ/Q-OKKPQ):R1^5 +R>Q4+!-=")1.\8'&TR;B,<'J.#7( #'2EK\'Q
M.>TJN11RVE2<5S1DVYN4>:,91O"+7N.?->I[TN9I648KE/TFCELJ>9/%SG=V
M:7NI.S:=I-?$HVM'163=[MW"BBBOG3U@HHHH **** /IS_@FY_R%/%G_ %[V
MG_H4M</_ ,%UO^2#>#?^QN;_ -)9:[C_ ()N?\A3Q9_U[VG_ *%+7#_\%UO^
M2#>#?^QN;_TEEK_2#Z/O_)J\!ZU?_3U0_E'Q._Y+3$^D/_3<3\OZ***_;#X$
M**** /N+]@V;X36G_!.WXO:C\<+.ZNO#-IXFL[C4+"QF\N6\9/L[16X?^'S)
M0B$\8#'D=:S?@7J7[(?[>.O7G[.T_P"S1I'PW\17FGSR>#?$7AV^D;$T:%Q%
M<*0/-^4$DG.0K ;3@T[]C/X0^)_CE_P37^,/P]\%0";5IO$UG<:?:[PIN9(1
M!+Y2YZLP0JH[L163_P $UOV<OBCX#_:*A^/GQ;\'ZGX3\*^ ;.\O=9U;Q!8R
M6D8;[/)%Y:^8 6;YRQP#@+ZD QW YW]D[]EWX?67A+X@?M$?M->'K[4O#_PX
MO?[-_P"$7T^1EDU75-X3R&9?F"*S)G!'W\DX4@]I\)O$O[*_[7WC6'X!>,?V
M-K+X>3ZYOM_#?BOPO-*)+.YVDQB=655E#$8R>Y P,[AW7[%_QX^(WQ.^!OQL
M\,?LWZ]#I7Q'NO&%QXL\/64]O;RO=VL\J&6)4G5D9@J,O3AG3D9S6;\"/C!_
MP5Z^,WQ%_P"$,U7QCJ'A.QM5DDUCQ!X@^'MC;VVGHBDDL7M5W'(P%!SSGH":
M0'Q)\2O FL_"[XA:Y\-O$07[=H.K7&GWA3[K20R-&2OL2N1[&O=?^";?P>^&
MGQB\6?$.P^)GA&WU>'2?AM?:CIL=PS@07221!91M(Y 8]<CFO&?C?XBUCQ9\
M8/$WB+7_ !E!XBO+K6KAKC7[6U6"/46$A'VA(U "*^-P  X/2OHS_@DA_P C
MO\5/^R1ZE_Z-AJG\(#OV,_@Y^S1K_P"QI\1OC?\ '_P5-J*^$_$%N\<MC<-'
M<S1[8MMHK9PJRR,J,V,@,2".HZKX!#]DO]O?2?%OP7T[]E;2?A_X@TKPQ<:K
MX;US0]0=V_=%$VS$JOF'=(F=VX,N[[I )Y/]G_\ Y11?&[_L:M,_]&VE'_!&
MW_DY7Q-_V374O_1]K1W [7_@EM\2/AY9_!'XL:'=_!?3[F\T/P!?WNM:H]_*
M'UNVQ,WV211Q&FWY=R\X-4/V3?&7A'Q]\'OVIO%/@7X;6?A+3;CX<6XM]!L;
MIYH[?;;7BL0[_,=Q!;GN:YG_ ()C_P#)._V@_P#LD=]_Z)FH_P"">'_)L/[3
M/_9.8_\ T3?4O^ !S6B_!_X:W/\ P3 UCXV3^$K=O%5O\1H]/AUG<_F+;&.(
M^7C.W&6/;/-)_P $^/@_\-?BQI/Q;G^(GA*WU1M ^&UYJ.CM<,X^RW2*=LJ[
M2.1[Y%=Y\"_!'B7XU?\ !)WQI\/?AGI4VKZ]H_Q#CU"YT>R7?<-!Y<'S*@Y;
M(#D #)\M@,D8KH?^"=G[/7Q5^%_PA^,WQ#^)?A"^\/PZI\-]0L])L]8MVM[B
MZVPN\LBQ. ^Q?W8W$8)<8HON!Y?^RM\"/@_X5_9XUK]LO]H7P7>>*M/L]772
M/"?@^UF>-=2O,;FDE9>?+7GVPCY#?*#VGPFL/V;_ -N[6+SX&WG[*]C\,?%5
MUI\\WA+Q)X=DE6W,\:%Q#<QLH# @'YN20"!M.#75_L:?%;XVZU_P3MU7P/\
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M_%7QM\/]7\/Z3X=LKQ&FUJQDM3<W$MO)"((UD +L [N<# "<]LG>X'"_LS?
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M4 %%%% !1110 4444 %%%% 'T%^R'_R).I_]A3_VFE>6_P#!:_\ Y1P>//\
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M[WN^[NKW+WASQ1XE\'ZJNM^%->N].ND&%N+.=HVQZ$@\CVZ5I^,?BQ\2_B#
MEKXT\;ZCJ4,;;D@N+@^6&]=H^7/OC-<]16M/-<THX.6#IUYJE+>"E)0?K%.S
M^:,Y8'!U,0J\J<7-;2:7,O1VNC1\,>+_ !5X)U+^V/!_B*\TVZV[3-9SM&6'
MH<=1['BM#QE\6OB;\0;=;/QGXXU'4(8VW);SW!\L'UVC"Y]\9KGJ*=/-LUHX
M&6#IUYJC+>"E)0?K&]G\T$L#@JF(6(E2BYK:3BN9>CM<T_"OC3Q=X&U#^U?!
MWB2\TRX*[6DLYV3</0XZCV/%7?&7Q5^)/Q"CC@\:^-M0U**-MT<%Q<$QJWKM
M'RY]\9KGZ**>;9I2P+P<*\U1>\%*2@_6-[/[@E@<%/$+$2I1=1;2Y5S+T=KF
MAX:\5^)_!FJ+K?A+Q!=Z;=*N//LYC&Q'H<=1['BM;5?C3\7-;U"35-4^(VK2
MW$EJ]LS_ &QE_<MC='@<!3@9&.<5S-%5A\XS;"X;ZO1Q$XT[WY5.2C?O9.U_
M.UQ5,OP-:M[6I2C*5K7<4W;M=J]@' HHHKS3K"BBB@ HHHH **** /IS_@FY
M_P A3Q9_U[VG_H4M</\ \%UO^2#>#?\ L;F_])9:[C_@FY_R%/%G_7O:?^A2
MUP__  76_P"2#>#?^QN;_P!)9:_T@^C[_P FKP'K5_\ 3U0_E'Q._P"2TQ/I
M#_TW$_+^BBBOVP^!"BBB@#HO#/Q;^*'@OP[<>$O"/Q!UC2]-N[R*\N+'3]0D
MACDN(F5HY2%(^=612&Z@J,=*W/B5^U-^T5\8= B\*_$WXR^(-:TV$J5L;S4&
M,3,.C.HP'([%LD5P-%("]X9\4>)/!FN6_B?PCK]YI>I6<F^UOM/N6AFB;U5U
M((/T-=YX[_;$_:C^)OAM_!_COXZ^)-1TR5-D]E+J++',O]V0+CS![-FO-:*
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M9W8\LQ.233:**8!1110 4444 ?MQ_P $Y?\ DR/X=?\ 8#/_ *.DKVRO$_\
M@G+_ ,F1_#K_ + 9_P#1TE>V5S@%%%% !7._%?0M4\3?#W5-!T6W\VZN;<+#
M&7"[CN!ZGCH*Z*N3^.7Q?\/_  $^%&M?%_Q5I]Y=:=H=LL]U;Z>B-,ZEU3"A
MV52<L.I% 'A/_#-_Q?\ ^A93_P #8O\ XJC_ (9O^+__ $+*?^!L7_Q5<;_P
M_-_9>_Z)KX\_\ ;/_P"2J/\ A^;^R]_T37QY_P" -G_\E57+(#LO^&;_ (O_
M /0LI_X&Q?\ Q5'_  S?\7_^A93_ ,#8O_BJXW_A^;^R]_T37QY_X V?_P E
M4?\ #\W]E[_HFOCS_P  ;/\ ^2J.60'9?\,W_%__ *%E/_ V+_XJC_AF_P"+
M_P#T+*?^!L7_ ,57&_\ #\W]E[_HFOCS_P  ;/\ ^2J/^'YO[+W_ $37QY_X
M V?_ ,E4<L@.R_X9O^+_ /T+*?\ @;%_\51_PS?\7_\ H64_\#8O_BJXW_A^
M;^R]_P!$U\>?^ -G_P#)5'_#\W]E[_HFOCS_ , ;/_Y*HY9 =E_PS?\ %_\
MZ%E/_ V+_P"*H_X9O^+_ /T+*?\ @;%_\57&_P##\W]E[_HFOCS_ , ;/_Y*
MH_X?F_LO?]$U\>?^ -G_ /)5'+(#LO\ AF_XO_\ 0LI_X&Q?_%4?\,W_ !?_
M .A93_P-B_\ BJXW_A^;^R]_T37QY_X V?\ \E4?\/S?V7O^B:^//_ &S_\
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MX&Q?_%5QO_#\W]E[_HFOCS_P!L__ )*H_P"'YO[+W_1-?'G_ ( V?_R51RR
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M_P#Z%'Q)_P" ]O\ _'J/^'BOP?\ ^A1\2?\ @/;_ /QZC_7+P>_Z&T?O?_R
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M_P#Z%'Q)_P" ]O\ _'J/^'BOP?\ ^A1\2?\ @/;_ /QZE_KEX/?]#:/WO_Y
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M_@VMO_CE'_#OW]J?_HGT7_@VMO\ XY6]_P 1&7['G_1(_B1_X+[#_P"3*/\
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M (E?\/\ _G_B?_ Z?_RH^Z_XC!Q-_P ^Z7_@,O\ Y,^8O^&*?VC_ /H18_\
MP:6__P 71_PQ3^T?_P!"+'_X-+?_ .+KZ=_X:Y^'W_0!UC_OS%_\<H_X:Y^'
MW_0!UC_OS%_\<H_XE@\/_P#H(Q/_ ('3_P#E0?\ $8.)_P#GW2_\!E_\F?,7
M_#%/[1__ $(L?_@TM_\ XNC_ (8I_:/_ .A%C_\ !I;_ /Q=?3O_  US\/O^
M@#K'_?F+_P".4?\ #7/P^_Z .L?]^8O_ (Y1_P 2P>'_ /T$8G_P.G_\J#_B
M,'$__/NE_P" R_\ DSYB_P"&*?VC_P#H18__  :6_P#\71_PQ3^T?_T(L?\
MX-+?_P"+KZ=_X:Y^'W_0!UC_ +\Q?_'*/^&N?A]_T =8_P"_,7_QRC_B6#P_
M_P"@C$_^!T__ )4'_$8.)_\ GW2_\!E_\F?,7_#%/[1__0BQ_P#@TM__ (NC
M_ABG]H__ *$6/_P:6_\ \77T[_PUS\/O^@#K'_?F+_XY1_PUS\/O^@#K'_?F
M+_XY1_Q+!X?_ /01B?\ P.G_ /*@_P"(P<3_ //NE_X#+_Y,^8O^&*?VC_\
MH18__!I;_P#Q='_#%/[1_P#T(L?_ (-+?_XNOIW_ (:Y^'W_ $ =8_[\Q?\
MQRC_ (:Y^'W_ $ =8_[\Q?\ QRC_ (E@\/\ _H(Q/_@=/_Y4'_$8.)_^?=+_
M ,!E_P#)GS%_PQ3^T?\ ]"+'_P"#2W_^+H_X8I_:/_Z$6/\ \&EO_P#%U]._
M\-<_#[_H ZQ_WYB_^.4?\-<_#[_H ZQ_WYB_^.4?\2P>'_\ T$8G_P #I_\
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M  :6_P#\77T[_P -<_#[_H ZQ_WYB_\ CE'_  US\/O^@#K'_?F+_P".4?\
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M /0KJ_\ DO\ \D?-_P#PZ7_;J_Z)##_X4%E_\=H_X=+_ +=7_1(8?_"@LO\
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M^B1_$C_P7V'_ ,F4?ZPY3_S^B'_$&_$__H5U?_)?_DCYO_X=+_MU?]$AA_\
M"@LO_CM'_#I?]NK_ *)##_X4%E_\=KZ0_P"(C+]CS_HD?Q(_\%]A_P#)E'_$
M1E^QY_T2/XD?^"^P_P#DRC_6'*?^?T0_X@WXG_\ 0KJ_^2__ "1\W_\ #I?]
MNK_HD,/_ (4%E_\ ':/^'2_[=7_1(8?_  H++_X[7TA_Q$9?L>?]$C^)'_@O
ML/\ Y,H_XB,OV//^B1_$C_P7V'_R91_K#E/_ #^B'_$&_$__ *%=7_R7_P"2
M/F__ (=+_MU?]$AA_P#"@LO_ ([1_P .E_VZO^B0P_\ A067_P =KZ0_XB,O
MV//^B1_$C_P7V'_R91_Q$9?L>?\ 1(_B1_X+[#_Y,H_UARG_ )_1#_B#?B?_
M -"NK_Y+_P#)'S?_ ,.E_P!NK_HD,/\ X4%E_P#':/\ ATO^W5_T2&'_ ,*"
MR_\ CM?2'_$1E^QY_P!$C^)'_@OL/_DRC_B(R_8\_P"B1_$C_P %]A_\F4?Z
MPY3_ ,_HA_Q!OQ/_ .A75_\ )?\ Y(^;_P#ATO\ MU?]$AA_\*"R_P#CM'_#
MI?\ ;J_Z)##_ .%!9?\ QVOI#_B(R_8\_P"B1_$C_P %]A_\F4?\1&7['G_1
M(_B1_P""^P_^3*/]8<I_Y_1#_B#?B?\ ]"NK_P"2_P#R1\W_ /#I?]NK_HD,
M/_A067_QVC_ATO\ MU?]$AA_\*"R_P#CM?2'_$1E^QY_T2/XD?\ @OL/_DRC
M_B(R_8\_Z)'\2/\ P7V'_P F4?ZPY3_S^B'_ !!OQ/\ ^A75_P#)?_DCYO\
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M4-$N-0T^.]LX=0MS&TUO(,JXSV[$=0000""* .?HHHH **** "BBB@ HHHH
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M/PSHHHKYX_TE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /W2_X(.?\H\-%_[&/5/_ $?7O7[6
M?_)-+;_L,1?^BY:\%_X(.?\ */#1?^QCU3_T?7O7[6?_ "32V_[#$7_HN6OV
M;)O^170_PQ_(_P K_%'_ ).-FW_815_]+9\YT445Z1\&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?4O[.7_)&=&_[>/_ $HEKX@_X./O^3;? /\ V/#?^D<U?;_[.7_)&=&_
M[>/_ $HEKX@_X./O^3;? /\ V/#?^D<U>/Q#_P B>MZ+\T?J7@G_ ,G2RO\
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M0/AS\3O@-X_D\)^/?#U]H.O:7,LBQS*4=6#926-APRY&5=20<<&A2N!]]?\
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M$]_^2'W7_8P3_P#HN*O)/^"]G_*/;4_^QHTO_P!&-7K?_!/?_DA]U_V,$_\
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M;Q'_ .2!S;_L'K?^FY'O<*_\E-@O^OM/_P!+1\&T445_E8?V<%%%% !1110
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M5Y)_P7L_Y1[:G_V-&E_^C&K_ $M\/?\ DT&!_P"P=?J?SUD?_)],+_V%P_\
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MT7YH_4O!/_DZ65_XW_Z1,_'FBBBOQ\_TZ"BBB@ HHHH **** "BBB@ HHHH
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MPM\*F1O)N+@P)JDD(W2L\@(*V\8X;:0SL=H(P:]6^)G_  7J\)?"*Y_X5O\
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M*'ZXW#\!7B]?3'[4%O'-\*+B1\;H;R%T^N[;_(FOF>@ HHHH **** "BBB@
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MQLVVF@HHHKQS]0"BBB@ HHHH _H8_P""4O\ RCQ^%?\ V+I_]'RU]"5\]_\
M!*7_ )1X_"O_ +%T_P#H^6OH2OVS+_\ D7T?\,?R1_DUQM_R6>9?]A%;_P!.
M2"BBBNP^8"O#_P#@I-_R8Y\1/^P/'_Z415[A7A__  4F_P"3'/B)_P!@>/\
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M2<M;-N-]-DM+SQ%B..L0\4L%2IPH0BTG-MRJ+EU<;:+LD[:[OMZO^V+^SO\
M$7XV>(-"O_!"V+1V5K+%<?:KCRRI9@0>AR..U?-_Q0_9K^+OPCLO[6\5>'5>
MQW;6O[&831(>V['*_5@!7T5^V[\>/B#\*+G0]!\ ZHMA)J$,LUS=B!)'PK*
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MNO\ L8)__1<5>2?\%[/^4>VI_P#8T:7_ .C&K_2WP]_Y-!@?^P=?J?SUD?\
MR?3"_P#87#_TI'X9T445\\?Z2A1110 4444 %%%% !1110 4444 ?JE\&M T
M?_@JS_P28L_V?= UBVC^)/PI:%=/M;B0*9&@21+8GTCFMV:+=T$B9/"U^8GC
MOP!XV^%_BN\\"_$7PM?:+K&G3&*]T[4;=HI8F'J".AZ@C@CD$BOIK_@EG^S'
M^WEX_P#BS:_&/]DV[;PO9Z;*8+_Q=K&4TV5,@O;,F";O.!F-5(4A22AVM7ZQ
M_&SQ_P#L*6>DZ?X=_;H\:?!O5O$MG:HMY#KEK9LRR=VBMYVEFB0GMD]>M?8T
M\O\ [<P4*U5^SG%*/-+X9I;=4[KJ]OT_E_&<:?\ $).+,3E67Q6/P^(G*M["
MDVZ^&G/6<6E&47"3UC%N,E?;K+\'O@-^S_\ %G]I;XCV/PL^#GA"YU?5;V10
MPAC/E6T><&:9^D<:]V;CL,D@']V_"/[%_P $?AK^QKX9_9I^).L6EWX1\#K#
MJ7C#[0X6"_F@+7DAGY^6$SMYQ4]455.5)S8\$>/OV:O&/PTU+X>_\$[/C!\(
M_#_B"YA)L8]$L;2:.!\??>SMY(F)]&8$ \E6Z5\P_P#!4K5?BI^R=_P3!T3X
M->)?&-QK?BSQMKPM_''B>-G87COYEU<G>0"%9EBA52!^Z&T  8'IX++\-DF%
MJUY?O+Q=VK<NZM%:MN[W;TLCX'BOC7/O%KB++\IHWP%J\5&E+F]M=QDY5Y-Q
MC&*IQ4E!1;ES-N^S7R;_ ,%&_P#@K!\3/VI_$5[\+O@YJ]UX9^&-BYMK'3]/
M8V\NKQK\HEN"N#Y9 ^6$851C<"W(^.?PHHKX3%8S$8VLZM:5V_P\EV1_8'#?
M#.2\)Y5#+\LI*G3BNF\GUE)[RD^K>ORT"O3OV7?VO_CS^R!X[A\<_!;QK<67
M[Q3J&D3.SV.HQ@\QSPYPP(Z,,.O56!YKS&BLJ=6I1J*=-M-;-'I8_+\#FF#G
MA,92C4IS5I1DDXM>:>A^J/[6?PM^$/\ P5N_8U;]M_\ 9^\.1Z;\2_"5HR>*
M-$@P9KE84#2VLF #(RI^\@DQED^3J<)^5U?<7_! _P".FJ?#K]LP_"2:\;^R
M?'NCSVTUJS?)]JMT:>&3'J%69/I(:^>?V]?A!I_P'_;(^(WPKT>V6&QTWQ-.
M^FP*,"*UFQ/"@]ECE0?A7M9GRXW!T\>E:3;C.W625T_FMS\IX CB.$^*L=P;
M.;G0IPCB,*Y-N4:,Y.,J;;U:IU-(7N[/7HCR.BBBO!/V(**** "BBB@ HHHH
M **** /W2_X(.?\ */#1?^QCU3_T?7O7[6?_ "32V_[#$7_HN6O!?^"#G_*/
M#1?^QCU3_P!'U[U^UG_R32V_[#$7_HN6OV;)O^170_PQ_(_RO\4?^3C9M_V$
M5?\ TMGSG1117I'P84444 %%%% !1110 4444 %%%% !70?#CX<Z[\2M=71]
M(CV1KAKJ[9?D@3U/J?0=_P R#X<_#G7OB1KRZ1H\>V-,-=73+\D">I]3Z#O^
M9KZD\$>"-"\ :#'H.@VVV->99&^_,_=F/<_R' H /!/@G0? &@QZ#H%MLC7F
M21OOROW9CW/\N@KSOX\?'U?#HF\&>"[E6OR"EY>(<BV_V5_V_?\ A^O3T3Q]
M;^(;OP;J5MX4DVZ@]JPM6S@[O8]CC.#V-?(%[!=VMW);W\4B3I(PF28$,K9Y
M!SWS0!&[L[%W8LS'+,QY-)110 5-IVG7VKWT6F:9:23W$SA(H8URS,>U0U[#
MX.^(OP=^%/@RWU3PW9MJ/B"XM1]H\R-@T<F/F4L1A4SV7)/&?6@#1\6P6WP5
M^ ?_  A5Q<*VJZR6$RJW=L>8?HJ +GUJY^R7X2N=.T"^\6W<97^T)%BMMPZQ
MIG+?0L<?\!KE_ ?@/Q7\?O%+^./'-Q(NF+)C*Y428/\ JHAV4=S]>I)KWZ&+
M3-!TQ88EBM;2UAPJ\*D:*/T  H \R_:SUR.R\#6NAA_WE]?!MO\ L("2?S*U
M\\5V'QN^(P^(WC22^LW;[#:+Y%B#_$H/+_5CS],>E<?0 4444 %%%% !1110
M 4444 ?4O[.7_)&=&_[>/_2B6OB#_@X^_P"3;? /_8\-_P"D<U?;_P"SE_R1
MG1O^WC_THEKX@_X./O\ DVWP#_V/#?\ I'-7C\0_\B>MZ+\T?J7@G_R=+*_\
M;_\ 2)GX\T445^/G^G04444 %%%% !1110 4444 %%%% !1110!8TG2M4U[5
M;;0]$TZ:\O;RX2"SM+:,O)-(Q"JBJ.68D@ #DFOV$_X)S_\ !%CX9?!3PQ9_
M'#]K_2;+7/%7D?:X_#^H%7T[0U W?O0?EGF4<L6S&AZ D!Z\;_X-^/V-M*\<
M^+]8_:\\=Z0MQ;>&KK^S?"4<T>5-\4#37.#WCC9%4\C=*QX*"OHC_@N]X<_:
MRU_]F^&X^"-XTG@FU\R3X@Z?I887LL(P4=L??MEY,BCH<,V5!V_:9-E=/"Y?
M+,J]/G:5XQ].K_K1:G\K^*7B!C^(.-J/ >48U82$I*->NW9\TE?V<6K6TLFD
MTYS:@W%)W^POA=\4?AA\6?!+>)O@KXQT;7M)AFEM(;G2+M7MUEB.TQY3.W!
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M]3?L:?\ !3S7_P!C[X2S?"K3/A!9Z['-K$U_]MGUAX&!D2-=FT1MT\OKGO2
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M0^Z_[&"?_P!%Q5Y)_P %[/\ E'MJ?_8T:7_Z,:O6_P#@GO\ \D/NO^Q@G_\
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M_!6O2?A=\5O#<EG?>&])U2]DN(P6@N[4VLD,=Q"^/GC9Y% /4'((# @> ?L
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M'O!NH6NJ^'I)3(_A_649X8W/5HF4AHB>^#M)Y()YKPJB@#Z:_:V_X*C?&O\
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M%%?Y6']G!1110 4444 %%%% !6]\+-*UO6_B7H.E>&[EH+^;5K=;6X7K$WF
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MH **** "BBB@ HHHH _=+_@@Y_RCPT7_ +&/5/\ T?7O7[6?_)-+;_L,1?\
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M*[#Y@*\/_P""DW_)CGQ$_P"P/'_Z415[A7A__!2;_DQSXB?]@>/_ -*(J:W
M_$NBBBMP"BBB@ HHHH *^PO^",GQUA^''[2%U\+-9O%CT_QM8>1#O;"B]AW2
M1?\ ?2F5!ZEE%?'M7O"_B36O!OB73_%WAR^:UU#2[V*[L;F/[T4T;AT8>X8
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M3JQD)[N[@?,>N&KY_P#V>O%3^#?C7X;UPW;0PC5(HKEE; \N0[&S[8:O5/\
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MLCL/]C^?TH^.WQYD\7R2>%/"-PR:6K;;BX7(:Z/I[)_/Z5Y70 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?4O[.7_)&=&_[>/\ THEKX@_X./O^3;?
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M+R011S1/C$D;EP58?0X((&7_ ,'%6LVMW^UYX5T:)@9+/P#"TV#TWWES@?\
MCM<\H3APFX5%9QJ6L_7_ (<]C#XK"XGZ2%+$8&:G"M@U)RBTTTXMIW6C32A;
MY'Y_T445\B?TP%%%% !1110 4444 %%%% !1110 4444 %%%% ']#'_!*7_E
M'C\*_P#L73_Z/EKZ$KY[_P""4O\ RCQ^%?\ V+I_]'RU]"5^V9?_ ,B^C_AC
M^2/\FN-O^2SS+_L(K?\ IR04445V'S 5X?\ \%)O^3'/B)_V!X__ $HBKW"O
M#_\ @I-_R8Y\1/\ L#Q_^E$5-;@?B71116X!1110 4444 %%%% 'U!_P3#_;
M4_X9?^*[>#?'.HE?!?BB5(M2:0Y73[G[L=T/1>=K^JX/.P"NK_X*A_L%WOPJ
M\;_\+X^#.AR7GA'Q1>*UQ::?'Y@T^]E/"J%S^ZE8Y3' 9MO&4!^-*^_O^"7W
M_!1[3_#EK8_LT?M":VJZ:K+%X5\07S_+;'(VVLS'H@./+<_=^Z2!MVR^Z K?
M#C_@F5\'OA%^RGX@^,?[;?B.?0]3OM,SIL-O-^\T5CAHP$!Q/<NP ,9R I*\
M'++\&3")9F6!V:,,=C,N"1V)&3C\S7W]_P %H/A/^TWJ_B*S^)T]_)JWPWL8
M46SM--C(72)B 'DN$!.XN>DW0 A/EXW?G_THCM< HHHJ@"BBB@ HHHH ****
M "OO'2?^";/P+_:*_8QT7XA_LF^,9M2\9:? [ZJU],(SJ%S@-)9RQDD6SH>(
M\'!!!8L&#CX.K["_X)!^#?VI+CXVCQA\)Y&LO!L<BP^,+K4D;[%=1CGR4'&^
MX&<J5^YG+':Q5IEL!P_["W[!OC7]I?XV3>'_ !MH=]I/AOPO>8\737$+12+(
MI_X\ER,B5B,'^XN6/.T'U[_@K/\ M@Z%J1MOV.?@I+#;^'O#ICC\0-886)YH
MAB.R7''EQ8!;U< <;#GV/_@I3_P42T+X$Z7J7P,^ E];GQEJ6?[<U:Q"XTD,
MH4Y(^]<E0 .Z#!/.T5^6TTTMQ*T\\C/([%G=FR6)ZDGUI1][5@-HHHJP"BBB
M@ HHHH **** /U%_X(5_\F]>+_\ L<S_ .DD%?1/[:W_ ";GKG^_;?\ I1'7
MSM_P0K_Y-Z\7_P#8YG_TD@KZ)_;6_P"3<]<_W[;_ -*(Z^&\1_\ D@<V_P"P
M>M_Z;D>]PK_R4V"_Z^T__2T?!M%%%?Y6']G!1110 4444 %%%% !1110 !G4
M[D8JPY5@>E?87P^\4> ?VRO@\GP\\<WJV_B+3XEWLN/-611@7,>?O*P^\OJ2
M#CY37Q[4VFZGJ6C7\>J:1J$UK=0MNAN+>4H\;>H8<BOON N.)\&XRM"O06(P
MF(CR5J,M%./1I])1N^5^;6E[KYGB;AV.?4*<J=1TJ])\U.:WB^J:ZIZ77DO1
M_77[-7[).K_"_P <ZU<?$31=)U:QDLUCTN]95D4Y<[AY;C*'&,\>P)KYK^._
M@9OAW\7=>\)K9^1!!J#O9Q@<>0YW1X]MI _"N\\#?MW?&WPJ(;77IK/7+:-@
M&^VP[9BOIYB8Y]R&_&O8/$'A_P""W[<7A:'6M"UT:;XBLH=K94&XMQU\N1,C
MS(\DD,#P2<$9(K]FQ65^'_B1P72R7@^3IXS#SE5A2K\L:E13NYTXSO:5M.6\
MFTHI2T]Y?G]'&<3<)\03S#/EST*L5"4Z=W&+C;EDX[J^M]$KMV['COPM_;@^
M*_P\TJ'P_K%I:Z]8VZ!(/MC,DZ*. HD7J,?W@3[UWWAG]OOQ9XS\=Z'X7TKX
M=6-G#J&J06URTUX\[['<*=N @!P>X/TKCM4_X)]_&^TNFBTW4=#O(=WR3+>.
MAQZD,G'X9KO?@3^QVOP@\0P_%/XO^*]-7^R<S6]O#,1#$X'$DDCA?N]0 .N#
MGC!TX1H_2'HX[#Y96G6HX:$H\\ZJARQIQ:YOWDDY-**=E&3[+0G/)^%L\/5Q
M=.,)UI)\L8.5W)K3W$TDV^K7F=5^U%^U#XI^ GC#1](TCPQ97]G?6+S7'VIG
M5V8/M 1@<# '.0>HZ=_+O$O_  44\=ZA9-;^%_ 6FZ;*RX\^YN7N-ON  @S]
M<CV->L_%;P3\*_VQ_"*/X)\<VLE]I,SBUOH5+>4QX9)$.&VM@$'V!&1U\+N/
MV /CO'>&WM[C0Y8]V%N!J#!<>N"F?TKZCQ&QGC9_;M:MPQ7G7RZORRIRH*G-
M)<J4DI).4;23=T[.][WO;Q^%*'A[_9T*><4XT\53NIJHY1OJVG9M1>C6C5^E
MK6/(?%7BSQ#XVU^Y\4^*]4DO+Z[?=//)W[  #@ #@ < =*^LK?\ 9K>__8]M
MO".D^"[.7Q->6D-VLDRI'*DSS*YS(W(*QDJ1GH,5F?#/]B[P=\)F7XA_'/QA
M8W"Z>1,MJ&V6D;#D%V?!DYZ+@ GUZ5C_ !8_X*":_P#VO-I/PATFU2QB.Q-3
MU"%FDF_VE3("CTW9)[@=*^1X7X<RGP[RW'9GX@5'&MCJ<Z4*2<:E=QGK4J?:
M49-VM*3T=^9W=G[F<9MC.*L5AL'PQ"]/#RC.4W>%.\=(PZ-I:W2W5K:*YU?P
M5_9\\'_LNZ3<?%SXO>([5M2@@*QLA_=6@8<JF1F21ON\#V Y)KYJ^-WQ4U#X
MQ_$>^\;7D310R,(K&W8_ZFW7A%^O5C[L:H>/?B?X_P#BAJ(U+QWXHNM0=?\
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M:;GY#XSUX8/A_!8FHGR4L9AIRLG)J,9\TG:*;=DNBN?E;17Z9?\ #CS]C_\
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M_"_B3QEK5OX;\):#>:GJ%U)LMK&PMFFEE;T55!)K]"_"/_!&KX%?"C31XO\
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M8G)8D\DD]S4=%%4 4444 %%%% !1110 4444 ?J+_P $*_\ DWKQ?_V.9_\
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M8*X&5/9AD'L:P:QE&496DK,]2C6HXBDJM*2E%JZ::::[IK1H****DT"BBB@
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M7=Z;XX_:0UC3_+U+5PHEL?!\<B\QQYZR8/3[S\%]J81O#?\ @E]XI\1>-_\
M@IU\//&/B[6KC4-5U3Q-=76H7UU(6DN)GM;AG=B>I))-53G+#U:6&JRYJDJD
M)/6_+9VM?^9WU[62W,<PPM#/,#F.>Y;AUA\#2P.)HTFH\CQ"E!/GY;*U&'):
MES*\G*4DE&U_8_VD?^"=7P9U7]J+QDGQQ_;P\&^!?%OB[QAJ&H:'X5FTZ2\,
M4-Q<N]O]KG61$MF=64[6S@,#D]*^:_&_[#7Q:^%O[8.B_L=_$R>UTW5M<URQ
ML;'6( TUK/!=S+'%=Q_=+Q\GC@@JRG!!K'_;>N?$UY^V+\49O&#S-J'_  GN
MJK-YV=P474@0<_PA H'MBON/]I<SM^T/^P?)XL#?\)8VB>'?^$@,W^N(^U67
ME[\\YW^?U[Y]ZQE1P>,G5:I\KA-=7JI2LT[]>NENNAZ6'S+B;A?"Y?3JXWV\
M<3AJK2<(15*=*A[6,J;BDW"RY6JCFVW%\VK1X_KW_!)?X:?"#QS<> /VH/V]
M/!?@74KB^:+P_8R::]U<7EONVQW4Z"55M(W()7>QR.21R*\$_;-_8_\ B)^Q
M1\8F^$WC_4;+4EN-/CU#1M9TUCY&H6<C,JRJ&Y4[D92IS@KP6!#'L_\ @K;J
M%]J7_!17XH27UT\C1:U##'N/W8TM(551[ "O4/\ @LS))/IW[/-S/(SR2? _
M33)(W+,< Y)[\UGBL/@G2Q"I4^5TI))W;;3;6M]/N2.[AO..*J>89)4Q^-]M
M#,*,I3A[.G&-.2I0J)TW%*5M7&2G*5]UR['Q'1117@G[$%%%% '[I?\ !!S_
M )1X:+_V,>J?^CZ]Z_:S_P"2:6W_ &&(O_1<M>"_\$'/^4>&B_\ 8QZI_P"C
MZ]Z_:S_Y)I;?]AB+_P!%RU^S9-_R*Z'^&/Y'^5_BC_R<;-O^PBK_ .EL^<Z*
M**](^#"BBB@ KT_X^?\ (D^!/^P*?_0(:\PKT_X^?\B3X$_[ I_] AH J7'P
M%@T:WL]6\5>/['3=/N[2.6.XEA)=G89\M4!RV!C)R!R*Q_B)\*Y_!&G6?B'3
MM>M]6TF_8K;WUNNWYL9VD9.. >YZ'I6_^T9+*4\*P%SL7P["RKZ$]3^@INKD
MM^R]I>XYQXB8+[?++0!YM7;>*OBS)<>$M'\'>"I+S3;6QM<7PC?8;B;NV5.2
M,Y//K["N)KN_AM\,=*N]);XB?$6]^QZ#;O\ (O22\8?P+WQGCCD]NY !LV]Y
MJ^M?LWZE>^-[B2=8=0C&AW%TQ:0G*A@I/)'WA_WUZ5S/P\U3X:^&;"3Q-XJL
MIM2U2&?&GZ7MQ"< $22''3/;GIT-,^*'Q0N_']W#965HMCH]B-FGZ?'PJ+TW
M''\6/P X'<GE* /3/VIIVNO'&FW+KM,FA0L0.V7D->9UZ3^T[_R.&E?]B_!_
MZ%)7FU '1ZM\/+C3_A]I_P 0[74TN+:\N&@FB6,AK>09X//.<'T[>M-\(^ +
MCQ1H&L>)9=26TM='MQ))(\9;S'.=L8Y')Q^HKI_@S*OB_P '^(OA1<ONDNK7
M[;I@;M,F,@?7"_@&H\8 ^ _@AH_@_&R\UZ=M0OU[B,8V*?\ QW\5- $&@? <
MZEX=T_Q?K/C6RTW3;RW:22XN5QY3;MJIRPW$\GMC%5=(^#L&H2:IJ=WXVLK;
M0]+NOL[:RT999WXX10>>H[]^,UJ?$Z>5?@9X(ME<['$[,OJ0>#^I_.JGPY\;
MQ^'_  1=:%XX\"W&J>&KN\#?:(U*^7-@#"MP"?E' ((_&@"IXC^$5M:^%IO&
M?@OQE:ZY86K!;SRX6BDAST)4D\<^W\ZXJO4[CP/\/_%?A35M6^$/BO4K=[.U
M-Q?:->,=KQJ"<>_&<9+<^F:\L.>M !73?#J7X<Z>]UK?CY+FZ:UV&QTRW7BY
M8YSO/91@=^<]^E<S10!ZI^T?JPU[P]X-UI;1+=;K3))5@C^[&&$1VCV'2J_P
M_GE\$?!'7/'NEMY>I7EZEA;7*_>B3Y2V/0D$_B!Z5'\;?^1!\ _]@,_^@Q4:
M:?[2_9CU"V@Y;3_$"2S*.RL% /YM0!-\!O$NK>*M>O/AWXFU.XO;#6+"96CN
MI3)LD W!USG!QG\<'M1\+89/!'@'Q=X^A5?[0L]MA9RE<F)F8*S#WY4_A5']
MF>W:3XJV]]TCL[.>69NRKL*Y/XL*T/#EVNO?!'QM;VHS(FJ1WA0=?++J<_@%
M/Y4 5_@5XUUW4_':^%/$6JW%]I^M12P7=O=3&122A(;YB<'C'T-<'XBTLZ'K
M]]HI.?LEW)#GUVL1_2NG_9^LIKWXMZ3Y2$^3))(Y]%$;<U@^.KV+4O&NKZA
M<QS:E.Z$=P9#B@#*HHHH **** /J7]G+_DC.C?\ ;Q_Z42U\0?\ !Q]_R;;X
M!_['AO\ TCFK[?\ V<O^2,Z-_P!O'_I1+7Q!_P ''W_)MO@'_L>&_P#2.:O'
MXA_Y$];T7YH_4O!/_DZ65_XW_P"D3/QYHHHK\?/].CZ^_P""%_\ RD;\*_\
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M=@/(C8, A7?$23GB3...?T2\/ZGIMI\:+;_@DC/>1KI\G[-3:#<0[QM'B22
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MI[C9X;CETU[FZU&' 'VJ2$2K]EA+[E#.QSL8\"M#]M[XM:%XT_X*D?#GX/>
MV">%?A3X@\/^%-#MXVRB&WNH?./^\)/W9/?RA7G_ /P6FU"]U#_@I+\0EO+E
MY%MQI<,"LW$<8TVU.T>@R2?J2>]56H9?A:52:I\_)*,%=NS?*^9Z-/5IVM8Y
M\KS;C;B#,<!A98QX98G#UL3+EITW.,?;4U1@N>,DG&G4BI.2DVU+JTUY_P#M
MG_L3_$C]C#XKV/PW\3:M8Z_:ZY81WWAK7-&W-#J=N[;5*J>0^[@KD]5(+ @U
MZY>?\$M/A[\*M!TG3_VM?VW/"/PU\::]8I=6/@^YTJ6^DM4?[GVN6-U%OD\$
MD%00<,V#7MG[0AT*Y\=_\$_9?&+J]BWA[0A>-<$;2OF:;]XG^'U]J^7/^"M#
M>)V_X*(?$\^*A-YW]M1_9?.S_P >OV>+R,9_A\O;BC%87!X+VE7DYES123;L
MN:/,[V:;[+7UN'#_ !)Q3Q7+ 9=];]A-TJ]2K5A"#E4=*O["*C&<9PBG;GJ6
MBWJE'E3N>[_\%7/A7X@^"'["/[-/PH\4WMC=7VB1:U#)>:7=":VN5+6[I+$X
MQN1T964X!PPR >*Q=2_X(NZ5\/DAU7X]?MJ^"_ ^DZMI=O-X9OM9MUC;5+F2
M+S)(5C>="%C#("X+$E\!1CG+_;FN_$][_P $N?V49_%S3&[%OKR1>=G=]E6>
M-;;KV\@18]L5?_X+M:I?W'QO^&.D373M;6OP@TV2"'=\J,\UQO8#U.Q0?]T>
ME=&*C@^:K7J4^;EC1Y4VUO!;VMT_%'A\-U^*(X?+LFP>-5%UJ^9>UJ1IPE=T
ML3)IPC-22NV][KED]VDUY=^SI_P3MO\ XN?"[4/VB_BY\;]!^&_PQLM2DL;/
MQ;KEN\LFJ3*Q4BUME*M*,@C[P.00 Q5MMOXX_P#!.&'PO\#[W]I?]F+]H30O
MBUX*T>81^(KG2+&2SOM)SC#RVTC,VSD9;((!W;=H+#T/_@HJ;F'_ ()T_LGV
MWA,M_P (VWA>\>]$/^J.I;+??NQQOWFYZ\_>]Z/^"+1O)%^/EIKX9O"3?!J_
M.O+)_J3*#^ZW=L^6;G'?[V*YXX3!O%1P?L]7%/GN[W<>;17MRK;:]M;GM5N)
M.*EP]7XJCB[4Z5><%AN2'(Z<*[H.,I<OM56DDY)J:BI-1Y&CSW]G?_@F3XM_
M:$_9JA_:?M_C+X<\-^'X?$D^GZ_<>(<PPZ5:PQAWNWEW?/DLB+&%RS..0,D=
MG??\$?S\1_A]#\3?V.?VK/"OQ.TFWU5++Q).UJVEC1P1EKF7S)'_ '2+\[9
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MY1!\OVE(U)E&?F92Q0LS$*NXBOB^BM8YEC(SE*Z?,DG=)IV5EHTUIT=C@Q'
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M_1]>]?M9_P#)-+;_ +#$7_HN6OV;)O\ D5T/\,?R/\K_ !1_Y.-FW_815_\
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MM-*R=T4M]T?YZ\U@_#WX@:G\/M6DO[.VBNK>YA,-]97 S'/&>Q_S^>2*P:*
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MEYH\L^>[;24)7C'EFW)6MS1WUTU\%:"X6%;AK>01L<+)M.T_C32<=J]HT/\
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M_$"T\"ZE>^)#KO@/5[ZY,5HDQ(S:R2<;1@%>3R)"0"5 /R#DT9HY0/L;P/\
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MHHHKX,^E"BBB@#[3_P"">_\ R0^Z_P"Q@G_]%Q5Y)_P7L_Y1[:G_ -C1I?\
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M<=B<P57$TZDI_O*//ATI05/EA0]JN3E4>:,E4<N9R;;YK+](?''P\T/X8_\
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M[.7_ "1G1O\ MX_]*):^(/\ @X^_Y-M\ _\ 8\-_Z1S5]O\ [.7_ "1G1O\
MMX_]*):^(/\ @X^_Y-M\ _\ 8\-_Z1S5X_$/_(GK>B_-'ZEX)_\ )TLK_P ;
M_P#2)GX\T445^/G^G04444 %?H-_P31^$GA'XX?\$TOC[\-_&GCK3_#-O?\
MB#2A:Z[JTFRUM+P%/LYE;^&-IO+1F[!R>U?GS7TQ^SY^U%\*/AU_P3O^-7[-
MWB:]O$\3>.-1TR;088;)GA=8)X7??(.$X1L9ZUZ>4U:-'$RE4M;EGH]+WB]/
MGL? ^(V79EFF04J& YE4^L89\T5S."C7IN4[/1J"3D[Z66NA[E^QU^Q%K?\
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MM/,:38&< ]OU..U8_P -?A-=?$&^U?2FU(6=SIMLSJCQY5Y 2NUCGY1D=>:
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M7PX\,Z+I=S9^/]'&G:M-?1R-+!&%D7=$4=0&_>G[P8<#CK18#W/XQQ3>(O\
M@DE\+=0\*(TECH?C2]B\0K#SY%P[7/EM(!TR' !/_/1?[PS6_P""6.F>(I9/
MC%K5K#-_9</PEU*&^E /E^<ZYB4]MV$D(]@:\H_9K_;$^)?[-5MJGAO1]+TG
MQ!X9UY0-:\*^([/[1971 QOVY!5\<9!P<#(.!CT%_P#@I_\ $G1=&U7P5\,O
M@QX$\*^&=6T6ZL+C0-(TJ2.-GG4*URS*ZL\JKE5)^4 G*GK19@6OV4OCI\9O
MV?/V<=6UKQI\ --\=_!G6=>6WU*VU:2(I%?[1]T'>RDA$Y:,J&"$%21GKKOX
M/?L0?MC?!OQU\1/V;_!FO?#[Q5X*T)]7U#1KNX,VGW,:*[E02S8R$8#!3!(^
M4C./"_V;/VS?B1^S=HVK>";'0-$\3>%==8-JWA;Q-9_:+29P /, R"K8 YY!
MVKD' QO?%']OKQ9XN^&NH_!_X6?"+P?\.?#^M%?[<M_"6G&*;4%'\$DA/*>P
M X)!."11J!XGH/BKQ)X76^C\.ZY=62ZGI[V.H+:S%/M-LY4M"^/O(2JDJ>#M
M%9]%%4 4444 %%%% !1110!^HO\ P0K_ .3>O%__ &.9_P#22"OHG]M;_DW/
M7/\ ?MO_ $HCKYV_X(5_\F]>+_\ L<S_ .DD%?1/[:W_ ";GKG^_;?\ I1'7
MPWB/_P D#FW_ &#UO_3<CWN%?^2FP7_7VG_Z6CX-HHHK_*P_LX**** "BBB@
M HHHH **** "ANE%!YH ]R_:;>WC\%?""2Z'[M?"T)D_W=L&?TJG^W5%>'XW
M+?.K&SN=%M7TU_X#$ 1\OMNW?G[UPOQ(^+6K_$K0O#>@ZGIEM;Q^&M+%C:O!
MNW2J HW-D]?E[>M=)X9_::O(/"5GX)^)7P]T?Q=8Z:NW37U166:W7^Z)!G(X
M Z9P,9.!7[/FG%'#7$%7,L#4Q#HT\1]4G"JX2:4\/1]G*$XQ3GROFE9I2LXI
MVL[K\_P>3YOED<)B8TE.5+VT904DGRU:G,I1;]VZLKIM:-ZW1N>"XIK/]ASQ
MA+K";8;SQ%;#2O,_BD#P;ROX*PX]#1^TY-+_ ,*-^$5OO.S^P9FV]B=EOS7$
M_%?XZ>*/BI9V>@2Z=8Z3H>F_\@_1-+AV01'&-Q_O-R>>G)P!DU5\?_%K5_B#
MX3\,^$=0TNV@A\+V+6MK)#NW3*PC&6R<9_=CIZUAFG%V0RR3%97A:DI*.$H8
M>G-Q:]I*&)5><K:N,;.2BI._+%7LW8TP>1YG',:.,K02;KU*LHII\BE1=.*O
MU>B;MI=OIJ>A>$I98_V$_% C<KN\71*V.XQ;\4W]EEGC^%'Q:>)MK#PGD%>W
M[NXKS_3OBWJ^G?![4/@W'I=LUGJ&J+?27;%O-5U"?*.<8^0=N]'P[^+>L?#G
MPUXF\,Z;I=M<1>*--^Q74DQ;="NUQN7!Z_.>N>E9X'B[)</GV4XJ<WR8?!SH
MS]UZ5)0Q"22ZJ]2.JTU?9FF)R/,*F6XVC&*YJN(C4CJM8J5)MOMI"6FYWW[
MX'_"^UX_Y@US_P"R5X]INJZGH.L0:WHMZ]O=V=P);:>,X:-U.0P]P:Z/X,?%
MG5_@KXR7QIHFF6]Y,+62#R;HMMVOC)^4@YXKDV;<Q;'6OD\=G6%J<'Y;@:$V
MJ]"MB)RM=6514.1J7>].6VJLNZ/:P^7UHY[B\14BO9U(4HK9W<74YDUV]Y;[
MCIII;B9KB=RSR,6=F[D]33:**^/;<G=GO;:(**** "BBB@ HHHH **** "BB
MB@#[3_X)[_\ )#[K_L8)_P#T7%7DG_!>S_E'MJ?_ &-&E_\ HQJ];_X)[_\
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MUKO/B'XG_;A_9A^'W@OX4?$']FKP/^T?X230H+OP#XPN/!EUJPM(7'R6WF(
M<JJH=K#)4IAR!@4_^"HWQ8^+=Y_P3O\ A9X$_::AL],^(7B+Q=<:[)X7M;5;
M<Z3IL4<\5O%Y"_ZE526)0K9;@@DLK8]"M3IQGBZ[<DY1>C5DG*47:^SUVMNM
M3XK+,QQM;#<-9-3C2G3H5X*-2%12E4C1I58\ZI64X6BKU>>W)*T5S7N<)_P5
MHN;AOV=_V5;-IF\J/X2JZ1YX5FBLP3]2%7\A3-();_@@?J18YV_'!0OM_H\5
M?/\ ^TK^UYXP_:9\%?#GP1XG\*Z;IT/PW\,KHFFS6#2;KJ(+&OF2[V(W?NA]
MW Y-):_M>>,+7]C*X_8L3PMIIT6X\7CQ VK[I/M0FV*GEXW;-F%STSS7FU,=
MAY8RM43TE3Y5IUY8K\T?=8/A#.J/"^5X&4%[2AC/;37,K*'MZL[I[-\LT[+6
M[L>25]P?M@7EU'_P1R_9IT])F$,VM:O))'V9EFN I_ .WYFOA^O6_BC^UYXO
M^*?[+_P__9:U7PMIMMI?P]N;N;3]2MVD^T71G=W8298K@%SC:!TKAP>(IT:-
M:,GK*-EZ\T7^29]=Q-D^-S3,\IK4(IQP^(=2=VE:/L:T+J^[YIQT6O7H?0/[
M#?\ RBF_:H_[@O\ Z--6/@S^UGK'P3_9'\%_";]O3]BR'QY\)]4GN;CP!KDT
MZPW4*[MTHA<$G@RG!W1-ABNX@8'SM\(?VO/&'P>_9P^(W[->C>%]-NM-^)'V
M3^TM0N6D\^U\AMR^7M8+SWW UV_[//\ P4?\3?";X++^S;\7_@GX5^*/@.VO
M&NM+T7Q7"WF:;(Q);R)ER4!+,<;206;! )%>E0QU&,:24^5J#B]+QOSMVDFG
M=-/IL['P^<<'YMB*V859815X5<7"M&*JNE54%AJ=+GHU(RCR5(SB])-*4.97
M5T>C_M'_ +*_[&'Q8_8UU[]M3]AS7O%6BZ;X3UJWM/$W@GQ0Y=+=IY(8P86+
M,=V9HS]]P5!^Z1BOL%/VT/@C^R3\,?V7M-^)?@/S+GQE\-;72[SQFMQY<F@Z
M:UO ':,CYAF9H68KM(2,G)(4#\Z?VD_^"@OBCXW?"FW_ &>_AO\ "+PO\-?A
M]!?B^F\,^$[=A]NN1TDN)6YE(X(X'(!.=JXY;]I+]KSQA^TMX$^'/@+Q-X6T
MW3[?X;>&1HNFS6+2%[N(+$N^7<Q&[]T/NX')K:.;8;!U)U,-92<8K2-HN2E=
MV3V5M.GE8\>MX<9]Q-A<'@\]E.5"-;$2M*JI5J=*='EIQG4C;VDE4O)V<E9J
M,G))WN_M\?LK>,_V1_VCM8^'WB6_N-3T^_D;4O#GB"X<O_:MC*Q9)B_\4@.5
M?_;4GD$$^+U[7\6OVW/&_P <?V9/!_[.?Q-\':3J4W@5RGAWQA(TO]I16IX^
MS.=VQX]FQ>1G$2'.02?%*\/&?5WB'*A\+UL]U?=>=MK]3]>X86>4\GIT<W2]
MO3O!RC;EJ*+M&HDOAYXVDXNW+)M6LD%%%%<I] %%%% !1110 4444 ?T,?\
M!*7_ )1X_"O_ +%T_P#H^6OH2OGO_@E+_P H\?A7_P!BZ?\ T?+7T)7[9E__
M "+Z/^&/Y(_R:XV_Y+/,O^PBM_Z<D%%%%=A\P%>'_P#!2;_DQSXB?]@>/_TH
MBKW"O#_^"DW_ "8Y\1/^P/'_ .E$5-;@?B71116X!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% '[I?\$'/^4>&B_P#8QZI_Z/KWK]K/_DFEM_V&(O\
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M/XIQA%2E_BDE=_-A11161Z 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ']#'_!*7_E'C\*_^Q=/_H^6OH2OGO\ X)2_\H\?A7_V+I_]'RU]"5^V
M9?\ \B^C_AC^2/\ )KC;_DL\R_["*W_IR04445V'S 5ROQL^$?AOX\?"W6?A
M%XPN[R#3-<ME@O)=/D5)E4.K_*65@#E1U4UU5% 'QO\ \./_ -DG_H<?'?\
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M/_0X^.__  ;6O_R+1_PX_P#V2?\ H<?'?_@VM?\ Y%K[(HHYI ?&_P#PX_\
MV2?^AQ\=_P#@VM?_ )%H_P"''_[)/_0X^.__  ;6O_R+7V111S2 ^-_^''_[
M)/\ T./CO_P;6O\ \BT?\./_ -DG_H<?'?\ X-K7_P"1:^R**.:0'QO_ ,./
M_P!DG_H<?'?_ (-K7_Y%H_X<?_LD_P#0X^.__!M:_P#R+7V111S2 ^-_^''_
M .R3_P!#CX[_ /!M:_\ R+1_PX__ &2?^AQ\=_\ @VM?_D6OLBBCFD!\;_\
M#C_]DG_H<?'?_@VM?_D6C_AQ_P#LD_\ 0X^._P#P;6O_ ,BU]D44<T@/C?\
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M\2?^!D/_ ,9KWBBC_B$/AG_T*Z7_ ("_\P_UYXN_Z#)_?_P#P?\ X=Y?!/\
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M!36/_ B/_P"-UZA10!Y?_P ,E_#?_H*:Q_X$1_\ QNC_ (9+^&__ $%-8_\
M B/_ .-UZA10!Y?_ ,,E_#?_ *"FL?\ @1'_ /&Z/^&2_AO_ -!36/\ P(C_
M /C=>H44 >7_ /#)?PW_ .@IK'_@1'_\;H_X9+^&_P#T%-8_\"(__C=>H44
M>7_\,E_#?_H*:Q_X$1__ !NC_ADOX;_]!36/_ B/_P"-UZA10!Y?_P ,E_#?
M_H*:Q_X$1_\ QNC_ (9+^&__ $%-8_\  B/_ .-UZA10!Y?_ ,,E_#?_ *"F
ML?\ @1'_ /&Z/^&2_AO_ -!36/\ P(C_ /C=>H44 >7_ /#)?PW_ .@IK'_@
M1'_\;H_X9+^&_P#T%-8_\"(__C=>H44 >7_\,E_#?_H*:Q_X$1__ !NC_ADO
MX;_]!36/_ B/_P"-UZA10!Y?_P ,E_#?_H*:Q_X$1_\ QNC_ (9+^&__ $%-
M8_\  B/_ .-UZA10!Y?_ ,,E_#?_ *"FL?\ @1'_ /&Z/^&2_AO_ -!36/\
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M=.K!WC);IVMI\FSX*_XAW/V(_P#H?OB1_P"#JR_^0Z/^(=S]B/\ Z'[XD?\
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M (AW/V(_^A^^)'_@ZLO_ )#H_P"(=S]B/_H?OB1_X.K+_P"0Z^]:*/["R?\
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M_P"0Z^]:*/["R?\ Y\Q#_B,'B;_T-:OWK_(^"O\ B'<_8C_Z'[XD?^#JR_\
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M/O[&G[4/Q.^,6OZMX1^-?A^QTO4KK1[/Q-X3@LX6C,VB7194#AF.9(V4*[#
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M$Y*H/E!))SCTKOOAM\<?A'\7]&NM?^&OQ"TO5[73VVZA);7 S:G!/[U6PT?
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M2-+T_4H7ET^]NKY5CN46/S6:-NCC9\W&<CIG(H ZJBLGP/XY\)_$GPI9>./
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MI^B2?'KPR+K5&VV<?]I+\[;R@!/1,LK ;B,XXS61XB_;#\!>'OVM]-_9@O\
M6])@DNM#,\UQ->_OAJ$DL2V]D$Q@,\;F09))!& .X![)17FW@OXW^'-"^$,W
MQ*^+OQ>\)RV5OJUW;R:[ITI@LQMN)$2']XQ)E4*$8#JZM@=JU_A7^T'\%OC;
M+=V_PJ^(^F:U-I^/MUM:S$30 ]&:-@& /8XP: .RHK%\<_$;P+\,M*CUWX@^
M*['1[*:Z6VCNM0N!%&TK E4W'C)"M^1KE_\ AJ[]G/\ X5S#\6S\8-%7P[<7
MC6EMJC76$FG4X,2 C<[C^ZH)[T >A45ROA'XW?"7Q[X*N/B-X0^(>DWVAV:R
M&^U2*]416OEC+B4G'E%1R0V"!R:H?#+]I;X#_&75Y] ^%_Q2TG6KZWA\Z6SM
M;C][Y6<>8%8 LF<#<N5Y'/(H [FBO/=?_:M_9P\+>.#\-_$7QFT&SUI9U@EL
M9KY089FZ1R-]V-S_ '6(/M6O\3_CC\)?@O96U_\ %+Q]INBI>.4LUO+C$EPP
MZB-!EGQD9V@XSS0!U=%<;H7[0OP2\3_#RX^+/A_XGZ/=>&[.3R[S6(;P&&W?
M*C9(>J-EU^5@#\P]15/2OVH_V>-;\+ZUXWTOXQ:#-H_AVZ^S:SJGV]1!;3'H
MA<X!)[8)W=LT =]17C?Q%_:U\ ZI^SIX\^+'P \>Z-KFH>$]!N+L1JQ<03+&
MS1^;%E7"G'&<9P<&M/X4_M;_  )^(^H:7X"LOBYX?NO%EUIT4EQI%K>#>9_*
M#RQIV9E.<H"67!ST- 'J-%9.C>._"'B'Q)JWA#1?$-K=:IH;0KK%C#)F2T,J
M;XPX_AW*,CU%>-_M\?M)?%+]FCPGX1\1?"KPO:ZU=ZMXNCL;W2YX&=[FV$$T
MSI%M8;9"(L X;_=/2@#WJBO#?CQ^U=_9/[(,/[2_P.O;.\COYM+.GR7T)D0)
M<7L,$BNJL,.H=U(S\K+WQ7H7Q2^/WP9^"8M5^*OQ&TS19+W<;."\G_>S!>K*
MB@L5'=L8'<T =A17,:?\9_A3JUKX?OM*^(&DW4'BJ5XO#LUO>*Z:A(JEV2)A
MPS!58D=1M/I5VR^(G@C4?&M[\.+#Q193:]IUG'=7VDQS@SP0N<)(R]0I[&@#
M:HK)\(>./"/C_1F\0^"O$-KJEBMS+;FZLY0\?FQ.4D3(X)5@5/N#7SG\*?VV
M+;XK?M!^,I%^/'@O3O ?@WS"NEK;F2ZU*TCME:2_^T&0".))I .$(PI!YYH
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MT_[*Q-_Z0VE=Y^SO\-_$_P '?AU'\+-<U.&^T_0[J6V\-7BR,TK:7G-O',"
M!)&I\KY20RQJW!8J.LTKPUX>T">^O-"T&SLYM2NC<ZA):VZQM<S%0OF2$ ;F
MPH&XY. /2F!XSX-#S?\ !1/QO-I/_'K#\,-'CU;;T^UF[NFBS[^3^E>F_&T_
M\69\7?\ 8L7_ /Z3O6-\"OA-K/@*Y\3>.?'%U:W'BCQEKC7^L36;,T4$**(K
M6UC9@I9(H%49(&79VP,XKO+VRM-1M)=/U"UCF@GC:.:&9 RR(PP5(/!!'!%
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MV^UNT\37NA6DVHV$4D=C?R6ZM-;I)C>J.1N4-M7(!&<#/2E<#X(^'46NW_[
M-QHGBK]H/X;Z/X9&DW-IXFTF^\#S3:M:WQ9A*K_Z<K27OF_,K>6&9MK!<8KV
M/X<>$K.X_;K\+0^*Y/[8O--_9NM%6_U"Q,<DDIU$QO,T;Y,;LI8%2<C>P/>O
M=+_X"?!#5/&B_$;4OA'X;N->602+K$VBPM<[QT?S"N[<.S9R/6N@'AKPZ/$7
M_"7C0K/^UOL7V/\ M+[.OVC[/OW^3YF-VS=\VW.,\]:=P.;_ &B %_9\\=*H
MP/\ A#=3P/\ MTDKY1\,_L9^+O%G[$7A7QO\*?C5\19-<;PE8W__  BUQXZO
M1I>I)Y*O)8B)'7R4=<JFP@*<=NGVUJ%A8ZK8S:7JEG%<6US"T5Q;SQADEC88
M96!X((."#P13-(T?2?#^E6^A:%IEO9V5I"L5K:6L(CCAC48"JJ@!0!P .!2N
M!\3_ !5\5^!O$_[/'P+\1?!*WT?PCX)L?'"1:O:ZWIKW5EH=\L4RHE[%YD;-
MLN2V6=Q\[)(2<\]SH.D^)M0_;(\*ZKXS_: \):WX@L?"NJ&;3?!O@^:!KC3Y
M$4 74_VN9419O+>,,!E@P'7-?1D7PT^'<&E:GH</@71UL=:N))]8LUTV+RKV
M5\;Y)4VXD9L#)8$G JKX(^#GPL^%MC=V7PO^'6B: +P?Z1_9.FQ6_FG'&XHH
M+8SWZ4[@?&OP*\1?L[P_\$I_%&BZC?:+]LFL]8BU2Q=H_M4NK/++]E^3[[2$
M^1Y> 3@+CIQZ%\$IIO"?[6FDG]H2]AM]>F^">B0>';G5I%4-<(6_M*.-GX\[
MS"C, =Q7U%>B_LS?L=> OA#\.?#>G^/_  )X6U;Q;H*3*/$4.EI)(-UQ)*A2
M61 ^5#@9X((XKTOQY\+?AM\4M,CT;XD^ ])UZUCD\R*WU;3X[A4;^\H<'!]Q
M1<#XA^-:Z#K_ ,(OVD]0\#B&;P5J'CKPZEC)9X^RSWPGM%OVBQ\K OL#,O!8
M'K7NG[8EMX6\%^+?@;*5L=+TVU^*ELLDC;(88E%A<HN3P ,!5&?0"O;1\-/A
MVOA&/P O@72!H4841Z,-.C^RKM8.N(MNWA@&''49ZT[QQ\._ ?Q,T,^&?B'X
M/TW7-/:19/L6J6:3Q[QT;:X(R,GGKS1S 6?$OBGP_P"#_"U]XS\0ZG%:Z7IM
MC)>7EX[?)'"B%V?CL%!/%?)_@_XL?#K]K[Q_I7Q=^-GQ?\+^'_!.AZ@MWX)^
M']UXDM5NKZX4_NK_ %!=_P K#K';_P /!;G.[ZRU'PSX=UCP_)X3U;0[2ZTN
M:V^SS:?<6ZO"\.,>64(VE<<8(QBN1C_9:_9IB=98OV?O!:LK95E\,VN0?7[E
M(#SGX5>(O#WPT_;0^,FC>-]=L],D\26VB:YHTE_<+$MU:Q61MIF0L0&"/'\V
M.F[)XJY^P<O]M>%O'_Q*L@6TOQ=\4M8U70Y\?+<6FY(4F7_98Q,0>XY[UZGX
M]^$'PJ^*<5O!\2OASHNO+9MNM1JVFQW'DG_9WJ=O3MUK=T[3M/TBQATO2;&&
MUM;>-8[>WMXPD<2 8"JHX  Z 4[@>&_LCQQ3_%#X[PS1B1&^)KJR$9##[#;9
M%?/7BO2-'T[]C[Q3I/PT_:GU)? 4WV_3-"^&UWH]O'K*7SS/&FDF4LTOEF8C
M*!-YC)&X#)K[OTGPUX=T&YO;W1-"L[.;4KG[1J$MM;JC7,VT+YDA ^=L #)R
M< 5BI\$/@W'XZ/Q.3X6>'U\1,VYM<&D0_:MV,;O,V[MV/XLYHN!5^$1T?P#X
M'\(_!S6O$-C'X@L?"EJO]EM=I]HD2"*.*218\[B@;@L!@$BO,?\ @H'JGB3Q
M;X%T']E_P!>PP^(/BAK(TY7GW%(=/A7S[R5PO)01H$8#J)"!S7K6H_#'2-3^
M+.E_%J=U%YI.BW6GVZ+;J&99Y(G8L_WB!Y6 O0%V/)QC6N_"GAF_\06OBR]\
M/V<VJ6,+Q66HR6JM-;H_WU1R-RAL#(!&>]2!\C?&;1_VE/V?/B%X!_:G^+.N
M>";C0O"5ZF@ZS'X3TNYMFCTF]9(BTOFR.&CB<1LH&,$UV?@;4M$3]K3]H329
M-0M1=7WA_1)+*U:9?,N%&FR[F1<Y8#/)&<9KZ)\1>&_#WB[1I_#GBK0[34M/
MNEVW-C?6ZRPRKD'#(P(89 /([5F?\*H^&0\7VOC\> -'&N6-G]EL]673XQ<0
MP;2OEK)C<%VDC&<8-5<#X_\ AYJVC:I^S/\ LGQ:3J=M<-;?$/38;I;>97,4
MHLKW*/@_*P[@\U>U6:QN_@_^UUX7L[B%]3_X2#5;A=/CD4SF'^SK?]YL^]LX
M/S8QQ7U3X?\ @?\ !OPHJIX:^%GA^P6/5?[3C6TTF*,)>[2OVA0%XDVDKN'.
M#C-6[?X6_#>T\9W?Q%M? FDQZ]J%K]FOM82PC%S<0\?(\F-S+\J\$G[H]*.8
M#YE^.OQ:^&WBCP#^SCX>\->-M-U"\O/B9X5N8;6RO$DD$,:%7=E4Y4!G53G'
MS''7.-;X#Z[\*/#:?'K1_COJ.EVVIR>/-3N/$L.L2(LEQI+P)]D8!^7A,.50
M#(SN Y->Y>'_ -GOX$>%)C<^&?@WX8L)#J$=]YEIH<$;"YC),<P(7AU+':1R
MN3C&:M^*O@W\)?'/B&S\7>,_AIH6JZIIQ!L=1U#2HIIH,'(VNRDC!Y'H>:+@
M?!WPP?Q-:_!/]EO4M/\ %>BZ'H\=QKZ0:MXHTIKS3K;4FGF^RF5!+$ Y7S5C
M8N-K'(YKU8^'K35/CQXWO_BQ\=='UVY7X0WEIXNLOA]X.GM\6#OE))91<SJ;
ME '\M,;RA. 5KZBE^%_PVF\%_P#"N)? .C-X?VE?[#;38OL@!8L1Y6W;]XEN
MG4YZT>!/A7\-?A=I<FB?#?P%I&@VDS[YK?2=/C@61O5@@&XX]:+@?(GA#Q3K
MWPO/P;?4_%7@+XJ^#9M>L--\"WUG:FQU_2A/'Y*2B*-FCD$<?$H(4@#Y@#R/
MI+]K^(R_LJ?$@*I8GP1J>T ?].LE;/AGX!?!#P9XHD\;>$?A'X;TS6)BQDU*
MQT6&*8[OO?.J@C/?'6NJN[*TO[.33[ZVCF@FC:.:&9 RR*1@J0>""."#2 ^1
M=(\0>"S\4?V;?$_B_6M/D\+Q_#^XM=+O9)T:T@US[+:[5=L[%E,8D5,D'<&
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M]]I,>H6$G_"9:X^M022VB0VL@2T29(R&=7G).W(R8@>E>Z^#?A-\+_AVZR^
MOAYHNBLEI]E5]+TR*!A#O+^7E%!V[B6QTR<]:T(/"OAFU\17'BZV\/V4>JW5
MND%UJ26JBXEB4Y6-I,;BH.2 3@47 ^6;!?CQ^SS^V?X;^)7QVUWPO=:;\4+4
M>%[^X\,6,]O#%?0@RV+RB9VW2/F2%2#T/L*S_AA^TAX?_9Q^ 7C+5IK:'4-?
MUCXR>(K'PKHLDZQ_;;QKKC<S$!(DSN>0D!5[Y(S];>(_"7A;QA;V]GXK\.6.
MI16MVEU:QWUJDJQ3I]R50P.UUR<,.1GBL36O@3\%/$EJMCXA^$GAN^A2\FND
MAO-$@D59Y2#+* R$;W(!9NK8&<T[@> :?X$\"^"_V4/BQK-_\4]#\6?$3Q1X
M'U;4?&>KZ=J4,SR/]CD AB56)2VAR(T7 &.<#.!E_$[PGX:\._L/? EM$T6U
MM6M?$W@NXMWAA56CEEDA,K@C^)R[[CU.XYKZ0T'X _ WPJ;MO#/P=\,:>;^R
MDL[[[#H5O%]HMWQOA?:@W(V!E3P>];5WX(\&ZAHMGX;O_"NGS:?ITD+Z?8RV
M:-#;-#CRBB$84I@;< ;<#&*5P/DSP$_Q7M/VFOC59V7QB\">%]7D\21SS0^,
M?#+W5S<Z3]EC%L\<OVN$&W5 R[0I"MNR<L ,+PAH^F:-\,/@HGA_QW#X@TJX
M_:->XTN]L]#DT^UCB=+TM%;12.Y\A9/,V,&(*GCI7UYX^^"GP@^*EQ;WGQ*^
M&.@Z]-:?\>LVK:7%<-$,YPI=20,]NE:D_@CP;=6NFV5QX4TYX=&G2;2(6LDV
MV4B*51XAC$;*I(!7& 2!3N!\L?"WPCX9E^!W[56M7&BVTEU>^//%T-U<20JS
M21Q6BM&A)'W59W8#L6)JIXG\-:!H7[%W[,\FC:/;V[KXP\$72O#"%833(KRR
M9'.YV=B3W).:^LK7P5X/LK#4M+L_"VGQ6NL7$T^K6\=FBI>R2C$KR@#$C.!A
MBV2PZYI)_ O@NZT?3O#]SX2TV2QTB2"32K-[)#%9M",0M$N,1E!C:5 V]L4K
M@?('P=E^*5GX^^,UB_QK^'GAJ^7QY?S>(+'QGX5>ZNI;!E7[-*TIO(0UMY&%
M0;=JX;GDU0\ >#/#CZ)^R_X?/B1?$^BMXZUNZTN[N-%DLXVA6"ZFA"0S,["-
M'4>62QRJH1QBOKGQQ\#/@S\3-3M]:^(GPJ\/ZY>6HQ;W6JZ1#/(@SG:&=2<>
MW2MBX\'^%+NXTV[NO#5C)+H[%M)D>T0M9$IL)B./W?R';\N...E.X%^"W@MH
MQ#;PK&JYPL:A0,G/0>]?%7[./[*LGQJ^'WQ$UW1OCQ\1/">J3?$KQ#!9_P#"
M-^+KBVLX9%N#MD:V1@K9)^;H6'<<&OMBJ.@>&/#?A6WFM/#&@6>GQ7%U)<W$
M=E;+$LDSG+R,% RS'DL>2>M(#X=E$>G_ /!/KXM?"KPIX,;0_B+X;O(X?B1;
MI<3W<^H?Z3"T]^9)',LT,UH)6&6^[N XY/2>.K37/%.F_"^+6/VG_AS-8MXL
MTN?P1;^"_ ,WVQG1@1'#LOI/*B,89)"5VJI^;%?747@SPE!XANO%L'AFP35+
MVV6WO-26T03SPK]V-WQN91V!.!6+X4^ WP3\">(YO&'@KX2^'-*U:?=YNHZ?
MH\,,S9Z_.J@C/?UIW ^??V8?$?P.T+X]_M$#QOJNB6FJGQD[:HVK21H7TL6Z
M_P!_K$&\W<.F2,]17G?P;CMO#UC^SCK?Q,7[+X%3Q%XI;1GU3Y;>W>9W.CF3
M?PN8O,\HG&,C%?0_@']CSP5#XT\<>*?C!X*\+^)/^$@\;2ZWH9O--2X>RB:"
M%-A,J?*VZ,DA21TKUCQ%X,\(^+O#\GA/Q5X8T_4M+FC"2:=?6B2P,HZ HP*X
M&!CCBCF ^8OBG?\ A[7?VL?'FI?#6YM[B&U^!&H0^-;G3F#1?:BY-FDK+P9A
M&)2 ?F"8[8K#\?>'=!T#_@CSIC:5I=O;@^#M$GF>.(*2SW5M)(Y/NS,Q)[G-
M?5GA+X4?#+P#X<F\'^"?A_H^DZ7<AA=:?I^G1Q0S;AM;>J@!LC@YSQQ5R;P/
MX-N?"7_" S^%=/?0_LGV7^QVLT^S>1C B\O&W9CC;C%',!/X>U/2M8T2VU/0
M]1M[NUFA#0W%K,LD;CU#+P1]*^3OB-\?/ G[8?C;4OA3>_&GP_X1^%>BZDUI
MXDNKKQ%;VU_XJEC;Y[:%6<-%9[AAI>LHX7@DCZM\*>$?"_@3P_;>%/!GA^ST
MO3+-2MK86-NL4,*DDD*JX Y)/U-<H?V6/V9V.6_9]\%DGJ3X8M>?_(=(#R_7
M]6\#> ?VTOASX[M=7TVW\)^(/AG>^'O#VH07""R\Z.X@N(HDD!V#?%G9S\VP
M@9Q6A\#;^Q\??MJ?%;XB^%[R.\T>QT/1M!_M"UD#PS7D0FFF17'#&,2HK8)P
M3@\UZYK7PH^&/B/P;%\.]?\ A]HUYH-O&B6^C7.FQ/:Q*@PH6,KM7 Z8'':K
MWA'P9X1\ Z%#X7\#^&;'1]-M\^18Z;:I#"F3DD*@ R3U]:=P/&]"_P"4D>OC
M_JC]E_Z<9:\ML?A7\$/VA/BU\:-:_:A\6MI&M:5KLVC6]C%KATO[-H,<"-;7
M3A&3[0) [OOEWKQM  &*^ND\->'8O$,GBV/0K-=4EM5M9-26W7SW@#;A$7QN
M*!B3MSC)S6'XW^!OP9^)>JV^N_$/X5>']<O+50MO=:KI$,\D:@Y #.I.,]NE
M%P/._P!BCXI/>_LN>![[XF:[I]C=:A))IF@R7"1V7]J11RR1VIBA^4;I(8U8
M(HY'(&*]NKE_'OPJT'Q[+X;%\D4,/AO7K?5+6..U0G?"CB-$8_ZH!BI)7DJI
M7HQKJ*D#P+PE_P I*O&/_9)]+_\ 2V:HM0\/:)K'_!4*UU'5-,AN)M.^!_G6
M,DT88P2'5W0NN>C;69<CG#$=S7ND7ACPY!XBF\7PZ#9KJUQ:K;3ZDMLHGDA5
MBRQE\;BH))"YP":!X:\.CQ'_ ,)@-"L_[6-E]C_M+[.OVC[/OW^3YF-VS?\
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MJ>5!:>8#YI*!Y-S!E'!/6OH[6_@'\$/$OB^/Q_XA^$?AN^UR)E9-6NM%ADN
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MSVFK6$W@[2V@UYV?6X6L8RNH,5"$S#&)25 7YL\#%),#YJ_: \/>$_"/P2^
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M(:/I5GJ7B#P7>:9\/V\*W+S64D,,R7-U'<-*J2?: -C#Y?+V[L<TP/>_AO\
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M1\;2:E'X3UZWO_['U.33M2-NVX072*I>(GIN4.N<9P>.H(K6KXB^#GA7XZ^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM[V\EN99TN)(6G"EHO-*J&W $;N"<5]/44[@>)^+OV9/C+\4OA!XN^$/Q?\
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M"'@K6KJW\;WFK66I>)KH6<=Q)<7-W>))>K*9/E 5'96DY8+%D9.*^B!THHI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'C!.\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,W5;<LBW"DAH^#CT]?P/-6K*Y^TP988=
M>&'O4Y 8$$9!ZBL5%.GZB &.SH0>ZGI^1K*7NRYNC-X_O(<O5;&W37=8T+N0
M% R2:=65J3O<W,=C&< X+L.W^?\ "KE+E5S.G#FE88L;ZQ,9'9DM$/RK_?\
MK6M'&D2!$4*HZ 4D4:PQ+&@PJC %/I1C;5[CJ5.;1;(**;)(L2%W("CJ320S
M)/$)(SE3TJK]"+.UQ]%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !12%@.I _&E!!Z'- !1110
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MZ;@E<=1115F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML$HN.X4444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH :Z+(C(ZAD88*L,@BA$6- B*%4# 51@"G44 %%%% !1110 4444
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M;T)<?R_K6O67I-MC-P3GC8O]3^)K4J*2?+=FM=KFLN@4445H8A1110 4444
M%%%% !1110 4444 %%%% !1110 449Q3&EC099U ]S0%A]%4Y-4M(S@2%SZ(
MI:HCJR_PP2'_ 'B!4.I!=314IOH:-%9HU=1]^!P/53FK37UNL F\P%3TQU/X
M4*I%[,'2FMT6**SO[63/$$F/<BG#5H?XHY1^ /\ (TO:P[A[&?8OT51&K6IZ
MF0?6,U*-1M"/]>OX\52G%]1.G-="S14:7$,OW)4;Z&I*I.Y+36X4444""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?>3''X>M8.M*3M%'3'#QBKS9'GYB6(+L23[T9K933+583&T8?/5S]X_C4?\
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MZBJ-MJ&]@DP"D\!AT-7JZ(R4E='+*+B[,****9(4444 %%%% !1110 4444
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M*_3NM79^=[Z+[Q*K5NUY^?=&5J.GR:=<")^<J"&QP>.::FFWCV_GK;N8\9W
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M-Q+*[@]B>*S=>/0TCAI=6;$NI6L7'F;V_NH-W_ZJH2:G<R9V*L0_,U4 "C
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MN36/';W.I2R3XBB1AQE<AL=/K]:UKUHDM]\T)E12#@+NQ[XJJ-:M,<!P!V(
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M:VWLNV27!*_W%Z*OX#]<UG+WG9'1!>S@Y/=[%Y55%"J  .@ I:**T.<****
M"BBB@ HHHH **** "BBB@ IDK,D+LB[F R%]:?10",E5U6<99_+![# Q_,TL
M>DNTOF7$Y;Z$D_F>?RK5HK/V:ZZFWMI?9LB.&&.!-D2!1_.I*"0!DUE7FH&3
M,%L&.3MWKU)]%_QJI2441&$JC&ZA=B4F%<^4K8<C^,_W15BSLF5A-/C=_ G9
M/_KTMEIXMR))/FDQP.R?3_&KU1&+;YI&DZB2Y(;!5+4YBD @7.^;Y>.P[FI+
MF]BM@ <NYZ(O)/\ A67)*Q=IICEVX55[>PHJ325D%&FV^9@0SND$0^=^F/X1
MZUM11+#$L:#"J,57L;5H$:23_6OU]AZ5;ITXV5V*M/F=EL%'6BBM#$Y]4\K?
M$.B,5'TSQ^E! (P0"/0U->)Y=](.S@,/Y5$:XFK.QZ*=TF0?9HNP9?8,0/RI
MR01QG*KSZDY/YFI**CE2UL5S/N)24M)3 *2E-)2 CFGAMUW32I&IXR[ #]:\
M$^(LL<WC:]>*170A,,IR/NBO;-?T:#7M'N+"<#]XOR,1G8W8U\X7MG/I][-9
MW*%)H7*.I]16]!*]SGQ#=DCU3X275O!H]^LT\4;&X& [@9^4>M>F9!&1TKPC
MX>^&6UW74N95'V*S8/)G^-NR_P"/M7N]9UDE(TH-N 5L:7&%L(V(&7)?\SQ^
MF*Q9,E"%^\>!720IY4*1C^%0*J@KR;)Q+M%(?11176<0445'<2>5;R2#JJDT
M-V&E=V)**S-%FDE@E$C,V&&"3GJ!6G4PES1N5.'))Q844451 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9EQ<:A:NTAB6:'/
M 0<@?SJ92Y=67"#D[(TZ0JIZ@?E5*VU>TN#MW^6_]V3C\CT-70ZGHP/XTU)/
M84H2B[-6%QBBFET49+*![FJ\FHV<?WKA"?1?F_E0VEN"C)[(+NR6X^=#LF X
M<=_8^HK,_>1SG'[JX4>O##^HJ_\ VQ9?\]'_ ._3_P"%)-+8WT>T7$8<?=;(
M#*?QK*2C+6+U-X.<=))V(52*^9BI\B[ ^8#HWOCN*;+#/;J&E",F<%E/]*A9
M?WGE.P$J\HZ'K[BK27H*>1>+\K_+YG8_7TJ%9[[FC4EMJOZV$L)C%<- Q^20
M[D]CW']:L:F0;(H?XV5?UYK-:/8[6S$Y3!1P>H[$&GRW,DJPP2J2RMNW@<,
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M:!R,BBLFVNC /[T1YQ_=^E:J.KJ&4@@]#51FI$S@XL6BBBJ("BBFR2)$A9V
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M+^]'_P!\"C_A*-2_O1_]\"F)I=K&EJMU/*LUT,H$480'IGUJ62PMTTI(L/\
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MLC)-,[?+C[J+U/UI9=(@S"8S,@:81LLI7.#W&*GZC7Y>:WX^G^:*^LTKVO\
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M6/4@8)_*B#0M+MG#Q6408="1G'YU/<W@@=88T,L[C*QKZ>I]!4?_ !,\;O\
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M(RGT;YA2E0EV01Q$.[(+74)++;!=1%8P,*P7I^7!_"L[Q<ZR"R=&#*0Y!'_
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M]\+?^1VA_P"N,G\J]HU#2-/U39]NLXKC9G;YBYQFHK+P_I&G7 N+/3X()@"
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MDXRC[STOY73_ $,XX;EFI)Z+_@_YC**7!]#1@^AKSCK$KT#P_P#\@*U^A_\
M0C7 8/H:[_P__P @.U^A_P#0C7NY!_O$O3]4>9FO\)>OZ&E1117UIX(4444
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M,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
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MYN(_LY!GLI^H7./Q'ZBOEK&O]J6EK%6\GKZ[6?R=SLO&$GEZ4G_$R-B#( 6
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M#+JQLT_ZT_I!1115F04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*H10H& !@5B2/_:%^%CY0D+D?W1U-;E94]9-F]72,8L****U, HHHH ****
M"HKB!+F%HG'![CL?6I:*&KZ#3:=T<Y+$\$QBDQN'0_WAZTT.8G24=4;=6Y>V
MBW4..DB\HWH:PAGE64JPX*GM7#4@X/0[Z=15(G2HP= RG((R*6L[2)@8&MR?
MFC/'^Z:T:[(2YHIG%./+)H****H@**** "BBB@ HHHH **** "BBB@ HHHH
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M]9@B7[EO\[$=CZ5JU,97;+G'E2\PHHHJB HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-7A#F!^F6,1/LPQ
M_,+6G5/5%+:=*1U0!Q^!S4S5XLTI.TT26$QGL89#]XKAOJ.#^M6*S]/;R[FZ
M@_A8B>/_ '7'/_CP;\ZT*(NZ%45I,****H@*Q]!F812VDA^:)V*9_N[B#^3
MC\JV*PH&$>I,5R&2Z>-N.H<!OYUG/1IF])<T)1-VBH);RVA;;).BMZ$\U+'(
MDJ!XW5E/0J<U=T8V:5[#J***8@HHHH **** "BBB@ HHHH H6U@;;4[F=&_<
MRHN%ST;))_G^M7Z**226Q4I.3NPHHHIDA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NJW!"BV0$E_
MO >GI^-:595NGVG5IIF^[$V /<<?XUG4O:RZFM&R;D^A;L;7[-!\V/,;ER/7
MTJU115I)*R,Y2<G=A1113$%%%% !1110 4444 %9FIV9.;F+.X??7U'K]:TZ
M*F<5)69<)N#NCG;>807,<^?EZ,?8UT0((!'0U@7ULMM<[%7]U*"5'H>XJ>UU
M)H(%BDC9]O 8'MVKGISY&XR.FK#VB4HFQ15>VO(;K(1L,.JG@BK%=*::NCD:
M:=F%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5@RIY=S,@& './QY_K6]6-J VZB?]N,-^1(/]*QK+2YT8=^\T5G)"[AU4AA
M^'-;\4BRQ+(ARK#(-8#.JXW$#)P,]ZNZ;<B)OLK\*23&>WTK.E*SL:UH.4;K
MH:M%%%=1Q!1110!%<VZ74#12=#T(Z@^M<[(&$<D<G#KE6KIZP]555NWQ_%&"
M:YZ\5;F.K#3=^4BNK1[1L-DQ9^20=OK[UI6%_P"<!%,0)AT/9AZU=*+)'M<
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MHLLZSO:1[#*JX#<D]/QK=HHJF[N[)225D%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2$!@00"#U!I:* ,&]M39RY _<,?E/]WVJ&NC95=2K $'@@UBW5
MC);,6B4O"3P!R5_^M7)5I6UCL=M*LI:2W*\<C6\JS1_>7J/[P]*Z"*19HDD7
MHPR*YW(S@Y&?45-;W=Q;857#QC^!A_(TJ53D=GL56I<ZNMS?HJK;7T5S\H^2
M3NC=?_KU:KK335T<,HN+LPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *0]#2TC_<;Z4 8BIO8(!\S' J]>RL@6!#@
M;<L?:H+$@7*EO[A_I2X:^NF(^5  ,^W_ ->N:/PZ;LZY?%KLAMK=)"I(C9F8
M]NPK6!R,TR.&.(81 *?6T(M*S,*DE)W2(I(_W<IA"K*ZGYL=\<9KQ*Q\,>*X
M;B\M?^$9L[F\>=I&U&\PPY_NY."./0]:]RH(R"*Z:5=T[I*]S"4%(\2\+V&H
MZA\3H;353:&32%+M]EC54S@<< 9Y/Z5[;6!X<\)6/AN>_N+=Y)I[R8R/+*<L
M%/1<]^<\UOU6(JJI)6V2"G'E6H4445SEA1110 4444 %8>IR@7DC]=BJ@^N<
M_P!16VS!$+'H!DUSI#71ED8< &5O;)^4?Y]*QK/2R.G#+5R9(MN\@FF0DF+'
MR^HY)_&FK(49+B+YF7D#^\.XK2TH?NIF]9/Y 56OK?[/<>8H'E2GMV;_ .O6
M3A:*DC55+S<&1WRK)(LR\Q7"<>Q'^?TK2M2EW91^:H<@8.X9Y%9T"^?%+9$[
M6/[R)O0_Y_G2Z?=BVE=)OE1^<X^ZPX(JHR2E=[,4XMPLMU_7]>A:FTI&.8)#
M$?3J#^%9\UM/;,'="/22(Y_/O6\CI(NY&##U!IU:2I1>J,8UYQT>IF6&H%RL
M,[ L?NR#^+Z^]:3*'4JPR",$5FZCIZNAEA0;ARRCC=_]>I]-NOM5J-V=Z?*Q
M/?WH@VGR2"I&+7M(&7/#)I]RI5NAS&WJ.ZFMR"99X5D0\,*2X@6XA:-N_0^A
M]:S-,E-O=26LG!8\#_:'7\Q4I>SE;HRF_:POU1L4$ C!Z&BBMSF,&53IFH!T
M!V=0!W7N/PK<CD66-9$.589!IES;I<PM&_?H>X/K6;8R365Y]BF^97^Z<?J/
M:L5^[E;HSH;]K&_VE^*->BBBMCG"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *5[ ZL+RV7,\8Y4?\M%[K]?2FI:VU
MVBW5L[Q>8-VZ-MN?J/6K]4;,>3>75N/N9$JCTW=?UJ&E<UC)\NFZ_(7[)=#A
M=1EQ[QH?Z4+IX,BO<327#*<J'P%!]<#BKM,FE2"%Y9#A$4L33Y4+GD]$,N;J
M"SA,MQ*L:#NQKG+KQO:QL5MK:2;'\3'8/ZFN5U;59]5O&ED8B,'$:=E%4*X*
MF+DW:&Q[.'RR"C>KJSM(/',9?$]BRKZH^X_D0*Z2QU&UU*'S;:4..XZ$?45Y
M/6EH5])8:M Z$[78(Z^H-%+%2YK3U0\1EM-P;IZ-'I$]C;W#[Y(QO_O X/YB
MH_[-A[/./^VIJY5*>[D:9K:S17E7[[M]V/Z^I]J[VHK5GBQE-Z)@=,M<?,'(
M]Y&_QJLXT>([=B2-_=0%S^F:L#35D^:\FDN6]&.U!]%']<U;CBCB7;&BH/11
MBIY;]"O:6^TW^!E[!)Q;:-&!_>N J#\L$_I0VC&X_P!>T$8_NV\(4_\ ?1Y_
ME6O13]FNH>VDOAT_KS*-II%E98,4(+#HS')J]115)):(SE*4G>3N%%%%,D**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH J:C TUJ=@RZ'<!ZUB@Y&:Z6J5WIR3L98_DE/4]
MF^M85:3EJCIHUE%<LC'*@]:O6FI-$%CN"67H)._X_P"-4F5HY#'(I5QV/?W%
M%<\9.+T.F48S5F=&"& (((/0BEK!M;N2TX'SQ?W/3Z5M0SQW$8>-@1_*NN%1
M3]3BJ4G#T)****T,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1AE2/44M% &$5;( ."I(-:>GIMMMQ'+G=^':JM^%6X.W@E<M_
M2KB7%O'$J^<G Q@-6$$E)W.FI)R@K+<L45$+J _\MD_%L4QKV!>C%O\ =&:V
MYEW,.278L451;4-QVQ1,S=@:NJ25!88..124D]@E!QW%I"0 2>@I:S/$&MV_
MAW1+C4[E6>.$#Y%ZL2< 5:3D[(ENVIQUS\58)+*X_LW39YM0@FVM:2?*VP$Y
M8#KT'3MFL@?%2^CU%]2%LESH<@56BC_UMJWJWU]^..#7)^-?$D'B*>SO+;0+
MBPOW8&*YY!F';&!\QSC!JOX;M/$6O>+;A]/6"VO=I%T'4(NT\-N0]<GJ,=?2
MO7CAJ:AS25O5_P!?><KJ2;LF?0FFZE::OI\5[93++!*,JRG]#[U;KCOA_P"#
M[OPC9WL=W>).;F17$<8(6/ .<?7(_(5V->5448R:B[HZ8MM:A1156\O4MAM
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M/6L(Z/J:MM.GW6?:)B/Y5Y,Z4XNS1]+3Q-*I&\9(I5IZ!8O?ZO B@[$8.Y]
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MJX:/8Y[%/@F>UF$B#(/#KZC_ !J^^DKG]U*RCT(R*IW5J]HR9?>KY&<8P?\
M.:YW"<-3J52$_=+3:O\ W+=C_O,!0FL*N3<1&-?[P.0*SZ\E\6ZA?3ZM<6FM
M7OE6L;8AM+$[FF],^GX_@*Z<-"I7G:]OZ[&%94Z<;V/=K6]M;V/?:W$4R@X)
MC8'%3UX-\-M5L]/O=5,TWV)!AT$DG" $C!)ZFO3-)\=:5J%X+.&^AN9#GA.&
M./0=_P *Z*U.5*;C9V76QA!*<5)/?H=;144-Q%.,QN&]N]2UFG?8336C"BBB
M@04444 %%%% !1110 4444 %%%% !1110 4444 %,EE6&,NQP!3F8*I9C@#J
M:RKB<W$@.#L!P@]3ZU$Y<J-*<.9^0SYY9#P6D<YQ4\=G.Q^8*@^N:LVEOY*E
MFYD;K[>U6:F-/JRYU;.T2@]@X7*.&/H15;&)E67<B_Q>HK8J*>W2=<,.1T(Z
MBG*GV%&J]I"Q11Q)B, #U]:DJ."(PQ!"V['0XJ2K6QD]PK-UZUTZ]T6YM-5D
MCCLYEV.SN$ ].3WS6E6=K>AV/B#3C8ZC&TEN6#E58KR.G(JX-*2;)>QX;=)I
MUO<7/A?5=6B>PM@TVG7\3"0QMU"G;G@],=C56RU6\U'4-)O]-M+O^WXY0DTL
M*$I.G !;WQP>QKV2Q^'/A6P;='I4<C=C,2^/SKI8+>&VA6*")(HU&%1%  KO
MEC(+X5?U_'[S!4GU8Y"Q12XPV!D>AH=UC0N[!5'))IU8[%]5O#&IVV\1ZCO7
MF2E;;<ZZ<.;?9#I=1FN'*6JN!V(7+'_#\:=:Z5QNN3DDY*!LY/N>]:$,$=O&
M$B4*H_6I*E4[ZRU+=6RM!67XATK)7][KS \A>?R Q^I-:U95M\NO7 /4H<?^
M.T5-UZA2VD_(U:J7\[PP 1G#N< ^GO5NJ&J*WDHX!(1N<=ABJFVHNQ%))S5R
MI%IJR:>TXR;AQO5B?R_.J;>:RA8QD3%<K_M=O\^U;:S)::;$9,@B-0%[DXZ5
ME6LT<-W"TI'&<\_=)[_T_&N><8JR.RG.3YF]>QO1IY<2)_= %5+O3Q<SI*'V
MD$;N.H!R*N]:*Z7%-69Q1FXNZ"BBBF2%07<!N;9H0VW=P3[5/12:NK,:;3NA
ML:".-47[JC IU%%,04444 %%%,2:*5G6.1'*':P5@=I]#Z4 /HHHH **** "
MBBF1313 F*1) "5)1@<$=J 'T444 %%%% !1110 4444 %%%% !1110 4444
M 4I=-C9W:*1HO,Y=1@JWN0>*C:P2&(M->3+&HR<,$4?E6C6 \\^K7[QPIF&%
ML!V^XI'?_:/H.@K.7*NFIT4W.771$4D=H]S&Z6I* YC5@3+.?7GD*/4UK163
MS2+/?$.X.4B'W$_Q/O4UK9QVH)&7E;[\C<LU6*(PMN*I6OI$****T, JE>#9
M>V4XZ[S&?<,/\0*NU3O_ +UK_P!=U_K4RV+I_%_78N4R2:*(9DD1!_M-BJUW
M-(TZ6EN=LCC<[_\ /-?7ZGM2Q:;:Q'<8A(_=Y/F8_B:+M[!RI*\A?[2L2VW[
M9;Y]/,%3I+'(,HZL/]DYH\J/&/+3'IMJO)IMHYW"%4;^]'\I_2CW@]SS_ L3
M1B:"2)NCJ5/XU7TV4RV,8?\ UD>8W'HR\&HS%?6HS!(+F,?\LY3AOP;_ !_.
MJHO(XKQKB(,N['VF!AAUQ_$!W]\=JERL[LTC"\6EJ;-%-CD2:-9(V#(PR"#P
M:=6A@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<V
MZW,.QN.<@CL:FHI-75F--IW1@R6MQ#]^/(_O)R*\QUG0=5U'Q?<'2-/BLE.T
MR7[G);W7T/TYXKVRJL]A#-D@;'_O+Q^?K2I<U%N4-?7^OS-9351)3_#^OR/F
MO^Q)[?Q)?V0L'U9K=V7ABH)SPS8_49_&KVF&>R\:Z-)<6]G!F8(([0CC)QS@
MGGGO7H.M?#&:ZU>XO8=3G@@N2&N(X0?F/?O_ (US^I>#H=)\0Z"VBVEPRK<*
MT\Y)?&&'7L._I7J?6Z<URR>KB_R];?<F<WL)1]Z.R?Z_?]YZ:&:-Q*GWUZ>]
M;(O[?RU9I5!8 X[UC,RKU.,T*%QE0.:\"$W#8].=-3W-V.XAF_U<BL?0&I:Y
MW:"<XY]:E2:>/[DSCVSG^=:JOW1@\/V9NT5DQZC<)_K D@]N#5F/4XF($BF/
MW/2M%5BS-T9HNT4R2:.)-TCA5]34']H6W]\_]\FK<DMV0HR>R+5%5?[0M_[Q
M_P"^30=0M_5C_P !I<\>X_9S[%JBJR7UNYQOVD_WABHYM05&*Q+O(ZG/%#G&
MU[@J<F[6+M%937]RWW?+7\"::;JY/68CZ**CVL2_82->BL<3S_\ /=_TJ>&^
M=,B?YQV8#G\::JI@Z,EL:-,DE2)=SL *I-J6_P"6%-S>_/\ *HA!<SMN=23Z
ML< ?A0ZG\NHE2?VM!)[A[EL$;8QT7U^M1XY!!((Y!%6TT]R<R2X'HH_J:E^P
M0XZOGUW5'))ZLU]I".B(([R9" X$B_D:MQW44I #8;T/!K,EA,4H63/'((/4
M5.UFY4/&PD0\C/!HC*2%*$'J:5%9/GSQ'9YC*?1QD_A0B23N0,L1U+-5^T[(
MCV/5LUJ*S?L]S"-R'I_=/]*M6MSYP*MQ(.H]::EK9D2A973N6****L@**Y#7
M_'MEIOF6^F^5?ZC%.(I+3S1&PZY()ZGIP*J:=\4]%N+K['J45QI=T#@I<I@
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MEZM>:?9Z1'>-IRJU\SZA'!LR-Q6,,,R$#MQ78:;K,&K>'X-8LDDEAG@\Z-,
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MO^_Z_P"- %^BJ']N:3_T%++_ +_K_C5^@ HHHH **** "BBB@ HHHH ****
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ME(EUHF;2?>/EK\SGHHZUK"TMQ_RR4_7FI$C2/[B*OT&*?LGU)===$)&@1
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MX7WY)_\ %4?\+9TC_GPOOR3_ .*K6>-4X\M[+LBHY3BD[^S=_E_F=_17 ?\
M"V=(_P"?"^_)/_BJ/^%LZ1_SX7WY)_\ %5C[6'<O^S,7_P ^W^'^9W]%9'AW
MQ#;^)+![RVBEB19"A$N,YQ[$^M:]6FFKHY)PE3DX35F@HHHID!1110 4444
M9/B*\U:QTIIM%L$O;S< (G; QW/45Y=_PBGC;5=;N]5@TVPT=[B,Q3(TGRRY
MZG W<U[/16]*NZ:M%(B4.;=GE.D?!QHDMAJVL--#&_F/:0J0A;V)/ZX%>K44
M5-6M.J[S8XP4=@HHHK(H**** "BBB@ HHHH **** "BBJ5QJ^GVLS0SW<4<B
MXRK'D4FTMRHQE)VBKEVBL[^W]*_Y_P"'_OJC^W]*_P"?^'_OJI]I#NBO8U/Y
M7]S-&BL[^W]*_P"?^'_OJC^W]*_Y_P"'_OJCVD.Z#V-3^5_<S1HK._M_2O\
MG_A_[ZK1!R,CI5*2>S)E"4?B5@HHHIDA1110 4444 %%%% !1110 4444 %%
M%% !1110 A (P1D'L: H484 #T%+10 V2-)HVCD4,C#!![U0CT6U2Y2=MTK1
M_<WX.W\>I_&M&BDXI[E1G**LF%%%%,D**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[3O
M^0CJW_7RO_HI*9XEEDA\+ZI)%G>MK(01V^4\T_3O^0CJW_7RO_HI*O31)/#)
M#(-R2*58'N",&D]B9*\6D>3DW-G\)[4Z:KXN)_\ 2Y(QEE7)ST]P!5C6/%5G
MK'AN#P_I NKVYF54:253E0,9)-7XM"\4^$I)8- ,-_I\K;Q%/U0_F*1]*\9^
M( ;6]6TTJR?_ %OD ;F'X$_SK&SV/+Y:B7*D[VM:WY.]M2KX:A^W^/8#;,9;
M32;)+;SQT<@>OU)_*O3ZR] T&S\.Z8ME9@D9W.[?>=CW-:E:Q5D=^'I.G#7=
MZG/>)_#<GB"XT.5+A81INHQ7K!ESO"9^4>G6N=B^%T%O\2;OQ/#=*MK=V\D4
MMILYW.N&(/3'>O0Z*HW/-HOASJTVGZ9X?U'5[67P]ILZS1+%"RW$H0Y1'8G;
M@>P[5:M_AU-!HOC"P^WQDZ_=23HVPXA#=CZUW]% ')V7@^6UUGPY?&[1AI&F
M&Q90I_>$A!N'I]W]:Y&/X1ZC:P:=Y&IV-P]G>W%R;>\@9[>02_WE!&2/Y@5Z
MU10!Y99?":[M;&PMVU2W8VNM_P!JDI"5##'* 9XYK6^+5E>7_AFPAL$E:?\
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M;P=K7A=O"%Y=W\FJFZ2^5%,;(9 PD#9R6QQ@<X-)=>$M=L[OQ%IUSINLW?\
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M_":Z7_SSN?\ O@?XUP%%*&(G"/*BZN!HU9N<KW]3O_\ A-=+_P">=S_WP/\
M&C_A-=+_ .>=S_WP/\:X"E5&=PJ*68G  ')JOK=4R_LS#^?WG??\)KI?_/.Y
M_P"^!_C1_P )KI?_ #SN?^^!_C7!.CQ2,CJ5=3@J1@@TVCZW4#^S,/Y_>=__
M ,)KI?\ SSN?^^!_C1_PFNE_\\[G_O@?XUP%%'UNH']F8?S^\[__ (372_\
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M )Z0_P#?L_XT;;K_ )Z0_P#?L_XT 3T5!MNO^>D/_?L_XT;;K_GI#_W[/^-
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M%4I-7L8M9ATA[A1?30M.D/<H#@G\ZNT 9VO_ /(N:G_UZ2_^@&M =!6?K_\
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M(*__ $$%_P"_7_UZ/^$%?_H(+_WZ_P#KUV=%'U6EV#^T<3_-^".,_P"$%?\
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MBK@_B:Q_^$:U/_GG%_W_ $_QKS*\*CJ-I,^@P=6@J$5)J_R*/]HWW_/Y<?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (P!,,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBD9E099@H]2<4 +15.75M/A_UE[ #Z!P3^E4I?%&E1
M])VD/^PA_K0!LT5S4OC.U7/E6LS_ .\0O^-4I?&=R<^5:1+_ +[%O\* .RHK
M@)?%6JR?=E2/_<0?US5*75]1F^_>S_0.0/TH ]+9U099@H]2<53EU;3H<[[V
M $=@X)_(5YJ[O(VYV9CZDYIM 'H$OBG2H_NS/(?1$/\ 7%4I?&=L/]5:2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?YU=B\:1G_763+[H^?Y@5R%% '>1>+=,DQO,T?\ O)G^6:NQ:YI<V-M["/\
M?.W^=>;44 >K1S13?ZJ5'_W6!I]>3 D$$'!%6HM2OH/]5=SK["0X_*@#T^BO
M/(O$NJQ<?:=X]'0'^E78O&5ZO^MMX'^F5/\ .@#MJ*Y:+QI"<>=9NOKL<-_/
M%78O%FER?>:6+_?3_#- &Y15"+6],F^[>PC_ 'FV_P ZN1S12C,<B./56!H
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,HKJ[R9M1\'?:[D*\Z/PX4#'S8[>U7I(9-+L+.*PNK&VR-TC7# &4X'MS_\
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MW:]/N3O^!WE%0VJ>59P1[R^V-5W$8S@=<=JFKL1Y;5G8****!!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7)^-O^7'_MI_[+765R?C;_ )<?^VG_
M ++0!R5%%% !1110 4444 %%%% !1110 4444 %%%% &GHNK_P!D3RR>1YN]
M=N-^W'/T-9E%% &GI6K_ -F07<?D>9]H4+G?C;@'VYZU!IFI3:7=B>(!LC:R
MGHPJG10!M3:^@M)X+&P2T\__ %C!]Q(]N.*CL=:^SV#6%U:K=6Q.0I8J5_$5
MDT4 :]YKK73VJ1VZPVULP985;.2/>I9?$LS:NE_#"(\1B-HRVX,,YZX%8=%
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M)H[-!(#D$L2 ?H3BM.BFX1>Z$JLU>S>OF%%%%40%%%% !1110 4444 %%%%
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M?_B:XK^U]2_Z"%W_ -_F_P :/[7U+_H(7?\ W^;_ !H^NQ[!_9,_YE^)VO\
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MK4?_  *?_&C_ (237?\ H-:C_P"!3_XT?65V#^P*O\Z^YGM'_"&Z=_SVNO\
MOI?_ (FC_A#=._Y[77_?2_\ Q->+_P#"2:[_ -!K4?\ P*?_ !H_X237?^@U
MJ/\ X%/_ (T?65V#^P*O\Z^YGM'_  ANG?\ /:Z_[Z7_ .)H_P"$-T[_ )[7
M7_?2_P#Q->+_ /"2:[_T&M1_\"G_ ,:/^$DUW_H-:C_X%/\ XT?65V#^P*O\
MZ^YGM'_"&Z=_SVNO^^E_^)H_X0W3O^>UU_WTO_Q->+_\))KO_0:U'_P*?_&C
M_A)-=_Z#6H_^!3_XT?65V#^P*O\ .ON9[1_PANG?\]KK_OI?_B:/^$-T[_GM
M=?\ ?2__ !->+_\ "2:[_P!!K4?_  *?_&C_ (237?\ H-:C_P"!3_XT?65V
M#^P*O\Z^YGM'_"&Z=_SVNO\ OI?_ (FC_A#=._Y[77_?2_\ Q->+_P#"2:[_
M -!K4?\ P*?_ !H_X237?^@UJ/\ X%/_ (T?65V#^P*O\Z^YGM'_  ANG?\
M/:Z_[Z7_ .)H_P"$-T[_ )[77_?2_P#Q->+_ /"2:[_T&M1_\"G_ ,:/^$DU
MW_H-:C_X%/\ XT?65V#^P*O\Z^YGM'_"&Z=_SVNO^^E_^)H_X0W3O^>UU_WT
MO_Q->+_\))KO_0:U'_P*?_&C_A)-=_Z#6H_^!3_XT?65V#^P*O\ .ON9[1_P
MANG?\]KK_OI?_B:/^$-T[_GM=?\ ?2__ !->+_\ "2:[_P!!K4?_  *?_&C_
M (237?\ H-:C_P"!3_XT?65V#^P*O\Z^YGM'_"&Z=_SVNO\ OI?_ (FC_A#=
M._Y[77_?2_\ Q->+_P#"2:[_ -!K4?\ P*?_ !KU7X97UW?^&[B6\NI[F07;
M*'FD+D#8G&3VY-7"LINUCFQ>53PU+VDI)[=^II_\(;IW_/:Z_P"^E_\ B:/^
M$-T[_GM=?]]+_P#$UE:_?7<.MW$<5U.B#;A5D( ^4=JS?[3O_P#G^N?^_K?X
MUXE?B&E2JRINFW9M;KH*GE<YP4U):^IT_P#PANG?\]KK_OI?_B:/^$-T[_GM
M=?\ ?2__ !-<Q_:=_P#\_P!<_P#?UO\ &C^T[_\ Y_KG_OZW^-9?ZS4?^?;^
M]%_V1/\ F7XG3_\ "&Z=_P ]KK_OI?\ XFC_ (0W3O\ GM=?]]+_ /$US']I
MW_\ S_7/_?UO\:/[3O\ _G^N?^_K?XT?ZS4?^?;^]!_9$_YE^)T__"&Z=_SV
MNO\ OI?_ (FC_A#=._Y[77_?2_\ Q-<Q_:=__P _US_W];_&C^T[_P#Y_KG_
M +^M_C1_K-1_Y]O[T']D3_F7XG3_ /"&Z=_SVNO^^E_^)H_X0W3O^>UU_P!]
M+_\ $US']IW_ /S_ %S_ -_6_P :/[3O_P#G^N?^_K?XT?ZS4?\ GV_O0?V1
M/^9?B=/_ ,(;IW_/:Z_[Z7_XFC_A#=._Y[77_?2__$US']IW_P#S_7/_ '];
M_&C^T[__ )_KG_OZW^-'^LU'_GV_O0?V1/\ F7XG3_\ "&Z=_P ]KK_OI?\
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M>*R&H6KVUS=S&)85<2;3DX)8<8P ?QKE]*W37VG>'RQ8:7=32RG'54/[L_\
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MWPYI.HW9NKJT#S, K,LC+N ]0",_C6I10!FQ>']+@$0BM @AG-Q&JNP"N>I
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M6NO^OU__ $!*VP_QGE9U_NC]4-\1_P#(>N?^ _\ H(K*K5\1_P#(>N?^ _\
MH(K*KX+'_P"]5?\ $_S)PW\&'HOR"BBBN0V"BBB@ HHHH **** "BBB@ HHH
MH *M:9_R%;/_ *[I_P"A"JM6M,_Y"MG_ -=T_P#0A6N'_C0]5^:(J_!+T?Y,
M](HHHK]1/C@HHHH *H7VM:?ILRQ7=QY;LNX#8QXZ=A[5?K!USPW_ &S>)/\
M:_)V1A-OE[L\DYZCUJ*CFH^XM3:A&E*=JKLC<CD66))$.4<!E/J#3JCMXO(M
MHH=V[RT"YQC.!BI*M;&3M?0YF675;[Q3?6%MJKVD$$,;J%@1\ENOWAFEMM6N
M=+U:]L=6OEN8(+470N!$%95S@AE7\ZJG3EU'QQJBM=7=OLMX3FVF,9/'?'6I
M]8T6STKPOJ[P"1YIH29)IG+N_P!2:!%N37K&]:V^Q:IY0^UQQL?L[,)MP;"
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M-I>W7E_8]2>RVYW;84??TQ]X<8Y_.L/PVVLZG;)>W&M2%%G9&A^SQX<*V,9
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M0:?J$=REA=!YXHB^THRD#'7# 9'2N6D5725'4,K>*5!!&01\M:NK?\CE"?\
MJ&3?SH =H7BZQFTVR34-04WTH <F,A=Q/ ) V@]*77=5N+*QUZ6TU+=/;"'9
M%Y 'V?=CN1A]V<^U93HH^$\)"@8$9Z=_.'-&N#(\8C&[FTX]?E6@#J;/Q#I6
MH7?V6UO%>8@D+M8;@.NTD8;\*QI?%,6G6=D6O_M[3W9C>4VS)MC!.[  Y(X'
MOUYIEUJ%GKFHZ+;Z6K-+;7(FE_=E?(C P5;CC/ Q[5E6\J6_AK2[B4[88=;W
MR/CA5!?DT ===>)M'LI%CGO KE ^T1LQ53R"V =O'KBI+K7]+LX;>:>[01W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH S]3L+N[:"6SU&2SEB+=$WHX./O*2,]./3FJ<'AZ
M1(KYY]2G>^O H:ZC41E OW0H'0>O/-;E% &'#H5W)J%M=:IJAO1:DM#&L B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'J4*\(U%U75/JNS8.K&I3DX]G^3/2****_2CY(*:[K'&SN<*H))]!3J@O?\
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MVF:=J%K87=SY=S=$+"GEL=Q)P.0,#GUK2KR#55UZ+QOX=BUYX)9DN(O+FA&
MZ^8/8<@^PKU^B$W)LC%X:-"--IWYDWY;VT,NS\1Z3?ZI/IEM>![R L)(BC*0
M5.#@D8.#Z5)<:YIUKJ\&E37&V]G7='%L8[ASW P/NGJ>U>-7;7UEXMUG6;'[
MUAJ#N_\ NM(PY]NQ^M=-=:G!K/Q)\-7]L<QS6BG&>5.Z7(/N#Q6:K-_>=U3+
M(1::;<>5OT:BG;\3T^BO-]9\7:M>^)+K3-)U'3],AM"4:>[=%WL."/F![Y&
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M?5?AO/<H!#>-,MK-Y>1C/.1Z @8_.MOPKX/T5?#-G+<6$%S-=0++)),@8_,
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M.6M1=*?(W?T"BBBJ,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<>WO7.T5,)N#NBZM*-16D6]2OCJ6HS7;($,A!V@YP ,#^5=_P"%?^1;M/\
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M16O;>,M1M?$MQKR0VINITV,C*VP# Z#=G^$=ZPYK2YMKDVT]O+%< @&*1"K
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M$.A^&KBS\.:5<F74)$2<0"27Y%R>>3CDX]\FDL_A3I+V4#75U?K<&-3*$=
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M10 4444 %%%% !7'>._^8?\ ]M/_ &6NQKCO'?\ S#_^VG_LM88G^$SMR_\
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M;@9!#'G!Z8H Z>BBB@ HHHH **** "BBB@ KCO'?_,/_ .VG_LM=C7'>._\
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MZE8ZUXA:SLIWGN8XGMI/*)C)6/!R>F?05DRK?WD^ERO'KT[Q7D,MQ]IAV1H
MW)5%'/\ 09KT*B@#C(9[G0=/U33I=,O)V:2:2*:.+,;JW(+-VQWS6=;6-RMM
MHVI+_:/V=M/%NS:=@R*0Q;D$'*G/;TKI[CPM:SR7!6]OX8;ER\UO%-B-R?O<
M8SSWP:VH88[>".&)0D<:A$4=  , 4 <OHQ.EV^K:O/:ZJR-L.;HJTTBH#SL
M7;@'N>@[8KITD\RW66-<[DW*"<=1Q27-M%>6SV\Z;XI!AER1D>G%2    # '
M0"@#@(X+RW9!H]EK5A>&4;K9_GM -W/)XQCTJ62RN]-U'4ED_MT">Y>XA.G
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MB@ HHHH **** "N.\=_\P_\ [:?^RUV-<=X[_P"8?_VT_P#9:PQ/\)G;E_\
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MS 98] /<U0T6\O;RUD>]2VW*Y5);:3='*O\ >')(^AJE*_VWQI%;-S#8VQG
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M .8?_P!M/_9:[&N.\=_\P_\ [:?^RUAB?X3.W+_]YC\_R..HHHKR3Z8****
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MIK'\+0R+I3W4R[)+Z>2[*_W0YX'Y 5L2Q1SQ-%-&DD;##(Z@@CW!IX&!@=*
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M"J6I7.HW7B"/2;&[%FJVWVF6;RP['+;0H!X[&N<%UJ6CC77-POVL7UNC2K&
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MHH **** "BBB@ HHHH **** "O2O"O\ R+=I_P #_P#0VKS6O2O"O_(MVG_
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M8"$Y[>OZ58M= ^S:'J&F_:=WVLS'S/+QL\P8Z9YQ]:VJ* ,(Z'J$(A%CK4D
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M<-,L94-M(R#ST.>G2LL:=:Z)XLTJ'30T2W22BXB#DA@JY5B#WSWJWXJ ,>D
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M:ZIXZO(;R,RPK9QMY>XA2<D G'7&365""88-'DN)4TXZQ/;-\YY1>5CSZ$T
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MH=W##(9(H_$"JK%MQP-O?O0!Z/17'6FF:?K4^MW>K%I)8+J2)29"/(C4?*5
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MK#((/4&G44 95GX:TBPNEN;>R594SL)=FV9] 20/PK5HHH J:AIEGJMN(+V
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M &6L,3_"9VY?_O,?G^1QU%%%>2?3!1110 4444 %%%% !1110 4444 %%%%
M!7I7A7_D6[3_ ('_ .AM7FM>E>%?^1;M/^!_^AM77@_XC]#S,U_@KU_1GSU1
M114GTH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>Q?"?_D5KK_K]?\ ] 2O':]B^$__ "*UU_U^O_Z E;8?XSRLZ_W1^J&^(_\
MD/7/_ ?_ $$5E5J^(_\ D/7/_ ?_ $$5E5\%C_\ >JO^)_F3AOX,/1?D%%%%
M<AL%%%% !1110 4444 %%%% !1110 5:TS_D*V?_ %W3_P!"%5:M:9_R%;/_
M *[I_P"A"M</_&AZK\T15^"7H_R9Z11117ZB?'!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UXLTJ]U/[
M']CA\SR]^[YE&,[<=3[&NEK,E\0Z5!,\4EUM=&*L/+8X(X/:HJ04X\K-:-65
M&:G'='$_\(KK7_/E_P"14_QH_P"$5UK_ )\O_(J?XUV?_"3:/_S]_P#D-_\
M"C_A)M'_ .?O_P AO_A7/]3I]V=W]JUNR_'_ #.,_P"$5UK_ )\O_(J?XT?\
M(KK7_/E_Y%3_ !KL_P#A)M'_ .?O_P AO_A1_P )-H__ #]_^0W_ ,*/J=/N
MP_M6MV7X_P"9QG_"*ZU_SY?^14_QH_X176O^?+_R*G^-=G_PDVC_ //W_P"0
MW_PH_P"$FT?_ )^__(;_ .%'U.GW8?VK6[+\?\SC/^$5UK_GR_\ (J?XT?\
M"*ZU_P ^7_D5/\:[/_A)M'_Y^_\ R&_^%'_"3:/_ ,_?_D-_\*/J=/NP_M6M
MV7X_YG&?\(KK7_/E_P"14_QH_P"$5UK_ )\O_(J?XUV?_"3:/_S]_P#D-_\
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M,1?_ !5>P?\ "3:/_P _?_D-_P#"C_A)M'_Y^_\ R&_^%'U:(?V[B/Y5^/\
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MU:(?V[B/Y5^/^9X__P *\\4_] O_ ,F(O_BJ/^%>>*?^@7_Y,1?_ !5>P?\
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M<X4J!@<XYYK2I5A37--V6WW[$QA*;M%7+M%%%62%%%% !1110 4444 %%%%
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ME>XAAU&.2Y@R3&(ST[<Y_P <5)8Z7ILGAV>ZEN0')56F,1/DG*_*!WZ]1ZT
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MBBOH3RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFL6ESJNHS&:..,Q*D9D8+OQGU^M9%K<0KX.OH&FC$S3 K&6&XC*<@?@:PJ*
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MDG .,5-+XL6+2C=&QD^T1W2VLUJ7&Y&/H>_MTS0!T=%<_)K]_'-#9#1]VHR
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ML&9Y?$0"Q-(5,,A"X)QUP>W0UOW>LZE%-<BUT.6:"W)#2R3"+?@9)4$'(]Z
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M;NCJ4-CJ>FFRDN%)@83"57(&2I( P<4 ;5%%% !1110 4444 %%%% !1110
M5F2^'M*GF>62UW.[%F/F,,D\GO6G7FVI_P#(6O/^N[_^A&@#L_\ A&='_P"?
M3_R(_P#C1_PC.C_\^G_D1_\ &N!HH [[_A&='_Y]/_(C_P"-'_",Z/\ \^G_
M )$?_&N!HH [[_A&='_Y]/\ R(_^-'_",Z/_ ,^G_D1_\:X&B@#OO^$9T?\
MY]/_ "(_^-'_  C.C_\ /I_Y$?\ QK@:* .^_P"$9T?_ )]/_(C_ .-'_",Z
M/_SZ?^1'_P :X&B@#OO^$9T?_GT_\B/_ (T?\(SH_P#SZ?\ D1_\:X&B@#OO
M^$9T?_GT_P#(C_XT?\(SH_\ SZ?^1'_QK@:* .^_X1G1_P#GT_\ (C_XT?\
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MX1G1_P#GT_\ (C_XT?\ ",Z/_P ^G_D1_P#&N!HH [[_ (1G1_\ GT_\B/\
MXT?\(SH__/I_Y$?_ !K@:* .^_X1G1_^?3_R(_\ C1_PC.C_ //I_P"1'_QK
M@:* .^_X1G1_^?3_ ,B/_C1_PC.C_P#/I_Y$?_&N!HH [[_A&='_ .?3_P B
M/_C1_P (SH__ #Z?^1'_ ,:X&B@#OO\ A&='_P"?3_R(_P#C1_PC.C_\^G_D
M1_\ &N!HH [[_A&='_Y]/_(C_P"-'_",Z/\ \^G_ )$?_&N!HH [[_A&='_Y
M]/\ R(_^-'_",Z/_ ,^G_D1_\:X&B@#OO^$9T?\ Y]/_ "(_^-'_  C.C_\
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M*RO:S+;N$F9&$;'HK8X/YUY_<^'M7N],\N31Y7OP5+W4^H;]Q!&=B[L#/OC
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M%%% !6OX>MK.]O)+:[CW%DS&=Q&".O0^G\JR*L65R;.]AN%S^[8$X[CN/RH
MO:3I0N-;:TN%W)"6\P9(SCC^>*C?3I+^_N!IEL3 C87#<8^I/?K74:D8=.M+
MW48F_>W2JJG/?&,C\.?PK)T:V4:%/<"*2[;S,?9E<A3TZ@=?7\* ,Q-+GMM3
MM(+V JLLJC&>&&0#R*GO])>37;BST^#(C56";^@P,\D^IK<U,,#H>^(1-YZ9
M1>BGCBBT('C6^R>L Q^24 <I!87-S;RSQ1[HH1EVW 8[U)::1?WL7FV]NSQY
MQN) !^F3S6YIEG<6F@:H+B)HRR-@,.N%-6B%ETC2C%8M=J%4929D\ML 9./?
M//;\: .52PNI+LVJ0.9QU3'(J2[TB_L8O-N+=D3.-P(8#\C70O<W8\3NT-K%
M+*L 26-)ATSG.2!STIE[912Z1<SPK=V"IDM#*Q".?IF@#E**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [_ ,-_\@"V
M_P"!_P#H1K5K*\-_\@"V_P"!_P#H1K5H **** "BLS7KN>RTMIK=]D@8#. ?
MYU#X<OKF_LI9+F3>RR;0=H'&!Z5R/&TUBEA;/F:OY&ZP\G1]MTO8V:J:CJ=I
MI5NL][*8XV<("$9LL>@P 3VJW7.^,&D2UTMH8Q)*NI0%$+;=QR<#/;/K768%
MJ'Q3I%Q/'!%<2F21@B@VTHR2<#DK@5L5D6]]K<EQ&D^B10Q$X>07H8J/7&WF
ML?6-4N;:\N@_B2ULV0GR+:&$2L1C^/(R"?04 =?5>&]MY[NYM8I-TUL5$J[2
M-NX9'/0\>E<I!K.K:K-HD4%XMH;VU=YF6)7^93U /T^G-1RRZA87OB.YM9R\
M]JUI)*?+'[U5C&_C'&1D\4 =O16)'J<M_P"(K>"SE_T..U^T3_*#O+_<7/;C
M+<4:W=WPOM.TVPF6WEO&D+3E ^Q4 )P#QDY% &DM_;/J$E@LF;F-!(R;3PIX
M!STJS7#FXO-"U_5[N]F%W)%IRO')L";QNP,@<=<CCTJ&'Q5-;-9W$FO07QED
M59[18 NP-UVL!DD>_6@#NTECD=T21&9#APK E3[^E/K@;.[N]#C\3:@UT;@P
M7&SRWC4!Y&*@.<=,9Z#BIK3Q+)#J.GH=>@U,7,JPRPK (S&6X#*0.0#ZT =Q
M4,MW;PI.SRJ! F^4 Y*+@G) Y['\JYNQEU[6[-]3M-2BM4>1Q;VK0!E*JQ7Y
MV^]S@]*IP+J%MKWB:Z^WD/#;I(R+&I#$QN5&2.B]O7O0!V5O/%=6T5Q"VZ*5
M Z-@C*D9!YJ2N5AU#5M4DTRQM[Q;9WTZ.\N+GRE9F+<8 / YR>E5+_7-8T^T
MU"T:XCDN[.X@"7'E@"1)#P&7H#P0<4 =K17.13:MIWB*PL[S4%O8+U)3@P+&
M8V0 \8ZCGO71T 5H[^VEOYK%),W,*J\B;3P#TYZ59KD-9UO4+2[UY(+C8MK:
MQ20C8IVL3R>1S^-+-<:_#J&F0#5(F.IJ^0;=0L&%#$KW/&1S0!UU%<;=ZKK&
MGV&MPM>+<7-E);^3.8E4D2,N01C'?%7&N=7T?5=.2^OTO8+US"R"$)Y;XR"I
M'4?6@#IJ*XBVUC6E\/W.M2WRRB*1H8[8PJ Q+[5+,.>">V.!6C++K6C7&GRW
M>HI?0W-PEO+&8%38S\ J1V!]: .FHKDSKM_:Z+J-O+)YFK6]S]EB.P N7/[M
ML 8Z'/3^&JMWXAF&K3V$VO1Z<MHB(9#;J[3R8RS8(P!],4 =M59;^V?4)+!9
M,W,:"1DVGA3P#GI7*VGB+4=7M].M+6>*&ZGFFCENE3<NV, EE4^H858TBWO+
M;QO>I>W(N7-DA67RPA9=W<#C.<C\* .KJM>W]MI\22W4GEH[K&IVDY8]!Q67
MJ][?/K-GI%A.ML\T;323F,.54<  'C)/K65X@AU*WTJ*/4+J*Z4:A 89538Q
M&>0P''7TH ZFVO[:\EN(H)-[V[^7*-I&UO3GK^%6:XJ^U[5(;76'BN!OM]12
M"'<BX"$C@\?KUK2BFU;3O$5A9WFH+>P7J2G!@6,QL@!XQU'/>@#;LKVWU&SC
MN[23S() 2C;2,X..AY[58KB['6]5U+3]$M(KM8[R]262:Y:)255"1PO3)^G:
MM.X_MK3]/N//U:QQO7R[RX4(54_>RH&TGT]: .AJO97MOJ-G'=VDGF02 E&V
MD9P<=#SVKF-(UR:3Q)#8+K"ZI;31.Q?R!'L9?0@ &M#P5_R)^G_[K?\ H;4
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M44 %%%% !7FVI_\ (6O/^N[_ /H1KTFN:NO"?VF[FG^V[?,D9]OE9QDYQUH
MY"BNJ_X0S_I__P#(/_V5'_"&?]/_ /Y!_P#LJ .5HKJO^$,_Z?\ _P @_P#V
M5'_"&?\ 3_\ ^0?_ +*@#E:*ZK_A#/\ I_\ _(/_ -E1_P (9_T__P#D'_[*
M@#E:*ZK_ (0S_I__ /(/_P!E1_PAG_3_ /\ D'_[*@#E:*ZK_A#/^G__ ,@_
M_94?\(9_T_\ _D'_ .RH Y6BNJ_X0S_I_P#_ "#_ /94?\(9_P!/_P#Y!_\
MLJ .5HKJO^$,_P"G_P#\@_\ V5'_  AG_3__ .0?_LJ .5HKJO\ A#/^G_\
M\@__ &5'_"&?]/\ _P"0?_LJ .5HKJO^$,_Z?_\ R#_]E1_PAG_3_P#^0?\
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MS_I__P#(/_V5'_"&?]/_ /Y!_P#LJ .5HKJO^$,_Z?\ _P @_P#V5'_"&?\
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MI/VO_CWD1_-\O[VUMV,9X_.MVB@#G?\ A&KJ*YO3:ZLT%M>2M++&+=2^6^\
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M]:OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'RAEW=CNWY4\Y(./2[:V-ZNMAV#)>"XE9IQ9L0R$';ND+A63&W"@9&,<8)H
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M-,>#PN<9ST]./<4ZUNH;VW6>W??$Q(#8(S@X/7W%<PEMJ(,6N-&=QNS*UO\
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M.O QSTK*/AK4I+.ZBEFMV>2TCMD;<W.QR03\O]W'XT ;MMK5A=RI%#.3([%
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MG16@#2 A3SPP..01CI].U+?Z-=S22FVDA"W5HMK.7)R@!/S*,')PS#!QVYH
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M(:Y+".XGF.$QGS%88Z\8W=?:@!-/\1?:HH%DLKDW!M$N9?*52H!!Z#<2<XX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (J!)@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BJ.I:E_9[6R"SN+J2YD,4:0% =P5FYWLHZ*WY5!_:U[
M_P!"]J7_ '\MO_CM &K165_:U[_T+VI?]_+;_P".T?VM>_\ 0O:E_P!_+;_X
M[0!JT5E?VM>_]"]J7_?RV_\ CM']K7O_ $+VI?\ ?RV_^.T :M%97]K7O_0O
M:E_W\MO_ ([3DU2\9U4Z#J* D LTEO@>YQ+F@#3HHHH **** "BBB@ HHHH
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M37,44>TEW#ZGA_\ GVON1T__  L/Q3_T%/\ R7B_^)H_X6'XI_Z"G_DO%_\
M$US%%'M)=P^IX?\ Y]K[D=/_ ,+#\4_]!3_R7B_^)H_X6'XI_P"@I_Y+Q?\
MQ-<Q11[27</J>'_Y]K[D=/\ \+#\4_\ 04_\EXO_ (FC_A8?BG_H*?\ DO%_
M\37,44>TEW#ZGA_^?:^Y'3_\+#\4_P#04_\ )>+_ .)H_P"%A^*?^@I_Y+Q?
M_$US%%'M)=P^IX?_ )]K[D=/_P +#\4_]!3_ ,EXO_B:/^%A^*?^@I_Y+Q?_
M !-<Q11[27</J>'_ .?:^Y'3_P#"P_%/_04_\EXO_B:/^%A^*?\ H*?^2\7_
M ,37,44>TEW#ZGA_^?:^Y'3_ /"P_%/_ $%/_)>+_P")H_X6'XI_Z"G_ )+Q
M?_$US%%'M)=P^IX?_GVON1T__"P_%/\ T%/_ "7B_P#B:/\ A8?BG_H*?^2\
M7_Q-<Q11[27</J>'_P"?:^Y'3_\ "P_%/_04_P#)>+_XFC_A8?BG_H*?^2\7
M_P 37,44>TEW#ZGA_P#GVON1T_\ PL/Q3_T%/_)>+_XFC_A8?BG_ *"G_DO%
M_P#$US%%'M)=P^IX?_GVON1T_P#PL/Q3_P!!3_R7B_\ B:/^%A^*?^@I_P"2
M\7_Q-<Q11[27</J>'_Y]K[D=/_PL/Q3_ -!3_P EXO\ XFO6?!NHW6K>$[*]
MO9?-N)?,WOM"YP[ <  = *^?Z]V^'G_(BZ;_ -M?_1KUO0E)RU9Y&<T*5.@G
M"*3OT7DSIZ***ZSYD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH RM6_P"0EH7_ %_-_P"D\U:M
M96K?\A+0O^OYO_2>:M6@ HKS7XA>*M:T/7X+;3KWR(6M5D*^4C98LXSE@3T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5[M\//^1%TW_MK_P"C7KPF
MO=OAY_R(NF_]M?\ T:];X;XCQ<]_W>/K^C.GHHHKM/E HHHH **** "BBB@
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M7_T:]>$U[M\//^1%TW_MK_Z->M\-\1XN>_[O'U_1G3T445VGR@4444 %%%%
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M#^UL'_/^#_R/,**]/_X5!_U'?_)3_P"SH_X5!_U'?_)3_P"SH]A/L']K8/\
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M/^H[_P"2G_V='L)]@_M;!_S_ (/_ "/,*]V^'G_(BZ;_ -M?_1KUS'_"H/\
MJ._^2G_V==UX=T?^P="MM,\_S_)W?O-FW=EBW3)]?6M:-.497:/,S;'4,114
M:4KN_9]F:E%%%=1\\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI/\ S]_^0W_PH_X2/2?^?O\ \AO_ (4N6CY?>:_7\Q[O[E_D<+_PJ#_J._\
MDI_]G1_PJ#_J._\ DI_]G7=?\)'I/_/W_P"0W_PH_P"$CTG_ )^__(;_ .%'
M+1\OO#Z_F/=_<O\ (X7_ (5!_P!1W_R4_P#LZ/\ A4'_ %'?_)3_ .SKNO\
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M^OYCW?W+_(X7_A4'_4=_\E/_ +.J][\*?LEH\_\ ;6_;CY?LN,Y./[]>A?\
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MW_K<WHKV&1UB!=HFL!#*R(3Y9'<^P_K4-Q%!%X<VP3^<#=C+!"HSL/ SS_\
MKK,M[F:TF$L$A1P,9'I3[F^N;L*LTFY5^ZH4*!^ JO:)K7<CV+4E;;3]?\RO
M11161TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYW>X_91Y5'L;<FL6K79VPR?9'MA Z<;ACN/I5*273XUB%M',SK(&:67 ./0
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M3_SZ?^1'_P :/^$<TG_GT_\ (C_XUE?\)E_TX?\ D;_[&C_A,O\ IP_\C?\
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MCO/[_P#@FK_PCFD_\^G_ )$?_&C_ (1S2?\ GT_\B/\ XUE?\)E_TX?^1O\
M[&C_ (3+_IP_\C?_ &-']KY;_,ON?^0?5<=Y_?\ \$U?^$<TG_GT_P#(C_XT
M?\(YI/\ SZ?^1'_QK*_X3+_IP_\ (W_V-'_"9?\ 3A_Y&_\ L:/[7RW^9?<_
M\@^JX[S^_P#X)J_\(YI/_/I_Y$?_ !H_X1S2?^?3_P B/_C65_PF7_3A_P"1
MO_L:/^$R_P"G#_R-_P#8T?VOEO\ ,ON?^0?5<=Y_?_P35_X1S2?^?3_R(_\
MC1_PCFD_\^G_ )$?_&LK_A,O^G#_ ,C?_8T?\)E_TX?^1O\ [&C^U\M_F7W/
M_(/JN.\_O_X)J_\ ".:3_P ^G_D1_P#&C_A'-)_Y]/\ R(_^-97_  F7_3A_
MY&_^QH_X3+_IP_\ (W_V-']KY;_,ON?^0?5<=Y_?_P $U?\ A'-)_P"?3_R(
M_P#C1_PCFD_\^G_D1_\ &LK_ (3+_IP_\C?_ &-'_"9?].'_ )&_^QH_M?+?
MYE]S_P @^JX[S^__ ()J_P#".:3_ ,^G_D1_\:/^$<TG_GT_\B/_ (UE?\)E
M_P!.'_D;_P"QH_X3+_IP_P#(W_V-']KY;_,ON?\ D'U7'>?W_P#!-7_A'-)_
MY]/_ "(_^-'_  CFD_\ /I_Y$?\ QK*_X3+_ *</_(W_ -C1_P )E_TX?^1O
M_L:/[7RW^9?<_P#(/JN.\_O_ .":O_".:3_SZ?\ D1_\:/\ A'-)_P"?3_R(
M_P#C65_PF7_3A_Y&_P#L:/\ A,O^G#_R-_\ 8T?VOEO\R^Y_Y!]5QWG]_P#P
M35_X1S2?^?3_ ,B/_C1_PCFD_P#/I_Y$?_&LK_A,O^G#_P C?_8T?\)E_P!.
M'_D;_P"QH_M?+?YE]S_R#ZKCO/[_ /@FK_PCFD_\^G_D1_\ &C_A'-)_Y]/_
M "(_^-97_"9?].'_ )&_^QH_X3+_ *</_(W_ -C1_:^6_P R^Y_Y!]5QWG]_
M_!-7_A'-)_Y]/_(C_P"-'_".:3_SZ?\ D1_\:RO^$R_Z</\ R-_]C1_PF7_3
MA_Y&_P#L:/[7RW^9?<_\@^JX[S^__@FK_P (YI/_ #Z?^1'_ ,:/^$<TG_GT
M_P#(C_XUE?\ "9?].'_D;_[&C_A,O^G#_P C?_8T?VOEO\R^Y_Y!]5QWG]__
M  35_P"$<TG_ )]/_(C_ .-'_".:3_SZ?^1'_P :RO\ A,O^G#_R-_\ 8T?\
M)E_TX?\ D;_[&C^U\M_F7W/_ "#ZKCO/[_\ @FK_ ,(YI/\ SZ?^1'_QH_X1
MS2?^?3_R(_\ C65_PF7_ $X?^1O_ +&C_A,O^G#_ ,C?_8T?VOEO\R^Y_P"0
M?5<=Y_?_ ,$U?^$<TG_GT_\ (C_XT?\ ".:3_P ^G_D1_P#&LK_A,O\ IP_\
MC?\ V-'_  F7_3A_Y&_^QH_M?+?YE]S_ ,@^JX[S^_\ X)J_\(YI/_/I_P"1
M'_QH_P"$<TG_ )]/_(C_ .-97_"9?].'_D;_ .QH_P"$R_Z</_(W_P!C1_:^
M6_S+[G_D'U7'>?W_ /!-7_A'-)_Y]/\ R(_^-'_".:3_ ,^G_D1_\:RO^$R_
MZ</_ "-_]C1_PF7_ $X?^1O_ +&C^U\M_F7W/_(/JN.\_O\ ^":O_".:3_SZ
M?^1'_P :/^$<TG_GT_\ (C_XUE?\)E_TX?\ D;_[&C_A,O\ IP_\C?\ V-']
MKY;_ #+[G_D'U7'>?W_\$U?^$<TG_GT_\B/_ (T?\(YI/_/I_P"1'_QK*_X3
M+_IP_P#(W_V-'_"9?].'_D;_ .QH_M?+?YE]S_R#ZKCO/[_^":O_  CFD_\
M/I_Y$?\ QH_X1S2?^?3_ ,B/_C65_P )E_TX?^1O_L:/^$R_Z</_ "-_]C1_
M:^6_S+[G_D'U7'>?W_\ !-7_ (1S2?\ GT_\B/\ XT?\(YI/_/I_Y$?_ !K*
M_P"$R_Z</_(W_P!C1_PF7_3A_P"1O_L:/[7RW^9?<_\ (/JN.\_O_P"":O\
MPCFD_P#/I_Y$?_&C_A'-)_Y]/_(C_P"-97_"9?\ 3A_Y&_\ L:/^$R_Z</\
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MI44?5/,/[3_N_C_P#RVBO4J*/JGF']I_W?Q_X!Y;17J5%'U3S#^T_P"[^/\
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M-F]S:W?G"-PKJT>PC/0]30\)65[K;S7KHKZZ/H"KP=M=S/HK4NM)BM?-C:]
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M! ZX/>GQZ/ ?LBR7P22Z4,B^5GD^O-)8&NW9)?>K;VWOO?2PWB*:6_X/M?\
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MY62Y8LJ'_94]/UKI***M12V.6K6G5=YNX4444S,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#*U;_D):%_U_-_Z3S5JUE:M_P A+0O^OYO_ $GF
MK5H Q=7U_P#LJ[2#[-YNY ^[S-O<C'0^E4/^$R_Z</\ R-_]C57Q=_R%8O\
MK@/_ $)JP*^*S#-L91Q52G"=DGIHO+R/H,+@:$Z,92CJUW9U/_"9?].'_D;_
M .QH_P"$R_Z</_(W_P!C7+45Q_VWC_Y_P7^1O_9V&_E_%G4_\)E_TX?^1O\
M[&C_ (3+_IP_\C?_ &-<M11_;>/_ )_P7^0?V=AOY?Q9U/\ PF7_ $X?^1O_
M +&C_A,O^G#_ ,C?_8URU%']MX_^?\%_D']G8;^7\6=3_P )E_TX?^1O_L:/
M^$R_Z</_ "-_]C7+44?VWC_Y_P %_D']G8;^7\6=3_PF7_3A_P"1O_L:/^$R
M_P"G#_R-_P#8URU%']MX_P#G_!?Y!_9V&_E_%G4_\)E_TX?^1O\ [&C_ (3+
M_IP_\C?_ &-<M11_;>/_ )_P7^0?V=AOY?Q9U/\ PF7_ $X?^1O_ +&C_A,O
M^G#_ ,C?_8URU%']MX_^?\%_D']G8;^7\6=3_P )E_TX?^1O_L:/^$R_Z</_
M "-_]C7+44?VWC_Y_P %_D']G8;^7\6=3_PF7_3A_P"1O_L:AN_%7VJV>'[%
MMW8Y\W/?/I7.44I9SCI1<7/1^2_R&L!AT[J/XLT/[3_Z8_\ CW_UJ/[3_P"F
M/_CW_P!:L^BN/ZW6[F_L*?8T/[3_ .F/_CW_ -:C^T_^F/\ X]_]:L^BCZW6
M[A["GV-#^T_^F/\ X]_]:C^T_P#IC_X]_P#6K/HH^MUNX>PI]C0_M/\ Z8_^
M/?\ UJ1M2###0 CT+?\ UJH44?6ZW?\ (/80[$TLD3CY(=C>H;C\JAHHK"4G
M)W9JE;0*FM;N>RG$UN^R0 C. ?YU#11&4H-2B[-":4E9EB[O;B_E$MS)O<+M
M!V@<?A]:KT44YSE.3E)W;",5%62L@K3M[U8-#F@29DN&F# +D'&/6LRBKI5I
M4FW'JFOO)G!323[W+MC<QG489+]FEB7.=^6QP<<?7%:5QJ$3Z9=V[Z@L[R!?
M+"PE%&&!QTZU@45M2QM2G!P6M[]^JMWU\K[&<\/&<E+M^FIM?;[;_A)/M?F?
MN-F-VT]?+V].O6J0GB_L1K?=^]-R'VX/W=I&:I44I8N<N:Z6O-_Y-:_Y:#5"
M*MY6_"_^9M7U_;3?VKY<F?/>(Q_*?F SGZ5.VH63WM[*DZ1RN4\J=XBX  &1
MC'!_"N>HK7^T:O-S-+^N;_Y)_@1]5A:UW_5O\CHSJEJ;S3)'NS+Y!?S9#&1U
MZ' '2L&W6)KF,3OLB+#>W/ []*BHK*MBYUFG-+1WZ]DN_E^9=.A&FFHO^M7^
MIN3>(6&HF:*VMBB-A&,?S[1[]N*;-/89U*.*X CN7C9#L;CYLMV[5BT5H\PK
M2OSV=VWZ733VMT?X(E86FK<NG_ U-N^-C-!%;V^H1I;PCY4,;Y9N['CK5:>Z
MA>YTUU?*PQ1K(<'@AB36;14U,9*;;44KV[]'===!QH**M=O?\=S=74H7^W0K
M=R6WF7+313INY!/0@<]*;%?6\6J6SO?7%PD:.'EE)(R5(^4=0.E8E%5_:%71
MM+1WZ]V]KVZ]KV%]5AKY^G:W:_XFE]JA\C2EW\P,QDX/R_/G\>*>MY +[59#
M)\D\<HC.#\Q+ CZ<5E45G];GIHM/TCR_E^)7L(_UZW_,W5OXKB"U_P")G/9^
M5&L<D:;OFQW&.,GWJM)>0OI]Y&)9&>2=63S269E&>2>E9=%7+'5)*S72W7M;
MO9:+HD*.&BGI^G>_8LV#1)=JTTTL  .V2/JK=C]*O:G>QW%C'$UR+NX$F[S1
M%MVKCIR!GG^59%%90Q,H4I4DM'Z^7G;IH[714J*E-3?3^O4T;*X@:PN+*XE\
MI9&5TDVE@&'8@<U>BO+"VGTI4N2\=N9/,?81U]L5@45I2QTZ:225U;779/FM
MOW)GAXS;NWK^JL;.G7<=M;1[-2>W;<?-B>,NK#V 'I4BZG;.MW!#/)8J\WFQ
M2)G'3!!"\X[UA454<PJ1BH)*R]>UN^GRMKJ*6%@VY/KZ?Y:_.YMI=V:W\)GN
MYKI4C;][."RJYZ$*><4^YU&&32I[>2]^T2LR$;8MBX!Y XZ_6L&BFLPJ*,HI
M+6_?JK=]=M+W%]5@VG?;TZ?+\CH3J%LEO-&U^]U;M&1'!+&=X)Z9;';VJ-;^
M*X@M?^)G/9^5&L<D:;OFQW&.,GWK"HIO,JKZ*WS[WWO?Y7M;0/JD._Y>G:WX
M%YXDNUOKH3RGRBI42C<S@G'+=CT_R*32)XK;5(9IGV1KG+8)QD$=JIAV"% Q
M"M@D9X.*2N95^6I&I%:K7U=[_P# -73O%P;T?^1KVJZ98W"71OOM#1'<L2PL
MN6[<FD%W!?V!@N[@02K,TJOL+*0W4<<]:R:*U6,:7+&*4=;K76]O._16(=!-
M\S;OWT_X8VTU*VBU&S16+6L,7DNY7[X.<G'IST]JG76+4/>G>1L(-I\IY(0I
M^'&#S7.T5I',JT=K;W_"UO1637FKDO"4WO\ UK?^O(NF>+^Q%M]W[T7)?;@_
M=V@9HU*>*X:U,3;MEM&C<$88#D52HKFEB)2CR/LE]U[?F:JDE+F]7]__  QM
MZ=>0VT$.S4I(!G]]#)&74\_P\=Q3M+GM[C5+N,Q;;.8&0KCA0IW GT[_ )UA
M5/'>W$-M);QR;8I/O  9/X]:Z:6/:<%-:1^=]+6U>B?6WK8QGADU+EW?^=^B
MW70NQZ@DG]IR3.0]RGR @GG=G'Y5)::E%:6MB0=TD,[.Z8_A(Q]/6L>BLHXV
MK%J2WUU]9<WYEO#P:MT_X%OR-F(Z;:0WQCO#(TT+)&OEL, D'!]^E1OJ,<5]
MIUQ$=X@AC5QC'(SD<_6LJBF\;.R4(J-NU^CYNK?7\ 6'C=N3;_X:QLI-864U
MS=0W1F>1'6.+RR"I;U)XX]JC:\@-]I4@D^2".(2'!^4AB3]>*RJ*'C9VLDDK
MWZ[WYN_?\-@6'CNVV_\ @6-+[5#Y&JKOYG93'P?F^?/X<5?EU&&ZF2X.JW5L
MI4>9;QEL@@?PGIS7/44X8^I%6LK?/NWT:[ORL*6&@]?\NR75/L.D;?*[Y8[F
M)RQR3]3ZTVBBN)N[N="T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *[[PY_P @&V_X%_Z$:X&N^\.?
M\@&V_P"!?^A&OH.&_P#>I?X7^:/,S;^"O7]&:E%%%?;'SP4444 %%%% !111
M0 45S/B/5=;M]>T?2M%.GK)?1W$CO>QNX'E[,8VL.N\U!9:YKUEXJL]$UZ/3
MI1?PR26\]B'7#1X+*RL3V(P<T =;16%9^,M OUF>WO\ =%#$99)FAD6-%&,Y
M<J%R,CC.?:I=+\4Z-K%V;6RNRT^SS%CEA>(NO]Y=ZC</<9% &Q16#)XT\/1Z
M@;%]242B7R"WEN8ED_N&3&P-[$YI(?$<$#ZW+J5[9I:Z?<K$#&L@9 44A7R/
MF8EN-N1R.] &_17/2>+=.N]&U:YTV\C%S8VSS,MW!+'Y>%)5G0J'V\=ASSCF
MIKGQ1IFF6=B^HW:B>ZB#I';Q22,_ )944%MO/4CZT ;=%8[^*=#CTB/5FU&$
M6$D@C6?DJ&SC!X^7H<YQCO3M*\2Z3K=Q+;V%TSSQ*'>*2%XF"GHP#@$CW'%
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M%LL9C6XBD)(:*=>1[@X (JA7/5IRI2Y);FL)J:YD%%;<FD6L,*&3[5M:+?\
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M]*RJ*U^NUN?G3U]/[W-^?X:$?5Z?+R]/^!;\C4:ZT^'3;FVMEN2\Q4[I HP
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M]*CN;JR&E"SM1.6\X2EY0!G@CL?I6;14O&57%IVUNMNCM>WW(:P\$TU_6_\
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M'A_KG/6G2Q].W[R3U2OO=V33U7R^)-/U">&G]E+=V[;KI_E9E6/4+J*$1)(
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M)_C7>T4?ZMX7^:7WK_(/[6K=E^/^9P7_  CFK?\ /I_Y$3_&C_A'-6_Y]/\
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MS5O^?3_R(G^-=[11_JWA?YI?>O\ (/[6K=E^/^9P7_".:M_SZ?\ D1/\:/\
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M1$_QH_X1S5O^?3_R(G^-=[11_JWA?YI?>O\ (/[6K=E^/^9P7_".:M_SZ?\
MD1/\:/\ A'-6_P"?3_R(G^-=[11_JWA?YI?>O\@_M:MV7X_YG!?\(YJW_/I_
MY$3_ !H_X1S5O^?3_P B)_C7>T4?ZMX7^:7WK_(/[6K=E^/^9P7_  CFK?\
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M/$3QE24:;:;[/R/I<'7I1H03DD[=S*HK5_X1S5O^?3_R(G^-'_".:M_SZ?\
MD1/\:X?J&*_Y]2^YG3]9H_SK[T95%:O_  CFK?\ /I_Y$3_&C_A'-6_Y]/\
MR(G^-'U#%?\ /J7W,/K-'^=?>C*HK5_X1S5O^?3_ ,B)_C1_PCFK?\^G_D1/
M\:/J&*_Y]2^YA]9H_P Z^]&516K_ ,(YJW_/I_Y$3_&C_A'-6_Y]/_(B?XT?
M4,5_SZE]S#ZS1_G7WHRJ*U?^$<U;_GT_\B)_C1_PCFK?\^G_ )$3_&CZABO^
M?4ON8?6:/\Z^]&516K_PCFK?\^G_ )$3_&C_ (1S5O\ GT_\B)_C1]0Q7_/J
M7W,/K-'^=?>C*HK5_P"$<U;_ )]/_(B?XT?\(YJW_/I_Y$3_ !H^H8K_ )]2
M^YA]9H_SK[T95%:O_".:M_SZ?^1$_P :/^$<U;_GT_\ (B?XT?4,5_SZE]S#
MZS1_G7WHRJ*U?^$<U;_GT_\ (B?XU#=:+J%G;O<7%OLB3&YMZG&3CL?>CZAB
MO^?4ON8?6:/\Z^]%"BF[U]:-Z^M'U#%?\^I?<P^LT?YU]Z'44W>OK1O7UH^H
M8K_GU+[F'UFC_.OO0ZBF[U]?TJ!]0MHSAW93[HW^%'U#%?\ /J7W,/K-'^=?
M>BS153^U+/\ Y[?^.G_"C^U+/_GM_P".G_"CZABO^?4ON8?6:/\ .OO0:I_R
M#I?P_F*YRMJ_O[::RDCCDRQQ@;3ZBL6OK\@HU*6&E&I%I\W56Z(\+,YQG63B
M[Z?YA1117N'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ&[^=?W8$#(>_/S$#C-5M6\*7VL2>,H"%ACU.*V%K*Q!#-&G<<D#< #D?3-
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M&&EB(]"PKGJ* ->6VL).DL:'_9<52ELU7F.YA<>F\ U5HH 4C!P<?@<TE%%
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M>?9(4G-NNV(R,[CK@9' ]<U8EU*T;7-"N1-F*UAM5F;:?E*$;N,<X]JFFO\
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MO$6GH;V.\MI@6">7AMP_A=<_+Z]\XIQU73Y=4#0:A=6*VMJEO:W(4D/MZEU
MS@^G_P"JK#Z_8C6]&N9KD74ML7^TW:0;-X/W1C )QSV[T 9G]G)-HI%D\<X?
M44@CD:#9*Q9#QG<<+GM^.:9=Z)8VZW42:S$]Y;*2\31E%8C@JK$\GVQS4\.H
M6>F:<D,-R+J2#4XKE=J,H=%7KR..>*2\&A&6_O5NVN6N Q@M_+=&C=CG+-T.
MWGUS0 77ANWLR8)]46*\$7F".2$K&W&=HD)P3^%<]7:6NLV%K#L;6);K3O)(
M_L^X@+R9VXV[L8 ![@UQ= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7T!7S_7T!0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 96K?\A+0O^OYO_2>:M6LK5O\ D):%_P!?S?\ I/-6K0!Y?\1_^1AM_P#K
MT7_T-ZX^NP^(_P#R,-O_ ->B_P#H;UQ] !1110 4444 %%%% !1110 4444
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M=;TRSN=06""ZLX+B-4BEMV#2QX//+'^+O@B@"RFBV5I>Z)>B*]2"XN?+>"Y
M#A@1M/W<%23Z=*QO$'V?^WKW[.LBJ)G#"1@?FW'., <5IW?B&S>WTV.$7DKV
M=UYS/<,"THX/)SP>,8].]8^KSVMUJD]S9F;RYG,A$R@$$DDC@GB@#=/ANPAL
M;:6?[>5FMQ*;R% \,;$9P5 W8'3J*%@T^X\*:5"8YUDFO"FX,OWB5#$\=,9Q
MZ>],TW7=*TUX+FW&HPR(G[RUC<&&5\8R23G!^AJG'K-L-'@A>*1;JVNS<1!
M/+;)!(/.1T/3- "1Z/;OK&L6A>7R[**X>,Y&28\XSQ^?2K%OINF6)TP7LMR;
MN["3(8MNR)6/R[L\GIS@BIFUK1$N-4NX8K[[1?P2IM<)MC9QSCG)&?TJO%JV
ME7*:?+J45W]ILD6,"#:4E13E0<GCT.,T 6=?TZ&ZNM>NT:3[5:W2EEXVF-N,
MCOD']*Q]8T^+3&M8 SFX:!9)PQ&$9N0H'; Q^=;NDW8U+QA>7202'3KI9%N"
MZ\+&5)^8C@<@5S>IWK:CJES>-G][(6 /8=A^ P* -2+3M'M]!LM0OWO&EN'D
M3RX"HX4]>1V].^>U3/X<M;6YO)[BYD?3;>&.9'B WR+)]P#L._/M4C'3/^$2
MT==1%T,R3E'MPI(^9<@@D=>.?:HG\1VMU=7L-U;2KIMQ%'"J1$;XA']PC/![
MY'O0 MMH6G:A)IT]I+<BTN+G[-,DA7S(VQG@@8((]JCETG2KF+4(].FNOM-D
MC2'S]NV5%.&(P./7G_\ 5=T?4;(ZGI&F:='-Y"W?GR23X#N^,#@$@ "JEUJ.
MEV/]IC3XKHW5T&A8S;=D:DY8+@Y/3OB@"O)H]NFL:/:!Y?+O8K=Y#D9!DQG'
M'Y=:M7%O%#X:EMC(4B363'O89PH3&3CK3[?6]'^TZ7?74%X;FRBCB,:!2C;.
M V2<Y[X]>]5O[<M1#M,$C_\ $U^VE6 PR?W3SU_2@"R-"TVZM;YK1-37[/ \
MR7,R 12A>>F 1GMS5^T2R>+PLMM]IAF=WV2!D)7YSN)RO)ST]O6H)/$VGM)?
MNT^K3?:X9(E68J4AW#LN[G'3MQ5*PURPMX-%,RW/G:=(Q(15*NK,6ZD@YYH
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M.,GZ55L=?N+*R^Q/;VMW;!]ZQ7,>\(WJ.1BLJB@#7D\1WTMW<7#B$M/:M:;
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M110 45L>%K&WU+Q':6EW'YD$F_<NXC.$8CD<]0*](_X0CP[_ - __P C2?\
MQ5 'C]%>P?\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\ R-)_\50!X_17L'_"
M$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?_%4 >/T5[!_PA'AW_H'_ /D:3_XJ
MC_A"/#O_ $#_ /R-)_\ %4 >/T5[!_PA'AW_ *!__D:3_P"*H_X0CP[_ - _
M_P C2?\ Q5 'C]%>P?\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\ R-)_\50!
MX_17L'_"$>'?^@?_ .1I/_BJ/^$(\._] _\ \C2?_%4 >/T5[!_PA'AW_H'_
M /D:3_XJC_A"/#O_ $#_ /R-)_\ %4 >/T5[!_PA'AW_ *!__D:3_P"*H_X0
MCP[_ - __P C2?\ Q5 'C]%>P?\ "$>'?^@?_P"1I/\ XJC_ (0CP[_T#_\
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MZ!__ )&D_P#BJ /'Z*]@_P"$(\._] __ ,C2?_%4?\(1X=_Z!_\ Y&D_^*H
M\BAFEMY5E@E>*1>5=&*D?0BF5[!_PA'AW_H'_P#D:3_XJC_A"/#O_0/_ /(T
MG_Q5 'C]%>P?\(1X=_Z!_P#Y&D_^*H_X0CP[_P! _P#\C2?_ !5 'C]%>P?\
M(1X=_P"@?_Y&D_\ BJ/^$(\._P#0/_\ (TG_ ,50!X_17L'_  A'AW_H'_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH RM6_Y"6A?]?S?^D\U:M96K?\
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MT[_GC=?]\K_\57#T4 =Q_P )EIW_ #QNO^^5_P#BJ/\ A,M._P">-U_WRO\
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M_?*__%5P]% '<?\ "9:=_P \;K_OE?\ XJC_ (3+3O\ GC=?]\K_ /%5P]%
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M .*H_P"$RT[_ )XW7_?*_P#Q5 &C_8.C_P#0)L?_  '3_"C^P='_ .@38_\
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MM6LI-;T][5XFE(D$WDQLB?=." 1_+TJI(T>F:=8E+:WFDN$,DCS1[^_ &>E
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M:T;ZXLY+9(+22=8H^5B:( ,W=F8,<G\/:ETB)G>9EMH92J?ZR=@(XN>ISP:
M,VBNEFM86;296CM&=[D1R&W \MQD=1C%0EX+LZI;&SMXUMXW>)HT 8;6 Y/?
M.: ,*.-YI4B09=V"J/4FB2-X97B<8=&*L/0BNAW0Z?J>GV26L#J1$7D*?.S,
M1R&[8]*QM2_Y"EW_ -=G_P#0C0!5HKIY(K6[@E%A%931&([8@-DZ$#KG&3C]
M:BC:"!='C%G;.;A0)6>,$D;L?@>>OTH YVKKZ=Y>FQ7C3Q_O)-FU3G;QG)([
M^U:<@@GBU:W%I!&MJ/W3(GSC#8Y;J<UEK=1?V2MHRN6^T>:<8 *[<8SZ_A0
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ME:*V[>>*>WO;]K.VS;*JQ1",!?F;&6'\6/>K,4%OJEOIA>VAA:6X99#$@7<
M,]J .;JREA<R30Q+$?,F3?&"0-R\\_H:V+J33'ANHWDM 0K>2L-NZ.K#H"<<
M^AS5@2+=:EH\,L$#(]L'(\H>C\?3VH Y:BMKSXK+1+&5;2WDFE:0%Y8PW (X
M_6K5S;6UG-JEU';Q-Y7E".)QN52X!)Q_*@#FZD2"62&254)CBQO;TR<"M+4V
MCFTK3KA;>&&20RA_*0*&P0!3],N&AT+4\1Q-M,9^>,-G)QSG]* ,N:WEMR@E
M7;YB"1>0<J>AJ*NF>Y07NDVCVEO*DMO KM(F6Y&.#VQ3(;2TLK&6=V@5VN6B
M5KB(R *O8  \^] '.45H:L;)KB-[-T.Y!Y@C1E4/WP#VK/H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O0_#/_ "+UK_P/_P!#->>5Z'X9_P"1>M?^
M!_\ H9H UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ,K5O\ D):%_P!?S?\ I/-6K65J
MW_(2T+_K^;_TGFK5H X?QE_R%XO^N _]":N>KH?&7_(7B_ZX#_T)JYZ@ HHH
MH **** "BBB@ HHHH **EMHX9;A4GF\F(YS)L+8X]!6M_8^G?8_M?]KGR?,\
MK=]F;[V,XQGTH Q**EN8X8KAD@F\Z(8Q)L*YX]#45 !1110 4459T^S;4+Z*
MU5PAD.-Q[<9_I0!6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K
MUIJ;VMJUN;:WGC9]^)E)P<8]15&B@"[=ZG+=P+ (H8(5;=Y<*;03ZGUJ===N
M5*2&&W:X1=JSLF7'ZXS^%9=% %RRU.YL&F,+ F9"K%AG\1[TVSOY;-98U2.6
M*4 /'*N5..AJK10!H_VS<"Z@G6.%!;@B.)5(1<CGOG]:9!JDD-LEN]O;W$<9
M)3SDSLSUQ@BJ-% &W9ZH_D:I<SM$\\JQX20##_-@C'?BLZ\OY+Q8D*1Q11 A
M(XEPHSU-5:* )XKN2*TGME"E)RI8D<C;G&/SJ0ZC,;BSFVINM554&#@A3D9Y
MJI10!<N=2FN;9;=E14$C2G:#\S'UY_"DAU":&R:U"HT9D$HW Y5AZ54HH U)
M]>N)C,X@MHYI5VM+&A#X],Y_^O67110 5:L[^2S65!'%+'* '25<@XY'3%5:
M* -)]:G<6RB&W1;>42QJB$ 'TZ]/U]ZKQW\L<MU(%3-RC(^0> QR<?E56B@#
M3@UN> 0DP6TDD(VQR2(2RCL,YJA-,T]Q),V TC%SCIDG-1T4 :C:[<,6D\BV
M6X9=IG5"'QC'KC/X56.HS%K,[4_T3&S@\X.>>:J44 6QJ,P:\.U/]+SOX/&3
MGCFJE.2-Y&VQHS$ G"C/ ZFA(WDW;$9MJ[FVC.!ZGVH ;5FWO9+:WN845"MP
MH5BP.0!Z56HH THM9FC2$-!;2R0@+'+)'EE Z=^W:JSWTTEH]N^U@\WGLQ^\
M6P1_6JU% $UI<O9W4=Q&%+QMN ;I3UO9%@NH@J;;DJ7.#D8.>*K4 9.!UH O
MQZM/%):NJ1YMHVC3(/(((.>?>DM]4D@MT@>"WG2-BT?G)G83UQ@BJZ6=U+*\
M4=M,\B?>14)*_4=JB=&C=D=2K*<%2,$'TH M3ZE<7-O)%*5;S)O.9B.=V,?E
M@U-#K,T4<*M!;3-",1R2IEE'8=>WO6=10!LZ?<2SQ7)>YM7>1PSPW?"M_M Y
M'/M4FHZKY-]9O;F"22WA*,4'[O)!! ]@#6%10!?@U:XMQ:A%CQ;JZJ",[@QR
M0>?>EEU>1[.6T2VMHH9<%A&A'(.<YS6?10!/>7<E[=-<2!0[  A1QP /Z5<C
MUN9(+>)K:UD%N,1M(A)7WZUF44 7XM6G59EFCBN5F?S&$RD_-ZC!%2-KERTU
MM+Y< -NKJ@52!AAC&,]ATK,HH T(M7ECMX8FM[:7R<B-Y$)9><^N/SI+C5I[
MDW9=(P;H(), \;<8QS[50HH MKJ,Z16J(0AM69HV7KDD$Y_*I;C5IIX9(EA@
M@$K!I#"I!<CGGGUYXK/HH U#KMR6,ODVWVDKM-QY?S],9ZXS[XK-C=HI%D0X
M92&!]Q3:* -,ZU*99W-K:E;C'FQE#M8@D[NN<\TO]NW DM76"W7[,S&)50@#
M/48S6710!I:/(4>=5N($+)CRK@?NY1GH3GCU%6]3O_*M;&&%[<3PNTG^C<I'
MTP >YZDUA44 :4NLS2QS!;>VB>88EDC3#,#U[]_:DBUF>(VK"&!I+8;4<J<E
M<$8//3FLZB@">6[DEM(+9@H2 L5(')W8SG\JT[.^DN[F[E>:TC>1%!AG&(Y
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MXS]*1QH\EU=Q&4HCL'@N%1B%]5*\<?A2SW5M;Z/+917KWAD92,H56(#TSW-
M#K^6+2+K[#!:V\AB \R2:,.78C)Z]!]*K&[A_M6&>QB\G=MW*5!"L>NWT'H>
MM374EAJLJW<MY]EF90)4:)F!(&,C'\JIZC-;2SHMI'LAC0(&( +D?Q'W- &M
M(9FU'588['[6LDX#+O(P Q/0<_CT%8M_'##?SQV[[XE<A3G/']:KT4 ;;Z#
MEVMF-14W3J&1#$0"2,@$YX-4X;&V\G?=WH@;>4\M4WL,=21D8K8OO[/M]>%Y
M-=-YD01V@$9)9@HQ@],=.M5[;4+?[&&2[CL[II&>9C 7+Y.1@X.,>G% "6NE
M6]O>7T%U*'"6Q>-Q'N&"/O=>H]*9)9V#:18R2W(@W-(-XAW-)\W!.#V'\ZGF
MU*RGU:XD^T%8I[/R?,9"2K$#J/P[5FWL\+Z;8V\<@=X3*&P".K9'7U% #KG2
M&MH[PF8,]K(JLH7@JW1L_P!*GE\/O#J$%LT_R21&1Y=G"8SD8SSC'ZU9CU2R
M/B"ZDEDS93H%+;3C( P<8SU%,?6(9=+NBS$7;O(L8(/^K=@3[=B* *-OI]I(
MD'G:BL<LW1$CW[><#<<\4DVE-#!=N909+641R(!_">C _7M6E:ZC:06]IY-X
MMLJ*//B6WR\C=_FQW^O%):W$-YXDNXE;S+6\#*2 1QC(.#Z8H R+RS^QK;AG
MS)+$)&7;C9GH/RJK5K4KK[;J,\X^ZS?+_NC@?IBJM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>A^&?^1>M?^!_^AFO/*]#\,_\ (O6O_ __ $,T :U%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &5JW_ "$M"_Z_F_\ 2>:M6LK5O^0EH7_7\W_I/-6K
M0!P_C+_D+Q?]<!_Z$U<]70^,O^0O%_UP'_H353T)(&GNVN(5F2.U=]K#TQ^7
MUH RJ*V_-AU#1;Z5[.VBEMS&4:%-O#-@@^M:4UG#IYAMXDTHA4!D-VXWN3UZ
M]!0!R5%=*+*Q0ZR(/)FB2 /$P(?83GH:HV\,3>%[R8QH95F4!RHW <<9H R*
M*ZC4HX'UF+2X;2VBCFV;Y%C&\=,X/;@?SJ!+JTDUC^SFTVV%L9?(!"?O.N,[
MNN<T 8?D?Z)]H\V+[^SR]WS],YQZ>]15N-9Q0:<Z;$9X]3\K>5&2H!XSZ5>D
MDM1XD.F_V=:?9V?83Y?S<C.0>W- &#9:;+>QRRB2*&*+&Z25MJ@GH.E)>Z?)
M8K SO&ZS)O0H2>/Q%;=O/]DT'4XUAA<03A!OC!W#=_%ZTZ6%)Y]%22W>X7[(
M#Y:8YX[Y(P* .7HKJWM%FT^^%S!IJR11%T%KC>I'KCM52>>#3]+TV1+&UDDE
MC)=I8PV0#_/GK0!S]%=8PM(_$O\ 92:?;>0Q^9F3+9*[N#VZU2@2WLM(O93;
M0S2PW7EQF5<^W/J.O'K0!@45T=[<P6ME8W<>G69EN4)<-'E1@]EZ#.:=)IT,
M?B2>.*S\Y/*\R.(8"*Q ^]D_=SF@#FJMMI\J3VT4LD4?GHLBL[84*>F3VK<N
MH%.D74\T.F^?;M&R_90.,M@A@*?<3+=:KH\$EO;['AB<XC'<'Y?]WVH Y>1/
M+D9-RMM)&Y3D'Z4VM]XX-/LKB]^S0S2O=-%&LBY1%&>WK3HXK:^BTZ^^S11.
M;Q8)41<(XX.<?2@#GJO6FF/<VL]P941(T9@"06<CJ /3WK8MY;6[UJ;3&T^V
M2 F1%94PX*@G.[\*QM.GB@^U^8VWS+9T7@G+'&!0!);Z8DR6PDN/+FNL^2FS
M(X.!N.>,D8X!JE%!)-.(5 #\YWL% QR<D].E:EO=6C'3[B:?8]F,-'M.7VL6
M7;@8[XY(K.GC8+'<,R?O]S!1G(Y(YH GGTUXM3-DDL;L%#>83M7!4,3D]@*B
MO[3[#>R6WF"39CY@,9R ?ZT_5)X[B_:2)MR%(QG&.0@!_44NK3Q7.I2S0MNC
M8+@X(Z*!WH I44^**2>01Q1M(YZ*@R3^%6/[*U'_ )\+K_ORW^% %2BK?]E:
MC_SX77_?EO\ "C^RM1_Y\+K_ +\M_A0!4HJW_96H_P#/A=?]^6_PH_LK4?\
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M 5**M_V5J/\ SX77_?EO\*/[*U'_ )\+K_ORW^% %2BK?]E:C_SX77_?EO\
M"C^RM1_Y\+K_ +\M_A0!#<7$MU,TTS;I& !. .@P.GL*BJW_ &5J/_/A=?\
M?EO\*/[*U'_GPNO^_+?X4 5**M_V5J/_ #X77_?EO\*/[*U'_GPNO^_+?X4
M5**M_P!E:C_SX77_ 'Y;_"C^RM1_Y\+K_ORW^% %2K$%]<VT,L,,FQ)1A\*,
MD?7J*?\ V5J/_/A=?]^6_P */[*U'_GPNO\ ORW^% %2BK?]E:C_ ,^%U_WY
M;_"C^RM1_P"?"Z_[\M_A0!4HJW_96H_\^%U_WY;_  H_LK4?^?"Z_P"_+?X4
M 5**M_V5J/\ SX77_?EO\*/[*U'_ )\+K_ORW^% %2BK?]E:C_SX77_?EO\
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M_/A=?]^6_P */[*U'_GPNO\ ORW^% %2O0_#/_(O6O\ P/\ ]#-</_96H_\
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M;+#;6THE6(.26.<\L:RZ* +]MJ7V?66U#RMV7=O+W8^\".N/>J%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ"VO+6\#&UN89PIPQBD#8/OBJTNK)#=I#+:W*1O*(5G90$+D<#KNQVSC&>]
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MEJ>JV^DPQR7 <B1]@" $CC))]@!DT 7J*H2ZQ96][+;7$RP&)$<R2LJH=V<
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ME%&/*N;8!F7)99&8[O3&WCGJ*[^RF:YL+:=P TL2N0.F2 :H7-[?VFHVR/\
M97AN;CRDA16\P)M)+[LXXQR-O&>M '.B^MH-5^UBXM9%COI)PJWD(+H\6WC+
MCD$<YQ[9J&P-N(Y$EU#3X6DTZ6WW&[C(5VD8@<'T(-;^GZW=W#VSS0QO%>PR
M36\<(PZ[2/E)8X)((YXY_.F1Z[?2V:DPP0W,FH&S&[++&!DY."-QX(X(Y(H
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M::-)E4>61'DXZDYVC/3%/D\20_9F<0SP/LCEC\Z(-YD;.%W !O<=2",@X[4
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MS)#OF\H2X,#(-_E\'YC@8YQUJ*#1-0EL[R-X#;R2:;#;(6=3EE!#+\I/!X_
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M-'LE1)/W*0 M?=$5E90,0 =5_4^V.LHH YV72K^:YEN&M+8/)<17! OFQNC
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MW%Q'B15BE8%4#\-@@;CP2.2<#IVK2HH QU\.6VQO,N;J67$829V7?&$.5VX
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X BD# 2(  A$! Q$!_\0
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M \+EE,0$S2 J!W((X)&#Z]*7/*]K#6&H./,ZFAV\.LZ9<1O)'?V[(DIB9O,
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M:ZN)Q<V@26Q:P$(>3Y8S%@'<2?\ EISTS@]>U%D'M)=SJO[+B_Y^+S_P)?\
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M'-,O=*M+J*_N5N99+IY%E&<LA "[O]K YQWK9HL@]I+N4O[+B_Y^+S_P)?\
MQH_LN+_GXO/_  )?_&KM%%D'M)=RE_9<7_/Q>?\ @2_^-']EQ?\ /Q>?^!+_
M .-7:*+(/:2[E+^RXO\ GXO/_ E_\:/[+B_Y^+S_ ,"7_P :NT460>TEW*7]
MEQ?\_%Y_X$O_ (T?V7%_S\7G_@2_^-0^(M/FU30+RRM]GFS)A1(Q53R#@D X
M!KEV\'ZB]G>1A;:*.>(K':QSL$A_>J^T,5(QA2>5QDD8Q19![27<Z[^RXO\
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M;O*Z13-F4[L@$C!D! QZ], T60>TEW.R_LN+_GXO/_ E_P#&C^RXO^?B\_\
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ME6?BD7VJ6MG%8RJLQ<EY'480!L-@$]2C#'45T- %/R+[_G^3_OP/\:/(OO\
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MO>1GHG^%._X57I?_ $$;W\D_PKJ8M<T@1(#JMCT'_+PO^-/_ +<TC_H*V/\
MX$)_C1[.GV#Z]C_YI?=_]J<G_P *KTO_ *"-[^2?X4?\*KTO_H(WOY)_A76?
MVYI'_05L?_ A/\:/[<TC_H*V/_@0G^-'LZ?8/KV/_FE]W_VIR?\ PJO2_P#H
M(WOY)_A1_P *KTO_ *"-[^2?X5UG]N:1_P!!6Q_\"$_QH_MS2/\ H*V/_@0G
M^-'LZ?8/KV/_ )I?=_\ :G(I\+=+9,_VC>CKV3_"NUL+*#3;""RMEVPPH$4?
MU/N>M58M<T@1C.JV74_\O"^OUI_]N:1_T%;'_P "$_QJHQA'8QK5L57256[2
M\G_D7Z*H?VYI'_05L?\ P(3_ !H_MS2/^@K8_P#@0G^-5S+N<_LJG\K^Y_Y%
M^BJ]M?V=[N^R7<$^S&[RI V/KBK%,AIIV8R/HW^^:?3(^C?[YI] @HHHH **
M** &)]^3_>'\A45S:?:#GS-AXYV@G'XU*I"F4D@ '))[<"HK2_L[_>+.ZAN"
MF-PB<-C/2BUT"E9D1T_Y-JSD<CGRT_PI\=BJ,"[^:,=&1>??(%6]I]#^5(1@
M9/ ]Z5BG)VL-:-6C,9&%(Q@''%)##%;PK#!&D<2C"H@P!4FUO0_E4<<L<RLT
M3JX5BC%3G##@CZBJUL197N6X/N'ZU+44'W#]:EI#,S6/^6'U;^E9E:>L?\L/
MJW]*S* "BBB@ K4TC[LW^\/Y5EUI:2Z(LVY@/F'4^U ')W/P^\-:C<W#7&IS
MR2-=FZ=/,C4 KN##:% (^9@6.3P.>*EC\#>%KJ5K6.]:61DW,L<B%BKB?!R!
MG!\Y_P#OD?C>A\)0-+:2W=\)/)B$;1  J_8]>QY)XZL>:MV'ANSL;AI?MLC$
M\C:P0@G&>5YQP>.G)H QK/PUX<>6YC_M*XDN3*BSRS*L9,HF$P ^0*"3MX7M
MCCO0_P -?#?^B2O<S!;#RW&9$"X1$0;N,<^4I)ZY!K7U#PU;:A'Y;:@ZJUR]
MQ(!@[BQ''X!0H]B>/1R>'XET^[MSJ19[@Q@R;5&$3&%P.H/.3G)W'I0!B/X+
M\-65N'76)+4K$H$R2Q*VTK%&#]WD'RU]B6/K4VA^%?#VC:C'>VVKR.-/15\J
M66,+&3$(PS$*#RF!UQSG&:MQ^#K&&VMHDOCO@QB0JI+8V8SZX\O]32MX2MM^
M]=0"LA/EYB0@ C!W#^(XQ@GIM% '1'4;(7GV,W</VG:7\K>-P QDX_$5+#/%
M<H7AD610Q4E3GD'!'YBN3/@^V26(1W2O$CK@MM#K&&+,NX#+;L[3G&%KH-+@
M2QM"DDL9EDD>:3:> S,6('L,X_"@#0HIGG1?\]%_.CSHO^>B_G0 DGWH_P#?
M_H:YS6M1UN#53]AM9VL8HC'(RQ!LRNI*L!]XA2$' Q\[9Z5T$DT>8_WB_>]?
M8U)YT7_/1?SH YB*]U8Z1>R03W,A00&*:>U^?)(\T!<+N '?'<^E0G7?$,;$
M2V"E1 )#LMY,Y(/09Q\IP""0>I]!76^=%_ST7\Z/.B_YZ+^= '%6VM>*I=SM
M;*I8*PC>S?"C*J<'(/.6;GIBK,&M>)9[@P-810G<D8=H)#P64&3'3'+<;LC;
M76>=%_ST7\Z/.B_YZ+^= ',VFK:NVF23WJ-#(]W FWR2GDQL$W$9SGDM],^U
M,75_$20"6XM8E5P,[+:0^2#Y9+$9RV-[# QG:>E=0TD+J59HV4]02"*7SHO^
M>B_G0!Q,WB#Q/YD+K8B/:,3Q&UDPH.P!RW.?O,=HY&.3UJY<:YXA@^S$Z>KM
M+(%:.."0@*"H;YO7EB,@<+75>=%_ST7\Z/.B_P">B_G0!QUGK?B%HA'=1QJ_
M[E4<PLCR,S(>A&W!!DR <@+GUKM*C,D#%26C)7D$D<4OG1?\]%_.@!]%,\Z+
M_GHOYT>=%_ST7\Z /G_Q@!_PF.K\?\O+?R%8F!Z"O>I_#.A7MS-=7&EVTTTK
MEFD9<ECGKUJ/_A#_  Y_T!;3_OD_XUR/#R;;N?2TL[HPIQ@XO1)=.QX3@>@H
MP/05[M_PA_AS_H"VG_?)_P :/^$/\.?] 6T_[Y/^-+ZM+N:?V]1_E?X'A.!Z
M"C ]!7NW_"'^'/\ H"VG_?)_QH_X0_PY_P! 6T_[Y/\ C1]6EW#^WJ/\K_ \
M)P/048'H*]TD\(>'1&2-&M >/X3Z_6G_ /"'^'/^@+:?]\G_ !H^K2[A_;U'
M^5_@>$8'H*,#T%>[?\(?X<_Z MI_WR?\:/\ A#_#G_0%M/\ OD_XT?5I=P_M
MZC_*_P #PG ]!1@>@KW;_A#_  Y_T!;3_OD_XT?\(?X<_P"@+:?]\G_&CZM+
MN']O4?Y7^!X3@>@HP/05[M_PA_AS_H"VG_?)_P :/^$/\.?] 6T_[Y/^-'U:
M7</[>H_RO\#PG ]!1@>@KW2/PAX=,:DZ-:9('\)_QIW_  A_AS_H"VG_ 'R?
M\:/JTNX?V]1_E?X'A.!Z"C ]!7NW_"'^'/\ H"VG_?)_QH_X0_PY_P! 6T_[
MY/\ C1]6EW#^WJ/\K_ \)P/048'H*]V_X0_PY_T!;3_OD_XT?\(?X<_Z MI_
MWR?\:/JTNX?V]1_E?X'A.!Z"C ]!7ND?A#PZ4!.C6F<G^$^OUIW_  A_AS_H
M"VG_ 'R?\:/JTNX?V]1_E?X'A.!Z"C ]!7NW_"'^'/\ H"VG_?)_QH_X0_PY
M_P! 6T_[Y/\ C1]6EW#^WJ/\K_ \U^'3WB>+(EM!F)XV%R#T\OU^N<8KV6J.
MGZ-IFDM(VGV,-L9  YC7!8#I5ZNBE!PC9GB9ABXXJM[2*LK6\QD?1O\ ?-/I
MD?1O]\T^M#A"BBB@ HHHH J7EJ+ZQOK-G*+<1M$6'\(9,9_6N1N/#MS.T3/K
M<$6R".(1QAE5D52H;/4=0=O0$?C7;)]Z3Z_T%.VK_=7\JTA4E#8SG3C/<XA_
M#,C6T'EZ]ET9C.Q9_P#2,OE0W)Z#CH:1_"P:S1)-9666.?,C2ER)!\FU&YS@
M%#S[UW&Q<8VKCZ4;5_NK^55]8J=R?J]/L<3'X=G29Y3K,<ZAR6BD>39)G<1N
MP<\;ACK]WK6GH6B)IU\DJ:A'-(?/:94W?O-Y4J3DG[N#R>>:Z/8O]U?RH"*&
MW!0#C&0*3K3:LQJC!.Z+,'W#]:EJ*#[A^M2UD:F9K'_+#ZM_2LRM/6/^6'U;
M^E9E !1110 5IZ1]V;_>'\JS*T](^[-_O#^5 &G152WU33KMXTMK^UF:5#)&
ML4RL74':6&#R >"?6K= !13(IHI@QBE20(Q1MC X8=0?<>E/H **;))'#$\L
MKJD: LS,<  =R:KV^IV%WG[-?6TVU=Q\N56P/4X/2@"U15.PU;3=55VT[4+2
M\6,@.;>99 I/3.TG%7* "BBB@".3[T?^_P#T-25')]Z/_?\ Z&N<U/P_?7.O
MG4X'@*JT)5&&'(7=G#X)7D@X'4 CC.: .GHXKB8-#\4>3,9M1=6X,:+<L< F
M,L,GV5P"2<;NW;:DT1[F'1C=+%<SV;AI9)\,S#RV'7'/S%3VZ9H W**XNWTG
MQ;&)-UZH,L@Q_I#,(1F,DC()(^1QC/\ 'VR<-73/$RWT$8N)=NPL':Z8HC Q
MYW<?/NP^%_A#?D =M17"P>&-=FN4FOKIR<\%;R3,8&" #]<]\^_-6(]$\2AR
M9=2?#1MQ!,$PQ#9SE3G)((..,?F =E17,36&MG3M.@,BFZ$4L;2AV98W8860
MY.3A=W?J1SWJO:>'=0LQ%!+#;7T, \JV9Y73R5#[@P')S@[>N?D'/)P =?17
M*W.A:E+H]O:-Y$KQON1MY4PMDG=GG=^0(&<'/-5/^$<U$;$>U@=3,ADD6<[L
MJ23*N1@.^5&>H"GGF@#M:*Y?3]*U6TU?S;J1)6FO7G:6(MM$?DA2I!/'SA<
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M>&8=3O)+R2[N4G(54*-\J*%92NWH<AWZ_P![VK5D\W,?*?>]#Z&G_OO5/R-
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M'G]__!#ZS@?+[O\ @&/_ &_JW_/])^0_PH_M_5O^?Z3\A_A6Q_PAG_3_ /\
MD+_Z]'_"&?\ 3_\ ^0O_ *]'LL1Y_?\ \$/K.!\ON_X!C_V_JW_/])^0_P *
MLZ=XCOH[^(W5P\L!;:ZD#H>_ J__ ,(9_P!/_P#Y"_\ KU9L/"D=G>QW$MSY
MPC.X)LQSV[U4:6(YE_F14Q&"<&DE]W_ -^/^+_?-/ID?\7^^:?7HG@A1110
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MO#\Z3RX_[B_E1Y<?]Q?RH 7>O]X?G1O7^\/SI/+C_N+^5'EQ_P!Q?RH P)]
MTV[N9IY86:1W)8B0C/-,_P"$8TG_ )]W_P"_K5!=>,- T^\GM+F_$<T4A5T\
MIS@Y]A47_">>&?\ H)C_ +]/_A6+C1OK8[HQQMERJ5OF7/\ A&-)_P"?=_\
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MOGFFO[B:VV$+;J[*!DYVYS]WZ_TK:TBTDLM.2*;:)6=Y7"]%+N6('L-V/PH
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M?] F^_\  =O\*/[!UC_H$WW_ (#M_A1[6K_2#^S<O\O_  +_ ()WG_"UX/\
MH#2_^! _PH_X6O!_T!I?_ @?X5P?]@ZQ_P! F^_\!V_PH_L'6/\ H$WW_@.W
M^%'M:O\ 2#^S<O\ +_P+_@G=I\58%15_L>4X&/\ 7C_"E_X6O!_T!I?_  ('
M^%<&-"U@C(TJ^Q_U[M_A1_8.L?\ 0)OO_ =O\*/:U?Z0?V;E_E_X%_P3O/\
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M(>0. ?J!Q_/-:^UB2!,<CJ,#_"D?]V,O<;1ZG H R(/">E6Z[4CEQ@#!E/\
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MP 2O)H^KP#^V\5Y?=_P3Q[_A67B#^]9?]_S_ (4?\*R\0?WK+_O^?\*]C,"
M9,Y (SR1T_*FB.(J&%SE2"0<KC ZT?5X!_;>*\ON_P"">/?\*R\0?WK+_O\
MG_"C_A67B#^]9?\ ?\_X5[&L*. 5G+ ]""#G]*# @<(9V#'D+D9/Z4?5X!_;
M>*\ON_X)XY_PK+Q!_>LO^_Y_PH_X5EX@_O67_?\ /^%>R"V!SB9CC@]/\*0V
MZC(,S?I_A1]7@']MXKR^[_@GC:_#37V4,&LL$9_UQ_PI?^%9>(/[UE_W_/\
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M+<]Z?0!3OK+[9M4D;"CHP/\ M#&?\^M5GTAIK=H'F*(9 QV#D[5 'TY -%%
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J(F@SJ$!U"0A64G&><?C^5%% &[1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $, EH# 2(  A$! Q$!_\0
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M7 D<%E7N0.M5IM7T^WF:&6Z1)%."ISQ5&QM;E+RR>192BQR@F08*@D8!Y/\
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MCSPVPB3?RKMGJ#N/Z 5M'&3=10=-ZO?^EY?\$SEAXJ+ES(VZ***[SF"BBB@
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MM7=4>S_O/[_^ '/Y(K_Z;_T[_K49AN&D$C1VAD'1BIR/QJY12=%/=O[_ /@
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M.#FKEGXSF2VM[J[UNPEB>Y@%T%MVB^R!U<M&S$D9!4#GYASD<BCV?]Y_?_P
MY_)'<_Z;_P!._P"M'^F_]._ZUP6J^-]3M[F\GL##=:?"L[[HTW'RUBB*N/[P
M#29/J,^E++XNU,.J3:E9Z>@>0K--:M()V79B( '.?F)XR3D8'!H]G_>?W_\
M #G\D=Y_IO\ T[_K1_IO_3O^M</?>-K^&]UH)'Y=I%"_V&>2 A&DB($GS=&S
MEN.VPUVVGZE9:K;?:;"ZBN8-Q7S(F##(ZC-'L_[S^_\ X <_DAW^F_\ 3O\
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MUAW0?5ZW\C^YFC_:VG_\]AUS]QO\*!J]@!@3X'^XW^%9W_"2:5_S_#_OEO\
M"C_A)-*_Y_A_WRW^%'M8=T'U>M_(_N9I?VQ8?\]__'&_PH_MBP_Y[_\ CC?X
M5F_\))I7_/\ #_OEO\*/^$DTK_G^'_?+?X4>UAW0?5ZW\C^YFE_;%A_SW_\
M'&_PH_MBP_Y[_P#CC?X5F_\ "2:5_P _P_[Y;_"C_A)-*_Y_A_WRW^%'M8=T
M'U>M_(_N9I?VS8?\]_\ QQO\*3^U]/P!YPXZ?(W^%9B^(M+#.3>CDY'RMZ#V
MIW_"2:5_S_#_ +Y;_"CVL.Z#ZO6_D?W,T/[5TW.?-7/KY9_PH.JZ<0091@G/
M^K/^%9__  DFE?\ /\/^^6_PH_X232O^?X?]\M_A1[6'=!]7K?R/[F: U;3A
MTE'_ '[;_"E_M;3O^>PZY_U;?X5G?\))I7_/\/\ OEO\*/\ A)-*_P"?X?\
M?+?X4>UAW0?5ZW\C^YFB=6TXC!E&/3RV_P *!JVGJ,+, /9&_P *SO\ A)-*
M_P"?X?\ ?+?X4?\ "2:5_P _P_[Y;_"CVL.Z#ZO6_D?W,TO[8L/^>_\ XXW^
M%']L6'_/?_QQO\*S?^$DTK_G^'_?+?X4?\))I7_/\/\ OEO\*/:P[H/J];^1
M_<S2_MBP_P">_P#XXW^%']LV ZW'_CC?X5F_\))I7_/\/^^6_P *LPZA;W]N
M[VLXD56 )&1@Y'K34XMV3)E1J15Y1:7H6?[7L,Y\_D?[#?X4G]K:<>LP]?\
M5M_A3]QSU-&X^IJC,8=6TX]9@?\ MFW^%)_:NG!MWFC/KY;?X5)N/J:-Q]30
M W^U[#_GOU_V&_PH_MBP_P">_P#XXW^%.W'U-&X^IH ;_;%A_P ]_P#QQO\
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M^UJ7\K_ \\HKT/\ X1_2?^?&/\S_ (T?\(_I/_/C'^9_QH^I3[H/[6I?RO\
M \\HKT/_ (1_2?\ GQC_ #/^-'_"/Z3_ ,^,?YG_ !H^I3[H/[6I?RO\#SRB
MO0%T#2BS@V4?!XY/H/>G_P#"/Z3_ ,^,?YG_ !H^I3[H/[6I?RO\#SRBO0_^
M$?TG_GQC_,_XT?\ "/Z3_P ^,?YG_&CZE/N@_M:E_*_P//**]#_X1_2?^?&/
M\S_C1_PC^D_\^,?YG_&CZE/N@_M:E_*_P//**]#_ .$?TG_GQC_,_P"-'_"/
MZ3_SXQ_F?\:/J4^Z#^UJ7\K_  //**]#_P"$?TG_ )\8_P S_C1_PC^D_P#/
MC'^9_P :/J4^Z#^UJ7\K_ \\K>\+?:/MLWE_ZC8/-SZY^7\:Z7_A'])_Y\8_
MS/\ C4\5E;6-NZ6L*Q*S D+W.16E+"RA-2;,,1F5.I2<(Q=WW+?>BCO17<>.
M%%%% !1110 4444 %%%% "I_Q\1?4_R-7*II_P ?$7U/\C5R@#$U/_C^/^X/
MZU4JWJ?_ !_'_<']:S+ZW:\TZZM4E,+S0O&) H;86!&<'KC/2@"821F/S!(A
MCQG>&&W\Z/,C R9$ Z9W"N,M_ #0^'Y=+?579'E:7RE4K;DDJWS)G<2"O!##
MKT-5%\!S7<M[:RW*_9%LXX%E")M>Y^422"-3\O[M$3!QW- '?"2-@"LB$'IA
M@<U$U[:I<1V[7,0FD1W1=W54QN/X9&?K7)GP"ZW<CV^H)!:RW F:)+?!15F>
M55C(;"XWD=.PQBJTWPZ8Z?'$^I6]NL$97?#:^4K_ .JPTGS<D^3\Q[[O:@#M
MA=V[2R1">/?'M#@G&-PR.O7(]*FKA&^&T4D9CDOTE3[.T2B2'=M8P>4&&6/0
M_,/3 'O7<1(8X8T+;BJ!2WK@8S0!?TQ%>Z<,H/R=_K6MY$7_ #S7\JR])_X^
MW_ZY_P!:Y?4OB(^G>-;W3S;>9I=M;.GG>6P#7:QF79YOW.4&W;US0!WGD1?\
M\U_*CR(O^>:_E7FE_P#$S4XV"KIUI:A86>3?<^822D#H$. "=L_(]C@X'.Q=
M_$FSM_$EKI26%RZRDK([H\<J'$A&V)ERX/EG!'7/% '9^1%_SS7\J/(B_P">
M:_E7#M\3(4O+U7TUX[6U5)G>60K+Y.4#R&/;E=GF E20V >!Q5C2O'5QJ&LV
MMC-HXMHYY(XBYN=SH[VYN%!3:/X1@\]>U '8>1%_SS7\J/(B_P">:_E7!+\3
M3<:K<Z=9:5'-,ETMO"S7>U7R9@2?D)7!A/&#UK&N?BGJ9@DN8;>QAC9D:%))
M,D(T4$G[SIC_ %I^8<<>W(!ZMY$7_/-?RH\B+_GFOY5P:?$^,RJC:8&V/Y<H
MBN0[2$RO&#;C:/.7*$D\8!%4[#XH7,\\SS:=;R0SM!#9):W/F?OY8U=8G;'4
M@MSCC81SUH ](\B+_GFOY4>1%_SS7\JDHH C\B+_ )YK^5'D1?\ /-?RJ2B@
M"/R(O^>:_E1Y$7_/-?RJ2B@"/R(O^>:_E4<<$6Z3]VOWO3V%6*@+F..X<8RN
M2,_[HH ?Y$7_ #S7\J/(B_YYK^5<59ZYK\UM827=Q!907NS;<W$"K@F)W8!1
M(05^5<$D'D\5HS>(;QO LVJVYM1J"1_+N!,9;?M5B,YVL/F'/0]Z .D\B+_G
MFOY4>1%_SS7\JXY/'4O]HRVIT\O(DOER1[PAA*B,.I)X9MTF1TR,>HJ=_'"'
M_4V:2[+7[3*%G&4 4DKTZ\#KCK[4 =5Y$7_/-?RH\B+_ )YK^5<A-XLNYFO!
M'-8V?V*%I,NWFI<N"<JC?+D# S@9RP';E[>-9UV&33HX@X8A6N,R<2^5@)MY
M.[DC/ 'K0!UGD1?\\U_*CR(O^>:_E7&KX[DMK:V%[9P?:6$32+'.3E7$?S+\
MOK)T)'3J<UO:'K<FKF42VJP%8XYDVR[\H^[&>!@_*?\ &@#4\B+_ )YK^5'D
M1?\ /-?RJ2B@"/R(O^>:_E1Y$7_/-?RJ2B@"/R(O^>:_E1Y$7_/-?RJ2B@"/
MR(O^>:_E555QN"K@;VQCZFKU> ^,I95\9:L%ED $_0.1V%9U*G(KG;@<'];F
MX<UK*Y[EM/H:-I]#7SCY\W_/:7_OLT>?-_SVE_[[-8_6?(]7^P'_ ,_/P_X)
M]';3Z&C:?0U\X^?-_P ]I?\ OLT>?-_SVE_[[-'UGR#^P'_S\_#_ ()]';3Z
M&C:?0U\X^?-_SVE_[[-'GS?\]I?^^S1]9\@_L!_\_/P_X)]';3Z&C:?0U\X^
M?-_SVE_[[-'GS?\ /:7_ +[-'UGR#^P'_P _/P_X)]';3Z&C:?0U\X^?-_SV
ME_[[-'GS?\]I?^^S1]9\@_L!_P#/S\/^"?1:*=\G!^]_04_:?0U\X^?-_P ]
MI?\ OLT>?-_SVE_[[-'UGR#^P'_S\_#_ ()]&D$=117COP^UFYL_$L=H3+-#
M>_NW7).TCD-^'.?8U[%6].:FKGDXW!RPE3D;OI>X44459QA1110 4444 %,F
M_P!4?J/YT^F3?ZH_4?SH ?WHH[T4 %%%% !1110 4444 %%%% "I_P ?$7U/
M\C5RJ:?\?$7U/\C5R@#$U/\ X_C_ +@_K52K>I_\?Q_W!_6JE "K@,,],UP%
MKX=\1-?V,\5T+:.UNYVFW2,#(6FD8MMQM<,C)CI]W%=]10!P>IZ)XDLY-1U)
M=0DO)/(5X?)+[GG4H4"PK\JJ2I##)&"3QDTLGA75H$:ZFNY;K;"GF0_:)&,H
M\B03($^Z2TCKCV Z8KNZ* *>DPSVVBV$%TVZXBMHDE.<Y<* ?UJY110!>TG_
M (^W_P"N?]:U&MX&4JT,94MN(*C!/K]:R=,#-=/M;;\GIGO6MLD_Y['_ +Y%
M #6L[9\;[:%L'(R@.#C'\N*<UO"\RS/#&TJC"N5!(^AHV2?\]C_WR*-DG_/8
M_P#?(H J:CHUAJMK/;W=N&CN %FV$H9%!^ZQ7!*]B.A'%6Q!$&W") V<YVC.
M<8_EQ1LD_P">Q_[Y%&R3_GL?^^10 T6ELLAD%O$'+;BP09)]<^M(;&T))-K
M20%_U8Z#H*?LD_Y['_OD4;)/^>Q_[Y% "+:VZ&(K!$IA!$>$ V ]0/2JDVAZ
M;/<VD[VJAK24S1*A*J)""-Q4<,0"<$YQDXJYLD_Y['_OD4;)/^>Q_P"^10!)
M14>R3_GL?^^11LD_Y['_ +Y% $E%1[)/^>Q_[Y%&R3_GL?\ OD4 245'LD_Y
M['_OD4;)/^>Q_P"^10!)4<?+2_[W]!1LD_Y['_OD5'&DFZ3]\?O?W1Z"@!\M
MM;SQ"*:".2,=$= 0/P-(MI;J\CB% TH4.=OW@.F?I3MDG_/8_P#?(HV2?\]C
M_P!\B@ :WA=@SPQLP;>"5!(;&,_6D2V@C+%(8U+$DD*!DGK2[)/^>Q_[Y%&R
M3_GL?^^10 W[);!(T%O%MB.8QL&$/J/2F'3[1KY;TP(;A4**Y'0$Y./Q)YJ7
M9)_SV/\ WR*-DG_/8_\ ?(H 1K6W<J6@B8K]W* X[<4]41/NJJ\8X&.*;LD_
MY['_ +Y%&R3_ )['_OD4 245'LD_Y['_ +Y%&R3_ )['_OD4 245'LD_Y['_
M +Y%&R3_ )['_OD4 245'LD_Y['_ +Y%&R3_ )['_OD4 25YWK'PZBU?6;S4
M&U22(SREB@A!"]NN?:O0-DG_ #V/_?(JHH(W G)W-S^)J904M&;T,15H2<J3
MLSSW_A5$'_09E_\  <?XT?\ "J(/^@S+_P" X_QKT2BH]C#L=/\ :N,_G_!?
MY'G?_"J(/^@S+_X#C_&C_A5$'_09E_\  <?XUZ)11[&'8/[5QG\_X+_(\[_X
M51!_T&9?_ <?XT?\*H@_Z#,O_@./\:]$HH]C#L']JXS^?\%_D>=_\*H@_P"@
MS+_X#C_&C_A5$'_09E_\!Q_C7HE%'L8=@_M7&?S_ (+_ "/._P#A5$'_ $&9
M?_ <?XT?\*H@_P"@S+_X#C_&O1**/8P[!_:N,_G_  7^1YROPJ@+,/[8E^4X
M_P!0/3ZT[_A5$'_09E_\!Q_C7H*??D_WOZ"GT>QAV#^U<9_/^"_R.7\,^";;
MPW>RW8NFNIF38A:,+L'?')Z\5U%%%:1BHJR.2M6J5I\]1W84444S(**** "B
MBB@ IDW^J/U'\Z?3)O\ 5'ZC^= #^]%'>B@ HHHH **** "BBB@ HHHH 5/^
M/B+ZG^1JY5-/^/B+ZG^1JY0!B:G_ ,?Q_P!P?UJI5O4_^/X_[@_K52@ HHHH
M **** "BBB@"]I/_ !]O_P!<_P"M>?ZWX=\93^)K^2R-Q_9\^HQ78_TG&!%Y
M:A0-W",'<D?],_<9] TG_C[?_KG_ %KG_$'B+6K*\F;3+66X(NA;+&(&D50J
M(Q)V]"QDZGHJ'O0!FI_PG6%>[N+NWMHU:2Z<B#=YBQ2%@F ?W)<1[<C=US6=
M:0>.M7L++4DN-15DM))X)',"N\K6ZD*5'RF-I?NY&0,Y(KJ=5\1:[:ZBD:V2
M6L2P322"2)I5.U6*L900JCY1D=<L..<B:QUCQ!?:E9R?9DAL)G0M&]NV\(Z.
M_+9P"H$>>#\S$=J ,9T\>SWQC\VY@C>Y47$B"#:D9EX,&03CROO;P3NZ535?
MB:D5FOFN[,T+S.ZPY5S&N]2!@>6&W9[^AK7N]7\3C[4]I;MY)>1(T>W<R$D2
M;2#G"@!8NQR6/2JU]JWB>V2.(O-YL,AB%Q'82.LV#)C* _Q%$&<@?-G(S0!H
MVWAG4=9T"+^W-0NX]1+3992H,09L*%V8& H!'4Y--U[3_$>C^#H+#PY<75W?
MB9B]R60R8;>V2'X(WE1C(P#Z#%4+C7/$\-W/*%EB1QA83823B-LOC&TC.[8J
M]0!NR>HSN:5J&LW6LVPO?+B22.=VM4C(,2*RJI8D\DD-CH,9ZT 9E\_CE[[2
MW"+';;E$Z6C)DJ=FYI2X^4K\_"@@^H.*Q[2Z\<:UI O+.^D( NHXY+=8MLS0
MQ[8G^8=)90S<=B.0*]2HH 9$7,*&08D*C</0]Z?110 4444 %%%% !408()W
M;HK9/Y"I:A""03H<X8D''T% &%!XRL[DQ1PV-\\\JH\<*K&6965F#9WX'"-P
M2#[5K6^JVEQI2ZDLA2V*EB74@K@X((]001CUJF/#=G#96=M8N]B;1@R2VZH&
M8A"F6RI!X8]J6/0(TTN?3!=W M)%"IM8!T.<LV[')8\G/')H LOK6G1V,=ZU
MW&+>1MB.<\MSD8ZY&#D=L'TJ*;Q'H]NBO+J$"JX)7G.<$@_EM;_OD^E9Q\$:
M4;%K4-<C<26DW@DY9FQ@C:.6." "..:=;>$[=9+R2X=MT\SLOEN3M0Q&/&3W
M(9F/^TQH TIM=TNWC\R6^A"G.,'.<,5.,=>0?R-0'Q1I 1B;M X$A$9(#,$+
M X[<[&(]0*K+X0M(YTGBO;Z.2(,("KK^Y#%BVWY>^YNN>O&,"F'P3I9FEEWS
M[I582%BK%B=W.XJ2"-YZ$=LYH O'Q-HH60G48?W;;6YZ')'XXVMDCIM/I3O^
M$CT?,P%_$QA.'"Y)SG'&.O/IG%5)/"-BSQ21SW44L2NB2(ZY"N7+#D$<[R/R
M]*JQ^"K<P&*>\N=B22&!(W 6*-FSLP1SG"YW9Y QB@"ZGB[19+W[*MW\^<!B
MI",?EZ-T.=ZX/3FI5\3Z,4W-?Q*VQ7*$_-\V,# ZGYEX&>H]:K0^#]/@A,*S
M71C,:1@,XX"[/;OY:Y_&HD\#Z7''+'&\RI(H!!6-N?ER<E"3G:.#QUP!0!T<
M4B31)+&P9'4,K#H0>AIU0V=JEE906L;.R0QK&K2-N8@#')[FIJ "BBB@ KBM
M1UJ^MM2N88I%")(0 4!KM:XG4M&OKG4[F:*(,C2$@[P*\?.OK/L8_5KWOT[6
M._+_ &7M'[6UK=2O_P )#J/_ #U3_OV*/^$AU'_GJG_?L4G]@:E_SP7_ +^"
MC^P-2_YX+_W\%?,WS?\ O_B>O; _W?P%_P"$AU'_ )ZI_P!^Q1_PD.H_\]4_
M[]BD_L#4O^>"_P#?P4?V!J7_ #P7_OX*+YO_ '_Q"V!_N_@+_P )#J/_ #U3
M_OV*/^$AU'_GJG_?L4G]@:E_SP7_ +^"C^P-2_YX+_W\%%\W_O\ XA; _P!W
M\!?^$AU'_GJG_?L4?\)#J/\ SU3_ +]BD_L#4O\ G@O_ '\%']@:E_SP7_OX
M*+YO_?\ Q"V!_N_@+_PD.H_\]4_[]BC_ (2'4O\ GJG_ '[%)_8&I?\ /!?^
M_@H_L#4O^>"_]_!1?-_[_P"(6P/]W\#IM,NQ?6OGC@DX8>A &:N52TNT%C:>
M0.6!RQ]20,U=K[C#^T]C'VOQ65_4^=J\GM'R;7T"BBBMC,**** "BBB@ HHH
MH *9-_JC]1_.GTR;_5'ZC^= #^]%'>B@ HHHH **** "BBB@ HHHH 5/^/B+
MZG^1JY5-/^/B+ZG^1JY0!AZH2+XX7/R#O]:I[F_N?K5W4_\ C^/^X/ZU4H ;
MN;^Y^M&YO[GZTZB@!NYO[GZT;F_N?K3J* &[F_N?K1N;^Y^M.HH MZ6SBZ?$
M9/R>H]:U5RC.RVX#.<L01ECC'/X 5FZ3_P ?;_\ 7/\ K6IY\/VC[/YJ>=MW
M^7N&[;G&<=<9[T 1SQ+=0M#<6B31-]Y),,I[\@U)OD_YY'_OH4DUQ!;C,TT<
M8P3EV X&.>?J/SJO=ZOIEA,L-YJ-I;RL,JDTZHQ&<9 )]: +.^3_ )Y'_OH4
M;Y/^>1_[Z%4QKVCFU>Z&K6)MT?8TOVA-BMZ$YP#[5;:ZMUM?M33Q"WVAO-+C
M9@]#GIB@!=\G_/(_]]"F@%9&D6W =P S C)QTR?QJ)]5T^)V1[ZW5ED6%E,H
MRKMT4^A/I5N@"/?)_P \C_WT*-\G_/(_]]"DENK> XFGBCZ??<#KTZ_0T]'2
M2-71@R, 593D$'N* &[Y/^>1_P"^A1OD_P">1_[Z%+YL8F$/F)YI7<$S\V.F
M<>G(I] $>^3_ )Y'_OH4;Y/^>1_[Z%244 1[Y/\ GD?^^A1OD_YY'_OH5)10
M!'OD_P">1_[Z%1QO)ND_='[W]X>@JQ4:$*922  V23]!0 ;Y/^>1_P"^A1OD
M_P">1_[Z%!N(%2-VFC"2$!&+##$] /7-56UK2E>1&U.S#Q?ZQ3.N4YQSSQSQ
M0!:WR?\ /(_]]"C?)_SR/_?0J.&^M+DH(+J&4NA=!'(&W*#@D8Z@'C-/%Q 6
M*B:/*OY9&X<-C.WZX(XH 7?)_P \C_WT*-\G_/(_]]"I*0D*I9B !R2>U #-
M\G_/(_\ ?0HWR?\ /(_]]"DM[FWNXO-MIXIH\XWQN&&?J*D#J7*!AN !*YY
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M_;\/^?;^]'SWN7U'YT;E]1^=?0G]CZ7_ - RR_\  =/\*/['TO\ Z!EE_P"
MZ?X4?5GW#^WX?\^W]Z/GO<OJ/SHW+ZC\Z^A/['TO_H&67_@.G^%']CZ7_P!
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MVZ\NU[_D/WW_ %U-85ZKIQ31V8+#1Q$W&3M9':?V[I7_ #_P_K_A1_;NE?\
M/_#^O^%>=45R?79]D>E_9-+^9_@>B_V[I7_/_#^O^%']NZ5_S_P_K_A7G5%'
MUV?9!_9-+^9_@>B_V[I7_/\ P_K_ (4?V[I7_/\ P_K_ (5YU11]=GV0?V32
M_F?X'HO]NZ5_S_P_K_A1_;NE?\_\/Z_X5YU11]=GV0?V32_F?X'HO]NZ5_S_
M ,/Z_P"%']NZ5_S_ ,/YG_"O.J*/KL^R#^R:7\S_  /48B&+LI!!((([C J2
ML;PPTS:,GG=F(3/7;@8K9KT(2YHJ1XE6'LYN%]@HHHJB HHHH **** "BBB@
M IDW^J/U'\Z?3)O]4?J/YT /[T4=Z* "BBB@ HHHH **** "BBB@!4_X^(OJ
M?Y&KE4T_X^(OJ?Y&KE &'JC*M\<D#Y!_6J?F)_>'YU=U/_C^/^X/ZU4H ;YB
M?WA^='F)_>'YTZB@!OF)_>'YT>8G]X?G3J* &^8G]X?G1YB?WA^=.HH MZ5+
M&+I\NH^3U]ZU_/B_YZ)^=9>D_P#'V_\ US_K6Q0!'Y\7_/1/SH\^+_GHGYU)
M10!'Y\7_ #T3\Z//B_YZ)^=244 1^?%_ST3\Z//B_P">B?G4F0,9/7I10!'Y
M\7_/1/SH\^+_ )Z)^=244 1^?%_ST3\Z//B_YZ)^=244 1^?%_ST3\Z//B_Y
MZ)^=244 1^?%_P ]$_.CSXO^>B?G4E% $?GQ?\]$_.F1S1;I/WB_>]?85/4<
M?WI?]_\ H* #SXO^>B?G1Y\7_/1/SJ2B@"/SXO\ GHGYT>?%_P ]$_.I** (
M_/B_YZ)^='GQ?\]$_.I** (_/B_YZ)^='GQ?\]$_.I** (_/B_YZ)^='GQ?\
M]$_.I** (_/B_P">B?G1Y\7_ #T3\ZDHH C\^+_GHGYT>?%_ST3\ZDHH C\^
M+_GHGYUB3:'IEW<2W$MN'=W)+;SSS]:WZYJZ\4Z%8WD]M=:I!%/'(0Z-G*G.
M?2IDHM>\:T?:W_=7OY7_ $'_ /"-Z3_SZ?\ D1O\:/\ A&])_P"?3_R(W^-5
M_P#A-/#?_09MO_'O\*/^$T\-_P#09MO_ ![_  K/EH]E^!T6QO:7XEC_ (1O
M2?\ GT_\B-_C1_PC>D_\^G_D1O\ &J__  FGAO\ Z#-M_P"/?X4?\)IX;_Z#
M-M_X]_A1RT>R_ +8WM+\2Q_PC>D_\^G_ )$;_&C_ (1O2?\ GT_\B-_C5?\
MX33PW_T&;;_Q[_"C_A-/#?\ T&;;_P >_P *.6CV7X!;&]I?B6/^$;TG_GT_
M\B-_C1_PC>D_\^G_ )$;_&J__":>&_\ H,VW_CW^%'_":>&_^@S;?^/?X4<M
M'LOP"V-[2_$L?\(WI/\ SZ?^1&_QH_X1O2?^?3_R(W^-5_\ A-/#?_09MO\
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M4?9X;<P6MPPCEC^T,Q8;L$2*H4YZ$$C)KTOSHO\ GHG_ 'T*/.B_YZ)_WT*
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M,WG_ %U->7FN/G@J2J02=W;7T.S!8:.(FXR=K(ZS^U+#_G\A_P"^Z/[4L/\
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M_GFOY4>5'_SS7\JQTUZ38-UFY<@'K@?CZ>V:/^$A.YP+*0A3C@Y)X[#'7^5
M&QY4?_/-?RH\J/\ YYK^54EU!Y++S@B(^]5QNW8RVW/';O4=I?SSW!A8H02X
M5U4CH%.<9]R/RH T?*C_ .>:_E1Y4?\ SS7\JQ'U:]A@C=H]^$9I6$1PN20G
M?U'/UJ8:A="!O-*QLLR1EF3HI ))YQ]#F@#5\J/_ )YK^5'E1_\ /-?RK#&M
M7J<R6V0[E8RB-\Q"9 /IDD$>V1VJ8ZQ.D-N7@/F999@5*Y8 _=]SC@>] &MY
M4?\ SS7\J/*C_P">:_E6,^NSBV+"T*L48HSDXR,]>.I/0=Z!KTBP"1[0J"&.
MYFP/E )SQQG.![T ;/E1_P#/-?RH\J/_ )YK^59DFLLMSY"6Q=ODX#\C< <D
M8Z<_G4/]O2^:!]CRA48(?OUZD8XZ?6@#9\J/_GFOY4>5'_SS7\JS[35)+@-N
MM'&%<KSRQ7'&,=]W'/8U%9ZG<RRP"=40N&$B%2NP@X')]?\ /6@#5\J/_GFO
MY4>5'_SS7\JS)M2N5G"1Q#8971G*DA0JDC/U(S]*5]6:..1VCY$44B1C[S;N
MH_"@#2\J/_GFOY4>5'_SS7\JQY-;N$GB0V@4'<3\Q.<#H#CKG&/6I(];)LI9
MWMV!C0ML)PW'=N.![T :GE1_\\U_*CRH_P#GFOY5DG7)!D_8F8;BH*O][&.F
M0,YSQZXIBZ]+ND!M0^& 38QY! /IS@]?3WH V?*C_P">:_E1Y4?_ #S7\JR?
M[;F\T)]B;.TL?F., $]<=>#^8IHU]Y#*(K-CL&<DGGD <8ZY/2@#8\J/_GFO
MY4>5'_SS3_OD5ERZTT'V56M]S31JS%20%)'TZ<=:2WUTSQR/]CDPJ%AM;.['
M]#ZT :OE1_\ /-/^^11Y4?\ SS3_ +Y%9#:Y,L@4VFT*</EL]N.V1SCG%,A\
M0RR*6:Q?!Y4!N<8'KU/7IVH VO*C_P">:?\ ?(H\J/\ YYI_WR*SEO+J:&VD
M0HOF7#1MM4L-H+8(/']T<^]5H]1U"<Q)!Y<C/%O+!,!6QG:<GM^?- &UY4?_
M #S3_OD4>5'_ ,\T_P"^169<ZE<QW*Q+$8HS&Q,LB'&X$?D.3UHDUB6&.'-H
MSN\*R'G;R>P!Y[?J* -/RH_^>:?]\BCRH_\ GFG_ 'R*RFUMU!S:?,LAC*E\
M'COR/N\8!]:8FNRR.'6U_=!27PQ)'S!<<#J.21^M &QY4?\ SS3_ +Y%'E1_
M\\T_[Y%8L?B!W,C&T;8O09/)YR <<D\8'L:1_$3^2C1VFYG&5(8E>5SUQSZ'
MWH V_*C_ .>:?]\BCRH_^>:?]\BLJ#6)B\44UL \G1PV%[GG(XX!-27>H317
M11 NQ64'C+-D$\>O;\C0!H^5'_SS3_OD4>5'_P \T_[Y%9<VI77DP^1'&TK9
MX.<-B0+QZ9R3GZ57.LW;6TLZQA64GRX'C.YQD\_ACGZ'U% &YY4?_/-/^^11
MY4?_ #S3_OD5F1ZE,&VD"92&VO&AY("G./0$D55AU^XPWFVC'A<'[H)/7D^G
M7\NM &[Y4?\ SS3_ +Y%'E1_\\T_[Y%9UQJTD+*!:,P(3G>!@L"<>G;'7J:A
MEU\Q1[S:$@(7/[S&/8Y'4=QVH U_*C_YYI_WR*/*C_YYI_WR*R!KDHDE#6F5
M7[FQB=_^[QSZCIP#4ESK+V_EK]EWR-"LFQ7YY)&.G;')H T_*C_YYI_WR*/*
MC_YYI_WR*R)M<FCF"BTRH)#?,>#G')QQZ_3%36>JR7,_EFU9%+;=Q/0X8^G(
M^7KGN* -'RH_^>:?]\BCRH_^>:?]\BL^'49#:74K>6YAR5*@C<, YQ^.*CM=
M2N7N?+F10/,V$ =!\WO_ +.?H: -3RH_^>:?]\BCRH_^>:?]\BL5=>E20I+:
ML6?,D2@%2T?& !W;\J)/$$G[Q([4&14##YR0<Y]N0,<^E &UY4?_ #S3_OD4
M>5'_ ,\T_P"^162^NLO M6Y!Y#9P<=,8Z^OIZT]M;VV<DQMGW(Y7:,D?]]8Q
M0!I^5'_SS3_OD4>5'_SS3_OD5D?V^<9^QR=>@.3TR.,?_J[TIUP\_P"C\*P&
M0Q.\?WEXY7WH UO*C_YYI_WR*/*C_P">:?\ ?(K$C\02O(V;)BG10&Y."0>O
M!SVK1TV\>]BED=54+)M7:2>-H/7UY- %L1HIR$4'U IU%% &/>:FUM=R0_9%
M;<0H;GY_E)QP.O& />HSJ]W]G?99>4P0E V3R!PN /O?I6V0"02 2.1[4M &
M)=ZK>K!$\-I('9'W+LSAAC _F.U2Q:O.Z3O):&,11-)AF(.0,XZ?49]C6M2$
M!@00"#P0: ,<:Q<E2PL\J#@,"V'X)XX[]![U&FLWOE*6L27& <9&3CKC&<?X
M5NT4 9DNI3QQQG[*2Q#Y'/)4XP.._7GM5=]8O,96SPH<+OPQ!&1E@,=,9Q6W
M10!AIK5V^XBP?"@D]>0/3CJ:9+JTB+'-/8(&"DH[YR,$C'W>"<<5OTUXTDQO
M16P<C(S@T 9TM]*;VXACM-[0Q,\;D'EL#C\<]O0U6FO9ED1HXVN8T_ULGV?'
MRG P/QY./[N*W** .>2^OP2)EV2&+=@PY+MM!"\=B21CKP:NW^HO9VL1M[?S
M"P(VH"0N,#MZ>GM6I2  # &!0!CPZO<L8T>S;<6"L1G!Z=..O)./:G/<:FJS
M3HBM'&[@1L.7 ; QCD<<YK7HH QWO;R)9$+,]QDQHBP$C/ #Y]._7VJL^IZE
ML,GE-& =AW1YPP49XZ]<X/3BNAHH K6,LDT+F0[@'(1]N-Z^N/\ /2K-%% #
M6C1@P9%.X8.1UI=J[]VT;L8SCG%+10 4444 %%%% !3)(HYEVRHKKG.&&:?1
M0 @15)(4 GJ0.M+110 4A 88(!'O2T4 -,:$,"BD/][CKVYIU%% !2,JNI5E
M#*>H(R#2T4 %%%% !1110 UT61"CJ&4]01D&E5510JJ%4#  & *6B@ HHHH
M**** "BBB@ I%547:JA0.P&*6B@ (R,'I2*H50J@!0,  < 4M% #6C1R"R*Q
M (!(['K2[5#%MHW$8)QVI:* &B-!MPBC8,+@=/I3J** $VKNW;1NQC..<4M%
M% !2,JNI5E#*1@@C(-+10 4FU=^_:-V,9QSBEHH **** $**225!R,'([4FQ
M!M^5?E&%XZ?2G44 (54L&*C<. <<BC:N\OM&XC!..<4M% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. F8# 2(  A$! Q$!_\0
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M_P!^6_\ BJ +=%5-FH_\][7_ +\M_P#%4;-1_P">]K_WY;_XJ@"W1539J/\
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M+?\ Q5&S4?\ GO:_]^6_^*H MT54V:C_ ,][7_ORW_Q5&S4?^>]K_P!^6_\
MBJ +=%5-FH_\][7_ +\M_P#%4;-1_P">]K_WY;_XJ@"W1539J/\ SWM?^_+?
M_%4;-1_Y[VO_ 'Y;_P"*H MT54V:C_SWM?\ ORW_ ,51LU'_ )[VO_?EO_BJ
M +=%5-FH_P#/>U_[\M_\51LU'_GO:_\ ?EO_ (J@"W1539J/_/>U_P"_+?\
MQ5&S4?\ GO:_]^6_^*H MT54V:C_ ,][7_ORW_Q5&S4?^>]K_P!^6_\ BJ +
M=%5-FH_\][7_ +\M_P#%4;-1_P">]K_WY;_XJ@"W1539J/\ SWM?^_+?_%4;
M-1_Y[VO_ 'Y;_P"*H MT54V:C_SWM?\ ORW_ ,51LU'_ )[VO_?EO_BJ +=%
M5-FH_P#/>U_[\M_\51LU'_GO:_\ ?EO_ (J@"W1539J/_/>U_P"_+?\ Q5&S
M4?\ GO:_]^6_^*H MT54V:C_ ,][7_ORW_Q5&S4?^>]K_P!^6_\ BJ +=%5-
MFH_\][7_ +\M_P#%4;-1_P">]K_WY;_XJ@"W1539J/\ SWM?^_+?_%4;-1_Y
M[VO_ 'Y;_P"*H MT54V:C_SWM?\ ORW_ ,51LU'_ )[VO_?EO_BJ +=%5-FH
M_P#/>U_[\M_\51LU'_GO:_\ ?EO_ (J@"W1539J/_/>U_P"_+?\ Q5/A6[$G
M[^6!DQT2,J<_BQH L4444 %%%% !1110 4444 %%-D;9&SXSM!.*Y'3/'L%S
MM:_@AM(7MA<"2*X\[:"RJ%=0H*G+#U[T =A169_PD.E?:1;M=A)3C(=&4*2N
M[:21@-MYVGG':J=KXNTZ[U1K5&(A*0F*8JP\QI"VU0",_P .<]#F@#?HK*'B
M72&,06\#&0D+M1CCYBG/'R_,"!G&3TJ;1M6@UO3EOK=)4C9F4"5"IX)']* +
M]%%% !1110 4444 9,?B71Y=3.G+>K]J$ABV,C %QU4,1@GVS6M7&-X?UF:X
MFM"EM#9MJC7ZW0E+2 9W* FW@YQSGUJK:>%-=M=.E>.ZC748FB>W+2DH\BA@
M[M\H^\&/7)X&>E '>T50T>TDT^P2Q9 ([<+'')YFYI0 ,LW'!)SQS5^@ HHH
MH **K7\US!9O):6Z7$R\B-Y?+!'?YL'^58FE^+K>ZL[>?44BL6N462)!(9?D
M;@,Y"@)D\<_G0!TE%8,/B_27MGGFDEMT6>2'][$PY1MI/ X&2.3Z\\U/;:_;
MO:WUS=#[/#:7C6K,26!PP4-P.,DCZ4 :]%94WB32(&VRW@7]ZT).QL!E(4@G
M& ,D#/3-5[7Q58207,EVPMFMS,SJ<M^[CD*%^!ZCI0!NT51M]9T^[O7LX+E7
MG7=\N" =I ;!Q@X)&<=,\U>H **** "BJ>K7_P#9>D7E_P"7YGV:%Y=F<;MH
MSC/:L^3Q-:VU\\-VOD0K;0S>;DMEI&*A< 9ZC]: -RBN;G\9Z?%?Q1*<VODR
M3SW+*X$01MI!&W.<G!!QC\16A_PD.E?:(X&NMLK[<*\;+C=G:&R/E)QP#@F@
M#4HKGYO&>C):B>&:2X!:,!8H6R0[;0P!'(SGIZ8ZU;T;57U1[T,L&V"<QJT,
MN\'V/ P1T/O]* -6BBB@ KD/'<MY$NDO92S(\=RTQ$;$;PD;/M..H.W&#77U
M3O-4L[">W@N92DMP2(E",Q;&,]!P!GJ: /-;74=1;[9-+)<%KN5YT#2/^Y5[
M5W4+@X&../ZUKV?BG6(RMJEO$PAM>!,&+,! '$A()8@L<?=_'-=2OB;1WA,J
MW@90RJ (V+-NSMVKC+ X." 0<&E_X2/2F=(XKQ'DD0,@P=IRI8 MC ) )P>?
M:@#DX?$^L73:?.6"A+B:.2..,;;@B'<BA@Q!).0,'KCN,58M_%.KW,EI#$;6
M3[1+ K7"P-MB+JY:,C=RR[1W'7D"N@M/$VFW%G#-)<Q1O)L5E!8@,R>8!D@9
M&W)S@# IP\3Z0T E2[W9<(JB-]Y)7<,+C.-O.<8QS0!S5KXQUB>YL(VM(1YH
M3<-I'G$R,K%><C:%!P W7G'%:GA/Q!?:Q<7<-]'$&B565H4.WDD$9R?3H0#Z
MBK,/BJW;1=)U&:WE7^TI$C1(P7VEL]2!TXK0L=:T[4IWAM+E99%&[ !&Y<XW
M*2/F&>,C(H OT444 %%%% !116'XB\0G0Y+&,16[&Z=UWW%R($3:N>6(/6@#
M<HK L?%VG7&GVES=M]DDN%+>4V6V@.4W%@,!2>C' .:M_P#"0Z5Y:O\ :QAD
M=QA&)PC!&XQGAB!CN>E &I17,W?C:PMI59(Y+BV:$2"6($G=YHBV[<9&">?I
MC%6X_%&G#>+F>.(B9XP!N; 4@;F^4;>2 <\ GK0!MT50L]:T_4+J6VM;D22Q
M;MP"G'!VG!(P<'CBK] !1110 4444 %%%,FD\F"23&=BEL>N!0 ^BN3T?QO'
M?L/MEM%;(UJ+I6AN//PI8+M8!05;+#CG//I6A/XMT>&T:=+AYOW#W 2*)V8H
MI(8].,$$<XP: -RBL:W\4Z3/)%$;DQS2;!Y<D;+M9EW*"2, D?G2CQ1HS1K(
MMYD,ZQJ!$Y9BP)7 QD@@'!'!Q0!L450L=;T[4IY(;.Y$LD>2P"D#@X."1@X(
MQQ5^@ HHHH **** "BBB@ HHHH **** &NH=&4]&&*Q8_"FGQ: FDQ QH!'N
MF15$C[&# L0.>16Y10!A7/A6RN[N:266<V\TWVB2VR-C2[-F[.,].V<9YJNG
M@V!620ZC>--$(!#(VS,8B+;.-N#PQ!SUKI:* .>L?"<&G/&]K?WD; ;9B&7,
MP$C. WR\<L1QC@UIZ3IB:18_8XI9)(E=V0/C*AB3MX X!)J]10 4444 %%%%
M !61K^K2Z3%9&%(6:YNEM]TSE53()R2/I6O5+4-+MM4%L+I2RV\PF5>Q8 C!
M'<<GB@#CHO%]^UY)J CC-JMM 9;<R< M.\19#CG. >>P%3GQW.TMZD-G!*(P
M&@(EQN'F^6<YQD]\<9Z#UKL?LEMMV_9XL;0N-@Z#D#Z#M3?L%G^\_P!$@_>9
MW_NQ\V>3GCF@#D8O'DLTEFL=@K>8J&7#$<M*8\+D#D8R<_2NVJ 6=J#$1;0Y
MA_U1V#Y/]WT_"IZ "BBB@!'4.C*>A&*YP>#+(6T-L+FY$*V\=M,H*_OXT8LH
M;CCDGD8X-=)10!R]YX'LKU9$>]NA&SRN$&PA?,8.V,KUW#@]<$C-:D>A6J6.
MH6;L\D5_+)++NQP7ZX_I6I10!R\W@6PFM+.V^U702VB\O)*L7.\.7.0<,6')
M&,YQ3KCP5:3I,JWMW%YRS)*4*_,LDGF$<CC#>G:NFHH Q-.\+6.F:K)?P,Y9
MBY5&"X0N<MSC)Y]3Q6W110 4444 07MI#?V,]G< F&>-HW .#@C!KFKOPA-]
MD(@U"XN+MYK;,UPR@I%$^X!<+C(R3R.3UKK** .;?P992Q3J]U<L\\4L<LF5
MRQDD5V;I@'*@#MBK-UX9M;O4)+EYYPDTD<LT (V2/&,(QXR,8'0\X%;=% '-
M_P#"&V8MH8ENKE3#;16\;_+D>7)YBMTQG(^F*Z&.)(@=JJ"?O$ #)]33Z* "
MBBB@ JA>Z3!?7UK=3,^;=)4" \,)  <_E5^B@#F;7P38V42"WN9XYHG1X9@J
M;H]@*@?=PW#'.<YS2OX3TY-2CO)[N9IWVJ3,4+2R!"H.2,YQV&!P.*Z6N%U6
MUUV;6Q+]GO)V@OVF@"LH@$7DL$QGHVXX.?7TH V(_!NF));N[32>38_8=K,
M&7;MW' ^]M)&?0U73PMI>D+;-_:,EM<"8"&<F-6)V%-F-N#E2>V<\UB06GB.
M<VLURNH,UO>;XMS8(#0$9//*B3@Y[$\8-:.D:5K>J64D6LW-S$JR1/AT4L7
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M^U1^C?E0!%Y>H?\ /Q;?]^&_^+H\O4/^?BV_[\-_\74OVJ/T;\J/M4?HWY4
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MH?\ /Q;?]^&_^+H\O4/^?BV_[\-_\74OVJ/T;\J/M4?HWY4 1>7J'_/Q;?\
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MBZ%'>WUP^H(^GZ>@WVX8^5!G8^2VX@G]T,X [YS0!N6WB+2KNPN;V&ZW6]L
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M(/(((((/I4U0VEI#8VJ6UNI6),X!8L222223R22223ZU-0 4444 8GBC79-
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MRK?">EE:4JS76VFUOG^&VITGB7_D*>'?^OX_^BGK1K.\2_\ (4\._P#7\?\
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M$@>2LN<?\"Q^%0-XM+:A/9PV:R,DR11L9L!R9/+.>,C!^M %9;_Q+(L&&(!
M)86A^;,JKR& P0I8\ =,U#-JGB.1(HOL\Z[[9UE*VY!+;9,,"!\IRJ=^_2IO
M^$MNIL21P0Q1LL)4%MS9<29STR,IU_QX=!XQD-C&TMK"UP8U=F6XQ$1Y7F'Y
ML<-@$;?UH U?#]Q?3VDOVWS6",JQ22P^4[C8I;*^S9&>]:]<K+XME-XIAM4^
MS*)#(COB4A%1B=N/E #$]\X[5I:;K+W]]&OE!;>XMFN(3U.T2%03_O J0.U
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M8BHO#6N/KEK/)(]DS12!<V<K.N",\[@"#6CIOEYUJC)55S<C5F:ZVR)*9%B
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M'Y54GT;3+D8FL8'^8ORO.XL&)SV)8 Y]10!D#QSI)A\XQW2QF!)D9T5=^XJ
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M\3:P8Y!)X7O$E/\ JL'<IZ\MZ=N.O6ISXDNVMRT?A[4A*0=BN@QG'&<=!_\
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MZG-=V>H?9DN3$;A/)#,2G'R,3\N5X.0?48- "RZ]IT-I!<O,YBG0R1;8F8N
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MJ6G7-E,66.XC:-BO49'45FRZ%-J$]K)K%ZEZMO+Y@A6#RT/R,G3).26R3G'
M  H LV^NV-W<B"V-Q,W!9DMW*)DD#<V,#E3U]*DN]8L+&X>"XN LR0^>8PI8
M[-P4' '4L0 .I[5GZ-X5L](N//R)I%14B8KM\L N>.?]O]*2]\+1W.I2W\=]
M<Q32?-M8AT$@:-E./0>6!MS^5 &S:74-[;)<6[%HWS@E2I!!(((/(((((/I4
MU5--LC860@:7S9"[RR2;=H9W8LV!V&3P*MT %%%% !67K4TMO_9TT:W!C2\4
MSB!&<^7L?J%!)&=OZ5J44 <G=ZSX@CN[B2UL99K>,LX@^R,"T0V[2KG[SL"W
MR]1CH,<R0:CXI_L>>6;3(3=1[HR1P0R8!=8_XU8[F49' '7-=14%]="RT^YN
MV4N+>%Y2H.-VU2<?I0!R%GJ'B6+>B1W$V^>1H3-9,OG*9'R6)/[H*H4@'KG\
M KZMXAFOH+J&VNHPD918FLGVS2%825<'&T;O, <] #^-I_%\JQN9M/,&V0)N
M29922'B##&!VF7\0?8F.+QC/)9:M<BT5FA@66U2,F5!F+S/WLBC"?C^&>M !
MH-]XC75;>QO+2067S[I)48DK\Q#%\=<X7:3T[56O[_Q$FI3W*6\SB#<! T+1
MPH!+\IWYP^4 )/09.?:P_CZ*.26)M.D9T<1*RN2I?<J')V\+EL@C=D#H,BI%
M\:B6$R+I3F$I@!IU#%_)\W;@C&,9&<^G'- %"'5]<U&XCEM9YI8(;M8WN([(
MIN3,1*LF3_>;)ZX';FM&&^U^[\+W,LRSV]_'<1A7CMB"T>Y"^U",D8+#D9X/
M7J=K0[R"_P!'@N+:".WC;</*B&%0AB".@[@]A6A0!B:%>ZK=W%PNHPLB*BGF
MW,7ER%F!C4D_.  IW>_X#;HHH **** "BBB@#&\43W5OHI:V,R*946XD@&9(
MX2?G91ZX_*L>YU[P_H.D[?#YM);N<A(EA!=B?[\F,L0.O/)JWJ9\4C4+G[ &
M\L,OV79Y7E%<<^9N^;.<].U5;"UUZVO;R]ETB&76)_D6Y,R+;Q1CH% ^;Z\9
M/K7/)MRT7X?D>UAZ=.-%>TDFM[*25[VTE?HN_JK7=ROIUA"BF\U%OL]E9L+N
M?[01]HNI>TLJCE5'\*?2KL/BRY.I2FZM4ALDC'[L M/YC']VA XWL,G:.@ZF
MLZZTOQ%?:;;"6P*W*RQR7EQYD7G3[22 @^[A<\;CV%+<Z+JKSV0@TF:"PA63
M,4=VAG=VZN[GH6&06!)P3TJ$Y+X4=,H4*K;K23>JW6ENVN\GMY6VLD=7HVJK
MK-@;I+>6 "5XMDA!.5."01P16A7$VM_XBAU&?08+*U@DV)Y!B8-#90XQN/=F
M/8'&2*[.)&CAC1Y&E95 :1@ 6/J<<<UO3ES(\C&8=49W35GJDG?3IK_77IJW
MU-;?ZW\*AJ:V_P!;^%:'&7**** "F&*,G)C3/^Z*?12:3W"]C,U5&:XT_:I.
M)SG Z?*:D\J3^XWY58NKE;2#S6CED&0-L2%C^0JC_;L/_/G?_P#@,U1&"C*4
MK[V_*Q;DY)*VW^9-Y4G]QORIC6H=U=K=6=<A69 2,]<&F?V[#_SYW_\ X#-1
M_;L/_/G?_P#@,U7=$V8[[&O_ #[)Z?ZL>F/Y<?2D6R1  MK&N.F(P,4G]NP_
M\^=__P" S4?V[#_SYW__ (#-1=!9CVM Q):W5B>I* YXQ_+BD-HI+$VR$L &
M.P9('0'U%-_MV'_GSO\ _P !FH_MV'_GSO\ _P !FHN@LQQLD8.&M4(D.7!C
M!WGU/K^-!LD9RYM4+$8+&,9(],TW^W8?^?.__P# 9J/[=A_Y\[__ ,!FHN@L
MQ6LHV#AK6-@YR^8P=Q]_6I/*?^X?RJ+^W8?^?.__ / 9J/[=A_Y\[_\ \!FH
MN@LR;RI/[C?E1Y4G]QORJ'^W8?\ GSO_ /P&:C^W8?\ GSO_ /P&:BZ"S)O*
MD_N-^5'E2?W&_*H?[=A_Y\[_ /\  9J/[=A_Y\[_ /\  9J+H+,F\J3^XWY4
M>5)_<;\JA_MV'_GSO_\ P&:C^W8?^?.__P# 9J+H+,F\J3^XWY4>5)_<;\JA
M_MV'_GSO_P#P&:C^W8?^?.__ / 9J+H+,F\J3^XWY4>5)_<;\JA_MV'_ )\[
M_P#\!FH_MV'_ )\[_P#\!FHN@LR;RI/[C?E1Y4G]QORJ'^W8?^?._P#_  &:
MC^W8?^?._P#_  &:BZ"S)O*D_N-^5'E2?W&_*H?[=A_Y\[__ ,!FH_MV'_GS
MO_\ P&:BZ"S)O*D_N-^5'E2?W&_*H?[=A_Y\[_\ \!FH_MV'_GSO_P#P&:BZ
M"S)O*D_N-^5'E2?W&_*H?[=A_P"?._\ _ 9J/[=A_P"?._\ _ 9J+H+,F\J3
M^XWY4>5)_<;\JA_MV'_GSO\ _P !FH_MV'_GSO\ _P !FHN@LR;RI/[C?E4<
MUHMPFR>V65,YVR(&&?7!IO\ ;L/_ #YW_P#X#-1_;L/_ #YW_P#X#-1=!9CF
MLD:;SFM8VEV[?,,8+;?3/7'M1#9);(4M[5(4)R5BC"@GZ"F_V[#_ ,^=_P#^
M S4?V[#_ ,^=_P#^ S47068+81*J*MG$JQMO11$ $;U''!]Q4WE2?W&_*H?[
M=A_Y\[__ ,!FH_MV'_GSO_\ P&:BZ"S)O*D_N-^5'E2?W&_*H?[=A_Y\[_\
M\!FH_MV'_GSO_P#P&:BZ"S)O*D_N-^5'E2?W&_*H?[=A_P"?._\ _ 9J/[=A
M_P"?._\ _ 9J+H+,F\J3^XWY4>5)_<;\JA_MV'_GSO\ _P !FH_MV'_GSO\
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M#AQ]BAPZA7_<K\RCH#QR!Z4XV497:;6/;C&/+&,8Q_+CZ<4G]NP_\^=__P"
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M0<\BU]D']\_E1]D']\_E50:]:.P$2S2;F"J53AB>G-1#Q% UJ95@E+A"VS
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '\!) # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M+XF\36'A?2VN[QLN<B&$'YI6]![>I[5%XK\66/A333<7)\RX<$06X/S2'^@]
M37SSKFN7WB'4Y+^_E+R-PJC[J+V51V%95*G+HMST,%@77?-+2/YDGB#Q!?\
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M0$,H(((/(([TM>N?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5:[2]=%%E<6\+9^8S0&0$>P#KBK-% T[.YE^1KO_02T[_P ?\
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M:=_X /\ _'J/(UW_ *"6G?\ @ __ ,>K4HHL'M7V7W(R_(UW_H):=_X /_\
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MO^KC!X7_ .O6;117ERDY.[/HX0C"*C%62"BBBD6%%%% !1110 4444 %%%%
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MR<>4X89=0A7==+7\$^X5[%\)_P#D5KK_ *_7_P#0$KQVO8OA/_R*UU_U^O\
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MJ*<Q^7O821B56\MMI4].<8S[=: )J*** "BBJ]Y?6]A$LEPY57<(H5"Q9CT
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M)F5W99&7YE^ZPP>&'J,&J.I>&;:>PN4LXPMU.$5I)I7;> X;YB2<GCJ?ITH
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M=Y2K(9))G=BK#!!)))&!T/3G'6GPZ-80$%8"V(3;_O9&D_=DY*_,3D?_ *J
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MK"[G>::$EI HD"R,JR =-Z@@-^(-6(;*W@N9KB*,++,JJY!/(7(48Z#&3TH
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MC4N=HY!QM< C&"#_ #JW=ZIC7KBRN]5.F11QJT/RHOG ]3N=2.#Q@>]5=?\
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MD48D3Y43ALX/7N>O7J:U9I)M/U;5IX(4NEEA1W F0>2RJ0/,!((4CG(ST/%
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M_7Z__H"5MA_C/*SK_='ZH[NBBBNX^/"O*=7_ .0U??\ 7Q)_Z$:]6KRG5_\
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MV=;D7)B9<1&4@@C)&0.<XSTI;/1KI8M/M);&8M;2(9)I+UVAVH>&1!)G)P,
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MQ?\ PTGKG_0"T[_OM_\ &LS]H$"7X@Q-Y@#K81C8?3<]>2T >V_\-)ZY_P!
M+3O^^W_QH_X:3US_ * 6G?\ ?;_XUXE10![;_P -)ZY_T M._P"^W_QH_P"&
MD]<_Z 6G?]]O_C7B5% 'MO\ PTGKG_0"T[_OM_\ &C_AI/7/^@%IW_?;_P"-
M>)44 >V_\-)ZY_T M._[[?\ QH_X:3US_H!:=_WV_P#C7B5% 'MO_#2>N?\
M0"T[_OM_\:/^&D]<_P"@%IW_ 'V_^->)44 >V_\ #2>N?] +3O\ OM_\:/\
MAI/7/^@%IW_?;_XUXE10![;_ ,-)ZY_T M._[[?_ !H_X:3US_H!:=_WV_\
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M^7_T2]=M^TK_ ,A[0O\ KUD_]"%<3\&?^2M:#_OR_P#HEZ[;]I7_ )#VA?\
M7K)_Z$* /#J*** % S77:58"Z\.3Z3<2)!=/*MS"C#+,H&#D#D<5R*DJ00<$
M'(-=%H:M+(9H[AOMCG+S9^:)?;U8_H*SJ_"95E[IZ!X/T. V&OW1(,+!8Y3
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M[T2SPVZJTTJ1AF"@NP&2>@Y[T 9S:##))%)-=7<TL?F_/)(#G>-IXQ@8'0
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MZA<7QG^V2QQRPF)54!^ 00,Y'?G'7I45KKE_<6<6HQ/=S/)+G[&EDQB\HMC
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M\S77U104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWL0>F%P3D=*GT>[4:G86L-S9ZG$+=@MS%'ME@4= ^"1@\#''(Z<4 =51110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;^0'ZD*HXK<M_ D3-';W5ZS)*AD<CC<<9P#Z"B71]+\F"V5UC*N8G=3\Q(Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\HE<EL8RV.N*YK6IYSX>MEEU:Q:,M'Y5G:H#M'^\23Q6I>?\AGQ9_P!@X?\
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M5QQ^%/C'M8V__@2E>?4I2<VTCIC-**U.,E?G%1&3;WYKM&^$OC)O^7&W_P#
ME*B;X1>-&_Y<;?\ \"DI*E+L/GCW.2%Q[\5'+/QQ77K\(?&@ZV-O_P"!24-\
M(/&C#'V"W_\  I*/92[!SKN<#).2:;YQZ]#7=_\ "FO&>?\ CPM__ I*:WP:
M\:]K"V_\"DJ^278GF7<X4W#$]:3SV)Y-=O\ \*8\;_\ /A;?^!2?XTH^#/C?
M_GPMO_ I/\:?LWV#F7<X<S'U(IC/N[UW9^#/C<_\N%M_X%)_C2?\*8\;?\^%
MM_X%)_C1[.78.9=S@6XIFXUZ"?@SXW/_ "X6W_@4G^--_P"%+^-_^?"V_P#
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MA2<#Y?;FLI8G1-/=T,?G7YE5#U53TIUU_P >&L_]?2?^A+2^M55S5.MK]?\
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MP?\ D']G8G^7\4=317+?\)E_TX?^1O\ [&C_ (3+_IP_\C?_ &-']MX#^?\
M!_Y!_9V)_E_%'4T5RW_"9?\ 3A_Y&_\ L:/^$R_Z</\ R-_]C1_;> _G_!_Y
M!_9V)_E_%'4T5RW_  F7_3A_Y&_^QJ[IFO3ZG<>7%8;4'WY#+PH_[YZUI2S?
M!U9J$)7;\G_D3/ UX1<I1LEYHW****](Y HHHH **** "BBB@ HHHH ****
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M?F7)X/'OC-;">'6B:*YBO,:@LSS-.T65<N &!7(XP!CGC'6F0^&I%E\Z:_\
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M/'.>*NIHD?G0R7%[>7)A1DB\QP"FX;20R@$G'&22?QYIUOHZQ7<%S->75U)
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M$T:W1;X>9*?MJ*DI)' ";,CCKC]:@'ANQ\J:-FF82QPQY+ %/*&$92!PW.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>0223[YK3HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU6YDE:X,8>U-N $S@[U<-UYY4<=_6@#(GU^6X6[L'GMKI)+&9A-;Q.BAE4Y
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@D 9/ I"0H))
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MUM%;+;7%S!+;JR+.C*6*L22K J5(R<].U &#/JLZWUK//MEGT_[=&S 8$NQ
M0<=B1C/OFM"34+_3+33]0N;LW4=T0LL)C50I92PV8&>,8Y)R*T$\/V*FWXD;
MR1+G<V?-,@PY<XR2?PHAT*&!H"T\]REL#]GAG8%(R1CLN3@<#=G H R_M>JK
M::-?M?DB^N(A+!Y2;%1^0%.,\# Y)IUOJU]+]DTXS9OQ?/#/(%7YHT^8G&,#
M*E1T[U##HUY+/IT7D7=M;VD_G>7+/&\2 $D*FWYFZ\%N@S6E8::[>(KW5YK<
MP%T6&-'*ECC&6."0,X '.>* -NBBB@ HHHH ***HZOJT&BZ>UY<I(\:L%(C
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M7W&4YO'%)4JND_S_ .#Y?<?/8[ NB^>'P_D:-%%%>Z>:%%%% !1110 4444
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M*8H+1G_?N@."P.[@]2!MZ=^:FDUG5735I[9;0Q6$A 0QLS2* ">=P ./8YH
MZ6BN=O\ Q*;=Y9;=(Y;6&T6=V.02TC 1KGH,]3UJ(^))(3+$UWIUY(;22:-K
M0_*CHN2K#<20>QXZ'B@#IZ*YIM5U016@F:T7[?;2/&8T8&)@FX9^;YN/IS5"
MPU1M-TK19;F."<&TGEW^6?,4*JG .3R<\GOQ0!VE%8<6IZC VG27RVS0WS!
M(5(:%F&5!))W="#P*JV.N:G+9Z7?7*VGD7LPA,<:,&4G(#;B2.HZ8_&@#IJ*
M** "BBB@ HHHH *JW^G6NJ6IM;R+S8202NXKR/<$&K5% %73].M-+M1;647E
M0@EMNXMR?<DU:HHH *PKVPU*ZUA;B2&TN+.'!MX'N&0!^[L AR>P[#ZUNT4
M5IHIKG398G6..:2)E(5RR@D$=< X_"DTVV>STJSM9"I>&!(V*]"0H!Q^56J*
M ,2"RU.QU/4;B"&TFCNI%==]PR%<*!R A_G5VYAN[W1[NWECABGFB>-0DI=1
ME2 2=H/?TJ]10!!90M;6%M Y!:*)4)'3( %3,H=2K#((P:6B@#G=-T2]M6T<
M3-;[;!948HY.\,!@C*C'?(_4U6N_#=]+;ZE;Q)8E[R1V^V2$^;L)#!" O3(
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M_P!A:/\ ] JQ_P# =/\ "C^PM(_Z!5E_X#I_A6A10!G_ -A:1_T"[+_OPO\
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MXVW_ 'Z7_"C^S+#_ )\;;_OTO^%6J*/J]'^1?<O\@]K/^9_>_P#,J_V98?\
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M]^E_PH_LRP_Y\;;_ +]+_A5JBCZO1_D7W+_(/:S_ )G][_S*O]F6'_/C;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%5[N[CLXE=PS%W6-$7&68G@#/^>* +%%9HUNTDU"YL8!)//;Q&5Q$
M 02#C8"3RV>WYFK!U&T73O[0,R_9=GF>9@_=^G7/MU[4 6J*SK?5TEF$-Q;7
M%D[1F5!<[1O4=<%6.".,@X//UJ4:MIIMOM(U"T\C=L\WSEV[L9QG.,XYQ0!<
MHK,;Q!I:WL=L;R#]Y"9UE\U=FT''7/7J?P/I4_\ :^F9B']HVF9O]7^_7Y^<
M<<\\\<4 7**IV^I6UQ;W%P6\J*"62*1I2% *$@G.>G%*NJ:>\$LZ7ULT41Q)
M()E*H?<YXH MT53?5]-CCCDDU&T1)!N1FF4!AG&0<\\U))?V<0)DNX$ 02$M
M(!A,XW?3/>@"Q15=+^SE$9CNX'$BET*R [E'4CU ]::-2L#-%"+VV,LRAHT$
MJ[G4]"!GD&@"U15>XOK.TDCCN;N"%Y.$620*6^@/6G?;+7REE^TP^6Q95;>,
M$KG(!]MK9^A]* )J*S)O$&EQ"V9;R&5;B?R$:*56 ;&>3GH./S'K5G^T[ M,
MHOK;,'$H\U?W?./FYXYXYH M453CU;39G1(M0M'=V*HJS*2Q'4#GDU/]J@^R
MM<B9&@52QD5LK@=>1]#0!+163+KT<,2SR6-ZMN0C/,44+'N.!GYLGJ,[0<9Y
MYS5^VNX[EID4,LD,AC=&&"#V/T(P1['UR* )Z*Q8/$D$R6\K6=W%!<,4BF<)
MM9AGCAB1]T]0*MVNLV%S!:2?:(XFNT#PQ2NJNP/3C//X4 7Z*@6]M6NVM%N8
M3<J,M")!O ]2O7N/SJO;ZQ97FH-9VTRSNL?F,\3*R#G&"0>O/2@"_16?;:S8
MW5Y-9K,J7,4K1>5(RAG( 8E1G)&#^AIQUK2A$93J=F(PVW?YZXSC.,YZXH O
M452;5K&-I/-N8(HT"D2/,@5MP)&.<] 3R!GMFENM4M;;2I=2#^=;1H7W0D-N
M ].<'\Z +E%4X]5T^2T>Z6]M_(C($DGFKM0^C'. >10=7TP)&YU&T"R\QGSE
MP_...>>>* +E%48M7L9Y76*Y@DCCC,CRI,A50#SGG(QZXQ[TXZMIH@2<ZA:"
M%R0LGG+M8CJ <\T 7**B%S UNUPLR-"H),BL"H Z\^V#6=)KT44,<\EE>+;L
M$9IBBA4#G"Y^;)ZC.T'&><4 :U%5[:[CN9)XU#+)!)L=&ZCN#]"""/\ '-9\
M'B&*=()OL-Y';32B%)W\O;N+;1D!RPR>.E &Q154:E8%IP+VV)M\^<!*O[O'
M7=SQ^-5KK7]/MK477VB*: H[B2*5"#M'(&6&3VXSSUQ0!IT51@UG3;B,,E];
M9\OS2IE7*K@')&>, @TYM7TU;=+AM0M!"^=LAF7:V.#@YP: +E%1^?";?[1Y
MJ>3MW^9N&W;C.<],8[U7.KZ:(%G.HVGDL2%D\Y=I(ZX.: ,JY\%Z+<:C)?K
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MA_SVN?\ OI?_ (FC_A$;#_GM<_\ ?2__ !-;]%']DX'_ )]+^OF'UW$?SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1,6Y1CG/.<?Q#;GFNZHH X":-IK]-+A6.XN8[NZE,L<R,2&1^H!RIR0IW8Y
MZUH7>EZJ--M+2WM67&F?9W:'R0?,( *NSY.SK]WO^%=?10!P>EV-W</=V26F
MUTOK=Y+DLO[GRU0D=<D\$# (^8\BK<6A21:;IL=_'';PPVUU'<R,Z@1[R"IS
MG\?8UV-% &/X:29M(6\NO^/F[/G.?; "_P#CH%;%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (F!.<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-D_G56YT^.ZG::26<,W7;(0* .BHK%M4-G#Y44DA7.?F;)J&[LTO)1)++.&
MQ\DA H Z"BL.TA^Q(RQ2RD,<G>Y:FWELM\4,LLPVY V.5H WJ*PK.V%B7,4L
MQWXSO<MTI;R 7RHLLLH"'(V.5H W**P+2S2RE,D4LQ8C'SR$BI;J,WD7E2R2
M!<Y^1L&@#:HKGK:PCM9Q-'+.6&<;I"1^56;@-=0-#))(%;&=K8/7/6@#8HKG
M(=-B@F25);C<AR,RDBKDS//"\3R/M88.#@T :]%<TFE0QR*ZS7.5.1F4UHM+
M(Z,ID;!&#@T :E%<P-(@'_+:Y_[_ !K4$TH&/,;\Z -.BN9.D0$DF:YY_P"F
MQK1CDDBC5%D;"@ 9.: -6BN:DTN&61I&FN,L<G$I J] 7MX$B21]J# W-DT
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M%% &??W,2SPVY8^:X+ 8["H*;J<$K:Q:3A,Q+&ZLWH33J8AKND:%W8*HZDG
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MLVF[#>$C%J+>K?E^1MO(D2%Y&"J.I)P!0TB*R*SJ"_"@GK]*S]<(;1KD*0>
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M+E8Y=S'T&* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '>M<=!6
M1WK7'04AA1110 4444 %%%% !1110!1OYHUDBA+@2-E@O<@5EW>GI=S12F66
M-XP0IC..M8?Q%TWQ7?W6F'PI?QV,Z!_.ED4%2O&!RIKC/^$>^,?_ $-MC_WP
MG_QNDTFK,<9R@[Q9Z7_9-O\ 99H2TC&?'F2,V6./>I(M.@BFEE(\QY,9W@'
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MPCWQC_Z&VQ_[X3_XW0!ZU17DO_"/?&/_ *&VQ_[X3_XW1_PCWQC_ .AML?\
MOA/_ (W0!ZA>6"7K1,TDD;1$E6C.#S40TF#R)XV>5VG7:\CMEB/2O-/^$>^,
M?_0VV/\ WPG_ ,;H_P"$>^,?_0VV/_?"?_&ZAPBW=HU5:HDHIZ?TST^+3K>*
M=Y2#(S*J_/@X &!BF#2;;[-);D,8GD\P#/W#[>E>9_\ "/?&/_H;;'_OA/\
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MAITFF@E88=HFQN^M>9_\(]\8_P#H;;'_ +X3_P"-T?\ "/?&/_H;;'_OA/\
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MH6"RY8@=!B@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** #O6N.@K([UKCH*0PHHHH **** "BBB@ HHHH
MIWTB QQEU#G)"YY(K-2SA2\DN]N9G &X]@.PIVJ*W]NV38.T1.,XXJ6BR>XU
M)J]NH4444R0K"T_7AJ/BG4-.A(-O9Q*"1_%)GG\NE+XLUP:#H4UPI'VB3]W
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MTHP?2@ HHP?2C!]* "BC!]*,'TH **,'THP?2@ HHP?2C!]* "BC!]*,'TH
M**,'THP?2@ HHP?2C!]* "BC!]*,'TH **,'THQ0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5>2X\J\CB;[KKP?>K%9&L$B>(C@A?ZT
M:]%06=P+FW5_XAPWUJ>@ HHHH **** "BBB@ HHHH **** #O6N.@K([UKCH
M*0PHHHH **** "BBB@ HHHH J7S+\BY&[KC/-4ZAU0'^WK(X./*?FIJ8@HHK
MF/'.O?V+H31Q-B[NLQQXZJ/XF_+^= 'GOCG7?[:UYTB?-K:YBCQT8_Q-^)_0
M5@6E[=63LUK<2P,PPQC8KD?A5>E7K0,TQKNK_P#03N_^_P U*-<U;_H)W?\
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M&Y_[^FHO^$IUO_G_ '_[X7_"C_A*=;_Y_P!_^^%_PI_68]@_L"O_ #+\2?\
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M?_\ /_/_ -_#2C5K_P#Y_I_^_AK+_P"$KUS_ *"#_P#?*_X4?\)7KG_00?\
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ME^U7'_/>3_OHU#2TP)?M5Q_SWD_[Z-+]JN/^>\G_ 'T:AH% $WVJX_Y[2?\
M?1H^U7'_ #VD_P"^C45% $WVF?\ Y[2?]]4?:9_^>TG_ 'U45%("7[3/_P ]
MI/\ OJE^TS_\]I/^^JAI: )?M,__ #VD_P"^J/M,_P#SVD_[ZJ*B@";[3/\
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M_P# F/\ ^*I?^$7U;_GA#_X$Q_\ Q5')+L'UO#_SK[T8]%;'_"+ZM_SPA_\
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MR,6BMK_A$M;_ .?1/^_Z?XT?\(EK?_/HG_?]/\:7)+L:?6\/_.OO1BT5M_\
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M*K55.VAZ&!R^6,YN65K"?99O^?:7_OV?\*46LW_/M+_W[/\ A4?_  D&L_\
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MILMKY!E9 LW?^[]:DETL16XG-Y 48';C/S8]*N7%U;:A:7:([B0-YR^80/;
M_"J5TZG1[%0P+*7R,\CF@!/[+G^U>0&3A!(SDX50?6DFTYHH#-'-%/$#AFC/
MW3[UI330RW-S;&9%\^W15<GC([$U66(:=87*32QM+/A51&W< ]30!$^CW$=_
M':,R[I!E7[5GD8)'I75I?02ZL\4LBXC(>%\\?=P1FN5;[Q^M "4444P"BBB@
M HHHH **** "E%)2B@ HHHI 36LYM[A9!TZ$>HKHU8,H8'((R#7+5L:3<[XS
M Q^9>5^E &E1110 4444 %%%% !1110 =ZUQT%9'>M<=!2&%%%% !1110 44
M44 %%%% %.^13Y;E1N!(#8Y%?/'B-KU_$5^=0&+GSB&'8#MCVQC%>[ZH[#7;
M- QVF)R1G@UP'Q,T'S(8]:@3YDQ'<8[C^%OPZ?E3 \SHHHH ,#TI124J]: -
MNT\)Z[>VL=S;:9+)!(NY7!&"/7K5:YT;4+*&6:YM'CCAF\B1CC"R8SM^N"*V
M_"C-_8/BGYFXT\8YZ?-5[2IK"+X:S/J=K+=0G5<!(Y=AW>6O.:!'.0Z!JEQ/
M;P164CRW$7GPJ,?/'_>'M4MUX8UFQ6-KG3Y(UED6),D?,YZ#K7H5FT$GB70&
MMX)%MVT)]D1;+!>>,]S[URWV:WCU+2GM]!U.PQ?0[I+J5G4C<..1UH&9=QX3
MUZT@DGGTN=8XQEV&#M'J<&J5IIMY>P7$]K;/+%;)OF91PB^I_(_E7H[O8C7?
M$DVEQW,FM1+(#!-+^[D4\,R =<>AJ/PR+?0=!TV.ZOK6U?4)#/<Q3@[I82"B
MJ../6@1P6FZ/J&KF46%J\YB +[<?+G..OT-3OX;UF.Y-L^G3+,(S+L('*#J1
MZ_A74Z7IL&D6WC"POS.MO"(@6AQO*;F*D9]B*RKWQ2D!TB/1UN%CTPLR27+
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M^=._\"?_ *U'_"%ZE_S\Z=_X$_\ UJ/93[!]?PO_ #\7WG.T5T7_  A>I?\
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MXAP;JW&!]>ZG]*]*I&4,I5@&4]01D&D!S^C>-_#VN;5M=0C29O\ EC/^[?\
M7@_@:Z*N4UGX=^'-9W.UG]EG//FVQV'/TZ'\JY[_ (1CQOX7^;0-8&H6J_\
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M?-_SVD_[[->/_K%'_GW^/_ ._P#LE_S_ ('*#1]3_P"@==_]^6_PIPT?4O\
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MO%\C_F.OXUK2S^$Y6E!I>MR)Y7**NI7.F6&5T5TC9D895E&0?H:7R91UB?\
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M#T/J*82222<D]3110 [>_E[-QV9SMSQFD%)2B@ HHHH **** "BBB@ HHHH
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MF?\ 06M_^^'_ ,*/[,QG_/M_U\P^NX?^="44OGZ9_P!!:W_[X?\ PH\[3?\
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M)V__ 'P_^%&VR_Z"=O\ ]\/_ (4?V9C/^?;_ *^8?7</_.B&BI]EE_T$[?\
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M;KK:W;I;L:*O23NJBZ7W>WK^IJ7EG<7\&E26L1E18%C8K_"1US5V8&[O-=2
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M=G10!QOE2_\ /-_^^31Y4O\ SS?_ +Y-=E10!QOE2_\ /-_^^32^5)_SS?\
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M* "BBB@ HHHH **** "BBB@ HHHH .]:XZ"LCO6N.@I#"BBB@ HHHH ****
M"BBB@#/O[:-IX;@@^8@*J<]C4%)J5Q(NK6MN"/+>-F88[BEIB"BBB@ KGM,T
M#^R_%>HWT" 6MY$K8'\,F[YA_7\:Z&B@ HHHH \S^.W_ "3D_P#7Y%_6O,_A
M;\4I?"TZ:1J\CRZ-(WRMU:V)[C_9]1^(KTSX[?\ ).3_ -?D7]:^8Z0S[EAF
MBN((YX)$EBD4,CH<JP/0@T^OF?X6_%*7PM.FD:O(\NBR-\K'EK8GN/\ 9]1^
M(KZ5AFBN((YX)$EBD4,CH<JP/0@TQ#Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ IDW_'O+_N-_*GTR;_CWE_W&_E0!\=>&
M/%FI>#O$']HZ=)_$5EA8_),F>58?U[5]5^$_%FF^,=%34=.D_P!F:%C\\+_W
M3_0]Z^-YO]?)_O'^=;7A/Q9J7@[6H]1TZ3_9FA8_),G=6']>U(9]ET5A>$_%
MFF^,=%34=.D]%FA8_/"_]T_T/>MVF(**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.6".9XW<9:-MR\
M]#4E4[RXDAN+1$("R2;6XZC% %RBBB@ HHHH **** "BBB@"&\_X\+G_ *XO
M_P"@FOC[PGXOU+P;KHU#3WRI.V:!C\DR9Z'^A[5]@WG_ !X7/_7%_P#T$U\/
MO]]OJ:0S[,\+>*=-\7Z+'J6FR94\2Q,?GB?NK#^O>MJOC?PAXOU+P;K2:AI[
MY4_+- Q^29/0_P!#VKZN\+>*=-\7Z+'J6FRY4\2Q,?GA?NK#^O>F(VJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "L77O"6@^)X3'J^F07#8P)<;9%^C#FMJB@#R*?X1ZWX>G:Z\#^*+BT.<B
MUN6(4^V1P?Q%,'Q'\;>$F$7C+PN]Q;KP;RT&,CUR,J?TKV"@@,I5@"IX((R#
M0!R&@?$[PEXBV);:HEO<-QY%W^Z;/H">#^==>.5# @J>01T-<=K_ ,+O"7B'
M<\^F);7#?\M[3]VV?4@<'\JY _#KQSX2)D\'^*&N;=>EG=G&1Z8.5/Z4 >P4
M5Y%%\7-<\/2BV\:^%;BV(X-S;*0I]\'@_@:[K0O'OACQ(%&G:O TK?\ +&4^
M7)^3=?PH Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
MTMMYM[%*P^6-?S-6:* "BBB@ HHHH **** "BBB@ HHHH **** #O6N.@K([
MUKCH*0PHHHH **** "BBB@ HHHH S]0MHVN(;D@^8@*CGL:@HU*YD75;6V!'
MEO&S$8[BBF(**** "BBB@ HHHH \S^.W_).3_P!?D7]:^8Z^G/CM_P DY/\
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M)(TQE5$;@G\R*IZ]H/B/P]\1XO&6BZ2=7AGM%M[FU1]KH0@7C_OE3^=>JT4
M>,67@[Q+J-GXV\0ZEIOV74-:M&AM=/5@7YQU_(#GWKGM;^$^NCP7H]SI5A,N
MHO#Y.IV*D N0Y*/UP>V?P]Z^B** *>DPR6^BZ?!*I62.UB1U/9@@!'YU<HHH
M **** "BBB@ HHHH *\\^,>@:KXB\*6EKI%E)=W$=ZLC1IC(4*PSS]17H=%
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M\J3^XWY4>5)_<;\J &44_P J3^XWY4>5)_<;\J &44_RI/[C?E1Y4G]QORH
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M5@@KR&;2-4N/#VI3ZA!*TFD26^EVXV'A0[DX]N/UKZO\J3^XWY4>7)_<;\J
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MQ'DON  ZU:\J3^XWY5!.;B*6!4MV<2/M8X^Z/6@"2BG^5)_<;\J/*D_N-^5
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M/9I=I_6@#IN]:XZ"N+3QMX6==Z^(=-*^OVA:[-2&4$'((R#2&+1110 4444
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M^\/RH^U3?WA^50T4 3?:IO[P_*C[5-_>'Y5#10!-]JF_O#\J/M4W]X?E4-%
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M\*_ UP"/^$=@CSWCD<'^==A13$<'_P *:\#>:'&E2@@@X%R^/YUZBBA(U5>
MH %97>M<=!2&%%%% !1110 4444 %%%% &5J-HSZA;W>\!8T9-N.3FFU)J-V
M$O8+3829%9]W88J.F(**** "BBB@ HHHH **** "BBB@ I&941G=@JJ,DGH!
M2UQ7CS7?L]N-)MW_ 'LHS,0?NKV'X_RH Y[5/%ES-XE&HVFTQV^4MUD&1M/!
M)'J?\*G_ .%A:U_SSL_^_1_^*KE**8'5_P#"PM:_YYV?_?H__%4?\+"UK_GG
M9_\ ?H__ !5<I10!U?\ PL+6O^>=G_WZ/_Q5'_"PM:_YYV?_ 'Z/_P 57*44
M =7_ ,+"UK_GG9_]^C_\51_PL+6O^>=G_P!^C_\ %5RE% '5_P#"PM:_YYV?
M_?H__%4?\+"UK_GG9_\ ?H__ !5<I10!U?\ PL+6O^>=G_WZ/_Q5'_"PM:_Y
MYV?_ 'Z/_P 57*44 =7_ ,+"UK_GG9_]^C_\51_PL+6O^>=G_P!^C_\ %5RE
M% '5_P#"PM:_YYV?_?H__%4?\+"UK_GG9_\ ?H__ !5<I10!U?\ PL+6O^>=
MG_WZ/_Q5'_"PM:_YYV?_ 'Z/_P 57*44 =7_ ,+"UK_GG9_]^C_\51_PL+6O
M^>=G_P!^C_\ %5RE% '5_P#"PM:_YYV?_?H__%4?\+"UK_GG9_\ ?H__ !5<
ML4=5#,C!6Z$C /TIRP3.NY89&4]PA(H Z?\ X6%K7_/.S_[]'_XJC_A86M?\
M\[/_ +]'_P"*KE*E%M<$9%O,0?\ IF: .F_X6%K7_/.S_P"_1_\ BJ/^%A:U
M_P \[/\ []'_ .*KEUAE:0QK%(7'50I)'X4AC<2>64;?TV[3G\J .I_X6%K7
M_/.S_P"_1_\ BJ/^%A:U_P \[/\ []'_ .*KE_*E\SR_+??_ '=IS^5((I#)
MY8C??_=VG/Y4 =3_ ,+"UK_GG9_]^C_\51_PL+6O^>=G_P!^C_\ %5RSQR1O
MLDC=&_NLI!IS6\Z@EH)0!U)0B@#I_P#A86M?\\[/_OT?_BJ/^%A:U_SSL_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ [UKCH*R.]:XZ"D,**** "BBB@
MHHHH **** ,G4K61]3MKH$>6B,I]<FDJ;4+I$NH+4@[W!8'M@5#3$%%%% !1
M110 4444 %%%% !1110 5!>V<.H64MI<+NBE7:W^-3T4 >*7VCW=CJTNG>4\
MDRGY0BY+KU!'X4W^QM3_ .@?=?\ ?HUZ_<Z7%/JMGJ(^6>VW#/\ >4@C'Y\U
M?R?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P!
M^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!
M]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4
MT >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[
M]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_W
MZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(
M_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^
MQM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W
M9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C
M:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_
M .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:
M,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T
M#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?
M=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_ +]&C^QM3_Z!]U_WZ->W9/J:,GU-
M 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\ ?HU[=D^IHR?4T >(_P!C:G_T#[K_
M +]&C^QM3_Z!]U_WZ->W9/J:,GU- 'B/]C:G_P! ^Z_[]&C^QM3_ .@?=?\
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M_L+5/^@\_P#X"I1S/L'L8?SK\?\ (L457_L+5/\ H//_ . J4?V%JG_0>?\
M\!4HYGV#V,/YU^/^18HJO_86J?\ 0>?_ ,!4H_L+5/\ H//_ . J4<S[![&'
M\Z_'_(L457_L+5/^@\__ ("I1_86J?\ 0>?_ ,!4HYGV#V,/YU^/^18HJO\
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M^PM4_P"@\_\ X"I1S/L'L8?SK\?\BQ15?^PM4_Z#S_\ @*E']A:I_P!!Y_\
MP%2CF?8/8P_G7X_Y%BBJ_P#86J?]!Y__  %2C^PM4_Z#S_\ @*E',^P>QA_.
MOQ_R+%%5_P"PM4_Z#S_^ J52T^PU6]>]5M;9?L]PT(Q:IR  <_K1S^12P\6F
MU-:>O^1JT57_ +"U3_H//_X"I1_86J?]!Y__  %2CF?8GV,/YU^/^18HJO\
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M -F:G_T''_\  5*:=.U0?\QQ_P#P%2CF?8/90_G7X_Y&E166=/U3_H-O_P"
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M1.1PK=SC?^?M78^(8-0U'XU>)KC1+'3-3DCTX7(AOH?-22/RXON#NW(Q[9H
M]R/C[PH(+2?^WK(PW;F."0295V&,KGL>1P?6KUSXET6TUR#19]1A34[@ Q6N
M<NP.><#Z&O$O '@_0?$_P7UB#[49+QIWN7!0*;.9%^4*,]"!U[@^U:_P%T@:
MG;7OC+4[A[S59'^QQR2\F.-%4<'U(P/H/<T >UT444 %%%% !6#XT_Y%&_\
MHG_H:UO5@^-/^11O_HG_ *&M14^!G3@_]XI^J_,W4^XOTID\\5M;RW$SA(HD
M+NYZ*H&2?RIZ?<7Z5E^)O^14UC_KQF_] -6<S,NT^)/@R^NHK6W\1V#S2L%1
M?,QN)Z#FI-3^('A/1M1FT_4==M+:[A($D4C'<N0",\>A%?._@[P%X@\;>%--
MBLM.TNWT^.]=WU0L!<<=5..2!V%:WB&QU2;XR^+SI.GZ=J,]K9+(T&H0^;O1
M8H@=@_O_ /UZ />9/&OAJ+1$UIM:L_[->3REN1)E-_\ =X[\=*9I'COPOKVH
M+8:7K=K=W3*66*-B20.3VKYRN+?38OV>C-97C37$^LHUW$R[?(?8X"@9/&,'
M/?/M7;?#R>'3M3%S;:YH&M7JV$AM]-L+)(+AY H.WS H[ @T >TZQK>F>'[
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MQ:59)82V&][=85$;G$W)7&">!^0J[K=K!9?M(^$K:TAC@@BL&6..-0JJ-D_
M Z4 >CZK\0/">B:B=/U+7K.WNQPT3-DI_O8^[^-=!!/%<P1SP2I+%(H9'1@5
M8'H01U%?.'@VY\(:;%XUB\>0PMJOVF0M'<IF:1>>(R>C%O3'4&O<? L^E7/@
MO39=#L[BSTQHS]G@N,[U7)]2>,YQSTH Z*LC0O\ 7:O_ -?[_P#H*UKUD:%_
MKM7_ .O]_P#T%:E[HWI_PI_+\S7HHHJC *I:KJ^GZ'I\E_J=U':VD9 :60X
MR<#]:NUYU\<?^24ZG_OP_P#HQ: .ETCQSX7UZ]%EI>N6=U=$%A$DGS$#K@'K
M5)OB?X(25HG\2V"NK;2"Y&#^5>6> _A]K^J:_P"%O$=UI^F:7IMA;(ZR6A'F
M77&06 _B.>2<<9KSNWM-3_X1'Q/?6^G:;<Z>M]Y5U-+;^9<VX8G#(>PZ=^IH
M ^K=1\4Z#I.E1:I?ZM:06,P!BF:0%9,C(VX^]QZ4W2/%N@:]93WFEZM;74%N
MI:9D;F,8SEAU'0]J\!O;?1-,UWX<R7US]M\))9';<3I^[,A9V?>.0"&*Y'8
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M2Y+\_<4=?^ %371Z9+H=[^T%I,W@E8?L*VC?;6LTVQ?=;/;']S\: /?J***
M"LC6#B_T@GO<[1]=I/\ 0UKUD:T,WVC@=KS<?IL8?U%)MI:%TXQE*TMO^ S7
MHHHID!1110 453@U;3;F\>SM]0M);I,[X8YE9UQP<J#D8J.+7=(G\[RM5L9/
M(4O+LN$/EJ.I;G@?6@#0HJBVMZ4MO!<-J=D(;@E89#.NV0@X(4YP3GTJQ=7=
MM8V[7%W<16\"XW22N$49.!DGCK0!-15&SUK2M1E,5EJ5G<R 9*PSJY ^@-7J
M "BJ=KJ^FWMR]O::A:3SQYWQ13*S+@X.0#D<\5#-XBT2VG>"?6-/BF0[6C>Y
M164^A!.10!I44B.KH'1@RD9!!R"*6@ HHHH Q[/_ )&K5?\ KA;_ /L];%8]
MG_R-6J_]<+?_ -GK8J8[&^(^)>B_(****HP"LK7/$VB^&HH9=9U&&R29BL;2
MG&XCKBM6O(?CAIZ:M>>#M.D'R76HF$_\""C^M 'H&I>-?#6CQ6<FH:S:VZ7L
M?FVY=O\ 6IQR/;D4NM^,O#GAM83J^KVUH9EW1J[99AZA1DX]Z^5[\WNN>'IY
MK]6'_"-0V^F1Y_O&9_\ V52/P%>B13:+I_QUU.;QJ(!:2:?&;![Q-T6-D>,9
MXZ!Q]<]Z /:5\5Z"^@/KJ:M:OI:??NE?**<@8..AR1Q[U5TOQ[X4UJ]2RT[7
MK&XN7^Y$LF&;Z ]:^?K%4?P+\3[C3%*Z ]Q$+0 83/G#[H_W<?ABH-4F\/7?
MACP';^'%@;Q2DT0G^R1XD!X^^0.3NQ^M 'T'??$7P?IE]-97OB"S@N8'*2QN
MQRK#J#Q4EUX^\*V5C9WMSKEI%;7JLUO(S'$@4X)''8U\]:C'%)\6?%HFUO2-
M*Q<M\^I6JSJYW=%# X-:_CR$7G_"N+;3KK3+]GWQ),L.VUE?S%!R@'"[LY %
M 'O&B>+?#_B1Y$T?5[6]>(9=(GRRCUQUQ3$\8^'9-?.A)J]LVJ!RAM0WS[@,
MD?7%>)?#ZXMM#\>>+-7U];;3=8TRTDSIUK"(H610-S+SST7C_:S]//K?5KJT
M%KXM_LW4?[475C>O?M$?(>,GE-W<[@1^)H ^G9OB;X*MYY()O$=DDL;%'4L<
M@@X(Z5-+\0_",%A;WTNOV:VMRSK#*6.'*XW8X[9%>4?$S3]"F\4^ KO3M.LT
MMM3N5EE\N%0)E9T/S8Z]3U]:3XZZ=8Z9?>$+2QCL].MA-,?]2/*C)9,LRXP1
MW/% 'LFA^+O#_B26:+1M5M[UX5#2+$2=H/0FMJO+OA*+.*[U2./Q!H>JSLD;
M :99K 8U!;.[:HR"2OY5UM]X@UNV\66^E6_A>XN=-DV>9J:W"A(\YSE<9./K
M0!TAI*4TE !24M)0 4E+24 (:*#10 &D-*:0T"$--IQIM Q*::=330 AIM.-
M-H ::8:>:8:!#324II*8!1110 4444 %%%% &C:_\>R?C_.IJAM?^/9/Q_G4
MU(96;4;)'9'O+=64X(,J@@_G2?VG8?\ /];?]_5_QKBM1TZ]?4[MTL[AE:9R
M"(F((R?:JW]F7_\ SXW/_?IO\*^7J9[BXS<51V;_ )N[\CV8Y=1<4W4_+_,]
M&DD2*-I)'5$0%F9C@ #J2:AM;^SO@QM+N"X"\,89 ^/KBJ7B".WFTP17-U]F
M5IH]DA3>H<,"NX="N0.N!6!KEQ>69O3=)!]N-E*8+RR=T98P5X="3CD\')]*
M^H/&.THKD+RUDM]1U"V&H7Y2+3/M*_Z4X(ERPW9S_L_=Z>W2J.J:G<3Z1<W]
MO-=B:"*,23M>&&..3:AVI&OWR=W.X8]#VH Z^YCTK4)$ANDLKEU=D1)0KD,!
ME@ >^,$CTJR)H$F6V$D:R[-RQ;@&VCC('I7)VG_(S1?]A6Y_])Q4NN[HO%$5
MX@)>SL3<8!ZJ) ''_?!:@#J?.B\\0>:GG%=XCW#=MSC..N,]Z)9HH(C)-(D<
M:]6=@ /Q-<-<7LZ:E>ZQ;,#)-8SO"X7.V-9(T5L?0%_QJ77<V:36=M=3W%M+
M9+*XFG:7!$J!7!8G[V3P..* .WHKC5FU.Z>\O%N88'@O6CWS7[HD:A@H0Q;=
MAR.Y.26SGI5JT)N-.;4KC4;B&]:>5#'YY";@641",G&< =MV1G- '3.Z1QM)
M(RHB@EF8X  [DTJLKHKHP96&00<@BN*O+Z671]&7[4[F;2YVF'F$[R(1RWJ<
MYZ]\TVWEU&\BNC'.EO\ 8XH1$TE\\*PCRPP=D"%7!.?O=AB@#N**C@9G@C9R
MA9E!)C.5)QV]JDH HWG^O7_=_K5X=!5&\_UZ_P"[_6KPZ"@ HHHH **** "B
MBB@ HHHH QM3@E;6+2<+F-8W4MZ$U%HO_(>UGZ0?^@&M"_GB66* N!*V6"^H
M%9^B_P#(>UGZ0?\ H!J9=#:E\,_3]4;U%%%48C7=(UW.RJ/5CBD26.3/ER(^
M.NULXKS3X]DK\+K@@D'[5#T^M>>_#GP_J?\ PG>D:GHVB:MI>DQV7^GRWC-L
MN"4.2N>H)*D#GUXH ^@KZWTO5K8V=]':W4#$$Q2[7!(Z<&IU^RV<,=NIBAB1
M J1Y"@*.  /2OC&"&V'A6^NKC1[J2:2]^SP:H+HI# W!VLH!SQD__JKN/'FC
MW[>(? ND3LFLW;:2B,/M)1+CYG(_>9'&,<]\4 ?0\&D:!:V%Q9P65A'9W+'S
MHE10DA(_B'0GBFQ^'?#UE):S1Z780O;$_9W$2KY>3D[?3DD\5Y OP\GF^%'B
M*U;1$TS4$E6[@BBOOM.\QKG.<G!(+KCZ5E6&KM\3]>^'^C;S)'I]K]IU$#^\
MAVG/UV+_ -]T >Y2Z'X<DBN()M/TYDN)?.G1HTP\G]YAW/)YI]QH6@7DLLEQ
MIUC+)=*J2,\:DRJN, ^H&!^5?-<F@W?B#XD^+8[?0XM6\F\<E)+\VPCRYY'(
MSFMCXAZ-J,.H^ -)TB/[%J*69\F)+C?Y<H;=M#YY^;@&@#Z"N=*T>XTY-+N;
M.SDLXU7;;2(I10O3Y>P%1VNFZ#97IO;6VL8;HQB(S(%#;!@!<^G X]A7@OA7
M5D^(?Q>QJ=O)$UQHSV=]#DH1(J[7QZ>OM267P[\/3?'74?"KPW!TF"R$R1_:
M&W!MD9SNSGJQH ]]LM'T6PEN!8V5G ]R,SB%%4R#G[P'7J?SI]A9Z3HL:V%A
M#:6:L2P@B"IDGOM%>.6RG2?C_JT5DK$6>A%8$))^Y$FT>_05RFB>'-(\2?"W
MQ#XQUC4)Y/$,4DLBS-<$&-E *C&>Y./Y=* /IQI$1@K.JEN@)QFCS$$@0NN\
M\A<\U\O^)[C6O$_A3X;EIY!JUSYT4<SN0S,L@5&)]2 IS6QX0\3W?BCXXZ!-
MJ$#P:C:V$EI>QL,?OD63)Q[Y!^M 'T51110 5@^-/^11O_HG_H:UO5@^-/\
MD4;_ .B?^AK45/@9TX/_ 'BGZK\S=3[B_2H;J2U6$Q7<D*QR@H5E8 ,#U'/6
MID^XOTKQ?XK6'ABV\0276H"\UOQ!J%M]GT_2!)\D)/ D& "HR">2<DG\+.9G
MKMC8Z=H]JEK8V]O9P%B5BB4(I)ZX ID>F:7;ZM+?QVEK'J$Z[9)@@$CCC@GJ
M>@_*OG;QQX>UG3? _@+0[J]#ZFUS*BN)=PB9BNU-P_NY S5GP_XFO_$/QF\*
M1ZM#)#JVG0R65ZK<;I$$GS?B,9]Z /<1X:\+LDMN-*TPI/('DC$28=QG!([G
MD_G4EIX;\-Z/>)=6FEZ=:7*@[)$B5& /!P:^;M$\,Z/JWA3QOK-_<20:AIUP
M[6DJSE<'DXQWR>*->O+WQ%8?#A]2MKC49IXI(7@64I)<J)0H&X]"0!S0!].Z
MA::9JMBT&H0VMU:L>5F"LA/X]ZBTS1M%\/V[)IMC9V,4ARWDHJ!OJ>]>!?#+
MPI9>+[[Q9:#S-/TAXA --DN#)-!+GY9#D#E2K<^Y'K1X,T+6?&'BZ'PGXBO%
MFTOPB[JZ*3^_(?"J?4<8_P!T8[T ?02Z7ID&HR:LMI;)>R)M>Z" .R\<%O3@
M?E43:5HMY<W4[6=G-/<Q>5</L5FDC_NMZBN<^+?R?"K7@O $"XQQCYUKQ#P#
MX?U6\\1>$;_P_HNK60B82:CJ$S-Y$Z[N2N>,%01COGI0!]'QZ5H-O/;21V=A
M'+:(8H"%4&)3U5?0<GBI['3M+T.W,%C;6MC"[;BD2A 3ZX]>E?*.KQ6IU_QW
M=WFB7FH)!>.L=Q#<F-;1VDD"LX .X$@?E[UK^*].O8/AS\/K6>[34I+B>9H]
MLQVE79=L>_MUQ[<^E 'TKJ%GI&L6XBU&&SNX48.%F"N%/8\U8NK>RN;%H+N*
M"6T==I24 HP[<'BO%?#OPWFN/#WB?3[GP]#I,]W:!+=H]2^T[G5MR\;CC#!?
MS-<G!K%QXX\-^!_ 8D<74=X\=\,\I%&<*3_P M_WR* /H?2]%\/: TG]EV-A
M9-)]\PHJ%OJ:1M \.M:F%M-T\P2S^>4,:[6E_O>[>]?/'B?0YM7^-FOZ?9Z1
M'J2PPHRVSWAME10D0!#9&<9 Q[^U7OB%H=Q8^!O!&D0VJZ;=27TRB%+HRB-W
M88^?)SR<^U 'O5WX=\/W<TYN]+L)9;DJTOF1*3(5'!.>N*DO;#0]2LXK.]M[
M&XMHB#'%*%95(&!@'IP<5\_:3K][XG^+_A2QUN&2+4["WFTZ_4\;W"RC=^((
M_&I=7^'?AZS^->C^&(8;@:7<VOF2QFX8L6P_\6<C[HH ]_.F:/)J5O?&UM&O
MHH]D,VU3(J<\*>N.3^9HN;'1_P"UK?4+FWL_[00;(9Y OF <C"D\]S^=>/WV
MFV^A_M"^#M*L0Z6EKI0CB5F+$*//ZD]:Y[PMH.F>/[3QEKOBR\F_M2VE?RPT
MY3[, I(('H",8Z?+0![SJGAGP[J=VEYJFDZ?/<# $L\2ECZ<GK6J##"$A4I&
M,81!@<#L!7ROJ^I:GKGP3\-+>7$CS)K+VT,TC')0(<9/?!)'X5J6GB'4]3^)
MO@C2=;CD36-%N6L[IFZ2<C:WOD?GU[T ?3%9&A?Z[5_^O]__ $%:UZR-"_UV
MK_\ 7^__ *"M2]T;T_X4_E^9KT4451@%5KZPL]3M'M;ZVBN;=\;HI4#*<<C@
MU9HH C@@BM;>.""-8H8U"HB# 4#H *I6^@:1:6MS:V^F6D4%UGSXTB 67/!W
M#O6C10!E'PSH;:4=+.DV1L-Q;[.85V!CW [&I=/T'2=)LY+/3].M;6WDSOCB
MB"A\\<XZUH44 8MMX0\-V=PD]OH6G12H<JZVR@J?4<5=?2=-?4UU1[*W-\B[
M5N3&-ZKZ;NN*NU2UG_D!ZA_U[2?^@F@"&WTG1(KRZOK>RLEN)P1<3(BYD!Y.
MX]\^]0:;X9\-Z?>M?:;I.GP7)SF:")0PS[CI7RSX?U.]\/>&;NSA,C_\)18"
M&#!/$JW!C('_  '=^=:!N-0\._"[Q%IMG<RHA\0_8IYE)!\M4/&?0E1_*@#Z
M;_LG0;^6]D^QV-Q)= )=,$5C(!T#^O0=:JZCI?AZ#3Y;M]&ANQ:6IA6*VM1+
M)Y8'^J10,G/3'2N$T?P7X+\(>+/#]SIWB*>QO;F'"6OG[UOLX'.<CG/3C)Z=
M*RO@[/>P2^/9K&U6\NX[TM%;O-Y0D(+_ "[R#MSZD8^G6@#T?P]=:'KVE7VC
MQ:*UG!92_9[G3KF&,!"0''",R'.X'@]>N*NR^#O#<ZQ"70M/<1((XPUNIVJ.
M<#C@<FL[P?INI6FI:[>7-F^FV%[/&]IIKNC& A/WCXC9D&]R6P#[GDFNLH I
MZ=I6GZ1;FWTZR@M(6;<4A0("?7 I-/T?3=*,QT^QM[4SMOE\F,+O/J<=35VB
M@#$/@_PV;;[.="T\P>9YGE_9UV[\8W8QUQQ5S3=$TO1U==-TZUM _P![R(E3
M=]<=:OT4 %%%% !61K!Q?Z23WN=H^NTG^AK7K(UKF]T8#M>9/TV./ZBDW9:%
MTXJ4K2>G_ 9KT444R HHHH ^4C?S^%/&^M^+K?<1!K%U92*OI(C[3^!&?PJ3
MPII;Z3:^,H)L^=)X5^T29_O2!'_]F%?0EQ\/_"UU:WMM/I$+PWUP+JX4LWSR
MC/S=>#R>GK5B3P;X?ENK^Y?38S+?VPM+EMS#S(@ -O7@8 Z>E 'SOJC+'\)?
MAH[L%5;^X)). !YYKU/XPZWI6J_"?7(]/U*TNW0V[,L$RN5'GIR<&NKN?AYX
M5O-&LM(N-'B>PL2[6\)=L1ECEL<YY)J"W^&'@RUL[NTAT.%(+M52= [_ #A6
M# =?4 T >%ZE9:'HEK\/-2\,21)XAG:$W*6TV]G)"YW+DX))(QQG)KZ#\;:^
MOACP9JFKE@)((&\K/>0\(/S(JMH_PZ\(Z#?I?:;H=M#=)]R4Y8I[C<3@^]:V
MN:!IGB33CI^KVHN;4N',;,0"1TZ$4 ?*WP]\0Z=X;\9^&]1ANYFN+DR0:J)%
M(4>8Y"D'OP5)]Q76P:3X8U;XJ^/T\3&W6")7>%YIO+*OD<KR,GVYKW+5?!WA
M[6M,MM.U#2X9K2V(,,?*[,# P0<]*S;[X7^#-3OY;Z]T.&:YF;=)(SOECZGF
M@#F/V?[F[G^'LD=PSO;PWDD=LS_W, X'MDFO5:K6&GV>EV,5E86T5M:PKMCB
MB4*JCZ59H **** ,>S_Y&K5?^N%O_P"SUL5CV?\ R-6J_P#7"W_]GK8J8[&^
M(^)>B_(****HP"JMWIEC?RV\MW:0SR6S^9"TB!C&WJN>AJU2.P1&9F"J!DD]
MJ ,>30_#C&>SDT_3B;J03S0M&N97'(8CN>O-/U?1=!U=(X=7L;&Y$8^1;A%)
M4>V>E?,FKZ-<:6-0U?4(8=>T[^T!(VNZ7J(\^)L_<)^;&<@X*]>]:_C^,^)_
MB;H(L;-M22\T:"6."XN?(,@PYRSY&#W^M 'T,-,T/^R?[+6TL?[/;Y?LP5?+
M/.<;>G7%,LO#WA_1[E9[+2]/M)SPKQPJC?@<9KQ76O EQ!\&[R>/2ETO4M.O
MC?)%#>&X^0*JL=V3CCG'^S[U9T?5/^%G_%?PY=JQ:RT?38[J< \"X/)'UW[?
M^^: /6;KPUX4O+J6YNM*TJ6>1BTDDD2%F/J2:G.A>'HELU.GZ>HM/FM08U'E
M9.<KZ<\\5\O^'O#5YX@U#7)(/#T.K"*\=2\NI?9O+R3QC<,UTGQ'TZ,_$[P[
MISZ1<:A!'H<2MI]M<%78+YIP'[XQGWQ0![[>^'O#^I3M?7NF6%Q*R[6GDB5B
M5Z8)]*D_L[1)=+72?LMD]CC:MKM4IUSC;TZU\X>'+>1OA/X^U*UN3%ILIC2'
M3S.9'@(D!RV0.<$#/?'M6G\+O"-U)J'A[5YO#4(M]PF_M#^U#NXSAO*W>N!C
M% 'OK^']'D6S5],M&%EC[*#$#Y./[OIT'2FW^D:+KQC^WV5G?&+.SS4639GK
MCTZ5D_$;Q#_PB_@/5=25PLXB,4'KYC_*N/IG/X5X-\(];L?#OQ T>"WU(W,6
ML68AO%(8>3<$DJO(YY"\C^^: /HS3=&T#1YW;3+&PM)I!L<P(J,PST./>M:O
MF'2?"^C>(M1^)5WJ]Q)#-IL\LEI*)]FQMTQZ=#RJ\5Z[\%M5O]7^&=C-J$CR
MRQ220I+(26=%;C)/7'3\* /0324II* "DI:2@ I*6DH 0T4&B@ -(:4TAH$(
M:;3C3:!B4TTZFF@!#3:<:;0 TTPT\TPT"&FDI324P"BBB@ HHHH **** -&U
M_P"/9/Q_G4U0VO\ Q[)^/\ZFI#"BN)OO&&H6VH7-ND-J4BE9%+*V< D<_-4'
M_";ZE_SPM/\ OAO_ (JN9XJFG8[UEM=I-)?>=W)&DT;QR(KQN"K*PR&!Z@CT
MJM%I6G00RPPV%K'%*,2(D*@./< <U'J^H-IED)TA$SM*D2HS[!EF"\G!]?2H
M&U:XM;E8-0M(H3*C-#)%,9$8J"S*QV@@X&>A[^E=)P&BUM \CR/#&SNGELQ0
M$LG]TGN.3Q[U ^DZ;)()'T^T9PFS<T*D[<8QG'3'&/2JI\1:?%;I+-*W^I2:
M0PQ22+&K#()(7@?[P'TI]UXATNR9A-=<(JL[)&SJH;[N64$ GL"<GCU% %Q+
M*UC=72VA5E8N&6, AB,$_7''TI[6\#RF5X8VD*&,L5!)4]5SZ>U4&U_3$N7M
MVN&#QRB)SY3[4<] 6Q@9SW-2?VS8?;/LOGGS/,\K=Y;;/,QG9OQMW>V<T 6D
MM;>)HVC@B0QIY:%4 VIQ\H]!P./:H8M+T^"%X8K"UCBD(+HD*A6QTR,<U4E\
M1:>D4S1O)(R([H!$X$NSKL;;AOPSZ]*;;>(;6:!9YBMO&;1;E_,W!E!)'0J,
MC(X.<GL,$$@%]]/LI+L7;V=NURN,3&)2XQ_M8S2BPLQ>&\%I +H\&;RQO/&/
MO=>G%-L]0MK[S1 S[XB Z21M&RY&1E6 .#ZXJU0!332=-C9F33[16?.XK"H)
MR,'/'<$TZ73+"=XGFL;:1X@!&SQ*2@'0#(XJU10 4444 4;S_7K_ +O]:O#H
M*HWG^O7_ '?ZU>'04 %%%% !1110 4444 %%%% &+J<,AUJTE"$QK&X+=@:C
MT7_D/:S](/\ T UHW\L8>.(N!(V2%[D5AQS:AIVKWT\&G?:HK@1;6$ZI@JN#
MP:F70WH*ZG&^Z].J.IHK _MS5/\ H!'_ ,"TH_MS5/\ H!'_ ,"THYD'U>?=
M?^!+_,G\3>&=-\6Z,^E:M'(]JSJY$;E3D=.16A:64-EI\-C""((8EB0$Y.T#
M Y^E9']N:I_T C_X%I1_;FJ?] (_^!:4<R#ZO/NO_ E_F9UI\,O#%GX:O_#\
M=I(VGWTGFS))*6._C!![$8%4;[X/>$]1M[""ZCO9%L(?(MR;ILJFXMC/L2<5
MO_VYJG_0"/\ X%I1_;FJ?] (_P#@6E',@^KS[K_P)?YD7A7P-HO@V.[CTF.<
M+=%3*)IC)G;G'7ZFHO#'P]\.^$-2O+_2+5XKBZ7;(6D+ +G.%'89Q^0JU_;F
MJ?\ 0"/_ (%I1_;FJ?\ 0"/_ (%I1S(/J\^Z_P# E_F<]J/P9\'ZIJEUJ-Q!
M>?:;J0RRE+IE!8G)X%:<'PX\/6]QH<Z0W'F:("+,M,3MRQ8[O7DU>_MS5/\
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M/TI=)^'?AS1/%-UXCL;1TU&Y+EV,A*@N<MM7H*M_VYJG_0"/_@6E']N:I_T
MC_X%I1S(/J\^Z_\  E_F8FN?"/PIXAUNYUB_@NC>7)!D:.Y9 <  <#V J=?A
M=X973=+L/)N3!IERUU;9G8D2$@G)[C('%:G]N:I_T C_ .!:4?VYJG_0"/\
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MB!$+W,QD\H'CY0>G%:_ASP=I'A6?4)M+BE1]0E\Z??(6RW)XSTZFC^W-4_Z
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M"TI/[8U3_H!-_P"!:4<R#ZO/NO\ P)?YFV:;6-_;&J?] )O_  +2D_M?5/\
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MZU>'050NV5IE*D$;>QJ^.@H **** "BBB@ HHHH **** ,S4M*DO;J&XBNC
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M_<_\BK=Z5/+(#;WS0*!@KL#9-.M-,EA#_:+MIR>AVA<58_M.P_Y_K;_OZO\
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M3L/^?ZV_[^K_ (T?VG8?\_UM_P!_5_QH^L4OYU]Z_P P]E/^5_<_\A?L4?\
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M/L4?]YOSI/[3L/\ G^MO^_J_XT?VG8?\_P!;?]_5_P :/K%+^=?>O\P]E/\
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M\_UM_P!_5_QH^L4OYU]Z_P P]E/^5_<_\A?L4?\ >;\Z/L4?]YOSI/[3L/\
MG^MO^_J_XT?VG8?\_P!;?]_5_P :/K%+^=?>O\P]E/\ E?W/_(7[%'_>;\Z/
ML4?]YOSI/[3L/^?ZV_[^K_C0-2L"0!>VQ)[>:O\ C1]8I?SK[U_F'LI_RO[G
M_D+]BC_O-^='V*/^\WYU9HK4@K?8H_[S?G5FBB@ HHHH **** "BBB@ HHHH
M \WU/_D*WG_7=_\ T(U5JUJ?_(5O/^N[_P#H1JK7Y=B/XT_5_FS[&E\$?1?D
M@HHHK(L**** "BBB@ HHHH **** +>GZA/IUR)H3[,IZ,/0UWMA?P:C;":%O
M9E/53Z&O-ZMZ?J$^G7(FA/LRGHP]#7L95FLL'+DGK!_AYK]5^IPXW!*NN:/Q
M?F>CD @@C(-8&I::8"9H1F(]1_=_^M6K87\&HVPFA;V93U4^AJT0""",@U]G
M5I4L7233O?9G@0G.A.S^:.-HK3U+33 3-",Q'J/[O_UJS*^;K49T9\DSU:=2
M,X\T22&9X)1)&V&%=)97J7D61PX^\OI7+U)#,\$HDC;#"NC!XR6'EWBS.O05
M5>9UU5YH?XE'U%-LKU+R+(X<?>7TJU7T2<*T+K5,\KWH2LS/HJQ-#_$H^HJO
M7).#B[,VC)-70H)!R.M6XI1(,'[U4Z4$@Y'6JIU'!A*/,7Z*CBE$@P?O5)7;
M&2DKHYVK:,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXIYK>>W3RTFB*[BF.5.001P#R.HXJ-M#0M;RK?7BW$._$Y=6=@V,@[E(QP.
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MY>)!=26L4Q0L]HT3Q2QGMC<2)!@')&/6KEW>W+:I%IUF84D,1GDEF0N H.T
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MKTK1N;4V)L#I<0BNKC3I]QC&&D8(A4G'5LD\]<F@#J9[Z*WO;6T=7,ESOV$
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M%% !1110 4444 %9EQHJ73R":\NVMI)!(UL7!0D8XR1N R,X!Q6G10 4444
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M //:V_[Z;_XFC_A$;_\ Y[6W_?3?_$T?V3CO^?3_ *^8?7</_.OZ^1@45O\
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M0Y/W:5H'12VTOC^%",G\\"@74P&!IUSC_>C_ /BZ<8J+]_\ )_HF#;:]TM
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M^@?<_P#?4?\ \71]KF_Z!]S_ -]1_P#Q='MX>?W/_(/9R_IK_,M455^US?\
M0/N?^^H__BZ/M<W_ $#[G_OJ/_XNCV\//[G_ )![.7]-?YEJBJOVN;_H'W/_
M 'U'_P#%T?:YO^@?<_\ ?4?_ ,71[>'G]S_R#V<OZ:_S+5%5?M<W_0/N?^^H
M_P#XNC[7-_T#[G_OJ/\ ^+H]O#S^Y_Y![.7]-?YEJBJOVN;_ *!]S_WU'_\
M%T?:YO\ H'W/_?4?_P 71[>'G]S_ ,@]G+^FO\RU157[7-_T#[G_ +ZC_P#B
MZ/M<W_0/N?\ OJ/_ .+H]O#S^Y_Y![.7]-?YEJBJOVN;_H'W/_?4?_Q='VN;
M_H'W/_?4?_Q='MX>?W/_ "#V<OZ:_P RU157[7-_T#[G_OJ/_P"+H^US?] ^
MY_[ZC_\ BZ/;P\_N?^0>SE_37^9:HJK]KF_Z!]S_ -]1_P#Q='VN;_H'W/\
MWU'_ /%T>WAY_<_\@]G+^FO\RU157[7-_P! ^Y_[ZC_^+H^US?\ 0/N?^^H_
M_BZ/;P\_N?\ D'LY?TU_F6J*J_:YO^@?<_\ ?4?_ ,71]KF_Z!]S_P!]1_\
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MU'_\71]KF_Z!]S_WU'_\71[>'G]S_P @]G+^FO\ ,M455^US?] ^Y_[ZC_\
MBZ/M<W_0/N?^^H__ (NCV\//[G_D'LY?TU_F6J*J_:YO^@?<_P#?4?\ \71]
MKF_Z!]S_ -]1_P#Q='MX>?W/_(/9R_IK_,M455^US?\ 0/N?^^H__BZ/M<W_
M $#[G_OJ/_XNCV\//[G_ )![.7]-?YEJBJOVN;_H'W/_ 'U'_P#%T?:YO^@?
M<_\ ?4?_ ,71[>'G]S_R#V<OZ:_S+5%5?M<W_0/N?^^H_P#XNC[7-_T#[G_O
MJ/\ ^+H]O#S^Y_Y![.7]-?YEJBJOVN;_ *!]S_WU'_\ %T?:YO\ H'W/_?4?
M_P 71[>'G]S_ ,@]G+^FO\RU157[7-_T#[G_ +ZC_P#BZ/M<W_0/N?\ OJ/_
M .+H]O#S^Y_Y![.7]-?YEJBJOVN;_H'W/_?4?_Q='VN;_H'W/_?4?_Q='MX>
M?W/_ "#V<OZ:_P RU157[7-_T#[G_OJ/_P"+H^US?] ^Y_[ZC_\ BZ/;P\_N
M?^0>SE_37^9:HJK]KF_Z!]S_ -]1_P#Q='VN;_H'W/\ WU'_ /%T>WAY_<_\
M@]G+^FO\RU157[7-_P! ^Y_[ZC_^+H^US?\ 0/N?^^H__BZ/;P\_N?\ D'LY
M?TU_F6J*J_:YO^@?<_\ ?4?_ ,71]KF_Z!]S_P!]1_\ Q='MX>?W/_(/9R_I
MK_,M455^US?] ^Y_[ZC_ /BZ/M<W_0/N?^^H_P#XNCV\//[G_D'LY?TU_F6J
M*J_:YO\ H'W/_?4?_P 71]KF_P"@?<_]]1__ !='MX>?W/\ R#V<OZ:_S+5%
M5?M<W_0/N?\ OJ/_ .+H%U,2!_9]R/?='_\ %T>WAY_<_P#(/9R_IK_,M444
M5J0%%%% !1110 4444 %%%% !5.[O'BOK.TB"^9.S,Q89 11\QZ]<E1^.>V*
MN50O+:5M2L+R)=_E%XY%&,[' YY]"J_AGZ4 5+?5+^[U74;$6\5N8(4>'S?F
M))+#+;3C' X'_P!87K/4(KK2H[]AY2&,NX8YV8^\#],&H38O:ZE>ZI%F>26!
M$6W4!22N?XB<<YJ$:+(WAI=*-R(V=<32*N<Y.7 Y'7)'XT 45\17HT/4;J6"
M%+JW1)HTP=IC< IGG.?O ^XJ[>ZZUK--;?8;A9A#+*CL8V0A 3N(5]P4D <@
M=<5!?^%;:?S!8F&P66!H95B@&'!((. 1R"/UJ2/1;Y1>K)?V\@O-XD<VK>9@
M@A1N\S&%SP,>O<DT -M/$T+6/FWD$\$JVT=P1L&) W * $GEN,'!Y%/E\0Q(
MR*T4T$JW AEAEC5F&49QR'Q@A>N3Z8](Y_#$=Q!Y,ESE?L,=I_JQU1MP;D^H
M''ZT@\,#RD7S;:)A<";%M9K$F C)C .?XB<DGVQ0 @\7VIA$HL+_ &F#[3]Q
M/]5SE_O=!CZ^@(YJY-K]K#=&+RIWB5HTDN%4>7&SXVAB3GNO(! W#-5$\,;+
M7R/MF?\ B6-I^[RO7^/K^GZTC^%HC?\ VE7ML.8S(9+1)'R@ ^1C]T$ 9X/<
MCK0!:M];-ZOVB"WECLX9'6>695Y50V2N&SPP';H?RLZ?J0U!-PM+F!2BR(95
M7#JW0@J2.W3KTXINF:8=-T][47!8M)(XD50"NYB> <CC-1:1HYTV::5I("TJ
M*A6WM_)0XR=Q7)RQSR>.@XH JWOB(QW4,-K;R-&;O[-).Z ID*2P7YLY!'<8
MX-26/B%+N.#9;7,Y:.)Y9(H@%CW],KN+>_&[ []:9)X=E:YRE\$M?M;7?E&'
M+;V!!&[=TR2>G>HX_##(EE&UW"Z6J1*LAM1YJ[#GY'SE0V.0<]3ZT 78M>MI
M+L0^5<+&[O'%.4!25T^\JX))/!QQ@[3C-1MXD@B$OVBSO+=DA68)*J[G5FVC
M&&.#D@8;&,\U7@\+1VUX\L4L"1EI&1DM5$RE\_\ +7K@$G& #T!)%16?A1[/
MS&CN[9'>U%L?+LE"L 0<N"QW$X(.>N>,4 :3:TJ)&&L+P7$LIC2V*J'8@9)!
MW;=N.^['XU9L=0CU""*>".3R9$W!V &"#@J1G.0<]L<=:QSX3C-M$I>U,D<[
MS*C6@, W  J(]W X!^]UR:T]/M9[ 06:B-K9(3N=8EC_ 'F[/"KP!R>,>G)Y
MH 9)>7<][=VUB( ;=$!:8$C>W/8] O..Y(Y%4X]:NX[>\EG$$J65T(I9(E*J
MZ8&2H).&4MSR?ND?26YTV]>[U!;2X^SK>HC?: NXHRC:1C(/*XP1TYZ<4V;2
MKH:*-+7[.T4C+'F"(Q+%'G+$AG8L3C'KD_4T /U[6)])DL3#")4EE83#!+!%
M4LQ7GJ "::OB!5NKQ67S8D>%+80C+2F1<CDG'X\#%7[JP^TW]A<^9M^R.[[=
MN=VY"N,]NN:QO^$/@6.ZC6=6CDN(YXHY8@Z1[<_(03\RX)&..* -&WUVVN;F
M"V$4R32O*A1P/W;1XW!L'W&,9!J"V\46=T04@N1']F%U)(P4+'&<\M\V?X3P
M :8GAV2#[+);75O!<0/*V8[15CPX (" C&,#!)/3G-,L?"L=M!+!-<F:.6R6
MS8!-IP-WS#D_WOTH L#Q):BWEDFMKJ!XTC=89%7?('.%V@,0<GCKP>N*@MO$
M;O/=136<WFK=>1!;HJ^8?D#')+;>.><XQBD/AF2>.1KN^$ESY44<,J0[!'Y9
MW*2N3N.[D\CT&*9+X6>Y>2>YNH)[EKCSQYMKNB^X$*E"W(P!CG(XH LR>)[-
M;9)HK>ZG!A:>18T&Z)%.UMP)'(.1@9Z&GR>([2,@^3<-$%C,LH4;8?,^[NYS
MW&< XS67J&B7EM;K#IT;/*]F]M(Z0Q)&0Q)X7>NSDGD!N#W-63X51ITF+VI9
MDB64RVBRL"@ ^1F^[D #D'\* +D/B*VFOA;?9[B-3/);B9PH0NF2P^]GH#@X
MJ)_%-G';O<26]TD0A,\3,BCSXP0"R<^X.#@X(.*5?#JB2,M<;E6]ENROE_>$
M@8;>O;=U]NE41X-C%E/:)/;(CPF&-TLD63&>"[9RQP .-N>IH TKK7A9P>?/
MIM^L:H'E8HF(P3@9.[D]\+DCOBJ?_"1S1O<^?;.B0WQMD"H&,BB(OC[_  W'
M7IR!CKA^L^&/[7N9Y6N(E$T2QCS;<2-$5).8VR-N<\\<XZCM-_8+_;3.;I=G
MVY;T)Y7.[RRA&=W0\$<<>] #W\16:KN5)I 8(IEV*#N\PX1!S]X^G3'.:N6&
MH1W\<A5)(I(I#'+%(!N1AZX)'((.03UK(C\)0)I=S9&?S#),)8WDC#! I&Q2
MN<, !@],Y/2M+2M,73K:2(BW)D<NP@MUA0=L!1GT[DF@#'O/%A0QRV\$B6C6
M\TPFEB#>8$*@% ''')X.#TZ5K)K,4EW+"MO<>5$[1O<[1Y895R0>=P],D 9[
M]*R9?",LMJMH=2 MXH);>!?(Y57(^\=WS$8 Z"KTF@>?JS7D\\+*2_W;<)*R
MLI78S@_,H!X&,\#GB@!]OX@M[A7(M;Q#Y'VB)3$"TT><90*2?3@X/(I#XBB5
MGB>RNTN5F2'[.?+W,S*6&#NVXP#W[52@\)"&QN+9;F"/S+?R$DALUC?&<DN0
M<N3@ X*@\\9Z.A\,/!'=*D]D!<O&SP_8%\DA0>-F[IR#USD=>U %V;7XH8T)
MLKQI#"T\D0C >)%."6!([]ADGMFGQZY!/>>1;V]S,@*!IXU!1=Z[ESSNQ@CG
M&!FLZ3PE&T5L%EMWDA@,!-S:B9<$[LJI/RD$D#J,<<U:?0#)J-M<&>'R[<IY
M>+95E4*,;1(,84GDC;W(&.P!IO=+#9274\;Q)&K.ZM@D 9]"1T&>M8NH:MJ5
MEH\6H,;&/,8<Q2!BTCDY$:\C!QWYR>P%:GDS7VE36]X%1YEDC;:.BDD XR><
M8/6J3Z?J5YI4=LUTEKNMS;SQ-") >VY2",9&>N>". <T 78KR3^U9;*5 ,Q"
M:(C^[T8'W![CLP].<B'Q+(MUK,=U'&$LPS0; <N%X(//)R5Z>M:%I8/%JOFE
M"L%O;+;0%B"7'!9N/HHY]#527PPDUPLK71_X_6N67R^&4[28SSZHIS[=* **
M^*+P:3'/(D NC!)(R",[,K,(^N[/0],?CV.A<^("+^WM[6WD:-KW[+).ZC9D
M*2P7G.0>Y&.#UJ!O">ZV6'[;C$,D6?*_O3"7/7MC'Z^U6/\ A'Y1>I(EZ%M5
MO#>>28<MO(Y&[/3))Z=^] %V]U5+.X%NMO<7,WEF4QP*"50'&>2,\]ADGL*A
M'B"U-X(!%.8S,L'VC:/+$A&0O7.>@Z8R<4^]TV>:_%[9W:V\_DF!B\7F#:3D
M$#(PP/KD>U5?^$><7>[[:3:FZ6\:(Q#>90/[V<8) )&W\10 ?\)3:?>^S78B
M:*6:.7:NV5(_O%?FS],@=J:_B:)H^(;BWDS RB:)6WI(VT, '_F<CT/2LRWT
M&_GE6UD62WL8+:X@A:5$W#S.!]UVW8'?Y>G3FM.X\->?)$_VO;Y<-O%CR\Y\
MIR^>O?./;WH JV_BMUMUGO;=XQON-R)&"=L;*,YW\8W<]<X.,<9U)==MXYI8
M4AGFE25846(*?-<KOPI) X7DDX JK#X:"3 RW0DA!N0$$>#MF()!.3TP><=Z
M8OA6(:1;6CS1SW$$QF\V> .DC'((9">1M..HQ@&@#0_M:*71+C48@Z"*.0LC
MIED9,Y4KD<@CID?7O5%?%=M]W[)>2$2+"72-0#(R[E4#=GGIZ#N1UJY%HXCT
M&?3!)&IFCD0O' L:@L#R$7 P,^N?>J4/AGR0!]LSB\BNO]7_ '%"[>O?'6@"
M;_A);=A;K%9WDLTYE40JJ[U:,@.&RP //K_2EG\1VT-DEZEK=S6K0B9IHT&U
M%)QSDC)]0,D52ET*_AU6TELKA !)=RO,\08)YI4A=NX$]^1Z<^E1W7@J.>W$
M"W2>6+80 S6XD=""3N0Y&TDGGC\1V - >($6\:U\B>>9KF2"-8D5<;%5CDL^
M#P>O'T]85\6VSK&R:??L)$D>,A$^<)]_'S=O?&>V:F@T PZHE\UT&*W$LY01
MXSO15QU[;<_C4</AKR8;*/[7G[-%<1Y\O[WFG.>O&/U]J )I?$EG$JN(KB2$
M11S2RHHVPH_W2V2#[X )P*/^$CM_MC6XM;K"W!M?-VKL,N,A?O9Y]<8Y&<52
M?PC$6A(EMF*P102--9K*Q"#&Y-QPI(XY##IQQ5P:!\S'[3][41??ZOV V]?;
MK^E $^@ZC-JFDQW=Q#Y4C,XP,8.&(R.3Z?GFM*J.DV#Z98"T:82JKL48)M(!
M).#R<GD\\?2KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !63KGB&T\/I"]W'.XF)"^4H.,8ZY(]
M:** ,7_A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJBB@ _X6/H__/M?
M?]\)_P#%4?\ "Q]'_P"?:^_[X3_XJBB@ _X6/H__ #[7W_?"?_%4?\+'T?\
MY]K[_OA/_BJ** #_ (6/H_\ S[7W_?"?_%4?\+'T?_GVOO\ OA/_ (JBB@ _
MX6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*HHH /^%CZ/_S[7W_?"?\
MQ5'_  L?1_\ GVOO^^$_^*HHH /^%CZ/_P ^U]_WPG_Q5'_"Q]'_ .?:^_[X
M3_XJBB@ _P"%CZ/_ ,^U]_WPG_Q5'_"Q]'_Y]K[_ +X3_P"*HHH /^%CZ/\
M\^U]_P!\)_\ %4?\+'T?_GVOO^^$_P#BJ** #_A8^C_\^U]_WPG_ ,51_P +
M'T?_ )]K[_OA/_BJ** #_A8^C_\ /M??]\)_\51_PL?1_P#GVOO^^$_^*HHH
M /\ A8^C_P#/M??]\)_\51_PL?1_^?:^_P"^$_\ BJ** #_A8^C_ //M??\
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MPL?1_P#GVOO^^$_^*HHH /\ A8^C_P#/M??]\)_\51_PL?1_^?:^_P"^$_\
MBJ** #_A8^C_ //M??\ ?"?_ !5'_"Q]'_Y]K[_OA/\ XJBB@ _X6/H__/M?
M?]\)_P#%4?\ "Q]'_P"?:^_[X3_XJBB@ _X6/H__ #[7W_?"?_%4?\+'T?\
MY]K[_OA/_BJ** #_ (6/H_\ S[7W_?"?_%4?\+'T?_GVOO\ OA/_ (JBB@ _
MX6/H_P#S[7W_ 'PG_P 51_PL?1_^?:^_[X3_ .*HHH /^%CZ/_S[7W_?"?\
MQ5'_  L?1_\ GVOO^^$_^*HHH /^%CZ/_P ^U]_WPG_Q5.;XBZ0AP;:^Z _<
M3N,_WJ** &_\+'T?_GVOO^^$_P#BJ/\ A8^C_P#/M??]\)_\5110 ?\ "Q]'
M_P"?:^_[X3_XJC_A8^C_ //M??\ ?"?_ !5%% !_PL?1_P#GVOO^^$_^*H_X
M6/H__/M??]\)_P#%444 '_"Q]'_Y]K[_ +X3_P"*H_X6/H__ #[7W_?"?_%4
M44 '_"Q]'_Y]K[_OA/\ XJC_ (6/H_\ S[7W_?"?_%444 '_  L?1_\ GVOO
M^^$_^*H_X6/H_P#S[7W_ 'PG_P 5110 ?\+'T?\ Y]K[_OA/_BJ/^%CZ/_S[
M7W_?"?\ Q5%% !_PL?1_^?:^_P"^$_\ BJ/^%CZ/_P ^U]_WPG_Q5%% !_PL
M?1_^?:^_[X3_ .*H_P"%CZ/_ ,^U]_WPG_Q5%% !_P +'T?_ )]K[_OA/_BJ
M/^%CZ/\ \^U]_P!\)_\ %444 '_"Q]'_ .?:^_[X3_XJC_A8^C_\^U]_WPG_
M ,5110 ?\+'T?_GVOO\ OA/_ (JC_A8^C_\ /M??]\)_\5110 ?\+'T?_GVO
MO^^$_P#BJ/\ A8^C_P#/M??]\)_\5110 ?\ "Q]'_P"?:^_[X3_XJC_A8^C_
M //M??\ ?"?_ !5%% !_PL?1_P#GVOO^^$_^*H_X6/H__/M??]\)_P#%444
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G &MH?B:RU^25+6*X0QC)\U0/Y$UM444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '.!'$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &7_ ,(_8^DG_?5'_"/V/I)_WU6I10!E_P#"/V/I)_WU1_PC]CZ2?]]5J44
M9?\ PC]CZ2?]]4?\(_8^DG_?5:E% &7_ ,(_8^DG_?5'_"/V/I)_WU6I10!E
M_P#"/V/I)_WU1_PC]CZ2?]]5J44 9?\ PC]CZ2?]]4?\(_8^DG_?5:E% &7_
M ,(_8^DG_?5'_"/V/I)_WU6I10!E_P#"/V/I)_WU1_PC]CZ2?]]5J44 9?\
MPC]CZ2?]]4?\(_8^DG_?5:E% &4= L1VD_[ZI?\ A'['TD_[ZK3/2EH R_\
MA'['TD_[ZH_X1^Q])/\ OJM2B@#+_P"$?L?23_OJC_A'['TD_P"^JU** ,O_
M (1^Q])/^^J/^$?L?23_ +ZK4HH R_\ A'['TD_[ZH_X1^Q])/\ OJM2B@#+
M_P"$?L?23_OJC_A'['TD_P"^JU** ,O_ (1^Q])/^^J/^$?L?23_ +ZK4HH
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MZ=;12##I$BL,]" ,T 6**** "BBB@ HHHH **** "BBB@ I/XA]*6D_B'TH
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M03P9<Z>UOBZ>3*Q[UY&Y3USCL:DO]+NI5M%ET>WOXT@5,";RI48 9!;.".O
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M.#[4 ;%%%% !1110 4444 %%%% !1110 59LO]<W^[5:K-E_KF_W: +U%%%
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M#@GN1VH T:*QM%-R-1UF*YNY+DI<IM+X 0&)&VJ!T4$G'4^I)R:V: "BBB@
MHHHH **** "BBB@ HHHH 9)]S\1_.GTR3[GXC^=/H **** "BBB@ HHHH **
M** "BJM]<75LB26UBUX,_.D<BJX'8J&PIYZY8<>O2N:\1>*HO[(6*RFN;:[G
MNH;61# RW$(<\E489)(! (!!/0G% '7T5S'A^41Z[>6?F:G;D0K)]@U&3SF'
M./,27S'RIZ%<\$=LU%X^GUFVT*2?3KF*UMX]IFE4MYS9=0%7'"CDY.<]L=Z
M.LHKA?$^J7NF>-K*>*[F2QM[19;J$,=C(TPC9BO3(#YSU^6I]:U2\?QOI%K;
MW$L=G%="&94; ED:)W*MZX7RSC_:H [.BLO5M6EL+BRL[2U%S>WC,(HWE\M
MJC+,S8)  QT!Y(KF;OQ+>ZA+;0M;R:?-:Z[!:3+'<%A("I)Y &5.>_48) Z
M [JBN77Q;*UF-6_LT#0S.(A=>?\ O=N[9YGE;<;-W^UG'..U9NG>(]3TZTUJ
M]NK-[G3;34[A9)WN3YB1B4CY$VG*J,?Q#O@<<@'=45RVM>+I-(2ZNOL,/V&W
M(7S;FZ\A[AL;B(%*GS  >#D9.0.F:P]3UB[DU34'M[VY2 WVE^4HD8!4DP6
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M 4444 95S_Q\R?7^E15+<_\ 'S)]?Z5%0 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH 9)]S\1_.GTR3[GXC^=/H **** "BBB@ HHHH
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M<J-N!\PP#G!Q@JW@_4G:1C+: O-I\F [' @ #C[O?''KWQ7<44 <3;V$%_\
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MEON]C4%6;+_7-_NT 6_+']Y_^^J/+']Y_P#OJGT4 ,\L?WG_ .^J/+']Y_\
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MWC)/S=_H*EJ.+K)_O?T%24 %%%% !1110!E7/_'S)]?Z5%4MS_Q\R?7^E14
M%%%% !1110 4444 %%%% !1110 4444 4]3LYKZR:""[>U<D'S4SD>W!%<A:
MV.IW%_J%L=<OA]CYRI=B_7H-W7BN[KFX=)O_ +=KK "$7:X@D+#D\^G(H ?%
MXFE_M"VMKO36MQ<-M3,P+C)P"R8R/Q_6I(-?NKO4[BSMM,,@MYO+DE,X4*,X
MW=/8\"L2UT+48WTUO[*BA^S3JTKB52\G()/7H,=,]ZWM$L+FTU#5I9XMB3W&
M^,[@=RY/ITZ]Z *S^*9#'=7-OIDDUE 2OG^8%W'_ '<9QGZ\<U+_ ,)&\J6<
M=I8-/=W$7F^2)0H1>>K$>WI6%MO+'0M2L8!;7%DK$_:DG4X!QP5'.>WU]:>-
M!FN+;3+Y;$7L9ME22 S>6>Y# _B* +>K^(;B?P\9[-)+>3S?)G.\;HCZ>^?4
M8KH].EFFTZ"2XA,4I7YD+AOH<^XY_&N<D\/7+>&)K>.TAANI)%D\F.0D8'8E
MF//7OBNCTYKAK"+[5;_9Y5&TQ[P_3C.10!:HHHH **** "BBB@ HHHH ****
M "BBB@ JS9?ZYO\ =JM5FR_US?[M %ZBBB@ HHHH **** "BBB@ KBKK2XX_
M&VG:>EYJHM9K.:62/^U+GEE9 #GS,]S7:UCW.DSS>+;'55>,06]K+"ZDG<68
MJ1@8QCY3WH QV\7'2VL8KFQ6WM)YUMX5N;QC>%=VP2&)ER5SW+$X.?:KDWBS
MRM U35/L6?L%Y):^5YOW]L@3=G'&<YQ@UA#P5JJ:5%811:2CQ727$E]N;SKS
M9+N'F?)\IP2<Y?D8Z'(MW_A?6I=+U?2;5[#[+?7K7:SRR.' 9U<H4"D=01NW
M'C'% ';5P-_K6HZ3X\U*\>:231;:.VCNH2Q(A$F[]\H[;2O..S>U=C:7LES?
M7]NT(1;61460.3OR@;D8&",CCGJ*I0:(PU[6[NY$,EIJ,$$(CR22$#A@PQC!
MW#OZT <OJVIWJZKJXAOIQ&FKZ<D824X".B%@,'H<G([YKH/'-S+:>#[V>&XD
MMW5HOWL<A1E!E0'Y@01P36!!X$U2RL[V""ZM[C.H6UQ:^?*P/E0X"HY"G!"@
M+D ]*W-9L-<UW1;G3YK73K8R&-D=+QY.5D5B"#$N. >>><?6@#*NKO38[_2O
M^$;UN:\O'O8UD@34Y+M6A/$A=6=@ %R=V!@@5#8WVBR76M_VWX@EMYXM1G2.
M-M8E@*QC&-J"0#'7'%='K>C74^H6>KZ2\46IVQ\MO-8JD\)/S1N0"?<'!P?K
M4V@Z7/I?]I^>\;?:K^6Y382<*V, Y YXH P].AOKWPYI^HZU>ZGY44+;K>U6
M5)IB7(C=C%AS\FWY0.I)/2LZ;5)6\(Z;=W6KRIJ(B=HE^UF+S-KGL@VS3 !5
M\HG!)((%=A?IK27\5QISVLUOY926TN&,0SG(=756.>V",4GA_2I=)TYX[B5)
M;J>>2YG:-<)YCMN(4>@SCGKC- &F6"IO;Y0!D[CT^M<+H>JZ@==M-7N[F9M-
MUV2:*WA=SL@*_P"IP.@W(C'CJ36YKGAZ6\T^^&FW,\=Y=*8]TU[,8D5N'(3)
M4':3C X..E5M5\$Z:^D>7HVGV%EJ4)22UN1"%971@1N91G!Q@_6@#+U+4K>U
MUC4_^$HGUBQ@\Q4LKBVDGCMA&5& #$<>9NW$[\]NW%:!NKF\O-%T1=8-S'-;
MR7-S?6V(VN(T(555E)VY+<E2#\O!&:T4'B6VGGPNGWT,C;X_-N&@:'/6/Y8V
M#@=FX/J*H6WA2?2K'26TV:W:^TXR#$BE(IHY6W.G&2@SC:?FQCH<F@"S<:8=
M+2[D;5[V+27AQ,KS/+)"V1ETD;<RC'7GC[P*XJ3PC<M<Z1*3/YZI<R(DBW!N
M$*]0$E;YI ,XW'G((Z 5+9VFL3ZN+_4IXH(8HVCBLK29G0DXR[L57<>, ;>/
M7FMF@ HHHH **** "BBB@ HHHH 9)]S\1_.GTR3[GXC^=/H **** "BBB@ H
MHHH **** "BBB@#!UG7[C3)91%9P>1!$'EN;ZY-M#EB=J(Q1MS<'/0#(YR>-
M#1M4BUO1K34H$9([F,.%;JOM6)?^'[Y_$=WJ<%OIMT9X8XX9;PGS+(J&!* *
M<@[MV 5R<\]ZE\/^%AIVC:=;WLTYNK1 A^S7TR1-AB0=@95/;.1[<T &C^)+
MW6D2YM=,@>QD=X_,6\#21$=/-3;\N>,@%B,CBG6GBM;RRT:2.S87.HSM"UN9
M.8"F[S"3CG:5QVSD=*IGPW?W6MV5_/::3:3VUR9I;^R+K+<K@C:R;> PQG+M
MC'>J_AJPAN?&6KZI:SK/IL3L+5D.4\V4*TQ4C@\J.?4D4 6M,\87=]:Z3?3Z
M0MO8ZE*(8W%UOD5R#C*;0-I*D9SGO@5,/%N?#-OK/V'_ %UW]E\GS>G[XQ;L
M[?;.,>WO4%KX6OH/#/AW36EMS-IMW%/,P9MK*I;.WC)/(Z@54?PMK?\ 8\.B
MQOI_V2"_%TD[2OYCIYQDVE-N%/)YW'H!CG( -B'Q!?WS33Z?I N;"&Y:W:0W
M(25]IVNR(5P5!SU8$X/'3.1H?B"\CA-G'&]_J%SJ5XL2SSE5CBC?DLV&(49
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MB@ IB??D_P![^@I],3[\G^]_04 /HHHH **** "BBB@ HHHH **** "BBB@
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MZ-'E)_M?]]&@ HH\I/\ :_[Z-'E)_M?]]&@ HH\I/]K_ +Z-'E)_M?\ ?1H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /'?'^LZG9>+;B&UU"YAB"(0D<I4=/05R_P#PD>M_]!:]_P"_[?XUM?$C
M_D<[G_KFG_H-<E7GU)/G>I]M@J--X:#<5LNB_P C3_X2/6_^@M>_]_V_QH_X
M2/6_^@M>_P#?]O\ &LRBHYGW.KV%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CU
MO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+
M7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\
MW_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_
M !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,
MHHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYG
MW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%
M+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?
M<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\
M(T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^
M$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO
M_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7
MO_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]
MO\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/
M^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CU
MO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+
M7O\ W_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\
MW_;_ !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_
M !K,HHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,
MHHYGW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYG
MW#V%+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%
M+^5?<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?
M<O\ (T_^$CUO_H+7O_?]O\:/^$CUO_H+7O\ W_;_ !K,HHYGW#V%+^5?<O\
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M'K?_ $%KW_O^W^-'_"1ZW_T%KW_O^W^-9E%',^X>PI?RK[E_D:?_  D>M_\
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MD:?_  D>M_\ 06O?^_[?XT?\)'K?_06O?^_[?XUF44<S[A["E_*ON7^1I_\
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M )\[?_OTO^%']G6/_/G;_P#?I?\ "CV'F/\ ME?R?B>%T5[I_9UC_P ^=O\
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M9UC_ ,^=O_WZ7_"CV'F']LK^3\3PNBO=/[.L?^?.W_[]+_A1_9UC_P ^=O\
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ME_PH_LZQ_P"?.W_[]+_A1[#S'_;*_D_$\+HKW3^SK'_GSM_^_2_X4?V=8_\
M/G;_ /?I?\*/8>8?VROY/Q/"Z*]T_LZQ_P"?.W_[]+_A1_9UC_SYV_\ WZ7_
M  H]AYA_;*_D_$\+HKW3^SK'_GSM_P#OTO\ A1_9UC_SYV__ 'Z7_"CV'F']
MLK^3\3PNBO=/[.L?^?.W_P"_2_X4?V=8_P#/G;_]^E_PH]AYA_;*_D_$\+HK
MW3^SK'_GSM_^_2_X4?V=8_\ /G;_ /?I?\*/8>8?VROY/Q/"Z*]T_LZQ_P"?
M.W_[]+_A1_9UC_SYV_\ WZ7_  H]AYA_;*_D_$\+HKW3^SK'_GSM_P#OTO\
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M^E05/>?\?<GU_I4%9O<ZX?"@HHHH*"BBB@ HHHH **CGF6WMY9W!*QH7('7
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M(DHB"'D#C ^M-339$L).,7)M::VZZ.WYG244459RA1110 4444 :NG?\>W_
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MTU?"MQ!+)'9:S<VMA)+YK6\:@,#W ?.0/\\UUOV*Y_YY?^/#_&C[%<_\\O\
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M%%% !16?<ZQ;VNKVNF.DIFN02C*!M&,]><]O2M"E<J4912;6X4444R0HHHH
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MYUT5% '!ZQJUAK/@I=%LKJ.75;A(K<62G]\CAEW!TZKMVL22 !BNGUF\T_\
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MW<=L6M-56X^S@JW!"2AL%AUVMV;."":E\+7LD$%Y%=:J;S3END@TZ^N77=<
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M]VWWO;T/O3][?\\W_3_&A_O1_P"]_0T^@!F]O^>;_I_C1O;_ )YO^G^-/HH
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MHLPYX]R"G1_ZU/\ >%2_8[C_ )Y'\Q3DM+A74F(X!!ZBG9B<XVW->BF>8?\
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M>8?^>;_I_C3=S>9N\M\8QV_QH EHIGF'_GF_Z?XT>8?^>;_I_C0 ^BF>8?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT;W&]2)-QX( .<'&>0.31J%E=K<7316SK TC32&1HWB;]WC>,C>K]!@<<>]
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MH"+==2>^^T;UVE2"0N,YSDXZ8P.M+>Z7?2R:\T4*D77D>4&*GS H&\#/0XR
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M*%AR">#D]_6DLO#'V1($-YO6(P](MN5C9GQU[LP/X#\ #2MM0:^ANA! \5S
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M)" \X5F SN_O'H>G K,M?"UY=:.EM?W0AV"<11+&"4,A89+!L,,$D#CKUXH
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MN98A,]NZKM1%;)C+!@3O Y/O6]<Z?:W=F+2:/="-NT!B"I7D$$'((QUS55=
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MK/9VHM1&LC*99%9MJK&&<X!&<%U&..XJ\OA_35A:/R'.2IWM,YD&TY7#EMP
M] 1W]:FL](L;!P]M"48!QDNS'YB"W4GDE1S[4 8ZZ[J,<%I/.MGB^@>2"/E-
MC  H&8L0=V0.@P2.M+;:QJ=Q<QV&;5+IF?>S0N/*"JI8-'NY.77!#D$'/;G1
M3P_I<<4L0M<I*GED-(S;5SG:N3\@SS\N.0/04-X?TUX@C12_>9R_VB3>2P .
M7W;CD #!/8>E #=-N+J?4+I+I8Q);QQQMY3L4+D%FP#QT*]L\]35;Q%&PCS;
MW5V-0F 2TABF*@,#RQ48! R-Q;(  ]>=2WTZUM#FWB,0W;]J.0N=H7[N<8P
M .@QQ45QH]G<WANY/M"SE A>*YDC^4<@?*P]: ,)[JZ^W/>&YE#KJR68B#D1
M^7@ C9G&3DMGK5W3FOSKFLP2WHD=(X3%NC/EQ[M_1-WL,\Y..OIH_P!D6)OA
M>&$F<$-DR,06 VABN<%@.,D9JQ':017<UTB8FG"K(V3\P7...G<T 9?AJ2X>
MRNUN;A[B2.]FC\Q^I"MCIV'L.*VJAMK2"S618$V"21I7Y)RS')//O4U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *$!<D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YCHHHKRS])"BBB@ HH
MHH *4,P.02#244 7K;6-2LVS;WT\9_V9#6[9?$3Q#:8#70G4=?-4$G\:Y2BF
MI26S,:F&HU/C@G\CTZP^+/1;_3O^!0M_0UU6G>._#^HX5;P0N?X9AM_7I7@]
M%:QKS6YYU;)<+/X4X^G_  3Z9CECF0/%(KJ>C*<BGU\XV.L:CICA[.\FA([*
MQQ^5=GI/Q3O[?:FI6Z7*=W3Y6_PK:.(B]]#R:^15X:TFI?@SUNBN?TCQGHNL
MX6&Z6*8_\LIOE/X=C705NFGJCQZE*=*7+433\PHHHIF84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH **** 'PS202K+"[(ZG(93@BO2?"WQ*9=EGKAW+T6Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /F.BBBO+/TD**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?,=%%%>6?I(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %7-,U.ZTB_BO+20I+&<CT(]#[53HHV%**DFFKIGT%X:\1
MVWB/3%N(2%F7B:+/*-_A6U7SQX?UVY\/ZI'>6Y)'22//#KW!KWO2]3MM7TZ*
M]M7W12#/NI[@^]=U*KSJSW/B\SR]X6?-#X'MY>7^1<HHHK8\L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F.BBBO+/T
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKK? OBIM!U(6]PY^PW! <?W#V:N2HIQDXNZ,J]&%:FZ<]F?3:L'4,I!4C(([
MBEKS[X;>)_MMI_8]V^9X5S"Q/+)Z?A7H->C"2DKH^#Q6'EAZKIRZ?B@HHHJC
MG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F.
MBBBO+/TD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH LZ??3Z;?PWENQ66)@RFOH/1-6AUO28+Z \2+\R_W6[BOG.N\
M^&?B#[#JC:7.^(+H_)D_=?\ ^O6U"?+*SZGCYS@_;4?:1^*/Y=?\SV"BBBNX
M^."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F
M.BBBO+/TD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *?%*\,R2QL5="&4CL13** /H7PSK"ZYH-M> CS"NV0>C#K6
MO7D?PNUK[-JDNERMB.Y&Y,]G'^(_E7KE>A2GS1N?"9CAOJV(E!;;KT84445H
M<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S'1117E
MGZ2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %BQNY+&^@NHB1)$X<$>QKZ+T^\CU#3K>\B(*31AQCWKYLKV'
MX7ZK]KT.6Q=LO;/\N?[I_P#KUT8>5I<IX6>X?GHJJMX_D_\ @G=T445V'R84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S'1117EGZ2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !77?#G4OL'BF*)CB.Z4Q'Z]17(U/97+6E[!<(2&B<.,>QIQ?*TS
M'$4E6I2IOJCZ5HJ&TN%NK2&X0Y61 X_$5-7IGYZTT[,****!!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!\QT445Y9^DA1110 4444 %%%%
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M0RMRY>>V?RRYZLN,@GWZC\*ZBN<\'MHTMA/-HMG/;0M( _FDG<P';+'UKHZ
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MH7_723^<==]0!P7@"2>SU;5]&>4R16SG;GH"K%3CZ\?E2>'/^2FZW_USD_\
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M_,C >8GEJ">I)_S^58OA?_DFMU_URN/Y&@#*\"^&;+6-/FO-2C,\:.8HHRY
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M$CC&>O8@\BMSQ_K4^GV%O96DOES7C$,X."J#&>>V<]?8U1^)G_,(_P"NC_\
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MU.*72W&E?%"_BN,*+Q6\MCW+$,/Y$?6@"]K?@G3X-+EN=)1K2[MXV=661B'
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MXVW1(WJH-=6&V9\QQ!'WJ<O)CJ***ZCYT**** "BBB@ HHHH **** "BBB@
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M^V>?]J.=GE;=O)/7)SUH H1>!//NXYM8U>YU)8_NQN"H^AR3Q],5UCP120-
M\:F)EV%".,=,8J2B@#C6\!&VNI)='UFZT]7ZHH+?AD,./KFKNB^#;72[XW]S
M<RW]Z>1+-V/KC)Y]R:Z6B@ IDT23P20R#*2*58>H(P:?10!Q^E>!GT?5HKNV
MUB;R$?<8#']X=,$AL=.^*T='\-?V5KNHZG]K\W[8S-Y?E[=F6W=<G/Y5OT4
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MKK4#?Z?>3:==,2S-$,C/J!D$?G45OX$1[Y+K5]4N-39/NK(,#Z')/'M77T4
M8WB6^T[3]&(U."22SG80,L:@XR"0>HQT_/%8%KX)E^SAM,\1WD%A.-ZQ*"<J
M?<,!T]JZ[4M.MM5L9+.[CWQ./Q![$'L:Y6/P+?6R&"S\37D%KVB"GC\F _2@
M#'TC3+;3_B9!:6+M)%;1MYCLV26\L@Y_%@*[;7?#MCX@MECNE99$SY<J?>7_
M !'M4>@>&;+P_&Y@+RSR?ZR:3J?8>@K:H XD^ [V2 6LOB6[>S''D[#C'I][
M'Z5U&DZ19Z+8K:6<95 <LS<LQ]2:O44 8'ASPU_PC\]_)]K^T?:V5L>7LV8+
M>YS][]*L^(]$_P"$@TK[%]H\C]X'W[-W3MC(K6HH J6EA';Z1!ITN)HXX%A8
MLN X"@=/>N8;P$;:ZDET?6;K3U?JB@M^&0PX^N:[*B@#FM%\&VNEWQO[FYEO
M[T\B6;L?7&3S[DU)K_AC^W-2L;S[9Y'V4YV>5NW<@]<C'2NAHH 0@,I! (/!
M![UQS^ C;WLEQI&LW.G+)UC12<#TR&''US7944 <=+\/K:XLYQ<ZA<7%]+C%
MU-EMF"#PN?PY/>M^UTA8_#R:1=3&X00&!G"[25Q@<9.,#'Y5I44 <EH7@N30
MM52ZBU:62W7=FW,> V01R=V/0].U7- \,?V'J5]>?;//^U'.SRMNWDGKDYZU
MT-% '/:]X0L];N%NUEDM;U<?OHN^.F1_6LW_ (0.2[FC.KZ[>7T2=(R"OZEC
M79T4 4KC38I-%GTR +!%) T"[5R$!4C.._6JWAS1/^$?TK[%]H\_]X7W[-O7
MMC)K6HH P/$?AK_A()["3[7]G^R,S8\O?OR5]QC[OZUOT44 07MO]LL+BVW[
M/.B:/=C.,C&<5R%O\/!:01M:ZO/;WJ$_Z1$FW*GL5W?UKMJ* .7TGP7#9:D-
M1O[V;4;Q3E'E& I]<9//ISQ7445B>(M!DUV&!(M0DLVB).Y%)W XX."/2@#D
M[;3;;4_BA<R0#=;VS>=*>WF #_V;^1KT>L?P]X=MO#MF\,+M++(=TLK#!8CI
MQV K8H **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J*YMH+RW>WN8DEA<89'&0:EHH&FT[H\<\8^ 9=&WW^F
M!I;#JT?5HO\ $5P]?31 92K $$8(/>O)_'?@;[ 9-6TJ,FV)S-"H_P!7[CVK
MDJT;>]$^HRS-O:-4:[UZ/OY/S//:***YCZ **** "BBB@ HHHH **** "BBB
M@!\)VSH>F&%?2=H=UG ?6-3^E?-:?ZQ?K7TG9?\ 'A;?]<E_D*Z<-U/G.(=J
M?S_0GHHHKK/F0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E5U*L RD8(/0BEHH
M\6\>>$3H5Y]NLT/]GSMT'_+)O3Z>E<;7TE?V-OJ5C-9W2!X95*L#_.O -?T6
M?0-8FL)LD*<QO_?3L:XJU/E=UL?891F'MX>RJ/WE^*,RBBBL#V0HHHH ****
M "BBB@ HHHH ?$,RH/4U])V8Q96X](U_E7S?:+NO(5]7 _6OI.$;8(U]% _2
MNK#=3YOB%Z4UZ_H/HHHKJ/F@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BJU_?VVF64EY>2>7!'C<^TG&2 .!SU(J+^V+#^R/[5\__ $+;O\W8
MW3..F,_I0!>HJM87]MJ=E'>6<GF029VOM(S@D'@\]0:LT %%%% !1110 444
M4 %%%% !1110 4444 %%%4+76M/O=1N+"WN-]U;Y\U-C#;@X/)&#SZ4 7Z**
M* "BBB@ HHHH **** "BBB@ HHHH ***:[K'&SN<*H))]J '450TO6;#68GE
MT^?SDC;:QV,N#^(%7Z "BBB@ HJAI>M:?K22/I]QYRQD!SL9<$_4"K] !111
M0 4444 %%%% !14=Q/%:VTMQ,VV*)"[M@G"@9)XJ#3M3L]6M?M-C-YL.XKNV
ME>1[$ T 6Z*** "BBB@ HHK/EUS3H-6CTN2XVWD@!6/8QSGWQCMZT :%%%%
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M)+!CS54YV9S@'WX/% $]%9\NN:=!JT>ER7&V\D *Q[&.<^^,=O6M"@ HHHH
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M'<96)!N=AZX]/K63:_$+1+B=8I!<VV[H\\8"_H37'V>O:</%U]JFLQ23_,1
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MQRY(Y)]: $T;7]/UZ!I+*4DI]^-QAE^HJE?^,=+TS59M/NA.DD*;V?:"IX!
M'.<\^E<YH"+9_$W4K>W41PLK_(!P/NMQ^-,O+.&^^+2PSJ&C 5RI&0=L>1^H
M% '4:)XLL->NWMK6&Z1T3>?-0 8^H)]:AU+QSHVFW+6Q>:YE4X9;= V#Z9)
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MM>;>$O$MII>IZFTT%TXO9E,?EH#MY;[V2,?>'KWKU2N%^'__ "%?$7_7=/\
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M%8X50,LQ] *P$^(^BLX#PWL2GH[Q#'Z,3^E4?'MM<PZMINKBU^U6=OCS(\9
M(;//H#_2ISXS\.:]8/8Z@LMLDJ[2)$R%/8@C."/7% '8VUS#>6T=Q;R+)#(-
MRNIX(J6LS0=/LM-TJ.#3YVGM22Z.SA^O7!'&*TZ /*KGQ/:-X^M]8%O=>1%&
M4*;!O)VLO SCOZUH^/KZ/4_#6EWD*2)'+*659!AAP>N*M7?_ "5RQ_ZX'_T6
M]'Q/_P"058_]=S_Z#0!<?Q[HUA'';C[1<-'&H<P("H./4D5MZ-K^GZ] TEE*
M24^_&XPR_44NAZ;;:=HMM;P1*H,2ESCER1R3ZUQV@(MG\3=2M[=1'"RO\@'
M^ZW'XT ='?\ C'2],U6;3[H3I)"F]GV@J> 0!SG//I3M$\66&O7;VUK#=(Z)
MO/FH ,?4$^M<O>6<-]\6EAG4-& KE2,@[8\C]0*ZCQC>'3_#-[<1?+.Z")7
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M!9Q*5W@8)&,]?PH [ZBHK9VEM89&^\R*Q^I%2T %%%% !1110 4444 %%%%
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M%W81O*;:/+JS(3\HZ[2,T 8*3#Q7\0K>YL\M9:>H)EQP=I)'YL<?09IVK?\
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M?5O#EY:Q*&F*AXQZLI!Q^.,?C5G^Q=/_ +8_M;[/_IV,>;O;IC;TSCI[5?H
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MNXR,4 7_ !)XITNTT2X6&\@N)YHVCB2&0/R1C)QT'-9W@/\ Y$J\_P"NLO\
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M70]2G:>ZT^-I6.6969"Q]3M(S6Q10!GZ;H>F:1N^PV<<+-P6&2Q_$\UH444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 4]2TJRU>U%M?0^;"&#A=Q7D>X(]35F&&.W@C@B7;'&H1!G. !@4^B@ H
MHHH **** "LW4M TK5V#WUE'*X& _*MCZC!K2HH R=/\,:+I<PFM+"-)1T=B
M7(^A8G%:U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_2A*[L14FJ<'-]$V>\:=;"STVVMU&!'$J_D*LT45ZA^=2;DVV%%%% @HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#;6L/GZA<G$49Z#G&3Z\\ 5F&W\?+;_:?MUF7QG[+L7/TSMQ^OXT =K17/\
MA;Q*-?MYDGB$%[;G;-&.GU&>>W3M67J'B35M3UN72/#D<>Z$D37,@!"D<'KQ
MC/'0YH [2BN%O;_QAX;07E_+;:C9@@2;%"E<_0 CZ\UOZAK/F^$)]6TZ0J3
M9(V*@E3[@\9!R* -NL#6-4U>SUW3K6RL//LYV43R^2[>6"V#R#@<<\US>BZG
MXP\16 >SN[>!8,J\\J+F5\YQC:0, @< 5;U/6=;T[6_#UC+=J&N/+%T%C7#$
MO@@'''''% '<45R'CG7;_1!ISV4_EK([^: BMN V\<@XZFH4;QOJMO\ ;K>>
MTL8W&Z*V906([9)4]?J/PH [6BN5\(>)+K5WNK#48@E]:GYB!C<,X.1V(/\
M.J^M^)=2GUO^P_#\:-<I_KIG&0GTSQQW)^E '945P>H:AXO\.6KW%_-;WMNR
ME#)$H!A8C /W1WQU!%;O@[4KO5?#T=U>R^;,SN"VT+P#QP !0!OT45Q=]KVM
M:KXBGT?0## +8'S9Y0#R.#U!XR<=#0!VE%<%?:KXL\,2P3ZG+;ZA9R/M;RT
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M HHHH **** "BBB@ HHHH **** $HHHH **** "BBB@ HHHH **** "BBB@
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MTZ,V[A;RV)>')P&SC(SVZ#\JRHO%/B2"U%O/X9N9;M1M\Y5;8Q]3@$?D?RH
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M 3R<#J 01Q[&@"CXP/B:328Y=:^RQ6YN $@BQG=M;GOP!GOWK=\9?\D_L_\
MMC_Z#63XEM?$WB&R6\GTUH+>%L16B O(<]6( SQQZ?3K6UXGMKJ]\!V<4%I<
M//B'="L3%UPO.5QGB@#H/#J*GAK2PHP/LL1_$J":Y2?_ )+!;?\ 7,_^BFKK
M]#C>'0--CD1DD2UB5E88*D(,@CUKF)K&\/Q4M[P6LYM1&09O+.P?NF'WNG7B
M@"K;%G^+MQYPPRH=@]O+&/TS7?NBR(R. RL,$'N*Y#Q3H.H'5;?7M% -Y" )
M(^[@=QZ\<$>E5[C7O$NKVAT^V\/SV<TPV23S;@J@\$C('OZ_C0!'\,@!:ZF%
M.5$JX_(UWE<5\.["[T^UU!+NVF@+2+M\V,KN !Y&:[6@#@O%"))\1-"5P"N$
MX/\ OM7>UYOX[BN)O&&E1VC;+EHT$39QAMYQ^M:3^)O$XMC:CPW.+[&WSP"8
M\^O3'ZXH K>$P$\?Z\B#$>9.!TSY@_\ KTSP$!_PDNN''(8C_P ?-;OA#P[+
MHEK-/>L'O[IMTI!SM'IGUR23_P#6K+\$V%Y::_K,ES:3PQR,=C21E0WSGH2.
M: %^)S.-%LU!.PW&6^H4X_K2V5AXV^PV_P!GU731!Y2^6-O1<<?P>E=%XBT5
M->T>6R9@CY#QN?X6'3^H_&N6TS5_$OA^U73KS0;B^6$;8I8<GY1T&0#D>G2@
M G\*^*-0U:ROK^_L'>V=2&0LI #9[(*2<"3XO0K-RJQ_(#_UR)'ZYJ73M*UC
MQ!XDBUK6(&L[>WQY5N3@G'(&.N,\DGK_ "N^+?#][<WMKK6D8^WVN,H<?. <
MC'J>O7J* .MKE_$!TS_A#]573?LFT(-XMMN <CKMJA-XH\2W-J;:W\-7,-VX
MV^<P;8I]1D ?F?SI(_#$^D> ]1M]C3W]RH:18@6.<C"C'7'/ZT 7?"=E%J/P
M]MK.<$Q3)*C8ZC]XW(K&30/%_AS<FD7:W5J"2(\C_P!!;H?H:V-$T>>[^'D>
MEW"RVL[I(,.I5D/F,1D=?3\*R])U3Q'X;M!IMUH-Q>QQ$B.2 $\9SU .10!<
MT3QI=RZM'I.M6/V6YD(5&"E<GL"I]?6JL_\ R6"V_P"N9_\ 134^QTS6/$/B
MFWUK4[/[#;6N/*B8_,<$D#UZG)) J6:QO#\5+>\%K.;41D&;RSL'[IA][IUX
MH K8$GQ?(E&=L8\L'_KE_P#KKOZY#Q7X>OI]1M]<T?'VZWQNC)^^!T(_48[B
MH'\5>));?R(?#%S'=D8\UE;8#Z\C^M %;PN GQ&UQ(N(MLA('3/F+_\ 7IG@
M(#_A)M<;'(8C/_ S6WX/\-S:+%/=7SA[^Z.9,'.T9SC/<D\FLWP387EIK^LR
M7-I/#'(QV-)&5#?.>A(YH T/B%_R*4W_ %U3^=:/A7_D5=-_ZX+5/QU:W%WX
M8EAMH)9I3(A"1H6/7T%7_#4,D'AK3XIHWCD2$!D=2"#[@T :M<!X04?\)YXA
M;'(DE /_ &UKOZXGPM8WEOXSUV>>UGBAEDD,<CQE5?,A(P3P>* '_$S_ )%N
MW_Z^U_\ 0'KJ-* &D60 P!!'_P"@BN=^(=G=7N@01VEM-/(+I6*Q(7(&Q^<#
MMR*Z33E9-,M$=2K+"@((P0=HH XKPA_R/7B+_KI+_P"C36)X3@UVYO-2?1[R
MU@EW#SOM"Y8Y+8Q\I]\_A71^%K&\M_&>NSSVL\4,LDACD>,JKYD)&">#Q5>]
MT;5_#?B&75M$M_M5M<$^9;CJ,\D8ZXSR".E %FYTCQO=VLMM/JFFO%*A1UV]
M01@_\LZSM4TB^T#X<W%E<21NS72LQB8D!"1QR!W%6-3U?Q'XAM#IMGH%S9+-
M\LLLV1\O<9(&!Z]:Z"T\,PP^%&T2:0OYB'S)/]L\Y'T.,?2@";PH$7PKIHC.
M5\@$\=^_ZYKF/'R1C7]!<?ZTR$-] RX_F:32[OQ'X4C;39M'FU&V1CY,EODX
M!]P#Q['%9NJV?B+5=;T[5+S39D1I0J0QHS>4BL#EL=,Y/7'0T :GQ,_YA'_7
M1_\ V6CXE',FC(_^J:1]_P#XY_B:L?$*QO+W^R_LEK//LD<OY49;;]WKCI6S
MXKT#_A(-)\F-E6YB;?$S=,]P?8_X4 ;@    P!T JFG]F+J<@C^R"_(RX7;Y
MIX[]^F*Y.T\1^)-/M%L[OPW=7-Q$-BS1@[6QP"< @_4'FK7A70;]=4N=>UE0
MMY< A(_[@/KZ<  #TH H?#/_ )B__71/_9J3P@!_PGGB$XY$DHS_ -M:L_#V
MQO++^U/M=K/!OD0IYL97=][IGK1X6L;RW\9Z[//:SQ0RR2&.1XRJOF0D8)X/
M% &IX[_Y$R__ .V?_HQ:YK4V9?A/8A2<,R!L=QN)_F!74^,[>:Z\)WL-O#)-
M*WE[4C4LQ_>*> *KZ7HWV_P';Z7>QR0L\."'3#(VXD'!_"@#&T2Q\8'1+,Z?
MJ>G):&(&-67D \X/R=?6FZKX4\6:UY/V[4-.D,))C(RI!.,]$]A1I=WXD\*1
MMIL^CS:A:H3Y4EODXSZ$ \>Q /-.&GZWXNUNWNM2M'T_3K<Y6)B0S<\CL<G
MR<#B@#OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV?99_LOEX\[RSL_U6/O=.O%=M10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5PE[9:WX<\3W&JZ=:O?V=T29(4)R"3DC'7KT.#UKNZ*
M.!U34O$?B:U.FVNA3V,4I EEN,CCKU(&!^==AHVFII&D6U@C;A"F"WJ2<D_F
M35ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .)\26-Y/X[T6XAM9Y((_+WRI&2JX<GDC@5VU%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<WX]NOLG@V
M_.<&11&/J3725Y[\6+WR](L[,'F:;>1[**BH[0;.S+Z?M,5"/G^6IY-1117G
M'WH4444 %=7\/=)_M/Q/$[KF*V'FO]1T'YURE>S_  TTC[!X>^V2+B6[;</]
MT=/\:THQYIGG9IB/88:36[T7S_X!VM%%%>@?#A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "4444 %%%% !1110 4444 %%%%
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M84444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX($6.*-0JJHX J2O0IP4%8^&QN,GBJO/+;HNR"BBBK.,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M [^Y]35JNZG24->I\=F&93Q3Y5I#M_F%%%%:GF!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=""@K(^.Q>,JXJ?-4?HNB"BBBK.4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #(HHX8UCB1
M411@*HP!3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ([ ]\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L3Q+X3T?Q;9):ZO:K,B-N0]"I]C6W10!YQ_P */\%?\^,G
M_?PT?\*/\%?\^,G_ '\->CT4 ><?\*/\%?\ /C)_W\--D^"/@I8G86,F0I/^
ML->DU'/_ ,>\G^Z?Y4 ?(W@+PSI>M_%"31KV%GL@\H";L< G%>[?\*/\%?\
M/C)_W\->0?"O_DMDO_76;^9KZFH \X_X4?X*_P"?&3_OX:/^%'^"O^?&3_OX
M:]'HH \X_P"%'^"LC_07_P"_AKO--TVTTC3X;&QA6&VA7:B*.!5NB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'F/Q2^*%WX$NK.UL].%P\ZER[DA0!V^M>>?\-&ZY_P! 6U_[Z:OH/4='T[5E
M5;^SAN O*^8H.*H?\(9X<_Z ]I_W[% 'A?\ PT;KG_0%M?\ OIJ/^&C=<_Z
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MY7(Z&KM(JJBA5 "@8 ':EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN(UWQN8[V&TTK#XF"2RE?E'/0>]=N1D8KA?&UI;V<.FQV\21JUT&(48R3WH
MZ/7]4?2O#\U\F/,51MSTR:P-,U/Q?<W%J\UM;?99""Y'4*:TO%D5G<:)#;WM
M[]DBD90'QG)]*YK4;(^%=2TJXT[4)I?M$@1XW?<''TH V-3\0:M=:Y+I>AQQ
M%K=-\KR?R%:GAC77UNQD,\8CN8',<JCIGUK#\/LL7CC6U<A6*!AGTIO@N80R
M:[=X+1"8D;>^,]* .[K@-!_Y*/J?^Z:F_P"%D6Y)QIUSC/I5#PC=C4/&UY>*
MA02H2%;J* /2**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT>:-+;9R&ZYK)^R^//\ GYAKO78(C.>BC->?>=XD\5W,\^GW0L[*)RB>K$4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<Z]&KF?#&DZ1IMS,^FZA]J=EPRYZ"NFH **** "BBB@ HHHH **** "BBB@
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M@'Y6P<''YT =Q1BBB@ HQ110 48HHH **** "BBB@ Q1110 8HHHH ,4444
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M "BBB@ HQ110 48HHH *,444 %8?C+_D3=8_Z]9/Y5N5A^,O^1,UC_KU?^5
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M "BBB@ HHHH **** "BBB@ K#\9?\B9K'_7J_P#*MRL/QE_R)FL?]>K_ ,J
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MC_[I_E7'?!O_ )*Q%]9* /K&BBB@ HHHH **** "BBB@"E?:K9:=@75S'$S
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MB@ HHHH *XKXM?\ )-=7_P"N?]:[6N)^+7_)-=7_ .N?]: /.OV;/^/;6O\
M>2O>Z\$_9L_X]M:_WDKWN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*P_&7_(F:Q_UZO\ RK<K#\9?\B9K'_7J_P#*@#Y6^&O_ "$;S_KG7HU><_#7
M_D(WG_7.O1J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JMJ/\ R"[O
M_KDW\JLU6U'_ )!=W_UR;^5 &1^SW_R.UU_U[G^=?3]?,'[/?_([77_7N?YU
M]/T %%%% !1110 4444 5-5_Y!-Y_P!<6_E7Q_X)_P"1QN?J_P#.OL#5?^03
M>?\ 7%OY5\?^"?\ D<;GZO\ SH ],HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $/W'_ -T_RKCO@W_R5B+ZR5V)^X_^Z?Y5QWP;_P"2L1?62@#Z
MQHHHH **** "BBB@ HHHH *JSZE9VTJQ37,:2,<!2W)J>9BL+LO4*2*\G2"U
MN;5M5N;@OJ0O0"C-]Q<^E 'K$<T<I8(ZL5.& /2GUPNCND/C^ZCLKEIH)H1)
M,,Y"O7=4 %%%% !1110 4444 %<!H/\ R4?4_P#=-=_7 :#_ ,E'U/\ W30!
MW]%%% !1110 4444 %%%% %>;3[.X??/:02/_>>,$_K4?]D:;_T#[7_ORO\
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MUQ;^5?'_ ()_Y'&Y^K_SK[ U7_D$WG_7%OY5\?\ @G_D<;GZO_.@#TRBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_<?_=/\JX[X-_\E8B^LE=B
M?N/_ +I_E7'?!O\ Y*Q%]9* /K&BBB@ HHHH **** "BBB@"A<ZI917BZ?)<
M*ES*I*)W/O7#6^F^%8[R2?4]6^V3[R<.W"^V*Z[4;+1EU6+4;PQK=QH1&S-@
MXKG-.T[P?JT<MPUO'"WF$$2N 2?6@#I-(U31)Y/LFF2P;@,[(QCBMFN-T5/#
MUEXH:STRUQ<>5GSE;*D>E=E0 4444 %%9VN:G_9&D3WNT,8QP">IKG-/\4Z[
M=W-JKZ&Z03,,RYX ]: .THKEM8\3W<.K?V7I5E]JN53?)DX"BM#P[KRZ[9NY
MC,4\3;)8SV- &S7 :#_R4?4_]TUW]<!H/_)1]3_W30!W]%%% !7C7[17_(H6
M/_7S_2O9:\:_:*_Y%"Q_Z^?Z4 <#X#)_X1:/D_ZQN]=+D^I_.N9\!_\ (K1_
M]=&KI: %R?4_G1D^I_.DHH 7)]3^=&3ZG\Z2B@!<GU/YT9/J?SI** %R?4_G
M1D^I_.DHH 7)]3^=&3ZG\Z2B@!<GU/YT9/J?SI** %R?4_G1D^I_.DHH 7)]
M3^=<I\02?^$:3D_ZVNJKE?B#_P BVG_76@#U3]G_ /Y)R/\ KY>O5:\J_9__
M .2<C_KY>O5: "BBB@ HHHH **** /.?C=_R36]_WE_G7B7PW_Y!-W_UU'\J
M]M^-W_)-;W_>7^=>)?#?_D$W?_74?RH [2BBB@ HHHH **** "BBB@ HHHH
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M?]=:ZJN5^(/_ "+:?]=: /5/V?\ _DG(_P"OEZ]5KRK]G_\ Y)R/^OEZ]5H
M**** "BBB@ HHHH \Y^-W_)-;W_>7^=>)?#?_D$W?_74?RKVWXW?\DUO?]Y?
MYUXE\-_^03=_]=1_*@#M**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#$\7?\BM>_05TW[-O_ ""=9_Z[)_*N9\7?\BM>_05TW[-O_()UG_KLG\J
M/=**** "BBB@ HHHH *P_&7_ ")FL?\ 7J_\JW*P_&7_ ")FL?\ 7J_\J /E
M;X:_\A&\_P"N=>C5YS\-?^0C>?\ 7.O1J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JMJ/_(+N_P#KDW\JLU6U'_D%W?\ UR;^5 &1^SW_ ,CM=?\
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M_P"5 'RM\-?^0C>?]<Z]&KSGX:_\A&\_ZYUZ-0 4444 %%%% !1110 4444
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MMXL$][+"8)X1F;)VG'O0 W0Y;>3Q]=/IDK26TD(:<YRN_P!J[VN,\,:KI/\
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M_(K7OT%=-^S;_P @G6?^NR?RH ]THHHH **** "BBB@ K#\9?\B9K'_7J_\
M*MRL/QE_R)FL?]>K_P J /E;X:_\A&\_ZYUZ-7G/PU_Y"-Y_USKT:@ HHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 %5M1_P"07=_]<F_E5FJVH_\
M(+N_^N3?RH R/V>_^1VNO^O<_P Z^GZ^8/V>_P#D=KK_ *]S_.OI^@ HHHH
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M_P#KJ/Y5[;\;O^2:WO\ O+_.O$OAO_R";O\ ZZC^5 ':4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &)XN_Y%:]^@KIOV;?^03K/_79/Y5S/B[_D
M5KWZ"NF_9M_Y!.L_]=D_E0![I1110 4444 %%%% !6'XR_Y$S6/^O5_Y5N5A
M^,O^1,UC_KU?^5 'RM\-?^0C>?\ 7.O1J\Y^&O\ R$;S_KG7HU !1110 444
M4 %%%% !1110 4444 %%%% !1110 56U'_D%W?\ UR;^56:K:C_R"[O_ *Y-
M_*@#(_9[_P"1VNO^O<_SKZ?KY@_9[_Y':Z_Z]S_.OI^@ HHHH **** "BBB@
M"IJO_()O/^N+?RKX_P#!/_(XW/U?^=?8&J_\@F\_ZXM_*OC_ ,$_\CC<_5_Y
MT >F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'[C_[I_E7'?!O
M_DK$7UDKL3]Q_P#=/\JX[X-_\E8B^LE 'UC1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7 :#_ ,E'U/\ W37?UP&@_P#)1]3_ -TT =_1
M110 5XU^T5_R*%C_ -?/]*]EKQK]HK_D4+'_ *^?Z4 <!X#_ .16C_ZZ-72U
MS7@/_D5H_P#KHU=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\0
M?^1;3_KK755ROQ!_Y%M/^NM 'JG[/_\ R3D?]?+UZK7E7[/_ /R3D?\ 7R]>
MJT %%%% !1110 4444 ><_&[_DFM[_O+_.O$OAO_ ,@F[_ZZC^5>V_&[_DFM
M[_O+_.O$OAO_ ,@F[_ZZC^5 ':4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &)XN_P"16O?H*Z;]FW_D$ZS_ -=D_E7,^+O^16O?H*Z;]FW_ )!.
ML_\ 79/Y4 >Z4444 %%%% !1110 5A^,O^1,UC_KU?\ E6Y6'XR_Y$S6/^O5
M_P"5 'RM\-?^0C>?]<Z]&KSGX:_\A&\_ZYUZ-0 4444 %%%% !1110 4444
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M\*^$O$'@R">'1;41I.P9_,;=R*]?HH X'[1X[_YY0_D*/M'CO_GE#^0KOJ*
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MSP=I[6^EF]N/FN[P^;(QZ\]!71T %%%% !1110 4444 %%%% !1110 4444
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MBTZZU0/I43A@@'S$#L:[>*-88DC0850 ![4^B@ HHHH **** "BBB@ HHHH
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MX67?_P#/E!_WT:/^%EW_ /SY0?\ ?1H ]-HKS+_A9=__ ,^4'_?1H_X67?\
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M0?\ ?1H ]-HKS+_A9=__ ,^4'_?1H_X67?\ _/E!_P!]&@#TVBO,O^%EW_\
MSY0?]]&C_A9=_P#\^4'_ 'T: /3:*\R_X67?_P#/E!_WT:/^%EW_ /SY0?\
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M0?\ ?1H ]-HKS+_A9=__ ,^4'_?1H_X67?\ _/E!_P!]&@#TVBO,O^%EW_\
MSY0?]]&C_A9=_P#\^4'_ 'T: /3:*\R_X67?_P#/E!_WT:/^%EW_ /SY0?\
M?1H ]-HKS+_A9=__ ,^4'_?1H_X67?\ _/E!_P!]&@#TVBO,O^%EW_\ SY0?
M]]&C_A9=_P#\^4'_ 'T: /3:*\R_X67?_P#/E!_WT:/^%EW_ /SY0?\ ?1H
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M'_?1H_X67?\ _/E!_P!]&@#TVBO,O^%EW_\ SY0?]]&C_A95_@XLH/\ OHT
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M@"E_9&G?\^4'_? H_LC3O^?*#_O@5=HH I?V1IW_ #Y0?]\"C^R-._Y\H/\
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M[X%7:X[7O$VJ67B%-+L+:*5G0,H8X)- '2?V1IW_ #Y0?]\"C^R-._Y\H/\
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M %+^R-._Y\H/^^!1_9&G?\^4'_? J[10!2_LC3O^?*#_ +X%']D:=_SY0?\
M? J[10!2_LC3O^?*#_O@4?V1IW_/E!_WP*NT4 4O[(T[_GR@_P"^!1_9&G?\
M^4'_ 'P*NT4 4O[(T[_GR@_[X%<;\0[*UM=.MF@MXXR9#DHN,\5W]</\2O\
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M*0,VXXX% '20,7MXV/4J":DJ.!#'!&C=54 U)0 4444 %%%% !1110 4444
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M%']IV/\ S]P_]]BO.O\ A7&J?\_47YFC_A7&J?\ /U%^9H ]%_M.Q_Y^X?\
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M_/W#_P!]BO.O^%<:I_S]1?F:/^%<:I_S]1?F: /1?[3L?^?N'_OL4?VG8_\
M/W#_ -]BO.O^%<:I_P _47YFC_A7&J?\_47YF@#T7^T['_G[A_[[%']IV/\
MS]P_]]BO.O\ A7&J?\_47YFC_A7&J?\ /U%^9H [C5]1LGT>[5;J$L8FP X]
M*XOX:?\ (3O/]P5'_P *XU/_ )^H?S-=#X2\*WF@WMQ-<2QNLB@ +0!RWBP@
M>.E). &0DFO3%U.Q"+_I</3^^*Y#Q'X+O]7UJ6]AGB6-@  W6LK_ (5QJ?\
MS]0_F: /1?[3L?\ G[A_[[%']IV/_/W#_P!]BO.O^%<:I_S]1?F:/^%<:I_S
M]1?F: /1?[3L?^?N'_OL4?VG8_\ /W#_ -]BO.O^%<:I_P _47YFC_A7&J?\
M_47YF@#T7^T['_G[A_[[%']IV/\ S]P_]]BO.O\ A7&J?\_47YFC_A7&J?\
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MT7^T['_G[A_[[%']IV/_ #]P_P#?8KSK_A7&J?\ /U%^9H_X5QJG_/U%^9H
M]%_M.Q_Y^X?^^Q1_:=C_ ,_</_?8KSK_ (5QJG_/U%^9H_X5QJG_ #]1?F:
M/1?[3L?^?N'_ +[%']IV/_/W#_WV*\Z_X5QJG_/U%^9H_P"%<:I_S]1?F: /
M1?[3L?\ G[A_[[%']IV/_/W#_P!]BO.O^%<:I_S]1?F:/^%<:I_S]1?F: /1
M?[3L?^?N'_OL5QGQ$N[>XTZV$,\<A$AR%;/:LW_A7&J?\_47YF@_#C5,'_2H
M: .M\#?\BI:?0UT=9/AS3)='T6&RG=6=,Y*]*UJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )R!@0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@'H"S@N1T) Z@UU'PP^+5]XNUB?0=<TM;348E9A)"C*A*G!1E;)1OQYP>G<
M]8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\ _::Z>%_P#M[_\ :->_UX!^TUT\+_\ ;W_[1H ]3^&,
M5M%\,_#JVBHL9LHV;8.-Y&7_ !W%L^]>#>+U6U_:8C^R 1YU6Q;]WW9A$6_,
MDY^IK<\.:9\5/"GA#3W\*20ZII6I6J721LJ%K-W4$@!V]3VR#@D@$G.M\,OA
M3K\7BT^+_&;8O%=I8H&D$DCRMD;W(R !G@ ]<=,8(![G7S)\;/\ DLVF_P#7
M&V_]&-7TW7@GQ5\#>)=>^*%CJFEZ3+<V4<4"O,K* "KDGJ<\ T >]]J\F^(O
MQ \*Z)XEM]./AF/7_$D+QF%5A7=$Y(**'VEMW0@*#VKUFOG[XD_#+Q@OQ";Q
M;X53[2TLB3KY;HLEO(H Y#'# XSWZD$>H!#\4M8^(6K^#+I]:\-6.CZ(LD3'
M=.)9V;=Q@AN.<9^4?6NT_9^_Y)DG_7Y+_2N/USPK\6/B!HER?$)@LK>UC\VW
MT^()NN91TX4G'!/+-P<8'.:[KX)Z-K7A[P9<:7KFG264\=VSQ!B#O1E7G()Y
MR&_2@#R']G]&C^)\B.I5ULI@RL,$'<O!KT/]I C_ (0;31D9.I*0/^V<E<EJ
MWPT\>^#_ (@S:]X0@%W"T[RP21NGRJY.8Y$8C/!QGD=#D'H[QAX'^*/C725U
M77HXC<6[A+72K;9D!OON2&P.B]22?;% '?\ POOY]*^ 5GJ%M;&ZGMK>[EC@
M7.9&6:4A1CGGI7.?\+M\8?\ 1.[O\IO_ (W7H'PIT>_T'X:Z3IFJ6S6UY#YW
MF1,02N9G8=..A!KLZ /'?B)\/+OXE^']$\1VQAT[6!91F6WN257:P#["V,@J
M6;J.YSBN+DUWXT^"+8G4K6YO+"&,A_M$*7480#EGD3+ 8'4M]:[SXP_"R_\
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M%B",DYPPQGMUKH?A9\)=6TKQ&WBSQ8Z_VCEWA@$F]A(^0SN1QG!. ">N>"*
M/:Z\=_:/_P"1#T[_ +"2_P#HN2O8J\Q^.'AO6/$_A"QL]%L7O+B.^65D0@$*
M$<9Y([D4 <]X8>9/V6[PP#+_ &6[!_W3*X;],U7_ &:H;3^S-?F4@WIFB5QG
MD1[25_,[_P O:NY^&?ARXTWX4V^A^(;/R69;A+F"4C[CN_4@XP5->60?#[XC
M?#CQ3/=>#4_M"QF&U9 \965,Y"R(Q'(]1Z\'DB@#9_:6BM_L'AZ4[1<^;,J\
M\E,+G]<?G[UHZSIT^I?LPVJ6Z[GAT^"X(_V4(9OR4$_A7FWQ4T?QD+#3M?\
M&EY']LN9'AAL(@NVW0 'JIQDD^YX&3V'T)\-XUD^&'A^.10R-81AE89!!7I0
M!YS^S;JELVAZQI&\"ZCN1<[2>61E"Y'T*\_45V/COX2Z5X]UJ#5+[4+RVEAM
MQ;A(-N" S-GD'GYC7 Z[\%O$GAG7VUWX>Z@5 8M';-+LEB!_@#-\KKU^]CC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %</\0_B/;^!H[2VCT^XU
M#5;_ "+2WB'RLP(')Z]2,  D_K7<57>PLY;Z*^DM87NXE*1S,@+HIZ@'J <#
M./2@#P+X/:]XBU;XOZS'KUY<M<+;3^=:O(?+BD65%("9P,<CBMWXQ>*]>E\2
MZ1X&\,W,EI=W^QYIXG*,=S%57>.5 VEFQVQVR#B?##_DXGQA_OW_ /Z4K5GQ
M#N3]J;1C(2%,<>S)[>6XX_'- &7+<>+_ (-^-M'75_$,NIZ-J#8E\V5F0H"
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MH@:1W=1N;:&&X_(RL02 3E2/;'T+7@OQZ#/XU\&HF3(7. .N3(F*]*^(^O\
MB3PYX>M[SPOI']J7SW:Q/#]FDGVQE');;&01R%&>G/O0!V%%?-%]^T!X\TR\
MDL[_ $/2K2ZCQOAGM)XW7(!&5,F1D$'\:]O^'?B2\\7>!--UR_C@CNKKS=Z0
M*0@VRN@P"2>BCO0!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **@OKVWTW3[F
M^NY/+MK:)II7VD[44$DX')X!Z5SWASXB^%/%NHOI^AZK]KNDB,S1_9Y8\("
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8/C?_ )$'Q'_V"[G_ -%-7SY^SG_R42]_[!<G_HV*OH/QO_R(/B/_ +!=
MS_Z*:OGS]G/_ )*)>_\ 8+D_]&Q4 ?4-%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >'_%3XP?V1?>(?!?]A>;OM#;?;/M>W'G0@[MFP]-_
M3=SCM78?!+_DD.A?]O'_ *425T'CO_DGGB7_ +!5U_Z*:N?^"7_)(="_[>/_
M $HDH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(/&_QS_X
M0[Q??:#_ ,(Y]L^R^7^_^W>7NW1J_P!WRSC&['7M7K]?('QM_P"2O:Y_V[_^
MB(Z /K^BCM10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7G'BGXU>&_"/B.ZT._LM5DNK;9O>"*,H=R!Q@F0'HP[5Z/7R
M!\;O^2O:Y]+?_P!$1T ?7XY%%(/NCZ4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &#XW_Y$'Q'_ -@NY_\ 135\^?LY_P#)1+W_ +!<G_HV*OH/QO\
M\B#XC_[!=S_Z*:OGS]G/_DHE[_V"Y/\ T;%0!]0T444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7R!\;O^2O:Y]+?_ -$1U]?U\@?&[_DKVN?2W_\ 1$= 'U\/NCZ4M(/NCZ4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &#XW_Y$'Q'_ -@NY_\ 135\
M^?LY_P#)1+W_ +!<G_HV*OH/QO\ \B#XC_[!=S_Z*:OGS]G/_DHE[_V"Y/\
MT;%0!]0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"YT2;X+_ !7T(:9J$\ND:H4CF6=@"5+['#8P#MW!@<#T]<Z'Q->Y\??&/2_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU@BM<2;=QP!U/UI2DHJ\G9#C%R=DBS12*RNH92&4C((/!%+3$%%%% !1110
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MW(>,\;AZBM'.,6DWJ]B%"33:6B+]%%%42%%%% !1110 4444 %%%% !1110
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MO_6_F?/8E4E5:I;!11172<X4444 %%%% !1110 4444 %%%% !1110 4444
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M3"W*CD?WO<44\;1J572B]?S] GA*L*:J-:?D:U%%%=9S!1110 4444 %%%%
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M4>*)8P<G&UL,5'J.F<@]#9^)&M6WB3P;X*U.UC*VMYJML_E,!\N<_*>W'(H
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MT UIJFL2>)I-0O;*64'3H[>V@#0IN;(;!7)P4[MT/X@&3_PF7QS_ .?77/\
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M>1X>6T,K6'V^=<QI"/,7RPNSYBK<9P<\]378?!+_ ))#H7_;Q_Z425T'CO\
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MET5EZ/K$>I1;6PMPH^9?7W%:E>K3J1J14X.Z9YM2G*G)QDK-!1115D!1110
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MUBZ:]EB==K(&Z CL>^.V<5WQMX&F$QAC,HZ.5&?SJ2@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLN6MY'A;T/S+_C^M>DH8JBK1:FEWT?W[' YX>J[R3BW\U_F;U%<I]GU[2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KYMTGX@:)\-OB;XJ\KS-4TS4I][/;H5E@
MD5W)3:X4'!9AP<8"G/45[G>^-?#VG>)K;PY=:AY>K7(4PV_DR'=NSCY@NT=#
MU->5:K_PH3^U[W^T/^/WSW^T?\?W^LW'=TXZYZ<4 :G_  T=X/\ ^@;KG_?B
M'_X[7HGA+Q38^,O#\.M:=%<16TK,JK<*JN"IP<A21V]:\;_XQX_S_:%>M^ _
M^$8_X12W_P"$0_Y V]_*_P!9][<=W^L^;KGK0!TM%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X?\5/@_P#VO?>(?&G]N^5LM#<_8_LF[/DP@;=^
M\==G7;QGO78?!+_DD.A?]O'_ *425Q_Q4^#_ /:]]XA\:?V[Y6RT-S]C^R;L
M^3"!MW[QUV==O&>]=A\$O^20Z%_V\?\ I1)0!Z!1110 4444 %%%% !1110
M4444 %%%% !69KU]]BTU]K8EE^1/ZG\JTZY*Y)UWQ$L"DFWAX)'H.I_$\?E7
M+BZKA3Y8?%+1?UY'3A::E/FE\,=7_7F:?AJP^RV'GN,23\_1>W^-;5(
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MGUKNO^$;T7_H%VO_ 'Z% %ZTN8[VSANHL^7,@==PP<$9%34R**.")(HD"1H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-M H:23'4@$@ #U)% '445P?@SXN^&?&VH'3K-KFTOB"T<%VBJ90!D[2I()
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2[;2+".TM5PB]6/5CW)]ZNT 87A31;C0M*DM;IXGD:8R Q$D8( [@>E;M%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9)=R\MN.!CCFKOB;PCHGC"P6SUNQ6YC1MT;;BKQGU5AR/Y&MNB@#CO"OPO\
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M9_\ 00G_ .^!7<44 96@:'%H%@]K%,\H>0R%G ') ']*U:** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M _&GQYU>P\57>C>&],M)8[69H#+.CR-,Z\':JE< $$=\X!XZ5[Y7SOX<\5^'
M_AK\5/%46I31W-KJ,WF07UKMF\@;G9D8*2PY;:1UR@.,'- %'_A>7Q&_Z -E
M_P" $W_Q=>U_#GQ#JGBCP;;:IK%O';WLDDBO''&R !6('#$GI6-_PO'X??\
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M8>+/B_X$U/P;KEA9Z[YEU=:?/#"GV2<;G:-@HR4P,DCK0!YM^SC_ ,E#O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y'\3OA-H.JP^(O&$]WJ2Z@ED
M]P(TD01;HH<*,%"<?(,\^O2MSX)?\DAT+_MX_P#2B2L/XG?%G0=*A\1>#Y[3
M4FU![)[<2)&ABW2PY4Y+@X^<9X]>M;GP2_Y)#H7_ &\?^E$E 'H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_\;?^20Z[
M_P!N_P#Z41UY_P#LR_\ ,T_]NG_M:O0/C;_R2'7?^W?_ -*(Z\__ &9?^9I_
M[=/_ &M0!] 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445R7C;XBZ#X&LV;4+@27S)NAL8CF63.<$C^%
M<@_,>.#U/% '6T5X[\%_'_B#QMK.O?VQ=K);PJDEO L2*(0S-P" "0  .2>E
M6OBE\2-9T77+'PGX3MEFUN\4,9"@<Q[LA0JGC=QDEN !TYX /6**\.\)_$GQ
MEH?CBT\*?$&W02WVT0S;8U96<D)S'\C*2-O'0_0U[C0!Q?Q!\-:#<^$/$FJ3
MZ)ILNH#3+AQ=O:HTH983M.\C.1@8.>,"J?P2_P"20Z%_V\?^E$E=!X[_ .2>
M>)?^P5=?^BFKG_@E_P DAT+_ +>/_2B2@#T"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \_^-O_ "2'7?\ MW_]*(Z\_P#V
M9?\ F:?^W3_VM7H'QM_Y)#KO_;O_ .E$=>?_ +,O_,T_]NG_ +6H ^@****
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M_P"@;KG_ 'XA_P#CM<A^SQH6CZW_ ,))_:VE6-_Y/V;R_M=NDNS/FYQN!QG
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M/*QG:!G&3^9KV_\ X03P?_T*FA_^"Z'_ .)H \__ .&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =KT#_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0
MJ:'_ ."Z'_XF@#S_ /X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#Q
MVO0/^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XF@#S_\ X:.\'_\
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MH?\ X+H?_B:\0_:'T'1]$'AS^R=)L;#SOM/F?9;=(M^/*QG:!G&3^9H Z_\
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MOFSC" C"C"C@>@]*]4_X03P?_P!"IH?_ (+H?_B: //_ /AH[P?_ - W7/\
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M_@NA_P#B: //_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]
M_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)H \_P#^&CO!_P#T
M#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KD/V>]"T?6I?$@U72K&_$/V;R_
MM5NDNS/FYQN!QG Z>@KV_P#X03P?_P!"IH?_ (+H?_B: //_ /AH[P?_ - W
M7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVO0/^$$\'_]"IH?_@NA_P#B:/\
MA!/!_P#T*FA_^"Z'_P")H \__P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_
M[\0__':] _X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XF@#S_P#X
M:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=KD?VAM!T?1%\.?V3I
M-C8>:;GS/LMND6_'E8SM SC)_,U[:O@3PAM'_%*:'T_Z!T7_ ,30!P'_  T=
MX/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[7H'_"">#_\ H5-#_P#!=#_\
M31_P@G@__H5-#_\ !=#_ /$T >?_ /#1W@__ *!NN?\ ?B'_ ..T?\-'>#_^
M@;KG_?B'_P".UZ!_P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\
M$T >?_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM>@?\()X/_P"A
M4T/_ ,%T/_Q->(?L]Z%H^M2^)!JNE6-^(?L_E_:K=)=F?-SC<#C.!T]!0!U_
M_#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..UZ!_P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q- 'G_\ PT=X/_Z!NN?]^(?_ ([1_P -
M'>#_ /H&ZY_WXA_^.UZ!_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$T >?\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..UZ!_P
M@G@__H5-#_\ !=#_ /$UY;\>_#6@Z/X#M+C2]$TVQG;4HT,MK:)$Q4QR'&5
M.,@<>U &E_PT=X/_ .@;KG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM=^G@3P@
M47_BE-#Z?] Z+_XFE_X03P?_ -"IH?\ X+H?_B: //\ _AH[P?\ ] W7/^_$
M/_QVC_AH[P?_ - W7/\ OQ#_ /':] _X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B: //_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\
M':] _P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)H \_P#^&CO!
M_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KD/V?-"T?6I_$@U72K&_$/
MV?RA=6Z2[,F7.-P.,X'3T%>W_P#"">#_ /H5-#_\%T/_ ,30!Y__ ,-'>#_^
M@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM>@?\ "">#_P#H5-#_ /!=#_\
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M_P""Z'_XFC_A!/!__0J:'_X+H?\ XF@#S_\ X:.\'_\ 0-US_OQ#_P#':/\
MAH[P?_T#=<_[\0__ !VO0/\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\
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M_A8-03Q1XV35)%DODN(DFD1=H<CS!N '3.,_C1X6\<67@[08?#?BB&ZLM4L
MT4:+;O(+I03M,9 (.>G.!_1?A?=7-]XI\;75W:O:S37$+F"3[T8(D(!]\8S2
M=[,:M=%'P!INO^,?#T\VI^*M8MK2*ZDCA%I<%9G(P26D;)*C. HP.*?X5C\3
M>(-2UKPQ?>)[V.RT:X,;7=N0MU."2$!D(. -I)/7)QG%;?P:_P"1%?\ Z_I_
MYBH?AW_R/OC[_K^C_G)0WN"6P[PI<:KHGQ%U'PG=ZM=ZG8BS%Y;2WC;Y4^8
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MG(R >5((((.<9')SQL?$;QM!X%\*3:B=CWLG[JSA8$AY2.,@?P@<GITQG)%
M'6T5P/PD\::GXZ\*W6IZK';1SQ7KVZBV0JNT(C<@D\Y8UWU !117GGQ$\0^/
M-&U*SB\(Z'%J-O)"6F=X&?:^>!D,.U 'H=<_I?@GP[HOB*]U_3]/\G4[W?\
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M./F&YCN R,CKS^! />J*16#*&4Y!&0:6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH XSXH>$!XR\$7=C$@:^@'VBT/?S%!^7_@0ROXCTKSW]GCP:;6S
MN_%5Y$1+.3;6@8<A ?G;\6&W_@)]:]UID4,4$8CAC2-!DA4& ,G)X^M #Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *AN[NWL;26ZNYXX+>)2\DLC!511U))Z"IJI
M:QI5MKFCW>EWF_[-=1&*38V#M/7!H S[3QMX6O[N*TL_$6EW%Q*VV.**[1F<
M^@ /-<#XN^&?A[1/#?C+Q'Y+7>JWD5U<":X((@,A+$(O0=?O<GKS@XK7T7X*
M^$=!UFTU6R2^%S:R"2/?<9&1ZC%;?Q*_Y)IXC_Z\)?Y4 <M^S_\ \DQ3_K\F
M_I7/ZP3\8_B*^EQNY\)^'MS7#QN0+F;IC\2" 1T4,01N%:WP0MI+SX.W%K%)
MY<DTUS&C_P!TE0 ?UKE[/X&>--'M)8].\9K:0MEWCMY9HU8XZD+WP* )/V9>
MOBC_ +=/_:U?0%?+/P(T#5M5\237]AJSVEGITT#WEN)'47*MOP"!P<;3U]:^
MIJ "H+R&&YL;B"Y.()8V23G'RD8//;BIZR?%.FSZQX2UC3+5E%Q=V4T$98X&
MYD(&3Z9- 'S[X(\5Z[X,B\1Z)X/TEO%&FQ3M-#?Q0R!4<J%RP ^8?*/E!&=I
M(.#QVW[/MKI:Z!JE_!JBWFJWDR-?1!2I@QN**0>N=SG<.#T'W:Y7X3^/]'^'
M6BZOH/B>*[L;^.[:<(;=BS915V<=#\N><#YNM;/P$L+Z[UKQ)XH>VDMM.OY"
M( W20F1F./4+TSC&21V- 'N=%%% !63JOAC1-<NK>ZU/3+>ZN+<@PRR+EH\'
M<,'MR*UJ\B^.7Q#N_"VF6^B:1/Y.I:@A>693\\,/3*^C,<@-VVMCG! !@?&G
MQ+!XQU+3? /AY/M^HK?!YGCR5CD"LNS..<!F+'HNWGOCU2R\ Z!%8:+'?:=;
M7EYI5M!;PW<B?./*Y4@]OFR<>]>)?#_XF> ? >DI'!HVKS:E*@^U7C1Q%G;N
M%^?A,]!^>371_%KXM36WAK2K+P^TEM<:U9+>22MQ)! X^4#' 9OF&0>,<=00
M 5?C%KT?CO6]-\!>&XQ>WL5WYEQ.A.R)P"NW([*&)8]!C'7('M^CZ;'H^B6&
MEQ,6CL[:.W1FZD(H4$_E7SWX"^*'@#P'HZV]IH^L2WTB@W5XT46Z5O0?/PH/
M0?GDY-?0FD:E%K.BV&J0(Z0WMO'<1K)C<%=0P!QQG!H NTC*KJ58 J1@@]Q2
MU#=I/)93QVTODW#1L(I-H.QB.#@\'!H XGQ1Y_@'PW,W@?PE'<7-U(QDBM8B
M%C^0_O"JCYN@&T8S7F_PR@TW2?A#XSO+#4O-UI[*4W<01D:UVQOL7!ZG)<[A
MQGCM2:#\;M<\*76I:5X^L;VZU"*3,92..-D.,;2 %4J<9##.<]QBCX0^&M0\
M4ZEXM\0W]O)::9K=M<6RK@XD,S[F*>H3&,X_BX/!H Y7X:>,O%&A>'[[3_"/
MAS^TKPW!N;JX,+RA(]@"KA2.<ASR>><"O9/A/\0K7QG%>6L^EVVFZQ:?--'
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MCIGYVYY7#?>!)Z@YZXX/68I?BO-XH\770E3P]H=C/%ID>XJ)950G>1^3'I_
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M9K#1=9>ZE -S=O'$7E;Z[^%'8#^9)KZ%L+Q-0TZVO8E98[B)95#=0&&1G\Z
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MQC?3:IXG^%T%WB1)-/L)G!_B:20!L_7:*[C]HV-#X%TU]HW+J"@''(!C?/\
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MX53E1-&' ^F15BB@!$18T"(H55& H& !398HYXGBEC62-P59'&0P/8CO3Z*
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M#(_WWCB52WU('-,N='TR\F,UUIUI/*1@O+ K-^9%7:* ,W_A'=#_ .@-I_\
MX"I_A6@B+&BHBA448"J, "G44 17%M!=PM#<PQS1-U21 RG\#1;VT%I L%M#
M'#$N=L<:!5&>> *EHH K?V=8F]^V_8[?[7_SW\I?,Z8^]C/3BK-%% %>[L+.
M_55O+2"X53E1-&' ^F14R(L:!$4*JC 51@"G44 %5?[-L?MOVW[%;?:_^>_E
M+OZ8^]C/3BK5% #71)$*2*KHPP589!J&UL;.Q4K:6D%NK')$,80'\JL44 !
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MRXU;1+NP@N_#MQ+]KM1*%=(RQRT10]@PW XQSZUUL<:11K'&BHB *JJ,  =
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M ";I_P!RW_[0KS;X8:'+XD^"?C'2H$,D\T^Z% <%W14=1^)4"OH(:-IPT/\
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M,W*VJ&-".K@O@?G6)\+6\):IXDUF\^(-S#)?#;) =1E*J[982;L\,WW,*??
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %1SP0W,+0W$22Q/PR2*
M&4_4&I** &10Q01+%#&D<:#"HB@!1Z "GT44 %%%% !5633+"6[%W)8VSW(Z
M3-$I?T^]C-6J* "BBB@ J*XM;>\A,-S!%/$>J2H&4_@:EHH :B)%&L<:JB*
M%51@ >@%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %!!-\# 2(  A$! Q$!_\0
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MY]A3H[EA$TD\7V6$_<+?>/U%'-*P796_LJ%03(\@';&/\*K26+M+L@MY@O\
MSTD8 ?EBMJ(QLNY&)8C[QJ-;I)5\QA(@5M@##&34^T879F-811PG,C22@<(G
M>IH=*C=1YC2(WH<5=2WV2/(GWF/Y58*)(H+\[>>/6I=63T3"YG2Z3;Q1[MTI
M/IN'^%$6D6\D8?S),'I@C_"K"V4HO//>=G4Y^4]*MY6-#@9P,X%3SS[@V9_]
MBV_]^7\Q_A37T:'Y@C2Y R"2,']*THW\Q%?:5SV/44XC((SBFJDNXKLQX](0
MR[9-X!&00P_PJ8Z+;_WY?S'^%7EB57#G)8# /M1&[/NW*%P<+SU%#J2Z,+LH
M_P!BV_\ ?E_,?X4CZ-;@<22#ZD?X5*\@NG:+S&C,+@G;_%[4U)?-,TDLC$'[
MJ ?=JDY]QW8S^Q[8+DRR?F/\*ADTVU10?-<#/))'^%+;^:8Y(F;.Y\@TZ5RJ
MJG?=CFJ][N/J5EM+4S;#YP&,[LCG]*D.FP[?,!E9>RC&ZIWC)FSMR#Z=Z?*T
MUN%.-P] .E.[[BN4Y=-2(KDOM8^HI?[/@XYD]QD<?I5F<2+$2%+N>@/:FP[@
M@$H'F8YQ1>5MPN0OI]NP_=/)GON(_P *?_94#'*RN5'49&<_E2S2HA#YQQ]T
M=Z2%D@4,7//0'N:7OVW'<JO:PI*(\2ER?NY'^%/DL%5@J[R<@=1R*LB1A,1)
MAB>0*=.K^=')& Q0<*3SFIO/N.X?V/!_?E_,?X4'1[?^_+^8_P *ECNI))MH
M V@<^N:EE<Q2;F($6._K4<\^XM2I_9$']^3\Q_A3(M-M9@VQY?E.""1P?RJZ
MK>9,"K_*HY7'6I %#-C 8\D4>TGW SCIEL) A>7<1GJ,?RIO]GV9QB9VR=H(
M(//Y5J<=ZB^SHJA8@(USG"CO2]K/N.Y4.D08X>3\Q_A4#:7N*&)CLSA]QY_"
MM8L .< 57GAW+YBNP(XPIZT>UGW!%3^S84D"N92&. 5(X^O%1M900S2"X=DA
M&-DF\<^W2KR1&.++2,6'.3426T<D6V?9,'SN+?TJXU7W S;VREMY4:*2-H#U
M+>GUJ00VV&WB= .C$@@G\JFMXDM%-G;$,G)$4G(Q]:LMLMHV:-#*<?ZD'^5:
M*HVA-F<MMY/-U')Y9Z21$$8]QBI#'IH ?SI3$?\ EH,8!]#Q6O"=\*MMV\?=
M/:HWC@'[LA0)#T X)I>T=Q7*HTNWD3=%*Y4CAL@C^50IIJK,ZS,=N<*4(S^(
MJY#B &$+LY^7'2GF.-9?M.PM)C!*GJ/I2YWW"[*D^DX*F LP_BW,,_AQ4<^F
MA,21$R0@?/\ , <_E5YC+&%C$FYW.06'04\PAHB4!5O[IX!--38KLSUL(FA+
M;)T;'1L'^E-32C*!Y-S&[8R5QBKT-ZJ%XYMP9,9XJ0F!VS#*(GQDE1UJN:0[
MLS/[/9)F1[:<H/XU88/Z5(]G:(O_ "\;LXVG _I5^.*:,Y%RTBL<[CVJ>*42
MKD$,@_B-)S8KLR6L[*)=T\DL0_VB.?TJ4:3"Z!DDDP>03BK4I\^-WC5)0OW4
M8<9J-+IF!\X& XP.. :7-(+LC&CV^>9),?A_A3AHUN?XY?S'^%,F;5!<AX1%
M)$HY3."U3+<33AE>)H>S#NOO1>7<>HPZ-;A2=\IQ[C_"D_L>W(!620^OS#_"
MKL2A0I,Q;(QD]ZB=/(D$BJ?*[@=JGGEW%=E+^RX&=/+=V0]<L,_RJ/4M/BLX
MHVC9R6)!W$5KQQK/<+(!D(./:JOB 8AA_P!XU4)-R6HT]34\(_\ (*E_Z[G_
M -!6M^L#PC_R"I?^NY_]!6M>_O8=.T^XO;APD,$;2.Q[ #)JI;F4OB9\\?M%
M>)OM>L6/AR DI:K]HFP>"[<*/J!G_OH5YQXI\(7?A.RT&]EW@ZA:BXY'W&SG
M'Y%33H;^W\6_$H:AK-XEM:W=[YLTLS8"1@\#/LH %>R?%_7O!WBGP,T&GZ]I
M\E[9NLMO&D@RV."H_"I)/1OASXD7Q5X'T[42<S!/*FR<G>O!_/@_C755\W?L
M[^*/LFM7?AZ>0^7=KYL /0.O7\Q_*OI&@#F=9=_[1"(0N[^+^E5RK1P[5RS$
M\X-2:T =1*^9@Y#8%4I02ZJ<J5&Y55OO5#74V6Q8>*3R7S)ENHSTIN',<>=K
M(?O 4&-+F$&5V /1>E"1%XO+!:-5X'J:.@#]J+*&10K,.6]J,H)7QZ<CUJ%%
M*^:)G)C''3  IB7 64 0MM' D/3%"0#Y#':PMN)PYSCN!3K=H9H/M$+B2'G;
MCVJ5)(KD';AAT.142D;GBML*%7"@#"@T]0(4?S[4%H9)D?D@]J;+=%Y(XE*D
M<AF[J>P%6VF6VMRV=[*,$+W-021.]MDR+#GYG;'(^E4K 2%QD1,[1RNGY5(J
MK&I<L6XY)[U3$D$<2S2LTL@^5 !RU6/-58@\GR$CA#VI- ,DD*?O(+=GD(ZD
MX&*0:E L@1YD4@9//>DD>2>!EQA2.IHMM-@B7'E+@C+9'>DY12'8)/-N8_\
M1;A85/\ %C)-4[07=B[QWDAGG9]T:QCJOO6O%:6\ )B0*<<XJ:':Z*^!NZ9Q
MS24N@7*<$$<%TX08>7YWXX%6FAA>,P%4VGDKZT*T=R)$VL /E)(QGZ4RUM3;
M,W.5Z(2<D"D)NY8*_NMBC'&!4, $:K'(1YF.@J<],9JO$-\A+KED.%:DA$X
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MNH%C=YL3.5V$="W-1*R.=H<+,!GY>X]:B:6=;==^T]F9.PJ>0Q;8R?D+# D
MY%4G831*KK)&=Q/ YIFR&X8312<XP<=Q3/,N "0B;E.#Z$>M2FWC9A*GR-U^
M7O57L(@AWB*2)V+D'A0/NBK*(P8%L$8[]:CD1+R+!+1GV.#2(/LJ8DE:16;
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MB5<X_=E0>]$Y%E:QI9D--&F(QZ^HJO);7"Z>/**K*"7!]O>K*X$T5_%+B$J
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MVLB@"9O,)YW'O5EH X&0#SQ4R\)CT&*T]IHAMW,F=0!RI!/RJ!TIT**(/*=
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M;DD=Z&2-AC$:%%8L,]2<TLL@BB9R"P S@=33?W4 8DA<G)R:?O79NS\N,YH
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M1I)77<KC&]CT-"_ZIGA?S68Y S2!&G=^7B)QGTI%L?)V["3SSBGU$3K$4D!
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MY4,A>6'[W/W<U9<!BBL.#0] $B7+,22>PJ.X7SAM#80'YO>FN9[.'Y5\T$X
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M!OY"@XR:6?#Q87DD<549@9TEO!.Z$I@+\V1TJP) 2,. I'YT]$_=!0>@YJL
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MR>"QJ>:S'8VHF\R ?*,]@*J7"[5WMA5 Y/H:3[2T,">2AD<$!N>@J2[O;:"
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MA<'J*LQRJS!<_,5#;?04VK /48X[XH?[N*:)%,C*"=PIDS,%^49(&?K4,!L
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ME)/Y1.3(L<GW5)//X4K/=(P.^%HP/FR,&J\W]G71267#,1A74_=HL!,;-"J
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MJ 117D4#N,D'>HSTJ9U$VZW9CRO;TIXA5 @5>5& ?:DT+8#DE=J\9Y-/+*@
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MD\S8-_K2O(L>"<\G%,DFE5V"PE@HR#GJ?2G"1"RJV!(1G::A@$R*P#%2VPY
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M GS!SRX&..E*X"EP'"'J>E11;A<,JKMC7M_>/K4C*6/7!]:&=4QN('IGO2N
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MD^40SMSQ]X>M6$T]X)I)(I 5;G:>WTI4G25,JAW [2Q'2IVU'<6(D(4*[0O
M^E021S1P\GS/GR/85.F\#+'<3[5#<1RO-$8WPJG)4=ZE;@7(I=S.A4C;_%CK
M3R^63805/4U&[D1\C/M4!62.,M!QD<J>E4F*Q<9/ESNX[<TV1%D4!F8!3GBH
M%D5;5%,10]DSS4L4@EA#;6 ]".:?705B5F& 0.M5I5=I#EOW9'W?2GQ.9')*
MD*.F:2.0RC<R%&SC!J6"(+\2)9/Y?#8^7VIEK;%-."3,9&8?,3_%4L\HD)0
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MNU6D$?F.#E5/8^U/+C*JWWF'2I CCN$N&($;8!QDBG/,B2B//S-V':GET4[
M1D#) ]*A,D,JAP-P)QD4] )DW ?,>:AN8C=1>6&*$'K3C&WF[PQZ8QVIR@C
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M8\S)(]*C9G-Q%!).4D7YB0.#3O?4KT':49(Y_+DB<;%^7(X^M6==CC\N*54
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M=XSUP*M6L/V>/R@#QSG/4U*(T60N!ACU-#D%R.1#.OEL"J,O)!Z4R>/<]O&
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ML%R=9"%9",LPXSTJ)^B!R"QX%-RT8_=G('KT JXEA++$LK2*D>> PYJVXQW
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M.W-0QR*;7S(8BN[G8>"*99S*RF/:ZLO)W_XT-#+50(SSPR#?@Y(! Z4[>(W
M9BQ8\ =J8MPI,@  5.I!ZT6 CPA18O*WJAY)XYJ1-LD6UDVAOX:9<L9851$)
M60X;M@4DLWEQYCC,FT8 '4^U+<8X@Q!B<>2J_< H>8)!O4<D?*&XYJLFH"62
M*-4/FN?F0_P?6K0CPNUSOYSR*EW6XRO#:F%596*R,=TH)SGVJP7 ./7M2&1#
M*8]WS@9(]J8BE<Y.[G(/I2;OJ,BBOH)LX)# X*L,&G2P>=-%)NPJ9ROK0;=)
M;L2E/F1>&]:?'&L2,JC&3G\:3LM4,;$)1*P;'E_PFI-Z\@')'4#M35).2PQ@
MT((A*Y4@NWWL4@(T0+<.4VC(RP[DTR6:2"/>5W<XPOI4[83+;<GV[TSS/D+.
MI4YZ4UJP&%"RI+(VQAT . :AN+H)#YDB84'@GUJ.:]MYD.X;@C<#IS6;=S&X
MC#.X*+S@]JVA3;>H%^>\+(5D  QU4]:R1<Q)*^UO,)'*$]JK1WB/>&':=[+G
M@<8J6*V=)BP R1C'<UU1IJ(Q2R3[3)O12?D!JK""CR",%@6Y&>E78EFMX\S)
MNR>"!G'M5U+18)!,L>YY!A0HY'UHE540(((W!DBPJ3 #&_HPJQ'I<B3)([>8
MK#:R <'W-6C#M;SIB9 H&%QTJ=@7C8!V4..H[5QSKN]@L)Y@M58H@ QSQVIJ
MW$>W('R8SN P,T^'_1U D#..@/<UG:Q%=320PV^!"QR_O65-.;LV,T@ZCHO4
M9J%;:-9#)\Q=SW/2G11E+6) -K 8Y.:D&X!5)WD=ZANVP#0I6;RB">,[L<5$
MZ1)<H%4F7O@_SI]Q=/$FXQ,R],*,FG)&N_>G#'!;U--]P(X8XC/\Q+NIR,]C
M4%W8QR));1 !Y&W-W_&M%QO''&>U5GAD#!A*L8'4D<D52;3T$4(+<0P"W5 S
M@D,Q7C'M5.Y6>.!5@B96SA5!Z_A6Y'F0E0,<?>'0TD09'(8?O!_'BM8XB2>H
MS#&((2MQE),_ZK/0>IJ%9!(2C+@YS@'M6U<6,%_:R)/&R[FRS9^8X]_2J/V.
M/RF:% HCX5\Y,OM[5TPQ%-[[@1,T:KA"0 .?I4EO?2QE5())&5SV JKLNX(C
M/- 823PO4TR*X2\>$E61\E#$W?WK3E3 VDU0K*D4^[>PSN X%6!=J]Q&58]/
MF Z5C@%)6A.69>_9:19-EL&9V"DG*CJ?_K5BZ*>H&_%<QS;QN&Y3SCH*<(V.
M<.0,YK'6?RE#*ZC!&5QU%::W$4ZM$)0KGI@US3IN(#FC83EU;DKBI0"< ]>]
M,96,)6)_G_O&AV9 @"[F/6L7J OSM(04 C[$]Z0[5EW!<LPP33TD69-R'CIS
M39"X7Y "<]#2; 8TI5T4J6W=QVID]W''!YJ R?-M 7UJ9NU(JIM. N,]O6A6
M  5VB1AA\<>U1)'&8<QC#GJV,&A]S1MY3?-G^(4Y)D:-CS\GWN,4^@%>6/[(
MA>-<G=DY-0I;DSRR'<@<#C/>M+(=1T*GUJ-X"SEED*DC'M4^0TS.\^.RNCN+
M!91A=H[^]/C(GA=IX1R<[DYS3=\$N_!)>$D[3P<U-&&9%B.Z.3&[<!Q]*-XZ
MHHKW-PB.MLKA7D7]WD4.4_=3RR?NDXW*>]6Y%VOND56';CD4U+:UO82 -BG(
MVCBIC:]POH6C<;+4,@#A1U![4V.]CEGV#[VW=[8JNMA%"@ <D< C=1/'#<)Y
M0! SPR\8JI.Q-D2M.D,PG+LT6<'G@?A3[I%NGBE60@H>!_":SS!#-9N@D95W
M<M[BKEE)OBVE.%X!/>KYW'5 T2_VA#<L88'VS*<$'VJ59L-F4KO YQ5%5C59
M56$JZYPQ'?UJG93!MANI&63D;R,;_:FWS;"Y38B,GFLK-P>14:1YO968MNQ@
M#T%1>=]FC,K.SJ.V.11<.-R3EG2-1N9U&<CTJ%?9#L7U0(P<\[1U/I5366W1
MQ8Z9Z_A6A;H'7<C;E8 K6=J\<D<,?F;=Q<\BNJBK2,[ZEG0S_H3_ /70_P A
M5VX5I$*<@'^('D50T5@EC(QZ>8<_D*O"4LN[ (]/:JE\3)>Y$0=R;1Y@'WFS
MTI9"P;<SHH_A)/>E$:1QE(AM#')YJ"2"&=524!U1LJ<]Z3:6K$M2<KN5?, +
M#GBID.>:KF55QD]3BI$9XE)E8$%OEP.@K)7>I318H&/2D9@J[B<"H529/-=7
M\PMRBMT%:(D6*$PF1@S,S'.":A!EDF1I%")T9.^?6K"RX*+(,2,.@Z5(W(/K
MCBG<5QJN&8[6! X(':J<UXEG=+ EK*[2G)91\H^IJ:W=EB_>J!+U8**L!N,]
MJ-AD0^>8''"]&!IJVR@8/8DJ<\C-*YCM8I)0 %QN-0^?/<6\;0*JAQDLQSMH
M EA0 Y$KN5X.:D ?S#N(V=AWJ.W\SYO,7!!P#_>'K4DF_;^[QG/.?2I>X#F(
M"Y/0=::KHR@@_*>E&X%&V89@.F:2,$Q*9$"OW4=J 'GBH9I4B +YP3BGR1B3
M;EF&TYX/6FRHSMVV$8(/>E8$,7)&3CVP:8NW>VT8;N:21C#)%!"H /Y 4\R(
M'V9&_L.YJ6F4*14%P)&"A%#+GY@3BG%2[[HY,]BO84K HN ,CZTMAE>222(,
M$'FMD87I4=U<I$FX',OH*B=9(RTLTX[[5K%NG>]8L&C4H?F(/6M*<.9ZE6)I
M6>Y=[B38L@X4#KCVJ 0N[%U7)SN)/'X5$S*1M<;3'R"IXIK^9Y*RH974MA@O
M-=T8V&303(SK,0'VY!7H/RJRMM#??OX %D<X?/1<4^WT"6]=7D"Q6KK\R_QF
MME+)+6-8>D?W5V\Y'O6=2I;2.Y+:,Y--@'SNY>1!G(Z"K,*K&!,IRC#YN.35
MN.T2WRL?RQ]0.^:AF^56+,2FW&U1W]:XIMMZL=[@_F[D$6W!/.[L*3RF5VPY
M8'H#VJ-2(K:,NQ&> >M,B@,4;AI78L=V2?Y5B]-&43AG5]@B C ^^#WI6S"N
M\*6(/0556^=K\6?E.%";C)C@U=YP #DFG)6W$,&0Q9LX/:G*GE1.YD9@3NRW
M:FC<9 "!L[^H-/;]ZFP;D&>>.M$>S!D%K*;B1L[3&?\ 5D=ZD+F69XP5,2C:
MX([T\%(V5%4*/4< 5EW6LB.:2UMK8RN#@'.%;\:UA3<OA0C4W00^6@*C(^7%
M4I-4=;@1_9695."VX  >OO6=#*6MY(W8I&,_(>J^O-5T8R!8R1A1\A/\0]ZZ
MHX=?: T)=3QJ+"2S9D4?)(K<&ECU7>HCF0E58^8V<8':LB.';+*S3MGM2O;M
MMP7&",]>:T]A3&:K7"QR)(EXSP*Q^0#)J-KFWGE,R7[ESQY?9:STC9&+JVW*
MXP#_ $I (XT9$C4@G);WH]C#8#9EU)8Y%3R 82.)-W]*CFO[,QLR7#ID@C K
M+4K%$_FN YX((IH\R-SNR\3+AACC\*?L8"-HW4/GH4*KT.-V"_X4MU=CSH\
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MIR=O>I(\; !G'OUHO8"&+[.,21MG^#.?THC2"WF\F.,AI/F)QQ4A1(HFVJ%
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M1213W"A9]NW/(7KBEN2Q19"Y"I\S*O4FB&X6]B)4O'^&#3U: L*NQ % "C@
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MJ$D R'IUZ"K;*,#(8#&W _G5#2)2L!0(2#(26].!6FWS'(Z"JE\3$]R(1JC
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MX7:X6(!W^\1U-3$A4W'@8S2VV 141"2J@9ZTO>F(OS&0,3N['H*;+,L!W2,
MIX [FAZ@5IY[U9)8XX  HRKDY!JT?.\J,#;OXWG_  II@+3B82L#CA3T%38S
MR>M4WV 1L*,G!Q47D12,DK( XY!]*)B[2"#RCL8?ZS^Z:=N6.#))?R^"1UI6
MT IRO);SXM[;S Q^<*<$>]17MP@DBCP^\G*XZ?C6@LCO)Q$0I&0QIT:.4_?A
M"_JH[4]$TVAW.0O99EE)^9NRJ5Z'U%01VLLS;(XI-YZDKC-=ND$4:!508'3(
MI%4[7!<$]BHZ5LJR2T0^<YB/0I(T#W1W*Y 2).N?>MVUTZ.V#'N1]WLM6XB&
MC!YXX^8<TV-8QOC4G.<G)K.4Y2W$VQ0&,1#X4D$<=JI+']A)&6:!5SDG)S6@
MP7'/2L>8K'#/,TK&-6)VX_2HYK+0(JY:EGW! %R&[^@JO))MD50"<GKZ412;
MFP4894$9I9&^5"L1()Y8=JPDFWH:+0;*F^,;7P2>3UICHS3!?,&,<@T@_P!9
M)(H"JW3WH*N9X@JJ^/XNZU=DY6 E;RFPZX&W@'WIX=$8LS<CM27)C@(5QG)P
M"HXS4I#?99"B_O,<<5-KRU#H0K'=$H$\OYFR['L/:HKO48K0M&9(S-C(3=CB
MJ5_X@CM@UO$ZO<)%N8#J#Z5S%P\]P_F&!&$V"0/\:ZZ6'YM9 D:AU">X6:W*
M;5)YR>>?0U#&BHHBCW>F6Z_A4J0XA\WRRI(Z=<U8MXV+1KL 7N.N#75:,%H%
MR*&+S!@YSG!4]J>D9WE74K@X3(XK6MM.;>8W *!MQSU_"KRV4*G(&03D@\\U
MSRKI:!<PA8LLD89-Q?(R!P/<U+#I<L*G)4OR-Y'K6S!+YQE0J T;8(J9BJC+
M$ >]9.O+85S!_LF=%# KF,<#^]4XTGY _P O3)7'>M8H'4JPX/:E  &T=JCV
MT@N8(TYGC4DC>3RI':G_ -GOETSNW<8 ^[6NJ'SF)3'^U2/(RR%1"Q']X4_;
M28&%=:;B(1D,9%&1M'%1C3[D[<!53C+'DDUTA Q42EB2HZ#UH6)F.Y@BU;+J
M>@/;UJI+!\A#[L.W.!QQ73/"$W2*@8]P.]-%FK)\PQGG;5?67T0[G-/;!+@$
MX"8SGVH*[)%>-E(&<^_O712Z7!.RELG8,*N>*J2:&"%*N RGY0>@]:U6)5M0
MN8)B>6\5VVDCE5(XYITMF+A)"ZNN5QM!K4NM,:.+=;Y5EX<#H15=H"K^8FYE
M*#Y<]#6L:R8&7]A1E/\ RS*CC=T-)NDW>401CC(X!J]Y,B)YA(92WS9[FHP7
M%P 4S$QQ_NGTK52 B".TRAHUP.S<;C4OVIUN$7@.!PA/%231!07=S(I&5P<$
M5"T#%$EC53\N5K.H]- 1H6-R]["\5Q&QDSGCH/I6K;Q_9XPB_.>Y/4UCVS7$
MWDSQX55&&7'-:_E#9^[4X+!B,\UY=56E8H?*?+0[,*/Y4_39"[DLROZ8IDH<
M*S;5;GH?2H]..+F5A@HQXQVK-;B>QM,RA@2A( SD=JQKV>?$LD+L87&067[I
M]*W(0",DTBH[QNK[>6^7(XQ79"UKM&-[,P]/D>VD$4B23Q7 W[@,K$?>M*YL
M6NH=@EX;AB.#BKPC4#@ '&.*KJ\5D@B#%I&/&[JQJT^PG+6YR^L27^CW=O=K
M^^M5 C\E5^8>IS2+KWF7+IET29ALD8<1"NDOT%S T3D+%T?*Y.?:L/4?#;7A
M0(8H6C.8SG[WN:UBX22YD6I)[FI_:UH;5IU/R!O+9@.3[U6M]:L;6U+P*7+'
M !ZGZU6N-.EBTZ*&68RN)55=HQC-:']D.SQ$11IL.'/JM%H)$Z%BSU%;M=R'
MY#TSU_&G/>1PW*0PJ,NWSGTJ:UT^"TA>.)>&.3FHX=,@M@2BE\-N 8]#6;<;
MB=BZ7 QFHI+N.,#AFR<845(Q(3(7)]*;D%26&W'>H7F2:6ES)-;L4S\K8/UJ
M]5/30@MLICDYR.]7*9+W.36S,>J75RS<NW2K&R-I Q4%UZ'TJ"YL(TU66[:>
M4#=]S/RYJT,=:SLEL:MC)8RZ[0V!WIJH+:!57.T<"GRRK$A9LG'8=:J21LTK
MR>8^UP,+Z4T(CD7+%ROS'C('-264)@5A*X+.V12)$2X'S*@'>I8 EP#NC/R-
M\I/?WJW+2PRP\BQ@%CC)P*<<-UZ4C$9 *YSW]*2.99(]XX7/?BLQ H=79F8;
M/X1Z4B&.8^8%!(XR10[1OB-R!NZ GK4@&!TH ;\_F @_+W%12.&N4B$A5@,[
M<?>%2!]ZL$(W#L:0'"J9 -_3(H 50%7:&S0>" ,5#;NGG2HN RG+#-*$9+@L
M/F1AR2>E%M0'MB6,A6P#QD41Q+''L4<?SIAECBD$*@JS#*GM36N/+ C9@9CT
M I68#V4@ (0D8Z]L4B(%3@@D\Y'>H[B5E15*A@?O@#J*; T4@\R(G8/E ["B
M6PT2D G-1RQH\9W)NP<@>IIKQR)(\D9W;A]T^M2(S'(9<8J-BB$>?GY8U521
MU/.*ED^9<!L$]*>67D$C-02^473<"6'*X[&E?48LCB-.3STS3;9G:!7D #=Z
MB=6%O_I$BDLW7'&/2J,]P(E6WC9R@'S,>U7&#EL!;NY04D+2@QD97;U%8B3I
M]DSEG )RW\1ITC+"$D^9ESP<U7CF7<V20QYZ<5V4Z=D,4,QB\V3(7.  .:+>
M)YI/-P0F>6QT%6H;>::S4R9/5MRBKMK;F+3L>9M).6+CJ/2B=6,-%N D-FT<
MH$<RA VXC&2PJ[,75MRX1.I-("!&"5 &.U*A9B0Y^7L*X)5)28"*8K@ HV67
MGBF2N_FB)%(+#/F]@:E*')P-H]0*B!$8R[ #/4UG=H:) !M'.6Z9/<U(!^[]
MJ:JH6!89V\@^E&YB6W# )X'M3\Q#(\*=HSBH4+QPF18V?:V,'[V*GDC=X76+
MARIQGUI;6*2.()*P+8Y^M.*TNQW'11,H+%R03GGM[4!=F\E!@G/UI7V1%I9)
M-B!>=QX%5YKZ QJ P*R(65L\'%6H2>Q(Z<>5Y<IYYVJH'--,NV%_,<*0>#W-
M4[F\9(UD68*0G(7D >M02:L'MXY8H]QZ#<OZFMU0;2&;$3)/#YFX%0.0:KRW
M!DF6*"0! ,ECUSZ5S]S=W4V9%*@>B<9-*TAG*F3<F0,D=S6L<,EN%C95-D@N
M;V50T? V'[V?454:[!F95D$>#DXZX]JSG@N(YT<Y\H'(SU-6FFB:5"H7*\Y]
M36BI10%Y=79Y1N5A'C XZFJTQ8R()2[<[G3H#Z8J+[3(S' 78>"!ZU%.LKA7
M+<'@9ZFJ4$F!:6^F1Q! -D1RQ/4CZU5GO;TRB6-XVAS@0],#WID(>"8^8&(
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MGCI4$C6C5L94'!S2YI2>*04@$=@B%B#@>E*/F /K1FF131S F)U< X.T]#3
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M#..1S[58^PI]TG*=ZR=>*"YS[PS7$+E]S8^Z!VHCM\(K%29,?,%KHTMH8E"
M$BEB\A<J@4$'&*AXCL%S"73V9 R[D?L,5(+7"E)&! Z'T-;;%X\G:'],53FM
MFAMB=K3.9-Q ZU/MVP*ALYI@%VJJ _*Q[U-_9!\P'*M$>2OO6BR%E0K\O0D&
MH(VN'>8/E!G"'V]:S=:6X%&;2O.BDB!50PY [4TZ6T4&P , OZUJQ?*Q3.^1
M0-S>M2+O(.X8YXI^VDM0N8L5C(RON C5EP<\FG0Z3'L0QG&."1U(K7EB\Z-H
MR< C!(J-85%NT4$F#C ;K@TO:R87,RZTV*8"1#D+U8'/-1?V?',T4PQ(H7@X
MZFMJVMEMK=8LY/5CZGUIKQF)Q)&,K_<'\Z%6DD%SGKVQGFB1AA2A_P BHY%>
M*V+>6"PZG'6M^>U5TD4QDJ6# @]ZA>V\P*5'S!L,!V%:*MW'<P$MK:Y5II(P
MQ(R:RK'3$<R2!I(>3MP>E=;)IK1.3&!M/:LX6S174FYB% ST^\?2M%630S#%
MC<$S"5_M$@^Y)NP1[5''=W.F6@L71;B1FSOQG\*VWB9K9WV;5;ICK^-5HK:-
M> .G.X\X-:1FF,JQZW;LZQSQ&&5?O%^%%3RW%D&DDBN(^0"0IJ*^M+&.V65H
M3(X8$@G.:AN-%@FN!,B$*PRT8XS1)0>@%Q_,=HR4958;ED7DK]:TM-O93*RN
MV\QJ!EN-WO7/0V^M1W9@6Z3R@OR[NX]/K3UENUD*>4)60ABRG''O6,Z*=P.Z
M@<,S2;^#P >U3;2/O]:YBTUF24-^ZV'@+GI^-:\&H[IH_-( 88V^AKDE3:6I
M+1>R X3!Y[TY%"H%ZX.<T@(DDXP=OH:>!SQ4"(_-F$H5$#)W.>15D3;75-I.
M[N.U11LD@8KU!P:>CA6 [GI57$T6-N3DT@0-R&S4%M-.\LJ3* %;Y".XJRB)
M&"J# )S5V1+T'HI%3#D5$G/0YJ0<&KCH0QV*0  DXY-+FBJ$'>L;Q#_J8?\
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MWC188-(4F"^6=K#EQZT.L3S(K'YU^914N>*./O8&?6D!#=RO' S1+E^@Q4$
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M%<'/%*P8L.1BE4[@#C&:CD:3S0BK\I'+>AI>0")"D4LCAN6Y(STJ2-UD0,K
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MR&!(TWQQ@_*<G/K4X& /2H#)B?(P%88)]ZF5E95.[K2DM0(F^8O&R QD8_\
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M4D^80,#/85H);@D228,I7#8Z5D:9?1VT7ER.JAG).020,#TK2.IV6!MNP/\
MMFW^%3-2N[('>Y,D48VJ ?D/&:CD8&Y"*K XSO["FC4; ,Q^U=>VQO\ "HY+
M^S9'VW@#'[I\MN/TI*+N%B?YF<<!HSU'?-(R."", @_I4,5_9*@WW8+XY(C;
M_"A;VP7=_IF=QSRC<?I1ROL*S+ .]N3\P[T-N"$D<"JSW]D(R%N%9O38P_I3
M_P"T;)E -T!_P!O\*.5]A69.D:E=S=>U,*/N.<8J)]1L1@I< G_<;_"FM>V+
M9S=@Y[[&X_2FHR'9CI6,>W:JB(??SU'TJ3:9$8HP 8?*<=*C-_I[ $W"[AQ]
MQO\ "C[=I^"!=8S_ +#?X46?8+,D!$:[,@N!R?6A6\R R&,AL=*9]NT[[WVA
M2P& ?+;_  J*;4(/LVV&]19<CYC$Q&/RHL^P6)4+CRR\9R1DMV'M1;+*\\LI
M?="Y'EJ1ROK3FU#3G0*UT"/]QO\ "E.I:>5*_:1@C^XW^%*TNP6)@K><VY %
M['UJ#[)#YP8EF=26 S5>YU"&.R*V5ZOG#[IDC8Y_2I8M4M?LR-)<)Y^WYL1M
MC/Y4<L@LRW')%+DKR5ZY'2HX@OVJ5ED!&.5 Z54;4;=X5(NDCD/WU\MB#^E.
M74+*.-529.GS81O\*.60[%N5XP 0T8<?=)J-;VUEB<K.CJH^<@Y K$B=)KQI
M+BYCCA4D)&J,01[U:#Z>F^*&6&.%ASMB;G]*?LPL:*WUG# KJX\MON[1UJM)
MK"><T*@[L94*,G%,,]@L21I<(%''^J;_  H2YL8VPL\87N?+;)_2FHVZ!8L&
MXN6BV,%4-P'SBHX((K4[5'S.>IYR:@,UD;G/VE?*'(RC<'\JG.HVPN,BY3R@
MO'[MLY_*BSZ!8F53)T=2HXRO:FB)H?F\TLF.0>IJ"6[LF552X506R^$8?TI?
MMUFUVY:=/*V *=C9_E4VEV"Q/$"[LTJJ"/N_2I(ED9M[KY8'11WJF+JS#/F[
MW*Q& 4;Y1^5/%Y910.L=YN8_=W(W'Z4.+[!8N2;L90#W]ZJH\=W. T3IY7S;
MNQ/I38]0MMH#W:CY>T;=?RI(;NRCA,;7F[G.?+;_  II,"R?FDSL4Q 9SWJ#
MS+B>%I(0BC/RG/44T75AYXF:\R0,8V-C^5+)<:9(K!K@#<,'",./RHL^P"M&
M8(QY91IOO,2.H[XJ2-Y&$K.24QE01BHTO;&-$1;H$*,?ZML_RJ!;FTD:1I+H
MJ)#@KAN![<46?8"O,EXE]#?0V^8<;9(LY)]ZT)8@87$04O\ >954 GVH2^LD
MQ_IG Z?NV_PIPU&Q#%OM*@G_ *9M_A3O+L&HRT$LEJ6>W6"7G:O7'H:EMF<Q
M%;A<,O#,>AJN=0MU0L+I&D8\GRVZ?E55YH)Y)8YKS,+'Y,*W&.]+E;"QH-.L
M9D6.,E8USQT-2I''M>4GB5?F#'@5GK)8O;^7)=!6)RQ5&Y_2IOM.G#Y1< (1
M@C8V#^E)Q?8+$B?9UMWM8OW*H,#Z'THTVVCAL_)2+;$"=NXY)]S3/MUBSE'F
M0QA0 WEMS^E*=0LXH2L5R"P'R@HW^%%FEL \+>16<N[RS(I_=!.F/>I%63R1
M(8D\]L;QVJK!J,)W//=)N/0*C8'Z5-'J=GM^>Y /^XW^%#4NP:C)VNO,C>*#
M#AL-D\$59PTL $F8V/4*:B;4K+:<70)[?(W^%48;J&&$A+P;V8L2R,<>PXHY
M9-;!9LTGC+21D!2J^M$IMY289 K$\E:I6MY;QO*TUX&+'C]VV/Y4Z6YT]U8I
M<*DC'.X(W^%'*[A8?:PHA:3>P'01D\#\*ANY8II8UAD!D5ONL,8HB;2X]Q-T
M6D;EG*-U_*H99(-I"7Z'D;<PG(_'%4EJ-"6JR07!AO@1(Q(1E/RL#ZU/<I"C
MV\5PBMUPQ' J2.[LO)"37@E/]XQM_A4<K:;,[&2]+ _=!1OE_2C6^P#[3?<,
M9V7RPK8"CO[U)<W,=JZ%X]Q;N!TIAOK2*VV0W2[P/E)C;K^510S62R>?+>!Y
MB,-^[;'Y8J>5MZ@3S2_/&S.(XCT<MC)/:HK=9@PCN@SD/^[8>GO3C=V$C$2R
MQL@Y&8VZ_E55Y(7=I4U-HF;@KL8CV[4*+M8#1?; C23'(!XXSBHS;VT%Q]J*
M$ROP#UIL=_;>65DNT+ <'RVY_2HY+JVDFAD^W !/O+Y;?-^E2HR!"VYBNK]W
MS+YD1^ZPP!5B8P6BR32%B",D'D56%[;JXV7 "C)QM;D_E5::XB\J(QS([[OG
M5U8@4^1W"Q8\]+>2,6\,C^>-VT<!!ZU9MMA<M"!LZ,>^:JK>1>2VZ\C\W^$B
M)N!^5/>XL6C&+S:^,G:C#)_*DX2?082+=?;EW-YD)!^3;P/K3Q!+-:.&<PES
MT_NTC:E"L"[9T,G0_(W'Z52EO9%A5$NHI2S_ #[T;A?:GR2[ :-S>16-LKRY
M9>%RHSDU2@DFF5##%)"CN<[^<CWJ:>>Q>#$5T@95^0&-B ?7I3([JWF(^U7*
MY50 RJPR:%!VV!$TL5G&Q$DF"XVA0>/P%,$5M)&MO$8R%&TYX;'M4,[6LBX%
MZI(&5/E-D'\JGBFTU1&[3)YJC[WEM_A1RM("%[>6"YMA C""$=%/7ZU?CN'B
MN"KR[E(R=W&P5#-=V$R;3=X[Y"-_A5*Z:&X>)!?@1#[_ .[;YQZ'BA*3W0;G
M1)*C]'!_&GUAVES:6L0B:[5U'1O+8$>@Z5?35+!4 -WD^NQO\*?*R'$N]Z6J
M0U73_P#GZ'_?#?X4#5K#_GZ'_?#?X4<K["LS>LO]1^-6:Q+77M,BBVM=<Y_Y
MYM_A4W_"1Z5_S]?^0V_PI\K[$N+*.HB<R,;=D5@_.[H1488XR8PI]J;/JEA)
M*["Y!!/]QO\ "JT6HVYW&6Z7K\H$;=/RJ.678M)ELL%QGJ>E*9 "H)Y/2J3Z
MA;>:NRX0J>I*-Q^E2MJ%@1_Q\KD=/W;?X5+A*^P[%H2KYGE_QXSBHI[E41C&
M-\BG;@#.#[U76^LG1?-NQN4YR$;_  IYU"R$@:.Z103E_P!TWS?I5*#70+%J
M)-OS-CS&'S >M$L?G*O/RYRP(ZU7&H:?OW_:AG&/N-_A2MJEB.ER#_P!O\*.
M65]A69+%)DL^?W7\)--==EVLR1;G<;2V> *@CU"T,3)/=J_/!$;#C\JE&IV&
M,?:A_P!^V_PI\LK[#L*+B.%U65-CN>"O()JR<\C]:SDU*T<A9I8]H)((1N/T
MJ?\ M2PS_P ?(_[X;_"AQ?8+$MK'-'"!/()),GY@,<5-57^U+#_GZ'_?MO\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %&!98# 2(  A$! Q$!_\0
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M 'P*/LMO_P ^\7_? H B_M73O^?^U_[_ "_XT?VKIW_/_:_]_E_QJ7[+;_\
M/O%_WP*/LMO_ ,^\7_? H B_M73O^?\ M?\ O\O^-']JZ=_S_P!K_P!_E_QJ
M7[+;_P#/O%_WP*/LMO\ \^\7_? H B_M73O^?^U_[_+_ (T?VKIW_/\ VO\
MW^7_ !J7[+;_ //O%_WP*/LMO_S[Q?\ ? H 2&]M;EBL%S#*P&2$D#''X5/6
M;Y4<6OP^6BIFV?.T8_B6M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBN6\9ZQ=:5':?9-2^RRS,56/['YYE/IDLJK]210!U-%<MX67Q<]Q)<:]=V;V
M;Q_N88X@L@;/5BI*XQV!-=30 5'-/#;IOGECB7.-SL%&?QJ2L[5%5YM/5E#*
M;GD$9_@:@";^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&I?LMO_P ^\7_? H^R
MV_\ S[Q?]\"@"+^U=._Y_P"U_P"_R_XT?VKIW_/_ &O_ '^7_&I?LMO_ ,^\
M7_? H^RV_P#S[Q?]\"@"+^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &I?L
MMO\ \^\7_? H^RV__/O%_P!\"@"+^U=._P"?^U_[_+_C1_:NG?\ /_:_]_E_
MQJ7[+;_\^\7_ 'P*/LMO_P ^\7_? H B_M73O^?^U_[_ "_XT?VKIW_/_:_]
M_E_QJ7[+;_\ /O%_WP*/LMO_ ,^\7_? H B_M73O^?\ M?\ O\O^-']JZ=_S
M_P!K_P!_E_QJ7[+;_P#/O%_WP*/LMO\ \^\7_? H B_M73O^?^U_[_+_ (T?
MVKIW_/\ VO\ W^7_ !J7[+;_ //O%_WP*/LMO_S[Q?\ ? H B_M73O\ G_M?
M^_R_XT?VKIW_ #_VO_?Y?\:E^RV__/O%_P!\"C[+;_\ /O%_WP* (O[5T[_G
M_M?^_P O^-']JZ=_S_VO_?Y?\:E^RV__ #[Q?]\"C[+;_P#/O%_WP* (O[5T
M[_G_ +7_ +_+_C1_:NG?\_\ :_\ ?Y?\:E^RV_\ S[Q?]\"C[+;_ //O%_WP
M* (O[5T[_G_M?^_R_P"-']JZ=_S_ -K_ -_E_P :E^RV_P#S[Q?]\"C[+;_\
M^\7_ 'P* (O[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&I?LMO_S[Q?\ ? H^
MRV__ #[Q?]\"@"+^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&I?LMO_P ^\7_?
M H^RV_\ S[Q?]\"@"+^U=._Y_P"U_P"_R_XT#5-/) %];$GMYR_XU+]EM_\
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M!<WNJO;RS@!F*9F&,'CHHQ]!6A%J$^B-XGM+S6+EK6PMXIXKN=!++%O5L\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#D<U)-HNG7$E\\UJDAOHUBN0Y)$BKG (S@?>/2K]% &+IGA/1='NQ=65HR7
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M\$+ _,9HR^1[8(KE/!*W"^)O%XNI(Y)OMT>YHU*J?W*=B30!VU%%% !1110
M4444 %%%% !15.XU6RM+A;>><)*Y 52#R:N4KIE.$HI-K<**J:E)/#832VS1
MK)&I;YU)!P*?9&X:U1KEXWD8 YC4J/YFB^MA\GN<]_(L4444R HHK(U*QM;C
M5;!IH@Q8N#DGD!212;LC2G%2E9NQKT4    =!13,PHHHH **R]/CF-[=F2[F
MD6*78J,1C&T'T]ZU*2=T74AR.U[A1113("BJVH336UC+-;HCO&I;:[$ @=>1
M18R7,ULLES'$CL,@1L2,?B*5];%\CY.?H6:***9 4444 %%%% !112$@ DG
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M5'E#^\__ 'U4E% $?E#^\_\ WU1Y0_O/_P!]5)10!'Y0_O/_ -]4>4/[S_\
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MIYL;>7MAPJ85CG(Z8S[U=T*]5-0\.+I'B*ZU$7*;;RSED1UAC$9.2JJ/+(8
M?I7HH1%9F"J&;[Q Y/UIL=O!"[/%#&C-]XJH!/UH7]?C_F)K^ON_R.2\>&(R
M:%'J#[-&DOMM\6;"$;&*!S_=W8SGBL/3[C1M,N/&EQI,)N=/AM+<B*UD8*WR
MR9",.@]UX'->ER1I*A21%=#U5AD&FI!%&,)$B@C;A5 X]*.C_KL4>9>%TLV\
M916]K_9"V]UITIGATR1G4\KCS">&;D\]>:?H@N=1UC3O"ER6V>'KB2:YW?\
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M8O+>VU'25FF2,M<,1N;''EM_C4LFOZ<EY%:+/YL\HW(D2ELC&0<CBN:U/P=
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M=*>?$5N+BX@:SOP85+,3;-M8#T/>MBFN 8V# D$'('>BTN_X![2C_)_Y,_\
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M6=HF 4#))Q4":LBQJ#9WV0 /^/9O\*TJ* ,_^UX_^?.__P# 9O\ "C^UX_\
MGSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_ )\[_P#\!F_PK0HH S_[
M7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_^UX_^?.__P# 9O\ "C^U
MX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_ )\[_P#\!F_PK0HH
M S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_^UX_^?.__P# 9O\
M"C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_ )\[_P#\!F_P
MK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_^UX_^?.__P#
M9O\ "C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_ )\[_P#\
M!F_PK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_^UX_^?._
M_P# 9O\ "C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_ )\[
M_P#\!F_PK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_^UX_
M^?.__P# 9O\ "C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_M>/_
M )\[_P#\!F_PK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T** ,_
M^UX_^?.__P# 9O\ "C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_  H_
MM>/_ )\[_P#\!F_PK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O\*T*
M* ,_^UX_^?.__P# 9O\ "C^UX_\ GSO_ /P&;_"M"B@#/_M>/_GSO_\ P&;_
M  H_M>/_ )\[_P#\!F_PK0HH S_[7C_Y\[__ ,!F_P */[7C_P"?._\ _ 9O
M\*T** ,J&<W>M1RK;W$:);NI:6(H,EE]?I6K110 4444 <CXK>>'5+269M0&
MF>4RM]DNEM]LF1@L2RYXS@9K?T8 :5#M6Z48) NI?,DZ]VR<_G7->*+BSCU>
MVO)!I]VJ1O!]FO&*A6R,LIVD9['BMKPK$D6@0B.2%T9G=1#G8@+$[5SV'2A
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MQG\*XSPE)IL^O6_]FII]HT5NPN%M;H2M<GC!('8'G)YYH6X,]!HHHH ****
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M4,R^L;AOY58J6FM&9A12$@=2!2@@C(.:0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y[XO2YL_$236<^KS2RQ#=%#=)%%$I
M<*#\P/5C72^$,_\ "/1;XYXY1)()4GF\UP^XYRPX//IQ69XD>*7Q!!!+I\.H
M0FTD61%F2.6/+#G)894X_ @&MOPX;0Z-&+*$PQ*[@HT@D(8,=V6!.3G/>A;
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M+_XXW^%:OAOPOXRT37[2X\1>*_[7M'8HD&TC:^"0W/L"/QKTNL_4O^/C3O\
MKY_]D:D :[:7%_H&H6=KY7VB>W>./S1E,E2!GVKB_#/AW7[#5K0B&^L+-%(O
M!=ZF+I9QMP BX^7G!SQQVKT)W6-&=CA5&2?:HK*]M]1LH;RTD$EO,H>-P"-P
M/?FBVH/:QG1^&-,3PRGA]XWEL$CV ._S=<@[A@@@\Y%16?A6UMH;F*XOM3OT
MN(3 RWMVT@"'J .!D^O7WK=HH YS3?!=AINIVNH"]U*YGM8VBA^U71D"(1C:
M ?I]?K4T?A/3DN-1=GNI+?4-_GV;S$P$OC<0O8G'K5C6M<31S:1"UFNKF\E,
M4$$)4,Q +$Y8@  #UK3C8O&K,A0D E3U'M1N&QBZ5X7M]*G$J:CJER$0QQQW
M5XTB1J?0=_3)R15_2=+M]%TN#3[7?Y$((7><GDD]?QILFJQ1ZU'I9C<RO;-<
M!N-NU6"D?7YJ31-6BUS1[?4H(WCBG!*J^,C!(YQ]*  Z-:-K$^INK--/;"UD
M5CE#&"3T_P"!&L_3?"%GI=U%+!?ZJ\,!)AM9+UVAC[8"]P!T!R!7044 8\?A
MG3HO%$OB%5D^W21>4<M\@'&2!_>PH&?055G\&V,M_-=0WNJ6BW#^9/;VMX\<
M4C=R0.A.!G!&:V);T1:A;V?V>Y8SJS"5(B8TVXX9N@)SQZU:H RYM!LY[B]F
M<SA[R!()"DI4A5S@J1R#\QYS3-&\.VNBS7%PEQ=W5U.%62XO)C(Y5<[5![ 9
M/YUKT4 <]J/@W3]1O[B\%S?V<ETH6Y%G<M$LX P-P'?'&1@XJ[)X?L'DTIEC
M:)=+)-LD9PHRNW!'<8K4HH Y_P 7:+)KUC8VBQF2);Z&28"381&#\Q!R#G'I
MS3]/\)V-@MXQGO;J>\C\F6XNYS+)Y>" H)Z 9)^IK=HHZ6 YZ\\'Z?=)I^RY
MO[2:QM_LT4]K<&.0Q8 VL1U' /UI4\'V$.D0Z;:W6H6L<$K31RPW3+("Q).6
M_B')ZYKH*K7EZ+,0DP7$WFRK$/)B+[<_Q-CHH[GM0!FV7A73=/?3G@\[=8&5
MHV>3<7:3[[.3RQ.2:DF\.6,]EJUHYE\K5&9KC#<Y*A3MXXX K7HH>H+0YN]\
M$Z;>W)G^TZA;,\"6\XMKIHQ.B\*'QUX)'&.M;>GV46FZ=;6,&[R;>-8DW')P
M!@9JS10 445GZIJ\.E-8K+&[_;+I+5-F/E9LX)]N* -"LSQ#_P @*Z^@_P#0
MA6G69XA_Y 5U]!_Z$* -.BBB@#)\2PRRZ!=F+4)K QQ,YGAC5V "G. P/^-<
M?X/O[V[\111WTFL 1QR(@NH[>.-G 7((CY+8(.#ZYKN=8Q_8M\/W7-O(!YOW
M3\IZ].*Y?P[!;)K5K-<:3-9WDD&$+WJR(Q"J"54,<G: -V.@H6X,[6LS7;ZZ
MT[3?M-JD3,)$5A)G&TL <8[\UIU2U72;/6;3[+?([P[@VU9&3D=.5(- &!>>
M)+ZVU"[ 6$V\?F1QIM.X.JALDYY'/2H+CQ'JML@B9K9YX#(TS^60LBJ5X49X
M)W=>>E= /#^F?:I+DVV998O*<L['*XQT)QG'?K48\,:0+6WMS:DQV[^9'ND8
MG/?)SEOH<T+^OZ_KL ZZ\1Z;93>3<23+)@$A;:1QS[JI%>+_ !<U*SU'Q)HD
MMHTI_> $O \?8]V S7O; ;#T'%?.OCJYM1XGTFTCN+:[47>YC#<SLRGG@ARR
MC\/RKHPM7V552Z?\%'5@JWL:RD_G]Z_R/2/ <-I?Z:HOH+:25,[&.XRD>_M7
MH DC"A1G&,8VFO(M-TF^=DN;*VU%@R9#!BJC)_A;(R.M>G1:DT$*+>VL\!4
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M8!\*>&;V0RP6D*N.K6DICQ_WP12+X12W8M9ZSJUOGH/M)D _!\T6IO:7X?Y
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M^'O'$FJ:I=P7<=G%!#$\S&*1BT 5MNV3( R>ORY'%2IXMU"ZLIS;:;''=OJ
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MN(=,.MSV<\YF(<Q+N,<9DZ@$X7.<X[UZ8UM URERT,9G12B2E1N53C(!Z@'
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MY4I<R7WKU7ZJZ]#TJBH+.]MM0M4N;2>.>%QE71L@U/7.TT[,Y0HHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?C/_D2M:_Z\Y?\
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M<1B-UD[@J.!VZ5N5S_A%P^ESY"-,+F02S1N765\\L"><=L=L8KH* "L_4O\
MCXT[_KY_]D:M"L_4R!/IQ) 'VGJ?]QJ -"BF>;'_ ,]$_P"^A1YL?_/1/^^A
M0 ^BF>;'_P ]$_[Z%'FQ_P#/1/\ OH4 /HIGFQ_\]$_[Z%'FQ_\ /1/^^A0
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MLQTN=9TO;'%#$;,<ONR6&*YLQS6%6;A"_-9Z6ZV[]NNQW8?!OE52>U^_3T_
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MI:IX@M-)F\J9)I'$9F<1)N\N,'!8^U &K13(I4GA26-@R.H92.X-/H ****
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MG^*-PU6:R3OL9RBXNTE9A1110(**** "BBB@ HHHH **** "BBB@ K#\9_\
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M@:ESGI4#V5K)]^WC/_ 14)TNW!S&TL9_V)#_ "K.T'U NT52%G<I_J[Z0_\
M710U*1J"#AH)![@J:.1=&!"NG3"_%T98,CC AYQGUSUK195888 CT-<<))!"
M'(;?]G+Y%V?O9ZX]?:NC2YOMB_Z$#P/^6H_PJG@U1^%[ERJRG:_0F?3[1^3
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M[F$>;IX5HXT)S*KKE,>Y;*_45N6K3O:0M<HJ3E 9%0\!L<@5D7_AJ*^UFPU
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MIK2WM;J=6 (N#+YC'J[N5!R3UXJ+6M UB>]U-=/^R-:ZM;QPSO,[!H2H*DJ
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M70XH&GCGGFN)/+@M[>/?)*W7 'L.2:YSP[XH6[U7Q5>7<]S#I]FT)6*Z0HT
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M[196S+*%V(9)6D\M?[J;B=H]A0!;T>WO[72X8=2NENKI!AY47 ;TX^E7J**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //&O8EU?5&>\
MU71K47;H9H2LEO(PQN8Y4F,G\!79:'%8PZ3$NG7'VBV.6$WF;S(2<EBW<YS7
M,?\ "1L=6ET72/[/M=0FOIQ*9V+8"@'<4!!);/TX-=)X>O3?Z1',8X48.Z-Y
M'^K8JQ!9?8XS0M@>YJ4444 %%%% %2^LY+Q4$=[<6I4Y)AQ\WUR#7@VBRV^G
M_'Z_GEOWN(HI=AD\G<6+(%YVC ^; S7T%(^Q&;N 2!GK7SAX+_M23XE:PWV5
M=MW/$L[F3_5AG#J??.VNW!13E)OL_P 4/7E;N?2-%%%<0@HHHH **** "BBB
M@ HKC]3\1ZC9:Q=K'-9M!;S11"T*'S9=X&2&W=L_W>U+IVNZNL&G7]^]K-9W
M\HAVQ1%&A9B0O)8[AV[4D[@]#KZ***8!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CZOX7TC6QF[LU\X?=G
MB/ER*?9A@UL454)R@[Q=F!Q-[X<URSM_+@GM]<M%Z6VI*!*!_LR@=?K6;::L
M-+E$"WEYH<Y.!9ZJOF0,?1)/3\:](J&ZM+>]MV@NH(YH7&&210P/X&M'.G4_
MBQU[K1_Y/[C6GB*M-<L7IV>J^Y_I8P8?$MQ:J/[7T]XHSTNK4^="P]<CD?E6
MG%KVESJK0WD<JL,Y0[L#WQT_&L5_!?V ,_AS4I]*<\^1_K+<GW0]/P(KB-0D
MU/3_ !8L-]HUL'DQ]IN[-R$=2C<[<@C@%B#Z4OJTY?P)<WD]'_D_D=%.6%JO
M]ZN1^6J^YZK[V>P-(B1F1F54 R6)P *\\\0?$/PWK%EKGA[3K[[5>KI\SEHE
MW1\*<C=TS7EWQANOB%"I@OE,7ATX6(V))C9>WF-US]>*Q_"B>+XO ^H2>'[7
M1&L'MW%Y*I0W&W!R&R=PX[5D<3\CZ+\,:;/%H^F3MJEY(OV=#Y3E=OW1QP,U
MT=>&Z7>?&D:7:+9VVE&W$*^5DIG;CCOZ5<^U_'/_ )\]*_\ '/\ &@#V:N=\
M37=MIL4<C:I<:>6+,1:6ZR/)@<DC:3QZUC^!)OB%+?W8\906<=L(QY!@VY+9
MYS@^E:7BZ N8&C\\2RQR6W[KRR&#CIAV&3D C'I0!;\+/+<Z<\]Q>+?.)G6.
MX:,))LSPK# VL.XQVK=KGO"YGBADAFM+P.[&62YG\L"1S@$ (QQTZ>U97CV;
MQ[%/8_\ "&0VDD95_M/VC;P<C;C)^M ';5GZE_Q\:=_U\_\ LC5Y3]K^.?\
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M4@J1D$4M;+R,F1^2O^U_WT:/)7_:_P"^C4E% $?DK_M?]]&CR5_VO^^C4E%
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MM],TZVLK<,(H(UC7YCT JSY*_P"U_P!]&I** (_)7_:_[Z-'DK_M?]]&I**
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MRJG!YSGCIBM.\U[48]=@T72]-AGD>R%SYDTY1$&[;@\$GMTJ5?#!'@VX\/\
MVL9E65?/\OIO=F^[GMNQU[5;BT4Q^)%U?[1D"Q%IY6S_ &PV[.?;IBA?U]W^
M8/\ K[_\C&G\<+;^'+:_EM8X;R>Z:S\F68+&DJL0Q9\<*-I.<9]JA@\>%M-U
MF5X;.:YTV%9\6=SYL4JG.,-@8/!R"*N2^#M^F) E\$NH;^2^@F,(959V8[64
MGYAAB#R/PJ:7P[?7NA:CI][J%LSW<?EK);V8B6,?3<2?SH_K\O\ @A_7Y_\
M *3>)]?36+72Y-"MEN+V!I[<_:\J@4C<)#MX(W#[N>M68?$UY<:!)>+9VL5W
M#<O;3K/=!(HV4X+;\9(Z8XSS6C/HIF\1Z=JWVC L[>6#RMGW]Y3G.>,;/3O6
M-<^"7EM\17\0F74WU",S6WF1Y88VLFX9QV.1S@T?U^/^0?U^'^9F:GXE.O\
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MQ-99I-_E_P"J\Q0N,9YQCVI=/Z\O^"'7^O,W895G@CE7.UU##/H1FL_Q#_R
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MZ)]LD%]/=1-%+D;A P#,1],,*PCJKH3.KTNQG@TPP7TQN)9&=I&))'S$\#V
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M8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*P_&?_(E:U_UYR_^@FMRL/QE_P B5K7_ %YR_P#H)H B\,7=\^BZ9')IK1Q?
M9D'F^<IXVCG'6NAK-\/?\BWIG_7K'_Z"*TJ "N3\;75U' EO'<O:V[P2NTBP
MA][*,A#D$ $9/(YQBNLK%\0ZR^C0PN$M&60E3]HN/*Y]N#F@"MX)1(]!*0HH
MMQ,_DR+#Y0E3/#;> ._0 '&:Z.L;1-4OM44326MHMHRY2:WNO-#'/3H*V:&
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M1110 4444 %%%% !1110 4444 %! (P1D444 (J*BA44*H[ 8I:** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K#\9?\B5K7_7G+_P"@FMRL/QE_R)6M?]><O_H)H M>'O\ D6],_P"O
M6/\ ]!%:59OA[_D6],_Z]8__ $$5I4 %<=KNJ;]5CETG=-J-HSV_DM:F1),A
M2V"",;?ER??%=C7-:EX9L/[1_M(:M>Z;(SLQ\FX5$9F !X8'K@?EF@"QX4"G
M3)I#*7GDN'>X4PF+RY#U78>F/UZ]ZW:S-"T^VTZP:*VO9;U7E:1YY9 [,Q/.
M2 !6G0 5GZE_Q\:=_P!?/_LC5H51U*&>7[-);HCO#-YA5FV@C:1UP?6@"ZRA
MU*L,@C!%8%KX/TZTT\V"SWKVHF2:.*2<L(BC;E"YZ#/:M#[1JG_0/@_\"?\
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M '3UIW_"S]%_Y\M7_P# "3_"NDUK3GU*Q2"(HK+<0RY;T216/Z"M' ]!0!Q
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M_P!@Z/\ ] JR_P# =?\ "@"I_P )CX;_ .@Y8?\ ?]?\:/\ A,?#?_0<L/\
MO^O^-5-9T32DN]'"Z99C=>@'$"\CRW]JUO[!T?\ Z!5E_P" Z_X4 5/^$Q\-
M_P#0<L/^_P"O^-'_  F/AO\ Z#EA_P!_U_QI=1\/:9+IEU'#I5F96B8)B!0<
MX..U26OA_2DLX%DTJRWB-0V8%ZX^E $7_"8^&_\ H.6'_?\ 7_&C_A,?#?\
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M(8-9GT[9HL]I'/N^<749973'*^QKD?!,-O:>(KB _9X[TQLTL45OD=N1('8
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M>[,,DPB0L4C W''IFL:_UK35U+2VEA,EQU5@P'D;U[_4=JV-1M7OM.GM8YC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Y!24# 2(  A$! Q$!_\0
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M5]6N%\;0Z.!']F?3WN2<'=O$BJ.<],$TF[%1@Y7MT5S:HHHIDA1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H,VWYG_  H_X3?PS_T&;;\S_A61_P *I\-_]/G_ '^'^%'_  JGPW_T^?\
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ML+)1LE[VONOKI>]I)[)6NB74_%5SJWB2^LE\1)H5E9L41]FYI7!P?3C@UO>
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M_P *R/\ A5/AO_I\_P"_P_PH_P"%4^&_^GS_ +_#_"B];L@]GE7\\_N1K_\
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M5D?\*I\-_P#3Y_W^'^%'_"J?#?\ T^?]_A_A1>MV0>SRK^>?W(U_^$W\,_\
M09MOS/\ A1_PF_AG_H,VWYG_  K(_P"%4^&_^GS_ +_#_"C_ (53X;_Z?/\
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M,VWYG_"LC_A5/AO_ *?/^_P_PH_X53X;_P"GS_O\/\*+UNR#V>5?SS^Y&O\
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MUS_KPG_]%M52V9C1_B1]5^:+6A_\B_IO_7K%_P"@"K]4-#_Y%_3?^O6+_P!
M%7Z%L*I\;]7^;"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5R\O\ R5.V_P"P-)_Z.2NHKEY?^2IVW_8&D_\ 1R5,NAO0^U_A?Z'4
M44451@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5#=6L-[:2VMPF^&52CKZ@U-10--IW1PG_"N
M[N.%[2#Q3J"6#\& C/R^F<C^5=9HVD6NA:7#I]F&$,0."YRS$G))/K5^BHC3
MC%W1TUL97KQY:DKK?9+7N[)7?J%%%%6<H4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6-XN_P"1,US_ *\)_P#T6U;-8WB[_D3-<_Z\)_\ T6U*6S-*/\2/
MJOS1:T/_ )%_3?\ KUB_] %7ZH:'_P B_IO_ %ZQ?^@"K]"V%4^-^K_-A114
M=Q.EM;R3R'"1J68^PID$E%>>V^I>*?%<\T^E31V-E&Q5"YQGVS@DFK>CZ_J^
MFZZFB:^%D>7_ %4Z]_3Z@T =O17(Z;JE]-\0=1T^2X9K2*+*1'& <+_B:ZZ@
M HKS6SG\4ZYJ^IPV&K+$EM,RXE..-Q  PI]*Z/0M,\3VNH^9JVJ0W-ML(V(Q
M)SV/W10!T]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5R\O_)4[;_L#2?\ HY*Z
MBN7E_P"2IVW_ &!I/_1R5,NAO0^U_A?Z'444451@%%%8>N^+=)\.3Q0ZC+(C
MRJ64+&6XSCM2<E%79I2I3JRY*:N_(W**X[_A9_AC_GYG_P"_#4?\+/\ #'_/
MS/\ ]^&J/:T^YT_V;C/^?4ON.QHKCO\ A9_AC_GYG_[\-1_PL_PQ_P _,_\
MWX:CVM/N']FXS_GU+[CL:*X[_A9_AC_GYG_[\-1_PL_PQ_S\S_\ ?AJ/:T^X
M?V;C/^?4ON.QHKCO^%G^&/\ GYG_ ._#4?\ "S_#'_/S/_WX:CVM/N']FXS_
M )]2^X[&BN._X6?X8_Y^9_\ OPU'_"S_  Q_S\S_ /?AJ/:T^X?V;C/^?4ON
M.QHKCO\ A9_AC_GYG_[\-1_PL_PQ_P _,_\ WX:CVM/N']FXS_GU+[CL:*X[
M_A9_AC_GYG_[\-1_PL_PQ_S\S_\ ?AJ/:T^X?V;C/^?4ON.QHKCO^%G^&/\
MGYG_ ._#4?\ "S_#'_/S/_WX:CVM/N']FXS_ )]2^X[&BN._X6?X8_Y^9_\
MOPU'_"S_  Q_S\S_ /?AJ/:T^X?V;C/^?4ON.QHKCO\ A9_AC_GYG_[\-1_P
ML_PQ_P _,_\ WX:CVM/N']FXS_GU+[CL:*X[_A9_AC_GYG_[\-1_PL_PQ_S\
MS_\ ?AJ/:T^X?V;C/^?4ON.QHKCO^%G^&/\ GYG_ ._#4?\ "S_#'_/S/_WX
M:CVM/N']FXS_ )]2^X[&BN._X6?X8_Y^9_\ OPU'_"S_  Q_S\S_ /?AJ/:T
M^X?V;C/^?4ON.QHKCO\ A9_AC_GYG_[\-1_PL_PQ_P _,_\ WX:CVM/N']FX
MS_GU+[CL:*X[_A9_AC_GYG_[\-1_PL_PQ_S\S_\ ?AJ/:T^X?V;C/^?4ON.Q
MHKCO^%G^&/\ GYG_ ._#4?\ "S_#'_/S/_WX:CVM/N']FXS_ )]2^X[&BN._
MX6?X8_Y^9_\ OPU'_"S_  Q_S\S_ /?AJ/:T^X?V;C/^?4ON.QHKCO\ A9_A
MC_GYG_[\-1_PL_PQ_P _,_\ WX:CVM/N']FXS_GU+[CL:*X[_A9_AC_GYG_[
M\-1_PL_PQ_S\S_\ ?AJ/:T^X?V;C/^?4ON.QHKCO^%G^&/\ GYG_ ._#4?\
M"S_#'_/S/_WX:CVM/N']FXS_ )]2^X[&BN._X6?X8_Y^9_\ OPU'_"S_  Q_
MS\S_ /?AJ/:T^X?V;C/^?4ON.QHKCO\ A9_AC_GYG_[\-1_PL_PQ_P _,_\
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MBN._X6?X8_Y^9_\ OPU'_"S_  Q_S\S_ /?AJ/:T^X?V;C/^?4ON.QHKCO\
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MJHRC+9F%;#U:+2JQ<;]PK&\7?\B9KG_7A/\ ^BVK9K&\7?\ (F:Y_P!>$_\
MZ+:G+9DT?XD?5?FBUH?_ "+^F_\ 7K%_Z *OU0T/_D7]-_Z]8O\ T 5?H6PJ
MGQOU?YL*S]=A>XT*^ACSO:%@,?2M"BF0<7\/-2M3H1L6E1+F&1BR,<$@GK_2
MJ'B"YAU;QYI-O9.)6MR/,=#D YR1GV_K6WJG@/1]3NFN/WUO(YR_DD ,?H0:
MOZ'X8TW00S6L;-,PP99#EB/Z?A0!SNELJ?%'52S #R>I/LE=P)8V.!(I/H#7
M,:IX#T[5M2FOIKFZ228@LJ%<#C'&1[4FF> =.TO48;V&YNFDA;<H<K@_7 H
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M7:A+L,#\"*U:*32>C+A4G3ES0=GY',_\*^\*_P#0(C_[^O\ _%4?\*^\*_\
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MJZ:BCV<.R#Z]BO\ GY+[W_F<S_PK[PK_ - B/_OZ_P#\51_PK[PK_P! B/\
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M9P[(/KV*_P"?DOO?^9S/_"OO"O\ T"(_^_K_ /Q5'_"OO"O_ $"(_P#OZ_\
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M;L[J*YM]+1)HF#HPD<X(Z'DUT-%%4HI;(QJ5JE5WJ2;]7<*QO%W_ ")FN?\
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MO$UXF@: MN4,IOI/*+#Y=V< _GDUO74>M>&Y(+^;6'OX))ECGAD3  8]5YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****  D 9/ J.&X@N4+031RJ#@E&# '\*2Y_X]9O]QOY5PGPC_Y%N\_Z
M^S_Z"M0Y6DH]SJIX=3P\ZU_A:7WW_P CT"BH+V\@T^RFN[EPD,*EW8]@*X=?
M'FM75M)J=EX:EETF,\S-)ARHZD+W_#BB4XQW%0PE6NG*"T6FK2U[:]?([^BN
M-U+QY'#X<L];T^V%Q;2S"*<.Q#1'\/I_*CQ5XY'AZYT^**V2<72B1R7(V+D<
MTG5@E>YI#+L3.2BHZNZ_\!W.RIKND:,\C*J*,EF. !7.:KXHDL_$NEZ/:6Z3
MM>+O=V8C8O8^_0U<\6_\BAJ__7I)_P"@FGSJSMT,EAIJ5-3T4[6]+V+W]JZ=
M_P _]K_W^7_&K2LKH'1@RL,@@Y!%>4>$?A]H^O>&+?4+J2Z6>4N#Y<@"C#$#
MC'M5WP1/=Z#XOU#PO<7+36J(9(F8_=Q@_AD']*SC5EIS+1G?6RZBE45&HW*&
MZ:MHG9V=STNBN'D\<:CJ%_<P^'-#;4(+8E9)VD"*3[?K[UH:1XWL=2T>]O)8
MI+>:P7-S;O\ >7Z?B"*M58MVN<L\OQ$(\SCVZJZOM=;J_F=117GR^/-<>S75
M$\-%]*9P!*DP+[2<#Y1SG\*Z#7O%4&B:3;W36TSW-UA8+4J5<L>Q'44*K%JX
M3R_$1E&%KMNVC3U6]]=+>9T-%<=8^,;^'5[?3O$.CG37NN()!('5CZ$CI78U
M49*6QA7P]2@TI]=K.Z?HT%%%%48A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !03@9-%8_BQBO@[6V4D$6$Y!'
M;Y#2;LKE0CS24>Y1O_%HDNFT[0+4ZG?CABIQ##[N_P#0<TW2O"135EUS6;D7
MFK!<*T:[(XAZ*.I^IK3\-6EO9^'-/2V@CB5K>-F"+C)*@DGWK5J4KZLVG54+
MPIJW1OJ_\EY(*9+&LT+Q-]UU*GZ&GT59SG/^&,II4VDS$K/9.T+8X.TDE2/P
M-4&T'Q-Y3:>FM0G3VROF.I,VT]NG]:Z@6D O&NQ'B=DV,X)Y'N.AJ>@##O?#
M-O/H,&FV\C0-;8:"8<E7'?\ 'O5&+0==O[F#^W-0MI+6W<2+' I!D8=-V0*Z
MJB@ HHJL]_:QW\5D\N+F52Z)@\@=>>E %FBBB@ HJ&6[@@N(8)9 LDV1&"#\
MQ';/3-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<O+_R5.V_[ TG_ *.2NHKEY?\ DJ=M
M_P!@:3_T<E3+H;T/M?X7^AU%%%%48!7'>,_"^LZ_>6TNF:DMHD495U,CKN.<
MY^45V-%3**DK,VP^(GAZBJ0M?S5SRC_A7'BO_H84_P# B7_"C_A7'BO_ *&%
M/_ B7_"O5Z*R^KP\_O/1_MO%_P!W_P !1Y1_PKCQ7_T,*?\ @1+_ (4?\*X\
M5_\ 0PI_X$2_X5ZO11]7AY_>']MXO^[_ . H\H_X5QXK_P"AA3_P(E_PH_X5
MQXK_ .AA3_P(E_PKU>BCZO#S^\/[;Q?]W_P%'E'_  KCQ7_T,*?^!$O^%'_"
MN/%?_0PI_P"!$O\ A7J]%'U>'G]X?VWB_P"[_P" H\H_X5QXK_Z&%/\ P(E_
MPH_X5QXK_P"AA3_P(E_PKU>BCZO#S^\/[;Q?]W_P%'E'_"N/%?\ T,*?^!$O
M^%'_  KCQ7_T,*?^!$O^%>KT4?5X>?WA_;>+_N_^ H\H_P"%<>*_^AA3_P "
M)?\ "C_A7'BO_H84_P# B7_"O5Z*/J\//[P_MO%_W?\ P%'E'_"N/%?_ $,*
M?^!$O^%'_"N/%?\ T,*?^!$O^%>KT4?5X>?WA_;>+_N_^ H\H_X5QXK_ .AA
M3_P(E_PH_P"%<>*_^AA3_P ")?\ "O5Z*/J\//[P_MO%_P!W_P !1Y1_PKCQ
M7_T,*?\ @1+_ (4?\*X\5_\ 0PI_X$2_X5ZO11]7AY_>']MXO^[_ . H\H_X
M5QXK_P"AA3_P(E_PH_X5QXK_ .AA3_P(E_PKU>BCZO#S^\/[;Q?]W_P%'E'_
M  KCQ7_T,*?^!$O^%'_"N/%?_0PI_P"!$O\ A7J]%'U>'G]X?VWB_P"[_P"
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M%>KT4?5X>?WA_;>+_N_^ H\H_P"%<>*_^AA3_P ")?\ "C_A7'BO_H84_P#
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M!1Y1_P *X\5_]#"G_@1+_A1_PKCQ7_T,*?\ @1+_ (5ZO11]7AY_>']MXO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:E \CQ*50K(RX&<]C4RYK>[N;8?V/M%[>_+Y;_B4O\ A8GA3_H++_WXD_\
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M/_B:/^%B>%/^@LO_ 'XD_P#B:@_X5EX6_P"?*7_O^_\ C1_PK+PM_P ^4O\
MW_?_ !H_?^06RGO/\"?_ (6)X4_Z"R_]^)/_ (FC_A8GA3_H++_WXD_^)J#_
M (5EX6_Y\I?^_P"_^-'_  K+PM_SY2_]_P!_\:/W_D%LI[S_  )_^%B>%/\
MH++_ -^)/_B:/^%B>%/^@LO_ 'XD_P#B:@_X5EX6_P"?*7_O^_\ C1_PK+PM
M_P ^4O\ W_?_ !H_?^06RGO/\"?_ (6)X4_Z"R_]^)/_ (FC_A8GA3_H++_W
MXD_^)J#_ (5EX6_Y\I?^_P"_^-'_  K+PM_SY2_]_P!_\:/W_D%LI[S_  )_
M^%B>%/\ H++_ -^)/_B:/^%B>%/^@LO_ 'XD_P#B:@_X5EX6_P"?*7_O^_\
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MG^!/_P +$\*?]!9?^_$G_P 31_PL3PI_T%E_[\2?_$U!_P *R\+?\^4O_?\
M?_&C_A67A;_GRE_[_O\ XT?O_(+93WG^!=M?'?AJ]NHK:WU,/-*P1%\F09)Z
M#E:Z*N6L_AYX<L;R&[@M)%FA<.A,S'!'(XS74UI#GM[YQ8I8;F7U:]NO-;]
MK&\7?\B9KG_7A/\ ^BVK9K&\7?\ (F:Y_P!>$_\ Z+:JELS&C_$CZK\T6M#_
M .1?TW_KUB_] %7ZH:'_ ,B_IO\ UZQ?^@"K]"V%4^-^K_-A1113("BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YV2TN#\1K>\$+_9AI4D
M1EV_*',JD+GUP":Z*BDU<N$W"]NJ:^\****9 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97B>"6Z\*:Q;P
M1M)-+93(B*,EF*$  >M:M%)JZL5"7+)2[%+1XWAT2PBD4I(EM&K*1@@A1D5=
MHHIBD[ML****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 R1BJ$CK4/G/Z_I4LW^J-5J )/.?U_2CSG]?TJ.B@"
M3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\
MY_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH
M D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*
M/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ
M* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_
M2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ
M.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]
M?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]
M*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y
M_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U
M_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/
M.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG
M]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"
M3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\
MY_7]*CHH D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH
M D\Y_7]*/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*
M/.?U_2HZ* )/.?U_2CSG]?TJ.B@"3SG]?TH\Y_7]*CHH D\Y_7]*/.?U_2HZ
M* )/.?U_2D\Y_7]*910 [SI/7]*//D_O?I3#330!)]HD_O?I2?:)?[WZ5'24
M 2?:9?[WZ4GVF7^]^E1FFT 2_:IO[WZ4GVJ;^]^@J*DH E^US?WA^0I/MDW]
MX?D*A-)0!-]LG_O#\A2?;9_[X_(5#24 3_;9_P"^/R%)]NN/[X_(5 :0T 3_
M &ZX_OC\A2?;[C^^/R%5S24 6/[0N/[X_P"^12?VA<_WQ_WR*KTE %G^T+G^
M^/\ OD4G]HW/]\?]\BJQI#0!9_M*Z_OC_OD4G]I77_/0?]\BJM)0!:_M.Z_Y
MZ#_OD4G]IW?_ #T'_?(JJ::: +?]J7?_ #T'_?(I/[5N_P#GH/\ OD54I* +
M?]JWG_/0?]\BC^UKS_GH/^^15,TTT 7?[6O/^>@_[Y%)_:]Y_P ]!_WR*I4A
MH N_VQ>_\]!_WR*3^V+W_GJ/^^15$TE %[^V;W_GJ/\ OD4G]LWW_/4?]\"J
M)I#0!>_MJ^_YZC_O@4G]M7W_ #U'_? J@:0T 7_[;O\ _GJ/^^!2?VY?_P#/
M4?\ ? JA2&@"_P#VY?\ _/5?^^!1_;NH?\]5_P"^!6<:2@#L-(N9;NQ$LS!G
MW$9QBBHO#_\ R"Q_OFB@#0F_U1JM5F;_ %1JM0 4444 %%%% !1110 4444
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MY!R*MT4 %%%% !574+&+4K&2TF9UCD #%#@XSFK5% ',#P)I0&!->@?]=O\
MZU:ESH-C>:9%83HSQQ "-]WSK[@^M:=% &3I7AS3](E:6W1WF(QYDK;F ]!Z
M5K444 %%%% '.3^"M,N;J6XDFO/,E8LQ$N.3^%7M,\/66E1SQQ&65)QAUF;<
M"/3I6K10!S\/@S1X;H3".5U4Y6)Y,H/PKH ,# HHH **** *FHZ;:ZK:FWNX
M]Z=00<%3Z@^M4=,\,:;I5Q]HA622;&%>9]Q7Z5LT4 8^J>&=.U:<3SK)'-C!
M>)]I8>]7--TNTTFV^SVD6Q<Y8DY+'U)[U<HH **** $(# @@$'@@US[>"M&:
MY,OES!"<F$2'R_R_^O70T4 5[BRAN+![(@I"Z;,)Q@>U/MK>.TM8K>('RXD"
M+GT J6B@ HHHH **** *>FZ;!I=J;>WW[-Y?YSDY-+=Z?!>S6TLN_=;2>8FT
MXY]ZMT4 %%%% !1110!3;38&U5-1)?SUB,0YXQG/2JNJ^'=/UB19;A7251CS
M(FVL1Z'UK6HH HZ9I-GI%N8K2/;N.6=CEF/J35ZBB@ HHHH AN[6.]M);:7/
MERJ5;:<'%1?V=;'3%TZ2/S+81B/:_.0!@?C5NB@#"L?".E6%VMRB2RNAR@E?
M<$/J!6[110 4444 4]2TNTU:U-O=Q[EZJP.&4^H-5-+\-:=I,QF@622;&!),
MVXJ/0>E:]% &/JGAG3M6N!/,LD<V,%X7VEA[U=T[3+32K46]I$$3.2>I8^I/
M>K=% !1110 5S]QX-TBXNVG*2IN.YHXY-J$]^*Z"B@"%;6&.T^RQ((X0FP*G
M&!CM3+"QATVRBM(-WE1C"[CDU9HH **** "JU_86VI6C6UW$)(V['J#Z@]C5
MFB@#%TSPQINE7'VB%9))@,*\S[BOTK2N;=+JVEMY,[)4*-CK@C%3FFF@"&VM
MTM+6.WCSLC4*N3S@5)2TE "&FGFG&FT 8$OA#29;HS>7(H9MS1*^$/X5I7>F
M6E[9?9)H5,('R@<;?3'I5RDH QM.\-Z?IEQY\2R22C[KRON*_2M:E-)0 E)2
MTE &1J7AZPU.<3RJZ2XP7B;:6'O5FVTRTM+(V<4*B$@A@>=V>N?6KII#0!A0
M^%-+@N1,(Y'"G*QN^4'X5M4II* $I*6DH JV]C#:S7$T>[?.^]\G//M27MC;
MZA;F"YCW(>1V(/J#5HTAH R;#P_8Z?/YT:N\HX5I6W%?I6G2TE "&FFG&FF@
M!*2EI* $---.--- "4AI:0T --)2FDH 0TAI32&@!II#2FD- "4AI:0T --)
M2FDH ZOP_P#\@L?[YHH\/_\ (+'^^:* -)UWJ1G%1?9S_>_2I)&*H2.M0><_
M][]* '_9S_>_2C[.?[WZ4SSG_O?I1YS_ -[]* '_ &<_WOTH^SG^]^E,\Y_[
MWZ4><_\ >_2@!_V<_P![]*/LY_O?I3/.?^]^E'G/_>_2@!_V<_WOTH^SG^]^
ME,\Y_P"]^E'G/_>_2@!_V<_WOTH^SG^]^E,\Y_[WZ4><_P#>_2@!_P!G/][]
M*/LY_O?I3/.?^]^E'G/_ 'OTH ?]G/\ >_2C[.?[WZ4SSG_O?I1YS_WOTH ?
M]G/][]*/LY_O?I3/.?\ O?I1YS_WOTH ?]G/][]*/LY_O?I3/.?^]^E'G/\
MWOTH ?\ 9S_>_2C[.?[WZ4SSG_O?I1YS_P![]* '_9S_ 'OTH^SG^]^E,\Y_
M[WZ4><_][]* '_9S_>_2C[.?[WZ4SSG_ +WZ4><_][]* '_9S_>_2C[.?[WZ
M4SSG_O?I1YS_ -[]* '_ &<_WOTH^SG^]^E,\Y_[WZ4><_\ >_2@!_V<_P![
M]*/LY_O?I3/.?^]^E'G/_>_2@!_V<_WOTH^SG^]^E,\Y_P"]^E'G/_>_2@!_
MV<_WOTH^SG^]^E,\Y_[WZ4><_P#>_2@!_P!G/][]*/LY_O?I3/.?^]^E'G/_
M 'OTH ?]G/\ >_2C[.?[WZ4SSG_O?I1YS_WOTH ?]G/][]*/LY_O?I3/.?\
MO?I1YS_WOTH ?]G/][]*/LY_O?I3/.?^]^E'G/\ WOTH ?\ 9S_>_2C[.?[W
MZ4SSG_O?I1YS_P![]* '_9S_ 'OTH^SG^]^E,\Y_[WZ4><_][]* '_9S_>_2
MC[.?[WZ4SSG_ +WZ4><_][]* '_9S_>_2C[.?[WZ4SSG_O?I1YS_ -[]* '_
M &<_WOTH^SG^]^E,\Y_[WZ4><_\ >_2@!_V<_P![]*/LY_O?I3/.?^]^E'G/
M_>_2@!_V<_WOTH^SG^]^E,\Y_P"]^E'G/_>_2@!_V<_WOTH^SG^]^E,\Y_[W
MZ4><_P#>_2@!_P!G/][]*/LY_O?I3/.?^]^E'G/_ 'OTH ?]G/\ >_2C[.?[
MWZ4SSG_O?I1YS_WOTH ?]G/][]*/LY_O?I3/.?\ O?I1YS_WOTH ?]G/][]*
M/LY_O?I3/.?^]^E'G/\ WOTH ?\ 9S_>_2C[.?[WZ4SSG_O?I1YS_P![]* '
M_9S_ 'OTH^SG^]^E,\Y_[WZ4><_][]* '_9S_>_2C[.?[WZ4SSG_ +WZ4><_
M][]* '_9S_>_2C[.?[WZ4SSG_O?I1YS_ -[]* '_ &<_WOTH^SG^]^E,\Y_[
MWZ4><_\ >_2@!_V<_P![]*/LY_O?I3/.?^]^E'G/_>_2@!_V<_WOTH^SG^]^
ME,\Y_P"]^E'G/_>_2@!_V<_WOTH^SG^]^E,\Y_[WZ4><_P#>_2@!_P!G/][]
M*/LY_O?I3/.?^]^E'G/_ 'OTH ?]G/\ >_2C[.?[WZ4SSG_O?I1YS_WOTH ?
M]G/][]*/LY_O?I3/.?\ O?I1YS_WOTH ?]G/][]*/LY_O?I3/.?^]^E'G/\
MWOTH ?\ 9S_>_2C[.?[WZ4SSG_O?I1YS_P![]* '_9S_ 'OTH^SG^]^E,\Y_
M[WZ4><_][]* '_9S_>_2C[.?[WZ4SSG_ +WZ4><_][]* '_9S_>_2C[.?[WZ
M4SSG_O?I1YS_ -[]* '_ &<_WOTH^SG^]^E,\Y_[WZ4><_\ >_2@!_V<_P![
M]*/LY_O?I3/.?^]^E'G/_>_2@!_V<_WOTH^SG^]^E,\Y_P"]^E'G/_>_2@!_
MV<_WOTH^SG^]^E,\Y_[WZ4><_P#>_2@!_P!G/][]*/LY_O?I3/.?^]^E'G/_
M 'OTH ?]G/\ >_2C[.?[WZ4SSG_O?I1YS_WOTH ?]G/][]*/LY_O?I3/.?\
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M>JL,@TZB@#(@TRQ.JW:_8X,!(R!Y8X^]6L    , =!5.#_D+WG_7.+_V:KM
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MHJ?[/_M?I1]G_P!K]* (**G^S_[7Z4?9_P#:_2@""BI_L_\ M?I1]G_VOTH
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MI0!!14_V?_:_2C[/_M?I0!!14_V?_:_2C[/_ +7Z4 045/\ 9_\ :_2C[/\
M[7Z4 5P     !T I:G^S_P"U^E'V?_:_2@""BI_L_P#M?I1]G_VOTH @HJ?[
M/_M?I1]G_P!K]* *^!G.!D]Z6I_L_P#M?I1]G_VOTH @HJ?[/_M?I1]G_P!K
M]* (**G^S_[7Z4?9_P#:_2@" C(P>E'08%3_ &?_ &OTH^S_ .U^E $%%3_9
M_P#:_2C[/_M?I0!!14_V?_:_2C[/_M?I0!!28&<X&>F:L?9_]K]*/L_^U^E
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MU?[(_P"F_P#XY_\ 7I/['_Z;_P#CG_UZ ,HTTUK?V-_TW_\ '/\ Z]']B_\
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M=?\ /S-_W\-)]MNO^?F;_OX:AI* )C>W?_/U-_W\--^VW?\ S]3?]_#41IM
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M-2N[S84445H8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\?SH G\A?5J/(7U:H-S?WC^=&YO[Q_.@"?R%]6H\A?5J@W-_>/YT;F_O'\Z
M)_(7U:CR%]6J#<W]X_G1N;^\?SH G\A?5J/(7U:H-S?WC^=&YO[Q_.@"?R%]
M6H\A?5J@W-_>/YT;F_O'\Z )_(7U:CR%]6J#<W]X_G1N;^\?SH G\A?5J/(7
MU:H-S?WC^=&YO[Q_.@"?R%]6H\A?5J@W-_>/YT;F_O'\Z )_(7U:CR%]6J#<
MW]X_G1N;^\?SH G\A?5J/(7U:H-S?WC^=&YO[Q_.@"?R%]6H\A?5J@W-_>/Y
MT;F_O'\Z )_(7U:CR%]6J#<W]X_G1N;^\?SH G\A?5J/(7U:H-S?WC^=&YO[
MQ_.@"?R%]6H\A?5J@W-_>/YT;F_O'\Z )_(7U:CR%]6J#<W]X_G1N;^\?SH
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MZ3S9/^>C?G0!>_L^+^\_YC_"D_LZ'^\_YC_"J/FR?\]&_.D\V3_GH_\ WT:
M+_\ 9L/]Z3\Q_A1_9L/]Z3\Q_A6?YTO_ #T?_OHTAFE_YZ/_ -]&@#0_LR'^
M_)^8_P */[+@_OR?F/\ "L[SI?\ GH__ 'T:3SI?^>K_ /?1H T?[+@_OR?F
M/\*/[*@_OR?F/\*S?.E_YZO_ -]&F^?+_P ]7_[Z- &G_9,']^3\Q_A1_9,'
M]^7\Q_A669YO^>K_ /?1I#/-_P ]7_[Z- &I_9%O_?E_,?X4?V/;_P!^7\Q_
MA65Y\W_/63_OHTGVB;_GM)_WT: -7^QK?^_+^8_PH_L:W_OR_F/\*R3<3?\
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M_(JW_P#N#_T(4 -M/%VEWEI<W,9F$=OC?NCY.>@ %&G>(_MFF7U]-:M"MJ[
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MI:0T --)2FDH 2D-+2&@!II*4TE "&D-*:0T --%!HH [Z3_ %;?2JE6Y/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA0!BTE;7]EVO]]_^^A1_9=K_ 'W_ .^A0!B&FUN?V5:?WW_[Z%']DVG]]_\
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M. <$\?4@G\J .ZHK*\/ZN^L:?YTL#03(VUT(.,^HK3DD2*)I)&"H@+,3V H
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M_JV^E5*MR<QM]*J[&_NG\J $HI=C?W3^5&QO[I_*@!**78W]T_E1L;^Z?RH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9H>H1^1=Z$UNRC&^$]:9)8^#]64+-.;8A0%5DP/Q-3+!2M=%*:V::/-V\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ%IJ5O\ :+.=9HLE=R],T 6:**R[GQ)HUI=&VGU&!)@<%2<X/O0!J44PS1+
M9C(@B"[M^X;<>N?2J-CKVE:E,8;.^BEE'.T'G\,]: -&BBJE_J=EID0DO;F.
M!6.!O/7Z"@"W15>RO[748!/9SI-&>-R'-5;O7])L+H6UU?PQ3''R$\C/KZ4
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M_9594[WLVON"BBBF9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]K OB*Y$BKO3A1Z5>\":(=,T*&5U RNXMG!J.U?9J-S=)!YOF,1D5[.%:@E
M\VI7O7<5T-Z>XT](_+F51D]2.2:M0[ @$9PF.#7,.DNH:DB+;D3#LW0"NB%M
M-IT2FY<,'Z =JWG-.\$]37#5J:J<KW&L]G>S&#>KS+SMSS6-J=C=QW"&.WS&
M#Z5FZ[I%U%<MJ5G(R3+R0#VK6T?Q&NHZ+MNF"SI\K,>]<T<1*G%J2U/0E2@Y
M<Q?L[6VMH?M<Z"'CDYJV)T>$W$;YC R#[5R%WJ3:[>_V;$2+2,?O&'<UUFAV
ML<5LMM_"!@!JWHSE*'/(PQ$HPC9&KH^I0W05-RN#VJMXNLTDTUV7DYXQU%<K
MJI;0/$*74,9,3?P@]ZWV\117-@QNK61,K]['&:YZUU)3BMSPJVDN:/4Y>[TY
M+KP^J3("DL?);L?:O$[^U:SO98&'*L0/I7O=I/#>Z>UJ5R(FW >M>6_$72WT
M_7%F(4+<+N 7^'VKFQ4'93/5P=1RIVENCJ?V>?\ D?;S_KP?_P!#2OIJOF7]
MGG_D?;W_ *\'_P#0TKZ:KB.H0,K$@,"1P<'I17.^'/\ D-^)/^OY?_1:T4HN
MZN:UJ?LY\M^WXI/]0\.?\AOQ)_U_+_Z+6NCKG/#G_(;\2?\ 7\O_ *+6NCJ8
M?#_7<TQ?\7Y+_P!)B>6WWQ2U"UUR:P73[5DCG,08LV2,XS7J*G<H/J,UQMS\
M,M#NM2DOGGOA+)+YI D7&<Y_NUV0&U0!VXJ:2J)OG.G'U,'.,/JT;-+7UT\W
MY@WW#]*\]\"YL+FUS_J=1B<?]M$/^!->A-]P_2N L(Y(_ 5E?1*3-8W'G@ <
MD D,/R-:GFB^,<WVIL^?W5@\*#G^-SD_IBE\6VTEQXHC>'_76]CY\?U5R:=>
M12MX-2\F4B>]O4N'&.1EN!^0%:UPF[X@VX(RIL&!_P"^C0!-K-^;KPQ";8_O
M-1$<47K\^,_D,UD:%83-X.U>QL3B7[1+''SC/ X_&ET*&X;7TTR96\C2&D9&
M/1MWW/R!-2:2NH_\([JQTQMEX+V5H\J#GIQSQ0!0L=4\+6UFEAJFCFSF5-CM
M/;;MS=\,,GW[5I7MI:V7P]O8[*Z-S:E"T3$@X!8<"HW\::7- (-3TRY6ZQM:
M!X-W)[<^M5TL9K3P%K#R6S6R3NTL5LW6-"1@8[4 1VVO^'$M85?PW.[A &86
M$9R<=<YKL-&EM+C3(Y[*T-K#)DB(Q",@YQR!]*YVT\>Z-#9P1.MWN2-5.(>X
M'UKH=(UFUUNU:XM!($5MI\Q=IS0!>D4O&RABI((##J/>N<;P[H6CZ',+N"*8
M!6,D\R R,3[]<_2NAGF2W@DFD.$C4LQ]A7G\/B_3+V^-YJPN6$;?Z/;+%E(_
M]H_WF_E0!)):W$?A/1-*N&=%N[L*RD\B,L2%/X8K1\4:38Z9I]MJ%C:Q6\]K
M/'M:)0I() (..M/U>Y.NZ%:ZOI44LK6EP)EC9<,P4\C%4K[7%\6K;:7IUI<?
M-*CW+R)@1*#GK0!W"G<H/J,UE:EI6ER7)U34(?.\F+:%==ZJ,YR%QR:2ZT(W
M-RTPU;5(0V/W<,X5!QC@8JIJ>MW.@7T?VN"2;2S$ )T0LZN/[W;F@#/\//:_
MVQK%[IR""S\L8@(VDL,_-L["G^%]$T_4- -Y>VL5Q<7KN\DDB[F^\0,'J/PH
MTV8^(?$K:G;6TL-BELT)ED7:9B?;OBJFF^(?^$8M'T?4+.Y-Q"["W\M,B522
M1@_CB@#7\&.ZZ1-:LQ86MS)"I)YV@\5T=<SHK'P_X9EOM31XWDD:>5%&2NX]
M,5T<,JS0I*F=KJ&&?0T <IJUN-=\8PZ5<EC8VT'GO&#@2,3W_2M34/"VDWUD
MT"64%N^,I+%&%96['(ZU0U^&]TS7+?7K*V>Z01>3<0QC+%<Y! J&;QO#?0FV
MT>SNY[Z0;44QX"?[1/H* %\26Q2V\/VMRXN"+R))&=>'['(]ZV+OPUH]W:R0
M-IUM'O&-\<2JP]P0*P?$CSZ?I>A2ZC*T\L%TCS.J\G')X%32^/;*:,QZ=:WE
MQ=MQ''Y6,F@#.2YEE^&^IV\SF1K1S &/=0PQ4UKKW@E+.%98K3S!&H?-B3SC
MGG;3I]+FTSX<WT=R/]*F_>R@<X8L.*W6T2QU30(K::WC&^%<.J@,IQU% &7X
M*B!GU2ZM;>2#3IY0;='&.W) ]*ZN6010O(>B*6_*N:T&\N9TNO#^I2R1WMNN
MU)HSM9X^S*?7I6G9Z)]DF,C:GJ-R"I4QW$P9>?;% &'X7TBUU:V;7-3A2ZN;
MEV91*-RHO0  \47<?AAM1M+FQU&QL;NWE&3"5&X=U(''-166HW'@T2:?J-G/
M)IZN3!=1+N 4]C[UGWAT[Q"$@T#0F$IE5GNS"(U3!R<F@#7\4Q>5K=CJ-W82
M7^FQ1LK1QC=L<G[Q7OV_*H()O"NN7EI]@==/OXI ZA(1$V1_">,']:T=7U;4
M=#U5+B2"6XTAX@'$2 F%QU)XSBL74M0L/%+06VD:;*UV)58W)BV"$ Y))'KS
M0!W]<CH6GVFK:IK&H7T$=R_VDP()5#!57T!KK5!"@$Y('6N+351X2U;48;^W
MG-I=2F>":--P)/5: +WAJ)=/UK6M+A&+:*59(DS]W<,D"K'C*5T\,W*1J[-*
M5CPBY.">:K^'C,3JNO7<$D"W3;TC8?,(U& <>^*N7NKW4NA1:GI%N9P2&:)T
M.YD[X /6@#%M=2TVTNX$N_"QL82P2*[EMU^]VSQQ]<FNUKB-1U^'Q5:#2M,M
M;EY99$,CO'A8E!!))_"NU1=D:KG. !0!BW>L7LNJOIND6T4TT*AIY9W*QIGH
M..233M.UJ::>ZL;ZW6"_MDWE4;<DB]F4^E9PND\.^)=1FOU=+.^V/'<!"RA@
M#E3CI2V+/JOB"]U>*)ULEM?(BD=2OFGDDC/:@";1-9UC6HH;I;.UBLRQ5V9V
MWG'4J.F/J:S/$NF7*W-IJ%Y>M*?MR)#"HPD:$G\SP.:V?!HQX7M 1C[W_H1J
M/Q>";+3\#/\ IT7]: .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K&\6_P#(H:O_ ->DG_H)K9K&\6_\BAJ__7I)_P"@FIG\+-\-_'AZ
MK\T7],_Y!5G_ -<$_P#015JJNF?\@JS_ .N"?^@BK5-;&=3XWZO\V%%%%,@Y
MSP'_ ,B7I_TD_P#1C5T=<YX#_P"1+T_Z2?\ HQJZ.HI_ CIQO^\U/\3_ #"B
MBBK.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \8_:+_Y%K1_^OMO
M_0:^?-*MFN]2@A49)85]!_M&?\BUH_\ U]M_Z#7C?@"Q^V>(8@/[P ]C6E*/
M--(+VU9ZGXE"VGAK2M+@P%D7>1W![U?TZ."&QCAEASE1\V.:R/$KS-XH@MU*
M3M$HY[9]*VK*>:9<2Q",KQ7MP2Y;MGGTJ,JJYUU9H1CY!&"=HZ9[T^3(4@ =
M.M,4C^*04V3<9/EZ5EBI+E2B]#TZ%/E5FCS3QNFV^CD/&[N*G\.^+)X[::VN
M&)\I,H:L>.HW+Q J!@US%M;LQGV\9C.:\F4'?0<HN^A5O]0GO[MKF5R78\9]
M*]'\#"2+1F#GESNYKS5HF\P#C@#->L^'8_+TB#Y< H**;DI70033-U99(,&)
MCGK@UG26=[JMZTEZ0D0Z#/6K>]  ,@'US2B"YN@R0N=^.#7MSI0J14I'FXNA
M!SOM8XO7;9M)U>WN+10H5AM'J?6L?XL6((L[U%!W(,N/XB1S70^(M!OK2PDN
M+R<M*.GH!1XH@34?AU9%!NV0XWGU%98N*E231KAY*ZMU1X@O^ID_"M;PIIIU
M3Q!;0;=RA@2*R4!$4H/M7H?PDL/M.L2S ?,@RI]Q7DT$I5%<ZINT;^1Z5XEO
M!I>GK;H1RHB0KZ5SVF7TMO=^6P"1GKNXS[U+JCC4/&-O9N24B^:0#H#5CQGI
MGDP)<0#Y N"1VKUJ5-Q^9XE.,MWU+ELTUWJN+)@P0YW ]JW=187 2)NJC)^M
M</X.NKK[8P@90 /F4]376^;NNG.3D=:TC2M4<C2G1?M6R&Y0W-C*JC]XBD#W
MKA+?3;FWC_?_ "&:;"@GK7HRJ!$SC&#TKA/%<$[ZC$T3G9V&>%-9XIQM9;GM
MTD^74L^#=*NDUJY$R$1CJ37;W%L\4@DCR .E9F@I+;VD6Y@SD99O6M.:_P J
MRL<[.@%:0NX*QPXJE4<[QV,3Q-$ D4[Q$E2"6STJW.UEK>D*(+L1!%Y7U-5O
M$KS-H;2Q.I4CY@W6N$TB*\NKV..WW^63\Q'2IY+JYPK#N<'+L3P3W&EZU&^2
M4>38<GJ#5KXIZ9#_ &+921-O>,%I&/OVK=\5Z'Y.C1742X:+!)JIXN(OOAM#
M,J O*>3WP*QK7J0L:8:L^>*[F-^SS_R/M[_UX/\ ^AI7TU7S+^SU_P C]>_]
M>#_^AI7TU7DGIG.>'/\ D-^)/^OY?_1:T4>'/^0WXD_Z_E_]%K140^'^NYTX
MO^+\E_Z3$/#G_(;\2?\ 7\O_ *+6NCKG/#G_ "&_$G_7\O\ Z+6NCHA\/]=P
MQ?\ %^2_])B%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!#=VRW=I);L[*LB[6*]<=ZDC18HUC0850 ![4ZB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L;Q;_R*&K_]>DG_ *":V:QO%O\
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M/<]A[G.>'/\ D-^)/^OY?_1:T4>'/^0WXD_Z_E_]%K16</A_KN=&+_B_)?\
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MZI)X=MWMM7L8[58\,C6N=GJ&.[K5.&**UM/#K&[%SIZWCDRF,HH)^[P>V<T
M7M7U^WO[C2HK9[B&7[;$6CE1HV92>N#U%=E7*^+7MS?Z$I*F?[=&5]=N1G\*
MZJ@#C=8T[^V/&J64EW=01"S\S]Q)M.0WX^M5-<T >'--;4[/6[];B(@HL\P8
M/[8P*LZQH]IK?CI+6\#F,66\;&P<AO\ Z]9]_P"&]/\ #&L6U_+;M<Z6Q"N'
M.3"W9CZB@#LY=8M[+2K>\OG\LRHI" $DL1G '4FF6.OV-_<_9D,T-QC<(KB(
MQLP]0#UK"\0F=_%.CO!=0P1M$_DS2Q[T#GVR.2.E.OK.]_M?2O[1UFW:59PT
M*16A#-ZC()P,?A0!M7_B*PT^Y-NYEEF5=SI!$9"@]6QTJU'J=E+IW]H)<(;7
M:6,F> !US6+X8*+J&N)+@7/VLLX;KLQ\I^E5KK4-&C\.W;6VG-);&[\ORV.U
M)9-WWLY^[D4 :*>+=+::)'^T0K*VV.66!E1CVPQIE](X\:Z5&'8(T$I*@\'C
MTK!\72:N-! U"33H(]Z;(K<LS.<^IQC'MFMJ\_Y';1O^O:7^5 $GA^21]8UY
M7=F"W0"@G.!CM6IJ&J66E0":]N$A0\#=U)]A63X=_P"0UX@_Z^Q_*K'B*#2)
MH8/[4NA:LK$P2B78RMWP?RH ICQ->ZA(J:/H\\L;8_TBX_=I@\Y ZFNFKA(]
M5N-.F1;'Q-8ZA!D#R;IP'QTP&'4_6N[[4 <!+%'J^KZF=7UN;3WMY2D$*2B,
M!.S<_>S[5HZ9JMVO@:\N[J5I'A61(9B,&1>BM^9_2J6CVNDZU]MGUZ19;Y)G
M5DFE*^4H/ 49Z4_3;ZU7P]JJWPGO](@N/+B;[S%..Y(R <4 5-*TK1)WM8I/
M$=Z;YE5FB6Y&W=C..G]:]" P /2N.\0V_AU?#4KVL=DLNT?9VA"ARW\.".:Z
MNQ\W[!;^=_K?+7?]<<T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8WBW_ )%#5_\ KTD_]!-;-8WBW_D4-7_Z])/_ $$U,_A9
MOAOX\/5?FB_IG_(*L_\ K@G_ *"*M55TS_D%6?\ UP3_ -!%6J:V,ZGQOU?Y
ML****9!SG@/_ )$O3_I)_P"C&KHZYSP'_P B7I_TD_\ 1C5T=13^!'3C?]YJ
M?XG^844459S%74;"#4[":SN 3%*N#CJ/<5S<>A^*K-!;6NO0M;*-JM+%EP/R
M/\ZZZB@#!B\*VRZ%/ILTTDSSN9);@_>,G][]*B;2_$5S;"QN=3M1;?=:>*-A
M,R_G@$UT=% &1/H[OJ^F744BB*S1E*L26;(P*K'1M2TZ^N)]%N;98KEM\D%T
MC%5?U4KSS7044 8EOH#26-[%J=RUS->C]Z5X5.. @[ 53?0-7NK--+O-0MVT
MU2 72-A-(HZ*><"MR[OX[.>UB>*5S<2>6IC7(4^K>@JW0!B:II-Y+J=CJ&G2
MVZ2VRM&4G4E2I^E36FES0>(+[47D0I<1QJ%7.05&#6K574;Z+3-/FO9E=HXE
MW,$ )_#- &/;>&6@\3R:D9E:URTD4/=)& #']*FO=&O$U5M4TFYBBN)%"313
MJ3'(!T/'((K9AE6>&.500KJ&&>N#3Z ,C3=-O4OI-0U.[66X9/+6*$%8HUSV
M!Y)]S6K(@DB>,\!E(_.G44 <HOAB_?0)-'GNK?RHVWVTB(V[(8M\X/!'/:EU
M/0M=UK36M+V_LHE7!1;>-@'(_O$]!]*ZJJEU?QVMW:V[12NURQ561<JN!_$>
MU &;J.C7DUQ8ZA97$,5_:IL(D4F-P1R#CFH[71-1_P"$BAU>^NX9'6%HVCC4
MJJYZ!<]NO)-;4=Y;RW<MJDH::( NH_ASTS4] !67H.ERZ39S0RR(YDG>4%<]
M&/2M2J6J:G#I%D;NX61HPP7$8!.2<=R* +M<;:Z!XITY9(K'5;..!I&D"M'N
M(R<]2M=.^H1QZG#8F*8O+&9 X7Y !V)]:MT 8FD6OB&&Z9M5U"VN(-N L4>T
M@^O05/KFERZI#:I%(B&&Y28[L\@9X_6M2B@ K.US33J^D36:R"-WP58C(!!R
M*DN-3@MM1M+%UD,MSNV%0,# R<\U=H P9-)U&\DTJ:[EM?-LYB[^4& 9<8&,
M]ZEUS2+B_GLKNSFBCNK1RR"92R,#U!Q6S5*ZU."TO[2SD60R718(5 P,#)SS
M0!BW.A:Q?WUA?7E];>;:S!Q#$A6,+WY.23TJS<:/?VVJSZAH]Q;HUR!Y\-RA
M*$CHPP<YK3M[^.XOKFT6*56M]NYF7"MG^Z>]6Z ,&#PS$VDW=K>S&:>\?S)Y
M5&/F[;?8=JA.E^(I;7^SY=3M1:XV&X2-A.4_/ /;-;-_?QZ>D+212R>;*(QY
M2YP3W/M5N@#'GT5FU+2IXI (K%64AR2S9  Y_"MBBB@#G?['U:QU6]NM+N+/
MRKQ@[K<HQ*M[$'I1I?A^[L+O5)9KU;G[=& 79=K;@".@XQS6K?ZG!ITEJDRR
M$W,HA38 <$^O/2KM '-GPY<'PWI^F>=%YEM,LC-S@@,3Q^=:>LZ3'K%F(6D:
M*1'$D4J]48=#4,'B*QGUV32$$HGCR-Y4;&(&2 <]1GTJSJVJP:-I[WMPLC1H
M0"(P">?J10!EMI>O7ZQV^HW]JELI!=K1&627'8DG S[4ZZT;48-<DU/2I[4-
M-$L<D=TC$#'0@@YJI_PGVG#E]/U1$[NUN, >I^:NCLKVWU"T2ZM91+"XRK"@
M#%L- O8-?EU*\O([G[1;F*5=FW!R.%'IQWYID6B:Q8PR:?8ZA;KI[$[&EC)E
MB!SD+@X/XUTM% &+I&CC2_#;:=>2HZ 2;W'3:23W]C57P38M:Z()Y&+O<-N#
M$=4'RK^@K:OM.M-3@$-Y LT8;<%8GK^%6418T5$4*JC  & !0 M<Y_PCMQ_8
M^KV7G1;[Z5W1N<*#ZUT=% &5J&ERW?AN33$D19&@$8<YQD8_PJ_:Q&"TAA8@
MF-%4D=\#%344 %%%% !10>!FJ6EZG#JUD+NW618RS+B0 '(.#T)H NT444 %
M%%% !1110 4444 >,?M%_P#(M:/_ -?;?^@UY1\,IY(/$*F,@'<O)],\UZO^
MT9_R+6C_ /7VW_H->'>$]06PUJ)G.%9@*THRY9IA:^AZS9J&\57J2,8U,Y",
MO7!K:U.*^LY(TM)WEW?P8YK!U^[BMM;L]3M,>7<Q@A/[I'6NJL=5MVFBO5RP
M*Y)QTI9RJD%"O#IH>:J:G4Y:FB:_(@CM[J&U62XR&;KD=*P/$^FSZK:+!",G
M.<^E=<+Y]6U!FVE;-%Y)'4UFSR+ LLK#*K75AYO%T%.2LT=>"J:.D];=3)\+
M:!'I%LTDQW7#=6/:MJ]TZXN8XY%N%A&[(]_K7._VQ<SS[A&ZP=?>N@T_6+6_
MM0A4Y0X;<.HK2NIT,.Y0C=HK&59P2Y'9#KFQ6XLGM+S:Y(QD=#[UY;J7AF_L
M[[:(R8R^58>E>AZUJ,ESJD%EISJ@098GI4SAI+8"4?../8TJM+GI*HM/(JA7
M]M"SW'Z47>TAB^\X %;8UO3[&.2'(::(9,=9>E!HW)C7<R X'K6#J>EZC<:T
M]U! 8_-X8$]17G8^K-1A0>B:NS>AAZ>)Q#53:".CU_7%E\*R7< P77&VN7D=
M],^'6[<?],+.2>XQ6/K-U+YJZ;'N#!@%3/4U-\1M2M].\/V>DPOB1(0"N>A/
M6NO"TOJ^#C?KJ<48*=:51+2^AY$3E9VSR6_K7J'P=U%8[JXM)"-DJL"#WXKR
MU?\ 52?A75_#S48;'Q HF^[(-H_'O65"5I^ITU(\\>7NCU'PS%!=7-]9RP!C
MYQP>X&:Z]]&TNS ,L>' RHSUKCK:6/PYXR<7$H>*X0,DB]#793W-I=1K< LV
M>!FIQ<YT\7!_89X<Z4>63>Z,+7KMAIMPT2C 7  ["O.=#>=M622 XP<N3T K
MT^:Q9X7<J"AX93Z5B6>BV]D9MBC;(V3]*]JE>4E*#]T]FC.DZ*4.A4OOLNHM
M]GM8QYA.6D [5@7T$%C*86;<5'&>]=X+>WA3]W&J ^@KE[_38[R[8GY60YY[
MBMW3A>[&Z[C&[#3+:- MW<Q[T*_<QTJ'Q1(18Q_9L?9F^_M_K716,*FT0AQN
M'0>M,O-/AGLKA6C"EU.<>M34@W%M="*#DI^\[IG#:'<.=7M!#P0<<5Z];6D6
MJP%+@$&/[K XKA/ _AHQWK7-WT3)45W<.O6*.8(HV#=.?6O$QV)4:+IR5Y27
MW&E7#SQ,E3IQ^&UWV,W4(X=!T?4)XWS*5(#'N:YZSN?['^'EY-%(#+>'<ZGM
M5SQKJ+LD6D[5#S,"".]8_CRYL]'\,164&5DEC!D#?WO:EET/981RDM]?\C*<
MU5Q3:6BT^XI?L^$M\0;]CWL7/_CZU],U\R?L\_\ (_7O_7@__H:5]-UB;'.>
M'/\ D-^)/^OY?_1:T4>'/^0WXD_Z_E_]%K140^'^NYTXO^+\E_Z3$/#G_(;\
M2?\ 7\O_ *+6NCKG/#G_ "&_$G_7\O\ Z+6NCHA\/]=PQ?\ %^2_])B%%%%6
M<P56L-/M=,M_L]I%Y<6XMMW$\GKUJS10!3N]*LKVZM[F>'=/;MNB<,5*G\#S
M]#5"]\(Z'J-W)=75EYDTARS>:XS^ .*VZ* ,O3_#NDZ4L@LK-8C("K-N8L1Z
M9)R*N6-C;:;:):VD0CA3.%R3UYZGFK%% %2\TVTOY+>2YBWO;OYD3!BI4_@:
M=;:?:V<]S/!%LDN7WRG<3N/KST_"K-% %*]TFQU"XM[BZ@#RV[;HGW$%3^!Y
M_&DU+1]/U>(1WUJDRCH3P1]".15ZB@#)T[PSH^DS&:RL4CE_OLQ<CZ%B<5K4
M44 96I^&])UFX6>_M?-D5=H/F,N!^!%1V'A71-,N//M;!%E'1F9GQ]-Q.*V:
M* *][86NHVS6]W"LL1_A;^8/8U4L/#^F:;.9K:VQ+C =W9R![%B<?A6G10!5
M33;2.XN9UA'F7( F))(< 8Z'BJ$/A31()-Z6(/7"M(S*/HI.!^5;-% &)?)#
MHVBBPL;"XF616CCBC5G"DC^(GH.>]7-&T]=+T>UL@!F- &QW;J?UJ_10!CS>
M%=%GN&G>R&YSN8+(RJQ]U!P?RK0FL+2XLOL<MO&UMC;Y97@#M5BB@#'A\+:-
M \;I9_/&XD1FE=B".G)/3VZ5L444 5O[/M?[2&H>5_I0C\K?N/W<YQCI3[JU
M@O;62VN8Q)#(,,I[BIJ* *#:+I\FF)ITEN'M4&%1V+%?H2<C\Z98:!IFF3&:
MUMMLI&-[NSL![%B<5I44 9M_H&F:G,)KJVW2@8WH[(2/0E2,_C4SZ58R:;_9
M[6L?V3&/* P/\^]7** ,5?"6B"&2(V6]7&#OD=B![$G(_"M Z=:F[M[HQ$SV
MZ%(W+'A3U[\_C5JB@"M;6%M:3W$T$>V2X??*=Q.X^O/3\*+S3K+4%1;RUAN
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MI%50.YKB->U.Y\4:R-+TW/EYY8=Z\K%8.6)Q2LK16[[^1PTL5752<:>E]/\
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M-W"L[I?.(]_(3!SQZ<T =B2 "2< <DUR?]NZWK4\H\/VMNMI$Q7[3<DX<CJ
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M:@\\1_VEY_EF@#NV94&68*/4G%->6./&^15STW'%<K>WB^(9M$LH\F*<"[G
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MN.I -9MYXD50RPJ!G[V>*>=%T* F2?5\H#\VW%4[S6?!NFS>; DEVVS"B0Y
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M^$@UK_H5+W_P(B_^*HYU_28?5*OE_P"!1_S'+X?OK"6;^R-36VMY6+F&6'S
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MC65%2>)X]V\#T.>*FTG2CIOVW=*)1<SM-C;C;GM[UG?\)!K7_0J7O_@1%_\
M%4?\)!K7_0J7O_@1%_\ %4<Z_I,/JE7R_P# H_YDVA>&TT6[NIQ.91*<1 KC
MRTR3M_,TDF@W=M?3W.D:@+07!W2Q21>8A;^\!D8-1?\ "0:U_P!"I>_^!$7_
M ,51_P )!K7_ $*E[_X$1?\ Q5'.OZ3#ZI5\O_ H_P"9H:3I TWSI9)VN+NX
M8--,PQN/H!V'M6G7.?\ "0:U_P!"I>_^!$7_ ,51_P )!K7_ $*E[_X$1?\
MQ5'.OZ3#ZI5\O_ H_P"9T=%<Y_PD&M?]"I>_^!$7_P 51_PD&M?]"I>_^!$7
M_P 51SK^DP^J5?+_ ,"C_F='6-XM_P"10U?_ *])/_0357_A(-:_Z%2]_P#
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MT*E[_P"!$7_Q5'.OZ3#ZI5\O_ H_YG1T5SG_  D&M?\ 0J7O_@1%_P#%4?\
M"0:U_P!"I>_^!$7_ ,51SK^DP^J5?+_P*/\ F='17.?\)!K7_0J7O_@1%_\
M%4?\)!K7_0J7O_@1%_\ %4<Z_I,/JE7R_P# H_YG1T5SG_"0:U_T*E[_ .!$
M7_Q5'_"0:U_T*E[_ .!$7_Q5'.OZ3#ZI5\O_  */^9T=%<Y_PD&M?]"I>_\
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MSK^DP^J5?+_P*/\ F='17.?\)!K7_0J7O_@1%_\ %4?\)!K7_0J7O_@1%_\
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M #/)Q^SE(.GB-O\ OU3O^&=9O^AE?_OU7JW_  D&M?\ 0J7O_@1%_P#%4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X C$# 2(  A$! Q$!_\0
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MA0 HX50JJ .>G6MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ/R4_O/_ -_#_C1Y"^K_ /?;?XT 29%&14?D+ZO_ -]M_C1Y"^K_ /?;?XT
M29%&149A0#)9_P#OMO\ &@0J>C/_ -]G_&@"3(HR*C\A?5_^^V_QH\A?5_\
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M )ZM^0_PH EHJ+RY/^>K?D/\*/+D_P">K?D/\* ):*B\N3_GJWY#_"D\M_\
MGJWY#_"@":BH8@P=PSEL'@D>U34 %%%% !1110 4444 %%%% !1110 4444
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M/_031U$]CR[PA<W&J>-]-U6Y?S)9K5H6D/5BD$18_FYKN/$__'YX=_["B?\
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MQOL.GU_K3ATIA.0,>H_G3QTJ449/B#6&TBWB*/8QR3,562^NE@C7C.23RWT
M_*LS1M=U2\NQ&;G0=4BR/,.F71\R%3_$58D,/Q!] >E7?&3"'PGJ5TJQ^?!
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M:]%K/U#_ %UC_P!?*_R-*$]=A5(+EW/&M+T2^O?%&EW*?VI&YAG*"*Z"-\C
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M&'B6/;CI@DY_6G"SQJ'VK=_RR\O;CWSFN=SO?T-E!JWJ5[#2OL6IZG>>=O\
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MP)P3ZT =-1110 4444 9X_Y&!_\ KT7_ -#-37W_ "#[G_KDW\C4(_Y&!_\
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MM55I\\VPHQY8)!11161J%%%% !1110 4444 %)BEHH **** "@T44 )2T44
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MFVO&N.2I['TKS'3;G3)Q:M/J$4'AB[O9&:V^W[Q;A8/W8E<-\C.P+[<]<=Z
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MRRVY"%=JHS;0RC(.%X&0,"@#U2H)[.WN61IX(Y3&VY-Z!MI]1GH:GHH @%G
ML[3B&/SF&UI=HW$>A/7%+!:P6R%((8XE+;BL:!03Z\=ZFHH SQ_R,#_]>B_^
MAFKY]ZH#_D87_P"O1?\ T,U:N&*02..JJ2/RH!Z&#N,GC(?W4A*?CC-:.I_Z
MVP_Z^5_D:H:!&+Y3J4O^N+MR. <J ?Y5H:F/WMA_U\K_ "-:2^)+L<\=8-]P
MUQ'DTJ144LVY. ,G[PJU/#Y]M+%DCS$*Y],\5-C(I0.*SN;<NI%;Q>3!'%G.
MQ0N?7 J:BB@I*P4444 5C:H;M;GYO,"&,<\8)S5FBB@+!1110 R1=R,/48J.
MS@^S6D4 8MY:A<GOBIZ*!6UN%%%% PQ4$EK$]S'<,#YD:LJG/8XS_*IZ* $%
M9VM_\@M_^ND?_H8K2K-UO_D&/_UTC_\ 0Q50^)$5/A9?/;ZBG#I3">GU%/7I
M4(M"%$9E8J"R_=)'(^E.HHI@,EACG0I*BNAZJP!!_ U!_9UEY31?9(/+8Y9/
M*7!/N,5:HH A-I TB2-$A=,[&*@E<]<'M52Y&-:T_P#W)OY+6C6==?\ (;T_
M_<F_DM &@W2N7\5?-!=+ZVNW_OJ1174&N5\1$O-.OJUK'^<O_P!:KI_$9U7[
MH>$1G5O%#_\ 44V?]\Q1BNKKE_!J_/X@D_YZ:S.?R"K_ $KJ*F6Y<=@HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/2B@]* (U_P!8_P!?Z"H)
M-3L89&CDNHE=3@J6Y%3K_K'^O]!2F*(G)C0GU*T 5X]3L9I%CCNHG=N H;DU
M3\1:V=!T^*Y6!)GEN(X%6281*"QQEF(.!^%:@AB!R(T!'<**I:OI$.L0VT5P
M?D@N8[C;M!#E#G!![&@#"L/'=K<7,D%Y;BW\A)6FECF$T8*&+A&4?/GSE' R
M"",5?;QEH20I*]XRAF=2I@D#H4(#[UVY0 LN2P &13=9\*P:GM-O<-9%+9[=
M!"@"@-)&YR!C(/E@$ C(8UG6/@:32SYFG:P]K/(T@F>.V3:4<JQ5%Z*00<'G
MJ<YZT 7[_P :Z/90W++.96MS\X",%8!U1RK$8?:6Y"YQTJ23QEH,5LL[WQ5&
M+@J8)-Z;,;RZ[<H%R,E@ ,CUK'3X<VL,D_D7@A4EV@9+9/-B9I!(29#DM@C
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MIG;SUK@?"^I7\NNZ4TFHS7*ZI9W4]Q [ K"\<JA=@_A #%<=\>M>@4 %%%%
M!1110 53GM9)+VWN$D53"'&&7(.['O[5<HH @Q<_\](O^^#_ (U5\[4?[3,'
ME1?9?)WB?!Y?.-F,^G.:OMTK@M-U.^/B?39&U"60:A>WUO/:,P*1I#NV;1_"
M1M&?7=SVH [G%S_STB_[]G_&DQ<_\](O^_9_QJ>D/0T 0'[0/^6D7_?L_P"-
M5+"XU*=;@W4,5N4G9(^"WF(,8?KQGTKD]9U/6=-\3:PPO=\4>@RW5M;A,)$Z
MO@,?[S>_3'&*S)]0U"WUV+P]'K-Y)8SWEHC79D!E420RNR!\<;C&I]MQQU%
M'I8^T'I)%_W[/^-&+G_GI%_WP?\ &L/P-J%UJGA.TNKR7SIR\T9FQCS%25D5
MOJ0HK=N21 ^V41':?G(R%XZ_AUH AN'O$MY'B,4DBJ2J;2-QQP,Y[TVSEOIK
M*"6X6*"=XU:2':6V,1RN<\X->=VMWJ,HA6WUG49='OKVWM!?3R*))F^<R/%C
M[D;E54?CM[&J4VNZL=)U2Z.MW"2:/"S6K J!=$7,D8:08^?Y8U7_ ($3U(H
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M!!&,)'&NU5'L*L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\,,K@AG6,G"DYYQ[^M:.D:;%H^D6FG0$M';Q+&&/5L#DGW)Y_&BB@"[1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &= ]4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7^4597AP?\4]XJ/^Q)_Z ] '47?BW3+2SL;MO.>"\SL9$!VXP#N&<\9[9Z5
M/&VF^<\$EM?Q3J 5A>#YY,]-HS[YYQ7'R?\ (N^%/^OB7_T:*Z"<?\74MO\
MKW/_ * U &U8^*+"_LKVYC2=#9(7FAD0!P ">F<=CWH?Q/9)X>36S%<?9G;:
M%VKO^\5Z9QU'K7,:?$\^K>,88E+2/'*JJ.I)W "LN;5K9OA_'I0$OVN*4^8O
MEG"C>3DGIW H [>]\6Z?I[6:S1W/^EQ"5"J X!Z \YS],U+I?B6SU6^EL4BN
M;>YC&XQ7$>QB/ID^M<M=_P#(P>$O^O:*KCJ6^*$B*Q0O;$;AV^3K0!J7/C/3
M8)YXXX;NY2 XEFMXMT:?4YK,\8ZR7T?3;W3;V5(I9N7B<KD8Z''\JH:+JD'A
MO1]1TG4X98[S>Y1!&2)<J ,'_/%9E_87%AX/TQ+I"CR7C2!&ZJI QG\L_C0!
MW-IXMT^[U**Q\F[@DF&8FGBVK(.V.<\_2J]EJEA%KFKEKS42;92TRW#@PH ?
MX .:I>*#CQGX>(Z^8!_X\*I6*12>)_$Z302SQ-&P:.(?.PW#IR.: -N/QOIK
M&)I+:^A@E;:EQ+#B-C]<U7U+Q9<6GBB#3X["Z:!0QD5(=TDW#8*#/*Y .?8^
ME<S#J']F>4/#VJ7TDK28_LZ> D@>_;/3I6UK=V-.\=:1J-\IBA6T(<J"P#$2
M# QUY84 ;NH>*;&POFLEBNKNX1=SI:Q[R@]^15BT\0Z;>:5)J,<^VWBSYF\8
M9#Z$>M<O8ZA#X;\2ZO+J:2+%>MYL$X0L"N6( QZY'Y52@TJ^U#P]X@NX+>2-
M+R=9H(<8+*KECQ]"/^^: .GM/&>FW5S!"8;N!9SMBEFBVHYZ<'-8\.ORV'C7
M58[A[VYA"[8K:+,G/RGA<X'&:=;>(;&[LM*TZ#21J%XBI&T,J8$)  +9*D=O
MRJ30_P#DHNM?]<S_ #2@#;LO$^F7NE3ZBLCQPP'$HD7#*>W SUJ&R\7:?>7<
M%N8;NW-Q_J7GBVK)_NG)KB8;.XOM&\116REVCNTDV*.2 7SC^?X5/9Q66JW6
ME6UO-K%[,N&E66XVI:D8SU0\<=O84 =9/XQL(+ZZLQ:WTL]N2&6*(-D#J1ST
M'OBHCX[THVXGCAO94 !D*0Y\K)P-QS@?F:I>'/\ D?->_'_T(5D:*!_PK76#
M@9,Q&?P2@#I=:U:P==(N#=ZBD=R^8OL;A0_W>'![<_SJQ>>++*TOIK1+:]NI
M8!F7[-#O$?UY%<?>_P#("\)?]=&_]"6K>MC3+;Q!=3K?:CI%YU+^4628_P"S
MM.>??B@#:U;QA'#X?34--ADF\TE%=D^6)AC[_H>>!WI4\96UKINGS:A;7L;W
M(V[FA R0%RV,_=.[C'O6+=W6JZM\/)YKZ)F=)EVOMVET!'S8^IZU#?W=KJ?_
M  B"PL9(TE6"3((^8>5D?K0!U-OXMM)K^WLY;.^MI+ABL9N(@H)'XY[CMWJX
MVN6JZ\FCJDSW)3>S*HV(,9Y.<_IW%9GC>R>;1EOH>+BQD$R$=<9Y_H?PJMX+
M234+G4=?N!B2ZD\N,?W4';Z=!_P&@#;T?7;76_M/V:.9/L[[&\P 9/M@GTH\
M1:E_96A75T#B0)MCY_B/ _Q_"C1]=M=;^T_9HYD^SOL;S !D^V"?2N;\;-/J
MNJ:?H%H5\QR97W'@=<9QZ ,?QH B\):CJ-IK2V&JW,\HO;99H#-(6QQD8R>.
M,_B*Z'4?%5CINJ#3IH;EYR@8>5&&!ST YSG\*Y#7=/\ $>FFUUG4+NUN#:2*
M$\D8*C.><*..WXUHQW,=Y\2;"YB.8Y;3>I]BC4 =!IOBC3]26Z($UNUJI:9+
MA-K*!U. 3Z54'CC3?W;R6U_%;2-M2Y>#$9/US_2L%9;J#Q3XG>Q!^T+;LR!1
MDYRO('KUKGM1EM;K1()O.O;G4M^;EYBQ2,<C'/KQ^5 '9WNHW-O\0DB\ZX:V
M6U:0VZ.<,0C'A<X)XK:M_$=A<Z#)K">8+>,-N5E&\$=L9QD\=^XK =UD^*%I
M(C!D:VRI'<%&K$U"TNK76+KPQ;_+;WUU'*A'0(<D_@./^^* .RD\76$=I9S>
M1=M)=@F&W2,-(PSC. <<_6I+7Q%8ZI;WT:"ZMYK>-C+$Z;)5&.HYZUC^++32
MH3IZ7/VZU\I D-W FY(P.S<YXQV%5M$U/4+E=5M3=2:AIT=JY2[EC*'=CISR
M>_7TH TM-\1:98>'5O&N=0GB:8QI]J(>9F]!@]*T-.\3V>H:@+ P7=K=%=RQ
MW46PL.O')KC-/BL9? D?V^"\:-;IR);503$<#DY/2KWA_4[U=>M['3]1GU33
MV7]ZTT17RA]3SQQ[=J .[GGBMH'GG=8XHP69F/ %<\GCC2V9&:&]CMW?8MR\
M.(R?KG^E7O$]G/J'AN]MK92TS*"JCJ<,#C\A7(7>LVU_X.M]"M[:9M2VQQ&'
MRCE2I&6Z=\'\^: +?BS6KDZ]9Z?;OJ,5OP7-IPTP.#^[(^]QQ]<UV%H1;:3$
MS-<.$A#$S\RGC/S>]<9J$$EKXG\+6\IS)%!&C'W'!KM[S_CQN/\ KFW\J .=
M7Q[ICVWVA;74#$K;7<0@A">F3G'-3?\ ";:5Y\2;+H0RML2Y,.(B>_).>,^E
M<QIO_)+M3_Z[_P!4I-< '@KP]C^\/Y4 =4U]:+XS-LUUJ(G$6XQ&0?9@-N<X
MZYJ(^.=,"M*+:_:U5MAN5@_=@_7/]*SI0#\3G!0N/LIR@ZM\G2L)KFUTKSI-
M%U/4K.Y#\:?/!DL??''KUYH V_%^NSFZTVTLGOXH9F#&:W7!F4[<",Y^8\]/
M4BM5?$-EI%G9VD@U*YNI$W+"Z;[C!)^^,]?\*R-<ENI[[P?+>Q>5<O.#(F,8
M.Z/MV^E2WLPT'Q[+JE_&_P!BN8 B3!2PC.%';_=/YT ;"^(+75M%U)[-Y8IX
M()-T;C9(AVG!K.\/:\ECX-34-4N9I/WK(&8EW8YX S6?9A]1U'Q'K<,+QV,M
MD\<99<;SM'('_ 2?QK*^R3S>!-/N8HVDCMKMVD11DX)Z_I^M &SJGB1[_6]!
MCM#?V8:X'G12@Q^8K,F"0#A@?FK=OO%MA97DUL(;NY> 9F-O%O6/_>.17-:U
MK5GK7B+P[)9!V1+E<R,A4$ET^7GKC^M4'CBTK5-8AU.[U2V>1R\(M7*+<9)X
M)P<YR/UH [R?Q'IL&BIJK3%K9R NT?,6_NX]>#^5<UJGB1[_ %O08[0W]F&N
M!YT4H,?F*S)@D X8'YJH:AH\T'@_3[B&TN$CBN#/)!(^]U4XY.%7CCT[U/K6
MM6>M>(O#LED'9$N5S(R%0273Y>>N/ZT =]<Q-/:S1)*8G=&59%ZH2,9'TKSK
M5-/UC3=9T[3_ /A([Z3[8P7S-[C9R!TW\]:]*KB_%/\ R.7A[_KH/_0Q0!-:
M:B/#<\VFW-WJ.M7;8D(BB+M&N/=C]:TD\5Z=)H4^K()FA@8+)&%&]22!TSCN
M.]<UK=X&\575MK=Q>Q:>L8-O%;D@2' QTZYY_'TK.TJ"27P/K]M'$YF69"8L
M?,H# G(]L'\J .YO_$UEI^FV5]+%<-%>!3&$4%AD9&>:V:\LUK6+6_\ #FB6
ML'F&2V")*2A 5@N,9[],UZG0!Q-GJ5WJ2>)M26ZF6"&"2*V17(5<*3N [-P#
MGWJGX'UJ[-[/#J-Y-+'+ 98VFD+8VD@XS[9_*G>&3Y?@CQ!;-GS8O/W _P#7
M/'_LIK"N(9K/PII.I0G:SFXA9A_=;(Q]?O4 :7AW5]2O?&=JT]Y<&WN3+(L)
ME;9MVO@;<XX(_2KUHVM^,;JYNK?5)-.L(I#'&(LY/?L1G@C//>HK.P_LWQSH
M%O@AA8@L#V;9)G]0:32]4D\$376FZE9S/;M*9(IH@#G( [X!X [\4 ;^@1:]
MIINX]7E%Q:Q*6BFW[G;'ZXQZUS_]OZKJ'BO2W=9[*SFD C@WD>8N>K#OFNB\
M.:]?:Y<W$CV'D6*C]U(<[F/I[]^G3BLWQ'_R/F@_A_Z$: +NKWT^D^+--E,[
MFRO5,#QLYVJV1A@.@ZC\C71W#!;:5F+ !"24ZCCM[UR/CE&GN]#MX_\ 627)
M"_FH_K75WG_'C<?]<V_E0!S6F^(M/L/#3ZAYNJ7-N+CR\W3*\NX@>^,5:B\9
MZ;)=V\#0W<2W! BFEBVQMSC@Y]>_2N*3_DFLG_80_P#916SXL^72_#9'!!7!
M]/E6@#O)9!%$\C9(12QQ[5SMGXOL]7VP6EKJ ,K>69!"-L1/0L0W'_UJW;S_
M (\;C_KFW\JYCX=*H\.RL!R;ELGU^5: ,/7=/UC1)["/_A([Z;[7(4SO==O(
MY^^<]:Z.)O\ A#[*:?5M7N=0\YE6)6!+ C.0H+'^G2J7CO\ X_M"_P"O@_S2
MI?'$4D<ND:CY32VUG<;IE SP2IY_[Y(_&@"]#XQL9M0MK$VM]%<3D )+$%*Y
MZ9R>GTS6;XX\03VD7]GZ?(Z3A1)/)&2#&F0 ,CIDD?IZUGW^JVVK^-]%GM Y
MA!51(R%=QR3QGTS_ #J'5]%UO3-$U6YO'T^5;ED:>52YE^^,!<@ #./\XH T
MO$.JW%MX*T@QW<T=S<I%NF5R&QLRQ)Z]<5H>'/[-GNVEL?$&HW[HN&AN)B1@
M]]I /XU1CU";3?#>D3ZKI5O>P80))$NXP1[5VDA@?FZ],#@4W3Y8]:\>IJFF
MQ,+*& K--M*B1B"._?D?]\T 4[SQ#JM_X@TAU2>RT^6Z5(U#E?. =0Q;'4<C
MVZUL^(+F\N_$VG:%;7<MK%+&9I9(6VN1\W /_ 3^=0^,/^1A\,?]??\ [/'1
MXA=M+\8:9K4R.;)8C#(ZJ3L/S=<?[WZ&@";PQ?7::SJ>BW=S)<BV;=%+*<OM
MSW/?J*B\=7UQ8IIK074T"M,=YC<KD<=<=:;X4C:^\0ZMK2HRVLQV0LP(WC/4
M?D/SJ'XBG$6ED+OQ,WR^O3B@#:L_%EA=ZBEBT5U;RRC,1N(M@D';'/>H9?&=
MC'?7-FMI?S3V[E76*(-G'4CGH,=\5C:AJ,7B3Q1HBZ=%,QM)?,G9XRNP;E)!
M^FT_G4_A=0?&GB!L<B1@#_P,_P"% &K=>+[&VN9X%M;ZX:W'[\P0[A%Z[CGC
M%5];US3KCPY;:A]KU&*WEF"JUBX23=AOE;/;@_I7,7UT;O4-6@UJ6_:Y5F6S
MM8L[">0.!V^[]?>JURP/PULP""5U @^WRO0!WFH^*K'3=4&G30W+SE P\J,,
M#GH!SG/X5-H_B*SUJ6>&!)X9X/OQ3IM8=O4U@S_\E4MO^O<_^@-1H7'Q$UL#
M@&,G'XK0!TNKZQ::+:BXNV;#-L1$&68^@%5-.\3V>H:@+ P7=K=%=RQW46PL
M.O')JMXRBL9=+C^WP7C1K)D2VJ@F(XZG)Z5A^']3O5UZWL=/U&?5-/9?WK31
M%?*'U//''MVH W;GQGIMO<31K%=SQP-MEGABW1H?<YJYJ'B/3M.L8+MY6E2X
M_P!2L2[FD^@_&O.[>.+3+2^T_49]6BNQ(0MI;RE(YP<#^Z1^/<8K6OK"71QX
M=U"2VG6TM?\ 6HS>8\66W<D #OZ#IB@#I8?%EI<07ACM+T7-JN][5XL2D9QG
M&?<9K(T[Q1)JF@:C-J$=["J$MY]HH4*N5 56)^]SW[5>L]5MM<U2[_L_2TD0
M0E?[1*[68D8"C*Y]NO:N8TJ\A7P+JVFL6%VA:5HRI&%R@Z].O:@#L(=>T[3?
M#=I>RW%T\4@Q'YY#S2')ZXZFI=.\3V6H7WV(Q7-K<E=RQ74>PL.O')KD);>>
M/1/#&JB)YK6S;,R(,E1O!SC\/Y5?GNH_$WC#2Y]+61X+3#S3E"H SG'/Y?C0
M!KR>--/2YO+=;6^DEM79'6.(-D*2"PP>@QU..HK5TG5;76;%;NT+&,DJ0PP5
M([&N<\(JK>(?%&Y0?]*QR.V^2E^'!)\.S^UTW_H*4 =A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ[
MI-UK%LMO#J+6D+ B91$'\P'&!G(QWZ=<U<TZQBTS3X+.#/EQ+M!/4^I_.K5%
M !1110 4444 %%%%  >1BL#3O#<EMK+:K?ZB]]=;-B,8A&%'T!^OYFM^B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH R;'1!I^MWU_#/^ZO "\&SHX_BSGW/&.]:U%% !1110 4444 9,^B
M"Y\16^JS3!EMXRD4.SHQS\Q.>>OIZ5K444 %%%% !1110 5FZSI<VJ6Z);ZC
M<V,B-D/"Q&?8@$9K2HH YZT\,S#6(=3U/5'OIH%VQ#RA&%_ 'GJ:Z&BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!<\#]* .ICU2R?3X;Y[B.*WF4,K2L%ZCISWJ7[=:?9UN/M4'D,0%D\P;23T
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M9W$^IK-N;@7*AQ:PQ2%R6:,M\V?8D]_3UJHPE+9&G(C[&_X3?PG_ -#1HO\
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MJ;@<CFF[O:K<6MR/9Q[GVN?&_A,'!\4:*#_V$(O_ (JC_A./"0./^$IT3/\
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MY"9R> 3T[4 7J*K7NH66FPK-?WEO:Q,X0//*J*6/09)ZGTJS0 4444 %%%%
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MTC1IKR"(2R(5 #?=&2!D^U &I17.VD_BQ[J'[5;:8MN6'F&,MN"]\?-UKHJ
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MN^:^H+L.VJTF,E5/0FE:(@G:0V/2AGW;<Y.!C!IH^4AB 1Z&MW[)NUM+[_\
M VW^8M1VW:F2H.>!S3"3C:>@[4O.-V>II,\DL,DUFVMEI_EY]0%7 ;J,#UH'
M)S2[LH5)P.HX[TT DTI?"E$%N+_%@&E9F##YLD<<4[((((4[1QCBHNQJFN2/
MNO?]/^".X]N0ORX'KZU])?L]?\B#?_\ 84D_]%15\V;W\O;N.WTKZ3_9Z_Y$
M&_\ ^PI)_P"BHJBHXNS6_7^OZ9$]CUJBBBLS$*^:OVA9(T\>6H9<L^DQA3C.
M/WLM?2M?-7[04D47Q%L'EC\P+I49"]B?-EZTX[FM'X]['CBG I>^>].E=7<L
MJ! ?X1VIH4L> 2:J22>Y:[(.E/15"[M^'';%-.2>>U',;<UI"7(W.*NOR^X5
MKZ,5G.]7"@,#D_6D&=^>1GKB@G<2?6IM\D$#1-%@28(++R/<5,ZLI:ME0A&^
MNW]?F0'&_ H((%.506P6 ]S1L&TDL ?3UI*-]1.XU< \\TYFRPP3QT]J1DP.
M >:5(I'5L(2%&6XZ4*ZU3"S?NV$4@'YLE<\CUI2OREAT)QUI67 &3@XIN"%!
MP<'I3NW&SU_K^M MRLZ#P/\ -X_\-=!C5+7MU_>K7VM7Q1X'4_\ "?>&3_U%
M;;_T:M?:]3-<MDS*;NPHHHJ"#YG_ &B,_P#"?V'_ &"X_P#T;+7D>0.M>M_M
M$'_BX%A_V"X__1LM>1D^U!U0?NH.]3)$7B9P,JO4U"&&.E*./QJUIJF4FNJ)
M"Q=MO!'0<]*3?Y;G.&QP:8V-V%.1V-!4DGCI6LG-R<MW?UV_K[B;Z S*>@(-
M&XXV]J3;2 5#G)OL(<#C/H:0' QQS28(I1[U*;V&P((^\*DV[4#<'/3VIK,6
M()).!2 X!'ZT*W0=[7#DMP,YKHO!+[?B%X<7&!_:=L/?_6K7.8R 1G.:W_ X
M(^(/AO/_ $%;7_T:M6I."NOZ\B7J?:U%%%8G,%%%% !1110 4444 %%%% !6
M-XI6R/A^X-^THMUP2(2 S'/ &?4ULUS_ (EN=(N;&YTV^O?L[A5D+!&)3D;3
MP.>: .:T>TMK;6;%;VRU6QWN#;-+<!T=AR%(VC%>BUP&G7<.HZQ8?VEXCBN_
M(D!MXHX&4L_0$G:*[^@ HHHH **** "BBB@#C/!'_(=\8_\ 87/_ *+6NSKC
M/!'_ "'?&/\ V%S_ .BUKLZ "BBB@ HHHH **** "BBB@ HHHH 1E5T*.H96
M&"",@BL'2O!>A:+J'VZRLV68 K'OE9UA!ZA%)(4'VK?HH **** "BBB@ HHH
MH *X#2/^2X>(_P#L%VO\S7?UP&D?\EP\1_\ 8+M?YF@#OZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8?\ 8+C_ /1LM>1X;:2.U>N?M$_\E L!_P!0N/\ ]&RUY<T%PEHNZ+$;MPQ
MS33L==*FYQTZ(J\;03UJ4NCK\PPQ_NCBHRK*Q1AR*"N"<$'Z4[/>Q2=M!K(R
MYRIX_2@$]0:EDE,B(I PH_/ZU&V"> %![527=DR2^R-&:.IH!/X4N<GICVJ;
M=A+L+GC&!FG$J5Z8]*3?QC&!T..]!.,@UIS<JTU770:5WJ$;%'#8!QZTCL68
MD]2<T@)!S2LQ9LGK6?0+Z6$S6_X'/_%P/#?_ &%+7_T:M9$TL)@C1( LBCYG
MS]ZM;P./^+@^&_\ L*VO_HU:6O56'-*.D7?0^UZ***1QA1110 4444 %%%%
M!1110 5R?C&+5#$7L;6W>$JIDEVCS!@].?X>E=961XGT^YU30+BUM>96*D*3
M@/@@XS0!@6T.K76L:<);;2;-%<3YMV7=*@].3D?2NVKBTCU'5M5TEFT4Z;%8
M."TLCY^7@;!P.N,5VE !7">.]=UJ/Q#X=\+:!>QZ=>:P\S/?/ LWDQQ)N.$;
M@D\]?3WS7=UPGCO0M:D\0^'?%.@64>HWFCO,KV+SK#YT<J;3AVX!'/7U]L4
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M/&)!R/[6/_HM:[.N&^'MK!8ZGXMMK:,1PQZJ0J@DX_=KZUW- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7 :1_R7#Q'_P!@NU_F:[^N
M TC_ )+AXC_[!=K_ #- '?T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/C?_D0?$?\
MV"[G_P!%-6]6%XU)7P'XB(ZC3+D_^0FIJU]01\7KA3D@\48^7.1D]J4N=Q+
M,3ZT1J2PQUK5)2]U:_G_ ,$Z1-K8#$';G%*RD-\JGISFG':6)9N,]AUI)'8G
M;D';P"*T]G",&W^E^OW>6_Y"OJ1YSWIP9=IR#G''/2D XZTI0J@;L?>L8J;O
M)*]O^&#8/+<('(X/0T#<%/7%.$CF,#?PO0&F54U3C;EOJO+].E^@*XH)VD9_
M"EW,J\$@&F?2E.,#&??-*,VE=.S7F-CF?(PN0OH3WIA&,9!YH(P2,Y]Q4JPE
MHM^[@>OI34)59-):_P"07(Z^E/V>?^1!O_\ L*2?^BHJ^;7"DC:^[CN,5])_
ML]?\B!??]A23_P!%15$X<KLR)O0]9HHHJ#$*^9?VB0/^%@6))Y_LJ/ ]?WLM
M?35?,O[1:,?'U@V#M_LN,9_[:RU<-]K_ -;E1W/(B#@''% !)P.:>=H3"Y).
M/PIJ[DRZCIW]*N,4Y)=/O-7HK@.IXJQ=1"-E>+)B(&&QP3WJ!0"&+=<9'-3&
M]F>R%HS9B#;@/0TG%JSOW-:<J;C*,M^GK_D1(^'#'IWQUHP ISG!Z<T^&W^T
MS1Q1M\[9Z]*:P,4S1R -L)4@&M8S:?*Y?Y:[W_K<S<'R\]M-A"6?:@RQ[8ZT
MCJR.5<%6'4'M2 D<@].](6Y))R3W-8RFY/WG^H[)(/O'- SGI29YP*<,@\5/
M2Y.[%<#(P#T&<TG?BGO*7X)P, 8 ZU&1SQ6E7DYKP?Z#1O\ @5C_ ,+!\-\]
M=4M>/^VJU]L5\4>!T8>/_#3[3M.JVO/_ &U6OM>HFFGJK&4PHHHJ"#YH_:&0
MO\0+' SC2HS_ .19:\G>[F>!(WD)1?NCTKU?]H=RGQ!L<'&=*C!^GFRUY&"I
M!!'/:KC%2.J%1QA:+WW)068DLX#$=?6HB,'&:4(-^'^6D*G&1TZ5<TW%:;>>
MOW=/N'?4,^U#'.#^%/1FA979001G!Z$4Z.*2YEQ$H)8_=';_ .M3E&7PO1];
MZ=K?F$5?;5D)4KU&,C- . < 4YP1^!Q2*=IR1GBIU4NR^\5D)QWH.3R:=D+A
MESG/>FTG:UK_ -?Y@+MP 2>.X[T'!9CN^A-"N58$@'!S@U+<3"X8,5"D#&%&
M!24NEM"K1:O?4BR&.6X^@K?\#\?$#PV.#_Q-+7_T:M8 (7J.,5O>!F'_  G_
M (;_ .PI:_\ HU:;=U?KJ3T9]K4445F<H4444 %%%% !1110 4444 %8?B]+
MB3PU<K;,0V5W '!9=PR![UN5R/C/4[.2TFTAYA%< )+ND4[<;NV.<_A0!SVF
MZ<UMXFLXUL;QF%T)5\W.T0D J3C^)?R[5Z?7)6%UK37MND_B#1YXRZATC9=[
MC/(&!UKK: "BBB@ HHHH **** .,\$?\AWQC_P!A<_\ HM:[.N,\$?\ (=\8
M_P#87/\ Z+6NSH **** "BBB@ HHHH **** "BBB@#E)/ L<DC/_ ,)%X@7<
M2<+>  ?3Y:P=%\,R7^NZ]9S>)-?\JQN(XX<7@!PT88Y^7GDFO0KRZBL;&XO)
MR1#!&TKD#.%49/Z"O/\ PMK=[!XFENM2TLVMIXEE$MBXE#LI6,85P.A*C/Z4
MFTM .JT?PPFCW;7"ZOJUV2NWR[NX#H/?&!S6[113 **** "BBB@ K*M_#]C;
M>);S7X_,^VW<*029;Y=J=,#UYK5HH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QO
M_P B#XC_ .P7<_\ HIJWJP?&_P#R(/B/_L%W/_HIJ!K<^,3\PW$C/3 %  P6
MW8([>M)G"D #GO2#&#GKVK3F3=_+^OZV.@>=I90,CCG/K22+M8Y;)SR,8I-Q
MVX[4F\X(SP>M6JD7!Q:_JWK_ %J)K44!<#+<]P!TI <'GD=Q2[OE"[5^N*3;
MD'VI-JZY.G]=7J'J*=N!@G/<4A!'48I#Q2J=S#<2!ZFHTDQB 'IB@^_Y5)O;
M!R!\W<CFF-A7X.X>OK5RC!1O%W_#^OR%J &03Z4[>QPK$[1V%#L'.0@7V%-S
MP12;4':+T^>OR 4, >%#?6OI3]GK_D0;_P#["DG_ **BKYL5PL;#!RWO7TG^
MST,> ;[C'_$TD_\ 145$_A23O\MB9['K-%%%9&(5\V?M#3QIXYL8FBW.=,C.
MXGA1YLOZU])U\R?M%_\ )0;#_L%1_P#HV6FF^YI3DXRNCRFVNGM6D:-4)9"O
MS+GK42(9,C(X&>33TC#@*)%!;UX ^II&4PN8V!##@UM%QNK[=KFKYW%7V0"+
M.X[@ HR3FF#%(:<BDY..!R:RC%R=D%TMD/C,D>)4&WT:E="%WLAV]-P[FAV&
MU0&S3C=.4\O "9S@#VQ5**7Q/7[RTU;EO_PY$FT,-Q.W/.*20JS'8,+GC-*S
M;E"A<#.::!@'CI1:ZLC-OIT #G.*>DI0G@8;@@]Z1FW'/ ]A33@C)IQDX3O3
M8/;4#@#UIS*R$!AM.,T A2&[BB21YF#R-D]*BQ6EC>\#,?\ A/\ PTO;^U;7
MC_MJM?:]?%'@9C_PGWAI>,?VK:G_ ,BK7VO1+IK<PF]0HHHJ2#YF_:) /C^P
M]?[+C_\ 1LM>2%'7DCM7K7[1/_)0;#_L%1_^C9:\F:1F(!/ & *T4O=T.B"5
MM1 Q4ANOUIN<Y)HQSBGJ,G!X%"5Q@K<J6^8#L?2C./F4D<]!VI#Q[4!F4@XR
M#5-NW*]?Z_KR&G9W#&023SVHR PSR/2DQGJ13XC'YJ^:"4[@=:G5),:5W89N
MZCMGI1NXQ^M2%E$A$8^4GC=S1+$T#A7VDX!_,4<R=M=_Z_JP.#2;Z(CV'9N
M^7.,T<8Z4$88@'(]:3.0>.?6AI+1;_UL3<<WRC!7!K=\#?\ )0?#?_85M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %"X_P#T;+7G?AK2UU[Q#:6,\QAM2QENILX\N% 6D;)XR$5L9XSBO0_VBO\
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MN?\ T6M=G7!_#B_M=4OO%=]92B6VFU4LC@$9&Q?6N\H **** "BBB@ HHHH
M**** "BBJFIZA#I.E76H7.?)MHFE?:,G"C/% #M1CN)M,NXK23R[EX76%_[K
ME3M/X'%>5^#M/8^)M.CT_1[O3K[30R:Y<S-\L[%>%)R=Y)(8'L*Z[1_%VI7&
MJV-IK&CI8IJ432V4D<XDSM )5QCY3@@\9%+X?F2W\2>,IY3B..YB=CZ 0J34
MZ2LTP.NHKB-+\<7]U>:9)>Z,+;2]6?R[*=9P[YP2N]<?+D ]":[>FFGL 444
M4P"H;MKE+.5K2..2X"GRTD;:I;L">PJ:J&M:U8^'])GU/4IO*MH1EFQDD]
M.Y/I0!Q?B+Q9XU\-:'/JMYH6D&&':&$=ZY/) '\'J:Q?"?Q(\7^)=0GTZWTC
M2I9XHQ,7:X>-=I.,8P>:[/0_%'AWX@:;>VD2F6-1LN;6YC*G:>A(/8^M8GPL
ML=&T7P=<ZE&L,!:>;[1<,^3L1V !)/  J=6TT]#?W(4Y0G!\]U9WM;NFO/\
M Z_1)]>F2;^W+*RMF!'EBUG:0,.^<@8K6K$T'Q=H7B9IETC48KEX?]8J\$ ]
M#@]O>MNJ,&K;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !63XHLI]2\(ZU8VL?F7%S83PQ)N
MW.T; #)X')[UK44T[.X'R:?@UX_Q@:!C_M\@_P#BZ!\&O'NX$Z 2.X^V0?\
MQ=?65%-2L[V+YV?)W_"FOB [Y?0\>YO(#_[/0_P;^(#G)T#GVO(/_BZ^L:*<
MIMK4.=GR>/@YX_7.WP_U&#F\MS_[/3?^%->/MA!T Y[?Z9!_\77UE11[1]0Y
MV?)O_"FO'X!']@ Y_P"GR#_XND/P9\?9X\/\?]?D'_Q=?6=%)S;5@YV?)W_"
MFO'Q'_( Y_Z_(.?_ !^D/P9\?$\>'\#_ *_(/_BZ^LJ*<IN6X<[/DW_A37C\
M#C0CGO\ Z9!_\73A\&?'A89T#:.^+R _^SU]844<[^7]?TPYV?)Q^#7CT;@-
M )]";R#_ .+KV[X-^&=8\*>$+NQUJS^RW,E^\RIYJ/E#'& <J2.JG\J]#HJ7
M*XG)L****1(5X=\9OA]XG\6>+;6^T72_M5O'8)"S_:(D^<22$C#,#T8'/3FO
M<:*J,K/:XTVG='R,/@O\0U(*Z!R/^GRW_P#BZ!\%_B&&W#0,'KD7EO\ _'*^
MN:*%)K9E<[/D;_A2OQ!S_P @#/\ V^6__P 72_\ "F/B&4V_\(_QG./MEO\
M_%U]<44*35[,7.SY&7X+?$$$'_A'LX/3[;;_ /QRK:_!;QK,TSR^'FBYRBK>
MP?\ Q=?5U%2W<TA6<.B?J?(Y^"OQ!R"N@XQ_T^0?_%TYO@KX_1_ET$,!W%Y!
M_5Z^MJ*I2L1[1GR9/\'?B!+(KCPX,A=IS>V^/K_K*@_X4K\0O^A?_P#)RW_^
M.5]=44<SM9CE5E*7,SY%_P"%*_$+_H ?^3EO_P#%TY_@IX_!^30=W'7[9!_\
M77UQ12OI87.SY=\)?"+QQIGC#1+^\T+R[:VOX)I7^UPG:BR*2<!R3P#P*^HJ
M**1+=PHHHH$>%_&?X>^*?%GC"TO]$TO[5;1V"0L_VB),.))"1AF!Z,/SK@(O
M@QX[5<OX>8N#G'VVWP?_ !^OK.B@TA5<=CY1OOA!X^NYED3PVL05<8%Y;\_^
M/U7?X+_$ ,#'H+?4WEO_ /'*^MJ*<7961=3$3J2<Y;L^2D^#7Q!!_P"0 5/]
MX7L'_P 733\%?B 6/_$A&!W^V0<_^/U];T57-?=$>UE:Q\D?\*8^(1 SH!/_
M &^P?_'*3_A2WQ!SQH'_ ).6_P#\77UQ14N3;NP]HSY*_P"%,?$#((\/X_[?
M8/\ XNEB^"GCYV(?1/+&.&-W ?Y/7UI12DVW<J-9K=7/D@_!?X@Y(_L'('0_
M;(/_ (ND'P7^((/_ "+^?^WR#_XY7UQ133L3[5GR,?@M\02<_P#"/_\ DY!_
M\<K8\*?"3QSIOC#1+^\T/RK:VOX)I7^UP':BR*6. Y)X!Z5]0T47%[1A1112
M("BBB@ HHHH **** "BBB@ KGM;FL+K6=.TN6.X:[W^?'+!UA SR3Z$CFNAK
MEM:\_3-?75[$VTTC0>3/;23+&Q7.05)_S]: -:ZUJ&SUNVTV:&5?M*_NYL?(
M6_N_7_$5IUQD-U=^(]8L);N.VL;:TE\Q4^TJ\DC]@,?X5V= !7+>,/!S^)9=
M-O['5)-*UC3)&>TO4A67:&&'4HV P(%=310!QNA>"+SPWI5C9Z9K\B2"^-[J
MD\EJCM?LV-Z\G]WG &1D@#O61>?"5+K6+G;KUQ%X=O-0&I76CB!2)9^IQ)G(
M4D#*XZ#Z$>DT4 <YXH\*?\)+>Z#<_;?LW]DZ@E[M\K?YNW^'.1M^O/TKHZ**
M .,\$?\ (=\8_P#87/\ Z+6NSKC/!'_(=\8_]A<_^BUKLZ "BBB@ HHHH **
M** "BBB@ J*XMX;NVEM[B-9(94*.C=&4C!%2T4 >7:;JO@7PU?/>B_U2>2UC
M:.(72RR+;IW5/EX''7GIUI-)\6?V-JMYJFO:9+9Z9XBD66TD!$I^6, *Z+D@
MD#->GS11SPR0RH'CD4JZGH01@BN;TCP-IND:A!=I=7UR+566TAN9M\=L&Z[!
MCTXR<\5-GI8#"\*6?@^YUZ-M*N=1GDM0TEM;7)D\FVSP2@8#!YQU..U>B445
M5@"BBB@"EJ.K:=I,:2:A>P6J.<*TSA03[9KD_%M]X2\6>'I]*F\1V4.\J\<J
MS*2CJ<@XSS79W%I;7:A;FWBF53D"1 V/SJO_ &+I7_0,L_\ OPO^% TVG='B
M\?A[3-&\':]%I_BZPNM9OXDC!281+Y:MDH.>"1GGWQ6%X"M+*_T/Q#9W>KVV
MDZ??VX@CCEG&3,K9W[<]. ">]7?B%J&M:?X_EMK2!;98C'_9]O#:(4GSCK\O
MS9/!]*]%^%FFVMUX"M)K[3;3[2TLOF PJ<-O.1TK*,8WT5K:>1W5JM=4[SDI
M>T]Z^CEH[:O=>G4Y?X=Z5I?A?7)]5U7Q3HSR>1]GBCMI\@C.2S$X]!@5ZG:>
M*-"O[I+:TU>SGG?[L<<H+'Z"K']BZ5_T#+/_ +\+_A3XM+T^WE66&PM8Y%Z.
MD*@C\0*N,5%<L=CEKUZE>HZE5WD]V6Z***HR"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!&!(P&*^XJK?7=KIEG)>7^H1VEK'C?-/(D:+D@#+'@9
M) _&K=<]XML;V[M]+N;&W>Z>PU&*Z>VC95>5 &4A2[*N1N#<D?=]<4 ;#W]G
M!I_V^6\@6S$8E-R\BB/9C.[=TQCOTIO]JZ=_9R:C]OM?L+A2MSYR^4P8@ AL
MXY) '/.:X@>'M9A^'>F:']BEEN[)K6[=5DCV2;+A9&@!+#Y@JX!("]/F],/6
M?!WBV]\)1V=O8VTBF]FOQ9R7OER12271D4'"LC!8R<C>!EF(W%5R >O45!-%
M/<6FP3O:RLA!>':Q0E2,J64@X)R,CL,C&17.Z&EW9^--8L+K6KW4E73[.9/M
M1B!0M)<AL+&B*,[5R<9/&3@# !U-%%% !1110 4444 %%%% !2$9& 2/<4M%
M #/+;_GJ_P"0_P *<H(&"2?<TM% !1110 4444 %%%% !1110 444R::*V@D
MGGE2*&-2\DCL%5% R22>  .] #Z*R])\1:9K<DD=E-+YL:+(8Y[>2!RC9VN%
MD525.#AAD<'FH]0\4:/I=[]DN[IDE&PR%8)'2$,<*9752L8)Z%R.AH V**Q[
MGQ3H]IJW]F373+<ATC8B"0Q1N_W$>4+L1FR,*S G<O'(SL4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<3XPTC2Y[_[;<ZO#:S[ ODR
M+OW8SC@<_C7;5@:MX1L=8U'[=-<7<<VT+^Y=0!CZJ: .3\.)&^K6^S08[B-)
M5Q>P>:BKS]X[N./3BO2ZYZU\(V]I=Q7"ZEJ;M$X<+)."IQV(V]*Z&@ HHKC?
M&OBK5=)U/1=!\/VUG-K.KR2"%KTL(8DC7<[-MY/'3'O]* .RHKEO 7BJ?Q7H
M=Q+?6T=MJ5C=R6-[%$24$J8R5SSM.1U^F3BN-OOBGKMO=7^M0Z;I[>$=-U3^
MS+EW=_M3$$!I5_AV@LO!&3T]2 #UNBO*O$'Q*\16>IZ]=:1I>GSZ#X=EBAOS
M.[BXG9C\_E8^4;<_Q ^O.<#U"VN([NTAN83F*9%D0^H(R* .1\$?\AWQC_V%
MS_Z+6NSKC/!'_(=\8_\ 86/_ *+6NSH ***I7NL:;ITT4-[?VUO++_JTED"E
MOIF@"[16,WB[PZD7FMKFGA-Q7<;A<9'4=:3_ (2_PWY'G?VYI_EYQN^T+C/Y
MT ;5%8J^+O#CQ>:NN:>4R%W"X7&3T[U<L]9TS49Y(+*_MKB6+[Z12ABOU H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **KRZA902>7-=P1O_ '7D /Y$U.K!E#*0
M5(R"#P10 M%%% !1110 5\Z:!X"\:6_QRDNY[HD6]PMY<WOFC$MN[. ,9S\P
M1UQCC'IBOHNN?L_^2AZS_P!@JP_]&W= '04444 %%%% !1110 4444 %%%%
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M!"T:C(R6  [UL1R1S1)+$ZO&ZAE=3D,#T(/<4 .HHHH **** "BBB@ HHHH
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M6,UU+:^+M=BDNI/-G97B_>/C&3\GH*M?\(3J7_0[:_\ ]]1?_$5V%% ''_\
M"$ZE_P!#MK__ 'U%_P#$5Y=XZ^$&O:GKES<I-?ZT\T:+:W,L\:^61U60'''H
M5%?0-% 'R[+\%M6\TO%H6H^3Y)55:YAW>=ZGG[GZU7M_@YK*W/E7'A_5&'V8
M'<DT0'G=^<XV_K7U510!\L0?!37O+5I]$ON("KA;B'/G]B!NY3IGO72^"_@_
MKFG:_9W._4-%>"-A=W4=Q&WF$CA8\9X]2PKZ"HH X_\ X0G4O^AVU_\ [ZB_
M^(H_X0G4O^AVU_\ [ZB_^(KL** ./_X0G4O^AVU__OJ+_P"(H_X0G4O^AVU_
M_OJ+_P"(KL** ./_ .$)U+_H=M?_ .^HO_B*HV7A'7I;_4([CQ?KZ012*ML^
M8AYBE 2?N?WB1^%=]38Y$E3<AR,D?B.M '(_\(3J7_0[:_\ ]]1?_$4?\(3J
M7_0[:_\ ]]1?_$5V%% ''_\ "$ZE_P!#MK__ 'U%_P#$4?\ "$ZE_P!#MK__
M 'U%_P#$5V%% ''_ /"$ZE_T.VO_ /?47_Q%'_"$ZE_T.VO_ /?47_Q%=A10
M!X_K/P5NM0UA[B/Q%)+!=$&[>[C#3'L=I7 Z>HXJ'1O@\^LV1O-?U75(;MR\
M,D;!,LBDK&<XX^4#ZU[-6/K6LO8E;.SA>XU*:-FAB4 @8[MDCBH]G'73<Z%B
MZZY;3?NII:[)[I&#;> +NRM8K:V\9:]%!$H2-%:+"J.@^Y4W_"$ZE_T.VO\
M_?47_P 16SH6NQ:Q Z.A@O83MGMVX*'_  K7JSG./_X0G4O^AVU__OJ+_P"(
MH_X0G4O^AVU__OJ+_P"(KL** ,G0]&N-'CF6XUF_U,R,"&NRI*>PV@5K444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3)HA/!)"Q95D4J2IP0",<'L:?10!P&I06-
MEJDMC::#8RA.-]Q/@LVP.>I]&[GG!KJ?#]C:6VFPW-K%Y(NH8Y'C1V* D9^4
M$\=?T%<]X@N;>77)K:Y_LV.%?E;[0I#NPA9D<G^Z&.WCGMWKK=-D\[2K.7RA
M%O@1O+ P$RHX_"@"U61XAUJ31K:T^SVR7-W>726EO%)*8D+MDY9PK%0%5CPI
MZ =ZUZS=:T:'6[6&*2>>VE@G2X@N(-N^*1>C#<K*>"1R",$T 9)\9Q-X*L_$
M,%H7>[>*&*V:3:/.DD$6TN < ,>6P>!T[50F\>7BZ-;ZE!H2S*+B6UNT%X 4
MF2;RO+B&W,KL<E1A00.2I.*U6\'6)T&'14NKN.R@CB$*J4W1RQN)%F#%22^X
M G.5./N\G-:?P%8SZ0FF#4]4CM669;I4E3%X)7WR>8"A&2V?F0*0"0"!Q0!T
M\\RVUO+.XD*1H781QL[$ 9X502Q]@"3VKE]!U.#5?'6MSV\=VB+IEBA%U:2V
M[9\V[/"R*I(YZXQU]#75JH10JC  P*P+/_DH>L_]@JP_]&W= '04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(_^18U;_KRF_\ 0#6G
M10!Y]9>%RGAK1AHNEQ8>U26X9-;N=.:21D7+OY"'S6..6;FN@TZ+7]/MK2UC
MTRQ,.X^>TVMW%P\8+'.UI(2S\<X)7GCIS70T4 >6:'=07.D^#/#\,JR:UIEZ
M&OK8'][;B*.19)'7JJDL ">&\P8R#6WXDN?#%QK.GWVK:U=V=L;.86UW!J!M
MK63+)N7S8V5B_P JD+G! /!*\=Q10!YK_;%F?#5M;^)=5N="U"\TXG^UI8H8
M9)X0[@1;G4_O-I5B@4'Y\KSG'9>%#<-X1TC[59"QG%G$&ME5E$6% V[6)88'
M8G(Z'FMBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J*YN8;2WDN+B18XHQN9VZ 5+7,^,I
MM0@M('M+5;J#YQ<0O$77& 0Q],8S0!7TKQ#=:[JM[]FG2".* BWM9%^:0D<.
M3Z=.!Z_C6 OVO3=8:6UNU;58FCBGBDD+&\D<Y( /10,<\=/I717=A;^(]/M-
M2TRYBBU2.,-%)%\N2,94CK@$X]LUM6-@K""^OK2V&I^6!)(B@D'V- %V!I7@
MC>:,12%060-NVGTSWJ2BB@ HHHH *@FO+:VF@AFF2.2=BL2L<%SZ"I=Z>9Y>
MY=^,[<\X]<5R^JS0^(KB73%L)6@@D*-J&X*()%&3CUQT/3^M #];\47%A>W$
M%G:QRBU">>9)-I)?E50=SBMS3KV+4+47$:[6/$B9!*L.H..,BN'L=-NM3UE/
M.N3!J=O&'COXXA+'<1]%;GC=VS_45VVE:9%I-@MK$S/R6=VZNQY)- %VBBB@
M HHHH *:R[AC) [^XIU8^M:O+:R)I^GPF?4IXV:).-J@?Q,210!CR^+;F&9K
MJ2#;IK!H#A<O;S#^_P#7^6/?./;ZDNJ+IDZ7TUKKD0*+)-$S)/ECQD ^OI5V
MSU**YU1FFM2OVLBUU.R9<[9.BR >AZ'T_*NHT;1UT:V>V2XDFA$A>)9,?N@>
MP/Y_G0!RNE6-Y<^)8KH),+F*=VO+HQF.-Q@ (H/)''H.M=[110 445D>*=4G
MT3PGJ^JVR1O/9V<L\:R E2RJ2 0"#CCUH UZ*\^U'Q[J%KX?T*:&"T?4[F\6
MWOHRK%(U69()F4;LC$DB;<D\,,YK=M_&EC/>>3]BU!(9!-]FN3"&2Z,.=ZQJ
MI+D\-@%1N"G;F@#I**Y&7X@6ML9(KO1=7MKQ'MU6T=(C(_GLRQD;9"O+(P.2
M".XK8TOQ#::EI-SJ$B26"6DDL=TEX44V[1D[MQ#%<8&<AB,'.: -:BL/0O%^
MA>))KF#2]2M;B:W=E:..='8JI W@*Q.PDC!KG[OQCJ<7B&ZL5FTJ&>&Y2.#2
M+M3#<WL1('FQ2NZH<_.0 K?=P2"> #O**X#3_&%S?ZU=6DOBCPS8R1:G+9QZ
M?- 3<NJR%%&?M"_,P Q\G4]#4>G^/M0N/#6N74\%H-2M;DPV44:MMD5Y&AA9
MQNS_ *Q'W8(X4GCL >AT5E^&M2FUGPKI&J7"QK/>V4-Q(L8(4,Z!B!DDXR?4
MUJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ''ZQ<SVVM7.\:++&2KQ"^G42)\H!P#T&03]3FNILIFN;"WG
M?9NDB5SY9RN2 >#Z5@:MX:N+O49[VW:R=Y",)<P[A@IL8$C_ '5(]#GUK>L+
M=K33[:V9][0Q+&6]2 !F@"Q1110 4444 %>4Z3\5/#=W\6[[3HY)O]+@M]/A
MG*CRWFBDG)&<YP3*H!QU'XUZM7@&B:;\.E^/$PM+QB8R'M86SY1OM[;@K8Z#
M"E1G!8\$\"@#W^BLVWU27[%?W>I6,MA%:2R@%V$ADB3D2@+DX(R=O7BK%KJ5
MG>:=;:A#.IM;I$>&1\IO#XV\-@@G(X/- %JBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0D 'IGM74T4 >:R6NIGX6:;I-S:WDMS$+66[M_L\CEK47"EH^A#,(P08P2Q
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M[.0H& ,L23QZFK%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'<^M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(S;5+8)P,X R:6L'5IO$-E??:K**"\L0 &M@-L@]2#W/^<4
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MVJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[9XP_P"@%H?_ (.9O_D6C[9XP_Z 6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\
M@YF_^1:/MGC#_H!:'_X.9O\ Y%H Z"BN3CU[Q5+K-SI:Z!HWGV]O#<.QUB7:
M5D:15 _T;.<Q-GCN.O9NM:EXXM]#OIK/0='-RD#M%Y6IRRON .-J&W4,?;(S
MTH ZZBO ?A#XL^(NKZQJ<-Q'_:=JBEI#J,S0+#+N'RJZQN0>OR8QQVQSZ]]L
M\8?] +0__!S-_P#(M '045S_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-
M_P#(M '045S_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-_P#(M &J--LX
M[:Z@MX$MENF=YFMP(V9V&&?*X.X_WNO%5)=)NH-"M=-TG4Y+-[?RE6XF3[0[
M(A&Y3N/)8 C/49S57[9XP_Z 6A_^#F;_ .1:IQZ]XJEUFYTM= T;S[>WAN'8
MZQ+M*R-(J@?Z-G.8FSQW'7L ;]Q/J":K90V]E'+8R"3[3<--M:$@#9A<?-DY
M'48I+;4X[G5;W3UM[I'M!&6EDA*Q2;P2-C=&QCG'2LW[9XP_Z 6A_P#@YF_^
M1:/MGC#_ * 6A_\ @YF_^1: -FTO;6_@\^SN8;F'<5\R&0.N0<$9'<$8K.L_
M%6@:AK$^D6>KVD^H09$ENDH+ CJ/?'?'2L>>Q\12Z/<Z7#X=T*SMKA7#"SUF
M6$@MDLP*VHP223FO*O#7P1\9>&?%ECKEM>:+(+6?S/):[E!=>ZEO)[@D9Q^%
M 'T+17,G4_&GVT6__",:3Y1CW_:/[:?RP<XV8^S[L]_NX]\\57L?$7B349[Z
M&VT71B]E-Y$^_59U ? /!-I@C!'(H XS5/@/;:E\09?$!U=UL9[HW<UMY?S[
MRVXJ&ST)SSCC./>O8:YV+4?%DT2RQ:-H$D;#*NFM2D$>Q^RT[[9XP_Z 6A_^
M#F;_ .1: .@HKG])UG6+KQ#=Z3J6EV-K]FM(KDRVU^\^[S'D55PT*?\ /)R3
MG^[UR<=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4=8T_2E0WUTD._P"Z
M#DD_@.:M/<0QS)"\T:RORJ%@&;Z#O7(W4MI9^/)FUB-#!<P(MK),H*+C&1SP
M.<_G[T 6+/Q+/:ZD;;5=C071\RRNHUVHZGHO/3\?Q]:LPOXAU6REE#1Z4WG9
MA5XM[E!P0P/ ]:J7\L.O:]_88\F?3A:[W:(<POG@AO7IQ[UT>GVAL;""U,TD
MWE(%\R0Y+4 0:-I4>CZ>+9)&E8N9))&&"['J<=JT*** "BBB@ HHHH ****
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M<DKI$T=R9,?,$)#*'4XVX.",]Z .J.OZ#%KT5H)XSJ%W'&HECA9E=2':-6E
MVC/[PJI;)R2!SS/I/B/2M;FGAT^Z,KP %@T3IE264.I8#>A*L RY4X/-<E;_
M  _O++5+"*&Y@DTR%[&:29W99M]K&450@4@AL(22PQ\W!JYX+\'WWAZ\62]E
MMVCM=.CTRV\F1F,D:2._F."H"L0RC:-V,'DYH [6BBB@ HHHH *KWU];:987
M%]>3+#:V\;2RR-T50,DU8JKJ7V[^S+K^S/L_V_RF^S_:21&),?*6P"<9ZXH
MR&\<>'UL6NVNYPJS& Q&SF\\.$\PCR=GF?<^;.W&WGI4O_"0Z!'K<%NMQ&;Z
M]BB"RQPLRNAWM$K2@;1G]X5#,,Y.!S7(6O@CQ%#IUI<R_P!GSZ[%<SW%U-+?
M2,MXTT#1,Y80CR]N5VHJD!5 SWJ>V^'E[97NFV\-S!)IT/\ 9SS3.[+,'M%(
M 5 I#!SMSEACG@\4 =AI?B/2M:N;BWL+DRRV_P!\&)T##<R[D+ !UW*PW+D<
M=:U*XOP?X0OM U$2WDMNT5I8C3[7R9&9I8Q*S[W!4!6P5&T;N_-=I0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#P01QBL_2O#>BZ'<7$^DZ7:6#W*(DPM8A&KA"Q7*K@9^=N<9/&>@P :E%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^!"L# 2(  A$! Q$!_\0
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M?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
MB:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G
M_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!_
M_0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+
MH?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_
M (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\
M]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"
MB@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A
M!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:
M'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03
MP?\ ]"IH?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH
M?_@NA_\ B:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
MB:Z"B@#G_P#A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B:Z"B@#D
M='T?3-&\?7\.EZ=9V,3Z7 [):P+$K-YLHR0H&3Q775ST/_)1+S_L$P?^C9:Z
M&@#F_',$-UX;CM[B*.:"74]/22.10RNIO(000>"".,5)_P ()X/_ .A4T/\
M\%T/_P 31XR_Y =M_P!A73?_ $MAKH* .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A
M!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?
M_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)K
MH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X
M03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*F
MA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_X
MFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y
M_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__
M $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""
MZ'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$
M\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^
M"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@
MHH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!
M/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'
M_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:
M/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_
M^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA
M_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH**
M.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?
M_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\
M@NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFOEC
MXOV%GIGQ2UFSL+2"TM8_(V0P1B-%S!&3A1P,DD_C7V/7R!\;?^2O:[_V[_\
MI/'0!]/^ _\ DGGAK_L%6O\ Z*6N@KG_  '_ ,D\\-?]@JU_]%+704 %%%%
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MXXK5UO\ Y.*\.?\ 8.?_ - N*SDW+2_5#/2[&TCT_3[:SA+F*WB6)"YRQ"@
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M8!!J-C;7D*MN$=Q$LB@],X8'GDU:HHL!7LM/LM-MQ;V%I;VL )/EP1A%SZX
MQ4-OHVEVE]+?6VFV<-Y-GS+B.!5D?)R<L!DY//-7J*+(#.30-&CFN9H](L$E
MNE9;AUMD!F#'+!SCY@3USUJQ'I]E%8&PCL[=+,J4-NL0$>T]1MQC!R>/>K-%
M*R S4\.Z)'9BS31M/6U$OG" 6J!!)C&[;C&['&>M<=XY\'^)_&FH0Z>]YIMO
MX=CN$E^3?]I;Y<'.05)!+XP0.1FO0Z*3BFK!<9##%;01P0HL<4:A$11@*H&
M!3Z**H HHHH YZ'_ )*)>?\ 8)@_]&RUT-9R:85\23:MYH*R6D=MY>WD;7=L
MY_X'^E:- '/^,O\ D!VW_85TW_TMAKH*SM:TPZM816RRB(I=VUSN*YSY4Z2X
M_'9CVS6C0 4444 %%%% !1110!4O=+T[4FB:^L+6Z:$DQF>%7*$XSC(XZ#IZ
M5+=6EM?6SVUY;Q7$#XW13('5L'(R#P>0#4U%%@*TFFV,VG_V?+96[V6T)]F:
M)3'M'0;<8P,#CVJNF@:-&ELB:38*MJQ>W"VR 0L2"2G'RG(!R/05HT4K("LF
MG6,=_)?QV=NM[*NR2X6)1(Z\<%L9(X'Y"BVTZQLYYY[6RMX)KAMTTD42JTIR
M3EB!R<D]?4U9HIV I6^D:9:6<MG;:=:0VLV?-AC@54?(P=R@8.1QS4"^&M!6
MS^QKHFFBU,GF^2+5-F_&-VW&,XXS6I12L@*K:9I[:BNH-8VQOD&%N3$OF 8(
MP&QGH2/QI4TVQCU"34$LK=;V1=KW B42,.."V,D<#\A5FBG8"I>Z5IVI&(W]
MA:W1B),9GA5]A.,XR..@_*K=%% &9)X<T.;SO-T;3G\Z3S9=UJA\Q^?F;CD_
M,W)]3ZTZST#1M.N/M%CI-A:S $>9!;(C8/49 S6C12L@"JUYI]EJ,:1WUG;W
M2(V]%GB5PK>HR.#[U9HI@4H='TRVOY+^#3K2*]ESYEPD"K(^>N6 R:>=-L#J
M U V5L;T+M%SY2^8!TQNQG%6J*+("GJ&D:;JRQKJ6G6EXL9)07,*R!2>N-P.
M*$TK3H[M;N/3[5+E4$:S+"H<*!C:&QG&.,5<HI60%!-#TB.PDL(]*L5LI6WR
M6ZVZ"-VXY*XP3P/R%23Z5IUU8QV-Q86LMI& $@DA5HU &!A2,# Z5;HHL@&Q
MQI%&L<:*B( JJHP !T %5[_3+#58!!J-E;7D*MO$=Q$LBANF<,#SR?SJU13
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MI]I>(ARJW,*R!3[;@<5++>VD-S%;2W4,<\O^KB>0!G^@ZFIF944LQ"J!DDG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L7QA_R)&O_P#8.N/_ $6U;54]6L%U71K[3FD,:W=O) 7
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M'PU>?7KK5] \07FAW%[G[6L";DE)[@ K@]3GGDY&*IP>]NHKG,>+]&T[P_\
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MCJOB+Q+>ZW)I[![2.1/+1&!R"?F.3D ]L[1G(&*7)*ZT[!<[^BBBN@D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM/)P#CC->;W2(/V>+(A1DW!).._GN,_E73^*(TA\<^ DB0(BF15"C   3 H
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M"408   93@9P6K'N+FPT:VU5]!UZZTU8YCOT'5;4/N;CH/G4]  2,C:,GH:
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MKR/H:\8UGQ!+?3>++6_UG^RMDDL,.FVEF%>Z(#!2\@!8@_Q<\@GH*[[X6?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(KJ<JPR#[4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !17B]K'J&B7_ ,7MNJ75W?V^FVT@O9"$DW_9I6W+M "XS\H'3 KH? -K
MIFE^+-1T_P /LATDZ187,B12;D6=@X#=<!GC5&)ZMP3F@#T>BN/\0>)M=T#5
M[!9-)L)-*O=1M[&.<7C></-8#<4V8XY_B["NPH **** "BBB@ HHHH ****
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M%Y.)?,E8 %L2NHX  Z "@#L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>*GP_K'_  D0T?\ LV]W_P#";_V]]K$#
M?9_LNS=_K<;=W\.WKFO:J* /,?'GBK53IEFNA^'->CO+T3037L.EM+<64 <J
M2H! W.5#+\PX ;TK$UO14@MK"[T?1_&-K?CP['9:5+:DH4D60%8[A4 V-DAF
M+G85W8^917M-% %""VN;O0([75' NI;41W3VSLGSE<.488*\YP1R.*XS1+'^
MQ/BY<Z5;7VHRV3:$ESY5W>RS@2&=E+#>QQPH%>A5Q"?\ETG_ .Q:C_\ 2EZ
M.WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN$X'(KV_J*FG4C43<?0;5@HHHK004444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 445D^(O$5CX8TK[??"9U:188H8(R\LTC'"HBCJQ]*
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MUVE% '@%S9:?XG\.>'O"FF>"[RTUBWF@%P]QI_EI9!<>:[N1APP!X/W^I^;
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MB_NN,;@W8CWR.TKDOB/%J,WA3;IHU-W%U 9H=,.)IH=X\Q P(*Y7/(],=":
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M#IMIK=BDNJ37$&JR1W,NIW"SR2,(X]CAU RIB\H@$9&2.U '7T5@^-KNZL/
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MX>1!#<NC,P^T,=P*,1CDCKGBO1HHHX(4BB18XT4*B*,!0.  .PKBT_Y+I/\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //OBG%!<0:-#?\
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M%QC([UW'ANV\FSDE7Q%<ZW%*WR33-$P7'!"F-5'7US7!^+=7N/&G@A#%I&H
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M8XSG':NGHH CM[>&TMHK:VBCA@B0)''&H544#   X  [5)110 4444 %%%%
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M6?E*D8S_ +.>]=C\/;"[T[0)X;S0;C19#=,PMY]3^W,PVH-_F9X!P1M]L]Z
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M(/'/7C'4T4I14E9@<_X3\,OX;L[O[3J,FI:C?7#7-W>21B/S'("@!1]U0J@
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ML<*J ;BQ]L<UP&B:[I?B#XTW-WI%_!>VZ>'DC:2%MP#"X8D?7!'YUZ''#'%
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M?9>ZCY7VN7>Q\SRUVIP3@8!QP![UH44 <5\2?^/;PQ_V,EA_Z,KM:XKXD_\
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ML;.YE *Q3SJK8/0G/0>YP* -JBD5E=0RL&5AD$'((I: "BBB@ HHHH ****
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MI&"N3DC'(KA= T&Q\/?&>ZM+#[1Y3^'DE/GW#S-N-PP^\Y)QP..E 'I5%%%
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MZE?:GX4>6[N)KNVCO)X=/O;C_6W=JK8CD?(!W'D9(!.,GK0!V5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45Y9\:?$VLZ):Z-8:7>26$.HR2K<
M7D7#J%5=J*W\);<3D8/R\=Z3X+>)M9UNVUJPU2\DOX=.DA6WNY>9&WJVY&?^
M(KM')Y^;D],1SKFY.NYT?5JGL/K&G+?EW5[VOMO\SU2BBBK.<**** "BBB@
MHHHH **** "BBB@#R;XL:8\=Y-J(U+181?::MAY.HW[VKE4G65Q'M.'5P0KC
MY3@##<D5L_#'1X;)=7U.RDT>.POGB$5EH]VUQ!"R*0S%S@;VW $* ,(O6HO%
M%AJUK\0AKECX(C\1#^S8K>&=[R*'[,PDE+@!\\D.G('3(SR:D^'>EZS:^(_%
M&I:CX=70+74&MGM[..XCE3>JN)&'E\ D[23@9SWH ]!HHHH **** .'\3?\
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MOC'_ ,%\?_QR@#MZ*XC_ (6-+_T(OC'_ ,%\?_QRC_A8TO\ T(OC'_P7Q_\
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M1110 54_M33_ .T_[,^WVO\ :&SS/LOG+YNW^]LSG'OBK=>"LK_\)>+7Y?\
MA(_^$]\_;Q]H_L_RLY_O>5Y?X4 >X7^IV&E0+/J-];6<+.$62XE6-2QZ %B.
M?:B[U/3[":VAO+ZVMY;I]D"32JC2MZ*"?F/(X'K7GGC#5/#$OB/2=4UZ2UN-
M!.FZC!%*Z[T%P&C#J#T#E$D4#J2"!S7&ZI%IUIX=:U\16JC4+CP79V^EQRPG
MS&F!<&-,C_6!VA)4<XYZ T >_P!<0G_)=)_^Q:C_ /2EZZMH[U]&,4<Z0W[6
M^U9F3>J2[>&*Y&0#SC/-<*/!7C4>)FU[_A+]/^VM9BR+?V5\OEAR^-OF=<D\
MT >C45Q?]B_$#_H<=,_\$_\ ]LH_L7X@?]#CIG_@G_\ ME ':45Q?]B_$#_H
M<=,_\$__ -LH_L7X@?\ 0XZ9_P""?_[90!VE%>7:5=>/M4\5>(-#'B?38SHY
MMP9O[*SYOFQ[^GF<8Z=3FMW^Q?B!_P!#CIG_ ()__ME ':45Q?\ 8OQ _P"A
MQTS_ ,$__P!LH_L7X@?]#CIG_@G_ /ME ':45Q?]B_$#_H<=,_\ !/\ _;*/
M[%^('_0XZ9_X)_\ [90!VE%<7_8OQ _Z''3/_!/_ /;*Q/$-QX_T"?1HCXGT
MV?\ M/4$L01I6WR]RL=W^L.?N]..M 'I]%<7_8OQ _Z''3/_  3_ /VRC^Q?
MB!_T..F?^"?_ .V4 =I17%_V+\0/^AQTS_P3_P#VRC^Q?B!_T..F?^"?_P"V
M4 =I17%_V+\0/^AQTS_P3_\ VRC^Q?B!_P!#CIG_ ()__ME ':45PMYIOQ M
M+&XN?^$OTQO)C:3;_9&,X&<?ZRJ7AQ?'_B#PWIVL#Q5IL O;=)Q$=)W;-PSC
M/F#/Y4 >CT5Q?]B_$#_H<=,_\$__ -LH_L7X@?\ 0XZ9_P""?_[90!VE%<7_
M &+\0/\ H<=,_P#!/_\ ;*/[%^('_0XZ9_X)_P#[90!VE%<7_8OQ _Z''3/_
M  3_ /VRC^Q?B!_T..F?^"?_ .V4 =I17E^G7/C[4/%NMZ"/$^FH=+CMW,W]
ME9\SS58]/,XQM]3FMS^Q?B!_T..F?^"?_P"V4 =I17%_V+\0/^AQTS_P3_\
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M>SZ?%*^<+YCE <^@R>?QJ&[\ ^%[S1K'29=)C6SL%9+9(9'B:-74JXWH0Q#
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MA+'7(E^=&*L,%!T(->EU1TK1[#1+-K33H/)@:5YBN]F^=V+,<DD\DF@#D/\
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MMZX/F6@G6;R^2!\Z@ Y&#^-7J** "BBB@ HHHH **** "BBB@ HHHH ****
M"BF3316\$D\\B10QJ7>1V"JJ@9))/0 =Z\?\5^/7F\0Z5<K)>R^')(DN=(72
MV.=8N]P BD<8,85CS&1_"2<G"@ ]B"J&+!0&;J0.32U5TR6]GTNUEU&VCMKU
MXE:>&.3>L;XY ;OC_.>M6J "BBB@ HHHH *1E5L;E!P<C(Z&N:\7^.]#\#K8
M-K4DZ+>S&)#%"7"@8W.V.PR.!DG/ .#CRSPU\1=7\->*-677-5.N>&I;@2C4
M(VWM;QR'$<R@?\LL_(RJ,(XQP3AP#WFB@'(R.E% !1110 4444 !&1@]*15"
MJ%4  = *Y/Q'XGNTN+O2?#9MI_$%DD=V]A=QNGVF D[A$W +=MPW '@\]-7P
MOXET_P 7>'[;6=,=C;S @JXPT;#AE8>H/X>G% &Q1110 4444 %%%>/?$'XA
M6NMV&M^&?#.NW.G>(-/F4 !3$;TH</#"_7=GC P6*X7<&)H ]@"J&+!0&/4X
MY-+7G_PV\>S^)8!I6L(JZS%;+<I/$/W5];DX$R>G/#+QALC (*KZ!0 4444
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MKP+X-/AFQ6XOWCEUR>!(;ZX@=_+GV$A&*G&7VD L1DD$]SD ZZBBB@ HHHH
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MB@ HIDHD:)Q"Z++M(1G7<%;'!(!&1[9'UKP_3==\:^!-*U75]8M;25(M0/\
M:;7D\OVB_;<J&6U&%01A6B &/X2.,   O>.?%%IXCT::\:W^V>';&<V>MZ5-
M"(K^SD9]L=Q&2<[@<8'0@D'^+9N^ ?AQ#HUXFO7[K+J862.*Y@\R#[5;N%*O
M<1,!B7@Y'J<MN<;AJ^)OAY9:WXFTKQ+9F"TUBQGC=Y9+<2I<1@]'4_Q ?=<<
MCCT!'9T %%%% !1110!E>(?$6G>%](DU/4Y2D*D(B(-TDSG[J(O\3'L/J3@
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M_6QGB0  X!(Z]Z .8U_XH16WAA]1L56T>+63I-W)>0O(+/:6+2,B<O\ *HP
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBHYY&AMY94A>=T0LL494,Y
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MG>*1KN!DD>=98\YD=Y7"Y8':J*>V6]@TW3+'1[".PTZUBM;2+.R&)=JKDDG
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M.TVUCM;.!=L<48P%'4_4DDDD\DDD\U;H **** "BBB@ HHHH **** "BBB@
MHHHH **** $9E12S$!0,DD\ 5QD?Q)TS5DFB\+6T^N7\863[*G^CEH2V&E5I
M=H90<CY<_-@< Y%K3_%>A^+-4U[PK(DB75H7MKFUN!L::(C:73!R4.>O7!!X
MR*YC7=!\0:3XST.W\(6:)!_8LFF1WTY,B6*K)&=[9SO(4 *IZD]P"* */A#Q
M+K_BO0K?19$O[3Q#:W-P9]7O='$]NKJ\@94(<*KA7"^@&Y0.0:]%\)>'(/"/
MA6PT*WF>>.T0@RN,%V9BS''8%F.!S@<9-6='T:TT2VGBM4PUS<275P_>29SE
MV]LGMV&!6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7F/C/Q@=6T#67T&\OHM.T:3&HW]BP5I_W9(BMY 'P0YC#M@;0
M2>15?Q=K_B?1O%4>E:IK<.E>']1N-UMK-O NZV'EL%@EWY"Y8!MYZX;! R$3
MX::/=ZAJ-SXG6]6(27%Q9ZBL$(^S:UL.$NT'1"23DKD,0>F3D S_  !X;OO$
ME]_;&JW,<KV;-8S:K:$20:_;;65HY5=1OV,%7S,?, 1R5#CV.WMX;2VBMK:&
M.&") D<<:A510,  #@ #M3D1(HUCC5411A548 'H!3J "BBB@ HHKF?&'B>Y
M\.KI<%C90W5YJ=W]E@^T3^3"K;2PW/@\G& O<GVH T)O$^A6^NQZ)-JUFFJ2
M#*6K2@.>F!CU.>!U/:O*O!'Q*U31=4L_"WBN4:C<W5T\$%W',GF1,)GB99@Q
M&/F3*]RI&,GBJ^H7VG/H>HZJ-)OX];M/$ME>ZGITBK+<6S[T4")@ 65@,(<X
M.[C@UZ9X/T9K?3[G4=2T33M.U/4[DWEU#;#<0<Y0.Q^\XZDC W%B!R20"NGP
MYT4_$*[\97*M=7TRQ^5%* 4@=%"[U'KA5QGH<GTQU]%% !1110 445A>++'6
MM3TF.RT6]%D\UQ&MU<*^R5+?/[SRFP<28X!(]>^* ,'QAX\?2+^]TJST:_OD
MM;03ZC<V<J)+:1OD*\:-S(1@DXX7C)ZXX&2WT'P_-H$7A[34UP:WX;GTU!91
M^2-1D+1 M(004P-Y9B=RX()XXNC2=?B\7:)I=S=36FO(EV--ULW(NY)K>.4L
M(;N/"Y4H00V>"1QG('I'@WPE'X6TKR'DAN+IYYIVDCA$:1>:P9HXER=D?RK\
MN>2N?8 %CP[X7TGP_86:V>D6=I<PVP@+Q .X7.YE\TJ&8;LG) R><"MRBB@
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M %%%% !7D7C[QLOB/29-"\/M?1"\N#:0W\EI_H&I-@JULLV<C<<J&& 2I&X
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MV\5O;Q)#!$@2..-0JHH&  !P !VH +>WAM+:*VMHDA@A01QQQJ%5% P  .@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 445YOXZ\=6DVEZGI?A_5)9;^QGC754T\$W4%KN F:'(P74<$C.S))P10
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M2RV\;NV,9)4$GBKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 56O=1LM-2)[Z[@MEFE6&(S2!-\C?=49ZD^GM5FOG/XBZ_K&OK
MJVA^*/"T*7FE2&\L9;(M(5A!_CSAGA900TB;=K*NY5(P #U#Q3XROX[O6](T
M;09-4&F6:RZBZ7WV62,2*Q"Q84DOM!;((QC YQ6-X,\(/J.EZ:+P2M8631ZE
MH6LQ2B.[,<Q,CPR@9YY(;LP;UZ4/!GA&+QE81:IJ=Q>S6;6JPVNIV]ZT,U[;
M$L'M;I5^\8V4J6&-PQSQ7K]K;065I#:VT216\*+'%&@PJ*!@ #T % $M%%%
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M;V]N=00/9P+//YCJK7)R!M /4E1(<#N5KIHY$EC62-@R. RL.A![T .HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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9U-YR0.P_#I4]% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B EH# 2(  A$! Q$!_\0
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M.3EG!#%L\L3D_C6O4:SQ//) K@RQ@%U'50<XS^1I(;F&X:58G#&%_+D _A;
M./R(II);$3J3J.\W?^KDM%%1R31PM&')!D;8N 3DXSVZ=*9!6OM,M]0N+*:?
M?OLYO.BVG W;2O/J,$U0NO"MA<ZA/>"6\@:YQ]HC@N&C2; Q\P'MQQBMRBI<
M4]T:PKU8?#*W]7_/4P/^$/TL:7:V$9N(DLY&EMI8I2LD)8DD*P[<D8]*MZ3H
M%EHT]U/;&=I;K9YSS2ERY7/))[\UJ44*$5K8J6)K2BXRDVG_ ,/^>OJ9M[HE
MK?:G9ZB[SQ7-ID(\,A7<I()5AW4X'%0GPUIY\.2:%^^^QONS\_S<MN//U-;%
M1QSQ2R2QQN&:)MK@?PG .#^!%'*NPE7JI)*3TV^6QE7_ (9LKZ\^V+-=VET8
MQ$\MI.8VD4= V.N/SIUOX:TRT?36MXGC&GF0P@.>2XPQ;/+$]<UKT4<D;WL'
MUFMR\O,[?TOR;,2[\+6%UJ,UZ)KR![@ 7"6]PT:38&!N ]N.,5CW_A"&.?0+
M"SBN!I]M<3R.Z2[6@W*2I##!'S'BNM2Z@D@>=) T2%@S+SRI(/Y$&J4'B'3+
MBX6"*X9I20NWR7&">F>./QI.G%]#2GC:T+>]M_DU^">G^1%:^&=,M[2\MY(Y
M+K[:,7,ETYD>48P 2>P[8Z5%9>%-/LKR"Y,UY=/; BW6ZN&D6'(Q\H/?'&3D
MUNT4^2/8CZS6U]YZ[_E^6FEM--CFKCP-I%PES"SWBVL[F1K9;EA$KDY+!>@.
M>?3VJ_<^';.YU0:@7N(YC;FV<1RD+(F" &'?&XD5K44<D>PWBJ[WF_ZM_DON
M,2;PKI\MI80H]S!)8Q"&"X@F*2JF ,%AU!P.M7M+TJTT>T^S6B,%+%W9V+/(
MYZLS'DDU=JLVH6B3F%I@)!(L17!^\PR!^5"BD[I$2KU9QY92;7]?YLY6S\)K
M>ZEKLU\;VV6YO3@0W!C6XBV+]X \C.[T-=%%HEC!J-M>PQF-[:V-K$B'"+&2
M#C'X"M&BDH11I5Q=6H]7I:UODE^2,*]\)Z?>W<]P);RV-SC[2EM<-&D_&/F
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M5+A'.5(5=HP.W%6;"S33[""SCDED2% BM*VYB!TR>]6:*:26IG*K.2Y6]/\
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MU!X2QG=52/?QG&<)QV&>>M,L+B?S8HUF=HUU-0NQGV[#"3@%N2N<]>,UV5%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME^TZ*9"BP!CV*PG!;;NV@XQNQSCK0!M45BQ3:4VDV^H26@B2<+M0Q$L2W0
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M?[-LO^?:/\J/[-LO^?:/\J +5%5?[-L_^?=/RH_LVS_Y]T_*@"U157^S;/\
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MGOHXHY#&[71C4"(,C-MYXY*X!/\ .FQZQJ<MO+<_:$5+>.)M@B&)@TC+NYY
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MQ1"OS D DY/T!J7S[<Q-+YL1C'#/N&!]37,_\(]>RPR!<6YD+_\ +13MS$R
M@*J@<D=.PH@T*[C*SM:Q.$D5C:O(NV0!&7/RH%!&X8R#G';B@#>;4+(7$D =
M7D!42!1G;N!(+>V!5AY($0[WC55 8[B  /6N=BT&X%TA:UM4B+PLZQMP JL&
M7D9/WA_]:F'P]??94+LDDT,RA5##YX44J@^92,_-NY'6@#I)9(XHA(5W*Q"C
M:,YW$#\N:BN+VSM[=Y7=&2(J"$PVW)P./QJA'I4Z:#;V8"B1)DD*E\A0) Y
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M<LI$BMC"KD*>>3D^O>H6CV0SW3:?$8K@W"Q6Y1M@+!,,OR]3@CH,]J .Y-Q
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M444 %%%% !1110 4444 %%%% !1110!0US_D :C_ ->TG_H)KPL=!7NFN?\
M( U'_KVD_P#037A8Z"@!:*** #Z=:V)?#MX)BD03&]HE$DJAGD5064#/.,UF
M6TB174,LB%XTD5F0'&X YQ6JVO[KN&Y,#;XDN,?-_P M)2QW?AN'Y4 94=M+
M-;37"*#'#MW\\_,<#COS5Z?1+JWM)9)% DA9MX#J0%4+N]\@N ?Q]*9H^IKI
M<D[-!YP>,!5)P X8,K'U (Z59M=<2%[7S[9IXHX)8YD9_P#6M(Q8DGZ[?RH
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MM<N)&$7V8S7<FTB(,%51Y:LQW>GS#\35J#3=)NI9)X'68$L2J3%D5F&&( .
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M#C!([@4 <Y-:WQTZ%9Y-0E62WAFF!+$K()4SC'(.TG@>GM6WJ4=Y+?P_97G
M2VE=0K$(T@*[ WKWX-.?Q!99B$1DD,DHBP(V&TE2P)!&<$#K4D.M6;B!7E D
ME5#A59E!<94;L8&>V<9H Y^V?5#"/-EO?L^8OM.U9/,7KN*D@'KMR%S@=*2*
M6]L[&X$::AB6&?R/W3%S(96()P."00<FNCAU:!M)@OY_W*S*I"C+')Z  #)/
MT%00>(;*2#S97,8+R  *S?*C;=YP/E'UQB@#'OX[NYMM1AE.I-<LLP\M ?**
M8^3!Z=,=.2<@TZ1KH7$N]M12R+2&)H%;>S[4V9XSC[W7C/6MR77-.ADE22Y"
MF(,7.UMHVC)&<8) YP.:5=9L6E2+S6#/@?-&PP3]T,2/E)[ XS0!CP)JWFI<
MSR70G6Y@1HU)\O:47?QTQDMSV(J75WOAJ$_E->!Q&GV)8%)C9\G=OQQZ9W=N
ME:(UW3B'/V@X1=V3&PW#=MRO'S<D#C/6E?6K!$5VF8!@QP8FRH4X)88RH![G
M% &6L4NG>%]5DC:>*;?<.K%B6'SM@C/M@^]599;X;D@;46LVF4+)*) X.P[@
M<#?MSC&,#.><5OZA>VL"K'=>4;:2-VD+\C:HR>,'(J6UU"UO$E:"0D1'#AD*
ME>,]",].: .3BM+RZ\A[I;T7$J6GF-AAC;(VX^@(&/?DFK$QU&/SHI9-2\N,
M3+:M$&+.X8[=QQSQC&>#SFMR/7M-EB:5+@E0%8?NV!8,<*5&,MD\<9J5=6L7
M1G$_"1M*V5(*JIPV1C((/;K0!SI6^BFN/M O8HW:1P;16RTVU,=!TZX[=<T@
MNK\75N+N>Z6\:Z6-HX\^24\O./3.<^^?:N@?6]/1Y$,S%D<1D+$QRQ&0HP.3
MCG [54^WZ,EZ+W9;[G12LZH2[,Q9<8 SGY2/7M0!G6LE_&B--_:7VI8X_)BB
M3Y&7RAG=D;<[MV<\YQBH;+^T)KF$3+=21+-;R R*YPWSA^6 ]LX 'I6I=>)H
MHYHUMH6G1H_,9SN4#YPF/N]<YR#C&*O-K>G(9=]QM$2LS,48*0IPV#C!P>N,
MT 0:K;E]3TV5+<R;&E+$(#_RS;&3]>.:P[.YU99-[B^,.V&23<LA((D&\<@9
M.T\A1CTKHDUW3I)/+$[!@2I#1.N"!NP<C@X&<=Q38_$&F3,JI<$EMN,Q.!AN
M%.2. 3P#T- %,R7D_A_4Y MQYK2R^2KH0VW/RX!YQCI1:1WR:E!,\MVRR7-P
MDB.246,;MG';H,'WJU<^(;""WN)5:24PHS[5C;YP#@[3C!P3C(IW]NV<8<SR
M!,.X 568[5QEF&/EQD9SP/6@#-DM9CKMPB->QK-=QL[(S!3'Y)Z'H!N ''M6
M>\^LO)/Y?V]"\4H8$.2C;UVXXV@XSC;QCKFNG36+"2[%JL^92^P85MN[&[&[
M&,XYZT^?4[2VN!!+*1(=H.$8A=QPN2!@9/ S0!SVHKJ-L\T44U\T,<V4/SDL
M#&IQO7+?>SC@C/![5'+=WWVN(M+>1W;72(D1)\K88\[6(^7.<Y[Y]JWUU[36
M\S%R (U9B61@,*<-@D<X/'%065QIUW=7M\MK&CVS;6G:/#GY 22" 0<''X4
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M** ,K3@ZZQJ2YR@6'<>WF;3N_396K34C2/=L15W,6; ZGUIU %#7/^0!J/\
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MGZY%5QX;>*-HX+XJLNPS[H@Q=E8MD<C;G)'>M3^S++_GW7]:/[,LO^?=?UH
MQ)O"ZQPSF)A)@.T*A<.&9MWWB2./H,]Z2+0KN_EEO+UECN#-NC#Q\;=@4Y56
MXZ<?-_A6Y_9EE_S[K^M']F67_/NOZT 48O#Z0VTD*S@!_(Z1@ >60>F>^/PJ
MLGA2-$>-9U";2L9\KYU!8-R2>>F. *U_[,LO^?=?UH_LRR_Y]U_6@#/G\/M/
MJJWK7>0MPLZJT>6& !M!S@+QGIFF1>'9(?L\B7H\^V5%B<Q<87>.1GG(<CJ.
MF:T_[,LO^?=?UH_LRR_Y]U_6@#.'AW]Q=(UV2]S"4D?9_$79BV,_[73VK<JI
M_9EE_P ^Z_K1_9EE_P ^Z_K0!;HJI_9EE_S[K^M']F67_/NOZT 6Z*J?V99?
M\^Z_K5N@ HHHH **1F5%+.P51R23@"H/MUI_S]0?]_!0!8HJO]OL_P#G[@_[
M^"C[?9_\_<'_ '\'^- %BBJ_]H67_/W;_P#?P?XTG]H67_/Y;_\ ?U?\: +-
M%5O[1LO^?RW_ ._J_P"-']HV/_/Y;_\ ?U?\: +-%5?[2L?^?VV_[^K_ (T?
MVE8?\_MM_P!_5_QH M455_M.P_Y_;;_OZO\ C2?VII__ #_6W_?U?\: +=%5
M/[5T_P#Y_K;_ +^K_C2?VKIW_/\ 6W_?U?\ &@"Y15/^UM._Y_[;_OZO^-']
MKZ;_ ,_]M_W]7_&@"Y15,:OIQ( O[8D] )13O[2LO^?J+_OJ@"U15,ZKIX.#
M>P ^A<4?VMIW_/[!_P!_!0!<HJK_ &E9?\_,?YTG]J6'_/W%_P!]4 6Z*J#5
M+$]+J(_C2_VE9?\ /RGYT 6J*J_VE9_\_"4G]I6?_/PM %NBJG]I6?\ SW7]
M:/[2L_\ GNOY&@"W153^TK/_ )[C\C1_:5G_ ,]A^1H MT54_M*T_P">W_CI
M_P */[2M/^>W_CI_PH MT54_M*T_YZ_^.G_"C^TK3_GJ?^^&_P * +=%5/[2
MM/\ GJ?^^&_PH_M*T_YZ-_WPW^% %NBJG]I6O_/1O^_;?X4?VE:_WV_[]M_A
M0!;HJI_:5K_??_OVW^%']I6O]]_^_3?X4 6Z*J_VC;?WG_[]-_A1_:-M_>D_
M[]-_A0!:HJK_ &C;?WI/^_3_ .%']HVWK)_WZ?\ PH M455_M"W]9/\ OT_^
M%']H6_K+_P!^7_PH M455_M"W_Z:_P#?E_\ "C^T(/\ IK_WY?\ PH M455_
MM"#TF_[\O_A1_:$'I-_WY?\ PH M455^WP_W9O\ OR_^%'V^'^[/_P!^'_PH
M M455^WP_P!R?_OP_P#A1]OB_N3_ /?A_P#"@"U157[?%_SSN/\ OP_^%'V^
M+_GG<?\ ?A_\* +5%5?MT?\ SRN/^_#_ .%'VZ/_ )Y7/_?A_P#"@"U157[=
M'_SRN?\ OP_^%'VY/^>-S_WX;_"@"U157[<G_/&Y_P"_#?X4?;D_YXW/_?EO
M\* +5%5?MR?\\+G_ +\M_A1]N7_GA<_]^6H M455^W+_ ,\+G_ORU'VY?^?>
MY_[\F@"U157[<O\ S[W/_?DT?;E_Y][G_OT: +5%5/MP_P"?:Y_[]&C[</\
MGVN?^_1H MT54^W#_GVN?^_1H^W#_GUNO^_5 %NBJGV[_IUNO^_=6^U !111
M0!D>*O\ D5=3_P"O=OY5XI7M?BK_ )%74_\ KW;^5>*4 %%%% !1170:38V\
MFA-=/;6<LWVORLW=P8E"[,\$$9.: .?HK=U#0X8;B[>.Y$$*W7V>".56+,<
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M\R1[CG8JDKDEC_"/\14*Z[(UR$BMWF>8QB.,,@"YC9S\P."/E_PH W:*PO\
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M26@9BJ?=DP<9R2%8XY^9B*5H;LO=7EO+J.Z."+R2ZX:3$C_>&/FX]><')YH
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M2M+=S>-Y=S$SLRE9,<C+!?PS60EQK$KR*&OD$L8WY#;D;S4'=0 =I;A>,>M
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MU-%=7$"A8IY$ 8L K8Y(VY_(D5Z!_P *R@_Z"<O_ 'Z'^-'_  K*W_Z"<O\
MWZ'^- 'GCRR211Q.[-'$"$4GA03DX_&I#>W3-(QN92965I#N.6*]"?<5W_\
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MM/4?0U'/J%Y=0I#<74TL:?=5W) [5Z!_PK.T_P"@C-_W[%'_  K.T_Z",_\
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M^?N/_OS_ /94>3>_\_<?_?G_ .O0!:HJKY-[_P _<?\ WY_^O1Y-[_S]Q_\
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M+?X4?7<-_P _(_>O\P^KUOY']S-.BLS_ (2#2O\ G\7_ +Y;_"C_ (2#2O\
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ML+ _R?BS3^TL3_-^".3_ .$.E_Y_4_[]G_&C_A#I?^?U/^_?_P!>NLHH_L+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\ EH# 2(  A$! Q$!_\0
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MWJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*YN([2VDN)=WEQC)V(6/X
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M_A,1(T-['=F2[.H&7>8_*+#R "?D.!C&WT;WH [RBN:TW7]5D\7SZ%J>G6L
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M"I_A0!!_PE_AG_H8M(_\#8__ (JC_A+_  S_ -#%I'_@;'_\54__  CNB?\
M0&T__P !4_PH_P"$=T3_ * VG_\ @*G^% $'_"7^&?\ H8M(_P# V/\ ^*H_
MX2_PS_T,6D?^!L?_ ,54_P#PCNB?] ;3_P#P%3_"C_A'=$_Z VG_ /@*G^%
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MD_[ \7?]#N?_  50_P"-:FBZ=K-C),VJ:]_::L $7[(D.P]SE>N: -BBBB@
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M/[/GANQXBN+FXO(KN:X_L.=-S1LA4!0F ,1J/S-;_P#PG^E_] _7O_!/<?\
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M!RO_  D7B?\ Z$>[_P#!A;__ !5'_"1>)_\ H1[O_P &%O\ _%5U5% '*_\
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M>RA&E+ [MIM\CYOFV[PI/7J:],TS3H=*TZ&QMR[1Q#&Z1MS,2<EB>Y)))^M
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M +5%-CD25 \;JZ'HRG(-.H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *_I_P#T8U?4]?+&N_\ (QZM_P!?T_\ Z,:@"A1110 5[5\%?^1;U+_K^/\
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M %-=50 5\L:[_P C'JW_ %_3_P#HQJ^IZ^6-=_Y&/5O^OZ?_ -&-0!0HHHH
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M^"O_ "+>I?\ 7\?_ $6E 'IE%%% !1110 4444 %%%% !1110 4444 %%%%
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M^08+AN^3WKN* "BBB@#E#_R5M?\ L!'_ -'BNKKE#_R5M?\ L!'_ -'BNKH
M**** "BBB@ HHHH **** "BBB@ K*\3?\BMJO_7K)_Z":U:RO$W_ "*VJ_\
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M3S6O^N'_ +,* /G+O11WHH **** /HOX:_\ ).]&_P"N)_\ 0VKJZY3X:_\
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M^>W/K] !0>AHH/0T <K\-O\ DG6A_P#7O_4UU5<K\-O^2=:'_P!>_P#4UU5
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ME^8ZS8!C&,G=S@8[\UYEX=>TB\0-%(VC13_VI/B*72I'N03*V/W^0"3U#8P
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M^&W_ "3K0_\ KW_J:ZJN5^&W_).M#_Z]_P"IKJJ "OEC7?\ D8]6_P"OZ?\
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MU_0C$A8C?ITA/S,6/_+3U)JU]@^(G_0>\/\ _@MD_P#CM49'945QOV#XB?\
M0>\/_P#@MD_^.U4L(OB7=+<&XU+0[4QSO$@?3Y#YB*<!QB7@'KB@#O:*XW[!
M\1/^@]X?_P#!;)_\=H^P?$3_ *#WA_\ \%LG_P =H YS5?\ D8-5_P"OH_\
MH*U5IS^'O$5]XEOM/'BK0SJFT74]N-.D!56P 1\_3@=ZJQ:)K$]GJ=W'XPT)
MK?3))(KR3^SY,0N@RX/S\X'IF@"Q156ZT?6++2;/5)O%VC?8KTJ+:2/2Y7\T
MLI90%5B>0">G:J_V34?[.-^/%VDM;K*87*:/<,T;@;L,@.Y>.>0* .N\&_\
M(T?]N<G_ *''7H=>1^%-.\1WT[:EHGB?2)PL6S?)I$Z*5?# C<PS]T<C-=5]
M@^(G_0>\/_\ @MD_^.T =E17&_8/B)_T'O#_ /X+9/\ X[4^E'QI:^(K>WUB
M?3KW39H)6>:TM6B,,BE-H.YSG<"W;^&@#JZJZD;4:;<F^A\^U\L^;$8C+N7N
M-@!+?3!JU574M1M])TZ>_NV9;>!=\C!2=H]<"@#R[2-*TY=9L[2UTRRAB34?
MM<5^-(N([CERP0YB"KUV%MV-O8'IZW7DVE7&GWWB*W:UO-)EOFU)I/[77509
MIH_,/[H1?>.5_=[?NXY':O2==2[D\/ZDE@6%XUK((-APV_:=N#V.: -"@]#7
MGME%/'X>\00:-:W]M!<1;;")XI$?S!"/,V[N5R>,G&6!QZU>T>UU'^R]67PY
MMTZ![I#8C4+:0JJ^6GF?NV*L 6W>G.3WH M?#;_DG6A_]>_]3755YIX3T3XA
MZ?X5TZT74]&M!%%M\B>P=WCY/#$2 $UL_8/B)_T'O#__ (+9/_CM '95\L:[
M_P C'JW_ %_3_P#HQJ]U^P?$3_H/>'__  6R?_':X:Z^#'B*\O;BZE\1Z<))
MY6E?;9,!N8DG'S],F@#S2BO1O^%(:_\ ]#'I_P#X!-_\71_PI#7_ /H8]/\
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M=2M?$6F&>V<N@>Q<KG!'/S^A---/8B=.<':::?FK'LE%<;]@^(G_ $'O#_\
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M5=VQAN;8YP#(I^\G/WA7=JP90RD$$9!'>LKQ1<VEKX8U*2^V^0;=U*M_$2,
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M1@3GOEC6U0 4444 %%%% !1110 445BW&L30^,K#11%&8+BRGN6D.=P9'C4
M=L?.?R% &U1110 4444 %%%% !145S<P6=M)<W4T<,$:EGDD8*J@=R3P!2&Z
MMUDAC,\0>?)B7>,R8&3M]>.>* )J**:)$:1HPZEU +*#R,],C\#0 21I-$\<
MB*\;@JRL,@@]0:Y-=%UOPT['P]+'>:<3G^S;IR#'[1OV'L:ZR21(HVDD=41
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-'*CM7944 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &J!6,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M';^+!P0?]KVJIK?C2+Q)XTUFQU'QS/X7TG2YS:P0V99)KAU)#N7';(Z?3W)
M/=Z*\C^&WC*23Q=?^%#XC_X2*Q6U^U66H.I$@P0&C<GJ><Y]O? H_##3O$_C
M+1K'Q#JGC'58DM;LI%;0OA9T5\MYO/S9R5]@!0![54<\R6\$D\IQ'&I=CC.
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M20S(8Y$/1E(P1^5>'_#/0M0F\?MIFHMYMAX+$\%HQ.=TDSL5;_OC/TP*]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<  !<DGTJ924=6;4</.M+EA:_FTOS.NHK N]=OUN[?3K'35GU%K<3SH\^V.
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M;4+7R0V2>%Y.3Q735Q7A#7]=;Q'JWACQ*+>2_LT2YM[JV&%G@<D#([$$8_\
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MM?E)]H\ORO-Q\VS.<9],\U+5PCRJQSXK$*O*,E&UE;KY]V^X44459RA1110
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MN<8YP><>DUYUK5GXG\*^-=0\2>'](36['58HEO;,3B*6.2)=JNI/!&WMR<T
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M9V]QLSM\Z)7VYZXR.*MRASJ5NA"C/D:OU,C0M4U&]OGCN[[0IXQ&6"Z?,SR
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MWVX1!?)R,Y\S/KCI6]%0?Q=T85G-?#V9V<KF.)W",Y520J]6]A7/?\)+?_\
M0KZK^4?_ ,570RQB6)XV) =2I*G!&?0USW_"&6'_ #^ZK_X'2?XU--T]>?\
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M  H^U1>K?]\'_"IJ* (?M47JW_?!_P */M47JW_?!_PJ:B@"'[5%ZM_WP?\
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M (4?:HO5O^^#_A4U% $/VJ+U;_O@_P"%'VJ+U;_O@_X5-10!#]JB]6_[X/\
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M (4?:HO5O^^#_A4U% $/VJ+U;_O@_P"%'VJ+U;_O@_X5-10!#]JB]6_[X/\
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M+Q79:W<3-9:!81R65@DI1)'>(N96 Y;! '^>0#UU)$D4,CJP(R"ISD>M.KQ
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M**C^T0?\]H_^^A1]H@_Y[1_]]"@"2BH_M$'_ #VC_P"^A1]H@_Y[1_\ ?0H
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MT* )**C^T0?\]H_^^A1]H@_Y[1_]]"@"2BH_M$'_ #VC_P"^A1]H@_Y[1_\
M?0H DHJ/[1!_SVC_ .^A1]H@_P">T?\ WT* )**16# %2"#W%% "T444 %>1
M?$RZ^'D^O^3K6O7VC:]!"(S<6"2AS$PSL8JA#+@]/>O7:\NFU71]%^,NK3>+
M)(K?SK2W&C7-WQ$D8!\U58\*Q<Y_SR <CX8U7X4>']2L[ZZ\8:EJMQ8KLLA?
M0SM':C&/D0)@5[?HVN:9XATY;_2+V&\M6)421'.".H(Z@^QKSCQ7K7A[Q!XP
M\*6_AN>TU#6TU)))IK/$@2T /FAW7C:01P?_ -=[X>R6%SX\\:76A*@T5WME
M5HEVQ-<!&\PH.G<9QU- 'I-%%% $-W$9[.>%5C9GC90)!E3D8Y'I7EF@^&_B
M=X8TX:;:Z_X::TCSY,5PLK>2I.0JG&=H[9)KT_4A=-I5X+$@79@<0$]GVG;^
MN*\8\'^ _AUK'ARWNO$$BSZZ<C4?MFH/',D^3N5EWC&#ZCGK0!IZ9X2^)MEK
M6H:O%K_ARXO[X(LLLL<C%47[J* H"J,GCOWS7J>EK?II=JNJ20R7XC G> $(
MSXY*@\XKG?!WA/P;X<N+J3PND"RS*JS^5>--P"<9!8X[UUM !7G/Q-T[4[75
M/#OC#2+&6_FT2=_M%K",O)!( &*CN0 ?^^L]J]&K'\2>*-'\):6=1UF\6V@W
M;%X+,[>BJ.2: /,M8UR?XLZMH>BZ3HVIV^E6MZE[J-W>P>4JA,XC')R3D_CC
MMDUZ;K7A70O$4L4NKZ;#=O$I6,R9^4'KT-8&@?%CPMXAU:/2X)[FUO)O]3'>
M0&+S?]T],^W>NWH \I^#5O#;W7BV"*-5BBU(HBCHJ@L *]-O;&"_L9[.=/W4
M\;1OC@X(QQ7F_P (/^0EXR_["C?S>O4:-QIN+NMT>76_P@ O&^U:J6M1G:(H
M\.?3.<@?K4Y\">)M%^;0/$!>,<B&;*C\CE3^E>E45G[)=+_>ST'FN(EI/E:[
M.,;>;VW?5W/,SXM\8:%QK?A];B)>LT2X_-EROZ"M73OB=X=O,+<B:R<]?-CW
M+^:Y_4"NWK)U+POHFK9-[IMO(YZR!=K_ /?0P:=IK9W]?^!_D+VV#J?Q*;B^
M\7I_X#*_X,M66H:=J2;[*ZMKA?\ IDX;'UQTJWL7^Z/RKSV^^%%EO\[2M1N;
M.4<J'^<#Z$8(_6J9L?B-X>_X][H:G O8L)#CZ-AORHY[?$FOQ_+_ "%]3IU/
MX%5/R?NO\;K\3T[8O]T?E1L7^Z/RKS6#XIW5E*(-=T.6"0=3'E3_ -\-_C73
M:=X]\.:E@)J*02'^"X'EX_$\?K5Q:E\+O_7W_@85L)7H*]6#2[]/O5U^)TFQ
M?[H_*C8O]T?E21R1S1B2)U=#T93D'\:=0<XFQ?[H_*C8O]T?E2T4 )L7^Z/R
MHV+_ '1^5+10 FQ?[H_*C8O]T?E2T4 )L7^Z/RHV+_='Y4M% ";%_NC\J-B_
MW1^5+10 FQ?[H_*C8O\ ='Y4M% ";%_NC\J-B_W1^5+10 FQ?[H_*C8O]T?E
M2T4 )L7^Z/RHV+_='Y4M% ";%_NC\J-B_P!T?E2T4 )L7^Z/RHV+_='Y4M%
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MR?S4_P Z/[5^(-C_ ,?&BV=X@_BA< G_ ,>_I1]7O\,T_G;\P^L6^*+7RO\
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MI0%B7V554?7/7K7M] 'EWP@_Y"7C+_L*-_-Z]1KR[X0?\A+QE_V%&_F]>HT
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MN%'W82TJ 1K[*H _ T >VUY=\&/]1XF_["C_ ,J]1KR[X,?ZCQ-_V%'_ )4
M>HT444 %%%% !1110 4444 %%%% !1110 5P?CGP;/KDPO;>2SMX[>)G;]U\
M\AZG) Y' P/K7>4UT62-D=0RL""#W%1."FK,Z<)BJF%JJK3W/(/#'AC7-?1?
M$,&N?9)I7*.Z JY"X'\. >@XKK]OCK2/NO8ZU".S#R9<?H/YUU5E8VNG6PM[
M.WC@A!)"1K@ GK5BLX45%;NYVXG-95JC;A%QZ)Q6BZ*ZL_Q./3X@6UJXCUS2
M[_2G/&Z2(O'^##D_E70Z?K>EZJN;"_M[COM1QN'U'45==$D0HZJRG@JPR#7/
M:AX$\.Z@V\V"V\O426Q\L@^N!Q^E7:HNM_P.?FP=3>+@_)\R^YV?XG1T5QO_
M  C/B32^=&\2R31CI!J"^8,>F[DC\ */^$F\2:7QK/AJ2:,=9]/;S!]=O)'X
MD4>TM\2L'U'G_@SC+RO9_=*WX,[*BN<T_P =^'=0;8+];>7H8[D>60?3)X_6
MNA1TD0.C*RGD,IR#51DI;,YJM"K1=JD6O5#J***HR"BBB@#G/&V@W?B+0196
M;1+*)EDS*Q P ?0'UK2U#0]/U>R6VU&UCG55P"1\R_0]16C16GM9)))[$>SB
MVV^IP+>&?$7A9C+X:OS=V8.3871S_P!\GI^6#]:T=(\?:?=S_8M4B?2K]3AH
MKCA2?9CT_''XUUM9VKZ#IFN0>5J%HDV!\K]'7Z,.16OMHSTJKYK?_)F7L90_
MA/Y/;_-&@"" 000>A%+7 G0/$WA0F3P_>'4+ <FQN3\P'^S_ /6Q]#6GHWCW
M3-0F^QWROIE^#M:"Y^49] Q_K@U,J#MS4WS+\?FAQKJ_+-<K_#Y,ZNBCK16!
MN%%%% !1110 4444 %%%% !1110 4444 %%%% $-S=VUE#YUW<1019QOE<*N
M?J:\AG@\(:S\7];?Q5=:?=PO:6_]D^?<J8=@!$JCG&[?S@\\DUZ-XQB\//X9
MN9?%$4,FE6^)I!+G&1TP!R3DX [DUQ_A3P7X \5Z&NJP^#/L<,CL(DNT9&=1
MT<#/0^U &O8^&?AM!?VTUC9Z"MVDJM 8I$W!P<KMYZYQ7;UY%HEI\/X/'YT.
MX\'G1]6M[@OITTZL$NMC95XVSUXR!^N>*]=H **** "BBB@ HHHH *\T\=>'
M/&>J^-=*U718](NK#38]\%MJ+N$%P2<R%5QD@;<9/'I7I=-DD2*-I)'5$499
MF. !ZDT >#"?XAGXUPO+:^'QK?\ 8^"BM+Y'V?S3D]<[\Y]L5Z=XO\$-XKN;
M:9=<O].\A"NVU; ?)SD\U;L'\)ZQXF;6-.O=.O=8BM_LS2VUV)&6+=G:55B!
MSWQ714 >2?!>R-M)XIMOM$K>1?\ E[R>7QN&3[\5ZKY!_P">\OYC_"O-/A!_
MR$O&7_84;^;UZC0!#Y!_Y[R_F/\ "CR#_P ]Y?S'^%344 0^0?\ GO+^8_PH
M\@_\]Y?S'^%344 0^0?^>\OYC_"CR#_SWE_,?X5-10!#Y!_Y[R_F/\*/(/\
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M'!_#!]J*M*-6;E1?RZ_+N32J2I04:R^?3Y]CN?(/_/>7\Q_A1Y!_Y[R_F/\
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M=K?,<[NM>:ZGX0;PK\2O!\3:S?:A]IN2=URV3'AEZ=>N?TKW:-$CB1(P BJ
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M/\ZZG1=>TO7XMUAJ3M)C+0L0KK]5Q^HXK<ZURFM> =*U.3[5:;M.O@=RS6W
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M>QO^0?\ GO+^8_PH\@_\]Y?S'^%345@;D/D'_GO+^8_PH\@_\]Y?S'^%344
M0^0?^>\OYC_"CR#_ ,]Y?S'^%344 0^0?^>\OYC_  H\@_\ />7\Q_A4U% "
M*-J@9)QW/6BEHH **** /._C*B_\(C83W"%]/M]6M9;]<9!@#$-D>F2M>@02
MQ3P1RP.CPNH9'0@JRD<$$=J9>6=MJ%E-9WD*3VTZ%)(G&593U!KSC_A4$NGL
MT?AWQIKVD61)(M$F+HGLO(Q^I]Z )?BR]O)<^$+2+:=8?7+=[4+]]4!^=O\
M=^[G\/2O2:XSPO\ #;2O#>IMJ\UU>ZMK++M^WZA+YCJ#U"^GZGKS79T %%%%
M !1110 4444 %>5?%J]@OM<\.>%K^_\ L6CW;2W>IRF38##$NX*3Z$@CZXKU
M6O'_ (J:?IZ_$CP1JFMHC:,97MYVE'[M7^\F_/&"3WXPIH HZ=:_#7Q'XGT@
M^"-7AT;6;"X$B^7;2+]JC ^:/#;0V1WR3C/!KVZO)?C*FG&S\.#3Q!_;YU.#
M^S_)QYFW/.,<[<[?;.*ZWQ?H?BG5[FV?P_XA72XXT(E0INWG/!Z4 <W\(/\
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M/3%<E\0?^2I> _\ KN__ *$E0?"6UU*Z^$=W;Z?=/:>;=7 TR>0$^7'D8/\
MWUNKG]3T?Q)I/Q*\'KK^NKJDDER3"VS C 9<^F<Y'Y4 >\45#MN?^>L7_?H_
M_%4;;G_GK%_WZ/\ \50!-14.VY_YZQ?]^C_\51MN?^>L7_?H_P#Q5 $U%0[;
MG_GK%_WZ/_Q5&VY_YZQ?]^C_ /%4 345#MN?^>L7_?H__%4;;G_GK%_WZ/\
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MQ?\ ?H__ !5 $U%0[;G_ )ZQ?]^C_P#%4;;G_GK%_P!^C_\ %4 345#MN?\
MGK%_WZ/_ ,51MN?^>L7_ 'Z/_P 50!-14.VY_P">L7_?H_\ Q5&VY_YZQ?\
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MTV-DCGMG&:E^*MA=7O@Y);6S>]%C>P7DUH@R9XD?+*!WXYQ[589?#/Q7\&N
MK3V,I*J[1F.2"4=UR.&&>HX[<B@#6\0>);/PV-,^V1SO_:-_%80^4H.V23."
MV2/EX.<9/M6S7@.O:KKMCJ'A/P=XEBEFO;+Q%:36FI@?)>6X)4$G^^-R@C\_
M4^_4 %%%% !1110 4444 %4=7T;3M?TV73M5LXKNTE^]'(./8@]0?<<U>KS;
MXOZG?VMEH6G0:C+I=AJ>H+;7VH1':88SVW?PYYY_V?3- &UX=^&'A'PMJ/\
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M^@V[ZF0=^I3WGF&4YSE0>03TYQBNIEMM8TK7+O4;#3TOHK^*+S8?/6-XI$7
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M.[)Y_P!GTS7/R:='X ^('A>U\,Z_?7T>JW'DWNG7%R)P8N,RX'W<#)S[>F:
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M9MO.3P/RYS7H= 'DGP7%\9/%/VAHEN?M_P"_PN1O^;=CD<9S7JNVY_YZQ?\
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M!/&EP-(UEA)875WI\:2)-;DF*56..F<@CN,T+#S:NOZZ \1!.S_KJ=CMN?\
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M_:3]G-L,C&Y=V?TKV;0-!T_PUHMMI.EP^3:6ZX49R23R23W)/-<!\0?^2I>
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M)_$DU8\R;_GA_P"/BCS)O^>'_CXJ95)25F5&G&+NB:BH?,F_YX?^/BCS)O\
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M<$HED%O<%Y)B.BY &%]:LZ?HLL::[#=[?*U"YD==AR=C(%_/@UK^9-_SP_\
M'Q1YDW_/#_Q\4W5=K+3^KDJDKW>O]6.+M?#>J06L.F_V/H9\HA#J+1JQ9!W\
MLK]['J>M='8:;/;>(]6OG">1=) L6#S\BL#D=NHK1\R;_GA_X^*/,F_YX?\
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M)!!)P!SSTZ8KH_,F_P">'_CXH\R;_GA_X^*GVS2LDO\ AQ^Q3=VW_P ,<T-
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MN(-KWNLSQEK73X06>3KACC[J\'GV.,XH N^!?#DOA+P9IVA3W"7$EJ'#2H"
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MT?\ 3&7_ +YJ:B@"'[1_TQE_[YH^T?\ 3&7_ +YJ:B@"'[1_TQE_[YH^T?\
M3&7_ +YJ:B@"'[1_TQE_[YH^T?\ 3&7_ +YJ:B@"'[1_TQE_[YH^T?\ 3&7_
M +YJ:B@"'[1_TQE_[YH^T?\ 3&7_ +YJ:B@"'[1_TQE_[YH^T?\ 3&7_ +YJ
M:B@#@_''@&V\;ZGHUY///;#3Y"98Q!N^TQEE;83N&.5Z\]>E=)XATZ+Q#X=U
M#1YXY4CO('A+[,["1PV,\X.#^%;%% '+>#/#,/A'PI%H>9;W#2/-.\(7SF=B
M22N3V('4]*Y6+X;:YHZSV/ACQEJ6E:-,[,+)K-)C#NZB-RP*CZ<^Y/->IT4
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M_IC+_P!\T?:/^F,O_?-344 0_:/^F,O_ 'S1]H_Z8R_]\U-10!#]H_Z8R_\
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M)]H_Z8R_]\U-10!YG+\.]6TW4KZ;PEXIOM#L[^4S3V?V))T5SU9-Q&W/M^?
MKIO!_ABR\':2]G:B[N)IY3/=74_,D\IZLQ_I_7)KIJ* (?M'_3&7_OFC[1_T
MQE_[YJ:B@"'[1_TQE_[YH^T?],9?^^:FHH A^T?],9?^^:/M'_3&7_OFIJ*
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MBTCQA>/XETBS_MZVU>&_=XYEAL'B2%A&6!23HPRN,')QS0!W/]DQ?\_FJ_\
M@TN?_CE']DQ?\_FJ_P#@TN?_ (Y7+Z/J'BO7=/MO$%G=6(M+B7='IKP8S!OV
MY,N<[]HSTQVQ6)=>/=2N)M2NK.^\@6D\D5M8?V3/.+@1DCYY5&%+$'&.G&:
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MO\L$<;&/YGY.]EZ^U9>K:7>0:5X@U:73/[*M;^\T\0V192P*3(&D8(2H+9'
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MYL#M6/?>)/$\>E>(-<AO+-+71[^:%+5K;)N$1P#N?/R\' P.WO0!W7]DQ?\
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M[@OJ:6WB&\MK/4[AYKNW2-#G?P0C$93(X)KJ[:VAL[2&UMT"00QK'&@Z*H&
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M.L7D[ZL\$D\[A0X:(@Y7   .  ,< 5U7_"N?#W_45_\ !O=?_'*/^%<^'O\
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M4MMS[YQG\:P/%'@J^U_P_I.CVVM1VEO9;#.LEIYR76P *&7>ORY&2IR#QZ4
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MK\>_]#Y<_P#@7<?XT?\ "J_'O_0^7/\ X%W'^->ST4 >,?\ "J_'O_0^7/\
MX%W'^-'_  JOQ[_T/ES_ .!=Q_C7L]% 'C'_  JOQ[_T/ES_ .!=Q_C1_P *
MK\>_]#Y<_P#@7<?XU[/10!XQ_P *K\>_]#Y<_P#@7<?XT?\ "J_'O_0^7/\
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M\GKTN@ HHHH **** "BBB@ HHHH *Q?%NH:II?A:_N]%L7OM22/%O J[B6)
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M  . !_>YH ]]HHHH **** "BBB@ HHHH *YSQ7X?UC75M!I/B:YT0PE_,,$
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M&6.)6/11P2>_OC-=E\/KW2?&?PAD\-3?:+=+:P6WN9IH]B*6W89&/!P5S^5
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M"0B#VZD>Q'I0!<\667C+Q!XIM]'TJ]FT30DM_.N-2A"F263./+7G([<\=^N
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MPDWBLZ(5O!;?V9J45^<Q[_,V9^7J,9SUYKIZ* "BBB@ HHHH **** "BBB@
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M_AQM%NK[/V*=+A9H9F')3(Z-^/ITR,Y.CZG9:-\8/B+J.HW"6]I!;V3R2N>
M/*7\S[=ZR)_#GAJU\9^'+2Z\>>(M:U'[8D]I;&[%TJ,A#9?KL!QU] ?2LW7?
M S^.?BMX[M8[^6VEMH+66"-3\DDWDKLW^PP1_P "S]0#TK2O'LMWX5U+Q3J.
MC2Z=HUNC2VK22[IKF,=&\O: N>,?,<Y].3SQ^)GC&WTV+7KOP!(N@R!9!)%>
MJ\PC;&&V 9[CC ^HJUI/C;3O$/PPU9O$UE*9]-B:TUFQB3YU(^4L%R, \GVP
M?2N)GTYO"GA=O$?@OXF.NGQP^=%IM]*L@/&?+"YP&[8VYSW% 'J'Q L/[?\
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M/,XO9IR!U"*J%OT!_*O3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR%6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>image_043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_043.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" HH# 2(  A$! Q$!_\0
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MB\U8N6#;BG.=NWG!(-4[?XFZ?=:$^L1:+K9M$ )<VZ*N=[*WSE]@"["68L%
M(YSD  [:BN&7XEV,]_I'D6=S_9M[I<NJ3W<@5?L\28SD;LG'.[;GMC=DD//Q
M.TJ/3GNY]-U2$QSVT4MNT<;2HEP,Q2D*Y!4],*2V0?EH [:BO/IOB+:V&L:A
M<:E_:5C:6UA"_P#9]U:Q1GS'E= P??G+'"X;"@+NS@YK5TOXA:5K5[IUMI]M
M=SF^A,P=/**Q*'9#N^?+89""4# 94DX8$@'645S>N^-=/\/:YI^EWUK>YOI(
MXH[A8U\H.[;57)8%CGJ%#8!!.,BJFF?$33-3UYM'%AJ4$ZSW-MOEB0HTD !D
M4;'8GA@1QS]>* .OHKS'6?B1_:7AZ\GT,WVFW^GZA9PW,5U#$6"RN 589< X
M+ CAE*X('2M^/XA6;V6H73:1JL8TZ2XCNXW6'?"84#DD"0_*V0%(XYR<+\U
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MM(O=(N;?4M2;^RGN7MXY&B*GSSF0-^[R1GISD>M=A10 4444 %%%% !1110
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M+&T"E71/NJPQ@J,G / JD?!WA<Q/$?#>CF-RI9/L,6&V@A<C;S@$@>F:P?\
MA*O''_1/&_\ !Q%_\31_PE7CC_HGC?\ @XB_^)H Z6;PUH-RERD^B:;*MU()
M;@/:(PF<9PSY'S'D\GGFK%YI.G:C'#'?:?:W20.)(EGA5Q&PZ,H(X(]17)?\
M)5XX_P"B>-_X.(O_ (FC_A*O''_1/&_\'$7_ ,30!T$/A'PU;L&@\/:3$51H
MP4LHUPC AEX7H02".^33AX4\.K:S6JZ!I0MY]GFPBSCV2;/N;AC!V]L].U<[
M_P )5XX_Z)XW_@XB_P#B:/\ A*O''_1/&_\ !Q%_\30!TTWAO0KC[5Y^BZ=+
M]K*FYWVJ-YQ7[N_(^;';/2I;?1M*M+]K^VTVSAO&B$+7$<"K(8Q@!2P&=HVK
MQTX'I7*?\)5XX_Z)XW_@XB_^)H_X2KQQ_P!$\;_P<1?_ !- '7?V5IPU,ZF+
M"U_M IY9NO)7S=O]W?C./;-4Y?"GAR>*6*70-*DCFF\^5'LXR'EY&]ACEOF;
MD\\GUKG?^$J\<?\ 1/&_\'$7_P 31_PE7CC_ *)XW_@XB_\ B: .F?P[H<LU
MS-)HVG/+<Q"&=VM4+2Q@ !&./F7"KP>.!Z4Z70-&GM+6UETFPDMK0AK:%[9"
MD)'0H,84CVKE_P#A*O''_1/&_P#!Q%_\31_PE7CC_HGC?^#B+_XF@#HQX7\/
MB^^W#0M,%WYQN//^R1^9YI.2^[&=V><]:=_PC>A?9;JU_L73OL]XXDN8OLJ;
M)V!R&<8PQSSD]ZYK_A*O''_1/&_\'$7_ ,31_P )5XX_Z)XW_@XB_P#B: .L
MN=&TN]TY-.NM-LY[% H2VE@5HE"_= 4C QVXXHETC3+BZM;J;3K22XM!BWE>
M!2\/^X2,K^%<G_PE7CC_ *)XW_@XB_\ B:/^$J\<?]$\;_P<1?\ Q- %/P]\
M(](T?5;B\NX["]2>-HY8_LC@3@LK?O5>5XS@JI 5$ (R , 5VB^']%2X%PND
M:>LP@^S"06R!A%C'EYQG;CC;TQ7+_P#"5>./^B>-_P"#B+_XFC_A*O''_1/&
M_P#!Q%_\30!TUAX;T+2KA;C3M%TZSF5#&)+>U2-@I.2N5 .,\XK3KAO^$J\<
M?]$\;_P<1?\ Q-'_  E7CC_HGC?^#B+_ .)H [FBN1\,>,-0UKQ!J.C:IH!T
MF[LH8YBINUGW!R<=% '2NNH **** "BL_6-3.EV:2I#Y\TLT<$,1?:&=V &6
MP<#G).#P.E41XE":!?:C<6I2>RD>&6W23<#(#@!6(&0<K@D#KTH WJ*Y"^\:
MR:;FWNK&VBOUNA Z-=GR@IB,@??Y>2,#&-O7\ZL'Q:XE#+90RV<36Z7-Q'<[
M@C38V[!M^=1N7)RO!X!H Z>BN1UWXF^$_#UQ=6M]J?\ IEL0)+:.-F?)QP.,
M=#GK5(?%72B 1HGB,@\@C2WH [NBN%_X6II7_0$\2?\ @K>C_A:FE?\ 0$\2
M?^"MZ .ZJ*>V@N51;B&.4(ZR*)$#;74Y5AGH0>0>U<5_PM32O^@)XD_\%;T?
M\+4TK_H">)/_  5O0!U,^@:-=0107&DV$T,,K31QR6R,J2$EBX!& Q)))ZY)
MJ&#PIX=MGB>WT#2XGA5EB:.SC4H&SN"X' .3G'7)KG/^%J:5_P! 3Q)_X*WH
M_P"%J:5_T!/$G_@K>@#IX?#FA6YLS#HNG1FRW?92EJ@\C<<G9@?+DDDXQUI;
M_P .Z)JEP;C4-&T^[F,?E&2XM4D8IG.W)!.,\XKE_P#A:FE?] 3Q)_X*WH_X
M6II7_0$\2?\ @K>@#HU\*^'421%T#2PLCI(X%G'AF3.QCQR1DX/;)J2+PYH<
M M!#HVG1BS#BVV6J#R-V=VS ^7.3G'7-<Q_PM32O^@)XD_\ !6]'_"U-*_Z
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M%;T =U17"_\ "U-*_P"@)XD_\%;T?\+4TK_H">)/_!6] '=45PO_  M32O\
MH">)/_!6]'_"U-*_Z GB3_P5O0!W5%<%)\6-'AB>671_$21H"S.VF. H'4D]
MJ[/3;^'5=+M-1MMWD7<*3Q[A@[64,,CUP: +5%%% !1110 4444 %%88\7Z$
M=9?21?K]L258678VWS&SA=V,9X(QGKQUK<H **** "N+^+7_ "2_6_\ <C_]
M&I7:5Q?Q:_Y)?K?^Y'_Z-2@#J'N?L>DBX$$T_EQ ^5"NYVX' '<UA7/C9+2V
M>>?0-;CC09+/:@ >G.[UKI+;_CUA_P!Q?Y5%?Z=::I:FUO8%F@)#%&S@D<CI
M4R4NC-Z,Z47^]C=>K1S%AXKU"T9]/U;2+ZXU% )3]BA#KY;\KW'(Y7_@-;VE
M:P=4:4'3=0L_+ YNX=F[/IR<T:?X?TG3+DW-E9I#,5V%U8DE<].3ZUITHJ2W
M9=>K0DW[.%OF_P M5^)Q?C?4KRTU?0[6WN]0@AN?/\T:?$))6VJI7 (/>J.F
MZWKUK<Z.NK22J'@OI7CG"1-(B;3&9.RG!/I[UVMU864M]::C<J!-9[_)D+D!
M-XPWMT]:COM%TW5Y(Y[N$3E89(5.XX*2 !AP><@"H=.5W),Z*>+HJG&E*'1W
M>E[Z[??WZ'+6_P 0WD@NQ)IL9N8VMU@6&<LDIF)"C<5&,$<D CTS5G4O&5]I
M2VMO=Z5#'J$[R@(;K,6Q #N#*I/.0 "H/K6BG@O0UMYX6MY9!/&D<C2W#NQ"
M'*8).05[$4'P9HOV5(1#.K)(THG6X<3%F&&)?.XY& >>U+EJVW+=7 <UU!V_
MX'KM?IU[HYYO&.J'5+B]M+%IK)-(CO9+6>41&+YFWX^4Y; ]AQ5Z?QXP6XO+
M;3#-I=GY/VJ=I@KKY@4C:F.<!AGD>U:=UX*T*\93+:R#; MMA)W7,2]$.#R.
M><]:DN?"&B7=\+N6S.[Y-T:R,L<FS[FY =K8P,9%'+5[C=? .UX/^OGJ^SZ=
M4S3M9KJ62X%Q;+%&LF(6$F[S$P/F(Q\O.1CVJS5:VL8+26YDB#[KB3S9-SEO
MFP!QGH.!P*LULO,\N;3?NA12;EW;=PW8SC/.*6F2%%%% '-Z]XFNM*U,6%II
MJW<GV*2\):?RP%0X(Z'FL>]^(PMV@,5O8!)K>*=1<7_EN ZAL%=A]?6NMN=&
MLKN^-Y-$6G-L]J6W$?NV.2,?AUJ6TT^UL;*"T@B40P1K'&&Y(4# &363C4;=
MF=\*V%C"/-3N^O\ 5_0YR35M5B\<VD-U/!%I4MG-,D<?)(79\SDCW. .U4?"
M_BZ77O&5Y']LA^P26HDL[=74L '();ON(&<=@176S:=8SZK!>R*&NX8GC3YN
MB-C=\O?H*CM]$TNUU=M0M[6&*[:$1$H ,)DGH/<]:.2=]]+C6(P[IM.'O<MN
MF]_^&UW-*BBBM3SPHHHH YC7_%%WI.I365IIB730V#7TC//Y8"*Q!'W3D\<5
MEW_Q#:VNXXXH-/\ +DBBE7S[THX#H&P5"'U]:ZNZT6PO+J:YGA+2S6K6;G<1
MF(G)'Y]^M6;>T@M;:&WBC BA18T!YPH&!S]!63C-MV9WPK86,5>G=]?ZOW.6
MFU76+;QO)#<2P_8?[.FN(+>+)SM9<,Q/<Y/ X%5/!VL:I<:K:0WU\]VFH:6-
M0(9%'DOOP57 'RX(ZYZ5USZ?92ZNE\RAKR.!H0=W2-B"1CZ@54T?PWI&B7,T
MNGP%)'4(=TC/L3)(502=JY).!2Y)\U[Z%?6J#HN/+K9+9;J__#WZFQ1116QY
MQPNC_P#)9O$__8.L_P#V>NZKA='_ .2S>)_^P=9_^SUW5 !17 7GQ(:T\73:
M.;.V,<=PELJM<XN'8M&I81XZ8DR.>0K'C%=_0!0U?3!JMDL(F,,L<J3PRA=V
MQT8,"1W'&"/0FLW_ (1@OI-S837[,+MI9;B18@I:5B"KKR=H7' Y[9KH:* .
M>C\/:A#)+=Q:SMU":7S)I?LP,;@($"[-V1@#(.[J3U'%5;?P1%9I%;6]](MC
MF![B%HP6E>(@J=W\.2JY&.W&*ZNB@#B/BQ!#_P *SUV3RD\SRD^;:,_?7O73
M27IT_18K@6MQ<[8T'E6Z;W.<=!7._%C_ ))?KO\ UQ3_ -&+7667_'C;_P#7
M-?Y4#BTG=JYS=YXU-M;EO[ UA)'(CB\ZW"JTAX4$[NYQ4=AXLO+='T_4=(U&
MZU*T(2XDLX \;$\JPY'48-='J.E6.K0I#?VZSQHV]58GAO7CZU%INAZ9I,DD
MMA:)"\H =E).X#IU-9\L[[G:JV%]G9T]?5_GOM?2V]A=*U0ZI%(YL+VSV-C;
M=Q;"WN.3Q7&^*M4U./Q?+86EYJR1KIRS11:= LI,I=AE@5.!P/2O0JHM8V,&
MJMJSA4NGA%N9&? * E@,=.I-$X2DDDR,/B*=*HYN.EG9;ZZ=UZ]#C[;Q'K&G
MW-RVJF,S0:5;2O;R2+$@F=V5B6[=N!GT JS:>.[B^AA@MM,C;4I;V2T6,SE8
MOD0.7W%,XP1QMS6_J'AO2M4EN)KJ!FDN(XT=UD93A&+(1@\$$YR*K'P;HIMF
MA\F8%I_M/FBXD\P2D;2P?.X$@<\\U')46S.KV^"FKSAKILM.OGM?YZ;F1J7C
MV?3KB.VDTC_24MEN+F'S\LH+$;4VJ0[<$\X'XU!'XMU&QU+6)I[?[3I<.H10
M^890KPK(J !4QS@MDY(ZUNOX+T)X[>-;5XEAC\H"*9TWIG=M?!^89YYSUI\O
MA#19M2:_DMG,SS+.X\Y]CNN-I9,X.,<<4.-7N.-? I6Y'MK]_KI^G6YGV_C.
M6:]MW;3=NEW-ZUC#<^=ES("1DICA25(ZY]JZ6QENIK57O+9;><E@8UDW@#)P
M<^XP?QK-A\*:/!JO]HQVK"82-,JF5C&LC=7"9VACZXK2L;&#3K5;:W#B-2S#
M>Y8Y))/)YZFK@IKXCDQ$\/)+V*M_7K]_?I8L444@92Q4,"PZC/2M#D%HHHH
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M^XO\JEJ*V_X]8?\ <7^52T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUW_KBG_HQ:ZRR_X\;?\ ZYK_ "KD_BQ_R2_7?^N*?^C%KK++_CQM_P#KFO\
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M*([VVFN7MXYE:9,[D'458HKE.HX'0IHYOC)XH:-PP&GVBDCL07R*[ZN%T?\
MY+-XG_[!UG_[/7=4 <!=_$;['XMGTC[%;>6EREN%-R!<2,S1J6$>.F) 1SR%
M8\8KOZ\CU^'79/&%T\,FMQ7@O$6V-OIL4D2VN!N83%#@CYC@G.>,<YKTGPY-
MJ%QX;TZ;54*7[VZ-.K+M(;'.1V/J.U &G1110 4444 <9\6/^27Z[_UQ3_T8
MM=99?\>-O_US7^5<G\6/^27Z[_UQ3_T8M=99?\>-O_US7^5 $]%%% !1110
M4444 %%%% !1110 4444 %%%% !114%[=QV%C<7<H8QP1M(^T9. ,G% TFW9
M$]%0VMREY9P74>1'-&LB[AS@C(S4U --.S"BJ&K:U8:);">^G"!CA$ W/(WH
MJCDFL/[%K'BGYM2\S2])/2SC;$\P_P"FC#[H_P!D?B:ERMHMS:G0<ESS=H]_
M\EU_J[1/>>)9;RZ?3O#D"WUTIVRW#'%O;_[S?Q'_ &14^E>&8K2Z_M'4)VU'
M5".;F8<1^T:]%'TYK6L[*VT^U2ULX(X($&%2-< 5/24>LBI5U%<E)67XOU?;
MR6GJ%<UXL_X^_#O_ &%8_P#T!ZZ6LG6M*EU.?2WBD119WBW#[L_,H5A@>_-.
M:NM"<-)1JIRVU_)FM1115& 4444 8?C/_D2-=_Z\)_\ T TG@G_D0O#O_8+M
MO_12TOC/_D2-=_Z\)_\ T TG@G_D0O#O_8+MO_12T ;M%%% !1110 4444 >
M01_V9J/Q&NS>MHD%TU\]J;9M)D>6:/[O^NSMW,O?''2O7(HHX8DBB14C10JH
MHP% X  KRF<ZK%\0X4D\0F0R:GS:#641(X@X*@P9!.4.W:.=RY/!KUF@ HHH
MH *XOXM?\DOUO_<C_P#1J5VE<7\6O^27ZW_N1_\ HU* .OMO^/6'_<7^52U%
M;?\ 'K#_ +B_RJ6@ HHHH **** "BBB@ HHHH **** "BJ.IZSIVCP>=J%W%
M I^Z&/S-[ =3^%8O]KZ]K?&C:?\ 8;4_\ONH+AB/5(AR?QQ4N26AM##SFN;9
M=WHO^#\KG0W=[:V%NUQ=W$4$*]7D8*!^=<^?$U[JQV>'-,>X0\?;KK,4 ]Q_
M$_X"IK3PA9+<+>:I--JUZ.1+=G*H?]E/NK^5="    , =J7O/R+O0I[+F?GH
MONW?S:]#F5\(_P!H,)O$=_+J;]1 /W=NGT0=?J2:R9_#VB6_C,6K6*"Q32WG
M:(%MN1(!G&?3BN\KD/$#&Q\076J3HZV::-)$9<?+O,@POU/I1[--I)=4:T\9
M5M-N5DHOR739*R_4Z+1VLFT>T;3DV631!H5P1A3R.#TJ[7$>'?%NGP>%]+M;
M=)[R_6!8_LMNFYP5X.>RCCJ36E_9^O:WSJ=W_9EH?^72S;,C#T:3M_P'\ZZI
M4.634M%_70\N-?G2:U;_ *U9=U+Q+I^G3_90SW=\?NVMJOF2'Z@=/QQ5+[)X
M@USF]N/[(LS_ ,N]LP:=A_M2=%_X#6QIND6&D0>58VL<*G[Q ^9CZDGD_C5V
MIYXQ^!?-_P"6WYCY)2^-_)?U?\BAIFBZ?H\12QMDC+??DZNY]68\FK]%%9N3
MD[LT45%604444AA@9SCFBBB@ HHHH X71_\ DLWB?_L'6?\ [/7=5PNC_P#)
M9O$__8.L_P#V>NZH \BO38VWQ'N%ODTFZN9-0B:%YM;=)X@=@51"!C@\A>^>
M:]=KRJ[TI;_QE.VFZ=K311ZH#=W,8@$>[,3LH+$.%!16R.>6 X->JT %%%%
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MM+XS_P"1(UW_ *\)_P#T TG@G_D0O#O_ &"[;_T4M &[1110 4444 %97B>
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M_#K^.B_,Z6X\:Z'%*8;>X>_G''E649F/YKQ^M1?VMXEO_P#CPT%+.,])=1F
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M0 4444 8?C/_ )$C7?\ KPG_ /0#2>"?^1"\._\ 8+MO_12TOC/_ )$C7?\
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M_P 10!TU%<S_ ,+!\,_]!"3_ ,!)O_B*/^%@^&?^@A)_X"3?_$4 =-17,_\
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MKN/1&M;DP+,([B4M&D:!/D!7&2!GGO7>455OIKR&-396B7+DX97F\O ]<X-
M%DL 0"0">F>]!8*,L0.W->=^)S+/=WS:I9"*[?30FE(C&7%QO;E&P,/GRO?
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MEP36VD65O<-NGB@1)&SG+!0"<_6@!O\ 9&G_ //I%^5']DZ?_P ^D7Y5=HH
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MF>"X8 K,(CA]H!+#U&1R.E5])T'4[":*>:YM));:UCLH-J, 8E8%F;G[Q '
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MC44 ><_V+\5_^AKT3_P"_P#K4?V+\5_^AKT3_P  O_K5Z-10!YS_ &+\5_\
MH:]$_P# +_ZU']B_%?\ Z&O1/_ +_P"M7HU% 'G/]B_%?_H:]$_\ O\ ZU']
MB_%?_H:]$_\  +_ZU>C44 ><_P!B_%?_ *&O1/\ P"_^M1_8OQ7_ .AKT3_P
M"_\ K5Z-10!YS_8OQ7_Z&O1/_ +_ .M1_8OQ7_Z&O1/_  "_^M7HU% 'G/\
M8OQ7_P"AKT3_ , O_K4?V+\5_P#H:]$_\ O_ *U>C44 ><_V+\5_^AKT3_P"
M_P#K56U&Q^*VG:9=7K>)]'D6WA>4HEC\S!03@<=>*]/K(U[Q!;Z##;M)$\TM
MQ,D211]<%E4L?11N&3[@=Z .#TBW^*NL:-9ZE'XFTB%+J%9A')8_,H89P>.M
M68?#_P 4[>)8H?$^A1QKT5;# 'X;:ZTZY>IXEATA]*^24.XG6Y#;8U_C9<9
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M.O?^#.3_ !KO** .#_X5+H7_ $$=>_\ !G)_C1_PJ70O^@CKW_@SD_QKO**
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MCCN8UTU?+N0!(GF/M W[\*,X4;N<+@9I;KP7X?O/,\W3_P#62R2OY<SIN:0
M/]UAPV!D=#Z5OT4 9&F:##IFJWU\C*3<)##%&J;5AAC7"H.>>2QSQUZ<5KT4
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>image_044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_044.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $F 5(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(Q*Y"$#(^[R3QA^D>$Y[+Q(-;U#48;R[CLC91RQV@ADD0LI+3-N/F-\BXP%
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MVCTHVCTH H_VC<_] >^_[ZA_^.4?VC<_] >^_P"^H?\ XY5[ ]*-H]* */\
M:-S_ - >^_[ZA_\ CE']HW/_ $![[_OJ'_XY5[ ]*-H]* */]HW/_0'OO^^H
M?_CE']HW/_0'OO\ OJ'_ ..5>PN<<9]* %(R.0: */\ :-S_ - >^_[ZA_\
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M_H#WW_?4/_QRKV !S32\0;:77=Z9YH I_P!HW/\ T![[_OJ'_P".4?VC<_\
M0'OO^^H?_CE7L#THP/2@"C_:-S_T![[_ +ZA_P#CE']HW/\ T![[_OJ'_P".
M5>VCTHP/2@"C_:-S_P! >^_[ZA_^.4?VC<_] >^_[ZA_^.5>VCTHP/2@"G;:
MB9[MK:2TN+>41B0"7801G'&UC5VLT#'B0_\ 7G_[/6E0 4444 %%%% !1110
M 45#<W5O90-/=3Q00K]Z25PJCZDTVSO[/48?.LKN"YBSC?#('&?J* +%%%%
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M\^69I&P/F9Y55B<8'?@#F@"UJWB"2PU.#3+2Q-W>2PM/M:98E5 0,[FZG)Z
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M_KT?VM_U#[__ +\?_7K1HH SO[6_ZA]__P!^/_KT?VM_U#[_ /[\?_7K1HH
MSO[6_P"H??\ _?C_ .O1_:W_ %#[_P#[\?\ UZT:* ,[^UO^H??_ /?C_P"O
M1_:W_4/O_P#OQ_\ 7K1HH SO[6_ZA]__ -^/_KT?VM_U#[__ +\?_7K1HH \
M#MM"U&6UAD7Q'XEC5T#!(XUVJ".@]A67K7@^_6UGOK&\UJ^U0%70301*68'
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M)KE=Q:*,CUHR/6MSD"BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH
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MB12@\;7"$'KC!'(]QQ6EX:T>31O#5EIUQ-++/'"JS.T[R?/M ;:S<@9Z=,4
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M4?8+W_H,7/\ WZB_^(K0HH S_L%[_P!!BY_[]1?_ !%'V"]_Z#%S_P!^HO\
MXBM"B@#/^P7O_08N?^_47_Q%'V"]_P"@Q<_]^HO_ (BM"B@#/^P7O_08N?\
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M8X&2!FM.VL+:SFNIH(]DEU)YLQR3N;:%S[<*!QZ59HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>image_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_025.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" )%!1,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I&;:,FEILV[82.PH 4,#2[AZU\:_$3_@KUX$^'7CS5_
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M2?\ #Z[X=_\ 1&=6_P# Z.CED!]Q;AZT;AZU\._\/KOAW_T1G5O_  .CI?\
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MW_#Z[X=_]$8U?_P.CH_X?6_#S_HC&K_^!T='+(#[AW#UHW#UKX>_X?7?#O\
MZ(QJ_P#X'1T?\/KOAW_T1C5__ Z.CED!]P[AZT;AZU\/?\/KOAW_ -$8U?\
M\#HZ/^'UWP[_ .B,:O\ ^!T='+(#[AW#UHW#UKX>_P"'UOP\_P"B,:O_ .!T
M='_#ZWX>?]$8U?\ \#HZ.60'W#N'K1N'K7P]_P /K?AY_P!$8U?_ ,#HZ/\
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M5_\ P.CH_P"'UOP\_P"B,:O_ .!T='+(#[AW#UHW#UKX>_X?6_#S_HC&K_\
M@='1_P /K?AY_P!$8U?_ ,#HZ.60'W#N'K1N'K7P]_P^M^'G_1&-7_\  Z.C
M_A];\//^B,:O_P"!T='+(#[AW#UHW#UKX>_X?6_#S_HC&K_^!T='_#ZWX>?]
M$8U?_P #HZ.60'W#N'K1N'K7P]_P^M^'G_1&-7_\#HZ/^'UOP\_Z(QJ__@='
M1RR ^X=P]:-P]:^'O^'UOP\_Z(QJ_P#X'1T?\/K?AY_T1C5__ Z.CED!]P[A
MZT;AZU\/?\/K?AY_T1C5_P#P.CH_X?6_#S_HC&K_ /@='1RR ^X=P]:-P]:^
M'O\ A];\//\ HC&K_P#@='1_P^M^'G_1&-7_ / Z.CED!]P[AZT;AZU\/?\
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MZ/\ A];\//\ HC&K_P#@='1RR ^X=P]:-P]:^'O^'UOP\_Z(QJ__ ('1T?\
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MZY%5:8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7%O?::L:QWZQ-MF:-=JS*R@['P>0>.O45,A>Z=S\&/BY^QY\%/@'K7P9C_:
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MMPB:_P#P59M;/6OV3?"?B[6X!'K4.HVK02?=D#/"?,7/H>N/49I_Q0N;H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A1S ?FE_P (OX@_Z -Y_P" [?X4-X7\0;?^0!>?^ [?X5^EO]F:;_T#H/\
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M/^_*_P"%']F:;_T#H/\ ORO^%',!^:7_  B_B#_H WG_ (#M_A1_PB_B#_H
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M5^EO]F:;_P! Z#_ORO\ A1_9FF_] Z#_ +\K_A1S ?FE_P (OX@_Z -Y_P"
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M(/\ H WG_@.W^%?I;_9FF_\ 0.@_[\K_ (4?V9IO_0.@_P"_*_X4<P'YI?\
M"+^(/^@#>?\ @.W^%'_"+^(/^@#>?^ [?X5^EO\ 9FF_] Z#_ORO^%']F:;_
M - Z#_ORO^%',!^:7_"+^(/^@#>?^ [?X4?\(OX@_P"@#>?^ [?X5^EO]F:;
M_P! Z#_ORO\ A1_9FF_] Z#_ +\K_A1S ?FE_P (OX@_Z -Y_P" [?X4?\(O
MX@_Z -Y_X#M_A7Z6_P!F:;_T#H/^_*_X4?V9IO\ T#H/^_*_X4<P'YI?\(OX
M@_Z -Y_X#M_A1_PB_B#_ * -Y_X#M_A7Z6_V9IO_ $#H/^_*_P"%']F:;_T#
MH/\ ORO^%',!^:7_  B_B#_H WG_ (#M_A1_PB_B#_H WG_@.W^%?I;_ &9I
MO_0.@_[\K_A1_9FF_P#0.@_[\K_A1S ?FE_PB_B#_H WG_@.W^%'_"+^(/\
MH WG_@.W^%?I;_9FF_\ 0.@_[\K_ (4?V9IO_0.@_P"_*_X4<P'YI?\ "+^(
M/^@#>?\ @.W^%'_"+^(/^@#>?^ [?X5^EO\ 9FF_] Z#_ORO^%']F:;_ - Z
M#_ORO^%',!^:7_"+^(/^@#>?^ [?X4?\(OX@_P"@#>?^ [?X5^EO]F:;_P!
MZ#_ORO\ A1_9FF_] Z#_ +\K_A1S ?FE_P (OX@_Z -Y_P" [?X4?\(OX@_Z
M -Y_X#M_A7Z6_P!F:;_T#H/^_*_X4?V9IO\ T#H/^_*_X4<P'YI?\(OX@_Z
M-Y_X#M_A1_PB_B#_ * -Y_X#M_A7Z6_V9IO_ $#H/^_*_P"%']F:;_T#H/\
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M^%?I;_9FF_\ 0.@_[\K_ (4?V9IO_0.@_P"_*_X4<P'YI?\ "+^(/^@#>?\
M@.W^%'_"+^(/^@#>?^ [?X5^EO\ 9FF_] Z#_ORO^%']F:;_ - Z#_ORO^%'
M,!^:7_"+^(/^@#>?^ [?X4?\(OX@_P"@#>?^ [?X5^EO]F:;_P! Z#_ORO\
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M%-?PQXB!^70;S_P';_"OTO\ [,TW_H'0?]^5_P *0Z9IV?\ D'P?]^1_A1S
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MBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%'J 444QFP>31J
M^BF!R.,T\'(S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112%P#@T +11D>M
M% !1110 4444 %%%% !1110 4444 %%%% !1110!]%_!K_DG>F?]>_\ 6NIK
MEO@U_P D[TS_ *]_ZUU-1+<T"BBBD 4444 %%%% !39?N4ZFR_<H ^8?''_(
MXZG_ -?C_P ZRZU/''_(XZG_ -?C_P ZRZT(EN%%%% @HHHH **** "BBB@
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M(VAN]<OHG[.36NIZ>-?\=:AJFF:1,LNFZ9<XVHR_=R?XL=LU>^/BXTW0^/\
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MU/\ Z_'_ )UEUH1+<****!!1110 4444 %%%% !1110 4444 %%%% !1110
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MN/G7VKHM2_95^'.HZA-=6USJEE;W$F^XL;2_9(9/7Y>V:Z>^^%/@N_\  O\
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MS6%DTOGFTC:1A@R,HW&GO:V\T1@E@5D(QL9<BIJ* (8+2UMX_(M[=57'W47
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M\1KY#B;,\7@9TU1E:^Y_3OT?^ .&.,L+BYYI1YW!JVK6Y]U?\/H+WM\%H?\
MP8M_A7G/[2/_  4JNOV@?"&G^%Y?AG'I_P!AURWU#S!>%]_EY^7IWS7RR=Q'
M)H^93FOD:V?YI7CR2GH_(_IG+_!?P_RW%1Q&'PUIQV=WVL?<UI_P6;OH+6.
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MU?\ #Z*^_P"B,0_^#%O\*/\ A]%??]$8A_\ !BW^%?"O[RC]Y1_K'FO\X?\
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MDHI<H'TW_P /&+O_ *)S'_X$FC_AXQ=_]$YC_P# DU\R44<H'TW_ ,/&+O\
MZ)S'_P"!)H_X>,7?_1.8_P#P)-?,E%'*!]-_\/&+O_HG,?\ X$FC_AXQ=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M],YITFAZY#I]OK$NB7:V=Y(T=G=-;L(YW4X94;&&()&0"<9H JT5N>)?A?\
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MA?X=&<DH\K#/M1GVHR/2C(]*\L09]J1B,XQ_.ER/2FR?,NT+0!W7@;XQZEX
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M0<-T% .1\W:O;O$VJ?"+Q/\ M$7'@3POX7L;+1+Z!M(^T6\8"BYR=LZ>G[S
MXZCZUXWJ^D7>@:U>:%J$'ESV5U);S)_=9&*D?GFKQ6#^KIN,N97M?S1GEN<+
M,)*,H.$G%22?9E7(Q3U(QP*"H/:@#' KA/:%HHHH **** "BBB@ I&&>M+2$
MXH GTB]?3]1CN 3U^85W$3B5%D4?>&1FN-\.Z8=2U-0?]6G+5V:C'&WVK\&\
M4*N#EFD(T_C2][]+G/4^(=^ _.C\!^=!*]A29]J_,#,7\!^=(3BC/M1P3R*
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M*JD]"OZTOX#\Z0&C/M7BGK"_@/SH_ ?G29]J,^U "_@/SH_ ?G29]J4%>XH
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M ^B_@U_R3O3/^O?^M=37+?!K_DG>F?\ 7O\ UKJ:B6YH%%%%( HHHH ****
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M+)Y;G9'D]L@?0"O0KWX(_$/6OAS\0K[7/%&AR7.LS6DL'D:DK1Q1Q2,=I/\
M#\O %>)?M&6]I?>.5\=Z2NZQ\264>H0L!_&RCS%/OO!R.U8OAKXA2>'OA[X@
M\!KIWF+KTELQFW_ZLQ.6Z=^M?1T\=A<+5J4JL;W;=T][K0_/ZV1YAF."P^)P
M]3X5"+C9.W*_>=_S.DTCX7?!FX\&?VUJ_P :X;?5EMF9M*^QEOW@S\N[/?BK
MOP)=O OPW\9?%Q!BZMK,:7I$AZI-,>77W"\_A7E6P@?=[>AKIU^(TL7PF?X7
M0Z>-LNK"]FN=_P!["[0/UKS*&,PZJJ2BHN*>W5]#Z+&93CZF%=)U744YQO>R
MM%/5*W3U,CPE<W-OXJTR[@D<S1ZA"Z-W+"0$?B:[/]J.SM+#]H'Q-!9(JHUY
M'(P7IN:&-F_'<363\#_#\&O?$[2_MT@2SL9A>WTK=$AA^<D_]\@?C6;\0/%<
MOCGQYJ_B^7/_ !,;^2=%;^%&8[5_ 8'X5GS<N6OFW<OR.B--RXBBX;0IM/U;
M5E^#,FBBBO-/H@HHHH **** "BBB@ ILF>*<2!UJ]X<TX:EJ*EAE(^6KS\SQ
M]'+<#/$5'I%7$W8Z#PKI0L+!6<?O)/F8XK4YZY:FQCY!A,>U+C_9-?RKF6.J
MYECIXFIJY.YRMW8O/JU'/JU)C_9-&/\ 9-<(A>?5J.?5J3'^R:,?[)H 7GU:
MKGAF))_%6EP3#*M?PA@WIYBU2Q_LFG0SR6=Q'=PDJ\4BNI]P<C]177@*D:.,
MIU)[)IOT3.?%TYU<+.$'9M-'J=UX:L_&_P"TS>:;KUW';VT%T7;SF"JRH/E3
M)XP>*[AOA1XUU;P[XRO]5U[2'DU&.(6ZPWP98D0G"^P Q7DGQP>WUG7K3QQ8
MC_1]8LHY/E_AD"A67/KD5C^&_&TWAWPOK/AI;$N-62-6DSR@4YK]1H\297E>
M88G#8NBVI.4N9.W,I1T3\K/0_/IY'C\=@\/6P]2W*HQY6MFFKZW\M?0W](^'
M7PMF\,F^UKXLPV>H*C;]/6W+8<9XW>]=E\2OBAJ7@?P7X/'A.TM1)/HZM)>2
M6XD9U!($8ST'4GZUX@$<\J*[CPO\5-$A\+6_A+Q]X1_M:WL)"^GR"8H\6?X/
M=>*\G(^),#3HU,/2C'#N44N?5W::>OJCT<VR/&2G3K3E*NHR;<796336FU[/
MN6?CC;VEOXBT?Q=I-FEI-JFGPW<L,*[0DOJ!VR>:C_:3MH+7XQZHL0QO6%W"
MC^(Q+FF6FLW?QB^+5A<7]M':V<4J'R5/[NVM8OF(_P"^0?Q-87Q&\4-XV\=:
MEXE^;;<W3&'_ *YCA?T K'/,9A:V5XBI3VJU8N+VORI\SMYMFF4X?$4LPH4Z
MF].G+F\N9KE3?DDS&S_M&EY]6IN-QY5J7'^R:_/S[07GU:CGU:DQ_LFC'^R:
M %Y]6HY]6I,?[)I".,;6H &YQDFN<^)_BZ+P=X5N-05AYSKY=NOJYZ5T,C #
M.['%>#?'+QB?$OBG^R[6;-M8_*N#U;N:_3/"KA&7%G%%.G)7I4WS3]%T^9\?
MQQGL<BR6<HOWYZ+U[G&2O).[33-N=VRS>IHCR!@B@ A<^U. Q7^@M*G&C35.
M*LDM#^493E.3E+5L****LD**** "BBB@ HHHH **** "BBB@ IDN0P(I]-DS
MGA: /:OBN%L/V-?AO;6(_<W6HZA/<XZ&4.%Y]\"MV[^*'P"^)7@#PC-^T)X:
M\46?B+PYHL-GI\FF6Z^3K5G&?W(+.1M[J6'7FN:TF]_X6+^R#>^$8FW7W@O6
MOMT<?\36LXVL?HK 9^M7O _[5W@1? OAWP]\7?@^GB6_\(Q&+P_J'VPQ[8@V
MY(Y5P=ZJ>@]*GJ4K'IW[6'AKX-?%O]HFUTSXH_$R'P/;Z=X%TSRU:T:?]ZR%
M_*XZ81@:^9?C#X7\$>"/&]UH'PU^(/\ PD>E+&GEZK#;M")21DC:3V/\JA^*
M'Q%\2_%OQ[J7Q"\4NK7FI7'F2*OW47& B^@ P /:L':2.E,D]O\ VW<?VAX!
M^4?\D\TWC_MG6C\#OAYX9_9X\#VG[5/QJM4ENI&W^ _"\A_>7TP^[<N.JQ*<
M')ZGIVKSCXL?&1/BOK7AG4=0\.^3#X?T6TTZ2$2?\?"0X!.>V1FO8?B%^W%\
M#_BGJ=OJ_CG]ENWO)K.TCM;-3JTBI!"@P$11P!CM^=)#B<7^RAXR\0^./VU?
M#WC#Q#=-=7NN>(9)-1D/\?FAR_\ P'G'TKS'Q[;6]EXZUJSM&!BCU2X6/']T
M2$5Z]^S[XA\+1?&;Q-^T1HOA9="T'POI,U[9::LQD6"=HQ%#&&/4ESNKPVZO
M9M1O9KZY.Z2:9I)&]23D_P Z>PAM%%%, HHHH **** "BBB@ HHHH **** "
MBBB@ I'^[G-+5C1-'O/$>LVNA:9$9+B[F6*-5Y)8F@#W7]A'X1MK_BZ;XDZQ
M:YM=-^6SW+PTI'+?@*^PE&!C%<I\'?AU9_#'P#I_A2TA56BA!N&"_>D(R2?Q
MKJUX%9@+1110!]%_!K_DG>F?]>_]:ZFN6^#7_).],_Z]_P"M=342W- HHHI
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M .1XTW_KZ6OIJID.(4445)04444 %%%% !1110 4444 %%%% !1110 4444
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M*O& :D!]J_T"A"-."C%626A_*\I2FW*6X44451(4444 %%%% !1110 4444
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M^M3_ -4LU\OO#_B9+P__ .GG_@/_  3\Q\I1E.U?IQ_PZ1_9G_Y^-:_\#/\
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M+[P_XBMPSWE_X"?.V4]*!M/2OHG_ (9=^'G_ #UN_P#OY2?\,N_#S_GK>?\
M?RC_ %,S?LOO#_B*W#/>7_@)\[LI.%7UZ>M=EX=TT:;8+&_#'EJ]8B_9D^'U
MM*MPCW;,K9 ,E:R_ [PAG/F7 _X'7P/&WAKQAG>'AA\)RJ/6\GO]QG/Q4X;:
M^U]QY",=FI<XZD5Z\/@;X1/5[C_ONC_A1GA'^_<?]]U^:KP"XXZ\G_@7_ ,E
MXI<-_P![[CR#</[RT;A_>6O7_P#A1GA#^]<?]]4?\*,\(?WKC_OJJ_X@'QM_
M<_\  O\ @%?\12X;_O?<>0;A_>6C</[RUZ__ ,*,\(?WKC_OJC_A1GA#^]<?
M]]4?\0#XV_N?^!?\ /\ B*7#?][[CR#</[RT;A_>6O7_ /A1GA#^]<?]]4?\
M*,\(?WKC_OJC_B ?&W]S_P "_P" '_$4N&_[WW'D&X?WEHW#^\M>O_\ "C/"
M']ZX_P"^J/\ A1GA#^]<?]]4?\0#XV_N?^!?\ /^(I<-_P![[CR#</[RT;A_
M>6O7_P#A1GA#^]<?]]4?\*,\(?WKC_OJC_B ?&W]S_P+_@!_Q%+AO^]]QY!N
M']Y:-P_O+7K_ /PHSPA_>N/^^J/^%&>$/[UQ_P!]4?\ $ ^-O[G_ (%_P _X
MBEPW_>^X\@W#^\M&X?WEKU__ (49X0_O7'_?5'_"C/"']ZX_[ZH_X@'QM_<_
M\"_X ?\ $4N&_P"]]QY!N']Y:-P_O+7K_P#PHSPA_>N/^^J/^%&>$>SW'_?=
M'_$ ^-NT/_ O^ '_ !%+AO\ O?<>0;A_>%+E,YR*]>/P.\)#K+<?]_*:_P #
MO"1Z27'_ '\I?\0#XW[0_P# O^ 3_P 12X;_ +WW?\$^=_B]XQ_X13PE-+;O
M_I-Q^ZMQ[GJ?P%?/6XNQ=CRQRS>OO7W5XR_9%^&_CJXCN=9NKX>2N%2.;"__
M *ZQ_P#A@KX,+_RWU+V_?_\ UJ_I7PKX%EP3D;I5[.M-WDUKZ+TL?CO&W$W^
ML>9<]*_LXJT4_P SXQ!["BOM ?L%_!D<>=J7_?\ _P#K4?\ #!GP9_Y[:E_W
M_K]/N?%GQ?17VA_PP9\&?^>VI?\ ?^C_ (8,^#/_ #VU+_O_ $<P'Q?17VA_
MPP9\&?\ GMJ7_?\ H_X8,^#/_/;4O^_]',!\7T5]H?\ #!GP9_Y[:E_W_H_X
M8,^#/_/;4O\ O_1S ?%]%?:'_#!GP9_Y[:E_W_H_X8,^#/\ SVU+_O\ T<P'
MQ?17VA_PP9\&?^>VI?\ ?^C_ (8,^#/_ #VU+_O_ $<P'Q?17VA_PP9\&?\
MGMJ7_?\ H_X8,^#/_/;4O^_]',!\7T5]H?\ #!GP9_Y[:E_W_H_X8,^#/_/;
M4O\ O_1S ?%]%?:'_#!GP9_Y[:E_W_H_X8,^#/\ SVU+_O\ T<P'Q?17VA_P
MP9\&?^>VI?\ ?^C_ (8,^#/_ #VU+_O_ $<P'Q?17VA_PP9\&?\ GMJ7_?\
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M***0!1110 4444 %-E^Y3J;+]R@#YA\<?\CCJ?\ U^/_ #K+K4\<?\CCJ?\
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M<?\ 0LQ_F?\ &C_A3GPX_P"A9C_,_P"-=311=@<M_P *<^''_0LQ_F?\:/\
MA3GPX_Z%F/\ ,_XUU-%%V!RW_"G/AQ_T+,?YG_&C_A3GPX_Z%F/\S_C74T47
M8'+?\*<^''_0LQ_F?\:/^%.?#C_H68_S/^-=311=@<M_PISX<?\ 0LQ_F?\
M&C_A3GPW_P"A9C_,_P"-=34<]Q!!%YLTJJN,EF. *+L#F?\ A3OPV_Z%J/\
M[Z/^-'_"G?AO_P!"U'_WT?\ &MQ-=T::[_L^+4[=IMN[R5E&['KBG6VLZ7?R
MM%9:C#,T;8D6*4,5^N*/> P?^%._#;_H6H_^^C_C1_PI[X;#_F6H_P#OH_XU
MN3Z[H]K=+97&JP1S-RL+S ,?PJ:]O+:VMVN;FY2)%^\TC8 HNP.=_P"%._#;
M_H6H_P S_C1_PI[X;9Q_PC4?_?1_QKB=9^.GB*/]IO3/@QHBV=QIM_X3N-1^
MTAMS&9'PJ@CC%=E\*M9\<WG@R/4_BA#9VFHB:42K:3 Q",.0ASZ[<9]Z-0)/
M^%._#;_H6H_^^C_C1_PIWX;?]"U'_P!]'_&M[3M>TC5"PT[4X;C;][R90V/R
MIL^OZ+;E?M&KV\>Y]J^9,HRWIR:?O 8?_"G?AM_T+4?_ 'T?\:/^%._#;_H6
MH_\ OH_XUT\<D<B[P5QV-5K_ %G3-,3?J.H06ZG@>=(%S^=+4#!_X4[\-O\
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MS_C74T478'+?\*<^''_0LQ_F?\:/^%.?#C_H68_S/^-=311=@<M_PISX<?\
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MS_KZ6OIJID.(4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ^APP/0TM8_@CQ7IWC7PKIOBS2IA);:E8QW,+KT*NH;^1K8H **** "BBB@
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MV\=_M:>*OB%&-UGH.GQ:3;R#HTOWG'X4M /<4P.AIU-0'K3J0!1110 4444
M%%%% !39#@4ZFRC*]/I0!X/\*KL:C^VA\6M6U!_FT72]'LK5F_@A:W\]@/;<
MQKY[^(W[07P?^)&C_%3XG^-_&$46NWFEW6@>"]!FADS9V29!?[NT23298\\
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M_/O>V[;6##/0.A!'I571/@9^T+\3O'_A_P 1?M'>(-#;2O"MU]JT_3=#5_\
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M_P#@8_\ C2GXB>/>WC/4_P#P-?\ QHY0YCZ76,=W[8H\M/[U?,__  L/Q_\
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M_P#@8_\ C1RAS'TP(E'\=#1@+A6KYG_X6'X__P"ATU/_ ,#'_P :/^%A^/\
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M?_&C_A8?C_\ Z'34_P#P,?\ QHY0YCZ<W#UIK*K')-?,O_"P_'__ $.FI_\
M@8_^-'_"P_'_ /T.FI_^!C_XT<H<Q],&)1R&K#\<_#_P_P#$&PM]*\20O-;6
M]Y'<^0&^5W0Y7<.XSSCVKP/_ (6'X_\ ^ATU/_P,?_&@?$/Q]W\::G_X&/\
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M?_"P_'__ $.FI_\ @8_^-'_"P_'_ /T.FI_^!C_XT<H<Q].;AZT;AZU\Q_\
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MP<>,-3_Z_'_G67FM#,**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T
M9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H *
M*,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9
MH **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **
M,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,
MT9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T
M9H **,T9% 'T7\&O^2=Z9_U[_P!:ZFN6^#1_XMWIA_Z=_P"M=342W- HHHI
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M]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\
M ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS
M_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!
M='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\
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MPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\
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M_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\
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M /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\
MGE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_
M\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO
M_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?
M^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3
M_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(
M/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H
M_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !
M_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:
MT_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&
M=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z
M]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\
M ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS
M_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!
M='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\
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MPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\
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M_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\
M/:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG
M;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O
M1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_
M\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_
M\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:07
M1Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__
M *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK
M_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_
MPSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'
M_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "
M#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\
M.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__
M (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_
M /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\
MGE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_
M\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO
M_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?
M^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3
M_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(
M/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H
M_P"&=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !
M_P#Z]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:
MT_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&
M=OAS_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z
M]%I!='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\
M ?\ ^O1_PO\ ^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS
M_P \KK_P(->?_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!
M='H'_#.WPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\
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MPY_YY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\
M^(/_ #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?
M_P#"_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_Y
MY77_ ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_
M #VM/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"
M_P#X@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_
M ($&C_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM
M/_ ?_P"O1:071Z!_PSM\.?\ GE=?^!!H_P"&=OAS_P \KK_P(->?_P#"_P#X
M@_\ /:T_\!__ *]'_"__ (@_\]K3_P !_P#Z]%I!='H'_#.WPY_YY77_ ($&
MC_AG;X<_\\KK_P "#7G_ /PO_P"(/_/:T_\  ?\ ^O1_PO\ ^(/_ #VM/_ ?
M_P"O1:071Z!_PSM\.?\ GE=?^!!I&_9Y^':](;H_]O!K@/\ A?\ \0?^>UI_
MX#__ %Z:WQ^^(><B6U_\!_\ Z]-7%<]N\-:'9^'-)CT;3PWDPIMC#-DBM(<#
M%8/PWUJ^\0^$;/6=293-/#N?8N!6]4,H**** "BBB@ HHHH *;+]RG4V7[E
M'S#XX_Y''4_^OQ_YUEUJ>./^1QU/_K\?^=96\9Q6AF*3BF[_ &H9D/4XHSGH
MHH#4<&'<T$XY-1[USC'2JGB?Q'I?A3PY?^*-9N!%9Z=9R7-U(?X8T4L3^0H
MGU#5]+TFW-YJ=_#;PKRTDT@51^)ING:SI6KVXN]*U&&ZB;I);R!U/X@U^3_P
M1^ 7Q5_X+N>/O$W[1WQ^^-GBSPO\%]-UJ;3O WA'PG?"U:^CC;'GR,RL"3P2
M2I/.!BN@UO\ 8P^.W_!(3]H;P3\1OV._B#XZ\;?#'Q1K4>F>,O!&N7!OI+0.
M<"X0HJC ]=H([DB@=C]2!*C=#2E@!FN,^*'QV^$GP-\'+X]^,'CS3?#FEE1F
MXU:Z6)02,[1NZFLSX&_M8_LZ_M,VDUW\"_BYHGB1;4XN%TV]61X_JH.1^5 C
MT,74!?RUE5F'\(-/# U\&?LM>*-:D_X+'_'?2=3U^Z?3[/PS8O#:S7#&*+C)
M(7.%K[/^&GQ;^''Q?T.3Q+\,?&-CK=A#=26TEUI\XD19D.&3([@\&@#I:*XO
M2/VAO@MX@MO$5UHOQ'TFZC\)3-%XD:&\5O[.=1EEE_ND#UKB?%__  4._8N\
M!S:1:^*OVC_"ME)KD2RZ6LNJ)^_1CA6'/ /OB@#VHG')J.6Z@@7=-(%7^\QQ
M7D_Q6_;J_9*^"5UIMA\4OCYX;T>76(UDTU;K4D!F1ONN,'H?7I7SA_P7L\?O
M-_P2U\0>./AQXP=([C4M/DL=3TF\*[T9SRKH1P1Z&@#[I\Y,9!SSCBFR75O$
MP6655+' #-C->#^"/V\_V0]/U'0?@KJO[0OAE/%3:7:1/I,NJIYOFF)?D/.-
MWMUS67^W_P#"3P%\7+#X=Q^,_P!I#_A7L>E^.K2^T^11D:S*H.VS_P!:G#>O
MS?[IH ^C@X/.#^5.KA_BU\?/@S^SSX3C\7?&?XDZ3X=TUE"17FK7:Q+*V.BY
M/S'Z9Q6/\!_VSOV8?VF[JXL/@1\:-!\27%HNZXM]-OE>1%]2O7'OB@#U"BO-
M_'7[7?[-7PTDUZ#Q[\9M TN3PSY8UV.\U!$:S,@R@<$\%AT'>K/P)_:A^ 7[
M2^AS^(?@3\4]'\36MK)LN)-+O%D\IO1@.1^- '?;@#@U7N=9TFRN8[*\U*"*
M:7_5PR2A6?Z GFJWB7Q)H?A/0+SQ1XEU.&RT^PMVFO+JX?:D,:C+,Q[  <U^
M0G[)5A^SM_P4,_X*K?%3XR_'/]JK5Y;[PI\0K.V^#OAO1_$20VM_:P^:V0A5
M_-B CCX0J<LY).[@ _8S<*6O&?C%_P % /V./V??%'_"$_%W]H/PYH>K+PVG
MW>H*)8_]Y1RO'K7=^&OC?\)O&?PW;XO>%/'^EZAX9CLY+J36K6Z5[=(47<[E
M@<   DT =7D=,T9KQ3Q;_P %$?V*/! T5_$_[2'A2U7Q%"LNCM)JB?Z3&Q(#
M+ST)!YK2^+?[<G[)WP-N=+L_BK\>/#>BR:U"DVEI>:D@-Q&W*NN#]T]CT- '
MJTEQ#$N^5PH_VJ0W=N&5#*H9ONJ6Y/TKP#]O?PE\,OVB?V0K[2]9_:-B\"^'
M]3FL[B'QM9LLB(OG(R@$2("'("_>'7O7SA^UAJFJ^$_^"F'['GA'0O&]W<Z6
MUA>Q33PSLL6H(D$>V5U#$'(YY)QF@#]$@V>E%<Q\//C#\,_BI_:(^'?C33]8
M_LF^:SU);&X#FVG7K&^.C#TH7XS?"^3XDM\'X_&VGMXG6S^UMH:W ^T+#_ST
M*]<>] '3T%@.M1M.H4LWR@=Z\:\7_P#!0[]B[P)\0Q\*/%G[1GA>QU_S1$VG
M3ZH@='/16YP#[&@#V5[NWC*B295W'"[FZFG[E[FO@#_@L'XRU6T^,O[+MQX0
M\37$5GJ7Q5A69K"Z94N8C$3ABIPR_7(K[$^-?[2/P-_9RT1?$7QM^)VC^&[2
M3B*35+Q8O,_W0>3^% '>45YI\"?VP/V:_P!I=+AO@9\8]#\2&UYN(],OED>,
M>I7KC\*C\<_MF_LO?#9=<;QO\;_#NFGPW=+;ZXEYJ*(UI*1D(X)R&([4 >GT
M5Q/P2_:,^"?[1OAIO%OP1^)6D^)-/CDV27&EW:R!&]&QR#]:Z+QCXT\,?#_P
MQ>^,_&>M6^FZ7IL)FOKZZDVQPQCJS'L* -2BN9G^,OPOMOAFWQEF\<::OA5;
M(7C:ZUROV<0'_EIOZ8]Z;IOQH^%VM?#0?&/2?'.G3^%S9_:O[=CN%-OY(ZOO
MSC% '2/=6Z.(GF4,WW5+=:=YL8ZM7RU\8?#GP6^/7[2OP5^/FB?M96^EI8PW
M<_AWP[9D20^)XY ,LK>:O"_[K=>U>.?#/_@I/I'B?_@L/XU^"NO_ +0FF#P'
MIOA&RL_"FEK=(L,NJ.R^:N1S)-N)7DG X '< _0:.Z@E9DCD#,OW@IZ5(#GF
MOS=_85_:A^'7P2_:=_:F\4_'[XP6NBZ+:?$B.&PDUS4ML:9B!V1AC^@%?=OP
M3_:'^"_[1?AG_A,/@I\1])\2:<'V-=:7=+(J-Z''0_6@#M68*,FJYU731UOH
MA]9!4TGW,$?6OPX_X):?\$M](_X*._"?QM\:OB=^U1\3-"O]+^)&HZ1#9Z'K
M0$)BC2&56(<$YS*1U &.,4 ?N)'>6LR[H9E=1_$IR*>)%8X%?D7K?P@^/?\
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M*1?4,.*\Q\0?MY?LAWGC2_\ @;:?M"^%V\5M;S0QZ.FJIYQEV,-@YQN]LYH
M]F6^LVB,ZW*>6/\ EIN&W\ZD21) &0Y![BORK_X)O^'++]H/_@@]K7A7XO\
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MV#(HQL&.G08KT?5/^"FG["6C>-O^%=ZC^T]X2CU<7'DM:MJB<29QMSTSGWH
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M"?I(*^6_^"TFL:KH7_!-OXD:MH6ISV=U#I:F&YM9C'(AWCHR\C\Z^1?V<?\
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M( HHHH **** "FR_<IU-E^Y0!\P^./\ D<=3_P"OQ_YUD2#TK7\<?\CCJ?\
MU^/_ #K(<\\"M(D2W.0^.OCS4_A=\)M=\?Z/:Q376EZ>\\,<^=K,!T.,'%?!
M7_#Y'X\J/^2?>&O^^9O_ (NOMG]K[>W[-?C!0I/_ !)I1@>N*_&T6=Z!Q:2?
M]^S7Q/%.88[!XB*H2:36NA_67T?^"^$>),DQ%;-J$)RC-).3MI;U1^I?[ '[
M8OCW]K!/$3^-/#^F6/\ 9#0"#^SU?Y]X;.=S'TXQ79_M\G5_^&+/B@OA\O\
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MA7_P1/\ &G[(UWJ#-XJT;X@2> H(_P"-C+<C'OC! K3TKX%_$"S_ ."XMO\
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MF_\ !3#]HR;2?A7HEM-X3UJV_P"$9D2R7_B6LZ#)B_NY)SQUK%_97_: U_\
M:S_X+4V/QZTWX<ZUHOA&]^'US;^%[S6+%X7O8%;F;:PRH8] >M6?@3\?-%_9
MN_X*M_M ?!7QS8:MIWB#XH31GP1=K8.8)I?(^0^8!A?F'6@9>;X6_P#!)_\
M8W^)GQ!\2_MV?'OPI\3?'OBS7IKZX_MG3/M-Y8V[$[+6.W1I67:.,C&<#@5S
M'_!'Z7X$_%C7/VJ/A3\,_#$TWPGN+Y+S0_#NM6+QI$C0G(\F0 H">0"!VKS7
M_@GE^T]^Q!^Q]I_C;P5^W%\#=6O/CI'XVOYKB34/!DVHW&J;I,PK"_ELJ^V<
M=1@U[-_P2'\1?$'QI^UI^T_?_$/X77OA+5O$EK;ZCI^@7EMY;QVKH5B&!QG&
MW('0\4#,?_@F/\#_ (2^'/\ @F-\:OB9H7@'3+77Y(?$U@VK0VX6<VRB3;#N
M_NCTKS?Q#XE\6^,/^"8?[*_['WAO7[C3+/XJ>)(;#Q!<6LA1Y+)7W/%D>HS^
ME=I_P3Q_:,\%Z3^R;\?/V'->TS5K'Q]I=MXFU![&ZTV18Y8"LA!1\8)Y''7F
MLN^_9_\ C'K?_!)7]GS]I'X/>#KO5O$?P@U2/6[C0XH3]HN;17_>JJXR2%SQ
MCI]* /?O^"BO_!*[]E#X=?L,ZUXP^ WPRL?"?BOX<Z4NI^'O$>D1^5=^; 0<
MR2#ERW4Y[UX#^V=KFH?MR?!+]B;5_&FI7$$WCB[B&MR6\Q21MT2B4!@<_-@Y
M^M=M^UU_P62^&G[:'[,<_P"R]^R7X#\6:M\2OB%:QZ5<:%-X?N(1I.\@2F21
ME"D+SR">/2K_ .TW^S_JG[/-S^Q'\$(+:2Y;PEK,=G>30QEE5UA7<3C_ &B>
M:!$7_!6_]B/]FW]D[X8?"OX\?L[?#33_  GXF\.?$?2;.'4M'0Q27,,C$.LI
M!^?IG)YY/K7Z<^')9;G0+&[F;,DUG$[MZL5!KXD_X+UV.H:E^RGX0AT^RFN&
M7XIZ*S+%&6( D;)X[5]L>%&;_A&--1EP18P\?\ %!+W/A'Q7<)9_\' 5C=3M
M\L7P7E=SZ 2(3^E?'W[%_P"UG_P32^(GC_XD?M'?\%%[T>(/''B+Q9=PZ;IV
MK>&[N_M]-TU'*Q1Q;(V09'IR !7V/XGT>]N?^"_&GW<MA,UJWP<DB>8QG9DN
MG&>F<5X%^R[\=O@5_P $D_'WCW]DO]N_X120Z6OB:[U;P-XP;P>=1CU&RF8L
MJ!DC=LC\@<CC%!70Z;_@D=\7?A+;_MQ_&3]G[]CKQ9J#?"/7-!BUSPHMU83Q
MQ:/?,H2=(DF"D('8D#T4<U+X7\!?\$</V)]/\5>%/VO_ (R^$_BI\1-<UN\O
M/$&J7FE&\U%O-=MD"P1F5H]JX& >3D]P*]'_ &-/CA\?OVR_#WQM^,/PK^!N
MF^"? =UH]SI_PDD/AV.QU*_F$+ S$A0=I< @= S8R=M?,7_!.#]L+_@GY^RI
M\"F^'OQU_9XU:\^/ECJ]XFJ:?>>")KZ_U:]:9MACF:-E4'*CEE(H$+^QG^TU
M;_!'_@EI^U[XZ^ =SJ-AH7AKQE<6W@."^C>.73HKT6T,>$?E"IN-P!Y&*^G/
MV8_^"/'[*'C3_@G5H?AKQ)X#M6\:>*_"<>JR>/&4_P!I6^IW$/G)<I-]X>6[
M*< X.#7@G["WP-^)G[7/[*'[9G[/'C_P3/X7\8>,/&,FH6^BWT?E_99C##-:
MJ>V!) %./0^E=S^SU_P6>T/X2?LJ:;^RYXL^$/C _M >&=-7PSI7@2/P].YO
M[^-?)@<2[=@CR$)R<X!([4#^9XK\%K"?2_\ @V"^(FFW*XDM]:O8Y$;^\M_
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MLE_!/QK_ ,%$_B9\?OVT/$?@^^T/P_\ $3PC)X7\ V^K6YBEGMPI_P!(*GD
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MZ'-%XJ\4^.(?$FLZ<L9:2VDNKN-A&P X*JHR.Q)H$ST;]I__ ()=_LC^#O\
M@D]JWB_3_AC9+XPTCP3'K</C#:3J#7RQK)YAESD@GC'3%?8W_!./Q9K?C?\
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M^Q[X=UW5?!^@>+K3Q)X\\77^BSV=K;0V[!EA_?*&+$Y'UZ9YKU;X:Z1?V?\
MP</>-[L6$RVB_ .QBCN/+.QB+B+Y0?7';K04<3K7P&^&7[&W_!>GX-:5^SIX
M8M_"^C_$;P+K,/B;1=,!CM;AH;:X=)-@X!W)&WU0?CY%\1_BK^S3^R7_ ,%)
M_BWJ?_!3_P#9NU3Q#IGB[4H9?!7C2[T-M1LK+3A&%\H)RPYSRBL<YR!UKZ5_
M:WTW4KC_ (+O_LQZA;6,S00^$?$(FF6,E$)L[G&3V[5SOQ-_X*3^"O@I^T1\
M0OV</^"J_P +HV\+M>BX^'FMKX/DOK2[L&7[AV([!\]P.O'% &%X4U[]F7]C
MS]@7]H#]J;_@GU^T"->\/ZY:M=Z5X?M6'D^&KJ0",*B$[D.Y\X8#' [5XE^R
MW\1/^"&&B?L>:?X&^/-RVO\ CSQ)HGVSQAXEU+PG?S7W]I3IYD@6?R3_ *MV
MV@J<';G/-:W[(_[&]K^V#H7[4^O?LR_#C4/"/PK^(.BQV7@&PU2V>WCO;Z+$
MGF)&_*IY@'T!_"NO_9Z_X*P_LH_L_?LO6?P-_:B_9KN=-^,G@325T.X\--X
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M^S7^TQX@^$^K>-]%\):I'??$;PA'&WFW\2HJJ\B=6&03R, GGK70? 'XP?\
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MJ::+R;0[900((HDW=<]< \ 5P/\ P2F^)_P3\8_\%4/C8?V7O!NJ>&? VL>
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MU&:Y:/XQ:U&C3R%BJAUP!GH/:O /^":?Q/\ @?XO_P""JGQ6N_V5_!.I^&?
MNN?#F.[_ +)O]->R6:X!;=<)"V-J-@8..QKK_P#@EO\ M2_"/]CO]C#XL?&G
MXV:E>6FA6OQNU:&::QL7N) [R*%^1 2>: Y3]-I)%2,NS8'7FO O&G_!2/\
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M:-BX'L*^KOV[?V@M._9;_8]^(?QZOYE1O#OABYFLE8X\RZ9?+MX_JTSQK^-
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M"VZC5IM'5UMGF[F,/\P7Z\T!\S*^-'Q]^$7[/7@^3Q[\9?'NGZ!I4?'VJ_N
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M_L:^'?"?C+0/#7[1N@KXET70+BXAA6X#-'+Y1,9'8G<17+_\$3_VQ=*_:?\
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MBBB@ HHHH **** "BBB@ HHHH ^B_@U_R3O3/^O?^M=37+?!K_DG>F?]>_\
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M)CP#^WM^SMJW[)'_  SE^QA^QAX@F^*%UX6?3KBQ_P"$.,"V,WD[999;ETY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:A-K%O)YD0MU7<S\>@H [0NH."::L\3':K\C[P]/K7RYK/\ P6*_8!T_7_\
MA$1\>;.2^ET1M2B6"%W'D["^<@==HSCK7AO_  1'_;Y\,_M 7?Q*\'>-OBW<
MZWXGO?'VJ7^E1WNX[=*61O)VDC"J$"X6@=F?HN'!&:K:MKFD:#ITFKZUJ,-K
M:PKNFN+B0(B#U)/ KYA^)?\ P66_X)]_"GQK=?#[Q)\;H)KZQN##?/I]I)/#
M;N#@AG4%1BNN_:*\:_LV?M(?L2^(O%FO?%7R/A]K>BL;SQ+I,V3%#W=2.A%
MM3W+3]5T_5;*+4=,NX[BWF0/#-"X974]"".HJ?<H[U\_>"OVA_V5OV6/@/\
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M2>79PW%PJ-.W]U03\Q^E<-^TI^UE\!_V3O!B^.?CMX^M-#L99-EOYQ+23O\
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M +7GA2;QE\ _B#9ZY:VL@CO$ARLMNYZ*Z'YE_&NV\;Y'@_56'RXTZ?\ ] -
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[\)_A]JO[/WQV,MO:Z'<2?$SQ%IX\06\*)-8VQFD7Y'_ (0J_@,5]5_\$R-
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MY.3C! KT;X[CXK_\$P_^"B7B_P#:X@^!>L>.OA3\6-/MU\1)X=T\W5UI-]$
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M/G['NN?LH>&/V*OB!9_&"Y\*SZ7XF^U:+*EA9^7$5N+A9=N&# ,549R6&":
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M8IW[<_PT\(_LA?\ !37]G7XX_ [1;?09/''BC_A'?%5CIL8BBO()"!N9%X)
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ML[\.O'/P$\(_LLWGPZ^%7B+QE#\,_$PGOK3P[I<UU(R010]?*1MNXJ<$UO\
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MTHH KWVEV&J6<FGZG8PW%O*NV:&XC#JX]"#P1[&G0V<-O MM;0K''&FV-$4
M*/0#T%2[AZTNX4 4-/\ #/A_2;V;4M+T*SMKBX;-Q/;VJ(\O^\0,M^-7V&1B
M@L*:[8% $<MI#/$8)H59&ZJZA@?SI8K:.")88(E1%&%5> !Z4GVB-95A>3#-
M]U2W)J:@"O-IUG<.LUQ:12,OW2\8)7Z$]*E\H9XXI]&>,T ,\L__ *JB.G6G
MVC[8;2,RXQYGEC=CTS3KJXCMXVGFE"1HI:1F.  .IK-\*>./"/CO1O\ A(/!
M7B:RU6Q\QH_MEA<++'O7[R[E.,CO0!H#3K03-<K:QK(WWI-@W'VS4OE_Y]*(
M9HYHUDC?<K?=8=#3Z &"+G.*4Q\$#O2L<+FHFN(T=4>0!F^ZI/WOI0 7%K#-
M$8YXED1OO*RY!_.OAC_@J%\/_P!O;]HWQ/8_LC? [X>:9!\,/$D-O_PDGBQI
MMLEM&'S+#M]QTP*^ZR0RTFS(XH YOX/_  ZT?X1_#30_AGX>A6.ST/3(;.%4
MX&(U KIF4.,$4FW9S3LCUH @GT^TN65KFUCDVG*^8@;!]L]*>(?[U*\@ ZTD
M$\<R;XI%93]UE;(- "^61T%*4_NT[-(QPN: (18VR3-<K;()&X:0*-Q'UIYB
M.<@5E^+O&OA/P'HS>(?&GB2STJQ218VO-0N%BC5B< %F.,FM"TO(+V".ZM9U
MDCD4-')&V58'D$&@"2:W2=&26-65N&5N<BFV]E;V<8BM+:.%=V=L: */PJ;.
M.M .: (9["UNHQ%=VL<B@Y"R*&'ZT\1    ?+T]J?G')H!!&: (?L-J+G[:M
MK'YVW DV#=CTS4@CQQC@'BE+ '!-*6 ZF@"N=-LS.+IK2)INGG>6-WY]:D\L
M]^_6I <]** ((;"TMW:2"TCC9_O,J $^YQUJ3RN,9I^X8S1D&@"-X1(C)(@8
M-U!'7VIL-G!;QB&WA6.,=(XQ@#\*F)QVI-PH 9);1S*R31JRG^%E!!IL-G!;
MQ+!;P+&B_=5%P!3IKB.)=TDH5?[S'%95_P"._!VE>([/P?J?BFQM]6U!&>QT
MV:Z59YU7J50G) ]A0!K^708^>G3WH5^,&G9]* *\FFV<LRW$MI&TB_=D9 67
M\:D\KVJ3=0#F@!GEY&TBHHK*UM 6M;:.+<V6\M ,_7'6K!('6FN0?E- 'R'\
M9?V8/B]XK_X*I?#G]I+1- CD\)Z#X3NK+5+TW #1S.WRKM[BOK:UM+6V4QVM
MM'&"<[8TVC/KQ4I0-P5I0I#9H 3R\]11Y7 XI^:SO$_BOPYX.T2X\2>*M;MM
M-T^U4-=7UY,(XH@2!EF/ Y(% %\1CN*BN;"UO8Q%=VT<BJ<A9$# ?G3-)U;3
MM:TV#5])OHKJUNHQ);W$,@9)$/1@1U!]:DDN8XEWRRA5_O,V/YT .6!0NT*
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MLW JUIFIV.KV,.IZ;>1W%O<1++!/$P971AD,".""* )@F#2&/OBGALT9YQ0
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M:7[.W[,GB?P_X2^-?Q!M]#NO$T%Y+I,ETC>6Z6T)FF)<?*N$!(R>3P*^=?\
M@LE^RA\&KC_@GEXH\3>&_!.FZ1K'P]L(]5\,:GI]FL,MG) RD!64 X*@CWS7
MS5^U'X7T_P#;;^+/[ ^@_%53<6_BBQN[K7(Y.ERL%FD[QMZA_)VD=PQH#W3[
M9_9W_P""N7[$7[3?Q2C^#WPW^)-Q'KUUN_LVUU;3I;7^T .\)D \SVQR:[#X
M_?\ !07]E3]F+QK-\/OC5\2X=&U2+0#K'V>:%V\RU#;!M('S,6X"CDU\F?\
M!?KX*^ /A'^R#X?_ &G_ (5>&-/\/^+OAEXRTRY\/:EIUNL+JGF8\K*XRN0I
MQ]:S?C=\%_ G[47_  7&^%%U\1](CO-.T[X.#6UTVZ4,LDRR,4#@]0I;.#W
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M[A07;GN!0/W3[>^._P"U'\&_V<+KPW8?%;Q.;&X\6:U'I6@V\=N\KW-TY "
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MS/XX\ _"_P"(7@=)M6T?Q7X?:SMUU:-BKR(O*#>F.AR2[UL?\$^?C5:_L/\
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M+X]?M4_!']FK1M%\0?&#QG'I=CX@U2'3]+NFC+1R32?=!(^ZI_O'BO$_"_\
MP6F_X)_>,/C!#\&M*^+LBWUU?&TL=0N-.ECLKF;.-B3$;6Y[]*^&_P!K"T^(
M7Q>_X)-?LP^$/CSI.I6.M77CO3=)UB'4X6BN2B3M$I<, 0?+VCGD]:^CO^"T
MO[-GP3\!_P#!.-M1\&_#C2=+NO"=YILFB75C9I');,LJ $,!GIU]<T"L8/\
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MGKCI534?VLOV5/V5OA1\-]&\6?$?^SM#U[0[6V\)WFH*Q\^WCME9&=L?*?+
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M **** /HOX-?\D[TS_KW_K74URWP:_Y)WIG_ %[_ -:ZFHEN:!1112 ****
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MS: <\-S]>*^L?^"9W[)'QC_9E^(GQP\1?%33;.WMO''Q$EU;P^UK>"0O:LN
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M/#'[1'_!1G_@H]X?_;]^+_P+UWX=_#OX8:#=6?@'1/%-JT%]J-Y<1NC7#1.
MRJ [-D@<J@&<9KT;_@E3\,/B-X!_:+_:>UKQSX"UC1[/7OBA]JT6ZU+3I(8[
M^'R<>9"S "1<_P 2Y'O7VP("$VJO'I_GI3O*?M]*!<S/S;_;4\6_%W]D7_@K
MOX4_:QM?V=/%OC?PEKO@<>';B\\*Z;+<&RG,W+2>6C[0 V>< @=:Q?C5XV^/
MO_!-_P#X*C>/OVM]-_9=\7_$3X?_ !D\.Z>DDGA#39+FXT^\MX(8A&Z(K%>(
M5.2 #O/<8K]/&MRZ[716'HP%#0%AAE5O][U]:!'Y@?LD:3^U]\8_^"QG_#7?
MQP_9UU[P=X?\0_"VXAT2WN[*1UT^W#.L4%S*%V)<.=S^62& 89 KVO\ X(]_
M#+XC_#3Q#\?)/B%X"UC1%U;XM7=WI;:II\D O+=E7$L>X#>A_O#(K[4\E\=!
M2F%B<^_3TH'<^$OV:OA1\3M$_P""C/[3WC36OAYK5KH^O>';./1=4N--E2WO
MG$4@*PR%=LA!(^Z37EG[+'[+_P =M3_X(3_$#X#WOPOUK3?%VH7VMR6.@ZGI
M[V]U/EU*820!OF .WCFOU ,+D8_K2/&V,GI^'- ^8^,_^"6_Q@U;]J3]B9_@
M#\4_V?/%7@>^\(>&[?PUJ5KXJTN6W6_Q;F,RQ>8BY7Y>1SC-?(__  1 _9Q\
M;:I_P4 \?ZYX_O!?:-\"K>Y\+>%9 VZ.)Y[B1PH/3.PL>/05^BW[>&L?MA>'
M/@G)+^Q)X-T76/%<]TL,EMK#^7&D+9#2 Y'*YS7-_P#!+?\ 8Z\6?L?_ +.\
MFC?%"^MKSQOXJUF?6_&5];-E7O)6SL![JHX'U- <Q]*,I"=>U?F]_P %#/$G
MQ;_94_X*?_#O]L/2?V=_%?CKPJWAF71;YO"UA+<26LLC ;F\M'V@9SR.:_20
MK\NT5$UOYG#CB@D_,WQM??M"?\$T_P!M?Q5^UKX%_9R\4>/_ (6_%ZUM]0US
M3_#-@\VH:1>E <M H+>QXXZ$BM7]G70OVC/^"D'_  4!T']MGXH_ 77/AS\.
MOAWIDMMX/TGQ5;M!?7]Q)]Z9HF 91[D8],U^CK0$KMVKCTIR1LF %Q0.Y5U2
MVN[K3;BULKMH)I862*9>2C$8#?@>:_-72/V]OVO?V0M3\6?L^_MI_L;_ !$^
M*K2:O<OX4\3>&_#[7]MJ-J['RXG,:,JD# YY'<5^FTJ,_ J,VP8#?&K;>F[F
M@$?F+^R1^PU\?H/^"?G[0U[K7PG?PKKGQ=74+_PYX#8JLEE&4W1PE> CMC&W
MC!/.*Y;X5Z5\<?VW?^".6N?L3Q?LZ>+O!WCCX;Z+96UI;^)=-EM4U:>W.1Y)
MD1!DX/<\XYZ&OUD,+'DC\:1;;R\F,;6;[S* ,T#YF?DG\4/VX_VV?VM/V(M6
M_8^\!_\ !/[XA:#XOA\+_8/%FM:UI,\-G''"@5Q!NC!F>3;\JKD\]^M=I\6/
MV,_VB?$/_!.O]G3XN?"+P/>'XG? ^.VU2'PS>PM!<749C07%L5;!#_NUPI]Q
MWK].5@*'<J@'^+;QN^M!A<]3^/O0',?CU_P4/_:^_;0_X*/?LL2_!WX-?L%?
M$CPY:Z7J5A>^.[C6M#G62X=)U46UI'Y>Z8;SYC, 0%CYQW^]_P!K[]GB#]H;
M_@FCXF^"6OVBV]Y<?#WS+7[8/+^SWEO )H]V[[F)(P"3T!-?1HM]@^4!><]J
M^1?^"I_A_P#X*(_$?P9#\$/V*?#N@OHWC329]+\6:WJEP8YM-BERCNGUC+#(
MY&>/6@+GAG_!N%\/_&WB[X5^-?VQ?BS*UUX@\::Q'IL%[,"6>ULHUB!![@L/
M_':_3&097CM[5YC^QU^SCX?_ &2_V;/!_P"S]X<D62+PWH\5M/<*O_'Q/C,L
MO_ G+-^->GN0%YH)/QJ_9-_;(^.7[&W[:'[47B_2/V;_ !3\1OAUJ'Q6N(=6
M7P;:M=7VDZBI<I(85!9HI(SM+8P#$,E> ?I#_@GQ\*?C_P#M%?M@?$3_ (*=
M_M#_  GU#P.NM^%?^$9^'GA+6(RE[!IP9'>:5" R,QB3@@'YFXP17I__  3D
M_9*^,/[.OQK_ &AO&WQ1TNRAL/B)\2CK/AMK>Y$K26I5L%Q@;3R..:^LA$R_
M=';%!7,?%G_!#+X8?$;X4?LG>)/#OQ0\":OX?OKCXFZY<PV>LZ?);2O"]QE)
M L@!*L.00,$5X7\/_&GQ^_X(T?';XE?#W7/V4?&'Q&^$OCGQ9<^(_"&M>!]+
M>\ETZ:X;<]K*B*VP G:,@ A003SC]2!$XY'&/\YIK6H<;& V_P"U@X_S_G%
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M7%>9P_$G]KC]MO\ X*9_!G]HN_\ V3O&G@_X;Z.]S!I;:YI,JSKE?FGN!LQ
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M]OVF/%WB_P !:QI>DZYXAMI-%U*_TV2*&^4(,M$[*!(!ZJ31X#^%_P 2;/\
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M]"[)_P!]#_&OHW ]*,#THYF'*?.7_"G?B+_T+LG_ 'T/\:/^%._$7_H79/\
MOH?XU]&X'I1@>E',PY3YR_X4[\1?^A=D_P"^A_C1_P *=^(O_0NR?]]#_&OH
MW ]*,#THYF'*?.7_  IWXB_]"[)_WT/\:/\ A3OQ%_Z%V3_OH?XU]&X'I1@>
ME',PY3YR_P"%._$7_H79/^^A_C1_PIWXB_\ 0NR?]]#_ !KZ-P/2C ]*.9AR
MGSE_PIWXB_\ 0NR?]]#_ !H_X4[\1?\ H79/^^A_C7T;@>E&!Z4<S#E/G+_A
M3OQ%_P"A=D_[Z'^-(WP;^(Q((\.R?]]#FOH[ ]*,#THYF'*?-_\ PI?XC?\
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M$7_H79/^^A_C7T;@>E&!Z4<S#E/G+_A3OQ%_Z%V3_OH?XT?\*=^(O_0NR?\
M?0_QKZ-P/2C ]*.9ARGSE_PIWXB_]"[)_P!]#_&C_A3OQ%_Z%V3_ +Z'^-?1
MN!Z48'I1S,.4^<O^%._$7_H79/\ OH?XT?\ "G?B+_T+LG_?0_QKZ-P/2C ]
M*.9ARGSE_P *=^(O_0NR?]]#_&C_ (4[\1?^A=D_[Z'^-?1N!Z48'I1S,.4^
M<O\ A3OQ%_Z%V3_OH?XT?\*=^(O_ $+LG_?0_P :^C<#THP/2CF8<I\Y?\*=
M^(O_ $+LG_?0_P :/^%._$7_ *%V3_OH?XU]&X'I1@>E',PY3YR_X4[\1?\
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>image_026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (^!7<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;4I)/0I_\+M^'G_0P_\ DE<?_&Z[;3=1M=7TVVU"QE\VUN8Q)%)M*[E/(."
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M('!'4]Z<7K!=F_NU!VM-]U^-T8?QNU[PYJT&@WOAW4;2[UU+H&.2RD#R*F.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HK$U+Q38:7>M:2I.\B@%O+48&>
M<<D=L?G5/_A.=,_YX7?_ 'PO_P 57'/,,+"3C*HDU_78Z8X2O)*2@[,Z>L?4
M/$NG:==I;2R%G)P^P9$?U_PKGM8\:-<P>3IJ20AA\TKX##V&"<?6N2)))).2
M>I->5CL\C!\N&U??H=^%RMR7-6T\CV.*6.:)9(G5T895E.013Z\OT7Q!=:/(
M%4^9;$_-$3^H]#74_P#"=:9_SPN_^^%_^*KKPV<X:K"]27*^S_0YZV75H2M!
M<R.GHKF/^$YTS_GA=_\ ?"__ !5=)#,EQ!'-$VZ.10ZG&,@C(KNHXJA7;5*2
M=CDJ4*M*SG&P^BO'IM4\4_$KQ9JNEZ%K+:)HNF/Y4EQ"#YDKY(R""#R5/ (&
M.N<UM>'/#WC_ ,-^)(()M>37-"<'SI+QB)4_W<[FS^)!]JZ(ZV\S)Z7\CT>B
MN(\1?%/P_P"%];NM*U)+T3P0B;='&I63.,*OS9W<]P!P>:GN_B9X>L/"MEX@
MO'N8(+U2UO;O&/.DQZ*#C\<XY'/-%]+CMK8["BN1\(_$CP]XSF>WTZ6:&[1=
MQM[E KE?48)!_ U1U3XN^&=&U34].OOMD=Q8,%($2GSF/.$PW_H6!0]-Q+4[
MRBN8\'^/-%\;03OI;3I+!CS8+A KJ#G!X)!!QV-8VM_&7PGH>KMILDEW<R1O
MLEDMH@R1D'D$EAG'^SGI0]'8%KJ>@45RVK^/]#TGPE#XF#S7FG3.J(UJH+$G
M/9B,8P<@\BN8L_COX7O;V"UCL-8$D\BQJ6ABP"3@9_>>]%KNW4'HK]#U"BN>
M@\9:=/XVN/"BPW0OX(1,TA5?**X4\'=G/S#M1!XRTZ?QM<>%%ANA?P0B9I"J
M^45PIX.[.?F':A:V\P>E_(Z&BO/;[XS>%M-GU&WN1?+<6-P;<PB)2TK D$I\
MV,<=6QU%+<?&?PA!H4&IBXN)3,Q46D<8,ZD8SN!( QD<YP>V:+Z7"VMCT&BL
M;0?%&D^(]"&LZ?<9M!N\PR#:8RO4,.V*Y>3XP^'XU^T_V?K;:7YGEC5!9'[,
M3_O9SUXZ9H>CL"U5ST&BO*_BOXBFLH?"E]INJSV]G<W8>26WF9%DB^4_-@\C
M![UJZ;\9/".IZZNE13W,;.X2*YEBVQ2,>@!SD?B!0M=.M[ ]-?*YW]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15+5]5M=$TFXU
M*\+""!<ML7)))   ]22!Z<\XKC/^%P>'_P#GSU/_ +]1_P#Q=;TL-6JJ].+:
M,:F(I4G:<DF>@55U#4;32K*2\OIT@@C'+L?T'J?:N&D^,.A"-C%8ZBTF/E#(
M@!/N=YQ^5>8>(_$^H^)K[S[V3$:G]U GW(Q[#N?>NW#976J2_>+E7];')7S*
ME"/N/F9[CX;\9Z3XG,D=G(T=PA/[B7 <K_>'J/Y5T-?+%O<36EQ'<6\KQ31G
M<CH<%37J>A?%Z&.P$6N6L\ERG EME4AQZD$C!^GZ5KB\IG!\U#5=NIGA<SC-
M6K:/OT/5**\__P"%P>'_ /GSU/\ []1__%UM>&O'.D^*;N:ULDNHIHH_,VSH
M!N7."002."1UQU[\X\^>#Q$(N4H-)';#%4)R48R39TU%>:?&[4]0TKP?9S:;
M?W5E,U\B&2VF:-BNQ^,J1QP*YS7_  ?XS\*^'9O$-O\ $/4KMK5!*T$Y<*1W
M^](P)YZ$5RWT;>QTVV2ZGMU%>-^-_%VJ7WP9T77K6[GL+VYN(Q*]K*T9) <-
MRIS@E<XKT#6/%^F^&-)T^746N)KBZ54@MK>,R33O@<*O?\?4535KWZ.PEJDU
MU5_T.DHKD_#WQ!TGQ#J\ND"VU'3M3C7?]DU&W\J0K@'(&3Z].M5O%?Q3\->$
M;[[#>27%S>#!>&T0.8P>FXD@#Z9SR.*3T!:G:T5S_A_QIH?B31)=6L;P"V@!
M-QYPV-#@9.X=N._3WKF(OC?X-EU;[#YUXD9;:+MX,0G]=P'N5HMK;J'2YZ/1
M7EWQ=URZTH^%[BRU.>TMY;W,SP3LBO'\I^;:>1C-:6F_&3PCJ>NKI44]S&SN
M$BN98ML4C'H <Y'X@41UV[V!Z'?T5A>*/&&B^#[)+K5[DQ^82(HD7<\A'7 _
MJ<#D<UC^%/BEX:\7WOV&RDN+:\.2D%V@1I .3M()!^F<\'BA:[ ]-SM:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,V]T'3-0N#<7
M5J'E( +!F7./7!&:K_\ ")Z)_P ^7_D5_P#&MJBN>6$P\FY2@FWY(V6(JQ5E
M)V]3D=8\&0/#YNEKY<BCF)F)#_0GH:XF6*2"5HI49'4X96&"*]DJC>:-87]Q
M'/<VZO)'T)[CT/J*\K'9)3K/GH6B_P /^ =^%S.5-<M75?B<-H/AB?5"L]QN
MAM.N?XG^GM[UUO\ PB>B?\^7_D5_\:V@   !@#H**Z\-E6&H0Y7%2?=K^K'/
M7Q]:K*Z=EV1B_P#")Z)_SY?^17_QK81%CC6-%"HHPJJ, #T%.HKMIT*5*_LX
MI7[*QS3JSG\<FSQ3X=:O9>"/%WB;P_X@N8["2:Y\Z":X;8CKEOXCP,@@C\:]
M 'Q'\+R^(K70[745O+JYX1K0>=&#Z%ER/4^@ YQ6CKWA+0?$Z*NLZ9#=%!A7
M.5=1G. RD,!^-1Z#X+\.>&6+Z/I,%M(009>7DP>V]B6Q[9K6.R3Z&;W;74\_
M-K#=?M)EID5_)L1*FX9PP0 ']:S_ (JB>#XJ>'+F74UTNV-OMBOI;=9DA<,V
M24;@]5Y/3(/:O6%\-:0OB1O$(M/^)JT7E&?S'^YC&-N=O;TJ76=!TKQ#8FSU
M:QBNX,Y"R#E3C&01R#[BDM%'RO\ K_F/=R\_\E_D>6Z+I]G?_$_3;Z7XAV^M
MZO;QDB.TTM562/:00TL1V=^^3T'I4W@RUAF^.OB^>2)6DA3]VQ&2N2H./PKT
M'P_X/\/^%A)_8NF16K2<.X+.Y'IN8DX]LU-8^&M(TW6[W6;2T\O4+T8N)O,<
M[_P)P.G8"J6C7DG^)+3:?JOP/-O!T/E_%_QU%;(J$PG8%& &)!_F:XSP!));
MZ!JEK+X[L_#K+,XNK*[TZ&5I>,$Y<@MW&T9QCWKWRQ\-:1INMWNLVEIY>H7H
MQ<3>8YW_ ($X'3L!6=JWP[\):YJ/]H:AHD$MT6W-(K,F\^K!2 W3OFI2LDO*
MWXL?5OSO^"..\+:QHGPZ^&$VHQ:T^L64ERYM#]E>W,DA &Q5;)QE22>G6L7P
M(=*UO7V\9^,?$.DG49&_T*QDO(QY SP=I;@CL.HZGDUZMJ_@[P_KFDVVE:AI
ML;V-LP:&"-VB5" 0,;".Q-8:?"#P)'(LB:%AE((/VN?@C_@=6G[_ #/^O^")
MKW;+^O\ @')MJ=CHO[1.H7&IW<-G!+8JJ2SN$0DHG<\#[IIOAG5;+6OVA-5O
M-/N$N+8V1194.58JL8.#W&0>:]'U_P %>'/%$L4VLZ7%<RQ#"2;F1@/0E2"1
MST/%.T[P;X>TC5QJFGZ9%;7@A\@/$S!0G'&W.WL.<9J8:6OTO^-RI.][=;?A
M;_(\]^%UO#)\1O'<SQ(TB7916(R0&DDR/QP/RJ/X-V%IYGC$_9X\B[:#E?\
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ME>)[!;'6+7[3;+() GF,GS $ Y4@]S5?7?!WA_Q+;P0:OIL=REN,1$LRL@]
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MO^O]>0/9VZJWZ?UYF_1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WB
M?Q/IOA'0Y]6U21E@BX")@O(QZ*H)&3^-/'B/35\+1^([B4VVG-;+=%IA@JC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7G5W\6K5?%$.CZ;HM]?6YO
MTL)]2 *6\<C,%(#8.XCTXS7HM>'ZOX;\?Z 5TC1]&M=8TB'5AJ=K,LRQR*0Y
M?RW#,.YZ_KVH3]Y7V_K] ?PNV_\ 7ZGJ7AKQ78^)CJ$=M'-#<:?<M;7$$R[6
M4@\-]".16]7%> = UNQGUC7?$@MX]6UB5'DM[<Y2%$7:JYYR>N>3]:[6FU:P
MK[A1112&%%%% !7)2?#'P5+K8U=_#UH;S=OS\P0MUR8\["?PKK:*.MPZ6,S7
M/#VD^)--;3]8L8KNU)SL?(VGU!&"I]P13= \-:-X7L/L6BZ?%9VY.YE3)+'U
M9B26/U-:M%&P',2?#KPA+X@_MV30;5M1W;_,.[:6SG<4SM+9YSC-=/111TL'
M6X5X_P"(?^3H?"?_ &"I/_0;JO8*\?\ $/\ R=#X3_[!4G_H-U0![!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA\)_]@J3_P!!NJ /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Y(W<G...U=17$_#G[OBC_L/W7_LM=M1T7HOR0=6O-_F%%%%( HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVA_M.%C:M",A//W;0<=<<AL?A3;+Q!XM\,>*_#UAXFU:VU2TU\,HV6@@-I*
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M &CO^2>:?_V%8_\ T5+0![!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_BJ[U2QM8K
MG3WV0IGSVPIQDJ%X/N3TKH*YSQC?6\.C26C/^_GV[4'7 8')]N*X\P=L--\W
M+9;IVUZ?>=.$5Z\5:^H_PK=ZI?6LMSJ#[X7QY#849P6#<#W ZUT%<UX-U*WF
MTJ.P#8N(=Q*G^(%B<C\ZZ6EETE+"P?-S::N]]>OW!C(N->2M8****[3F"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445SOB#Q,FG VMIB2\/![B/Z^_M6->O3H0<ZCLC2E1G5ER06I9UWQ#
M!H\6Q<273#Y8\]/<^@K#T?0+G5[G^U-8+,K<K&W!<=L^B^U6-!\,R--_:6K9
MDG8[EC?G!]6]_:NMK@IT*F+DJN)5HK:/ZR\_([)U88>+IT7>767Z(15"J%4
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M<****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M      !T I:**]4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !#_ ,G0^$_^P5)_Z#=4 >P4444 %%%% !1110 4444 %%%% !1110 4444
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MX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)?O!,_PX_'/->EHBQQJB*%50  .P%4Y7N^]OP5A6V7:_XNYP/Q-\5>,/#/\
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M%5\2G'V5)6@OQ\V%%%%=YR!1110 4444 %%%% !1110 4444 %%%% !1110
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M4*H50  , #M2T5TX7"PP\;1U;W;W;,:^(E6E=[+9=$%%%%=)@%%%% !1110
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M. *?5X7!JC><GS3>[_1=D3B,2ZMHQ5HK9?UU"BBBNPY@HHHH **** "BBB@
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MT)]$:W.MI_9@B#[EDR?+\W(Z8ZXKU[PHGBA-.E'BN73I+WS3Y9L VSR\#KN
M.<Y_2M.]TRPU(P&^LK>Y-O()H3-&'\MQT9<]#[BK=).T;?UT_'0;U=PHHHI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+&59':<W0*$']T A+?3 /Y&O4$TNPCTL:8EG M@(_*%L(QY>S&-NWIBL?0/
M7A?PO>S7FC:/!:W,N=TH+.P!ZA=Q.T>PP*::3\DT_N5A.[3[N_XNYP_@B:+2
M?&'Q,AO95C=+G[4=Y _=%7;=],$?G6I\#+:6W^%UBTH8"::65 ?[I<@?RKI-
M?\!>%_%%[#>:SH\%U<PX"R%F4D#H&VD;A['(K>M[:"SMHK:VA2&")0D<<:A5
M51T  Z"ICI&WDE]PY:N_FW]Z,3QMI6L:WX0OM.T"_P#L&IS>7Y-SYSQ;,2*S
M?,@+#*AAQZU\X?$?P7X\\.>'K>\\4>)O[4L7NUB2'[?//MD*.0VV10!P&&>O
M/O7U?7C_ .T=_P D\T__ +"L?_HJ6@#V"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHH) !). .IH *Y77_ !,8Y#I^EYDN6.UG09VGT'J?Y57UKQ%-
M?W']F:-N<N=K2IU;_=/8>]:N@>'(=(C$LNV2[8<OV3V7_&O*JXBIBINCAG9+
MXI?HN[\^AWPHPH152NM>D?U?D5_#_AD61%[?XDO&^8*>0GO[M[UTM%%=V'P]
M/#P4*:T_K<Y:U:=:7--A1116YD%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>6WO@2\T_
M0[S3['Q%:PW,&I_VGHYN,+]G8DED;N02S#//7I7H&L^(-(\/PQS:OJ-O91RM
MM1YWVACC.!7@VB:3\,-9GU6Z\6:]%/JSWTK-*UZR(Z%LH4(X(VX^G3M26^G]
M:H>RU_K1_P##'J/PZT'5]/FUG5M?U6SOM4U.5&E6R;,481=J@<#G'MV'6NIU
MW1+'Q'HUQI.HHSVEP )%5BI(!!ZCW KG/AWI?@S2[*^3P;=1W$#R*;@QW!E
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M^BI:]@KQ_P#:._Y)YI__ &%8_P#T5+0![!1110 4444 %%%% !1110 4444
M%%%% !1145S<PV=N\\\@2-!DL:3:2NQI-NR'R2)%&TDC!$49+,< "N)U/6+O
MQ%=_V;I*L(#]]^F\>I]%_G^E1W5Y?^+K[[)9J8K%#EB>F/5O4^@__777:7I5
MMI-J(;=>3R[GJY]37DRG4Q[<*;M2ZOK+R7EYGH*$,(N:>L^B[>;\R#1="M]&
MM\)\\[#]Y*1R?8>@K5HHKTZ5*%*"A!62.&<Y5).4G=L****T("BBB@ HHHH
M**** "BBB@ HHHH **** "BO"?L_C#_A,/\ A&?^$CNOMO\ ST^W3>7_ *OS
M.O7I[=:]VKJQ6%]AR^\G?73L<V'Q'MK^ZU;34****Y3I"BBB@ HHHH ****
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MLS0B3 B8X8IY?ED^QQS7L5CXO\/ZA#')#J]FID (CDF5''L5)SFO%Y_!S?\
M"P&\,070(,GRS.O1-GF<@=2%_,^E>A2?"#064;+O4$( !^="#[_=KOQT<&U#
MFDUII97TZ7.'!RQ2<[)/776VO6QW<5W;7&/)N(I,]-C@_P JFKR^?X-6S?\
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M87-J< 31-&<^X(J>BDU=68T[.Y\YKJ3V?PEN/AHUG=GQ4;@PI9BV<[T,V_S
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M$;8(+>I/'T^O3LQ-/#K QY)=7;S?5')0J5WC)<\>FODNAZ)1117B'KA1110
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M$3#*C?C'[Q>I'0_C(SZ;HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
MOQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =
MH ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_
M .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\
M] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\
M0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH
M[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_]
M W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_
M /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@
MHKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7
M/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_
M - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/
M^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':
M /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ_
M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__
M $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$
M/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_
M (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W
M7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/
M_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8*
M*\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[
MP?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=
M<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QV
MC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.
M\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
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MKG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M_P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\
MH&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B
M'_X[1_PT=X/_ .@;KG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#
M1W@__H&ZY_WXA_\ CM 'L%%>/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN
M?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\ ?B'_ ..T?\-'>#_^@;KG_?B'_P".
MT >P45X__P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\
M\-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\
M^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA
M_P#CM'_#1W@__H&ZY_WXA_\ CM 'L%%>/_\ #1W@_P#Z!NN?]^(?_CM'_#1W
M@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\ ?B'_ ..T?\-'>#_^@;KG
M_?B'_P".T >P45X__P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.T
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M_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FN'^+_ (3\-Z9\+=9O+#P_I5I=
M1^1LF@LHXW7,\8.& R,@D?C7K%% '/\ @3_DGGAK_L%6O_HI:Z"BB@ HHHH
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M3QBMRB@#ROX!:3J6C>!;ZWU33[NQG;4Y'6.ZA:)BOE1#(# '&01GV->J444
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M$GB?PO)>GP9XMWVZ7=HLLD]R_D6TN",J)0P.<CV'OVJY+33O^G]?,2WN^O\
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MF\GM-%U>&[N(,EXU5E. <9&X#</<9%5]7^(_A#0M6&EZEKMM!>DX,>&;8?\
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M)TS3='\,>-/.BDU73@ES<RGR[<MLPZM)N!4GGIZ]156TLNEOGI_5Q7UOWO\
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M63^Z6QDC@<9J&70=&N-234IM)L)+]/N73VR&5?HY&1U/>M"B@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8<C!<]V(]SD_C6K10M$UW!ZM-G!>%?AA9Z#X7UG0-0O?[2M=4F:63]SY14$
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MV[_U"M4_\!__ *]:U% &3_;O_4*U3_P'_P#KT?V[_P!0K5/_  '_ /KUK44
M9/\ ;O\ U"M4_P# ?_Z]']N_]0K5/_ ?_P"O6M10!D_V[_U"M4_\!_\ Z]']
MN_\ 4*U3_P !_P#Z]:U% &3_ &[_ -0K5/\ P'_^O1_;O_4*U3_P'_\ KUK4
M4 9/]N_]0K5/_ ?_ .O1_;O_ %"M4_\  ?\ ^O6M10!D_P!N_P#4*U3_ ,!_
M_KT?V[_U"M4_\!__ *]:U% &3_;O_4*U3_P'_P#KT?V[_P!0K5/_  '_ /KU
MK44 9/\ ;O\ U"M4_P# ?_Z]']N_]0K5/_ ?_P"O6M10!D_V[_U"M4_\!_\
MZ]']N_\ 4*U3_P !_P#Z]:U% &3_ &[_ -0K5/\ P'_^O1_;O_4*U3_P'_\
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M6M10!#:S_:;=)O*EBW9^25=K#G'(J:BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *ANI_LUN\WE2R[<?)$NYCSC@5-10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]'
M]N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M1
M0!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]'
M]N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M1
M0!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]'
M]N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M1
M0!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]'
M]N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M1
M0!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]'
M]N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M1
M0!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!D_V[_P!0K5/_  '_ /KT
M?V[_ -0K5/\ P'_^O6M10!D_V[_U"M4_\!__ *]']N_]0K5/_ ?_ .O6M10!
MD_V[_P!0K5/_  '_ /KT?V[_ -0K5/\ P'_^O6M10!7L[O[9"9/L\\&&V[9T
MVL??'IS5BBB@ HHHH **** "BBB@ HHHH *YSQUXG_X0_P '7^M",2RPJ%B1
MNC.Q"KGVR:Z.N2^)?ANY\5^ M1TNSP;M@LL*DXW,C!@OXXQ^-3+8J.^IPB^!
MOB;J.G1^(#X^N8M6>(3)IR*5@!(R$/S;>^.4/]:[:^\83^"_!6GZGXRAW7KR
M+;S_ -G@.N\YPWS%<# R<=.U<3#\<QIVFQ:1>>%]7'B:*(1?9/) 1Y ,9Z[L
M'&>%-.^*MUJ.K?"C1;G6M/6PO+C48#+:JY;8#NX.0,''4=NE:/>T=KK\7;0B
M/>6]G^"N=U%\0M'_ +%U#6+VWU'3=/LV"B>^M3$+@-]UHE^\P/;@=:CT+XCZ
M1K>K1:7)9:KI5].I>VAU2T,!N% R2AR0?YUB?&K0]0U?P-;'3HIY?L-Y'<2Q
M6W^L,8!!*8[C(/X5Q_ARUT7Q%X^T*71-5\7>(%L2;B>[U*^(BL2,?(0\.6)Q
M@A2,^I[*%G*W];;_ -:=-PEI&_\ 7I_6IZ'<_%/1;?7-6T9-/UBZU#32 T%I
M:><TV1DE I/ XR6VCD5IZ%X\T'Q!X8G\06]RT%C;;A<_:5V- 5&2&'/.".F:
MX[P"JGXR?$%L#<'@ /M@_P"%<GI6B7NN?#3XBZ;IB%[DZU*R1+R7",K%1[D"
MI^Q?^ZG^-BK>];SM^%STG3/BMH.HZA:VTEIJ]A#>N$LKR^LS%!=$]/+?/.>V
M<=:3Q#\3[7PU=7D=[X7\4/;VAP][#IX-N1QR'+@8YZUY+96>C^(6\/Z19:GX
MTU?4TFC-WI]S?&.+32HY<[X2 %Y  [<9!XK0^(WC;2O$WCQ/"VKZF^F>&M-F
MS>N(Y&:ZE7JH"*3@=!GCJ?2J:U27=_=W_P"&WZ$I[MKI^/;_ (<].?XH:+'X
M%M_%SV>I#3[B80I&8D\W)8KG&_&,@]ZU?$?C'3_#%SH\%[#=2/JMRMM 854A
M6..6RPP.>V:\_P#B->:=XH^#/VCP@AN]/L[F(*L,#KL2,X.%(!P,CM6/XW\8
MZ;XMU?P#+I N)K5-5C+W#P/&F_<@V L!N(YSC('K323E;^\E\F@^S?R?WH]%
MU7XF:/I7B.^T!['5KK4K6)91#9VOG--N&["!3G('4D #UK/'QF\-R:0U_:V6
MM79BS]JM[>Q+26@'4R\[5'_ OY51T)%/[1/B=B!N&F0X/IQ'6%X$4#PG\4"
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MG>8.0% !+LYVG^'\:Y[X@*;?XK?#Z]E'^C^?-!N/0.P&W\?\*AOU5OVE],+
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M(BM?M)M+JWN([FUNA'O,,B'(.,C/&1U'6N@4,$ 8@MCD@8R:RO[/UC_H.?\
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M!K45D_V?K'_0<_\ )1/\:/[/UC_H.?\ DHG^- &M163_ &?K'_0<_P#)1/\
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M_P!!S_R43_&C^S]8_P"@Y_Y*)_C0!K45D_V?K'_0<_\ )1/\:/[/UC_H.?\
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M@R\LT@15'N3P*\\\1^"/!N@>#+J&XTJ*]OIPT<-Q+&KWMS</DKAP Q8MSQ@
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M'HO]JZ=_S_VO_?Y?\:/[5T[_ )_[7_O\O^---WOYM_-@U=6\K?(\WM-"\7^
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M_P#:_P#?Y?\ &C^U=._Y_P"U_P"_R_XT 6Z*J?VKIW_/_:_]_E_QH_M73O\
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M-']JZ=_S_P!K_P!_E_QH MT54_M73O\ G_M?^_R_XT?VKIW_ #_VO_?Y?\:
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M\:/[5T[_ )_[7_O\O^-("W153^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\
M&@"W153^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&@"W153^U=._Y_[7_O\O\
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MK_A5NB@"I_96G?\ /A:_]^5_PH_LK3O^?"U_[\K_ (5;HH J?V5IW_/A:_\
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M+7_ORO\ A5NB@"I_96G?\^%K_P!^5_PH_LK3O^?"U_[\K_A5NB@"I_96G?\
M/A:_]^5_PH_LK3O^?"U_[\K_ (5;HH J?V5IW_/A:_\ ?E?\*/[*T[_GPM?^
M_*_X5;HH J?V5IW_ #X6O_?E?\*/[*T[_GPM?^_*_P"%6Z* *G]E:=_SX6O_
M 'Y7_"C^RM._Y\+7_ORO^%6Z* *G]E:=_P ^%K_WY7_"C^RM._Y\+7_ORO\
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;V0I!#'$I.2J*%&?7BI*** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>image_027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (]!2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHUU=^7J%Z,V\/EN=_7N!@=#U(H UJ*** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>?ZO\ \))_:]UY?]H^5YA\OR=^S;_#C;QTQ_7FO0**
MX\9A/K45'G<;=CHPV(]A)OE3OW/,O^*F_P"HO_Y$K.O?MOG_ .G_ &CSL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9X#\'ZCX0L[R'4?$EUK;SR*ZR7"L#& ,8&YV_I6FJNI;_P##?U\C-V=K;?\
M#G6T445)04444 %%%% !1110 4444 %%%% !1110 4444 %?/_[37_,K?]O?
M_M&OH"OG_P#::_YE;_M[_P#:- 'T!1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *FIZ;::QIMQIU_%YUI<(4ECW%=R^F00:LHBQQJB*
M%10 H'84ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O/_C!_R*5K_P!?R?\ HN2O0*\_^,'_ "*5
MK_U_)_Z+DKKP'^\P]?\ ,Y<;_N\_3_(ZOPO_ ,BEHW_7C!_Z+6M6LKPO_P B
MEHW_ %XP?^BUK5K"K_$EZO\ -F]+X(^B_)!1116984444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5S7C;P@GC31XM.?4;FP$<XF\VV^\< C'TY_2NEKF/'5YXLLM%AD\'V$%[J!
MG DCG(VB/!R>67G..])^8XWOH<)_PH&W_P"AOUK_ +Z%4M,T[6OAA\3]"T@Z
M_=:IHVMAXA%<L28V4>F2 02.1C()%3?\)!\=?^A6TO\ [ZC_ /CU6O#/A#QO
MX@\=6/BKQT;:U&G(PM;*!E.&.1GY20!WZD\"JC\2[=29?"^YZ_63XGU.71O"
MNK:G H::TM)9D!Z;E4D?K6M45U;0WEI-:W,:R03(8Y$;HRD8(_*HDFTTBHM)
MIL^<HM%\=ZG>>%Y;GX@ZG /$D3RHT,TH2%@@<)M5P.1Z8Z5Z/\)(KVQD\1Z5
MJ^LW>I:M97BQSO<2M( FW*%"Q)P03P>AS7):\?AIIOAQ/",?C*XM+FRO&N;6
M[B22=K60DC;N08P.1@$&N]^%WA;2_#^AW%Y8:W_;DVI2>;/J&<^81G ZD\9/
M4DY)K1-:M;?\-;[M5YD23TOO_P /^>AW=%%<GXE^)/A3PG*8-4U:,7(ZV\(,
MD@^H7[OXXJ+E6.LHKRJU_:#\$W$[1R_VG;*#@2S6P*GW&UF/Z5Z'HOB'2/$=
MG]KT?4+>\A[F)\E3Z$=0?8U5@N:5%%%( HHHH **** "BBB@ HHHH **** "
MOG_]IK_F5O\ M[_]HU] 5\__ +37_,K?]O?_ +1H ^@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\6-W)&>FWC&,5N_!VVTV.X\4W&A7,;:'-?+]CMUDW&,!>6(SE03T!YPHJ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW! Z\\<5Y9]NU3_HO6A_^ -E_P#%TKCMI<]@KF=?^(/A3PQJ$=AK&LPVUU(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^F^%="TG:;+2[:-UZ2%-S_\ ?39-;%%%<<IRF[R=SIC&,5:*L%%%%24%%%%
M!1110 4444 %>?\ Q@_Y%*U_Z_D_]%R5Z!7G_P 8/^12M?\ K^3_ -%R5UX#
M_>8>O^9RXW_=Y^G^1U?A?_D4M&_Z\8/_ $6M9OAG_D-^(/\ KY_]F>M+PO\
M\BEHW_7C!_Z+6LWPS_R&_$'_ %\_^S/7DX__ 'RE_BE^3/1PG^[3_P ,?S1T
M]%%%=9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF<WXUO?%=CHT,O@_3+34-0-PJR173!5$6ULL,NG.X*.O<\>GSI\8-1\<W_\
M8W_"::-8Z;L\_P"R?9'#>9GR]^<2/TPGIU/7M]7U\_\ [37_ #*W_;W_ .T:
M0SZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO%'_(I:S_U
MXS_^BVKE/@__ ,BE=?\ 7\__ *+CKJ_%'_(I:S_UXS_^BVKE/@__ ,BE=?\
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M()"0NJ$GH68]?Y5A>&O#VH>)-2^Q6.40C]_*<[8T]_7V'>O??%'_ "*6L_\
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M.'SFP><(2#CIUK2_-=F;5K([HXP<]*XW1?B'X9U_5M7L;%RR:5$9;BZ9 (B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_1;5RGP?_P"12NO^OY__ $7'75^*/^12UG_KQG_]%M7*?!__ )%*Z_Z_G_\
M1<==]/\ W*I_BC^IQ5/]\A_A9Z!17%:A:ZB?%::>FLW2)=!IE*LV(Q\QV@;N
M?NX[5V%M$T%K#$\IE=$56D;JQ QD_6O%P^)E6G.+@URNVZW^7E9GJUJ*IQB^
M:]]>I+11176<X4444 %%%% !1110 4444 %%%% !1110 4452N=6T^SR+B\A
M0C^'=D_D.:F4XP5Y.R*C&4G:*N7:*YFY\;Z;%Q!'-.?4#:/UY_2J!\3ZYJ'&
MG:=M4_Q!"^/QX%<,\TPL7RQES/M%-_D=4<#7:NU9>>AVM5;G4K*S_P"/BZAC
M/HSC/Y=:Y3^QO$^IX-Y>^2AZJ9,?^.KQ5JU\"VB8-U=2RGT0!!_6H^MXJI_"
MHV\Y.WX:LKZO0A_$J7]%<L7/C32X<B'S9S_LK@?K6:?%NK7Y*Z=IO?&=K2$?
ME@"NCM?#^E6>#%91%A_$XWG]:T0 H 4  = */J^-J?Q*JCY17ZL/;8:'P4[^
MK_1'%?V;XKU/_CXNC;H3T,FWCZ)_6K%OX%A!W7=[)(2<D1J%_4YKKJ*<<JP]
M[U+S?]YM_P# $\?6M:%HKR1E6WAO2+7!2R1V'>3Y_P"=:BHJ*%10JCH ,"EH
MKNITJ=-6A%+T1RSJ3F[R;84445H0%%%% !1110 4444 %%%% !1110 4444
M%<QX9_Y#?B#_ *^?_9GKI)IDMX))I6VQQJ78XS@ 9-<EX7U&U;7M502_-=S%
MX!M/S@%R>W'![UYV+G&.)H)OJ_\ TFWYZ'9AXR=&JTNB_,["BBBO1.,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *YGQQ>^*['1HI?"&G6]_J!G"O%<$!1'@Y/+KSG'?O735Y
MQ\9M9U+1/#6ESZ7>S6DLFIQ1.\+;2R%6R#[<"BUVEW:_,:TN_)_DS _X2/XY
M_P#0H:1_WTO_ ,?K7\,:W\6KKQ%9P^(?#>FVNE,Q^T31,I9!@XQB5N^.QK1\
M;^*=5T/QCX-TVQF1+;5+IHKI6C#%E!3H3T^\:[ZFMK^OX$OMY)_?_P ,%9'B
MG39M8\)ZOIML0)[JSEAC).!N92!6O5#6M4CT30[_ %25&>.S@>=E7JP4$X_2
MHG;E=RX7YE8\55[GP_X1\'^)[GPU<0-H$LMCJ-JL0WO$4VM)@CIN //KU[UU
M/P=U"?5W\2ZI;V,MCH5W>B6P@D&,$C]X5 XP3@\<9)K!LO&'QGUVSCU+2_"V
ME_8+E?,@WN@)0]/O2@].^!FO0/ =WXTN[.[/C/3;6QG611;K;LI#+CDG:[=_
MI6MW=M_U>U_Q7RU,W:R2_K>WY_D==7G7Q%DT+P=IDOB^#P[I5WJT<\:^9)$H
M<ECC=D#.1ZUZ+7A7Q8^$VEP:-J&OZ1:ZC<ZQ<78D:.,F0'>V6P@&<<UF]U_7
M5&BLSN/'C:19>'3XUN-(L]1U/3;=&@6<DJNYU[=,Y.<XS76:!J+ZQX>TW4I(
MUC>[MHYV13D*64' _.O)O$'PJTKPS\-]<N-!MM0FU"\LXXFA+&0M^\1CA0,Y
MXKT_P=%)!X*T.&:-XY4L(%='4AE(09!!Z&KLK2]5^MR.D7Z_I;]3;HHHJ1A1
M110 4444 %%%% !1110 4444 %?/_P"TU_S*W_;W_P"T:^@*^?\ ]IK_ )E;
M_M[_ /:- 'T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%'2@ HK*OO$NB::2
MMWJMI$X&2AE!;_OD<US5[\6/#EMQ;_:KL]O+BVC_ ,>P?TK>GAJU3X(M_(QG
MB*4/BDD=U17E,GQ4UG4BT>B>'R[9P"0\Q_)0/YTA3XH:VV&8V$+#U2+'Y9>N
MC^SZD?XDE'U?Z(Q^NP?\-.7HOU/5))8X4+RNJ(.K,< 5A7WCCPUI^?.U>W9A
MP5A/F'/_  '-<5'\*-3U"19=;\0-(XZA0TI_!F(_E6[8_"GPW:@&=+F\;K^]
MEVC\EQ1['"0^.HY>B_5A[7$S^&"7J_T12OOC!I$)9;*QN[EAT+XC4_CR?TK-
M_P"$^\9:S@:/H&R-AQ)Y+R?^/'"_I7HEEX>T;3>;/2[2%O[RQ#=^?6M.CZQA
MH?!2O_B=_P $'L<1+XZEO1?YGD__  C_ ,2=; ^W:H;-">5,X3CZ1#GZ&K-K
M\'HG<R:GK,\SL<GRD"G_ +Z8G/Y5Z?12>8UEI"T?1) L#2>L[R]6V<G8_#?P
MO8D-]@-PX_BN)"WZ=/TKH[/3K'3TV6=G;VZ^D,80?I5FBN:=:I4^.3?S.B%*
MG#X8I!11161H%%%% !1110 4444 %%%% !1110 4444 97BC_D4M9_Z\9_\
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M>'O[2%TU^@D;3PY=8RK9)V<[<X]NE)]/5?F5'KZ/\F<1J7PU^+>KZAI]_?\
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M -HT ?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !14<T\-NF^:5(T_O.P4?K7/WOCWPQ8 ^9JT$A](,RY_[
MYR*N%*<_@39$ZD(?$['245YO??&+3(@PL=.N;AAT,K"-3_,_I5#_ (3;QSK+
M8TK0O)C(X?R&;_QYL+^E=<<NKVO)**\VD<[QU&]HN[\DV>KU4O-4T_3EW7M]
M;6X_Z:RA?YFO,QX7^(FM;3J.L&U0_>0SX_\ '8Q@_G5JS^#MH#OU'5KB9B<D
M0H$_4YS3^K8>'\2JODKB^L5I?!3^]V-^^^)?A>RW!;U[EU_AMXBV?H3@?K7.
MW/Q@\Z40Z7HDLSMPOFR<D_[J@Y_.NGL?AWX7L<$:8LS_ -ZX<OG\"<?I716U
ME:V48CM+:&!!_#%&%'Y"CVF#A\,'+U=OR#DQ4]Y*/HK_ )GEW]M?$O7 /LFG
MFRC8]1"(^/K(2?RI?^%>>+=8).M>(-J-_!YKRX_X#PH_ UZO11]?E'^%",?E
MK][#ZE&7\23E\_\ (\]L?A#HL&&O+N[NF'4 B-3^ R?UKI+'P7X<TX+Y&D6Q
M9>C2KYC?FV:WJ*PJ8NO4^*;_ *]#6&&HP^&*&HB1H$1551T"C %.HHKG-PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#F+[_DH.F_]>Q_E)73UQ%_K5D/&MK=B0M! AB=U&1D[AD>H^85OW/BC2+;@
MW:R-Z1 M^HXKRL)B:,95G*:7OOJNR_R.^O0JR5-*+^'MYLV**X^?QRK-LLK!
MW8]#(V#^0S_.HOM?BW4_]5 ;:,^B!/\ T+G\JMYI0;M23F_[J;_'1$K 54KS
MM%>;.T9U12SL%4=23@5EW7B32;7.^]C=O2+Y_P"58"^#M0O&#ZEJ>3UP"9#^
M9QBM2U\&Z3!@R)).W_31\#\ABE[?'5/X=)17]Y_HA^RPL/CFY>B_5E&X\=0
M[;2RED8G ,C!?T&:@_M/Q7J?%M:FW0GJ(]O'U;^E=;;6-I9C%M;11?[B $U8
MH^IXFI_&K/TBK?CJP^LT(?PZ:^>IQ0\)ZM?-NU'4N#VW-(?UP!6E;>"M+AP9
MC-.?1FP/TKHZ*TAEF%B[N/,^[;?YD2QU>2LG9>6A5MM-L;/FWM(8S_>5!G\^
MM6J**[8QC%6BK(Y92<G=NX44450@HHHH **** "BBB@ HHHH **** "BBB@
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MTCXH>*['7]+M?&OANWTZPUAPEE<0/RI/0/\ ,WJO]T]\5Z]7C_QO99--\()
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M&L=-V>?]D^R.&\S/E[\XD?IA/3J>O9#/J^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN:\=7>L67AF>71H]TO25U^_''CEE'K[]NOTN
MG!U)J"=KDSGR1<GT-:VUO3;S5+C3;>\CDO+< RQ \C_''?'3O4UY?VNGQ"6Z
MF6)&8*">YKYGL+B^AU*&:PDF6]W_ +MHB=Y8\8&.N<XKT*\AU"WE$.I27+W"
MC)-PY=N>>N<8^G%1Q!;*J49Q]YRT7ZW_ $_X 9-+^T)RC+1+^M/U/1K[Q9H&
MG!OM6KVBE1DHL@=O^^5R:YN^^+7A^VR+6.[NV[%8PB_FQ!_2N8A\)/K)-VFF
MF<?=+[B@/ZC-:MAX2U73RK6NCVRLO1Y(X78?BV37-0S?!.E&;HU)-KHE;[^J
M.BME^*4W&-2"7FW?[NA WQ.\0ZJ2NB>'MW.-VUYL?]\@ 4AL_B?KA;S;@V$3
M=/WBQ8_[XRWYUT4=OXRV[0XC X S'_2G+8^+VSF["_61?Z"MEGJC_!PC7JKO
M\69?V2Y?Q,0GZ.WY(Y^'X27=Y()M8UYY9.^Q2Y_[Z8_TK?L?A;X9M IE@GNV
M'.9YC_)<"E&D^+&SG40OUF/]!2#P_P"*&))U8K_V\R?T%9U,^QTU94I_+E1<
M,HPD=>>/SNSI;+0]*TWFRTVUMS_>CB4'\\9J_7%KX8\0$G?J^/I/(?Z4H\):
ML22^KD>X9S7*\=BIZNA+YM?YG0L)0CHJJ^YG9T5Q@\%WK$E]6/UVL?ZTG_"!
MNS$OJ0R>_DY/_H5)XO%]*#_\"0_J^'ZU?P9V1D0'!=0?K3#<P X,T8/H6%<D
MO@%0?GU$D>T./_9JD7P';Y^:^E(]D H6(QK_ .7*_P# E_D'L<*O^7O_ )*=
M,;ZT4X:Z@!]#(*C;5M-1BK:A:@CL9E_QK '@2RS\UW<$>P _I3QX%T[/-S=$
M>Q7_  H=;']*4?\ P+_@![/"=:C^XV3K>E@X.HVOX2@TTZ_I*G!U"W_!\UEK
MX'TM3DRW3#T+K_1:D'@O20<D3GV,G_UJ%4S%_8BO^WG_ )!R8/\ FE]R+K>(
M]'4X-_%^&34;>*M%0X-\/PC<_P A4(\':.#GR9#[&0TX>$=%!_X]6/MYK?XT
M-YB]E!?-A;!=Y?@*?%VB@\79/TB?_"F-XPT8'B>0_2,U*OA31%((L1QZR.?Z
MU(/#>C@Y^P1_B3_C0EF+W<%\F%\%VE^!3;QII /#3-](ZC?QOI:XQ'=-]$']
M36F/#^D@Y_L^#_OFG_V)I0/_ "#K;_OT*'#,']N"^3_S#GP?\LOO1C'QUIW\
M-O='ZJH_K36\=V7\-I<'Z[1_6MX:1I@((TZT!'_3!?\ "I/L%F/^72#_ +]C
M_"A4<PZU8_\ @/\ P0]IA/\ GV_O.:;QY;#&VRE/U<"HW\>QC&S3F/UEQ_2N
ML^RV_P#SPB_[X%/\N/\ N+^5#P^-?_+Y?^ K_,/;87_GU_Y,<8?'S?PZ:!]9
ML_\ LM.;QK>8^72B/JQ/]*[.BA83&=:__DJ#ZQA^E+\6<8WB[52/ET@CZJQ_
MI0WBC7BOR:1@^IAD-=G10\'B7O7?W1#ZS17_ "Z7WLXH^(?$Y'&D$>XM9/\
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M7_1_>0[67;3];?JCO****@H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"OG_ /::_P"96_[>_P#VC7T!7S_^TU_S*W_;W_[1H ^@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#F+[_DH.F_]>Q_E)73USMSX-TZ
MZNIKAYKH/*[.P5EQDG/'RUNVT"VMK#;H24B144MUP!CFN'"4ZT)U/:124G=:
MW[+MY7.K$2IRC#D=VE;;^NY+1117<<H4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
MX,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ
M.@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T
M->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7
MH?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HK
MG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!
M_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_
M^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*
MH_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_
M -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
MX,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ
M.@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T
M->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7
MH?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HK
MG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!
M_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_
M^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*
MH_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_
M -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
MX,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ
M.@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T
M->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7
MH?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HK
MG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!
M_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_
M^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*
MH_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_
M -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
MX,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ
M.@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T
M->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7
MH?\ X,8?_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ .@HKG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HK
MG_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HKG_\ A._!
M_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ .@HJ.">&ZMXKBWECF@E0
M/')&P974C(((X((YS4E !1110 4444 %%%% !1110 4444 %%%% !1110 5X
M'\6OB=XCT#QK)H5AJ7]GV"Q1NTL%LDLOS#)^\<?EBO?*B>V@D;<\,;-ZLH)I
M-7:&GH?)<>O>"]3=9O%>M>-=:D#%BA2)(\_0RL1^!%>Y?""_\'7VD:@/!VEW
MMA!',HN/M9RTC$<'.]NWTKT'[':_\^T/_? I\<4<6?+C1,]=J@9JD[$M7'T4
M44AA1110 4444 <]XR\&Z=XXT1=*U.:ZB@699@ULRJVX @<LI&.3VKS7QA\(
M(-$^&5[8^&3?WL\=XE_Y<[*[MM4J0NU1V.<8).*]KHI;;:?U_P  :>U_Z_JY
M\_ZGXHF^+VK^&M$TK1[^#^S[Q+C4Y9XP%A*\$9!/^UUP2<<5ZYJ7C;3=+\::
M9X6G@NVOM1C,D4B(IB4#=]XE@1]T] :Z2BJO^=V2E^5D>&W^MO\ ";XH^(-6
MU73+R?1M;5'AGMD!Q(.=I)(&<[N,YZ&M'X<>%]0U7PWXRU'4K:2R?Q-+*88I
M5VLJ,'P2/JY_+->PT5*7N\K[6^15WS77>_S/FFV\7WVD?#BY^&4_A_4SXC<2
M6T2+$"C([DEASD\%L$ COFO1=8L_&'@SX1:1!X:"OJ.GQQ_;(UB$K%.KA 0<
MX/Z9Q7J-%4VW=]7;\!65_+7\3Y\\0^)Y/C/?:#HNA:)?0&SNQ/?7-P@"08&"
M,@GCKUP20.*^@P, "BBB^EEZBMK?Y&/XD\+:-XNTZ.PURS^UVL<HF5/->/#@
M$ Y0@]&/YU\\?'3P3X=\'?V#_8&G_8_M7VCSOWTDF[;Y>W[['&-S=/6OI^L_
M4]"T?6_*_M;2K&_\G/E_:[=)=F<9QN!QG Z>@I#./_X4E\//^A>_\G;C_P".
M4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
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MA7Q=X-O+_7-*^UW4>H/"K_:)8\((XR!A& ZL?SKZ'JGINDZ;HUNUOI>GVEC
MSEVCM85B4M@#)"@#. !GV% '%_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\
MG;C_ ..5Z!10!Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY7H%
M% 'G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.5Z!10!Y_P#\*2^'
MG_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE>@44 >?_\ "DOAY_T+W_D[<?\
MQRC_ (4E\//^A>_\G;C_ ..5Z!10!Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_
M *%[_P G;C_XY7H%% 'G_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^
M.5Z!10!Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE>@44 >?_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWXL?\DM\0?\
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M)_W/P>OX%7]YOSE^*T_$Q_$"^(/!_C;PE>+XGU2_35[L6U[;7+KY SM_U<8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(&>+(R-R@Y&1TS5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[QUH \3>"=6T
MG:#)- 3%GM(OS+^H%<9\(_%\3?"22>^?#Z$LD4^[J$0;E_\ '>/PKU2OE;QK
M%JGA7QKXF\(Z9$3;^))87B4'LS[L ?4LOTI*]W%?:V]5_P !L>EDWT?X/?\
M(ZCPA8O'\(O&?B_4;.*XGU@RR^5,6"/&">#M*L 6+=".@KJ+?Q[#X-^"N@:O
M%I<(>Y"P06L<CK%&Q+')9BS;0 3R2:V_&6DQ:%\$M2TJ ?N[32_*'O@ $_B>
M:YBW*?\ "@-!6X\+OXALVB7[1;Q3%)(EW-^\3"DDCVQU],TY-7DH[+E7RU1*
MNW%O=\S_ "-K2_&'C6WU;3(]7TG2M6TO46"K?>'?.F2VSCF3.1CD<\#&3DU6
M\4WL$7QX\)VKZ9:2S26S%;MVE$L7^LX4!PG;NIZUYE#I6BP^*-+F^%.K:S<7
M[W*_:K=HG5+>/.2'8JOR]L'/?FO0/%__ "<3X-S_ ,^C?^U:I:RAZO\ )_U<
M?22\OU7]6.6L-7\>/\>]0,6FVTU^B>3+;R2YCAM"R?.F9, [=K8!/)/%?15>
M$ZCK*^"_VB;W4=2LKR2WU2VCM[5H(PV]F$8SR1P"ISC)]J]VI+^''^N__#_,
M<_XC^7Y?TOD>4>!KJ3Q5\5?%NOR %-- TVQW<A "VX@>Y7/_  *I]'^)NH2^
M!_%6IZM!8Q:MH4TL#10AA&S#A,@L3RV1U[52^"BFRU?QOI<HQ<0:H6;</F()
M8 Y_#]:X_P"(^D7UK\4I] LT9;'Q7):R2XZ$J^&Q^()/UI)748]TOOT=_P P
M;LY2?1_@M/\ ([/1?BY=W_PBU7Q5=06::E8R&$11H_E,YV[,@L3CYAGGL:OZ
MS\2-5T7PWX=C_LJ.^\4ZW$KQ64(9(U) .3DDX&0,9]>0*\Z\5:#=K\7'\&6J
M :7K5[;:@Z<XVHK;_P .&/X"NF^-OAQY-7T#Q!)H\NJZ/9 PWUK 6#!,Y!^7
M! Z\^PSUH;32ELFU\K+7\1)-.W5)_C:WX&YX:^(?B6+Q5:>&O'.@0:9>WZLU
MG-;.&C?'\)^9N>/[WIQS4>O_ !&\3WGBB^\/^ _#]OJ=QIQ O+BZ<+&I/\(&
M].<]\]CQWKE_A_!X(\0>,;.?PKX OX;:T/FOJMU?2J()!T 3<ZN>G!;OTXK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <A!X2NM.^)D_B73Y8%L=0
MM/)OX'8AC(N-CJ "#P,')'KS77T44=$@ZW"BBB@ HHHH **** "BBB@#D/\
MA$KJ\^)I\4:C+ UK9V@M].@1B65FSO=@0 #S@8)XKKZ**.E@ZW"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2B?XUK44 9/]GZQ_T'/_ "43_&C^S]8_Z#G_ )*)_C6M10!D_P!GZQ_T'/\
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MM10!D_V?K'_0<_\ )1/\:/[/UC_H.?\ DHG^-:U% &3_ &?K'_0<_P#)1/\
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M_P!!S_R43_&C^S]8_P"@Y_Y*)_C6M10!D_V?K'_0<_\ )1/\:/[/UC_H.?\
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M^9(W6-$4R@.0!D%@._/-,UOXBZ+X?U'2K*]BOC)J<)FMS##YG0<*0#N+'(
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M5?$US\4;.'6%2QLYM,FFATZ*4OLPZ -*1\K/UZ<#H"<DUZ)7%7G_ "6;2O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=!=6VG6T%[>?;+J.,++<^4(_-8#EMHX7/H*LU+&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%9DM]JJ3.L>C^8@8A7^TJ-P['':F?VAK'_0#_P#)M/\
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MI_A2\A^9K45D_P!H:Q_T _\ R;3_  H_M#6/^@'_ .3:?X4 :U%9/]H:Q_T
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M3:?X4 :U%9/]H:Q_T __ ";3_"C^T-8_Z ?_ )-I_A0!K45D_P!H:Q_T _\
MR;3_  H_M#6/^@'_ .3:?X4 :U%9/]H:Q_T _P#R;3_"C^T-8_Z ?_DVG^%
M&M163_:&L?\ 0#_\FT_PH_M#6/\ H!_^3:?X4 :U%9/]H:Q_T __ ";3_"C^
MT-8_Z ?_ )-I_A0!K45D_P!H:Q_T _\ R;3_  H_M#6/^@'_ .3:?X4 :U%9
M/]H:Q_T _P#R;3_"C^T-8_Z ?_DVG^% &M163_:&L?\ 0#_\FT_PH_M#6/\
MH!_^3:?X4 :U%9/]H:Q_T __ ";3_"C^T-8_Z ?_ )-I_A0!K45D_P!H:Q_T
M _\ R;3_  H_M#6/^@'_ .3:?X4 :U%9/]H:Q_T _P#R;3_"C^T-8_Z ?_DV
MG^% &M163_:&L?\ 0#_\FT_PH_M#6/\ H!_^3:?X4 :U%9/]H:Q_T __ ";3
M_"C^T-8_Z ?_ )-I_A0!K45D_P!H:Q_T _\ R;3_  H_M#6/^@'_ .3:?X4
M:U%9/]H:Q_T _P#R;3_"C^T-8_Z ?_DVG^% &M163_:&L?\ 0#_\FT_PH_M#
M6/\ H!_^3:?X4 :U%9/]H:Q_T __ ";3_"C^T-8_Z ?_ )-I_A0!K45D_P!H
M:Q_T _\ R;3_  H_M#6/^@'_ .3:?X4 :U%9/]H:Q_T _P#R;3_"C^T-8_Z
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M^@'_ .3:?X4 :U%9/]H:Q_T _P#R;3_"C^T-8_Z ?_DVG^% &M163_:&L?\
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M*\T^SU2_C7$(D$8>0@'8BLQ)(R!U-7K/6=+U&YGMK'4K.ZG@.)HH)U=HS_M
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MX)QN(SCK7;4E\,5_6K;&_B;_ *V2"BBBD 4444 %%%% !1110 4444 %%%%
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MY\(>']5;4],T.W@O"2PDW,^PG/W Q(3J?N@5U%.^A-M0HHHI#"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#S]_\ D-_\*UJ* ,G_ (2;1_\ G[_\AO\ X4?\)-H__/W_ .0W_P *UJ*
M,G_A)M'_ .?O_P AO_A1_P )-H__ #]_^0W_ ,*UJ* ,G_A)M'_Y^_\ R&_^
M%'_"3:/_ ,_?_D-_\*UJ* ,G_A)M'_Y^_P#R&_\ A1_PDVC_ //W_P"0W_PK
M6HH R?\ A)M'_P"?O_R&_P#A1_PDVC_\_?\ Y#?_  K6HH R?^$FT?\ Y^__
M "&_^%'_  DVC_\ /W_Y#?\ PK6HH R?^$FT?_G[_P#(;_X4?\)-H_\ S]_^
M0W_PK6HH R?^$FT?_G[_ /(;_P"%'_"3:/\ \_?_ )#?_"M:B@#)_P"$FT?_
M )^__(;_ .%'_"3:/_S]_P#D-_\ "M:B@#)_X2;1_P#G[_\ (;_X4?\ "3:/
M_P _?_D-_P#"M:B@#)_X2;1_^?O_ ,AO_A1_PDVC_P#/W_Y#?_"M:B@#)_X2
M;1_^?O\ \AO_ (4?\)-H_P#S]_\ D-_\*UJ* ,G_ (2;1_\ G[_\AO\ X4?\
M)-H__/W_ .0W_P *UJ* ,G_A)M'_ .?O_P AO_A1_P )-H__ #]_^0W_ ,*U
MJ* ,G_A)M'_Y^_\ R&_^%'_"3:/_ ,_?_D-_\*UJ* ,G_A)M'_Y^_P#R&_\
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M_P#S]_\ D-_\*UJ* ,G_ (2;1_\ G[_\AO\ X4?\)-H__/W_ .0W_P *UJ*
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MJ* ,G_A)M'_Y^_\ R&_^%'_"3:/_ ,_?_D-_\*UJ* ,G_A)M'_Y^_P#R&_\
MA1_PDVC_ //W_P"0W_PK6HH R?\ A)M'_P"?O_R&_P#A1_PDVC_\_?\ Y#?_
M  K6HH R?^$FT?\ Y^__ "&_^%'_  DVC_\ /W_Y#?\ PK6HH R?^$FT?_G[
M_P#(;_X4?\)-H_\ S]_^0W_PK6HH R?^$FT?_G[_ /(;_P"%'_"3:/\ \_?_
M )#?_"M:B@#)_P"$FT?_ )^__(;_ .%'_"3:/_S]_P#D-_\ "M:B@#)_X2;1
M_P#G[_\ (;_X4?\ "3:/_P _?_D-_P#"M:B@#)_X2;1_^?O_ ,AO_A1_PDVC
M_P#/W_Y#?_"M:B@#)_X2;1_^?O\ \AO_ (4?\)-H_P#S]_\ D-_\*UJ* ,G_
M (2;1_\ G[_\AO\ X4?\)-H__/W_ .0W_P *UJ* ,G_A)M'_ .?O_P AO_A1
M_P )-H__ #]_^0W_ ,*UJ* ,G_A)M'_Y^_\ R&_^%'_"3:/_ ,_?_D-_\*UJ
M* *-GK%AJ$QBM9_,<+N(V,..G<>]7J** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>image_028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )0!8,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%G4!QABIR 2.H]:UZX+X+_\DGT3_=E_]&O7>UI-*,FD1%W5V%%%%04%%%%
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:]+7/3Z*.M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** &2Q1SPO#-&LD4BE71QD,#P00>HK-_X1?P__ - +3/\
MP$C_ ,*U:*J,Y1^%M$N$9;JYCR^$_#LL31MH>G ,,$K;(I_ @9'X5Y)XR^'=
MUH!DOM/WW.F]3QEX1_M>H]_SKW.@@$$$9![5U8;'5:$KIW79G/7P=*M&S5GW
M1\T:#X>U'Q'?"UL(2W]^5N$C'JQ_R:]MT'X?Z'HU@(9[.WO[AN9)KF%7R?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"I/_ $&ZH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XC6?A;H>K:O<ZE%
M>:MIDUYQ>+IMV84NAZ2+@Y[],=374Z-HVG^'])@TS2[9;>S@7:D:_J2>I)/)
M)J]10M%9 ]7=A7C_ .T=_P D\T__ +"L?_HJ6O8*\?\ VCO^2>:?_P!A6/\
M]%2T >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\23-JMOXDCMSI;3JL5K$LN!E#ST&=W HBKRM_78'\-_ZZL]@\'?\)A]FNO\
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MUL=%17#> ;[7+K6O%,.O74<MS;W<2". MY4(,2MM3/;GKW/-=S1;8.X4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_\
M:._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\ HJ6@#V"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#Q3['X@_X6!_PBW_"6ZG_ -?/FR?\\O,^[O\ PZU[77E/_-?_
M //_ #ZUZM7HYA)OV?\ A3V2U?HC@P,4N?\ Q-;OH%%%%><=X4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!YI\8--M/[)M=5\G_3?/2W\W
M<?\ 5[9&QC..O.<9KJ_!.FVFF^$M/^R0^7]I@CN)OF)W2-&NX\GCH.!Q7/\
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M\^+/PFT'P'X5M=4TN[U*:>6]2W9;J1&4*4=LC:BG.4'?UI ?3=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'E/_-?_P#/_/K7JU>4_P#-?_\ /_/K7JU=^/\ ^77^!'%@
MO^7G^)A1117 =H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!Y_\8/^12M?^OY/_1<E=7X7_P"12T;_ *\8/_1:URGQ@_Y%*U_Z_D_]%R5U
M?A?_ )%+1O\ KQ@_]%K7?4_W*G_BE^AQ4_\ ?)_X4:M%%%<!VA1110 4444
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M,%_N\/3_ #"BBBN0Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *M_IMCJMJ;74;*WO+<D$Q7$2R(2.APP(JRJJBA5 50,
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M?'.*^?\ D9_78OX8R?R_S/5J1F5!EF"CU)Q7E1\%^/K]\W?B+RU/51=R>_\
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MX^;&C5EW!L$<9%MD'ZYY^M=_XL_Y%F\_X!_Z&M<'_P U_P#\_P#/K7>>+/\
MD6;S_@'_ *&M;9Y_NR_Z]_HS#*?XS_Q_J@\)_P#(LV?_  /_ -#:MJL7PG_R
M+-G_ ,#_ /0VK:KS\%_NU/\ PK\CNQ/\:?J_S"BBBNHP"BBB@ HHHH ****
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILDB1+ND=47U8X%
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MNF,XR5XNY@XN.ZL+1115""BBB@#RG_FO_P#G_GUKO/%G_(LWG_ /_0UK@_\
MFO\ _G_GUKO/%G_(LWG_  #_ -#6ML\_W;_N'^C,<I_C/_'^J#PG_P BS9_\
M#_\ 0VK:K%\)_P#(LV?_  /_ -#:MJO/P7^[4_\ "OR.W$_QI^K_ #"BBBNH
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_\ C!_R*5K_ -?R
M?^BY*ZOPO_R*6C?]>,'_ *+6N4^,'_(I6O\ U_)_Z+DKJ_"__(I:-_UXP?\
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MC7JO_P U,_S_ ,\:\7/YRE7AS/\ Y>+]3T\GC&-"5E]A_H=G111729!1110
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ML)X6A/XH)_)?Y&L:]6/PR?WG+2^!;!L^5<W"?[V& _055_X0J\MR3::IM/\
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MBSTWVB+G\ZM^#O!>K6'CG_A(=9\76VMW/V-K4*D85@NX$=#T'/;O1'XM?/\
M(;V?]=3TZBBBD 4452U+6-+T:%)M4U*SL8G;:KW4ZQ*QZX!8C)H NU6LM0LM
M2@,]A>6]U"&*&2"574,.HR#U'I7)>+1K/BK1[:+PEK5E#I=R)/MNHP.)6"#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7&?\U,_S_SQKLZXS_FIG^?^>->9F?\ RY_QQ_4[<%_R
M\_PL[.BBBO3.(**** "BBB@ IKQ1RC$B*X]&&:=10!GRZ'I<V=^GV^3U*H%/
MZ51E\'Z/)G;#)'_N2'^N:WJ*YYX3#S^*"?R1M'$5H_#)_><G+X#M"#Y-Y,A_
MVU#?RQ5?_A#]4MA_H>JXQT&6C_EFNTHKF>4X1ZJ-O1M?J;+,,0M'*_JDSBS9
M>,+0?N[DS8_Z:*W_ *%0=8\56F/.T_S1W/DD_P#H)KM**7]G./\ #K37SO\
MF/ZZG\=.+^5OR.,'C>XA8+=:9M/LY4_D15N+QSI[D"6"XC]P 1_.NG95888
MCT(JI-I.G3G,MC;L?4QC/YT?5\='X:R?K'_(/;867Q4VO1_YE*+Q7HTIQ]KV
M'_;1A^N,5>AU73Y^(KVW<^@D&?RK/E\)Z-+S]E*'U1V']<51E\"V#9,5Q<)]
M2&'\J.?,(;QC+T;7YARX.6TI+Y)G4 @C(((]12UQG_"$W<!)M-4VG_=*?R-(
M-)\66@_=7_F^WG;O_0A1]=Q$?XE"7R:8?5:,O@JKYW1VE<9XB_Y';2O^V/\
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M :1H]M]GM(U?RXO,9\%B2>6)/4GO7*?"CPOJ7A[X?MH^NVGV>X>>8M%YBO\
M(WNI(KT"BAZWOUT#MY:GB1\#^-H?",WP[@L+0Z/)<;EUHW8&V$R;]IB^\6^G
M'\Z]FLK6.QL;>TA&(H(UB0>RC _E4]%.[M_7H'6_]=S/U/0M'UORO[6TJQO_
M "<^7]KMTEV9QG&X'&<#IZ"O(]0TG3=&_:9\*V^EZ?:6,#:9([1VL*Q*6V7(
MR0H S@ 9]A7ME>/^(?\ DZ'PG_V"I/\ T&ZI >P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<9_S4S_ #_SQKLZ\X\W7?[=_M?^RIOM']W[.^S[NWIUZ>]>1FM11]EH
MW:2>B;T6^QZ& AS>TU7PM:NVYZ/1117KGGA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7!^(;"V'C"RA$0$=R8S*HXW$N0?T%=Y7&>(O^
M1VTK_MC_ .C#7E9O%.A&Z^U'\SNR^355V[/\CL8XTBC6.-0J*,*H& !3J**]
M4X0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y76
MOAOX3\1:S_:^JZ3]HO\ "CS?M$J?=Z<*P'Z5U5%'6X=+'A/B+PWXXUKXE/K>
MI^#FUG1[-RFGV3:G!#'M!X9@2<YQD@CG@'@8KV'P]>ZKJ&E+-K&B_P!CW6\K
M]E%TD^%'0[E&.?2M6BA:1Y0>KN5[ZPL]3LY+._M(+NUDQOAGC$B-@@C*G@X(
M!_"O$_C[X:T'1O MC<:7HFFV,[:G&C26MJD3%?*E."5 .,@''L*]TKQ_]H[_
M ))YI_\ V%8__14M 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !1110 4444 %%%% !1110 5QGB+_D=M*_[8_\ HPUV=<9XB_Y';2O^V/\
MZ,->9FW\"/\ BC^9VX#^*_\ #+\CLZ***],X@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BN9UWXA>$_#6HQZ?J^M06UV^
M/W6UG*YZ;MH.WK_%BNAM[F"\MHKFVF2:"50\<D;!E93T((ZBC=7#;0EKQ_\
M:._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\ HJ6@#V"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#C/#O_([:K_VV_P#1@KLZXSP[_P CMJO_ &V_]&"NSKS,
MI_@2_P 4OS.W'_Q5_AC^04445Z9Q!1110 4444 %%%% !1110 4444 %%%%
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M>P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5[!7C_B'_DZ'PG_V"I/_ $&ZH ]@HHHH **** "BBB@ HHHH **** "BBB@
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M4NB)6MV%%%%(84444 %%%8OB3Q;H?A"SAN]=O?LD$TGEHWE/)EL$XP@)Z T
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M^#L:E>/^(?\ DZ'PG_V"I/\ T&ZKL/'7C#6/"GV#^R?"5]K_ -I\SS/LA?\
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M *)-KGYS?_&* /8**\?_ .%O^,/^B3:Y^<W_ ,8JGJ7QUU[1K=;C5/AMJ5C
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M_P",/^B3:Y^<W_QB@#V"BO'_ /A;_C#_ *)-KGYS?_&*KWWQN\2:99R7E_\
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M_P#T(7_E'N__ (NC_A:?Q?\ ^A"_\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\
ME'N__BZ/^%I_%_\ Z$+_ ,H]W_\ %T ?0%%?/_\ PM/XO_\ 0A?^4>[_ /BZ
M/^%I_%__ *$+_P H]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q
M?_Z$+_RCW?\ \70!] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/
M=_\ Q= 'T!17S_\ \+3^+_\ T(7_ )1[O_XNC_A:?Q?_ .A"_P#*/=__ !=
M'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T ?0%%?/\
M_P +3^+_ /T(7_E'N_\ XNC_ (6G\7_^A"_\H]W_ /%T ?0%%?/_ /PM/XO_
M /0A?^4>[_\ BZ/^%I_%_P#Z$+_RCW?_ ,70!] 45\__ /"T_B__ -"%_P"4
M>[_^+H_X6G\7_P#H0O\ RCW?_P 70!] 45\Z1_&GXFS:I-I<7A*T?4(4WRVB
MZ=<F5%XY9-^0/F7DCN/6K?\ PM/XO_\ 0A?^4>[_ /BZ /H"BOG_ /X6G\7_
M /H0O_*/=_\ Q='_  M/XO\ _0A?^4>[_P#BZ /H"BOG_P#X6G\7_P#H0O\
MRCW?_P 71_PM/XO_ /0A?^4>[_\ BZ /H"BOG_\ X6G\7_\ H0O_ "CW?_Q=
M'_"T_B__ -"%_P"4>[_^+H ^@**^?_\ A:?Q?_Z$+_RCW?\ \71_PM/XO_\
M0A?^4>[_ /BZ /H"BOG_ /X6G\7_ /H0O_*/=_\ Q='_  M/XO\ _0A?^4>[
M_P#BZ /H"BOG_P#X6G\7_P#H0O\ RCW?_P 71_PM/XO_ /0A?^4>[_\ BZ /
MH"BOG_\ X6G\7_\ H0O_ "CW?_Q='_"T_B__ -"%_P"4>[_^+H ^@**^?_\
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MTG4IOVC?#&J1:?=OI\.F.DMVL+&)&VW'#/C /S+P3W'K7JE%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\K^*>DZEJ'CKX=W%
MEI]W<P6FIE[F2&%G6%?-@.7(&%&%)R?0^E>J44 %%%% !1110 4444 %%%%
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MO-_C7X6UGQ=X-L[#0[/[7=1Z@DS)YJ1X01R G+D#JP_.O2** "BBB@ HHHH
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M_P =/!/B+QC_ &#_ &!I_P!L^R_:/._?1Q[=WE[?OL,YVMT]*]@HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\8_:!CLI8/"T>I3/#8M?E;B6,99(R!N(X/(&>Q^E>SUY
M-\;]/U"[3PU<6.A76LI:7QFGM8(&E#H #M;"M@'&.14O=7[HJ/7T9YF^G^#M
M-U/2W^&?B76;SQ%)=HB0R(R(4SEMQ,:<<#(R1CM7O_BGQ-J.A?9H-,\.7FL7
MDX+?(XA@C ZEYF&U>^ >N*\4UJ+4_&-DNCZ/\'/^$?O))49-1^S^3Y0# GYO
M*3'Y_A78?$'2-4_X2OP[<:OH^I^(_#=M;;)[6P4R,;D _.\8(W \=>.OT-]$
MO/\ 3^OF1U;\OU_KY'2^%OB=9Z[;:W]OL&TV[T5#)>1+.EP@49Y61.&^Z<^]
M4=,^*&KZI#!J</@749=!GD")>6MRD\P&<9:! 6 '.>:P_A_HNI:;XK\:.WA%
M[&WO+>-[.QF01P.N#^[,BJ4!.1D#."3UQ7*7WA:5KE3X2\&^+_#?B4N 3%+_
M *"OS G,Q/(QTQ@9[<4+=>B_X/\ 5]!O9^OZ+^MM3V+Q-XX?1]8M="T?1YM:
MURXB,ZVD<RPJD8/WG=N%[XX[=JJV?C*+Q/X<\26<]A-INK:=;21WEE,P<QDQ
MD@AAPRGGGBN,\?>"I7\::?XAUKP_>^)=+:P6VO(-/+>='*O1U564L"3TSCKG
MM6EX'\*M8:%XHO[?PJ-#AO;=XK*U9IGNI(PK8,@>1@&)(P  >O6HDKPE?L_^
M 5%^]'U7_!,&POM+T_\ 9ST.;6-'_M:U^U;?L_VEH/F,SX;<O/'I7?\ B+XA
MMX?\9Z7X;BT.>^DO[8S1M!, ^[YL*%(Q_#U+  <]J\^O?#^M/^SMHVF+I%^V
MH1WBL]J+9S*H\USDIC(&"#T[UUFM:5J$WQV\+ZC'873V,&GR)+<K"QCC;$F
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M$_7\F#UA+^NJ*GB2VA\:_&*+PGJK2R:)9Z8;N2T29D6:4L "VT@G&1CGM3?
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MF"S 87H>M$?CB_/_ #"7P27E_D0>//\ BI/B;X<\&74THTB:WEN[V".4IY^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN[9\[9K>02(V#@X8$@\T 6**** "BJ\%_9W5Q<6]O=P33VS!9XXY S1$C(#
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MMK>W@M+:.WMH8X8(E"1QQ*%5%'   X ]J\EL&:X_:=U+SUQ]GTH"'//&$_\
MBFH5G426VK^Y7_R*L^1O^M78])L?$VCZEKM_HMK>;]1L #<P&-U* ]#D@ CD
M=">M1:)XOT'Q%?7]EI6H+<7&GOLN4\MUV')'5@ >0>1FO,_'VI#P!\5;;Q.>
M+74]+FMY0.,RQKE?KD[!7!:%<W/PR2#6;F9B?$6A3S+O/'VC<2@Z>A7\6-2G
M[M_)_?KI^ VK.WI]VE_NN?1.D^+M!URPO+_3]122SLY&CN)W1HT1E&3RX (
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <CXX^'.B^/X[-=5DNX6M"QCDM756PV,@[E;C@5T.DZ5:Z)H]I
MI5DI6VM8EBC!.3@#&2?6KM%'2P/5W.5\-?#[1?#.C:CI,'VB\L]0E:2X2\*O
MG<,$<*.,"L7_ (4UH&S[*=5\0'2-V?[(_M%OLOTVXSC//WNM>B44!<Y;Q'X
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M)110W?425E9!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#D(/"5UIWQ,G\2Z?+ MCJ%IY-_ [$,9%QL=0
M0>!@Y(]>:Z^BBCHD'6X4444 %%%% !1110 4444 <C:>$KF3XE7OBO4I8'1+
M9;33HHV),:=79L@88DGIG@]:ZZBBCHD'6X4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M,E9TA=HT\QPI*IG&X]AGM3Z* ,G^T-8_Z ?_ )-I_A1_:&L?] /_ ,FT_P *
MUJ* ,G^T-8_Z ?\ Y-I_A1_:&L?] /\ \FT_PK6HH R?[0UC_H!_^3:?X4?V
MAK'_ $ __)M/\*UJ* ,G^T-8_P"@'_Y-I_A1_:&L?] /_P FT_PK6HH R?[0
MUC_H!_\ DVG^%']H:Q_T _\ R;3_  K6HH R?[0UC_H!_P#DVG^%']H:Q_T
M_P#R;3_"M:B@#)_M#6/^@'_Y-I_A1_:&L?\ 0#_\FT_PK6HH R?[0UC_ * ?
M_DVG^%']H:Q_T __ ";3_"M:B@#)_M#6/^@'_P"3:?X4?VAK'_0#_P#)M/\
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M_0#_ /)M/\*UJ* ,G^T-8_Z ?_DVG^%']H:Q_P! /_R;3_"M:B@#)_M#6/\
MH!_^3:?X4?VAK'_0#_\ )M/\*UJ* ,G^T-8_Z ?_ )-I_A1_:&L?] /_ ,FT
M_P *UJ* ,G^T-8_Z ?\ Y-I_A1_:&L?] /\ \FT_PK6HH R?[0UC_H!_^3:?
MX4?VAK'_ $ __)M/\*UJ* ,G^T-8_P"@'_Y-I_A1_:&L?] /_P FT_PK6HH
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M_P"@'_Y-I_A1_:&L?] /_P FT_PK6HH R?[0UC_H!_\ DVG^%']H:Q_T _\
MR;3_  K6HH AM9)I;='N(/(E.=T>\-CGU%3444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4-U)-%;N]O!Y\HQMCWA<\^IJ:B@#)_M#6/^@'_Y-I_A
M1_:&L?\ 0#_\FT_PK6HH R?[0UC_ * ?_DVG^%']H:Q_T __ ";3_"M:B@#)
M_M#6/^@'_P"3:?X4?VAK'_0#_P#)M/\ "M:B@#)_M#6/^@'_ .3:?X4?VAK'
M_0#_ /)M/\*UJ* ,G^T-8_Z ?_DVG^%']H:Q_P! /_R;3_"M:B@#)_M#6/\
MH!_^3:?X4?VAK'_0#_\ )M/\*UJ* ,G^T-8_Z ?_ )-I_A1_:&L?] /_ ,FT
M_P *UJ* ,G^T-8_Z ?\ Y-I_A1_:&L?] /\ \FT_PK6HH R?[0UC_H!_^3:?
MX4?VAK'_ $ __)M/\*UJ* ,G^T-8_P"@'_Y-I_A1_:&L?] /_P FT_PK6HH
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M_P"@'_Y-I_A1_:&L?] /_P FT_PK6HH R?[0UC_H!_\ DVG^%']H:Q_T _\
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M%<2P>8Y*A>&YR..^14NC:*R?%GPQJ^E>"-0T/1%@EA/FVNU]VQOGE"YV9W
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MB@ HHHH **** "BBB@#S.\BUY?BIX6GUB^B:.8WGDV-LI$<*K'P2QY=R#R>
M.@]3O^+/ ?@_Q!,^L>)-.69[: AIFN98PD:Y;D*P'&33?$%G=3?$3PC=16TT
MEO +OSI4C)2/=& -QZ#)Z9I_Q&AO;WPDVFV4$\K7]S#:R^1&7*1.X$C' X&W
M.3VS1:\4EO=_FA_:;\E^IA_"CPAIFDV]YXCLM/:P752#;6QD9_*MA]S)8D[F
M^\>>X Z5Z13(HD@A2&-0L:*%51V X%/IMWV)2[A1112&%%%% !1110 4444
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M6EWVKZ8^B>"]0\.Z=871N[F74XMDT\@1E1%W,S%07)STXXKURF]E?^MB>O\
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MAMH4B0>@4 5;JY=ELB5KKW"BBBI&%%%% !1110 4444 %%%% !1110 4444
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M_@1_]:C^PO\ J*ZI_P"!'_UJ -:BLG^PO^HKJG_@1_\ 6H_L+_J*ZI_X$?\
MUJ -:BLG^PO^HKJG_@1_]:C^PO\ J*ZI_P"!'_UJ -:BLG^PO^HKJG_@1_\
M6H_L+_J*ZI_X$?\ UJ -:BLG^PO^HKJG_@1_]:C^PO\ J*ZI_P"!'_UJ -:B
MLG^PO^HKJG_@1_\ 6H_L+_J*ZI_X$?\ UJ -:BLG^PO^HKJG_@1_]:C^PO\
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MJ -:BLG^PO\ J*ZI_P"!'_UJ/["_ZBNJ?^!'_P!:@#6HK)_L+_J*ZI_X$?\
MUJ/["_ZBNJ?^!'_UJ -:BLG^PO\ J*ZI_P"!'_UJ/["_ZBNJ?^!'_P!:@#6H
MK)_L+_J*ZI_X$?\ UJ/["_ZBNJ?^!'_UJ -:BLG^PO\ J*ZI_P"!'_UJ/["_
MZBNJ?^!'_P!:@#6HK)_L+_J*ZI_X$?\ UJ/["_ZBNJ?^!'_UJ -:BLG^PO\
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M$ C@]_6K5SO3XS:>8P0LFB3"7'<+*FW/T)/YT):V?6_X?\,#\NEOQ.THHHI
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MZ,VIZK(PBWA$CC +R,>BJ"1D]^O05SW@-;?3KWQHL<:0VUOJS82-<*BB&/@
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ML6&@6VEZ1I]O;P0376FVOV>TN+A,LOR@?>Z@' SBCI?^O,.O]?(@\->+M/\
M$ZW"6\%[9WEMM^T65_ 89XMWW25/8X/()K?KSSPPVJV7Q N8_%<5J=<U"Q#0
M3Z?(QMC#$W*!6 96!<')SG/!&,5Z'3>R8ENT%%%%(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !113)94@A>60[412S'&< <F@!]%9/_"3:/\
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M_/W_ .0W_P */^$FT?\ Y^__ "&_^%"T^ZWXW!Z_UV1K45D_\)-H_P#S]_\
MD-_\*/\ A)M'_P"?O_R&_P#A0!K45D_\)-H__/W_ .0W_P */^$FT?\ Y^__
M "&_^% $?AGP_P#\(Y8W5M]J^T>?>SW>[R]FWS'+;<9.<9QGO1XH\/\ _"2:
M9#9?:OL_EW<-SO\ +WY\MP^W&1UQC/:I/^$FT?\ Y^__ "&_^%'_  DVC_\
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M?_G[_P#(;_X4?\)-H_\ S]_^0W_PH UJ*R?^$FT?_G[_ /(;_P"%'_"3:/\
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>image_029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *(!84# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[V=V<=\[,8_.O3_#^NV?B70K75K!B8+A<@-U4]"I]P<BBS'<TZ***0!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5'4X4$G\!4MO<0W=M%<V\BRPRH'C=3D,I&010!+1110 4444 %%%% !1110
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MZ>6W+1+ZNI#*/Q( KRGQ[J::S^S]X:N48AO/MX7QU5T5D;\<@U,>J\X_=?\
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ME[6UCB<C^\%&?US6O6E2W.[&</A04445!04444 %%%% !1110 4444 %%%%
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M_P#%.@W(*WFCFYM9E/\ O;@?H=W%6-)\(>+_ !3\-=#T3^VM-3PY=6T,DSM
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M1L^J7YJ[_,IOEE?S_1M+\C:U>]\0>!])^'F@:#<0PS79^SW"31!D=R%R6XW
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MIU% .0".]%( HHHH R5\+>'EU#^T%T'2Q>[MWVD6<?F9]=V,YK6HHH ****
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M AN[.UU"UDM;VVAN;>08>*9 Z,/<'@U*JJBA5 50,  8 %+10 4444 %%%%
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M3Z7J4I9C"H0,6>-LC X&,Y[]:[/2O&GAO6]&N-7L-7MY+"VSY\S$QB+']X,
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MFT=M(CTC>9"LD7ERYC*;(@C$[,G/S!3\J\>G844[ZW_KK_F&_P#7]=@HHHI
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M];W!JZL%%%%( HHHH *Y7Q5H\FH:EI]U/I(UO3((Y%ETTB([I&V[) )65#M
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M_P"E$E=!X[_Y)YXE_P"P5=?^BFKG_@E_R2'0O^WC_P!*)* /0**** "BBB@
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M[TQG]W@L%617)YZ9VX_'VK2\%75I_P (UI^F0.Q?3[6*V*O]XA%"AOQQ7/\
M6:7M?8\WO;V.CZM55+VW+[O<Z*BBBMS **** "BBB@ HHHH **** "BBB@#S
M_P",'_(I6O\ U_)_Z+DKJ_"__(I:-_UXP?\ HM:Y3XP?\BE:_P#7\G_HN2NK
M\+_\BEHW_7C!_P"BUKOJ?[E3_P 4OT.*G_OD_P#"C5HHHK@.T**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBN=UWQOH?A\,ES="6X'_+O!\[_ (]A^)%7"G.H^6"NR9SC!<TG9'15RWC;
MQA%X7TS,7ERW\IVQ1%A\O'WF'7 _6N-E\8>+_&,S6_AZQ:TM<[3*O4?60\#Z
M#GZUI:-\*(!)]J\07CWL['<T4;$+GW8_,WZ5WPPM.@U+$R_[=6K^?8XI8BI6
M3CAU\WHOEW/-='\3:CH_B!M8BD\RYE9C.&'$H8Y8''J>:^B=,O?[1TRVO?(D
M@\Z,/Y4HPRY[&O(?!>@Z=-\3=4LY8 ]O8-.T$;'(!24*N<]< U[16N;5*<IQ
M48ZV6OD]D9Y9"<82<GI=_>MV%%%%>0>F%%%% !117&>)8O&VHZ\MEHE]!H>D
M16_FR:H\,=P\DF?]6(V/  YR1^-*X'9T5Y1!\2-7G^&MKJ*"U.L7>I_V5;SA
M#Y+L7VB4+Z8!./45H:3XHUKP[K6N:%XGU&/59+#3/[3AO$M1 TD8R&5E7Y>"
M!C%-Z7_KI?\ )AKI_76WYGH]%>2Z3XK\66<WAC6]:U.UN=*\23K"+&.T"&S+
MJ3'M<'+=L[OPJ;7/$GBW4-3\476@:G;6-AX9&&MI+02F]<)O<,Q.4 Z#;0U;
M?S^5K7_- M=%Y?.][?DSU2BL[0-537?#VG:JB;%O+=)MO]W< <5HTVFG9B3N
MKGC_ ,(/^2A_$[_L*C_T;<5[!7C_ ,(/^2A_$[_L*C_T;<5[!2&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\
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M)<,Z5)R<KW;TZ:-K\;'IYMB56J**C:RWZZI,****]D\D**** "BBB@ HHHH
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M>)K[Q=X*M=8U%($N99)%98%*KA7(& 23T'K76U<E9V)04445(PHHHH ****
M//\ XV_\DAUW_MW_ /2B.N@\"?\ )//#7_8*M?\ T4M<_P#&W_DD.N_]N_\
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M110 45'<7$-K \]Q-'#$@RSR,%51[DUP>N?%;2[%F@TJ)M0N.@8?+&#]>I_
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M!IUAI.H>-_$7B'7;G2M0TBTN]&.E6T6H1B.5BQ)9BF20 <8]:]3HIO6_G?\
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M5S_P2_Y)#H7_ &\?^E$E=!X[_P"2>>)?^P5=?^BFKG_@E_R2'0O^WC_THDH
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M60/#_CCQLPDU>Y-A8MSY;@J,>T8Y/_ OSKT71?"VC: @&GV,:28P9F^:0_\
M CS^ XK8I_6Z5'3#PU[O5_Y(/JU2K_'EIV6B_P V<EH?PYT#1=LC0?;;D<^;
M<@, ?9>@_4^]9?Q? 'A&T & +Y./^V<E>@UY_P#&#_D4K7_K^3_T7)2PE6=7
M%PE-W=_\PQ5.%/#34%;3_(O:1XKL=-T#2K2:*Y:2.QM\E%4CF)3W/O6UI/B2
MSUBZ:WMXYU=4+DR* ,9 [$^M9$G_ "2RQ_Z\;7^25J^$_P#D6;/_ ('_ .AM
M7@5*N(_M&5%R7+K+;IS-6O?\?P/7IPH_4HU%%WT6_DM=OP-JBBBO0.4****
M"BBB@ HHHH *^?\ ]IK_ )E;_M[_ /:-?0%?/_[37_,K?]O?_M&@#Z HHHH
M**** "BBB@ HHHH **** "BBB@ HHJO>7]GIT(FO;N"VB+;0\\@0$]<9/?@_
ME32;=D)M)79++*D,32RN$1!EF8X %>>?VW:_\)F=4(?[-DCISC9MSC]:U/%F
MOZ?<Z?\ 8K:5;AG(?S(GRBX]QP?I7,6^D74^K1Z:R>5.^,A_X1MW9/X5\SFV
M+G*M"E15^5K_ ,"Z+^OT/H<MPD(T95*VG,G]W<Z.X\4ZGJTIMM&M'7_;QN;'
M\EJ:R\&RW$OVG6+II)&Y**V2?JQ_I^==+INGPZ78QVL.2J]6/5CW-6Z]*GE[
MJ6GBY<[[?97R6YPSQZIWAA8\J[]7\R"TLK:QB\JU@2)/11U^OK4]%%>E&*BK
M)61YTI.3NW=G*>-/^$M_T'_A%O\ II]H_P!5_L[?]9_P+I7%>&O$GC?5;BTO
MI;^-M)6\2&YDD%O&,9!8<@'[I[?A7L%>8?#728-8\$7%O</(J+J3.#&0#GRT
M'<'UKOC6E'!U'"G&4HV2OYWW?Y'#*DI8J"E.2B[WMY6Z'0>';^S@UC7'ENX(
MTDN,HSR !AN?D>O45U]<Q_P@VF?\][O_ +[7_P")K)\6_$BVTIVT[1PMYJ).
MPLOS)&W3''WF]A_]:O&RG"XN2=&<5U>CONVW?M:YZF88C#Q?M%)_-=DEIW.C
M\1^*--\,V?G7LN96'[J!.7D/L.P]Z\UBMO$?Q0OEGN";+18W^7&=@_W1_&WO
MT'/3I6GX=^'EYJUX-:\6RR2RN=XMF;YF]-_H/]D?_6KTZ**.&)8HD5(T&U54
M8 'H!7NNI2PFE+WI]^B]/\SR?9U,3K4]V';J_7_(SM#\/Z=X=L1:Z? $'\<C
M<O(?5CW_ )5J445Y\I2F^:3NSNC%15HJR"O.OA-;077@^Z2XACF07[D+(@89
M\M.>:Z7Q/X/T_P 6?9?M\UU']FW[/(91G=MSG*G^Z*Q[#X5Z'IVHVU[#=:BT
MMO*DR!Y$()4@C.$Z<5UTW0>'E3G+65M+76E_S.6:K>WC.$=%?K;>WY'5_P!C
MZ9_T#K3_ +\+_A5VBBN",(Q^%)>B1VRE*6[N%%%%42%%%% !1110 4444 %<
ME\1M=U/0/"OG:.T2:A<W,-I!),,I&TC8W'Z?C76USOCA/#TGA&^7Q2ZII.T>
M:Q)R#D;=N.=V<8Q2>PX[GD5U<_%:WA\1&3QE;%M#(-U&MM$&>(H'WI\@[9X)
M'(KW'19UN="T^=+@W"R6T;B9A@R94'<?KUKP;Q-KOPC\3W]O=7&LZQ;-'"EO
M*MM$ZK<1I]T."IS]>*]\TL6JZ19BQ39:"!/(7&,)M&T?EBK7P_UY_G_F0_B7
M]=O^#J<-XW\*>)7\5V7BSPA<6:ZE%;-9SPW>=CQDD@CW!/\ *L+PMH6MZ#\-
M=0N/"^H:;JWB'4;PO=72R!HD).'PV1RH)/U)X-=YXO\ ^$Q\JV_X1+^RM^6^
MT?VAOQCC;MV_C7EGPB_X3?\ X1__ $7^Q_[ ^V3_ &G?O\_/\>WMUZ5G?22\
MOUO]S-'O%^?Z?F>C?"[2+/1? =E:V>I6^HY9Y);JW?<CR%OFP>^.GX5V5><_
M W_DE>G_ /7:?_T8U>C5K/XOZ\B([?UW85G:]HUOXAT*]TB[>5+>[B,4C1$!
MP#Z$@C/X5HT5FU?1C3L<!8>#M0^'?AB2U\#HFHR-=?:)H-4E :5=H!6-U"A6
M^48+ CK6?;>#=;\5ZKKVM^([*+1Y-0THZ7!91W(G**227=E&#SC&.U>GT4WK
M>_\ 6E@6FW]=3RO1/#?BW4-4\,6NOZ9;6.G^&AE;B*\$IO7";$95 RH'4[J]
M4HHIMM[_ -7$DD>+_&#X=^%=/\$Z_P");72O+U=I4F-Q]HE.7DG0.=I;;SN;
MMQGBO2/ G_)//#7_ &"K7_T4M<_\;?\ DD.N_P#;O_Z41UT'@3_DGGAK_L%6
MO_HI:0SH**** "BBB@ HHHH **** "BBB@ IDL4<\9CEC61&X*L,@T^BAJ^C
M!.VJ.9U'P797),EF[6LG7'WD_+J*Y/4KK5K-9=)N[F1XU894\A@.1@GG%>I5
MSWC&R@FT.6Z=!YT&W8XZX+ $?3FO$S'+H*E*K0]UVUMHFNJL>Q@,PE[2-.M[
MRZ7W3,+PKXC^QE=/NV46Q)\N0D#RSUY]J[U65U#*P93T(.0:X[1?#.GZGX=@
MFE5TN'+DRJW/#$#CIVJ%M$U_06,FF7!GASDHO]4/].:C!5<5AJ$?:1YX6NFM
MTNUNI6*I8;$UI>SERROL]F_4[BBN2L?&R!_)U.V:"0<%T!P/JIY'ZUTUK>6U
M[%YEM.DJ>JG./KZ5ZN'Q='$?PY7?;K]QYM?"5J'\2.G?I]Y/11172<X4444
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M9:9;BWL;6*WB'\,:@#\?6K-%*MB:M;XW\NGW#I8>G2^!?Y_>%%%%8&P4444
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M,**** "BBB@#S_XV_P#)(==_[=__ $HCKH/ G_)//#7_ &"K7_T4M<_\;?\
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MA':-"?UZ5C4Q%&G\<TOFC:&'K5/@BW\F;=%<E/X\M5!^SV<SG_;8+_+-5_\
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MM-!T/Q5>:2/"$_AS7C:"3;)?-=+/!N'S!MQ4'(&0/SHCJW_72X2T2/5Z^?\
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M;6. WV0S?J !3? W@NRO?%>KQWK_ &B'2)_+6,K@2MN8 M[?)G'?/Y^S
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MH/ G_)//#7_8*M?_ $4M(9T%%%% !1110 4444 %%%% !1110 4444 %%%%
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M,4 >P45X_P#\+?\ &'_1)M<_.;_XQ1_PM_QA_P!$FUS\YO\ XQ0![!17C_\
MPM_QA_T2;7/SF_\ C%'_  M_QA_T2;7/SF_^,4 >P45X_P#\+?\ &'_1)M<_
M.;_XQ1_PM_QA_P!$FUS\YO\ XQ0![!17C_\ PM_QA_T2;7/SF_\ C%'_  M_
MQA_T2;7/SF_^,4 >P45X_P#\+?\ &'_1)M<_.;_XQ1_PM_QA_P!$FUS\YO\
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M (P_Z)-KGYS?_&*/^%O^,/\ HDVN?G-_\8H ]@HKQ_\ X6_XP_Z)-KGYS?\
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M+?\ &'_1)M<_.;_XQ6?IGQ]UC6_-_LGX=WU_Y./,^R73R[,YQG;"<9P>OH:
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M=.OQ.!;LKV\\,FR6%U& ZL.A_3VJMH'@72= CO3YM[J5U?)Y=U=ZE.9YI4Y
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MZ\\ 'KWZ58USQKJ>DQ:19P>%[F]U[4HRXL([E%CA*@%PTQ&WCG''..U'2_\
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M8YZL.M>C5';V\%I;I;VT,<,,8VI'&H55'H .!4E4W<204444AA1110 4444
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MHHHH&%%%% !1110 4444 %%%% !1110!4U1H$TF\:Y>1(!"_F/$I9U7:<E0
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MR@SGR[:%8USZX4 5':Z)I-C>RWMII=E;W4W^MGAMT1W_ -Y@,G\:I.S3[?\
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MOV^&VC:9%IVM1R7FOI<W$<LPNIX$8,K2,R(H7^\<@X)Y-$?U7Y_Y:@O/L_\
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MVPC70;=IS/YV?."CYQC'RX) ZFL31M)F\5_L_P!MIEHI74(;?9$I(4K<0R'
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M PH'\SS6K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445'//#:V\EQ<2I##$I>221@JHHY
M))/ % %73=(L-(%R+"W$"W,[7$JJQ(,C?>(!.!G'08%7JAM+NVO[6.ZL[B&X
MMY1NCEA<.CCU!'!J:@ HJK::G8:A)<1V5];7+VS^7.L,JN8G_NL ?E/L:M4
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M#5YELQ+)KNDQKNDY 5)'4 ,<=NV.]7_'W_)7/AY_UUN/_05JN7WH^?\ P?\
M(5_=EY?\ S_%>K?$#P5\+9KS5==M)M<-^BQW-M"C*(F'W<-&HSD'^'\:H:HW
MQF\,Z--K]_XGT2[L[6/SI(/*4%U]/]2O/T85O?'X9^&;#UO(?ZUY_P"+_A-I
M?@2+3O$EO;W6LZ-$Z_VA:7,F'53_ !!D"\9['VSQ4IWN]M4OP70;6B2UT?YG
M;>._''B$>!?">J^'[I=-O=9GB1MT:2*-Z$X^96XSCD#-+:^'_C8EW"USXPT1
MX!(ID585RRYY _T<=JR?C5=:/JG@3PG<02B/1Y[Z,AX1]R$QG.  <$#M@]*Y
MO2=,^">F:Q97]MXPUEY[:=)HUDA?:65@0#BW'&1ZU<;<[]?\NA#^%>G^?4Z;
MXI>/?%GASXAVNGZ+?B.Q2Q6\GMS!&V]5+E_F92?NKV(K7^+GCK6M$T?2CX6N
M?*N;F-[R241H^+=5'.'!'5Q[\50\2Z='K'[0=E9R*&BFT&5&SZ,LJ_\ LU</
MHIO]>\)^+)]2B(;0-"&E1\\95RQ/UP@'X5'_ "[\]7]S:_R+^W]R^])_YGJM
MOK'CC6O 'AB;0UADO]1C4WVIS+'MME/5Q'D!CSP "..G-'ASQ%XATKXCOX+U
M_5(=:\RR^UQ7T=LL#IS]UT7Y<<?R]:QO^$^C\!?!'PY<1QK-J-U:+%:1,?EW
M8Y9O8<?7('O5GX3:9I-O>W&L:AXFTW5_%NIKOF6&\CE>%.I10ISZ9QP, #@5
MHTN>797_ . OEN1?W%?=_P">_P"AZ3KNKP:#H-_JUQ_JK2!IF'K@9Q^/2N6\
M/>+6TOX<6?B7QGJ0C^UGSBX@.(ED/[M J+D@#')!/J:3XQI,_P *=<$.=PC0
MMC^Z)%)_3-<K\3FCD_9^T]HO]68K+;],+6:>C?FE]Y=M8KU_ [RV^(OA"\UU
M-%M]=MI=0?A8UW88_P!T-C;N]LY]JL^(_&WASPD85US58K1Y_P#5H59V/OM4
M$@>YXKSWXG6-M:V'P]$$*1B'5;:*,(H&U2 <#\A1+?6&A?M#7][XCN(+6"?3
M5&GW-TP2-<;=P#'@'A_S]ZJVMO-K[E?\2;Z7\D_O=CT71?&/A_Q%J%U8Z1J4
M=Y/:HKS")6VA6&00V-K?@37/:1XXCM[+Q!K_ (@U PZ-'JK6=D?)W!%3"9^1
M=QW/NY.?PKAO"VNZ7I_C;XEZYI83[##:+/$4&%<@$Y7V9N0>^<U)XVTIM(_9
MQT^TE4B8FWEFSU+N^]L_BQH6R?>WXO\ R15M>7S?X+_-GH\/Q,\%W&ISZ?'X
MBLOM$"EGW,53 &3AR-IP/0GI5SP[XV\-^*Y;B+1-5ANY;<_O$565@/4!@,CW
M&17G/Q%T^S'C3X96PMHO(%QY8CVC&T&/ QZ5?MU5/VEKK8H7=H@+8&,G<O7\
MA323=O\ %^!+>E_)/[S:^&_B+5=?N_%,>IW7GK8ZM);6P\M5V1@G"_*!GZG)
MK5\?ZCJFB^$;G5])E"SV#)<21E5831*?G0Y!Q\N3D8/'6O,? GC_ ,,>$-:\
M8VVNZG]DFFUJ:2-?(EDRNXC.44CK7>ZIXLT#Q7\-/$E_I-[]KLXK.>*1_*>/
M#>7G&' /<5$G[BDNB3_!%Q5ZCB^K:_$ZS2=2M]9TBTU*U;=;W4*S1GV89JY7
M&?"=)8_A;H ESN-OD9/8L2/TQ79U<TE)I&<&W%-A1114E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %5-3@N[G2[F&PNS:7;QL(;@(K^6^.#A@
M0>>QJW12:NK M#R?P]\4IM,\*Z['XO=1X@T)BDT>T(;G)Q&5  ')(' QC![T
M2:WXUTGX+:EXDU;4BFM2JL]NOV>("VC9U 7;MY.#_%GK5'XC:%IMW\:O!+SV
MJ.;PN+@'I)Y>"N1[9KK?C%_R2C7?^N2?^C%I3?[MRZO3[FOS*@E[11Z;_??3
MY&)KGQ#U0Z9HGA_PWMO?%VIVD4CN5&RV#("TCC&W/4XQ@=<= ;7CW5?$O@OX
M6"[77&N=:2:)9+PVT0!W-\P";=H'8<9KA;KX=2>$_ FC>.- GGFUVQ6.^NG=
MR1-$R@LNW/ 4<>XS[8Z'XH^(K/Q3\#$UFR;]U<30,RYR8VW?,I]P<BM963?^
M)7^]?ANB*>JCVM]^FO\ F>OP,7MXV8Y9D!)_"I*\^M/C/\/W2"!=?S(0J!?L
M<_7IC[E+K6D_$VX\8&ZT?Q%IEOX?\R,BUEC4R; !O&?)/).['S=^U2UKY"C\
M/G83XL>.I_!WAWR]+.[6;H-Y ";S$BC+RE<$8 ]>.?8U4U+QYJFD_"30M87R
M[K7-42"")I% 4S2#)8JH XP3@8KCO%MKXRMSXTUC5/" GCO+:2VAO_[2A M+
M09QMCY8Y^\>A)[5#J3:M=_!?PKJ-YI#6EMHU[:S!EG$OG6X7'FX4?+R>AY%*
M%FM>\?DGT_KS[%RT>G9_-V_S_K4[O1]<\3>'?'UCX6\3:M!J\>IVKSVUVEJL
M#1R+RT9"\$8!YZUZ+-*D$$DTK!8XU+,Q[ #)KR>\U"P\7_&_PQ-HEY#?6VF6
M4MQ<SV[AT3<"%4D< YQQ[UZ#XO2:3P7KB6^?.:PG"8ZYV&E-M4^;KK^#T""3
MGR^GXG*^$_'9E\(:EXR\27_V?2)KQA9IY&?(A#;%^XI9B6ZYS^ KJ]4\5:+H
MNFV6H:A>^3:WLB1V\GE.V]G&5& "1D>N*\=U%HW_ &4K<Q= D8/U^T<_K3/'
MOB[0]9\#>"K+3]2MKB[^V6KR01R!GB"IM.]1RO) YQ6C7O<O9Q7WV(4O=YGU
M4G]U[(]?\1^-O#GA(P+KFJQ6CS_ZM"K.Q'KM4$@>YXI^B^,?#_B+4+JQTC4H
M[R>U17F$2MM"L,@AL;6_ FO.I;ZPT+]H6_O?$=Q!:P3Z:HT^YNF"1KC;N 8\
M \/^?O65X6UW2]/\;?$O7-+"?88;19XB@PKD G*^S-R#WSFLT_=N^S?W="VM
M;+NE]YW.D>.([>R\0:_X@U PZ-'JK6=D?)W!%3"9^1=QW/NY.?PK2A^)G@NX
MU.?3X_$5E]H@4L^YBJ8 R<.1M.!Z$]*\X\;:4VD?LXZ?:2J1,3;RS9ZEW?>V
M?Q8U=^(NGV8\:?#*V%M%Y N/+$>T8V@QX&/2KY?>Y7W4?PW^^Y-]')=F_P ?
M\CT;P[XV\-^*Y;B+1-5ANY;<_O$565@/4!@,CW&16%\-_$6JZ_=^*8]3NO/6
MQU:2VMAY:KLC!.%^4#/U.36+;JJ?M+76Q0N[1 6P,9.Y>OY"L#P)X_\ #'A#
M6O&-MKNI_9)IM:FDC7R)9,KN(SE%(ZTHVW[I_G;]!ROMYK\KGIWC_4=4T7PC
M<ZOI,H6>P9+B2,JK":)3\Z'(./ER<C!XZUMZ3J5OK.D6FI6K;K>ZA6:,^S#-
M<GJGBS0/%?PT\27^DWOVNSBLYXI'\IX\-Y><8< ]Q4OPG26/X6Z )<[C;Y&3
MV+$C],4)?$GY?C?_ "N#^RUY_A;_ #.SHHHI %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>5>./%OBNX\>0>#/"=UI^FW+6PN7O+TCYL
MG[J@JP[?W23[8KU6O&_B5JG@VX\7+HWCO1);6V2W#V6LPNY+YZKA%SP<\?-]
M!FD]T-;,Z'P/JWCJ#Q%=>'O&-FMR(X!-#J]K 5AD.1E2VU5SST !X/%<_P#$
M'XKWUGJ]OI/AE)XQ!J*6M]J#P QA\\PKN!!. 23[<>M97PUU6.#XE)HWA+7=
M5UKPP;,M<&^#;;=AG;MW*,?PC@#.>^..@^.$4<.A^'1%&B!M<B8A5 R2&)/U
M)J^L'W:_.W]=R'\,UY/\F_Z['3?$;Q7>^&=(L8]+2)M3U.\CLK8RC*HS=6([
MX_K67X?U[Q%HOQ 7P?XEU2'5OM-E]KM;Y;46[9!(9"J_*>AY]O>J_P 987AM
MO#.LLK?9-,UB&:Y89(2//WCCMD#\ZIK=V?BSX]Z=>Z/=Q7EGIFDL9KBWD#QA
MG+ +N'&?F''U]*F/ZO[E&Z_$J6WR7WWM^13E\8^,]:TKQ!XNT;4[.TTC1KB2
M.'3GM!)]K2, LS29W+P<C;]/>K_C+X@ZC;Z5X'U72KQ;*VUBYC^U!D1AY9VE
ME)8'&,GD8KD](UG3O#/PJ\;>&=3NXH-6BN;F&.UD?$LV\!595/+ ]<C/'--\
M<6*:)X&^&=KJT),<%Q&;J)ER<85F4COP2,4XV]WM>/XK4);O_M[\-CV'1/'W
MA7Q'J<VFZ1K5O=7<6<QJ&7<!U*D@!Q[KFNC9@BEF("@9)/85XSXMU32?$?Q1
M\"CPQ>6UY=V\S27$UFP<1P?+PQ7IP&X/3/O7K.MK(^@ZBL.?,-M($QZ[3BID
M[0YO7\!I7GR^GXG&^#_&DNI:-X@\6ZQ>^5H,=TZV:"($101\%_E7<Q8\]^G%
M=)>>,-"L/#$7B2YOO+TB54=+CR7.0YPORA=W.1VKRO0&0_LM7@3J+6Y#?7S&
MK%\4>+-%N?V>=*TB+4;=M2*6\36@?]ZI0@DE>H&!U/!R,54E9M+IRK[]Q1UL
M^]_P/;]<\7Z!X;TN'4=7U**UM9L>4S*Q9\C/"@%CU].*KZ3X]\+Z[JD.FZ7J
M\5W=RP?:$2-'(V=,EL8!]B<^U><>))K;3/BCX$U/7&2/1ET[RXYIO]5'-M/)
M)X'5.?;/:GZ9J6C:C^T8]YI$L$L!TEO-N("#'*X/+!APW&!D=P?2G97_ / O
MPO\ Y$W]V_DOQL=BWBM[?QKXA>\OC#X?T.QB^T 1;@)G)8MD*6.%QP/7I5B+
MXH>"9M1MK!/$-J;BY17C!#!<,,@%B-JG_9)!]JX?!O?@SXUU]\EM8FN;E2?^
M>8;8@^F%_6L3QQ96R? SP,BP(%:>U) 7&2\;%OS/6E%;)_W5_P"!?Y7_  *?
M5_XO_)?^&9Z[H_C_ ,*^(-7ETK2M:M[J]C!)C3<-P'7:Q&'_ . DUC^&_$6J
MW_Q5\6:+<W7F:?81P-;0^6H\LLH)^8#)Z]R:P_%L,<'QO\ B&-8P(9D^08^4
M*<#Z5E6OC'0?!_QK\9S:]?\ V2.X2W6(^3))N(12?N*<?C1&VC_Q?A8'>S_[
M=_$]8\3?VD/#6HMI%QY&HI SV[[%;YU&0"&!&#C'XU6\&>)(O%OA/3]9B 5I
MX_WJ#^"0<,/S!J'P_P".?#7B^*]_L34?M8M4!G_<R1[0V<??49Z'I7*_ =6'
MP[=_F\I[^=HLG^'('\P:$MT^R?XV_KT![)^=OPO_ %ZGIU%%%( HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N3^(/C1?!'A]+U+7[7>7,RV]K!
MG >0YZGTP#765Q?Q,\(7?B_P]!'ILR1:E8W*7=J9#A6=<_*3VZ_G2?3^M.HT
M<[J'COQSH6HZ)HFKZ1HW]IZO<HL%Q:M(\*ID"0,A(;>H(Z$CKZ5Z#<^)_#]G
MJ']GW6NZ9!>Y"_9I;N-9,GH-I.<G(Q]:\VU;2O'_ (DU[PUXAN_#]K8-H]TN
MZQ2]26216(\R3=D*  HPN2>:[/4OAMX2U?Q!_;U]I/FZF723S_M,J_,F IVA
M@O&!VJNBOW?W:6)].R^_6YQ4GQ2\0:IXCU.QT,>&;9+"Y:W%GJUT\=U=LIP?
M+Y"C.,#-=%XK\:ZYX:T/0=:N=+@M[6:X2+5H)&\U[=6XW(Z-M/.?7.1TKF_%
MWA77M9OKV+4/A[H>M/.Y^SZI9WOV-XUZ*90Q+,1WP<<8KH+#P*]I\&I/"FMW
MD<LHM9-\S,2D+9++@GLIQ^52G:',^EOGW_K[BFKSMWO\NQ>UGQ=J$7Q$T+PO
MH\5K*MU"UU?22JS&*$="N& !.#USVKF]+\>^./$5UXGM-&TO1#)I%X\23W32
M(A12P"E026<A>N5 JM\"[.^U.TOO%FK2&:ZG6.PMW(_Y8Q*!D?4]?=36_P##
MKPSJ^@W_ (PEU*T\A-0U)Y[4^8C>8A+8/RDXZC@X-5)<MUY-_.^GX?J2G?7S
M2_!W_']"A_PM&^NO@S<>,K6QMH]0@<1-#+N>+=YBJ3P0<8.>OYUH>./'6I^&
M?!NAZQ906DEQ?SP1RK,C% '0L=H# YR.,DUS^C?#O79?@CJ?A:\A2SU.>X>6
M-))%93\ZLN2I(&=N/:J'B/P_\0_%'@[0M+G\-6]H=,N8=ZC4(Y))@BE?,ZA5
M'MN))/M3T<OG'[M+@]%\I?K8[3Q)XSUE?%T'A'PK96,^K-;?:II]0=A!"F>,
MA?F)/MTR.M5+G7M<U7P!XOLO$.BOI^H6-E,C2Q(_V:Y!C;YXF8<CCIDXXH\1
M>&_$.E?$&+QKX<L(-4=[/[)=:?)<"!F&1AE=AM[#.?3OFIX].\;:OX5\4'7?
M)2?4+62/3])A:-A;Y0C#2@#<Q)[DBLVKP?>S_/2WR_X)I!VG%^:_X-SGM)\<
M)X*^#?A-TAAFO;Y1;VZSRB*)3N.7=CT4=ZU?"?Q*O+WQ;#X:UN?P_=W%U$TM
MO>:%=F6$D9)1@22&P":R;[X:ZOJ/PT\)VWV6U_MK0V$C65VRO%,-V6C8C*G.
M![=JU/"'A?5Y/%R:W?>%-$\,6-M"4BLK6"VEFDD((+^:B948., C_'71S=^[
M^ZVGXF*5H*W;\;_Y?U<J:;XTN+32/B)J-II.D6UQI%Y((S!;%/M!!/S38;+M
M[Y%5[WXF>--.\'Z3XNN=$T<://Y8N(Q-)]H;=QO4?=5<] 2QZ9QV?;^"?$*>
M'OB1:MI^)M9NY)+!?.C_ 'RDG!SNPO7^+%6_$?@_7;_X%6/ANVL?,U>*&V1[
M?SD&"C*6^8MMXP>]1'9-_P!W_@FCMS-><OTL>H0R":&.5<[74,,^A%>:^')S
MK_QN\37LQW1Z+;1V-LIZ*7Y<_7((KT>TC:*R@C<898U4CT(%>;>$8VT?XT>,
MM/F^4ZC%#?V^?XU&0V/H6Q^%-?'IV?\ 7W7)U]GKY?U]]BCI/Q!\=>(=/\02
MZ3I.B%M)NI8_-N'D171.BA026? /)91R*TS\6(T^%%OXP?3LW5P_V>.T5^&F
MW%<9_N\$U)\.?"^LZ#I'BB#4K/R)+[4)YK=?-1MZ,, _*3C\<5RLG@6\MO@1
M::/K=S9:-J5E=FYB:]N8UB#[V*J7!*\@GO2TY=>T?TN5]KYR_6WXFKK7COX@
M>&(=#_MK2-#!U.]CA,MLTK+&K=4921A_<%AP:Z+5S_:WQ<T&P!)BTFSFU"4=
MM[_NT_\ 9C7GGCW5?%&KV7@U];TNRTZ-M5@V1P7BW+W#?\]!MX5,'@98_-^?
MJ'AW1M0A\9>)];U&$Q"[DB@LP75LP1I][@G&69C@\U2[]F_R5OS)Z>J7YZ_D
M<3;?$CQQJFB>(-2T[2M$\G1;J99I)VE'F1ISM1 3E\#))8#D8%+>_%3Q5#X5
ML/&2:%ID?A^5UCEADN':Y8D[2RX 55W XSDGCI5WPSX/U[3_  'XVTVZL?+O
M-2N;N2TC\Y#YBNF%.0V!D^I%4-3\#^([CX!:?X9BT[=K$3H7MO/C&,2%C\V[
M;T/K26B_\!_&U_ZZ%.U_G+_@&AXXD6;XK?#F5?NN\[#Z%5KU.O*?B+H'B^;6
M?".K^%])AOKK24D,B33(J*Q"  Y=2>AZ'M5WPQK7Q8NO$-I#XC\,:39Z2Q;S
MYX)%+H-IQ@"9N^!T--6:Y5W?YDZ[OLAO@2[;2_B5XR\+ _Z*DRZA;KS\GF %
MP/;+#]:]+KS'P7&VJ?&#QMKB<VT/E:>CCHSJ!O'X%?UKTZI^S'T7Z_I8;^*7
MK_E?\;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;LA)$K\_O%=5+YZ<9']*[NB@#@O"?@":RO=<U7Q0^GW]]K.P7%M!#FV15Z*
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M7&HVD-Y/_JK>2=5DD_W5)R?PJ[0 4444 %%%% !1110 4444 %%%% !1110
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MEJUUJ%Y;VENOWI;B01H/J2<4 6:*@L[VUU"U2ZLKF&YMW&4EAD#HWT(X-3T
M%5=0TRPU:V-MJ-C;7D!.3%<1+(OY,"*M44 5-/TO3])M_L^FV%K9PYSY=M"L
M:_DH HO]+T_5$C34+&UNTB<21K<0K($<=&&0<'WJW10 R6*.:)HI462-AAD8
M9!'H15;3M)T[2(#!IFGVME"3N,=M"L:D^N% %7** *,^BZ5=:A%J%QIEE->P
M_P"KN)(%:1/HQ&13[W2M.U)X'O["UNFMW\R$SPJYC;^\N1P?<5;HH HV>C:7
MIUS/<V.FV=K/.<S2P0*C2'_:(&3^-7B,C!HJO?7]GIEJUU?W<%I;I]Z6>01H
M/J2<4 >?Q_#W4K/PCXN\-V=Q:?8M3E>73M[L/)W@;E?"\ $<8S6]X?\ !&F6
M/A>PT[5]*TN\NXK.*VN93;K()=F,#++EE!&1FN@;4]/73?[2:^MA8;/,^U&5
M?*V_WM^<8]\T^SO;34;5+JQNH;JWD&4E@D#HWT(X-/;3T_#1 ]=?7\3E/''A
MOQ!K-O9QZ#=Z2+:''G:9JEDDMM< $8R=I9<#/3VZ5G>%_ FK0^+9/$WB6;2O
MM0L_L,%EI<3+;QQ?\#Y/?C&.:]#HI+3^NX/4J?V5IW]E_P!F?8+7^S]GE_9?
M)7RMO]W9C&/;%1SZ'I%U8P6-QI=E-:6Y4PP26Z-'$5&!M4C P.F*OT4 5)M+
MT^YOK>^GL;:6[MP1!.\*M)%GKM8C(_"J5[X2\-ZE=R7=]X>TFZN9,;YI[*-W
M; P,L1D\"MBB@#FM1\+6]IX;U6T\*Z;I6EW][;F)9(X%A7)! +%%R<9)'!J]
MX7T"#POX9T_1K<Y2UB"%O[[=6;\22:UZ*+@%%%% !1110 45''<0RR2QQS1N
M\1"R*K E"1D CMP0:K6>L:9J-Q/;V.HV=U/;G$T<$ZNT1]& .1^- %VBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK/77=(?5#I:ZK8MJ"];07"&4?\
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M X!Q[4)I6_KJOTO]X.[O_71_K;[C=4Y4'U%+0!@8%%(:"BBB@ HHHH ****
M,GQ1/!;>%-6FNI98H%LY3))$,NHVGE?>N'#W>F:EIDWB""&PBAT*XAA;3YC-
MO"JC.6RJ[2%7*@;ADGYNF?2YH8[B%X9HUDBD4JZ.,A@>H(]*R['PQI&GSM-%
M;R22,AB!N;B2?8AZH@D9@BG ^5<#@>E*V_\ 71K]1WV_KJO\CC-"BU"SUGP8
MNJ6UM;11V$MK:/;3&1IF,:MB4%5V?*A. 7&>_KZ561I_AC2=,NQ=6T$OFHI6
M/SKF6580>HC5V(C'LH'&!6O5R=_Q_%DI6_ ****D84444 %%%% !1110 444
M4 %<;KVG0Q>.O#%^7EDGEO)D!=\B-?LTGRJ.@!(R>Y/T&.RJK<Z=:W=U:7,\
M6^:S=I(&W$;&*E2< X/#$<^M-:-/^NHGJFCS7Q!]MFL_&LMK#%+I;7*&[N9)
MRL\!CCCW^3'M(;:!D9=?FS^/J,+K)!&Z$E64$$]QBLJ\\+:/?WCW-Q;2%I2#
M-&MQ(D4Q  !DC5@DG  ^8'H*V  !@<"A?#;^MAO5W"BBBD 4444 %%<;XCUO
MQ?\ \) FC>%M'M"5M_M$VHZHLHMNN/+4H.7[]:S(_B=))X 36QIR'5)+[^S8
M[42_NVN-^WA_[O>A:_UYV_,.O]=K_D>BT5Q'ASQ=JW]M:GH/BRWT^#4[&U6]
M\W3W<Q2PG.2 _((Q@UB:;\2/$$DNC:OJ6EZ=#X9UN[%K:-'*YN82V0C29^4@
ME>@Z9II7=E_7]68KZ?UZ_EJ>I45YMK_CSQ''JFNGP]IFFSZ;X>4'4&NY7668
M[=Y6+;P,#NU7]:\<W<EMX=M_#-M:SZGX@C,MK]M=A%%&$#LS[>3C.,"DM5=?
MU_5G]P^O]?UU1W5%<OX*\3W7B&UU"WU.VAMM6TRZ:TNXX'+1E@ 0RYYVGMFN
MHH8!6#XM\.'Q)I44,-U]DO;6X2ZM+G9O\N5#D$CN#R#[&MZB@#CM#TSQQ+K*
MWWB76-,2WBB>-+'2HW\N8G&'D,G.1Z#\^M92?#6XNOA*/!^H74"W0D:42Q;F
MCW>:9%!R%)'.#T]JVO$WCZT\-:S;Z2=%UO4[R> W"IIEJ)B$!P21N!Z^W>F0
M_$?19] CU=(;X(UZEA+;/"$F@F9@-KJ2,8R,\G\:/B5E_6O^8]OS_#_(Y30?
MA1=Z9X7\0VK6>@V>HZE9M:1&PENF3!'5VE=N^/NKQ[UT@\'7Z^(_!^H++:B#
M1;*2WN%#-N9FC51L&W!&1WQ7;44[N]_ZV:_5D\J_KY?Y(****0PHHHH ****
M &R)YD3IN*[@1D=17%V/A75HX=#TVX-BECHTJRQWD4KM//M4K@H4 0G=\Q#-
MGGCGCMJYZS\865Y>6L0M;N*VO':.SO) GE7+*"2%PQ8<*Q&Y5!QQFA;@]C*M
MO"NK);:9I$ILAI^G7:727R3.;B7:Q;!CV *6R0S;SD9XYX[:N>@\864]]!%]
MENTM;FX:UM[Y@GDS3*6!088N.58 E0#C@\C/0T^G]>7_   >_P#7G_P0HHHI
M %%%% !1110 4444 %%%% &/JVDSW^M:%>1/&(["YDEE#$Y(:)T&WCKEAUQQ
M6'J?A?5IX==TVV^P266M2-)+=3RN)K?<BKA4"$/C;E<LN/PJ_<>-;&WFN&-E
M?/I]M-]GN-21$,$4F<$'YMY . 6"D#N>#BWKOBG3/#T^FV][(QGU*Y2VMHHP
M"S,Q SU^Z,C)IKI;^KV?Z(-G_72YKQ1^5"D>XMM4+N/4XI]%%($K!1110 44
M44 %%>7:G\1_$$<FL:QIFEZ=-X:T6[-I=F65Q<RE2 [1X^4 %N_6O38)X[FW
MBGB;='*@=".X(R*%M?\ KN#T=B2BO.HOB:VI?$;3?#VF6+'39I+F&>]GC9?,
MDB4DB+D< \$D=^/6KGB/Q5XA_P"$I;P]X4LM.FN[6T%[=RZ@[A A. BA>=QQ
MU/ HZ)]_T#JT=S16'X/\21>+?"UCK4<7DFX4^9%NSY;@E67/?D&MRFU9V8)W
M"O.]<LK+6?B]I^G:];P7.GII3S6=O<@-')/Y@#G:>&(7'4<9KT2LCQ!X7T3Q
M59+9ZWIT5Y"IW+ORK(?]EE((_ TNJ8=&CC=3;1?!_A#QC<>#+J&WOK8^;-#"
M5=+:7  Q&057([8_EQA>)?%'C3P];:-I9U:ZO=1U8/=&YTW1DGD@153$4<18
M!ADG+$YQ7H]OX*\.6GAN?P];:5%#I=PNV:"-F4R=.2P.XG@<YS4NN^$=!\3:
M9%IVL:='=6T./*5F963''#*0P_/FA_Y?@O\ ,%_G_7YGGTWB_P 97'AKPPRI
M)I6K7NL?89OMMAL\V/#8<Q,<C(P<*PY! .*Z/P'K&MSZSXCT'7-0CU*;29XE
M2\6W6 R*Z;L%%X&*W(O!^@06>F6D.FQQ6^F3"XM(XV91'( 1NX/S'D_>SG-7
M++0].T[4]0U&UM_+N]09&NI-['S"HPO!.!@>@%5=7?S_ $M^3^\FSLOE^M_S
M7W&A1114E!1110 4444 %<GXK:X;Q!X<CL(XY]0CFFGC@GE,43((RK%G"L01
MO&,*>OXCK*HZGI%EJ\2)>1R$QMNCDAF>&2,_[+H0R^AP>:.J8'G$#3)IUO8J
MB'61XGDD^QF0BW\W#3%-^"=@0[@VW.['R]JZ?P;YZ:KXECO8TAOVOEFF@AD\
MR) T2!=C$ MD+DDJISGCN=C_ (1K2/[+&G"U80!_-#"9Q*)/[_FYW[_]K=GW
MJQIFD66CPR1V43+YC;Y)))6EDD;&,L[DLQP .2>!36G]>G^0/7^O-_YEZBBB
MD 4444 %%%% !1110 4444 %,FC,L$D8D>,NI7>APRY[CWI]% '!Z+#9Z)_P
MG*EY8[6"</)(&+R8^RQEFR>2W4Y]:HZ%%J%GK/@Q=4MK:VBCL);6T>VF,C3,
M8U;$H*KL^5"< N,]_7OX=+LH)KV6. ;[YP]SN)82$*$Y!X'RJ!@53T_PQI.F
M78NK:"7S44K'YUS+*L(/41J[$1CV4#C IIZZ^7Y/_,<M;V_K;_(UZ***0@HH
MHH ***Y7QGXFOM$;2]-T>VMKC6-5G,-JMTQ6)-J[F=]O) '8<\T =517*>"_
M$]]KCZKINL6]M;ZQI,XANEM7+1/N7<KKNY //!]*B\7>)M7L-8TSP]X<M;*;
M6-06257OF80PQIC);;\QSG Q0]+>8+KY'845YV/B1<+\.==URXM;:#5]'EDM
M)[?<7B\]2%7'0E22/\:M>"M=\4ZO-+<ZQ?>$KC3XXCO&CS2O-%+P=K[B0,#.
M1USBGW\O\K@=U17E=I\2]>D6P\07&F:<GA*_OOL4+K*_VI,N4$K9^7:2.@YK
MU2BVEPZV"LKQ-->6_A;5IM/!-Y':2M !UWA3C]:U:*F2NFAQ=FF>5:1X:\ ?
M\*_T'5;]+&V9A;S'4E<),]P2"<RCYB2V<C/Y8K035/$U]\2=>M8-;2#1M'%O
M,UH+1)'F#1DL@?@J#@G/)Z8Q6W#\-O!T&O?VW%H%JM_NWAQNVALYW!,[ <\Y
M S6W:Z+I]GJU]JEO;[+R^""YDWL=^P87@G P#V JF[N^V_IY?UZ$I65M]OSU
M/(_!7Q"\8ZYXAT^YGLM5N-*U"4I)'_8WEVUJO.&2X#$OR!G<!WHA\6>-HM%M
MO$DVN6TEDNM-8M8_84!FC,Q3+2 \$=L =.<UZ-8?#_PII?B!]=LM$MX=2<EO
M.!8A2>I52=JGW '4U.?!F@-HZZ2;#_05NOM8B\Z3B7=OW9W9^]SC./:A-*W]
M=5^E_O!W=_ZZ/];?<;U%%%(84444 %%%% !7E%V]U)I=]=)#$VA?\)"+A[WS
MC]J4I.JL!%MP0'4KG?G;_#V/J]8TGA71I;_[8]M(7,@E,7VB00-(#G>8=WEE
ML\[BN<\T+25_ZW3![6_K9K]3A-=:_P!+\*^*[>VM%O&DO)+A-1CGC*(Y=2J,
M WF"5#A0-I'"\CMZE'N,:[OO8&?K64_A?1Y-4?46M6\]W61U$T@B=QC#M%NV
M,PP/F*YX'/%:]"^&W];6![W_ *WN%%%% !1110 4444 %%%% !1110 UUWHR
MABN01N7J/<5P5IH\4%SXXT^VNC;&6WB#7<TA)5FA8&1V/?N37?U5CTVSBNKN
MY6$>;>!1.220X48'!XZ>E)J]_1C3LT^S3.#MKJ__ +;\$VRZ4+*.(2Q-()HW
M6:,0'F/RRV8R0IRVT_=XKT:LG2_#6DZ-+YEC;NC!2B>9/)*(D/\ #&'8A%X'
MRK@<#CBM:KD[_C^)*5OP_ ****D84444 %%%% !1110 445R/Q)U;5]&\'RW
M&B2)#>23Q0?:)%!6!78*7.<C SU/2DP1UU%>5+X'^)C*&_X64#D9XLE(KT^T
MCEALH(KB7S9DC59),8WL!R?Q-4*YYY\2_"/A/6;VUU77?$<FB7MO'Y<$RW21
MY&2>C#).2>AKRFY\9:GH%Z+7PWXIMO%A#;1;S:,2V/7=C+?4-7HGQ8^'C>)=
M:L]>DU_3-*M[2W$):_4%"=S')W?+WZ&JVF>!/']I8(VE>/M+AL]N4-KI\2Q[
M?;:N,5,=NQ<NG4[[P#J>IZOX/M+W5]*72[V0MOMEA:(##$ [6Y&1S^-=-7.>
M!Y;N7PS%]MUR#6[A99$>^@4!'(8C P,<=./2NCJY;D+8*X7XOQH/A=KT@10[
M11@L!R0)%P,_B?SKNJ*AJY<7RNYSNJ^)[+PMH6EW-]%<2)<RPVB"!02'<<$Y
M(XX_^M7G^IZS#X(\7^-EU.*X!UV*)],,=N\@N)/+*&,%1C=G'!KV*BG+6]^M
M_N9,=$EVM]Z.;^'^EW.B^ -$T^\4I<0VJ^8A&"K'D@^XSBL?QK\)M!\>:S#J
MFJ7>I0SQ6ZVZK:R(JE0S-D[D8YRY[^E=Y13D[ML45RJQXG\"M-AT;Q5\0-+M
MVD:"RO8K>-I""Q5'G4$X &<#T%>V5X_\(/\ DH?Q._["H_\ 1MQ7L%(9Q/Q0
MUK4=#\-VDVF:HFERSZA!;O=O&CK$CDAF(?C Z]NG6N?\/^*M:CUO5-);Q78^
M*+>/2I+U=1M;>*/[-(#@(?+)4YZ\\UUWCGPQ-XKTNPLHOLQ2'4(+F9+G.UXT
M.67&#DD=CQ6C_P ([IUEHU]8Z/IUC8"YB=2MO L2EBI )VBI=^67?7\O\RM+
MQ_KK_D<?X*^)MMJ=CH-CJT6I+?W\"A;^>R,5M<38R41L $\'H,>AK1NOBEH%
MIJTEH\&IM:0S?9Y]42T8V<,N<;&D['/'3'O6)HG@#Q8B^&M.UW4])?2-#=+B
M,6D<@FDE4$*K%N-HSU !/<4MS\//$K6MYX:M]5TQ?"E[<M<2L\+_ &R-6DWM
M&O.PC/&X\\UJ[.7]=U]VE_N7<S6VO];_ ']/O?8]0!! (.0:*;&BQQK&OW5
M ^@IU04@HHHH **** "BBB@"KJ<\]KI5W<6L/G7$4+O%%_?8*2!^)KB?#OBB
MZOM3BAL=937DETU[NY5?*_T28;=L?[M1M#98;7RWR]>M=CKFF_VSH5_I@G>
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M]#Y^L[IKOP3H?PX6WN5\16NII]I@-LX$4*3%O-+8QMQCG/.:^@:**;=]]_\
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MQCJNLQ>$M.\/7,>G7GB&!KAKN2 3?9HU0,<(3@G)QSQ26JNOZO?_ "8WIO\
MU:W^:/1Z*X_P%KVIZFFKZ7K4L4^I:/>&UDN(H_+$ZX!5]O0$CJ!Q72:EJVFZ
M-;K<:IJ%I8P,X19+J98E+8)P"Q S@$X]C0!Y7XA_Y.A\)_\ 8*D_]!NJ]@KQ
M/4-6TW6?VF?"MQI>H6E] NF2(TEK,LJAMER<$J2,X(./<5[90 4444 %%%%
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MXY\6^(/#=^G]G:;%-IX@5Y+B6"1E1RQ7!92 /X>/?WKNZY3XD_\ )/\ 4_\
MME_Z-2NG!\OMHJ<;IZ:^9SXKF]C)Q=FM?N,_P-XM\0>)+]_[1TV*'3S SQW$
M4$BJ[A@N S$@_P 7'M[5W=<I\-O^2?Z9_P!M?_1KUU=&,Y?;24(V2TT\@PO-
M[&+D[MZ_>%%%%<QT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '/\ CO\ Y)YXE_[!5U_Z*:N?^"7_ "2'0O\ MX_]
M*)*Z#QW_ ,D\\2_]@JZ_]%-7/_!+_DD.A?\ ;Q_Z424 >@4444 %%%% !111
M0 4444 %%%% !5*\UG2].F$-[J5G;2E=P2>=4)'3.">G!_*KM<3X]\'Z?K%I
M>:W<372W-G8OY:QLH0[ SC(*D]3ZUM0A3G44:C:3[:F5:4X0<H*[\SIK;7M'
MO;A;>UU:QGF?.V.*X1F; R< '/0&M"O)OA/X;L[F,>('DG%W:W,D*(K#RR#&
M!R,9S\Y[^E>LU>+HPHU73@V[;W[D86K.K34YJUPHHHKF.@**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^*6DWNK>"I$L;3[;);
MW$-TUI_S\(C!F3WR.U=I7#?%P7G_  KZ[?3Y-12[26-HCI^?,+;NG!!QZXI2
M=M?3\T..KL<7X@^*FC^+_#=UX7TGPWJ=QJUY$;=+*6V4"W;H&)R<;3R#CMSB
MO7M#LIM.T#3K&XD\R:WMHXG?^\RJ 3^E>8V/QGG2SA%UX%\1"X"!9#' 7!('
MJ0"?QKU>TN/M=E!<^6T?FQK)L?JN1G!]ZO9/U(O>QYS\2_A<?&FJ6NLQ:S#8
MS6D/E;+BV66-ADG)R<=^X->3:EJ%KX-F\K5=#\!Z^BMM;[ P64>[ <#Z;:]$
M^+GP^\2^,?$6GW.E1VT]C!;A9(+FX9$9]S'H"#T(YR*Q](\$>/\ 0MAT_P )
M>"HY$&%E=&D?_OIF)_6LX[=C27WGI?PTU73M:\#65]I>D1Z3:R,^+2-LJA#$
M'!P.IR>E==6-X7.NG08?^$DBM(M3#,)%M/\ 5@9^7')[8K9K26Y$=@HHHJ1A
M1110 4444 >/_"#_ )*'\3O^PJ/_ $;<5[!7C_P@_P"2A_$[_L*C_P!&W%>P
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '/^+]+T^Z\.ZK=W%C:S7,5C-Y<TD*LZ81B,,1D8/-9/PVTO3_
M /A#],U#[#:_;?WO^D>2OF?ZQU^]C/3CZ5T/BC_D4M9_Z\9__1;5D_#;_DG^
MF?\ ;7_T:]=L9R^IO7[2_)G)*,?K2T^R_P T=71117$=84444 %%%% ',?$:
MUN+[X=Z[:VEO+<7$MHRQQ1(7=SZ #DFH-3-U9>!=,9?#"ZX\$=N9;&0JKIM4
M99593EU/\/!]ZZZBC:_R_ .J?K^)Y9I>G:AXP\>7_B,Z+?Z)ISZ0VG;=0A$4
MT[L3R4!)  [GVK%T_3?$.IZ7X5\%W/A_4K1]$OXY[W4)47[,T<98KY;Y^8G(
MX'2O;:*:=FK=/T;?YL'K_7E;\CQ_68=>\/:CXSTVT\/:EJ2>),O8W-HBM%&[
M1[&$I)^0 ]SUJYJ7A[4_"@\#ZO;6%WJBZ%:O:7MO9*'E*O&!N1<C=AAT%>J4
M4EHE;R_"Z_5@]=_/\;?Y(X?X=:=J"/K^NZE936,FLWWVB*UG $D<04*NX#HQ
M[CM70>)/"VC>+M.CL-<L_M=K'*)E3S7CPX! .4(/1C^=;%%'D@/!U\+:-X1_
M:0\+V&AV?V2UDT^69D\UY,N8[@$Y<D]%'Y5[Q7C_ (A_Y.A\)_\ 8*D_]!NJ
M]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \I^"_P#S&_\ MA_[4KU:O*?@O_S&_P#MA_[4KU:N_,_]ZE\OR1Q9
M=_NT?G^84445P':%%%% !1110 45XEJ&I^(=3TGQ1XUMO$&HVCZ+?RP6>GQ.
M!;/%$5#>8F/G)R>3TKV2RO!>:7;7NTJ)H5EV^F5!Q1]F_P#6JNOP![V_K1V9
M9HKPLZYKY\)CXE#7]2S_ &CY?]EAU^R_9O.\O;LQ]['\76M'XE:U<S>/+'2T
MN?%<5C;Z<US.GAPL)G9WPN['& %)R:+/3^NE_P AVU:_K>WYGL=%<[X&GT^Y
M\(V4NEZO?ZK:MN*W6H2^9.3N.0Y('(/&,=JTM3UW1]$\K^UM5L;#SL^7]KN$
MBWXQG&XC.,CIZBFU9V)3N>7^'O\ DZ'Q9_V"H_\ T&UKV"O%_"%_9ZG^TKXI
MO+"[@N[632DV302"1&P+8'##@X((_"O:*0PHHHH **** "BBB@ HHHH ****
M "N4^)/_ "3_ %/_ +9?^C4KJZY3XD_\D_U/_ME_Z-2NC"_QX>J_,PQ/\&?H
M_P @^&W_ "3_ $S_ +:_^C7KJZY3X;?\D_TS_MK_ .C7KJZ,5_'GZO\ ,,-_
M!AZ+\@HHHKG-PHHHH **** "BBB@ HHHH **** "BLR[\0Z78W3VUS=;)DQN
M7RV.,C/4#T-/L=<T[4IVAM+CS)%7>1L8<9 [CW%8+$T7/D4U?M=7-71J*/-R
MNW>QH4445N9!1110 445PGC_ %"_EUCPWX8L;^YT_P#MF>03W5J0LJ11IN(1
MOX2<CGM1U20SNZ*X3X?W]_%K'B3PS?W]SJ']CW$8@NKI@TK12)N 9A]XC!Y]
MZB\9SZAK'C71?"-IJM[I=K<V\UW=W%BXCF(3 55?!VC/6A]+=?\ A_T%WOT_
MK]4>@45Y=H-UXNUSPGK6AV.KHNJZ9JSV!U*Z^^8%(.[A2"^TXY'XYI?"DU[H
MWQ.O?#%MK^IZYID.GBXNI-0F\][:?=@*'P,9'.VGU_'\+_UYZ [KY?YV_KR/
M4**^?-!UZ'4]:;4]>\0>.+&"ZU1Q:RP3.FFA?,PD1)!ZXY XQZ<U]!TK:)@]
M)-'/^._^2>>)?^P5=?\ HIJY_P""7_)(="_[>/\ THDJQX[\6>&_^$-\2Z=_
MPD&E?;O[/NH/LWVV/S/,\MEV;<YW9XQUS5?X)?\ )(="_P"WC_THDH ] HHH
MH **** "BBB@ HHHH **** "LKQ1_P BEK/_ %XS_P#HMJU:R?%)"^$=9)(
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MCUKU:O*? _\ R5KQ)_V]?^CUKOP?\&M_A_4XL5_%I?XOT/5J***X#M"BBB@
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M6)05Y[X@TGQ-H_C>X\2>&]*@U5=0LELY[>2Z$#1.I)63+<%<=0.:]"HJ6AG
MZ/HGB3P5X!T;2]&M;6_U%;E3?>8_R*CL6D9267.,\?R-6/$5]X]M]1N[32]
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M^=)G)!P. *T[1G\4WL":KH-I-:2;LW'V9LC /1\\<C%.\&_\DEC_ .O:Y_\
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MOZ]3=HHZT5S&X5Y_\8/^12M?^OY/_1<E>@5Y_P#&#_D4K7_K^3_T7)77@/\
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MYL****D84444 %%%% 'C_P (/^2A_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\
ML*C_ -&W%>P4 %%%% !1110 4444 %%%% !1110 4454U2]_LW2;V_\ +\S[
M- \VS=C=M4G&>W2FDV[(3:2NRW7&>(O^1VTK_MC_ .C#7.?\+H_Z@'_DY_\
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MECY;OU95/"I2YZCYI>?3T04445Q'6%%%% &5XH_Y%+6?^O&?_P!%M7.>#?\
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M+M*T;Q[H_B*]UNWT.U:YO/,\Q9)D*#>X<X D!ZCUKOPU*-2A6A*27,K;V?\
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M2,_K7C*Z=\4]&U/1((/#MA?_ -BV\MI:W:3JD<B.%4,ZE@00%'IFIZ_UY_\
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ME_R2'0O^WC_THDI >@4444 %%%% !1110 4444 %%%% !1110!2UC_D"7_\
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M_($O_P#KVD_]!-95_P"%+T?Y,NE\<?5?FC%\"_\ ($F_Z^6_]!6NGKF/ O\
MR!)O^OEO_05KIZYLL_W.GZ?YF^-_WB?K_D%%%%=QRA1110 53U75;+0]+N-3
MU&<06=NN^60J6VCZ $G\*?J-]%IFF7=_,KM%;0O,X0 L54$G&<<\5YE=:_!\
M:_!>I:7X9\ZR:.X@$[ZB@4%-VXXV,V?N]#BEOHAZ+5['8>&_B#X7\77DMIH6
MI_:YX8_,=?L\L>%SC.74#J:?8^/O"NI>()-"L]:MI=2C)4PC/)'4*Q&UB.>
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MCPS+XPTRTT_4!92K'%:L&4Q>7<88X=^=Q8=>PX]?H.@84444 %%%% !1110
M4444 %%%% !115'5M6@T>U6XN$D9&<(!& 3G!/<CTJ*E2-.+G-V2*A"4Y*,5
M=LYKP#_S$/\ MG_[-79UYQX8UVUT7[5]ICF?S=FWRP#C&>N2/6O1Z\O):L)8
M2,$]5>_E=L[LRA)5W)K1[?<@HHHKUSSPHHHH **** "BBB@ HHHH HZMI,&L
M6JV]P\BHKAP8R <X([@^M9=MX-TZUNH;A)KHO$ZNH9EQD'//RUT5%<U3!X>K
M/VDX)R[^AM#$581Y(RL@HHHKI,0HHHH **** .+U/X7Z!JFM3:C-+J*17$HF
MNK"*Z*VMS(,8:2/N>!T(K:N_#%C>>*=-\0R23K=Z?#)#%&C*(RKC!W#&<^F"
M*VJ*%I:W0'KN<5_PJ_0!KO\ :7FZCY/VC[7_ &;]J/V3S\Y\SR_[V??'M5CQ
M#\/=+\0ZJ-5%]JNF7YC$4L^F79@::,=%?@@CGZ^]=;11T2[!YF?HFB:?X>TB
M#2],MQ!:0#"("2>>223R23SFM"BBAN^X'C_A[_DZ'Q9_V"H__0;6O8*\?\/?
M\G0^+/\ L%1_^@VM>P4 %%%% !1110 4444 %%%% !1110 4444 8^K>&[/6
M+I;BXDG5U0(!&P QDGN#ZU%IWA2QTV^CNX9;EI(\X#LI'(([#WK=HKE>"P[J
M>U<%S7O?S^\W6)K*'(I.W8****ZC **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K%\3>%]/\56$5M?-<PO!()K>YM93'-!(!@,C#H>?>MJB@#E+
M?X?:/;^$]1\/+->M%J6XW=W+-ON)6( +EV!&>/3'M3M7\!:7K&E:99O<ZA:S
M:6@CM+ZSN/*N(AM"G# 8Y &>/RKJ:*'J"T_KN<9??#+0[SP8/"RSZA;6!F\^
M5X9@99GSDEV96SD\GCL*D\.?#^'PW=K*GB/Q'?P+"81::A?"6 *1C[FT= .*
MZ^BCOY_\,'D<):?"7P]9W\4JW&JR6$,OGPZ5+>,UG%)G(98_KZDCFN[HHHOI
M8.MSG_'?_)//$O\ V"KK_P!%-7/_  2_Y)#H7_;Q_P"E$E=!X[_Y)YXE_P"P
M5=?^BFKG_@E_R2'0O^WC_P!*)* /0**** "BBB@ HHHH **** "BBB@ HHHH
M AN+.UN]OVFVAFVYV^8@;&?3-1PZ;8V\HEALK:.1>CI$H(_$"K5%0Z<&^9Q5
M_1?Y%<\DK7T"BBBK)"BBB@ HHHH **** "BBB@ HHHH XOP[_P CMJO_ &V_
M]&"NTKC/#O\ R.VJ_P#;;_T8*[.O,RG^!+_%+\SMQ_\ %7^&/Y!1117IG$%%
M%% !1110 4444 %<MX_\/7WB/PS]GTQH1?V]Q%=VZS_ZMWC;.UO8UU-<7\4M
M6O='\$RS65VUDTUQ#;RWBC)MXW<*SCZ _K2?^7YH:_K[F<GXNT'QO'=:S;:)
MHUG?V7B2WC%WOD51:3A CL 6Y& #GGD?GZGH]I/8:)86=U-YUQ!;QQR2_P!]
M@H!/XD5X.]MI7AK3O&L6G>,)]R06=W:W[W:R2SS .P4$?>!.!@=CS7NN@W5S
M>^'M-N[Q-EU-:QR2KC&'*@G]:O[/W?D_RU_ GJOZ[?GI^)S'C+6_$^E:K FA
M>#H]:B:#Y[@RJA0DD%.>V/YUS'_"3>/?^B46W_@1'_A7IVNW=Q8>']1O+2/S
M;F"VDDB3&=S!20/SKPSPU#IAUW0=<O/&,UY<ZKIMX;^XN+I-MHY1>%!^X1N/
M!]!@"H7]?C_D4]K_ -=/\SVCPG=ZC>^'X9]5T=-(NV9M]FC!@@SP<CU'-;=<
M3\*=2O-3\"PR7EV][Y-Q-!!=R?>GB1R%<_4?RKMJN6Y,=@HHHJ1A1110 444
M4 >/_"#_ )*'\3O^PJ/_ $;<5[!7C_P@_P"2A_$[_L*C_P!&W%>P4 %%%% !
M1110 4444 %%%% !1110 54U2>XM=)O;BTB\ZYB@=X8]I;>X4E1@<G)QP*MT
M4T[.XFKJQXC<:IXTN?%-IX@?PW.+NUB,*(MC-Y9!##D9SGYSW]*]9\-7VH:E
MX?M;O5;7[+>R;_,A\MDVX<@?*W(X /XUJT5UXC%1K145!*W:^W8YJ&&=*3DY
MMW[VW[A1117&=04444 %%%% !1110 4444 %%%% !5+6/^0)?_\ 7M)_Z":N
MU2UC_D"7_P#U[2?^@FLJ_P#"EZ/\F72^./JOS1B^!?\ D"3?]?+?^@K73US'
M@7_D"3?]?+?^@K73US99_N=/T_S-\;_O$_7_ ""BBBNXY0HHHH *R/$GAK3?
M%6E_V?J<;M&'$L<D3E)(G'1U8="*UZ* 3L<SX;\#:9X;N;B\2YU#4=0N$$4E
M[J5P9YB@Z)G  'T%4=,^%^@:5K4.HP2ZB\5M*9K2PENBUM:N<Y:-.QY/4FNT
MHIWUN%M+'':_\--$\0ZM+J$]QJ5LURJI>PV=T8HKQ5X E4=<#TQ6CX@\&Z7X
MAT^SM96NK-K$@V=S8S&*6W.,?(PZ<<<@UT%%+I8.MS'\-^&M/\+:6;'3_.8/
M(99IIY"\LTAZN[=R:V***;=P/'_$/_)T/A/_ +!4G_H-U7L%>/\ B'_DZ'PG
M_P!@J3_T&ZKV"D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/\
MA[_DZ'Q9_P!@J/\ ]!M:]@KQ_P /?\G0^+/^P5'_ .@VM>P4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!S_CO_DGGB7_L%77_ **:N?\
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M\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>@#V"BO'_\
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M/0_^_*__ "/0![!17C__  CWQS_Z'/0_^_*__(]'_"/?'/\ Z'/0_P#ORO\
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M#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**\?\ ^$>^.?\ T.>A_P#?E?\
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M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\
M(]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\
M<_\ H<]#_P"_*_\ R/0![!17SY9:I\8;[QYJ/@^+Q9IHU"PMQ<2R-;Q^45(C
M.%/D9S^\7J!T/X]'_P (]\<_^AST/_ORO_R/0![!17C_ /PCWQS_ .AST/\
M[\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]\<_^AST/_ORO_P C
MT?\ "/?'/_H<]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS
M_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_
M^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\
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M=W*R[&PRDJNY@"6(QU_/I6MIZZEX7^(:>%[77M1UBROM+EN62^E$KVSCA2K
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MH ]@HKQ__A'OCG_T.>A_]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'H ]@HKQ_\
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M&W.?WC=".@_'I*\<O/&WBTZ9J7C:UU"V30M/U VO]DFT#&:)9 C2&7.X-SG
MXKV"*19HDD3[KJ&'T-"U5_ZVO^0/1V_K31_B/HHHH **** "BBB@ HHHH **
M** "N;\2>"M-\4:SH6J7L]W'/HMQ]HMEA=0KMN1L/E22,QCH1U-8OQ7\4W?A
MG0].%AJ::9<7M\D#7CQ+*(8\$NVU@0< =*;X0U75M0\*:I?Z;XNMO%MV5Q:;
M[);,12 'Y748/.0><=*%LWV!Z-+N>@45Y=X9\0>++;Q[;>']8U6TUDW%JUQ?
M1V]ND9TM\9$99"=P/3GDY!^OJ--K2XKA1112&%%%% !1110 4444 %%%>9:7
MXXU_5_B;IU@]A)INAW%O<-%%,JF6YV8'F'C*KGH >1SSQ0M78'HKF[XZ^'&C
M_$#[!_:US?0_8?,\O[(Z+G?MSG<K?W!TQWKL*\XUS6O$^L^,-5T;PUJMOID>
MB6T=Q.TEJ)S<R."PC.?NK@=1S6=X@^)%X_PDT77[.\CTR_U2>*W,YB#K"VXB
M1MK9! V-1TOZ?B[+\F.VMOZVO^1ZQ17#?#?4Y]8M;R[;QS'XGARJJ%TY;1K<
MC.<J/FYXZCMQ7<TVK$IW"BBBD,**** .;OO /A74M?CUR\T2VEU)"&$QR-Q'
M0LH.UB/4@]*T[C0M-NM<L]:FMMVH6<;QP3;V&Q6^\-H.#GW%:-%&P/7<S[K0
M].O=8L-6N+???6 <6TN]AY8<8;@'!R/4&J/B+P7X<\6- VN:5#>/ <QN2RL/
M;*D$CV/%;U% $-K:V]C:16MI#'!;PJ$CBC7:J*.@ J:BJ>K:A'I.CWNHRC,=
MK \S#U"J3_2E)V5V-*[LC'LO!6FV/CS4?&$4]V=0O[<6\L;.OE!0(QE1MSG]
MVO4GJ?PZ2O)=)\5^++.;PQK>M:G:W.E>))UA%C':!#9EU)CVN#ENV=WX5ZU5
M--;DWN%%%%(84444 %%%% !1110 4444 %%%>3?$OQO=Z/XQL-&@\6+X<M19
MM<W-R;!;LLQ;:BA"">QZ4=4AVZG:V7@K3;'QYJ/C"*>[.H7]N+>6-G7R@H$8
MRHVYS^[7J3U/X=)7!RR^+)_!6F#0/$-CJMS<2_Z1KCP1HL<!)^=8@=I*\#'L
M>*7X;>(M7UQ-8MM1O(=4@L+D0VVKP1"-+P8Y(525X/<<<T[:M=O^!_F3?1,[
MNBBBD,**** "BBB@ HHHH **** "BLOQ#K#:%HD^H1V-Q?R(56.VMQEY&9@H
M _$_E7)^ /%6M:II_B>[\1B-)=.OI(Q!$%Q BH&* @#=CGDTK[^6H[/3S-RR
M\%:;8^/-1\813W9U"_MQ;RQLZ^4% C&5&W.?W:]2>I_#I*\@T[QCXN@@\/>*
M=3U"VFT;7;U;8Z8EH%-HKE@C"3.YCP,Y]>*9XZ\<WEG\0I-%B\;1>&K&WM(R
MTC:<EV9)G).,$94;<<YP/QIM-67]:?\ #B\_ZWL>Q45GZ&96T*R:;4TU21H5
M)ODC5%GR/OA5X /M6A3:L["3N@HHHI#"LW7/#^E>)=-;3]8L8KRU8YV/D8/J
M".5/N"#6E11:X&%;^#?#UIX:F\.V^F11:5.I66!&8;P>N6!W$\#G.:-6\&>'
MM=T6WTC4],BN;*V55@1F8-&  !M<'<. !UY[UNT4/7<%IL9">%=!3P]_8"Z5
M:_V3C'V4IE.N<_7/.>N>:@\-^"O#GA%91H6EQ6AE_P!8X9G=AZ;F)./;.*WJ
M*+ZW"VECF[?P#X5M?$;:_!HELFIDEO.&<!CU8+G:&]P,UTE%%'2P=;E/5M-A
MUG1K[2[AI%@O;>2WD:,@,%=2I(R",X/H:I^%O#=GX1\.6FAV$D\EK:[]CSL"
MYW.SG)  ZL>U9/C_ ,17^AZ=IUMI31)J.JWT=C!+*F]8BV<N5[X Z55\':SK
M<7B?5_"OB"_BU&ZL8HKB&^2W$)FC?.=R#@$'CBA:_P!=M_S!Z?U\CN**** "
MBBB@ HHHH **** "BBB@ HHKRSXH>-+O0_$FCZ5;>)T\/6\L$L]W=FR6Z(&0
M$ 0@DY.>GU[4K[(:1U]EX*TVQ\>:CXPBGNSJ%_;BWEC9U\H*!&,J-N<_NUZD
M]3^'25P27/BJY\"6;^'O$%EKU]<S@-JSV\<2QPDX+",':67T/H>,\4WX<>(]
M8U>^US3M0U"'6;73I42WUF"%8DN21EEPN5RO3(JK:M=OZ_4F^B9W]%%%(844
M44 %%%% !1110 4444 %<WXU\%:;X\T:'2]4GNX8(KA;A6M756+!67!W*PQA
MSV]*Y;6_'&O_ /">Z-I=E8266C-J?V*>ZF52;M@I)" @X08^\.<\<8-:7BO6
M-=O?&-CX1\/:E%I=Q+:/>W%Z]L)V1 VU55&XY.<DT+5)KK_PX=6NQU^DZ;#H
MVC6.EV[2-!96\=O&TA!8JBA03@ 9P/05<KRV3XA:E'\)-=U>XDBBUK3)Y;!I
M8XQM,P<(KA6R/X@<?6I_AKK=WKE_-)+\1(?$"Q0XEL%TM+9HG)'S!A@LHY&0
M,'--*[?]=+@]%=_UT/2Z***0!1110 4444 %%%% !1110 4444 <)X^U7Q/"
M6TK2/"/]MZ?=VK)<2?:!'MW94K^7\ZX_1?$7Q5T7PY;Z3'X#25K:(0P3/.HP
MH&%W*#R0,=,9KVNBDEHT-LY'X;6%[I_@R"/4M-:POY)I9;F)F#%I&<DOQQSU
MP.@P*ZZBBJ;NR4K!1112&%%%% !61XJTE]=\)ZMI4;!9+NUDB0GH&*D#]:UZ
M*35U8:=G<\@T>'7?$6I^#=-N_#VIZ:GAO#WUS=HJQR2+'L41,"=X)[CI7K]%
M%4W?\_O)22V_JP4444AA1110 4444 %%%% !1110 53U42-I-V(;&*_D,+!;
M25PJ3<?<)(( /3D&KE%)JZL-.S/(9O[2\::QX6M+3P?J/AY-$O5N+F:Y@6.*
M)5'^KA8??!(QP .G%0^,KCQ#K\&H>']1\$SW&LBX(T?5;.#]Q#&6!5S,6S&W
MR\@8S@<5[)15;_UZ?Y"6FJ_K?_,JZ;#<6^EVD-W+YUS'"B2R?WW  )_$U:HH
MH;N[B2LK!1112&%%%% !1110 4444 %%%% '$:=87B?&36KY[2=;.32H(TN#
M&1&S!SE0W0D>E<3J&F^(=,TGQ1X*MO#VHW3ZUJ$L]GJ$:*;9(I2I;S'S\A&#
MP>M>VT4):)=-OQN'5OY_A8X?6=0F\)76E./!UWK4%O:"W&H:?&LUS$0 -GEX
M!VG .0V/:F_##1-1TK3M8O-0M#8'5-2EO(;)L9@1N@.. 3CI7=44[O5OK_G<
M5M$ELOT5@HHHI#"BBB@ HHHH **** "BBB@ HHHH \-O-(\10^&M6^'D7A_4
M9'OM2:6#4E13:K;M*'+,^>& !^7K7MT$0@MXX@<A%"@GO@8J2BA:*W]:*WY
M]7?^M7=A1110 4444 %%%% !1110 4444 <QXPOY]*_L^_3PH^O102EG:W"O
M<6O'#QH1EB>1P0:Y/P_9^)?MWC'Q=INBFPGU)(O[/T[45V-(R+RTBJWRD\\9
M'/7UKU.BA:7_ *WM_D._]>AY'IB:IXD^(>BZS:>%;_P_+:+)_;5S<P"!;LE0
M BX.91D<,>@KURBBG?2Q-M;A1112&%%%% !1110 4444 %<1JUA>2?&#P[?1
MVD[6D6GW*23K&3&C'& 6Z GTKMZ*.J?;_)K]0>J:_KI_D>7ZP-6\)>/->U6U
MT#4]6MM=M(8XFL(Q)Y4Z*5Q(,_*N,'=TJ73=-OO!/PY\.V]QX6.OS63>;<1Q
M;'FM6;<Q>-2#O8%BO!!KTNBA72MZ?A?_ #!ZN[_K1+]#SOP39:CJ/CK7?%TV
MDW6D6-]!%!#:WD8CFE9>LCH"=I[#->B444=$ET#JV%%%% !1110 4444 %%%
M% !6?KNG?VOX?U'3=VW[7;20AO3<I']:T**35U8:;3NCQC2K+7M;7P9X;N_#
MVIZ?_P ([<QS7UY<(H@?RE(01/GY\\=.E>ST45;DWOZ_>2E8****D84444 %
M%%% !1110 4444 %<3XCUZ;P_P"(FF/@6]U..>W$2:CIL2SRL>?W<BX#*HZY
MR1S7;44F@/)M!M?%G@7P'8;-!6^CEO9I]0TV%?,F@@<DA(@" Q'<<]<5I?#;
M3+V+7=?U:+1[C0M!O3%]BTRXC$3*RC#OY0XCR>W>O1Z*I/6_]=/\A-?U\V_U
M"BBBD,**** "BBB@ HHHH **** "O/O!NC79/CJVO+:>V2_U6X\EY8RHD1D
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MBBB@ HHHH XCQU87EWXC\%RVUI/-';ZKYDSQQEA$NPC<Q'0>YJEXKBU#P_\
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M_I@_C7=54[\VN_ZZ7_&XHVMIMK]UW;\+!1114C"BBB@ HHHH **** "BBB@
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MR*L>(/AA+=6&@2Z9_8T^HZ1&T9AU"P06=R'Y;='&H"<Y(VCO^-0OA5_ZWO\
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MZ*<9 ;J <#/TJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>"&Y@D@N(DEAD4J\<BAE
M93U!!X(HHH 6**.&)(HD6.-%"HB# 4#H .PI]%% !1110 4444 %0Q6=M#<3
M7$5O#'//@S2(@#28&!N/4X' S110!-1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V2-)
MHGBE17C<%61AD,#U!'<444 -@@AM;>.WMXHX88E"1QQJ%5%'   X J2BB@ H
MHHH **** "H4M+:.ZENH[>);F956294 =PO0$]2!DX^M%% $U%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>image_030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!9$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#E:ZX8J$M]#S*V75J>JU7D=/14<,\5P@>&177U4YJ2NDX6FM&%%%% @HHHH
M**** "BBB@ HHHH ***;)(D,;22.$11DLQP!0 ZBL%_&>@1NR-?#*G!Q&Q_I
M3?\ A-O#_P#S_?\ D)_\* .@HKG_ /A-O#__ #_?^0G_ ,*/^$V\/_\ /]_Y
M"?\ PH Z"BN?_P"$V\/_ //]_P"0G_PH_P"$V\/_ //]_P"0G_PH Z"BN?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVIS/J9O[Q[N)+@I!(R!>!U _2MO5--MM7TV>QNDW0S+@^WH:N  =!10!PO\
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M[@ 1C]:W:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1QV88KU2H+FRM[R,I/$KJ?45S5,+%_#H=]',9PTGJ>8 TM=/J7A%AF2P?/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !11534=0ATVT:>8\ <#N3Z4FTE=CC%R=EN1ZKJL&
ME6IDD.7/W$[DUYM?W\^HW33SMDGH.P%.U/4IM3NVGF/^ZO8"J=>57KNH[+8^
MDP>#5"-W\3"C.*#3>78*H)8G  K%*YV2DD@R2< 9)[5U>A>&L;;J^7GJD?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP6)G"4:22LWV.6L+'4]21WMYF(4X.Z4BM1K*_P!.T*[-S(=Q8;2),U8\'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW%I;/(,0IZX]376/X6T.2UGMGTR!H;B7SI4(.'?^\?>JW_"#>&!_S![?]?\
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MT"R1YSC[F,?A7I]IIUG8VOV:UMXXH/[BCBLW_A#_  ]]I^T_V3;^;G=NP>M
M%?P-:Q6OA.T6!;A8FRZBXQOP?7%='2*JHH50 HX %+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGBS
M2]0O&6:']Y"@_P!6O4>]<2RLC%6!##J".E>PUDZIH%EJ2$LGER]I$X-<=?#<
M[YHO4]7"9@J<53FM/(\S)IUM;27MRD$0RSG'TK0U;0KO3&)8>9%V=1_.NB\,
M:1]CMOM4R_OI1Q_LBN>E0DY6:.[$XR$:?-!WOL:VFV$>G6:01CH/F/J:MT45
MZ:22LCYV4G)W84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ! (P1D&N \1Z0=.NO.B7_1Y
M#Q_LGTKOZKWUG'?6DEO*,JP_(UE5IJ<;'1AJ[HSOT/,0:6K9TB\74'LUB9G4
MXR!QCUKK=(\(P0XEO2)7ZA.PKSHT)R=DCWYXVE3C=LYW1=)O[N[CFMU,80[O
M,;@5Z6FX(H<@MCDCUI$18U"HH51T %.KT*-%4E:YX6*Q3Q$KM6L%%%%;'*%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17GWBKX@
M2Z+X@2TM$26.(?OP>Y/;_/K70>'_ !EI>OJJQ2"*Y(YAD.#^'K4*I%OEN=<\
M#7A255Q]U_UJ=#2'I2TF:LY"K<0[P>,U '*?*PP/45HD U$\(8=* *X((R#2
MTQH6C.5/X4BR<X88- $E%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444UG"]>OI0 ZF-(!P.32
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBCI0 4A8*,DTPR9.$&?>G) 7.6YH 9N9^%&!ZU+';]SUJ=(@
MHJ4 "@!JQ@"G<"FLX6J\MP!0!.\@6JLET%SSTJ+,DW^ROO3UC5>@Y]:7H,P;
M[Q4?FCLQST+M_2N>EGDN'+RN68]R:L:Y9?8=2;:,1R?,O^%4E/%? 9M6Q$ZS
MC6>W3H?38*%*,$Z:W'5W7AR^-WIP1SF2+Y3].U<+6KH%]]BU)-QQ')\C?TJ<
MGQ?U;%)OX9:/]/Q'CZ'M:+MNM3O:***_0CY<**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLX7J:9\\AXX% #FD X')I%C>0\]/2IHK<"K"H!0!%' %'2I@H%*2!43RA>]
M$A8"H))PHZU7DN"QPHR:01%CF0Y]J5P!I7E.%Z>M*D07EN6]:D  &!118 HH
MHI@96OV(O-.9E&9(_F6N*0\5Z20&!!Z'BN!U2T-CJ4L?\).Y?H:^8X@PMTJR
M]'^AZ^65MZ;(10"001U%-!IU?(;'NGH>CW@O=-BDS\P&UOJ*OUR'A.\V7,EJ
MQ^5QN7ZUU]?HV5XKZSA8S>^S]4?*XRC[*LX]-PHHHKT#E"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;G[3I,8/WH_D/X5]'PWB+5)T'UU7R/+S:E>,:BZ:&M1117UYX04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH2\DI^7@>IIZ1*G/5O4TK]AD8#R\L=JU*B*@PHIU%%A!1113 **** "BBB@
MHHHH **** "BBB@ HHHH I:O!]ITN>/OMR/K7!1GBO267<I7U&*\[N8OL][-
M%V1R!^=?+\14=(5/D>QE4_B@ I58HZL.H.::*6OD=F>X>EV<HGLH9 <[D!/U
MQ4]8_AF?S='1<Y,9*G\\UL5^G82K[:A"IW2/D*\.2I*/9A111709!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)?BS.6U2QASPD;''U
MQ7GE=I\3YM_BPQYR$A7]:XNO.JN\V?<9='EPL%Y"BNG\"0>?XJM,C*IN8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'A/Q D\SQA=\YVX7\JYBM_QLV[Q?J/M*16!7FS^)
MGWN$5J$%Y+\A17HGPO3_ $J]?_IF!^HKSL=:],^%R_N;YO\ : K2A\:.+-W;
M#2/0Z***[CX\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?/OC Y\7:I_U\-_.L2MOQA_R-VJ?]
M?#?SK$KS)?$S[_#_ ,&'HOR0X5ZA\+Q_H%\?^FB_RKR\5ZA\+_\ D'W_ /UU
M7^5:T/C/.SC_ '9_+\SOJ***[CY$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Y7XAL5\)38[R(*\9KV7XB#/A*7VE0UXU7%B/C/K<C_W9
M^K_0]9^$JC^RK]\<^?C_ ,=%>B5YW\)6']D7Z]_/S_XZ*]$KIH_ CP<S_P![
MGZ_H@HHHK0X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\BO(****^D/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6/ L>LZR=0GU&09(Q&(P0 .V<UUU%=DHJ6C/EJ->I1ES4W9C8XUBC6-!A5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_E^==.'G9\I\_G.%YH^UCNOR._HHHKK/F@HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \6^(V@?V7K7VR%,6]U\W'0-W'\C^-
M<77T)XHT1->T.>T('FXW1,>S=J^?IH9+>9X95*NAPP/8UPUH<LK]S['*<7[>
MCRR^*.G^0T5>TO4)=,U"&[A;#QMGZBJ%*#62=F>A5@IQ:9]"Z;?PZGI\-Y 0
M4D7/T/I5JO+OAYX@^RW1TRX?$,O,9/\ "WI7J->A"?-&Y\1B\.\/5<'MT"BB
MBK.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *CB_U[?6I*CB_P!>WUH T%Z55NONFK2]*JW7W30!''_JU^E.IL?^
MK7Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC$3G^(>GUKKHU/LL^:S; 6;K4UZ_YG>4445TG@!1110 4444 %%%% !1110
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M%%%;GDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4=4T:XUZ\2UTZ9D25'(E?GC+=:?I&K:E#HWBO39[^:>33@WDW#-\X!48YZT
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M^_\ _P#6H_X0>T_Z">I?]_\ _P"M7444 <O_ ,(/:?\ 03U+_O\ _P#UJ/\
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M +Z;_&C_ (1#0/\ H&Q_]]-_C6W10!B?\(AH'_0-C_[Z;_&C_A$- _Z!L?\
MWTW^-;=% &)_PB&@?] V/_OIO\:/^$0T#_H&Q_\ ?3?XUMT4 8G_  B&@?\
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MQGLM4OO%NB:A%X>>QL() FU4^8?[3  8%=%X7L+NU\4>)IY[>2.*XN5:%V7
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ML?V+J3Z%=S6EM\L^GN"')'\6.]>F44 >4^(++4M7M[$Z=X6DLK:WN%9U\O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQMX(36HS?6"*EZ
MH^91P)/_ *]=O14RBI*S-J%>=":G3>I\S30R6TSPS(R2(<,K#!!J.O;/&/@B
M#7HFN[0"*_4=>T@]#7C5W:3V-R]O<Q-'*APRL*X*E-P9]E@L=3Q4+K1]40@U
M)%,\4BR1L5=3D,#@BHJ*A.QURBI*S/4?"GCM+@1V.JN%D'"3G@-]:[X$, 0<
M@]"*^<PV*['POXXN-**VUZ6FM.@/\2?2NJG6Z2/G,?E.\Z/W?Y'KE%5K'4+7
M4K9;BTF62-NX[59KJ/ ::=F%%%% @HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *CB_U[?6I*CB_U[?6@#07I56Z^Z:M+TJK=?=- $<?^K7Z4ZFQ_ZM?I
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"0!DG KG]6\1
M)#NAM"'DZ%^PK#$8FGAX<]1V-*5*=67+%&AJ>KP:<F&.Z4_=05QEW=SW\YEF
M8GT7L*B=GFD,DC%F/4FG 5\5F6;5,2^5:1[?YGT&$P4:*N]6(!BG44H!8@ 9
M)[5XVK/0V$KI]"T#=MN[M>.J1G^9J30_#^S;=78^;JL9[>YKI^@XKZK*,EVK
MXA>B_5_Y'BX[,-Z=)^K_ ,@ P,#I1117U9XH4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'6?[?\+_ &7[)M\I?LWF*?O;.=W/UKKEUB\3QS:Z3<6]IO;31/)*J'>&W.,
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M7YAM'?CK4=UHNF7EL\$UC;M&X((\L"O,;":6U\)>--#9V>&RC<Q%CG:K+TH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M54.',6_B:7S_ . 3+-:*V39Y_5B*QNIC^[MY&^BFO0X[*VA_U<"+^%3!0.@
M^@KLI\,_\_*GW+_,PGF_\L?O9PT'AK49L$QA!ZL:T8/"'0SW'X(*ZFBO1I9!
M@X?$G+U?^1RSS/$2V=C+MO#^GV^#Y.]AW<YK22-(QA$51Z*,4ZBO4I8>E15J
M<4O1''.K.;O-W"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#
M1M!GTWQ'K>I22QO'J#1E%7.5V[NOYUOT4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%5AJ%J;>:?S@(820[G@#'OWH LT5
M4CU.TE%N4EXN!F(E2 U.OK^VTZ 3W3E$+!00I8DGV% %FBJ=GJ=M?.R0>=E1
MD^9"Z?\ H0%7* "BBH#>0+>K9E_W[)O"X/W>F: )Z*CGFCMX7FE;:B#+''04
M031W$$<\3;HY%#*<=0: )**** "BBB@ HHJ":\@@G@@D?;).2(Q@\XZ_SH G
MHJNU[;I>I9M)B=U+JN#R![_C3[FYBL[:2XG;;%&-S-C.!0!+13(94GA26,[D
M<94^HI] !115>XO;>UDACFDVM,VQ!@G)QG^E %BBBB@ HHHH **** "BH+J\
M@LHUDN'V*S! <$\FG0W"3EPF[Y&VG<I'/MGK0!+1110 45%<W,5I TTS;47J
M<9JC)K^G13>4\S [MI;RVV@^A;&!0!IT5##=0SRRQ1OEXCAU(((IE]J%KIL'
MG7<HCCR!G!//X4 6:*0$,H(.0>AI: "BBD=Q&C.QPJC)/M0 M%16US%>6Z7$
M#;HGSM.,9YQ4M !115>TO;>]A:6W?>BL5)P1R.M %BBHH)TN(]\>[;DCYE*G
M(]C2SS1VT#S2MMC0;F..@H DHJ.":.Y@2:)MT;C<IQU%,6\@>\>T5\SHH=EP
M> : )Z*** "BH&O(%O4LR_[]U+A<'D?6IZ "BBH+:]@NS*('W&)]C\$8- $]
M%%% !1144%Q'<!C'NPK%3N4KR/K0!+114-Q=0VNSS6V[VVJ "<G\* )J*SX=
M;L)[H6\<S>8V0N48*V.N&(P?PJU;7,5W%YD+;ER0<@@@CL0: )J*KVU[;W;3
M+ ^XPOL?@C!I\-Q'.7";OD;:=RD<_CUH EHHJO:7MO?1-);OO56*$X(Y'6@"
MQ144$Z7"%X]V 2/F4KR/K4M !1110 445!#>07$\T,3[I("!(,'@F@">BBB@
M HJ*&X2<N$W?(VT[E(Y]L]:EH ***@N;R"T:)9GVF5PB<$Y)H GHHHH ****
M "BBHKBXBM;=YYFVQH,L<9Q0!+13(I$FB25#E' 93Z@U%%>V\UU-;1OF:$ N
MN#QGI0!8HHJ WD"WJV9?]^R;PN#]WIF@">BLRZ\0:?93F&=YE?=M_P!0Y!/L
M0,&DD\0Z?%Y09Y@TH+(OV=RQ .#QC- &I16;_;VG?8GNS.1$C;6RC;E/NN,_
MI3K76K&[N!!&\BR$9421,F?IN S0!H44UW6.-G=@JJ,DGL*H'7=.%FEV)RT4
MC;4VHQ+'V &: -&BH+2[@OK=;BW??&W0XQ4] !1110 444CN(T9V.%49)]J
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M* +-%-DD6&-I'.%49)]JCM+N&]MDN+=]\3C*M@C/YT 34444 %%%% !1110
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M(7\Z8M_:)M\F0_ZO=C%=P-,LEN_M0M8A/G=YFWG/KF@:;9* !:Q "3S1\O\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>image_031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** ,R'P]I4"6J1VNU;60R0CS&.UCU/7GIWI9M
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MC0=,&FS:>+;_ $69_,DC\QOF;(.<YSU JW)9V\UD;.2(/;E/+*'D;<8Q4]%
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M#YTR<K+YP;[1MR Q88('?&.,^W:K1T33C'91FW^6R8-;C>WR$?CST[YK0HH
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MB$BRR-F1H@BPN9-X&2-F-W Z\4/KNG)#'-Y[.DD9E7RHG<A!U)"@E0.G..:
M-&BL^XUO3[;=OF9PL8E9H8GE"H<D,2H( (!/-/\ [6L?+N'^T K;A3(0I. P
MR,<<Y!XQF@!\.HVUQ=/;1NQD7=G,; ':<-AB,'!.#@G%6JS+6WO_ .U);F\2
M KADA9)F)1,CC:5')P"3D]!VK3H **** "BBB@ HHHH **** ,[6+RXM(K46
MQB$D]RD.Z5"P4-GG (]/6L[4=9O]*^U1S-:SR1VGVE'2)D"X<+AEW'KG@Y'0
MUHZQIIU.*UB*Q-''<I+(LHR&49R,8YZU%J&B02:-=V>GV]M;/.H'RH$4G/?
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M/WB$#9C..3R2,4NGR//=Z'8P3VUQ#9R.2T;-Y@558 R(0/+/(&#G)/:NTHH
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M\S 9KJ:C6WA6X>=88Q,X"M(%&Y@.@)ZT 24444 %%%% !1110 4444 %%%%
M!1110 52O-5L[!]EQ(P?89"J1LY5!U8[0<#W/%7:R)8[NQU>[O(+-[M+F)%
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MF(ST&34NJ6LUS-IK1)N$-V)).0,+L<9_,BLS3]*O(%T$20[?LIF\[YE^7<I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(2%!)( '))I:;(BRQM&ZAD8%6![@T 1?;+7_ )^8?^^Q4RLKJ&4@J>00>#7!
M76GVLEW?FVMM&M8K)RGE7*G>^ #D\\ ]J[+29(Y=(LY(H?(C>%&6+^X".E %
MRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *XSQA%<VOB7P[KJ6=S=6MB;A)TMHS
M)(#(@"D*.HRN/Q%=G10!Y[X<T[4+/X?6GAF>RN8KR\L9\R;/D@9LX5SV/-8V
ME:;K5X]O-#H\\,NG>&Q8-'>1;5EN.05']X#&<].17K=% 'FWP]LK^WUUG,&H
M?9/[+AAGDU",JZ7"$YCCS_!@G@<#C%/A\/:IX;\;Z#-)XMUK4;>^NIXI+2ZF
MS$!Y$KCCV*C%>C5S7B+_ )&GPA_U_P __I)-0!TM%%% !1110 4444 %%%%
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M10 445R7Q#7.@0>UTO\ Z ] '6T5X0(R5^4@D=*1E^4' .3CCF@#WBBO!_+
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M?VUU7^S_ +/[9\W=^?2DS2"3O?L_Z]?(N4444S,**** "BBB@ HHHH ****
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M /0)\/\ _@TF_P#D>NB1Q)&K@$!@#AA@CZBG4 <W]I\;_P#0)\/_ /@TF_\
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M5M&D5I#'&VZ-$55;.<@#@U+0!P7@S_DI'Q _Z^;/_P!$5WM<%X,_Y*1\0/\
MKYL__1%=[0 4444 %%%% !1110 4444 %%%% !116=JESJUN8O[,TVWO0V?,
M\Z[\G;TQCY&SGGTZ4 :-%<Q=:WXGL[2:YE\-V/EPH7;;JI)P!DX_=4Z+5_%,
MT*2IX;L=KJ&&=5/0\_\ /&@#I:*H:7<:G<1R'4]/@LW!&Q8KKSMP]SL7%7Z
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M/]K&S./QZU?JGB]_MC.5^P?9^G&?-W?GC%)]"Z=M;]G^G]6+E%%%,S"BBB@
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M:YC4#;007,L7B#1GE0,RQ?9826/]W@DY[=*[9$2- D:*JCH%&!7&M=L;6XU
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M03W0QLCGF,2-R,Y8*Q'&?X3Z<=:P_ QF;PW(UQ'''.=3U R)&Y=5;[9-D!B
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M^C!6M'^)$XLR_P!TJ>C/IBBBBO7/SH*PO%8SI<7/_+<?^@M6[6+XG_Y!D?\
MUV'\C0!QFW@^O>HRG?C\JG.2>,U8TN2W@U2WEN6"Q"3)+G@'L?SQ0!2FL;B
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MYI]2B@80.R0M&O[F17("8ZL2 /SXKM*X(WD-S=O=76OP6MXDC*52PCD\LJQ
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M_>SOQG\.E0ZTIMA!JT8):R),H'5H6^^/PP&^J"GJ;%O$892YO39Y!'W#%O\
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ME?+'@S_D5[;_ 'Y/_0S7+B_X?S/>X=_WI_X7^:-^BBBO-/M HHHH *G\&_\
M)9=#_P"O*X_]!-05/X-_Y++H?_7E<?\ H)KHPO\ %1Y&>?[E+U7YGT#1117J
M'P@4444 %%%% !1110 4444 %%%% !1110!'/M^SR;E9EVG*IU(QT&.]<O#+
MJR7(%G(;2WSDQZI<+(<>@49<?BU=+>8-G,OG+"70JKL< $CBN$_L2")K?RM-
MMO/DCAP_GHPAE1CO+9/(9<'O0!UERLU[H=S%?VDH?)4I:L"SX/#)G&/7!KG[
M2"]MK9(?^*H^7/W%MU'7/0D_SKMJX"]T!S$9KG3[VXN'$\<C1N6/F[@8W'.-
MI&1_2@#:\9V%WJG@'4;.SCEEN9+<;8VQO;!!(..,D \=ZQ]%TW5[RW\37&DS
MRZ(]_=PM9RW-EDH$BB5V\I\<-M8?K7;VB-'9P(ZA76-0RKT!QT%34 >:?#6W
MU"T\9^.8-4OUU"]2XM!+<K"(1)^Y./D' XP/PKTNN"\&?\E(^('_ %\V?_HB
MN]H **** "BBB@ HHHH **** "BBB@#YRM_]4W_723_T-JEJ*W_U3?\ 723_
M -#:I:\:?Q,_2\+_  (>B_)!1114&X5GZI_KM)_["EK_ .C!6A6?JG^NTG_L
M*6O_ *,%:T?XD3BS+_=*GHSZ8HHHKUS\Z"N,^)8D;P]:B,9/VQ<_38]=G7)?
M$+_D V^>GVI<G_@#T >;1H#P3CUJ9(R%^G<TP1AQZ'H#4XCPN.OXT +M)[?,
M3GKCBGQQA0<=3S3T5<!F/!J5%W$8!'I0!5:-E+,3D#/6FXW)D@J??O5S8<!&
M)&#S4+# SR#V'I0!F3QLRL%(Z<>U4S"R0@2,Q]3G&:TV))9N/?ZU0NCGUY/)
MH S)X\J0>5'&*]^\+KM\):,OI8P#_P AK7@<N2IX[_Q5[]X;_P"16TC_ *\H
M?_0!0!J4444 <^?%.D.V4CN)E5CMDCMF92?4'%=!7'Z-_:4EHD&FZ]IDL2YV
MH(>4!YQC.0/K784 <-JW]FW6N3DZ.) &>.24W?E>9(D9< J#TXQN/K77Z;-#
M<:9:S6\?E0O$K)'C&U2.!7+7T^FRWU[=:GH2-%#*T2W:#<"R_P#/0#D=N3D5
MT^E7/VS2;2Y\M8_-B5]B]%R.@H N4444 5[Y[R.SD:P@@GNAC9'/,8D;D9RP
M5B.,_P )]..M8?@8S-X;D:XCCCG.IZ@9$C<NJM]LFR Q )&>^!GT%;E];RW=
MG)!#>SV4C8Q/ $+I@@\!U9>>G(/7UYK#\#1M#X;DB>:2=TU/4%:60*&<B\F^
M8[0!D]> !Z 4 =)1110 4444 %%%% "#@X)X[<\U2\G_ (GOG?;?^7;9]DS_
M +6=^,_ATJZ1D8Y_ UG+]C/B/)+_ &_[)@KSM\O?_/-3+H:TOM>CZ>G]7(]+
M_P")?=2:._$: RVA]8L\I_P G'^Z5]ZUB,C!JCJ=G)=0));LJ7ENWF0.W3=W
M4_[+#(/USU J:QO$O[19T!4G*O&WWHV'#*?<'(HCI[I57WU[5?/U[_/\[DP^
M7@GCM_A3J.M-SMX)X['^E48CJ***!!1110 4444 %%%% !1110 4444 %%%%
M !1110 5D^(FN%TU?LXNSF9!(+0'S"F?FVD=/K6M6?K.PV05K::X9I (TAD\
MMMW8[LC'YT 9ND"'^T%V1Z\&P>;UY#'T[[CC-)XEU^]TW4=+TK2[>"6_U$RF
M,W!(C58UW'..<G( IEA_;P,[1W5LZQ+Q:32B:0-Z%U"X)P>NZD\1Z%J.IWNC
MZOILL$&HZ>9,1W*EXV61-K [2#D'!!]O>@"QHWBB#4_!J>(G0QQ^0TLJ#^$K
MG</TK%T3QKJE[/';WNF0">\TQ=2LH[>0DLI_Y9L3_%TY''-7=+\*7.F>'[/P
M\+B"73/LLD-XQ0B1W;/*G. .3ZUGZ-X.UO3G6ZFOK.6]L=-&G:>Z1,HVC^.0
M9.3TX&!Q0!H^'_$>K7?B";1M7L[6*Y2SCNS]E<L(MQ(V/G^+CMZ&LZ]\4:%K
MGC3PM::7JUI>7$-[.TD4,@9D M9@21]2!5_P9H&M: )TU.:PN3/^\FNHD<3S
M2^KEF(P!P   *KZIH>D:7XQ\*7&GZ58VD\M].))+>W2-G!M9B02 ">>: .UH
MHHH *^=_AY_R)T/_ %WF_P#0S7T17SO\//\ D3H?^N\W_H9IH#J:***8!111
M0 5GZ5_R6GPO_P!>EU_Z U:%9^E?\EI\+_\ 7I=?^@-28'M]%%%( /2OECP9
M_P BO;?[\G_H9KZG/2OECP9_R*]M_OR?^AFN7%_P_F>]P[_O3_PO\T;]%%%>
M:?:!1110 5/X-_Y++H?_ %Y7'_H)J"I_!O\ R670_P#KRN/_ $$UT87^*CR,
M\_W*7JOS/H&BBBO4/A HHHH **** "BBB@ HHHH **** "BBB@"KJ$-O-92_
M:;6.ZC12_E2(&!('H>]<7:M:+;373V>CNZR6[QI':( P?JBGKD9Z^HZ5V&JW
MLEE:H8$5[B:588@YPH9CU;V')_"L)]*ET6Y_M>>/3;C#KYWEV?E.F2!N4[CD
MC.>V: .FN9)(K=Y(8&GD4?+&K!2WXGBN.M]*E,;-?^%Y[FX9V9IC>1Y?))!/
MS\<=J[:B@".!0EO$HC\L! -A.=O'2I*** ."\&?\E(^('_7S9_\ HBN]K@O!
MG_)2/B!_U\V?_HBN]H **** "BBB@ HHHH **** "BBB@#YRM_\ 5-_UTD_]
M#:I:BM_]4W_723_T-JEKQI_$S]+PO\"'HOR04445!N%9^J?Z[2?^PI:_^C!6
MA6?JG^NTG_L*6O\ Z,%:T?XD3BS+_=*GHSZ8HHHKUS\Z"N1^(@SH%MR!_I:]
M?]QZZZN1^(AQH%OQG_2E_P#0'H \]C)9>.]2/+Y0#.< ]:J1O\HY/X593$BX
M_/- %E&&WY1EC[BI&;;@'<!C_.*A3&>P7W[TKS)%'O8\ 9)- $I8F/<-Q(_0
M"L\2,X>1DV_-@@GM5HME2JL0#UXJ(G*#+ 'H>* (7;*DE1R>.>U9\S@E\-TZ
M'^=7)FRX''2LZZ.8B >,$$T 4)9XG#A&4D#H*^@?#))\*:.2,$V,'_H KYP\
M@0/(WF%LXX/I7T?X9_Y%31_^O&'_ - % &K1110!Y]<+IE_<07&L:I%ND8E?
ML5L$"[6VY,A!;;GC)Q77VUI)I6F72-?RRHN]XY)AO:)<=#W;!!/Z5SZZ!9PZ
MX=):2Y=)K4,',@^2)7_U0XZ$]>>U=E0!P)\2+R%\56ZAOO#^S&Y..3TKM-,D
M$NF6LBRK,&B4B14V!N.H7M]*Y75I=82\GG-[>PVZSM%LMX-VQ=F48<<@G(-=
M1I/F_P!D6?GJZS>2N\.<L&QSGWH N4444 9^M_V/_8\_]O\ V'^S/E\[[?L\
MG[PV[M_R_>VXSWQ6/\/OL?\ PB8_L[R/L/\ :%_]G^SX\OR_M<VW9CC;C&,<
M8KH+ZXEM+.2>&RGO9%QB" H'?) X+LJ\=>2.GKQ6'X&D:;PW)*\,D#OJ>H,T
M4A4LA-Y-\IVDC(Z<$CT)H Z2BBB@ HHHH **** "L\SX\0>0+09^R[S<XYQN
MQLS^O7\*T*J9O?[7QA?L'D=>-WF[OY8I/H:4[:W[/K;M_5BW65>(VFW3ZE"A
M:!P/MD:C)( P) .Y X/<CW4 Z8PIVXP.W3'TIU#5PA/D?=/?S7]?<QJ.LD:N
MC!D8 JRG((/<4ZLF19-&E,L,;2:<QS)%&N6@/=E ZKZJ.1U'I6G%+'-$LL3J
M\;C<K*<@CU!H3OHPG3Y?>6J?]6?G_P .M!>4'&2H_$C_ !IU%-*]2O!ID#J*
M;NQ][C^5.H$%%%% !1110 4444 %%%% !1110 4444 %<]KOFP:E#=_89[L1
MV[BW$47F>7/D8)';COVP:Z&H+R\M["V:XN9!'$"!G!))/0 #DGV% '/:3IPL
M-1TZW@MRLUO;-]MG"8#LP!P6_B.[)[XQ745B:)?Q23W5N[3I/)*\Z17$+QMY
M9QTW#D#VK;H **** "N:\1?\C3X0_P"O^?\ ]))JZ6N:\1?\C3X0_P"O^?\
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M /7I=?\ H#4F![?1112 #TKY8\&?\BO;?[\G_H9KZG/2OECP9_R*]M_OR?\
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M@$]3IUOG_OVM*?"'AD]?#ND'O_QY1_\ Q-:T,,5O!'!!&D4,:A$C10JJH&
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M  17O_QFC_A,M+_Y]=<_\$5[_P#&:V+N]M;&W\^ZG2&+.-[G JQU&10!S_\
MPF6E_P#/KKG_ ((KW_XS4<_BK1;F,QSZ?K,J'JLGA^]8?D8:Z2H)+VTANH[6
M6ZA2XE_U<32 ._T'4T#3:=T<@;SPF"3#I&M6Q/>UT2_@/U^2(<U'#KFC2H9+
M#4O%JH'9"R:7>3 ,K%6'[R!N0P(([$$>M=U6+I L-%TAMVIVTD$U[<S+.755
M+2SR2; <D$@N5Z\[>@Z5/)'L;?6:W63?KK^=S#_X2 I_J]4\0M_UW\,7+?\
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MZ"HH^KTNP?VOC?\ GX_P_P CY]_X0_XD?]"W8_\ @<G^-2:3X3^).D^+;/Q
MGANQDEM89(EB-\@5MP(SG/O7OU%5&C"+ND95LQQ5>'LZD[KY?Y' Z?K?Q*EU
M*UCO_".FP6;S(L\J7X9HXR1N8#/) R<5WU%%:'$%%%% !1110 4444 %%%%
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M **** ,^;0M*GF>6;3K9Y'.69H@235V**.")(HD5(T&U548 'H*?10 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4C*KJ58 J>H-+10  8&**** "BBB@
M HHHH **** "JNHV2ZAIT]HQQYBX5O[K=0?P.#^%6J* .6T'1Q/;_;6FDMIG
ME(FM8 %A!5L%2A!!S@G/7FNH50JA5   P .U+10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #7DCC*!W52[;5!.-QQG ]3@'\J8;F ,ZF>,,C*K#>,J6QM!]"<C'KFJ$@9
M_$T2R?ZM;-VC_P!XNH8CWQM^F?>LNWM+:!_$]OMQ -I;<Q8\P@DDG))SDYH
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M35[-UNI9=/BU$+!.\[,I)B)(W$_,-PP,D]2.YH [""[MKK/V>XBEP Q\MPV
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MX#^+H<=CBKJR1KX?\A(O*U&TNHO,C9MSF8N/FR>6WY)SW!- '54444 %%%%
M!1110 4444 %%%% $4EO%++%(ZY>(ED8$@C(P>G;VHN+:*[@:"=-\;8W+DC.
M#GMVXZ=ZEHH **** "BBB@ HHHH *IW&F6MW,))Q*^"#L,[^6<'(RF=I_$5<
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH @%I"+TWFUC.4\O<7) 7(. ,X'0=/2IZ** (8[6&*ZFN43$TP42-D\
MA<XXZ=S4U%% !1110 4444 %%%% !1110 4R*)(4*QC"EF8\YY8DG]2:?10!
M%!;Q6L7EPKL3)8+DD#)R<>@]J([:**>:=$Q)-C>V2<X&!]![#U/K4M% !111
M0 4444 %%%% !1110 4444 %%%% !1110!#=6L-[;F"X3?$2I*Y(Y!!'3W J
M:BB@ HHHH **** "BBB@"":TAN)H)95+- Q:/YC@$C&<9P3Z9Z=JGHHH ***
M* "BBB@!'4.C(<@,,'!(/YCD5232+)!)\DCF0*&:69Y&(!R!EB3C/;I5ZB@"
M*>WBN8PDR[E#!A@D$$'(((Y%2.H=&0Y 88."0?S'(I:* *LFG6DNG'3WA'V4
MH$\L$CY1VR.:M444 (ZAT9#D!A@X)!_,<BHK6VAL[9+>!-D2=!DGWZGDU-10
M 4444 %%%% !4<T*7$+Q2;MCC!VN5/Y@@BI** &0PQV\$<,2A8XU"(H[ # %
M0+IMHEREPL1$J,[*=YPI?&[ SCG&?KGU-6J* "BBB@ HHHH *CCA2)I&0$&1
MM[$DG)P!_("I** "BBB@ HHHH CEA2=560$A6#@9(Y!R/UJ2BB@ J*6VBGDB
M>5-S1-O3). <8SCH>O>I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>image_032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_032.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" (B!5\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7[)OQ7TOX2>,/A_KGA_PI;>'?&_@/QUI$EGJ6@:Q#/KT\EM(KJI=?*N8)%?
MRLJ[E1@R* ?T 0?&[X,77Q*F^#%K\7?#$GC"WC\RX\)QZ];MJ4:^6LNYK4/Y
MH'ELKY*_=8'H0:ZBOR9\!>-/V#YO^#JOQKX)TOX&^/(?CI'X;C;4?'$GBR%M
M#EA_X1>Q8*ECY7F*WV4QQY,A^=6;H<#=\<_\'07PE\,?M/\ Q7_8V\'?L2?%
M+QO\1OA_XJU#P_X9\+^![7^T[OQ7=6<UPD\D44,;/;P1I;M*[D2,JD81L,0
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M_8[\??M)?%'P_:^?XPT'X=1S-#HI 4O 9(+:YDFEC#Q^;LB,<32+&T@E$D:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 ,P4;F. .23VKRG_AN_]A__
M */*^%/_ (<33/\ X_7J5Y_QYS?]<V_E7\H__!!K]@__ ((R?M;?!;QUXG_X
M*<?M0Z%X"\1:3XHAM?#5CJWQ9T_PZUU9-;*[2+%=,&E D)&]>!TH _J@\!_$
MSX<?%/1?^$E^&/Q T7Q'IN[;_:&@ZI#>0%L9QOB9ESCWK<K^:']EKX??L^_L
M)?\ !RO\(/@O_P $:/VE+KXE> _%5C;P>.OL/BF'4K(6\\=U)J-FUU:A8;V.
MWM(8;U?O^7,JJ6,D1 _6#_@I9_P7Q^%W["O[0VE_L6_ _P#9N\:?'KXV:E:"
M\D^'?@&-VDLH# TX$K10SRF8P*9Q#'#(1"#(Y12F\ ^_J&8*-QKX<_X)8_\
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M]FGQAXND@C\)CQ]%*;>[:>1HH!-Y]M:S0"65?*CD\IXB^X,Z!2:]?_X*T?\
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M"R'P)_9\\<>'U;6+^^\=1^,O%UMJ-YK%]96TNJR0VCI!&ML)I-21,$L&<QY
M\L9FTS_@[4T/XC_L\:E\;_V=O^"7_P 9/'TOAMIY_&R:/#*^D>%[".-G^T:A
MJ<-I*D#,D<LFTQE%B3<TJG*J ?L%17SW_P $PO\ @HK\*?\ @J/^R1H_[5WP
MF\.ZEHEO>7UQIVL:#JS*\^FW\! EA+I\LJX9'1QC<DBDJC;D7A?^"PW_  5K
M\-?\$@_@[X5^-GCCX%ZQXUTGQ-XF;0RNCZI%:M9W!MY)X]WF*P8,D,O3&-G?
M/ !]?5B^/?B-\/?A7X;E\9?$_P =Z/X;T>!T2;5=>U.*SMHV9MJJTLK*H))
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M6-YX.TO1+75K<MAHX(M-N)DF\FYN--FD#;2@V-R 2,.RT;5?B9_P0^\(0?M
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M=Z3J6GN&M[]6\1Z+ONHV'#)+)OE5APPD!'6MS_@W2^-?PC^!7_!6/]OCP/\
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MX-\+V\D&AZ/_ &A<77V:-Y7F9?-N9))7R\CG+NQYQT %?"/_  =6?!+XS_M
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MR:->64"3R 1H?L=M+$K,RJSQ&($NRHWW)\/?^"N'_!,/QS_P5)\6?LN? 3X
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MJ'VY[8SF$_Z=<S>7M-S/_J]H._G.%Q[U0!^/O[2__!-O_@Z)\=_M'_$#QO\
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M85=-R.Z'!&59@>"17IU%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;^'O"NAV31B6]O4MW2>=YW8V]O%&R R*[.P5-K@'V%17P[^RQ_P45_:*T_\
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M1_&J3]N7X3KX/FUZ31(?%!\>6'V!]22!)WLQ/YNPSK#(DACSN".K8P0:PO\
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M?BGKZZ3X9\(Z'=:QXAU1K>286EE;1--/+LB5G?;&C-M168XP 3Q0!T-%>?\
M_#4_[/,/[-EC^U_JWQ<T?2_AGJ7A>S\16OC'6IS8VG]FW44<MO.YN C1^8DL
M>U'"ON=5V[CMKYQ^#_\ P<(?\$@/CI\5M-^#7P__ &S-+_MK6KS[+H;:UX=U
M32[/4)L[?+BO+VUBMV8O\BCS!O8JJ;B10!]G45YC^TI^V5^S+^R%9^'I_P!H
MCXPZ3X:F\6Z]:Z+X7T^Z=I+S5KZ>>.%(K>WC#2R@/+'O95*QJVYRJ\UM2_M
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MX&BU>=$LIKY[O_1KUX/,6.XAABB<R-E H5@ #])Z* <C-?/'A#]KSQQ\8/\
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M[+/_  4@^%"?"N2SUKXV?$K7M6^%D%YJ5LBZ_;O:Q^04<R[8?->/RP9C&%+
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M:I!*\4TUC&QC@N(989(Y3%MC)9=JC&Y^$\N/_B*9V[%Q_P , YZ?]3O7>?\
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M@8X5V&X=%.]@N&*HQ ) ! /S+_9G_:1\9?\ !57Q3^P[^P_\2;9_^$B^#_\
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MW\8/#?2FWOY[.%H(+GR"QBCG\DK$\J*K2)#"'+>4FWMJ* # ]**** #';%!
M/!%%% !7$7?[//PLU']H2S_:BU+0YKKQEIGA6;PYI.H7%]*T5AI\UPMQ.D$!
M;RHY)9(XO,E"^8ZPQH6VJ%KMZ* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *, ]1110 4444
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MPCW/[ O^'[O_  2$_P"C]? __?\ G_\ C5'_  _=_P""0G_1^O@?_O\ S_\
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M^51U<N;=D_=/C..M4SP<5\'4CRR/J82YHA7ZR?\ !G'_ ,I-O'7_ &0G4_\
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M(HW_ ((4?]'R_P#F,_$__P K*/\ B*-_X(4?]'R_^8S\3_\ RLK[U_L71O\
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MQ/\ _*RC_B*-_P""%'_1\O\ YC/Q/_\ *ROO7^Q=&_Z!-K_X#K_A1_8NC?\
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M% 'C7_!1@!O^"?'QV!'_ #1OQ/\ ^FFYKS+_ ((3<?\ !'W]GH#_ *)O9_\
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MZ"BO@G_B)V_X(;#_ )OE@_\ #>^(_P#Y74?\1.__  0V_P"CYH/_  WOB/\
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M^9CEJUO#MUIZ3M8ZA9JZW#!5D90<>W_ZO_U1Z#H5]XEU:'1M.:-99B<-(V%
M R3^0[5UUA\*4T&7^UO$NHJT=N=_EQC:O'<M_3]:X<7BL/37)4EJ]DM_([L+
MAZ]3WX+3:[V.<USPF+>![S3G^55W/&QZ #G!_I_^JN:NX!'B11P:Z37_ !,;
MQ6L=-/[OH\G][V'M6%?L%BP>_2ML+[;D]\RQ'L^;W"E11174<@4444 %%%%
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M6T_\T(U/_P!/6B5C#XD74^!G]*E%%%=1Q!1110 4444 %%%% !1110 4444
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MHHH&%%%% !1110 4444 %%%% 'C?_!1?_E'Q\=O^R-^*/_33<UYC_P $)O\
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M;2J^^Z_$;_@O)^V/_P %7?BM_P $I?BIX"_:4_X(T?\ "I_!-]_8?]M>/O\
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MQ<^(NI^-?!VN>)OB'_8\W@34]3"->0WULT#F^LEN!YL2VS"7;N#'+@I^B=%
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M+7X9_"70OW-]J&H6D#2S7T=Z'1M-CMHG/FWB.'BCF8GY#(1\/?L:_!W]G/\
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M%EMJ7PWE\+3:N-2:ZL;.*/4C;&-K2=;.41;HKAT8I=-)"LKQ>6<7X6_MS?\
M!JGXB\<>'=/^'7P+^$-EXFOM6M(]!$/[*-Y;7$%\\J"#;,-%"Q.)"N)-X"D;
MMP S02?J>OW1Q2T+]VB@H**** "BBB@ HHHH ^!/^#H/_E!?\<?^Y9_]2;2J
M^^Z^!/\ @Z#_ .4%_P <?^Y9_P#4FTJOON@G[04444%!1110!^4O_!?[_E)!
M^PS_ -U-_P#3/IU<[71?\%_O^4D'[#/_ '4W_P!,^G5SM:T_A,_M,****L H
MHHH **** "BBB@ K8_X-Z?\ E(K^W1_U\_#G_P!-FIUCUL?\&]/_ "D5_;H_
MZ^?AS_Z;-3J)[!]I'ZR4445D:!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7YL?M\?MG?\$G_ -L>P\"^-/AA_P %
MB_AS\*_B=\+O%7]N?#[XB:3JUAJ+V#2PO;7MK-:SL$N+:YM9'C>/>GS+$Q+*
MKQ2?I/7PU^WYX)_8T_9?A\"?"CX%?\$S_@SX\^,'Q<\1RZ)\-O"-]X+TFPLW
M:"V>ZO=1O+@VS&.TM+=#+((U>5R8T1?G+H ?&'[3[_L"_&?XC_$OP9\(O^#@
MKX7^ _@+\=O&$7B3XQ?"ZULM-NKZ[O#%:17OV'4Y)?-MQ>K:1[\@K$PRJR*S
M1U^V4:JD:H@X48%?C#X*_:%'PT_9L\1?M1?M3?\ !)G]EG6?#/PE_:$U[X??
M'FX^&_@..&30M-M)K"UAU;3X;J&5[](Y[B<S*?+=D\HK'&/-=/V>1@R!@<^]
M #J\-_;J^%7[:/QO\!:9\)_V0/V@-!^%L6N7DD'CCQW=:+)?ZQINF^7G_B4Q
M;EA6Z=AY9EF.(D=GC_>*A'N5!]Q0!^<O_!O_ .*(/@A_P13F\:7MQ=ZG%X0\
M0>.[V::^G,EQ=K:ZO?R%I'Q\SL(^6QR23BO#_P!G3_@F'\#?VD_^"$.N?M>_
M'#X9Z'XA_:*^)7@'7_B2WQBNA)'K=MX@D%S?:5/!>J_FVD=NJ62>1"R0D0MF
M/YW!^I/^"(G[/_C7P[_P2UN/@5^T!\-->\,W6L>+/&D&I:+XBTF:QNOL=YJ]
M[M?RIT5@LD,@=6(PRL&&017S+\*OCS^V)^RM_P $IM>_X)$>)/V(_C=XB^/6
MA^']8^''@GQ!X5\#W$WAG5X+TW$&FZW#K1_T2"RM[>YM3*T[QM$T95U3$GEA
M/J/UGXQZA_P5,\2?\$X/V=/VA;B77_"'Q*^'^J_$'XT>&[B)(;7Q+J6DZ3"+
M,W 11YEO_:!N)7M1^Z<,FY&V(5]C\%_"3X5?\$U?^"U^B^ OV<_".F^!_A?\
M=/@;K&H^(O _ARU,&FPZ_H-Q"XU.&U3]W;NUE/Y++$B*Y4L078L>5^,/[&?Q
MD_X)VZ?^PQ^TK\._@QKGQ+L_V9?"5]X+^+N@_#&QEOM8O[75=)@LVU&SM=JR
M7D$%\DDS1*OF;9P^U5222/T/X!-\1O\ @H-_P57A_;<F^ GC?PC\'?A3\);_
M ,)>$G^)WA&?1;[Q+KFIW44MY=VUE=@3?85LXHH_-DCCWR,5 ;:X0 ^>OV%O
M^";W[.?[?O\ P1=UK]L/]I7X>:;XB^/'QDTOQ'XQU'XMW<.-9TO6%NKL:?)8
M7((DLH;86UKLMXF6+$;*4*L5I_\ PN/Q'_P5!\(?\$UOV=_C_?OKW@SXN>'=
M;\6?&.PN6:,>)[_PWI4/DQ7*HRK+;RW[M-)"04<JAQA0*M_LR_'K]J'_ ()Z
M?\$U]>_X)4ZY^PM\;/%'QF\%PZYX2^'6N>%?A[=7?AOQ7'>W%T^G:NFJ+_HM
MK:1K=P&X$TJO"%(8!@Z1]?\ $W]BGXY_\$\OAC^PI^T/\//A!X@^),W[+FCW
MWAOXJ>#/AKIQOM1O[37-+BM+Z_L;?B2[\B]02^4@WNLFXA51V4 Z?2/A?\'?
M^":O_!=/X4_"O]F7X?:?X+\$?M-?"[Q!8:YX'\+VJVFDKKNA*E_#JBVL8$<4
MGV0S6Y\L(K;]Q!8DGW?]N7_@L'^R]_P3\^+6G?!GXV>"/B9J6K:GX=AUJWG\
M&^ Y]4M5MY)YX%5I8R LFZW<E.H4J?XJ\B^#1\7_ /!1G_@KCX3_ &V8OV?O
M'GA+X3_ 7X;ZMI7@O6_B1X7NM!O-?\3:N\<5Q/9V5W&LS6D=BKQM,ZQDROM
M8 D?H1^% S\I?VS/^#BW]A?XJ_L?_%;X7^'/A?\ &R'4/$GPUUW2[";4?A5=
MP6Z37&GSQ(TLA;$:!G!9CPHR>U?5'_!"8_\ &GW]GK_LF]G_ .S5Z=_P47_Y
M1\_';_LC?BC_ ---S7F/_!";_E#]^SU_V3>S_FU =3ZRHHHH&%%%% 'YL_\
M!T)_R99\)?\ LYKPC_Z#>5Y37JW_  ="?\F6?"7_ +.:\(_^@WE>4UI3(EN%
M%%%:""BBB@ HHHH **** "N5_P""=/\ RL9V?_9I]W_Z?JZJN5_X)T_\K&=G
M_P!FGW?_ *?JF7P@?M-1116)H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?CC_P>9_\ )F7P
ME_[*=)_Z;KBOV.K\<?\ @\S_ .3,OA+_ -E.D_\ 3=<5%3X&73^-'\ZM%%%<
MQVA114D$0DY;H* 2N1T5,]KSE&_"F_9I?3]:GFB5RR1'2JCL,JM2):L?OG\J
MFP$3@<"AR[#C'N5**#UHJB HHHH **** "BBB@"2* R#<3Q1);,B[E.:EMW!
MB">E/+*OWC6?-+F->6/*5%8J<BIX[WC$H/UJ!NO!I*MQ4MR(RE'8L2WF1MC'
MXU BEVVBDI\&?.4X[T6Y=@YG*6H^:*-(\J.?YU#5BYC=\;.U0F.1>J&E%Z#D
MM1M%'?%%40%%%% !1110 444=>* )($WMG/2K XXIL481!3C4,VBK(='%+,V
MV&/<?Y58&DW13=E?ID_X5TWPQ^'FN_$7QGH_PY\+)#_:&M:A#:0/<,5C621P
M@9VP<*">< G'0$\'Z\_:%_X)=>#_ (*_L[7'C[3?B!JNI>)M/D@^U>8D<=E,
M'<(42,*74[F7#&0]#QS@?-9IQ1E648RCA<1.TZK2BK-[NUW;1*^FOZ,^DRSA
MO,\UP=7$T(7A25Y-M+97LN[MK_2/A6>WGM^)HL;N,]C56: I\R\BMC5R&ME(
M.?F%9Y&1@BOHJ<G*-SY^I!7L4Z_67_@SB_Y2;^.O^R$:G_Z>M%K\G)4"/@5^
ML?\ P9Q?\I-_'7_9"-3_ /3UHM=$/B1QU/A9_2G11174<(4444 %%%% !111
M0 4444 %%%% '@/[<_A'_@I'XJ@\,K_P3Q^+?PO\*S0279\6-\2M#N[U;E2(
MOLWV?[/]PJ1/OW==Z8Z&OCG]H'XI_P#!P5^QE:>&_C3^T5^T7^S??_"]/&FB
M:7XZU30/".HI=Z39WVH0V?VDI*54PB2:)'=79T$F_P ME1L?4W_!3C4?'GA3
MP/X<\>Z!_P %7-#_ &5-&L;ZXM=5USQ#X9T'4+?7IY8Q)!;JVL$*DJ+;W#*D
M7SR!G)!\L8^&)O\ AE_]K'QWX/\  7[:O_!S5X:^-'@VS\7:?J(^%>CZ;X7\
M/V_B2^@N8Y+6UO#8?-=P&=(\P,IW$*5*.%<!+/V%'3@44#@44%!7F_[57QT\
M9_LZ_"&Y^)O@/]G?Q=\4=0M[R"!/"7@>.%]0F61]IE43.B;4'S-ELXZ9KTB@
M]* /SWU;_@N[XY\'?%OX??!KXH_\$G_C[X5U;XF^*(M"\)QZQ%I:M=W#$&5U
M1;HN8H8SYLLF-D:#<Y48KUC]LS_@J='^RS^TQH?[(_PX_9 ^)7Q@\<ZMX%E\
M7W.D?#VWM';3])2]%D)Y//F3@SG;QG''K7E/_!.&(?M_?\%"/C5_P5 \:)]L
M\-^ ?$%Y\)OV?[>9C);VVGV+#^U]9MSM$<AOKEMJ3I\ZQ1R0,2%J_P#'G_@F
M-^VW\8?^"E_C+]M+X6?MXZ?\*='U/X:Z7X/T&Z\-^#;;5]?BL89)+F>T+:A&
MT%I!)>2>>3$'DD,48W1X;<"/I_\ 8[_:1\??M0?#6^\>_$3]E?QU\(;VSUR7
M3XO#?Q A@2]N8EAAD%V@@D=?)9I6C!)SNA?C&"?6,U\9_P#!*K]I7]JOQ5\5
M/CW^PK^VIX[TOQQX^^ 'BS2[?_A9&CZ+%IJ>)-'UBR-_I\D]I"!%!=)$&618
M@$ ,:C>RM+)F_M4?LV?\%S/''Q^\1>*OV3O^"C_P[\#_  ]O)H#X<\+:U\,;
M>_NK%!;QK*LD[PLTA:82N,DX#@=J!F%_P="''_!"_P"./_<L_P#J3:57WW7X
M6_\ !<[]G#_@M_X#_P""6?Q1\5_M?_\ !1?X>>//AW:_V)_PD7A70_AE;Z?=
M7V[7+!(-EPD*M'LN&AD."-RQE>]?NE03U"BBB@H**** /RE_X+_?\I(/V&?^
MZF_^F?3JYVNB_P""_P!_RD@_89_[J;_Z9].KG:UI_"9_:844458!1110 444
M4 %%%% !6Q_P;T_\I%?VZ/\ KY^'/_ILU.L>MC_@WI_Y2*_MT?\ 7S\.?_39
MJ=1/8/M(_62BBBLC0**** "BBB@ HHK)\?:?XMU;P+K6F> -<ATO7KC2;B+1
M=3N;<31VEVT3"&9D((=5<JQ4@@@8H UJ*_.%?V0?^#E7:/\ C;K\)_\ PS-I
M_P#(]'_#(/\ P<J_])=?A-_X9FT_^1Z!?(_1ZBOQ?_:\^(O_  <2_LB?M"_
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MQ7*K'B2ES.[*T[9E;%?K%_P9Q?\ *3?QU_V0C4__ $]:+7Y/3(0_3WK]8?\
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MQ_[EG_U)M*K[[H)^T%%%%!04444 ?E+_ ,%_O^4D'[#/_=3?_3/IU<[71?\
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MBJJI4>(*<I/91HIMVUV6(N?M-_Q%'_\ !#;_ */0F_\ #;^(O_E?1_Q%'?\
M!#;_ */0F_\ #;^(O_E?7XV?8;/_ )]8_P#O@5B?$VRM!\-_$!%K'_R [O\
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M??!G]D#]I&'QCXETS09=:OM-C\,ZK9&*QCFA@>;?>6L2'$EQ"NT,6._(& 2
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M?\;-?'(_ZH3J?_IZT6M*?QHRK?PF?TF4445V'F!1110 4444 %%%% !1110
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M !1110 5^./_  >9_P#)F7PE_P"RG2?^FZXK]CJ_''_@\S_Y,R^$O_93I/\
MTW7%34^%FE/^(C^=6BBBN4[ HHHH * 3W%%':@ HHY]** "IK*.)[A6N%8QA
MAY@4X)7N![U#5BTQY?7^*IE\)4-9'H?C[P98>&1"WAVV%O#-'M'5L2#N2>N0
M?7L:P-%\+WD.Z9;=Y99.6E9<?EFNH\+>,X-5\,#1=3+?:;%0T<A'#QCC)^@.
M/?@^M<C>>-=;&H-<07)5=^1&1E<>E>)A98SEE2>ZW;>_8]O$+"\T:BV>R73N
M9FO"26\DCECVM#E-IZ\&LRNB\8:WI6O7\-[IEB\+?9U6XW8^9_ZX]>"?3BN>
M<88CWKU\/*4J:NK/L>5B(Q51V=Q***DA@,@WGI_.MC!*XU(7?H/QJRB!%V@4
MJ@*-JBBL92YC6,>4*/>IK&QN-1N/L]N!G&26Z >M;.GQ>"=(!&NI+?2?W8),
M >V!C_T+\*QG4C#HV^R-H4^;K;U,*!XTG225-RJX++ZC/2NN_LG3?$>FR/8^
M4S(ORLBC<I[#V^E94NO>#WD4IX(5$W ,QOI6./S%6SXNLK"T^R^&=)^SJ_+/
M+R<_F<_B?PK*I&M4MR1:?G:WX-FT'1I7YI)KYW_(P+="!O(ZU+R>@IN0B#<?
M:I;:)WDV$=?O5ZM./0\NI+J/M;?=\S?=_G5R.+(X&!340<(HK2TO3UN,S3#]
MVO&W^\:]3#8?VC.&M5Y2O:6%Q</F!,C_ )Z-TK2M?#D;/F7=(QZ*HQG^IKI/
M#GA.XU.6*)X&_>,%AA3@L3_(5]/_  1_85E\4:<VJ:L8]L0S<223&*VC.,[-
MX!=R!R2, 9^A/T%/!1IQ4JNB//\ :U*TG&FKL^:-"\$Q%%WV_P S+EE V@?4
M]372V/@68J#:VW7C='!Q^=>QZY\#M,\.7_GZ#B2W;/\ KF)5#GM\N<8Z;N:G
ML/"5G"-UVYF;^Z.%'^-?J^6<(X6-%2J[]NWKY_>?G^.X@Q$JCC3V[_U_P#Q;
M6/A[J#VWF7>G>9&O(VM\R^_!KC?$?@8&(F%FW+R-XZ>QXZ5]/:MX8M)[<FPA
M$<BC*[>C>U>;^+/#<.UKA(-HW8D&WE&]?_K4\XX5PM3#MTU^7Z6)R_/<1&LE
M,^=-0TZ2UE9#'M93ADK*OK< >>G_  *O2O'?AEHRUQ"GSQ\C'=?3^HK@KJ%4
M<KM^5O\ .*_%LTR^6#K.G(_2,#C(UH*469! ;J*CY!P:FFC,,C1GM4,F5.>U
M?-U8GN4Y!FFO*$ZFHYIRIV)4))/6LE$N4K;$XNE)P1CWK]8_^#.Q0?\ @IIX
MY8=_@1J?_IZT6OR5K]9O^#.-V/\ P4T\=(?^B$ZI_P"GK1:N"]]&527[MG]*
M5%%%=9YX4444 %%%% !1110 4444 %!) R!110!^8_[3_P"T)_P7MT']O7X=
MV7PJ_P""?/@O6/"]A<>++*TU*Q\21R66O:?Y<!MYK^^DM'DT+=Y44R0"5?M$
M@\MC)Y(QT7Q/\:_\'$G[1N@6WP@T']E[X8? U=5UJP.J?$S3?BDFL7.DV,=U
M%)<^3:_9B)'DB5XP./OGE#AUTOVU_P!EG]AWX'_"#X#_ ++_ ,??VVOVA-!E
MN/&%UX=^'<GAOXF:BWB#Q-?:E=+-)]MEMXVDN8;;(_?2!8[>,A2V716^7;'2
M/^"9OPH_;H@_9^'[3G[=^I)X3^)&G>&-7^)TWQ$U"\\"V/B:1T:#1;V\#9$K
M2E(71HO+#289PNY@"/VBBAC1FE5 &?ECCKQBI*%Z44#"BBB@ HHHH **** /
M@3_@Z#_Y07_''_N6?_4FTJOONO@3_@Z#_P"4%_QQ_P"Y9_\ 4FTJOON@G[04
M444%!1110!^4O_!?[_E)!^PS_P!U-_\ 3/IU<[71?\%_O^4D'[#/_=3?_3/I
MU<[6M/X3/[3"BBBK **** "BBB@ HHHH *V/^#>G_E(K^W1_U\_#G_TV:G6/
M6Q_P;T_\I%?VZ/\ KY^'/_ILU.HGL'VD?K)11161H%%%% !7\R?[:O\ REY_
M:M_[*!9?^D*5_397\R?[:O\ REY_:M_[*!9?^D*5X/$W_(EJ?]N_^E(_9OH_
M?\G7P/I6_P#3,SFZ***_*3_1X**** "BBB@ HHHH *P_B=_R3;Q#_P!@.[_]
M$M6Y6'\3O^2;>(?^P'=_^B6K6A_&CZK\SS\V_P"177_P2_\ 26?N9_P;=_\
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M_P#E'Q\=O^R-^*/_ $TW->8_\$)O^4/W[/7_ &3>S_FU OM'UE1110,****
M/S9_X.A/^3+/A+_V<UX1_P#0;RO*:]6_X.A/^3+/A+_V<UX1_P#0;RO*:TID
M2W"BBBM!!1110 4444 %%%% !7*_\$Z?^5C.S_[-/N__ $_5U5<K_P $Z?\
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M_P#C=;WP_P#CY\)/BEK,GA_P#XUM]2O(;8W$D$,,BE8@RJ6^90.K*.O>M/\
MX5?\,_\ HG>A?^"B'_XFK6D>"_!_A^Z:^T#PKIMC,T>QIK.QCB9ER#M)50<9
M ./4"N6I++?9OV<9I]+N+7S]U'T. H\?1QD'C:V%=*_O*%*K&37]URK22?K%
MFG39?N_C3J;+]W\:X3[ _3K_ (-%O^3&/C1_V<_XA_\ 39H]?JQ7Y3_\&BW_
M "8Q\:/^SG_$/_ILT>OU8K]NP_\ N\/1?D?Y'9U_R.<3_P!?)_\ I3"BBBMC
MS HHHH **** "BBB@ HHHH **** "BBB@ K\<?\ @\S_ .3,OA+_ -E.D_\
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M&V0<5)'<]I/SKDE2Y7H=$:O,K,FJ&XB(/F"IJ*49<HVN8KP1;VR>U6.G H
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MD;\4?^FFYKS'_@A-_P H?OV>O^R;V?\ -J!?:/K*BBB@84444 ?FS_P="?\
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MRG_X-%O^3&/C1_V<_P"(?_39H]?JQ7[=A_\ =X>B_(_R.SK_ )'.)_Z^3_\
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M.O\ LA&I_P#IZT6LX_$@J? S^E.BBBNHX@HHHH **** "BBB@ HHHH ****
M/B/_ (+/V'[".MZ'\-?"G[4W[&=W\??B#X@UR^TOX,_#'1V9;_4;QX4EO9 _
MFQI;VT<4$4D]Q(2D**K$=:^,_@7\-_\ @DOX5\!? _\ :A^,/_!%&S^'=GXN
M^*&K^$O$'B+1?%DNM6OPY\2:=K@TW3Q?3*T0>"XN8IA]J1?+A>)%.\2JU?=G
M_!2CX%_M33?'/X'?MW?L@_#73_B%XG^"=]KUIJGPOO-:M]+E\1:1K=M!;7)M
M;VY!A@N;=[:"95<H)$$J[\XCE^'_ (+_  I_X*1_MJ?LRC_@FSXF_P"">OB3
MX5_#S7OCAJ7BCXL?$KXB:U;6TD.CS>++CQ"NGZ=9H3+<7#CR(?M*[HD;<#A7
M610GJ?LVOW1Q2T+THH*"N7^-7P6^%O[1/PKUWX)?&SP/8^)/"OB73VLM;T34
MHRT-U"W.#@AE8$!E=2&1E5E(901U%% 'S#\ _P#@D)^Q=^SS\5=!^,GA_2/&
MGB36O!L,UO\ #_\ X6!\1]7U^V\(6TJ"-H-,@OKF2.V78-H<*9 "0'P2*Z#]
MK+_@FM^S%^V)X]T7XQ?$"T\4^'?'GA[2Y=+T;X@?#OQI?^']:M]/ED#RV9N;
M*6,S0,=W[N4.$\R0IL,CD^_44 >=?LM?LG?L_?L6_".U^!G[-/PYM_#/ANUN
MI[LVD5Q-<37-S,^^6XGN)W>:XF8XS)*[-M55SM50/1:** /@3_@Z#_Y07_''
M_N6?_4FTJOONO@3_ (.@_P#E!?\ ''_N6?\ U)M*K[[H)^T%%%%!04444 ?E
M+_P7^_Y20?L,_P#=3?\ TSZ=7.UT7_!?[_E)!^PS_P!U-_\ 3/IU<[6M/X3/
M[3"BBBK **** "BBB@ HHHH *V/^#>G_ )2*_MT?]?/PY_\ 39J=8];'_!O3
M_P I%?VZ/^OGX<_^FS4ZB>P?:1^LE%%%9&@4444 %?S)_MJ_\I>?VK?^R@67
M_I"E?TV5_,G^VK_REY_:M_[*!9?^D*5X/$W_ "):G_;O_I2/V;Z/W_)U\#Z5
MO_3,SFZ***_*3_1X**** "BBB@ HHHH *P_B=_R3;Q#_ -@.[_\ 1+5N5A_$
M[_DFWB'_ + =W_Z):M:'\:/JOS//S;_D5U_\$O\ TEG[F?\ !MW_ ,H3/@/_
M -@34_\ T\7U?<%?#_\ P;=_\H3/@/\ ]@34_P#T\7U?<%?MY_D3'X4%%%%!
M04444 %%%% !1110 ,P4;CVK\?/^"4'Q[_X*E?\ !.3]@/P'^QGXD_X(D_$S
MQ1>^#3JOG:[8^.-(MHKK[7JMW?#;&SL5VK<A#DG)0GOBOV#/2OQJ_P"")O\
MP<!?\$__ ((_\$QOAG\,/VUOVQ/$DOQ-TPZU_P )-)K/@_Q+K5R?,UJ^EM]]
MY#93I-_HSP8Q(VU<(<%2H!&G_P %7OCU_P %2O\ @HY^P'X^_8S\-?\ !$GX
MF>%[[QE_9?DZ[?>.-(N8K7[)JMG?'=&CJS;EMB@P1@N#VQ7[!5\)_P#$2Q_P
M18_Z.\U#_P -/XJ_^5=?=@.:8(****0PK'N/B#X$LYY+2[\:Z1%-#(4EADU*
M)61@<%2"W!![5J75S!9VTEW=3+'%%&7DD=L*J@9))[ "OYR_V6[W_@E5\5?@
MUKW[;_\ P4-_X)$_'_QU=?$+XF>)O%/C[XS:3X-U(>%_#\-WK5SM5);>_A:6
MUMXUW32) QCD,D?SL H /Z+KO6]'L-&D\1W^JVL.GPVQN)KZ:X588X0NXR%R
M=H4+SN)QCFJ_A+QCX3\>^'[7Q9X&\3Z?K6E7R,]GJFDWL=Q;SJ&*DI)&2K ,
M",@GD&OS?_;8T3X*?M.?M>?L+_\ !._P?/;ZU^SOXA\.ZQXRU?PK9WADTWQ!
MI>D:3;MX>221B6NK19&$AA9F24;&D5BJL-KP9\)?A3_P3?\ ^"V^C^"_V=?"
M&D^!_AG\>/@;JVH>)? _ANP^S:;#KV@W$,@U.&UB'EP,UE<F)DB1%8@N0SL2
M0#[^O_B/X TKQC9?#O5/&^CVWB#4H'GT[0KC4XDO+J)<[I(X2V]U&#EE! P?
M2M34-0L=*LIM3U.[CM[>WC:2XN)I B1(HRS,QX50!DD\ 5^0?["__!.']G7_
M (* ?\$5];_:[_:7^'>E^)/CK\:-+\1>,-4^+5]:@ZWI>KI=70T]["Z_UME!
M;+;6H2VB98=L90H48K39/C!XA_X*B^#/^":_[.O[05]-KG@SXO>'=:\6?&33
MKB1XQXGOO#>EPF"*Y"%1+;R7[M-)"04<K&<#8*!7/UO\&^.?!?Q%\/V_BSX?
M>+=,UW2KK=]FU/1]0CNK>7:2IVR1L5;# @X/!!K5K\W]-^&/P=_X)L?\%V?A
M;\,_V9?A[IW@OP3^U!\,-?L=?\#^%;2.QTA-=T"-+Z#4TM(E$<,AM#- 1&$5
MC(SD%R2WL7[?W_!:_P#9)_X)O_&33?@=\>?!GQ(U'6-5\,PZ[;3>#_!YU"V6
MVEN+BW56D\U<2;[60E<<*5.>:!GK7_!1?_E'Q\=O^R-^*/\ TTW->8_\$)O^
M4/W[/7_9-[/^;5\=_MB?\'-G_!/OXO?LC_%+X2^%OAI\:(M4\4_#G7-(TV74
M/AR8;=)[FPFAC:23SSL0,X+-@X&37V)_P0F_Y0^_L]?]DWL_YM0+J?65%%%
MPHHHH _-G_@Z$_Y,L^$O_9S7A'_T&\KRFO5O^#H3_DRSX2_]G->$?_0;RO*:
MTID2W"BBBM!!1110 4444 %%%% !7*_\$Z?^5C.S_P"S3[O_ -/U=57*_P#!
M.G_E8SL_^S3[O_T_5,OA _::BBBL30**** "OP._X.)_^4VOAG_LU>P_]274
MZ_?&OP._X.)_^4VOAG_LU>P_]274Z\K//^116_PGZ3X/_P#)S,K_ .OJ_)GS
M!1117Y ?Z=A1110 4444 %%%% !39?N_C3J;+]W\: /TZ_X-%O\ DQCXT?\
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MC1_V<_XA_P#39H]?JQ7[=A_]WAZ+\C_([.O^1SB?^OD__2F%%%%;'F!1110
M4444 %%%% !1110 4444 %%%% !7XY_\'F'_ "9E\)O^RG2?^FZXK]C*_'/_
M (/,/^3,OA-_V4Z3_P!-UQ05'XC^=A S.JKW:KXZ55M$W39_N\U:K2GL:2-#
M2E#6K8'\7]*M0[D<;5[]/6J^EHRVI.?O-FK43%<.M>AAI<LCDQ"YHG6>'M5^
MR72RJYV^W\_PZU]'_"7XAZ;J%K:O%=KYT<(CNK?=R5'&X>HZ'CUP37RSI\S
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M=&CM_P "4'/YYKKD)(S7ZQN[GP&PM5[]$,>\CG/6I9)XHCM=L9I)MLT93U%
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M8;."YL;MF<:BL,ES&;A9<GY2L18$S+]"?L+?\$X)_P!B?P]XV^ "?&V;QO\
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M$DS$!([2XFT\QLSEE"AV3>S*JY9E4_MZGW>*!(6BBB@84444 %%%% !1110
M4444 >-_\%%_^4?'QV_[(WXH_P#33<UYC_P0F_Y0_?L]?]DWL_YM7IW_  47
M_P"4?'QV_P"R-^*/_33<UYC_ ,$)O^4/W[/7_9-[/^;4"^T?65%%% PHHHH
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M51M'V^$IN,$BK=L""H-?JU_P9T_\I-/'7_9"=3_]/6BU^4=RP;YA_>K]7/\
M@SI_Y2:>.O\ LA.I_P#IZT6OGV[RN>G)6IG])U%%%4<X4444 %%%% !1110
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MB^.FC^!/''P]^,OB>+6[?5+"_P!ZW.IZ?$L4<FG-:'9(?)(A&^)7^7*R8?\
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M "=? ^E;_P!,S.;HHHK\I/\ 1X**** "BBB@ HHHH *P_B=_R3;Q#_V [O\
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M9+:9TNVA\W>5N-N]$("AFW)^DD3!XU<?Q+D4"0ZBBB@84444 %%%% !1110
M4444 >-_\%%_^4?'QV_[(WXH_P#33<UYC_P0F_Y0_?L]?]DWL_YM7IW_  47
M_P"4?'QV_P"R-^*/_33<UYC_ ,$)O^4/W[/7_9-[/^;4"^T?65%%% PHHHH
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MZQ=D$Z=#8VRRS1N?F47H4 +YK+^Z$098E5SD@<GU]Z '4444 %%%% !1110
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MM ? 74/&5^NF^"]3^/'PNDT+3M>U)C\FGV]RLTT8N7'W4D,8<X5279$8)/M
M=.E%%%!04444 %%%4?$GBGPSX-T>;Q#XO\16.E:?;C,]]J5XD$,?^\[D*/Q-
M %ZBJ^E:MI>N:?#J^B:E;WEK<1A[>ZM9EDCE4]&5E)!'N#5B@#X$_P"#H/\
MY07_ !Q_[EG_ -2;2J^^Z^!/^#H/_E!?\<?^Y9_]2;2J^^Z"?M!11104%%%%
M 'Y2_P#!?[_E)!^PS_W4W_TSZ=7.UT7_  7^_P"4D'[#/_=3?_3/IU<[6M/X
M3/[3"BBBK **** "BBB@ HHHH *V/^#>G_E(K^W1_P!?/PY_]-FIUCUL?\&]
M/_*17]NC_KY^'/\ Z;-3J)[!]I'ZR4445D:!1110 5_,G^VK_P I>?VK?^R@
M67_I"E?TV5_,G^VK_P I>?VK?^R@67_I"E>#Q-_R):G_ &[_ .E(_9OH_?\
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M ,IM?#/_ &:O8?\ J2ZG7[XU^!W_  <3_P#*;7PS_P!FKV'_ *DNIUY6>?\
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MX)L?\%&K*X>SNOV OC4K*V&!^%FK\'_P'K0L?^"=W_!1O3Y1-;_L'?&I2/\
MJENK?E_Q[U_8AUZBDV+Z5W4\QJTK<J.>6'C/<_DF\%_L5_\ !132;O[5;_L+
M?&:WF*[663X7:MY<@_\  ?BN]M/V5_\ @H$(UDN_V$?B_NSC;_PK?5#_ .VX
MK^IVBOIL#QUFV I\D$FCQ<5PW@,9+FEN?RNZE^RI^W]/$T<?["/QA^;H!\-=
M5Q^(^S_UKB_$G[#_ /P4.U$M+_PPO\9"S<?\DQU4D#V M^*_K6*@\D48 HQG
M'6;8ZFX32MY!A>&L#A9<T+W/X];G_@G3_P %#KF8R-^P;\9_8?\ "KM6X_\
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MHC^:K2?V2OVT;!/);]COXJ-&6SAOA[J0(_\ (%;,/[(W[83!9!^R+\4AWY\
M:A_\9K^CS%&*ZGXH8U_\PT?_  )_Y&,>"\.O^7TON1_.@?V6?VR N1^R)\33
M_P!T_P!1_P#C54[K]DO]M"=]Z_LB?$[VW> ]1P/P\FOZ.\48I?\ $3L:O^8:
M/_@3_P BO]3</_S^?W(_F>U?]D_]O*6YDCL?V0_BE'&K$*T?P[U([O?)@/Z5
MQGC/]C[]O5(W^S_L8?&"XD"_O)E^&^JR$>R_N.OZ#^7]2F!2%5/45CB/$S,J
MU)PA1C&_5-A2X-P<*BE*HWY61_(GXB_80_X*+ZTS)_PPG\9TAW?+$OPPU;YO
M=C]GY/Z?SK OO^"=/_!0\IMC_8-^-!9NZ_"W5^/_ "7K^PP #I17Q.*S;$8R
M7-4/J,/A*6'C:!_''-_P3A_X*),%3_A@CXU<?]4LU?\ ^1ZS]1_X)L?\%&)'
M4)^P)\:VPO;X5ZO_ /(]?V648S7F2ES.YW1J<I_&3)_P32_X*-$@_P## 'QM
M_P##4ZQ_\C4W_AVE_P %'/\ HP#XV?\ AJ=7_P#D:O[.,8HK)T[N]S3ZQ+L?
MQC_\.TO^"CG_ $8!\;/_  U.K_\ R-1_P[2_X*.?]& ?&S_PU.K_ /R-7]G%
M%3['S']9EV/XQ_\ AVE_P4<_Z, ^-G_AJ=7_ /D:C_AVE_P4<_Z, ^-G_AJ=
M7_\ D:O[.**/8^8?69=C^,=O^":?_!1P+D?\$_\ XV?^&IUC_P"1JK'_ ()O
M?\%)<\?\$^/C;_X:C6/_ )'K^T&BCV2[B^L2['\7<O\ P38_X*32]?\ @GW\
M;A]/A/K'_P C5#_P[-_X*0_](^_C=_X:C6/_ )&K^TJBG[)=P^L2['\6O_#L
MW_@I#_TC[^-W_AJ-8_\ D:C_ (=F_P#!2'_I'W\;O_#4:Q_\C5_:511[)=P]
MN^Q_%K_P[-_X*0_](^_C=_X:C6/_ )&H;_@F?_P4?12S?\$_?C< .23\*=8X
M_P#):O[2J.O!H]DNX>W?8_BM_P"'<?\ P4,_Z,.^,W_AK]6_^1Z_5K_@TS_8
M/_;#^!_[9_C[X_?&_P#9S\7^"?#*_"VXT"&\\8>'[C3'N[ZXU+3[A$@CN$1I
ME6.SF+LH*H=@)!<"OWXHQCM3C3Y7<F5:4HV"BBBM#$**** "BBB@ HHHH **
M** "BBB@#X&_X+ ^*?V@?@/^U'^S5^V%^SI^QAXR^.&J>!9_%FG:MX8\+Z&)
MEMM.U.TLHI;G[7\[6=TKPQ>5B%UFB-W&SQ AC\^_\%*OV]?VL?VX/@OI'[-?
MA#_@B]^U%H_AW5O%^BZEXS\47_@R%=4TJUT_4K:^_P")5%',R-=2&W\L322Q
M"(,2%<G"_KW@'FB@#PO]BO\ ;-\5_M>6_B*?Q-^Q?\7_ (/_ -@/:K#'\6/#
ML&GMJOG"4DVHBGEWB/RAOSMQYJ8SDX]THP,YHH **** "OSG^./PQ\"?\% /
M^"\J?LU_M)^"M/\ &7PK^"?[/L?B.R\$^((1-ITWBG5-2\@7TULP\NZ"V"-&
MJRAUC8EE"LQ-?HQ7Y^_M56GQ*_8;_P""OFD?\%$X_@CX\\:?"GXB?!D> ?'3
M?#7PW<:U?>'M8M=0-[::I=V-LC3O:-;>9!YL2OL8'=M+Q+( 1_\ !-OP;I/[
M&'_!57]I3_@GU\+=.CTGX6WWAOP[\2?AWX1LG?[)X=DNUDM-4B@5RWEQS7<0
MF$2E8XQ\J(HKM/VH/^"[W[%_[(_QW\0?L[?%+P7\5KK7O#<T,>H7'AWX;W=]
M9N9;>.=?+G3Y9!LE4''1LCM6/_P32\$_&3X[_MU_'S_@IU\5?@[XJ\!^'?'6
MFZ%X0^$7AKQ]I+:;KJ:/IB2&\N[FR<E[:.XO7:2%7VNR*6*!61W^Z@ .@H$?
MAQ_P76_X+I?L:?MC?\$KOBE^S?\ "CP9\5+77_$G]A_8+CQ)\.;JPLD\C7-/
MNG\R>3Y8\QPN!G[S%5')KZW'_!S9_P $\._P\^.'_AH;ZOT.F@AN8_*N(ED4
M]59<@_A3@,< 4 ?G?_Q$V?\ !.__ *)Y\</_  T-]1_Q$V?\$[_^B>?'#_PT
M-]7Z(44#U/SO_P"(FS_@G?\ ]$\^.'_AH;ZC_B)L_P""=_\ T3SXX?\ AH;Z
MOT0HH#4_ /\ X*N_\%:_V=_VOOVQ?V8OC7\&_A=\6IM#^%/_  FG_"6/J/PU
MO+>1/[3T^T@M?*0@^9EX7W8QM&#SFL?_ (>H? ;_ *);\5O_  V]Y_A7]"E%
M5&7*3RG\]?\ P]0^ W_1+?BM_P"&WO/\*/\ AZA\!O\ HEOQ6_\ #;WG^%?T
M*44^=ARG\]?_  ]0^ W_ $2WXK?^&WO/\*AU/_@K'^SIHNGS:MK'P\^*%K:V
M\;27%U<?#R[2.) ,EF8X"@#DDG K^AJOFS_@L> ?^"4'[1V?^B+^(_\ TWS4
M<\A<I^/&G_\ !6#]G?5K"'5-*^'7Q1N;6YA66WN+?X=W;QRQL,JZL.&4@@@C
M@@U-_P /4/@-_P!$M^*W_AM[S_"OV8_X)4<?\$O/V;O^R!^#_P#TR6E>^4<[
M'RG\]?\ P]0^ W_1+?BM_P"&WO/\*/\ AZA\!O\ HEOQ6_\ #;WG^%?T*44<
M[#E/YZ_^'J'P&_Z);\5O_#;WG^%:'_!)+_@K'^S[^QQ^U[^T]\9_C1\+OBQ#
MHGQ6F\'MX3?3?AK>7$CC3;*]AN?-4 >7AYX]N<[AGTK^@2BDY-ARGYW_ /$3
M9_P3O_Z)Y\</_#0WU'_$39_P3O\ ^B>?'#_PT-]7Z(45)6I^=_\ Q$V?\$[_
M /HGGQP_\-#?4?\ $39_P3O_ .B>?'#_ ,-#?5^B%% :GYW_ /$39_P3P_Z)
MY\</_#17U?BO^TC^T_H7Q0_X* _';]HWPM\(_B0WAOX@>++?4/#SW'@6[29H
M4MEC)D3;\AW \9-?U<45RXW!T<?AW0JWL[;>3N?1<)\49IP;GU+-\!RNK34D
MN9-Q]Z+B[I-=&[:[G\E__#0=C_T2+XB?^$/=_P#Q-'_#0=C_ -$B^(G_ (0]
MW_\ $U_6A17A?ZI95WE]Z_R/V'_B9?Q(_EH?^"Y?_+#^2_\ X:#L?^B1?$3_
M ,(>[_\ B:/^&@['_HD7Q$_\(>[_ /B:_K0HH_U2RKO+[U_D'_$R_B1_+0_\
M%R_^6'\D.H_M4^#M(U2QT35O /CBUO=29UTVSN/"-RDMT4 +B-2,N5!!.T'
M(S5[_AH.Q_Z)%\1/_"'N_P#XFOVP_P""L0!_X+3?\$Y3C_F9OB!_Z;--K](*
M/]4LJ[R^]?Y"_P")F/$?^6A_X+E_\L/Y+_\ AH.Q_P"B1?$3_P (>[_^)H_X
M:#L?^B1?$3_PA[O_ .)K^M"BC_5+*N\OO7^0_P#B9?Q(_EH?^"Y?_+#^2_\
MX:#L?^B1?$3_ ,(>[_\ B:R_&OQN37?!NK:)8?"'XA&>\TRX@AW>"+L#>\;*
M,G;P,FOZY**<>%,KC)23EIYK_(RQ'TD?$3$4)4IQH6DFG^[ELU9_\O#\5O\
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M!K'C3XT3ZJ/#-MH-O;2164&G0)/=75XTL\;10K&Q*E%D9S&ZJI( /M .1F@
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MR]FSG?GY:]:SQF@#YO\ VL?^"?1_:A_;3_9Q_:__ .%N?V'_ ,,_ZGX@N_\
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M^T?8'=OLWE^?#L\S?CS-QVX^ZU?18KX_^-G_  69^#/P>_:6\<?LJZ'^R?\
MM#?$;Q)\.Y--3Q7<?"OX33Z]96;7UC%>VP:6"3*%H91PZKDHX&0I->C?$#_@
MHS\ O@Q^QC#^W'\?-$\9?#_PU<1QK%X;\8^%)[/Q"UU+.T$%C_9W,OVF5P-L
M?]QO,8J@9E />J*^7?V4O^"L?P&_:C^-C_LUZO\ "'XK_"7X@S:&VM:)X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]G-OAX^ALTW]H&__ +;DU#[0!L\OR/+8+]_=N_AQS0(_/+]CW]O[]N+XU_\
M!+#]D'X%^%_VD-9M_BW^TI\6-?T37/BMJR)?:AI?AW3;^]FU"6V><,@O!;I!
M#"71P%WXV.$D7[N_9Q_84_;(_8__ &JM!U;X=_MU^-OBE\$]9T.^A^(7AGX[
M>*I-8US3M35 UG>Z1=+:C*.^4FMY'BC12SIYA*)%X;\%/^"%OQD^&7_!+_X,
M?LTV_P >M!T7XX? 'XA7?C3X=^/-)L9KK2C?/J%U<?8;J.18II+*>"X\F94V
M,&56_>*ABD]B^ /[*/\ P4S^)7[7'A3]J7_@HG^T!\/;'3_AOHFH6G@[X;?
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M"@7[)F@_MT?L9?$3]E#7KF*V_P"$R\-S6VF:A,'*V&HH5GL;LA"&/DW<4$V
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MJL<_A36;U@]XME-I>!/:22#>(9 GE@*JD$222@CX_P#C[^US^TS^VM_P1O\
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ME-82NDR(&FCDM661$8!HI75)4+;UT;/]F3_@M_\ 'W6_!_@#]K;]K+X0^"_
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M#9KK_P#@D-\&?A7^SU_P4E_;B^"_P1\ Z9X7\*^'=>^'MKHVA:/:B*WMH_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHR,XI-RYQF@!:*,CKFC(SC- !1110 4444 %%%% !102!UHH ** P/0T9QUH
M ** <]** "BC<,XS10 4444 %%&<=:* "BC/.** "BB@D 9)H **-P'4T;AZ
MT %% (/2C- !12;E]:-R^M "T49[T4 %%&:,@=30 44 @\BB@ HHHH ****
M"BBB@ HHHH ***,T %% .>11F@ HHI-R^M "T4;AZT YZ4 %%&X=,T9!.,T
M%%%% !1103CK0 44 @]#10 44$@=:"0.M !10"",BB@ HHHH **-P]:,CUH
M**** "BBB@ HHHH **,CUH!!Z4 %%%&<=: "BC-)O7^]0 M% (/0T9'K0 44
M9&,T YZ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S\:OB
MSX0^ GP<\6?'/X@W;6^@^"_#5]KNMSQQEFCL[2W>XF8 <DA(VP!R3735YE^V
MI\%-8_:4_8Y^+'[.GAW4H;/4/'WPUUSPY8WEPI,<$U[836R2,!_"K2@GV% '
MBW[/&M?MX3?\$[O#WQB^&]CH/BWXS?%A8_%=S;_$/Q-=Q:'X6.K(+F.W5(U>
M0V>GP-!;K:VXC:<PLY=))I)CC?\ !,*/XV_M7_\ !):/0/CU^T9XJO?''B/5
MO'NC:K\3M$O/[/U2&XC\3ZQ:17MH8\K:F%8H_)B4&*)8HXPIC7;7L/\ P3=^
M+5K\;/V#_A/X\6%K>^/@BQT_7].D7;)IVK648L]0LI%ZI)!>03PNI *M&0:Y
MO_@F]\*_%O[&?["4/@[]HX6/ANZT#Q/XUUS6I[C4X7MK/3[KQ+JNI17$DR,8
MU7[)<12,2WR9(;!4@ '0_P#!.3]HWQC^U-^Q_P"%_B;\4=/M[7QI9R7_ (>\
M?6MGCR4U[2KV?3=0,8 &(GN;661!VCD05\T?"+_@H7/^S#H?[97[0/[2OB+Q
M;XG\)_#?]J"S\.Z3I]EOO[C2["^AT&SBAM8"V?*CN-0,QBCRQ!DV*SD*?8O^
M"-WAGQ)8_L,Z;\4/%NAW&EWGQ4\9>)OB)'I=V );2SUW6KS4[.-P/NO]DN+<
MLO\ "[,O:O&=8_8%_:>NOAY^TUH,7@:U:Y^)'[7WA'QWX3C.LVV+O0K'5O#%
MQ<W#$R8B98M-O"(WP[>6 %)=00#LX?\ @L!X_E^+NI?LP2?\$S?C-#\7_P#A
M';?Q+X:^'-QJ7A[S-5\/2230OJDE\FI-96<<,T20RPRS><);J!423,ACE7_@
MM?\ "_6? ?P1\0_#[]ESXJ^)/$7QYG\3V/A'P+I^GZ?#J=KJ>@SFWU"SNS<W
M<4%OLE2;,IE\L)!(Y(^56ZJY_9A^,4O_  6WL_VSU\-P_P#"O8?V5[GP5)J_
M]H0^8-9?Q)!?+!Y&[S=OV=&;S-NS(VYSQ7C?[,/[ G[3WPV^+W[+?BWQAX%M
M;>Q^&7C#XUW_ (QD76+:0V<'B+6+JYTIE"N3+YL4J,P3<8R</M((H UK_P#X
M+H7-E\.O&WQ"'_!.#XW21_!R\NX/CS;_ /$EC'@K[,AEE"R27ZKJK>1LN1]C
M\Q1!(DC,H=0?JKX7?M3> _B[\<O%7P,\(V-_)=>%?!GAOQ-/JTD:+:WEGK3:
MB+41?-OWJ-,E+AE4 21X+?-M^:?&7[%?[0NL?LP?M\?#2P\'V[:Q\==<\27'
MPTMSJMN!J,=WX/TW3("[%]MONNK>5/WI4@+N.%()S[GP#_P40_9%_:GL_BO^
MSO\ L=Z-\6-#^(?P5\&>$O$XN/B;::%+X4UC1)=3_?3^?')Y]D\>J$EK99I@
MT#XB/R"0 WM;_P""U_PR3PY\&-1^'?[,'Q-\9ZQ\=M?\8:-X(\+^';?3?MGV
MKP]<S6]T9VN+R***)V@>02%RJ1 O)LVD5L>&O^"PWPHM_@S\3O'/QM^!/C[P
M+XU^$?BK3?#7BKX375M9ZCKEWJFII;-I4&G_ &*XE@O!>M=1I"PD4%ED+;$4
M2'Y__9"_X)M_MH_"[Q;^PIKGQ6\(:;)/\$_%7Q>O_BG?6>JVHCM1KQU(Z?+%
M&LK&03-<QMLC+F(/A\;371?'K_@FM^U'\3?VC/VE/C?X&T?0[6^U3XM_"GX@
M_!QM>U@1V>M7GA>SMOM%K=>2));5))(I8 [(>65PK*,T >T7'_!0CQ3XBN/%
M_P"SS\9OV:O'7P6^(5U\+-:\4>!U\1:EIMY;ZU:VD02=K2\TRZGC%W;/-;M+
M;L5=!*CIO3+CQW_@G_\ \%<_&+?LW?LO:5^TA^RY\6K/1_B=X;\+^$M/^.'B
M6;3I;37?%,VF)N>:!;Q[Y(KFXAE$=W+"%F9U8?*X<[VL?!7]M;]O#X_:'^T3
M^T!^R4OP;T[X6_"_Q=I7@WPQJGCS3M7U37=?UVQM[625FT]Y+:&RAABEC0O*
M)7DEW-&BJ*N:_P#L1?M$W_\ P3X_8G^ MOX,MF\4?!GQE\*]0^(%C_:UN%L+
M?1;6&/4623?LG\MD8 1EB_\ #NH K_"'_@I+\./AGIGC3P[\--"^,WQ6\8^)
MOVM/&7@'PWX3\6>(-*\X:O8I)=7=O8W,\L%O9Z+;PV[F".5VG (0)(S8!^VS
M_P %(_VEO#7[#-]\8/A5^RW\1O 7CK1?C?X8\&>(M \0VND>=##<ZMIR3RVT
M\UPUI>VMU#<BSBN8'8I+=;CY7DR21>5:G_P3L_:>TG]GSXP>!?B7^PSX ^-?
MA?QI^V1XV\=:G\+?$6NVUMJFK>&]39EL-2T;4C.L.FZA$S^85E:.1H3-&)8'
M8;Z%C_P3W_;ZT_\ 82^+G@_P/\+]>L=+N?B5X(\1_ _]F_QI\68M;OO#=CH6
MIZ?=7MF-:N)YH8!>?9"T-KY\L%ML7]YNFD"@'UEXQ_X*3>*H_BG>_ 7X&_L4
M>/\ XB^./"GA?2];^*'A_0]<T*W7P:U_"9H--N+FYOTAN-0,:LX@MWD1DVOY
MH1T9H;K_ (*R_"KQ=\-OA3XE_9Q^"OCSXD>*OC-#JDOA'P#I>GV]A?V*:6PC
MU5]4EOIHK?3EL[ADM9=\C,;B1(XEER2/,]$T#_@H3^RW^TK\2/VMOAA^PI)\
M1K3]H;P_X7UK7O -G\2-'TW4O /B6PT:/3Y]/N+BY=;:]LV2*#_2K:21UDCE
MQ Z%&;GOA;^PO^VU^PXWPI_:H^'OP[\-_%GXA:9IOCBQ^,W@?P_KR:7]O7Q1
MX@@UV231;B_:. &RNX5CVW+1>?!N(*2;5( G[4/_  4R^* \:_L[^._#?[/?
MQH\-ZI!^T!KG@WQY\'5L(8]4UJ[B\-7\L%NA2X^QWUFTTMG<I=B<VP1?-9U\
MI]OKG@[_ (+ ?#2T\ ?&#6OVD?@#X\^%_BSX(-HZ^,O &J6]IJE]<MJ[>7I"
MZ?+I\\T%\UW/_H\8608F^5]@^:N7MOA!_P %$?VB/CY\"_VB_P!HSX5:#X8L
M_"7QNU;7E\$Z=XAM;RY\)>')?"-[IL$=Y<Q[8[R\EOYWD=;<RQQK.JJ[*C,.
M1_;9_P""7OQ[_:T\?_M=V6F:3X>M]*^*WA/X7CP+<>)+OS+#5K[PYJ-YJ%U8
MW<=NWGP02MY$#2[<A;AG0.4*T ?0OPA_;^\1^(OCQX>_9T_:/_9(\;_!_P 0
M>.-/O;WX?R>)M4TG4+37!:1I+<VGG:;=SBWO8X6,Q@D #1QR,COL8#PCPO\
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M>\._%"[^(MK8+X4O9O#-AH]S%J%A*GGW.U]-26%;<%)!*JR2Q;F:+S;XK?\
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M%G5-2UGQ'X\\-PLUQX<\,Z/:F>>4R1LLEL;B_ETVT23A6\V2,G#%3Z'^QO\
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M+:66&=-LT3I-$[(ZN"#UKX-U/]EG_@H+\4?"'P+M/VHOV(_&GBCX8>&?@?\
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M?'B%M:\.:!^R=^R3X]^-'_"3> [7QC9^(/#<UAI>AQZ5=,1:YU#4[B")[F8
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MZU2&WM+>) D<,4: +&B(H554      5>P#U%%% !@9SBC ]*** # '04444
M&,]11C/4444 '3H*, <XHHH -J_W:,#THHH ,#KBC ZXHHH , ]11@#H***
M# SG%&!G.*** # ]*,>U%% !CVHP/2BB@ "A>BT?A110 8'I1@>E%% !@>E&
M >HHHH /PHP/2BB@ HP/2BB@ HQ[444   '04;0. M%%  0#U%&!G.*** #:
M/[M  '0444 &!Z48'I110   =!054]5HHH , <@4A4$8Q2T4 8/@;X7_  X^
M&/\ ;'_"NO FDZ'_ ,)!KEQK6N?V3I\=O_:&I3[?.O)M@'F32;5W2-EFVC).
M*WMH_NT44 ! /448'I110   < 4;5Z[:** #WQ1M&<[:** # ]*,#THHH ,>
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>image_033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +^!/4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\._\_D__ (!3_P#Q%=)11>';\?\ @!:IW7W?\$YO_A//#O\ S^3_ /@%/_\
M$4?\)YX=_P"?R?\ \ I__B*Z2BB\.WX_\ +5.Z^[_@G-_P#">>'?^?R?_P
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M#O\ S^3_ /@%/_\ $5TE%%X=OQ_X 6J=U]W_  3F_P#A//#O_/Y/_P" 4_\
M\11_PGGAW_G\G_\  *?_ .(KI**+P[?C_P  +5.Z^[_@G-_\)YX=_P"?R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#G8_P#DH]Q_V"(O_1SUT5<['_R4>X_[!$7_ *.>NBJY]/1&
M=/KZL****@T"BBB@ HHHH **** "BBB@ HKA?B+XDU/P[)I+:=.(UE,AE4HK
M!PNS Y!QU/3UI/$7BVZ_LWP_?Z1<^5%?S!9!L5N. 5Y'8Y'% '=T5RECK-_-
M\2M3TB2?-C#:"2.+8ORM^[YSC/\ $>_>KOC/4;O2?"=]?6,OE7,7E['VAL9D
M4'@@CH30!O45YC-<>/K30%UR36[%[7R4G\ORUW%3@@?ZL#//K5C6O%.MW5CX
M7?2;A+*?5=Z2!D5EWY11]X$@9)_ ]Z /1J*\Y&L>+?#OB/2[37+ZTOH+^01;
M(E&5RP&[A5.>?<=>]6=?U'Q;8PZEJ[W4&G6=K(JVUHT<<GVE=V,LV25)'8?I
MUH [VBJ>E7C:AI%G>O&8WGA21D/\)(!Q6+9:Y;P7^MR76O?:8+-LO!]C*?91
MDC&X#+^GX4 =-17.Q^.O#,L\,*:K&7FQL^1P.3@9.,+^.*YSQ1XSEB\50Z59
M:RNG6L:$7-Q]D\XK)S\NTCD<+R/[WM0!Z+17'>%=<O;C5?$D&JWZR6^G3*B2
M.B1A%RX)) ']T=:TK#QKX=U.\CM+34E>>3A%:-TW'T!8 9]J -^BN?NO&_AR
MSFGAN-35)8)3%(GE.2&&<\!>1P>1Q^=#^-_#22P1-J\&Z=59" Q #=-Q PON
M&QCOB@#H**Q=0\6:'I=W-:7NH+#/"@=T9&S@XQC Y/(X&3U]#59_'GAA+:.X
M.K1[)"0H".6X]5 R/Q S0!T=%95]XDT?3;""^N[^)+>?_5.N6W_0*"31IWB3
M1M5M)[NSU")X(/\ 6N^4\OW(;&![].#Z4 :M%8.G^-/#VJWB6EGJ2/._W4:-
MTW>P+  GVJ;5O%.B:',D.HWZ0RL,A K.P'N%!QU[]: -BBLJX\2Z/:Z3%JDM
M\GV*5@J3("X).>, $@\'KTJHGC?PU)-/$NKP;H0S.2&"D X.UB,-[!2<]LT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK71=*LIQ-::99V\H& \4"HP'U J2\TRPU'9]NLK:Y\O.SSXE?;GKC(XZ#\J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#G8_P#DH]Q_V"(O_1SUT5<['_R4>X_[!$7_ *.>NBJY
M]/1&=/KZL****@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X
MSQ;*'U2.,'[D0S]23_\ 6KH]7U-=+L_-V[W8[47W]ZX*XN)+JX>>9MTCG)-?
M,\18V"I_5E\3LWY+_@GKY7AY.?MGL14H9E! 8@'J >M)17Q]['NG4^$[^1GE
MLI&+(%WID_=YP1^M;FK2F'2;IP<'RR ?KQ_6N2\,/MUN(?WE8?IG^E=/XA.-
M"NOHO_H0K[3+*\I97-MZQ4E^&GYG@8RDEC(I=;?F<!1117Q9[X5V?A>P2*Q%
MVR@RRDX/HHXKC*Z_PMJ?G0_8'7#Q*61AW7/_ ->O:R%TEC%[3>VGK_PUS@S)
M3=!\OS]#HZ**I7>K6-ED37"AA_ O+?D*^]2;T1\S*2BKMEJ:9((7EE8*B#)-
M<?>>*KR64BT AC!XRH9C]<U9OO%-O/&T,=F94/7S3@'\!69_;]VG%NEO;CTB
MB _GFN7&9=C<2U&E4Y(]>[_X Z.8X6C=SCS/\"]:>(=51AYML;A#Z1D'\QQ^
ME=/:7D=Y$'170]TD7:PKA6UO4F/-Y)^!Q0NM:DO2\E_$YK3"97B:&DZW.O-?
MKN95\TH5/AI\OH_T/0J*X:'Q/J46-TB2C_;0?TQ6M:>+8'(6Z@:+_:0[A^77
M^==DL/->9G#%TI=;'0NZQQL[G"J"2?05AVGBB"ZOEMS Z*[;4<MG)[9':M*6
MX@O-,N&@E613$PRI]C7 V3;;^W;TE4_K54:2DI<VY&(KRA*/+LSTJBBBN8[
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YZ3_DHMM_V"9?_ $;'70US
MTG_)1;;_ +!,O_HV.KAU]#.IT]4=#1114&@4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSMC)25T%%%%(84444 %%%% !1110 4444 %<])_R46V_[!,O_HV.NAKGI/\
MDHMM_P!@F7_T;'5PZ^AG4Z>J.AHHHJ#0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?B-XVF\.Q1:=IS*+^=-[
M2$ ^4G0$#U//Y5XO<ZA>7EQ]HN;N>:;.=\DA8_F:ZGXHK*OCN[,F=C1Q&/\
MW=@'\PU<;7JX>$8P374^>QE6<ZK3>B.V\'?$+4-$OHK?4+B2ZTUR%<2,6:(?
MWE/7CTKWA65U#*0RD9!!R"*^4:^GO#Z2Q>&]+CFSYJVD2OGKN"#/ZUSXN$5:
M2.W+JLI)PELC1HHHKB/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .=C_ .2CW'_8(B_]'/715SL?_)1[C_L$1?\
MHYZZ*KGT]$9T^OJPHHHJ#0*C,\*RB)I4$A&0A89_*I*\ZU29IM5NI"?^6A /
ML#@?RK6C2]HVC#$5O9).USMH=:T^>Y^SQW*F3.!D$ GV/0T:U&\NCW2QYW;,
M\>@Y/Z5RNE7.GRP_8;^!%#'Y;A1A@?<UM^1K>G#%K+'>P#[JR?> _P ^_P"%
M:2I*$M/Q,H5G4@[J]^W3Y'&45KW6D:C<22W(T\0K]XHA_D,UEPQ--.D2CYG8
M*/Q-=JDFKGFRA*+LT>CV*&*PMHSU6)5/X 5/0   !T%%>4W=W/=2LK!7"^);
M,VNJM(!^[G^<'W[_ *\_C7=51U73DU.R:$D*X^9&]#_A7EYM@GB\,X1^):K_
M "^9V8+$>PJJ3V>C/.ZUM U/^S[X*Y_<2X5_;T-9UQ;2VD[0SH4=>H-1HC2.
MJ("S,< #N:^#HU*F&K*<=)1?]+]#Z6I"%6FXO9GJ-%16R-':PQN<NJ ,?4@5
M+7Z=%W2;/D&K.QPOB:!(-9<H,>8H<CW[_P JQZ[37- EU*X6X@D17"[65\@'
MWK,C\(79/[RXA4?[.6_H*^&Q^58J>*FZ=-V;NMK?F?18;&T8T8J<M4CGJ559
MV"J"2>@ S73-H^C:<<WUZ9''5 <9_ <T#Q#IMB"NGV'/]XX7/X\DUA_9D:;_
M -IJQAY?$_N7^9K];<_X,'+\%^)1L?#5]=$-*OV>,]2_WOR_QKM$6.TM43=M
MCB0#<QZ #O7'S>*]0DSY:Q1#MA<G]:H7>KWU]$(KB<LF<[0 ,_7%>UE.*RZA
M65&CS-S:5VON/-Q]+%SI.K.UHINUS1UO7VO2UM:DK;]&;H7_ /K53TG1Y]3E
MR,I I^:0_P AZFIM%T-]1<2RY2V4\GN_L/\ &NSMS;HOV>W:/$7!1"/E^HK[
M.I6A17)#<^8I4)UW[2IM_7X$<6GV\-BUI$FR)E*MCJ<C!.?6N.OO#M]9EF1/
M/B'1HQS^(ZUTGB.ZGM-+WV[E&:0*6'4#!_\ K5R4>LZE$<K>S'_>;=_.OB\]
MKX2554J\9<R6ZMU]=SZG+:5:,.>DU;L_+TV*1!4D,"".H-)6H==N)AB[@MKD
M>LD8S^!&*:)M(G/[RVGMCZQ2;Q^1KYMT*4G^[J+YIK_-'K*I-?%'[M?\F9M;
MWAG38+Z>:2X7>L.W"'H2<]?RI;;0K"^;%KJH)_N-'AORR*Z;3=,ATRW,41+%
MCEG/5C7L93E-25>-6JDX+S33[;7_ !.'&XZ"IN$&U)^30^33K*5-CVD)7_<
MQ5"7POILA)59(O\ <?\ QS6S17U=7!8:K\=-/Y+_ (!XL,15A\,FOF8*^$M/
M!R9+AAZ%A_A6K::?:V*E;:%4SU/4G\:LT4J.!PU!\U."3]/^'"IB*M16G)M!
M111748A1110!%<VT%Y \%S"DT3C#(Z@@_A7$ZM\*-!U"0RVK36+DDD1'<A_
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M )*+;?\ 8)E_]&QU<.OH9U.GJCH:***@T"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY&W3O^O"Z_\ 1EO6M63<?\C;IW_7A=?^C+>JB1/9>J-:BBBI+"BBB@ HHHH
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MU'>;N%8LOAFQEO?M'S*I.YHA]TG^@K:HI5\-1KI*K%.W<=.M.G=P=KB !5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU%!;"4P[]C9+CJ ,9/4<@8I\OBO0X=)BU1]1C%G*VU) K$D^FT#.?PKSC3-
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M1)IER< M;L?D?^A]ZS*_-:U&="HZ=16:/K*=2-2*E%Z,T8-=U*W4*ETY4=G
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M=>"J4G=,*E.=.7+-685S7B+0VG+7MHF9/^6D8'WO<>]=+166,PE/%TG2J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Y;5_$]Q?-Y=J7@@'<'#-]3VJK9>(=0LB )C(G]U^?UKS)9W1C/D5W'O_P
M[5E5245-VYOZZGHU%8FE^);6_*QR?N9C_"3P?I6WG(R*]*C7IUH\U-W1QU*4
MZ;Y9JP4445J9A1110 4444 %<])_R46V_P"P3+_Z-CKH:YZ3_DHMM_V"9?\
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MRUID-U<:I:160;[4TJB+;U#9X-?4M7B*4:;7*8X+$3K1?-T"BBBN<[0HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX.7=L****R-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM\WTZG]*]*DN2FKGC5Y.I5=O0Z_PY8_9-,61AB2?YS].W^?>MBD "J   !P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5STG_)1;;_L$R_\ HV.NAKGI/^2B
MVW_8)E_]&QU<.OH9U.GJCH:***@T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2_\
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MNQJ'_A%9O^AGU[_O_'_\;KHJ*?/+8ETH-WM^?^9SO_"*S?\ 0SZ]_P!_X_\
MXW1_PBLW_0SZ]_W_ (__ (W7144>TE_7_#![&';\_P#,YW_A%9O^AGU[_O\
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MBLW_ $,^O?\ ?^/_ .-T?\(K-_T,^O?]_P"/_P"-UT5%'M)?U_PP>QAV_/\
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M1[27]?\ #![&';\_\SG?^$5F_P"AGU[_ +_Q_P#QNC_A%9O^AGU[_O\ Q_\
MQNNBHH]I+^O^&#V,.WY_YG._\(K-_P!#/KW_ '_C_P#C='_"*S?]#/KW_?\
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MS-4NG'0RMCZ9KL?#<WFZ+$"<F,E#^>?Y$5PK,68L>I.378^$C_Q+)A_TV/\
MZ"*[\1']WZ'E825ZS\[F_1117 >J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&&" M]3R?YUOBG:%CEP4;U&^Q<HHHK@/4"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!16I<:<C*6A^5O[O8UED8.#UK2,E+8AQ:"BBBJ$%%%% !1110 4444 %%%%
M'8^"O^17A_Z^+G_T?)705S_@K_D5X?\ KXN?_1\E=!7E5?C?J>Y0_A1]$%9V
MJZQ!I2+O!>5N51?3U/I6C7+:II5Q>^)4WQN;9]OS@<!0.1GMW_.O-S*M7I45
M[!7DVEZ7ZG=A*=.=3]Z]$FS0TOQ%!J,_D-$T,I&5!.0WXU;U?4#IE@TZIO;(
M50>F3ZU@:G#;Z=XEL6B588SL+8X ^8@G\JZ*[OK*WA1KF5/+D.%R-P./I7+A
ML16E2K4JU1*<';F]4K.QM5I4U.$Z<6XRUM^AR?\ PD.L+B<X\HGO%\OY_P#U
MZZK2]074K%;@+M;.UU]"*P-4U9M8(T[3HBZ,1EL8W8Y_ 5NZ58KI6G")G&<E
MY&/ S_D5SY9*M]9DHU74II:M[<WD:XR-/V*;@HROHEV\R_14<4\,ZEH94D [
MHP/\JDKZ!-25TSS&FM&%<7XU_P"0SI/_ %[W/_H4-=I7%^-?^0SI/_7O<_\
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MXDU.R2&;/E2-<(%?'!VG.#CVH O456GU&RM9A#<7EO#*R%PDDJJQ4 DG!/0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ:-5N=3^RJ;NYB\F9V8D.G P5)V_PCM64/ 'A<)(@TE,28SF5R1@YX.[C\*
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M/I @D"%PLUJJE@.N*CU:_M]1M;86<^66[C&[8?E)#8.#UIC++#J4J:E.991
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;]ZI]Q';V\5K L,*!(UZ 5+117%N>DE;1!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&8*I9B
M ,DGM2U@>*;_ .SV:VJ'YYOO>R__ %_\:J$7.2BB*DU"+DS UK56U*Z.TD6Z
M'"+Z^YK,HHKU8Q459'ASDYOF85TWA_0DF1;R[4,AYCC/0^YK!L;;[7?0V_\
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M&O35W'3[S7HHHKTCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNZD;X&2Y7$EHHHKD.\*:Z)(C(ZAD88*D9!%.HH Y?4/"F6,EBX Z^4Y_D?\
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MSJWR@#)W'G(!SSD$CH!0!Z517F$OBCQ%+8^%5MK]5N=2+I*SPH0Q\P*"1C@
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M;;6U"S)_V;A"/S!KUNBMHXIK=7.>6!3V=CR+^UM-_P"@A:_]_E_QH_M;3?\
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M5GIUCIZNME9V]L'.6$,2IN^N!S6%XCF\.Z*\%YJ.C03RW4P02):QL^[U);%
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M!R9SDLAEE>1OO.Q8_4UTW@^'BZF/^R@_4G^E<M7>>';8VVCQ9&&E)D/X]/T
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M]TY6"%Y".NT9Q5Z/P[JDG_+MM'^TX']:B3@OBL:051_#?\2 ZOJ)_P"7V?\
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M@'1Z%?:W/<7=IK6GQ120%2ES;D^3*".@W<Y'^<=Y-5\4:-H=R+?4;T02M&)
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M,_U^\9V;OFW;,^_7':G:*FFR:I9IX4EO8HC92#5)$61MAV'8<=W#9P%[].]
M'J<TGE0R2;'?8I;:@RS8[ >M4;?6K69;%95EM;B]W>3;7";9?E!)RO..!G\O
M6O,?#;V-KJ%W:6$<%Z&LI@U[;_:(V50A.94?Y>3@<=#3+>TTM/\ A#+O4XR+
M:6*5)G^?!*D^6/E_VCV_'B@#V*BO%M"6^?Q/:F2XMH=9%YF<.+DW$BY^9&P"
MFTCZ< <BO:: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P">^I_^#2Y_^.4?\([9?\]]3_\ !I<__'*=H]Q7EV_'_@&M163_ ,([9?\
M/?4__!I<_P#QRC_A';+_ )[ZG_X-+G_XY1:/<+R[?C_P M_^1MU'_KPM?_1E
MQ6M5&QTFTTZ:::#SVEF55=Y[F28D+D@9=C@#<W3UJ]2DTWH.":6H4444B@HH
MHH **** "BBB@ HHHH **** "L[6M&MM=LEM+IY4C65908B <KTZ@\5HT4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9/AW_ )!DW_7_ 'G_ *4R5K5D^'?^09-_U_WG_I3)6M52^)D4_A04445)
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #719$9' *L""#W%><W]JUE?36
M[?P-@'U'8_E7I%<QXLL<K'?(/N_))].Q_I^5=&&GRRMW.3&4^:',NABZ+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG@CN8'AE&4=2I%244 U?0
M\XU"QET^[>"4=.5;LP[&I-(NVLM3AE!^4MM<>H/^<_A7=WEC;7\7EW$0<#H>
MA'T-9]OX:T^WG64"5RIR [9&?P%=JQ,7&TCSG@YQG>#T-BBBBN(]$*RI+#0]
M'BDO)+6SME!RTIC _+_ 5I2RI!"\LC!8T4LS'L!R37C7B'7[KQ'J.0'$ ;;!
M .?QQW8UT8>C*HVD[+J<N*KQI)-J[Z'0ZU\05D#6^EVB>7T\Z=0?R7I^?Y5Q
ML%O>:O?>7!"TUQ(<[44#\>. *T]7\-3:)I-M<WC@7-P^!"/X% YR?7I5BWU2
M'PSX#O;U74:EJ+-!;C^(*."P^F2?KBO1CR4X7I*]]#RY^TJ3M6=K*YRCW$ O
MI;(NKR(_E_+RK'I@'OSQ[UCZA)&KM;P+M0-E@.[5L>&%&EV5]XDE0'[(!#9[
MAP;EQP??:N6_*J&E:9<WJS:BR,]O ZB20\Y=LX^O3^7K5J=W8Y7'1/O^1T/A
MOP7:^(O#UXD<KPZY ^^-'8;)$P,#'USSVXS3_AMX@GT+Q,-*NF9;:[D\EXV_
M@EZ ^QS\I^OM6=]K%K.A\TQ2=48''ZU%<6XN;W[<97%T7$AE!R2V<Y/O4RHN
M5TW=/\#6%50<915FOQ/H2ZM+>]MV@NH(YX6X9)%# _@:XR?X4^'9=32[07$4
M(;<ULKY1O;GD#\?RJ2T^).G2 "ZM+B!O]C#C^A_2M)?'?AY@";UE]C"_]!7F
MJG7I[)GL2J8:KK)IG1T57L;^UU*U6YLYEEA;HR_U'458K!IIV9U)IJZ"BBBD
M,**** "BBB@ KB/%&/[9;'_/-<UV]>>ZU<"YU>YD!RH;:/H./Z5TX5>_<X\<
M[4TO,H5Z%HF?[%M<_P!RO/E4LP51DDX KTJUA%M:0P#_ )9H%_(5KBGHD8X%
M>\V34445PGI!1110 4444 %%%% !1110 4444 %%%% !1110 5XM?>$-;U#X
MG2R3V$ILY+T2FXV_N_)W9^]TSM&,=<U[316E.JZ=[=3"M0C624NCN%>>Z[X.
MU/4O%CW2"-K29T9I"P&T  $$=>W:O0J**565-WB56HQJI*055O\ 3K+5+8V]
M]:Q7$)_AD4'\1Z&K5%9IV-&DU9GG6I?"#2+FY$EC>3V49.6BQY@QZ*2<C\<U
MW]G:QV-E!:0@B*"-8DR<G:HP/Y5-15RJ2DK29G3HTZ;;@K7"BBBH-0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R?#O_ "#)
MO^O^\_\ 2F2M:LGP[_R#)O\ K_O/_2F2M:JE\3(I_"@HHHJ2PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W7[";4]"N[.W<)+*F%).
M!P0<?CC'XURG@_P==Z=J1OM3B1#$"(4W!CN/\7'M_.N]HK6-:48."V9C.A"=
M15'NCB?B-I>H:A96<EA;O.T1D!5!N() P<>G!KS+3? GBC6[Q(I[.XMXU.&F
MNP55!GG /)Z]J^@Z*TAB90AR)&-7!0JU.>39X5\18[715TSPQ89\BSC,TK'K
M)(_<^^!_X]7H7A3PO'%\.X].G4++>QF:0D=&;E3^ "_E7E_BHOKGQ+N[<9S+
M>+:J/H0G]*^@E4(H51A0, #L*TK2<8177<PPL(SJU)6T6AX5;:3;WNK+I6I;
MH@\AA+KUBDZ ^_/!'IFLC6_#VM>$+TI<(Q@W8CG49BD']#['FNJ\4+Y?C6[\
MC[WG*1_O$ _SKUZXMX;NW>WN(DFAD&'CD4,K#W!K>M7<.67=&%'"QJ\\-G%[
MGA>CZKX:U#;#JHN=-G/'G0GS(3]0067\R/I7:6_P\LKZ!;BRUU9H&^ZZ1!P?
MQ#5'K_PCL+LM-HMP;.4\^3)EHS]#U7]?I7(:=X8\;>'=>@2QM;B-VD'[R)MT
M+#/\9'&/K4^VYU>$[>H>RE3=JM.Z[K^O\CV30-$BT#3!9Q2M+ER[NPQDG';M
MP!6I117G2DY.[/8C%12BMD%%%%(H**** "BBB@"CK%Z+#3990<.1M3_>/^<_
MA7GE='XNFD-W!#SY8CW#W))']*Y^&)YYDBB4L[G  [UZ&'BHPOW/)Q<W.IR]
MC6\-V!N]2$K#]U!\Q]SV']?PKN*IZ98)IUDD"X+=7;U-7*Y*U3GE?H=^'I>S
MA9[A11161N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &3X=_Y!DW_7_>?^E,E:U9/AW_ )!DW_7_ 'G_ *4R5K54OB9%
M/X4%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &3_P (QHO]M_VQ_9\7V_.?.YZ^N,XS[XS6M113;;W$HJ.R,Z?0
MM,N=134)K.-[I,$2'/4="1T./>M&BBAR;W!12V04444AA1110 4444 %%%%
M!1110!5OM.MM1B$=PF<?=8'!7Z5!I^B6>FR&2$.TA&-[G) ]JT:*KGDERWT(
M=.#ES-:A1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9/AW_D&3?]?]Y_Z4R5K5D^'?^09-_P!?]Y_Z4R5K
M54OB9%/X4%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=S_\;HY9=@]I'N:U%9/_  D5C_SPU/\ \%=S_P#&Z/\ A(K'_GAJ?_@KN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_M*F[SOQY&3NS_#MVXQCMUYIHT^WB\*2:TGF"_AU8K%*)&&Q=PX SCWSUH
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MOXUTU='L-16WO9?M[,MO;11!IG*D@\ X[>O>I[;Q9IMU;Z;<1B<17\I@1V3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>image_034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *@!3(# 2(  A$! Q$!_\0
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M_?1H^TS_ //:3_OHT =#17/?:9_^>TG_ 'T:/M,__/:3_OHT =#17/?:9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )&N3_KX7^E>@T 07O\ QX7'_7)OY&N.\&_\AB7_ *]S_P"A+78WO_'A<?\
M7)OY&O/=&M+V\O'CL;CR)1&6+;RN1D<9'U% ':>(8;:31[A[A5W*A*,1R&[
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M!I-XKU.WD0W-@B1MR 4921[$G^E=+:ZA%>Z<;NW.1M)P>Q'8U5\2Q)+H5P7
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M<CZCO7<T4 >=Z1')%XF@CF_UJRD/]><U=\5V-PFIF\",T+J,,!D*0.AKMZ*
M.*GUO4-:L6M+>R !7,KKR,#G\*D\%3*MQ=PG[SJK#\,_XUV-% 'GVI_\C7)_
MU\+_ $KT&BB@""]_X\+C_KDW\C7'>#?^0Q+_ ->Y_P#0EKN** "BBB@#@(?^
M1S/_ %^-_P"A&N]=%D1D<95@01ZBG44 <')::AX:U(W$*&2'D!\95E/8^A_P
MIU_K=]KT8L[>U*JQ&Y4RQ;'J?3O7=44 9>@Z5_95AL<@S2'=(1V]OPKA=+^U
MK?I)9+NGCRX7U ZC\J].K@/"G_(>C_W&_E0!)J>OWFKPBQCM3&6(WJN69CZ8
MQP,UOZ+I;Z9HLPF&)I5+,/[O' _SZUN44 <%X2_Y#@_ZYM_2NVO?^/"X_P"N
M3?R-3T4 </X-_P"0Q+_U[G_T):76-.N])U<ZA:H6B+^8K*,A2>H/M7;T4 <7
M+XKU"[$<5G;".7/.T;RWL!CBNHTPWK6*-?[!.>2%&,#MGWJY10!YS!+/H6M^
M9+ 6>-F&TG&X'C@_C6AX@BNM1M+/4Q"=ACVNJY.PY-=M10!Q-OKU_=:>FFVM
MF&EV>5O7GC&.G;COFHO"CBVUYHI.&>-H\'U!!_I7=T4 <!K_ /R-4O\ OQ_^
M@K7?T44 <[XOLO.TY+E1\T#<_P"Z?_KXK#\,VK7NM)+)EE@7>2?;A?\ /M4V
ML>(;B_B>P2V\OYMKX8L6P>G3BMWPQIDFGZ>SS*5FF.XJ>H Z _K^= &W1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
MQI7_ !ZM_OG^0J:?[X^E0Z5_QZM_OG^0J:?[X^E $5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5#H/_(.E_P"OV[_]*)*FJ'0?^0=+_P!?
MMW_Z4252V9+^)?/]#3HHHJ2@HHHH **** "BN"^)5O<7;Z%!:/LN7NB(FSC#
MX&.>W.*IZ7K7]N^-?#URZ[+E+6:*YCQ@I(H;(_'@_C0!Z317'_#;_D5W_P"O
MN7^8KF->_L=?'NMRZUI5Y?V\<4+?Z,&_=?(O+$,N!]: /5Z*\G>WEB^&.O3Q
MJ\6EW%PDEA#))O9(_-7W./IG.0?J9=,TN-]<T2;0- U;37BD#WEQ<JR1O'QN
M RQSGG@8Z]#V /4Z*\X\4Z/'HNLV6K(;L-+?+)<:J\^YH5.1Y008^7'?' XY
MZ5TWCF5(?!NH226\=PH"9BD+!6^=>NT@_D: .AHKB#K^O2:VFBZ/::>0MA'<
M!K@N G SG!YZX ]^O%<[XBUO4O$WA71Y6CM8XY[WR9H\L THSCH?N8Z\YSB@
M#UFBO.=%#:!XA\2"*W@\RULK;$0EV1[A&N?G<\+GN3TJ72?'6HW.HW=E<_V9
M.\=G).LEEO**Z@G:Q8X;ZKQZ$]@#T&BO.K?QKXE:#2;A[#3'CU1FB@1&=6#@
MX!;)("YQQR< ]*EG\;ZO::'K$D]M9?VCIMTD#; YB8,<9 )SV/>@#T"BN"_X
M2CQ2-4GTHV6E?:_LXNXVWOL2/DD-W9N@XP,^U3/XTO9O"FFZG;II\$UP7$SW
M<VV./9D'"YW-G' 7)&>] ';T5Y]%X^OY?!MQJHM;9[F&[%LTBJ_DJIP1(1][
M'(&/4CZ5;LO'$\?AO4-4OX[*<VS((C93?++NX *G+(?]X#Z4 =M17)66OZ[9
MZUI]AXAM+)%U%3Y$EH6_=N!DJX8GGD#CCZ]L*W\>>(CI5EJTMAITEG/<_9?+
MC9UD9^2""20HXQSGI[T >E45Q">,]0TY-=AUJVM6N],2-U^R%@DF_&!\V3U9
M>?<\<<L\*^.I]8UI--O#92M-$7CDLUD4(P&2K!QSQW'''?/ !W5%%% !6+9_
M\A/6/^OM?_1$5;58MG_R$]8_Z^U_]$14ULR7NOZZ%VBBBD4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!/;_P 7X5-4-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5#H/_ "#I?^OV[_\ 2B2IJAT'_D'2_P#7[=_^E$E4MF2_B7S_
M $-.BBBI*"BBB@ HHHH **** ,W7U9M#N@O7:#^&1FN'L+?[7?P0=G< _3O^
ME>DLJNA5@"K#!![BLRRT"SL+PW,7F%N=H8Y"Y]*\',\JGB\33J1MRK1^E[_\
M ]+!XV-"E*#WZ?<6=1A1M)N8MH"B%@!Z8'%<7X>.-=MOJP_\=-=KJ3A-+NV/
M3R6_E7GEM</:7,<\9^>-LC-<>>U(TL90F^FOR4D=&71<Z%2/?_(]-HK%TCQ
MNIW+0-!Y3!=R_-NSZ]JK>)=4NK*>WBMI3&=I=B #GGC^1KVIYGAXX9XF+O';
M3O\ ,\^.#JNK[%Z,WKFYAM(&FG<(B]S7!ZQJKZI=;\%8DXC7T'J?>J]W?W5^
MX:YF9\=!T _ 5M^&=(BN0;V<;E1]J(>A([FOG<3CJN;55AJ"Y8^?EU?IV/4I
M8>&"@ZU35_UL:7AK36L[1KB5<2S8P#V7M_GZ5N45!=7#6\8*1JY/]YP@_,U]
M3AZ$,+15.&R^]GC5:DJU1SENR>BJ,6IP%?\ 2)[6)_[HN W^%6HYX9O]5+&_
M^ZP-=*NU>QC=7M<DHJEJ>I1:7;":12Y8[54=S46DZQ%JJ/MC,<B8W*3GCU!J
MN27+S6T)]I'FY+ZFE1114EA1110 4444 %%%% !6+9_\A/6/^OM?_1$5;58M
MG_R$]8_Z^U_]$14ULR7NOZZ%VBBBD4%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!/;_ ,7X5-4-O_%^%34 %%%% !7/7/\
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M48M1>\L#*R2'<1&WS*WTJ*XU#Q%>6S6K6,BAQM9A P+#ZGB@ \%_\?\ <_\
M7+^M;'BJS%SH[2@#? 0X/MT(_P ^E)X:T>73())+C FEQ\H.=H%9.K7.NWQE
MLC92"$.1NCB;YP#QD],4 5/"UG]JUA96&4@7><^O0?X_A7?5C^'=*?2[%O.
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MQ6S/]G>"-0Q()92.H7.7VGJ.3TJ./3KJ/PWJ.C75I<0107BM#]FC:X01,P<
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M+]FG_P">,G_?)H^S3_\ /&3_ +Y- $5%2_9I_P#GC)_WR:/LT_\ SQD_[Y-
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M -C^U8/[DGY#_&C^U8/[DGY#_&L>B@#8_M6#^Y)^0_QH_M6#^Y)^0_QK'HH
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M-UQTQC &<5;T?PW::/*TJ,TLIX#N.@]JRJ4WS6N=^$Q=.%!WC:7YFU6+9_\
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M_%GP1+(L::X-S' S:S#]2E ':45QT_Q4\%VTA2;6MK#@C[+,<?DE1?\ "W?
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MD#JY],X&#7;5$X2B[2-:52%2-X/0X/QE\0G\/:C_ &=8VL<UPJAI'E)VKD9
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M26%0Z#_R#I?^OV[_ /2B2IJAT'_D'2_]?MW_ .E$E4MF2_B7S_0FU#5K/3#
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M&NBF\1:N=<O+2TMXYEM[J*$1+:2DLC!2Q,H;8A&3U':I?#VA2Q3+>W:%"O\
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M+W7]="[1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH GM_XOPJ:H;?\ B_"IJ "BBB@ KGKG_CZF_P!\_P ZZ&N>N?\
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MO;7<X':^@4444Q&QI7_'JW^^?Y"II_OCZ5#I7_'JW^^?Y"II_OCZ4 14444
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MJ3(#\D7R#Z]_\^U94(<T_0Z,54Y*;MNR'2;/[9J$:$91?F?Z"NVK*T"S^S6
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M 'S_ #KH:YZY_P"/J;_?/\Z (JQ/&7_(C>(/^P;<_P#HIJVZQ/&7_(C>(/\
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M*ZN+@*(F9GPV>O![Y]*^@?A_H)TGP^^J7Z*VI742;LC[J ?(OY8/XUY_X7T
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M3FQ%2+LE%.VB\MPF2_LE65K@L,X^\3_.M>.4-;K*W *!C[<9K#,4ANUAO9G
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MVD5MI\;)AFE4,S>OM^%6OW%._5F<O]IJV7PHGT^PCT^V$2<L>6;^\:J^'_\
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MZ^U_]$14ULR7NOZZ%VBBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!/;_P 7X5-4-O\ Q?A4U !1110 5SUS_P ?4W^^
M?YUT-<]<_P#'U-_OG^= $58GC+_D1O$'_8-N?_135MUB>,O^1&\0?]@VY_\
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M'M_^?C4?_!C<?_%UH44<S[AR1[&?_8]O_P _&H_^#&X_^+H_L>W_ .?C4?\
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MC!I'_7D?Y5L:G=/9:9<7,84O&A8!NE8\?_(P:1_UY'^5:6O_ /(!O?\ KD:
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M9V%^MTNZ38K#8D9[CY0<Y_''%<^DDN9VL=>M-OD3=_TLK$^OV:V6K.L8 CD
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M&.R.JHHHKB/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.%!_.@"1AN4KDC(QD'FL(V.O+:O9K>6LD3 J)Y-QEVG],UJ7%T#I\EQ:SVW
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MO]\_R%33_?'TJ'2O^/5O]\_R%33_ 'Q]* *=["UQ8W$"$!I(F0$],D8KA)O
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MQ3_V9>*ZVBL_J2CK2DX_BON9W_V_.JK8RE"KYM6?WHYV#Q=93#;<0R19'/\
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MO^(!JPFG6C>,Y83;Q^2ML)?+"C:6R!G'3H36NVE)_:-E=1OL2UC:-8@N<@C
MYSVI4TW;KCZEYN=\'D^7MZ<@YSGV]* .<O6.FIXCCM 8T!@VA. F\?-]*?-I
MUS)IBV]OX?6*10#'<+<1[@1WSU-;IT>*2YU*29]\=\$#)C&W:,=<\^M5#H%U
M);K9S:O*]DN!Y8B 8@= 6H V+;S?LL/GC$NP;Q_M8Y_6N4G_ .//Q-_UU%=<
MB+&BH@PJC 'H*Y"2^T5X=3C_ +5Q]N<-G[._R?X_I0!8U/3+.#PCYT<"+,D<
M<@E ^?<2,G/7N:FU"SNVO[?4ELX[^/[.%:%R 5/4D \5%>:QHMWHQT_^TMF4
M5/,\ASTQVQ[5!<:EI)N8[JSUIK:X6,1LWV=G5P/4$4 ([V?]AZS';PSVTV%:
M6VE& AS_  CTJU%$E_KME;W*!X8+!94C;D,QP,X_STJE]KT9[2]2;6&ENKL
M/.UN_ '0!<=/QJ6ZU'19A:R0:LT%U;($698'.1CH5QTH G>VAT[Q;OMHPH-F
M\GECIG)Z#MTJGI4,UQIAE?0A>M<%F>X>= 6.3TSR,4MG?Z5;ZM_:,^MM<2E"
MC VS+^6!P/:FK>Z;;>;'I_B"2UMI"3Y7V5GVYZ[21Q0!T.@0WEMI*07JE9$8
MA06#';VY%4WACO\ Q;+%=*LL=M;AHXV&5R3R<5<T)K Z8J:=*TL,;%2[ @EN
MISD#UI;[2FN;N.\MKEK6Z1=GF!0P9?0@]: ,O68+;2;#49+&3RYIE0/"C !
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MC2O^/5O]\_R%33_?'TJ'2O\ CU;_ 'S_ "%33_?'TH BHHHH **** "BBB@
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M%-_X2/1_^@C;_P#?5'++L:\\>YIT5F?\)'H__01M_P#OJC_A(]'_ .@C;_\
M?5'++L'M(=T:=%9G_"1Z/_T$;?\ [ZH_X2/1_P#H(V__ 'U1RR[![2'=&G16
M9_PD>C_]!&W_ .^J/^$CT?\ Z"-O_P!]4<LNP>TAW1IT5BW'BK28/+(NX9$9
MPK%7Y7/0X[UM4G%K<:E&6S$;.QMO7'%<7I=^FDZC<-?12><WRDCJO.3_ $KM
M:RKW0+6^O/M,C.K'&Y0>&Q7FX_#UJCA4H_%%]=M3NPE:G!2A5V9J*P90PZ$9
M%+2* J@#H!BJCZMIT<C1O>P*ZDAE+C(([5Z*39QMI%RBJ/\ ;.F?\_\ ;_\
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M:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH GM_XOPJ:H;?\
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MEO;^9O6&20N=T;*, H!U8=Z]FH ***1F"*68X &2: (6O;=)Y(3(/,CC\QP
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M'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\
M&C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C
M^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U
M9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_
M[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D
M?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y
M'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_
M !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@
M"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H
MC_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\
ML^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^
MZ_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_
MYY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY
M?^/#_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^
M/#_&C^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#
M_&C^S[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&
MC^S[K_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^
MS[K_ )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[
MK_GE_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_
M )Y?^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE
M_P"/#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?
M^/#_ !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/
M#_&I/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_
M !J3^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I
M/[5G_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3
M^U9_[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G
M_N1_D?\ &C^U9_[D?Y'_ !H C_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !J3^U9_
M[D?Y'_&C^U9_[D?Y'_&@"/\ L^Z_YY?^/#_&C^S[K_GE_P"/#_&I/[5G_N1_
MD?\ &C^U9_[D?Y'_ !H NZ?#)! RR+M);.,Y["GS_?'TI+*X>YA+N%!#8X_"
MEG^^/I0!%1110 4444 %%%% !1110 C(KJ5=0RGJ",@UF3:!83'(1HR?[C?X
MUJ4549RCLR)0C/XE<QU\-V*GEIF^K#_"K4>CZ?%]VV0G_:RW\ZO44W4F]V2J
M--;10U(TC&$15'HHQ3J**@U"BBB@ HHHH K7ME#?P&*4>ZL.JFN/U#3Y=.F"
M2896Y5QT-=R3@9-<IX@OHKJ>.*%@RQ9RP[D__JKJPTI<W*MCBQD(<O,]S,MK
MAK>7<.5/WAZULQRI*@=#D&L"GQ3/"VY&P?YUU3AS:GG1E8WZ*SX]4&/WD9SZ
MK3CJ<6/E1R?? K'V<NQISHEOR!9OGOC'YUC5/<W3W! (VJ.@%05O"+BM3*3N
MPHHHJR0K+UN!S;)>P?\ 'Q:'S%]U_B'Y5J5)#:37C&.&%I21R%&>/>HJ14X.
M+.C"UI4*T:D5>W3NNJ^:NBO!,MQ;QS(?ED4,/QJ2FZ/X=UBSTUX9[&8"&5T3
MH2RYR" .<<TX@@D$8([4J4^>"?4>,H*C7G".J3=GW73\&@JGJW_(&OO^O>3_
M -!-7*IZM_R!K[_KWD_]!-:'*]BY1110,**** "BBB@ I41G<(BEF)P .])6
MKX>,8U5=^,[3LSZ__JS4SERQ;+IQYI*/<EA\-73J&DDCCSVZFE?PS= ?)-$W
MUR*ZFBN#ZS4/4^ITK'%2Z+J$6<V[,/5"&_E4)L[UV"FWG)]"AKNZ*M8J75&;
MP,.C9FZ+8/8V9$O$CMN(]/05I50NM8LK3(:7>X_@3D_X5BW/B*ZG;9;((@>!
M_$QJ%3J5'S6-76I48J*>QTLT\5NF^:147U8XK&NO$L*96VC,A_O-P/\ &JMM
MH5U>-YU[*R9[$Y8_X5LV^D6-M@K K,/XG^8T[4H;ZL7-7J?"N5?B<S+/J6JG
M&))%_NHORBK5KX;N9"#<,L2]P.6_PKJ@ !@=**'B':T582P<6[S=V5;/3[:Q
M3$*?,1RYY8_C5JH8[RVEN9+:.XA>>+!DB5P63ZCJ*8FHV4AN-EY;M]FSY^V5
M3Y6,YW<_+T/7T-8-MN[.J,5%619HJ"UO+6^B,MI<PW$8.TO$X< ^F14](844
M5'-/%;Q&6>5(HP0"[L% R<#D^Y H DHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI.WEAD<KM^;!'OGBMKPSJ.I/K6KZ1J5VMX]F4*3"(1DAATP./3]: .HHHHH
M**** "BBB@">W_B_"IJAM_XOPJ:@ HHHH *YZY_X^IO]\_SKH:YZY_X^IO\
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M6VKZO56>[V.=\7:#=:_8V\-K)"C1R;R920,8QV!J'Q%X8N-8TJPA@GCCN+0
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M"D=,8_6NHHJ914MS>AB)T&W#JFODPKE_$_AR\UK4;"XMI($2W/SB1B">0>,
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M W_D[/,O^%N_]0/_ ,F__L*/^%N_]0/_ ,F__L*]-HH]G5_G_ /KF _Z!O\
MR=GF7_"W?^H'_P"3?_V%'_"W?^H'_P"3?_V%>FT4>SJ_S_@'US ?] W_ ).S
MS+_A;O\ U __ ";_ /L*/^%N_P#4#_\ )O\ ^PKTVBCV=7^?\ ^N8#_H&_\
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M_'JW^^?Y"II_OCZ4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5QNMW@O-0/EG,<8V*1W]36OK^I>1%]EB/[R0?,1V7_ .O69H6GFZNA
M,X_<Q'//\1["NNC%0C[21P8F;J25&'S.GLH3;V,$1ZJ@!^O>N8^)/_(F3_\
M76/_ -"KKJY'XD_\B9/_ -=8_P#T*N&L[PDSV\L5L722[HO^"?\ D3-,_P"N
M1_\ 0C6Q>3+;V<TK' 5"?QK'\$_\B9IG_7(_^A&JWB#4?.E^R1']W&?G([MZ
M?A6F&@Y\J.;,ZJIUJK_O/\V5-#C\S5X?1<L?RKLZY[PU:,HDNG7 8;4]_7^E
M=#6V)E>?H<6#ART[OJ%%%%8'4-D021LC9PP(.*\J^)DD&F6%GH]O(6>60W$V
M3S@#"Y]N6_*O3[]+B33KI+1PERT+B%CV?!VG\\5X7:>"/$NIZB8IK&>)B^))
M[G(4>IR?O?AFNK#6NVW9(\_'.32C&-V^IUOPMT2*YTC4KN=<B:185(Z@*-Q(
M_%A^5>E6UO':6Z01 [%Z9ZU4T328=#T>VTZ Y2%<%L8W-U)_$YK0K*K4<Y/L
M=.'HJE!*VM@HHHK(W.9\3IBY@D_O(5_(_P#UZPE9D8,K%6!R"#@BNPURR-Y8
M$H,R1'<H]1W'^?2N.KT</).%NQY&+@XU6^YLP>([N)0LBI+CN>#4_P#PE#_\
M^B_]]_\ UJIZ1I2ZCYC22%$3 PO4FMA?#=B.K3-]6'^%9S]A%V:-:7UF4;Q>
MA2_X2B7_ )]D_P"^C4D?BA<_O+4@>JOG],59;PW8L.&E4^S#_"J%UX:FC4M;
M2B7_ &6&#27U>6A4EBHZWN:]MK5C<D 2^6Q_ADX_^M6A7GKH\;E'4JPZ@C!%
M;&@7EU]M2V#,\)!RIYVC'4>E*IADES18Z.,<I*,T=51117(=X4444 1SS1VU
MO)/,X2*)2[L>@4#)-<>_B>R\9Z;?Z3HE\]IJ#IB)IQLWC(SM(R<8R/7GI78S
M0QW$$D,J!XY%*.IZ$$8(KP[QAX0N?"E\MU:/(UC(W[J4'YHV_NL?7T/>NBA"
M,G9O7H<>+J5*:NE>/7N.\)>)K_PKKBV%^TB6;2>7<02_\LB>-PSTQW]1^%>D
MV'CBTOM72R6VD6.1]D<Q8<GMD=LUX;<S_:764C]X1A_<CO72:1?&S%G?$ F!
MEDPQP#M/_P!:N^6'A.[>YY='%U*=HIZ7/=Z*\2\6^/;OQ&PL=/62"R) *#[\
MQ]\=L]!_D>D^!M-U'2_#$,&INQF+%UC<Y,2'&%_F?;->=.BX1YI/7L>M2Q4:
MM1P@M%U.DHHHK$Z@K)UK5+G34C:WLS<#S(U?)VCYW"!5)XW9;Z #GJ*UJR_$
M'_(.A_Z_;3_THCJHVOJ14ORNQI1N)(DD 8!@" RD$9]0>AIU%%26%%%% !11
M7#Q6^J?\),FO&QD$4EXUN0=WF" @("4V\+D;LY[].] '<45P-Y8:A_:>IC3+
M6<SSBX+3O"T3IG;@++NV2*<':.J^W-;VG);0F1]$T9X'\I XN$>UC;D\$%3E
MA_>VG_>H Z"BN"?6?$,K7QM)+J62*>[C,:6H:.-4!\O:VSYFW8&"23Z=ZO7%
MSXAMY419;R5_)A:$?95*32,WSK(P3Y !Q_#QSDT =?17GL<OB2Q,EO;O> &X
MN&:66V9ANW_)]V)B5(YXQ]1TJ\\FOK=W$<"S6RM-=.S06JX8K'&8^2ASD[AG
MJ?PX .THJMITD\VF6DMRI2=X4:12N"&*C(QVYJS0 4444 <OXML=7O)K$V$4
MMU9J7%U:1W/D&4$<9;/(Z\?X\<[!X3UB'0VLOL*AAJR7 59E*^4%(R"3GCWY
MKTJB@#D;[P_>WWBG59BFRTN],-LDVX8WDKVSGL>U9::5XDN%\/6EQI,<4.EW
M,1>87*,752/F SP !R.IR.*]"HH Y[QGIEWJVAK;64/FR^>CE=P7@=>I%5=8
MT*]U'Q8UPB;;232Y+5IMP^5VW]LY[@]*ZNB@#SSP_P"$KJUU*Q^TZ#:VYM6+
MRWS7;R&4@_*40,-I_P!X8]NQKW&@>)$\/7VA1:7%+$]R9EN1<J-XW X"GOQG
M)QQFO0--O&OK5Y60*5N)HL#T25D!_';FK=-JV@D[JZ.9TK2;VV\7W5_-!MMW
MLHHE?<IRP"Y&,Y[5BMH7B&TTN^\/6UC!-:74Q9+YIPH16()W)U)X[?K7H%%(
M9QK:1K&A:ZEYI5I'J$4EDEJ^^41&-D  8YZ@XS@<]>G&<1?!NJMH&GBXT])Y
MK6ZE>2R,X3S4?;T8' ^[Z_X5Z;10!YGJ>B'2O!US=2V=MIDOVM)H[=)))N%R
M%5VRPR<GI@=,XSP^&>?Q3XN<E;>$R:3+$1!.)A$&+*-S+QG+9P.@([YKT::&
M*XA:*:-)(G&&1U!##T(-0VFG65AO^QV=O;;\;O)B5-V.F<#GK0!POA_PE=6N
MI6/VG0;6W-JQ>6^:[>0RD'Y2B!AM/^\,>W8O/AK5O^$"OM,%I_IDMV94C\Q.
M5W*<YSCH/6O0** /.M7\)WKZQ/>?V-'JJW,"!=]V8O(D50O."-PXZ#\Q6O9>
M'KNR\2Z1.MM$MK:V+12-$YV*Y+' #$L1SUKKJ* /./$'ASQ!J=WJB26;7B/)
MYEE.][M2%?[JQYQDCC)XXS[UK0Z5JMEXKT_48[#SH&L8[6<^<JF$\9..^,=N
MM=C10!Y[9>&-9M- TB5+9#J&FW+R_97D7$BL1T8' / _SQ4MWH&MZI#KFHW-
MFEO=WD"006:S*QPK*<ELX[5WM% ')7&BZ@VK^%YTM_W5C$5N"'4;#M QUYZ'
MIFNMHHH **** )[?^+\*FJ&W_B_"IJ "BBB@ KGKG_CZF_WS_.NAKGKG_CZF
M_P!\_P Z (J*** *]W:1W<)C<=1C->3>,O"\D3M(8\IT5@.1]:]AK!\6R!-(
M*A SN=H)[5RXFE%QY]FCIPU5QER[IGS-?1-;S,C#!!J"UU&>RF\R"4HW3([B
MM[Q@%74F10/E&#7).>:BE[\;LWJ/EDTCK8-;M[T*+A%MYAQO0?*?J.U7);(K
M&&5"5==VY.0P]Q7$J^!UK8TG7KC3)  3) ?OQ,>#_A4SI-+W3II8^K35M_7^
MOZ['=:;X:/DQRRE0YY*'C8".QJ_)Y$0GN(;AWDB7RU57WEL]B&XQ6AX;U[3-
M:@5(I!')&IQ$WWP<<G-3WEC ))Y'M1)$W,DJ+S*<="._UKS:G.I:FRK>TUEN
MSAM-U.YMI^1&"G13CD^G%=?)-*VF0D)/;&66/"MDHN>H(].OXUG6FB65IJRR
M-$@5PVP$;P#C(Y[<5J1VWG;Y=2\ORE.$!;"8SP>._P#C71C<11JU%*FK*R.;
M"T*M*FXU'=W9JQ-F]@@B7$>-Q+C(*GC (Y&".]7XY)4G=IL",,0O/+\YZ#VK
MF-2U1+2R*93SAA2D0.Z)?][O_P#7J]I.L0W4XA 9IG +^:V[C''T-8PPM65-
MU8Q]U=15,12C45*4O>?0WM.UUKG59;6&(B!!DG'\5=<CAT##H17':)I"V]X]
MW(-D\@ =0>!776X @4#H,C]:];#S@U:GM97]>IYLXS3;J=W;TZ$M%%%=)!@^
M&_#7_"/R7C?:_M'VDJ<>7LVXW>YS][]*HWW@>.2_DO--U&?3GDSO$8)'/7&"
M"![5UE%9^RA;EL=JS#$JJZJE[SWT6ORM;\#$T#PS:Z"LCI(\]S+]^9^I'H!V
MIGAOPU_PC\EXWVO[1]I*G'E[-N-WN<_>_2MZBFJ<5:RV(GC:\^?FE?GM?Y;>
MEO(*X_7/ O\ ;.L3W_\ :7D^;M^3R-V,*!UW#TKL**)PC-6D3AL76PL^>B[/
M;^KGG_\ PK'_ *B__DM_]G6WJ/A/^UM>CU"]OO,MXR-MJ(L#:.V=W<]>*Z6B
MI5"FE9(Z9YMC)R4I3U2:V77?H8OB/PY!XAM(XFD\F:)LQRA-V!W&,C@_TJ_I
MMK/9:?#;7%S]IDC7;YNS:6';(R>:MT5?*E+FZG)+$5)4E1;]U.Z\OU,+3_#G
MV'Q+>:Q]JW_:59?*\O&W)4]<\_=]*/$WAS_A(H+>+[5]G\IBV?+WYR/J*W:*
M7LX\KCT-%C:ZJQK*7O122>FR5E^!6FL8;G3FL;A?,B:/RV]^.M<O%X(NH-)N
M=,36C]FG<,5-OTP>WS]\#/TKL:*)4XRW"CC:]%-0>C:>R>JV>I1TC34TC2H+
M&-MXB7!?&-Q)R3CZFLR]\+FY\30:W!>>1)'MWIY6[?C@\Y&,KQ70T4W"+278
MF&*K0J2J)ZRO?SON8'B#PG9:^RS,S07*C'FH,[AZ$=ZR+#X<6EO<K+=WCW2*
M<^6(]@/UY/%=M14NC!OF:-Z>9XNE2]E";4?ZZ[F%XD\-CQ!;6\*W(MA"Q(Q'
MNSQC'48KG/\ A6/_ %%__);_ .SKT"BE*C"3NT.AFF+P\%3I3LEY+_(Y=?!^
MWPLVB?;OO2^9YWD^X.-N[V]:Q_\ A6/_ %%__);_ .SKT"BAT*;W15/-\93O
MR3W=WHMW\CE%\%[?#+:-_:'WI_.\[R?8<8W>WK65_P *Q_ZB_P#Y+?\ V=>@
M44G0IO=!#-\93ORSW=WHMW\C#TSPU!9>'Y-'N9?M4,A8LVS9U_$],5STGPRB
M,I,>J.L>>%: ,?SW#^5=[13=&#236Q%+-,72E*4)V<G=[;F7H6@VN@6;06Q9
MV<[I)'ZL?Z"N3_X5C_U%_P#R6_\ LZ] HIRHPDDFMA4LSQ5*<IPGK+?9W^\X
MS3O <FG+>>7JN6N;=K?=]GQM!()/WO0$?C6[X>T-- TS[(LOG,7+O)LV[B?;
M)[ 5K441I0CJD37S#$8B+C4E=.U]%TV.?\0>&/[:OK2\BO#:SV_1O+WYP<CN
M,8.?SHG\,F?Q3#K9O #&!F$1=<#'7/\ 2N@HING%N]A1QU>,5!2T2:V6SW1D
M^(-!@\0:>+>5_+D5MT<H7)0]^.X(J?1[&?3=,BLY[O[48OE60IM.WL#R>E7Z
M*?*N;FZF3Q%1TE1;]U.]O,****HQ"BBB@ HHHH **** "BBB@#8TK_CU;_?/
M\A4T_P!\?2H=*_X]6_WS_(5-/]\?2@"*BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,:ZT$7>HM</.1&V"5 Y^F:UHH8X(EBB4*BC  I]%7
M*<I))]"(TXQ;:6K"N1^)/_(F3_\ 76/_ -"KKJY'XD_\B9/_ -=8_P#T*L*O
M\-GH9;_OE+_$BQX4E:'P!92K]Y+=F'U!-95C$MSJ$,4A^5W^;WK:\%HLG@G3
M4895H2"/49-8]U"^FZD54\QN&0GN.HKLP3_=\JWM^AYF<I_6I2>W,_S.X50J
MA5 "@8 ':EJ&TN4N[6.=.CC./0]Q4U8--.S-4TU=!7-2^.]"AU\Z/)<.LROY
M;2E<1J_]TMGUXZ8]ZZ6O+OB%X'8O/KNF*6SE[J =?=U_F1^-:48PE*TS#$SJ
M0AS4U>V_H<SJ<OB'P9XKDGDNY'G=M_G$DI<*><'/7T(['IV->A_\+&L6CMGA
MM9)5DC5I"' V$]5'J1^%>-2W;W%L(YF9V0_(Q.3CIC^7Y5HZ,Q-NZGH&X->G
M["$[<YXL,5.FVJ;T?S/H6&5)X(YHSE)%#*?4$9%/KQW4_B1<KH=OIFF+Y,T<
M8BEN0<G &!L]#[_EZUL_"S3-6A%UJ-T\J65PG[N.0G]XV0=^/ID9[YKSYX=P
MBY2=CUJ>,C4FH05^[['I-%%%<YV!7,:YI!A9KNW7]V>74?PGU^E=/2$!@00"
M#P0:TIU'!W1E5I*K&S./T.^%G>[9#B*7Y6/H>Q_SZUV-<AK6E_89O-B'[ASQ
M_LGTK2T#4_.06<S?O%'R$]QZ?A6]:"FO:1.7#3=.7L9_(W:***Y#O(+BSM[L
M 3PJ^.A(Y'XT6UG;V@(@B5,]2.I_&IZ*?,[6N3RQO>VH4444B@HHHH Y/Q%X
MR;2+]K&VM1)*@!=Y#@ D9& .O!KF[[QG<:I8SV5_86DMO,I5E7<"/<')Y'6M
MCQKJ6G072Q+90W&H!1F209$8[9'<_6O/YIA&CRO@ 9)P,5ZV'HTY04G$\7%5
MZD:CBI:&)-I<T;C;\\9/4=1^%)?W@FQ##Q"G'UI\NK/+;-'L"NW&X'M1I^GK
M<QM)*2%Z+C^==/DCSA-)U.ZT._AU&VCC,BYV&:/<I]<9_F.:]>\(_$&W\172
MV%S;_9KXJ2NTY23')QW!QS@^G6N2\(7=CI,=Y8:N@NM.N,.J-$&V/T)Q[CN/
M05TV@P>"--U@7>GRLEU)\L8EW[8\]0,C ].37%B(WO>+OT9Z.#<H6<9JSW3.
M[HJI>6<]RZF+4KJT &"L*Q$-[G>C?I5;^RKS_H8-2_[]V_\ \:KSDEW/8;?;
M\C4K+\0?\@Z'_K]M/_2B.C^RKS_H8-2_[]V__P :ICZ)-,8Q<:SJ$\:2QR^6
MZP ,48.,[8P<94="*I63O<F3DU:WY&O1114&@4444 %0W5U!96LES<R".&-=
MS,>P_K]*FJMJ%C#J=A-9W&[RY1@E3@@YR"/<$ _A0!2?Q+I21"0W$G)<;!!(
M779][*!=RXXSD#K3&\5:,LQB%T[L&V?NX)'!;&[ (4@G'/%-F\-1S8=]2U W
M&)%,^]"Q5\97!7:!P,  8IL/A+3K>2-H6G18Y_.1 PP#LV8Z9Q@?7WH =#XA
MT*)MD$RH)2DK-' X3,I^5F8+@$D]2>O6I3XET@"5C=X6-68L8G"L%.TE#C#X
M/'RYK*M/!D<%S<1-=S?V>T<"+$KC=((R3B3Y>F<?=([U>3PK9HNP7%PT:I)'
M#&_ENL*N<L%!4YST^;=Q0 FJ>*+;3;<3F*1E,,DHC>.2.0[2!]TIP,D9)(QU
MP:O0:YI]S>+:1S/YS<!6A=1D*&*Y( W $$KU'<5F?\(7IOV;R#)<;2DJ'!1?
M]8020 H QM&  ![59L_#-G9ZHVH!WEG9B[&2*(DL1@MNV;AGK@$#D\4 ;5%%
M% !1110 4444 %%%% !1110!E^'_ /D&S?\ 7]=_^E$E:E9?A_\ Y!LW_7]=
M_P#I1)6I52^)D4_A04445)84444 %%%% !1110 4444 %%%% !1110 4444
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M)I"R7%AY]\%* !8]W *]#^M:.FZ9;0WL[16Q^4;-^<9)&<GVZ=*FMHXO+-M
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MEFT18UT!9C-'N^TF=-Q)YW<\CZ5;GTW4Y++2YI;=+F:U#"6VE<8;L#GH3@4
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M .0;-_U_7?\ Z425J5E^'_\ D&S?]?UW_P"E$E:E5+XF13^%!1114EA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 3V_\7X5-4-O_%^%34 %%%%
M!7/7/_'U-_OG^==#7/7/_'U-_OG^= $5%%% !7EGBOYKG45'4#/Z5ZG7!>*;
M2,:I,K_\MHL@@=ZX\:OW:9U81VJ'@%__ *P@>M9;UT&JVICN)%(PP/-84B$$
MBJI231I4C9D-%.VT!2:WN96&BI4'I0J5*J<U+948DL1P:[7P9JD\%X;<DFW<
M$L,_=QW'O7&Q1,S!5&23P!WKM],TN31[;$ZG[1*N64?PKUQ7'7:M8Z8)15Y:
M([NRU*.[N!&K!;Q$R">-P]"*V_[/@:9YV@A#Y&2.W_UZY7PM9PW-TUVP65BP
M^4@':/Q.1723VE_?"!;27]VS$2G;M) -<<(<]50C+EZ7%7FH4W*W-ULM3I=/
MA*[%&#&%X([UJU4TZT-I9QQNQ=P.6-6Z]BC25*/*CSI3<WS-6"BBD9@JEF("
M@9))X K4DY2S\$"QU5KF#4YA:N^Y[;;PXYX8@\CD]J2W\$RV8N+>TUJXAL;@
M_O(5C!8CTW9]..E=7'+'-&LD3JZ-R&4Y!_&G5E[&'8[WFF*>\NW1=-NFZ[[G
M,:=X0.GZ-J.FB_WI>#Y6\G!CXQ_>Y[>G2M+P_HW]A:6++[1Y^'+[]FWK[9-7
MI;VT@E$4MU#'(>B/( ?RJ6.6.:-9(G5T;D,IR#^-5&G&-FC*KC:]92C.5U)I
MO1;I6/-=270_[>N9XM7O-'N0["9/(8DG/.TJ> >OXT[P;;12^,9Y[#S7LH8S
MB60<L2 .?<G)KT"XTVPO'WW-E;3MZRQ*Q_45+!;06L?EV\$<*?W8T"C\A62H
M>]<]*>;Q>'=))W:Y=6FE^";\KO0Y>\\#JU_+=Z9JD^GF4DNL8)'/7&"./:M;
M0_#\6BV4EN+B:X\S[YD;CZ =JUZ*T5*"=TCSZF/Q%6G[.<KK3MTVUM=V]3DM
M,\$'3+UI(M6N#:MNW6X!7=E2O)#=1GKBH3X$N$,B6WB&\BMY#EHR"=WUPP!_
M*NSHI>QA:UC3^U<7S.7-J_)=/EOY[F9H>AVV@V/V:W+,6;<\C=6-2:EIO]HO
M:[IML4,HD:/;GS,=!G/'>K]%:))*R.*I4G5FYS=VQ&4.I5@"I&"#WK#M_#K0
M16L7VS=';7/GH#'V_N]?UK=HID%&^T[[;=64WF[/LTF_&W.[VZ\5 ND21:E=
M7,5X5BN1^]A,8.3@@$-GCKFM6B@#"D\-^9IEC9?;&7[*Y?S%3!;DGCGCK[U/
M#HTS7T5U?W[7;09\I?+"!3ZG'4UK44 8\FBS17<T^G:@UH)SND3RPZEO49Z&
MI(]!M5TJ6QD+R"8EY)6/S,_]ZM2B@#GKGP[>7D"0W.L22)&04!A Z>O//%:*
MZ6O]J7-X\@=9XA$8BO;ZYK0HH PAH%U%;M:0:M+'9-G]UY0+ 'L&SFIY]"3R
M[3['</:S6J[8Y -V1WR#UK4WIY@CW+O(W!<\X]<4Z@#,LM*DAOFO;N[:ZN2G
MEJVP(%7V J75=-35+00M(T;*XD1U&2K#O^M6VFB25(FD19),[%+ %L=<#O3Z
M ,&Z\/W=_&HN]6>5XV#1XA"J".Y4'D_C4=]]G_MZ0PZ@=.O!&-[2*I25>V,G
MDC^E;T4\,X8PRI(%;:Q1@<'T..]-GM+:ZQ]HMXIL=/,0-C\Z .8TK3HM0N=8
M4W#W$$H6,W!_C;J2.W!_I5]_#]W/9?8[G5Y)( NU56(+TZ;CG) XXK<CBCA0
M)$BH@Z*HP!3J ,N'2#'>V5R;@,;6#R=H3&[C&>O%3:7IW]FPS1^;YGF3-+G;
MC&>W6KU% &(OAU5L! +IUE2<SQS(N"I/;&>:E@TB<WT-W?W[73P@^4HB$:J3
MU.!U-7_MMKY)F^TP^4&VE_,&T'TSZU/0!FV>ER6>I7-Q'=DP7#EVA,8^\>^Z
MM*BB@ HHHH **** "BBB@ HHHH K7'@O2/$<@O-029I4'E#9)M&T<_S)JI+\
M,?#:, ([GI_SV-=9I7_'JW^^?Y"II_OCZ5#I0;NT=<,?BJ<5"%1I+S.*_P"%
M9^'/^>=S_P!_C1_PK/PY_P \[G_O\:["BE[&GV+_ +3QG_/V7WG'_P#"L_#G
M_/.Y_P"_QH_X5GX<_P">=S_W^-=A11[&GV#^T\9_S]E]YQ__  K/PY_SSN?^
M_P :/^%9^'/^>=S_ -_C7844>QI]@_M/&?\ /V7WG'_\*S\.?\\[G_O\:/\
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M_P"_=O\ _&J/[*O?^A@U+_OW;_\ QJBR[AS2[?D:E%9?]E7O_0P:E_W[M_\
MXU1_95[_ -#!J7_?NW_^-467<.:7;\C4HK+_ +*O?^A@U+_OW;__ !JC^RKW
M_H8-2_[]V_\ \:HLNX<TNWY&I167_95[_P!#!J7_ '[M_P#XU1_95[_T,&I?
M]^[?_P"-467<.:7;\C4HK+_LJ]_Z&#4O^_=O_P#&J/[*O?\ H8-2_P"_=O\
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MDT_QH_LW6O\ H/\ _DFG^-;-% &3#8:NDT;2ZWYD:L"R?94&X9Y&<\5K444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &QI7_'JW^^?Y"II_OCZ5#I7
M_'JW^^?Y"II_OCZ4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOY3.I4R$$@L6YP..#C H ZZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#Z=:LV^A6\%TES)/<W4L8_=FXDW;/IQ1<Z%;W%S)<1S7-M)(,2?9Y-H?Z\4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO1_9'_3?_P <_P#KTR3,HK3_ +(_Z;_^.?\ UZ/[(_Z;_P#CG_UZ ,RBM/\
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M5*$H/EDK,@HJ?[/_ +7Z4?9_]K]*9)!14_V?_:_2C[/_ +7Z4 045/\ 9_\
M:_2C[/\ [7Z4 045/]G_ -K]*/L_^U^E $%%3_9_]K]*/L_^U^E $%%3_9_]
MK]*/L_\ M?I0!!14_P!G_P!K]*/L_P#M?I0!!14_V?\ VOTH^S_[7Z4 045/
M]G_VOTH^S_[7Z4 045/]G_VOTH^S_P"U^E $%%3_ &?_ &OTH^S_ .U^E $%
M%3_9_P#:_2C[/_M?I0!!14_V?_:_2C[/_M?I0!!14_V?_:_2C[/_ +7Z4 04
M5/\ 9_\ :_2C[/\ [7Z4 045/]G_ -K]*/L_^U^E $%%3_9_]K]*/L_^U^E
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M_P#Q-'_"Q_"?_05_\EY?_B:\"HH^MS[(/]6L)_-+[U_D>^_\+'\)_P#05_\
M)>7_ .)H_P"%C^$_^@K_ .2\O_Q->!44?6Y]D'^K6$_FE]Z_R/??^%C^$_\
MH*_^2\O_ ,31_P +'\)_]!7_ ,EY?_B:\"HH^MS[(/\ 5K"?S2^]?Y'OO_"Q
M_"?_ $%?_)>7_P")H_X6/X3_ .@K_P"2\O\ \37@5%'UN?9!_JUA/YI?>O\
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M/X3_ .@K_P"2\O\ \37@5%'UN?9!_JUA/YI?>O\ (]]_X6/X3_Z"O_DO+_\
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M44?6Y]D'^K6$_FE]Z_R/??\ A8_A/_H*_P#DO+_\31_PL?PG_P!!7_R7E_\
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M33U.$HHHK$]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]?#5F6>HW&G:DE_9,MO/&Q:/:NX)G/ #9['OFH[V]N-1O9KRZD\R>9MSOM
MR?H.*GF7)R^9TJA+ZU[?IRV^=[G=>,?^2=^%?^N?_LHJ+X2_\C=-_P!>;_\
MH25R=YKFHZAIUII]U<>9:V@Q FQ1L&,=0,G\:32-9U#0KQKO3;CR)V0QEMBM
M\I(.,,".PJ_:+VBEVL<KP-3ZE4P]U>7-Z:NY#J/_ "$[O_KL_P#Z$:[[Q?\
M\DP\,_\  /\ T UYU)(TLKR.<N[%F/J36A>:]J=_I=MIMS<^9:6N/)C\M1MP
M,=0,GCU-1&:2DNYT5\-.I.C)?8=W]UM#J_AEI5I>2ZK>S6:7ES91*UM ^,,Q
MW'OQG*@9[9K3L?$7CS5]3@M(K V,/F#S2MH45$SSDOG''XUYUIVIWND7BW=A
M<O;S@$;D[@]B.A'UK5O_ !OXDU*U:VNM5E,3##*B+'D>A*@'%:0JI12U7IU.
M3$X"K5KRJ6C).UN:_NZ=%L^_34W/BT"/%T''6S3_ -">C2/^2.:__P!?D?\
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M11.,.<J0N1VZL<>@KG?AQ_R/VF?]M?\ T4]8FJZWJ6MS++J5Y)<,HPN[@+]
M.!46FZE=Z1?Q7UC+Y5S%G8^T-C((/!!'0FFZBYHVV1E'!U/85E-KGJ7]%I9+
MOH6/$/\ R,NJ_P#7Y-_Z&:ZKQ[_R+7@[_L'C_P! CKA[BXEN[F6YG;=+*YD=
ML 98G).![U;O]9U#5+:SMKRX\V*RC\JW78J[%P!C( SPHZYJ5-6EY_YFTL-)
MSHR_DO?_ ,!MI\RA11169VA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =_\
M(O\ D;+K_KQ?_P!#CKVBO%_A%_R-EU_UXO\ ^AQU[17IX7^&?!\0_P"_/T7Z
MA11170>&%>,R_#S1()7BE\;Z?'(C%71U0%2.""/,X->S5E>'O^0;-_U_7G_I
M1)652G&;2:/0P6,JX6,Y4Y-;;6\^Z9Y9_P (#H'_ $/6F?E'_P#':/\ A =
M_P"AZTS\H_\ X[7M%%1]6AV_/_,[/[=Q/\[_ /)?_D3Q?_A = _Z'K3/RC_^
M.T?\(#H'_0]:9^4?_P =KVBBCZM#M^?^8?V[B?YW_P"2_P#R)XO_ ,(#H'_0
M]:9^4?\ \=H_X0'0/^AZTS\H_P#X[7M%%'U:';\_\P_MW$_SO_R7_P"1/%_^
M$!T#_H>M,_*/_P".T?\ " Z!_P!#UIGY1_\ QVO:**/JT.WY_P"8?V[B?YW_
M .2__(GB_P#P@.@?]#UIGY1__':/^$!T#_H>M,_*/_X[7M%%'U:';\_\P_MW
M$_SO_P E_P#D3Q?_ (0'0/\ H>M,_*/_ ..T?\(#H'_0]:9^4?\ \=KVBBCZ
MM#M^?^8?V[B?YW_Y+_\ (GB__" Z!_T/6F?E'_\ ':/^$!T#_H>M,_*/_P".
MU[111]6AV_/_ ##^W<3_ #O_ ,E_^1/%_P#A = _Z'K3/RC_ /CM'_" Z!_T
M/6F?E'_\=KVBBCZM#M^?^8?V[B?YW_Y+_P#(GB__  @.@?\ 0]:9^4?_ ,=H
M_P"$!T#_ *'K3/RC_P#CM>T44?5H=OS_ ,P_MW$_SO\ \E_^1/%_^$!T#_H>
MM,_*/_X[1_P@.@?]#UIGY1__ !VO:**/JT.WY_YA_;N)_G?_ )+_ /(GB_\
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M^4?_ ,=KVBBCZM#M^?\ F']NXG^=_P#DO_R)XO\ \(#H'_0]:9^4?_QVC_A
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M_':/^$!T#_H>M,_*/_X[7M%%'U:';\_\P_MW$_SO_P E_P#D3Q?_ (0'0/\
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M\7_X0'0/^AZTS\H__CM'_" Z!_T/6F?E'_\ ':]HHH^K0[?G_F']NXG^=_\
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M';\_\P_MW$_SO_R7_P"1/%_^$!T#_H>M,_*/_P".T?\ " Z!_P!#UIGY1_\
MQVO:**/JT.WY_P"8?V[B?YW_ .2__(GB_P#P@.@?]#UIGY1__':/^$!T#_H>
MM,_*/_X[7M%%'U:';\_\P_MW$_SO_P E_P#D3Q?_ (0'0/\ H>M,_*/_ ..U
MI1?!^.>))8O$2R1NH9'2UR&!Y!!\SD5ZM65X8_Y%/1O^O&#_ - %"P].]FOS
M"6=8QPYHS>]M5'M?HCSZ7X/QP1/++XB6.-%+.[VN H'))/F<"LW_ (0'0/\
MH>M,_*/_ ..UZGXG_P"13UG_ *\9_P#T UJT/#T[V2_,(YUC%#FE-[VT4>U^
MJ/%_^$!T#_H>M,_*/_X[1_P@.@?]#UIGY1__ !VO:**/JT.WY_YA_;N)_G?_
M )+_ /(GB_\ P@.@?]#UIGY1_P#QVC_A = _Z'K3/RC_ /CM>T44?5H=OS_S
M#^W<3_.__)?_ )$\7_X0'0/^AZTS\H__ ([1_P (#H'_ $/6F?E'_P#':]HH
MH^K0[?G_ )A_;N)_G?\ Y+_\B>+_ /" Z!_T/6F?E'_\=H_X0'0/^AZTS\H_
M_CM>T44?5H=OS_S#^W<3_.__ "7_ .1/%_\ A = _P"AZTS\H_\ X[1_P@.@
M?]#UIGY1_P#QVO:**/JT.WY_YA_;N)_G?_DO_P B>+_\(#H'_0]:9^4?_P =
MH_X0'0/^AZTS\H__ ([7M%%'U:';\_\ ,/[=Q/\ ._\ R7_Y$\7_ .$!T#_H
M>M,_*/\ ^.T?\(#H'_0]:9^4?_QVO:**/JT.WY_YA_;N)_G?_DO_ ,B>+_\
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MY1__ !VC_A = _Z'K3/RC_\ CM>T44?5H=OS_P P_MW$_P [_P#)?_D3Q?\
MX0'0/^AZTS\H_P#X[1_P@.@?]#UIGY1__':]HHH^K0[?G_F']NXG^=_^2_\
MR)Y]X%\,:9HNMS7-EXEL]3D:V:,PPA<J"RG=P[<< =.]>@UE7'_(V:?_ ->-
MU_Z'!6K6M.*BK(\[&UYUZBJS=VTNWFNED%%%%6<@5E>'O^0;-_U_7G_I1)6K
M65X>_P"0;-_U_7G_ *425+W1M'^%+U7ZFK1115&(4444 %%%% !5/5IY+;1K
MZXA;;+%;R.C8S@A20>:N5GZ]_P B]J?_ %Z2_P#H!H P],MO$>HZ5;WH\1A#
M,@<1FRC./;/_ -:K>A:Y++:7ZZM)$DVGRF.68<(P]?\ /M6=H6EZW/H%FT'B
M$P0/$-L0LT)0>F[.?QJ:^T[3/#_AYH[J&74&N+A2P9]K32GIDYZ<'UH U+;Q
M3HMY<I;P7RF60X0,C+N/L2 #4E[XBTK3KAX+J[$<J;=R[&)YZ=!S^%<MXGFU
M>2RLVOK&TM(5NH_+59=\@//0CC&!S^%:UI&C?$/4'9062T3:2.F<4 6]+U5[
MK6]81YP;*!('AR H56C+$YQGWYHNM:M;K3X+JSU0VT37*Q>;]F9Q(>?D ([_
M -[VKEM=@U";7/$)M0&M(OL\EU&"0TBA!\HQVQN)^E:WB":UN/#>CRV05;9K
MN'RU48"CGC\* -R\\0:783R075VL<L84LI1B>>F,#G\*EL=8T_4;:2YM;I'B
MC^^Q^79WY!QC\:QK6&-_B'?R.BLR6J;21G;G'2J<MK!/K_B:TEF6V@FMXB[D
MA55B/O'MU/Z^] &Y;>*-%N[I+:&^5I7.U 490Q] 2,&K&HZUIVDE!>W2Q,_W
M5P68_@ 37*WAU#3--MUUJPM+_2[=D*SVSE&0=%..,]NE:6DHDOC;6Y+A5^T1
M+$L.?X4*\D?7C/UH V;?6=/NM/EOH+I9+:)2TC@'*@#)R,9Z>U4SXLT)95C.
MH("V,':V!GU.,#\:PK]1%X@\21P@+&^DN\H7IOQP3[X)JU/:01_#,(L:X-DD
MIX_B(#9^N: -N9[X^(+587;["86:9?+&W/\ "=WK[#TJ&X\4Z+:W+6\U^@D1
MMK85B%/H2!C]:MZ02=%L"3DFWCR?^ BN6CLM3TS3KF.Q6PU?1Y6=F7?A\?Q#
M<."?S/% ':HZNBNC!E89# Y!%+6=H-Q;76AVDUG$T-N4PD;')7!QC/?D5HT
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M"6N_]?R_^D\-:M96D_\ (2UW_K^7_P!)X:U:F.QM7^/Y+\D97AC_ )%/1O\
MKQ@_] %:M97AC_D4]&_Z\8/_ $ 5JT1^%!B/XT_5_FPHHHJC$**** "BBB@
MHHHH **** .8U6YU6;Q;!I=CJ7V.)[3SB?(63G<P[_0=ZBO;K7O#FR\O+Z/4
MK#>%FQ (WC!XR,5+/_R4FV_[!Q_]#:I_&LT<7A>ZC8C?,5CC7NS;@<#\ 3^%
M &G?:OI^FV\<]W=)'')]P\DM] .344'B#2[JRGNX;L/# ,RD*V4'NN,_I6%I
M\&/&L4-X 9+;38Q &YP> Q'OG-27T$;>/8(44!;JQ=;D+_$O(!/Z4 ;MSK%A
M9Z='J$]P$M9 I23:3G<,C@#/2I+C4;2UDMHYI@KW+[(0%)WG\/YUP,<<FK:=
M8>'FW>;:M<B4#U0$)^K 5H:!='7-8TEFY73[$EL]/,)V?R&: -Y_%NA1HCMJ
M"X?.,1N2,$CD8XY!ZUK03Q7,"30R+)$XW*RG((KF?!-K _AJ4-$I\^:029'W
MAG&#^%6_!))\(6&3G_6?^C&H WZ*** "BBB@ HHHH **** "BBB@ K*U;_D)
M:%_U_-_Z3S5JUE:M_P A+0O^OYO_ $GFJ9;&U#X_D_R9JUE6_P#R-FH?]>-K
M_P"ASUJUE6__ "-FH?\ 7C:_^AST2Z!2VGZ?JC5HHHJC$**** *>K3R6VC7U
MQ"VV6*WD=&QG!"D@\UAV%EXBO=.MKO\ X279Y\22;?L,9V[@#C/?K6QKW_(O
M:G_UZ2_^@&L/2?#7GZ-8S?VWK,?F6\;;([K"KE0< 8X% &NVHPZ):6\6L:DL
MD[ASYS1; ^.3PN0,# ]Z4^(])&GB^:]5;<L4#,K DCJ I&3^59.O6R#6O#-O
M(6E5)6&Z0[BV%7D^IXJ2\5)OB%8). 42S9X01D>9N.?QP,_A0!KZ=K6G:MO%
ME<K*R?>7!5A^! -5)/%NAQ*"]^HR2,"-R1@X.1CCFJ6JJL7CC1)+=1Y\J2K/
MCN@7@G]?RIO@FWA.CW;&)"9;J0.2 =PZ8/M0!+XD\2)I^E6T]E<(6N7'EN%+
M H"-Q';/(ZUI3:_I=O80WLUVJ03?ZLE6RWT7&?TKB5)_X5_:+DX74 %&>@W&
MNA54F^(LGVD F*R!MPW;GDCWY- &M:Z[IM[:3W-O=+)% I:7"G*@#/*XSV/:
MLWPQXC35K:Y-S.OG1N[D;"JI'VY/'ZYJ.=1#\1+0P *9K1O/V]P,X)_$"N?9
MY4^'E]Y?W6OF60^B[A_7% '86_BG1;JZ6VAOT:5SM4%6 8^@)&#4M[K^EZ?.
M\%W=K%*BABI5B<'IC Y^@KGM4T[6;K0OLL_]@V]FH4I*LDBB/!&""1@?_7J>
MQA$GCPO.4EECTY"''(W9 +#]?SH U#XJT06JW/\ :">6S%1A6W9'7Y<9_2K!
MUS3?[.74!=*;5F""103R3C& ,BL7P]#%_P )=XBDV+O5XPK8Z AB?SP*P[R.
M-/"NM0_<A3670 ?PKE: .QMO$NCW=X+2"^1IF.%&" Q]B1@_@:EU'6]-TED2
M]NEB=QE4"EF(]< $XK'\8V]M#X5!A1$>!X_LNP=#N'3\,TNA*DOBW7I9P#=1
MNB)NZK'CM]>* -B/6M.FTV348KI7M8P2[J"=N/48S^E1VGB'2KZ:6*WO%=HD
M,CDJP"J.IR1CC-<IJBB'5/%$4 "PM9*\BKT\SC]>36W*^GV'@.$WD.^U^RQ[
MHE.TN2!QD8ZDY_.@"S'XMT*6=85U!-S':"48*3_O$8_6G?;KC_A,OL'F?Z+_
M &?YVS:/O^9C.>O2N:\22ZL_A:5)]+L[*Q0($1I=\B\@ +CC/],UKVK%O&\#
M,26.C*23W_>4 =-1110 4444 %97AC_D4]&_Z\8/_0!6K65X8_Y%/1O^O&#_
M - %3]HV7\%^J_)AXG_Y%/6?^O&?_P! -:M97B?_ )%/6?\ KQG_ /0#6K1]
MH'_!7J_R044451B%<=8^)+V;Q$CR2*=)NIY+:!=HX90N&SUY/]:VO$^H'3M
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M[8SGKQBN@HH AM;6&RM8[:W0)%&NU5'85-110 4444 %%%% !1110!E>(?\
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MQQ4T-UYUY<V_V>=/(V_O'3"2;AGY3WQT- %6#0[.%;]&#31WTADF20@C)[#
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M8HH YY/!]B!''+=7\]K&VY+:6?,0QTXQ_6M./2H(]8DU-6D\YX1"5R-H4'/
MQG/XU>HH HV>DP6.H7UY$\ADO&5I Q&!MSC''O7.^*M,@T_PU>")G875\+A]
MY!PS,,@8'3BNPJHFI6\FJRZ<A8SQ1B1^. #TY]: ,V#PI8PW$$KSWEPENVZ&
M">;='&>V!BI]0\/VM_>+>":YM;H+M,UK)L9AZ'@YJ[8WGVZV\[[-<6_S$;+A
M-C<=\>E6: ,B+PW8PZ7=6*&;%UGSIF?,CGU)(JS-I-K<:.-+F5GMQ&L?)^;"
MXP<^O -7J* .<D\&V,]N8+F]U&X0+B,33[O+]U&,9[<YK4ATF"'4H[\22M,E
MJ+4!B,%0<Y/'7/X>U7Z* "BBB@ HHHH *RO#'_(IZ-_UXP?^@"M6LKPQ_P B
MGHW_ %XP?^@"I^T;+^"_5?DP\3_\BGK/_7C/_P"@&M6LKQ/_ ,BGK/\ UXS_
M /H!K5H^T#_@KU?Y(****HQ*&H:3;ZG/9RSO)BUE\U$4C:S=MW'-7R,C!Z44
M4 85OX4L;9+=(YKG9;W/VF-2RX#>GW?N^U7[C28+C5[34G>036JLJ*"-IW @
MYXSW]:O44 49+&WBU1]8=I/-2U,)4<KL#;LXQG-8.DK;ZUXOGUNU1S:PPB))
M2I422="1GT7BNLHH S-3T*UU2>*X=YX+F(82>W?8X'IGTI=+T2UTIY98VEFN
M)C^\GG?>[>V?2M*B@# 'A&R%C=V*W5Z+6Y()B\P%4(8-\N1QR.^:UK^PMM3L
MWM;N,21/U'<'U![&K-% &';>%K.&Y@GFNKV[-N<PI<S;UC/J!BLR/28M3\8:
MZ[7%S;RP_9]DMO)L8 Q\CZ' _*NBL-4@U&:\BA616M9C"^\  D>F#TJ[0!DQ
M>'+&'2+C3H_-"7&?-E+9D<GN21UJ>XTF"YT7^RG>00>4L6X$;L#&.<8SQZ5?
MHH SH]%MH]1MKY7E\VWM_LZ D8*^IXZU1G\)6,LDQCN+RWAG.Z6W@FVQN>^1
MBM^B@".WMXK6WCMX(Q'%&H55'0"J+Z%9RSZE)+OD&H*BS(Q&!M&!MXR*LI>;
M]0EM/LUPOEH&\YDQ&V>P;N:LT <[_P (;8O;_9Y[S4)X I6.*6?*Q\8! QU'
M;.:M7?AVUN[2Q@:XNHVL@!#-$X5QP!UQCL.U;%% &/>>'+6[NDNUN+NVNE0(
MT]O+L=P/[W'-)'X8L(]*NK!6GQ=<S3,^9'.<Y)(_I6S10!GWFC6E_I2Z=<!F
MA55"D'##;T.?6LV;P=97,.RZO=1N6  C>:?<8^0?EXQVQR#7144 48]*ACUB
M34P\AG>$0D$C;@'.<8ZU>HHH **** ,JX_Y&S3_^O&Z_]#@K5K*N/^1LT_\
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M/7V^E:5C)KMWJ@FNX$L+%$(^S[UD:1CW+#H!0!M4444 %%%% !1110 4444
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M** "LKPQ_P BGHW_ %XP?^@"M6LKPQ_R*>C?]>,'_H J?M&R_@OU7Y,/$_\
MR*>L_P#7C/\ ^@&M6LKQ/_R*>L_]>,__ * :U:/M _X*]7^2"BBBJ,0HHHH
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M:G>1?N4FM%CAF)4@.,=NOZ5FZA9Z[K&G"PO-%M?M! 1K]ID( !Y8*.1]!ZT
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M65]HU_\ Z!FF?^#"3_XS1]HU_P#Z!FF?^#"3_P",T<P>Q?=?>C5HK*^T:_\
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MG_@PD_\ C-'VC7_^@9IG_@PD_P#C-','L7W7WHU:*ROM&O\ _0,TS_P82?\
MQFC[1K__ $#-,_\ !A)_\9HY@]B^Z^]&K165]HU__H&:9_X,)/\ XS1]HU__
M *!FF?\ @PD_^,T<P>Q?=?>@\0_\@V'_ *_K/_THCK5K"O(=;U".&"6RT^&,
M7,$KNEZ[D!)5<X'E#).W'4=:W:%NV.HN6$8W3>NSOV,K5O\ D):%_P!?S?\
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M?^#"3_XS1]HU_P#Z!FF?^#"3_P",T<P>Q?=?>C5HK*^T:_\ ] S3/_!A)_\
M&:/M&O\ _0,TS_P82?\ QFCF#V+[K[T:M%97VC7_ /H&:9_X,)/_ (S1]HU_
M_H&:9_X,)/\ XS1S![%]U]Z-6BLK[1K_ /T#-,_\&$G_ ,9H^T:__P! S3/_
M  82?_&:.8/8ONOO1JT5E?:-?_Z!FF?^#"3_ .,T?:-?_P"@9IG_ (,)/_C-
M','L7W7WHU:*ROM&O_\ 0,TS_P &$G_QFC[1K_\ T#-,_P#!A)_\9HY@]B^Z
M^]&K165]HU__ *!FF?\ @PD_^,T?:-?_ .@9IG_@PD_^,T<P>Q?=?>C5HK*^
MT:__ - S3/\ P82?_&:/M&O_ /0,TS_P82?_ !FCF#V+[K[T:M%97VC7_P#H
M&:9_X,)/_C-'VC7_ /H&:9_X,)/_ (S1S![%]U]Z-6BLK[1K_P#T#-,_\&$G
M_P 9H^T:_P#] S3/_!A)_P#&:.8/8ONOO0:3_P A+7?^OY?_ $GAK5K-TBUO
M()-0GO4@CDNKD2A(93(% BC3J57GY">G>M*B.PJ[3F[>7Y(RO#'_ "*>C?\
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MT?:-?_Z!FF?^#"3_ .,T<P>Q?=?>C5HK*^T:_P#] S3/_!A)_P#&:/M&O_\
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M *!FF?\ @PD_^,T-V81CS4K)J]^KMT1JT5E?:-?_ .@9IG_@PD_^,T?:-?\
M^@9IG_@PD_\ C-',+V+[K[T:M%97VC7_ /H&:9_X,)/_ (S1]HU__H&:9_X,
M)/\ XS1S![%]U]Z-6BLK[1K_ /T#-,_\&$G_ ,9H^T:__P! S3/_  82?_&:
M.8/8ONOO1JT5E?:-?_Z!FF?^#"3_ .,T?:-?_P"@9IG_ (,)/_C-','L7W7W
MHU:*ROM&O_\ 0,TS_P &$G_QFC[1K_\ T#-,_P#!A)_\9HY@]B^Z^]&K165]
MHU__ *!FF?\ @PD_^,T?:-?_ .@9IG_@PD_^,T<P>Q?=?>C5HK*^T:__ - S
M3/\ P82?_&:/M&O_ /0,TS_P82?_ !FCF#V+[K[T:M%97VC7_P#H&:9_X,)/
M_C-'VC7_ /H&:9_X,)/_ (S1S![%]U]Z-6BLK[1K_P#T#-,_\&$G_P 9H^T:
M_P#] S3/_!A)_P#&:.8/8ONOO1JT5E?:-?\ ^@9IG_@PD_\ C-'VC7_^@9IG
M_@PD_P#C-','L7W7WHU:*ROM&O\ _0,TS_P82?\ QFC[1K__ $#-,_\ !A)_
M\9HY@]B^Z^]&K165]HU__H&:9_X,)/\ XS1]HU__ *!FF?\ @PD_^,T<P>Q?
M=?>C5HK*^T:__P! S3/_  82?_&:/M&O_P#0,TS_ ,&$G_QFCF#V+[K[T:M%
M97VC7_\ H&:9_P"#"3_XS1]HU_\ Z!FF?^#"3_XS1S![%]U]Z-6BLK[1K_\
MT#-,_P#!A)_\9H^T:_\ ] S3/_!A)_\ &:.8/8ONOO07'_(V:?\ ]>-U_P"A
MP5JUD6]OJ<^MP7M[;V<$<-M+$!#<M*6+M&>\:X \L^O6M>B/4*UERJ][+]6%
M%%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBVAN?0[2>G<#Z5H:O>/!X?N[VTDPZP&2-\9[9!P:SKJVFLM&OS.R2ZAJ;>6
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MW,ZVUN\S*[A!G;&I9F]@!U-<_=Z#=SQQHL%B)4B1(KQ)'CFB(7:3E1\_<@9
M]16A>Z1)+:3_ &6[N8[R1/ED:YDVY_W<X7/3@<9XH ;)X@@MGG2\M;FU>*#S
M\2!&W+G;QM8C.2!SCK3Y=;2WBD>YL;R!E9%5'13YA8X 5@Q7KZD8K+@\/W<%
M_+<PVNFPJ]H]OY19Y0Y)!RY(!?."#G]:DBT.ZA-R8;:PB@E4?Z"TCRP.V[+-
MR %., 84CB@#2DUE(8&>>TNXI/-6)(60%I&89 4@E3^?&#G%1G7[9$F$L%S'
M<12+&;9E!D9F^[C!(.<'G/8UGQ^'KN*+="T,!BN$GMK7S7DB3:&!&X@$;MQZ
M#C ZT^;0[VZNI=1D>W2]$T4D42LS1@1@\%L \[CSCCB@"X^L)]LM89HKVTD>
M4IY;HF&^4MDMDC;P?NG.1S2_VZJS01R:?>Q"X9EA:1%&\@$XQNRN<<;@/PJ&
MYT_5+^[LYYFM(!;S,ZK&S.5!0KG) W')Z8'3O5"'PY?"ZTZ>5+/SK:4//<&9
MY)9^,9RRY'^[DCZ8Y +FF>()+C3;62XM9GN[EY!'%$%^8*3DC+8 ' Y(.?7(
MS:&O0.(TCM[B2Y>1XOLP"AU9!ELDD+@ CG.#D8S67'X;N4@LA+!87+6C2KY<
MQ+)*CG.>5.U@?8]^:LQZ-=6\UM>6MOIT,\32!K>(&.,HV/X@.6&T<[1GICB@
M"UH-_-J,-[)-O&R[>-$=0K(H PIQW&33[76X[LJ\=I=_9W#F.X**4;;UZ'*Y
MP<;@*-%L;JRANC>-"99[EY_W1)4;@..1[5FG1;I+P70BLK0IN,TMH[K]H7YL
M!H\;1UR22QXH N6GB2UNEMI3;W4%O<\13S*H1FQG'!)'0]1@X.#4L.NP2O 3
M;7,<%RVV"X=0$D/;&#N&>HR!FL71=.N]4\/Z3#<F%+*)?-W1N3(YP0HP1A<9
MY.3G';/%JR\/-;I!;OI^DE8OE:[$>9749P=NT;6Z<[CWX- %F;7A)I\L]O;7
M2Q-%(8+HHIC) .#U) )'&X '\:DTC6%OXX(E62:58$:>=0 BN5!VDYZ^P!QG
MM5>+3=6ATD:4IL_(2)XA,S,6=<$+\N %/3)R?I1IV@S:>4@1U%G+ BW$<<K1
ME95 &]"N#SCGD9ZT /U34Y++5)$::5+5-/DG81*I8,'49&X=<$\'BHH=>\O4
MKR"5I9R6A6UMT5?,;=&&;T'?)).!1J'AZ6>2?[-+\DEC);#SYG=M[,I!).3C
MCU_"HF\.7*WL^H0R0K>J83;N2<85 KJW'W3ST]C0!H2:_!'YSFVN3;P/LFN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>image_035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G EH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#J2>U,>\MHY8XGN(EDDY1"X!;Z#O536M/EU6R6T25(XGE4S[EW;D!R5QT.2
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M'8 T98[\<X/;\Q5?_BHO^F'Z5/9P2P2:?:2S_:);2#$LV,%N H)]S@G\*UJ
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M<W;65U%KTMV C,V3Y?G>O;..<?X5L>=??\^<9^D__P!:KE%%+#*FFHR>KO\
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M[T%@!DD >I-*R#GGW?WL8FGV1EW_ &.#?NW[O+&=V-N?KCCZ4X:5IZJ%%C;
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M[[[MVACN68R);YP,!B,GC< Q'#8/3%2:X\WE:/ )[X3/=Q-(T2L,J#EO,V#
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M;ZP[IO\ BNM*_P"P==_^C(*U-]8ETW_%<:7_ -@^[_\ 0X* .CWT;ZK[Z-]
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M_A+M/_YXZI_X++C_ .(J!O%6GEC^YU/_ ,%D_P#\16IYQ]3^=)YA/<T 9?\
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M# '!_.IZBMK>.TM8K:%=L42"-!G.% P*:][:1W:6CW4*W,@RD+2 .P]0O4T
M4->OX+.V59[9[A3F4JK8VK'\Y;/M@<=ZU48.BNIRK#(/M534-,M=3C1+I&8*
M3C:Y4X(P0<=01P15P    8 H *S=;NX+2SA-S;37$<MS#%B,?=)D4*S'(P <
M5I5#=6L-Y"(9UW('1\9QRK!E_4"@":BFM(B%0[JI8[5R<9/7 _(TZ@#+UR[C
ML[1)IK1YX4D61BKA=I5AMQS\Q)Q@#K6I5.^TR#4);:29I0UNY>/9(5 ;&,D#
MKQ^6:N4 %9>M7D5I%;M<6S2PF9"6#A=C;UV]^3DCCV-:,DT4) EE1-W3<P&>
MW]1^=5K[3+;40BW(=E7(*K(RA@<9# 'D<#@T 7***8)8R[H)$+H 77<,J#TS
MZ=#0!F:SJ5E83:>MRC2S2W*+"J'E2QV;SS]T;\'ZBK][*8+&>99(HC'&S!YO
MN+@=6]O6J]Q9:9K B>:."Y\IDEC<88J00ZD'TR ?>K%Y<QV5E-=3!C'$A=@J
MY. .PH PO"NJR7YN8VC@\M3Y@EM\[)&8DL1N.[K_ +('H32:W<W2WDN'>-K9
M%FLHU@+BXDPP()_'&!C&<^F&>%FVW5Q#)*LL_EAVD#%RP)."2'90?88_*JOB
M/RGUE[635!"TL09(=DI;=AE7&W@@$E_7<!0!V*%BBEEVL1R,YP:6FH,1J"Q;
M ')ZFG4 %%%% !1110 4444 %%%% !1110 4444 5;S3[>^0+,G(Z,."*Q9?
M"[D_NKI<?[:\UTE% '+_ /"+7'_/U%_WR:0^%KG_ )^H_P#ODUU-% '+?\(M
M<?\ /S$?^ F@>%KA1@7,0'H%-=3118#E_P#A%KG_ )^HO^^31_PBUS_S]1?]
M\FNHHH Y?_A%KG_GZB_[Y-'_  BUS_S]1?\ ?)KJ** .7_X1:X_Y^HO^^32C
MPQ< ?\?,7_?)KIZ* .9_X1BX_P"?F/\ [Y-'_",7'_/S'_WR:Z:B@#F?^$8N
M/^?F/_ODT?\ ",7'_/S'_P!\FNFHH YG_A&+C_GYC_[Y-'_",7'_ #\Q_P#?
M)KIJ* .9_P"$8N/^?F/_ +Y-'_",7'_/S'_WR:Z:B@#F?^$8N/\ GYC_ .^3
M1_PC%Q_S\Q_]\FNFHH YG_A&+C_GYC_[Y-'_  C%Q_S\Q_\ ?)KIJ* .9_X1
MBX_Y^8_^^31_PC%Q_P _,?\ WR:Z:B@#F?\ A&+C_GYC_P"^31_PC%Q_S\Q_
M]\FNFHH YI?#$V?FND ]E-:ECHMM9,).9)1T9NWT%:-% !1110 4444 %%%%
M !1110 4444 %%%% &;8Z%8Z=<-/;+*)&SN9YF<G/KN)S6E110 5Q<NCWD>L
M7H/AVUOWN;U+F+49I$'E*-N W\8*;> O!XY&37:44 >=67A_Q))LANFOX8C)
M +QSJ18W#AR9)(R&S&A7C:-O4# QFJEQHVNZ<-,2=]5NTN62.YB34F5Y' EP
M V[Y?D"YP1G R<\UZA10!Y[!HGBH7-H)WNVG"Q!;H7_[J&, [XW3/[QS_?P<
MD@Y&*DM]&\0ZK-91ZI'>VEK&($G6/4,-)LAF5FW(V<%VC/J< GI7?44 >>:;
MH/B+^V='GU2*ZGDMY(I)+EKX&-4%N4*F//+^82=P'.<Y[5<U72O$$NIZJ]JE
M[YTJG[+=)J'EPI%L \OR\\/N#8;;P2#GC%=O10!YRWAO7[JWG*MJ5I%'!=/8
MVYU-C)%*1%Y0=PQW?,LI )( ;!]*V]'M-5LM:O)[RTO9GDD?-Q]N#0NC2#8%
MB+?*57KP.A^]FNKHH Y/7[*ZO=;DA1-Y>WMFMMW0;+D--U[[?+..^*YFYM=:
MTBP:XU9[V*S#1)>AM5(-W)ELO$^?W2GY3C*9'R\8Y]2HH XC2M.U#5_!7AV*
M>2^0&;S+H_:V64Q8DP"X(9NJ?6J-MX8U]+KS9%W/>6T%A>RO."YA"G<^?XF&
M,>_F$UZ+10!R?A:PN-.N;.T:+ROLNCV\%RJD%1("=J@CJ0-WX$5OZO+Y&CWD
MOVAK;9"Q\Y4W%..H'>KM0W2RO:RK (C*5(02@E"??':@# \.W"G4KBW^T.L@
MB!>S?<6C(/WB6Y&<CIP>N353Q+$;^YNP\TCV=C$LD]LSQA&."W *DDX'<@=/
M>M'P[K*:J6WBS^T1QA6-OOP0#VW*/EYX^M&N7-E;3 /I4-W<O@ RJ@#+S_$?
MRYQUH W(F5X4=>5901]*?2+]P<8XZ>E+0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>image_036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 C$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BLF#Q+I%RFJ26]XDL>EDB[=.5C(7<1GN0.N/I5:
MU\8Z7<:==:A(E[9V=M&)7FO+.2%2IZ;=P&[Z#GD>M &_167HOB#3]>CG-D\H
MDMV"30SPM%)&2,C<C $9'(/>M2@ HHHH **** "BBB@ HHHH **** "BBB@
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M MHIH;J6*7RAT1G5@S+[$FJ),:V2&U\2^%[*TU6;4((#J$)DEEWL"H7Y&/\
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M%49'<%E! ) )Z#/6EK@(!ID6K>$+?1[R2ZLK>^O84=Y"^TK%("@8]54_*.O
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MCBM_[3K/_0/M_P#O_P#_ %J/M.L_] ^W_P"__P#]:MY.BU;D?_@+)CC,<O\
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M_+[U_F:E9VK/:1P*T_E!V=<%P,D!AFH_[5NQ][2+G\"#7/ZX+J]NQ<?8[F-
MH7#IT.?;ZURXO%Q5)\BN_1_Y'1A<,W47,[+U7^9V,/E>4# $\L\C9C!_*I*Y
MO1=1ATVP%O=^>CAB<-$V #VK436]-D.!>1@^C97^=;T<52G!-M)]K_\ #&57
M#5(R:2;7?^KFA7):[I3R:D9HIHCYS %6< J<?RXKJ8YX9AF*5''^RP-#01.Q
M9HD8GJ2H-&)P\<33Y18>M+#SYB#3+86FG0P"02;1RR]"<]JMTBJJ*%50H'0
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M4KRK)R<].<&O1J\X^(&C:]+K$M_HUE;7/V[2GTHS2W"Q&R+/DR#=U!4G@<Y
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MC-H****T,PHHHH **** "L@ZAK(8@:&I&>#]L7G]*UZR->\0VOA];,W*2/\
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M=VCB;)RSCJN,9&.^1QWJ6Y\206WA--?-O,Z20)+';QX,CL^-J+V+$D"@!_\
M:&M?] )?_ Q?\*/[0UK_ * 2_P#@8O\ A6C9W<5_907<#;H9XUD0^H(R*GH
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MNFG+<SS:%.&-J1I+W;Z>EE^';R"BBBMCS@HHHH **** "BBB@ HHHH ****
M,J/_ $3Q%(G1+N,./]]>#^E:M9>M@Q1V]ZO6VF#'_=/!K4!!&1T-<]'W9SAY
MW^__ (-S>K[T8S\K?=_P+!111708!1110 4444 %%%% !1110 4444 %%%%
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M<>:GR-_=<<J?P(%4_!^L2:OH*?:LK?VK&VNT/42+P2?KP?QK*/NS<>^O^?\
MF=]7]_AHU>L/=?I]E_G'[C?HHHK4X HHHH **** "BBB@ HHHH **** (+V
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M_= )]*WY_"FBSVMO;M:%5MI'EA:.9T=&<DN0ZD-\Q)R,\TC>$]%>:"1[,L(
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MDG,R !7.3R0% _"@#'\'ZAK&IZKKD^IR,D*R0K!:%0/LV8]Y0D#);#IG)ZY
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M[#TC_H%V7_@.G^%']AZ1_P! NR_\!T_PH I_\)GX6_Z&71__  .B_P#BJ/\
MA,_"W_0RZ/\ ^!T7_P 55S^P](_Z!=E_X#I_A1_8>D?] NR_\!T_PH I_P#"
M9>%\9_X231\?]?T7_P 51_PF?A;_ *&71_\ P.B_^*K%U31M.'Q$\.HNF6OE
M&ROMX%NNW.8,9X^N/QKIO[#TC_H%V7_@.G^% %/_ (3/PM_T,NC_ /@=%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU\0WL6B6TNF:%=^3<2-=%9)5PA.Q=I&X!NY Z4 >AT5Q!\::K97MY:ZII%O
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M^.RCTD:6JNQ^SBY\_J<[M_OZ=J -ZBBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>image_037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& 4,# 2(  A$! Q$!_\0
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M <\>M=+X'\:0>,["\D2**.>RG,$PAF\V)CC(9'P,J1Z@'B@#J:*** "BBB@
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MUZ#HNF3Z59&&YU2ZU*9G+M/<A >>P"* ![5I44 %%%% !1110 4444 %%%%
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M69XBMVN_#FHVZV/V\RV[I]D\XQ><".4WC[N>F: /.+.U2]T#6M4\5GQ"D?\
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M4M=,:\07MVKO!#@Y<*,L1QVK1KR^Y_Y+!X0_Z]+W_P!!%>H4 %%%% !1110
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M0!Y[\7?^0-X>_P"Q@L_YM6PWWC]:Q_B[_P @;P]_V,%G_-JV&^\?K0 E%%%
M'-7/_)8/"'_7I>_^@BO4*\ON?^2P>$/^O2]_]!%>H4 %%%% !1110 4444 %
M%%% !1110 4444 %</>_#/3[WQH/$CSA9!,DAMA"/+< '=N&?F8MM;=VVC@U
MW%% '"V'PPTVQ\6RZ_YPD,LDK-:F$")0P^7:,\,/FRW?>W J'1?A3INC3:A+
MYZ7)O;=XFCFMP8XV8GE%S\J[=JE>^T<UJ>+_ !-JNBZIHFF:/IUM>WFJ23(H
MN)S$J^6F\\@'MFG>#O$NIZ[<:S9ZMI]O9W>F7"P.MO,9%;*!LY('K0!'X*\
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MKU"O+[G_ )+!X0_Z]+W_ -!%>H4 %%%% !1110 4444 %%%% !1110 4444
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M#5HGDL;A9521XFX((9&*MP><!@1GIQ5V@ HHHH **** "BBB@"EK'_($O_\
MKVD_]!-?)VFC.DVH]85_E7UCK'_($O\ _KVD_P#037R=IG_(*M/^N*_RKS\Q
M^"/J?8\'?[Q5_P *_,K1:)%$8A]IN6CB<.L;.-H(.>F*S9;.8VT\/]F,TSS%
MEFPO3=GKUZ5TU%<$<1-.[U_KR/JJV3X><>6'NK5:)/=6^U>UEM:UNAG:[_R!
M;G_='\Q7U_:_\>D/_7-?Y5\@:[_R!;G_ '1_,5]?VO\ QZ0_]<U_E7H9?_#?
MJ?(<8?[Y#_#^K):X#Q]!XTEU33W\-L7M;<BYF38!RI(V@[QO)#YV'"_)UKOZ
M*[SY,\WURT\>MXOTZ73[HR:=;HBS2^0J\R *[!/,Q)MV[CNQMW<;JD6V\<_\
M+)-R9_\ B1;OLV\Q#A ?,SY?F8Q_!YGWO]GO7HE% 'GGA>V\<Q^-;R?6)B=)
MN"=C&,981Y105WD1;L[AMSG;SCI7H=%% !1110 4444 %4=6TFWUFTCMKDN$
M2>*X&PX.Z-PZ_AE1FKU<#/X%GEN)9/[+T [W+98SY.3W^;K0!T_AG5IM;T5;
MVXC2.0W$\15,XQ',Z#K[*#6O6=H6FC2=&M[$6]K;^7N_=VH(C!+$\9YYSD^Y
M-:- &?K=H+[1KJV?4)K"-T_>7,+A'C0'+88_=R 1GMG-<?X5D31[?7=6TVWU
M:?PXJ1M96[,\\L[KN\R2%7.[:V5 R>2I(X(SUVO:):>(]&N-*OS-]EN !((I
M"C$ @XR/I4&A^&X-!>9H;_4[GS0%(O;QYPN/[H8\=>U '#IXK3Q+\3/"BIHN
MM:;Y"7ISJ=F8!)F(?=Y.<8Y^HKU&N.\1?\E*\%?2_P#_ $4M=C0!Y[\7?^0-
MX>_[&"S_ )M6PWWC]:Q_B[_R!O#W_8P6?\VK8;[Q^M "4444 <U<_P#)8/"'
M_7I>_P#H(KU"O+[G_DL'A#_KTO?_ $$5ZA0 5Q=U\-=)N_&0\32,/M0F23RA
M GED '(88^9BQ#;S\P*C'2NTHH XG3_AEH^G^*Y?$"[7GF>4O"T">4 P 4*N
M/E*\_,.6W-GK4.B_"O1]$DU"2)TF>^MWAD$UK&R*S$G<BXPHP0-@^4A17<RS
M10A3+(D89@BEV RQ. ![FGT <IX-\!:;X)%T+!VE^T!,O*B[P0/F^8#."?FV
M] 2<5U=%% !1110 4444 %%%% %+6/\ D"7_ /U[2?\ H)KY.TS_ )!5I_UQ
M7^5?6.L?\@2__P"O:3_T$U\G:9_R"K3_ *XK_*O.S'X(^I]CP;_O%7_"OS&7
M]S<13VT%L(M\Q89DS@8&>U+87-Q-)<Q7(C#PN%S'G!XSWJ2[L8+W9YRL=A)4
MJQ&,_2EM+*"R5Q"K#><MN8G)_&O/YH>SM;7_ (/?T/KU2Q7UOGYO<]>G+:UK
M?S:WN5M=_P"0+<_[H_F*^O[7_CTA_P"N:_RKY UW_D"W/^Z/YBOK^U_X](?^
MN:_RKTLO_AOU/B^,/]\A_A_5DM%%%=Y\F87C'Q'%X4\+7NK. TD:[((R?]9*
MW"+^9&?;-9/PW\2W>NZ)/9ZO-#)K>F3&WO6B=65^Z2 KQAE].X-:^L0^&=<M
MQ::P=-O(8Y-XBN'1@K#(S@GKR:@T?3_!_AZ2632(])L7E $A@9$W =,X- '1
MT4BLKJ&5@RL,@@Y!%+0 4444 %%%% !1110 4444 %%17,YMK66<0RS&-"PC
MB&7? Z >IK#\+^(+G6-+OKO5+:*PDMKR:W:+S 1&J' W-G!/J1Q0!G^(O^2E
M>"OI?_\ HI:[&N'UF^M+SXE>#1:W4$^U;[=Y4@;'[I>N*[B@#SWXN_\ (&\/
M?]C!9_S:MAOO'ZUC_%W_ ) WA[_L8+/^;5L-]X_6@!**** .:N?^2P>$/^O2
M]_\ 017J%>7W/_)8/"'_ %Z7O_H(KU"@ K.UV:^M]#O)]-DMH[N*/>CW2.\8
M Y8D)\QXST[T:]KECX;T6XU;4G=+2WV^8R(6(RP4<#D\D5QW_"Z?"'_/34O_
M   E_P *3DENQJ+>R/&==\1>(/BK!;&34;.V6RU&&U2&W29%9IGVI,<Y'!!_
MV@,\5[!X.USQ-?:R='DU_P -:@FEE8;Y8%F-P0%QD,QVL<]3TSD=:X7QK\0_
M!T.EV,'A_2[A2=9AU&Y"VA@#E&W-]X<LW05H^&?$/PN\+:]?ZUIL&J1W5YT5
M[&0BW4\LJ#' )Y[^@XI<\>X^678]QHKAM.^+?A35-4M-.MYKT7%W*(8A)9R(
M"QZ#)%=S333V$TUN%%%>>7U_XW7XC11VULK:&I%N9O(D\L;\/N*Y^8J$*[QA
M07Y'%,1Z'17G6EW_ (YD\>WD5U;(FD2;HHIVMY/+S'DY"[LJ6W@;CPWEG'6H
M?#>J>/9;O6GU*U2")HWN;1I;65@V!L"J@;*<H7V'+'>,4 >ET5P_P\N_%MS%
M>KXGM3;[7,L2R(Q<B0[P Y.,*#LVXR"O)KN* *6L?\@2_P#^O:3_ -!-?)VF
M?\@JT_ZXK_*OK'6/^0)?_P#7M)_Z":^3M,_Y!5I_UQ7^5>=F/P1]3['@W_>*
MO^%?F6Z***\H_0#.UW_D"W/^Z/YBOK^U_P"/2'_KFO\ *OD#7?\ D"W/^Z/Y
MBOK^U_X](?\ KFO\J]?+_P"&_4_.N,/]\A_A_5DM%%<F?B=X(5B#XFTX$<']
M[7>?)F/XX\.>!O#GAG4]<N_#6FR3*I* PC=+,QPH^I8_SKF?@]H?@SQ7X(B%
MWX>TZ74[%C#=-)"&9L\JY/N#^8-=1XA\8_#7Q#I;6NIZQI-[&F9(XY7R ^"
M?KR?SKG/A;XD^'WASP?I\CZEIEEJTUNJWI+X=F!.-WYT >PP016MO%;P1K'#
M$@2-%& J@8 'MBI*Y+_A9_@?_H9]._[^UT]G=V^H6<-Y:3+-;SH)(I$.0ZD9
M!% $U%%% !1110 4444 %%%% !7/:9X:1-.UFPU2."ZMM0OI[@Q<E3&YR%;W
MKH:* /-IO"NA>&OB9X1;1M+M[$SK>B4PKC>!$,9_,UZ37'>(O^2E>"OI?_\
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M<[@-S84').">@J[#X^UK6[@IJGQ&_LB.WM_/!ALT4R2@D/%\A(.,#'9@<XH
M^E**\&L/BQXAU+1+G5?[8T&P?2K:-I+&XPTFHOLW-MPPVYZ *#SP:]QL+HWV
MG6MV8FB,\22^6_5-P!P?<9H BUC_ ) E_P#]>TG_ *":^3M,_P"05:?]<5_E
M7UCK'_($O_\ KVD_]!-?)VF?\@JT_P"N*_RKSLQ^"/J?8\&_[Q5_PK\RW111
M7E'Z 9VN_P#(%N?]T?S%?7]K_P >D/\ US7^5?(&N_\ (%N?]T?S%?7]K_QZ
M0_\ 7-?Y5Z^7_P -^I^=<8?[Y#_#^K):^('D6*Q8A4\UY712P'7<>?PK[?KX
MHMXHY8#YD:OB1\;AG^(UWGR9%#<0G3VF=(R\?RL HY;_ .O2PSQ_8WEGA19(
MLB1=HZ__ %Z34(H(K%@L(!)&T(,<^IQZ5%ID4)6:,KO.1EF!PX[<&@!()1+:
MW,<JQ&54+@J!T(_I7U[\/?\ DG'AO_L&P?\ H KY.F@ABMIFCB1#Y;#*J!VK
MZQ^'O_)./#?_ &#8/_0!0!TM%%% !1110 4444 %%%% %74M1M-(TVXU"^F$
M-K;H9))#V ^G7Z50T'Q-8>(?M"VJW4,]L5\ZWN[=H94##*L589P<'!]C57QW
M:7-[X/NTM()+B:-X;@01C+2B.5)&4#N2%( [FLC3)[GQ-XDU;5](^TZ?"=.A
MLH+N[LV4M*'D<D1O@L%# <XY)]* +/B+_DI7@KZ7_P#Z*6NQK@+KP3XKO-5L
M-3F\;0FZL/,\AAHZ #S%"MD>9SP*O_V!XW_Z'FW_ /!*G_QR@#-^+O\ R!O#
MW_8P6?\ -JV&^\?K6-K?@'Q/XA@M8=1\:Q.EK<QW<032$7$B9VD_O.1STJP?
M!_BXG/\ PFUO_P""6/\ ^+H T**YC5]+\7Z5JFB60\76TO\ :=TUN7.D1CR\
M1/)G&_G[F,<=:U_^$/\ %W_0[6__ ()8_P#XN@#*N?\ DL'A#_KTO?\ T$5Z
MA7G$GP[\22ZY8ZRWC2+[;8I)' PTA H#C#9&_FM?^P/&_P#T/-O_ ."5/_CE
M $'Q=_Y)EJO^_;_^CXZX\_>/UKI];\#>*O$.DS:7J/C:)[68J75-'12=K!AS
MYGJ!5'_A6&O$_P#(YI_X*4_^+KQ<VR^KBW%T[:7W/6RS'4L*I*I?6VQBT5%X
MK\*:_P"&;;3)AXHCN/MNHP6)!TU5V>82-WWSG&.E;_\ PJ_7O^AS3_P4I_\
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M%5?'%OA1@?\ $E3_ ..5WX6C*E!QD?)9_F5',,1&I13LE;73JWYG95\5V?\
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MLPM2H9+)V4;TB/54W9.W) S@<5T]%% !11534M3L](L7O;^<0VZ$ L0222<
M #DDDX '- !J6IV>D6,E[?3K# G5F/4GH .Y)X '6O,;K3+'Q9YR:1J+6[ZC
M!/)I=[SE2W_'Q9S*>=N3OVGE<L1]VK&H>(-6UFRTG63'80V#7HGTZZ4NZ0R
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MP>>I P,#I2 !0 !@#@"EH ***SM=U4:'H5[JC6T]T+6(R&&!=SMCT_J>PR:
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M&^^C E2<#!YKK=-\-7CZM9:KKFHQ:C<6$3QV3):^2R[\;G?#'+$ #C"]>.>
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MRT[4VL_#M^Q>^T]%YR?O+"W_ "S5\G>![[<;C78Q11P0I%$BI&BA451@*!P
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M&78CV YS0!Z)17#Z+XBU/4Y;EI+FRL+7?]GA20*TD4IEVQKM#9)90<[MISC
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M.C(PRK#!HHH CMK:&SM8;6WC$<$*+'&@Z*H& /R%2T44 %%%% "8'H*6BB@
MHHHH **** (9K2">6&66)7>!M\989VM@C(]\$C\:FHHH **** "H+RRM]0M7
MM;J(2P28WH2<-@YP<=1QT[T44 3T444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>image_038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I SX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY9%'ZC!_&NT$$2VPMP@\D)LV=MN,8_*N6M_!36^BZAI8U+,-VR,I,/\ JRK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHKF_%OBE?#J6<$0B:]O7*0B8D(H499VQR0..!R<U?\/WYU'1XKEK^VO68G=-
M;H43.>F"<C'O0!JT49%% !1110 4453L=5L=2DN$L[@2M;OLEP",'GU'/0\C
MB@"Y165>>(]*T^\:TN;AUG0 LBPN^ >G*J15C3M7L-51VLKA9=APXP59?J"
M10!=HHHH ***9YL?FB+>OF%=P3/..F<>E #Z*K65_;:C;^?:2>9'N*;MI'(.
M#UJS0 444P2QF4Q"1#(!N*;AD#UQ0 ^BBB@ HHHH **** "BBB@ HHHH ***
M1LXXQGMF@!:*XW2]>U4^,_[&N;O3[^-H9))?LB%6LRI&T-DG(;)'KD5V6: "
MBBB@ HHHH **** "BBB@ HHHH ***;)(D4;22.J1H"S,QP% ZDF@!U%,AFBN
M(EEAD22-AE71@01[$52_M[1LX_M:PSTQ]I3_ !H T**KS7UI;6ZW$]U!%"V
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M "BBB@ HHHH **** "BBB@ HI*6@#F/$FCWDNMZ3KNGV\5U/8"6-[:5MN])
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MZTSQNI?1K9 [(6O(@&7J.>HJU;Z#.U^MYJ>I->21QM'"%B$0C###' )R2.]
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M&5N_XU5_LO5M1U"SFU9[*.&TD\Y([7<Q=\8&2P& /:@!GAK_ )"GB#_K^/\
M(58UG4]0M=4TVQT^*W=[P2Y,^<+M"G/!]">/ITJ72-,FT^]U2:5HV6[N?-0(
M22!C'/'6GWNG37.O:7?(R"*T$PD!)W'>H QQ[4 8T.M>(;@ZA!'!IPFT]B)9
M&W[9.,@*,Y!Z\D^E3QZV+J[\/3O;0 7<$TC.ZY>+:@)V'L#W]15NSTBXM[K6
MI7>(K?.&BP3D?+CYN/Y9JK:>'KF$Z")7A9;""6*<!C\V]0!MX]N^* &V>K>(
M-1M%U*TL[)K-VS';L["9TSC.[.T'O27/B"]GU2[M=/?3H([0A'>]<@N^,D*
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M?,6VCVI\Q&,#';Z5JTR7_4O_ +IH R?"3M)X2TEG9F8VL>68Y)XK9K%\(?\
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M0 4444 (RAL9SP<\$BEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M G'6O)]=\(W\TEQJ6HVNI:C<32W,92UNRI12W[AE7<  %P,5Z%XC@GN=&EAM
M[%;UW9<PM,8@0#G.X>F*\]O=.-Q>SS77AW3Q<2.6D!US:=W?CM0!Z/H,-S;^
M']-@O$5+J.UC255.0'"@$9[\UHU3TK9_95HJ*BJL*+M23S N !@-WQZU<H *
M*** .;\$_P#((O/^PC=?^C6KI*YOP3_R"+S_ +"-U_Z-:NDH **** "BBB@
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MIH6GKJ9#7XMHQ<$=Y-HW?KFK] !1110!S?@G_D$7G_81NO\ T:U=)7-^"?\
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M5EY9=E&2=V3CBNLKS[PNK7?B.&XU*YUV]N8(G6V:]LQ!%"#C)^7JQ'&37H-
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M_@_/_"':/NQG[)'G'KBMNL3PA_R)^D?]>L?\JVJ %KC?"_\ R/?C'_KM;_\
MHNNRKC?"_P#R/?C'_KM;_P#HN@#LJ*** "BBB@ HHHH **** "BBB@ HHHH
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MF_\ NLOD=V7?[POF<O1117QY](%=[X0_Y @_ZZ-7!5WOA#_D"#_KHU>ODO\
MO/R9YV:?P/F;]%%%?6'SP4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5SWC33[K4O#CQ65JMW<1S13);NX59"K@[6)[<5T-9/B+5)M&TL7
ML,!F5)HQ-A2VR,L S8')P.: ./GD\43>(--U-/!D</V..12([U SEP!@G;]T
M8S]:]!MGDEMHWFB\J5E!:/=G:>XSWKD=(\2:U?Z];/+:1IH^H-,MJOEL)D6,
M<2.3QAN<#'I79B@ HHHH YOQI_R#M/\ ^PG;?^AUTE<WXT_Y!VG_ /83MO\
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M!'"DCW E,NU<$G XZ5T=4=%OI-3T2POY8#!)<V\<S1-U0LH)'X9J]0 4444
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M=7%U/<Z5-))),^?^6HP .@ %>BUER:';2>)8==+2?:H;5K55!^7:6#'CUR*
M/,O[-L[SX9>(M<N(D;5?MES-]J;_ %B/'*0@![8  Q7I$VH7T.D6LL6G27<D
ML(,@20+M.W/>LBZ^'FG75_/+]LO8[*YG%Q<6"28AEDSDDCW(&1762 + X P
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MQI_R#M/_ .PG;?\ H==)7-^-/^0=I_\ V$[;_P!#KI* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ ->32_ZY_\ >->LFO)I?]<_^\:^?SW:'S_0]C*=
MY_(91117SA[0^'_7Q_[P_G7K(Z5Y-#_KX_\ >'\Z]9'2OH\AVG\CQ<VWA\PH
MHHKZ \<*X.XT+Q1J$]Q97E[)'80R3SQ3VUP4EG+$F)#_ '0N<>^!71>*-3GT
M?1_MD!5=L\2R.XR$1G 9C] :OZA=I::5=79F2-(H6D\QONK@9S0 S1DO8]$L
M$U)P]^MO&+AAT,FT;C^>:O5F>';VXU+PWI=]=ILN;BUBEE7&,,R@GCMS6G0
M4444 <WX)_Y!%Y_V$;K_ -&M725S?@G_ )!%Y_V$;K_T:U=)0 4444 %%%%
M!1110 4444 %%%% !1110 4444 <'XQ_Y#2?]<5_F:Y^N@\8_P#(:3_KBO\
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MO-:,1_%961_[A3^?YL,#T%)@>@I:*P/5/9/A)_R+5U_U]'_T%:] KS_X2?\
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M %RD_F*\UKTKXP?\?^E_]<I/YBO-:,1_%961_P"X4_G^;"BBBL3UCV3X2?\
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M @''U%;0^'OA,_\ ,%M_U_QH Z7S$_OK^=)O3^^OYUS?_"O/"?\ T!;?]?\
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M>.,?TH K>$9$'A#2/G7_ (]8^_M6-XS=3>6Q#*?D/?WK77P7X>10J:9$JC@
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MQR/4?G1D>H_.N]M_ VC#7+YI='@^R&./R<CC/.[C\JT?^$(\-?\ 0'MO^^:
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M]J ^T)_K<YWYSUH Z:BJ-KK&F7LWDVNHVD\I&=D4RLV/H#5Z@"KJ?_(*O/\
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M>7VC<1@G'- %'2-$T[0K4VVFVRV\)8OL7H":T*** "BFR2)%&TDC!$499F.
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MC<JG'3(Z4ZB@!I12P8J-PZ''-+M'/ YZTM% #=BG&5!QTXZ4NT8Q@8],4M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&['TJG_PB,C-!I<+/J/AJY/G6ER)LS:=(!D,CGDJ>WI7;:-I,>D6*0">:YE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>image_039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_039.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &6! T# 2(  A$! Q$!_\0
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MXQTIWBW6+[2]8\+06DPCCOM3%O< J#O3RW..>G('2@#J:*** "BBB@ HHHH
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MJ0'GUH8,G1L+BM"/G19_^N@_I6:O2M*+_D#3_P#74?TK)G;EO\2I_P!>Y_\
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M4M_&DIPI/2IJ3Y(N7852?)%R*BZ-<-%O$;;<=0*S[FV,38/Y5[>+6U%IC:N
MO6O-/$-DIOG, &T>E>?@\Q=:;BU8X<)CW6FTU8Y ]<5&1C\*M3Q,C$,.:K-W
MKVHNYZT7<8>*81DT\_G3#T-:(T0WM29&.,"E/;'ZTG%4,U_"Q_XJW1O^OZ#_
M -&+7VY7Q#X7_P"1NT7_ *_X/_1@K[>JX%Q"BBBK+"BBB@ HHHH **** "BB
MB@ HHHH *\Q^#W_'QXV_[&&X_G7IU>8_![_CX\;?]C#<?SH ].HHHH **BN;
MF"SMWN+F9(84&6>1@H ]R:K:;K6F:NKMIU]!<A.&\MP2/J*5U>Q:IS<7-)V7
M6VGWEZBBBF0%%(S*BEF(50,DDX %46UK3?L-S>17UK+#;J6D:.92%QZG/% %
M^BL#PSXKL?$7AFQUGS8+<7*Y,1F4^6W)VD^N!FF1^)A<>,[;1[4V\]G-I[W8
MN(WW?,L@3 QQCF@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTUUV#FID<1R9(R*CF/GR@*,9XKH3=S9/4JEB#D'!%2><LG$PR?[Z]?Q]:?/
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M5[+6B+04444 %?,'Q9_Y*5JW_;+_ -%)7T_7R_\ %D_\7+U;_ME_Z*2N?$_
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M--_&K12$R:3/?%*>*3 S3*-;PMQXMT7T^W0?^C%K[>KX@\+9_P"$MT7/_/\
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MY::DM%%%=QZ04444 %%%% !1110 4444 97B#P]I_B;3?L&I([V^\281MIR
M1U_$UR!^"7@LDG[+=<_]/+5Z)14N$6[M$N,6[V/.O^%(^"_^?6[_ / EJ/\
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M)?\ XJF_\*E\#_\ 0"7_ ,")?_BJ[6BGR1[!R1['%?\ "I/ W_0"7_P(E_\
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M<.:US6K4]G'FL<R1BMBTR?"E]S@^<G]*FO;&T:%Y%^63JH]:A@'_ !2M^/\
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M]_Q\>-O^QAN/YUZ=7F/P>_X^/&W_ &,-Q_.@#TZBBB@ HHHH **** "BBB@
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M_/:U_P"_O_UJDB\/7T3[EEM?^_G_ -:L/:3VI=C>AJFI/=_@4ZV!_P"?+_\
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MIQ^(!J*^M;:T\.7%O(9WMTA8'!W/CV)_K6=HNGZBFHB>_B.T&1T8,@ +X)R
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MC ?ZO;CTKKXX[.QOGM6820]-RFM#5K?0SIG[A)3\A)?;GYNU>;'&.$U=-IG
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M<N">:U<4]S1Q1LZ7=D72>8WRYYKN+FWMFL]Z%1QG->:*_EG(-:3:W,\*INP
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M!CC_ %H_H:D,WCIONVVD)_O,QS^M<RRV;^*I%?\ ;W_!9P?VK46L8K_P&/\
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M(_4&LBZ^'K\FWO4?CI)&!G\JS?\ A.?B-_T3)_\ P9)_A1_PG/Q&_P"B9/\
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MF9C577_ \D%M&([G3H!R3O&PM@= <<U)_P )S\1O^B9/_P"#)/\ "JM]XO\
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MSA>%/7!K0_X3GXC?]$R?_P &2?X5;J3:LV[>H[L].I&574JP!4C!![BO,O\
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M;.$6[M&SA%N[19EU"XFMU@>1C&O0&JM%%-14=AI);!24M&TGD#BJ&)12TA%
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MI/3WK-UZQ@L)T2"X28$9RO:N.-7GJ.G->ARQJ\TW3FC(/6DHHKL.H6EIM+2
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M %_Q?^A"OL^OC'X=_P#)1_#O_7_%_P"A"OLZNR.QUQ"BBBJ*"BBB@!*6BB@
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MBIG0A.W,B9T83^)'S;+^SMXC)!CU/2AZ@R2?I\E,_P"&=?%'_04TC_OY)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>image_040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_040.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( EH# 2(  A$! Q$!_\0
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MQ4,"1U&>E "T4T2QLVT.I;T!IHGB:=H!(IE50S(#R >A(_"@"2BBB@ HHHH
M**** "BBB@ HHIGG1&8PB1/-"[BFX;L>N/2@!]%1S7$%N%,\T<08[5+L%R?0
M9IEQ>VMIM^TW,,.[IYD@7/YT 3T56EU"UAA29I@T;Y*M&"^0.2>,\#UJPK*Z
M!U(*L,@CN* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH YO6?^1U\-?2Z_\ 18JK?6,M_P#$"2*.^N+1!I:EVMR [?O6P,D' KI)
M].MKF_M;V5"9[7?Y+;B-NX8/'?BE%A;#4VU$(?M30B ON/W 2<8Z=36;A?[S
MMABE!*VZBU\V[G"?V]JTMAI>G^==RR2W5U#-/:JGGR)"V!C=A03QD^QKH?"]
MSJ3W%_:WJ7?V>(HUN]X4\[!!RK;2>A'!/4&KC^&=*DLOLC6Q\L3M<*1(P=)&
M))96!R.2>AJSIFCV.D)*MG$5:5M\LCN7>0],LS$DU,823NV:U\50G2<81LWY
M>=[_ ':6,&:.^U3QAJ=B-6N[6T@MH9%2W*@[VW<Y(/''3O6-'K^K7]EH%JSW
MKM<V\LUQ)8J@FDV-M &[  YR<<UW<>G6T6HSWZ(1<3HL<C;CRJYQQT[FJ+^&
M-)?3[:R^SLL5J2T#)*RO&23G#@Y&<^M#A+HQT\715E*.R71;\K3?GK9G+3ZW
MKMII;6CK>J\FHQVT,TBQ&Y\IE+$8!V[^" 3CJ#2RZSK6C6FJLJ7YMX[02POJ
M7EF2.3>%/W3DK@YY'8UU2>&=(33)=/\ L:M;ROYDFYB79_[Q8G=NX'.<TMGX
M<TNR6X"6YE:Y3RYGN)&E9T_NDL2<>U+V<^YI]<PUG[G7MOJONV?W^;.?ETV>
MP\7>'&EU:YO1)Y^1<%3AO+Y9< 8'M]*M>-;,W,NAXNKF'.HQQ_N7VXR#\W3[
MPQP?<UHV?A32+"]@O(()?/MP1$SSN^Q2,;0"3@8[5HWFGVU^;<W"%C;S+/'A
MB,.,X/'7J:KD?*UW_P" 8O%Q56$TV^5-;);\W3;JCD8WU+4M/UC51K-S:/93
M31P0IM\M!%_ST!'S$XR>>_%26%S?Z]K]MOO[FTMVTJWO&@@8 &1F;/)!XXZ=
MZVKOPKH]]=RW$]JQ:8@S(LKJDI'0NH.&_$5?CTZUBU%[Z.+;<-"L!()QL4D@
M8Z=S24)7U*EBZ7*^5:VTT6FB5O/5-W\_4Q_%D]Y&NDPV=Z]H]S?I"\B@'Y2K
M9&#QV_/%8>M7VI:'%KFGP:G<3B/3UNX)IB#)"Q?:02 ,@XR,^]=#XFT9];33
M81&CPQ7J2SJS%?D 8'&._(J5/"^DI87=GY#M'=@"=WE9GD Z9<G/'UHE&3;M
M_6@Z%>C3IPY]=[JR_F3O??9/3K<Y_5YM1TZ[TW28KS5+D78DGGEA*&8[0ORI
MG 5<G)[U$-6UN&R>QD>YM_.U"&U@NKH1F=(Y!D[@I(W#& 3_ 'A77ZCH]EJL
M,4=W$6\IMT3HY1XSTRK @BJ\?AK2(]-GL/L8>"=M\N]BSNW]XL3G(P,'/%#I
MROHPAC*'(E.-WUT7=Z].EM/*VQA:U]LT+3[I(=>GG8M;LD<Q4S1@S*K'<,94
MCCD>O-5-7OM5LM2OKJZN]1AM8ILP7-HJ36T48QD2Q_>SUR:Z1/"ND);30F"1
M_/9&DDDF=W;80R@L3G (Z=*+GPIH]W=2W$ML^9FWS1K,ZQRMZL@.T]!U%)PD
M]BJ>+H1?O*_=\JUV_P G^I@:AKFH17NL0V]X462\L[:"5@&6!95&Y@/\>Y%2
MZA-?Z!?264>J7-W%<Z=<3#[00TD+QJ"&! '!ST/>NCET'39_MPFM5D6^V_:%
M8DAMHPO';  Z5#;>&=+M4N D,CM<1&&2269Y',9_A#,20/I3Y)?U\R5BL.DO
M=^5EKI'6_2UGZW\V<_:2:G9?\(S>RZO=7+:BR1W,4NWRR&B+94 <$$#G/-:_
MB^XO(+"Q6RNGMI9K^&$R* <*QP>#UK2.D6316$9B.VP96MQN/RD*5'UX)ZU)
M>Z?;:@D*W*%Q#,LZ88C#J<@\57(^5HR>)IRJQJ-;7OHN[MIMHFCDQ:ZBVL:O
MIG]O:@+:TMX[B-MR^;O8-P6V\J-O3WJBFO:KJG]D6S-J!633$NYSIP022.3M
MY+'A1CMW-=R-,M1>75V(SYUU&L4K;C\RKG QV^\:I2>%])DM+.W\AT%FGEP2
M1S.DB+Z;@<X_&I=.71FT,;1^W'MT6_+9O3S_ ,SG(-2UJY33M)NI[BS:XO98
M3=,$$S1(F]0<957/0_2JEW]KT9_%9BU&>6>,66R=R/,52V,$@<G!//H:[ ^&
M=(.EKIPLPMNDGFKM9@XDZ[]^=V[WSFHH_">CQ6UW;K;N4N]AG+3.S2%#D$DG
M.<TG3E_7H5'&T$WI9=K+7WD[_<K6V,T"]US4]:/]L7&GQZ?*(84A*@ A Q=\
MCY@2>G P*S=3UG44M?$#V^IES#;630318V!G/S,H]&KJ-0\,Z5J=TUS<P/YD
MBA)?+E=!*HZ!PI 8?6G3>'-+G2[1[;"W21)*JL5!6/[@&#QCVIN$B*>*H1:;
M6FFEEI;EOKN[V?WF'<W-_P"'M<\O^T+F^BET^XN7CN-I DCP1MP!@')&*SM-
MU'7=FEWX&K327+QFY%QY*VS(_7RP#D8R".YQS7<2Z=:S:C#?21[KB&-HD;)P
M%;&1CH>@K/M_">C6MU%/%:M^Y??#&TKM'$WJJ$[0?H*'"5]&$,91Y/?C[UM=
M%KOZ=UKY>1M4445L>6%%%% !1110 4444 <_K-Y':>)-(:5(?+$5P[2.N60*
M@)VGM[UR_AV^>WU^TU&:WNXO[6:1)WEB*QDL=T6T]^!BO0;BQM;L@W-M%,0I
M4>8@. >HY]:62SMI88X9+>)XXRK(C*"%(Z$#MB@#S1K;3(_#5[?*8X]92^D^
MSNC8E+>;P,=37H5O9NFJ2791%$MNBOMX)<$DY_ BECT;2XKK[3'IUJL^=WF"
M%0V?7.*O4 %%%% !1110 4444 %%%% !7%ZPUQ'XKU&>UNC;R0:1YNY45BV&
M) Y[5VE,:&)F9FC0LR[22HR1Z?2@#SS6KB?Q*]E;BSFNS%IXGD%N5'ES2+\C
M')'3!/XU,=4L-2O?#5YJIMA%Y$Z3BXQM$B@ @YXSD5WL<,41)CB1"<9VJ!G'
M2HVLK1QAK6%ADG!C!Y/4T <CH%M+=6VJ1:64729+UO+^8J&CVC<$.#@%N_IG
M%=G&H2-4"A0H "KT'L*5$6- B*%4<  8 I: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH "0!DG IOF)_?7\ZQ_%,:2Z*L4BAHWNK964]"#,@(-
M2?\ ",:%_P! JT_[]BIN[V1O&%-04IMZWV2Z6\_,U/,C_OK^='F1_P!]?SK+
M_P"$8T+_ *!5I_W[%'_",:%_T";3_OT*/>%:CW?W+_,U/-C_ +Z_G2>;'_?7
M\ZS/^$8T/_H$VG_?H4?\(QH7_0)M/^_0H]X+4.[^Y?YFGYL?]]?SH\V/_GHO
MYUF?\(QH7_0)M/\ OT*/^$8T/_H$VG_?H4>\%J/=_<O\S3\V/_GHOYT>;'_S
MT3\ZS/\ A&-#_P"@3:?]^A1_PC&A?] FS_[]"CW@M1[O[E_F:?FQ_P#/1/\
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M4>\%J'=_<O\ ,T/M$'_/:/\ [Z%'VB'_ )[1_P#?0K/_ .$;T/\ Z!%C_P"
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MZ5:-1:;GQ^8996P4O>UB]G_6S+=%%%:GFA1110 4444 %%%% !1110 4444
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M$"QN;ZWL$MQ&0KNS;Y%3L,=3SWKU)2C%7D[(_/$FW9'F5%:G_"/:C_<A_P#
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M)49;=W^T&43;CE<L&[@YS@YP1VK;LK.*PMA;P[O+#,P#-DC))Z_C0!8HHHH
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M]O?&0,_F10!;HJ+[3!L5_.CVN<*=XPQ]!0UU;INW3Q+M.&RX&#[T 2T5&;B
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M0+@+CD<=SWZ5TM% &)>:5>3:A(\9@\B2:.5BS'<-JXQC'TYS5-O#ERULT/\
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M=WX\\T 9W_"02@H&LE!F)6#$N=Q$@3YN..H/>HGUN]>>-(X8XW\T1.C/E?\
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M?JKI]DMA:^2K!F9VD=PNW<S$DG';DU:H **** "BBB@ HHHH **** "BBB@
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M2@#76XA;I*AXS]X=*#<P!MIF3.-WWATXY_45C?\ "+VWEE?.?)Q\P4 \;O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>image_045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_045.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X D8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BL/P[J]]JLNL)?V<=H]G>B".%7WLJ&"&4;R.-_[PYVY Z MC<=R
M@ HHHH ***S]9FO+?3GEL[FQM-F7FNKX%HX(P"68J"N[H!RR@ ELG;M(!H45
MGZ)=7E[H\%Q?V_D7#;LC84WJ&(5]C?,FY0&V-\R[MIY!K0H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O&?C;J6B7FI:5X<UK5%L;06UQ>
MN_DO(?.V&.#A.0-Q=CZ[<<9KV:LJST&WL_$6I:V+BXDN;^.*)DD*[(DCW8"
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MW#HM];RZI<Z=J<<%Q>WJW8\VV\V, 01PE'7<"P_=[@59"#CJ 0V'J/AJ\L?
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M ._$W_QV@#Z?HKY@_P"&CO&'_0-T/_OQ-_\ ':/^&CO&'_0-T/\ [\3?_':
M/I^BOF#_ (:.\8?] W0_^_$W_P =H_X:.\8?] W0_P#OQ-_\=H ^GZ*^8/\
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M(H R:*N76GO"OF1L)8C_ !+V^M4Z "BBB@ I0">E)2JQ4Y!P: $Q1BE)S24
M%%/CB>9PD:EF/0"M>'1X((_-U"?8!SL7K0!BT8K8:\TJ(_NK(R#U<TX7^E./
MGT[;_NM0!BT5M+!H]YD12R6[]@_(JE>:;/9G+ /'V=>10!2HHHH ,5]?_!+_
M ))#H7_;Q_Z425\@Y.,5]??!+_DD.A?]O'_I1)0!Z!1110 4444 %%%% !7Q
M!X[_ .2A^)?^PK=?^C6K[?KX@\=_\E#\2_\ 85NO_1K4 <_1110!M3>$]<MX
MT>73Y$$@0J"1DA\;>,YYR/SJ._\ #.M:7"TUYI\T<2OY;/C(5O0D=#[&NO\
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M5/536?76R:<MI?;L9AE^5@?6N>U.S^QW;(/NGE:0%.OK_P""7_)(="_[>/\
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M"?\ )0_#7_85M?\ T:M5/$5TM[X@OYU.4:=MA]@<#]*M^!/^2A^&O^PK:_\
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M"6A_]_YO_C5'_#./C#_H):'_ -_YO_C5 'C]%>P?\,X^,/\ H):'_P!_YO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M060 !L ?*#L>';:[276+^[M9+0ZC>BXCMY61I(U6"&+#["RY)B)&&/!'0Y
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M'N-./C'P]/I7]E6LEU=RI=6MM;,;Z-?LTS;+VXWG,A9 S1NN[>IY<QEC7?\
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M%%% !1110 5')!#,\+RQ1N\+[XF902C;2N5]#M9AD=B1WJ2B@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.""&UMXK>WBCA@B0)''&H544#   X  XQ4E%
M!1110 4444 %%%% !1110!GZEI*:I+:>?<SBWMY5F:V3:$F=&5XRQV[OE=58
M;67/1MPXJ35M-AUG1K[2[AI%@O;>2WD:,@,%=2I(R",X/H:N44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %.#388-4O-1W2/<721QL6(PD<>[:B@ <
M;GD;)R<N><!0+E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C[JVI:-X%L;C2]0N[&=M3C1I+69HF*^5*<$J0<9 ./85ZI7C_[1W_)/-/\
M^PK'_P"BI: / !X[\7@_\C5KG_@QF_\ BJ=_PGWB[_H:-;_\&,W_ ,57.T4
M=$?'OB__ *&G6_\ P8S?_%4G_"=^,/\ H:M<_P#!C-_\57/5<MK/>!++E8^W
MO0!M1>-?&<QPGB;7&_[B,W_Q565\3>-F^]XKUI?^XE+_ /%5FP1W%P?+MD\M
M!W[FIQI,YW!I"30!H?\ "1>,CT\8ZP?^XE+_ /%5$_B7QNIPOBS6F^FI2_\
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M "BBB@ HHHH *^)OB'_R4/Q%_P!A*X_]&-7VS7Q-\0_^2A^(O^PE<?\ HQJ
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MKW/1[MHK;X"N;< G^W2A<=3^Z!KRD\FO7/#WAW5O%'P(DLM(M&NKE=>:0HK
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MWY FP $CI&G@+5?[/M[6.[M+&>)V#WUL\AEG?[)<0F\8<#SV:9&('/R<RO\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>image_046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_046.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 B\# 2(  A$! Q$!_\0
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MI_[^O_C1_P (WI/_ #ZG_OZ_^-:M% &5_P (WI/_ #ZG_OZ_^-'_  C>D_\
M/J?^_K_XUJT4 97_  C>D_\ /J?^_K_XT?\ "-Z3_P ^I_[^O_C6K10!E?\
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M?^?4_P#?U_\ &M6B@#*_X1O2?^?4_P#?U_\ &C_A&])_Y]3_ -_7_P :U:*
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MF,%Q)YA6X F"D!0!\V<CY<\]<U<AT2T328-.F4SQ1'(W';SDGMC Y.!T XH
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M(O\ T 5H4 %%%% !1110 4444 %%%% !1110 4444 %%5KNS%V$!GN(MI/\
MJ9"N?K6==:/-^Y\C4KY?WJ^9NN#RG<#CK0!M45FC1U!S]OU#_P "#6E0 5E+
M_P C7+_UXI_Z&U:M92_\C7+_ ->*?^AM0!JT45AWNJR6OB*UMOM40MW!\Z,K
M@H-K-O)SG!( ST&"#R10!N5EVG_(R:G_ -<+?^<E5="U2[O9[]+@QRM$VZ,0
MXVJ"S (3_>^7D'U'K3M)FGGU_4WGM'MG\FW&QW5B1^\Y^4F@#<HHHH ****
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M8*3E<X^M $FA?\B]IO\ UZQ?^@"M"L_0O^1>TW_KUB_] %:% !1110 4444
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M+-HHD0[I58L2PSV(KO:\A\<?\CE>_P#7.+_T&@"W_P +&U[_ )]M-_[XD_\
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MD\9!S@9P 2> *T:* ,?PLH7PQIZC.!%@9.3U/>MBLGPQ_P BU8_]<_ZFM:@
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MN/\ KDW\C0!6T+_D7M-_Z]8O_0!6A6?H7_(O:;_UZQ?^@"M"@ HHHH ****
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MK=Q7D1DA\S:#C]Y$R'/T8 U/0!F>(/\ D"S?[T?_ *&M:=9GB#_D"S?[T?\
MZ&M:= !0>E%% ''VD.H'2KP?9=2C,UPC&WDDR_E*R[\/N^\Z[NA R<#U.U81
M:G'H=M&'C2Z'WOM(,F%R< X(RP&!G/8UK44 8_A;=_PC&G[R"WE<XZ9R>E;%
M9/AC_D6K'_KG_4UK4 %%%<__ &Q/_P )_P#V+]LLOL_]G?:?LVQ_/W;]N[=]
MW9CC'7- '04444 9VM:LNC:?]J:!YR9$C6-" 26.!R>*PO\ A-W_ .@+<_\
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MTZE](?\ T"O0Z\\UW_D:=2^D/_H% %*BBBF 4HZBDI1U% ':>$?^16LOH_\
MZ&U>6?$5-7;QQ=FPGLTB\F+(GC9CG:?3M7J?A'_D5K+Z/_Z&U<OXI\(:SJGB
M.XOK..V>"5(P-\Q4@@8/&TT@/*_*\2?\_>E_]^7_ ,:/*\2?\_>E_P#?E_\
M&NUNO"&KV04W<FF6X?A3+>A-WTRM4IM'N8/+S>:.V]P@V:@IQGN>.E '+^5X
MD_Y^]+_[\O\ XTOE>)/^?O2_^_+_ .-=8/#]V3@7^B9/_417_"M#_A O$?\
MSPL__ D__$T =MX $H\"Z4)RC2^6V\H,*3O;./:KZ_\ (UR_]>*?^AM3?#&G
M7&D^'+*QNMGGQ*0^QLC)8G@X'K3E_P"1KE_Z\4_]#:@#5KG[L7/_  E4,J6U
M]Y$419I4;*2<$>6%W8'J21DD*!WKH** ,#P_;ZC";O[4LR,54$S/O#RY;<Z\
M\*04].G05)I0NQK^I_;'@>3R;?!A0J,?O.Q)K;K+M/\ D9-3_P"N%O\ SDH
MU**** "BBB@ HHHH YGQO_R"+7_K]B_F:Y6NJ\;_ /((M?\ K]B_F:Y6@ HH
MHI@%;'A/_D8G_P"O1O\ T-:QZV/"?_(Q/_UZ-_Z&M '<4444@"BBB@ HHHH
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M!Z31110 4444 %%%% &9X@_Y LW^]'_Z&M:=9GB#_D"S?[T?_H:UIT %%%%
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MH5D5FQ>/\RCJ.O>@"M_;?CO_ *%?5?\ P.LO_B*/[;\=_P#0KZK_ .!]E_\
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M>Y@\F%;<F&3:9(QT5C_48/)YYJ[96<5A:K;P[O+#,PW')RS%C^I- %BBBB@
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MR^4%VOY9'\&W&S;M^;./]J@#T&BL"XU*:W\)SR6OG27UK BNJQEW5RBGH>N
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M!I:** "BBB@ HHHH CG@BN8)()XDEAD4JZ.,A@>H([U)110 4444 %(5##!
M(]#110 M%%% "      #H!2T44 %0SVMO<F(SP1RF%Q)'O4'8XZ,,]#R>:**
M )J*** "D*A@0P!!Z@T44 +2%02"0,CH:** %JJVFV+Z@FH/9P->(NQ9S&-X
M'H&Z_P#ZZ** +5%%% !1110!'!!#:P)!!$D4,:[41!@*/0"I*** "BBB@!,#
M.<#/K0Z*Z,CJ&5A@@]"*** ((+"SMC$8+6&(PQ>3'L0#8G!VCT' X]A5BBB@
M HHHH 0 #. !GDU'<VMO>0F&YACFB)!*2*&!(.1P?0@&BB@!4MX8YI)DB199
M<>8X7!;' R>^*DHHH **** *MIIMC8R326EG! \[;Y6BC"ESZG'6K5%% !11
E10!'-;PW"JLT22*KJZAQG#*<@_4$ BI*** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>image_041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_041.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& @D# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *CN+B&TMI;FXD6.&%#)(['A5
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M-8N+6?0IK^.WU6XBFDE=5+(X6/\ U8.,;<]ZC35-:BTGP'K/_"8:A<7&NZK
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MD34HRMW=&S@)5AYDPZH,CK6Y7SM<:IJ&K^'O"EQ?ZQ+'/_PE<D2WLI#&%0<
MC=QQVSQ6YK>MZYX>'CK1+77K^]AT_3X;NWNYY T]O(S %-X Z@YYZ"@#VVLF
M?Q/HMO:K<OJ,)@:Z%F)$)<>=TV?+GFN#DU>^O?'7@[2DU>Y2WO\ 0Y9+E89L
M%F,7$G^]G)!]17#^'IK[0OAI87>GZM?QO=>)X[:1?.^4)O<$ 8XW?Q>N!0!]
M%45Y!>:EJVN7?CB_D\3WFCMX>D>.SM;=T2,!%W!Y00=X<CO45IK&O>+O%OA>
MTFU>_P!*AU'P]]JNH[)@A9]Y^9<@[2>#GKCB@#V2BN'^%.KZAJ_@]VU.[>[N
M+6]GM?/D W.J-P6QU.#7%WWB#Q#;:I??#Y-3O/[7NM9C^R7NX^8EBX\QF#?[
M(4C\: /;*H3:SIUOK%KI$UTB7]TC200'.75?O$=N*\UN;S4_$'B7QA%+XGOM
M&B\/QH+2"VD5,_(6\V7<"7!(''3!K+TK6[[Q!XP\ :Q?(([VXT:\=]J[<D!@
M& [9P#^- 'MM%>%V/BO6)/AIX"NVUJX:^O=>C@N)#-\\T?FN"K=R,;?TJ'6M
M6\1)I_C[6H?$VIPMHFK!+.W1U\H NH(8$$E<'A<X&.^: />J*\=?7M?\+^)]
M4MQJUYJJOX8?5ECN]K!;A3_ % VK_LBD\!ZCXSN=5T"_?^U[O3=0@9]1DO[B
MW:+)7*O J'<H#<$8Z=1F@#V.BO._B9=ZHFL>$-/TW5;K3EU#43!/);L Q0@9
MZY&<9QGO7-^-M1O+&ZU'3=(UWQ+<7&B:<)93'=0PQPG!8232/\TI/'R@>PH
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ML2QMICD-'NX.,>M&G:'IFDW5[<V%E%;S7TOG7+H,&5^>3^9_,U@_\+1\#_\
M0S:?_P!]_P#UJ/\ A:/@?_H9M/\ ^^__ *U %ZU\#>%[+6O[8MM#LHK_ '%Q
M,L>"K'J0.@/N!5RV\-Z-::?>V$&G0+:7TCRW,)7<LKOPQ8'UP*Q?^%H^!_\
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M:D,N\;6YSZ<>W:B7P)X6FT2#1Y=$M'T^W=GAA92?+8G)*G.1DGL:I_\ "T?
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MFU.*(PI<D?.J'/'ZG\ZP?^%I>!O^AFT__OL_X4?\+1\#_P#0S:?_ -]__6H
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MG.,@<>U2?\(EX?\ [*N=+;2;9K&ZF:>:!TW*\C=6Y[\=:R_^%I>!O^AFT_\
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ME817,5LXDA#9!C8< @CD5B?\+1\#_P#0S:?_ -]__6H_X6CX'_Z&;3_^^_\
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MS;.%DC)&#U!!!'!!!%5M.\*V.FWL%Y'-=2W4?G%Y9I-S3-+LW,_'7]VH&,
M=*W** &NB2(R2*K(PPRL,@CT-9\6@Z?!J4E[%"$,EL+5H5 $>P,S?=QU)<YK
M2HH Y:'P+96D4"6&IZK9&*'[-O@N "T(9BD9RI&$W$*<;@.,UT-A8V^F:?;V
M-I'Y=M;QK'&F<X4# YJQ10!\C?&S_DK6L?[L'_HI*\_KT#XV?\E:UC_=@_\
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MUNX5+= &^7(_G0!R0N[%LJT,L;#JWEAL?A4%[#.5\T3K<0#HR<!?JO:NS%O
MUS/%Y.58YR@YX'2J-SI23J9;6-8Y@,#' QZ$=\T <715W4K/[).I0$12#<OM
MZBH[*SDO)2$0LB#+XXX]* $MA=KF6V\P;>ZU=CO;R:,M(5=@/D+(#5_^R+F9
M$:(I%&,"2-6Y3GKCO5:\F22^O5C7Y!&$..^!U_K0!3:[U.[4KOE95ZA1@"J!
MSDYZ]\UTIMI]26UDLB$)@^<9V@8X))]ZJ:EILGER3)#S%]]U.?,'<X^M &+1
M110 4444 %%%% !6UX._Y'GP_P#]A*W_ /1BUBUM>#O^1Y\/_P#82M__ $8M
M 'V_1110,**** "N.U;3]7NO'\<NFW8LD&E%'N)+3SD8^;G:.0 >_?Z5V-%
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M<B[A?;!,P$G_ $S?O^!KI9E*CS(G4IU!['VK6G%27YB;);BT=8P)+D2",C8
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MZR%[9=A/!SC\Z(I%BMF,> Q ^;/)/M536+YHH"B9)^Z!GJ>WXTYVYG81S5P
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MDW"6)ERO'-6;[6)8=/$+PQB)?FD"_>QTJMIMT;F%'"!$"X*YY4CMBB6,F&6
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MI,B9 ^H[&IHM<L$,[2.0LG&%!RWK]*YRSLI2S>69'=1EEB. /QJ^+*\:7RA
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M:E3V6[]=E\SSW1+.6\U@)"$+!2?F&1S77Z;!<V&J"1HEAE9"AYP,]B*Y_P
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M)R2<DTE%%2 4444 'XFBBB@ K:\'?\CSX?\ ^PE;_P#HQ:Q:VO!W_(\^'_\
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MOZ"NFL]*62*)[YGR1S%G"*OIBL_2XREI$D:[Y)7#%?4#D_I731ND\G$C"1B
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MDC[UP&4<CZTR[M-TR#<Q09SAN]2M+%_:,>)<X3#;>YIDLJ)(V6D<DX+1CO\
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M /1BT ?;]%%% PHHHH **** "BBB@ HHHH **** "BBB@#Y&^-G_ "5K6/\
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MDI!(ZG: S8(4@X5@3CH#FK0\2:4UY+:)<L\T8;(2)V#%1EE4@89@""5&3[4
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MH-*\::7J5M \CFWEEA,S(58K&GS$%GQA<A"><=* /#?^&<?$G_09TG_R)_\
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MX=CFTJ[M+YMQO+LW4WEGC(<,J\CH B@\<X-3W&BZ;J,L1(79;+- 8HB N)%
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M_=G;NY4GG /(YY.:=J%OXLE\.VWF3/YX2$E+-=LV[RSO$C>8 1NQRF,>A&:
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MQQ(UWYXS]Z12PE^SS!F5BQ^4N8\#@ ]!C- '12^ M(FO4NF:?S!(7?=M??\
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MB7!"F(,=JY!/<'GK26\.O'P6T4B727HFY"S_ +YX?,!;:S$[6*9 !8D<<]Z
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M>.?RB@@PGV=HQ\C1X'RD8S6[10!SZ^$K6*YDGAO;Z$S.S7 CD"B;,C28;C(
M9VZ8X)!R*BG\%:?-!#"+F[18H8(!AE(98E=5# J0W#G.1U (QBNEHH YRV\&
M6%G91V]M=7D30F%HI@Z[XS''Y:D97!RI(.0<Y-0CP'I9-J);B[F2WB:(*[KE
MP0P.Y@H;G><@$ G!Q74T4 <]%X0M$N/M$U[>W-QL:/S977<4*% O"@< D_4D
MG-;5E:QV%A;V<18QP1+$A8Y)"@ 9_*IZ* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0J"02 2.AQTHHH 6BBB@ HHHH *3:-NW QTQ110 M%
M%% "!0,X &3DX[TM%% !1110 4@ &< #/-%% "T444 %(0",$9%%% "D XR.
ME%%% !1110 4444 %%%% !1110 4444 ! .,CITHP,YQS110 4444 %(5!()
M )!R,]J** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>image_042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_042.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ) !6D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDZ5-Y-[>I'+C.P*6(^H .*TZ\Y\$V-IK.H:G=:G$EQ<A@=LH##YLY.#^'TH
M[NPU.RU2$S65PDR X.WJ#[@\BJ)\5Z&JSEK]5\APD@*,"#SP!CGH>E<QI,46
MF?$J>RL#MM60AT!R!\F['X-_A57PEIUIJ'BG4_M=NDZQEV59!E<[\9QWH [S
M3=8T_5XW>QN5F"'#  @CZ@\U/>WEOI]I)=74GEPQX+-@G'..@Y[UPWA&*.T\
M=:O:PKMA19 JYZ 2+@?K7>3017,+0SQ)+$WWD=0P/U!H XOP?XJ-]=3Q:G>%
MKJ>11!'L.W&#D# P/QK1\*309U!EU^;4E7:6\Y'00CYO[Q[^WI6-\.+6WEAO
M)Y((GFCD79(R LG!Z'M53P?8MJ6G>(K-)/+>98U#'H#E^OM0!US>,_#ZR;#J
M*YSC(C<C\\8K4DU&SBL?MSW,0M<;A+N^4BO/4L;C1-/-OJOA:&[@3+-<Q-\^
M,YR6&3CVXK9N[&W\4>#88M#18$BEW"%OEY .5/O\V: -:+QAH$TPB344#$X&
MY&4?F1BKFIZWIVCK$U]<>4)<[#L9LXQGH#ZBN&D>#38H4UWPE&D41"_:(. 3
M[XX;\34OQ F@N-,T::VQY#JYCP,?+A<4 =KJ>LV&CI&]_/Y*R$A3L9LD?0&I
M+O5+&PM%NKJY2*%L;6;OGT'4UQ_Q+8?8].&1DNY'Y"L_Q.TMQXCT>U:V-Q&(
M(MD!DV"4DG(SVS@#\* .XT[Q#I6K2F*RO$DD SL(*G\ 0,UIUYY<:)K$FN66
MH6/AY-/\EE+K'<QD-@^@(QQQ[UZ'0!Y_::W):>.]0%]J$J6,7F?))(Q1>1C"
MUV&FZYINKEUL;M96099=I4@>N" :X:QL;:_^)-[%=1++&KR/L89!(Z9'>K&G
MV\.G_%*6VMHQ'"5.$7@#,88\>F: .NU'Q!I6E2".]O$BD(SL +'\@#BI]/U2
MQU6$RV-RDRJ<-MX(^H/(KA?!]G:ZSKNJW.IQ)/<*P94E (Y)R<>V /QJ6P@B
MTOXFFTL/DMW0B2-3D#]WNQ^8% '3?\)?H/E-(=00*K;3E'!S[#&3^%2'Q/HJ
MV*WAU"+R&;:#@YSZ;<9_2N-\":58ZC=:F]Y;I/Y6U4#C(&[=DX]>!3? >D66
MH7>HO=VZ3+"%5$<9 W;LGZ_+0!Z!I^IV6JP&>QN%FC!P2,@@^X/(JE=^*M$L
M;AK>XU!%E4X955FP?<@&N(\+W,UE9^)!:@AHX=R$=5(W#(_//X5I^!]$TN_T
M.:>ZM8KB9Y61C(,E1@=/3Z]: .VM;NWO;=9[69)8FZ,AR*S?^$JT/[9]E_M&
M+S=VWH=N?][&/UKA=(N);&U\3VUE*S6T<;>6P_WMN1_P$G\JUO".AZ3?>%99
MKNWB=W9P\K<L@'H>V.M '6Z=K.GZL)C97'FB$@2?(R[<Y]0/0U3?Q=H,=P8&
MU*/>#@D*Q7_OH#'ZUP6@S2P>#_$+Q$A\1+D'G!)!_0FK&F:7/>^%_*@\-1W#
M3!BM[]J16W9(!P>0!Z9YQ0!Z)?:K9:=9K>74X2W8@!P"P.>G0&J,OB[089%1
M]10,P!&$8XR,\X''XUR6J6=_8?#M+748S'+'= (I<-\O)'()]33KS1M/C^&T
M=ZEL@N0J2>;CYB2X!Y],'I0!WMQ?6MK9F[GN(TM\ ^83P0>F/6LZU\5Z'>W*
MV\%^C2N<*&1ER?3) %<N]_ID'@;2!J=I)=E]WE0K(R E21DD'L#[]:SO%TNI
M2RZ9)?:?!9+\RPI&V6P-O!(],C ^M &WXN\3RV6KVUA:W1B1&4W6U3N ."!G
M'3![5TW]NZ9_9::D;M%M')"R,"-Q!(P 1GJ#VKCO'-O"/$>E-Y,>9F'F':/G
M^8#GUXXYJ/QG"J>(=)T^&T5K54!2V1A$K,SG('89P.?>@#LM.\1:3JLQALKU
M))<9V%2I/T! S2ZCXBTG2IA#>WJ1RXSL"EB![@ XKC;W0]7FU.SO;#PXFG/
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M>L:1<%+JYD:0NDI.\'G./3/'I79V6F1?VC_;3F1;NXMUCDCR-B]#P,9SQZT
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MKX;GT::Z,T<I;$BIL*YQVR>_-;]% ')6/@N6SLKRT.KR20SPM$B&,[8R2#N
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MP\WP\:XA19M:FDE3 5Y(RP5?[H&[C\ZVM:\+6VM6MNCRM%<6ZA4F0<X]Q_\
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M$H=(OGOIKN6\O&! D<8QGJ>IY_&NCHHH **** "BBB@ HHHH **** "BBB@
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MC1_^?F^_[[3_ .)KJK2V2SLH+6,L4AC6-2W4@# S^5/FFBMXFEFD2.->6=V
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MS!I$WAU4%0,D<\Y[>E5=/\<:1J-\EHAGB=SM1I4 5CZ9!/ZUSWBXQCQ7HO\
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M-UG0II)=*NH]2LXM3M[=(MDS#;(1GD9Z\D]JBAU^]TWQ!;VNN:;9&XF*J+F
M#>,G )Z_EQ0!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_AGP?I[6FG:L9KK[1A9MNY=N0<]-N<?C76:G=RV.G37,%J]U*@&V%,Y;D#C
M/UZ53\+_ /(L:=_UQ%:] 'FO@+4[J&ZEMUL9KB.XE!EN021'P>O!Z^Y%:=M\
M0)KT;+70IYYL\QQ2%L+Z\+57X<WEM!'=V\L\:32R)Y<;-AFX/0=Z?\,U'EZD
MV!NS&,_]]4 ;EYXGDBU--,LM->\OM@>6,3!!'QG!8C'>GZ%XG36+VXL9;1[2
M[@!+QLVX8!P><#H2*QYM8U/6/%=UH]O?KIUO"&^8("[[<9P3W[\8X%9WA%,^
M,=6CBNC,3!*J3LV2YWK\V?UH VKSQRJWTUMINF3ZAY.=[QL0..I& >/>M#2O
M%EAJ>EW%ZP:#[,,S(YSM';'KFN8\":C9Z3_:-MJ$Z6TV\'$IVYQD$?4>E6]5
MU/3]9\*:I%HT#1>24>51 %#+NSG(X[9]>* )#\0N#.-&N38A]OVC?Q_+&?;-
M:^K^*8=.T*VU:WA^U17$@11OV8R"?0]-N,5R&GRI/X76WG\50VML5*/:-:*S
M+D_7<?7(J37K.&Q\ 64-O?+>0_;=R2JNT8*OQC)[YH Z"S\9-<K-<RZ5<0:=
M%&7^U,20V.  , $DG'6J?_"?SF(7 T"Y-H6P)MYP?_'<9_&MGRK!O!<$6H.(
M;-K2,.V<8X&,>^<5R(N9M%T\S:/XJMY[:/.VVF&'Z] IR?Y4 >AV-XE_8PW4
M:2(LJY"R+AA]15BLGPWJLNM:+%>3Q".1B5(7H<'J*UJ "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M K,T_1;FT\4ZCJ<CQ&"Y4*BJ3N&,=>,=O6@# \3:=H^C:;=Q;7NM3U!]T9E
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M%CM=01XW22.:0*I>9 V$W; ,,1@# [8KVRO/_C;_ ,DAUW_MW_\ 2B.@#H/
MG_)//#7_ &"K7_T4M=!7/^!/^2>>&O\ L%6O_HI:Z"@ HHHH **** "BBB@
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M/_M=1_\ #1?_ %*O_E0_^U5YIIO@;6-1;.R.W4\[I6Q6I'\,[Z1\+?6S!>N
MU<53 Y/3=I)?>_\ ,YY9C3B[.:.Y/[1( _Y%;/\ W$/_ +72?\-$G_H5?_*A
M_P#:JX>3X;7JA2E[ V]L$ $;1ZU.?A?= [4U&%L#.-A%0\+DJW_-_P"9']JT
M?Y_Z^X[+_AHD?]"L?_!A_P#:Z/\ AHD#&?"__E0_^U5Y=J_@O6M*3S'M6FA
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M_P"5#_[51_PT7_U*O_E0_P#M5>&\8R:0C'-']AX#^3\7_F'M9=SW/_AHL_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCD9(KMAL>IA96=NYE$8'!K[)\$_\B%X=_P"P9;?^BEKXUZU]E>"O^1#\._\
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MKTH SKG2O"FI:0\=DUFLJ1GRWB<"0$#(SW/XU<\#7T]]X;0SN7:&1H@Q/)
M(S^>/PKGM-TW1M7U&33-0TB33-05=X$4APPZ]#D#BNST/18="LGM()9)(VD,
M@,F,C( QQ]* -*BBB@#PW]HHX_X1O_MZ_P#:5>%]#C'->Y_M%XQX;)_Z>O\
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MOR@[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7]XFGZ?<7D@)2%"Y
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M /I1'7H%>?\ QM_Y)#KO_;O_ .E$= '0>!/^2>>&O^P5:_\ HI:Z"N?\"?\
M)//#7_8*M?\ T4M=!0 4444 %%%% !1110 457O;ZVTZW,]W,(HP0,G)R3V
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MK3BXMNR2U\@HHHK0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8,J#&1CH:K69%TWF(<!QU]ZLW,@M(B\TNUL\ M_2L)N[L>=-MOE-*)<J'C<
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M%% !1110 4444 %%%% !1110 4444 %%%% '*^*[BRM[FW:ZT>>^9HG4/$[
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M;5_'.2/? -;M%%=M&C"E'EBO7S?=]3DJU9597E\O)=D%%%%:F04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S&O\
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M#?A7:DHI)'IQBHJR&8SG)Q2CD4'.,4I/O2L4-(&:4'CG-!(VY %)CCK@^E#
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M4R9!')QT%<[\6?AIX/T7P#K6NZ;HL=KJ"/&Z21S2!5+S(&PF[8!AB, 8';%
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MZY2U\Y!E Y4E?KCFNG(L+0JX-2J03=WND^Q-634M&=P?C!X]SC^WA_X"0?\
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MG.[)R>1766\Z7-M%/'G9*@=<]<$9% $E%%% !1110 5Y_P#&W_DD.N_]N_\
MZ41UZ!7G_P ;?^20Z[_V[_\ I1'0!T'@3_DGGAK_ +!5K_Z*6N@KG_ G_)//
M#7_8*M?_ $4M=!0 5%<W,-I;O<7$@CB099CVJ6L74/\ B9ZO!IB\V\&+B[]#
M_<0]1R>2".@!%8UZCA#W=WHO5_U=^2-:--3EKLM7Z?UHO-CM"@DF#ZO=$FXO
M "BM@^5%DE5!'L03T[<9K8HHJJ--4X**_P"'?5_,56HZDW+^DNB"BBBM#,**
M** "BBB@ HHHH **** "BBB@ HHHH **9++'!$\LKJD: LS,<  =S698^)M'
MU*[6UM;U7F8$HI1EW@?W20 WX4FTBXTYR3E%72-:BJL6IZ?/<_9H;ZVDN,9\
MI)E+8]< YJE!XCL+S6(-/M)4G,D4CET/"[2H Z<@[CS_ +-',AJE-WT>FIKT
M444S,***9)+'"F^6147U8X% #Z*CDGBAA::65$B49+LP"@>N:AMM2L;V*26T
MO;>XCC^^T,JN%^N#Q1<?+)J]BU167%XCT:=I5CU*W8Q1>=(=_"IQR3T[C\Z;
M9^)M'O[CR+:]5Y2A<)L8%E'4C(Y_"ES+N:>QJZOE>GDS6HKBD\5'4-!UBXEE
MNK(6UR0EQ';'Y8PZ@#G@L1U&<C-;U_XA@LM0^P16EW>W03S'BM8PQ1>Q8D@#
M-)33+EA:L7RVU_X9[[=37HKGIO&%C'I5O?Q0W$JRW7V0PA,2))@G:5/?C'XB
MI]-UZ2ZU5M,O=.FL;KR?/17=7#IG!P5[@GI1SH3P]51<FMOTW^XVJYB]^;XC
MZ6/[MC*?UQ73US%SS\2K(>FFR'_Q^E/IZE8;>7^&7Y'3T4459S!1110 5S-]
MXXTNSOYK.*"]OI8,^=]CAWB/'7)R.E=-7F?@/4[+P\VL6.LW"6EXLV]C-\I<
M =O7UQ[\5G.332.W"T8SA.;3DXVT7F_F]#N+'Q%I>H:.^JPW2BTC!,C-P8\=
M01Z_Y%8T?Q#T=FC:2WU"&UE?8EW+!B%C_O9_I7$6&GWMYX-\47=I%(+:XN$D
MB4#&]$<EL#V!'Y>U=-:>*O#,/@K2XKV.*\*1QQ-9K&LC[U&"=C>^>?>H51OR
M.R>!I0;Y8N?O6LGJM+_?TULM#I-:\4Z?HDL$$PGN+F<9BM[:/>[#UQ46G>+]
M-U*VO9(UN(I;)&DGMIH]LJ@#)XSCMZURMS/%I/Q0LM0OT^QV4]H!"90%$7R8
MVG'"X/!],^E;#ZMHNLW.M6NDV(FO19R"2^BA3:^5P%W@[CS@=.WM34VV]3*6
M%IQA'W6[I/FOHM;-=M/6]S7T_P 3V6I>'KC6X8KA;:!9&9750Y"#)P <?K5*
M7QWI<7AR#7&@O#;33F!4"+O#8)R1NQCY3WKC_#VN:;9_#/4[*:ZC6[=9HU@S
M\[%UP,#N.>M9M[_R2+3O^PD?_09*EU7;3L=$<NI^T<9)VYTEZ6;_ *9Z OC_
M $?[7#%+%>PPSG$-U+ 5BD[9!SG'OBKNL>*;'1[V*Q:&[N[R1=XM[2+S' ]2
M,CWKBO&>LZ9JWA#2[#3YDGNWDCVP(,NF%((([') I+J^F/C!M.N;^WT06]JB
MO>>4OFS$(N1YAYY[<_P]S0ZC6E^Q,<#3DE)Q:^*Z;?2R3VOUZ+TT.TT[Q?IF
MIZ3?:A;B<+8HSSPN@$B@ GIG'.#W[5F_\+'TAK%;R.TU*6'_ ):LD (A.2 '
M.[ )QGJ>"*Y+P@Z-HGC?9*T@:U8J[GYG&V7D_F/SK3T-5'P=OR!RR3$^YS_]
M:A5)-+T8YX*A3E)--^]%;V^)7['93^)]*M] CUJ2X_T.0#80IW,>?E ]>#^1
MJE8>-].OK^*R>VOK2>89A6[A$?F^FTY[]J\_O89?^%<>&KS87MK>XE,P SC,
MC8S^1'XUW5YXG\-7>J:; D$>JW<K#R&AB20PG(Y)8C;Z^HQS351OK;8SG@J<
M$[1<M9+1[<NU^GF[M>1IZ#XDLO$,%Q+;)-$;=]DJ3J%93CKP2,=?R-&@>)+3
MQ'%<2V45PL4$GEEY5 #'KQ@GVZXZBO/?%%Q/X1\1ZP+92(=7MB4(_A<G#'\/
MG_[Z%=[X/TK^QO"]E;,N)63S9?\ >;D_EP/PJH3DY<KZ;F6)PU*G1]K':5N7
M7RUOZ/0W:***U/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q
M/$VOOX?L8ITM?/,C[.6VA>,Y/!K;J&[:V2UD:[,8MPO[SS<;<>^: . O/%6O
MP645U';:?;PW,F%>(B0LV.^&(STZC-=KH\6IPV975KB*>X+DAHA@!<# Z#WK
ME=3\'Z;?68U'1KQ+>-R&"NW[ECG QGD<\?C74:)<:E<6+?VK;K!=(Y0A>C
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M3[JVGMI7@.%'WPP'#CL1[4U)7L3?6S((3B(L6(P.F =WM4ZQO)^\W!<':>,
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M50-I'7)ZT$@J !EMV<4#'(Y)C9AM"@@D"KMN[KN>.W+*, L1D#UJ"154;<=
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M>X%:PA&"]U%QC&"]U#K6*=[@[B N[R@WF @'O]/K[5VD$,<MMYD7F.Q',C9
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MJ-O#-O(_A&1U-1G C.Y@PS]U?\:^GIT8TU:)[T*<(:11]P4445^5'J!1110
M4444 %%%% !1110 4444 %%%% !1110!2UB:XM]&O)K49GCA9D]B!UKDH=5T
M]O!C6LWB!C=2)YA<D^8K$[BOKUR*[2[NHK*SFNICB.)"[?0"N#L[BUO;Z[G?
MPS;(\=K]KBC_ (I!D8R.G(.>E '7>&[BXNO#MC-=EC,\>69NK#/!/U&#47B.
MWM=2TN:PDO8;>8X="[@8(.1D>E7M+OHM2TRWO(%VQRID+_=[$?@:QO$FBZ)(
MDVK:HDI\M "4<C/8 #UR: ,*]T[4";N"UU73#;:AM>YWRK\LF!N(]B>:[JSB
M$%C;Q+)YJI&JA_[P QG\:\XM[3P])97EU/I%]"EJ\:R+YQ+ -GDC QC^M>D6
M:PI90);G,"QJ(SGJN./TH FHHHH Q+GP=X7O;F2YNO#>CSW$K%I)9;&)F<GJ
M22N2:T4TRPBOY+^.QMDO9%"O<+$HD8#L6QDBK5% %5-,L(K^2_CL;9+V10KW
M"Q*)& [%L9(KB?C;_P DAUW_ +=__2B.O0*\_P#C;_R2'7?^W?\ ]*(Z .@\
M"?\ )//#7_8*M?\ T4M3>)?W]C#IR_ZR]G2,8Y*J#N9L=P,<_6H? G_)//#7
M_8*M?_12U-/_ *1XPM(GX6VM'G3'4LS;#GVQ7-B]:7)_,TOO>OX)G1A=*G/_
M "IO[MOQL;5%%%=)SA1110 445R6H?$'2X;B2STF"ZUN\6-G,>G1^8J\#&YA
MQ@E@,KNQWYXJ93C#XF1.I&"O)V.MJO>ZA9:=")KZ[M[6)FVAYY BD]<9)Z\'
M\JY(Z?XU\0E1J-[;Z#8EB6AL6+W)&\84R= < _,I[\J<X%NQ^'7ANSF6XFLW
MO[K<S//>R&5I"V<EE/RD\_W??KS4<\Y?#'[]/PW,_:5)?!'[]/PW_(K3?$K1
MY<Q:+;7^LW7EL_E6EL_RXQC=N (!) R <?EDDO/'^I><MKI6EZ.GE[0UW<>>
MY8Y^92F1QQPR_GT'8111P0I##&D<4:A41!A5 X  '04^CV<W\4ONT_S8>SG+
MXY_=I_FSCSX1UR]F4ZIXTU*2)%.U;&);1LG')*YW#CH1WZCG)'\,?"^TFZM;
MB]N&9FDN+BYD\R0DDDMM(&>?2NPHH]C3ZJ_KK^8_J]+JK^NOYE&RT72M.F,U
MCIEE:RLNTO! J,1UQD#IP/RJ]116B26QJDEH@HHHIC"BBB@ HHHH **** "L
MGQ'XCL?"^E_;[_S3&9!&B1+N9V.3@9('0$\D=/7 K6K.UO1+'Q#I<FGZA%OA
M?D,.&C;LRGL1_B#D$BIGS<KY=R*G-RODWZ$7ASQ'8^*-+^WV'FB,2&-TE7:R
M,,'!P2.A!X)Z^N16M63X<\.6/A?2_L%AYIC,AD=Y6W,[' R< #H . .GKDUK
M40YN5<^X4^?D7/OU"BBBJ+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX _ST!K-\+^()HM1ALYV'D3$J3CYFD8Y#L<$DGA?ICTKS,7BZ5/$TJ<WUO\
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M6=I+93'SI_E22),H3C( Z\>I[UT>IZYI?AVW%Q<72K(L?R0J?GD/!QM'W?R
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MU7P_INL@&\M@T@&!*IVN/Q'7\:L:7I\>EZ9;V4;%EA7;N/<]2?SJW0!RG_"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$,OOD5[1Z9+&BLY0L6&TD#U-1E N K!SWQ2%F7Y0>@YQVHW$ >W'I0 A.<'
MSG\*,!OXN.PQ3@B[0=V"?3M1NR2&'WNXXH <QP N01[=J1&+2(&&>P'2F<!>
M#R>HH]#DY- %B")I#DJ62/G'3)JPK#(QDEE&!G)ZU")8TM?*PRR!MPD!Z5'
M4:Y7>_RAOK5;$/7<NO:2*=S'@KC)&WD'GKBK5G92;5#["C*,[>2N3Q^-+',K
MM&SI&5!^8.2<X_PYHCGD8+M*N [;4 )V^G!J6V]#"4I-6)@%,HC4_+DY56&.
M.GXU9B9GDE:21&56R1DL,YZ_I52>=S!*W[M5?DC !/KG'M_2LA[MED(A<HK
M#.>,UFH\RU(5)R1TF5AB:5%/EY9#M(QQR3S^%8.IW4-Q+&L+2"- <@@'YO48
M[52,LL[,LDK,3R,MG)[4T<_+D8)[]*<:=G=F].BH.[!G5EVD!>>W3ZU( !U
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M6+,+B9I)YMTS$Y>1GW$D\]3WH"EL[B.S$;N#_GVIPD,.&D^8D9"D'G(J$/\
M+MPPXSQU^N:]E)+1;'=J/8LP8$8!Y4=B!ZBDB.YE5U;:1@G&XC/3&:<B,RAE
M  ;C.W_/>FG*!2R 1D\>C8I -&"0$#;@2<8SQ1Y;ADW(0K\KP<5/-&S3%4$8
M*?+F-LYY/(YY_"HRJ^4) ZY)PJEN>U-,=QF[&,;3MXR>>*<CJ%W;AN!Z=,FF
M%<N<!BN>.G7K3-KL,;>@SD>E%PL2^5Y;$297'48[>M-WIO8;N#U8CK^%!F8;
MFSS^=-4;XCD-N!R,>E T2*1MV%<DC:I'&?<UI:4C>>[ A3@X)7)'N/6LU95
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M\,P W/8<T^1HVP8TVC/->W_\*S^%9/\ R.QS_P!A6U_^(IZ_#CX61E2/&P&
M0,ZI:G^:4?VSA_Y9_P#@$O\ (/9O^F>%LF3A&W =ZD4F,1L "021ZBO;A\-?
MA7T'C8_^#6U_^(I1\-OA6H.?&N<^NJVO_P 33_MC#_RS_P# )![-GC"W!0J%
M+;@=ZD=<_C3CJ&6#(/G))W#Y3GUR.E>S#X<?"W(_XK?<0,#.JVIP/3[M,_X5
MG\*NA\:]/^HK:_\ Q-']LX?^67_@$B/8'B]Q=R3MMR0O\2=L^M1'$@(;A^QZ
MD\5[=_PK'X5@C_BM3D_]16UY_P#':#\,_A9P#XV/'3_B:VO_ ,10LYP_\L__
M  "12I-;'B,05R7X!4#''I[4,Q8E_O\ &3QC%>X)\-_A8!M'C;([C^U;7_XF
MD;X;?"MCSXTY'_45M?\ XFC^V</_ "S_ / )![*1X?D%6!(7/MUHV@#YB0I^
MZ?4U[?\ \*U^%6W_ )';Y<_]!6UQG_OBD/PT^%6?^1VQ[?VK:_\ Q-']LX?^
M6?\ X!(/9,\/#<* ,!<\T H 3R#Z9ZU[A_PK7X4X _X3;_RJVO\ \32K\-?A
M2IS_ ,)H&[<ZK;?_ !-']LX?^67_ (!(?LV>(F4NP4X5 >@[?XTS!$A&#D'&
M,5[C_P *U^%04K_PFO7O_:MK_P#$T?\ "MOA6?\ F=NV.-5M?_B*/[9P_P#+
M/_P"0O9,\2+,RE@ORYYP, =^/RK["\%\^!?#W_8,MO\ T4M>5CX:?"S@#QJ>
MN0/[5M?_ (FO8M&M;6RT+3[2QF\ZS@MHXX)=P;?&J@*V1P<@ Y'%>'GN.I8F
MG",$U9O=-=/,UI0<6[GG'Q^4MX$L0,X_M./.!GCRY:^=@1C@,1C/WOP_"OK_
M ,7^$-/\::3%INI2W,4,4XG5K=E5MP5E_B4C&&/:N+'P#\+ 8&H:QTQ_KHO_
M (W6F49OA<+AE3JMWN^E]Q5*<I2NCYQ8MA2"Q &<L.O^<4T@CGJ,#.#7T>WP
M"\*LH']H:SP,?Z^+G_R'2#X >%5SC4-9_P"_T7_QNO3_ -8<%W?W?\$GV,CY
MT$F%X)SG)!/!_*E:-6 *,#],_**^C/\ A0GA7.1?:P. ,>=%_P#&Z%^ GA9=
MV+_6?FZ_OHO_ (W1_K#@>[^[_@B]C,^=E9X&<DYXVDDGIZ4W>PCV@LRJ0WRG
M'Y^]?1H^ WA7YMU[JS9 ',L7'T_=TC? ;PLS;A?ZPG&,+-%_\;I_ZPX'N_\
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M&H@\BU6\7RH0>$.P;AQP#GJ!TH ["BBB@ HHHH **** "BBB@ HHHH ****
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M^,D5!%$DKEIRS CCCJ:I;&BG<S1M/<Y]:68 2#!SP.:F>!-AD!;// '0U6;
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M !1110 4444 %%%% !1110 4444 %%%% !7)?$FZN;/P5=3VN<AXPY"J0%+
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M]_E_^2*]@HH \?\ ^$A^.?\ T)FA_P#?Y?\ Y(H_X2'XY_\ 0F:'_P!_E_\
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M !IPP O(YZ \_C0,T(95-NH)*Y(^51PW^%)M1)&?#2(#D Y'YTEI.L2JSLP
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ML=3B6*_LK>ZC5@ZI/$L@##H0".M '+_"C[9_PJWP]]N_UWV7Y?\ KGN/E_\
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MBO/M*\+?\)1IW]KZI?W#7-QN\O81A "1R".F>PQ6Z+NY\)^%O-U2X^VSH^U
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M-O@+XJPH6_T8$=3YTN3_ .0Z:/@'XIVX-_HQ_P"VLO\ \;K6.:X!*RJK\?\
M(Z%2DE9(\M78L;!B1(/R/XTBR*@W9RW3'?%>I#X!>*,;3>Z+CU\Z7_XW3O\
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M...::WW <AE!VBO4_P#A0'BL* -0T;W_ 'TN/_1=*OP!\5@C-_HS =C-+_\
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M-G!9BHX'_P"JO6/^%"^)]FW[;H^>>3/*?I_RSIB_ /Q4OS?VAHQ8#'^ME_\
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MDK*<7]P$8%#SROWC_D5KKI%VGCB._6!19+:^5O4J #CH%SFNEHH Y"TT"_\
M+\41RPB/[?([6Y+@AN7(Z'CJ.M4IM'UNZ\*6.FMIGES6ERC?Z]#O3#9;KQ@D
M<5WE% '->*])O+^XTVZM;:.\6UD)DM9&"B0''KQV[^O2J6EZ-JIU?5KB\LX[
M>.]M2B!)%94)  4XYX'?&.*[*B@#@!HFMMX,ET9]-VRQRJT;"=") 6)/?C''
MUK4O='U*UU/3M8T^W2XFAMU@GMFD"%N.H8\=_P!!UKJZ* .2M]$U*>/7=1O(
MD2]U"W>**V1P=@VD %NA/"\_Y%6_T#4Y_ =AIL=MNNXI SQ^8HP/F[YQW'>N
MWHH *X+0X';P?J^CKM^V+/)"L;,%+,0,=?H?RKO:HOHVGO+=2-; M=;?.^8X
M8KT.,X!'J.:&.-KZ['):AIUQ=>#-'T^#R7NH[D*R"=.JA]P!S@D>@YX/I4UW
MIAOO%5[<[H&M+NV>UBD\Y#OE"X*@9SD8/TQ73-HFF-O_ -!A&]!&=JXP!C&,
M=.B\CGY5]!@;1-,;?_H,(WH(SM7& ,8QCIT7D<_*OH,3[QM:AW?X?YG +X?O
M&\)&W'DO?3WX"I]IC.0BL, [L$CYN,Y&/:NBUUA?^+] MH2'\EGG9@<@ $?U
M0UNMHFF-O_T&$;T$9VKC &,8QTZ+R.?E7T&'P:58VUX;N"W6.8Q"'*DX"#&%
M Z <#H*:OU(G[.WN7^=OT+E%%%,S"BBB@ HHHH **** "BBB@ HHHH ****
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M1!.OE[OD;#$#D8/49.>O2MV"%+>WC@C&$C4(H] !@4 24444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&6[ABCOK2+S?+4';@IO7/.?4'Z&@#H**QT\1V"1JMQ,5G6)))E2%V$8*@Y)
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MPB19+E2WF,6VA%&Y>?Q[CB@#8HKF]1US5-,CL_/L8GD>9UE$9)WQJNXNG/'
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M-7\L!C(0P9B"#QR"/SK:-G(WAB*TFM!/(MNBO;M+LW$ 9&X=#QP?7N.M:M%
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M0F[\2#5?2- MD@G;4--M7G:YE<-)&CL5+$KSSVK<BBCAB6*)%CC4855& !Z
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M-]-:);..1))#*A!)B*#;@YP3CJ!UKJ:* .1BTN_MM/MECL;N&^CMHU$]K=(
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061634232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AC Immune SA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">71,936,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061311880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">SFr 4,416<span></span>
</td>
<td class="nump">SFr 3,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Long-term financial assets</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">6,973<span></span>
</td>
<td class="nump">6,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaid expenses</a></td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">2,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Accrued income</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes', window );">Other current receivables</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Short-term financial assets</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">160,893<span></span>
</td>
<td class="nump">193,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">231,767<span></span>
</td>
<td class="nump">292,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">238,740<span></span>
</td>
<td class="nump">299,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">346,890<span></span>
</td>
<td class="nump">346,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(132,850)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders' equity</a></td>
<td class="nump">215,478<span></span>
</td>
<td class="nump">272,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Long-term lease liabilities</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Net employee defined benefit liabilities</a></td>
<td class="nump">7,464<span></span>
</td>
<td class="nump">7,485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">9,244<span></span>
</td>
<td class="nump">9,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">11,085<span></span>
</td>
<td class="nump">11,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">4,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Short-term financing obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Short-term lease liabilities</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">14,018<span></span>
</td>
<td class="nump">17,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,262<span></span>
</td>
<td class="nump">26,808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total shareholders' equity and liabilities</a></td>
<td class="nump">SFr 238,740<span></span>
</td>
<td class="nump">SFr 299,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables and receivables from value added taxes and withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061241944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Income/(Loss) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Contract revenue</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">15,431<span></span>
</td>
<td class="nump">110,456<span></span>
</td>
<td class="nump">6,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ExpensesOperatingAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research &amp; development expenses</a></td>
<td class="num">(59,487)<span></span>
</td>
<td class="num">(50,432)<span></span>
</td>
<td class="num">(44,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General &amp; administrative expenses</a></td>
<td class="num">(18,557)<span></span>
</td>
<td class="num">(16,058)<span></span>
</td>
<td class="num">(12,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expense)</a></td>
<td class="nump">1,353<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(76,691)<span></span>
</td>
<td class="num">(65,920)<span></span>
</td>
<td class="num">(56,462)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income/(loss)</a></td>
<td class="num">(61,260)<span></span>
</td>
<td class="nump">44,536<span></span>
</td>
<td class="num">(49,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expense</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(1,926)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument', window );">Change in fair value of conversion feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Exchange differences</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance result, net</a></td>
<td class="num">(661)<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income/(loss) before tax</a></td>
<td class="num">(61,921)<span></span>
</td>
<td class="nump">45,442<span></span>
</td>
<td class="num">(50,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income/(loss) for the period</a></td>
<td class="num">SFr (61,921)<span></span>
</td>
<td class="nump">SFr 45,442<span></span>
</td>
<td class="num">SFr (50,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings/(loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic income/(loss) for the period attributable to equity holders (in CHF per share)</a></td>
<td class="num">SFr (0.86)<span></span>
</td>
<td class="nump">SFr 0.64<span></span>
</td>
<td class="num">SFr (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted income/(loss) for the period attributable to equity holders (in CHF per share)</a></td>
<td class="num">SFr (0.86)<span></span>
</td>
<td class="nump">SFr 0.64<span></span>
</td>
<td class="num">SFr (0.82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ExpensesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ExpensesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the change in fair value of a convertible instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935059896200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Income/(Loss) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statements of Comprehensive Income/(Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income/(loss) for the period</a></td>
<td class="num">SFr (61,921)<span></span>
</td>
<td class="nump">SFr 45,442<span></span>
</td>
<td class="num">SFr (50,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income/(loss) not to be reclassified to income or loss in subsequent periods (net of tax)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement income/(losses) on defined benefit plans (net of tax)</a></td>
<td class="nump">726<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss), net of tax</a></td>
<td class="num">SFr (61,195)<span></span>
</td>
<td class="nump">SFr 44,138<span></span>
</td>
<td class="num">SFr (51,253)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061052072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Equity - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Capital [Member]</div></th>
<th class="th"><div>Share Premium [Member]</div></th>
<th class="th"><div>Treasury Shares [Member]</div></th>
<th class="th"><div>Accumulated Losses [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning of period at Dec. 31, 2017</a></td>
<td class="nump">SFr 116,839<span></span>
</td>
<td class="nump">SFr 1,147<span></span>
</td>
<td class="nump">SFr 188,299<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="num">SFr (72,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income/(loss) for the period</a></td>
<td class="num">(50,951)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(302)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss), net of tax</a></td>
<td class="num">(51,253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees', window );">Proceeds from public offerings, net of underwriting fees</a></td>
<td class="nump">111,529<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">111,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction offering costs</a></td>
<td class="num">(2,015)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,015)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issuance of shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IssueOfEquityRestrictedShareAwards', window );">Restricted share awards</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period at Dec. 31, 2018</a></td>
<td class="nump">177,623<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">298,149<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(121,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income/(loss) for the period</a></td>
<td class="nump">45,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss), net of tax</a></td>
<td class="nump">44,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees', window );">Proceeds from public offerings, net of underwriting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issuance of shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion note agreement, net of transaction costs</a></td>
<td class="nump">47,778<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">47,705<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IssueOfEquityRestrictedShareAwards', window );">Restricted share awards</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period at Dec. 31, 2019</a></td>
<td class="nump">272,442<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">346,526<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income/(loss) for the period</a></td>
<td class="num">(61,921)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss), net of tax</a></td>
<td class="num">(61,195)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees', window );">Proceeds from public offerings, net of underwriting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issuance of shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Held as treasury shares, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IssueOfEquityRestrictedShareAwards', window );">Restricted share awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period at Dec. 31, 2020</a></td>
<td class="nump">SFr 215,478<span></span>
</td>
<td class="nump">SFr 1,538<span></span>
</td>
<td class="nump">SFr 346,890<span></span>
</td>
<td class="num">SFr (100)<span></span>
</td>
<td class="num">SFr (132,850)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IssueOfEquityRestrictedShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of restricted share awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IssueOfEquityRestrictedShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing ordinary shares net of underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935058545512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows<br> SFr in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income/(loss) for the period</a></td>
<td class="num">SFr (61,921)<span></span>
</td>
<td class="nump">SFr 45,442<span></span>
</td>
<td class="num">SFr (50,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile net income/(loss) for the period to net cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance result, net</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Changes in net employee defined benefit liability</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Change in fair value of conversion feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,542)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestExpense', window );">Interest expense</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">(Gain)/loss on sale of fixed assets</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense', window );">(Increase) in prepaid expenses</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome', window );">(Increase)/decrease in accrued income</a></td>
<td class="num">(507)<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">(Increase)/decrease in other current receivables</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses', window );">(Decrease)/increase in accrued expenses</a></td>
<td class="num">(757)<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">(Decrease)/increase in deferred income</a></td>
<td class="num">(4,157)<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities', window );">Decrease in financing obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase/(decrease) in trade and other payables</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="num">(1,845)<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash (used in)/provided by operating activities</a></td>
<td class="num">(59,247)<span></span>
</td>
<td class="nump">55,227<span></span>
</td>
<td class="num">(43,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Interest income</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Finance costs</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows (used in)/provided by operating activities</a></td>
<td class="num">(59,517)<span></span>
</td>
<td class="nump">55,220<span></span>
</td>
<td class="num">(44,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Short-term financial assets</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(1,706)<span></span>
</td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(1,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CashAdvancesForRentDeposit', window );">Rental deposits</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows provided by/(used in) investing activities</a></td>
<td class="nump">28,329<span></span>
</td>
<td class="num">(66,885)<span></span>
</td>
<td class="num">(32,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Repayment of short-term financing obligation</a></td>
<td class="num">(514)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal payments of lease obligations</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from issuance of common shares - option plan</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares', window );">Proceeds from issuance of treasury shares, net of transaction costs</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Payment for the issuance of treasury shares</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssueOfConvertibleDebt', window );">Proceeds from issuance of convertible loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Transaction costs on issuance of shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(510)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees', window );">Proceeds from public offerings of common shares, net of underwriting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PaymentsForShareIssueCostsOnPublicOffering', window );">Transaction costs on public offerings of common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from long-term financing obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows (used in)/provided by financing activities</a></td>
<td class="num">(803)<span></span>
</td>
<td class="nump">49,616<span></span>
</td>
<td class="nump">109,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="num">(31,991)<span></span>
</td>
<td class="nump">37,951<span></span>
</td>
<td class="nump">33,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">193,587<span></span>
</td>
<td class="nump">156,462<span></span>
</td>
<td class="nump">124,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange gains on cash and cash equivalents</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(826)<span></span>
</td>
<td class="num">(1,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">160,893<span></span>
</td>
<td class="nump">193,587<span></span>
</td>
<td class="nump">156,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="num">SFr (31,991)<span></span>
</td>
<td class="nump">SFr 37,951<span></span>
</td>
<td class="nump">SFr 33,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in accrued income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AdjustmentsForDecreaseIncreaseInAccruedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AdjustmentsForDecreaseIncreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense for right-of-use assets to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AdjustmentsForDepreciationExpenseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AdjustmentsForIncreaseDecreaseInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in long-term financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CashAdvancesForRentDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for deposit of rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CashAdvancesForRentDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PaymentsForShareIssueCostsOnPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs for public offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PaymentsForShareIssueCostsOnPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssueOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssueOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing ordinary shares net of underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssuingSharesNetOfUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935066791848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SupplementaryNonCashActivityAbstract', window );"><strong>Supplementary non-cash activity includes the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="nump">SFr 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember', window );">Convertible Note Agreement with Lilly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SupplementaryNonCashActivityAbstract', window );"><strong>Supplementary non-cash activity includes the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RepaymentOfConvertibleDebtEquitySettlementAmount', window );">Settlement of convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 48,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of property plant and equipment acquired through noncash investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PurchaseOfPropertyPlantAndEquipmentClassifiedAsNoncashInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_RepaymentOfConvertibleDebtEquitySettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of the settlement of convertible debt that is settled via shares of entity's common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_RepaymentOfConvertibleDebtEquitySettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_SupplementaryNonCashActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_SupplementaryNonCashActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935066664728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GeneralInformationAbstract', window );"><strong>General information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock', window );">General information</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">1.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">General information</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">AC Immune SA (the &#8220;Company,&#8221; &#8220;AC Immune,&#8221; &#8220;ACIU,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; or &#8220;us&#8221;) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#8217;s disease, or AD, and Parkinson&#8217;s disease, or PD, with common mechanisms and drug targets, such as Abeta, Tau, alpha-synuclein and TDP-43. Our corporate strategy is founded upon a three-pillar approach that targets (i) AD, (ii) focused non-Alzheimer&#8217;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop novel medicines and diagnostics to target misfolded proteins.</div><div><br /></div><div style="text-indent: 18pt;">The Company was initially incorporated as a limited liability company on February 13, 2003 in Basel, and effective August 25, 2003 was transitioned into a stock company. The Company&#8217;s corporate headquarters are located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063148408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_BasisOfPreparationAbstract', window );"><strong>Basis of preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">2.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Basis of preparation</div></td></tr></table><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Going concern</div><div><br /></div><div style="text-indent: 18pt;">The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company&#8217;s cash position of CHF 160.9 million and short-term financial assets of CHF 65 million as of December 31, 2020. This total derives from multiple capital raising efforts and revenues from license and collaboration agreements (LCAs). In 2020, the Company received CHF 10 million for a development milestone from its licensing agreement with Lilly. In 2019, the<font style="color: #000000;"> Company received CHF 80 million for an upfront payment, CHF 30 million for a development milestone and USD 50 (CHF 50.3) million from a convertible loan with Lilly. </font>In 2018, the Company completed three offerings, raising USD 117.5 (CHF 116.3) million in gross proceeds b<font style="color: #000000;">efore underwriting discounts and expenses.</font></div><div><br /></div><div style="text-indent: 18pt;">To date, the Company has financed its cash requirements primarily from its public offerings, share issuances, contract revenues from license and collaboration agreements and grants. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#8217;s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company&#8217;s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel and (v) acquire capital to support its operations.</div><div style="text-indent: 18pt;"><br /></div><div style="text-indent: 18pt; color: #000000;">In addition to the foregoing, based on the Company&#8217;s current assessment, the Company does not expect any material impact on its long-term development timeline, its liquidity or ability to remain a going concern due to the worldwide spread of the Covid-19 virus. The Company continues to assess the effect on its operations by carefully monitoring the spread of Covid-19 and taking appropriate steps intended to offset any negative impacts from the Covid-19 virus.</div><div><br /></div><div style="font-weight: bold;">Statement of compliance</div><div><br /></div><div style="text-indent: 18pt;">The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These financial statements have been approved for issue by the Board of Directors on March 19, 2021.</div><div><br /></div><div style="font-weight: bold;">Basis of measurement</div><div><br /></div><div style="text-indent: 18pt;">The financial statements have been prepared under the historical cost convention except for items that are required to be accounted for at fair value.</div><div><br /></div><div style="font-weight: bold;">Functional currency</div><div><br /></div><div style="text-indent: 18pt;">The financial statements of the Company are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial information presented in Swiss Francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands), unless otherwise indicated.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063147560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Summary of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 18pt;"><div style="text-align: left;"><font style="font-weight: bold;">3.</font></div></td><td style="align: left; vertical-align: top; width: auto;"><div style="text-align: left;"><font style="font-weight: bold;">Summary of significant accounting policies</font></div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.</div><div><br /></div><div style="font-weight: bold;">Current vs. non-current classification</div><div><br /></div><div style="text-indent: 18pt;">The Company presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be non-current.</div><div><br /></div><div style="font-weight: bold;">Foreign currency transactions</div><div><br /></div><div style="text-indent: 18pt;">Foreign currency transactions are translated into the functional currency, CHF, using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of income/(loss) in the period in which they arise.</div><div><br /></div><div style="font-weight: bold;">Revenue recognition</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Company has adopted IFRS 15 (<font style="font-style: italic;">Revenue from Contracts with Customers</font>). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Company enters into LCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and IP to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized from the Company&#8217;s IP. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Licenses of intellectual property</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Milestone payments</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Research and development services</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Company has certain arrangements with our collaboration partners that include contracting our employees for research and development programs. The Company assesses if these services are considered distinct in the context of each contract and, if so, they are accounted for as separate performance obligations. These revenues are recorded in contract revenue as the services are performed.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Sublicense revenues</div><div><br /></div><div style="text-indent: 18pt;">The Company has certain arrangements with our collaboration partners that include provisions for sublicensing. The Company recognizes any sublicense revenues at the point in time it is highly probable to obtain and not subject to reversal in the future.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Contract balances</div><div><br /></div><div style="text-align: justify; text-indent: 18pt; color: #000000;">The Company receives payments and determines credit terms from its customers for its various performance obligations based on billing schedules established in each contract. The timing of revenue recognition, billings and cash collections results in billed other current receivables, accrued income (contract assets), and deferred income (contract liabilities) on the balance sheets. Amounts are recorded as other current receivables when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be 1 year or less.</div><div><br /></div><div style="text-align: justify; text-indent: 18pt; color: #000000;">For a complete discussion of accounting for contract revenue, see &#8220;Note 12. Contract revenues.&#8221;</div><div><br /></div><div style="text-indent: 18pt; font-weight: bold;">Research and development expenses</div><div><br /></div><div style="text-indent: 18pt;">Given the stage of development of the Company&#8217;s products, all research expenditure is expensed as incurred. Research and development expenditures include:</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management and laboratory services;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>fees and costs related to regulatory filings and activities;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>costs associated with preclinical and clinical activities; and</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses.</div></td></tr></table><div><br /></div><div style="text-indent: 17.85pt;">For external research contracts, <font style="color: #000000;">expenses include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing from CROs or CMOs for services rendered do not always align with work performed. We accrue the cost of services rendered in connection with CRO or CMO activities based on our estimate of the &#8220;stage of completion&#8221; for such contracted services. We maintain regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and</font> accrue expenses as of the balance sheet date in the financial statements based on facts and circumstances known at the time.</div><div><br /></div><div style="text-indent: 18pt;">Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.</div><div><br /></div><div style="font-weight: bold;">Grant income</div><div><font style="font-weight: bold;"></font><br /></div><div style="text-indent: 18pt;"><font style="color: #000000;">The Company has received grants, from time to time, from the Michael J. Fox Foundation (MJFF) and other institutions to support certain research projects.</font> Grants are recorded at their fair value in the statements of income/(loss) within other operating income/(expenses) when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.</div><div><br /></div><div style="font-weight: bold;">Leases</div><div>&#160;</div><div style="text-indent: 18pt; color: #000000;">Effective January 1, 2019, the Company adopted IFRS 16 (<font style="font-style: italic;">Leases</font>), which provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company applied the modified retrospective approach, which required the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting, see &#8220;Note 5. Right-of-use assets and lease liabilities.&#8221;</div><div><br /></div><div style="text-indent: 18pt; font-style: italic; font-weight: bold;">Right-of-use assets and lease liabilities</div><div>&#160;</div><div style="text-indent: 18pt;">At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate. The lease liabilities are classified as current or non-current based on the due dates of the underlying principal payments.</div><div>&#160;</div><div style="text-indent: 18pt;">Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company&#8217;s estimate of the amount expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase, extension or termination option.</div><div>&#160;</div><div style="text-indent: 18pt;">At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability. When the lease liability is re-measured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</div><div>&#160;</div><div style="text-indent: 18pt;">The estimated lease term by right-of-use asset categories are as follows:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Buildings</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Office equipment</div></td><td style="width: 49.69%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">Both the right-of-use-assets and lease liabilities are recognized in the balance sheets.</div><div>&#160;</div><div style="font-weight: bold;">Property, plant and equipment</div><div><br /></div><div style="text-indent: 18pt;">Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">3 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Laboratory equipment</div></td><td style="width: 49.72%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Leasehold improvements/furniture</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&#8217;s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.</div><div><br /></div><div style="text-indent: 18pt;">Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the statements of income/(loss).</div><div><br /></div><div style="font-weight: bold;">Fair value of financial assets and liabilities</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s financial assets and liabilities are comprised of receivables, short-term financial assets, cash and cash equivalents, trade payables and financing obligations. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments and<font style="color: #000000;"> are held at their amortized cost in accordance with IFRS 9 (</font><font style="font-style: italic; color: #000000;">Financial Instruments</font><font style="color: #000000;">).</font></div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Receivables</div><div><br /></div><div style="text-indent: 18pt;">Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor&#8217;s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Short-term financial assets</div><div><br /></div><div style="text-indent: 18pt;">Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Cash and cash equivalents</div><div><br /></div><div style="text-indent: 18pt;">Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months.</div><div><br /></div><div style="text-indent: 18pt;">The Company assesses at each period whether there is objective evidence that financial assets are impaired.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Trade payables</div><div><br /></div><div style="text-indent: 18pt;">Trade payables are amounts <font style="color: #000000;">due to third parties in the ordinary course of business.</font></div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Financing obligation</div><div><br /></div><div style="text-indent: 17.85pt;">The Company&#8217;s financing obligation related to its agreement with a third party. This financing obligation has been fully repaid as of December 31, 2020.</div><div><br /></div><div style="font-weight: bold;">Share capital and public offerings</div><div>&#160;</div><div style="text-align: justify; text-indent: 18pt;">Common shares are classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax, from the proceeds received from existing or future offerings. <font style="color: #000000;">Should a planned equity offering not be assessed as probable, the issuance costs would be expensed immediately. </font>See &#8220;Note 9. Share capital.&#8221;</div><div><br /></div><div style="font-weight: bold;">Employee benefits</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Post-employment benefits</div><div><br /></div><div style="text-indent: 18pt;">The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.</div><div><br /></div><div style="text-indent: 18pt;">The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. The<font style="color: #000000;"> defined benefit obligation is calculated annually with the assistance of an independent actuary</font> using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#8217; projected salaries and pension increases as well as discount rates of highly liquid corporate bonds that have terms to maturity approximating the terms of the related liability.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately in the statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized immediately as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses are recognized in either research and development and/or general and administrative expenses within the operating results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses related to defined benefit plans are recognized in the statements of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Share-based compensation</div><div><br /></div><div style="text-indent: 18pt;">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding adjustment to equity over the remaining vesting period.</div><div><br /></div><div style="text-indent: 18pt;">Stock options granted under the Company&#8217;s stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model (see &#8220;Note 17. Share-based compensation&#8221;). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management&#8217;s estimates.</div><div><br /></div><div style="text-indent: 18pt;">The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.</div><div><br /></div><div style="text-indent: 18pt;">We estimate the fair value of non-vested stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards vest.</div><div>&#160;</div><div style="font-weight: bold;">Provisions</div><div><br /></div><div style="text-indent: 18pt;">Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.</div><div><br /></div><div style="font-weight: bold;">Taxation</div><div><br /></div><div style="text-indent: 18pt;">Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</div><div><br /></div><div style="text-indent: 18pt;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.</div><div><br /></div><div style="text-indent: 18pt;">Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets as the probability for use is low.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Income taxes</div><div><br /></div><div style="text-indent: 18pt;">As disclosed in &#8220;Note 15. Income taxes,&#8221; the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.</div><div><br /></div><div style="font-weight: bold;">Earnings per share</div><div><br /></div><div style="text-indent: 18pt;">The Company presents basic earnings per share for each period in the financial statements. The earnings per share are calculated by dividing the earnings of the period by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation.</div><div><br /></div><div style="font-weight: bold;">Critical judgments and accounting estimates</div><div><br /></div><div style="text-indent: 18pt;">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.</div><div><br /></div><div style="text-indent: 18pt;">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on LCAs, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation and (vi) right-of-use assets and lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</div><div><br /></div><div style="font-weight: bold;">Segment reporting</div><div><br /></div><div style="text-indent: 18pt;">The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.</div><div><br /></div><div style="text-indent: 18pt;">The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located in and revenue is attributable to the Company&#8217;s country of domicile, Switzerland.</div><div><br /></div><div style="font-weight: bold;">Accounting policies, new standards, interpretations and amendments adopted by the Company</div><div>&#160;</div><div style="text-indent: 18pt;">The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935118040840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">4.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Property, plant and equipment</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The following tables show the movements in the net book values of property, plant and equipment for the years ended December 31, 2020 and 2019, respectively:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Furniture</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT </div><div style="text-align: center; font-weight: bold;">equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Laboratory equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Leasehold improvements</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Acquisition cost:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>158</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,187</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,698</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>402</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>8,445</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquisitions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>96</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>310</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,566</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>62</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,034</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(40</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(306</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(346</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,497</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,958</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>464</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,133</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Accumulated depreciation:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(627</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,619</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,528</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(33</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(343</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,092</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(67</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,535</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>40</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>306</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>346</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(61</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(4,405</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(281</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(5,717</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Carrying amount:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,079</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>188</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,917</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>153</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>527</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,553</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>183</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,416</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Furniture</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT</div><div style="text-align: center; font-weight: bold;">equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Laboratory equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Leasehold improvements</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Acquisition cost:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>126</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,025</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5,367</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>350</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,868</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquisitions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>65</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>291</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,470</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>59</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,885</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(33</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(129</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(139</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(7</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(308</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>158</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,187</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6,698</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>402</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,445</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Accumulated depreciation:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(77</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(455</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,857</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(155</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,544</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(24</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(285</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(899</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(66</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,274</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>33</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>113</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>137</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>7</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>290</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(627</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(3,619</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(4,528</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Carrying amount:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>49</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>570</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,510</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,324</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,079</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>188</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,917</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company incurred CHF 1.5 million, 1.3 million and CHF 1.0 million in depreciation expenses, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060836872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Right-of-use assets and lease liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">5.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Right-of-use assets and lease liabilities</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company recognized additions of right-of-use of leased assets for buildings or for office equipment totaling CHF 0.4 and CHF 0.5 million for the years ended December 31, 2020 and 2019, respectively.</div><div><br /></div><div style="text-indent: 18pt;">Regarding lease liabilities, the amortization depends on the rate implicit in the contract or the incremental borrowing rate for the respective lease component. The weighted averages of the incremental borrowing rates as of December 31, 2020 are 2.5% for buildings, 4.2% for office equipment and 2.6% for IT equipment.</div><div>&#160;</div><div style="text-indent: 18pt;">The following tables show the movements in the net book values of right-of-use of leased assets for the years ended December 31, 2020 and 2019, respectively:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Buildings</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Office equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>81</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,255</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(400</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(18</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(14</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(432</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>63</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>54</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,223</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Buildings</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Office equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>79</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,185</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>29</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>500</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(400</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(17</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(420</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>81</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,255</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">There are no variable lease payments which are not included in the measurement of lease obligations. All extension options have been included in the measurement of lease obligations.</div><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, and 2019, the impact on the Company&#8217;s statements of income/(loss) and statements of cash flows is detailed in the table below.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;">Statements of income/(loss)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation of right-of-use assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>432</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>420</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest expense on lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>53</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expense for short-term leases and leases of low value</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>603</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>565</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,088</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,037</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;">Statements of cash flows</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total cash outflow for leases</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,088</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,037</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The following table presents the contractual undiscounted cash flows for lease liabilities as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Within 1 year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 1 and 3 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 3 and 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>912</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>948</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,367</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,403</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063442984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents and financial assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Cash and cash equivalents and financial assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents and financial assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">6.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Cash and cash equivalents and financial assets</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>160,893</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>193,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>160,893</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>193,587</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">By currency</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>152,537</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>158,173</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">EUR</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,215</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>10,169</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">USD</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>4,141</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>25,245</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>160,893</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>193,587</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">At the balance sheet dates, Company funds were held in CHF, EUR and USD currencies. As of December 31, 2020 and 2019, funds in EUR and USD were translated into CHF at a rate of 1.095 and 0.891 and 1.096 and 0.978, respectively, for each currency and year.</div><div><br /></div><div style="text-indent: 18pt;">The following table summarizes the Company&#8217;s short-term financial assets as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financial assets due in 1 year or less</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>65,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>95,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>65,000</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>95,000</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company also has two deposits in escrow accounts totaling CHF 0.3 million and CHF 0.3 million for the lease of the Company&#8217;s premises as of December 31, 2020 and 2019, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063161912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and accrued income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrepaymentsAndAccruedIncomeAbstract', window );"><strong>Prepaid expenses and accrued income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock', window );">Prepaid expenses and accrued income</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">7.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Prepaid expenses and accrued income</div></td></tr></table><div><font style="font-weight: bold;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Prepaid expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,954</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,788</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,591</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,095</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5,545</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>3,883</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The prepaid expenses relate mainly to research contracts with down-payments at contract signature and the related activities will start or continue into 2021.</div><div><br /></div><div style="text-indent: 18pt;">Accrued income consists of CHF 1.1 million as of December 31, 2020 associated with our Janssen collaboration (see &#8220;Note 12. Contract revenues&#8221;). This amount represents 68.1% of our total accrued income as of December 31, 2020.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of prepayments and accrued income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrepaymentsAndAccruedIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrepaymentsAndAccruedIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060669096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OtherCurrentReceivablesAbstract', window );"><strong>Other current receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfOtherCurrentReceivablesTextBlock', window );">Other current receivables</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">8.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Other current receivables</div></td></tr></table><div><font style="font-weight: bold;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Swiss VAT</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>309</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>234</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Withholding tax</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>20</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>70</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>329</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>304</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The maturity of these assets is less than 3 months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate their fair value.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfOtherCurrentReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfOtherCurrentReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_OtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_OtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060681288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Share capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share capital</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">9.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Share capital</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">As of December 31, 2020 and 2019, the issued share capital amounted to CHF 1,538,896 and CHF 1,437,351, respectively, and is composed of common shares of 71,936,738 and 71,859,431, respectively, and treasury shares of 5,000,000 and nil, respectively.</div><div><br /></div><div style="text-indent: 18pt;">The table below summarizes the Company&#8217;s capital structure:</div><div style="text-indent: 18pt;"><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">In CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Common </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Treasury </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Share </div><div style="text-align: center; font-weight: bold;">capital</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Share </div><div style="text-align: center; font-weight: bold;">premium</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Treasury </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>67,562,333</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>298,149</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares &#8211; incentive plans</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>681,770</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>13</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>672</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion of note agreement, net of transaction costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,615,328</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>73</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>47,705</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>71,859,431</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,437</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>346,526</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares &#8211; incentive plans, net of RSU expiration and forfeiture</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>77,307</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>364</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares to be held as treasury shares, net of transaction costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>76,936,738</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,538</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>346,890</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The common shares and treasury shares have nominal values of CHF 0.02 per share. All shares have been fully paid. These treasury shares are held by the Company and are not considered outstanding shares as of December 31, 2020. Finally, as of December 31, 2020 the Company has an additional 9,500,000 authorized shares for issuance which have not been issued nor are outstanding. Additionally, 19,632 RSUs either expired or were forfeited in 2020.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">At the market equity offering</div><div><br /></div><div style="text-indent: 17.85pt;">In September 2020, the Company<font style="color: #000000;"> established an &#8220;at the market offering program&#8221; for the sale of up to USD 80 (CHF 71.3) million worth of our common shares issued from time to time by entering into an Open Market Sale Agreement</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup><font style="color: #000000;">(Sales Agreement) with </font>Jefferies LLC (Jefferies) as the sales agent. Issuance costs incurred in connection with establishing this facility and execution of the Sales Agreement with Jefferies primarily consist of legal, printing and accounting fees.</div><div><br /></div><div style="text-indent: 17.85pt;">No common shares have been sold pursuant to the Sales Agreement as of December 31, 2020. For the years ended December 31, 2020, 2019 and 2018, the Company has expensed issuance costs of CHF 0.5 million, nil and nil, respectively, in the statement of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Convertible note agreement</div><div><br /></div><div style="text-indent: 21.3pt; color: #000000;">The Company and Lilly entered into a convertible note agreement effective January 23, 2019 for USD 50 (CHF 50.3) million. In April 2019, the convertible note agreement with Lilly automatically converted in line with the terms of the agreement. As a result of this conversion, 3,615,328 of our common shares were issued to Lilly. This note is now fully settled and there is no further equity or cash consideration due to Lilly thereunder.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Follow-on offerings</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">On July 24, 2018, the Company announced that it had closed the first subscription rights offering and underwritten the primary offering of its common shares, and that the underwriters had exercised in full their option to purchase an additional 1,108,695 shares at a price per share of USD 11.75. The underwriters&#8217; exercise of the option to purchase additional shares brought the total number of common shares sold by the Company to 8,500,000 shares, resulting in total gross proceeds raised in these offerings, before underwriting discounts and estimated expenses of the offering, to approximately USD 99.9 (CHF 98.9) million. On July 20, 2018, the Company commenced a second subscription rights offering of up to 1,500,000 shares. At closing of the second subscription rights offering on July 31, 2018, the Company issued 1,500,000 additional common shares, resulting in gross proceeds of approximately USD 17.6 (CHF 17.4) million.</div><div><br /></div><div style="text-indent: 18pt;"><font style="color: #000000;">At the conclusion of these three offerings, the Company raised gross proceeds of USD 117.5 (CHF 116.3) million. Net underwriting fees and transaction costs totaled CHF 6.8 million for a net total of CHF 109.5 million. </font>Transaction costs associated with these offerings and related to the issuance of new shares were charged directly against the share premium account thereby reducing the total equity reported.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Shelf registration statement</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">On May 4, 2018, the Company filed a Shelf Registration Statement on Form F-3 (Reg. No. 333-2246694) (the &#8220;Shelf Registration Statement&#8221;) with the SEC. The Shelf Registration Statement was declared effective by the SEC on June 8, 2018.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Shelf Registration Statement allows the Company to offer and sell, from time to time, up to USD 350,000,000 of common stock, debt securities, warrants, purchase contracts, units, subscription rights or any combination of the foregoing in one or more future public offerings. The terms of any future offering would be determined at the time of the offering and would be subject to market conditions and approval by the Company&#8217;s Board of Directors. Any offering of securities covered by the Shelf Registration Statement will be made only by means of a written prospectus and prospectus supplement authorized and filed by the Company.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">As the Company raised USD 117.5 (CHF 116.3) million in its three offerings completed in July 2018, the Company may execute one or more future offering of securities covered by the Shelf Registration Statement up to USD 232.5 million.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061602984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade payables and accrued liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade payables and accrued liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">10.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Trade payables and accrued liabilities</div></td></tr></table><div><font style="font-weight: bold;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; font-weight: bold;">&#160;In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,184</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>142</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;">Total trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,184</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>142</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Accrued research and development costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5,298</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,228</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Accrued payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,494</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,896</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Other accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,293</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,673</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;">Total accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>11,085</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>11,797</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">An accrual of CHF 2.1 million and CHF 1.8 million was recognized for performance-related remuneration within accrued payroll expenses for 2020 and 2019, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060754648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancingObligationAbstract', window );"><strong>Financing obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory', window );">Financing obligation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">11.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Financing obligation</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">On January 4, 2016, September 13, 2016 and January 26, 2018 for the fiscal years 2016, 2017 and 2018, respectively, AC Immune obtained separate funding commitment notices from the LuMind Research Down Syndrome Foundation (LuMind) totaling USD 200 thousand in each instance. Per the Research Grant Agreement, AC Immune has an obligation to reimburse LuMind for an amount equal to 125% of the then funding commitment made by LuMind to AC Immune.</div><div>&#160;</div><div style="text-indent: 18pt;">On October 31, 2018, LuMind and the Company modified the repayment terms in an effort to fund a Down Syndrome Clinical Trials Network. The repayment terms were modified such that the Company will repay the outstanding balance in three installments in 2018, 2019 and 2020, with the total repayment to equal the total the Company is to receive in funding plus the additional 25% interest.</div><div>&#160;</div><div style="text-indent: 18pt;">As of December 31, 2020, the Company has fully repaid this financing obligation.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FinancingObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FinancingObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDebtSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935066645432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Contract revenues</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">12.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Contract revenues</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, AC Immune generated contract revenues of CHF 15.4 million, CHF 110.5 million and CHF 6.9 million, respectively. For comparability, the Company reclassified CHF 0.3 million, CHF 0.6 million and CHF 0.3 million from contract revenues to other income/(expense) for the years ended December 31, 2020, 2019 and 2018, respectively for prior grants from the MJFF.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The following tables provide contract revenue amounts from its LCAs for the years ended December 31, 2020, 2019 and 2018, respectively.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lilly</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>14,348</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>105,662</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Genentech</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Janssen</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,083</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,173</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,157</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Life Molecular Imaging</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,206</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Biogen</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,063</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,024</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>352</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>731</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total contract revenue</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>15,431</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>110,456</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>6,912</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">Lilly accounted for 93% and 96% of our contract revenues in 2020 and 2019, respectively. Biogen and Janssen accounted for 58% and 31% of our contract revenues in 2018, respectively.</div><div><br /></div><div style="text-align: justify; text-indent: 18pt; color: #000000;">The following table presents changes in the Company&#8217;s contract assets and liabilities during the years ended December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div>&#160;</div><div>&#160;</div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"><br /></div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"><br /></div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF Thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Balance at </div><div style="text-align: center; font-weight: bold;">the beginning </div><div style="text-align: center; font-weight: bold;">of the </div><div style="text-align: center; font-weight: bold;">reporting period</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Additions</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Deductions</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Balance at </div><div style="text-align: center; font-weight: bold;">the end </div><div style="text-align: center; font-weight: bold;">of the</div><div style="text-align: center; font-weight: bold;">reporting period</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Twelve months ended December 31, 2020:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,354</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,858</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(5,638</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>306</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Twelve months ended December 31, 2019:</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,667</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,211</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,783</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,686</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(3,560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">During the years ended December 31, 2020, 2019 and 2018, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Revenues recognized in the period from:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Amounts included in the contract liability at the beginning of the period</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div></div><div>1,551</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Performance obligations satisfied in previous periods</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,206</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 22pt; vertical-align: top; font-weight: bold;">12.1</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Licensing and collaboration agreements</div></td></tr></table><div><br /></div><div style="margin-left: 18pt; font-style: italic;">Morphomer Tau small molecule &#8211; 2018 license agreement with Eli Lilly and Company</div><div>&#160;</div><div style="text-indent: 18pt;">In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. More specifically, this is an exclusive license with the right to Lilly to grant sublicenses under the ACIU Patents, the ACIU know-how, and ACIU&#8217;s interests in the Joint Patents and the joint know-how to Exploit the Licensed Compounds and Licensed Products. The agreement became effective on January 23, 2019 (the &#8220;effective date&#8221;) when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. In Q3 2019, the Company and Lilly entered into the first amendment to divide the first discretionary milestone payment under the agreement of CHF 60 million into two installments, with the first CHF 30 million paid in Q3 2019 and the second CHF 30 million to be paid on or before March 31, 2020 unless Lilly terminated the agreement earlier. In Q1 2020, the Company and Lilly entered into a second amendment to replace the second CHF 30 million to be paid on or before March 31, 2020 with two milestone payments, one of CHF 10 million to be paid on or before March 31, 2020 and the other of CHF 60 million following the first patient dosed in a Phase 2 clinical study of a licensed product in the US or EU.</div><div><br /></div><div style="text-indent: 18pt;">Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly. To date, the Company has completed a Phase 1 clinical study with ACI-3024. The program will be expanded to NeuroOrphan indications and ACI-3024 will be further evaluated for efficacy in models of rare Tauopathies.</div><div>&#160;</div><div style="text-indent: 18pt;">Additionally, the Company and Lilly have continued candidate characterization across the research program, identifying new and highly differentiated candidates with desired cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent neurodegenerative diseases by Lilly.</div><div><br /></div><div style="text-indent: 18pt;">Lilly is responsible for leading and funding further clinical development and will retain global commercialization rights for all indications.</div><div><br /></div><div style="text-indent: 18pt;">Per the terms of the agreement, the Company may become eligible to receive additional milestone payments totaling up to approximately CHF 880 million for clinical and regulatory milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low double-digits to the mid-teens. The agreement will terminate by the date of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly may terminate the agreement at any time by providing 3 months&#8217; prior notice to us.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations under the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. Per the agreement, the Company was responsible for the preclinical and Phase 1 activities for the first clinical candidate, ACI-3024, which the Company determined was distinct and capable of being completed by Lilly or a third party. Preclinical activities for which AC Immune was responsible prior to their completion in Q2 2019 included final manufacturing of materials for use in the regulatory submission of the protocol and in the Phase 1 study. For the completed Phase 1, AC Immune was responsible for leading the study design, obtaining relevant regulatory agency approvals, arranging necessary third-party contracts, completing patient selection, ensuring patient treatment, following up with patients, drafting the clinical study report development and other relevant clinical activities to ensure that the primary objective of the study was completed. The Company used CMOs for certain of its preclinical activities and CROs to complete certain Phase 1 activities and to issue the final clinical study report.</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s preclinical and Phase 1 activities did not represent integrated services with the licensed IP for which Lilly contracted. Lilly purchased a license to the Company&#8217;s Tau therapeutic small-molecule program, which was delivered at commencement of the agreement, and AC Immune&#8217;s preclinical and Phase 1 activities did not affect the form or functionality of this license. The Company&#8217;s objective for the Phase 1 activity was to assess safety and tolerability and did not modify or customize ACI-3024. The completion of these preclinical and Phase 1 activities does not affect the licensed IP.</div><div><br /></div><div style="text-indent: 18pt;">Finally, per the agreement, each party has three representatives on a joint steering committee (JSC); depending upon the agenda, additional field experts can attend the JSC to provide the technical and scientific contribution required. The JSC meets on a regular basis depending on agreements between the representatives. The JSC is responsible for serving as the forum to (i) discuss, review and approve certain activities by reviewing and discussing the development progress with updates on back-up candidates, (ii) discuss, review and approve all amendments to the global development plan, (iii) periodically discuss and review commercialization of licensed products and (iv) review and approve reports related to development costs among other activities. The JSC is intended to ensure that communication between the parties remains consistent and that the development plan is progressing as intended.</div><div><br /></div><div style="text-indent: 18pt;">The valuation of each performance obligation involves estimates and assumptions with revenue recognition timing to be determined by either delivery or the provision of services.</div><div>&#160;</div><div style="text-indent: 18pt;">The Company used the residual approach to estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research and development activities. The right-of-use license was delivered on the effective date. The research and development activities were delivered over time as the services were performed. For these services, revenue was recognized over time using the input method, based on costs incurred to perform the services, as the level of costs incurred over time is thought to best reflect the transfer of services to Lilly. The Company determined the value of the research and development activities to be CHF 6.9 million and deferred this balance from the effective date. As of December 31, 2020, the Company has cumulatively recognized CHF 6.9 million in contract revenue, resulting in no deferred income (contract liability) on the balance sheets. The remaining CHF 73.1 million from the upfront payment was allocated to the right-of-use license and recognized on the effective date.</div><div>&#160;</div><div style="text-indent: 18pt;">At inception of the agreement, none of the clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully constrained. Through December 31, 2020, the Company has recognized CHF 40 million from milestone payments triggered in Q3 2019 and Q1 2020 related to the right-of-use license for IP as there were no further constraints related to these milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, we have recognized CHF 14.3 million, CHF 105.7 million and nil, respectively from this arrangement.</div><div>&#160;</div><div style="margin-left: 18pt; font-style: italic;">Anti-Abeta antibody in AD &#8211; 2006 agreement with Genentech, a member of the Roche Group</div><div>&#160;</div><div style="text-indent: 18pt;">In November 2006, we signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal therapeutic antibody targeting misfolded Abeta. The agreement was amended March 2009, January 2013, May 2014 and May 2015. The agreement also provides for the development of a second therapeutic product for a non-AD indication based on the same intellectual property and anti-Abeta antibody compound. The value of this partnership is potentially greater than USD 340 (CHF 303) million.</div><div>&#160;</div><div style="text-indent: 18pt;">The term of the agreement commenced on the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party, provided a cure period of 90 days from the date when that notice is given.</div><div><br /></div><div style="text-indent: 18pt;">Genentech commenced a first Phase 3 clinical study in March 2016 for crenezumab (CREAD). In March 2017, Genentech started a second Phase 3 clinical trial (CREAD 2). Since 2013, crenezumab has also been studied in a Phase 2 trial in individuals who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD (autosomal dominant AD (ADAD)). In 2019, Genentech initiated a Tau Positron Emission Tomography (PET) substudy to the ongoing Phase 2 trial in ADAD to evaluate the effect of crenezumab on Tau burden, which may also increase the understanding of disease progression in the preclinical stage of ADAD.</div><div>&#160;</div><div style="text-indent: 18pt;">If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the US and Europe ranging from the mid-single digits to mid-teens. To date, we have received total milestone payments of USD 65 million (CHF 70.1 million) comprised of an upfront payment of USD 25 (CHF 31.6) million and of USD 40 (CHF 38.2) million for clinical development milestones achieved all-in prior to January 1, 2017. Genentech may terminate the agreement at any time by providing 3 months&#8217; notice to us. In such event all costs incurred are still refundable.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conducting of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech&#8217;s right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company&#8217;s obligation to perform research does not significantly impact or modify the licenses&#8217; granted functionality.</div><div>&#160;</div><div style="text-indent: 18pt;">At execution of the agreement, the transaction price included the upfront consideration received of USD 25 (CHF 31.6) million. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestone payments since inception, totaling USD 40 (CHF 38.2) million. The Company could receive greater than USD 275 (CHF 245) million or more for further regulatory milestones for this exclusive, worldwide alliance. In assessing that future regulatory milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</div><div>&#160;</div><div style="text-indent: 18pt;">On January 30, 2019, we announced that Roche, the parent of Genentech, is discontinuing the CREAD and CREAD 2 (BN29552 and BN29553) Phase 3 studies of crenezumab in people with prodromal-to-mild sporadic AD. The decision came after an interim analysis conducted by the Independent Data Monitoring Center (IDMC) indicated that crenezumab was unlikely to meet its primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score. This decision was not related to the safety of the investigational product. No safety signals for crenezumab were observed in this analysis and the overall safety profile was similar to that seen in previous trials.</div><div>&#160;</div><div style="text-indent: 18pt;">Crenezumab continues to be studied in the Phase 2 preventive trial, which began in 2013 in Columbia, of cognitively healthy individuals who carry the PSEN1 E280A autosomal-dominant mutation and are in a preclinical phase of ADAD. This study will determine if treating people carrying this mutation with crenezumab prior to the onset of AD symptoms will slow or prevent the decline of cognitive and functional abilities.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, we have recognized no revenues from this arrangement.</div><div>&#160;</div><div style="margin-left: 18pt; font-style: italic;">Anti-Tau antibody in AD &#8211; 2012 agreement with Genentech, a member of the Roche Group</div><div>&#160;</div><div style="text-indent: 18pt;">In June 2012, we entered into a second agreement with Genentech to research, develop and commercialize our anti-Tau antibodies for use as immunotherapeutics and diagnostics. The agreement was amended in December 2015. The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million and includes upfront and clinical, regulatory and commercial milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to low-double digits. The agreement also provides for collaboration on at least one additional therapeutic indication outside of AD built on the same anti-Tau antibody program as well an anti-Tau diagnostic product for AD.</div><div>&#160;</div><div style="text-indent: 18pt;">The term of the agreement commenced on the effective date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the agreement, terminates on the date on which all obligations between the parties with respect to the payment of milestones or royalties with respect to licensed products have passed or expired. Either party may terminate the agreement for any material breach by the other party, provided a cure period of 90 days from the date when that notice is given.</div><div><br /></div><div style="text-indent: 18pt;">To date, we have received payments totaling CHF 59 million, including a milestone payment of CHF 14 million received and recognized in Q4 2017 associated with the first patient dosing in a Phase 2 clinical trial for AD with an anti-Tau monoclonal body known as semorinemab, a milestone payment of CHF 14 million recognized in Q2 2016 and received in July 2016, associated with the announcement of the commencement of the Phase 1 clinical study of semorinemab, and a milestone payment of CHF 14 million received in 2015 in connection with the ED-GO decision. As we met all performance obligations on reaching these milestones, we have recognized revenue in the respective periods. Genentech may terminate the agreement at any time by providing 3 months&#8217; notice to us.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) conduct of research under a research plan. The Company considered the research and development capabilities of Genentech and Genentech&#8217;s right to sublicense to conclude that the license has stand-alone functionality and is distinct. The Company&#8217;s obligation to perform research does not significantly impact or modify the licenses&#8217; granted functionality.</div><div>&#160;</div><div style="text-indent: 18pt;">At execution of the agreement, the transaction price included an upfront consideration received of CHF 17 million. At inception, none of the clinical or regulatory milestones had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestones since inception totaling CHF 42 million. The Company could also receive up to an additional CHF 368.5 million in clinical, regulatory and commercial milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</div><div>&#160;</div><div style="text-indent: 18pt; color: #000000;">On September 23, 2020, the Company reported that Genentech informed us of top line results from a Phase 2 trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer&#8217;s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. The primary safety endpoint was however met. Two secondary endpoints, Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer&#8217;s Disease Cooperative Study Group &#8211; Activities of Daily Living Inventory (ADCS-ADL), were not met. A second Phase 2 study of semorinemab in patients with moderate AD remains ongoing.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, we have recognized no revenues from this arrangement, respectively.</div><div><br /></div><div style="margin-left: 18pt; font-style: italic;">Tau vaccine in AD &#8211; 2014 agreement with Janssen Pharmaceuticals, Inc.<br /></div><div>&#160;</div><div style="text-indent: 18pt;">In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen) one of The Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership is potentially up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. In April 2016, July 2017, January 2019 and November 2019, the companies entered into the first, second, third and fourth amendments, respectively. These amendments allow for the alignment of certain payment and activity provisions with the Development Plan and Research Plan activities. We and Janssen are co-developing the second-generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054, through Phase 1b/2a completion. AC Immune and Janssen will jointly share research and development costs until the completion of the first Phase 2b (AC Immune's contribution to the first Phase 2b trial capped). From Phase 2b and onwards, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of the second-generation vaccines.</div><div>&#160;</div><div style="text-indent: 18pt;">Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the first Phase 1b clinical study in 2016 by providing 90 days&#8217; notice to us. If not otherwise terminated, the agreement shall continue until the expiration of all royalty obligations as outlined in the contract.</div><div>&#160;</div><div style="text-indent: 18pt;">The agreement also allows for the expansion to a second indication based on the same anti-Tau vaccine program and based on intellectual property related to this program.</div><div>&#160;</div><div style="text-indent: 18pt;">The Company received an upfront, non-refundable license fee of CHF 25.9 million, which we recognized as revenue in 2014. In May 2016, we received a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study. As we met all performance obligations on reaching the milestone, we have recognized this income as revenue.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Janssen is a customer. The Company identified the following performance obligations under the contract: (i) a right-of-use license and (ii) research and development services including a development and chemistry, manufacturing and controls work plan. The Company considered the research and development capabilities of Janssen, Janssen&#8217;s right to sublicense, and the fact that the research and development services are not proprietary and can be provided by other vendors, to conclude that the license has stand-alone functionality and is distinct. The Company&#8217;s obligation to perform research and development services does not significantly impact or modify the licenses&#8217; granted functionality. Based on these assessments, the Company identified the license and the research and development services as the performance obligations at the inception of the arrangement, which were deemed to be distinct in the context of the contract.</div><div>&#160;</div><div style="text-indent: 18pt;">At execution of the agreement, the transaction price included only the upfront consideration received of CHF 25.9 million. At inception, none of the clinical, regulatory or commercial milestones has been included in the transaction price, as all milestone amounts were fully constrained. The Company did receive a payment of CHF 4.9 million for reaching a clinical milestone in the first Phase 1b study in May 2016. The Company could also receive up to more than CHF 458 million in clinical, regulatory and commercial milestones as well as tiered, low-double digit to mid-teen royalties on aggregate net sales of products. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, we have recognized revenues totaling CHF 1.1 million, CHF 1.2 million and CHF 2.2 million, respectively from this arrangement.</div><div><br /></div><div style="margin-left: 18pt; font-style: italic;">Tau-PET imaging agent in AD &#8211;2014 agreement with Life Molecular Imaging (LMI) (formerly Piramal Imaging SA)</div><div>&#160;</div><div style="text-indent: 18pt;">In May 2014, we entered into an agreement, our first diagnostic partnership, with LMI, the former Piramal Imaging SA. The partnership with LMI is an exclusive, worldwide licensing agreement for the research, development and commercialization of the Company&#8217;s Tau protein PET tracers supporting the early diagnosis and clinical management of AD and other Tau-related disorders and includes upfront and sales milestone payments totaling up to EUR 159 (CHF 175) million, plus royalties on sales at a percentage rate ranging from mid-single digits to low-teens. LMI may terminate the LCA at any time by providing 3 months&#8217; notice to us.</div><div><br /></div><div style="text-indent: 18pt;">In connection with this agreement, AC Immune received a payment of EUR 500 (CHF 664) thousand, which was fully recognized in 2015. In Q1 2017, we recorded a milestone payment of EUR 1 (CHF 1.1) million related to the initiation of &#8220;Part B&#8221; of the first-in-man Phase 1 study. In Q3 2019, the Company recognized EUR 2 (CHF 2.2) million in connection with the initiation of a Phase 2 trial of Tau-PET tracer in patients with mild cognitive impairment and mild&#8211;to-moderate AD in comparison with non-demented control participants. The Company is eligible to receive variable consideration related to the achievement of certain clinical milestones totaling EUR 8 (CHF 9) million should the compound make it through Phase 3 clinical studies. We are also eligible to receive potential regulatory and sales-based milestones totaling EUR 148 (CHF 162) million. Finally, the Company is eligible for royalties from the mid-single digits to low-double digits.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that LMI is a customer. The Company has identified that the right-of-use license as the only performance obligation. The Company determined that transaction price based on the defined terms allocated to each performance obligation specified in the contract.</div><div>&#160;</div><div style="text-indent: 18pt;">The upfront payment constitutes the amount of consideration to be included in the transaction price and has been allocated to the license. None of the clinical, regulatory or commercial milestones has been included in the transaction price as these variable consideration elements are considered fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts.</div><div>&#160;</div><div style="text-indent: 18pt;">Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to LMI and therefore are recognized at the later of when the performance obligation is satisfied or the related sales occur. The Company considered LMI&#8217;s right to sublicense and develop the Tau protein PET tracers, and the fact that LMI could perform the research and development work themselves within the license term without AC Immune, to conclude that the license has stand-alone functionality and is distinct. The Company believes that the contracted amount represents the fair value. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company has recognized nil, CHF 2.2 million and nil, respectively, from this arrangement.</div><div><br /></div><div style="margin-left: 18pt; font-style: italic;">A-syn and TDP-43 PET tracers &#8211; 2016 agreement with Biogen</div><div>&#160;</div><div style="text-indent: 18pt;">On April 13, 2016, we entered into a non-exclusive research collaboration agreement with Biogen International GmbH, (Biogen). Under the agreement, we and Biogen have agreed to collaborate in the research and early clinical development of our a-syn PET tracer program for PD and other synucleinopathies, and a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic lateral sclerosis (ALS). In addition, we have agreed to share the costs of the collaboration, with Biogen primarily funding the majority of research costs, subject to a cap, which includes an upfront technology access fee and funding toward research and development personnel. We own all intellectual property rights to any invention relating to a-syn or TDP-43 PET tracers.</div><div>&#160;</div><div style="text-indent: 18pt;">AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Biogen is a customer. The Company has identified two performance obligations in our Biogen collaboration: (i) technology access fee and (ii) research and development services. The Company determined the transaction price based on the defined terms allocated to each performance obligation specified in the contract. In instances where the Company is reimbursed for research and development contributions procured from third parties such as negotiated terms with clinical CROs, AC Immune records revenues for such services as it is acting as a principal in procuring the goods or services. The Company has the primary responsibility for fulfilling the promise to provide the specified good or service, it has inventory risk before transfer to the customer and it has discretion in negotiating the price with third parties. For other research and development services, revenues are recognized as work is performed, which correspond with and best depict the transfer of control to the customer in line with the terms outlined in the contract.</div><div>&#160;</div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company has recognized nil, CHF 1.1 million and CHF 4.0 million, respectively, from this arrangement. <font style="color: #000000;">This collaboration ended in April 2019.</font></div><div>&#160;</div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 22pt; vertical-align: top; font-weight: bold;">12.2 <br /></td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Grant income</div></td></tr></table><div><br /></div><div style="text-indent: 18pt; font-style: italic;">Grants from the Michael J. Fox Foundation</div><div><br /></div><div style="text-indent: 18pt;">In Q3 2017, we formally signed a grant continuation with the MJFF. This grant provides funds for the development of PET tracers for pathological forms of the protein alpha-synuclein, to support the early diagnosis and clinical management of Parkinson&#8217;s disease. We subsequently signed two additional grants which facilitated the <font style="color: #000000;">execution of a first-in-human study for a potential alpha-synuclein-PET tracer (PET tracer) with the current lead compound and to further develop the PET tracer. </font>The Company retains its intellectual property rights for these alpha-synuclein-PET tracers. These grants concluded in Q2 2020.</div><div><br /></div><div style="text-indent: 18pt;">In May 2020, the Company, as part of a joint arrangement with Sk&#229;ne University Hospital (Sk&#229;ne) in Sweden, was awarded a USD 3.2 (CHF 2.9) million grant from the MJFF&#8217;s Ken Griffin Alpha-synuclein Imaging Competition. As part of this grant, AC Immune is eligible to receive USD 2.5 (CHF 2.2) million directly from the MJFF. Sk&#229;ne will receive USD 0.7 (CHF 0.7) million of the total grant directly from the MJFF over two years to conduct and support the clinical arm of the project.</div><div><br /></div><div style="text-indent: 18pt;">The MJFF expects that AC Immune and Sk&#229;ne will complete tasks according to the agreed timelines. AC Immune&#8217;s funding is variable depending on the satisfactory achievement of these specific tasks within a specific period of time.</div><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company has recognized CHF 1.3 million, CHF 0.6 million and CHF 0.3 million, respectively, from these grants.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063151208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses by category<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ExpensesByCategoryAbstract', window );"><strong>Expenses by category [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesExplanatory', window );">Expenses by category</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="vertical-align: top; width: 18pt; font-weight: bold;">13.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Expenses by category</div></td></tr></table><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Research and Development</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>43,787</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>37,465</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>32,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>14,424</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>12,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,662</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,276</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>585</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>694</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total research and development expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>59,487</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>50,432</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>44,277</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">For the year ended December 31, 2020, 2019 and 2018, the Company incurred CHF 59.5 million, CHF 50.4 million and CHF 44.3 million in research and development expenses, respectively. These increases are predominantly driven by increases in investments in our research and development projects and full-time equivalents (FTEs).</div><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company had 115.3, 102.7 and 87 FTEs in research and development.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">General and administrative</div><div style="margin-left: 9.35pt;"><font style="font-weight: bold; font-style: italic;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,471</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,637</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,903</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,274</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,172</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5,740</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,812</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,249</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,824</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total general and administrative expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>18,557</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>16,058</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>12,467</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">For the year ended December 31, 2020, 2019 and 2018, the Company incurred CHF 18.6 million, CHF 16.1 million and CHF 12.5 million in general and administrative expenses, respectively. These increases are predominantly driven by increases in full-time equivalents (FTEs).</div><div><br /></div><div style="text-indent: 18pt;">For the years ended December 31, 2020, 2019 and 2018, the Company had 26.7, 24.1 and 17 FTEs general and administrative functions.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Financial result, net</div><div style="margin-left: 9.35pt;"><font style="font-weight: bold; font-style: italic;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Financial income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>78</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>303</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>127</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Financial expense</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(184</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,926</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in fair value of conversion feature</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,542</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exchange differences</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(555</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(2,013</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(1,194</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Finance result, net</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(661</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>906</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(1,401</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">Our financial income and expense primarily consist of interest income and interest expense associated with our lease liabilities and prior convertible debt instrument.</div><div><br /></div><div style="text-indent: 18pt;">For the year ended December 31, 2020, the following items from 2019 did not repeat:</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>the CHF 4.5 million gain on the conversion feature related to the Company&#8217;s convertible loan due to Lilly in 2019;</div></td></tr></table><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>CHF 1.4 million in interest expenses related to effective interest recorded to amortize the host debt per the convertible loan due to Lilly; and</div></td></tr></table><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>a CHF 1.2 million remeasurement loss related to the settlement of the convertible loan.</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ExpensesByCategoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ExpensesByCategoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063374392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related-party transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related-party transactions</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">14.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Related-party transactions</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">For key management, including the board of directors (seven individuals excluding the CEO) and the executive management (five individuals including the CEO), compensation was as follows.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term employee benefits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,497</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,526</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,681</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Post-employment benefits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>215</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>160</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,578</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,155</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,683</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>6,289</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>5,896</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4,524</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">In 2018, as part of the Company&#8217;s subscription rights offering, a major shareholder and members of the board and executive management purchased an aggregate of 614,147 of the Company&#8217;s common shares on the same basis and otherwise on the same terms as the other participants in such rights offering.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060764872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">15.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Income taxes</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company recognized no income tax expense or deferred tax asset or liability positions for the years ended December 31, 2020, 2019, and 2018.</div><div><br /></div><div style="text-indent: 18pt;">The income tax expense for each year can be reconciled to loss before tax as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income/(loss) before income tax</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(8,441</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6,194</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(10,507</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income not subject to tax/(expenses) not deductible for tax purposes</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>462</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(62</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of unused tax losses and tax offsets not recognized as deferred tax assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,979</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(6,132</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>10,173</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Effective income tax rate benefit/(expense)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The tax rate used for the 2020 reconciliations above is the corporate tax rate of 13.6% (13.6% in 2019 and 20.6% in 2018) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax losses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>121,948</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>64,125</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>109,294</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deductible temporary differences related to:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Right-of-use assets and lease liabilities, net</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Retirement benefit plan</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,464</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,485</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>5,665</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>129,412</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>71,610</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>114,959</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">Tax losses expiry dates are shown in the table below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Tax losses split by expiry date:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>16,566</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,338</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2021</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2022</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2023</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,628</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2024</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>15,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>15,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>25,868</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2025</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2026</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2027</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>57,824</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>121,948</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>64,125</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>109,294</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The tax losses available for future offset against taxable profits have increased by CHF 57.8 million from 2019, re<font style="color: #000000;">presenting the amount of tax losses that are additionally available as an offset, subject to expiration as disclosed in the table above, against future taxable income.</font></div><div><br /></div><div style="text-indent: 18pt;">Consistent with prior years, the Company has not recorded any deferred tax assets in relation to the past tax losses available for offset against future profits as the recognition criteria were not met at the balance sheet date.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935065179800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Retirement benefit plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Retirement benefit plan</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">16.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Retirement benefit plan</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company participates in a collective foundation covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits.</div><div><br /></div><div style="text-indent: 18pt;">Contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee and shared approximately 47% and 53% by employee and employer, respectively.</div><div><br /></div><div style="text-indent: 18pt;">This plan is governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a separately administered fund. The fund has the legal form of a foundation and it is governed by the board of trustees, which consists of an equal number of employer and employee representatives. The board of trustees is responsible for the administration of the plan assets and for the definition of the investment strategy.</div><div><br /></div><div style="text-indent: 18pt;">The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the different affiliated companies. The Company has no direct influence on the investment strategy of the foundation board.</div><div><br /></div><div style="text-indent: 18pt;">The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, as they are shared between a much greater number of participants. On leaving the Company, a departing employee&#8217;s retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This transfer mechanism may result in pension payments varying considerably from year to year.</div><div><br /></div><div style="text-indent: 18pt;">The pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners. For accounting purposes under IFRS, the plan is treated as a defined benefit plan.</div><div><br /></div><div style="text-indent: 18pt;">As of January 1, 2019 the Company changed from a fully insured plan to a plan for which the Company now bears investment and old age risks. The new plan has a higher statutory coverage ratio, which led to an increase in plan assets of 10% (CHF 1.2 million) for the year ended December 31, 2019. The increase is presented in Table B as part of the line &#8220;Return on plan assets excluding interest income.&#8221;</div><div><br /></div><div style="text-indent: 18pt;">The following table sets forth the status of the defined benefit pension plan and the amount that is recognized in the balance sheet:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(30,213</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(17,942</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair value of plan assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>22,749</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>19,139</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>12,277</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total liability</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(7,464</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(7,485</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(5,665</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The following amounts have been recorded as net pension cost in the statement of income:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Service cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,626</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,313</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>100</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(42</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(133</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(65</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net pension cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,655</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,375</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,130</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The changes in defined benefit obligation, fair value of plan assets and unrecognized gains/(losses) are as follows.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">A.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in defined benefit obligation</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Defined benefit obligation as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(17,942</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(14,278</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Service cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,626</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,313</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(100</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in demographic assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,428</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,138</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in financial assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,171</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in experience assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(931</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(2,003</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(888</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Benefits deposited</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,710</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees&#8217; contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(851</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(756</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(621</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Defined benefit obligation as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(30,213</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(26,624</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(17,942</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">B.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in fair value of plan assets</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Fair value of plan assets as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>19,139</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>12,277</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9,352</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>42</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>133</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>65</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees&#8217; contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>851</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>756</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>621</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employer&#8217;s contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>950</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>859</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>693</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Benefits deposited</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,710</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Return on plan assets excluding interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>300</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,732</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(164</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Fair value of plan assets as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>22,749</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>19,139</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>12,277</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">Expected contributions by the employer to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount to approximately CHF 1.1 million.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">C.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in net defined benefit liability</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net defined benefit liabilities as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5,665</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,926</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net pension cost through statement of income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,655</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,375</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,130</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Remeasurement through other comprehensive loss</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(726</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>302</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employer&#8217;s contribution</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(950</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(859</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(693</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net defined benefit liabilities as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7,464</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7,485</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5,665</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">D.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in other comprehensive loss</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Other comprehensive loss as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(5,587</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,283</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,981</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in demographic assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,428</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,138</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in financial assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,171</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in experience assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(931</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(2,003</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(888</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Return on plan assets excluding interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>300</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,732</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(164</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Other comprehensive loss as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(4,861</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(5,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(4,283</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The fair value of the plan assets is the cash surrender value of the insurance with the insurance company (AXA). The investment strategy defined by the board of trustees follows a conservative profile.</div><div><br /></div><div style="text-indent: 18pt;">The plan assets are primarily held within instruments with quoted market prices in an active market, with the exception of real estate and mortgages.</div><div><br /></div><div style="text-indent: 18pt;">The weighted-average duration of the defined benefit obligation is 17.6 years and 19.3 years as of December 31, 2020 and 2019, respectively.</div><div><br /></div><div style="text-indent: 18pt;">The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December 31, 2020, 2019 and 2018, respectively, are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Discount rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.20</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.20</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Rate of future increase in compensations</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.75</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.75</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Rate of future increase in current pensions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest rate on retirement savings capital</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Mortality and disability rates</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2020-CMI</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2015-CMI</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2015G</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">In defining the benefits, the minimum requirements of the Swiss BVG and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits.</div><div><br /></div><div style="text-indent: 18pt;">A quantitative sensitivity analysis for significant assumptions as of December 31, 2020 is shown below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Discount rate</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future salary increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future pension cost</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Interest rate on </div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">savings capital</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot; font-weight: bold;">Assumptions</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="30" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">In CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Potential defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,740</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">33,080</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">30,912</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,519</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">31,652</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">28,916</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">31,070</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,405</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Decrease/(increase) from actual defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">2,473</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(2,867</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(699</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">694</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(1,439</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">1,297</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(857</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">808</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">A quantitative sensitivity analysis for significant assumptions as of December 31, 2019 is shown below:</div><div style="text-indent: 18pt;"><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Discount rate</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future salary increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future pension cost</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Interest rate on </div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">savings capital</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot; font-weight: bold;">Assumptions</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="30" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">in CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Potential defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">24,248</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,396</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,317</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,930</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,993</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,393</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,447</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,848</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Decrease/(increase) from actual defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">2,376</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(2,772</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(693</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">694</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(1,369</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">1,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(823</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">776</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div style="text-indent: 18pt;"><br /></div><div style="text-indent: 18pt;">The sensitivity analyses above are subject to limitations and have been determined based on a method that extrapolates the impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061981768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">17.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Share-based compensation</div></td></tr></table><div><br /></div><div style="text-indent: 18pt; font-style: italic;">Share-based option awards</div><div><br /></div><div style="text-indent: 18pt;">Through the year ended December 31, 2020, there are equity-based instruments outstanding that the Company has granted under four different plans.</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s 2016 Share Option and Incentive Plan (SOIP) was approved by the shareholders at the ordinary shareholders' meeting in November 2016. The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights. The Company only grants equity-based instruments from the SOIP as of December 31, 2020.</div><div><br /></div><div style="text-indent: 18pt;">The following table summarizes equity-settled share option grants since inception under each plan type:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">PLAN</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of </div><div style="text-align: center; font-weight: bold;">options awarded </div><div style="text-align: center; font-weight: bold;">(since inception)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div>&#160;</div><div style="font-weight: bold;">Vesting conditions</div></div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div style="text-align: center; font-weight: bold;">Contractual </div><div style="text-align: center; font-weight: bold;">life of options</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan A</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>362,750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">At grant</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">15.5 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan B</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>819,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">At grant</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10.5 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan C1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,775,250</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from grant date</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2016 SOIP:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Executives and directors</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,898,222</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">1 year, 3 year and 4 years&#8217; service from the date of grant, quarterly and annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>989,279</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from the date of grant, annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The number and weighted-average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and the 2016 SOIP are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of options</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average exercise price (CHF)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average remaining</div><div style="text-align: center; font-weight: bold;">term (years)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,359,891</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2.09</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.8</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.16</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(151,814</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.15</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>484,403</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.79</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,618,856</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>4.25</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>6.3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>932,175</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1.25</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4.4</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,618,856</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4.25</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6.3</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,699</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6.71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(616,833</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.15</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,053,305</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5.24</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,981,629</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>5.93</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>8.3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>602,218</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4.94</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>6.5</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,981,629</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.93</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>8.3</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(53,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6.03</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,729</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4.38</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,669</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,073,027</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6.29</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,900,667</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>5.90</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>8.2</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>1,099,015</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5.49</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7.0</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The outstanding stock options as of December 31, 2020 have the following range of exercise prices. In fiscal year 2018, we began to grant awards solely with USD denominated exercise prices and discontinued granting awards with a CHF denominated exercise price.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total options</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Range of </div><div style="text-align: center; font-weight: bold;">expiration </div><div style="text-align: center; font-weight: bold;">dates</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Range of exercise prices</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF 0.15</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>243,125</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2020&#8211;2026</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF 9.53</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>223,646</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2027</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">USD 5.04 to USD 12.30</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,433,896</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2028&#8211;2030</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total outstanding options</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,900,667</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The weighted-average exercise price for options granted in 2020, 2019 and 2018 is USD 7.11 (CHF 6.29), USD 5.41 (CHF 5.24) and USD 9.97 (CHF 9.79), respectively. The range of exercise prices for outstanding options was CHF 0.15 to CHF 9.53 for awards previously granted in CHF and USD 5.04 to USD 12.30 for awards granted in USD as of December 31, 2020.</div><div><br /></div><div style="text-indent: 18pt;">Prior to the IPO, the exercise price was set by the board of directors. The volatility is based on the historical trend of an appropriate sample of companies operating in the pharmaceutical and biopharmaceutical industries. The risk-free interest rate is based on the CHF swap rate for the expected life of the option. The weighted-average share price of common share options exercised in 2020 is USD 6.86 (CHF 6.07).</div><div><br /></div><div style="text-indent: 18pt;">The weighted-average grant date fair values of the options granted in 2020, 2019 and 2018 are USD 5.25 (CHF 4.65), USD 3.71 (CHF 3.59) and USD 6.66 (CHF 6.54), respectively. <font style="color: #000000;">The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of these awards:</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercise price</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 5.04-9.16</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 5.15&#8211;5.54</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 8.33&#8211;12.30</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share price (weighted average)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7.11</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.41</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-free interest rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected volatility</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected term</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend yield</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000; font-style: italic;">Restricted share awards</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">A summary of non-vested share awards (restricted share and restricted share units) activity as of December 31, 2020 and changes during the year then ended is presented below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Grantee type</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of </div><div style="text-align: center; font-weight: bold;">non-vested </div><div style="text-align: center; font-weight: bold;">share </div><div style="text-align: center; font-weight: bold;">awards </div><div style="text-align: center; font-weight: bold;">granted</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div style="text-align: center; font-weight: bold;">Vesting conditions</div></div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; font-weight: bold;">Contractual </div><div style="text-align: center; font-weight: bold;">life of </div><div style="text-align: center; font-weight: bold;">non-vested </div><div style="text-align: center; font-weight: bold;">share </div><div style="text-align: center; font-weight: bold;">awards</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Restricted share units</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Directors</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>83,864</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">1 year service from date of grant, annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Executives</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>110,839</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from the date of grant, quarterly</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Restricted share awards</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,023</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">2.75 years&#8217; service from date of grant, quarterly</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center;">10 years</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of</div><div style="text-align: center; font-weight: bold;">non-vested shares</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average</div><div style="text-align: center; font-weight: bold;">grant date fair value (CHF)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2017</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>122,014</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.59</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(25,673</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.48</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>69,371</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.43</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(56,671</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.60</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>109,041</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.51</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>64,012</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.65</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>109,041</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(66,278</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>42,763</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.52</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>130,290</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.58</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>42,763</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(11,828</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.47</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(7,804</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(84,638</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(23,269</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>19,494</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.51</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>49,289</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.47</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company did not grant restricted share awards in 2020 or 2019, respectively. The weighted-average grant date fair value of the restricted share awards granted (restricted shares and restricted share units) was CHF 9.43 for the year ended December 31, 2018. The weighted-average grant date fair values of the remaining non-vested share awards as of the respective year end (restricted shares and restricted share units) was CHF 9.51, CHF 9.52 and CHF 9.51 for the years ended December 31, 2020, 2019 and 2018, respectively. These fair values of non-vested share awards granted have been determined using a reasonable estimate of market value of the common stock on the date of the award.</div><div><br /></div><div style="text-indent: 18pt;">The expense charged against the income statement was CHF 4.1 million, CHF 2.8 million and CHF 2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. The expense is revised by the Company based on the number of instruments that are expected to become exercisable.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935094440056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">18.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Commitments and contingencies</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;"><font style="color: #000000;">In the normal course of business, we conduct product research and development programs through collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations</font>. As of December 31, 2020, external research projects included in the schedule below for 2021 total CHF 24.7 million that have been committed.</div><div><br /></div><div style="text-indent: 18pt;"><font style="color: #000000;">We lease our corporate, laboratory and other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. </font>Since January 1, 2019, the Company has applied IFRS 16 and recognized a right-of-use asset for its leases, except for short-term and low-value leases as indicated in Note 3<font style="font-style: italic;">.</font> See &#8220;Note 5. Right-of-use assets and lease liabilities&#8221; for the contractual undiscounted cash flows for lease obligations.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Within 1 year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>25,072</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>19,907</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 1 and 3 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,885</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>12,993</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 3 and 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>341</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,816</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">More than 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>57</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,193</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>34,355</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>39,909</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060929752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">19.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Earnings per share</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands, except for share and per share data</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Basic income/(loss) per share (EPS):</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Numerator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income/(loss) attributable to equity holders of the Company</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Denominator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>71,900,212</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>70,603,611</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>61,838,228</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Basic income/(loss) for the period attributable to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(0.86</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>0.64</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(0.82</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Diluted income/(loss) per share (EPS):</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Numerator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income/(loss) attributable to equity holders of the Company</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Denominator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71,900,212</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>70,603,611</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>61,838,228</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of dilutive securities from equity incentive plans</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>499,730</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding &#8211; diluted to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>71,900,212</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>71,103,341</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>61,838,228</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Diluted income/(loss) for the period attributable to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(0.86</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>0.64</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(0.82</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">In periods for which we have a loss, basic net loss per share is the same as diluted net loss per share. We have excluded from our calculation of diluted loss per share all potentially dilutive in-the-money (i) share options and (ii) shares that were issued upon conversion of the convertible note as their inclusion would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share options issued and outstanding (in-the-money)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>412,191</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,081,836</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,472,589</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Restricted share awards subject to future vesting</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>28,418</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>109,041</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Convertible shares</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>911,261</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>440,609</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,993,097</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,581,630</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935059877272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Financial instruments and risk management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial instruments and risk management</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">20.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Financial instruments and risk management</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s activities expose it to the following financial risks: market risk (foreign exchange and interest rate risk), credit risk and liquidity risk. The Company&#8217;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company&#8217;s financial performance.</div><div><br /></div><div style="text-indent: 18pt;">The following table shows the carrying amounts of financial assets and financial liabilities:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Long-term financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other current receivables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>329</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>65,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>95,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>160,893</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>193,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>226,556</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>289,195</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Financial liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Long-term lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,780</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,813</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,184</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>142</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>11,085</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>11,797</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financing obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>652</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>443</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>442</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total financial liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>15,492</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>14,846</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Foreign exchange risk</div><div><br /></div><div style="text-indent: 9.35pt;">The Company is exposed to foreign exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency exposure is not hedged. However, the Company has a policy of matching its cash holdings to the currency structure of its expenses, which means that the Company holds predominately CHF, with lesser balances of EUR and USD (see &#8220;Note 6. Cash and cash equivalents and financial assets&#8221;). The Company recognized a loss of CHF 0.7 million, CHF 0.8 million and CHF 1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively, within &#8220;Finance result, net.&#8221;</div><div><br /></div><div style="text-indent: 18pt;">As of December 31, 2020, if the CHF had strengthened/weakened by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would have been lower/higher by CHF 0.8 million (2019: CHF 3.5 million), mainly as a result of foreign exchange gains/losses on predominantly EUR/USD denominated cash and cash equivalents and short-term financial assets.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Interest rates</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s CHF cash holdings (inclusive of those held in short-term financial assets) are subject to negative interest rates at certain counterparty thresholds. As of December 31, 2020 if the interest rates charged by the counterparties had increased/decreased by 10%, the net income for the period would have been higher/lower by less than CHF 0.1 million. Interest income and interest expense are recorded within finance results, net in our statements of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Credit risk</div><div><br /></div><div style="text-indent: 18pt;">The Company maintains a formal treasury risk and investment management policy to limit counterparty credit risk. As of December 31, 2020, the Company&#8217;s cash and cash equivalents and short-term financial assets are held with four financial institutions, each with a high credit rating assigned by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Trade and other receivables are fully performing, not past due and not impaired (see &#8220;Note 6. Cash and cash equivalents and financial assets&#8221; and &#8220;Note 8. Other current receivables&#8221;).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Liquidity risk</div><div><br /></div><div style="text-indent: 18pt;">Inherent in the Company&#8217;s business are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts will succeed. AC Immune&#8217;s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) acquire and keep key personnel employed and (iv) acquire additional capital to support its operations.</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 18 months. The Company has CHF 2.2 million in trade and other payables, which are due within 12 months from the reporting date. Finally, as it relates to the Company&#8217;s lease liabilities please see &#8220;Note 5. Right-of-use assets and lease liabilities&#8221; for detail of when corresponding lease liabilities are due.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063136728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract', window );"><strong>Capital risk management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital risk management</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">21.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Capital risk management</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against (i) AD, (ii) focused non-Alzheimer&#8217;s neurodegenerative diseases including NeuroOrphan indications and (iii) diagnostics.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063420056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">22.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Subsequent events</div></td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;"><div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Management has evaluated subsequent events after the balance sheet date, through the issuance of these financial statements, for appropriate accounting and disclosures. </font>We raised USD 8.8 (CHF 8.0) million, net of sales agent commissions, from the sale <font style="font-size: 10pt; font-family: 'Times New Roman';">764,977 </font>of our ordinary shares pursuant to our ATM program in February 2021.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935059915416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Summary of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock', window );">Current vs. non-current classification</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Current vs. non-current classification</div><div><br /></div><div style="text-indent: 18pt;">The Company presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within 12 months after the reporting period to be current and all other amounts to be non-current.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency transactions</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Foreign currency transactions</div><div><br /></div><div style="text-indent: 18pt;">Foreign currency transactions are translated into the functional currency, CHF, using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statements of income/(loss) in the period in which they arise.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Revenue recognition</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Company has adopted IFRS 15 (<font style="font-style: italic;">Revenue from Contracts with Customers</font>). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under IFRS 15, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of IFRS 15, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the goods or services promised within each contract, and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">The Company enters into LCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and IP to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and/or commercial milestone payments; payments for research and clinical services the Company provides through either its full-time employees or third-party vendors, and royalties on net sales of licensed products commercialized from the Company&#8217;s IP. Each of these payments results in license, collaboration and other revenues, which are classified as contract revenue on the statements of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Licenses of intellectual property</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are sold in conjunction with a related service, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the performance obligation is settled over time, the Company determines the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Milestone payments</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">At the inception of each arrangement that includes development, regulatory and/or commercial milestone payments, the Company evaluates whether the milestones are considered highly probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant revenue reversal would not occur in future periods, the associated milestone value is included in the transaction price. These amounts for the performance obligations under the contract are recognized as they are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments recorded would affect contract revenues and earnings in the period of adjustment.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenses</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt; font-weight: bold;">Research and development expenses</div><div><br /></div><div style="text-indent: 18pt;">Given the stage of development of the Company&#8217;s products, all research expenditure is expensed as incurred. Research and development expenditures include:</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data-management and laboratory services;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>fees and costs related to regulatory filings and activities;</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>costs associated with preclinical and clinical activities; and</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt;"><br /></td><td style="width: 18pt; vertical-align: top; align: right;"><font style="font-family: Times New Roman;">&#9679;</font></td><td style="width: auto; vertical-align: top;"><div>employee-related expenses, including salaries and bonuses, benefits, travel and share-based compensation expenses.</div></td></tr></table><div><br /></div><div style="text-indent: 17.85pt;">For external research contracts, <font style="color: #000000;">expenses include those associated with contract research organizations, or CROs, or contract manufacturing organizations, or CMOs. The invoicing from CROs or CMOs for services rendered do not always align with work performed. We accrue the cost of services rendered in connection with CRO or CMO activities based on our estimate of the &#8220;stage of completion&#8221; for such contracted services. We maintain regular communication with our CRO or CMO vendors to gauge the reasonableness of our estimates and</font> accrue expenses as of the balance sheet date in the financial statements based on facts and circumstances known at the time.</div><div><br /></div><div style="text-indent: 18pt;">Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GrantIncomePolicyTextBlock', window );">Grant income</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Grant income</div><div><font style="font-weight: bold;"></font><br /></div><div style="text-indent: 18pt;"><font style="color: #000000;">The Company has received grants, from time to time, from the Michael J. Fox Foundation (MJFF) and other institutions to support certain research projects.</font> Grants are recorded at their fair value in the statements of income/(loss) within other operating income/(expenses) when there is reasonable assurance that the Company will satisfy the underlying grant conditions and the grants will be received. In certain circumstances, grant income may be recognized before formal grantor acknowledgement of milestone achievements. To the extent required, grant income is deferred and recognized on a systematic basis over the periods in which the Company expects to recognize the related expenses for which the grants are intended to compensate.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Leases</div><div>&#160;</div><div style="text-indent: 18pt; color: #000000;">Effective January 1, 2019, the Company adopted IFRS 16 (<font style="font-style: italic;">Leases</font>), which provides a new model for lessee accounting in which all leases, other than short-term and low-value leases, are accounted for by the recognition on the balance sheet of a right-of-use asset and a lease liability, and the subsequent amortization of the right-of-use asset over the earlier of the end of the useful life or the lease term. The Company applied the modified retrospective approach, which required the recognition of the cumulative effect of initially applying IFRS 16 as of January 1, 2019 to accumulated losses and not restating previous years. As the Company recognized the right-of-use assets at the amount equal to the lease liabilities there was no impact to accumulated losses. For a complete discussion of accounting, see &#8220;Note 5. Right-of-use assets and lease liabilities.&#8221;</div><div><br /></div><div style="text-indent: 18pt; font-style: italic; font-weight: bold;">Right-of-use assets and lease liabilities</div><div>&#160;</div><div style="text-indent: 18pt;">At inception of a leasing contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate. The lease liabilities are classified as current or non-current based on the due dates of the underlying principal payments.</div><div>&#160;</div><div style="text-indent: 18pt;">Lease payments generally are fixed for the contract term. The lease liability is measured at amortized cost using the effective interest method. The lease liability is re-measured if there is a change in the estimated lease term, a change in future lease payments arising from a change in an index or rate, a change in the Company&#8217;s estimate of the amount expected to be payable under a residual value guarantee or a change in assessment of whether it will exercise a purchase, extension or termination option.</div><div>&#160;</div><div style="text-indent: 18pt;">At inception, the right-of-use asset comprises the initial lease liability and any initial direct costs. The right-of-use asset is depreciated over the shorter of the lease term or the useful life of the underlying asset. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability. When the lease liability is re-measured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</div><div>&#160;</div><div style="text-indent: 18pt;">The estimated lease term by right-of-use asset categories are as follows:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Buildings</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Office equipment</div></td><td style="width: 49.69%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">Both the right-of-use-assets and lease liabilities are recognized in the balance sheets.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Property, plant and equipment</div><div><br /></div><div style="text-indent: 18pt;">Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">3 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Laboratory equipment</div></td><td style="width: 49.72%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Leasehold improvements/furniture</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&#8217;s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.</div><div><br /></div><div style="text-indent: 18pt;">Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the statements of income/(loss).</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock', window );">Fair value of financial assets and liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Fair value of financial assets and liabilities</div><div><br /></div><div style="text-indent: 18pt;">The Company&#8217;s financial assets and liabilities are comprised of receivables, short-term financial assets, cash and cash equivalents, trade payables and financing obligations. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments and<font style="color: #000000;"> are held at their amortized cost in accordance with IFRS 9 (</font><font style="font-style: italic; color: #000000;">Financial Instruments</font><font style="color: #000000;">).</font></div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Receivables</div><div><br /></div><div style="text-indent: 18pt;">Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is evidence of the debtor&#8217;s inability to make required payments and the Company assesses on a forward-looking basis the expected credit losses associated with these receivables held at amortized cost.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Short-term financial assets</div><div><br /></div><div style="text-indent: 18pt;">Short-term financial assets are held with external financial institutions and comprise fixed-term deposits with maturities ranging from more than 3 through 12 months in duration.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Cash and cash equivalents</div><div><br /></div><div style="text-indent: 18pt;">Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with original duration of less than 3 months.</div><div><br /></div><div style="text-indent: 18pt;">The Company assesses at each period whether there is objective evidence that financial assets are impaired.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Trade payables</div><div><br /></div><div style="text-indent: 18pt;">Trade payables are amounts <font style="color: #000000;">due to third parties in the ordinary course of business.</font></div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Financing obligation</div><div><br /></div><div style="text-indent: 17.85pt;">The Company&#8217;s financing obligation related to its agreement with a third party. This financing obligation has been fully repaid as of December 31, 2020.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital and public offerings</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Share capital and public offerings</div><div>&#160;</div><div style="text-align: justify; text-indent: 18pt;">Common shares are classified as equity. Share issuance costs are capitalized as incurred and will be shown in equity as a deduction, net of tax, from the proceeds received from existing or future offerings. <font style="color: #000000;">Should a planned equity offering not be assessed as probable, the issuance costs would be expensed immediately. </font>See &#8220;Note 9. Share capital.&#8221;</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Employee benefits</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Post-employment benefits</div><div><br /></div><div style="text-indent: 18pt;">The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.</div><div><br /></div><div style="text-indent: 18pt;">The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. Significant estimates are used in determining the assumptions incorporated in the calculation of the pension obligations, which is supported by input from independent actuaries. The<font style="color: #000000;"> defined benefit obligation is calculated annually with the assistance of an independent actuary</font> using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#8217; projected salaries and pension increases as well as discount rates of highly liquid corporate bonds that have terms to maturity approximating the terms of the related liability.</div><div><br /></div><div style="text-indent: 18pt; color: #000000;">Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) are recognized immediately in the statements of other comprehensive income/(loss). Past service costs, including curtailment gains or losses, are recognized immediately as a split in research and development and general and administrative expenses within the operating results. Settlement gains or losses are recognized in either research and development and/or general and administrative expenses within the operating results. The Company determines the net interest expense/(income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, considering any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense/(income) and other expenses related to defined benefit plans are recognized in the statements of income/(loss).</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Share-based compensation</div><div><br /></div><div style="text-indent: 18pt;">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity-based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the statements of income/(loss), and a corresponding adjustment to equity over the remaining vesting period.</div><div><br /></div><div style="text-indent: 18pt;">Stock options granted under the Company&#8217;s stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option-pricing model (see &#8220;Note 17. Share-based compensation&#8221;). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management&#8217;s estimates.</div><div><br /></div><div style="text-indent: 18pt;">The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.</div><div><br /></div><div style="text-indent: 18pt;">We estimate the fair value of non-vested stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common stock. We measure equity-classified awards at their grant date fair value and do not subsequently re-measure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share capital and share premium as the awards vest.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Provisions</div><div><br /></div><div style="text-indent: 18pt;">Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Taxation</div><div><br /></div><div style="text-indent: 18pt;">Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</div><div><br /></div><div style="text-indent: 18pt;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.</div><div><br /></div><div style="text-indent: 18pt;">Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carry-forwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets as the probability for use is low.</div><div><br /></div><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Income taxes</div><div><br /></div><div style="text-indent: 18pt;">As disclosed in &#8220;Note 15. Income taxes,&#8221; the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Earnings per share</div><div><br /></div><div style="text-indent: 18pt;">The Company presents basic earnings per share for each period in the financial statements. The earnings per share are calculated by dividing the earnings of the period by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options or non-vested restricted share units were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock', window );">Critical judgments and accounting estimates</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Critical judgments and accounting estimates</div><div><br /></div><div style="text-indent: 18pt;">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.</div><div><br /></div><div style="text-indent: 18pt;">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on LCAs, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes, (v) share-based compensation and (vi) right-of-use assets and lease liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Segment reporting</div><div><br /></div><div style="text-indent: 18pt;">The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.</div><div><br /></div><div style="text-indent: 18pt;">The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment. Non-current assets are located in and revenue is attributable to the Company&#8217;s country of domicile, Switzerland.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock', window );">Accounting policies, new standards, interpretations and amendments adopted by the Company</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Accounting policies, new standards, interpretations and amendments adopted by the Company</div><div>&#160;</div><div style="text-indent: 18pt;">The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective. Such standards are not currently expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for judgments that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognized in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the basis for how the entity classifies assets and liabilities as current and non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for changes to accounting policies recently adopted by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfAccountingPolicyForChangesInAccountingPoliciesRecentlyAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value of financial assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FairValueOfFinancialAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060772136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract', window );"><strong>Summary of significant accounting policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock', window );">Estimated Lease Term by Right-of-use Asset Categories</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The estimated lease term by right-of-use asset categories are as follows:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Buildings</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Office equipment</div></td><td style="width: 49.69%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.31%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.69%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Estimated useful life</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">IT equipment</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">3 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Laboratory equipment</div></td><td style="width: 49.72%; vertical-align: top;"><div style="text-align: right;">5 years</div></td></tr><tr><td style="width: 50.28%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Leasehold improvements/furniture</div></td><td style="width: 49.72%; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: right;">5 years</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the estimated lease term by right-of-use asset by category.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ScheduleOfInformationAboutContractLeaseTermByRightOfUseAssetCategoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the useful life of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063407080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following tables show the movements in the net book values of property, plant and equipment for the years ended December 31, 2020 and 2019, respectively:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Furniture</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT </div><div style="text-align: center; font-weight: bold;">equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Laboratory equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Leasehold improvements</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Acquisition cost:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>158</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,187</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,698</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>402</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>8,445</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquisitions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>96</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>310</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,566</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>62</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,034</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(40</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(306</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(346</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,497</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,958</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>464</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,133</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Accumulated depreciation:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(627</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,619</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,528</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(33</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(343</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,092</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(67</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,535</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>40</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>306</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>346</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(61</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(4,405</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(281</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(5,717</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Carrying amount:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,079</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>188</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,917</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>153</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>527</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,553</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>183</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,416</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Furniture</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT</div><div style="text-align: center; font-weight: bold;">equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Laboratory equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Leasehold improvements</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Acquisition cost:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>126</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,025</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5,367</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>350</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,868</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquisitions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>65</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>291</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,470</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>59</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,885</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(33</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(129</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(139</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(7</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(308</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>158</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,187</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6,698</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>402</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,445</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Accumulated depreciation:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(77</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(455</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,857</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(155</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,544</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(24</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(285</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(899</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(66</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,274</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>33</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>113</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>137</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>7</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>290</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(627</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(3,619</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(4,528</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Carrying amount:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>49</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>570</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,510</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,324</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,079</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>188</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>3,917</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060843960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Information about Right-of-Use Assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following tables show the movements in the net book values of right-of-use of leased assets for the years ended December 31, 2020 and 2019, respectively:</div><div>&#160;</div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Buildings</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Office equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>81</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,255</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(400</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(18</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(14</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(432</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>63</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>54</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,223</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Buildings</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Office equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">IT equipment</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>79</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,185</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>400</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>29</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>500</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Disposals</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(10</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(400</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(17</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(420</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Balance as of December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,106</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>81</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>68</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,255</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock', window );">Impact on Statements of income/(loss) and Statements of Cash Flows</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">For the years ended December 31, 2020, and 2019, the impact on the Company&#8217;s statements of income/(loss) and statements of cash flows is detailed in the table below.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;">Statements of income/(loss)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Depreciation of right-of-use assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>432</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>420</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest expense on lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>53</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expense for short-term leases and leases of low value</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>603</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>565</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,088</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,037</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-style: italic;">Statements of cash flows</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total cash outflow for leases</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,088</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,037</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock', window );">Contractual Undiscounted Cash Flows</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following table presents the contractual undiscounted cash flows for lease liabilities as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Within 1 year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 1 and 3 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>970</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 3 and 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>912</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>948</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,367</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,403</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of right-of-use assets impact on the company's statements of income/(loss) and statements of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfRightOfUseAssetsImpactOnStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to the contractual undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ScheduleOfContractualUndiscountedCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087349080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents and financial assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Cash and cash equivalents and financial assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Cash and cash equivalents and short-term financial assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The Company&#8217;s cash and cash equivalents are maintained in the following respective currencies as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>160,893</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>193,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>160,893</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>193,587</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">By currency</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>152,537</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>158,173</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">EUR</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,215</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>10,169</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">USD</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>4,141</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>25,245</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>160,893</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>193,587</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">The following table summarizes the Company&#8217;s short-term financial assets as of December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financial assets due in 1 year or less</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>65,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>95,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>65,000</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>95,000</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087288552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and accrued income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PrepaymentsAndAccruedIncomeAbstract', window );"><strong>Prepaid expenses and accrued income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock', window );">Prepaid expenses and accrued income</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Prepaid expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,954</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,788</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,591</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,095</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5,545</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>3,883</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about prepaid expenses and accrued income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrepaymentsAndAccruedIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrepaymentsAndAccruedIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087340744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OtherCurrentReceivablesAbstract', window );"><strong>Other current receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock', window );">Other current receivables</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Swiss VAT</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>309</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>234</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Withholding tax</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>20</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>70</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>329</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>304</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about other current receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_OtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_OtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087288552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Share capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of capital structure</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The table below summarizes the Company&#8217;s capital structure:</div><div style="text-indent: 18pt;"><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-weight: bold;">In CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Common </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Treasury </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Share </div><div style="text-align: center; font-weight: bold;">capital</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Share </div><div style="text-align: center; font-weight: bold;">premium</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Treasury </div><div style="text-align: center; font-weight: bold;">shares</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>67,562,333</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>298,149</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares &#8211; incentive plans</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>681,770</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>13</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>672</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Conversion of note agreement, net of transaction costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,615,328</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>73</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>47,705</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>71,859,431</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,437</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>346,526</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares &#8211; incentive plans, net of RSU expiration and forfeiture</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>77,307</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>364</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Issuance of shares to be held as treasury shares, net of transaction costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>76,936,738</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(5,000,000</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,538</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>346,890</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(100</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935065710024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade payables and accrued liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock', window );">Trade payables and accrued liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; font-weight: bold;">&#160;In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,184</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>142</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;">Total trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,184</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>142</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Accrued research and development costs</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5,298</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,228</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Accrued payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,494</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,896</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">Other accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,293</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,673</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt; font-weight: bold;">Total accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>11,085</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>11,797</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about trade payables and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060682008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Revenues</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt; color: #000000;">The following tables provide contract revenue amounts from its LCAs for the years ended December 31, 2020, 2019 and 2018, respectively.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lilly</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>14,348</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>105,662</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Genentech</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Janssen</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,083</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,173</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,157</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Life Molecular Imaging</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,206</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Biogen</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,063</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,024</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>352</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>731</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total contract revenue</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>15,431</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>110,456</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>6,912</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">During the years ended December 31, 2020, 2019 and 2018, the Company recognized the following contract revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Revenues recognized in the period from:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Amounts included in the contract liability at the beginning of the period</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div></div><div>1,551</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Performance obligations satisfied in previous periods</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,206</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Changes in Contract Assets and Contract Liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 18pt; color: #000000;">The following table presents changes in the Company&#8217;s contract assets and liabilities during the years ended December 31, 2020 and 2019:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div>&#160;</div><div>&#160;</div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"><br /></div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;"><br /></div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF Thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Balance at </div><div style="text-align: center; font-weight: bold;">the beginning </div><div style="text-align: center; font-weight: bold;">of the </div><div style="text-align: center; font-weight: bold;">reporting period</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Additions</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Deductions</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Balance at </div><div style="text-align: center; font-weight: bold;">the end </div><div style="text-align: center; font-weight: bold;">of the</div><div style="text-align: center; font-weight: bold;">reporting period</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Twelve months ended December 31, 2020:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,354</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,858</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(5,638</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>306</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Twelve months ended December 31, 2019:</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,667</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,211</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,783</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 52%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred income</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>351</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,686</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(3,560</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>4,477</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060793560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses by category (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ExpensesByCategoryAbstract', window );"><strong>Expenses by category [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and Development</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Research and Development</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>43,787</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>37,465</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>32,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>14,424</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>12,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,662</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,276</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>585</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>694</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total research and development expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>59,487</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>50,432</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>44,277</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">General and Administrative</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">General and administrative</div><div style="margin-left: 9.35pt;"><font style="font-weight: bold; font-style: italic;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,471</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,637</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,903</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,274</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>7,172</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5,740</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,812</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,249</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,824</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total general and administrative expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>18,557</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>16,058</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>12,467</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial Result, net</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="margin-left: 9.35pt; font-style: italic; font-weight: bold;">Financial result, net</div><div style="margin-left: 9.35pt;"><font style="font-weight: bold; font-style: italic;"></font><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Financial income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>78</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>303</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>127</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Financial expense</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(184</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,926</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in fair value of conversion feature</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,542</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exchange differences</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(555</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(2,013</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(1,194</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Finance result, net</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(661</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>906</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(1,401</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ExpensesByCategoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ExpensesByCategoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087347688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related-party transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory', window );">Key management compensation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">For key management, including the board of directors (seven individuals excluding the CEO) and the executive management (five individuals including the CEO), compensation was as follows.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the years ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term employee benefits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,497</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,526</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2,681</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Post-employment benefits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>214</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>215</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>160</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share-based compensation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,578</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,155</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,683</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>6,289</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>5,896</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4,524</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18A&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935060737704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock', window );">Income tax expense reconciled to loss</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The income tax expense for each year can be reconciled to loss before tax as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income/(loss) before income tax</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(8,441</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6,194</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(10,507</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income not subject to tax/(expenses) not deductible for tax purposes</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>462</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(62</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of unused tax losses and tax offsets not recognized as deferred tax assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,979</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(6,132</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>10,173</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Effective income tax rate benefit/(expense)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>&#8212;</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The tax rate used for the 2020 reconciliations above is the corporate tax rate of 13.6% (13.6% in 2019 and 20.6% in 2018) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Tax losses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>121,948</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>64,125</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>109,294</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deductible temporary differences related to:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Right-of-use assets and lease liabilities, net</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Retirement benefit plan</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,464</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>7,485</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>5,665</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>129,412</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>71,610</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>114,959</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock', window );">Tax losses expiry dates</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">Tax losses expiry dates are shown in the table below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Tax losses split by expiry date:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>16,566</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>10,338</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2021</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2022</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2023</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,628</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2024</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>15,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>15,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>25,868</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2025</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>48,894</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2026</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">December 31, 2027</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>57,824</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>121,948</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>64,125</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>109,294</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the expiration of income tax losses that may be carried forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about income tax reconciliation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063194520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Retirement benefit plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Defined benefit pension plan amounts recognized in the balance sheet and statement of income</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following table sets forth the status of the defined benefit pension plan and the amount that is recognized in the balance sheet:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(30,213</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(17,942</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair value of plan assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>22,749</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>19,139</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>12,277</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total liability</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(7,464</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(7,485</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(5,665</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><div style="text-indent: 18pt;">The following amounts have been recorded as net pension cost in the statement of income:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Service cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,626</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,313</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>100</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(42</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(133</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(65</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net pension cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,655</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,375</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,130</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory', window );">Changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The changes in defined benefit obligation, fair value of plan assets and unrecognized gains/(losses) are as follows.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">A.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in defined benefit obligation</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Defined benefit obligation as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(17,942</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(14,278</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Service cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,626</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,313</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(1,095</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest cost</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(195</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(100</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in demographic assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,428</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,138</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in financial assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,171</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in experience assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(931</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(2,003</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(888</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Benefits deposited</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(1,710</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees&#8217; contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(851</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(756</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(621</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Defined benefit obligation as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(30,213</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(26,624</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(17,942</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">B.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in fair value of plan assets</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Fair value of plan assets as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>19,139</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>12,277</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9,352</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>42</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>133</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>65</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees&#8217; contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>851</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>756</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>621</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employer&#8217;s contributions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>950</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>859</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>693</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Benefits deposited</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,467</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>3,382</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,710</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Return on plan assets excluding interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>300</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>1,732</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(164</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Fair value of plan assets as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>22,749</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>19,139</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>12,277</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt; color: #000000;">Expected contributions by the employer to be paid to the post-employment benefit plans during the annual period beginning after the end of the reporting period amount to approximately CHF 1.1 million.</div><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">C.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in net defined benefit liability</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net defined benefit liabilities as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7,485</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5,665</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,926</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net pension cost through statement of income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,655</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,375</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,130</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Remeasurement through other comprehensive loss</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(726</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>302</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employer&#8217;s contribution</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(950</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(859</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>(693</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net defined benefit liabilities as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7,464</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7,485</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5,665</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 18pt; vertical-align: top; font-weight: bold;">D.</td><td style="width: auto; vertical-align: top;"><div style="font-weight: bold;">Change in other comprehensive loss</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Other comprehensive loss as of January 1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(5,587</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(4,283</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(3,981</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in demographic assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,428</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,138</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in financial assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(2,171</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of changes in experience assumptions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(931</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(2,003</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(888</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Return on plan assets excluding interest income</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>300</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,732</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>(164</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Other comprehensive loss as of December 31</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(4,861</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(5,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(4,283</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Actuarial assumptions and sensitivity analysis</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the years ended December 31, 2020, 2019 and 2018, respectively, are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Discount rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.20</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.20</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Rate of future increase in compensations</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.75</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.75</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Rate of future increase in current pensions</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest rate on retirement savings capital</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.50</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0.90</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Mortality and disability rates</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2020-CMI</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2015-CMI</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right;">BVG 2015G</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">A quantitative sensitivity analysis for significant assumptions as of December 31, 2020 is shown below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Discount rate</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future salary increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future pension cost</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Interest rate on </div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">savings capital</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot; font-weight: bold;">Assumptions</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="30" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">In CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Potential defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,740</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">33,080</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">30,912</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,519</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">31,652</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">28,916</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">31,070</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,405</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Decrease/(increase) from actual defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">2,473</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(2,867</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(699</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">694</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(1,439</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">1,297</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(857</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">808</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div><br /></div><div style="text-indent: 18pt;">A quantitative sensitivity analysis for significant assumptions as of December 31, 2019 is shown below:</div><div style="text-indent: 18pt;"><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Discount rate</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future salary increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Future pension cost</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">Interest rate on </div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">savings capital</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot; font-weight: bold;">Assumptions</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% increase</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">0.5% decrease</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="30" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: &amp;quot; font-weight: bold;">in CHF thousands</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Potential defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">24,248</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">29,396</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,317</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,930</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,993</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,393</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">27,447</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: &amp;quot;">25,848</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 20%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: &amp;quot;">Decrease/(increase) from actual defined benefit obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">2,376</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(2,772</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(693</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">694</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(1,369</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">1,231</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">(823</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div style="font-family: &amp;quot;">)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%;"><div style="font-family: &amp;quot;">776</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr></table><div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 142<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_142&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935073525112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory', window );">Share-based compensation plans outstanding</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following table summarizes equity-settled share option grants since inception under each plan type:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">PLAN</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of </div><div style="text-align: center; font-weight: bold;">options awarded </div><div style="text-align: center; font-weight: bold;">(since inception)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div>&#160;</div><div style="font-weight: bold;">Vesting conditions</div></div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div style="text-align: center; font-weight: bold;">Contractual </div><div style="text-align: center; font-weight: bold;">life of options</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan A</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>362,750</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">At grant</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">15.5 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan B</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>819,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">At grant</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10.5 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share option plan C1</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6,775,250</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from grant date</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">2016 SOIP:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Executives and directors</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,898,222</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">1 year, 3 year and 4 years&#8217; service from the date of grant, quarterly and annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employees</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>989,279</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from the date of grant, annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center; text-indent: -9.35pt; margin-left: 9.35pt;">10 years</div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Number and weighted average exercise prices of options under share option programs</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The number and weighted-average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and the 2016 SOIP are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of options</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average exercise price (CHF)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average remaining</div><div style="text-align: center; font-weight: bold;">term (years)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,359,891</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2.09</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.8</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,624</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.16</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(151,814</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.15</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>484,403</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.79</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,618,856</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>4.25</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>6.3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>932,175</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1.25</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4.4</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,618,856</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4.25</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6.3</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,699</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6.71</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(616,833</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>0.15</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>1,053,305</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>5.24</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>1,981,629</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>5.93</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>8.3</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>602,218</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>4.94</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>6.5</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at January 1, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,981,629</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.93</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>8.3</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(53,591</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>6.03</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(26,729</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4.38</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(73,669</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2.00</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,073,027</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>6.29</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Outstanding at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,900,667</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>5.90</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>8.2</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Exercisable at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>1,099,015</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>5.49</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>7.0</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Outstanding options, exercise price range and expiry dates</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The outstanding stock options as of December 31, 2020 have the following range of exercise prices. In fiscal year 2018, we began to grant awards solely with USD denominated exercise prices and discontinued granting awards with a CHF denominated exercise price.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Total options</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Range of </div><div style="text-align: center; font-weight: bold;">expiration </div><div style="text-align: center; font-weight: bold;">dates</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Range of exercise prices</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF 0.15</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>243,125</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>2020&#8211;2026</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">CHF 9.53</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>223,646</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2027</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">USD 5.04 to USD 12.30</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2,433,896</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>2028&#8211;2030</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total outstanding options</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>2,900,667</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Weighted-average assumptions</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The weighted-average grant date fair values of the options granted in 2020, 2019 and 2018 are USD 5.25 (CHF 4.65), USD 3.71 (CHF 3.59) and USD 6.66 (CHF 6.54), respectively. <font style="color: #000000;">The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of these awards:</font></div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercise price</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 5.04-9.16</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 5.15&#8211;5.54</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">USD 8.33&#8211;12.30</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share price (weighted average)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>7.11</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>5.41</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.87</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Risk-free interest rate</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>0</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected volatility</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>80</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expected term</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: right;">6 years</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Dividend yield</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of non-vested share awards (restricted share and restricted share units)</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt; color: #000000;">A summary of non-vested share awards (restricted share and restricted share units) activity as of December 31, 2020 and changes during the year then ended is presented below:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Grantee type</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of </div><div style="text-align: center; font-weight: bold;">non-vested </div><div style="text-align: center; font-weight: bold;">share </div><div style="text-align: center; font-weight: bold;">awards </div><div style="text-align: center; font-weight: bold;">granted</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div>&#160;</div><div style="text-align: center; font-weight: bold;">Vesting conditions</div></div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid #000000;"><div><div style="text-align: center; font-weight: bold;">Contractual </div><div style="text-align: center; font-weight: bold;">life of </div><div style="text-align: center; font-weight: bold;">non-vested </div><div style="text-align: center; font-weight: bold;">share </div><div style="text-align: center; font-weight: bold;">awards</div></div></td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Restricted share units</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;&#160;&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Directors</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>83,864</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">1 year service from date of grant, annually</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Executives</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>110,839</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">4 years&#8217; service from the date of grant, quarterly</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%;"><div style="text-align: center;">10 years</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Restricted share awards</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,023</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-indent: -9.35pt; margin-left: 9.35pt;">2.75 years&#8217; service from date of grant, quarterly</div></td><td valign="bottom" style="vertical-align: top; width: 29.333333333333333333333333333%; background-color: #CCEEFF;"><div style="text-align: center;">10 years</div></td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Number of</div><div style="text-align: center; font-weight: bold;">non-vested shares</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">Weighted-average</div><div style="text-align: center; font-weight: bold;">grant date fair value (CHF)</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2017</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>122,014</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.59</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(25,673</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.48</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>69,371</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.43</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(56,671</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.60</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>109,041</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.51</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>64,012</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.65</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2018</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>109,041</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(66,278</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>42,763</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.52</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>130,290</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.58</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2019</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>42,763</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Forfeited during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(11,828</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.47</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(7,804</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(84,638</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.51</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Vested during the year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(23,269</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>9.52</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-vested at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>19,494</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>9.51</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Vested and exercisable at December 31, 2020</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>49,289</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>9.47</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087335960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Maturity of commitments and contingencies</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;"><font style="color: #000000;">We lease our corporate, laboratory and other facilities under multiple leases at the EPFL Innovation Park in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our lease agreements have no termination clauses longer than a 12-month contractual notice period. </font>Since January 1, 2019, the Company has applied IFRS 16 and recognized a right-of-use asset for its leases, except for short-term and low-value leases as indicated in Note 3<font style="font-style: italic;">.</font> See &#8220;Note 5. Right-of-use assets and lease liabilities&#8221; for the contractual undiscounted cash flows for lease obligations.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Within 1 year</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>25,072</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>19,907</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 1 and 3 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>8,885</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>12,993</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Between 3 and 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>341</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>4,816</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">More than 5 years</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>57</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>2,193</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>34,355</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>39,909</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2020-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061483560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">For the Years Ended</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands, except for share and per share data</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Basic income/(loss) per share (EPS):</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Numerator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income/(loss) attributable to equity holders of the Company</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div>)</div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Denominator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>71,900,212</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>70,603,611</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>61,838,228</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Basic income/(loss) for the period attributable to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(0.86</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>0.64</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>(0.82</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;"><div><div>)</div></div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Diluted income/(loss) per share (EPS):</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Numerator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income/(loss) attributable to equity holders of the Company</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(61,921</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>45,442</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>(50,951</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;"><div>)</div></td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Denominator:</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>71,900,212</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>70,603,611</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>61,838,228</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Effect of dilutive securities from equity incentive plans</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>499,730</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Weighted-average number of shares outstanding &#8211; diluted to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>71,900,212</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>71,103,341</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>61,838,228</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td colspan="1" valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Diluted income/(loss) for the period attributable to equity holders</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(0.86</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>0.64</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>(0.82</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div><div>)</div></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock', window );">Antidilutive securities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2018</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Share options issued and outstanding (in-the-money)</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>412,191</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,081,836</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,472,589</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Restricted share awards subject to future vesting</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>28,418</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>109,041</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Convertible shares</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>911,261</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>&#8212;</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>440,609</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,993,097</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>1,581,630</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DilutiveEffectOfConvertibleInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935087302824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and risk management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Financial instruments and risk management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">Carrying amounts of financial assets and financial liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-indent: 18pt;">The following table shows the carrying amounts of financial assets and financial liabilities:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Long-term financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>334</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other current receivables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>329</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>304</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>65,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>95,000</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>160,893</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><div><div>193,587</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total financial assets</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>226,556</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div><div>289,195</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">As of</div><div style="text-align: center; font-weight: bold;">December 31,</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;"><div><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">In CHF thousands</div></div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2020</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div><div></div><div style="text-align: center; font-weight: bold;">2019</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Financial liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Long-term lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,780</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>1,813</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Trade and other payables</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>2,184</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>142</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accrued expenses</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>11,085</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div>11,797</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term financing obligation</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>&#8212;</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;"><div>652</div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-indent: -7.2pt; margin-left: 7.2pt;">Short-term lease liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>443</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div><div>442</div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;"><div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Total financial liabilities</div></td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>15,492</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td><td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><div><div>14,846</div><div></div></div></td><td colspan="1" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about carrying amounts of financial assets and financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063397960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Platform</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GeneralInformationAbstract', window );"><strong>General information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfTechnologyPlatforms', window );">Number of proprietary technology platforms</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfTechnologyPlatforms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of unique proprietary platform technologies to discover, design and develop medicines and diagnostics to target misfolded proteins.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfTechnologyPlatforms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057993592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Details)<br> SFr in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr) </div>
<div>Offering</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Offering</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GoingConcernAbstract', window );"><strong>Going concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Company's cash position</a></td>
<td class="nump">SFr 160,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 193,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 156,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 124,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Short-term financial assets</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssueOfConvertibleDebt', window );">Proceeds from issue of convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,278<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfPublicOfferings', window );">Number of public offerings | Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="nump">116,300<span></span>
</td>
<td class="nump">$ 117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember', window );">2018 License Agreement with Eli Lilly and Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GoingConcernAbstract', window );"><strong>Going concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">SFr 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_InitialPublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GoingConcernAbstract', window );"><strong>Going concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 116,300<span></span>
</td>
<td class="nump">$ 117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfPublicOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of public offerings issued or completed by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfPublicOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssueOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssueOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061206136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies, Right-of-use assets and lease liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_EstimatedLeaseTerm', window );">Estimated lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_EstimatedLeaseTerm', window );">Estimated lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_EstimatedLeaseTerm', window );">Estimated lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_EstimatedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated lease term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_EstimatedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935073532216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies, Property, plant and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract', window );"><strong>Estimated useful life [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract', window );"><strong>Estimated useful life [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LeaseholdImprovementsAndFixturesAndFittingsMember', window );">Leasehold Improvements/Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract', window );"><strong>Estimated useful life [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PropertyPlantAndEquipmentEstimatedUsefulLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LeaseholdImprovementsAndFixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LeaseholdImprovementsAndFixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063228152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies, Income taxes (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncomeTaxLossCarryforwardPeriod', window );">Tax loss carryforward period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncomeTaxLossCarryforwardPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period or time limit over which financial losses of the entity for preceding years can be deducted from the taxable revenue for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncomeTaxLossCarryforwardPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061111848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies, Segment reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Segment reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OperatingSegmentsNumber', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ReportableSegmentsNumber', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_OperatingSegmentsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments reported by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_OperatingSegmentsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ReportableSegmentsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reportable segments reported by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ReportableSegmentsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056647016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">SFr 3,917<span></span>
</td>
<td class="nump">SFr 3,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">4,416<span></span>
</td>
<td class="nump">3,917<span></span>
</td>
<td class="nump">SFr 3,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">8,445<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">10,133<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="num">(4,528)<span></span>
</td>
<td class="num">(3,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="num">(1,535)<span></span>
</td>
<td class="num">(1,274)<span></span>
</td>
<td class="num">(961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="num">(5,717)<span></span>
</td>
<td class="num">(4,528)<span></span>
</td>
<td class="num">(3,544)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture [Member] | Acquisition Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Furniture [Member] | Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member] | Acquisition Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member] | Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="num">(627)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="num">(970)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">3,553<span></span>
</td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Acquisition Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">6,698<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">7,958<span></span>
</td>
<td class="nump">6,698<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="num">(3,619)<span></span>
</td>
<td class="num">(2,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="num">(1,092)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="num">(4,405)<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
<td class="num">(2,857)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Acquisition Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning of period</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, end of period</a></td>
<td class="num">SFr (281)<span></span>
</td>
<td class="num">SFr (214)<span></span>
</td>
<td class="num">SFr (155)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=aciu_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057251800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities (Details)<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RightOfUseLeasedAssetsAbstract', window );"><strong>Right-of-use of leased assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, beginning of period</a></td>
<td class="nump">SFr 2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisposalOfRightOfUseAssets', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">$ (432)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="num">$ (420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, end of period</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract', window );"><strong>Impact on statements of income/(loss) and cash flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense for short-term leases and leases of low value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ExpenseRelatingToLeases', window );">Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total cash outflow for leases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract', window );"><strong>Contractual undiscounted cash flows for lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_UndiscountedOperatingLeasePaymentsDue', window );">Contractual undiscounted cash flows for lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract', window );"><strong>Contractual undiscounted cash flows for lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_UndiscountedOperatingLeasePaymentsDue', window );">Contractual undiscounted cash flows for lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Between 1 and 3 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract', window );"><strong>Contractual undiscounted cash flows for lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_UndiscountedOperatingLeasePaymentsDue', window );">Contractual undiscounted cash flows for lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Between 3 and 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract', window );"><strong>Contractual undiscounted cash flows for lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_UndiscountedOperatingLeasePaymentsDue', window );">Contractual undiscounted cash flows for lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RightOfUseLeasedAssetsAbstract', window );"><strong>Right-of-use of leased assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, beginning of period</a></td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisposalOfRightOfUseAssets', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, end of period</a></td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract', window );"><strong>Impact on statements of income/(loss) and cash flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RightOfUseLeasedAssetsAbstract', window );"><strong>Right-of-use of leased assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, beginning of period</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisposalOfRightOfUseAssets', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, end of period</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract', window );"><strong>Impact on statements of income/(loss) and cash flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_ComputerEquipmentMember', window );">IT Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RightOfUseLeasedAssetsAbstract', window );"><strong>Right-of-use of leased assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, beginning of period</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DisposalOfRightOfUseAssets', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance, end of period</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract', window );"><strong>Impact on statements of income/(loss) and cash flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">SFr 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractualUndiscountedCashFlowsForLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DisposalOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in right-of-use assets from disposals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DisposalOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ExpenseRelatingToLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense for leases recognized through profit and loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ExpenseRelatingToLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ImpactOnStatementsOfIncomeLossAndCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_RightOfUseLeasedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_RightOfUseLeasedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_UndiscountedOperatingLeasePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of undiscounted operating lease payments due for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_UndiscountedOperatingLeasePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061459608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents and financial assets, Cash and cash equivalents (Details)<br> SFr in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>$ / SFr </div>
<div>&#8364; / SFr</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr) </div>
<div>$ / SFr </div>
<div>&#8364; / SFr</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash and cash equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">SFr 160,893<span></span>
</td>
<td class="nump">SFr 193,587<span></span>
</td>
<td class="nump">SFr 156,462<span></span>
</td>
<td class="nump">SFr 124,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash and cash equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">152,537<span></span>
</td>
<td class="nump">158,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash and cash equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">SFr 4,215<span></span>
</td>
<td class="nump">SFr 10,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Translation rate into CHF | &#8364; / SFr</a></td>
<td class="nump">1.095<span></span>
</td>
<td class="nump">1.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash and cash equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">SFr 4,141<span></span>
</td>
<td class="nump">SFr 25,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Translation rate into CHF | $ / SFr</a></td>
<td class="nump">0.891<span></span>
</td>
<td class="nump">0.978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935063233560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents and financial assets, Cash and cash equivalents and short-term financial assets (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Deposit</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Cash and cash equivalents and financial assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Short-term financial assets due in one year or less</a></td>
<td class="nump">SFr 65,000<span></span>
</td>
<td class="nump">SFr 95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfEscrowDepositAccounts', window );">Number of deposits in escrow accounts | Deposit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Deposits in escrow accounts</a></td>
<td class="nump">SFr 334<span></span>
</td>
<td class="nump">SFr 304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfEscrowDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of escrow accounts with cash deposits of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfEscrowDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056559832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and accrued income (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PrepaidExpensesAndAccruedIncomeLineItems', window );"><strong>Prepaid Expenses and Accrued Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaid expenses</a></td>
<td class="nump">SFr 3,954<span></span>
</td>
<td class="nump">SFr 2,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Accrued income</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">SFr 3,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome', window );">Total</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">SFr 3,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember', window );">Janssen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PrepaidExpensesAndAccruedIncomeLineItems', window );"><strong>Prepaid Expenses and Accrued Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Accrued income</a></td>
<td class="nump">SFr 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PercentageOfAccruedIncome', window );">Percentage of accrued income</a></td>
<td class="nump">68.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PercentageOfAccruedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage that represents the percentage of total accrued income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PercentageOfAccruedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PrepaidExpensesAndAccruedIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PrepaidExpensesAndAccruedIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and current accrued income. [Refer: Prepayments; Accrued income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935094336376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current receivables (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other current receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Swiss VAT</a></td>
<td class="nump">SFr 309<span></span>
</td>
<td class="nump">SFr 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Withholding tax</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes', window );">Total</a></td>
<td class="nump">SFr 329<span></span>
</td>
<td class="nump">SFr 304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other current receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount', window );">Maturity period of assets</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables and receivables from value added taxes and withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the maturity period over which the entity considers carrying value of current receivables to correspond to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PeriodOfMaturityReceivablesFairValueCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056953400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Details) - CHF (SFr)<br> SFr / shares in Units, SFr in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Capital structure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 272,442<span></span>
</td>
<td class="nump">SFr 177,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of note agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt', window );">Conversion of note agreement, net of transaction costs (in shares)</a></td>
<td class="nump">3,615,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 215,478<span></span>
</td>
<td class="nump">SFr 272,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of additional authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement', window );">Number of RSUs either expired or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Capital structure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfSharesOutstandingIncludingTreasuryShares', window );">Balance, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,859,431<span></span>
</td>
<td class="nump">67,562,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans', window );">Issuance of shares - incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture', window );">Issuance of shares - incentive plans, net of RSU expiration and forfeiture (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares', window );">Issuance of shares to be held as treasury shares, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt', window );">Conversion of note agreement, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,615,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfSharesOutstandingIncludingTreasuryShares', window );">Balance, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,936,738<span></span>
</td>
<td class="nump">71,859,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Shares outstanding, excluding treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,936,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Capital structure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 1,437<span></span>
</td>
<td class="nump">SFr 1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedUnderIncentivePlans', window );">Issuance of shares - incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture', window );">Issuance of shares - incentive plans, net of RSU expiration and forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of note agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share Premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Capital structure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,526<span></span>
</td>
<td class="nump">298,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedUnderIncentivePlans', window );">Issuance of shares - incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture', window );">Issuance of shares - incentive plans, net of RSU expiration and forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of note agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,890<span></span>
</td>
<td class="nump">346,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Capital structure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfSharesOutstandingIncludingTreasuryShares', window );">Balance, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedUnderIncentivePlans', window );">Issuance of shares - incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans', window );">Issuance of shares - incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture', window );">Issuance of shares - incentive plans, net of RSU expiration and forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture', window );">Issuance of shares - incentive plans, net of RSU expiration and forfeiture (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">SFr (100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares', window );">Issuance of shares to be held as treasury shares, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of note agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt', window );">Conversion of note agreement, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">SFr (100)<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfSharesOutstandingIncludingTreasuryShares', window );">Balance, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value per share (in CHF per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity shares resulting from treasury share transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseDecreaseThroughTreasuryShareTransactionsEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of ordinary shares issued under a convertible debt arrangement upon conversion of the debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of ordinary shares issued under incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in number of equity instruments issued resulting from the issue of shares under share-based payment arrangements equity instruments other that share options net of expirations and forfeitures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseInNumberOfSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the issue of shares under share-based payment arrangements equity instruments other that share options net of expirations and forfeitures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseThroughSharesIssuedShareBasedPaymentArrangementOtherEquityInstrumentsNetOfExpirationAndForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseThroughSharesIssuedUnderIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the issue of shares under incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseThroughSharesIssuedUnderIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired or forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfOtherEquityInstrumentsExpiredOrForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfSharesOutstandingIncludingTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorized and issued, including treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfSharesOutstandingIncludingTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057472728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital, Convertible Note Agreement an Follow-On Offerings (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 25, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2018 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 24, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Offering </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Offering </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jan. 23, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jan. 23, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleBorrowings', window );">Convertible note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 50,300,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt', window );">Shares issued to settle Convertible Note Agreement (in shares)</a></td>
<td class="nump">3,615,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 116,300,000<span></span>
</td>
<td class="nump">$ 117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance costs | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember', window );">At the Market Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of common shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance costs | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember', window );">At the Market Equity Offering [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket', window );">Shares authorized for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 71,300<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_FollowOnOfferingsMember', window );">Follow-on Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 116,300,000<span></span>
</td>
<td class="nump">$ 117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfOfferings', window );">Number of offerings | Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance costs | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts', window );">Net proceeds | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 109,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_OptionForOverAllotmentMember', window );">Over-Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,695<span></span>
</td>
<td class="nump">1,108,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_FirstSubscriptionRightsMember', window );">First Subscription Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 98,900,000<span></span>
</td>
<td class="nump">$ 99,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_SecondSubscriptionRightsMember', window );">Second Subscription Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract', window );"><strong>Convertible Note Agreement and Follow-On Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 17,400,000<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common shares authorized for sale in the open market.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CommonSharesAuthorizedForIssuanceSalesInInOpenMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ConvertibleBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of debt identified as being convertible into another form of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ConvertibleBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ConvertibleNoteAgreementAndFollowOnOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of ordinary shares issued under a convertible debt arrangement upon conversion of the debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseInNumberOfOrdinarySharesIssuedUnderConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of offerings of subscription rights by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares net of costs to issue shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share received for common stock issued or sold in public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_FollowOnOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_FollowOnOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_OptionForOverAllotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_OptionForOverAllotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_FirstSubscriptionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_FirstSubscriptionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_SecondSubscriptionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_SecondSubscriptionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057184824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital, Shelf Registration Statement (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Offering</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Offering</div>
</th>
<th class="th">
<div>May 04, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShelfRegistrationStatementSharesAuthorized', window );">Shares authorized under Shelf Registration Statement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds received</a></td>
<td class="nump">SFr 116.3<span></span>
</td>
<td class="nump">$ 117.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement', window );">Number of additional future public offerings | Offering</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement', window );">Additional proceeds from Shelf Registration Statement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of future offerings of securities the entity may execute covered by the Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfFutureOfferingsOfSecuritiesAuthorizedUnderShelfRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential additional cash inflow from issuing equity instruments through a Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PotentialAdditionalProceedsSaleOfEquityInstrumentsShelfRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShelfRegistrationStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShelfRegistrationStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShelfRegistrationStatementSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock, debt securities, warrants, purchase contracts, units, subscription rights or any combination of the foregoing in one or more future public offerings authorized for sale by the entity through a Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShelfRegistrationStatementSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057128712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and accrued liabilities (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade payables and accrued liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">SFr 2,184<span></span>
</td>
<td class="nump">SFr 142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CurrentAccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Accrued payroll expenses</a></td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">11,085<span></span>
</td>
<td class="nump">11,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Accrual of performance-related remuneration</a></td>
<td class="nump">SFr 2,100<span></span>
</td>
<td class="nump">SFr 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CurrentAccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CurrentAccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061443704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing obligation (Details) - Grants, LuMind Research Down Syndrome Foundation [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Financing obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FundingCommitment', window );">Funding commitment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ReimbursementPercentageOfFundingCommitment', window );">Reimbursement percentage of funding commitment</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DebtInstrumentNumberOfInstallments', window );">Number of installments | Installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PercentageOfAdditionalInterestOnTotalRepayment', window );">Percentage of additional interest on total repayment</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DebtInstrumentNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DebtInstrumentNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for funding research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PercentageOfAdditionalInterestOnTotalRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to specific interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PercentageOfAdditionalInterestOnTotalRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ReimbursementPercentageOfFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of funding commitment amount required to be reimbursed as per a research grant agreement of which the amount includes the entire funding commitment plus an additional upcharge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ReimbursementPercentageOfFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_GrantsLuMindResearchDownSyndromeFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_GrantsLuMindResearchDownSyndromeFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061404424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Contract Revenue Attributable to Licensing Arrangements (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RevenueReclassifiedToOtherIncomeExpense', window );">Amount reclassified from contract revenue to other income/(expense)</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember', window );">Lilly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">SFr 14,348<span></span>
</td>
<td class="nump">SFr 105,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of contract revenues</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember', window );">Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember', window );">Janssen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">SFr 2,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember', window );">Life Molecular Imaging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember', window );">Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">SFr 4,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_OtherAgreementMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractRevenueAbstract', window );"><strong>Contract Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total contract revenue</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 352<span></span>
</td>
<td class="nump">SFr 731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_RevenueReclassifiedToOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue reclassified to other income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_RevenueReclassifiedToOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_OtherAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_OtherAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935096796968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Changes in Contract Assets and Liabilities (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Accrued income, beginning balance</a></td>
<td class="nump">SFr 1,095<span></span>
</td>
<td class="nump">SFr 3,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractAssetsAdditions', window );">Accrued income, additions</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractAssetsDeductions', window );">Accrued income, deductions</a></td>
<td class="num">(1,858)<span></span>
</td>
<td class="num">(4,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Accrued income, ending balance</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred income, beginning balance</a></td>
<td class="nump">4,477<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractLiabilitiesAddition', window );">Deferred income, additions</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">7,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ContractLiabilitiesDeductions', window );">Deferred income, deductions</a></td>
<td class="num">(5,638)<span></span>
</td>
<td class="num">(3,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred income, ending balance</a></td>
<td class="nump">SFr 306<span></span>
</td>
<td class="nump">SFr 4,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractAssetsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in contract assets for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractAssetsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractAssetsDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract assets for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractAssetsDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractLiabilitiesAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in contract liabilities for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractLiabilitiesAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ContractLiabilitiesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ContractLiabilitiesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935073621032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Recognized Revenues (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="nump">SFr 4,477<span></span>
</td>
<td class="nump">SFr 351<span></span>
</td>
<td class="nump">SFr 1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">SFr 10,000<span></span>
</td>
<td class="nump">SFr 2,206<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057078104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Installment </div>
<div>Representative</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">4,477<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember', window );">2018 License Agreement with Eli Lilly and Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">14,348<span></span>
</td>
<td class="nump">105,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">SFr 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod', window );">Period to provide notice of termination of agreement</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty', window );">Number of representatives in joint steering committee by each party | Representative</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 14,300<span></span>
</td>
<td class="nump">SFr 105,700<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Deferred income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Clinical and Regulatory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Expected transaction price allocation</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Commercial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Expected transaction price allocation</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Deferred research and development costs</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly and Company [Member] | Right-of-use License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Expected transaction price allocation</a></td>
<td class="nump">SFr 73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly, First Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments', window );">Number of installments | Installment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 30,000<span></span>
</td>
<td class="nump">SFr 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly, Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments', window );">Number of installments | Installment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember', window );">Morphomer Tau small molecule [Member] | 2018 License Agreement with Eli Lilly, Second Amendment [Member] | Phase 2 Clinical Study Licensed Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Milestone payment receivable</a></td>
<td class="nump">SFr 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of installments for satisfying a milestone payment associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of representatives in a joint steering committee by each party as per the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity&#8217;s future performance).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=aciu_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=aciu_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=aciu_RightOfUseLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=aciu_RightOfUseLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyFirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyFirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillySecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillySecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=aciu_PhaseTwoClinicalStudyLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=aciu_PhaseTwoClinicalStudyLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057079208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Anti-Abeta Antibody in AD - 2006 Agreement with Genentech (Details)<br> SFr in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues | SFr</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiAbetaAntibodyInADMember', window );">Anti-Abeta Antibody in AD [Member] | 2006 Agreement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod', window );">Period to provide notice of termination of agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">SFr 70,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentRecognized', window );">Milestone payment recognized</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">SFr 38,200<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 31,600<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfMilestonePaymentsReceived', window );">Number of milestone payments received | Payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiAbetaAntibodyInADMember', window );">Anti-Abeta Antibody in AD [Member] | 2006 Agreement with Genentech [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="nump">SFr 303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Total potential collaboration agreement value remaining</a></td>
<td class="nump">SFr 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized for the milestone payment(s) associated with a collaborative agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of times payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiAbetaAntibodyInADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_AntiAbetaAntibodyInADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2006GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2006GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057124104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Anti-Tau Antibody in AD - 2012 Agreement with Genentech (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jun. 30, 2012 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember', window );">2012 Agreement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiTauAntibodyInADMember', window );">Anti-tau Antibody in AD [Member] | 2012 Agreement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod', window );">Period to provide notice of termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">SFr 14,000<span></span>
</td>
<td class="nump">SFr 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfMilestonePaymentsReceived', window );">Number of milestone payments received | Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiTauAntibodyInADMember', window );">Anti-tau Antibody in AD [Member] | 2012 Agreement with Genentech [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Total potential collaboration agreement value remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 368,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized for the milestone payment(s) associated with a collaborative agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of times payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2012GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_AntiTauAntibodyInADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_AntiTauAntibodyInADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061401064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Tau Vaccine in AD - 2014 Agreement with Janssen Pharmaceuticals (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember', window );">2014 Agreement with Janssen Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 1,083<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauVaccineInADMember', window );">Tau Vaccine in AD [Member] | 2014 Agreement with Janssen Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod', window );">Period to provide notice of termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 25,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="nump">SFr 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 1,100<span></span>
</td>
<td class="nump">SFr 1,200<span></span>
</td>
<td class="nump">SFr 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauVaccineInADMember', window );">Tau Vaccine in AD [Member] | 2014 Agreement with Janssen Pharmaceuticals [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Total potential collaboration agreement value remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment(s) received for milestone payments associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_TauVaccineInADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_TauVaccineInADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056551064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Tau-PET imaging agent in AD -2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) (Details)<br> &#8364; in Thousands, SFr in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember', window );">2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) Imaging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauPETImagingAgentInADMember', window );">Tau-PET Imaging Agent in AD [Member] | 2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) Imaging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod', window );">Period to provide notice of termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 664<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementMilestonePaymentRecognized', window );">Milestone payment recognized</a></td>
<td class="nump">SFr 2,200<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="nump">SFr 1,100<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones', window );">Collaboration contract receivable for clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones', window );">Collaboration contract receivable for regulatory, commercialization and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 2,200<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_TauPETImagingAgentInADMember', window );">Tau-PET Imaging Agent in AD [Member] | 2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) Imaging [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 175,000<span></span>
</td>
<td class="nump">&#8364; 159,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that the entity is eligible to receive for clinical milestones from a collaborative agreement..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that the entity is eligible to receive for regulatory, commercialization and sales milestones from a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementCumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementCumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementMilestonePaymentRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized for the milestone payment(s) associated with a collaborative agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementMilestonePaymentRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_LicenseAndCollaborationAgreementOf2014LifeMolecularImagingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_TauPETImagingAgentInADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_TauPETImagingAgentInADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935067009512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, A-syn and TDP-43 PET tracers - 2016 agreement with Biogen (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember', window );">2016 Agreement with Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">4,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=aciu_AlphaSynucleinAndTDP43PETTracerInADMember', window );">A-syn and TDP-43 PET tracers - 2016 agreement with Biogen [Member] | 2016 Agreement with Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfPerformanceObligationsIdentified', window );">Number of performance obligations identified | Obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 1,100<span></span>
</td>
<td class="nump">SFr 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfPerformanceObligationsIdentified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of performance obligations identified applicable to the entity's assessment of a specific contractual arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfPerformanceObligationsIdentified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2016BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=aciu_AlphaSynucleinAndTDP43PETTracerInADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=aciu_AlphaSynucleinAndTDP43PETTracerInADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061853416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract revenues, Grants from the Michael J. Fox Foundation (Details)<br> SFr in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Grant</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 15,431<span></span>
</td>
<td class="nump">SFr 110,456<span></span>
</td>
<td class="nump">SFr 6,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_GrantsMichaelJFoxFoundationMember', window );">Grant from Michael J. Fox Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfGrants', window );">Number of grants received | Grant</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementPotentialValue', window );">Total potential collaboration agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,900<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Eligible grant amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized revenues</a></td>
<td class="nump">SFr 1,300<span></span>
</td>
<td class="nump">SFr 600<span></span>
</td>
<td class="nump">SFr 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_GrantsMichaelJFoxFoundationMember', window );">Grant from Michael J. Fox Foundation [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CollaborativeAgreementJointResearchCollaborationPeriod', window );">Period of joint research agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=aciu_GrantsMichaelJFoxFoundationMember', window );">Grant from Michael J. Fox Foundation [Member] | Skane University Hospital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Contract revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Eligible grant amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementJointResearchCollaborationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which collaborating entities are contracted to perform research, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementJointResearchCollaborationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CollaborativeAgreementPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total potential value of the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CollaborativeAgreementPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=aciu_GrantsMichaelJFoxFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=aciu_GrantsMichaelJFoxFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=aciu_SkaneUniversityHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=aciu_SkaneUniversityHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057410712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses by category (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr) </div>
<div>Employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense', window );">Operating expenses</a></td>
<td class="nump">SFr 43,787<span></span>
</td>
<td class="nump">SFr 37,465<span></span>
</td>
<td class="nump">SFr 32,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries', window );">Payroll expenses</a></td>
<td class="nump">14,424<span></span>
</td>
<td class="nump">12,382<span></span>
</td>
<td class="nump">10,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">SFr 59,487<span></span>
</td>
<td class="nump">SFr 50,432<span></span>
</td>
<td class="nump">SFr 44,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment', window );">Full-time equivalents in research and development | Employee</a></td>
<td class="nump">115.3<span></span>
</td>
<td class="nump">102.7<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense', window );">Operating expenses</a></td>
<td class="nump">SFr 7,471<span></span>
</td>
<td class="nump">SFr 6,637<span></span>
</td>
<td class="nump">SFr 4,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries', window );">Payroll expenses</a></td>
<td class="nump">8,274<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
<td class="nump">5,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">SFr 18,557<span></span>
</td>
<td class="nump">SFr 16,058<span></span>
</td>
<td class="nump">SFr 12,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses', window );">Full-time equivalents in general and administrative functions | Employee</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialResultNetAbstract', window );"><strong>Financial result, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">SFr 78<span></span>
</td>
<td class="nump">SFr 303<span></span>
</td>
<td class="nump">SFr 127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expense</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(1,926)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument', window );">Change in fair value of conversion feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Exchange differences</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance result, net</a></td>
<td class="num">(661)<span></span>
</td>
<td class="nump">SFr 906<span></span>
</td>
<td class="num">SFr (1,401)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember', window );">Convertible Note Agreement with Lilly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialResultNetAbstract', window );"><strong>Financial result, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Net interest expense</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued', window );">Effective interest recorded to amortize the host debt</a></td>
<td class="nump">SFr 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees calculated on full-time equivalents within general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_EmployeeFullTimeEquivalentsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees calculated on full-time equivalents within research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_EmployeeFullTimeEquivalentsInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FinancialResultNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FinancialResultNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) arising from the change in fair value of a convertible instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GainLossArisingFromChangeInFairValueOfConvertibleInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees allocated to general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses allocated to general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GeneralAndAdministrativeExpenseAllocationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries that are allocated to general and administrative expense. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_GeneralAndAdministrativeExpenseAllocationWagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees that are allocated to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses allocated to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ResearchAndDevelopmentExpenseAllocationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries that are allocated to research and development expenses. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ResearchAndDevelopmentExpenseAllocationWagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=aciu_ConvertibleNoteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935065171400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Individual</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related-party transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfPersonsKeyManagementBoardOfDirectors', window );">Number of individuals, Board of Directors | Individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfPersonsKeyManagementExecutiveManagement', window );">Number of individuals, Executive Management | Individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3,497<span></span>
</td>
<td class="nump">SFr 3,526<span></span>
</td>
<td class="nump">SFr 2,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 6,289<span></span>
</td>
<td class="nump">SFr 5,896<span></span>
</td>
<td class="nump">SFr 4,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfCommonSharesSoldRelatedPartyTransactions', window );">Number of shares purchased under subscription rights offering by related party (in shares) | shares</a></td>
<td class="nump">614,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfCommonSharesSoldRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of the entity's common shares sold to a related party in related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfCommonSharesSoldRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfPersonsKeyManagementBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of persons that are the included in Board of Directors excluding the Chief Executive Officer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfPersonsKeyManagementBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfPersonsKeyManagementExecutiveManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of persons that comprise key management of the entity that are Executive Management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfPersonsKeyManagementExecutiveManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057064248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Income tax expense reconciled to Income / (loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income/(loss) before income tax</a></td>
<td class="num">(61,921)<span></span>
</td>
<td class="nump">45,442<span></span>
</td>
<td class="num">(50,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Tax expense/(benefit) calculated at the statutory rate of 13.6% (13.6% for 2019 and 20.6% for 2018)</a></td>
<td class="num">(8,441)<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
<td class="num">(10,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Income not subject to tax/(expenses) not deductible for tax purposes</a></td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011', window );">Income not subject to tax/(expenses) not deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Effect of unused tax losses and tax offsets not recognized as deferred tax assets</a></td>
<td class="nump">7,979<span></span>
</td>
<td class="num">(6,132)<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Effective income tax rate benefit/(expense)</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenues that are exempt from taxation. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057035800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract', window );"><strong>Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Unused tax losses and tax credits</a></td>
<td class="nump">129,412<span></span>
</td>
<td class="nump">71,610<span></span>
</td>
<td class="nump">114,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">121,948<span></span>
</td>
<td class="nump">64,125<span></span>
</td>
<td class="nump">109,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Increase in tax losses available as an offset</a></td>
<td class="nump">57,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=aciu_NotLaterThanPriorYearEndMember', window );">Loss Expiry, December 31, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Loss Expiry, December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Loss Expiry, December 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Loss Expiry, December 31, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Loss Expiry, December 31, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Loss Expiry, December 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">15,231<span></span>
</td>
<td class="nump">15,231<span></span>
</td>
<td class="nump">25,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember', window );">Loss Expiry, December 31, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">48,894<span></span>
</td>
<td class="nump">48,894<span></span>
</td>
<td class="nump">48,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember', window );">Loss Expiry, December 31, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember', window );">Loss Expiry, December 31, 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_TaxLossesSplitByExpiryDateAbstract', window );"><strong>Tax losses split by expiry date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">57,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax Losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract', window );"><strong>Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</a></td>
<td class="nump">121,948<span></span>
</td>
<td class="nump">64,125<span></span>
</td>
<td class="nump">109,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember', window );">Deductible Temporary Differences Related to Right-of-use Assets and Lease Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract', window );"><strong>Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRetirementBenefitPlanMember', window );">Deductible Temporary Differences Related to Retirement Benefit Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract', window );"><strong>Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Unrecognized deductible temporary differences, unused tax losses and unused tax credits</a></td>
<td class="nump">SFr 7,464<span></span>
</td>
<td class="nump">SFr 7,485<span></span>
</td>
<td class="nump">SFr 5,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_TaxLossesSplitByExpiryDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_TaxLossesSplitByExpiryDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=aciu_NotLaterThanPriorYearEndMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=aciu_NotLaterThanPriorYearEndMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=aciu_LaterThanFiveYearsAndNotLaterThanSixYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanSevenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=aciu_LaterThanSixYearsAndNotLaterThanEightYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRightOfUseAssetsAndLeaseLiabilitiesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRetirementBenefitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=aciu_UnusedTaxCreditsRetirementBenefitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057424216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember', window );">Defined Benefit Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlanAbstract', window );"><strong>Defined benefit pension plan amount recognized in balance sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation</a></td>
<td class="num">SFr (30,213)<span></span>
</td>
<td class="num">SFr (26,624)<span></span>
</td>
<td class="num">SFr (17,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">22,749<span></span>
</td>
<td class="nump">19,139<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Total liability</a></td>
<td class="num">(7,464)<span></span>
</td>
<td class="num">(7,485)<span></span>
</td>
<td class="num">(5,665)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Defined Benefit Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NetPensionCostInStatementOfIncomeAbstract', window );"><strong>Net pension cost in statement of income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="nump">1,626<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestIncomeNetDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset', window );">Net pension cost</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Defined Benefit Plan [Member] | Defined Benefit Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NetPensionCostInStatementOfIncomeAbstract', window );"><strong>Net pension cost in statement of income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="nump">1,626<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="nump">SFr 71<span></span>
</td>
<td class="nump">SFr 195<span></span>
</td>
<td class="nump">SFr 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DefinedBenefitPlanPercentageOfContribution', window );">Contributions paid to the plan by computing percentage in salary</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployerMember', window );">Employer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DefinedBenefitPlanPercentageOfContribution', window );">Contributions paid to the plan by computing percentage in salary</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage', window );">Percentage increase in plan assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount', window );">Increase in plan assets</a></td>
<td class="nump">SFr 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DefinedBenefitPlanPercentageOfContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DefinedBenefitPlanPercentageOfContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase (decrease) in plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseDecreaseInPlanAssetsOfDefinedBenefitPlanPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in the net defined benefit liability (asset) resulting from interest costs resulting from the passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_InterestCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_InterestIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the net defined benefit liability (asset) resulting from the passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_InterestIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NetPensionCostInStatementOfIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NetPensionCostInStatementOfIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=aciu_DefinedBenefitsPlanEmployerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057198936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan, Changes in Defined Benefit Obligation (Details) - Defined Benefit Plan [Member] - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Changes in defined benefit obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Defined benefit obligation, beginning of period</a></td>
<td class="num">SFr (7,485)<span></span>
</td>
<td class="num">SFr (5,665)<span></span>
</td>
<td class="num">SFr (4,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(1,626)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Defined benefit obligation, end of period</a></td>
<td class="num">(7,464)<span></span>
</td>
<td class="num">(7,485)<span></span>
</td>
<td class="num">(5,665)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Defined Benefit Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Changes in defined benefit obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Defined benefit obligation, beginning of period</a></td>
<td class="num">(26,624)<span></span>
</td>
<td class="num">(17,942)<span></span>
</td>
<td class="num">(14,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="num">(1,626)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset', window );">Interest cost</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Change in demographic assumptions</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Change in financial assumptions</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Change in experience assumptions</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits deposited</a></td>
<td class="num">(1,467)<span></span>
</td>
<td class="num">(3,382)<span></span>
</td>
<td class="num">(1,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Employees' contributions</a></td>
<td class="num">(851)<span></span>
</td>
<td class="num">(756)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Defined benefit obligation, end of period</a></td>
<td class="num">SFr (30,213)<span></span>
</td>
<td class="num">SFr (26,624)<span></span>
</td>
<td class="num">SFr (17,942)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_InterestCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in the net defined benefit liability (asset) resulting from interest costs resulting from the passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_InterestCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057064040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan, Changes in Fair Value of Plan Assets (Details) - Defined Benefit Plan [Member] - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ChangesInFairValueOfPlanAssetsAbstract', window );"><strong>Changes in fair value of plan assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestIncomeNetDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">SFr 42<span></span>
</td>
<td class="nump">SFr 133<span></span>
</td>
<td class="nump">SFr 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer's contributions</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Fair Value of Plan Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ChangesInFairValueOfPlanAssetsAbstract', window );"><strong>Changes in fair value of plan assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets, beginning of period</a></td>
<td class="nump">19,139<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
<td class="nump">9,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_InterestIncomeNetDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Employees' contributions</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer's contributions</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits deposited</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets, end of period</a></td>
<td class="nump">22,749<span></span>
</td>
<td class="nump">SFr 19,139<span></span>
</td>
<td class="nump">SFr 12,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Expected contribution by employer to be paid to post-retirement benefit plans</a></td>
<td class="nump">SFr 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ChangesInFairValueOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ChangesInFairValueOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_InterestIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the net defined benefit liability (asset) resulting from the passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_InterestIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plans assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Interest expense (income), net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935073563448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan, Change in Net Defined Benefit Liability (Details) - Defined Benefit Plan [Member] - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract', window );"><strong>Change in net defined benefit liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liabilities, beginning of period</a></td>
<td class="nump">SFr 7,485<span></span>
</td>
<td class="nump">SFr 5,665<span></span>
</td>
<td class="nump">SFr 4,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Net pension cost through statement of income</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement through other comprehensive loss</a></td>
<td class="num">(726)<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer's contribution</a></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liabilities, end of period</a></td>
<td class="nump">SFr 7,464<span></span>
</td>
<td class="nump">SFr 7,485<span></span>
</td>
<td class="nump">SFr 5,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and gains (losses) arising from settlements. [Refer: Gains (losses) arising from settlements, net defined benefit liability (asset); Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935067023800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan, Change in Other Comprehensive Loss (Details) - Defined Benefit Plan [Member] - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ChangeInOtherComprehensiveLossAbstract', window );"><strong>Change in other comprehensive loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration period for defined benefit obligation</a></td>
<td class="text">17 years 7 months 6 days<span></span>
</td>
<td class="text">19 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Change in Other Comprehensive Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ChangeInOtherComprehensiveLossAbstract', window );"><strong>Change in other comprehensive loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss', window );">Other comprehensive loss, beginning of period</a></td>
<td class="num">SFr (5,587)<span></span>
</td>
<td class="num">SFr (4,283)<span></span>
</td>
<td class="num">SFr (3,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Effect of changes in demographic assumptions</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Effect of changes in financial assumptions</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Effect of changes in experience assumptions</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss', window );">Other comprehensive loss, end of period</a></td>
<td class="num">SFr (4,861)<span></span>
</td>
<td class="num">SFr (5,587)<span></span>
</td>
<td class="num">SFr (4,283)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ChangeInOtherComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ChangeInOtherComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) for the (increase) decrease in value of benefit obligation for the change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plans assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Interest expense (income), net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 147<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=aciu_ChangeInOtherComprehensiveLossDefinedBenefitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935058355784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details) - Defined Benefit Plan [Member] - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract', window );"><strong>Actuarial assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Rate of future increase in compensations</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Rate of future increase in current pensions</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherMaterialActuarialAssumptions', window );">Interest rate on retirement savings capital</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IssuedActuarialTablesSwitzerland', window );">Mortality and disability rates</a></td>
<td class="text">BVG 2020-CMI<span></span>
</td>
<td class="text">BVG 2015-CMI<span></span>
</td>
<td class="text">BVG 2015G<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">SFr 7,464<span></span>
</td>
<td class="nump">SFr 7,485<span></span>
</td>
<td class="nump">SFr 5,665<span></span>
</td>
<td class="nump">SFr 4,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">+0.5% Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Percentage increase in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">-0.5% Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Percentage decrease in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Discount Rate [Member] | +0.5% Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">SFr 27,740<span></span>
</td>
<td class="nump">SFr 24,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="nump">2,473<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Discount Rate [Member] | -0.5% Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">33,080<span></span>
</td>
<td class="nump">29,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="num">(2,867)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Future Salary Increase [Member] | +0.5% Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">30,912<span></span>
</td>
<td class="nump">27,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Future Salary Increase [Member] | -0.5% Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">29,519<span></span>
</td>
<td class="nump">25,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Future Pension Cost [Member] | +0.5% Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">31,652<span></span>
</td>
<td class="nump">27,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="num">(1,439)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Future Pension Cost [Member] | -0.5% Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">28,916<span></span>
</td>
<td class="nump">25,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Interest Rate on Savings Capital [Member] | +0.5% Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">31,070<span></span>
</td>
<td class="nump">27,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember', window );">Interest Rate on Savings Capital [Member] | -0.5% Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract', window );"><strong>Sensitivity analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Potential defined benefit obligation</a></td>
<td class="nump">29,405<span></span>
</td>
<td class="nump">25,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease/(increase) from actual defined benefit obligation</a></td>
<td class="nump">SFr 808<span></span>
</td>
<td class="nump">SFr 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IssuedActuarialTablesSwitzerland">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Published actuarial tables that detail assumptions about mortality and disability rates which are used to determine benefit obligations for defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IssuedActuarialTablesSwitzerland</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_SensitivityAnalysisActuarialAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_SensitivityAnalysisActuarialAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherMaterialActuarialAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Any other material assumption used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherMaterialActuarialAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2020-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_DefinedBenefitPlansThatShareRisksBetweenEntitiesUnderCommonControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=aciu_PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=aciu_PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_OtherMaterialActuarialAssumptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_OtherMaterialActuarialAssumptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056910504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation, Plans Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>Plan</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfEquityBasedInstrumentPlans', window );">Number of equity-based instrument plans | Plan</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">1,073,027<span></span>
</td>
<td class="nump">1,053,305<span></span>
</td>
<td class="nump">484,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanAMember', window );">Stock Option Plan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">362,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual life of options</a></td>
<td class="text">15 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanBMember', window );">Stock Option Plan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual life of options</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanC1Member', window );">Stock Option Plan C1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">6,775,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual life of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanMember', window );">2016 SOIP [Member] | Executives and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">1,898,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual life of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanMember', window );">2016 SOIP [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options awarded (in shares)</a></td>
<td class="nump">989,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual life of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember', window );">2016 SOIP, Vesting Condition 1 [Member] | Executives and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember', window );">2016 SOIP, Vesting Condition 2 [Member] | Executives and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember', window );">2016 SOIP, Vesting Condition 3 [Member] | Executives and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPlansOutstandingAbstract', window );"><strong>Share-based plans outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfEquityBasedInstrumentPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity-based instrument plans approved by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfEquityBasedInstrumentPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShareBasedPlansOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShareBasedPlansOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For vesting requirements for a type of share-based payment arrangement that existed at any time during the period, this element represents the period which an employees' right to exercise an award is no longer contingent on satisfaction of a service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanC1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_StockOptionPlanC1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_Two016ShareOptionAndIncentivePlanVestingTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061328168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation, Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="7">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>yr </div>
<div>SFr / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfOptionsAbstract', window );"><strong>Number of options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,359,891<span></span>
</td>
<td class="nump">1,359,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (in shares)</a></td>
<td class="num">(53,591)<span></span>
</td>
<td class="num">(53,591)<span></span>
</td>
<td class="num">(73,699)<span></span>
</td>
<td class="num">(73,699)<span></span>
</td>
<td class="num">(73,624)<span></span>
</td>
<td class="num">(73,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (in shares)</a></td>
<td class="num">(26,729)<span></span>
</td>
<td class="num">(26,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (in shares)</a></td>
<td class="num">(73,669)<span></span>
</td>
<td class="num">(73,669)<span></span>
</td>
<td class="num">(616,833)<span></span>
</td>
<td class="num">(616,833)<span></span>
</td>
<td class="num">(151,814)<span></span>
</td>
<td class="num">(151,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (in shares)</a></td>
<td class="nump">1,073,027<span></span>
</td>
<td class="nump">1,073,027<span></span>
</td>
<td class="nump">1,053,305<span></span>
</td>
<td class="nump">1,053,305<span></span>
</td>
<td class="nump">484,403<span></span>
</td>
<td class="nump">484,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">2,900,667<span></span>
</td>
<td class="nump">2,900,667<span></span>
</td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,359,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable (in shares)</a></td>
<td class="nump">1,099,015<span></span>
</td>
<td class="nump">1,099,015<span></span>
</td>
<td class="nump">602,218<span></span>
</td>
<td class="nump">602,218<span></span>
</td>
<td class="nump">932,175<span></span>
</td>
<td class="nump">932,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted average exercise price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding at beginning of period (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (in CHF per share) | (per share)</a></td>
<td class="nump">6.29<span></span>
</td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="nump">5.24<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
<td class="nump">9.79<span></span>
</td>
<td class="nump">$ 9.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding at end of period (in CHF per share) | SFr / shares</a></td>
<td class="nump">5.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 5.49<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="nump">SFr 4.94<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="nump">SFr 1.25<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageRemainingAbstract', window );"><strong>Weighted average remaining term (years) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining term (years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions', window );">Exercisable | yr</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageRemainingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageRemainingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of exercisable share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageRemainingContractualLifeOfExercisableShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057296840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation, Outstanding Options, Range of Exercise prices and Expiration Dates (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding Options (in shares)</a></td>
<td class="nump">2,900,667<span></span>
</td>
<td class="nump">2,900,667<span></span>
</td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,981,629<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,618,856<span></span>
</td>
<td class="nump">1,359,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price for options granted (in CHF/USD per share) | (per share)</a></td>
<td class="nump">SFr 6.29<span></span>
</td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="nump">SFr 5.24<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
<td class="nump">SFr 9.79<span></span>
</td>
<td class="nump">$ 9.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price of common share options exercised (in dollars per share) | (per share)</a></td>
<td class="nump">6.07<span></span>
</td>
<td class="nump">6.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price for options granted (in CHF/USD per share) | (per share)</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 9.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price for options granted (in CHF/USD per share) | (per share)</a></td>
<td class="nump">SFr 9.53<span></span>
</td>
<td class="nump">$ 12.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesOneMember', window );">CHF 0.15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding Options (in shares)</a></td>
<td class="nump">243,125<span></span>
</td>
<td class="nump">243,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesOneMember', window );">CHF 0.15 [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareOptionsDateOfExpiry', window );">Expiration Dates</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesOneMember', window );">CHF 0.15 [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareOptionsDateOfExpiry', window );">Expiration Dates</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesTwoMember', window );">CHF 9.53 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding Options (in shares)</a></td>
<td class="nump">223,646<span></span>
</td>
<td class="nump">223,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareOptionsDateOfExpiry', window );">Expiration Dates</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesThreeMember', window );">USD 5.04 to USD 12.30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding Options (in shares)</a></td>
<td class="nump">2,433,896<span></span>
</td>
<td class="nump">2,433,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesThreeMember', window );">USD 5.04 to USD 12.30 [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareOptionsDateOfExpiry', window );">Expiration Dates</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesThreeMember', window );">USD 5.04 to USD 12.30 [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract', window );"><strong>Outstanding options, exercise price range and expiry dates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareOptionsDateOfExpiry', window );">Expiration Dates</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_OutstandingOptionsExercisePriceRangeAndExpiryDatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShareOptionsDateOfExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which share options will expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShareOptionsDateOfExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=aciu_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935057977064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation, Weighted Average Grant date Fair Value and Assumptions (Details)<br> SFr / shares in Units, SFr in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr) </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr) </div>
<div>yr </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Number and weighted average exercise prices of options under the share option programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average fair value, options granted (in USD/CHF per share) | (per share)</a></td>
<td class="nump">SFr 4.65<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">SFr 3.59<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="nump">SFr 6.54<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average fair value, restricted share awards granted (in CHF per share) | SFr / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Weighted average fair value, non-vested restricted share awards granted (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 9.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageAssumptionsAbstract', window );"><strong>Weighted average assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price, weighted average (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected term | yr</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPaymentArrangementAbstract', window );"><strong>Share-based compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense charged against the income statement | SFr</a></td>
<td class="nump">SFr 4,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 2,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageAssumptionsAbstract', window );"><strong>Weighted average assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageAssumptionsAbstract', window );"><strong>Weighted average assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShareBasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShareBasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of non-vested other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageExercisePriceOfNonVestedOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935058307480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation, Non-vested Share Awards (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average grant date fair value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 0<span></span>
</td>
<td class="nump">SFr 9.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesAndRestrictedShareUnitsMember', window );">Non-vested Share Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPaymentArrangementAbstract', window );"><strong>Share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of non-vested share awards granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfNonVestedSharesAbstract', window );"><strong>Number of non-vested shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Non-vested at beginning of period (in shares)</a></td>
<td class="nump">42,763<span></span>
</td>
<td class="nump">109,041<span></span>
</td>
<td class="nump">122,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (in shares)</a></td>
<td class="num">(11,828)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (in shares)</a></td>
<td class="num">(7,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement', window );">Exercised during the year (in shares)</a></td>
<td class="num">(84,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year</a></td>
<td class="num">(23,269)<span></span>
</td>
<td class="num">(66,278)<span></span>
</td>
<td class="num">(56,671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Non-vested at end of period (in shares)</a></td>
<td class="nump">19,494<span></span>
</td>
<td class="nump">42,763<span></span>
</td>
<td class="nump">109,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">49,289<span></span>
</td>
<td class="nump">130,290<span></span>
</td>
<td class="nump">64,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average grant date fair value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Non-vested at beginning of period (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 9.52<span></span>
</td>
<td class="nump">SFr 9.51<span></span>
</td>
<td class="nump">SFr 9.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">9.47<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">9.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Vested during the year (in CHF per share) | SFr / shares</a></td>
<td class="nump">9.52<span></span>
</td>
<td class="nump">9.51<span></span>
</td>
<td class="nump">9.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Non-vested at end of period (in CHF per share) | SFr / shares</a></td>
<td class="nump">9.51<span></span>
</td>
<td class="nump">9.52<span></span>
</td>
<td class="nump">9.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Vested and exercisable (in CHF per share) | SFr / shares</a></td>
<td class="nump">SFr 9.47<span></span>
</td>
<td class="nump">SFr 9.58<span></span>
</td>
<td class="nump">SFr 9.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesMember', window );">Restricted Share Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPaymentArrangementAbstract', window );"><strong>Share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of non-vested share awards granted (in shares)</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement', window );">Contractual life of non-vested share awards</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfNonVestedSharesAbstract', window );"><strong>Number of non-vested shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (in shares)</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPaymentArrangementAbstract', window );"><strong>Share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of non-vested share awards granted (in shares)</a></td>
<td class="nump">83,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement', window );">Contractual life of non-vested share awards</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfNonVestedSharesAbstract', window );"><strong>Number of non-vested shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (in shares)</a></td>
<td class="nump">83,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | Executives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ShareBasedPaymentArrangementAbstract', window );"><strong>Share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of non-vested share awards granted (in shares)</a></td>
<td class="nump">110,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod', window );">Vesting conditions</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement', window );">Contractual life of non-vested share awards</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfNonVestedSharesAbstract', window );"><strong>Number of non-vested shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (in shares)</a></td>
<td class="nump">110,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum term of other equity instruments (ie other than share options) granted for a type of share-based payment arrangement that existed at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfNonVestedSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfNonVestedSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ShareBasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ShareBasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For vesting requirements for a type of share-based payment arrangement that existed at any time during the period, this element represents the period which an employees' right to exercise an award is no longer contingent on satisfaction of a service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesAndRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesAndRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=aciu_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_ExecutiveManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=aciu_ExecutiveManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056492408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Details) - CHF (SFr)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProvisionsResearchContracts', window );">External research projects</a></td>
<td class="nump">SFr 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_RentalContractPeriodForNoticeOfCancellation', window );">Notice period for cancellation of rental contract</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Commitments</a></td>
<td class="nump">SFr 34,355<span></span>
</td>
<td class="nump">SFr 39,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Commitments</a></td>
<td class="nump">25,072<span></span>
</td>
<td class="nump">19,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Commitments</a></td>
<td class="nump">8,885<span></span>
</td>
<td class="nump">12,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">Between 3 and 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Commitments</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More Than 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_CommitmentsAbstract', window );"><strong>Commitments and contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Commitments</a></td>
<td class="nump">SFr 57<span></span>
</td>
<td class="nump">SFr 2,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProvisionsResearchContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions for research and development contracts with external providers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProvisionsResearchContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_RentalContractPeriodForNoticeOfCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time required by the lessee in a lease agreement to provide notice of cancellation of a lease to the lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_RentalContractPeriodForNoticeOfCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935058151048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - CHF (SFr)<br> SFr / shares in Units, SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract', window );"><strong>Numerator [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income/(loss) attributable to equity holders of the Company</a></td>
<td class="num">SFr (61,921)<span></span>
</td>
<td class="nump">SFr 45,442<span></span>
</td>
<td class="num">SFr (50,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted-average number of shares outstanding to equity holders (in shares)</a></td>
<td class="nump">71,900,212<span></span>
</td>
<td class="nump">70,603,611<span></span>
</td>
<td class="nump">61,838,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic income/(loss) for the period attributable to equity holders (in CHF per share)</a></td>
<td class="num">SFr (0.86)<span></span>
</td>
<td class="nump">SFr 0.64<span></span>
</td>
<td class="num">SFr (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effect of dilutive securities from equity incentive plans (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">499,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted-average number of shares outstanding - diluted to equity holders (in shares)</a></td>
<td class="nump">71,900,212<span></span>
</td>
<td class="nump">71,103,341<span></span>
</td>
<td class="nump">61,838,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted income/(loss) for the period attributable to equity holders (in CHF per share)</a></td>
<td class="num">SFr (0.86)<span></span>
</td>
<td class="nump">SFr 0.64<span></span>
</td>
<td class="num">SFr (0.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_AntidilutiveSecuritiesAbstract', window );"><strong>Antidilutive securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding', window );">Share options issued and outstanding (in-the-money) (in shares)</a></td>
<td class="nump">412,191<span></span>
</td>
<td class="nump">1,081,836<span></span>
</td>
<td class="nump">1,472,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting', window );">Restricted share awards subject to future vesting (in shares)</a></td>
<td class="nump">28,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares', window );">Convertible shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">911,261<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares', window );">Total (in shares)</a></td>
<td class="nump">440,609<span></span>
</td>
<td class="nump">1,993,097<span></span>
</td>
<td class="nump">1,581,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_AntidilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_AntidilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive restricted share awards subject to future vesting that relate to the assumed exercise of the entity's incentive share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DilutiveEffectOfRestrictedShareAwardsSubjectToFutureVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options and potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DilutiveEffectOfShareOptionsAndConvertibleInstrumentsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive share options that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DilutiveEffectOfShareOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935056318552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and risk management (Details)<br> SFr in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr) </div>
<div>Institution</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">SFr 226,556<span></span>
</td>
<td class="nump">SFr 289,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">15,492<span></span>
</td>
<td class="nump">14,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Loss in finance results, net</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">SFr (1,194)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Foreign Currency Exchange Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Loss in finance results, net</a></td>
<td class="num">SFr (700)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">SFr (1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ClosingForeignExchangeRateIncrease', window );">Percentage exchange rate strengthened</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ClosingForeignExchangeRateDecrease', window );">Percentage exchange rate weakened</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DecreaseInNetLossForeignExchangeRateIncrease', window );">Net loss for period decrease, result of foreign exchange rate increase</a></td>
<td class="nump">SFr 800<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets', window );">Number of financial institutions holding cash and cash equivalents and short-term financial assets | Institution</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_LiquidityManagementRollingForecastPeriod', window );">Cash position rolling forecast period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest Rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PercentageOfIncreaseInInterestRates', window );">Percentage of increase in interest rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PercentageOfDecreaseInInterestRates', window );">Percentage of decrease in interest rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest Rate [member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_IncreaseInNetLossInterestRateIncrease', window );">Net loss for period increase, due to increase in interest rate</a></td>
<td class="nump">SFr 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_DecreaseInNetLossInterestRateDecrease', window );">Net loss for period decrease, due to decrease in interest rate</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Long-term Lease Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">SFr 2,184<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | Liquidity Risk [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialRisksAbstract', window );"><strong>Financial risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_BorrowingsDebtExtinguishmentPeriod', window );">Expected debt obligation payoff period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_AccruedExpensesMember', window );">Accrued Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">SFr 11,085<span></span>
</td>
<td class="nump">11,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember', window );">Short-term Financing Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_ShortTermLeaseLiabilitiesMember', window );">Short-term Lease Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_LongTermFinancialAssetsMember', window );">Long-term Financial Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_OtherReceivablesMember', window );">Other Current Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_ShortTermFinancialAssetsMember', window );">Short-term Financial Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_CashOnHandAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_FinancialAssetsAndLiabilitiesAbstract', window );"><strong>Financial assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">SFr 160,893<span></span>
</td>
<td class="nump">SFr 193,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_BorrowingsDebtExtinguishmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected period over which a debt obligation is expected to be extinguished in full.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_BorrowingsDebtExtinguishmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ClosingForeignExchangeRateDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage decrease to spot exchange rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ClosingForeignExchangeRateDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ClosingForeignExchangeRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage increase to spot exchange rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ClosingForeignExchangeRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DecreaseInNetLossForeignExchangeRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in net loss arising from a increase in the foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DecreaseInNetLossForeignExchangeRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_DecreaseInNetLossInterestRateDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in net loss arising from a decrease in the interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_DecreaseInNetLossInterestRateDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_FinancialRisksAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_FinancialRisksAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_IncreaseInNetLossInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in net loss arising from a increase in the interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_IncreaseInNetLossInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_LiquidityManagementRollingForecastPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The periodic interval in which the entity performs a rolling forecast of the entity's cash position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_LiquidityManagementRollingForecastPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of financial institutions holding the entity's deposits of cash and cash equivalents and short-term financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_NumberOfFinancialInstitutionsHoldingCashAndCashEquivalentsAndShortTermFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PercentageOfDecreaseInInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage decrease to interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PercentageOfDecreaseInInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PercentageOfIncreaseInInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage increase to interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PercentageOfIncreaseInInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_AccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_AccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_ShortTermLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=aciu_ShortTermLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_LongTermFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_LongTermFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_ShortTermFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_ShortTermFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_CashOnHandAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=aciu_CashOnHandAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139935061257096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - ATM Program [Member]<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PostBalanceSheetEventsAbstract', window );"><strong>Subsequent events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of common shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=aciu_SubsequentEventsMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_PostBalanceSheetEventsAbstract', window );"><strong>Subsequent events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts', window );">Proceeds from issuance of ordinary shares, net of agent commissions</a></td>
<td class="nump">SFr 8.0<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of common shares sold (in shares)</a></td>
<td class="nump">764,977<span></span>
</td>
<td class="nump">764,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_PostBalanceSheetEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_PostBalanceSheetEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares net of costs to issue shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aciu_ProceedsFromIssueOfOrdinarySharesNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aciu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=aciu_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=aciu_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=aciu_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>153
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M [RQ5M&:B[8VK;?*)J^:95Q+KO[-E9]</I""5!D%ZR:" '.P^OH$?ET_\=^
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MT?U.T<]"T[S+I ORKJ]-7K_M1?0'\9'"CV%1Y(?71PI;R&(_B,,CC>[>V"U
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MU!7],*/_%FJW@;ZO%1VM>N((FC_A^#=02P,$%     @ '$AW4M2Z):%W!
M  H  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RE5FU/(S<0_BNC5*I
M"GF%'CI>I 2.%NGH10?7^U#U@^.=[%IX[<7VD@N_OH^]FQ *1"?U2[*V9YZ9
M>>;%/EU:=^\+YD _2FW\6:<(H?K8[WM9<"E\SU9L<+*PKA0!2Y?W?>589$FI
MU/W18/!;OQ3*=,Y/T][,G9_:.FAE>.;(UV4IW&K*VB[/.L/.>N.KRHL0-_KG
MIY7(^9;#MVKFL.IO4#)5LO'*&G*\..M,AA^GAU$^"?RE>.FWOBE&,K?V/BZN
ML[/.(#K$FF6(" )_CWS!6D<@N/'08G8V)J/B]O<:_2K%CECFPO.%U=]5%HJS
MSG&',EZ(6H>O=OD'M_$<13QIM4^_M&QDQ[ H:Q]LV2IC72K3_(L?+0];"L>#
M=Q1&K<(H^=T82EY>BB#.3YU=DHO20(L?*=2D#>>4B4FY#0ZG"GKA_'<V[(0F
M99H$@ZG3?@!P/.[+%F3:@(S> 1F.Z,::4'CZ9#+.7@+TX='&K=':K>EH)^(E
MRQZ-AUT:#4:#'7CC39CCA#?^^3#I[\G<!X>R^&>'@<.-@<-DX/#_\;@;9-BC
MMQR=7-!U6=:&Z79">Z%@^O67X]%H<')ARTJ853<MAR?K[8W\ZX/K;__=6[Z2
MLK5[8\MO]JQ;;]>^W=LGY4F01$!*PGL?T- T5[8J!**07(>T+QN'2?,CHLR5
MR0G0%):6*F<KISA@,E!@61BK;;ZB2HL0F? 4+&7*2PO-+OK.JQP];3)\/F*T
M5&1PHKLO<$K.E 3'OA%4(C?6PQ-/@(0D-$TS&W <,-,"QDT@NR##M;,9YRD;
M<6Y$VXSN!Y3W5BH1.$.KAB(:#*P,FM,OK,X04X]NFF^(M*=0<TP-G-8KC#-I
M<Z.>("$0&E*J,5$C'U+4GG>[T,4(E454G.BG@C$C7<S#\,.)7\MT8Y8FE]T4
MV4RX>[A@S9M2,TBE0)"<$ER4(%\8Y<N6-5?G!#9S#MN&YV"X2W>BA@F-+!_X
ME:FECD1$K;O+V<'AN$=?D%UI7641 E-LM\#(JHH9J..LH+J*_(,"QWQ0*:V%
M(U&!-@%+H1!A;9SVU'X*:4_A8V$Q'*%NK#EXS<*.]"DC=9V8_C,*?7%PWF 7
ME9*ZK8D:-F!DJV)Z])TI9::MU]JHAYI?E-NZ5I_K5\5DW=:5$Q,4&MRA/6F?
M._O 5RS50LG8*E%<^OUD_@:4%181O2?O2Y01E1:76ZW9[W=_KCUV= 3T&Z+7
MA;Q5O#VZ0X6VTX:6(K*H@DJ5##[7^4VU+$BK4L6%5F*NM JK3=LCTU<\=W4D
M:SB.PWTP!@!-D1G=U"HO%IPN:IK4.:X_&AVU<M$LZ@?/@4@%\)6!SP)%9>7]
MVL0+3S?E\%R!!;KL ?8#NZ8EM96-YX$^S:X^T[4!4<W8C6U#TUJEGJ9IEX:#
MX1%]1G\*@]E*M^B:)W8:;O?>ND'Z6[<R4IFGMT=TIC:AN: WNYOGS:2YU9_%
MF[?1#3(3AXCF!50'O0]''7+->Z-9!%NE.WYN UX,Z3.&RBX*X'QAD<EV$0UL
M'GWG_P)02P,$%     @ '$AW4IU;R.26!@  F0\  !@   !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6RE5VUOVS80_BN$!PPQX/HM39MV28 D7=8 +5 DZ_9A
MV =:.EM<)%(C*3O^]WON*,EVEV;K]L661-[=<V_/D6<;YQ]"01358U7:<#XH
M8JS?3B8A*ZC28>QJLEA9.E_IB%>_FH3:D\Y%J"HG\^GTU:32Q@XNSN3;)W]Q
MYII8&DN?O I-56F_O:+2;<X'LT'WX<ZLBL@?)A=GM5[1/<7/]2>/MTFO)3<5
MV6"<59Z6YX/+V=NKE[Q?-OQB:!/VGA5[LG#N@5]N\_/!E %125ED#1I_:[JF
MLF1%@/%GJW/0FV3!_>=.^XWX#E\6.M"U*W\U>2S.!Z<#E=-2-V6\<YOWU/IS
MPOHR5P;Y59NT]W@^4%D3HJM:82"HC$W_^K&-PY[ Z?0K O-68"ZXDR%!^4Y'
M?7'FW49YW@UM_""NBC3 &<M)N8\>JP9R\>)*!Q.46RJDM-9><ZC.)A&:>7V2
MM5JNDI;Y5[3,YNJCL[$(ZD>;4WZH8 )(/:YYA^MJ_JS&=Y2-U?%LI.;3^?09
M?<>]G\>B[_@;_%2_72Y"]"B,WY^Q\+*W\%(LO/R?D7Q>RWRLGH3ZDS-VI3)G
M,_)6_5R06AJK;69TJ4+4D= H,:A"KTDMB&PK3+F"<,3VA6B-A8[R>NVJ6MLM
MJJTL66TTMB&E@])J=6!*+R-Y?@LF)\\K>^+??W<ZG[W^(:A,AT+5+A@!"^S7
M[V_4[-5T_ 9%6Y;2?S97H7 ^OH#":@^^#H%BZ(1>G>PDY",J@:H%,'35,(;[
M[(J+$&9,:PIJZ5VE*K2BJ4L"G-KPJM<F,&1:@KY@@S%X6A-\;45*DX%A2%;0
M2Z5>N#;B>N6IC>K1A^O+,!RK6RL 1@<1], '"'ER>=JCAT4$,X>UTM6LAU<(
M#6TIF3;0G,PSQ-X<4A(+]0%:MJW%V9MG+)Y^8=&JIH9ZZ*GUEO6-9-OQOP/&
M8?A\_TZ=3-41BYU,Q\?#G23#UEP,:_+1+!#ITL'B/F*">E(-:,!O/,H!KN4F
M9*ZQ;?SIL>:(!Z31J1R5>^A<@:RGVH"#'"(I+4]_-L:WZ:B]P0 QY787Q[I9
M()0HEZ74:!BAU%#]RH30L"I\X"+G7O\O!<"+*Z_Q.);>Z\ :[I<,/6RRU(<K
MU%Z[QC)8A[LNP)7HE$:KL:O>A(>@C"W(<_2Q@NAK.! *J02U:% 2% +G?[?I
MJ;[K=BIV=HV@N":T^ME^PST<,9JCX1 8FY5-WO5P:,!^\(E[<+=QRVT':YN"
ML F=WW@!4'OW!R9I2(P1FBPCR@^BT8.216"J]!9EAFPC$" D[2-J$X'EA.F%
M*0V,P=*1&>X"(+#Y,,%@$ KPLP/>&G7"(#J&X5U %--L'T$'*[%,51!UAYD,
MJ4 9@"7/D1?_:U1(I3-JHF2/52Z,^^*KL3F&L)?PP0BLM-XM&Y2[JASX5@K0
MN[Q!<6508[BJF6N]:U;%KC[V6HZ5K8=*QU22B9?$Y0?:JAHHG;640!WQQDSJ
MOR<VN!B:N@:IB76<T5I7A3)TGJ<PM57#+2FL/I(33#\3_L;B;:Z9D4-(./=[
M,W=PR[HH/2RP$0'XZKF$#/;@6YO?$EE+1+]/-!'G.9YXHY;\X%3.5<",M"L(
M]'E*_N$DRC&@6H=PTBMS')10Q'(4Y3F1@*Y-_F+V1JV-;[[HU6[(274G#T4&
MLX%VN'>15 O(H*VZ1%L373__=F9[DYRJJ!^D@VN4 U@*H4$!4\TEA_K-$PV
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M?NI@/]F[+E7D5W(I!/MQ@M+-J?_:WSLOTW5KMSU=6E%U*P.N*&D)T>GX]<D
MXU<N@NDENEHN7PL7<963QP+,09XW8'WI,,3:%S;0W\8O_@)02P,$%     @
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M!^^Z@+4##?'EHAB:VH=0M/2P.U0T*2]<7A6OAJZC,<5=N"J:MKE<Z>^KVH7
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M("TO+.^;MUZU'=@OA^G6:P^@-O&Z0B&!EX88$"8 %MN+,P*Z9B@G4[ $=*9
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MQ ?FD]/M/(H&'.E_;+'H!1A-1&-&EJ!N8:.#[NS\LF M >B&Q41QQ Z%)I:
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M"M:ZQGM6M1MP<E4K"W:+03O\TN@GY=4L5&TX:/'*^^L"3[+N45.OH3N+CT]
M,-PK:2PHWV# ]JAFI<S8HF##",TCO+.V4^'6U?L+N&_AYLT= NC>HHZ%N]ZT
ME>N-@OO'$R]OY4H;Z;39GQXJO'E;79=0-1CD,9-'[60-5P7JV2K<\D);=P'7
M$L,O%$CWWP!I#E1D0".:S2&-TCP#3AAD$>?B%,A"GJ()04V1II R8!%).-Q6
MMM-6UA:FG, O\/-/&:/L5Y@F)'TA<B^^'@<6BE&.Z#R?PSS*,2:>HDPBFB08
M2-$W?2T=5KA4^-H6E?11?26S:9JATVG*YGY)HA3/<.,=X<(CP?SWVQ- 4,_X
MO%OL_A3=>B,>%AJ1G 6L^2"*1'C3,7M,_IBKSWS<8]IGDYZFU /F<S*$Q(D(
M(6;A6$1SZAW>2&/VGL2RT7V+#?T\UYR 2 DD$9EC2[,,=SG:?NZ1B@0$5B2)
M!.YHE@!ZI>G_A8_(198B#P@3(*($ZYT(@LS,L)<O^)@*8#GUC,':"<PYRC)Q
MRL>A@92%GM,D+ ,12':6BU^Y$]]!Q0P]!]=<#.V-,C$0:9"Q%YR_3D7&!TX$
MW2P/F:3I0$0VYR^(B%E3BG\)7B,L$/D1-^2K],,"Y2"P#RP2_HW(!=(KP;"_
MF:=WW_*6'B .+VH6!8L;W72RW>,K7O3&H)EG,9T)G [J&NL8H9 <A6 [*)#Q
M#-__\DN%?_EBS[[T"QB?3!J-,ILP3UED.99I&#K&TW%DNQHFE7_5AWGOG32;
M"GE=JS6:DME<3, ,,]0@.-V%N66E'4Y!8;O%L5,9KX#?UUJ[H^ =C(/L\A]0
M2P,$%     @ '$AW4O5XSS?Y!   1PT  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&ULM5=M;]LV$/XK!PT=4L"Q]6H[:6(@S@N: <6*MELQ#/M 2V>+
M*$6J)!4G_?4[4K)B)ZX7=-L'2R)Y+\\=GSO29VNEOY@2T<)]):0Y#TIKZ]/1
MR.0E5LP,58V25I9*5\S24*]&IM;("J]4B5$<AN-1Q;@,9F=^[KV>G:G&"B[Q
MO0;35!73#W,4:GT>1,%FX@-?E=9-C&9G-5OA1[2_U>\UC4:]E8)7* U7$C0N
MSX.+Z'2>.GDO\#O'M=GZ!A?)0JDO;G!;G >A X0"<^LL,'K=X24*X0P1C*^=
MS:!WZ12WOS?6;WSL%,N"&;Q4XC,O;'D>3 ,H<,D:83^H]5OLXLF<O5P)XY^P
M;F6S)("\,595G3(AJ+ALW^R^R\.6PC3\CD+<*<0>=^O(H[QBELW.M%J#=M)D
MS7WX4+TV@>/2;<I'JVF5DYZ=^5TX5LOCQB P8] :8+( @10J",X67'#+T9R-
M++ES2J.\,SUO3<??,1W%\$Y)6QJXE@46NP9&A+,'&V_ SN.#%J\P'T(2#2 .
MX_" O:0//O'VDG\;//QYL3!6$X7^.N V[=VFWFWZ?^3\H&E7PJ>F9CF>!U2C
M!O4=!K-L""^/]%.)<*FJFLD'*KI<K23_A@6PHN"NC RH)>AM:S3V5HJ-7>H4
ML&BX*+A<D;CV$VJYY#D"?FUX335MP2K+"/T*+M_>0#A,/9SV.R.B"^%JUFE:
M O2 3!M 1R,@$F"U0-T3P6O&870R(,"F1E_GXH&"QA73#L7S, ?>+*N4MOP;
M\_VA0&IT!0&6?DTSB\"K6O"<6^#M9$Y\=BR #A>7N487#A.P4)IXX+QYU0WT
M1T@=BIR2JR3I#'VNU[YON.S=H:8VZ!-\V#9MG9?:DPF-$ ^S5[M[,(!T&+_:
MOPT^=\-QNWK[Z7&E1;=40K2.+5L(\FQ*XKJ#5ZD[C\YL<B/I!''=%^Z8:/"%
M//G1S3V%6^G98DO5&.;V;=Y3[M>G06['!9\<\6#.!),Y[L]D= +Q( K',(U@
M/*7O.,O@HJ^ - SAYY^F<12_Z=]N[HJ;6ADFS+/5I^\KI.K,>4N\(Z?[&HZB
MJ7^F[IDF,;T.@J3<M"#'"62I QDG_VU6?F&RH8,:=G,R.>G#H(GIT\3$)S")
M(-N;CJ/(!;H[VI^*B7LF/A-Q^$^9V+M=Q%XJ!E<04A$E-7?\[4JP9@\M==<E
MS\M.R!5Y+AK'PH[1%0DW;0WV[ 6U$'SET9HA7 @!>&^[.XJJVS245,JP0)0_
M8/'F)44QV*H*WRJH7;NFU#KINK=/\^0-E:REGM'&2SX)DJIP="24,:^]G=WU
MG)D2EE3T5-B&FJ)E7#P&X+L Q4;KCUC_\%BOGV-]QL:6M6[#/AX M4.)IVVD
M:QZN0!PU;J6E?3:6MH':M\NFW'.H950B,5QW(J[Q4!_3]IATJU9\ZSCTB"C
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M"&H70/LK1:IL)ZY ^UN:_ )02P,$%     @ '$AW4BJ%^=F( @  FP4  !D
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M/ETF,<%/,X MAX$6AN2L8@=XW>$0*T7M?;LSUGJ0TU= 2?S9%N893NZ$HLB
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M.7FP: HC%1Q+)D5J?9D5:$W\;=?.L8OIG;@7'Z31@?H5,)AU5BPIRMN"+Y
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M: 2*;R#60938WK]=G 2^^4=P,][4:D]*]J4P'E(RAQQ#I['Q2+'?CEX-NAN
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MI_"F?_S9TQTHO=?TO0,-FF(%KP('SH_8,;=_5,4.FXR6105&E'YN0*O($A^
M^ZL"U)3Y SM (T[#>_;_4$L#!!0    ( !Q(=U(E,0JZ'P4  '@-   9
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M@X:W;)#NG=Z\XKM\<F^OUM*&7]B,LBF=03U8I_N=,D;0"S7^LYL=#@<*5?*
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M;S;PL@?SNP/SXA3,:PFWKUZBC&H-@C$.G0/G</5)\\_(R?G@98+S+ F\=1C
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M7L<U">#OI5)V^" 'XTWQZA]02P,$%     @ '$AW4D0!LXR,#   R"0  !D
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MF!:.[*>/[D>C5_SI=**;1B_Y<J'RF:KI )[/M6ZZ'R2@_Y9^^3]02P,$%
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M.T5W4'DO5,A!!UOZ''L"^SB\A& 0*$,."]8:=*;//9$U'C/HL)G+K*#^QUS
ME;^D1X_U5\_NPU'P^A"Y& X+>C2,.5WO) V3/($DC!>N9&<TRN9I.%WD<(_T
MH>.%$]+G<<<T%9MIU[^[2TEENFEM2QN/9.G TT68$9']54OB/(SI,MP,\M&G
M<F^2)TF8SI+#_$=EF8 L<X]!3ESR?!+&^9Q&4^(WHWM\ZJL;#?H8>@.WOELS
M5 >MM%U+<U@]-(1771_T8MYUDQ^9WG(*G\ -'8W'\VD NNO0NHE5C>^*ULI2
MC^6'%36UJ)T![6\4E4X_<0X.;?+J#U!+ P04    "  <2'=2L@)90K@(  #-
M%0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RU6%USV[H1_2L8==IQ
M9AA]4)(M.[9G'"=I,KGW-A,G[4.G#Q )B:A)@!< K:B__IY=D!)EV6[GMGV0
M1(' 8C_.V5W@<F/=O2^4"N)'51I_-2A"J"]&(Y\5JI)^:&ME\&9E724#_KKU
MR-=.R9P75>4H'8]/1Y749G!]R6-?W/6E;4*IC?KBA&^J2KKM6U7:S=5@,N@&
MONIU$6A@='U9R[6Z4^%[_<7AWV@G)=>5,EY;(YQ:70UN)A=O9S2?)_Q5JXWO
M/0NR9&GM/?WYE%\-QJ20*E462(+$SX.Z565)@J#&KZW,P6Y+6MA_[J1_8-MA
MRU)Z=6O+O^D\%%>#Q4#D:B6;,GRUFX^JM6=.\C);>OX6FSAW/AV(K/'!5NUB
M:%!I$W_EC]8/O06+\3,+TG9!RGK'C5C+=S+(ZTMG-\+1;$BC!S:55T,Y;2@H
M=\'AK<:Z</U!&VDR+4NAC0^N@;^#%]+DPFE_CYT,0D.#EZ. [6C1*&M%OXVB
MTV=$3U+QLS6A\.*]R55^*& $/7?*IIVR;],7);Y3V5!,)XE(Q^GX!7G3G?%3
MEC?];XT7?[]98@(@](\7MIWMMIWQMK/_A\]?%IV.A^(_M^I;H<2MK6IIMG_Z
MPR*=G+WQD28Z:.6%^E%;KX0.(E@1,'=E2Y!8F[58[?8@F?X"4MT]4@CO<()<
M 388",@*:=:*-]<F**<\YLB@>.*K1&1.Y;I=1I-*_6NC,;+EH>&3&MH'Y619
M'EE3.[MVLH*6X W4!^=)Z<;4M$D6Y%*7)-FN>NI'O:-[O%+WGFP%SW2E_Z5$
M;0,DTSR98U<X0ZU6R"<[X8]UVPNNE>.4:3(5S=@[#YJ42OC";CP+R:1S6WHA
M*]M0K XTE-YW"NX'2QVM09@NQ VO #E4M52."?+)B-N/'R#=-AXK/3,&7Y/S
M'CQ:R3]9LWZ-V%3'FTZG,S$=S\1?H*9#.G*.'.VPDWX@(S C/><9=X5UX1DI
MI_-D/!Z+\_AS*WW!UF3TH!#O!UDR1">GXV1Q/A63\VDR7YR);S9 R)&X-#U-
MYO-3D2[.D\GY_'>;W_-ASP>E0HX_>#=)SA9C?"\F4_'-R3S"V;)+:KF-?DB3
MR6(F)K-4W&29:U1.[$'MHO639+R8T\_9^=D3CD+@[;+4:\EEBJ&4OH'3TO[<
M8[5FLRD^Z9&7#E2?)[/S%&HEB]FI^/"8ELR@'L6$[DB?$PV.:!QIBF]. <Y6
M+22R;5S6@-\)>*C!*EUN4<I" ;3X&I3I<LC[[U\3\?WN'3L18Q*F(:X.$HAK
M-/3GMU\2\>[S9YYR]_YSY,_15J2ML4$4*E^K?"@^VHT"29,^,44A01WPN-09
M,Q]U/"M(?0TD,0(+6^88\)V"NWTH=V:!-L(ZFMY%-!&;0F>%J)0TQ& 9#K>$
M0"\HZ5@D$B0[> )H3*([6FN7LJ34P-"%2]A4\LH)DA!C(!V_^0791YP.7V#,
M85*(_.#%DS>O#I(G<=:N#7):3AZWGC<FCHR'9\AW90GL)>W HAM@^30V&::[
M,:""S=TJZ> 3*NV'Y".N)9%LM!X/BZ1# 3JP<AL]H4UG9Z2DHCGHI1)A5!BV
M5CQ%[BA?KZ+3H5TA<PJ6,FN,&)6/-DK>TX-8;L5D_$<AUY)*88>_"#T\D\,Y
M*%1.(J$?@-S(Z$*5\+C%.FE"!!44B[[K?( DKVV.QK/!W$(^*+%4RF#.1KE1
M@8:0(KT]<NL).>>"AZ?#>3>,<DA=--#"F(W>X%KPF(=LSH@TB65NAS43L!H6
MCLBR7)D6@"URGH60?SYY#Y%+>W7;/UF1R9!#+IUHDY6-1[C) .1A)"]V**+^
MPFZOD%U0&9OE/]N,812E14C1AUJ <IER 7Y B!IZ5TN'VAX*3&("#I^#3H><
M1Q+A6K>.D.$LL)=*B90@!I,<9>%\E*OVJ078'AV88ROU[_ 1D3%BF) (R@F4
M1TR+E$D'B9[W6\D'G52;D-AI1'!'7&RYM3H@E4]:]81M<"0+,#FVA93:6/+H
MA/"$K'';:\GZ&82P20XG;')G4XI 7FC<=M^_:?, Q;@=ZW=F,?TBGB7ZJG 8
MLEX+^&S,DB>;K=\-:G88PY'9OR*?K ZZ9AT:JL9PFY+(]#%)<-QV^@*7U+)Y
M#VI&)'!<#)=QB(GS7G?SUJ@I0%+,RCC Z:JIVH:/3.XWPOK)MC 223W!T,=-
M2;\_(TM738FTT#:D$)APV:PE$)0W<2$-:'A70XW_70WB=WU!B^'SK>2^;OUT
M< @ !;"")NNG>^XE\HPA!I&ME+_1],5C">_?F#93$)$3P8DI[SH QB-,MO!.
M#%2A<>8&I+L:P3'?R]C&>F_4AMXZ62L ):,ZD:D: C<@+A)8EBEJ26YNQ:>J
M:HS:*<NOH&LEMTC0H"^G1&*":&JD<E*J.ZB +R?ZE0"AX"#=^K^C(>"(FH>V
M%8M#))G7H2O:. N%>.^10 8)(6P20BUT+4NYM(Z!ZB.V20&# T[GXQK9L)(9
M&T=1A<BEMH]&M<D;Z,!NQ2;816:(G(N0NE>JQA<#SUMC5"E459=V2RT(WI_H
MA]Z"/-<=;V2MJ:.%IKZI:Y"8G=)&"!H_?2J4-6PFKG*3A]1#P=P?)S7W=\B6
M#1>8U4J#C? :PYF.?'0!%A&Q;Y\W:">((KRC4U2'DWY>RY RJ;NKK-$ 34=;
M2-P%@ZZNX&]NF+$<+[''DFN'-9S LUU]7J$@1"WY@-CO*:D;;Q/ZH3.XU "0
M=#X(8K(@74)QZ"-N@JFRI+TVC@+]S&&FZV^)3Y0@VHHR25OAL?4G]9RB^)!Q
M.4 8KQY*:O"P(64S57)M;3OKQR$[/M/4<>AQ_ID/!=\6OK:KUPW5N_V1^$A&
MEWK(+[D"4TI"!$<2!9+:4&N8_L>[M_8.G[KB&?6NV"J%3H$N$GVL9/&V;3>Z
MNZN\B5=T^^GQHO-G-!I41DNUPE+TW_,!TA5?'L8_P=9\8;>T(=B*'PN%4#F:
M@/<K"Z>T?VB#W0WN]6]02P,$%     @ '$AW4NH<3^JQ @  V@4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&ULI53?;],P$/Y73D%"((VF33LVC;92
MVX'@83!M_'A /+CQ-3%S[,R^M"M_/6>G#47:*B%>$M_Y[KOO;-\WWEAWYTM$
M@H=*&S])2J+Z(DU]7F(E?,_6:'AG95TEB$U7I+YV*&1,JG2:]?NOTTHHDTS'
MT7?MIF/;D%8&KQWXIJJ$V\Y1V\TD&21[QXTJ2@J.=#JN18&W2%_J:\=6VJ%(
M5:'QRAIPN)HDL\'%?!3B8\!7A1M_L(;0R=+:NV!\D).D'PBAQIP"@N#?&A>H
M=0!B&O<[S*0K&1(/UWOT=[%W[F4I/"ZL_J8DE9/D/ &)*]%HNK&;][CKYS3@
MY5;[^(5-&SL\32!O/-EJE\P,*F7:OWC8G<-!PGG_B81LEY!%WFVAR/)2D)B.
MG=V "]&,%A:QU9C-Y)0)EW)+CG<5Y]%T(6I%0H-3_HYQ#5\$'SF-4V+P$)+F
M.Z!Y"Y0] 33(X,H:*CV\-1+EWP IL^JH97MJ\^PHXB7F/1@.3B#K9_TC>,.N
MU6'$&_Y;J_!]MO3D^'G\.%)DU!49Q2*C_S_/XT#9H =/,?Y<(BQL50NS??[L
M/!N<O?%@ES\QOG /FQ)-&ZY, ?D.1#@$LN#%"HM&. GT"(I8*JUH&P)SODUE
M&@3!;BALQ+(F1\>S9&0(81GPZ-88H?9U>-2"Z?"^40XE>!+4D'5;T+A&#<J
M=1)=)-/D.7(,^V38M'6H(OCA,UE1L*9X@A?J)<PN3_C/BY7EH> ,8\VKF?Y5
M(BN$Z^@;;)R56*!!)\)A@%0>>6@]E\AU(P/\QQ#TR=6E,.R5*A=!'WQLBFMP
M$:E$8:PGE?O>8V\B/9@W+E]$5?%\.HVA=O0Z;R=<LW9>_X2WJG<E'-^2Y[-9
M<6J_=\8ZX5HE:0VR=9S>I276@K@L67S1A0#>7UE+>R,4Z.1\^AM02P,$%
M  @ '$AW4E6PBJ9. @  ' 4  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&ULI51-;]LP#/TKA,Y![#AITQ:)@:;=L!T*%"VV'88=%)NVA<J2*\I-]^]'
MR8F7?308L(LEDH]/CS*IU<ZZ)VH0/;RVVM!:--YW5TE"18.MI*GMT'"DLJZ5
MGDU7)]0YE&5,:G62I>EYTDIE1+Z*OGN7KVSOM3)X[X#ZMI7N^P:UW:W%3!P<
M#ZIN?' D^:J3-3ZB_]3=.[:2D:54+1I2UH##:BVN9U>;1<!'P&>%.SK:0ZAD
M:^U3,#Z6:Y$&0:BQ\(%!\O*"-ZAU(&(9SWM.,1X9$H_W!_;WL7:N92L);ZS^
MHDK?K,6%@!(KV6O_8'<?<%_/6> KK*;XA=V S2X%%#UYV^Z364&KS+#*U_T]
M'"5<I&\D9/N$+.H>#HHJ;Z67^<K9';B 9K:PB:7&;!:G3/@IC]YQ5'&>SQ_[
M+>%SC\8#OO"75HEGVA!,BCW%9J#(WJ"897!GC6\(WID2RU\)$M8SBLH.HC;9
M2<9;+*8PGTT@2[/T!-]\+'(>^>;_6B1\O=Z2=]P2WT[0+T;Z1:1?_,\=GJ0(
MHW=%G2QP+7BV"-T+BCS+IO"G]#MI>%K:X&DDL5?J7GHL>:Y^A\K*HP/?(#>N
MEJ9 & :]9/R$_<[V=1/CBJB/ %L%FQ J9=BAI ;R# _GT03X%0#9=<YV3K&7
MAZJPO?'*U"!-":6B0EOJN80I+,\7D\OE$OYVP\E1Q[;HZCB7!)%L:-[1.X[^
M]=#Q/^'#NW$G7:T,@<:*4]/I\DR &V9Q,+SM8O]OK>=IBMN&GR]T <#QREI_
M,,(!XX.8_P!02P,$%     @ '$AW4@GJ40_>&P  <%H  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S N>&ULQ5QK;]M&L_XKA%_@A0/(=NR\29HF+>"X:9NB
MEZ#..?UP<#ZLR)6T#46JO%AV?_V99V;V0HIB$J3 ^=!&EI:[L[-S>>:R?+6O
MFP_MQMHNN]^65?O-R:;K=E]?7+3YQFY->U[O;$6_K.IF:SKZLUE?M+O&FH(?
MVI875X\?/[O8&E>=?/N*OWO7?/NJ[KO25?9=D[7]=FN:A]>VK/??G%R>^"]^
M=^M-AR\NOGVU,VM[:[O_VKUKZ*^+,$OAMK9J75UEC5U]<W)]^?7KRQ=X@$?\
MM[/[-OF<82O+NOZ /]X6WYP\!D6VM'F'*0S]<V=O;%EB)J+C+YWT)*R)!]//
M?O;O>?.TF:5I[4U=_N&*;O/-R5<G66%7IB^[W^O]CU8W]!3SY779\O^SO8Y]
M?)+E?=O56WV8*-BZ2OXU]\J(3WG@2A^X8KIE(:;R.].9;U\U]3YK,)IFPP?>
M*C]-Q+D*IW+;-?2KH^>Z;V_E-+)ZE;5N7;F5RTW5$;/RNJ\Z5ZVS75VZW-DV
M.WVGGQZ]NNAH:4QPD>LRKV69JR/+7%YEO]15MVFS-U5AB^$$%T1S(/S*$_[Z
M:G;&[VQ^GCVY7&17CZ\>S\SW)##B"<_WY,L9\3_7R[9K2)[^=V;=_X1U_\/K
M_N?(NC=]TUA:Z*X]SZJZ.LOU[[PT;<M40'JG./Y/S)N]W]CLIM[N3/60D5JW
M-*3-:(3%/U61E<XL7>DZ[-M564?#EZ8T56XSL1I0B2*CF72!B^.+G0]6\[_1
MQ*8L,[,%G]NLJ[.E)7TWI?L;$Y,%L5U7TL>]ZS9$ HG25D3)K#K;,$F-W=6-
M'))M7%WH+)X,; 1KU#2V&:V4D'L^<YQ/PW$^G64[F0HR!)X;^4-&@E*UADU0
M.W6*7S!=-O^K::Q\49J.V.<JVC"8M>HK'F'*\. BN_GQ^T76M\S"QMX9.G/Z
M:._SC:G6Q&":@F;L>(*"_R!%P1_IDN=0<MM!C8Z(4&&KFJR8$I2MAAM@69B@
MFHC#VHU?-Y"5D(K?@Q2 PO/LFJ1L38ZIA125-5'49JNFWH+N-JX2F.6JO.P+
MH0Q;:SN:9LL:08O2K_767IQBHD=^B(H;_;7?N'R#[VCOC6OMG# ]"\+T;/;T
M?[=WMNHAWGE-)NF8(?CL209ZN#&T^Z+>@=MOO__]-KM\FIUF_BGFUPWI&^Q=
MRSJ8W;!;LDT[F(?XA*_XP'Z^N6Z5(V"L:B[S-"=  7;J4B1TY! :'>PZDI:<
M?#Z=5&Z;C@XO:^!765L=_;-KZJ+/R;*09#D11,C8VW<92[=KBFQG&LB:6!NB
M:>MEE<[<- T$1PZU>]B192K+!W_R].@#?LI44_S6Z'&2:TC1E@362_ZJ+@G3
MD+A]S4:$T 1MQ2Q+2WO:$=^JL)EL96V[(.&_(Q2TPPH+.HYU3\)70U>JXH+F
M)O$BIN:.]'+K2DL\K@)%[<OP"4J3P5*;!NRES>=TY-@(6<KFCE9L!\03Q^Y<
MP5\V=;_>9-:Q&00W5WU9GG6$LC*[W97U@[6L*\S',_#Q(2,Q*.J&J,=*3?U@
M2E9D$B+2]*PUI:BD[K3P!]0FVV%#[A7/T_7O?WUU=?G\94M'=YZ],;25<$AA
MI[1+ E?L>'3^!4U;EF99-^*^0)18]48$E@B-<A=<#)E_$"12[(=B#Q]1\_/L
M9R^._%-'Z)'@9$^\IGV2\A.#WHHT^*,>BD[8Y?2S#A81(DHZZYU6X5JR841F
MX)ALD)Y@$ [76R]+MU;+16=+^(0WJ3J6"/EB( IJ OZV;6"7K'),?B&W\)QU
MSL98]^:WNM_8:O %;8>-ZLJ2.0_#<S47?%B#+V@\UL/ 'LI)OR]M95<NV;S.
M?0YG%XU#MR%[CR-NZY+W38?[I_HU,5*&MB@N1+5BR(H>L_S9%VNO[W!8K6@.
MN:<^JCF)PY*/9_H \&PX0["$#^M3'J3=M_2IY:.K[_ 4-)&VB;T1W"29X2.E
M;\^]F,W,I3 IS#3<<*!1]FAV$,+&$8>R+=%,3HSVN[6F[1L! ?6Z 4-@;79]
MLZM5";P,85"3.HDY&1HB/_+99<^F&Y3(FLSNL*B%/3@ =20?B\RMR/"0C6L)
M99!1*OXD83J<*.$2VRT5A>;0%Q)F.3"VV;4 '5)#NV/^ G08MBI!M40&U7.T
M7V3<AR<5V9-*4WA*L K)>TN:#S7;D(,LV<XO69N(UJ65XR&2+?,MHV?=-O!<
M(+ :G#'L21 =34J:H[B0J:A;>+4/EA;4241Z6$!);TD0Q_2(K@ZBJG@.)*SD
M0RAT[TF/J[K+ZIS (&/#GK50SEY91$I:YXZ/,G(1[&+;\]&-L!BV-D0 J[J9
M4:I6H8GHLOH.\#Z8478K"OEL5.9S+S^V*H+DM/VRM7_UMNH.!'MLI,^&"B*,
M!()F)$*3.6(;BR""U9XF3X4#L0Y/(R(/02'2'<02OTWK#\" %Q%O^&!($#5-
ML!'(FA>6Y[VWSNL&[)?#-*N5!5 ;>5VAD,!+10QH1S@:VPLSSB'HYP%!/_\(
M^$UP4J*B%$+LV)-,X>DOG#+[P=W9 "W6S,]TG+)WC! \<%IPJ!H 'L]:.-8%
MDG%=A"6/Y!UQ$\G;/$WR=-"/K[-__^O%L^<O7JIDMYV(U5^]@^D/.)6C*IJ/
M]*)?T0F*8Y T6K;;&%*8W/8=(T_ZA0AQ 9].P'0V QMS9UG-25@LS5,,3"5\
M$HG^(B+:KF&+21/@0SO >T>V' :_#/L4& .Q\T?D6:<J;HAZA8 ,'A*AU57J
M9FU(Y<4PD!>J[J N,!2TH=;Y.$1H R#S&1.:JK()+E%KPMPAM@]W*I-05!LA
M?=<73B<? 1HB0W00\1MY=@<]!ST+Q+_FC,[-J*OB,%Q0,QCM)YC@$,2A#2N1
M@TC.9\61MIH8B %O,DXBSR8VFC><[F80K:13X <_C0]%SCP5_M06*L$00W(:
M%&8KT<NZZOEW18_P%@U)FBS8DJC:,\E3D1O&7 *:_+R"+>T]R0V2(N',O130
M=*G@<*1(/J^U!WO]J-S0.C>__R8?PN"A@DT\\<MOBJ!([&J78Y3$Y325'\!J
M%P+ QE8"#HJ:U<V4>_, *(]L"Y.*9+EW?# A?UCD.IO>#JS"X803(DUD*!7)
MF<;$8$W^?.Q;8/6N'K\,]A'G4EI,R;]<OI3M],DI)(+/U*+D( D"EE"!6'WE
M$YM,&99.J--8%F*]-OW::N[0M'4%I%(!>B+63P@6 ?O=KE6[D.AD,6<K1P,X
M7PJ<0M&RWUUJLP^B]=16D;W[DS@IITO@N6XL@\>/+1:\ (=@P9B1)2AKV.A6
M=S:_+%B;D\RSF-!.(2A;Y'19 AK'=I37SLW.=0CD)8\[XYB_"H[YJUDO^D-C
M.+I!L#WE@S_]Z8-D5G M:XPB%9)8$K$5(E*.C$)X^8O+-X8,Q4\P O?T'^(7
MYOSI+S]]__VCQ*H[ E)TI@(-:::VWP''Q4259W<XU1D^O0A\>C&[TY]).J=1
MRJ<\E[UA$ 8?]1,9&21FN6)R^6*(.8?YOV?9::;/<Y7NK%Z=]6+M0DX7/P\R
MN]?=,%PR/ :FRBOP:$F.MY,@QT2#Z**!1/IVH9/9:%.&<;8^1A_N[(/*/@C'
M*?&O=<E?8A,@K4J3)KPKEG*3P% 6%U?%5/-*".*@:Z*:D:16C"P^X)KXS!';
M'GQ"7;[F$)%8R"HJ&>SWX<?X# <ZQ'-.7&K,6_B9M(2C,9&:(YDA!+<A=P)]
MWQD7'CX@8(%D%->_@)1"$(A<%JTC"?G,D>4FG]1Y*"^KU0V'ZKP6#R,DB/6D
MME.X,LE(# .@)&66-TP+^62"+@WG6GFR*<;XVL$HYZ<5(#J\M"X5Y(C+&?VH
MI,&8L'R0- A1X7;(V2G[SD4U(CO7Y#<:/@PLOW+W2';6(]'$3H\>9WJ(%)I2
M:/BW%226,-T&30[L]Y'WD6D)](29^2BLA!"D:"+2>F#>U7FM!JV+P2@-Q4=R
MA#)'@"+I<.@7L? >7&]8C,9+CH]Z# \TM0 WEW<A,THK<T)!,3L,KBN03Q5I
M7Y-](X-O)866TL.FQL=>WG20Q.X=15KV'GD9*"KR7/04LLP @])Y@)-D,16O
M4.]$]U-SMX@69ZCT0#6H!;6J-JRUAT9 (W;_>^$:<<ZM H.IJ3ES#&@MZ%.2
M?H@X-R0_]'F@^MA IB))4ZQZ(L*M[(2\\^1SBXJ%U+()25:?T^K+!U@!XQKF
ML53:6/UI6Y)UD*A>-2,Z3"^@(?O>'8HR@;V09YX5<A8SLA.VW5%\Q;L)N016
M,U.$]'QNFD8V+)*F2T_LN6YD&<UM..1 :F2HM::HJO49,P*C+*VM ON(IK]M
M4PO;I[01#)X2+QJVKAMO^4RK):GVZ^QU[\J"@[6GV0.ADC;[;;5"*L]2E"\@
MT/_P]OW$EZ]K#5739<]F < H,S;5+#"+B"X?QY:5Q[/8YIV63Q;9KC0:W88M
M3/:F?,%\V9OP"4GV3;VO8*<W!-&)]1+'THC6!;B^(.:07% TU6][B6"#JOJ:
M%2.@9,"!^IQG/\85) CPH><@IQ.<N5@->*&N:]RR[WQEA>UI0J(*YFYNT^?9
M=RG%M'$B(U=:Q2>9C-.*D [PTQ<1:,$](@=:QI=/))*4]#G+K99R1^:;35B:
MARP&MBJ5[H'(/E&1_3GF-P[EF7WVAFM%6R29Q.)<K/JFDC#-#WR_\3A7G=.(
M3)'^0-A=$/P[9_=L@U)K!Q,8"RT+" [S8=A"(UCO#_;/1MQ5%USCV*[06:P)
M04GG"SSM@&-00*1M<?;RP$*S\C@5\FD4Z>VK> +CT>?9#]PPP2HN'1-T_H0"
M=W7+Z2E(6JQ8DEV"CS.-1RE^),0KM[9HDZ37:"/,J,_KNI@U'TG'V^5\3PUI
M6@3(*_+L%==EIEM6)NW)/[E &D:$4__H0U(#$GA1:%V.HEX<)?*"0 %G[#K&
M,RWH(%KM&\ 'Z K1JF6HQA0!9\FB^CP24[$R(JYJ-=BGU.[C<@B7FUZA(I3@
M/A:@'.=$=@IH@V2HA@&0J^%*-K)%559K(++68 65IHTM?3SCFC&:!A;,X<A9
M^5@R.>)]00'O]X'PM\FTCY!;#XP=?!Y7@OR:=$1EV Q*)5Q W_.20#]%W2\[
M6 ]M+6P'^((S/34R/2 E 0.U#Y:KB.0M&CNX:"6VMK!+LG]) .6!$G%S:SZ
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M.W@DCZRY +9>4O]A+48<HEV:GVA-+.%/UGA?&6 ]"H4Z#U]5AQX&789H..N
MH;H]8%2B2%KOT2"3_JO./J)2OO0G35$/6ET(:'*>444?$B2^E;65^@4=D[0_
MI+X@[8..9:=?9P\L:3[RHI' T"F_<"QC.]L.?WNLEV;2<QL/J\ZT.7EQO!D'
M)!U)*P3?GK:C*/ :EV@QG.O^G'.4Q64U@T@V!-NQ?].$1B"],5(S(DT[9 /
M"F46[OZ*G<G#/GYDZRV!.HEHZ@G/)^6@F&9@BL&>:'!Y"/%3VL3 5A0PMZ;Y
M0'+@ET<CF=.,S*]S/Q]DVE+G:99U+^I6]1Q4\+E'ZD*.>5B/X^8+K9X!I')1
M[$AZ<]SB>L=5L31W&7W;E]'PMDMK\4,NBJ>CM142A/ V$!&K5@2]?8+JF&<;
MZ(9F?H]7H(A>C_B]%)$Q,H)GAO)$>M;5^0<M-@;Q2/J1QW%HFXQ7[;Y>9*\7
MV4UP\5>/+Y_IO+_M0B'B+9U3Q2[E'3O^1ONITWK_Z]+D'\YN\TW-EWWXX3-T
M F/ MBYLF9VV-C1U_5J3N;]\?MQ8:(O7(PU^I=D9!,E<I)-[6_*_%".;K>5[
M9>P_?+]C$(*[&@ OE%&C<'#%<Z6'EO+2]VI)_T1 YK%9\J HK7[T,.C3V)"=
MZW3U)>F<3L)2SIB)!+>#,/A4+D=JJ>%1[%X$&-^Z?ANOW*3;\15LZ>(+M?1#
MLP,+ DD#)YDI:A-/X5/H//D'#;>YWW3X+<D?:>RC4 "*G7.# KXW0JFQRS66
MEZ/0OHNTX ]"F'P-:1ZX"R_U%C%EZ4/_LS3\D9T,^O'U0HP+.03M[4N)D59"
MQ23'I_7)77$M3'G"6L9OTF@9V_PY97.6P)WM.:MM\'@'K;;'EQ?:T"5\S)OP
M2-"94!A3K,?\UN#AJ/!KI-2*T%_R!\,$?RYLB?D"@QA1%2@E]4"F#V58NQ/U
M 3P^F[R*%^DOYV^\O\-%Q_;8/>M/?CA+/HX04M"^41) (^72KFG#VB=&GDMR
MFRFH':*^'<(>!:E[28I*HP+2S'K)AO.L$"QQ@.BF[58EL89+/BV)<\Y1@&2S
M0GX?Q\#B+\8BD."]%$F=.U#<I/.&\#/F0\O$[.'$:_&7\Q?9WYO[HR\R^,1'
M,_]* ^W[[,S]L>K8*#+!,8X[Y:9;C+0BZC-ZW';KPDW&SE-B>M(,J1 H:"1:
M/.8M^*_2[-L0],#[]6J2F6Q-4/-E=^XDC_BFDEYG;G]>(D&@$$1_6/@-#&^[
M3]6VV%)0$,8][>O>7W4/0"@6X$!-\Z!"F IX N5]E,R!$S$"TB,G@6X!?^63
M-N=:?^<XM2DQ&O+7#4F5"-C7#?(<A5LI8([QFF?6TNC5PV.E4 $XKAF7F$4.
M8C4AN7?E+S1.\G*TGYD*[%BHHAA,XE4.CSV61+]!M"BAP2I]\\60;_&.YR)I
M8 PKGJ:2]RB+UVVXAO QL3K&B;>K8%1P,2BR)22YPED[J53,G/F"<Z"X4C9Y
M\),DM SI1\FTS^"VJFZL055J9<$!M';RZ,VPERE4!SR_^>8</W:,\_\HUX/\
M39BZH4O2[7&_HK^2VNFQ)-<OM1SA]59;V/PV#5ZB(5T@G+SJXMLLCAR5^H<>
MV/MO ,])C4D:8T(Q<&2V?-T^Z86;WD]5\]T&VXQV)NQ3# 5KH2F.Z!*-DGA=
MD@PBSS_VX.%H +"@0&CK8UMRI@5PB@MCPU=)T6'2HK#B_EY/2IP7UF++.%_[
M'1'YJ;(/KW!^(, :;W!RPP[(TFMR(57!.;P)+A_>$H79Z^4^/D&%<P1Y*D5H
MU&\Y,T>;%)T=1&U/AX,7_C;.F&6>35[W( ^QKK*4G@XG_0P,+L?]]<^UWRK6
MU/3%/=!$\'\_N.#X7M[8$E=MK$==L5M" /'HW1T3 I7^G+R"(.>VJI&.P!VM
M:O6*9%T<EZ 2\#P@Z[!$Y ^1FSN.':'3FK&^3N!@UCD$%M\E<SG_'I@W_LHM
MD2^(?!*+?>XDTV^00J-('F_YQM&0@[0I0)UA=-(QQ:+]L(=S2'@1O,$2IHE<
M4.B4]T^$HH]/3^.O/;^GS19G!IUOZS3?Y*/$OH,YX/D.,K=DZ5S9\ZW$0\(:
MN\(K/F1X$,L"#_#1LJ9PU59ON:_T1]PAM;GO.?%9#IG41_IZA4'#K>G8G';7
M6!^1\9U&S0S(:WGR045=+J91+!)SOZ'"+%?RDL%,NU2<.7LBGA//22%!<. U
M[?@L;BE6[B6OZ6&U2 ='S7[L!#>3^MVL!L2[X)?S-[=OP%^@8?_>#W^5-;SB
M+:1\)E7C'YM=\TD6Z2T?1D]I@%ZVQ!5-F/78L*:0K$W25J''*RR_&%UB3%.^
M ICDACY[I!TN\01BIMYZ%TN%6B3U(#L@\T6*H18>NZ3WKD6E#1)'&FQ<WV1O
M<6W3LK6$U_RL?8CGQS.G[M'4ZSW@<O$VJ@4-H!'A\O&@W(9[KZ:4,30($AU*
M#C,UH5-W]RA!:-CS*7USM,0!XD_O0.>GWJHCC9(W!ODW(6V-QV'IF\R23.6;
M :N&-SMBPC\%9DP8_7]=APX_-#WZ% B ])0(3Q>/)MZ'=O#,'1LD1M05N\3A
MFSY4+,GKSRE]O&=Z.7]5]-;**WX"[IQ4[<^<X\#-XSTDK8P:O>50<A9H-JES
M?ND0OXAPY3O@-8$C3=:<>_"O74C>PH"ZGMGQNQ;4:IIU5;?X,[QNJS/-VC)M
M6]>NZA+&EG[LK*M&L,1YLR&'H"&^=);1-F(7W'6&2*ZT RMCS5:LAS C%%$!
M:5=)#;JPN=19H,RC^C\N+O*4VDM*LM4,%N9$!M9^&!:.(+)2-O*#_1LJ>#+\
MH!2PF,N&(DWAA'Y-[@(FP8I_SY6K-/\MY@08<>)2Q;@&X[,H>-U'O26CB;ZM
MM!-I3I[C?>#+^8N]UX>F&5UJ^XPQB\0J7"8F=G>>$;":M/-"W9+>]E5$I/N8
MU(O_)UHF8;0?RGDI+G7[9<:K\ 5 OX:/R;69$A 'Z_4:5784B'3Q=N5Y=@OT
M%380+LI&14YS#!SJF_#.D5!KK()@=R'AD]Q%58LW?A&0OD-$WHO96LO2YD/W
M]#V;4Y)TD;P$>&O)&.!5QRJ5\C[@\&WF7Z=\+2\1CL/E7<R_D"U!#TMI5_3H
MX_/G3T_$9_D_NGK'KQ1>UEU7;_GCQAKR-1A OZ]J,CSZ!Q8(+YG^]O\ 4$L#
M!!0    ( !Q(=U*$)[EGT (  *D&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;*5544_;,!#^*Z<\;=(@;=IN"+656F :$M,0=-O#M <WN206CAWL
M"X5_O[.39D5 -&DOK7V^^[[S=^?+?&?LG2L1"1XKI=TB*HGJTSAV:8F5<,>F
M1LTGN;&5(-[:(G:U19&%H$K%R6CT,:Z$U-%R'FS7=CDW#2FI\=J":ZI*V*<U
M*K-;1.-H;[B114G>$"_GM2CP%NE[?6UY%_<HF:Q0.VDT6,P7T6I\NIYY_^#P
M0^+.':S!WV1KS)W?7&:+:.030H4I>03!?P]XADIY($[COL.,>DH?>+C>HW\.
M=^>[;(7#,Z-^RHS*170208:Y:!3=F-T7[.X3$DR-<N$7=JWO;!I!VC@R51?,
M&512M__BL=/A(.!D]$9 T@4D(>^6*&1Y+D@LY];LP'IO1O.+<-40S<E)[8MR
M2Y9/)<?1\K8M!I@<G"RTS&4J-+%8J6DT25U ;91,)3IXMQ%;A>[]/"8F]N%Q
MVI&L6Y+D#9)Q E^-IM+!A<XP>PX0<\9]VLD^[74RB'B.Z3%,QA\@&26C ;Q)
M+\,DX$W^7X9?JZTCR]WT>X!WVO-. ^_T#=X+1Y);"S.X0NXMV*"M8/L$X7$<
MF?RH8>/*.7Z=9^Q6&,LIO%: 89I-B8 ]E0I4U%'90RH1J-*>"H3U1LB-XN?K
M3F'=2)6Q'@YF\(3".OB6LU@,?]_(FE\K]0>7FY?& <EFO62S?Y2,$\X;!4KF
M^)HDPS#GR$,LE2+,!NGXSBIM5(?K"R[ ESF(XV.A0BI-!F1@9R4AMTH.Q+JF
MQI'O&Q1IV>G'/I(<SRPGLT8H>!"JX8 'M,&.K]W@F<K/I)MT>EZ)K;&"#+?I
M2[%#^Y1&92"KVC*5/W5QWE@MJ>$B#A0@/A@?%=HB#$E6Q+=^.TEZ:S^'5^WX
M^>O>#O&OPA92.VZQG$-'QY^X"+8=C.V&3!V&T=80C[:P+/E;@M8[\'EN#.TW
MGJ#_.BW_ %!+ P04    "  <2'=2QER:200$   N"@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6S-5MMNXS80_96!"A1>0(A(BI2EU#:02Q<;H L$
MNVG[4/2!EFE;6$G4DE0<_WV'E*TZW8U3!'WH0T(..7/F=L;B;*?-%[M5RL%3
M4[=V'FV=ZRZ3Q)9;U4A[H3O5XLU:FT8Z%,TFL9U1<A6,FCIAA&1)(ZLV6LS"
MV;U9S'3OZJI5]P9LWS32[*]5K7?SB$;'@T_59NO\0;*8=7*C/BOW:W=O4$I&
ME%75J-96N@6CUO/HBEY><Z\?%'ZKU,Z>[,%GLM3ZBQ?N5O.(^(!4K4KG$20N
MC^I&U;4'PC"^'C"CT:4W/-T?T=^'W#&7I;3J1M>_5RNWG4=Y!"NUEGWM/NG=
M!W7(1WB\4M<V_(?=H,O18]E;IYN#,<I-U0ZK?#K4X<0@)R\8L(,!"W$/CD*4
MM]+)Q<SH'1BOC6A^$U(-UAA<U?JF?'8&;RNT<XM[@_TU;A]#5\O6@6Q7H+[V
M58>%=S!YD,M:V7>SQ*$O;Y&4!]SK 9>]@$L9?-2MVUKXN5VIU7. !(,<(V7'
M2*_96<1;55Y 2F-@A)$S>.F8>1KPTC=E_L?5TCJ#G/GSC"L^NN+!%7^+J^_5
M]BR<G]-+V\E2S2,<1*O,HXH6#UL%:UWCD%7M!ESH&]@M!NKPIM&/RCNS4+7A
MH,5Y][,"C[+N45.OH3M;$)S_8+A7TEA0OJF +5'-4IFQ+<&&$5K$.+"V4V'D
MZOTEW+5P\^$] NC>HHZ%][UI*]<;!7</)UY^D4MMI--F?WJH<.RVNEY!U6"0
MQTP>M),U7)6H9ZLPXJ6V[A*N)89?*I#NGP'2 JC(@<8TGT(69T4.G##(8\[%
M*9"%(D,3@IHBRR!CP&*2<KBM;*>MK"U,.(%W\.,/.:/L)YBD)'LF<B^^' <6
MBE&.Z+R8PC0N,":>H4QBFJ882-DW?2T=5GBEL,-E)7U4KV0VR7)T.LG8U"]I
MG.$9;KPC7'@LF+^_/0$$]82_[1:[/T&WWHB'A<:D8 %K.H@B%=YTS!Z3/^;J
M,Q_WF/;9I"<9]8#%E PA<2)"B'DX%O&4>H<WTIB])[%L=-]B0[_-M2 @,@)I
M3*;8TCS'78&VWWJD(@6!%4EC@3N:IX!>:?9_X2-RD67( \($B#C%>J>"(#-S
M[.4S/F8"6$$]8[!V G..\UR<\G%H(&6AYS0-RT $DI_EXBLS\08JYN@YN.9B
M:&^<BX%(@XR]X/QE*C(^<"+HYD7(),L&(K(I?T9$S)I2_$MQC+! Y+^8D%?I
MAP4J0& ?6"S\;T0AD%XIAOVO>?J]3TIR\@UOE-F$EXI%"F$,P^=\/!T?0U?#
M&^!O]>$E]5&:386DJ=4:3<G%5$1@AM?)(#C=A1?!4CM\7X3M%A]TRG@%O%]K
M[8Z"=S ^$1=_ 5!+ P04    "  <2'=2H$H%P%T$  #7"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6RM5MMNXS80_96!"A0)X$0W6[:SMH'82; I
ML&BP2;HHBC[0TM@FEB*](A4G?]\A):MRXB@+M ^ZD)S+F<.9(2<[57S7&T0#
MS[F0>NIMC-E>^+Y.-Y@S?:ZV*&EEI8J<&1H6:U]O"V294\J%'P5!XN>,2V\V
M<7-WQ6RB2B.XQ+L"=)GGK'B9HU"[J1=Z^XFO?+TQ=L*?3;9LC?=H'K=W!8W\
MQDK&<Y2:*PD%KJ;>97@Q3ZR\$_B#XTZW_L%&LE3JNQW<9E,OL(!08&JL!4:?
M)UR@$-80P?A1V_0:EU:Q_;^W?N-BIUB63.-"B6\\,YNI-_(@PQ4KA?FJ=I^Q
MCF=@[:5*:/>&726;##U(2VU47BL3@IS+ZLN>:QY:"J/@'86H5H@<[LJ10WG%
M#)M-"K6#PDJ3-?OC0G7:!(Y+NRGWIJ!53GIFYG;A3*W.2HW M$:C@<D,!%*H
M(#A;<L$-1PTG#VPI4)].?$-^K;:?UC[FE8_H'1]A!%^4-!L-US+#[-" 3X ;
MU-$>]3SJM'B%Z3G$80^B( HZ[,4-"[&S%_]G%OZZ7&I34"[]W>&VW[CM.[?]
M=]S>RJJJ7'HNJ62@ ?)(?B\=D&-\=YJU=7RAMRS%J4>%JK%X0F_VL$%8*4%%
MR.4:C-M+T!L";&@E5T](I49A<^DF)/4#6TOPQ$1)DFH%19LD&CMRLCU=%(E3
M?$%6:$"[T4#;A/D2BV:K'*E1$(Y[5-!ZBZXDQ<L%W$I8?+XA ZK4)*-A7G*1
M$5(-OZ]6/$7 'R7?6HAP^] :/"C#!,R98#*U6V>!O7(;CB'JA4$"HQ"2$?U'
M@P%<9AFWO&OH!P'\^LLH"J-/S=?.77&]59H)_6;U]?<*B>:45_MX8G5/X20<
MN7??OOMQ1)].D,1-!3*)8="W(*/X_V7E-R9+:KMPR,EPW(1!$Z/7Q$1C&(8P
M.$K'26@#/1P=IV)HW[%C(@H^8N+H=G44VZ IMD%WL>54$@8(U[UAILYV<L]E
MJG+T3X32^M0EZ.'Z@ND-W%#='*W$3I_'*_'F9RJEURH5*\P;]':T4#24+X[[
MX2>JXP\B.EQ/;40K&Q%P34>885P0AKKR76N I3VNSV&/]4^']?HMUC<I6J6R
MW<4NF@_RY'5OJ3N*K1J;+[?2()%G )_I*F)[CSS2F =4-Q%<UR*V&U%S*\P9
MZ>:5>*NE.T048-7=( E(.1G491/V@M'(ON/AJQA:Q%6B;H+ZMIUS/FOK;1,=
MJ9LTJ9MTINZ"3D][YI3D\E%F7*>J)%*R#W*ST^A/GQ+@5BT#-A'2%I2R#:7%
M34/$P0:]U_;V>7Y!Y]T;B8[T^L;-AE(V='4$?6I=]IFCV2'::6LWKHML/ S<
MLU^-W>I@OTH7E'%_5.]IU(N3(;W[E!3']LYO7;9R+-;N2JG!\5#=NYK9YM9Z
M65W6_A6OKKQ?6+'FU&D%KD@U.!]2-RFJ:V0U,&KKKFY+9>@BZ'XW=//&P@K0
M^DHILQ]8!\U=?O8/4$L#!!0    ( !Q(=U(E;@BSXP(  !D'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;*U5WV_:,!#^5TZ9-&U2UOR \*,#)*"=
MVH=*56FWAVD/)CF(U<1.;5/*_OJ='<CH"CQ,?0#;E[OO^WR7NPS64CWJ'-'
M2UD(/?1R8ZKS(-!ICB739[)"04\64I7,T%$M UTI9)D+*HL@#L-.4#(NO-'
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M38].C@6X?I1Z@VP;VW=IB8<A;FM^?= % -^OK*6=$02&]ZSX"U!+ P04
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MZ7Y9T6A%[0+H?JV4W6^<P#"L%Z]02P,$%     @ '$AW4GY8T><[!   M@H
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULI59M;R(W$/XK(RI5B;0*
M^PJ$ R0@32^GG!KETO9#U0]F=P#KO#:UO>'HK^_8NRR$)ERJ2JM=O\P\\_9X
MUJ.MTE_-&M'"MU)(,^ZLK=T,NUV3K[%DYDIM4-+.4NF269KJ5==L-++"*Y6B
M&X=AKULR+CN3D5][T).1JJS@$A\TF*HLF=[-4*CMN!-U]@N/?+6V;J$[&6W8
M"K^@_77SH&G6;5$*7J(T7$G0N!QWIM%PECEY+_ ;QZTY&H.+9*'45S>Y*\:=
MT#F$ G/K$!A]GG&.0C@@<N.O!K/3FG2*Q^,]^JV/G6)9,(-S)7[GA5V/.X,.
M%+ADE;"/:OL1FWB\@[D2QK]A6\MF<0?RREA5-LKD0<EE_67?FCP<*0S"-Q3B
M1B'V?M>&O)<WS++)2*LM:"=-:&[@0_7:Y!R7KBA?K*9=3GIV,E?2:DH-)?@9
M984&+I[80J"Y''4MX3NI;MY@S6JL^ VL*(;/!+<V\),LL'@)T"7'6N_BO7>S
M^"SB#>97D$0!Q&$<GL%+VF@3CY>\.]H_I@OCE_X\ Y^V\*F'3[\'_]C OY;#
MLQ#N# [-AN4X[M A,ZB?L3-Y6B,LE: #Q.4*K*\/;+1ZY@5"?A(3L%)5TAI8
M:E4"I\']?$HSI<$2S@Z9-H"N0$#IQ7*!NDVQ>T?7P&3A!H. ,,T&_<$1NRNX
M_1[&G83YQUN2494A$.-!:TR'!_=<B!U$:9"D XC"+.CU8OCQAT$<Q1_@9Y0H
M+>;K=N7T^XE)8U!"%(2#A-Y1/X$XB+(^ 2^1R$=GO1),PUW)5BY5>\4XB,->
M.YMQM2*4_930>@FD01BG\ N%I]N=)(NAGT3PI"P3_TYTE 4I[491&*19#WK!
M-9V FTK[(OWG5#N-N2HW3.[(0JY6DO]-BO9%[4]],,#H<66B+@1J"?F:R14M
M<^DU6WE&B;/>VHMEP=F""VYWU-H$D_E!\U!YV*#FJC##_U___;DX#K"Q5QOQ
MI!W"M*$PE[FHBH/0*WXSZW<62 67+D64A".\-$C[?2HDE2G(Z/V VO_)*%10
M"\%7S/T<#!CZFB6O3=')>^84PCYRHFH0AN$)C<XTC*QM&-GYAG&H5ML[IJY2
MQI>J7;MOPN6OMY2S1M[=4L#ONK2?D*AAI8^[_\&<D*IV51P\A.*=1V!/_NOA
MGCA/+7%F-1W?+*_&C=+6+32%GA8%KTMY@T65U\,3%/+C3?VG+0KB>EG_P-[P
MF)B9Y[KR+,E5B:YW7&?$BR1+X2(*!MD +AW3KB-27J+6!]&:B5&0]OIP09TO
M<:()\>D=EEV*3BPGU#O[CI%1!!=IT*>&>-FX<VK9L;\?] 8]N$B"K!>28.W,
M:PSN'MTE2M0K?V-R-:<#65\KVM7V4C:M[R('\?I&]YEIJIH!@4M2#:_ZQ%-=
MWY+JB54;?S-9*$OW'#]<T\42M1.@_:52=C]Q!MJKZN0?4$L#!!0    ( !Q(
M=U(@O**XCP,  .4(   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+56
MVV[C-A#]E8$*%%E C22*NCBU#>2ZNP^+!LFV15'T@99&EK 2Z9*TG?Q]AY(M
M.VALM"CZ(G'(F3.7P]%HNE7ZFZD1+;QTK30SK[9V=14$IJBQ$^92K5#22:5T
M)RR)>AF8E491]D9=&[ P3(-.--*;3_N]1SV?JK5M&XF/&LRZZX1^O<%6;6=>
MY.TWGIIE;=U&,)^NQ!*?T?Z\>M0D!2-*V70H3:,D:*QFWG5T=9,Z_5[AEP:W
MYF@-+I.%4M^<\+F<>:$+"%LLK$,0]-K@+;:M Z(P_MQA>J-+9WB\WJ,_]+E3
M+@MA\%:UOS:EK6=>[D&)E5BW]DEM/^$NG\3A%:HU_1.V@V[,/"C6QJIN9TP1
M=(T<WN)E5X<C@SP\8<!V!JR/>W#41WDGK)A/M=J"=MJ$YA9]JKTU!==(1\JS
MU73:D)V=W[\0O08-+%ZA$!:72K_"Q5>Q:-%\F :67#C%H-C!W0QP[ 1<Q."+
MDK8V<"]++-\"!!3;&"#;!WC#SB+>87$)<>0#"UEX!B\>$XY[O/C?)/S[]<)8
M33?DCS,>^.B!]Q[X"0]/:%#HH@8A2[C##5W\%5UC^UXUSR*YAKPR*U'@S*..
M,Z@WZ)V$![JE8&N$W^AX5W\Z+[!;H.XK^%G"[:<'TE%K0\:F+RD]HHE[Y/#3
M"K6PC5P"[HO$8S_+,X@SGZ<)Q,R?L @>Q:M6;7O0BKC/&8>(^7'.( K]-&7P
M7 N-/[B.*:%0G5,5?2-&/LM22/($T@F'K\J*%O1Q4N514J./9.)SBB0)?1XS
MX)Q ,CC#5C*RE9QEZR-*RKKM'5^7U&&-NPGN4_$>7V>QWN?KV(%XX^!_88R8
MRB)(_33.@/N3,/X[73G5CI-BE#%(_(R'I[EB?DXMS7S&)\1;SO9\+4\G=;@5
MN9\D&42I'R:YNQP\/<M8.C*6GF7LH9%"%@UYIU:@CZ\/$M]MKG\*HP\P_YV2
M VPCJ90(60XQL1"Q[.AL5R2XB'(.'^A%C96Z11P[^;86<HF$ )5H-&Q$NT90
M%7$C-ZC[@5BAL&N-\/UW.8O8C\1UPMDHW;\4 T395!5JE 41<I$DB?/!_#"*
M!Z_1Q+D;XL(WA;A(TXB.)F'J]'A(PGO<!4>CIT.][ >LH4#7T@Y3:-P=9_CU
M,+H.ZL,/P!>AEXTTT&)%IN%E1LVFAZ$Z"%:M^D&V4);&8K^LZ3\$M5.@\THI
MNQ><@_'/9OX74$L#!!0    ( !Q(=U+.$"W VP(   T&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;)5576_:,!3]*U=Y:B4@)'P4*D JM%6GJ1IJ
MN^UAVH-);HA5Q\YLAX]_OVL',I!:I$E@;.?<<\Z-?2^3K=+O)D>TL"N$--,@
MM[:\#4.3Y%@PTU$E2GJ2*5TP2TN]#DVID:4^J!!AW.T.PX)Q&<PF?F^I9Q-5
M6<$E+C68JBB8WL]1J.TTB(+CQ@M?Y]9MA+-)R=;XBO9[N=2T"AN6E!<H#5<2
M-&;3X"ZZG?<=W@-^<-R:DSFX3%9*O;O%EW0:=)TA%)A8Q\#H9X,+%,(1D8T_
M!\Z@D72!I_,C^Z//G7)9,8,+)7[RU.;38!1 BAFKA'U1VR<\Y#-P?(D2QH^P
MK;$] B>5L:HX!).#@LOZE^T.[^$D8-3])" ^!,3>=RWD7=XSRV83K;:@'9K8
MW,2GZJ/)')?N4%ZMIJ><XNSL!06SF+9+INT>K&;2,/^^#%R]L95 <ST)+0DY
M>)@<2.<U:?P):13#LY(V-_ @4TS/"4)RV-B,CS;G\47&>TPZT(M:$'?C[@6^
M7I-VS_/U_C_M7W<K0QN)_7U!I]_H]+U._Q.=K[BGTY)TO>DB6TA40=5DF%/Z
MZ+5>)'/U>6M*EN TH (TJ#<8S.ANPON92@NX3$25<KD&FR.L%-,IJ Q2KJD6
ME*:C-;A!2;B4;WA:,6$ =Z<QBX=OU\!DZA>XPZ1RQ7.:RE7F-DX9SE4=0^LL
M8=@R _3)E*!68#K@K#OH'AEY0G=5@ X:BQ5J?]A?)"R>'@FC*D-FC#]]&J*Q
M&T;PFBMMVQ9U 5B40NV1LD6)&;<&>JW^^(;&03R$N#4<1;!4QK9KH$^A@<91
MG[X#B(9=XF0:VZ[0TW/W<6MP,Z(Q&A"0^'KPIBP3,&S%HS$,6J/Q$/JDUH>/
M[DUX4J(%ZK5O1(84*FGK:FUVFUYW5Y?X/WC=*)^97G.ZJ (S"NUV;@8!Z+KY
MU NK2E_P*V6I??AI3OT:M0/0\TPI>UPX@>8?8/874$L#!!0    ( !Q(=U+(
MN4KD[00  $P-   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+57;6_;
M-A#^*P</&VQ C:Q7ORPQD*0MV@\%BB3M, S[0,EGBZU$:B05)_WU.U*RJ]B.
MFPW;!TLB???<<Z^BSC=2?=4%HH&'JA3Z8E 84\]]7^<%5DR?R1H%_;.2JF*&
MEFKMZUHA6SJEJO3#\3CU*\;%8''N]CZJQ;EL3,D%?E2@FZIBZO$*2[FY& 2#
M[<8-7Q?&;OB+\YJM\1;-I_JCHI6_0UGR"H7F4H#"U<7@,IA?I5;>"7SFN-&]
M9[">9%)^M8OWRXO!V!+"$G-C$1C=[O$:R]("$8V_.LS!SJ15[#]OT=\ZW\F7
MC&F\EN5O?&F*B\%T $M<L:8T-W+S#CM_$HN7RU*[*VPZV?$ \D8;677*Q*#B
MHKVSARX.+U$(.X70\6X-.9:OF6&+<R4WH*PTH=D'YZK3)G)<V*3<&D7_<M(S
MB_<BEQ6"80^H87C'LA+UZ-PW!&T%_+R#N6IAPF=@@A ^2&$*#6_$$I=/ 7SB
MM",6;HE=A2<17V-^!E'@03@.QR?PHIVCD<.+7N+H'Y>9-HHJXL\3R/$..7;(
M\0^1 1^H6312M>92Y+S$)1@)I=3Z6$A/PMING.N:Y7@QH';3J.YQL+@K$/BA
M/6I.0)87\(A,0<X$9,=(T"Y)MJI,DU9)/:GG0/4-AI!_)^TN@T#QQRI#Y7+P
M7L#UN[<D(QO-Q%*[I- EF-G+%-H0^$-K9+2UTN,Y3 -O%@8P@CCQXCB$83+V
M9HG=N/ONAC_,4."*FQ&Y4.9-R0P18<9QTX:9QDCU"(JV0:X@B,[2GV'8WFP$
M'!^B1P^]K>D(AE,R:HVE7C"+267L)>,)K;O4"6EH*F5?:%+84!%C?]AQ(G?L
MOQ21AN8'=8>#M3[5C:HE"4"<DC_T&T$4Q?!FM;(PQ*\1C;:Q)UD;%Y*TW.Q2
MKE8:C7;(-DMKP;]93[6=)ZA4I\6TDYIXL\F,+'A!9(T0^6 2=79HHO7C[$+3
M!7'GP@A^^6D:!N&O!_<3Q9_LBC\Y6?R?1,^!7I0,5K54-.9AR8FI0I&C]IZ)
M26\W)^>Y.=HN)XD\WRZ[N#@;JZ[470%O.X0S^X8@+IFT\=1.(I?*>F!Z"/M%
MQ\5^S;4[5'(U>[2S%++''A *PPTGITG,FKAFPM";B6 _LV;IP>V&FV^H2HM'
M^V378=1*4CXUA6F);>V5;--B4'-\:1372^Y><F=PJ2W</VK>_RF%1.(_@[)9
MVQ2<!IR01WND8/>V\%$\Z2<:0LP8Q;/&N$#:WBZPFWM<K.=N^G2F@Y!F5#R%
M-/:",*$VFWDA#8L?>4$&VSEEY!S<F>:57+TB#[;4K$LETL$!J,XR*C9; 1X(
M.G ]UY<W:+A".OJ8;3-#345!DR!.8WN=)I!X:9K G32L).HS+Z97\"3PTF ,
M01#3<)V=:N]TU][IR?;NQ8>F";>ND[-'V_,DT#/M>1S=)4X7<B.VC=*F+[-'
MR/F_*?&>(5U3!FQ;]BS.GZ(YO?V<!*F7I.F^(%DY$!Q[430]$ R>S?:^9/AB
MR>A 8N*EX:'M&(+$"Z-@>PL3;YH>BB403[TIU?S3V[Y8^F)^$T@FWI3,[PMN
MR_9HQQTK6[]WPJU0K=TY7M-H;81I#[N[W=VGPF5[0OXNWGYG?&!JS6G8E[@B
MU?'9A-XKJCV[MPLC:W=>SJ2AT[=[+.AS!Y45H/]74IKMPAK8?4 M_@902P,$
M%     @ '$AW4@K(ED]V!P  \A<  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&ULY5A;;^.X%?XKA(LI'$ ;ZV+=LDF )#.S.P5F.\A,MRB*/M R;1,K
MB5Z2RJ6_OM\AY6L<)]-LG_HBD2)YKM^Y4.?W2O]F%D)8]M#4K;D8+*Q=GHU&
MIEJ(AIM3M10M5F9*-]QBJN<CL]2"3]VAIA[%89B-&B[;P>6Y^_9%7YZKSM:R
M%5\T,UW3</UX+6IU?S&(!JL/MW*^L/1A='F^Y'/Q5=B_+;]HS$9K*E/9B-9(
MU3(M9A>#J^CL.J/];L.O4MR;K3$C329*_4:33].+04@"B5I4EBAPO.[$C:AK
M(@0Q?N]I#M8LZ>#V>$7]H],=NDRX$3>J_KN<VL7%H!BPJ9CQKK:WZOYGT>N3
M$KU*U<8]V7V_-QRPJC-6-?UA2-#(UK_Y0V^'UQR(^P.QD]LS<E*^YY9?GFMU
MSS3M!C4:.%7=:0@G6W+*5ZNQ*G'.7MX**[6 E2V;B%;,I&7+FK=L^(U/:F%.
MSD<67&COJ.HI7GN*\3,4HYA]5JU=&/:AG8KI+H$1Q%O+&*]DO(Z/4GPOJE.6
M1 &+PS@\0B]9ZYPX>LEWZOS/JXFQ&CCYUQ$FXS63L6,R?E;H&;Y,-QQZ(#M.
MO%%=:PU07:EY*_^-?;)E=B& ,*Q7@OF(Y.V4&<NM%U;-L*M2C3CDE*/24&B?
MF26OQ,4 L6N$OA.#RV_@-U,UXE*V<V;)X<P(B(58MPLG#C'O#'&FV?2H3I"5
M-GG=,.26R1=5/&-7CCQ\+)J)T,[/GUIV\_-';%:= 5GC'(]'5-*C8/NV59-:
MSKF+\F$2!G&4L!,VC+,@B\<TBO*@',<8?>12LSM>=X)X>K&-4SF.@WQ<LJ@,
MH@2O.(CSG'U3EM>LEGPB:VD?V3 /QIFCB$&1TB -LHP&N[9<^7?![Z"O$*TS
M@T8X@!]KQ<9TE3)V99@#GCYCR#UN\1^"ZSZDOL]87^%L"7,[3A%,DN&9P$11
M$)8ICEL!1%B_GD<P0<JB,-PL>$G8T%EP&"7.N$[I7_85 ?DT)?(Y/:,D9$<B
M*5U'4GHTDFX6O)T+0U;:!^#&\0&;/>M;0F;7;@%Q.$>U,B=LQ&J%+>90/!V7
MB=Q=_>%R.;%&0R_4">-:$%P\K,PINSIEWA;'6;X=,D?BB[MH_0MO.Y1P%AV,
MLF$T1O@4&.U@;^C!1^L.?VY $#S9 ^$0**1%MS0D+)[L*-ZHN>;+A:S(D%VS
M),$,\#:."X>Z@OWY3T4<Q3]NG8)"2#H2X;Q]IN<4!Y$;Y&FX=40\+(66@E+5
MSIDRZ0^%H5.B*$C5:V\K _F6RDA+,(-(64Y;DB IO&6"/")U/C3+6CT*89RD
M^8]0O+5:3KJ>1Y$Z'GGJ[)7%-'O1*UL^?B$/7F\CZ7F OAE(S^?;?1SM)MXR
M2-+X20:"Z)1]D'I>,!]9CTQ'=NNWZGZGV=M:PN5%6K*L3 ZYT'O0N\_[#LU#
MIUNVKGI>'?%0U=V44K_<$SH!?'$RB6%^5SM>LLFV%P]6I0_ 947"[6HR>72^
M$KV^S"H@A2VYG-*0EJ"4_<&O/VE^H'2G71M );R%6VI&\%>$M[EL6U?69E9X
M1 BDKKXIT#"6MK3<[U\U (KQY5*K!XG>6=2/#BG1:80NMJXA,2"XC4(JBOLY
M;5-YWXS$7XZ0E^(I'GV!]]5]')3(6T^*G5UHU<T7A\KV@4)XBRW<='W?N3JK
MH)0&N09=V8*(HU^@](_0=ZD2%,(Q,!0?QS&24AJZ7 0H4\(HD[X\OZSS-MY\
M?[.M^_MM'STK[9O=\]?G*#^I-VF0%BZGHL84B4^N94'Y\<-LAKB@[3N5^?75
MXB"!5Q>.@Z>_KX:\.;>\8,:= C$.BBSR+>RN18^T;-FZ9<N.MD=7E86_]HWF
M;C,D%2[B%-2\Y?6CD0?;KZ/TG[_.\(.,.P,\SGJ,5KRNNMK7S3Z%[83UZAYS
MI,%ZS75HQ>[1A81X&A(4 8$/ 6))81 @F1I*[O!;_1CL-8"ON OL]W'25"X7
M:V0H%IYB\=WF5=+KEE:@SZP#]"C(*XTTY:*=8 2->!\PITAE[S:O]*73G=:4
MZ7JC&# ,/=_^Y0BL2[R3T/WG6=_-#;\#Z)'H^%+2/:P_LGXY^3^C]O#:HVG*
MIM*L*@81-.SZUY^<47ZX^?RIGT3ISN0G=L5^[WAKP8/L?A"ASIM&HDV?R0I[
M=V']] +K_(!C9J'N6^ #[CO;\\9';S*#RS 2V]IR_><=1#XQTKYEKK:D@7G>
M;<BYV51LS_[@M2>9_8NR\!Z%X)$(BG,T-B%+DB L\ J#,HI97 8IH)M0\<2L
MP,>,9F$>TMHX3,G*CNUHN!+GA,VT:GS@'V<9C/.$4F[A>_*LI%*9E6/7IR>E
MJ[9QF5,1I0U%6/QOH $5_S^@(?\[:* ,C0MR>%)F!)0DREF<!B6:*,Q*M#:8
M)?1"HS)V:\6X>!LTDCPC:.1YO&F?>F@D60\-*II%3"LY=A^JDJ.M_["-T'/W
MMYDZ-;C6_Y)=?UW_T+[R_W$WV_W?\,]<H^LVK!8S' V1=0=,^S_,?F+5TOW5
MG2AK5>.&"\&G0M,&K,\4C-U/B,'Z-__E?P!02P,$%     @ '$AW4D>KSIH
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M#3"P$(\$(P[/96'/\3-EX !]D 1.X/DH'M-Y0[SG 38$:2'SMSY$+'&2,(+
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MW7Z>WI*W'_E_%>JQP(I:RAFR>EA;)J#:#^?MC6D6]F/U0V-,4]G+N12Y5$2
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M9^?"P6;+OKYX;C6L/]\PC/$R*Q>JB1_9#)XDU1Q/!J\^CGP2IQ<Y9+-XEE[
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M1%WL@&L!]7[#F#PLM('ZJCCY'U!+ P04    "  <2'=2.^].B7D"  #-!P
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M<H)?>OCE!?A/?9N#=O6W@Z:93V!"2O-250/:RJ.YB3MF\Y0>7R"PF@BL_I-
M4,AR 5<9K/[)@)[U8PNZ]E-GB&^IT)K3[C38F]#/O]W#J_# =,VE(0(J&QK/
M;FU>'28M&*@ZW]VY0CLK?MG8QPFT<[#GE5)X,ER"Z;G+?@%02P,$%     @
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MF GA]A[+L%5DA,IO%HS#&/D3AC%=+]>+O+6S*+-=WC4M\MY73W!3!BQ@@\.
M 0W8)7"P:^3(IJ3BB3MYA$PHZ0F:#)C PE XF@O[N<N1&TMV$P?V,5/"C2FD
MC!OI&ADA2S7S# 80P,(,"+NXQFC"'HY%/(T]_0)\,#.L@QM\NY1!20,EPZ:4
M4;* *0&Y6!A=;]=U6;3KVI[DTT 4E@[MTQP@P<.0^#X^S3$G#HQHEV1CC4SI
M*>! $CXL23A!$N5RA!"YH\L(C7=TP! >9@@VL.B_Z#EY'P>@\,&!P@$H_!)
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M5%PQ3V*D "!J6( H'/2%0GMZE H-,2-4@2$"0%08($&C>V8.J Y.Q0<'B *
MJ$L 1&$T:)VZ.P6$2@GM61$J (@* ^2I'%!1VTT:/2= J*1O&:$ '.H,<"A,
MA;&(4<\(%1.>1% !/-2P\% XX)L4[>L2*FP9&:'R6X8&>.@SX'%F0J@!,'IP
MP&@ C+X$8#2Q]A":N82A9%VRY9LW0(P.(^;4E% 3.TPL3KG;34*6I!X'TD )
M':9$T+4U/L_ GDV(F/#=/>"''O:Q*DV<A4L9NR?KE S;2$;) C9R\'15&%R_
MV+RQ\VHQB]XM5W7UR6Y&UYSDN4 6/?AC5AI(H2_QH)4F%AJ)&Y0I4>I)U34
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M9.7'%8]B7A@#_?M2"/5X82;8ORUV_A]02P,$%     @ '$AW4HGIIB<6 P
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M,!4@OZ\I%:\3U?"[/P3)'U!+ P04    "  <2'=25WH=PZ("  !R!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RU54M3VS 0_BL:GV"FQ8Z=!V&2
MS$ H0P^9,H3"@>E!L3>V!EERI74<_GTE.7$#.&Y[Z,768[_'KN75I)+J16<
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M[!Q4*"F"1]DY:&=41@?,?_I#\UIAV:4-8;J.9Y=[<=S"L,RWD%VDE]UQP+@
MD]64SUB09 _YLJ>*K20-%9J)NL<I3"&J2#_O'E88NY)OMVYB&+<P+/,M)!CI
M)7CS^"=A@52+E*TO4X29%&4I=!GS4[E]BT<(=8\D5 0(2VUSWFMJFD)OD5YO
MVQ\/UPII5TD\UZM-9:]R.GB>UYC(0G.17G,G9$9EB_W?%B^4%7G'^99<**NE
M5]9#6GRDL$J24M?B5RT,RWP+M;;T<V_[-AHII-*!U.O6TH75(:/G5,@:.P]F
MTY].Y/"]"&(.0C*7?J;<)!W -K]&;&X$3;)GM5,J!(VRRR7!/F&I@?Q\3F7-
MU4WZ^#?_36CP'U!+ P04    "  <2'=2A-%+WR@#  !O"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,BYX;6RU5DM3VS 0_BL['@XPP\2OA 0FR4P>I>TA
M+4-*>V!Z4.QUK$&V7$DFT.''5Y(=$R!QAP,YQ'KL?OOM0RL--US<R111P4/&
M<CER4J6*"]>548H9D1U>8*YW$BXRHO14K%U9""2Q5<J8&WC>F9L1FCOCH5V[
M$N,A+Q6C.5X)D&66$?$X1<8W(\=WM@O7=)TJL^".AP59XQ+537$E],QM4&*:
M82XIST%@,G(F_L7<MPI6XB?%C=P9@W%EQ?F=F7R-1XYG&"'#2!D(HC_W.$/&
M#)+F\:<&=1J;1G%WO$6_M,YK9U9$XHRS7S16Z<@9.!!C0DJFKOGF"]8.]0Q>
MQ)FT_["I93T'HE(JGM7*FD%&\^I+'NI ["B$_@&%H%8(7BD$YP<4PEHA?*7@
M'U+HU@I=&YG*%1N'.5%D/!1\ \)(:S0SL,&TVMI]FIN\+Y70NU3KJ?$R)0(A
M(@55A)W",D66P#6NJ52"V,PL%5&H,ZW@>(Z*4"9/8'DI@.:PH(QI$7D*1[O3
MH:LT,X/O1C6+:<4B.,#"#V#!<Y5*^)3'&+\$<+5+C5_!UJ]IT(HXQZ@#H7\*
M@1=XLR^7<*PYGWQ/$A0T7^]A.'L'WLUR#L=';6CS=K0%>02O:\#\@309D"TN
MATTJ0PL:'DQE2^YN)RNS&JG?+9:ZC:6NM=1M*QH)I%0I%_0OQE#JM(G_5(^N
MD,K7$WB"?5Y7D:M,]ZQIT[7NQV'/JWY#]WX/ZU[#NM?*^K/@4D(A>(082]VT
M(M0M)]Y7K160'^R0\/VS3M@0J$JF$CM_(=7O]/;3/&MHGK72G'*E#SUP'4B2
MKQ%N%YBM4+3EK=] ]S^X0@:-I4&K$]]*P]DX0>*8&DN$05*J4C>;HEPQ&NF]
MZO1(70TM)VDZ>%,/_JLTM$F\8'_>L#]O9?^#%^^*O^\]=UOO@S/@[W1VO]6+
MR7/DFZ)/A"ZM5A)/<+2O.]:V=FL]"(,WM>[NW$09BK6]T25$O,Q5U;R;U>;5
M,+%WY:OUJ7\QJ^[^9YCJ*;(@8DUS"0P3#>EU^CKQHKK=JXGBA;WO5O8@V6&J
M7T0HC(#>3SA7VXDQT+RQQO\ 4$L#!!0    ( !Q(=U*[=:I!P0(  / '   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;*6546^;,!#'OXK%4RNM!4P2
M2)5$:E-5W<.TJNVVAVD/#ER"58.9[23MM^_9$)0&FD7:"V#S_]_][C#V9"O5
MB\X!#'DM1*FG7FY,=>7[.LVA8/I25E#BFZ54!3,X5"M?5PI8YDR%\&D0C/R"
M\=*;3=S<@YI-Y-H(7L*#(GI=%$R]W8"0VZD7>KN)1[[*C9WP9Y.*K> )S(_J
M0>'(;Z-DO(!2<UD2!<NI=QU>S1.K=X*?'+9Z[YG82A92OMC!UVSJ!18(!*3&
M1F!XV\ <A+"!$.-O$]-K4UKC_O,N^IVK'6M9, US*7[QS.13+_%(!DNV%N91
M;N^AJ6=HXZ52:'<EVUH;HSA=:R.+QHP$!2_K.WMM^K!G" >?&&ACH*<:HL80
MN4)K,E?6+3-L-E%R2Y158S3[X'KCW%@-+^U7?#(*WW+TF=FS8AF0BKVQA0!-
M6)EA9U.UAHP(SA9<<,-Q_NP6#.-"GY,+,K^_(V=/=^J<X(7PDCSG<JW1J2>^
M020;V$^;]#=U>OI)^EM(+TD4?B$TH$&/?7ZR/1Q_M/O8B+8;M.T&=?&B_^O&
M[^N%-@I7X)\C.:,V9^1R#C[+*0T3Q+C,-J$T.:B6H:^E=;R1BV?_TLV,ALE@
MXF_V&]<5A0/::CZ0#EK2P5'2ZZ85"C0PE>8.-X,-;@45_MB&I%*;7N(Z[G /
M9DC'R0%Q5Q13FO0C#UODX4G(V$XEA2#PBMN?[F_KL),_&HP/V]H5T60\ZH<<
MM9"CHY#?W1??+;1CB*-N=CJ.#A"[HG 41_V(<8L8G[!(3T&,N]G#(!D>,/:I
MXG'<#YFTD,F_/S9BRB6I0+D3KDSA0H%@QBW;8EV"8O;XZ"-/>GZK(#@ [XK"
M9$]4<_M[^[$]"[\QM>*E)@*6: LN8RQ<U>=+/3"R<EOT0AK<\-UCCD<R*"O
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M!$C#E"0:EH/@NGEUVW/VWN '@XW9F1,7R4*I9[>X3P=!Y 0!A\0Z!HK#"]P
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M=#8U+GAM;+58;6^C.!#^*U:DDUIIKV#S$E(ED9)RO=W55E>UNWL?5O?!@4E
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MKJYDP+6!FE\R)K<=O4![R1O_!U!+ P04    "  <2'=2_1K!_:8"  #-!@
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MHMEG-& ROAI,J23YXY1''RAF:#!&5TB5'1K,!:50(Q+4R@5ZH R>:;A EV,
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MV7[4P9W7@<=HO1%JP!H/MV0-3R"^;1^X?+-*EC!*@*81HXC#:M29X*L[QU:
MW.)[!/OTX!DI5Y:,_5(O=^&H8RM%$$,@% 61_W8P@SA63%+'/YJT4\ZI@(?/
MK^S7N?/2F25)8<;B'U$H-J-.OX-"6)$L%H]L?PO:(4_Q!2Q.\[]HKVWM#@JR
M5+!$@Z6")*+%?_);!^( X+@- $<#G+8 5P/<MH"N!G3? -PF'SP-\-K.X&N
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M*3:HUVJZM>6+\1M]P_^([5:S[-IO&R#JRU]#C3:@(J^!JF2XC4Y8(L_,C4)
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MG%1H1Y(M5-5=[RS27M]UC]-AE@GU2T)^NX9XOR#>;R1^G]"(+A/(O(=(JG-
MY3XD>KV*:__<>]X9UTP(=\I2[:":+'8/QXC[$468HQS5EW]*<5(AU3T5FE8(
ME9&.[2@=A_CCBE!G\I@K?42;+'\B+()+ZA-[!S+>9U0H/C1F[#=:^PB"\M"P
M_XM3FUX2B%C%A\*H#&(SJ(?>-(AL(GAH[;BYM__?<"Q>" /TS'2?$9*J-_3
MY8::%G!)8 Z=&@>?$IA#:\;=#Z_^'+)<$#=GU9\+E5N5V[XYJ1JG=)],043V
MYB]U[]0DLF._6"U>%W?V3GVR/L:W4URQ?F]>(_;^>H#/GC)S(B+*)$I@K;?2
MU'0@1/8ZR":*;^QM=FD+SPYC_:("803T]S77O3Z?F V*-]KH/U!+ P04
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M>IX^ETPPW_9"G:$!1EQ_Y$G%G93C:2T?G4T3K+>'O'HU+WXPIYK0)Q.(^/H
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M&3!E(-^O*17[A9K)S25O\AM02P,$%     @ '$AW4O 8'3/Q P  V@T  !D
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MCFV^0)60F_N;L404GVA38>T!FJV%9&EEK")(XZS\#I^J0C0,L'? @%0&9-?
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MQ"6NQ:'9T>)X;!&?'R]^,<#&J^/A%?K\7GU+_21!-U4P/B]2MJ)%B3S?0[8
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MW^^@-@:4-W/\!G7!<=IPG(YR? ;Q0B- $9?*1*"2GIX;Q?Z9T8J ">5BMT/
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M J"_[SA7IT%AH/D'8_DO4$L#!!0    ( !Q(=U+E^]I5] ,  !$.   9
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M*X\X>#^F@D0Q_P#.P%B&2>D,7%4!'V1 \.V>)A/*OLOOK[_<@O=/M^P#D']
ME(*_E]F:R]!\: F94[XR:UJM_ZI</^Q8OP/!?9:*)0<WZ8S.M@-8LAAU1>"F
M(E?0&'%,I^< .1\!M*&M6=#UP>Y.J'$?'^X>:-QO#G?W#<5 -3Q0$0]UQ%,H
M( T4?+N<<,'D/?[=< E<7P(7E\!=2X[X-%M+_#$BJ X 9G?['-KO=&TZS6V\
MSRULNVTE[=9)N\8XCS)7D,W!?"W6C,I[8"I9GN<?P#1+I IP4I1:5P]S9.?<
M=[7U.,UMO,_--=;#J^OAG5R/-6,Y/:U*==*6Q!S</K?U$#G-;;S/S5P2ORZ)
M;XQSEPK**"_O"U#(<DW5G#Q'Z8*#*5E%@L2ZDIB#:Q99EN0TM_$^-_-=$]0E
M"8QQ[C,FL\UU)]>A6<3))"H.\Q)I@6&.=_7U<\'R9]?W=[IB'.+MN!W>X\.\
M/QOJ$M9U"8TLW51DLE'D@TC:L=6<8!O7^Y )B;Q<"6:5O&_FA6P21XN"KK3R
M78;UBK#YV/H\\K&'A]9SL]):J\#=MAIKK%S/:UG=:*QP"+W::KL C4'),1;@
M+PG^=^!NPTR;><947*ABP[X:J)3<0>8&4C:5'933_Q:]$HW":_MHCMY)*,?[
M;>>GQ@C'+,UG17_D '1X?Y1:.VY?_5$*Z)AUH]&?&3VA/T>K4M6?WU,S1\F9
M8Q:!>LXKM+Y^'/@%3KBQE& X05^-4^3KA/TP8[C#4]#WL=VF1HT9ACC0\QE4
MA [-A+ZY4ZSW&SKX .8L2TK$'9M,=3%W:Y4^:N6BLT)^!S5#1<W03,V=T#J>
M$Z#B;-@79T/%V7 /9Y\(K2ILL\X(V4$;6AHS&**PJQ^*BN&>1[H_"RV\L\HS
M&'A^.QF=F>_#CF04]T/S(\YM^4CR1&+"7G=IZB0"@TH5H-<7RA0S0S,SGXPR
M?Q=E=NC =F-VS:"/'+^C,8K;H7F"_L,H"W;AXX5A.Q>M%>I(14D(-$O(?HP=
MSV1(*0&R>\(84A2-S!1]*L:JL-L4Y3KMONC,W!#9^L8@1?((OB'&JHLU5^F%
M[4>A/4;;B33V\<Q*4B'LH=KBO\ZX^#T*0TH-$.X+7HJDD9FD3X:7NTMACN>V
M*4QC!OVPZ[Y'BMV1>;K^P_#R=LG)P6CG7M&9(2_L2$;)"#++R!Z(G<!@2@I0
M7V,^4AR-^AGSJ[!;V E"QVMW16/FHBZ(847N^"W'?+P[P#LP;(]B6BOD=*2B
M- 2;-:3>$7VL=D2?JFW0ZW(;]/<(#2M1P'U-_ECQ->YG\L>:R=^Q_?;DKS&#
M/L8=,QEN_);SEI,_UHST@;N#-IT5[+IQE*1@LZ0<@[;CN0TKC<!]/0%@1=VX
MGR< K!GM0VR[[0YIS-R@:PL#*]K';_D$4%VLN=$2V$$[E5TC?V<#PVK\'I]0
MMBA>A."@V*,H?XBNS]8O6UP6KQBTSE\YG\;E*Q,J3/D&QSUABRCE(*9S&=(^
M]V5Q6?E21'D@LE7QJ_\D$R)+BH]+2F:4Y0;R^WDF>UX=Y!>H7TT9_0]02P,$
M%     @ '$AW4@47&HYD!   MA8  !D   !X;"]W;W)K<VAE971S+W-H965T
M.#4N>&ULM5A=;^(X%/TK%D^S4K>)[4!"!4@%9K7ST"T:M+,/HWTPQ$#4)&9L
MI[32_OBUG1#3:3!AU+Q G/B>^W5R=./1@?$GL:-4@I<LS<6XMY-R?^=Y8KVC
M&1&W;$]S]63#>$:D6O*M)_:<DM@89:F'?'_@923)>Y.1N;?@DQ$K9)KD=,&!
M*+*,\-<I3=EAW(.]XXVOR78G]0UO,MJ3+5U2^?=^P=7*JU'B)*.Y2%@..-V,
M>_?P;HY#;6!V?$OH09Q< YW*BK$GO?@2CWN^CHBF="TU!%%_SW1&TU0CJ3A^
M5*"]VJ<V/+T^HO]ADE?)K(B@,Y;^D\1R-^Y%/1#3#2E2^94=_J150GV-MV:I
M,+_@4.X-!SVP+H1D666L(LB2O/PG+U4A3@Q0<,8 50;H9P/_C &N#'!;@Z R
M"$QERE1,'>9$DLF(LP/@>K="TQ>FF,9:I9_DNN]+R=731-G)R7)'./U=5RX&
M:Y8I.@FB&W(#%BG)!7@LI) DCY-\"S[-J21)*GX;>5*YU@#>NG(S+=V@,VX@
M @\LESL!/N<QC=\">"KF.G!T#'R*G(ASNKX%&-X Y"-?Z"R$CK@AM%EK(#@L
M@1I YNU!HB:0-SGBNCG8H.(KFP.^WZ^$Y.J=^=?A):B]!,9+<,;+7T6VHARP
M#: _BD2^5@Z37+DHU"LNP=Y0X3]PIL#3$K]O\+70/$^"D??<$%*_#JG?.O'2
M.3OA8:OL![6K0<OLV5[75@!R(%QQ%'Q*<E"VLI'P@W=)0S_$/@KKU$OV->WK
M8^SWW^Z;O]\71$'@X^9*AG5ZH3.]I63K)_!H4C/] _?@^P/5.;NJ%]7P4=>-
M&M:NAMTT:OBNL'B PK[?7%CH6^7TG0'-E*#IY J2@C39T)/0&@72C0;[X)42
M+L  9$8I'26#)^H.KVS_M$W[(;(.4-<$@%8.(>Z& A7N*0<B./3]<QRPT@G=
MVGDM!]QHT+^" U9+8?]*#LQ@*Q)8"86#SDE@!0VZ%>W721"^(\$@#/OHK!)8
M$821,Z1O5$B=Z9JIC,\WWPT2E+UWU<A*)71KY;6T=*,=:>F:VJQJ(K?.J0%I
M ):/7Q8U!=5@\?F%K@O] :":F<=@GG#U6<#4B]""ILB*(8)=TQ19842H&YI6
MN&\&AF@8(82::8JL?"*W?%[)B@MH;5AA=12YE:^9%=D^9:^4MJ.!U4/4^7")
MK#2BCL9+]'X>'$9#% [/L,#J)W+K9SNQN@!R6:R054_D%KYK:>E&:T-+JZ/(
MK7PU+6_ L6RS8]D _"@%PU8\L=\U=;&52^R>'=L1Y0((--UPQ6,5%;L5U=D,
M]&'-./DX;_]U_JO-L *)W0+9LAEN$'SQU<!61;%[JG1V W]8-ZS0XLYG4&PU
M%'^$AEX <6BH=W*@EU&^-0>C0KDK<ED>D=5WZ\/7>W/D^-/]*;R;ET>H%J8\
MT7T@?)NH*J5THR#]VU"UFY>'I.5"LKTY-EPQ*5EF+G>4Q)3K#>KYAC%Y7&@'
M]5'UY']02P,$%     @ '$AW4G^YTBF#!0  /QP  !D   !X;"]W;W)K<VAE
M971S+W-H965T.#8N>&ULK5E=;Z,X%/TK5K0/'6D&L/FNTDAM"<D\S&XUU>X\
MK/:!!*=!PT?6.$TKS8]?#!2",>!LFX<V)N>>>^_QQ;[@^2DC/_,]QA2\)'&:
MW\SVE!ZN537?[G$2Y$IVP&GQRRXC24"+(7E2\P/!05@:);&*-,U2DR!*9XMY
M>>V!+.;9D<91BA\(R(])$I#7.QQGIYL9G+U=^!X][2F[H"[FA^ )/V+ZY^&!
M%".U80FC!*=YE*6 X-W-[!9>KU%I4"+^BO I/_L.6"J;+/O)!E_#FYG&(L(Q
MWE)&$13_GO$]CF/&5,3Q;TTZ:WPRP_/O;^Q^F7R1S";(\7T6_XA"NK^9.3,0
MXEUPC.GW[+3&=4(FX]MF<5[^!:<*:[DSL#WF-$MJXR*")$JK_\%++<29@6X,
M&*#: '$&QI"!7AOHLAZ,VL"0]6#6!J:L!ZLVL&0]V+6!S7M  P9.;>"4LUM-
M1SF77D"#Q9QD)T 8NF!C7\J"**V+*8Q25KN/E!2_1H4=73SN X*_L-D/P39+
MBELB#UA1?08_RFDO+M\^8U*4,5B^8+*-<@P>2+3%.;CR, VB./\T5VD1">-3
MM[77N\HK&O *$?B6I72?@V4:XK!+H!8I-'F@MSSNT"BCA[<*T.%G@#2DY2RI
M_)4\^@2HH!H)@KQ_)^5O8^2>-#ET)>-=OI-R-%Y?GMR1C'?U3LK1>-?RY'9%
M,AQMI^+TYL[12P_Z@(??C\D&$Y#M0'9@=TP._K[=Y)04J_$_(_1&0V^4],8
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M7"$4+#\^RF\XW62'$:]9,6>7:Q(L"),&XOLEI7Q_(U]0'N*-_P-02P,$%
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MJ#(_PK>SY,HKITENX!XAK4!"00%= *6A]2!F>'*IE0PD6\=W*F_Q^8P?5Y3
M]Z$"P/L%8_)SH!;(KA:'_P-02P,$%     @ '$AW4GRDM,,-!@  +"$  !D
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M(NVTZ5DL(;T60/:U@)DVST2*![*F0FL6:W<)LYC7 UBO$Y!]G3!$JL]'3<;
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MJ30 ^+X20K\/S 3M;7KV+U!+ P04    "  <2'=2W>!-$J(&  !,(0  &0
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MHMZ10.^(>D<"O2/J'0GTCJAW)- [HMZ10&]#O8U ;T.]C4!O0[V-0&]#O8U
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M+]\MM\=?E]\7)Z_*%>?ZOF)X^@M02P,$%     @ '$AW4GWS[C]# @   S4
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MN/_'\?,S[:MV>,W/YO\^W?P$4$L! A0#%     @ '$AW4@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  <2'=2A5@3/>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  <2'=2F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !Q(=U(4
MKABP+P0  ,D0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  <2'=2@Q+>.TT%  "]%@  &
M    @(%R#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M'$AW4L^'"KGR!   MQ,  !@              ("!]1$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !Q(=U)GDW.O_@(  %L(   8
M          " @1T7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  <2'=2P; R,&T&  #W(P  &               @(%1&@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ '$AW4HW6"R@?"0  Z2H
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M965T,3 N>&UL4$L! A0#%     @ '$AW4H^< $DG!   U H  !D
M     ("!H54  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M"  <2'=2]7C/-_D$  !'#0  &0              @('_60  >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !Q(=U(..]XT?0,  .$(   9
M              " @2]?  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!
M A0#%     @ '$AW4IF>@>?K @  H@8  !D              ("!XV(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  <2'=2*H7YV8@"
M  ";!0  &0              @($%9@  >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;%!+ 0(4 Q0    ( !Q(=U+3L/R P@@    7   9              "
M@<1H  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ '$AW
M4C,JCR/" @  :@8  !D              ("!O7$  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  <2'=2\_VJI8X#  #Q!P  &0
M        @(&V=   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( !Q(=U*./5)[=2,   2%   9              " @7MX  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ '$AW4B4Q"KH?!0  > T
M !D              ("!)YP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  <2'=2IWA9,U(#  !$!P  &0              @(%]H0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !Q(=U)OU4?T
ML 4  #4.   9              " @0:E  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ '$AW4D0!LXR,#   R"0  !D
M ("![:H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  <
M2'=2V^4 @$\*  !7'P  &0              @(&PMP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !Q(=U)QUH?AA ,  (@'   9
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M970R.2YX;6Q02P$"% ,4    "  <2'=2">I1#]X;  !P6@  &0
M    @('RV   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M !Q(=U*$)[EGT (  *D&   9              " @0?U  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ '$AW4L9<FDD$!   +@H  !D
M             ("!#O@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  <2'=2H$H%P%T$  #7"P  &0              @(%)_   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !Q(=U(E;@BSXP(
M !D'   9              " @=T  0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ '$AW4G(2=L]! @  #04  !D              ("!
M]P,! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  <2'=2
M+O(EB3D"  #;!   &0              @(%O!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( !Q(=U*#A!%%)@,  #4'   9
M      " @=\( 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ '$AW4E)BA,:" @  N 4  !D              ("!/ P! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  <2'=2?EC1YSL$  "V"@
M&0              @('U#@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( !Q(=U(@O**XCP,  .4(   9              " @6<3 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ '$AW4LX0+<#;
M @  #08  !D              ("!+1<! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  <2'=2R+E*Y.T$  !,#0  &0
M@($_&@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !Q(
M=U(*R)9/=@<  /(7   9              " @6,? 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ '$AW4D>KSIH "   R1@  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( !Q(=U)Q7^30#@0  #8.   9
M  " @4$\ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M'$AW4COO3HEY @  S0<  !D              ("!AD ! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  <2'=29CO$YH0"  "C!P  &0
M            @($V0P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( !Q(=U*$PJH@;P(  #<&   9              " @?%% 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ '$AW4F1$IVDG @
M^@0  !D              ("!ET@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  <2'=21<RMW:@'  #L-0  &0              @('U
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !Q(=U+*
M2%G+SP8  #DF   9              " @=12 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ '$AW4HGIIB<6 P  M0L  !D
M     ("!VED! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !Q(=U(D4'>W> 4  !\:   9              "
M@=EK 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ '$AW
M4H312]\H P  ;PD  !D              ("!B'$! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  <2'=2NW6J0<$"  #P!P  &0
M        @('G= $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( !Q(=U*_E#GJXP(  "P(   9              " @=]W 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ '$AW4J.69)(H!   TQ$
M !D              ("!^7H! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  <2'=2O:PH#0\#  #P"0  &0              @(%8?P$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( !Q(=U+]&L']
MI@(  ,T&   9              " @9Z" 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ '$AW4HU2F6O^!0  G!T  !D
M ("!>X4! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  <
M2'=2:3B@_GL$  "'$0  &0              @(&PBP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( !Q(=U+'N,B38P0  #X2   9
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M970W-"YX;6Q02P$"% ,4    "  <2'=2SVNY3C$%   N%   &0
M    @(&KI0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M !Q(=U(+*-451 ,  / )   9              " @1.K 0!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ '$AW4O 8'3/Q P  V@T  !D
M             ("!CJX! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  <2'=2/,UZ83X%   U'@  &0              @(&VL@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( !Q(=U*_=X#1D00
M )$2   9              " @2NX 0!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ '$AW4N[W#FXQ!   S1   !D              ("!
M\[P! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  <2'=2
MY?O:5?0#   1#@  &0              @(%;P0$ >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( !Q(=U*G #*>/P,  (H)   9
M      " @8;% 0!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ '$AW4E*[GK/1 P  :PP  !D              ("!_,@! 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  <2'=2GKW%BR@&  "F(@
M&0              @($$S0$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    ( !Q(=U(%%QJ.9 0  +86   9              " @6/3 0!X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ '$AW4G^YTBF#
M!0  /QP  !D              ("!_M<! 'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    "  <2'=2C  TGQ8%  #0&P  &0
M@(&XW0$ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( !Q(
M=U(+MS5!^@0  &84   9              " @07C 0!X;"]W;W)K<VAE971S
M+W-H965T.#@N>&UL4$L! A0#%     @ '$AW4GRDM,,-!@  +"$  !D
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M=#DS+GAM;%!+ 0(4 Q0    ( !Q(=U*GSS>O;0,  .X6   -
M  "  88  @!X;"]S='EL97,N>&UL4$L! A0#%     @ '$AW4I>*NQS
M$P(   L              ( !'@0" %]R96QS+RYR96QS4$L! A0#%     @
M'$AW4L[+*D/(!@  .#T   \              ( !!P4" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( !Q(=U(H*(&*L0(  +XV   :              "
M ?P+ @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !Q(
M=U)]\^X_0P(   ,U   3              "  >4. @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !E &4 NAL  %D1 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>384</ContextCount>
  <ElementCount>466</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>110</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>23</UnitCount>
  <MyReports>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>020000 - Statement - Statements of Income/(Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/StatementsOfIncomeLoss</Role>
      <ShortName>Statements of Income/(Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>030000 - Statement - Statements of Comprehensive Income/(Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/StatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Statements of Comprehensive Income/(Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>040000 - Statement - Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>050000 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>050100 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060100 - Disclosure - General information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/GeneralInformation</Role>
      <ShortName>General information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/BasisOfPreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Right-of-use assets and lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities</Role>
      <ShortName>Right-of-use assets and lease liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Cash and cash equivalents and financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets</Role>
      <ShortName>Cash and cash equivalents and financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Prepaid expenses and accrued income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PrepaidExpensesAndAccruedIncome</Role>
      <ShortName>Prepaid expenses and accrued income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Other current receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/OtherCurrentReceivables</Role>
      <ShortName>Other current receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ShareCapital</Role>
      <ShortName>Share capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Trade payables and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/TradePayablesAndAccruedLiabilities</Role>
      <ShortName>Trade payables and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Financing obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/FinancingObligation</Role>
      <ShortName>Financing obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Contract revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenues</Role>
      <ShortName>Contract revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Expenses by category</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ExpensesByCategory</Role>
      <ShortName>Expenses by category</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Related-party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RelatedpartyTransactions</Role>
      <ShortName>Related-party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061500 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>061600 - Disclosure - Retirement benefit plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlan</Role>
      <ShortName>Retirement benefit plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>061700 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>061800 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>061900 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>062000 - Disclosure - Financial instruments and risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/FinancialInstrumentsAndRiskManagement</Role>
      <ShortName>Financial instruments and risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>062100 - Disclosure - Capital risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CapitalRiskManagement</Role>
      <ShortName>Capital risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>062200 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>070300 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>080300 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Right-of-use assets and lease liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables</Role>
      <ShortName>Right-of-use assets and lease liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/RightofuseAssetsAndLeaseLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Cash and cash equivalents and financial assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsTables</Role>
      <ShortName>Cash and cash equivalents and financial assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Prepaid expenses and accrued income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables</Role>
      <ShortName>Prepaid expenses and accrued income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/PrepaidExpensesAndAccruedIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>080800 - Disclosure - Other current receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/OtherCurrentReceivablesTables</Role>
      <ShortName>Other current receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/OtherCurrentReceivables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Share capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ShareCapitalTables</Role>
      <ShortName>Share capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/ShareCapital</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>081000 - Disclosure - Trade payables and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables</Role>
      <ShortName>Trade payables and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/TradePayablesAndAccruedLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>081200 - Disclosure - Contract revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesTables</Role>
      <ShortName>Contract revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/ContractRevenues</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>081300 - Disclosure - Expenses by category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ExpensesByCategoryTables</Role>
      <ShortName>Expenses by category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/ExpensesByCategory</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>081400 - Disclosure - Related-party transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RelatedpartyTransactionsTables</Role>
      <ShortName>Related-party transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/RelatedpartyTransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>081500 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>081600 - Disclosure - Retirement benefit plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanTables</Role>
      <ShortName>Retirement benefit plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/RetirementBenefitPlan</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>081700 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/SharebasedCompensation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>081800 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>081900 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/EarningsPerShare</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>082000 - Disclosure - Financial instruments and risk management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables</Role>
      <ShortName>Financial instruments and risk management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://acimume.com/role/FinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090100 - Disclosure - General information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/GeneralInformationDetails</Role>
      <ShortName>General information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/GeneralInformation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Basis of preparation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/BasisOfPreparationDetails</Role>
      <ShortName>Basis of preparation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/BasisOfPreparation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Summary of significant accounting policies, Right-of-use assets and lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesRightofuseAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Summary of significant accounting policies, Right-of-use assets and lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090302 - Disclosure - Summary of significant accounting policies, Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies, Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090304 - Disclosure - Summary of significant accounting policies, Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of significant accounting policies, Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090306 - Disclosure - Summary of significant accounting policies, Segment reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails</Role>
      <ShortName>Summary of significant accounting policies, Segment reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Right-of-use assets and lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Right-of-use assets and lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/RightofuseAssetsAndLeaseLiabilitiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Cash and cash equivalents and financial assets, Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and cash equivalents and financial assets, Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Cash and cash equivalents and financial assets, Cash and cash equivalents and short-term financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CashAndCashEquivalentsAndFinancialAssetsCashAndCashEquivalentsAndShorttermFinancialAssetsDetails</Role>
      <ShortName>Cash and cash equivalents and financial assets, Cash and cash equivalents and short-term financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Prepaid expenses and accrued income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails</Role>
      <ShortName>Prepaid expenses and accrued income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Other current receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/OtherCurrentReceivablesDetails</Role>
      <ShortName>Other current receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/OtherCurrentReceivablesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ShareCapitalDetails</Role>
      <ShortName>Share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/ShareCapitalTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>090902 - Disclosure - Share capital, Convertible Note Agreement an Follow-On Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ShareCapitalConvertibleNoteAgreementFollowonOfferingsDetails</Role>
      <ShortName>Share capital, Convertible Note Agreement an Follow-On Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>090904 - Disclosure - Share capital, Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ShareCapitalShelfRegistrationStatementDetails</Role>
      <ShortName>Share capital, Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Trade payables and accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails</Role>
      <ShortName>Trade payables and accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Financing obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/FinancingObligationDetails</Role>
      <ShortName>Financing obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/FinancingObligation</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Contract revenues, Contract Revenue Attributable to Licensing Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesContractRevenueAttributableToLicensingArrangementsDetails</Role>
      <ShortName>Contract revenues, Contract Revenue Attributable to Licensing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>091202 - Disclosure - Contract revenues, Changes in Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesChangesInContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>Contract revenues, Changes in Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>091204 - Disclosure - Contract revenues, Recognized Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesRecognizedRevenuesDetails</Role>
      <ShortName>Contract revenues, Recognized Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>091206 - Disclosure - Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesMorphomerTauSmallMolecule2018LicenseAgreementWithEliLillyAndCompanyDetails</Role>
      <ShortName>Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>091208 - Disclosure - Contract revenues, Anti-Abeta Antibody in AD - 2006 Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesAntiabetaAntibodyInAd2006AgreementWithGenentechDetails</Role>
      <ShortName>Contract revenues, Anti-Abeta Antibody in AD - 2006 Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>091210 - Disclosure - Contract revenues, Anti-Tau Antibody in AD - 2012 Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesAntitauAntibodyInAd2012AgreementWithGenentechDetails</Role>
      <ShortName>Contract revenues, Anti-Tau Antibody in AD - 2012 Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>091212 - Disclosure - Contract revenues, Tau Vaccine in AD - 2014 Agreement with Janssen Pharmaceuticals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesTauVaccineInAd2014AgreementWithJanssenPharmaceuticalsDetails</Role>
      <ShortName>Contract revenues, Tau Vaccine in AD - 2014 Agreement with Janssen Pharmaceuticals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>091214 - Disclosure - Contract revenues, Tau-PET imaging agent in AD -2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesTaupetImagingAgentInAd2014AgreementWithLifeMolecularImagingFormerlyPiramalImagingSaDetails</Role>
      <ShortName>Contract revenues, Tau-PET imaging agent in AD -2014 Agreement with Life Molecular Imaging (formerly Piramal Imaging SA) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>091216 - Disclosure - Contract revenues, A-syn and TDP-43 PET tracers - 2016 agreement with Biogen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesAsynAndTdp43PetTracers2016AgreementWithBiogenDetails</Role>
      <ShortName>Contract revenues, A-syn and TDP-43 PET tracers - 2016 agreement with Biogen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>091218 - Disclosure - Contract revenues, Grants from the Michael J. Fox Foundation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ContractRevenuesGrantsFromMichaelJFoxFoundationDetails</Role>
      <ShortName>Contract revenues, Grants from the Michael J. Fox Foundation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Expenses by category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/ExpensesByCategoryDetails</Role>
      <ShortName>Expenses by category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/ExpensesByCategoryTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Related-party transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RelatedpartyTransactionsDetails</Role>
      <ShortName>Related-party transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/RelatedpartyTransactionsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>091500 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>091502 - Disclosure - Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails</Role>
      <ShortName>Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>091600 - Disclosure - Retirement benefit plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanDetails</Role>
      <ShortName>Retirement benefit plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/RetirementBenefitPlanTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>091602 - Disclosure - Retirement benefit plan, Changes in Defined Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails</Role>
      <ShortName>Retirement benefit plan, Changes in Defined Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>091604 - Disclosure - Retirement benefit plan, Changes in Fair Value of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails</Role>
      <ShortName>Retirement benefit plan, Changes in Fair Value of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>091606 - Disclosure - Retirement benefit plan, Change in Net Defined Benefit Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanChangeInNetDefinedBenefitLiabilityDetails</Role>
      <ShortName>Retirement benefit plan, Change in Net Defined Benefit Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>091608 - Disclosure - Retirement benefit plan, Change in Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanChangeInOtherComprehensiveLossDetails</Role>
      <ShortName>Retirement benefit plan, Change in Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>091610 - Disclosure - Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails</Role>
      <ShortName>Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>091700 - Disclosure - Share-based compensation, Plans Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails</Role>
      <ShortName>Share-based compensation, Plans Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>091702 - Disclosure - Share-based compensation, Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share-based compensation, Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>091704 - Disclosure - Share-based compensation, Outstanding Options, Range of Exercise prices and Expiration Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationOutstandingOptionsRangeOfExercisePricesAndExpirationDatesDetails</Role>
      <ShortName>Share-based compensation, Outstanding Options, Range of Exercise prices and Expiration Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>091706 - Disclosure - Share-based compensation, Weighted Average Grant date Fair Value and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationWeightedAverageGrantDateFairValueAndAssumptionsDetails</Role>
      <ShortName>Share-based compensation, Weighted Average Grant date Fair Value and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>091708 - Disclosure - Share-based compensation, Non-vested Share Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails</Role>
      <ShortName>Share-based compensation, Non-vested Share Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>091800 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>091900 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/EarningsPerShareTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>092000 - Disclosure - Financial instruments and risk management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>Financial instruments and risk management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="aciu-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>092200 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acimume.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://acimume.com/role/SubsequentEvents</ParentRole>
      <Position>93</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aciu-20201231.xml</File>
    <File>aciu-20201231.xsd</File>
    <File>aciu-20201231_cal.xml</File>
    <File>aciu-20201231_def.xml</File>
    <File>aciu-20201231_lab.xml</File>
    <File>aciu-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>158
<FILENAME>0000950103-21-004378-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950103-21-004378-xbrl.zip
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MW97,(=8^N7TI9TR#=M=>]D@JG;UT]O*")+,#GJP3J]Y8%>?KN8+<2Z^^Z)1
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M4];+KBM8<--_WNGO8QF#PTQW,-,QX^*T2Z>0<I:#T=RD=V723QM2Q+5U\.+
MVS#]U\676_4KR_Y0A:G^*AX^: VOG-R4]+M@Y,A=5U9Q:2/A+=-P+N,5[VV\
MX); .XG#LT6/;>%@?]':$^@\4?;:P. ,<_E(ZPY>( I.PP^,PC)T-)]ZP9GE
MJ I?S1^_6U2U<,M1TR\>"<I(W'[:H&X^*[A7?I[R7&3)O<E??DIN;@?4=6^-
MMME,]UD"<WKED8:ZV05"2[<<&4((UQ!">)/G;=GW-LT^?%79]7B<%H/::K &
M0)NH/A]\$-X;/O-;S@.?MTF6%Y>G@#:2[0#D8--AV"PL)RP@X$GZ,ZQB(07]
M^^W#I(X8AH^"=H)=;GB/-2@7:'<G1].M12FP/36(MJUC.Q!U"$1T?Q#1+JQL
M.A!U!T0=,V?4"SW<BVS8HD\87GE/XA/.EW5>ID61W@UY9:>%0B<A?K2^1O67
M#&"7OY_^FDSD)Y4KEHG;U^FWR>>'B<S2._4VG4[D(,YGW%";NB\3SA!#1J=;
M9R$.'7U'!SEU/U>'CAZCXY2G$RWY&@XG?<-)A]V6Y12#VV33]TTVW4U%K"1%
M]P4;^D5-X+,2MY>)KV7Z78KT,?KK[TEQ^SX9CQ\N#DQ+E#O-]&@SZ#13!S13
MMR"UD['[4-RJ;,;* 6.GC5!GOG;3.PXD3I,\QFV.7B;IC1IRX+\K\4[C[)9-
M<@%_3P/^;F67'@TVI[G.J;FZ!:;=S.#[1 #_U?5$;A+;]XE6OZ9C):9CEKV[
M8S<#*'+9 ++',L69S4?[8,YL=MEL=@QL.T6%3M,-1=-U*MI\M,_F4J'G3X5V
MRW/;#5).GPU$G_41?"[%>M$@>?3ZGTM4G#7%VBD/"F+% "#T,4OEU/!P(C^K
M["LH\A)%7]CTUS2[OTWO5/;YCHW'E>:N2ND/JF"PNW&OX2LY!/6UAG,5$+?P
M;QO^3BP0&Z?DJ61CL5=.\$1UJ0[P3U_ <PC*.B2,P_<LSBHE97,A)R;MC'!R
MXN1D& 6@@W"8G"3,).&IPX>!V8E!B,-!)NOX 821C9,%$*6B5YE.LSLV$>H#
M'R<WEA\E;#_>LEQ]^9:^&B<3LT+XN9C*ARHE*JM9KF#OQ.5P<5D[ 152=Y^&
M'KE4ER?')]R@ZO)=+OP_8UCS).;J#&G=RP6V@_)I4[?;/*]?D['*BW2B/K('
M0T]>V_YKL[/^9CIF19H]S*[*S^"%]5TX!N'=G$1.M_FCAX%S8#[7-@FV_7@_
MZ-]S57GJ3D2/C\0U3!ZT=/;+BIY5!E<557H'C!$)&SMI[+L<[&^EEB;?R>79
M;&/5&PIX]5I]5>/T?AX^.Y'L"N@&K1TV07!@TKB\L.OD\I+D\J22T"T5,?RU
MZ95MD$XHNP._#JF(DQ1Y=WN/II.$CF"O6T)Y$DGHU'8'5Z_G\#^86&4CE*]A
MM-=<%<Q\X*E\>#>Y?EW!>.,!(/MN)_.BP>RAW@SU#1P],\Q;I^&X8^K:X2IG
M2@<<(&R7*TY=Q/')1'SX\;23 2<# U+N/ME8(N?@?/$>T@G*Y,@I*SYWRW8Z
M8#L][3*>3AJ<-%Q,UM-'7A1X&V7@"YN>.E$TH&9[V['8RL\..$%[=_P;2IH(
M9,N+K@+OW&FB=D&[7%'J(HI/)-XN1>3P?\FFI%_IH<C#5001'>@]72ZHG5)_
M7/0077EXS^@A6G1OCAD]1!Z920)QZKT+J.NB.)Y*$LC^DD!.%$>'LZQ2Z!R=
M3H*P$])Y$DD(]\\HA:?+*!'?JR2!.$GH!NJZ*(XGD01RY7M[2@+I7F[U<O'O
M+$%7\Y@'JG*W3-!A17^LE'P79;Q?&:5]*C2<S7 VPU5G.$EPDG!L2>A690;>
MMA_M/Y@0R42=S-L:Z%FO??)Z'G7"[#$%M0UN9XAP\/DW]+0*GA,M!_*A5FX<
M8HB</#AYZ('2]R,OG*U?AP[D#N3G7<\.]U_/#L_5#<-%'SV*/HXO IW7$<-,
M #M#U"F0G5L*74+828:3C$M-$&\+63Z^^?+NCMTDDYOK&Z"XU57[DM[OX*>]
M+X\%@'=LPLO[1*NJR1?+JC</6'0>RY0G%J&U:'B"HH)EE)TEB[ 0*YTI=;Q>
M))W<=1+.9Y3_"T@M;ZZ5=_+2"YQV1;!/8#3"4T;\]=:IV(LWE D[(7!"< 8A
M6,X([+O5"FZ)3[3ID,PR IO[M#G)<9)S;LDA^V<,EAK!/>FBCI.7L\.P-W+;
MKP66/=+(3@BZ#[ZN2.L%I)GW6)ITDG-V0/9&@H>_=+E[\[?Q_2W[_#"9BK%*
M)O#KE]<?<0 0^ *3HK)'K&=&+Y,4\#-L<=F9?5VH:5F8$9<!WGV_EY.1L\.Q
MDT+K/# G(TY&G*^UY&NU(OR7C$V*_-=$W#(U_O>WZ?>WZ70B[90/&-I;J79N
M", G=*#I)&@6TH,G+.$Q\_\*:"Q4=@]03"J;^OD/-E&_3Y*O*LMAQ']+\_ND
M8.--=G3 @%EE4 67C6QZLKCKXD"[:/,.V( S8*R>$B?[C:1K1Q]TUPZOA#H.
MM-U3;MV- E:R20X^'8=/IQ(M*P;U99IEZ;=D<I._?/B-W:DJ33(!+Z=(^%C]
MEA9JEBOH.W;:B)TE1S:1[,P6Z!T25'K'?#H#"!XOA\W.Z+O)X<F:J5>V7]W=
MIQG+'EXG6JM,301$&--<R2_L^_LTSY5)F\V^>94IF50:?NFRODOFP8QH^INM
M/'GZ>&C9^A^UI/I8L*F^_*2*)+.*[J6:*)T4'\>L_R["X6"RMF /)CET;417
M<G-;?-"_Y^H:;K-K .\5R]7[A/%DG)@$RV^J]U[%T>&V!]<&A;]Z7<-IMXO5
M;B>MCW7HNG!T+0?6G427<^@[Y]#W 3;.Y1JNRW4Z_!W/Y7)JJVMJZX2^U/$]
M=:>V!J>V3N_+_\J*:0;C*K?:L$)E7V[9Y'/R_3\5RPPW?DN+^=?JJYK8'_H.
MHR;9]5:6/8D?HA%;0$.3^(_PS,P0_V8B!SCWFTF]'+G_\BUM@_Z7VTRI <K]
M_/M].3 HX:^2UD[XNR'\IU^>V,OHOS$>T@"%?R>COTS\H-#09O1GE+]-OJI6
M-ZABU)#!L!OMPW(+-FF&N?5;8LC;=)H-$ UM?L&.+!B4@MCH*\X(7V9(+3R#
MQ\2.'!B4K[C99CA(=!42I\]D.J>R/T[EN?(+'R96"I:#ZRKF'A846K3#+N0/
MREIL=B!<A-&Y".-<6'!FHHMFXEQH</%FE^/-IP6%2T2?+Q%]IC#2B7^'Q?^)
M0X<F[97[/-3)7TOJH"1_8Z+9)9 ZFT#JV*JD*T6Z2#2XG$$'<P9G6J%VFJ&+
MFN&D"PU+G3=>*YU,E&QLBRI+HQ>_S\T/;^[NQ^F#ZKWSN(;D"AY;"7\J/'2W
M"\<10*0N%42N ]FBC_*;*A:95>\:>+";"2R,/F8J!Y+_@XVGZH->O/P#'R<W
M@V@IM0,GFN'./DP9HD/C@#-(X)P^-^: ,TC@G#33?I"_8[^'B*+X?,LR]2G)
M_\A?JN*;4I,WAKY$Y;]/I,I>I7=WZ<1V$DS'?8?46K=HXR4',<FY4"M=.!TN
M+Q27W6KON=)<V.'R4G'9K:[%3X-&YV%V$=Z7[!J??'N+$ZE+"-IZ*_N]BC9]
MXD3*6:FNZX(3B!093@+'"9<3K@X(5X=35T^=(G 2Z22R8Q+9L>3(4R>3G40Z
MB>R:1'8JC>Y\52>'ER.'3U,"TJ7<"CR^;)CKQ*8G8K,T8X/*D73*ZQN,:)P8
M8;V5TWYEY+N4HG"BX42C.^N_'<VL.R%Q0N(RY$ZRG&1U0K)<IMM)EI,LE[%V
M\N3DJ7OR-*3,<W]1/FA@G3)OZ[;87#*P>E_:[X#536"=O'&I ]9% NOT!S!U
M(OQX=<LF-^K=Y$-Q:Q]RGZE;,]-?E3EB=W4H?<?L3D&*[8UT&&=<%'-!/H&3
M,"=AG9:PR]C]=VD2UB',]DLU]"IATLV2!2=K3M9<Y4.'*Q^<@#H!=044'2Z@
MN#0!/3?.>ZM.7!V&$TMG-SNG3]Q20XN$?7FX5_D';>\IRYI4)H 7[$;!MXKE
MZ83Q\<-'X'O"QS G(H,OX;_7HIBR+&%CF+SIW?T0=N<N\Z)"XZ,YX@Q=%Y86
MGLIF.8ER$M4AB3KI64^=E*C7RDG4WAQQ$M4%B>JHU^<DRDE43[V^2J):9JD$
M?LL/'_3K)!?I=%)\8H6J-CDXF70RV6&9W&_@ZZ2A.?)=!6-0VJ+R:/?3%F^^
MWRM1*&F9\D%_+/E=1S%.?YQ!?QP,\)WFTFF1LRKI/GKT3J/T7*/TPR-Q>L]%
M- /2*(/.C7<(_\-5,N=:@+@XC?*9C5GVX!3* (*>UJD<AECV5D,[?=))?3+H
MD*=#\'>QVI'5=:_TR3&RLDZ?G%V?.+%T_LGN^N3T=4LN@])SA=(A_+L,2O<S
M*!W7*/WP4)Q"Z:)"Z4<^96 13]=6C?M0M39H]3%P*3R@^*NWZG?X^9$^:(M!
MIT.<'';##;JTBK1MVL)NNOX5L&5_;+FJH\IBT*[%+LIBQXGK@,BYE=R>Z(IM
M<4A?=<6@'8M^K+-T2"0[JXI[%84,55<,VJ]P4C@4AZA7NF*P&0NG++JH+/H1
MI/1[5Z[+6+@HI']12&?=B [IVI[IBJ7F^Q4.+5<X0$M^9 ^&C.LL,TTFS<=2
M5C\7J?CC@YU1P\OK@0C@5L(KP6PG_ZFPT=UF\2N >@4/ODFSQ&HW-8:_@+.9
M$3 +H_^C'GYE$U8R&+0=:+B)&G_05@H?/F1P+?RP:#"V@_/+MQ1P8Z\KY^AZ
M(L%!,0S^JH;0U79/M.[(C^/JY,TSWU3-^X# B=C1=/8K_\+$8 W]#E+[:NTW
M=_?C]$'-\@I.,>^J]"P.E]AWDNC]B4W#!<K(H6KW9=\Q_CBM^](!JE>N\G^H
MO$@F-U_@/D#@E]M,J0L#\.$L<@ZU$\03">*'B1/#W1CDA- )X:FLX;>T[T)X
M'CQW25',)M$)H4]F)PG:<Z_/ .O'L=,G^Y_[1DY][MLG ]+<[,M3F4AR]3%+
MA,K?IMF':6%6<B1@L8'64A/9FY;O&8#1/X09E5QO9LG UN6.C)P!6*IC(^?)
M]7Y/D3.$B/_HV-D]QN\9>I:\<$N]!<?+M"C2.W 2S3>57^U0UA64'3#09?^^
M98*=1[Q!(+ZD]TX:!BL-R[/K1.%LML%%/8='/<XN#,DN#$42'JML>R)\ERH&
M+F,QD(Q%=X'GTUFFFFYW1GH.H8Y:9)_NGVRGIT-$/$-$O,4B#PP.70A5_'A_
M+,3GT X."TXO.$MQT=IA[VKW[TI,3>W O/QAW[J23RHOP(6#!]MJV-\G29'W
M'7"[E;JOX]U9*T363X?SK/>5CI<IRZ3959\I4:39WEM"AB@:3P;'$TAL^WPZ
MN3A\_T=C>LVU%XSN!OD.4)4[>C",KB=RZ:L+UYW;N?+TM1JG["!'''Z&CQ]R
M.OQ0AY_AXX>>$#]+23:'I.$AJ4=Y/0>_@<.OVTE$![]APZ];P:,#W6!!]Y3;
M1'YEQ32#<5F,O#=-&[_<LLF'B?I/Q3+@QF]I,?O6UM^:[WN/DB;5S=6R/1DP
M*$!43E0[(.:4+['D;?+U0B"Q*PN&E6+:!(K+F?N+G6)G"#IJ"$Y_V("3^3/+
M_+F</V?K.VSK3^\ -FL$WB83-A%E]W95!9*O6'[[8?(W-I' &_/'FW].DZ]L
M;"*KO@-C"^U5T+B= X.R!SOBXO-MFA5?5':W].-E8&(S]8/"0TM5F-,3?=$3
MIW<JG)[HDYXXOS]ACXOYI(0"T>#C_A?'[8:#=JHOT4ZX^3_G_)]?_M^GDYN+
M-0<;B;]$;>#0T!TTG,E7?)\PGHR3V?X2ZS(5P):7:9:EWY+)S3#AL$1W,S&U
ME@6# L4F@[$,BB\9DPK"*FM'/[*'X;H.*[ H6QROIW]09F,?3+PW1V$VOKP,
M.#32UZWT7RP<9J'V9>)B,=UP =C8VZ=PV.@6-CKB;UX+D4V5?//]'MA[48AH
MI?QB<7"9JJ%[[D1'X. BC@Y%'!V)0EUJHDNIB8[$'<Y_.+/_<$H<K-GR^BG)
M_ZC*'J99IB;BP7S3]ZE?)JXI]ZMT/M5$]V]'JD.'VS"Z?L.H0X?;S^DP<3Y,
MG.=<I96)?@?79RHO/@&@AC[9[;0Z);#/H1*#!] 9#HIPF#V)6Y,IF11#@.1&
M [9$I4/&QD:RA^19MQPXM0*\]\D_IPE,RN"=IQ9"CZL8GR9/? 3[T)%^YQT7
M1"<I+O9LXL,WP+#X@$^(_N/5F.7YK(_.*W:?%&Q<)K>++[?J5Y;]H0JSFZEX
M^* UO')R4^G@W]()D_\]S0OXZLU79;KMZ,)4NM^GF?GNHQU?N7@RY;GZYQ2N
M*2_L.^QV)[TNP&AEP)$5][J9K%/VF^?S++(!@H'VE U["Z(GD@TG$4XBGEHB
M&EFI)7 _)BLUG20ELG\'$"P!ZTZQ?)JIOU;CM_W0ZD?5OS4?;YZU[MEHS;.3
M/,7()S^_^MO;0Q\=+#U:)E\!O\OL,W?\-KU3&2O2%:3L/)XF@]N?V'C=:S5)
M[\ WWOC";<Q=?N/J0^M?&W3OPC:\9D8LYC^.6:'3[.[0.0FW3/?OGU\?^NAH
MT[AKT3STX633PS^7$GSHL^E&\;J'CX<^.3Z%!*R9HN-+P)XB=RP!\+U3<.W-
M[Y^&S;5U1L)*R&LPY'ERJ(3XRT:B7S@^ER;WEPW@PI2\,\[!>/P(Q>5OM!3@
MNP&]\'1FSO0Z]!7K[$5IC,J.K8<^>YW!V"*RNSQZH[GXP,?)#3/'^![Z^'46
MPS[^EXP=SI-EB['PY#=W]^/T01TZF6A9L2[AT:)[RL:'/GZC!@+'Y5!VHW4^
MZK3(?O[/0Q^Z53B38KH[1O['U=6U**8L2]AX!&'+],Z>$SU*-<0VN4BGDV($
M6DSE5Z^53B9*CKB:P*=B= ^,R4?%+2M&5D6-,I,-@Y^+;TI-1C8.250^FDXD
M!$HBO;N#QYJ (4O'H_^ZLS'-_W=U50YC'CS-1G,]&XPY*:P<BED9RRTCWC)1
M_,.+/8QDB! C"A,FF1=JY8LH($(@[:L?1E6 \DGI9I%E1<K+DA(SPV6.LN7[
M+T"?#>-LKN]E2=R;BK;?#6FO+&6O2L*J>'ID&&Q?:MVTD50BN6/C_"\_@.KS
MGD/TXOWYQ3XT#V"RD/ "+$(O\D." X*8\ 1%DI% ""R%OS)952;93=89)HL'
M*O84%8'/& 8A8UBA2*,PYI(JRO&J9-&.3%9\[,E2W^^5Z=5>3I;YYKY,^8R2
MB<C,#I;SSN";:GR6F@_Z8SFX=_78YG.*?25(9)0@HAA+R@A#4:!]HB6C@2#=
MU9;>]CG=PH7+F67"I502^UX$8AHIQ<,PBJ(0Z0C)R&=>=]6LF^7=9YE2SD4@
M0A(*C07C%&OX1C)% ^4CCW=7/X?GF.6<C5GVT,U)_FS'UC+'48@C"#:50'&$
M"8\Y05Q$C'IQ*#$)4&<EV2?AOG.\Q(1+F6*.!(X$!0W-?8QADI4)85!,!-4>
M:0M@.B+&_OYB?*%3[".F/<Y#B:3"$D)5ZD<Q@<FE)(P#U**I.^)U'5&*WV@-
MEYDI%+>F:@K8,X'WW:4W&;N_341CYD\UJ1_+G.+H*QM/E8W!EEZ3SI)KNR#A
M%Y9,\O>I6>:]AO$DDYNW67KWJJ3NW>3UG+8YN_+?5+$X>W5YVX/MPC;'3"Q%
M$$4(#'ND,$,!#SC#H1^'U(\5C=JBKZ5-@Z=&SS^VT&)?5O'\/PS+(>I:N'R>
MRVR#(VK"\2H /+9"\12SX$![(&@9C67 PR 6481C$G MN69!%%"FP<31%D6W
MM)=Q:*#U_8"NBVH<=#L$74DID@$CQ$;.6L5""ZY#P92*"9)MGO92N>O@H(O1
MQ4*WI,2\-S4%YN:Z^TS=FBCTJQJ-@?!G*V@V;Q[]UZ]GQG$0> *\RI@0Q'"L
M?2;#$ 4(@(TB' 2B)S@NV?%N8NO[7S6Y;SBW.A2'Z,$B.E22L!C,J%(*(^3%
M2(94AQ3B)TEXS'KB5)P&T;UP+QZ/O:>.\D^+Z"B,E1]PI$E,,94Z9E3Z(8LC
MJA&$?*OY^6[&=B=!=%>PK.O]9X-SE)M]W_>&+J*$2R\F.O(1C@R(A1>S@(/K
M0#3304_<BR.ZR5?$/U #'S 1#K,'8)9&F'B!R:?+"(<0VB&B? H0UI$G!&E9
M].ZDNCTB9DFX=JG58;83F)5QA"D+HX@Q@@-3G8%]S0BH6NDA?8F9M"OD7Z:F
M/6/D]B@(<P:S%7#!6$@PUQR<6X6CD @E8PX?>P+ADWBY/0#SX(*V1X%9>!2%
M" LOBA4.O""64<@\&7B"\DBQOO@0)P'SA7H3?=7+2G+LH4#X ?.P5(I*'0&X
M04-S/XA;H-S-$.XT>ODL6GF.)%/PDB5J(M10W.$W,XJN[29]L^EJC]ROCT&]
M8BREU)@31:.(DAC'$,DA7^JX)VKWF&XPI7MF? ^9 0?-[4E<GTA-XCB,),6*
M4G!T0P9!&Q<Q!<O45DK?1??VJ!$:^/L.FQW )A4J(D& )5(AQHA3[DD5DS B
M-"+$6UTRZZ:)/R8VXV!/R]Y':#Z]2_I('<K!B L22!8AS%A( XU)3*6O8\EC
MOR\Z]$0I@HYITZ$D!!X'6<)1Q#TD&&8!5B&B5'C*5X'PM(\#VK;KIHL>Z6D@
M>Q&^:=^4K.)^&/E8Q(S[V%<J5I* (R"4D*&.PM4\;#>=@=,@]FG=@FLI$PO-
M"CH Q0G\*TNG-[<C/H5WJ#PW@.*FA8NY\-GH/DOAC<7#,PNB8L0F<J3^.4WN
MS9NOK@5\S.U#1Z_2O)B#S+!H6L!+9A=O4IGUP"QW81(G7\I1O:P&]:HQIH_5
MB R7B^N)?#-[P;Q, (&AAE@H"B.,!9&4>5(C3 !^B >J;:/_2A?G+'L GE_?
MF6W:UT),[Z9C5BCYVO2&$8D="OR8%4E>?I[(=W?W+,G,2."/7S*8NJ6G&!RU
M?%^A<-:S;RV!)1 KQLZ^W0EI%F>+0#L*S\^"+7MHXVTZEB-@>99^558*-BFX
M(^,KB(3V/:JQ\CTL(@$1-_B2.E8A54K*MAU52XYC=_$U8VZ3MSMA+(S[!K&W
MTPP(FH(IGF%G/>I.CJHPU)J)&()EQ'% )"=A&'"/QX2")TY7%]U[I+7>)M\-
MGW/XX6U2%(U#)#=C*H[ZAJD.JZV(2RY##ZRACC#3FBO)*%'@G@F"-.^U63Q<
M;45H.! [.80H(9$7\4#[L<(^EES#WZ%/L RH9G[81<NWK8B=TK!O"'C/>&H[
M.SXT_>L.V##*N.>#MTU8'&/-@SB2&!%.5""]*-*]MF%SIN_G>T/\.R KUN(S
MG1Q5@C,LD>"*, ^SD,0TX#3R(Y\$'#%OU7!U0.N<VC.*>J>T.IHL4#SR$ KB
M0 4A)A3%U NIL6M":A]Y.]2Z=A=<AR4+4+R2E>HOMC:;RI.C2T=<D$@*XBF*
M@YA1P0G17H PUC+V=]@^V%UT'6P0,1E0-NKD$/*D1 %7'/L(83^.*:=$QEXH
M('IC+.YDV+9-PW@!?B($7'W0.A%J/]/R)?V4W-P6J9[FRN;0FRU_4:B \51(
M1+"G/"H]IF,B?; ;!.M=IJ,6K_+1EI/E*/>3HW;^K8Z]A2F'D1[X8"4]+P@#
MAC /PYC&$C,5(AV(2'FKS<*62=]"D,'$&E3L1-7+:3*6QH-Z[!QCI8GO!R04
M@5%6@DFN?"0$S#8B'FEK8;G#',^&M]/L/I89ASE5F[A"D)8!\3"E6.*0*4I\
MF'HO()(BCEJ:.ZS:LA:N'.:CK%;*[L6<8RL%@A5!1#%$HP@+JCF)P:DD8.>0
MKU7;)K]=6'.(4D!KL_!/*T),^8**R->A]#$+",7@4WNQSP,>J:AMR\(N''E:
M$3J,<J".^B;-BKG9K(&Y3Z2((@$Q:TA\NEU,MJVS=$XQ:.%Q%@7$EPPH)AY7
M$CQ>%%+E:T^0';9E'T\Q', 8LY"NY.B;,I? !_959>Q&C293\SY38YEF #K3
M^;$\"F643@MS/IE!8AO+R@?^O7K>=?FXS^6M\T5JC"'@C,#&H-"H5*8\'$K$
M9(Q8&.KMA1&+C/";C/",@HR-\D&+[-@PLK,S),:13SG3/@1&P W,./4)4R(@
M<1Q)VM:*=+&V:3-#X.$!1>:(N=XP1(O -+L'/TOB0$D>**81]KB@/@:([*E(
M5A'B>T& _4,94BY?Z30SC[7]-D<_UIU1?YH7*!E/G9F\U@A"#95\M6<EK^.)
M?>;;-'M=/;'NY%D5WGRHG_5I_JB&U\8E^*&,@ GVL=0!\Y7R8N)1XK$P4(]6
MO%?12GW9H8/N.BO-PK,BOJ9F [B,PIB%2&#L26*V'8A5C;Y9%E>SE_'%L))0
M EX/\F-S^@A&* :0!H&O.0(-1_SM+=&V5NJN9H*/S\IYGL"6.TYRM9U9\WO>
ME+<TVTY[H18^ 9=(8"\,*58L0*&/XQ!SOD,CEZUK+L$VKJR,[NFHEP&3GL;:
ME/#B*! LC)'IP11+Q02.5[L][JFH?).9Z"SUR@N%!T$TTU&,-6  B5"%@::Q
M!),?/EJWQ-%J;'@H\9HE6;759FQK,4<_WIC"S)^V<> MW&AWCC3J.!N6"OM<
MRB@*/!UB#RQZQ .J0P[_+_RXS;+OQX(-U+<-[*G)!U?,)T$0ZUC[ %2(&H)0
M4&Z.#%%!W-9=>D]#C4.\6M71-2YHC$(=*@$F56#&8N8)'RL?$VZTW0Y5JD\%
M KNWV)2<B_0.K*E(\V([Z>5-[^P]-F$^3Z!Z$8K-C&MP\C'!U.S"41#Z"$\3
MY+5HO_W ?P68VJP!5@;W=+2'*. , <R]&%,4Q#B&.8^YBI&9^L<[ P%9K37H
M!NE@\@(>4AY*"C&,8#'B+ Z1],#'U"K<7CJT==I)L)K[.HQV(]ZC'XVP_S0"
MJR>3_#[-X4W;5HFV<,=(FQ&V#Y/7]1-W6/]A@<=DB)FF0F -$4T@<,"E'TCM
M2:_-%]^/<1LXML^ ^\%,#DXWHII3%,8F_T)E&'$:AQ[&BFBTNJ5_3P&,-CM>
MPV.H"(16 O$X J=3>3(V'9:8+P.I*&)H>VN:,Z.SC@U'/];QXD]E,UFMLDS)
M2OUMXUT=7,V#K=?5 TIMT^R0':@(4 AN+X0Z@L;FB#0$;I]I\>.IEG*3?:W?
MYLAZVT@[PRC,!"62QG',,(AI#+9"APSYX"E13XCMI81;G40_),-@%0T583Z.
M<$0%]B-*O2@&%PMIX;%(B'T3A:OK*#[:[%4<FU.J.JYYMH-Q7.UH2[8G:5;'
M4A_^O+0[+EG(TD L#F*H(Q-_A$R"6\:E)C3B',>@W!XKEF999#\.KA]U][E)
M?19&,7"/$HQ#\/3""',=2,%]R3VZO<G3MM5?;W-V9UC<C/U8(I_R0/H,QR)F
M6DJPM-0C42!;3<:>"XK^OM)]/&X6&9-JQ(0]#C<?W;,'DXG<GX]?S'.NR\=\
M+!_2L+D: <-"ZE%%,(O-?M 8Y#?F'O<Y#]M.Z=XS]*!X7T"V#+B3O -OV:,Q
M&!$*P6K@>;&."1**0^C.?,VVGP2VA7=TB\?<8\[A@"D/ HM 4?#W(LJ1IP$I
M6'B!$.31U5+()_O:E/U85ZA,002_8\[W777]2K[7"V.!B0I0'$$4JR(JF<<1
MBT)S$"$2CS:MJ_T?-XWK]/1RI3SBR9 !F1A,'PM-I@,KL_O<'(3SZ.P^Q S=
MHEB&T@MQP*.0(NP#Q@.L64@D1H+%:H>=J]LH)MNTZVX$V[7Y*PZB((W,VQ^V
M$6V7ONTM'ZL[&B4<IIB;VW51AH7V8A+$/BA%#M&OCAZ_M(>]U8XF6P;W9+2;
M&$SR4 J?AQA"?:XU"R!(DV 3 BH?[90@VE(BW!':M0PXIE3Z$:$X"#7W"!:!
MDA$B)%)X>Q>>;;2'6X+X3;3?WX\382U1P;[;HVM;2)U=](5]-T>G-L)NHD00
M@F-)!<$T##D3G&(*?J=G6L%O/QUFP[&N[WY[:PYV15ZT0-KR8(Y&2ZRX](76
M0H(%AH]@>Q7'"I053)]NR;9OQF@;+7[P1+3P@(7,"WQ)/+-DHAD%"@*J/4T5
M4M&^*^:/H\56T+4,?[D&E A3X28B,/;8YQ "4D55P"(6((_PMC+J7:0CH'9Y
M>U$^EHKZ=ARABD"+$1_\M(!B)31##$DD P""].*@;7O.+B.,8[3JE2R.\"7+
M$S%2+)O8:MLJG7NO:FVU,G1[PYOJ>I/V_*A*/=#<FN"#CRY#A RZ=<ACINQ&
M!101\!GVS0,%3;J004B$FQ2M'=%)B?3# ",=(:8DP2J(&(% C@:1]B/.L+=O
M;F&9R"OO.8W.3R6,28<Q,AX5N%11P"135 J8Q1BPJO>M$&BC$NU'Y2N6W]H%
M!6$^F%6%KVS<;DG-I=<3:?[S9GY=(QXWY60^\1C $P-]$(Z#$H,@,R948;FZ
M%+B;EQA!H+K<L[!]**<@BIGFNQ&2(0>G@ 0ZYL($.UII:L]..4R5^'$0TN4P
M[^F(@K EUA@QAD*%%;@E,=$D)$01$#[>MGV1[%2?A(.5V/4)9RHB,#\1. '@
MQC&D8LQ"F(T0R S!SVESWW8J.8OP2B^1@XGZ'5X%WNKGPIQK;PJ,K^]4!M;X
MV>AU.AZS[ "RC4F*:1A D((PBGU&@M"/*8H9-2NB;5VKRMK\:9:IB7BP1?F_
M?WZ]U7E%*\FP@]GP9IJEH[+N?_3*9"VR1.7/1N;K_1D  *9(2Q_[! +46# :
M>LR/21@'"+4=3MO&@#>_?]H&!,^/E@L1NH2#$&9'2!U(%()'[WL\5!$6$?CX
MP(F0K.*@WJ.Q'PXP\/E87/C\+2G^I;(Q_/AL]#9C$W$ W1'FGF)Q!!Y>C".&
M8Y_K6(+K;$[:5KHM'[=*]ZN_O=VJ!U"XLMAS7LIC&L<:!1Q0:<Y XAQ4 !A@
M9@KN&.)ML?IAE)NRODZ*OHHEPHHA+0*-/0Z.0D28!O$WO6H@/MQI[K>+/D;^
M(:I/C]-O^4AGZ=WHQVEN%XA_J@^3F=R,@(#DZYKU)7/_6W.[Z0[Z>VX67-_6
M-U[/[FMXSR*,-(60'H&M\T 8P$WA<0!*,6)<AFV,V&]5G:ZTC=YMB&?C"&%@
M";B,([""6)@ T"0M"<8*T< /V_RV_1;/XVAE?:WC+!$RBDT2FW+-,!&4$6QV
M^W)PU2&.)(]>\_$AM";+&:ZC\229?%5Y<0!/WM4WMO%$4JE@PJED1&#" QX*
M+9F,-2C0 )&6'D1[UNT$R MVP$G+(,_&$T5\D!)0*5AZ.) >0Q!_*XPI1*N>
M:*GCWG>%BP8KVYF[SA(=@EZ%N(]KC440F86? /@#FD432A]?Y1I%J_WJCL:3
M^:ZH/7DRVTW4QA,(KP)/! 0K@2&ZCV,50!2I0T88BGE+^ZY];0ZXK7Z;Q[5]
MD&?C24AB$DASIA3XW5H2#L%H)#QD.U1+]NB2K3!$:#D#V7&6T"A&DO@ "Z2,
M"N&!ICJ,&<<";+2WZIKLJV$Q:*<=K,ZC>-+:-F#]2TR+HCDFJ,22!3)6OG%6
M%8]03#QMS(WVX^#1A=X&$[N+"0SM:<@60H"C!4&SD &.=<@1CWTFB=(QV)'P
M\?M!3+*I+3%S;KIEQ(%F4](:8>6)6,;"')-$? [.J-\6A^^K%A%^Q'RGT\*0
M;E=0QZ9^9 VI'\KKWJ:9;<*[L#XN0-4C)C4HN3!@3+-0$9/S]4.M15N>=Q.%
MX:H?N;(^WC:@8Y/%)<9@UGF() >!Y4R"@E+P;>A1\(6VMZ/<2E9K_F ]6>/4
MG ]A*%+)C=FD69Y)6BXR'I)!*A_XMGS>F^IQ2^O$,+7*8%> MO;"D($'R'R,
M0PR?H]8>^#MDD>*69<F8+/1L6#^X'1FR7V)A!U9$H*EC%&&?P[\TN*S@!L>4
M@6X2B)&H#0_;DPN^M\(*_SD$[-UF!>@N'(6"1C0B9B62Q^#.L!B9#?"4MV2:
M=LFSK&%%>%16G$A,* LC&OHH#CU0QF#9S&%X$6@.X?M$L+;]1@>*"8W]?1FR
M<'30NDT)"U>M[&;Q0@I.6^2SP&QG-2MYW'3= $4>>?3Q'>&N(M^/5\*=U1$=
MDZ8(M)JM%.&(8(:-8@=?V@\]A>.(M5BM?1-"V ]6S-9I2=(4"4JUZ5BH<"1%
M' 7@#%(<AZ'0L6Q9QMO3Q0*$ARMYOWUI^F*J5*?S'CKKNU)M)!8SI3ABG' /
M0G NJ?8]0L#] (O-8[P]H6<[3Z43DZ?]H$W2MBC%L!Y?V0UG_VY4>S/D79Y/
ME4F-WR<%VW3FW$9^A%ZD<$!]%03@A6$,P0322@J86J2"<)=.;.W\*(?WJAS=
M$[#CDRJ8/==L5FIQ*$<"TX(7@^N"? @N:4RQ" )A6G@&C/,=SG5>PY%ZA'4A
MQ6ZG@!U%>,KZD8^9NDNF=QNZTVYF3$1@[@F14GK8E'7R&)2[\FD@D(ST:JGV
M:B.W=L;8T56#ZX_@&&_>5%,19<J:&55A+,&SHR&HS;;^6[MRXZD%YTB*E0@O
MY$J ?8Q]#"$=#6*/A+X&B1&!5(>+S9,KUJ-I$LK!10##2B6E. +O%X4^6%0M
M0X8CX6_W?XZK28[B+1U'>)C9\"!CCW(I,40#+ (U&VM/F>R6;*M%W!$L/14>
MIIEOQ"3PI,9>H,#V*BFU5"KF8=B2W-L5*4\N/$>Q-)P$7(*$0% 888@28]/\
M"2%P2PD$$&TU6#LZ)4]L:8ZF2:2D$#]Y42Q]8;PU(-=87T ,1-1DATV>1]4D
M1XE1C@(43WMQ[ &]3##L2\X00L D9$H74,2WKPJ< RB3(H.QF]. 317Z%S8=
M_9IF][=P43;Z#$\<P]]C):9CU3P$93PN#U0PC=:N;S)E#S$;?4N*V]'[9#Q^
MF%_[2>6 -U%6SDCU58W3;0=;U(-:J8 /=>AC3AEP&$<*<>9K(6'J8P]L^OH$
MQ4>5Z32[,PUU/O!Q<E-FD"O$E:.[GLC7\[%59TM\S%(Y%84Y[^:SRKXF0I4W
M 9-F/+(LJCE4W??EX=[T!Z[)J%L$-W@V8]G?@6.68=NG-32M*%?Z*2_R:G5>
MFSN^]YFVM9/2NNT;^X2![02W,T98@X>!-.B%,":@,\V>JW5IQ=-P*OKAK]3S
MUK*J;0OXH_FUF^#LQU5$8H)MWS5?XS"0,2A9'%+M:Z4\[+?VG@L,WCN%VV/-
MQO6D2*ZN.9@(4"5%PE/Y8/9'7[]>IY?8;,)2/3)9OF>C7Y11K@JTT8%30L M
M],!]#@,4@^'!H()"[1,_" 4X"*AE2LC&*3%$69JN*Y+>3:Y?[S\='[2A;T;=
M3LHDL*5>1Q61W3B^PT3N-RE,"HAT?2EYK##W/*;]D$9("!:PR/=:=FUW95+"
M94DI]V*=<E)\M'Y2"E!BQYD2C!A2@8Z4*=>,<4Q- 1HB,A#<P[)MG0EY4>!M
MG!)07X^?$!_M(261V<]]A DQQN$_F!#@V^ZELGS\;/3O; *F?3+Z"#[@'1-J
M6B0"1G?PQ$0Q%0HCV\T1\X@J 5YJ&,>8H"@(6B8&ES[4>IM24?:(.<$5D4LT
M[J3&4+C>*5H[00F?EA4.16K;SXWX0]TL)WLVFJC"-,"RL=)RYYR'T8_65?[I
MRO1MJ]SF>2#U>NDV\_#<G.E5E#'Y*$OR/W+XN?BF8%*! >7\3"<2W 9PS>\
M!68&LG1S.J-!Q)?4#.7E0]7I)OM-%=4PEGK>/%@GL5%@+5444J9)( +L(<:D
MKVP_4NV#8ZVVU\[^8_$]9ACE7+=\_P5X8..83X8#+TL&O*GH_]V0_\I2_ZHD
MOD+2%EKLR\SC2_=WM],H5S?>/8*;#E>KN JQC)G/)*<>?/0Y(P$#K 5>A'P<
MHNW%8;W$%0U7ZG\=KHZ**QT(JD(B $XQ!@</HJ%(@*[RD1^&<4O_SI6\9!]Q
M%:]LS^\6KGH%(1PCI0*"/>(+C+BF@1>$2$IE^O^@74[+.S6$'!J>#@U$4<9]
MTU69@Z&2 =,1A6 >1QJ'YGRG\SM /?=E>H4&$1%B^@1&6L68(]O.@OK2\P,E
M5>SO4'QR9C0\M0=B_WO/,HC6DGLV*?+SPN)CIG(3.I?'7T  O3R0=);\WQ=+
MYM\?&X3N[@ISJCP1\@ KC"&^YDCQ("1Q&$D=$7^' J]NN"PE:^TY'!_TXN7S
M)97=%OY)N+)U\ @L=V@] EK!NH6:$N&;BBI0>S20A*) !9*%"HN6KA/=3 @<
M$:T0LCJT=A.M2L088C\1>@QC^"\8[3@FH&I9 #;;VZ%,97!HI6'/T-JYI,3A
MEIZ J1<8,ZV):=_!B0J99 @LO_3]'9I/=P2->R93^Z8>AP,XT^R,$R84(1A+
M''-.-6(\"CP4*4Q[XUKN![C>>8_# 9QB,HAP%&DI?!S%$3?U]R'5(2(>$RV'
M87;4WNZ;UC^MAK.;YPK3X#\SI<Q5?_/<ELN5Y_^*ZI*-AW=4S[DN'U-U%S>K
MM?8$W>K7UA5A&05$<M :**28!@&5C$ND_= #IRK$Z_9!;NN;XWNKO3_V'&.'
MF*2$%@)">8QHA(GR8LZ(HN9H-L14H%I*3';JF.F3>&7[]*.9M*:?</W@I:+*
MD(4>T@+L1T2QQTT!*V>^4)SHD (B#FU\[)-H'6E+I8J'C5OX$9$1$W93-](L
MUJ'06!'?- *7=%W)X=9VR(BL'$B\>=QBJ81V'0'KJEH1PTB9;!#V*,8448^(
MF F?:6).FFUKK[);WZHUXK>N8O1(Y'#I2V::+2G3H11YC#*?<5_Y,5(1:<FI
M[Z9.PGA%#1]$SBGJ;38SA$CCG+$(?#.-/0A20ZX]:<[0([[I+;ZN:ODIBVA\
M?[6&YDG0 IXKCSRLN0P8CC5H5<U#$H6!!U:(Q"T;F'?9XQM$ZW3/KN3L8D8V
MUEEY2!""-!4PR3C4E%&P%)Q!A.A% 6M;6MIM/_9J+^*U@SDA=9))RA0&!S#B
M&.(*&E$DF= AP=2<F'V8D ?>BF]_#N)\AGQ-/1UI[N'0;)=CH>88OO#-@5P'
M]EP.5OW(1Q)W_+T:![&+@X^(!(YTC!#87V$.O0PC8 OF+$2MG?6V512>ITI]
MW\GY?)MFQ56ALKNZMR4;;].#;^L+EQ4A* A/BU""98@P93KVB!>K*+)N-#G4
MP8S;RHE;1W(:JF04F<.60M"!($J@WN/ ]T,>0\P1R:"EC_=.>B(Z!E63FT;.
M>CME[;L!P,UAS!,Q>,[&DH$21%$4!9A#?,R"MCWH^QXCO&$<)R9.QYH$ 0J,
M]L,T)#P(9&#VUR,AB"?;EL-WFKN5]F8[4%CK0=L$:R<-;_M.K5'O081%K"&8
M,^<"QEQBT,TL\&/C8K;DS7::-(Q7*C':!W(2FI *0QK'B$LML8H9 TNLS(XA
M;$**UL; .]&T9JZVT[0+-:V$1-STO/<]IAEF/+ 1D0RD'X=$!-&!Q_#XV%LY
MI6J'2/I@*D(B0<VA"-PBA;$(F0>*3_M(^1HHBMN.U=OM:#E_C=K;1,5]IM8?
M)%9=]'%^3?-(JE!QH2-&!3;'6L-GB%QBGS D5(#;>DKLX@?%X9KXNC&(XQ'!
M(@I>)0*_!+18C!$5 *I 0(Q!J/)Q6X>D7=($9+6;WUY$E'WDE])::_LEK3S:
M=&E?R!.M-+NBD2EGXBB0#$=2Q>9T,>H13+3R_>A A1!0ND;+;1_;.;D1FV/'
MO!"9;HC84^880'"NA%:"$RU:G*N=D!R&JX>'/((;Z=<DMZL.IMOC\LG-FU!?
MW_@VS98..VYZZ8H),.0:@<."!:4T4H1K+C"*!1CWMN3]+H# *^=[[C*L)Z=>
M^,(/-"+@L(%SAD '@8V,%(J]2'(BVW8D[-3S.UX3L.Y'?::$2KZ:T^NJWJT%
M^VX:^]G$=G'+)I4LF._7<N+3_"&F7^H7\PB;,OX"#RA!!]\U;!3RF6DQS&,$
MRIT3S@@RI:^@)#@AWH$:@JPQ4+N-KAN<,9U?PP@)IGV-5:2 .:8''9?$5U*W
M.%.[9<2/RYF\#)EA*'G1M6K<<HA54/\*!KCS$B,"ET\0A8V/@ 4"[8(5T>!$
M@>_GLY;.(ETKS_<CM$8E[,Z."YGK0,#$1H)%(=$X$(@A)#G(7L198%K;G;]@
MYN E%C?7R[4J(2*Q*5$Q:US"!'D^D11""\P8UZ+EI-Z.E=;[@;_&\QW$7!^I
MO/-P@)CSFQF7=D$=LY!1CV-)>(!"2E@LMQ]/WI':DN/5<@[<DIP=<8J;PUPQ
M5Y%);J"(>21DOM38UW'@R0ZHI"='G--Q)T6<CI'V!8&8V;0OPWZL1>1KJGED
M6B^H[<?5#P]QI_"@ROEE4L+4VN/KYP'6VNFTQ%R;6\SY\8V@<VZ@ JF"".0C
MX!KSF'&/@^>JL"=)@$1K3\R=5KQ7=NQM'M 34>N), :_W =+;!8V5!RS4'H!
MDE1$BHM#\R7!FF315FH!  JN+$E<MQA97P3/6.D<&&,&UI0'/.:8\X@+/Y2Q
M\I#B/HO8NC,U]UFH6WG[T08?A4S[+! 24X)9[,7$ES# 6%)*% _;+%6'!J^#
MP$=^)/U F$52@%4$ B0(B0.PO6U;RDX[^-\G]F D\\TXS?.-77(WT.4+CT @
M X 6$-C _]G%;28Q^*Y,XW7U/?_XHN[NTXQE#Z\3#0]7$Z'*$<$[WMOQ7$_D
M[)M7\/*D*G%8NFRW[1FFA'=)Y@YFER@'\VST215)5E:1-$WTACJ2#8Q$&DN!
M- $^QI@*+\:$!@'R?17HV&\[4NMHC*R^G)/3,*"[;4; *S7.1^!N<G-;7*7Z
M"GZJ-PZ8]9&5=6+K31W$<TR"R)QD1K!$IC<;DYH!MX7@$'.$X2G!6_/<$/E!
M_YZK<FQPW_*B,MC]_7O==@S<$5%8\1AL)N,X"C"-%-*<>N#Z<85UVZEB'0)W
MM&RN.\;=&,M A $.*1>8@4,=4!'$$NQBH+24+353M#/<#:/H:*KC,7:,@UL1
M\HAJK)C-M8< U,B+--$0K[25T1^-AWO8,0@4T,I*8R]4K0!S1D)./!)%&/DQ
MY:%F6B)*,?=)W-9B9NBJ]C%P5326/@\0N,(QY@'H5FJ:$Q I8I\1OJX^Z*GA
M"A.-EPM$>@%7W_-]&?N>5-J4"9@,K*3(BT(>4HK8VD/Q!@/7C35?C6>TUWW!
M(*A"/M:28PC2P,.2+-8DHHR"0ETG[ >2T5;T=3Q:6$PXUS$.(T_CP)><LBB4
MF"&D@Q#S _=7G8<6;B@186C:0^,()D(P'T$,&G"8(TU78XQ'A?\[TS+/>.Y"
MT4H"&]-80*PI@#IP@8 XQ2D%MYY*CF"&#@.;[^-XI8W4VM&<DCZ-D1(L"$Q:
M'DM%N6]/(8Y8Q/T@D(?N2P4_PE\N:ST/?43*6!%?F9I03<V&2YA()7VS,0RW
M%(_O5H#C1RM%HCN1MR85_FS$;*G>/'5^I$3ZNL3Q==%,,#=2DG$@HTB)@$5@
M^36A7B@BR3"& -83+=M,JICUB5/:*(I0BZ.Z ZE]F@R":  S@0A$#]CSP5*8
M,,QL;]0A"8*VY=IS3$;@H94EK>%-AL2!#DU?9?@?E@A<Y C4IF(H\E#,2-M9
M=^>8#(AV5O83[#T9P&^15.R_S\S)]L7#,YM"**PKK/XY3>P1/E?70DSOIF-F
M3DJ6C?OL9>PNS8HD7YH)<U#2M%#9_"D;9VG^S(_52$ST7X##^F9V_[S:R9>^
M+R"B%MKT6O?CF$MDU@.9\#W1YAJNG)G%LNPAF=Q<WYG3KQOD-4=RW2 ,!O+N
M[IXEF1D)_/%+!H[XTE/LV0IK'C61S:=5*X2OQL;DY1_T6IJK_7@E*V??[J8\
M6]*I.W!Y"/@($>C/2!,/'#J,1!0S/^1:A4IY(?>\MA6JY3/WAH^/8&635:?P
M8>/4VW0L1\#7+/VJRLT-FP+QO3 "#J/R?-.B0_K89\;HFNY/,9&:!+ZW_;3O
M?F%DQLXF-W=;]EJNG.H63,J-RFGVT%0DQP))3)2(0AS%TH-HG6 >Q<K#E,<(
M?.9@ER[&_0+)C)G[J1(:KP:YI\+(Y@D_ $&/Q0B+**8XE"R"<)\+QD*?1%2A
MB'..!!J:L3D4(V;5H=.*Y,3VAH-3XBD: 2(\S +*?$P%0$;X,1,XVN7$Z%[!
MY'![L]R4I5,P>2P,))(\ECJ2/ @Q]0B-0&$HCAGVL/+B'2IE.P&#K8G!E;Y?
MPYI%K5C,-(%XTW@',2,065#"O4!X7JAW.#RG%[,8!IT.(1\[BZ"->4A]Q<.0
M8AD%/ YB+\3<;$35'MWEJ/H>S&(<+?=*.MTDOIUF,)1IIL[JD>D@"(/ $UR"
M1^91B/ZEST'9*M^<HZ:'YI&]3;X;EIO%W;=)4>Q\UGO0Z?B_!4J/Q84?<*8C
M+,RI1.:(1@A:P"?38'@)\6G+MOUNVMY3XZ)ER>5P7&2K9197+Z?)6)KA["CR
MMHHAU=.ZBJ&QCA5@3+#V<<PH#B2X4AR<*;/=/%(AW2F)4_.R*I PC)N-;R=V
MX97V69O&O@>;/FAM-OOLFQ]=SRWD,=!_ 0>[%V+!1>P%DL91&$2,QKRU'F59
M+[9PJQSFGL'@:CW/45AV*&,PUE+'OD\A%!,"QYZ,/-.,$1P\L["\%4;;(++2
MK^!(]!Z<1%_/"QQ%*I*1,-W8<. CZF-.=!"'OB]UVR%+.X'DL!2UOTD3=8MM
MX/J;K6>4**2Q9H023)4P)26FA7)KY?T.FNC S'Y/]!'7 M2W"DG$8^Q%DO)8
MT4"% 6%,\%W.\SJ:/MJ4<WAZ?20\P@,2Z1!Q@L&9Y<+4!B@4:0*Q9M#6]GE1
M!K?IHV!3*NX1]![/L@L(L,.0H2@$7TUPPD-- Y^C(!(HCEJ:#.VDACIBV0_D
M24@\Y/,HBCGRL)00@S+&4$B09!J)EJ.@-\,B?#)8'$BOJ<?SE:)(JP +%<=@
ME6E@FIT*0FG<LMUMHUE>I?=0LYR+++FWX4JJ38LUX\:;-J'WZ3@1#V77+0;A
MBQ$$\):KC=;_988ZXN-4_-$J%K.G F1GS_QH'VD:7U4/_*@RNQ7YS7<3:)4+
M(8V]2!*#[A3,!P_/G)MDNO-%02@,XR39WOGAA[_^V[CXDTR^CO+B8:S^\H.&
MZZ\TNTO&#S^/_M>7Y$[EH]_4M]&G](Y-_M>?1O;W//F7^GGD>_?%GW[XMYOB
M3VW/^*8,/W\>\70LRZO>K+#(W/<";FP\H_[(L]&+^O/2)?5K#%U7R42"TH?!
MT'HP7V[5R-A1-GFH*XSR$6=Y(MHFJ9P[<6N^2E+3.&]4P /FW7OS H(TF\U^
M/C*/;GF&^4>PL:@"7OXP@E$F1N_89\WN /"8OZLWP67FKY)/2EZQKRIC-VHT
MF1I592ZV3X?;I@4,8F*?)Z=9_=CR,<]'KY/QU+RV96"9TF,EBO+RM#![_8$B
M:6XP8+9- 0!X8SE*(1[-1HFN?ORJ1KF";\I2X'P*_&%Y]=#48A:&E8TFZ>3J
MJ\K-VV&@198(\[&\S$AB#M3!Q^H2P^GO*A-);AL4%FG=;:"F,S-/F8X+-9N&
M),^G, ^V'&SQ8COV;W;LLX.%"F7N,^7[96.SYZ-KH/AJ3E)YJQF=^B[&4[/M
MVS9&*]%A<A.S:UNX64\Q4/]\&9;UYT7E<K"$[ZE[ECO^/5;U+/7<:U4]2+'0
MG ;N^SK&Q!=Q' O%(=)D' =@P+NE>I8Y]#C-<\>RFV1R-58:WA(_#T(8334\
M<\'/HZ1@P,OJN]7A?$SSXJJ<M>9NOD>.:@=]:'(Y(":Y%2[@JBPGU1R38Q"6
MBUMEN&Y 96!4 RLW<O7Y6U+\2V6 !%EJPOIJ(QLW0$'&3#]\;1J)2'A!EDYO
M0*W674I!W)-)/LVL. L['M MY9/JX=V"DF&ST=B]C5+ER8VI C7'B;'94*U&
M-SIE8F1BEFL4S=.ES(_ #J.*IT:1LZ]6H"L9@E?_+?VFOIKSN(O;)"]?!_\5
MQH],= */L\-9+D.UUY7=4MY=?Q[Y\8HR.-JT;>[XDI33>+]<-VN^W% [RTI[
MP-G83D5^J\Q;C/*\2R;3\IF:)=G\@??S4]B>CS[#= !WA$GZ@EX']ZJH,# M
M]3J\VW133R:UH8([IW>5T3"*.3.;G1I*OJ%7YR:RA,!\V/FST;?;!.Q08NS1
M/3RB,K7)!"+F4HT;)L*=AI,PR\64937"#,N-+-8\%^DXS7X>_<^R%7[)\$T\
M,["8&W@VF4PMUNTQ$!6)B;'1I:6RG367A_)@(6 &85\VS6=V/$O_6UG#:4QF
MM6%M=*>*VU361%>&/*\[ N7PC4%@R8*YF(*0V-DWLPD#,3-8N>D-QN<+,P(B
M(Y0U1//G_!N[N__3_Z3()W]J#"\'Q!B.6D-9SQ \-S-+_^:A8.W'YK@#L**Y
ME;%1^3H8R2VH0&#8.($PW8AI-130B1-9&?-;<(!&!CF6#("5<3\>1NP>1O#=
MP*QF6'E-A91,E7,R$XNC2^.H#2R?U-4=D#W-JK*1:C0;!;:>3*/\LL1$2R5&
M03?=,-"-Y7;$<G^G^5B2!VR8C&IM6.U;_+%T7PQ#P(]2QO?Z:50Z?"(%\?R7
M$:Z[.P 2\&;\4 O:W)4UXZV.?C.#4;=F-K^JRF]Z\:,9Q4_/1Q]9OMB$*K=
MJEX-_F'!DK&U8"4!8#;*\3_;-!JK5?-[8(D9F-%>+#,.IG&_0!^/TS+;9/ZN
MS$JY;"2-3@$ODY4.6GV,G1'"BL#2O)FQE8ZD45>J*,:J;8PK0YR,5&)YLFE(
M+^#^QX^J:?1J=5E9Y=)]+2>U?MR+'\N)^6F43K;CS)KOQ4 #A&C\4,O/@G26
M6ML(7 GG7:V' @?(*HT*^:5.K%]I_(<)J,R\TH</H[QI-KZ6,5G5@JPA2%9S
MS=08_#.YVB)2H+[R!#2A&8IYC[AEDYO28=G.J)5HJL1F.4UES-'T)\Q\S[R
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MP;3_[>VS2@  IE\9F#^3A:J][,JU+V9Z:^:Y-5_Y?/1K"G:&90\+79T:G6R
M FLUJI3C$M(2U3YJ&)QY]RR#-1M68ZCF=V6ETBS-P95FQ>EA)=%0'KYSJW+5
M1/6JJ[S%\:LOF:]4EOFD2O>"?3N*2.\D+OL)]_R<H4>*\NQ(GU;)]?R0Q"I
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M.\E<%3KSIO^A,?/'[DAYSR3+95Q3K!7]F<-(@0[M?MX3&WQ?!E) ZW;>J9E
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M-_8BRL>2E?%-=!\JGU:ARRZ@R@VXDCRE\2J_\GE.PPBW_?W3&R;2>)W_ KF
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M5JEHNL$J%4TGQ49FNX$9\FT,<&6RV=R_FDA9_1X\D.9Q-C84+D![(-*E)-]
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M\SUUX6</\^X)Y<Z/*O#GOJD"]_)!"C7L4TV(3($//@^9 I$IL$U#M[5*1E;
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M!FOQ0SQ>+^Y2%BDRR\YIR/YB]IPSJ'#"0/4!+4* EX7@>&Y#)H7+Y\?DQ16
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M[IQ"M7K:;7BK1'/V0)+Z48@16]N3_)HT0^]OV_*<E"VA22?61<1M CEIA>S
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MX.YS<U=@E89QPUXIADTL]X5+B[^*4;.!/+LF6M#'0)_#_07'/MP"G"DXX+"
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MP?>!02&<B+(DY^;GRLW"PL>#"U85/J6X9=#+!QZS:\0@D*/QSD]XZXHR9.'
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M<Y;J'(@Z9ZE0)P?JC+$"G0+=B4%7KG=6F%.8:UB]5AS9.P_4M2/NJ#KSRT:
M*AIK)]^$$Z Z\[>0:<()4)WY6\@TX02HSOS1X<<LMYEGA=L[ T*O&/5\>+C
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M?H!XFTE&BVC_!E+5-KK$4;J6,TXX 36FZ,OFL<2XD2VZJU+TIPOP&H8^,56
MMRVS''K6_H"N/BT-\#9HP]U^6SN!RM*W4 -?C_5)3\H^2:<5> I'RI(3:<DE
M%^LI2ZYY2VXRT$=]9<FU91:5JE?UEDH#GVO!7,NY)YR "X>/;':<JK<\5>O+
MOFZ.Q-VZHXRX9HTX$<[D!==;F@=TK)*D$DD5K#7206FJ#Z;E>&";2]84?"\'
MOJJ!4MOJ+<5H'E49=WQEW&"JFY.2!=[:MC8*:Q)CK2I!WUJD;;WU+B']Q^^=
M11!V%K'KOGSCA+;KAW% /BS8_64WWCRY>NKFGMX\E22//@:.3<(/BP_1D@2W
M?\1.]/C."Z,@7H$8#V^_K5W+LR(_>/SIKW_1M!__UNEDH^/-@QZ['PV%]@.?
M0>.76R52G&AK.@E^G=WSZ:\CQ_="[5_(?FWF^O;7?W<Z;(;C'N,SCO^!#9\C
M7G/FKZ[>6G;TG^EDUN_/QC.C/X#_V>9T#/ID..GU%\9DTAL/KH#E'I+UB2Q>
M7=FH;'I&SXA\?&68?>/JIPVU=^@]@4^J3F.2?.O+DE0M<&?; E\[GH:W?N%*
M)VL,Y@/\'*-*^;6'7_AW@;4*@;Q ^PCK%&HWNO:SKKTVZ%SX WC@D?;YP[N/
M&KV<%;_KNOY#^'+'ME)7+ZK+\DK,WT0ZGVK?JQ<3+,LDS17[FV;_YEV)&]+N
M'.XW5) X$A(!65F.!XM0S_CPV4J[IC<0MQQ9-<8 1H-FRP<^Q%$8@<F!R2_P
M]7^QO-@"BTWUVVQ+&MC0^\.I/IFVJG-BRWDGG("ZP&-V>ZVZ.K/E;!-.0%VX
M&79%5&/*$)-'?:Q.@;6G,N%ZW-='IHCS$JKLY 1E)\9(&&?;O,H2\O)"VN\V
M[<^)/):BK*HCC_890T.?&.IPGT+2D4CJ=8W2]34RH.A,V2:< '6F0"K_3MR9
MK LS&@>3@3[HB>ADU/Z%EI"=T^Y8W &1-J^RA+R\)'_NU"=#-I)V4MQPJFKK
MI:NM-_21,=$GPW*,K,T%]@K!EX/@0=<L^[$*O-)2I<";>SGJGM<U"$U;34V=
M;+I5]\&?YQ&3OJD;X_.YIEN!36*P&166B$*:0EH#IS2[I01@:X'6HL3YSD)H
M=:F!L*UT0"'TMFB'Q)FKEO-.. &UW8A1%6A0N#E; NK"396/+S%L9$N4JT+H
MTQ9"3U7_O;;,<A!S1]VQ?$V4V[#*$O+RDA+GJA#ZK BHK1!Z9(ST25]*T^JT
M>DPA215"*P).CQM5"*T*H=MD-!IZ;]C7^ST1PJ[]2RTA0X==@8>6V[S*$O+R
MDCPZR4JA3Y*X4[5XC:?.CR^%GDX,?626\=#FBCR%X,M!\+ [/:]R4@7>RP'O
M1)5"MZ$46HBUI&H&CZ\9'/5,W:RH9)>^0%"A2F)4#;KR72RE(-5J2(VZTIWG
M4U7,]4)7N.$MHUE]0!7SMD"%Q&FGEO-.. 'UM>6MB!$HW)PM 77AILH]EQ@V
MLF6Y517SZ:J8AWU]*.2N U7%?((J9M7*3>)95,[[]/[<[;>U$Z@:YA;:5-?F
M2!_+Z<:=5HDI(!U[-+7?JLM66LXVX02H$F:IG#N1YX@NS&:D1U1'ZHAJ6V8Y
MB+EFM]>3SA-HPRI+R$OEW-7BW(D[':-LJV.S=#W053USW";+JN6\$TY ?3UC
MY P+G"G;A!.@'+I:%?+VZ]B/4,6[CQ&9!UBN]58HRU*L+EVYV29I;E6UF:E/
M>SUP*<MJ6H+B<X&G(Q2JCD'5L#LMRP,%* 6HYP)JTC7;AZ=3'(%IR/E^WND8
M,4; 7LL@03VZG+;U\617;EAP_Z=3O5=N+;1M!TM0XBX>1')2I:"]8=P,2L$)
MA>K64:5077@Y[I:4]SF".F>3?1^A&;/Y5#]^[RR"L+.(7??E&R>T73^, _)A
M\5N,ALZ--_]?:A21^0V0;MV1)/G],7!L$GY8?%Y:\/5UY/A>>/MM[5J>%?G!
MXT]__8NF_?BW3B<;4_,7FD='U2QOKCWP<36+#:P%9&4Y'H9;;##& LN.8LO5
M7&=!?^GGPC$ASJGY;%+M7P@@;>;Z]M=_=SILXL.>Z5,R\^MLXO<P[X=%+@BT
MY4$U9_[JZBW\YC_CZ7@V6,PFBU[?&BSZ9#JPYH.Q.1N-[3&93LTK^EQ ZR>R
M>'5EH_G8,WI&Y.,KP^P;5S]M6*_4*%U8*\=]?*E]]\59D5#[C3QHG_R5Y7W'
MC=;0^9, <'I)W&J7!6Q,DF]]69+BDD:P?.F26B$N><G:U9; *YJ46OBNZS_@
M#P/+NZ,,(AP8VIHBHZN]\[0%+#[P$%-8]%XM';BNS<B=Y8&UK]UALDNS'JQ@
M'J);1-Q'V ?14OO]\QL-"/97#JPQ(&1C: J?.0P-C^]X,7R!CD0#=6PP.HJE
MO?[GVQWC='?L_UF@?5^U_^D6TFSBNGR7OKKJ7=&_01#8R=_/9%]!$J)W\H.6
M['4F]3(QT>OE4K#/<;82N7-JU_VX^<R#YSO&":_ 1V%7\:ELV%HDV.I"?O$C
MV )\9\FD<EK'^B.?5SP4/B6RLI[A"%:"6XBKF@:<@Y1L.41KB$$U$4?ZM$5+
M-A4_:D*D9FNSIWPXCOD-BJ*S7YT:(['C4;,53VBC'=:2NVW)?N$$U%5M8 [Z
MNJ$NQ;HD FJ##N9*DF(5 _]LU9U\-<O36H3FM#L\X&BLE!7&$M8QFV9?'PU$
M@+/]"RTC.\44Y)[6.CMU@VT,SPV[O0'&\/"U87;[PLKA)-#,JJUK;L/I@WY?
MGTS+$E2"\A7Q6)&3*H7@HLJ8%$S5"MG69BPWK7V::E3,X^BYG-66F/JI4OK2
MY.VEVX+[-?[<6HHM<1Y>8 6)@EO=M$G20+:>NHQC:ABV%&OXL_\2.W+N2:AK
M:]"JML-S[^O MTD8PE\+/P 9[EEWM&S#6CLHH_<OR/B0SO"1CP\/]C$9_:T?
M_,K'?LV&KJR[L"?$-,?3T7PT6PP&PYXUFMO&>#0A_>&0+.:#$]9=[%<>8+M6
M&+ZZ>O/YX]OW3AA]P1\]OV@@7Q+P= 5!==$ GSL9"JM$M$K%OT4WFT:WO-6*
M@UIQY%</6F4L;)F'PP!$0_B5X8ZLP)[8H1VV[K,]BCWVJZ)Y[:] H#RF)N/X
MAS"W<[2')?'*6P3KE\![#JT%N8NM8$Z+:JI&LF:.ZT2/^.6DW 6K<RSMSN>5
M4C8)/+HKX2OK@(0DX#4ZR5R^1_\,R!\Q;1P&PB"*Z19RR3UQ-<?3J%RE!,6V
M3> [\-X</_37M*I&LU$D6'<@8<)(NW9>:#=O=/@OO%CX=HRM4#S?Z]RX?RX)
M(#8H/()'XL"?DSOB$<Q6 W5S)R06B@_'L]V8VG*_X9<^!.NEY<&[<\ (KT2"
M!X-Y8**Y8]UY?@CP"4N5.T\)S2/DS!;9"")P#5A^!,GHTBHFH!,7>(UX/$ "
M?N3C?,11@*C;9(Q*46<9X)S,^CW2FT\'@_YP.K-[\]YLT(/_S.W)7(FZQD7=
MX#22[N,N? F5=UGI'QT_U,*E_T ES,J_I^(8]S5]PR.P"7S_*UI6,0F?WC=H
M3B0]+T*-P/SSBBI$_ WVKM=!IH5KMK$!0MO<B*()=L[%?!OVL;G^QJ,AI2VQ
M?ZG0L6[[.X^6849+/PZ!<65OO0G/_?*J#-_&@>=$H%*$>,VM*R5L'7_??:FK
M:'"K$E% .0>@O+> !F8V*E:?.:O1B5K"GYJS KN*&U^*V6?);)K^: EO)2W"
MOK%!((8.+9BW_3 J>0RJOEA57ZO54:NC5D?2U:FQ=F'0:^Q<PS;]\[/E6IXM
M[IIE\75&,E81[=_A=:@N7;@@ NIK#&Q,5%/@"R*@MJ; ^FBJ),X%$5#;]4"]
M<O- !9NS):"V*U_UP:!5ASMK]@:./A>3BR^=HBCYPHYR51PI$7V0JPUK+"$G
M^X:Z]D?>60YBI:$/1VI?RCO+89<MBS ;V[_&$G+2U'O]@73,K#MZ>^ISSV^<
M<.V'EBODQ)DZ*2K=2='K03M/AE8^3/E^2P7P2P?XKNNEV@!T=9Q?8?BZWVMG
M+PHEI17"E916&+X(#%_W*WJNM0&\1TEIB1(8A]<LG>3RJTN+VQCR16W:L,@2
MLM+0!U/Y6@^V89DE9.98GPHI_FO_,DO(S,%("5EY9SE,R/9THW] %^26)CK$
M^RJ72<!QE54G[T)VH5P23H""B2) P>1,N"2<  4318""28M"I#>V':]BE]XP
M.B?K@-@.;5[86'N!2_/W3@W6]B^J8EUK%U6QKK6+JEC7VD55K),BD%FO8:;Z
M;;30,\F"^]<C*4^_NSO*/,Z&A\()J ]$0BX 5"B2@H#:4-371X?H#(6C\R*@
M-AR)*?!2*)*"@-I0--"'9HMM(XEBNNQ<9RYHJY%O:^*%1#7PJ,FAS2M1<94Z
MIQ5P%\?8@>)L6V8YC+.&WIN*ZPJA>-LD;\L7KRK&2CK+H9MVV!?1R$V@#:AZ
M@:@#C'NZ6<T<8&QI*Q!U]E9!5YT?;R55"L.YEVUM\J&PJ["KY&\KJ5(8SLO?
MEK;O:''9N>K,<=IHF2%Y1*4-2RXC8Z=C<=W(%6>;Y.Q '_1DCX.V8=5EY*TY
M4?*X+;,<QMFA/C9DSTRI!A_G0<"%'*)M.9>$$Z!@H@A0,#D3+@DG0,%$$:!@
MTJ)(ZVLK"!X=[TZS5O!\D>KK49/3)]=9YS8LJF)=:Q=5L:ZUBZI8U]I%5:P[
MP[X>JIE'6[R0+)H^%9%DO52F"2>@+M0,1PHV%T1 7;#IZ[VQE-TZSI1OP@FH
M"SC&1,JV"F?*->$$U"=OID)*%LXYZ*IJ6ALOM3&&\EV=TX9%EI"50R%=[MJ_
MR!*RLJ\/U;Z4>);#1.Q$L5+>60Z[-E ?&.5#3J*9F;/DOH^LF4LVJ,:7LT#[
M/OU2[GWZ?<TFKLO/3KVZZEW1O^$I[.1O3B@UTQ;6RG$?7VK??7%6)-1^(P_:
M)W]E>=]Q,RYT_B1 = _MNOSBHL'W@Y:8J.S,6?:,O;P)^1Q[-%FTC<-MYOH;
M/]B63+GE!%O!9N5CVF"XDH _QA%V[#M/>_W/MUJT]./0\N;E?B%-F+159^'V
MWTCFP?,]>:IPU_'7C45X@A];EOEM''A.% ?D>>M[Y&X];KT5?Y_F[[LO]8Q#
M_HB=]0J^HW!RECAY;P$-5N0'CYIB]9FSFE@A6<*?FK-:!_X]05X_4[\J9DO.
M["]^9+DMX6T-T=4F(JHW-@C$T*%=CFT_;*Z.M0DD9HMRDDJ:!C>O6AVU.FIU
MU.H\XQ':7;:WXSJN [+N;<LQ"R>@MMH(4T3T\U*Y)IR VF"C]TP135@NE6_"
M":BM]E/O"^E0?ZE\$TY ;=580U4T?$$$U 6;D3Z1\\+1%A3Q;<:7U.U9M9<?
MC,1ULFOS&DO(27,JKG5=FQ=90E8:^D!@]] V+[.$S!R*.#+4_C66D).&/IG(
MIR[5E5<'&,6JYW^-/E S/?^K[G-M0\__RH<I=WM5 +]X@!MFV210"%<(/R.$
M]Q7"%<+/&>'E%)+"M\+W^>"[WRLG+<X>X1*E/IY1[72*?F67%O$9BDC=M7^1
M962E;DQ4,P-Y9SDL:ZF/IFIGRCO+82?@>Z9BI;2S',3*B3X8G'^&1+RK<ID$
M7,C5%2WGDG "%$P4 0HF9\(EX00HF"@"%$Q:%"&]L>UX%;M61.;:G*P#8CL6
M%H^K^[5J<O=.#=;V+ZIB76L75;&NM8NJ6-?:156LDR*06:]AIAIUM- S<7,E
M3U(>FW=W5'F<#0^%$U ;B 9#*;MV*!2U"D6F/ADJ::1P="R.#"6-%(J.1E%?
M'PX&[<611#%==B T%[35R+<U\4*B.G_4Y-#FE:@(S(H0<!?'6(&GU!5GF^3L
M9"JNF83B;).<'8F[ THQMDG&&KHYEEW1JA8BZO3B.9U>;&D'D<9!(B=5"KJY
MEX:AL-LBJA1V\]CMM[,K@L*NPJY";HNH4LC-O32GY5:Q;<:N1.D(U81#BA"*
MD/[Y*C9V L::XCIR*,XVR=F^/CI$%"K>MHBWIB%[/+L-:RXC9P?ZT)1=UZIF
M'N=!P(4<F&TYEX03H&"B"% P.1,N"2= P401H&#2HDCK:RL('AWO3K-6\'R1
MZN%1D],GU[GF-BRJ8EUK%U6QKK6+JEC7VD55K#O#'AZJ<4=;O) LFCX0D8B[
M5*8))Z NU R%W$!]J5P33D!=L#'UH:& <T$$U 4<8RIE*XXSY9IP NJ"35_O
M"^EC<,Y!5U73VGBI347-MFC'M UK+"$GAR/%2GEG.8B5?;TW%E>TVN9EEI"9
MQD1=$"CO+ ?NRZDAW]6=.4/N^\B:N62#:GPY"[3OTR\5CVY5&FO&)&EI\=8/
MM&A)M$=B!:%&X//YYEDCL\>L,\WRYC06J]-?O/97L!*/FN/9<1# SU[_\ZUF
M=(?:RG%=Q_=T^*.?_$%_R[[02]]SO,+%&6D/-ET+2+@F=N3<$_>Q6^((?_WC
M]\XB"#N+V'5?OG%"V_7#." ?%A\#?PUK_OC1M;SHQIO?_A$[ZQ4\]^VW-;QE
M17[P^--?_Z)I/_ZMT\E^J/D+[8\8?N)$%LX,Y"W\8,5(LV9^'#$$=?Q%)PZ)
M9H4AB4+M7[BPVLSU[:__[G38N-5T_;_<X.^RL6]PZ$\XLK^ <6_HL#E2-6?^
MZNJM94?_&8WZP]EH/+/-WG1 9L-I?VH8$W,^ZT_M2:]G70$\/23G$UF\NK*1
M<SVC9T0^OC+,OG'UTP8HJ&&^L( ACR^U[[XX*Q)JOY$'[9._LKSON.$>.G\2
M@$PO@<Q^P/H"$%GXKNL_8%D%!6ZHA4O_@8)GY=\39$F((, W/ *+Z/M?<1?%
M\$U@1F&UX6^76"' C*_[8A_@)I"=%B%5*N](7A;W8.X+E'[-)J[+SR"^NNI=
MT;]!'-C)W\]<U8*40L?I!RUQ]=C9S4Q8]/*NV'/\ND3Z;!P2-=??^ '19,HM
M)T$+7.=CVL!($O#'.,(??.=1$1$M_3@$QI6[[#3A&E:=*=U?(YD'S_?DZ=P=
M1W"?$N\;_-AVJC1V7'SD9Z[OD6KON/56_'V:OQ\6"\<F&DG4GF+S6;+YW1?%
MXC-G\1<_LMR6\+;&>//0%'=G#+4\102F58+FV(2PT1/1V_12^2:<@+J ,S$4
M:BZ'@+I0(Z17S*4R33@!]2DI4\Z;8$YDU1UCNM'?WH!9BD%3=4]'[=F/04\E
MF.6=Y2!6,AHFIF&>SF,\I\56+#V[Q9:0I3(*W'9$<5CUX"DO8U!V[U%VKUCI
M=:G<$TZ @D^;N2><  6?-G-/. $7#I^Z3;GM*<%CC+A<_=\I[+A3YZSS?-PO
MG2QD+QR1Z;ZN<F,DN!=@!\GEMJ\*=6U#745'" 4Z!;J&05<^ :I IT#7L'[M
MFV>*NG8$&Y]5,F8>$-IMFU\EG !5,M9.O@DGH+;BG_+=J0HU9TM ;9VN6M4_
MI.5,$TY C25C9JO$S3'GE=4QRRHCE8^ICEFVZO"..F9YWOQ5QRPO@LWJF.79
MLU@=LQ03,_O%\F(K>-34(<OV.",J8G91!-0%'"'][BZ5:<()N/#*JY9S3S@!
M-6JKB3IM^3P+3IVVO+S#/VU89 E9::I>OO+.<A GQR):@;1_C27DY%!"\=J.
MT(TZ6]DR*U<Y21=)0%WPN9;S&JV,P'(UZ=GP4#@!2@:UF7O""5 RJ &S3IVS
M5.= U#E+A3HY4%=Q(8X"G0)=LZ KUSLKS"G,-:Q>*X[LG0?JVA%W5)WY92-
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M'%EI9+5V_4<"ECOQR,*)5&VS_%&9OCZ8E@L0)([*M)QOP@FH#SA#4^6<+HB
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M+P;S\7PV[(][Q!B3^7P^7I"Q:E_=>/OJT6FZ5Q\&M1T;M=F.UE^V%=-O)S_
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M\!7<L" U[RA& G]%EQ0T#[]UN#.'8>GZT ]6SKP3$= JFY8<)2/5[HD IN(
MGI#:3 Q!G(?@DD:</F85I**<?K*INKK:/_T'6+) S]D_VT#!]@7"(2.H:&W@
M*J!> &\7246SSZ&[I,];[.1,9/C4 =(\'_Q(NKIQ,Q+W-=B?JQ@PB37184@M
M)/00 N0.(]MA]P('<QKJI3+PW=M/GS5CR-W3)&\;+>$)4_%@:3:8M^C<,*XE
M&X9+7J=4SAV"JTQ]%53#6X++&1N2[/!+[=IY@57?*",Z_J(3AYE/@_1=._!Y
ME??%>,(D-$5K','NRO+/^:^!8>=UM8^;)G!1%#Q89:%(L].P,_+[-M'TN;F3
MKS*+*_UVJGOT5'G#]ELZ]K(P\9PPR 'M2 ,H M".-A.PMK6FX1H [(RPJOG$
MYDCT!-IE%O(] .2#IP(6R\<\R44RV?09<#:?F@&7[5PG2*9++"B365!IKG]!
MM2<P.E[ /.RX )"*(C  D<2F1):FE?BIS -_=.6$86Y[PXZ*?-MGJ\Q_D"PV
MM::Z6E)5G:T"_X*^XY'RVHT:]]0R0T/@S@.#?(9R%#\+0./?(WQS5(*X\\"6
MHJ(=S"P0GVQO,</#ACV'#A==_ Y=_!39\-5D\="GY%8XMRI\F!@@SA8L^2P-
M%.BY;06JA>Y9_B48=1Y8BRAYE@USD]T^5U+3S%](GZ\*&\!Q2A!A<H#Q W09
M/)T_^V_B:2]R"_B0MX"+0B*F;OVO'QC_$U4%OT:ML*X&)U5\GSY02I)ATY]6
M[#GJ"X&K&H9QX@DC%BL7I!D[(_?$A>C('@(#Q (J!R2/76Y.0RIW ;4H0Q+<
M.W9BL%+UEFBV=Q]SFYCM_@1OR /VSCH&46F%U"U)1"E7Q57D8NP*\6&M20SJ
MBL6Q.FGT+[6YV:140H'=<$_=:4 *-4! T">&R8:$99X+WYK/72:+1F^XP@&U
M#TL )JK-+#,TT.F\H+7XXQ;06)@TPW(BLS>F9;A&:XYJ5+" %B1ZY&AS8962
M6B;41)P\<+/ %T&JF,YT_B0;/E].C+(E"O?2*W,?_K6Q #DL- /KMP[WX-9E
M?4DL],*HG$,'.%K")QF(J2-#[4:+Q_Y"L/L"KK963@1_:=>_?'[]X@>-N4),
MPOD>GP?>L?2\T0UVADO],I #(>I30%Q$>!0$!D)&,4.,<.O.7F8K&MH.,U9L
MMDN<6<P<$O)'S,)Q7_@P*T(B3C@3_H$VLT(GS)%9"-Z#,HX>"$F46N'YLU$K
MO"RZM]'+"A,TQRM\"+2",(@7AR#A,>O.G5JF>#)!F /'[)%_,?':^.\3U5 P
M@' 3(YRI2(G7S"&&1\**A@[HF,Q-UIG)M8L8].+2T%EJYG/_;]/NHN/!@"RJ
MRF+9R>C<#Z(3E/U&V"F;)GW(;<+[%U5T,6&/B^ZR:*%?H,;V,6)M@;%^QS5B
MMIH%IJ$L3B(R>:6(),8>=UX+$, MX=":ZA5P"?4B\#R,$OV;JM3-Q<'9$MYP
M6"23-Z>S6+B(KS#;T97V.I!R[[NXH\%WI&XM6WZ0C/%JS2QZBB=^@#.I*&=.
MI[.B0*2!S9R%"Z@E#EU\KD6HW.3FW[V3V(.)#FS":RI9*CS&Y,QC%!P()EP4
M9#Y_;AX3=JFS#V:138I!Q"K'A69I\-@I!IM\#,2Z<<C+<;)):,2.S9+LVSV<
M'8;6RJF+^IE+UF+V@_]Z#Y_J 0;)CW:/&@']7RZ^,DL%O\A1A'*5V^EA]A4]
M10DSS].S!]F@<2JZ'&\=@UHET=*?ZRB)V:.P#0S.1TQ;EZ#L9U,6B-$3ZEQ\
M*!HK*?XNF]$)Z2D]GC";$0POD(6;J%JPJ[QPP2+MZ:/FXL+5/ES$MUAJ+N^S
MTFR?T'!^=YH&?M@/>*<6:N#PH\U9U&63M3<TN%%Q1+L4O(Y7Z.3 +]W"(>U-
M&FB,J7A26^>'M)%=\+'G9T2R=C+:=;GZ^T4"QN01PB4JW02,*^Z$X?3C?M?(
MXF;)DV[&^!%'H$Q\.Y'U.[=C'G&5FZ*)\ R:]399YV-8.6/*X[F@O!^GYYU/
M/Z@.[P'_0)"B[MDLNJ>(M:AAS.042T.Z^?"EQ0OVZ9Y=Q-R'".&G"%_D1X!;
M8A\,;<!FT"MRK2ID"@RZXYFX0LJ0Y^_RNGLK/U%H@B?$MCD\!'T20&$:KDX>
MIV@+,(&T&26E9CX3/*"D%W&$ZOXP=EA5"UE<+6H0S.F#>S$,@465&#+Q@Y"9
M*5Q\I*9"@5(Z _H!/,<!RF-F\;@MBU_H' KI@]!P[CKUR')C.316%B8F,]VI
MOIM\,9^R87F:.YI 1B,]C&V,>"#K-M8)^8KAGB1!R3E5=/A@PZ%Y!C(JMR \
M19!QB8:<.TSFYZB^SIXOC5"_2 /9.2"FZ?QD3!;#]FV0_APRCXEBRV2VS[^.
M7MG<Q_BO%['JB=SCI*G"M+J"/V_ LK4TN07+X+/-28LT:)0L$6&E[5E4(CR;
MTDD2>M6_P>6G5ALS=W,5"\PXT\ SYMX"BNN(H0<D-MIR<T0Q,WYS[35L)P!U
M$$:L:P9=JB;D845/A#V:B3SPA=T0-L:@VT_$C<[SZ</NN* [/8?NX*3[!S",
MLZ(8(S_J60^HLL*JD<X-^ T64!<Y,W].L[0W;S9*K'JCS?JD?Q /*QCL)<AS
ML(OH@O$-^\FWX=__ (FR;J;6ZC<L;V&U5KT190<&3LG\H"HK&@<,X"G^C%?6
M3 <)%&A+>,GX"2Z9;[O4X\]'HM)%BF"-61QUY80+WT7@T'4L992RHAM>.P%$
M3_6L/JAG]'7XA+X:4(SP/X:;0]%]S&,+680_;[[1>@E>*9(G.ZF<H E/U/(=
MX'"6]<SL66JU8BT3^GPNFIWH@,#/,=SQR+V(,F1L7B_%*,Z9FNA,@B/JD2!<
M.FOJ6_H1S82CK+K#\#(-Z0#C?O_\1NN#OKYF)2[]%\F^:<KAHNFZ31LH#1YN
M,<IP"?2D&"CT01$$^6H@\"57,5VS7%53@/'/,+9840^*52;N"N[E9AHH&3-,
MZ&!)2(\'/=& RN>QJEQ_[@E369/HC5PY2DZ5 8E9DG7S9^6(!Q5^:XMF]]!;
M3$K);ID;S:)QNQ*7%(<TU\VR,MHLH/J#YUO];!@] ?R<YO^"]$@X/,"T!XOR
M&&;*C"X1U[9@</!<)X#N#MBW'4='A2]2.9A#CL73;BQ^VM_, (" 322!,=J0
M0P#_3[<W;UY02S#]UEC/Y"T, @M#9^$[O30--7WX2)H)8WU&HY^+FMQ<2VJ)
M)\8!$N=L%F2QH1Q6^W-/XQ& D*6OV:"M&+<^?K[]S=!NS4GOAE8KA_[*<CN)
MR8+[@9?/H.OHL_ T^%G,U L<B@"Z"@!(M/!HO 8 YH )X@04+_.8&I;P-#Y&
M:594@N3>I7(IH/50<:BS)\@'L]?T:5BQZW5*HY;2B&_?O(%E9^O.BB&S%6<U
M76S-,3?QT0\=L% ][3;)%W[Q5YB36"\?M>N/MU]>8"Z1,9OO.]^[\U%;E-85
MIZ6!G;R%Q60.#11DW/)IQ8XVBP/ 8)+\P%U&60@<#K!:ASFFF-5&XVG.TY^\
ME">+[#$W>C.9'-)B"KI.-V^:D+OO"D_$"SS"0GJ3YS6+52%8W.HF5O%F50C=
M[&A11@[[BN5Y*(*9F7WON_$JK;5*2K'2HHV !1'7:Q!SU(')J@L15;<QZKYR
M:0E6D*!!X6*95%):DB\K22KT<K8BJQ&D)3I5CB@L.^K T3 U&*DJ'/>RT,,+
MJFD#APK>!9H[%66&.(@YY'K4Z(Y>% Q0_H54T4ZZYHOJBJ"\89%W_%C5SQQ5
M4(>>R./I^<2B8=<XC;NY#51;$4NA? 6W*CB 2^944)6X$5=#4(01\V&P@@P9
MW(ZJEYSP>4;E2]W5+JAF0/-S89)&#]EP5JX:DE:UY$G,11EV!AYI50E&Y6CA
MS"+W_/C-]*^"]YZ>*\@.$K!4/5O)+,>1?(CZCDK%CN7BUBMF;&F-1U;LLBMC
MF^8C<@'?]-'2%&FN_@@KF& @FUJ#/#F;HZR \<2E+U#74#"0?"-VO"48N,W5
M3V&:!4 W0R=<U.T21ETM'XNL#CU2N[2R)K'A<&,IILA%-TTN5XCND-I7N:=)
MZS"WRMK-;1*[\U2UE?PB<\R7T!P,,VE-H12PX&,2:*Q>+N8K K@KO6-8'0=%
MQ8[HXY;*T*.BC.<3(,S[3J*B?T6!J2* ^PK!#]E1K3Z/]%&C#6Q(/Z;>',4F
MC6GIB7O-+:U<#(PI#GZ,($D:,@>,E9%15TR[_ODW<SH<FO1-]KK_(G7@F <6
M;MC]:&,1?^URHP&]\("Z6)'?H2Y3"$MNS1T;K';&NSFQ65R!'DNS%BA+Z/$-
M]+56\-)R'[&4A*OU[*3).R\[#_#&BBSM5Q]<'Y_6R[RF!Y:TZW=O?GW](@D>
M)<N3(_>!<MMUOA*&5^KKL2H[5KP'XZ]I*4[:4)F!$8-06"^+#_PZV:1O$F?O
M$TU'=S['-&;SL_\-(_"OWWSJ?/[YA?89["J*6UH?PQ\>"6$5;87\#2^?XK+#
M\>XQV<W4.0MUL4+MW_SDFZC&D\+1_'/BEO5GF(5-U \]"<G7-CT8=0\"PW63
MP6#\A>.RE'/H /LL7MIJ824F56A9CPLFH9I _>OL.9*C+TG&-Q<&B-)B-),2
MA9RX)XRLQ &=D3L*+1I=H*Q#?VOF6#K+<W-O'@_:$!"2R\>:(@DH/W;Y^6PO
M.&%ZZLEU<SDM9\%J6YF@HIN+DL%V+OPJG8ONN1S;\]7(X))CWV\65P@?5VNP
MT;D."/'L 4;^V++Q2*U-\9U?E^1P"[?TM-0(ECK;X?E9BW3Q^0N,BNS,7ABF
M3-F+7]!/1*(J3HFGQT"WD)L_^*VGI[Z9X9,5JQ&:S+ VUB:IMT</#ZNZT&'U
M<UF"D)?L67<>>-'P]ZY4AE,\\3ZLBOSO-#9WY@)8ZKY7"%QP2S],G0[ZU%59
M\>)R5-CK0@XC54:,0$ITV DE_N;3.9]B]P9<G C/$H01/<B;JU3-)X!RN9[$
MD&92:Q8[>+5!+O.S"9O']'BHA2X3%EIZV9<RN!223,U$#U761F5M:BHZW1J>
M+1^E1&$TG&:)_<QKM2KZ&B0GZ0>I\,J=#B\4?6&YT8"&2M'I]FV68=AH;9 [
M*\]KVRH.R[-D MMW;(#\%LVELNEVQNX7Z.>#KEFA:4]H^GOO9\F3;[(4%G\P
M]I0.:CB79K!IRXGRDR6N5?Y\1M69C2T'V&GI8YYRU)>'<8*9JT->2>BQ\T\9
M@;=O.O_XD#H2M((1<+(B+,:\+;A*)\#H.//^"N52E5944GZZ]4Z8YD/H*A;^
MW%BX"H2K0#C#:"X+MST.3B71^(R"WZ6@=U%A#LQ=@6YJU286-6]5X.5M5QHN
M'TVZ62X41?4AQKXLM;1R1+G/H\)5Q;@/EF^5C0P_>-IGV+3<>^]7U=*S9ZS0
MP!X[4 /& P6FO]9H3(L=O^!6_6;Y4")2-SU+O6C(T?4-  '7:8R;.^?S%]J-
M^^>2@($3%#104M=R??/F!?>Q0MK8C<53T\&S@[&E:'32G"@?E@8\QMAW,@O9
M'1R2QD(-*SD3A%V\9G[2;(E-S /"Z;0875FR[B!H:L*7'WP>#LI'S4&@5"_%
M&[X4-U3D45OB,Y!+.J_36./G>!;B6YK1I_5.G_$SH_^"'8G>.>IK'TM 65^@
MS]0,IQ&R0J#M)M?Z8J&]L1P7^T'0PZ7O/-P1*&9AWM>?.S=OWK_0DU,2$7O>
MFV(]FUEI[M/X.&\\P Q'["A%(R[@^R2''7FU5;MCJ,4Z\2/]X -BJKA#[\$\
MYZF8<C1UL!F>_ 4D94AH3P0PM&T:<J*=*=YY=O<) FL(J.8#D8/*UIN'T*M=
M\X]?))WQ<-=6_X2+2X[X7_RE%X*DH(^#_R3OZ+ESOQ7!VFBCP+R3X\#NIIWY
M "I3+OF&:H<58S,SC 8[:H^\"FO_5 RN5K1_ K)N0"*[/%R11"[&A0)]MI-S
MIPZ27IEVROX"XM+PC<Y%&NV4&C!#8>%CJ4;NM/K&/N>=VW*GV?%(X4.* ]H!
M>+/G5A+SH)9(TC8BC53F^G:\R;F:'UV+,?A3XK&Q=W*'>O^7.;X)^M&@L?T.
MAW+:O88^8R?I' =<PMXV!5@G:.9MAX;=7I_UCOPE^7LXP$5BY_QXX&?VO6GE
M^E1T<PUU\D11[-#F#L"[<,F-KBW>-:T/! ?(<5,&%KI@%"JWS1FHJV3.[\)B
MRX9"+]3T^\S@ 2=^3>8ONMI;Q&+Z(:V_]!ZL8![J1?+I 7:2]69@'3T2EE>5
M9.H;/8XVQ4JA35F90PE#FE"1OS_9VBQY]GV#6JR$83>SC%E%G3T-3Q9"8CS\
MO*.H=$%-$BI.'YR0Y!(%^@:) #9:<\H2Z#E8%1O%X9>2<N-\!,HJMPA+0E%-
M94\V$DM4LF0JAO;]##FXTUSDSG-"F_HJ2Q;!+].O5Y\F*A1F)&TGK%73#1;R
MW5JY1J,1F$Y6(YR=ZR5I;UQSV,TE 7CKH8)%1Z,E:4@7C1%^BB,)AC_D\@S6
M9IQZD#OAOJ"Q'QY+MC)<9V$<CI>-#<![DCTK7IT-7FFNLE;?["Q]]J#M"" G
MXD:&\/%6U92V<\CGES;;IME+LG+"*'BL%O\T8!1BMOUKC2%HOGRIV'XJ]JRG
MQ4](7Q9]?OK1DT/E*"("AT168E-:'NU&G2059XFY"R"<TR";!.'NK4_53!Q<
M^SDGC,-DLW"+,MH.[3PB]^0*:UZR;2?PQ2[WE<B[LHF\I"% LF)2?T:RUI(Y
M!0AB(4L+-J</CXOZ^Y[+.+9?[#^O/?:)_N_;=2,\328 PV=I!^+&-!<[&<FT
MY9YI UH G]4,#2?/3QAD]2TAGB0+T-[;="'SI[R*CFG:?UOS0._R^/<BK;Z0
M)!NA.GNT,>^1NM\JZR$B4IN&:0L93B,[ELF;?73-0MB,BOWLO:/:?C01Y.U\
MO/T"1HAUQ_IB<+.Z&.ZMBO:^=Q9$^Y4U8[4"L-79"-?O?WWW0KNFZ2%,XGP$
M#Q@S.,GGGV]>-!/^37IG[([\L@8?R=TT6=%B%A#EU\K 8^C<!\ GJ7@.GL?)
MA5*3'V[>A;1/#Y*\#::7#?YM(9UM?7.Q937!_L3 7#2=@$*0I>MD[U(WGR;9
M^"+PHPJ9HK8\ZXYLQ)G3V'(G$71@MX'WA8-OC1 S6?CT)06WOW\"OVW*#K@9
MX^R F\X:%#XK_KNUVI;'?9%9Y>C3^]<W#113'56I^*ZJ1 V9E@$[<YBKHPNX
MP!C3IPL\&@U>:-AB,*0UL5D+9694% O\6&5W<I<11L5YQ"-@I9V517>4GYR;
M72,[KKAQ#H<W5>"0SEV,]1$VEO9S[D*L0K0/EJ@#&-ULP[[M%JO<\R!=)C]&
MF3_TOJ4(L$A?14H[$:%LEU4D)K>VL\#=@9_F!"V>Y<HE,MDU&B!BG#"A"2-4
MK/4%25U]5C1L._"H2>EXZO6%E<F4>QB2W;:XS2:B;M"6FSU*UGQN,^/R3MCR
M3K/%#9?4<D]B[=@D"/;=5UB.:"/<O]$F)4T_!-S(J7J:-'^U:>!O,>P*Q!H#
M3JXQRA_+39M-1UM6<U&HNSZTOK\5 ;-$E6T)EJ';68@J) &>RL@7BQY0?[DZ
MA+"C;RD.7+)("U'H.5FP[])40Z'[YJY&POP>P]-%WC<;=5#OS8GBB+#U8=XX
M.QN6WYDL3/*D?T^YF(8#2DU(TR[TOYT@UL!9'FZ5-L3E/<M9/C'U5BN"$#<L
M9YW<U$ *G:(YWWAGS9:5Y.WGOS8A+@1[Q&$6>J*>%@75<9TO05P5?6/F@V:9
M&1X/IB?,@'DIE=O:C.=OG4]M]-(#;0VO T%/%FCGPJUT_"W&>U4P'9^71<3R
MW::W!G)I.@"^L0H)[9V.TI_OW;1:'$]5X?N ]LR>;"RL#CQWT< (LT&S2T,2
M49A>8L O)@#KB56SJ##&TV&,O'C:Z(M,6Y!N!">TRMZDNN@HQ4TG?&2T?7GS
ML3/H%[S:C:JT4H?2GQT?Q'$S+2-8S9#![O8=51WD17,]NQ,YW9M;[M[.4PR^
M#(SD)1T)_K&:_5/7KMEG+[I:5EV1<P$?F#SA [#(('XZ9SLXF3-_UBB3%2P>
M4-GW"V0E/4I,^9!S=I(L/]K"'_,Q OA>;+L@PY(JM.1\%B\FR/^0>EG<C&0%
M!OIV(>9C609VST<J4%#3VYGOL-PSXNC0:3< )D%1I5.M 4_UE2W#Q@67S/-+
M[[BDC<3H >=''W3\&OQBIB_0'X$G"FBHY/KF_><7A6*V+&*8+3@K0F)2+8S"
MS%3)\5XOL)P5!6/!;'+1)35$K/_Z ;],*(>@$#-\H$G^RX]Z6IBQ35SY-!23
M.Y9"[Z#!FT(?T0E JP3K&GCG 3:;CU5)VU<?9&6(/K)+?3)Z?I#>FUE9UL$N
MU^2'9AU:^9M:&?P&#@8HP$!Y7[?#0^)\.\!)>O"W9E#Q)C+897S, DQ84<%V
M!NY74[#S9HA3.UBX>^AUWE1O/M!^^1N^=D"<U2P.D J64-Q:SI<5Y-'Z(3QK
MG&9 DNL'G=SV]LB=SWMYL@=B_3T2V8?7O6T$U  1:;D+*Y6B8^6SXTY$@< :
MY*$,P77T,"SCLGXN2%>RJ>]\?T[/;E<S9YEDV_DQ@8J20'"3%@Z[^85]$VQD
M=N(O?_%4Q@"<,3>ACO12=*9%^8$3?DTN^$ZO&.'V=H)N9M"Q7V:7N^/S)6N:
M$>0D.ZC !'8)2W+SWQ.0U;,UWS3F>8$+5HPE][LDT@^XQ19LGIR#GK-+5.9D
M[53<H9(X=)O/"D]%SWVDT4!>R7C"<KWF[+Y<YBI-5 VZO>I$U38;4,.G0+LM
M>8RJ@T:T 4_1Y$G;AZ1EUU.V>CC6L\X(1"S" )IHC4K9NWMUU;NB?X=KRT[_
M=D'TO[IZ\_GCV_?@DGS!'UTEM%/[<V'! CR^U+[[XF"_V-_(@_;)![GV76*?
MPBH"@WIHL#XX\VB)?_3^_H-&&4C+LE]J:-56'[JBI ;IJWDR-Q_*-''<>Q+0
M@P7)<)&_YK,_$%2K+[69[\[9@ ;:[R6;.YIOG0);*E5/<54!RRVS_@/=;EX(
MN,F)W.3?9X_Z/65074F1K;X")2P7C_T5Y($%]N(O*':^P3]8VXD0;"I-P_(/
M+$="-2(&LY*+"5BX(JD5MHJIAE]_>?N6=ZMB7\L:OL1HYFYI]9]WADKWP2,%
MJ>696,66NUY2TXO9Z#H+2=#DX*&9P8]6\-7!PRU5Y_&HE8@ML,D?,3/#^3J@
M%90[YGO'>,9D]P(V*^@XWE2.["5@"@5<5I8AHA<Y\*(B=NE!EBK86(1\#N<Z
M>_TB8P]M)NQ%[%1#FL6@89GLAI]\*"<;A8G)5+;E%3V[HSZD8<V=AO0BO;EL
M.^5A<FR$KVAFK29M.LQ>8_E)EH#?.$%*"\Z2T&UR^6;>WJ;+^_DK@X]I3G\
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M,%>NGK&V.80**>>HG.I$SCH@*R=>*>0HY73.RJG&*KU!TV=S*UKT;C28/J!
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M/P<L=(!I<XHML&$0#XQFMCX)B*A=0=<DW Y#9E>B(@3&;0VG-P:T!8WBT3U
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M%2S9T88D7,0.<+,#^UCZ%&HWNO:SKKTVDC-]6NICT;HS*^2U-:$J@#FZ+D1
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M4Q0)+KA:S;DC32Y8@3DE>#$=3U]1QP$[&3<:,PY,;;(U'Y1.03M:B W5OE7
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MM;BU7-!>6I/=@89)UDF.45K:>"DRD(7$).RG:)9T-6" S^7<BXW;#-]]/Q\
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M7IPGBI.4I6DL1$I!7_9%2#(B@I1E7$8\"T^1VZZBI0/=Q\;$M&M&JD22Q'%
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M,F1^2J,PR&0JMQX)2'BO*_[N-B]C+4+!F0RDQLDO3/JA+R.X ^J+)-RT"]O
M]+G- >_=B5R-/#D65058"7JHJ+SB3I>VNQWV(/RZI)M:=_$/L,KK9HU7U?MZ
MA5?- IV>N$FH<+R8] -* 0JI!+!S$G$J>4*3-9JE/0R'Q5DA&V[T= "EA68
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MSL&O5B<QX0D7<1"DE+.8AY2(+$E#/P/$'Y@/NB;";W6U2QSW#P&G.R*U+_5
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M98%**=$ZU7$,VHTO_,V4]5T#;0>85A<JN E/6P * *.(\ %6$05[.=4DY7Y
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MD92D5(/.15DD>)2D41B@,U:*(-Y:"<.\^,5$[W5W>53 H/<W(J!WIYR!A<6
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M0*$!;H&(PL%@"#6)?2'HUM([()OCR0F!1XE8J2  VE$,P ,,)4Z54)H3D?@
MK&WIB,2+AM#6X/G4<>UORU!Z?NZ.ORWFOE9)E"6QHJ%(>)R%!$@+;'> 5KRI
M?3004>HU5WC$?@\-E22)@B"AH%-D&>54LT0JT/H 1"D'17 '^,(6[<8S@$H6
M*#\4D: JEE1D?AK%\ \>!4Q(;<S#K7GPYDSX(:@4Y?0*M.A;S]*9UELQ&;,>
M+O?&K=;G,Y2F@1\&&/AB-!:2<P"5R,(,_^4/&=P;IB3';+&&<(M]'Q-2G$@*
M7!-8,=8-@D'%".>IC.!+L$'4UK@4@@WS-""E0E!R**&9IB%5F2^T5ED:QZDF
M*8^3K:V $$V^W4/JUX=\6(/>JH#( /1Z(7'2D1: &G&<<)V2+/"UUH\TZ(!D
M>B-CAQQ2F^]7*)8F":CEJ%0()AEEE),X(T2#JIH->?S7V6\8Q(MNM:']_G;$
MEK ?2EVA9/@JQC-3%/9 U_?EP:OYKJCOLX$6KAWDD%& E@\6-5$69IQP+.'F
M+ :E-Z)+YV'MO>WXBF:OMA.YA==_(+@6S]FV!%\O0R>.>R;;&H#<$&T>=<$'
M:C^\$=K$29H"E::Q3!@E69@FF4Y3%4:$1Y@W,2"0GR3:D(3WNI/L'FV>#+=)
MXCA*>29YA"TYPDP0D?H2!)-(6,K90)0@>9IH0X.>^79!FZ5H$X)U*(F($J7!
M!@!C&AN6<2R[C:,@'738/DFT"?V +-JWYX(VVV$ C31-!6=4^F#6Q"D/8Q[*
MA,<R54*H@0J#PS".57Y@WK.6GL=]\3"*62QU1'Q-!2CR3($QBC,=M1_!/X^E
M5J[J.DW9HJ?D>=R7Y#''MNL)SJH. E]DH-!A.0DA) V" 3/@)&:$1*!//,O[
M2C6-:9CI@!%.0RTX\$>297Y,0#8&R=+)XD>GK_@ 1M;**65UPO^QII2]VG8Z
M[T:XX@<\":2(=9!R2L&^IQ$H4SP4DB=9J@8:9SS5$;MU6N<6(W9YV MM[QZ#
ME^''1J-HCS5^<WWBVA*M&=<JD:FO-4Y498S"AS"2J58IF I+6>!F:'V>4VIW
M@.B,D_TC^BZQZ82)9CM$!W:<I$E$TS03E,@(;B9!GQL/B%2A'&H%>4'T]1$]
M"OFYVM0[0?F]CBS?#-$%F(8)=CE-(^H'6K 43$7.4AF%OAIP\SPC1*_WMP6B
M)_P B+X^2BX?J7V&8X8WB[E13E*99#%62B>@BZLL#E6LL26HC(9RY7> Y\]E
M<G>0A&0Q[GXN_/PXZM &L^TW0W,=^:"J9$G".$V3((W"..$B4=1/4[$T[^ Y
MH/DNU!;>&X_[5/3SY0AYBMP\)#(60@J?A)RRC*29REA .-.AB 595N5Q0?/U
M_"T16:RE.!=N_L2T<YJ0C"0JIC@K'K06SJD401@Q$3"BPZ&,YHMVOGYHE\2]
MJL]S0?1=XNCQU99$X?CM) E90*E*-38R$EC1!?B?B7"H=>]SX><[0'/0"/>/
MYH= R&6QFE-443@@<Z9E$,9"4251+PDQ'UA0&OM)-)"M]U0C0#NP+['.Z6AN
ME,-BW>D$>P1-291()=*$4!)P%F0Q8TD<9D$:ZJA?./0HIGP.&+R]3AV&)G%_
MSQC\?GH#F'4+D/S_V7O7YK:.'6WTK["FZM39NRK.VQ?T!5^FRG&2_7I.$KL<
M[YF:3U/H;G3,LV71+T4Y\?GU![U(2;2X2"[>),IV[8MMB5RK<6G@ 1H-S%6B
M1SF^HI1?4LYF!FH]?" EC48 AE$6"EFMTFHN9)O^=NS]=<'=OD^=J?H> RFK
M\+0R'Z=1R-TVV('J6U-*.6#B6@ $!CLH%DA7#CEEV#V5]U35]QB)N_@ ^.$<
M5.Y\4A=%Q5QRSD5E PZ0T)8:P5G'WF7=<^WX"U7?8QRO 'RYQRNG"PL/5&!?
M:C:E=?TK$+BV?@+*Q^0+:>R;=_/%PM]C:'" IX4?=C.[YPA_:_2A^&!#1@6Z
MY!BB1' N:$S>(^^>.WZJ!O@8)R*@#JIYGUP^R]?3:;O"U>EJS[5L^<SB(]T#
M/TN.UN1C",9Z!@R,QE6.P>9B%)%?%X=O:YB%X7YEROTE'&G]*J.NBI6IP4$4
M\%I39/2^36G G-9==]ZV?@CW:R4'K7] 5\J[YZQO1^F3]EP5)M0( "96!D/1
M6>#6L[ROA^F07BIA)4NP?C&G)*^8BJ)U8C8\M%8ZR494!87*JK+MG08[A+RX
M<I5N5_(&$M9'DR56XD2"[G!H&YONM+AU&Z,.U</J_:A!(D,#]Z]7]*[CZ.2T
M"9&Z6J-R4SKE2!12B9FRR>@$/;TT!HD(#=Z/E(:3\V$Z^3B^ZEQCG4R'=!6Y
M>_;KV^_^/)ENZ$I3O">C?"E0006@*/J868180G)AG5?;_8[,P)4]%A_05F\R
MM@X;! 9ME  !'#%&$L[$U88=@Z3?<Q=O5S[\R(*VNJ4*SKG*T\F? IXZB+N1
M[#=\-9N.V^G<"[IZ]_RR^Z.U8O](%_+KSX:_%5]%VYM+ 3&_U!IRHP8*FJGO
M8&5@2]?U"K!M;0]'>ZVF)*>BT0H@14? AME#-3Y"#3U7<@?U%U)'H/VWZP:D
MNJG:'72>#VL13MSVRQ[],:7+=IPLW.D;]D)3^?V\3\^SG_[B?-UU+[]KWG,'
MSN\6-?I]-LG_&OWSLG%]?>9BOKA7=:E[=X=FY[W^EW[ZCYLEW@WFU9&RJ0F<
MA@@Q"7)1A,+88J*!U8M<J[,%!#'_,9F..\C*%_*O\IJFS89VV/66TCM"/X>Y
M*TW!GM_QZ6HQIN"&'1TW.F;TX5J]+/B7O_TL#EFK:/$SR>_(J1/)?YN$?YC0
MM+27_3B><IY-IJ>1/B0J6AR+H(8(J%!\K)A(:PQXY>N@49^;I=_1T;( "RH>
M3O311@_G+?F;,3@G$*P3(*A(\ -HD67"%+3VXD&43AXR#A@9LH^(UH[&614/
M*&//6SIS:D9T64;W?WI">RR #RQ+ )ET!$TI*:RZ%N6Q5HJISP/>F\JUM^#$
M^=W[T0[;37T3YJHPHR=5C!?@VI!,C<@$0=7<@C++ ^;,?!/F^0A3938.P;"
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M6N/*UMIGP6?"+(!(V7H48PA5I>B)%(E)+*V#RX"A?CL=W3]=/F4H8E%#:RQ
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M_H2 (U+QI<C :S AZUQ]%7#G. 6!SL7;)@*GP^K@J&.:@&_\_Y]D2)&8%L@
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M>;W'\IUMSO5#F=)MV;U]!)DX1UM:IY)$@&@IUTJ%JV-5'82US?K.5Y#[Y_!
M]=0\G-2R/DC>*'MN+89<-KY"396,2#I'=EESNQ+U1<0O^UKA9R:Z\SYO+,%[
MB,&(TPQ0DH_<L*S\30)1[?W#'W;M>]X86R>*AS[O>) =QA"-*NU TA2(6:5V
M+)Z,S92:H/INLCS!';:W77VFCYXEV$.PFVWQ?@40D"R[6$%IP4 L9C5@SA4@
M^$384X7Y!$/,O0VK];JG5=F#2_T$F$DK2D 15$ #VA3,[%+2+6?O3'(]4[B?
MHMSWW^Y&'_O0[01[-R8R*;5F* AM)&FP8JHQ2TQ*%GN2NO?;H9QFUUCG>AHX
M/O2F.5+.!L0G!H\>L%C(T41P\B]C50 C4*!OTNO3VR?['UCVE.B>% SM)<(
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MAMVX^H3WOZ5(6B4/*MMV8[!=,,@6K9@!GV-/*ZR#S>WC[?\NM%CBZ5$8"%2
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MDM(Q:\%.6H,74) $5E01LNX^5D71TX_;<2:%IU91AD2P@3B="GDZ20,277!
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M1UT&?[9LY$=:PQ*:HX0?R[QB$GD#(PK:.!9A<IBMEJGT:=[8+_2VDN9ZI=I
M=?74 MTL(F^==):!.$ "6J8R.YABF>P/V4:]WORCB^I6;\MT)\RO+D+3]VV/
M"GQ];P.$C)[1H"TB)&H/<]6%X+;!8P">7KZ9IRYUL4S0U6"0=NHK:]E%6?5
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M#<@CX&W$P1"K-=',X*B$0IN7J57,K<^9,\E;L19C/.=P/2V+]\)+!5.0&Y+
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M\P>8TQ@B*<VHAE"*@8")"C!C(Q?<4FTX7K;<L"KSZ?K,UT=6-=V/$#2K^;/
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M23WN^7Y:RF$I\B1H'T!'&-+$8NNIPHX:3(AU6Q0%.T7E>+X%_K2TPX$Z"!5
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M2BR%M1K "Z8Q*N&M$1)B_WU] :2PHF(+8UA'9DMXI"4E1%+G(Q7,F6"""X:
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M*3E'HO?#\3:1;?I)1+U)^*/XO=V4,^P,I USJ[68(U8=4HV7/<UMT-LTYR3
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ME4ES.TSK3+DQ1T9KUDX9-X-Q-:DWLCWKC]M,*"?<:(VF2=@9S&2<N5-M@,T
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MV8G"OAVHOIJD<*#R/L'B[;A<6[\=!I:./G-'7;8(_3^IES]I=9!F\'U[0RW
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MHZO?*XHZ*+2E9<D3R+Z<]G\L8,%L:W\\#TG];RA/ZUY$:(CL<V/2\'.@QLT
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M!;O'ER)[9<\  ;2%L76&:[ !&:I?J!+<:&W-)[15R7?T &)?G\C=,:*X8:Q
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M"N=FL)L$LQE#<@_JUVJ]7YQY#;.RVD/5C-ZK4J;5[?75Q:.BD^EDFG\K5T\
M3Q=3/(=Y@K<5V^""^$/(;L.<7]G^,B]>L1GML3%,"S"ORIJ\)'A.'LJG?]*O
MC^BV+$H,_DYI:"UKW.<@2>(L*TG'"P.'P0_RZ=E>E/&J;]5?C='S#?:TJPR^
M(Z2L[F:<E@4IDGRN![@INT$($+/_%T#9TH=OBU^]<G$,6WB[O/:27KO%<?W@
MNVPAH_S[MNW%5E77[4[-!_8_MG_J3_\!4$L#!!0    ( !Q(=U+]92"=<UD
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M/%[$:#[)"7<SPMUM^7 K?2I@SV;<#1VS3;>.*K-'UW?8N5*A$C8M,F&XA>0
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ML4_AS,#SVO7 D(6)/VF[^@5Z?KN^BF2+F,9PR?@0.NXP!;2\77QX$R"=-^<
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MVW+UW_\Q29**)UJ4Y\2I7(?8\%O4H36L%CVZP5F6PA!!3@S9H%+&N+!Z#]6
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M(EO8ANVF[ON!2@O+9]?S[&9]/0:%<(9S<^W69N,A7JZ*Z>)+CO:.&<+I'?4
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M!+7YH]F[OC]1[3U0W)MIR0:FE3GP-O&Z66DO?\)4F(M=6=PLRHIX%F\BY8^
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M!K @#=E%+&](;U.4I#>V3'PJ]H+>P \">7JRPV$&IN]MTL\3&93,A=*OPO!
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M8K">%#\,NP9'>.#%")^VGG?1X$'A<1?_=L_A<9?PN(O/4 J/N[C%D[M*#F3
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M@5[S<YL6Y+.>%Y2#3@06O$<=F@7I,2JXJ>O('<I O!B^Q0D UQ'L4'!)>C#
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M^EJ;NTM#\29!_%D9]X>YKT\J]V/HWV-G!U8;010\!#&:M&%TTF2<6.)KX0R
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M4=XT:Q@$L?G0*!)G<V;5*2FBS#(N'J+U)OM:_#DDED-@IF$\$ $Z\FM,Z(3
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M LX.$,@K"(0A>M804"72: P$E^#N\YRERR>UT"D+M%(G*>".\X%1'W*G<F*
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M8*$CE[OCDSGC0:^)2$"$KX'GZ:KYL%F1?GJ9O5(:#?64BJFLYX$Y"E_^I@'
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M+IC#*WQE?6#HEM3W+D0#G]1'6MBY=Q,>N=5%_7'8LJ'&$$HOM-V*TXF!*9Q
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M;I/<![82T@P-)95!/:>FL+*ZFKL&C^/ATE-(,OHD N4@"*UXZ9-#3<(,/[[
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M2S<;<=!"NA*G'^[$:& H)L *1^4P5J"0"8,3L";\7&M"RNY%#QJS99A;HPY
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MD*_&5M=Y'7CH4QRL;4RB [<]CJQ"VP-.>D[OZB%(>9 M)-!9E,<V_>G-\\U
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M!9M&>2+;CF5AU*Q0TVR]LFR!Y[#O99N5M0-EZ)_?CJI0^(5( *8@V!R2@.8
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M1X^6=\$F=O+1DN+Q()VC&Q7U3'I-XC!#(%FE6C__UNIGQ86Z4"#'C"O[3T$
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M<[QHC1ZS*A*C%%I!T! _>1E=PXR"0^6J.5!"G!W!AW\[EO+17]Z89RM!LZ;
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MDO+US:K>(9T=KI(#/\86IW1(PGE][_'LO+8$6Y_R]M]_X S,5 W\A$U/YF&
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M537/]=VSI9-7"57S XI*164NCP[O:,75(=KB>,,X2PM&:'742A_7:F=.[$%
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MLVJ]] 6QS?KI/4H:6\$L^8\#A)A\RR[/I"(-F4:4>L,>3'PT:L(.=332^21
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M@<HFJ&X32-TK0 A)7#D AAP704:T&RUG/.#LCB@6-#1LV6*)+3*<.X8DV7X
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MB3(Z/X[6_SSDK TK1,2DJ^>\4,9NGY G//?N: L,$B=T=#V!OHZ&^:9FIR,
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MX@=LFOMTUE.]5@<]+G[!VBQX-.G:$ZF3<%/L.0MZ7W:.-XTZW:MUAY\&=:<
M@41CUT]9JVR\E6.G9F,G3 SKW 4_O*3Q[,^CU DZ+1H(:R01[LRT<8QVG6P#
MQKS._?!#GN"2I(%P01+JSLR%><+>D8VFSGI,PU[8S:;69N<+>TTWG+HIMMAR
M.A[*SKWIU!VTQFY&?^.IM4IS+P._^=3)],2!JO$&5$?-IH%J8)M0 R&-:YSJ
MAS53Q:F>MZ,Z]\,/=P+<DAH(&UPC53]LF"=2K7[X0+\/+_;R+LKQFLYO6-CU
M-8O2/%KQ.@B_Q\6V3J%99W&=C)G&O);&)O%(5GV;+WIVZ:Z[<[.WWHO#ZWB!
MWVC'R[B]OF.ZT+Y4AHJ6-KZYH;4?PC3Q?"*>UHV2QN[8&?B6+MO*KKE?=_CS
MPO8[$\\RG/HYH\<QGZ^X^*07%^,'XV?J8Z::;EEW<(XYF5-G9_0T=';WI>4M
M5F3'%'&=+V[!#RK/U"U,MYU\Y&_I3RM!=.EL,1_7Y6WSX)CI:;>=:_;&;D>A
MEG+7K>CA+Z/ H%IK6Z()N SV)XZIU=NIJ->Y68DWP3YVW6[XHYS>WG8-7KW0
M2@2=('GE<SN\COVI-L;K]L4?NU2;Y16<VAS2,EI[(94(-D&2:H[2(A"K-U.8
M,BM2,L/*C<^>S57NQ,NJC7?;D&LVMK533N+0.TS^9"K@6YV>=TN=^/_30O8X
MDU9T\;->X]^X66V8TUVK.2N7XE:/)FR?,DUEFQ!6:*;HZFR>)=C5F;-R!&ZE
M><)V!*"SR:LX7R4D/V3X9O,QW9!LQSNWO".'XCW9[>*"]8<=G6&7P<7I/4Y7
M,<Z_LBO@>FX&0E7UN=Q4N;A)%\O@LSF SDC]G+/NQ9?5%J\/";\%=5UJ8_N)
MXZ,R.I]*ZJG5ZJB31U2KMM:9IU4@R"7 ".IZ+A>MC6=R[]J<U(*9MD#TPANI
MZ+3CJ(+QJDVFB&E1\PA]XZIFKEL0%)TD4X(@^#0,Z:<?R3_%*?Y8X%T_]PNE
MSFU$;ZF;P?4TUD,9V?L=@G9$7?T+]D\4LW\?:["@BOALG6J5'-9T=(^I;T(%
M _6/Z.N6MCJV81G60UY& %6,P"Y4WY.,M^_ZMSPGJYC'"SQ!LB;L&F*TPVS;
M1X[6>$.[PZT1VBV2H5V4/J'H.^8U9(HMKOIPDLYOR!M'!RC$+H@/;#2[^L%>
M%^<F^*SQQ: G7JGM'F=PU\#UG6:PX9=OL$&''\*!!A]MH^)K-A4MJI<D;.'B
M% 0*X7BN4"ZEKE1FT7H2S+V"JB]&-%]Q%_^"U@VDY9H\0  P6:VP8(J#RRX.
M!%[W])$A2<Q:( -X4PT-UA/F+)GZ6YS%9/V!9+^2(EY1'_L^HN\B23KA?+-'
MQEBRV?)B(.FV]*-MR,.&%%/;BI49,U5\N\B>-^,3!+;/+F,;[3(ZB[A[XC.&
M!.<YQN4,)L$16]6]SS NEVP)VF?D(5YCE'(;3,NJ9847\*G$:.-:'\EFWR5B
M#DGBAI7^,HNVDM:JB:'A"1D!M6'"V"@4%_AV!B;!!Q0F<E$S@P:/$G@_&Q!+
M=PUX1['SFKZ1-= E>F/+4%BF45+YJ(W@OEO.NFA_-E"6KGM[AS)H.';+QMV<
MK7[7B^EU/_II:HV6U:M0MG1AH4(Q>#@U;DM*LS'1WN[:?=.<$TRZ,[:F6+VK
M[3MU'"FE7A4Z97.O[>H A)A]R2ZW%$(-ET85>\0?3/"B8<06>30X.;:X."*M
M0=;9 $@2:  @R#&0&-$.&#AH6++%$0T,KFOOTX"(NJ%_XG/"D&2$!\ 0Z C^
M-?K^B="Y=?YEG\3%NZ?K[_LX>[J*"BS)#^L+5'^XCH +)\;UPWE7?5M2<NBJ
M6-"&*.$M4<Z:LE0(YHW1FK8.)LEH  AB]\FZ#!H7;HBD;<<__@!=L[Y!1Q!>
MOH!0YL;!00CJU#]1Y=G7;91^B;__%QU V (CG0\>?Z;S@I0_^(5OVNC!VE:\
M>D7FXB[T,[4&/M6S[("4FU;ZZ*0PSJLM."@OZ.2OG Y&93K]CLT&Z621[?+-
MV)G*%.7Q=_3$M/"98DJ*SD-FHWP\\[30&HL$ !]=SIMJ:CR 71>F)@5,A&1K
M&90.-'KZ9(YT]*W4,/-0-@OB);'6I)!WC,-L3 )&9;;F08%/(S86:Z RQKA
M5WA5?I>W;RX0C1/^]IPQ+@GE)L4X:)C7-G:;Q21CQJ[3M3"HTVM<O9JQQBX\
M5>L&#\^TS$E)J"&M$WKU!IT]T\0''833]<P1EB8PB/'GZ]),+=>02D>]7_3!
MQ$%Z=AQP]X8OK\I1%8BG!T>7)%(!@Y=C%#)N ##FT#/F +*1>.+-W\\599)8
M 0QEDZ9[KN/[;6&?[I&):Z9[AN(^H_R^M<G3/9(.6(?Y0GT6Z9[6/%<0D6!F
MY202/E(TZDX-5 @QFQGT-6G/#,1=F)H6TR1\9)9!"=$D?%@#1 41;X"H*//9
MJ/60BU>/PQB\9D&\9<('%/*>$SXBDQ,F?&3F08$_EO#Y?YXSQBT3/J 8!PWT
M?DO9&>VOT??W&5['1?X9%W'&#T&\PRG>Q,4M198PQK.0K%Z:D:0+G0T,@0=U
MYK:E+#95)0OEBN@[6I4JRB*HV^B!1G88LVH]*QP_X'59=CK#:!5E68SY#NO'
M*"MW6A_X&9DH3O,";0X%.S],5?+#_/N,T'ZTB_ZP(S%9TU%JA?<4[6E79PX'
M;8!+W!#5]18&2AI'86QX0M[ 1'T61J$80V.]4J)-D0OT60S?0,:_"6$LB>PF
MP+%C/&=H#3"4L[ ,A68:P%WA]6%5Q,PS?\6[/<FB[ E=Q9L-SC %5$ZAW3CJ
M%LHK=>CV6:)<$MM-@'*_$1T+(6\VO^5XF>>85X;XQ,ZM?HJCNSB)BQCGO^)"
M+\2S4"6+^8Q4@?H  \O^HT+SSNB["5/=0<2-&>OU:[)YS:5XQ[GR\JQU<NQ[
M:%&D#3>DGLH2HR.>RT"KW)49=VU.\GH*32UZX8VVLN!5ET<HQ46H@_V<G-(-
M>N<@%718;&C>9YQLT15OU#*-I-N46QXIQVV@EI$7NBDP%2#=_"RM?Z"!DW"3
M7Y4*5J^LFTGW%]9UI4$64_2,^5M6-[(_OI9BH,Y\47W#+OJ3;RVO]YV'LJ)N
MB,+!THLY-"0++WJ*ANLN)AV8F S B^EFAB%IT#T[H8GP0,;(&9 ^MH[N'^I0
MJ^CZ%GTLHIM9AP3\V!+Z7Y\ON,<6T/V#&S28>T]-W./\8_HABK-_1,D!WVQ8
M;K>**R7U<(V$ZA*YFD).)5.U;,"-36;VY#55#=0LJL:L[N.&-D</K#VO>L06
M/:I$22AGT V10NR_8Z\FJY:"8YE6$WO3 !2RS*^140"47KZ@5/(Q)T(IZ!#Q
M98N3S6=\7UT/3M(O=,K*UP(EPX.^0/4Z= 1<6#>N'VY(T+<E)9JNB@5OB-HM
M4=,T&'(9H('8?:\NJ<:%&T)IVP$\GWI@8=S-Y@-?1KQA:=@XO<]O-E_PZI#Q
MS-WR4&Q)%O\;KW]+USB3=[('=1^JZ[.OH*J=SI(!]@3^7"U\Y^0'U:!M\1J:
M*=?*QNEJG9O4BMEO>:.:[XZDDG'QA'81JW]$'Q7L\J0'W"I1KG)0<Q_Q]<$6
MXAFEO9-W@%:.Y_3 NQX2W8$.,GOHU61$9X>D=5D>-8K1@6E6$OJ%S^8P/$%"
MNQX&!^X.Y-%Q#UV;C-:7;5I'ZW7,6D1)S?#]X2Z)5T>BOY#5'&$G2%;8RO:D
M8"%?E"P;>-UF9(7Q.O\2);2WU_\ZT(#P8TJ[P@/E7'ONXD-U73L?5+53I6K
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MNK<]]H[ O5%765^BQ$^"*'F\?HBCQZICF3C'&,0&0,OJCSO9TB8R32C&HQT
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M'20;UNO"W)Z!F]A?US*J3_22\Q_ZP-D$W$\0[8KT^;/ '2D%OHY)U(>(IAU
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M"6Q=_:&4K6V\6:$<G13"[$D=%"+N(->CT"+J#7L)*=C2A3R2A%17OJHV2]-
M**BH_LCW/58AV+@FR(!C[.)P,J A&]0REL5:>4TS3[3SZH8KF40<8$S"CA!!
M9LEW !80B0W0F@W4>,F^!F8<=)F VN[HH29A((A0P\V^4$UAC,E<MA/8**&
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M[A@F?0E)SB;;C.^RQ4RWQ[QV5\_1[,?.<=/"\R\8-]1@;/M^I9)L/ QFPC5
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M! DK7<P1<(M__.DGY/>$]2'-HGS_*\V>HMR/QVN 0-K6I4"FVUKEVY]2C<Y
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M^K,MUHI0_FR3RV2)HPMPN3&,.=*/*(WPZC99#8]X=RA;R#_G07H!4>D/9D[
M\%@KH!J$T>ZP0W\(\:Z$_'QXS="_#BC);]_(_V0W* ^B.)/C2R ="#[?__&[
M[TM=_[^XH+00NXL2HK>C(+XG&CPEGPC$1;)ZBK+?/P5)L$'T%P-LU>!KD7 ;
MI G=U8E4/6^#%!E@RP6EA=@UWNVBO";Y&B<Y@4WLE0B9S#\$JIZ,4HJI?4"
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MLUX<,P?$%& U0#Z+M@'+K F]&@X3##'M[$CU&SJ-XEEB0T'0@6TK,#OX+,8
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M8SC3FBFV&M5/^#;V2.48N,GUX#E0+CK3'1+.^=YI>TK)RPP6W"=OQ%K0+ X
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M&OC/4QO!8)\\H3"<52 -A(_0'5W8@[FM<WHX$:"@+@D]"P#"$'YX AB!OK'
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M5@-J3<QY]6'!)OZ40J^*QPA0EE=O,BV3KB>[*[O0]J?G\J3M/95,54[8$$_
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M1LGF#J<HVB2W[V'Q7@HM&M65#VG#4]US?D/WY 1*E416!& \S\L&ZGDL5(Z
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MC=Z;T,^YKH/FR]+TV$>O0I]1^D86!:NT@Z35^15I=BO7*69FPDC;\:FV7_6
M:+"3-FNI,G9Y"ECKNDZ%K/5H^ZU\"K JL>V=E#M $6PO ^QYB))L46/X&I!R
MM<XK$0"<4TNX/+]0=@EWY&F=I>921B)2YU)&<RFC@0F[B](L7Y"?5MPT9 ,(
M,*+9$!Q)8I9-J[R($X!!HM1F#@* 2D[L@?VHZW0BXAF%.%D92:@0!$Q$.2 F
M(Z,0%@TCI)R1/:\1.U>$FTLE.% J8>S3V%PEP9FCK(M5$FRE%(WMQ63>\K!<
MM]*&Y_11;D,/2&?[< %-A>3;/QM]BF)$!#9!C^53"]DUZ4-K]2WH&W2;0TPA
M'4^MV'29 :DHU@4RGL,2,IO8$G<Z+DW!T%3EZ [IVL&H3P?>$=T:1D$,%$1.
M>Z[,]=I[*%YBFDTEJ0?=M>2?^NE,(NLW9)..\9Y[:H8T/5U5BYHZ+R4*E*H)
MB!BP:R]#/46;;;Y<_TQ ER<.MEB(6]42P6OEOC" Z%.4 Q[,(9YN,GH<;!MD
MZ.4+KK?$Y_RP.E8XKZH[)[;UIMRQMN44.CHO.]I<4!,GE6'T$X6<<)0!CD18
MZ>P X?3I!EP(=O8<B)A_J7MPP>#Z^ZN+7H2YUJ*_[.?$?UJ%:8/Y0SQ:W?!F
MOYV=UX\X)_]+#DJ_!'&OC)I*E_[]G*"+GQJ7G6&HS"*+ZK>=G@C!Q#7G"1OK
M[H$>\(:R.2"A!,, 35VN-=AY46F'X>>:+PA&RQ,*$?G>3<O3ZZPDZ^?.'TV^
M.6P;5:;/.(WFMQHR3X<21P\5F4)Y:H4^)T<IJ,]TY%V'20.).1"5T5QR U93
MD)=1D)?A<:ILP@!Z6:U<CT7E:[6ZC[,R^)(&218414L>TRA$B[A @%81?T*[
M(*(9X6QG3D=4S0'5@?(&@*8C^-;8.=#Z,,%OF+>;[)O<GW%.*#M'0;V@=!<E
M!17,DAB&4(1&. #*=(3?#B,O:I8#D-.H"#7H.;,^#3^A,Z?>:(7G?^ HR9]S
M1/!.-C1V(LK)?UP=;X-P2RL?'#MR;PZHFC$30-.1?FOL'&@!F."G7]3*60M*
M7'U56'?;E6JK@YGM@/K<UBWV3B77OTU(U#[R2UT#N$!,WO6RZ/Z O@+VXS0N
MS#](*6+[.E6O@+$]_2JO5?F=OSEF]A^%&B**P.+4/C2?D+*$J^?57.8'IVP\
M.*7AH1\[\&Y^<,K!TH,+&J?RBO* _O&*5\?[9+$BB/[0RG3^"27D+Q1NYS*#
MWH3=S64&YS*#DRTS2+75HJ.V;IAH UI6B M;NE3\KI]Z 2=2H:R@$*CG1NA<
M4M!):WXN*3B7%)Q+"G[<DH++-3UZG$X;"O7,A#V%9<PX/2=3'0O"F6%J9'%&
MGBMEB1>E>Y6RG##9YG)9SIAI<[FLX9Q9]/UWAE76^[UV8)U_=X\.ML7"^M2D
MQL3:&(Z@*YP3<23B2E%DTB5H49'';#&>/YXU#QA"1\>[WH!#ERFS_V@ID ,>
M,?!>) Z\S_6QHO?9.4&04""6@GYGSZO6]C4P%NHR!GMJ^Z+=:[8J&KR\D"G1
M&&LNE#$7RG"#_7.AC+E0QEPHP_U"&7/&DE/B/)&,)<<K8UP?=K0X,/FIKO>J
M5!M#WETHYJ+N4Y=O,.LN*M@BK/1-ZLNFGC*J?.!-$OU;O]Y+I[MJQ9=3]ZG+
M-)AU8U=].6'E6K':N7Z1P[(\NG:6UB^:4G6-N<*+GQ5>-$I3#)NCWWO2@*,^
MP>T[&?>"]M,1-57F#)P_+T!CM%(1<Z&AN=#0Y H-3:G:Q%P"X".7 - H9N'U
M36S_AFY.K/8P0&%.K)X3J^?$:I<2J_/@T$ZK_N[[.:UZ?,KFM&H7DHSGM&HW
MTZI?6DJ+GU0M;-=(J>:T<RGUEYU0#2%0,9V: ])SPW-.IG;2@I^3J>=DZCF9
M^F,G4W_WO6XR-;>G-)F:T7-2R=0RS@R73,T8V7/384ZE=H'K<RKUG$H]IU+/
MJ=07(FA.I>;ZT\=*I9[S:*>SI<QYM&/?$3S,>;1S'NV<1^NG/IWS:.<\VCF/
M=LZC'4CHYSS:.8]VSJ.=\VCG/%J7M?2<1^N$+(^NG><\VHZ\SWFT<Q[MG$<[
MY]'.>;1S'NV<1SOGT<YYM',>[9Q'.^?1SGFT<Q[MG$<[Y]%:SZ-]"0Z_!&%(
MY:M,H?US*X7V'\3>(D,_;@-B487HD$=A$&=S/JTWP1IS/NV<3SO9?-J6\F*G
MTHJ:U$=_9A.7TCT9;\?(R5+(G65#\]S.G--FG338Y[39.6UV3IO]X&FS?V:?
M*U1S:$%@Y FU$C#3RJY5X=F J;82-#RW/>:\6Q>X/N?=SGFW<][MG'=[(8+F
MO%NN_WU^PGA^PGA^PGA.O9Y3K\=72G/JM;_LGU.OY]3K.?5Z3KV>4Z_GU&OG
MA'Y.O9Y3KS] ZO6<J#HGJO8352^?<#TGJLZ)JNU$U2DE2\\9@FX*_@?($+Q\
MOO><(>B%['N7(:B1,N[UA4'?D3QG"'IXCS9G",X9@G.&H$,9@GN4W^^"#3&=
M%ALR"C-3\"%:HT^D?WB(@[1J?4>L+)3&Q\<H#79!7/WZ',SY@][<.,[Y@W/^
MX)3S!Q]O7SJJC9M'*&UZSB<4-'4I'XZ95P@E4RV_4 #5<VMUSC-TTNR?\PSG
M/,,YS_ CY!E6(Y$Q1?EFK/,)DPNVP%5\,0?G8?ZA91Z:YB&:H^.YC3+G([K
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MRUVUM+)G'*\:5+:<8)RCJ6KWSMD4WMU?J31DE>73*1P+_2LIUML?%_7DE@$
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M6:9BN5UF,%O+>8+VWT4G8/SE#+,B;97U]-._9N:SL>Y04T;'\T!&6Y46K$:
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M/6*M'PW_HGLTO$V\4:;5]A(4=6#M&!!P6'(3 @++!QFVP28;9@1DT$KZ?YC
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MG^N'=GN?G1,$"05B*>AW]OS:K*^!L5"7,=C3MG=F*T;!BG'!-)GZ>U?6V/8
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MGB'L0VHSI/WB,98!_AN91X<YG+U(1PG\T<O%-M!+WHO&:=XJ;"2[.#HTL*-
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MD /V=PC-/B3!7()AA!S@@7'0+M,09KR!HILN6D7@X?B8B3^/BMO-NQ:%?<$
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M:74M,C R,#$R,S$N>&UL4$L! A0#%     @ '$AW4H=V>_D&)   :+4! !$
M             ( !*54" &%C:74M,C R,#$R,S$N>'-D4$L! A0#%     @
M'$AW4AGM[H0C%0  #C,! !4              ( !7GD" &%C:74M,C R,#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( !Q(=U+]92"=<UD  ,<S!P 5
M      "  ;2. @!A8VEU+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  <
M2'=2E.DBQ0<K 0#__A( %0              @ %:Z ( 86-I=2TR,#(P,3(S
M,5]L86(N>&UL4$L! A0#%     @ '$AW4E6JZ9)&C   G\L* !4
M     ( !E!,$ &%C:74M,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!
(   -H 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
